<SEC-DOCUMENT>0001737287-20-000012.txt : 20200227
<SEC-HEADER>0001737287-20-000012.hdr.sgml : 20200227
<ACCEPTANCE-DATETIME>20200227160708
ACCESSION NUMBER:		0001737287-20-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200227
DATE AS OF CHANGE:		20200227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		20661994

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>allo-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0,d:4bbd891a4ae94fb1b6070b8f551a6549--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:allo="http://allogene.com/20191231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF81LTEtMS0xLTA_ac72a589-a913-456f-801b-62218fdf7d0c">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF83LTEtMS0xLTA_142845e4-4605-4eef-858a-6937ae9f1543">false</ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF84LTEtMS0xLTA_87c1c85b-3e57-42f9-9784-ffa3f8a77fd3">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF8xMS0xLTEtMS0w_fd8fb21d-6bf9-49b9-a676-9e495acda43f">2019</ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF8xMi0xLTEtMS0w_22ff7cc8-b77a-41af-a31e-22ef66b12497">FY</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNi0xLTEtMS0w_45e7abc9-7d60-4b33-82e7-996db9cc09e0">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNi0yLTEtMS0w_cbd2b812-98c5-474a-b9f4-a0e96d810e2a">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNy0xLTEtMS0w_b120d0c9-dc21-4fc9-88df-e6482286007b">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNy0yLTEtMS0w_dc071f7c-f920-49f7-8cad-f0ad171317d2">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfOC0xLTEtMS0w_78891475-a5c5-4758-8fe5-bacaf02839a3">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMi0xLTEtNzIw_257b74d1-0d48-4f3c-8abf-8f84a68f51bd">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfOS0xLTEtMS0w_138b50ff-d666-469c-80a3-67d003a455bf">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMi0xLTEtNzIw_566d5275-e932-4bc4-aeb0-15da0154f974">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMS0xLTEtMA_d6037c66-676c-446c-b58e-e5ce13f66732">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMi0xLTEtMA_055900d5-f83b-4d50-b913-f3003e14bea8">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMS0xLTEtMA_8a4c529a-dfd2-4848-a27c-2d29592cc8f8">200,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMi0xLTEtMA_5f9201c9-692a-4751-99c7-5bb1292ecf36">200,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTItMS0xLTEtMA_97043e75-555e-4fba-816e-1e15d1cbc891">124,267,358</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTItMi0xLTEtMA_40738fe7-9d0a-4e3b-9b80-c5ed8908674c">121,482,671</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTMtMS0xLTEtMA_b7a6d94c-acab-4afa-ab62-d938a4d8623d">124,267,358</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTMtMi0xLTEtMA_5ff2218c-a667-4d65-9810-ff93435801b9">121,482,671</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i1e5eb452c8e54cac836b9b606a34f81f_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzMtMS0xLTEtMA_ed1d41bc-93da-42e8-92f2-edee1b8c571b">35.06</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6751f2efa70949c0876a6a519a946ac1_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzQtMS0xLTEtMA_aeba6397-66e7-4f19-af1d-1a42a290a91c">84</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzYtMS0xLTEtMA_2f090002-dfd5-4dd3-8618-8e5a81aa430c">29,272</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzctMS0xLTEtMTk2Ng_c91b9f8c-8d89-4f15-be78-3adc21eca32f">1.6</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzgtMS0xLTEtMA_6c470ed1-38b3-4b75-8059-b0f8ba69618d">35.06</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzktMS0xLTEtMA_f5028d53-10f5-4555-874e-2947fccd3a67">635</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i93e5135b941044599698b944919b6e62_D20181001-20181001" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTo0ZTQ0NmY1MjUxZWU0NzYyODI4MTQzZTA2NzY3YTM1Yy90YWJsZXJhbmdlOjRlNDQ2ZjUyNTFlZTQ3NjI4MjgxNDNlMDY3NjdhMzVjXzEtMS0xLTEtMA_8a844092-8055-4182-a08d-8bbf7d8615d0">0.1905</ix:nonFraction><ix:nonNumeric contextRef="i972ed925cd2646a487bc5bf253f44bf6_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTowZjNmZTMxOGFlNTg0YTc5OGRjMGJjZmUzOTZjNjVjOS90YWJsZXJhbmdlOjBmM2ZlMzE4YWU1ODRhNzk4ZGMwYmNmZTM5NmM2NWM5XzEtMS0xLTEtMA_b99586a5-78d0-48dd-a6fb-d2c3dc5d5243">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i216ca2a8a747453282fe3a3a74e6cdbf_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTowZjNmZTMxOGFlNTg0YTc5OGRjMGJjZmUzOTZjNjVjOS90YWJsZXJhbmdlOjBmM2ZlMzE4YWU1ODRhNzk4ZGMwYmNmZTM5NmM2NWM5XzItMS0xLTEtMA_117543c9-bad1-4446-8055-7fdd28bdc818">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNjc_5253a5b3-7a0c-4331-8539-db7f2e8159f7">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4OTk_9cc142d9-55cb-4a93-93b8-502c7e750f35">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzEwODk_5e3a8163-9ab6-4322-bca2-e60302945177">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc1MzQ_e0c6a459-876a-4698-840d-09c9bbd3a86c">P4Y</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i223cbc3f897946fe81924d54346ad635_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItMS0xLTEtMA_bd7c31ce-9032-4a0c-8c7c-232fa47e8ed1">25.94</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i1b2d9a5130cd42b0ac8aa561c995521a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItMi0xLTEtMA_b3715242-7c32-49b1-bebb-d7949617fd09">31.99</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i14d7dd8cae1641d99d20bd4d0c10c859_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItNS0xLTEtMTAyMjg_a156e747-70a0-41cd-bd29-1b2e4c0d3c74">2.27</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ice7bf540651747169b6723b0e5d61cc6_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItNi0xLTEtMTAyMjg_29ae867e-5223-4b29-95fc-5b1e9cf5f441">26.52</ix:nonFraction><ix:nonNumeric contextRef="i0990713fcec34063915c2606a9dbf9bc_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtMS0xLTEtMA_21cf0a1c-99f8-4a38-b3e5-dff0c3a61d70">5.27</ix:nonNumeric><ix:nonNumeric contextRef="ifac957e58b7a4baf9cebc33d2887fc43_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtMi0xLTEtMA_a0dec98c-0fc8-49bf-b2fb-bef51018c376">6.08</ix:nonNumeric><ix:nonNumeric contextRef="i9628aef98f7b416d9301a00cd797d731_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtNS0xLTEtMTAyMjg_4af24fad-ba8f-4196-a45a-a97adf6597a0">5.99</ix:nonNumeric><ix:nonNumeric contextRef="id0738f70da3241d28d73424c3601e393_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtNi0xLTEtMTAyMjg_d7a2abb0-d4d8-468c-85b9-434548cef5a2">6.25</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtMS0xLTEtMA_27544abe-3c4d-4a7a-8fa1-a3447eac5c91">74.14</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtMi0xLTEtMA_0714918f-cc69-4480-a255-4bb8312cc1c2">74.92</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtNS0xLTEtMTAyMjg_fb702665-86d6-4488-a353-c082bb2ab65f">74.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtNi0xLTEtMTAyMjg_4fb776ed-6b74-4c63-ac1d-4c85a4d8d217">77.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtMS0xLTEtMA_be7c1522-7859-44e6-a33d-cab2166aa58a">1.54</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtMi0xLTEtMA_9befaf36-86f8-43aa-932e-b951264c5743">2.62</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtNS0xLTEtMTAyMjg_867c911d-5773-4e0d-8ce9-eafee40f1ce0">2.74</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtNi0xLTEtMTAyMjg_960160c8-ef11-4ffd-b767-4fb05d441ad6">2.99</ix:nonFraction><ix:nonNumeric contextRef="i29aea4b9db71497caa6c78fddc404f98_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItMS0xLTEtMA_427f7da5-0ec5-461b-a2bf-e5a68b7211da">0.5</ix:nonNumeric><ix:nonNumeric contextRef="i66c447add08d461688d873b914f5e8ca_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItMi0xLTEtMA_5e3eee10-77fa-4207-98e9-135d3ad08b98">2</ix:nonNumeric><ix:nonNumeric contextRef="id80d84bc4ec941a3baa00789f4ab23e7_D20180101-20181231" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItNS0xLTEtMTAyODg_7cf12ebc-9249-424a-b764-8dde322d2924">6</ix:nonNumeric><ix:nonNumeric contextRef="i5c59ac91728042bdb034aae3cbf86b27_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItNi0xLTEtMTAyODg_db205efc-00a4-4c34-acd9-bdda75187efa">2</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtMS0xLTEtMA_f840a0d6-a43b-46f6-b16e-c916090cf0d4">60.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtMi0xLTEtMA_f3b533ac-1bdb-4b2a-a4cb-299ef2108fac">76.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtNS0xLTEtMTAyODg_7b01fac8-931e-4ba7-bfb7-ef9a53f9c89b">67.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtNi0xLTEtMTAyODg_44391cba-ee3c-4a82-85ea-0232dd1657c1">81.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtMS0xLTEtMA_4fecf541-24fb-4b8e-a558-b488430736f6">1.72</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtMi0xLTEtMA_eadb9367-60d3-48a1-b315-1cf7c2371b65">2.49</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtNS0xLTEtMTAyODg_69a47521-e0f5-4a38-9ccd-323b474f9985">2.37</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtNi0xLTEtMTAyODg_9a3b14a0-0179-4833-ba40-8a58a6c62c61">2.83</ix:nonFraction><ix:nonNumeric contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMxNTY_6ef0bf0c-3a55-4439-89b6-05ebb3b69460">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="allo-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie0e078145b0b454b877975418673c149_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1dcf05e5d867446b9e2cc22d8448cf5a_I20200224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a7d47bd645462aa3e6c38d02dd4202_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539b2ae7956d4b19badf4d751d50af35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931fe0adef2547279e3d242f0f22774d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99decb5567534b8497dffa86e0b1023e_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3201ab4ab1724c7ea1125d924e0873ff_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84465143443f4cf0ad45c2485bf6f687_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450d417e37254e0ab2024cc5cdb97eeb_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe813e0d64c4e969856a6e3723ab181_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed9b242005d4eda9f7a3d5117e787a4_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97c507021ed4124b41826a307eef5b4_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic178392ea1bb4a2d8265ba3c454059e5_I20171129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a7717940ad443ac959da4945a7df7df_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8da636562f1e4692894fbc13c7c7b15c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3039ba156d4b1da1b438ddb91e2eda_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371f0794baf348b8a900545a9f712728_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd581e624e4c4c0ca42cf1cf3eaa1f3f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c398c33948642ec8719c3f9f261004c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f0568066a04dd08c00592b4c8dbb52_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfdd74767fd7438889e77589cf703193_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib660932f6bce4ad6b6fba62272a8c8a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03e9aad02914725a696c4b00ae00db6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824f05079e344862807f10de3ec47704_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34e8122e6b44424adfde751afcccc0f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ba1414023a4bb6a54a2fe2c91369ac_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e44d1416c24d019f4334743e7793bf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894cb9f424d847fd87d8fcba20ed1e12_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1bc4e91f584f8a829f502e3581da80_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6bc6daa75634ee18f23d67b4d5b10be_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d942c4c69d247dc94894cc3832f4f13_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4504b4d5097a4954858c46286aa5dba4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdef23c610c643cd98f536491957b5ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1910421c5c43d585972f790a229f83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8800095a2bb4f63b85032f31ca50e7f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea539b4757a94514a3201e3bef9d08e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b75e8befc040d38153c0e4e0ed8a06_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d6273dcf9f4ca4b6c7f19445ea045d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658fd51e478545beb0ee00eed9c4872f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5eb452c8e54cac836b9b606a34f81f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6751f2efa70949c0876a6a519a946ac1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f77038b1af4fb8b9344a23d6e30de4_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d13410d6cb941fda6060aa13739c84b_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba5824b8755458399cf44363881b72a_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee39b6265afd4c15bb48df2ab24035ac_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08444efecc9e4a61b85b99875e786078_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i821e501b07404b9a9c7d2c5ca11840c7_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58cfdcb98b24158bdd7223f565fcd2b_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88cc8410c2e4057a11268c203ce1002_D20171130-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b21a198f1184844a973ffb0f8eb7de1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31559d28138348d0ab6ce2d61e8edf3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc4fa5d70e04dcaa95ad41bc1ee441d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e5135b941044599698b944919b6e62_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972ed925cd2646a487bc5bf253f44bf6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i216ca2a8a747453282fe3a3a74e6cdbf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dddefdb7f0347409c74598e8d7213a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4580516611428ea09e371d04ecdcf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41321b51b20b4ec3807a67d0a72c0075_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f9280b34fd4edca10d8753f9795f1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5d88729cac494eb409276d41aad939_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910ae198636f445ab767fe7a98e42da1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10fdb61401b746fca53090e64340f864_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7a233f74f545049d9e8aa6b0476dc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec915df35d44a74a0e37fe81e953ea8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06c178fec4d743b7a556aec06c2f821d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91027a1351f40f6a6ce39d721284794_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab948e17826146478ea922d2d145b16a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8402dc6dc845bc9113f9d66ed86178_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25faef9ff3c64269b6c008b1dc92e476_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86abab37a4774a968808425797205a1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67152294c6942b9ba899ab8f21e9ab8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0968abaaa5f7440c8eff4d639ac876db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689d4094b8024bcc8d34927e5f90f7c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0364d3024ca74ee5b4ea651c2620ca3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb123eb6e34d4fb79ca3d24126047e63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9990cf0b9413469cae5b763d89e229c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i413973bdc4c8478484b252834be4455d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d00b3947da248a9aa0a662b95549a62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131f8341b44741a8be5ad09784c38587_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af031995e6847efaf03df708bb7eb62_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29d551d20ae4eb8962e30ebfd31ed44_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeaa87c3871d4b7494311fa64fdb63ec_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd83064e20c54412994b903a9de5ffd4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a0862545c944c7970f75cf79d47b8d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdeb525a74b740d4b778fb321271ccce_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia306dfbbd94f4a72aa4930728fb27045_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769efc364d1b49ad9f1e5c3e1e33a712_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i985e7490d1a549e8a0feb30d7a02d3b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6a1cfe504a41018e8e5e0de30f51d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40117c0bb4854d40a4fa2a481a673eec_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9f4a396a4241bda2a780ca2c70f3be_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e9bfa620a94645901e0e79295a81c2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea078f2b943446d87c87029de76019d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae09226ae44c493cbda2c9500466d142_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4b10265f764f3ab736b5d47b1f9502_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98c546ec02943d0a92444708d47ad3b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576dbba691a54312ae4f7f7b9fa27f72_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b15926b27844890b92923069fc998a2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7eaa563c1f4ebc81ea162cae253d1e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6bcfc30bc543409ce74f21a01801ac_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af350b1cafc4cd1a2cbfc361f70255a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i712f2cfe4d6b404ab9882f4089185418_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5f2d0234854debb1249a5a134c8a88_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92883258851343719809a457e47461f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0083451548d0466897483be2bafb4bd4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4ea982fa834fa29129f07b46026122_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fce8d0645e412d8345a84455d09beb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedec35042c304a2d90f0918f919f1531_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec77988e07a84ed997297aea9582d919_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5226dd8eae048d5930a130fdebafb8f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62c57f1c9644743a2437ff300fafb50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8076cdf604b5489895933ef89fc34b2f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3ba3d3dc894efaacd3513306d920ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebbf8f4f5bf4febac60e511f7aa4329_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08b0bba7d634a958a96f0964cbad763_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db3a0119c79483e94242db1f548282c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5852e80f853444996e612e6a78b2caa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b72e2f0d4e48588b008f53598ce7d2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5647d962561c44b8b5b291742b6f3eb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2d346af52d45db8ca2a02108d6fb0a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if797f590c7f0479a9a697558f2de76e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23478e60d4914559b5221e0ebd4c4fa8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic080d00e479b47cb866477893266680a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6160b48a66c14241831dadcdf19fd045_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109b33bc252c4867bdf458174acbbebf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib026706ac7b34638a5206f120c795fcf_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983a7f491bc342188b274ebaacc4b537_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i418f7561acb7456a9cd8ab2b0b615390_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AntiCDNineteenCARTCellTherapyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c667c41352411c9e3641748894a942_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AntiBCMACARTCellTherapyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie103799a43e847da97be9090d9658fdb_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec3f1d9861bc4aec8c55821fb2f64337_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209e07dad467461eb9a9d4bec5f07fe7_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04f9a07e6ef4653bc71b89352bc570b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c18293923046afb816ad6ab2d44ca8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db1990140824815a537851541246079_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506e30c449204baba23fb44c640ebef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6017f1fd2aeb4f5dae24a3f6a824c26d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9427490ef4a44d8f9b59d11282662b76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff9430c2ddd4802ba7887cb075336c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NorthAmericaEuropeAsiaAustraliaAndOceaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61808ff845034c22af5a68f40821c91c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryAndSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c06fbacca5f491d8f5469bd4fb315fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75364e669b7b45f1a7aef2c29529fead_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9047b22f877746d385f33c4ed54f6267_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0e971edbd54b578a622c44aadb4b6e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i026e57edd43d4beb8496539196c89a2a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9afa63ed9142d29e23a8cc70154a6c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if9165b13a059438f9d7dce0930c8b3e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0156b166fd0646f1a182d6801df909d7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b1db0a202a4ae19712fb80c6cd0e22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191222ceb5b4462cb69b763179a7d5b9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f6805421204eae85b427c2f3c6052a_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5aa740645543fbb3c41bb7edf9788d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc9be9dbd394b6582ca42b028bc5605_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3adabcdd37fd4a4c9feddc86618ac41d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a7d0cfcf8146eb94cd73bc47ddd879_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="icbf3d6643fd944bc90b9feba06c32cda_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0412b597de74f279eae527af0469dbd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9597cce0a04b50aacae109805022c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a231e4e72e4029ac07d4f130b3076f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatinglease"><xbrli:measure>allo:operatingLease</xbrli:measure></xbrli:unit><xbrli:context id="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab52ee2110ab4c6bbcf51aecc895a232_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2210c6df794207907be5b74981ad04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515685bbda6b4ca09271838cbbbc3a24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490046a46cbd43ce9bd693d61995f8bd_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>allo:option</xbrli:measure></xbrli:unit><xbrli:context id="i54c6044221fa4585b6ea5a3c74e488dd_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80e95b53fb54d0e848be36d0b009f5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id582a2792aa240b5b2ce2ac625929e33_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245b301a06c44689b7b0147fb93ad43b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie63f9c3516964c56af3104a004c46f95_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3471d8f101c4d3ba94220c7aad9494d_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f92a81d50e2447da3666732666bc702_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if780bd54cfd745968c9507e6e347e804_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87618dee4474bd9a48ad4abc969f130_I20181010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fe5e85d46bc42af97edd8a33aeb5fac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21acb7c55f624e3ebf064ece42649a1c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43d81dd97134b1c840f4d8375d51b36_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79699a85746047d8bd631f0242942e41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a2bcc9c898478cbaded2c1853112a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98539d3bf6db493eb4bac0723e6ee092_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b4456ea01b4461ba585909bac7d890_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363161bd29bc4e10850ef908f85ad126_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3835f781ec444d7e9271140857371e43_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">allo:FoundersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e27365619214bc59bfb299e39609936_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b1551f5cd34b7ca95dd312bcae049d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af2cfd2ff1d4e4a9d19b9a090f83467_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebdfee99c3d44bbba77e1538670e241_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7d6e8325894802b105e402db61b959_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic335635d76f5410592d7071e11926b5d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5284d2ec96844b179d5bb270bb5844ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4ee5f686274fdeb535ec2690bb50dc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa574b7418b34ab89121de3fef9eb09d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3716dab85d4812af96ca87413ed4aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i223cbc3f897946fe81924d54346ad635_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2d9a5130cd42b0ac8aa561c995521a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d7dd8cae1641d99d20bd4d0c10c859_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7bf540651747169b6723b0e5d61cc6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0990713fcec34063915c2606a9dbf9bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac957e58b7a4baf9cebc33d2887fc43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9628aef98f7b416d9301a00cd797d731_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0738f70da3241d28d73424c3601e393_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29aea4b9db71497caa6c78fddc404f98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c447add08d461688d873b914f5e8ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80d84bc4ec941a3baa00789f4ab23e7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c59ac91728042bdb034aae3cbf86b27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad7357554cc448cb7cdccb352b3f230_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>allo:director</xbrli:measure></xbrli:unit><xbrli:context id="i0f25012c47684987b5c8de4583d7013a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6c8adf2175476b82e13eba7aa65e3b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed333deb19e4f8aa30fd212e8437454_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54626e66f62444da7a1a1a1bd878fa1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b3b4b6820d34ffe8a18270f928c827b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TwoRiverConsultingLimitedLiabiltyCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46512246cc53487190bb23e1f83b9f1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TwoRiverConsultingLimitedLiabiltyCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937aa356e7d74904be670337e39f839f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe223e780a54b2e9611b6aa31c1b596_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44e3cf19d214ae795601add9e69e7eb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b5cfb3c05f4d6b822f58dea1aab477_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice415ea64e2243bc968eb2884b47ca78_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14c29c033be4cfbb4eb48f42b7d40c5_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fdaf74dec9d4787bdf514649b2cd27f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b77ef1f61024c568c150dd64f256116_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02a067e56bf46b385d84dbd3ece5417_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb66cca6e6e14fb0b660ef62239b32cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27792aefa4b465fa4c423f1df05599c_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief267c01c710405abd30252861e3e24c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8b5580156846e28ce6eb93624129e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c74cfa985346f494f9d5736c6a5fe4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7523fadedd6b4e51ab3614c36301ac25_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpiration2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib540aeb004f94ffc9bfe1a2e2bed3e89_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpiration2037To2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08658a06a8a40aaa3b3aa34badf31cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpirationYears2038To2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2150c8f59c49ea84c39db5a3d27693_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c735ffeb0e4728ab0cf9f8a68323c0_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1685cab5677b4214acd1e61778618c7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db00b97645d4dfcb5199164cd300fd7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07955f1bc4d842309fb7054451349500_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d07f8ad8e24589b9cd7e9093f0cdb3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ced67d40264f25905f485ca894893f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e63cc94d1614433bc6dbbf8f222c887_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6803e703b349ab84305332583a3b58_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b6c63c353f4630aed12ad8c7160e52_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8a1d2d642b449f977d62cd68697248_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8943b433f73e48b1b575b63c35b128bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55c9b66b5bc4d93aaa9151719a26f75_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3a4d9d806b414bbbbd1501a52e6766_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b519b46465449bf8e62e676785a0c8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa11e1394d8e429a82692ed6d10cf29e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1db84ffd5f434f9c56d87b4cbf3f69_D20171130-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-06</xbrli:startDate><xbrli:endDate>2020-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb7544972f64173a049364e08f1fd95_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_1"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.610%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">_________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjU1_cfbd0ac3-38d6-47a8-b156-d15733f9a9e0">10-K</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">_________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Mark&#160;One)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MTY0_b54502f0-75da-4a60-aa3b-75ce1db11eb8">&#9746;</ix:nonNumeric>&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">For the fiscal&#160;year ended <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjE0_c053d8fa-fb76-46b6-a8ff-8bfdd30bfe6d">December 31, 2019</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjI4_1d733f97-bf63-4891-acb9-32f6378a5ee5">&#9744;</ix:nonNumeric>&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Commission File Number&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mjc1_75a598ee-44ba-4960-9124-96edac476751">001-38693</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">_________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMw_504e4414-687c-4638-aeb8-4cca20f14c8c">Allogene Therapeutics,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">_________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.468%;"><tr><td style="width:1.0%;"></td><td style="width:46.462%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.610%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NzEwNzNhNzFkMTI0NDhiM2E4NzcwMjIzMmM0N2M4NjEvdGFibGVyYW5nZTo3MTA3M2E3MWQxMjQ0OGIzYTg3NzAyMjMyYzQ3Yzg2MV8wLTAtMS0xLTQwMQ_2ae2d076-b3b5-405d-996d-dfab807220b7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NzEwNzNhNzFkMTI0NDhiM2E4NzcwMjIzMmM0N2M4NjEvdGFibGVyYW5nZTo3MTA3M2E3MWQxMjQ0OGIzYTg3NzAyMjMyYzQ3Yzg2MV8wLTItMS0xLTQwMg_b411bbcc-0dd6-4732-87f2-12aac529af9e">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction<br/>of incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMy_917f487c-c565-4346-9d51-a04d80dae988">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMz_9322996f-e272-4cd4-8419-131b661ca76d">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM0_d5474a9f-c449-441b-96b5-c0475a442cbe">California</ix:nonNumeric> <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM1_e08e9eff-51b1-48fc-8999-9532937777ed">94080</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Address of principal executive offices including zip code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM2_bac5a09b-aeec-4eef-a39e-77d4300fc609">650</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM3_aa921ee0-63cc-4b8f-890b-3c7aae51a52f">457-2700</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">_________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.711%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.506%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.506%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:35.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTAtMS0xLTQyMg_b136a1f5-7269-490f-b651-60481cf167e7">Common Stock, Par Value $0.001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTItMS0xLTkzMDc_0bea2b33-d74f-4dbc-9c3b-7f4c00c8eaa1">ALLO</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTItMS0xLTQyNQ_36977ecf-4304-4f80-b725-71f5fde9d1ae">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF82NTk3MDY5NzcxMTEy_5fe0bae9-95e2-47a0-8538-8b12a6f2928f">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc0_a6b9c9c9-c3c9-49e3-8fd2-95331ce11752">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc3_1e99a1eb-c45a-4cd1-b266-110b1b5a277e">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc5_010a33e2-afd4-4c46-9e49-a0312539c983">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.327%;"><tr><td style="width:1.0%;"></td><td style="width:21.313%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.700%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.082%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8wLTAtMS0xLTQ0MA_35f5a23f-5cdb-421a-b89a-50eab700fcc1">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Small&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8xLTQtMS0xLTQ0Mg_7bc3454b-0115-416e-a875-296a0ed414be">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8yLTQtMS0xLTQ0Mw_a41f757f-62ea-452b-872e-3b0f811cd0a8">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjQz_dbef3b43-a145-4e17-8945-aba8722e1472">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 28, 2019 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="usd" contextRef="ie0e078145b0b454b877975418673c149_I20190628" decimals="-6" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzMxNzI0_1fcba438-b8a5-430c-8a93-061832a374ba">1,601</ix:nonFraction> million based on the closing price of the registrant&#8217;s common stock on June 28, 2018 of $26.85 per share, as reported by The Nasdaq Global Select Market</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">.</span></div><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February&#160;24, 2020 was <ix:nonFraction unitRef="shares" contextRef="i1dcf05e5d867446b9e2cc22d8448cf5a_I20200224" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF83Njk2NTgxNDAxMjIx_a5cc4695-567a-4910-9a0b-6c547177545c">124,906,945</ix:nonFraction>.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjQ1_c91ae39f-483c-4046-851e-7acf8a3ec787" escape="true">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#8217;s fiscal&#160;year ended December&#160;31, 2019, are incorporated by reference into Part&#160;III of this Report.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.610%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_7"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:7.384%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.777%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.839%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_13">PART I</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_16">Business</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_19">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_19">36</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_22">73</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_25">Properties</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_25">73</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_28">73</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_31">74</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_34">PART&#160;II</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_37">75</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_40">76</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_43">77</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_76">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_76">87</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_79">Item&#160;8.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_79">88</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_175">Item&#160;9.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_175">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_175">121</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_178">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_178">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_178">121</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_181">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_181">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_181">123</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_184">PART&#160;III</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_187">Item&#160;10.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_187">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_187">124</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_190">Item&#160;11.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_190">Executive Compensation</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_190">124</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_193">Item&#160;12.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_193">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_193">124</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_196">Item&#160;13.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_196">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_196">124</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_199">Item&#160;14.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_199">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_199">124</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_202">PART&#160;IV</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_205">Item&#160;15.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_205">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_205">125</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_208">Item&#160;16</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_208">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_208">125</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_10"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the context requires otherwise, references in this report to &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc., and references in this report to &#8220;Servier&#8221; collectively refer to Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS.</span></div><div style="text-indent:40.5pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Annual Report on Form 10-K contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success, cost, timing and potential indications of our product development activities and clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of our planned investigational new drug application submissions to the U.S. Food and Drug Administration for our product candidates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our product candidates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans to research, develop and commercialize our product candidates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the size of the markets for our product candidates, and our ability to serve those markets;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully commercialize our product candidates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the rate and degree of market acceptance of our product candidates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to contract with and the performance of our and our collaborators&#8217; third-party suppliers and manufacturers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to develop and successfully operate our own manufacturing facility;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of competing therapies that are or become available;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to attract and retain key scientific or management personnel;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our use of cash and other resources; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this report and are subject to risks and uncertainties. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in this report in greater detail under the heading &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should carefully read this report and the documents that we reference in this report and have filed as exhibits to the Form 10-K, of which this report is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this report by these cautionary statements.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="text-indent:45pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Trademarks and Trade names</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork and other visual displays, may appear without the&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#174;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_13"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_16"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Business</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy, has emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, the first two autologous anti-CD19 CAR T cell therapies, Kymriah, developed by Novartis International AG (Novartis), and Yescarta, developed by Kite Pharma, Inc. (Kite), were approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) (Kymriah) and R/R large B-cell lymphoma (Yescarta). Autologous CAR T cell therapies are manufactured individually for the patient&#8217;s use by modifying the patient&#8217;s own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient&#8217;s T cells and takes approximately two to four weeks. As seen in the registrational trials for Kymriah and Yescarta, up to 31% of intended patients ultimately did not receive treatment primarily due to interval complications from the underlying disease during manufacturing or manufacturing failures.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our allogeneic approach involves engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world. These potential benefits led our Executive Chairman, Arie Belldegrun, M.D., FACS, who was previously the Chairman and Chief Executive Officer at Kite, and our President and Chief Executive Officer, David Chang, M.D., Ph.D., previously Chief Medical Officer and Executive Vice President of Research and Development at Kite, to found our company with the driving purpose of accelerating the development of allogeneic CAR T cell therapies.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have multiple clinical trials ongoing and have a deep pipeline to further the research and development of allogeneic CAR T cell product candidates in both hematological malignancies and solid tumors. We believe our management team&#8217;s experience in immuno-oncology and specifically in CAR T cell therapy will help drive the rapid development and, if approved, the commercialization of potentially curative therapies for patients with aggressive cancer.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Approach</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our allogeneic T cell development strategy has four key pillars: (1) developing product candidates to minimize the risk of graft-versus-host disease (GvHD), a condition where allogeneic T cells can recognize the patient&#8217;s normal tissue as foreign and cause damage, (2) creating a window of persistence that may enable allogeneic T cells to expand in patients, (3) building a leading manufacturing platform and (4) leveraging next generation technologies to improve the functionality of allogeneic CAR T cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We use Cellectis, S.A. (Cellectis), TALEN gene-editing technology with the goal of limiting the risk of GvHD by engineering T cells to lack functional T cell receptors (TCRs) that are no longer capable of recognizing a patient&#8217;s normal tissue as foreign. With the goal of enhancing the expansion and persistence of our engineered allogeneic T cells, we use TALEN to inactivate the CD52 gene in donor T cells and an anti-CD52 monoclonal antibody to deplete CD52 expressing T cells in patients while sparing the therapeutic allogeneic T cells. We believe this enables a window of persistence for the infused allogeneic T cells to actively target and destroy cancer cells. We are also developing ALLO-647, our own anti-CD52 monoclonal antibody. Our off-the-shelf approach is dependent on state-of-the-art manufacturing processes, and we are building a technical operations organization with fully integrated in-house expertise in clinical and commercial engineered T cell manufacturing. In February 2019, we entered into a lease to build our own cell therapy manufacturing facility in Newark, California, and we expect to commence manufacturing at our facility in 2021. Finally, we plan to leverage next generation technologies to develop more potent product candidates and to develop product candidates from a renewable cell source. We believe next generation technologies will also allow us to develop allogeneic T cell therapies for the treatment of solid tumors, which to date have been difficult to treat because of the lack of validated targets and tumor microenvironments that can impair the activity of T cells.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Pipeline</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are currently developing a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Several of our most advanced product candidates, including UCART19, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. We are also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, other blood cancers and solid tumors. Our pipeline is represented in the diagram below.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;"><img src="allo-20191231_g1.jpg" alt="allo-20191231_g1.jpg" style="height:415px;width:684px;"/></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">1</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Phase 3 may not be required if Phase 2 is registrational.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Servier will hold ex-US commercial rights. Servier is the sponsor of the UCART19 trials.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">3</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Allogene is the sponsor of the ALLO-501 trial and plans to sponsor a trial for ALLO-501A.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">4</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> ALLO-647 intended to enable expansion and persistence of allogeneic CAR T product candidates.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">5</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Allogene sponsored trial in combination with SpringWorks Therapeutics, Inc. </span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our lead product candidates include:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">UCART19.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Our collaboration partner, Servier, is sponsoring two Phase 1 clinical trials of UCART19 in patients with R/R ALL, one for adult patients (the CALM trial) and one for pediatric patients (the PALL trial). In December 2018, interim results from 21 patients in the CALM and PALL clinical trials were presented at the 60th American Society of Hematology (ASH) Annual Meeting. As of October 23, 2018, 67% (14/21) of patients achieved complete remission (CR) or complete remission with incomplete blood recovery (CRi). Eighty-two percent (14/17) of patients who received a lymphodepletion regimen consisting of fludarabine, cyclophosphamide and an anti-CD52 monoclonal antibody (FCA) achieved a CR/CRi. In the four patients who received fludarabine and cyclophosphamide (FC) only, there was no evidence of UCART19 cell expansion and no responses were observed. We believe the interim data of UCART19 suggest an anti-CD52 antibody is an important addition to the lymphodepletion regimen for allogeneic CAR T cell expansion, and we are progressing the development of our own anti-CD52 antibody, ALLO-647, as described below. The most common adverse events were related to cytokine release syndrome (CRS) and were generally manageable. Two mild (Grade 1) GvHD cases in the skin were observed and resolved. Subject to the continued advancement of the Phase 1 trials, we expect UCART19 to be advanced to potential registrational trials in 2021. See &#8220;&#8212;Product Pipeline and Development Strategy&#8212;UCART19&#8212;Pooled CALM and PALL Clinical Findings&#8212;Interim Safety&#8221; for more information regarding adverse events.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">ALLO-501.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> We are sponsoring a Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with the most common R/R non-Hodgkin lymphoma (NHL) subtypes. This includes R/R large B-cell lymphoma and R/R follicular lymphoma (FL). In January 2019, the FDA cleared our investigational new drug application (IND) for the ALPHA trial, and we initiated the trial in the second quarter of 2019. We expect to report initial data from the trial in the second quarter of 2020. </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">ALLO-501A.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> We plan to use the clinical data from ALLO-501 to accelerate the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. In December 2019, the FDA cleared our IND to initiate a Phase 1/2 clinical trial for ALLO-501A (the ALPHA2 trial) and we plan to initiate the trial in the second quarter of 2020,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">subject to completing the manufacturing of ALLO-501A. The Phase 1 portion of the ALPHA2 trial is designed to assess the safety and tolerability at increasing dose levels of ALLO-501A in patients with R/R large B-cell lymphoma or transformed FL. </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">ALLO-715.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> We are sponsoring a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715, an allogeneic CAR T cell product candidate targeting B-cell maturation antigen (BCMA), in adult patients with R/R multiple myeloma. In May 2019, the FDA cleared our IND for the UNIVERSAL trial, and we initiated the trial in the third quarter of 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">We expect to report initial data from the trial in the fourth quarter of 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">In addition, in January 2020, we entered into a clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. (SpringWorks) to evaluate ALLO-715 in combination with SpringWorks&#8217; investigational gamma secretase inhibitor (GSI), nirogacestat, in patients with R/R multiple myeloma.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">We plan to initiate this combination trial in the second half of 2020, subject to regulatory clearance.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">ALLO-647</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. We are developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing our other product candidates as part of the lymphodepletion regimen. ALLO-647 may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which our engineered allogeneic T cells can actively target and destroy cancer cells. We are currently utilizing ALLO-647 in the ALPHA trial and UNIVERSAL trial, and plan to utilize ALLO-647 in the ALPHA2 trial.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our History and Team</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe we have established a leadership position in allogeneic T cell therapy. In April 2018, we acquired certain assets from Pfizer Inc. (Pfizer), including strategic license and collaboration agreements and other intellectual property related to the development and administration of allogeneic CAR T cells for the treatment of cancer. We have an exclusive collaboration with Servier to develop and commercialize UCART19, ALLO-501 and ALLO-501A, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier is intended to give us access to TALEN gene-editing technology for all product candidates under our collaboration with Servier. In connection with the Pfizer asset acquisition, we hired a team of employees from Pfizer, who are primarily research and technical operation employees and were leading the research and development of our product candidates and next generation gene engineering and cell engineering technologies at Pfizer.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our world-class management team has significant experience in immuno-oncology and in progressing products from early stage research to clinical trials, and ultimately to regulatory approval and commercialization. In particular, Dr. Belldegrun&#8217;s experience in T cell therapy dates back to his time at the National Cancer Institute as a research fellow in surgical oncology and immunotherapy with Steven Rosenberg, M.D., Ph.D, a recognized pioneer in immuno-oncology. Our President and Chief Executive Officer, Dr. Chang, served as Executive Vice President of Kite and held senior leadership roles at Amgen, Inc. (Amgen). Moreover, both Dr. Belldegrun and Dr. Chang led the development and approval of Yescarta at Kite. Additionally, our Chief Technical Officer, Alison Moore, Ph.D., was previously Senior Vice President, Process Development at Amgen, where she led the development, deployment and oversight of manufacturing for approximately 80 multi-modality assets. Dr. Moore has over 25 years of experience in biotechnology, including in the immuno-oncology space leading process development of Amgen&#8217;s comprehensive bi-specific T cell engager production platform.  In September 2019, Rafael Amado, M.D., joined us as our Executive Vice President of Research and Development and Chief Medical Officer. Dr. Amado has more than 15 years of biotechnology and pharmaceutical industry experience leading clinical and research teams, and he most recently served as President, Research and Development, at Adaptimmune Therapeutics plc, a T cell therapy company, from August 2018 to August 2019, and as Chief Medical Officer from March 2015.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Strategy</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our goal is to maintain and build upon our leadership position in allogeneic T cell therapy. We plan to rapidly develop and, if approved, commercialize allogeneic T cell products for the treatment of cancer that can be delivered faster, more reliably and at greater scale than autologous T cell therapies. We believe achieving this goal could result in allogeneic T cell therapy becoming a standard of care in cancer treatment and enable us to make potentially curative therapies more readily accessible to more patients throughout the world. Key elements of our strategy include:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Capitalize on a validated target and our leadership in engineered allogeneic anti-CD19 CAR T cell product candidates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Autologous anti-CD19 CAR T cell therapies, such as Kymriah and Yescarta, have emerged as potentially curative therapies for B-cell lymphomas and leukemias. We believe developing allogeneic CAR T cell product candidates targeting CD19 is the next frontier in delivering potentially curative therapies against B-cell lymphomas and leukemias, including NHL and ALL. We plan to support Servier in advancing the CALM and PALL trials in R/R ALL. We also expect to report initial data from the ALPHA trial in R/R NHL in the second quarter of 2020, and build on this data by rapidly advancing the clinical development of ALLO-501A. We believe having the first anti-CD19 allogeneic CAR T cell product candidate in the clinic gives us a leadership advantage in efforts to obtain approval of and commercialize anti-CD19 allogeneic CAR T cell product candidates in B-cell lymphoma and leukemia indications.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Expand our leadership position within hematologic indications</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> In addition to UCART19 and ALLO-501A, we plan to advance our near-term pipeline against additional hematological targets where there remains a high unmet need. For example, we are developing ALLO-715, an allogeneic CAR T cell product candidate targeting BCMA. We believe BCMA is a promising target, as early results from clinical trials of third-party autologous CAR T cell therapeutic candidates targeting BCMA have been compelling. Our Phase 1 clinical trial of ALLO-715 for the treatment of patients with R/R multiple myeloma is the first to study an allogeneic CAR T therapy targeting BCMA and we plan to report initial data from the trial in the fourth quarter of 2020. In addition, we plan to initiate a combination trial of ALLO-715 with SpringWorks&#8217; nirogacestat, in patients with R/R multiple myeloma in the second half of 2020, subject to regulatory clearance. We believe nirogacestat has the potential to increase the cell surface density of BCMA and reduce levels of soluble BCMA, thereby enhancing the activity of ALLO-715. We also plan to develop additional allogeneic T cell product candidates targeting other antigens found on hematologic malignancies, including ALLO-316 targeting CD70 and ALLO-819 targeting FLT3, each for the treatment of acute myeloid leukemia (AML).</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Build state-of-the-art gene engineering and cell manufacturing capabilities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Manufacturing allogeneic T cell product candidates involves a series of complex and precise steps. We believe a critical component to our success will be to leverage and expand our proprietary manufacturing know-how, expertise and capacity. In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. We plan to phase the build-out of the facility, and expect to complete the build-out of the majority of the facility in the second half of 2020 and initiate manufacturing under current good manufacturing practices (cGMP) in 2021. We believe establishing our own fully integrated manufacturing operations and infrastructure will allow us to improve the manufacturing process, limit our reliance on contract manufacturing organizations (CMOs) and more rapidly advance product candidates.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Leverage next generation technologies to advance our platform and expand into solid tumor indications with high unmet need.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> We have a broad portfolio of solid tumor targets, including CD70 for the treatment of renal cell cancer and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. We plan to leverage next generation technologies to make more potent allogeneic CAR T cells and improve the characteristics of our product candidates. For example, we are developing TurboCARs, which include a CAR T cell-specific cytokine signal designed to augment the potency and durability of allogeneic T cells.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">In collaboration with Notch Therapeutics Inc. (Notch), we are researching and developing a process for production of product candidates derived from induced pluripotent stem cells (iPSCs). We believe iPSCs may provide renewable starting material for our allogeneic CAR T cell product candidates that could allow for improved efficiency of gene editing, greater scalability of supply, product homogeneity and more streamlined manufacturing. In addition, we continually survey the scientific and industry landscape for opportunities to license, partner or acquire technologies that may help us advance current or new T cell therapies for the benefit of patients. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allogeneic T Cell Therapy</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The Immune System and Cancer</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">White blood cells are a component of the immune system and are responsible for defending the body against infectious pathogens and other foreign material. T cells are a type of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating the activation of other cells in an immune response.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">T cells can be distinguished from other white blood cells by T cell receptors present on their cell surface. These receptors contribute to tumor surveillance by directing T cells to recognize and destroy cancerous cells. When T cells with cancer-specific receptors are absent, present in low numbers, of poor quality or rendered inactive by suppressive mechanisms, cancer may grow and spread. In addition, standard of care treatments, such as chemotherapy regimens, as well as disease specific factors can damage the patient&#8217;s immune system, thereby inhibiting the ability of T cells to kill cancer.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Engineered T Cell Therapies</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Engineered T cell therapy is a type of immunotherapy treatment whereby human T cells are removed from the body and engineered to express CARs which, when infused into a patient, may recognize and destroy cancer cells in a targeted manner.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Chimeric Antigen Receptors (CARs)</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CARs are engineered molecules that, when present on the surface of a T cell, enable the T cell to recognize specific proteins or antigens that are present on the surface of other cells. The CAR in UCART19, ALLO-501, ALLO-501A and ALLO-715 is comprised of a single chain protein that contains the following elements:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Target Binding Domain:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> At one end of the CAR is a target binding domain that is specific to a target antigen. This domain extends out onto the surface of the engineered T cell, where it can recognize the target antigens. The target binding domain consists of a single-chain variable fragment (scFv) of an antibody comprising variable domains of heavy and light chains joined by a short linker.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Transmembrane Domain and Hinge:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> This middle portion of the CAR links the scFv target binding domain to the activating elements inside the cell. This transmembrane domain &#8220;anchors&#8221; the CAR in the cell&#8217;s membrane. In addition, the transmembrane domain may also interact with other transmembrane proteins that enhance CAR function. The hinge domain, which extends to the exterior of the cell, connects the transmembrane domain to scFv and provides structural flexibility to facilitate optimal binding of scFv to the target antigen on the cancer cell&#8217;s surface.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Activating Domains:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> The other end of transmembrane domain, inside the T cell, is connected to two contiguous domains responsible for activating the T cell when the CAR binds to the target cell. The CD3 zeta domain delivers an essential primary signal within the T cell, and the 41BB domain delivers an additional, co-stimulatory signal. Together, these signals trigger T cell activation, resulting in proliferation of the CAR T cells and killing of the cancer cell. In addition, activated CAR T cells stimulate the local secretion of cytokines and other molecules that can recruit and activate additional immune cells to potentiate killing of the cancer cells.</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to the domains described above, ALLO-715 possesses two rituximab-recognition domains between the scFv and the hinge which allow it to be recognized and eliminated by rituximab. UCART19 and ALLO-501 possess rituximab recognition domains in a separate polypeptide termed RQR8 that is co-expressed with the CAR. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The figure below shows the constructs that support our lead programs: UCART19, ALLO-501, ALLO-501A and ALLO-715. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><img src="allo-20191231_g2.jpg" alt="allo-20191231_g2.jpg" style="height:262px;width:684px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allogeneic T Cell Therapies: The Next Revolution</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There are two primary approaches to engineered T cell therapy: autologous and allogeneic. Autologous therapies use engineered T cells derived from the individual patient, while allogeneic therapies use engineered T cells derived from healthy donor T cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The autologous approach, pioneered by Novartis and Kite, has been highly successful in engineering patients&#8217; immune systems to fight cancer, in particular CD19 positive cancers, resulting in significant remission rates. Autologous products are manufactured by first collecting a patient&#8217;s white blood cells, through a process known as leukapheresis, separating the T cells from the patient&#8217;s blood sample and proliferating the isolated T cells. After the cells have multiplied, the CAR construct is virally transduced into the T cells and the engineered T cells are then propagated until a sufficient number of cells are available for infusion into the patient. Finally, the engineered T cells are frozen, and then shipped back to the clinical center for administration to the patient. The process from leukapheresis to delivery to the clinical center takes approximately two to four weeks.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While the autologous approach has been revolutionary, demonstrating compelling efficacy in many patients, it is burdened by the following key limitations:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Lengthy Vein-to-Vein Time</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. Due to the individualized manufacturing process, patients must wait approximately two to four weeks to be treated with their engineered cells. As a result, in the registrational trials for Yescarta and Kymriah, up to 31% of intended patients ultimately did not receive treatment primarily due to interval complications from the underlying disease during manufacturing or manufacturing failures.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Variable Potency</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. In many cases, patients have T cells that have been damaged or weakened due to prior chemotherapy or hematopoietic stem-cell transplant. Compromised T cells may not proliferate well during manufacturing or may produce cells with insufficient potency that cannot be used for patient treatment, resulting in manufacturing failures, or that can show poor expansion and activity in patients. In addition, the individualized nature of autologous manufacturing, together with the variability in patients&#8217; T cells, may lead to variable potency of manufactured T cells, and this variability may cause unpredictable treatment outcomes.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Manufacturing Failures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Autologous cell manufacturing sometimes encounters production failures. This can mean that a patient never receives treatment, as additional patient starting material may not be available or the patient may no longer be eligible due to advanced disease. Furthermore, retreatment can be difficult due to a limited supply of usable patient starting material.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">High Production Cost</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. The delivery of autologous T cell therapy is complicated due to the individualized nature of manufacturing, which allows only one patient to be treated from each manufacturing run and requires dedicated infrastructure to maintain a strict chain of custody and chain of identity of patient-by-patient material collection, manufacturing and delivery. The complex logistics add significant cost to the process and limit the ability to scale. Additionally, the collection of T cells through leukapheresis from each individual patient results in a time consuming </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">and costly step in the autologous process. In part due to these logistics, autologous treatment is currently only available at select centers.</span></div><div><span><br/></span></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g3.jpg" alt="allo-20191231_g3.jpg" style="height:245px;width:490px;"/></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Allogeneic engineered T cells are manufactured in a similar manner as autologous, but our manufacturing has two key differences: (1) our allogeneic T cells are derived from healthy donors, not cancer patients, and (2) our allogeneic T cells are genetically engineered to minimize the risk of GvHD and enable a window of persistence in the patient.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our approach is designed to provide the same intended curative outcome as autologous therapy, while offering the following potential key advantages:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Availability and Access</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. Starting with T cells from a healthy donor, we believe that at scale we can manufacture approximately 100 doses of allogeneic product that could be used in any eligible patient. Because our allogeneic product candidates are designed to be frozen and available off-the-shelf, they could potentially be readily shipped and administered to patients. We believe having an inventory of off-the-shelf allogeneic T cell products can also facilitate delivering multiple product doses to a patient over time as well as enable treatment with multiple different engineered allogeneic T cell products directed to different cancer targets in a patient.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Speed to Patient</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. Many patients with aggressive cancer or rapidly progressing cancer that is refractory to existing therapies may not have multiple weeks to wait for autologous T cell treatment. Our allogeneic approach has the potential to create off-the-shelf product inventory, which could enable dosing of patients within days of prescription. This would represent a significant reduction in patient wait time, potentially allowing the treatment of patients who are too sick to wait for the autologous therapy, and could improve patient outcomes.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Enhanced Cell Consistency and Potency</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. Our manufacturing process produces therapies from selected, screened and tested healthy donors. Healthy donor T cells are potentially superior for engineered cellular therapy as compared to T cells from patients who have undergone prior chemotherapy or hematopoietic stem-cell transplant, which can damage or weaken T cells. In addition, greater consistency of the product may yield more predictable treatment outcomes.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Streamlined Manufacturing and Cost Efficiencies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. We are building an efficient and scalable manufacturing process and organization. The allogeneic approach utilizes healthy donor T cells which we believe provides enhanced scalability, reduces costs of engineered T cell therapy and reduces costs to the healthcare system as our allogeneic approach does not require us to collect and track T cells from each individual patient.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g4.jpg" alt="allo-20191231_g4.jpg" style="height:260px;width:521px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Manufacturing Allogeneic T Cells</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are similarities as well as key differences between the processes for allogeneic and autologous T cell manufacturing, as illustrated in the figure below.</span></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g5.jpg" alt="allo-20191231_g5.jpg" style="height:213px;width:521px;"/></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The three primary steps to creating our engineered allogeneic CAR T cells are: (1) collection and transduction, (2) gene editing, and (3) purification, formulation, and storage.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Step 1. Collection and Transduction</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The starting material for our allogeneic T cell products is white blood cells from a healthy donor, which are collected using a standard blood bank procedure known as leukapheresis. The collected cells are then screened, tested, and shipped to a central processing facility, where the T cells are isolated and stored frozen, creating an inventory of starting healthy donor cells for manufacturing.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The manufacturing process starts by thawing frozen healthy donor T cells, which are then stimulated to proliferate and transduced with a viral vector to integrate the CAR sequence into the T cell genome. The CAR sequence directs the expression of CAR proteins on the cell surface that allows the transduced T cells to recognize and bind to a target molecule that is present on cancer cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We can concurrently add additional genes to these cells that confer specific properties. For example, we can add an off-switch by expressing proteins that can make T cells susceptible to certain drugs, such as anti-CD20 monoclonal antibodies, and enable us to deplete our engineered T cells if needed by administering such drugs to the patient. We can also introduce cytokine activation signaling within a CAR T cell that is designed to enhance the proliferative potential, migratory behavior, and killing activity of cells. We are investigating multiple constructs designed to mimic cytokine signaling selectively within CAR T cells, a technology platform that we call &#8220;TurboCARs&#8221;.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">    </span></div><div style="text-indent:45pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Step 2. Gene Editing</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Next, we use Cellectis&#8217;s electroporation and TALEN technologies for gene editing of T cells. TALENs are a class of DNA cutting enzymes derived by fusing the DNA-cutting domain of a nuclease to the DNA-binding domains from transcription activator-like effectors (TALE). The TALE DNA-binding domain can be tailored to specifically recognize a unique DNA sequence. These fusion proteins serve as readily targetable &#8220;DNA scissors&#8221; for genome engineering applications that enable us to perform targeted genome modifications such as sequence insertion, deletion, repair and replacement in living cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Electroporation allows TALEN mRNA to enter into the cell, where it is translated into a nuclease that can cut DNA and inactivate specific target genes. Inactivation of genes, such as TCR&#945; and CD52, which is performed for UCART19, ALLO-501, ALLO-501A, and ALLO-715, is intended to reduce the risk of GvHD and allow the allogeneic T cells to expand and persist in patients. We believe the inactivation of other target genes using the TALEN technology can be incorporated into future product candidates, with the goal of enhancing T cell function, including increasing potency against solid tumors.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The figure below illustrates how we utilize Cellectis&#8217;s TALEN and electroporation technology to inactivate the genes coding for TCR&#945; and CD52 in our allogeneic T cells for UCART19.</span></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g6.jpg" alt="allo-20191231_g6.jpg" style="height:424px;width:508px;"/></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe the key benefits of TALEN technology are:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Precision</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. It is possible to design a TALEN that will cleave at any selected region in any gene, giving us the ability to achieve the desired genetic outcome with any gene.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Specificity and Selectivity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. TALEN may be designed to limit its DNA cleavage to the desired sequence and to reduce the risk of cutting elsewhere in the genome. This parameter is essential, especially for therapeutic applications, because unwanted genomic modifications potentially could lead to harmful effects for the patient. In addition, gene editing requires only a transient presence of TALEN, thus preserving the integrity and functionality of the T cell&#8217;s genome.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Efficiency</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. A large percentage of cells treated by the nuclease bear the desired genomic modification after treatment is completed. We believe the efficiency of TALEN editing helps to improve our manufacturing yields.</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">TCR</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> knockout:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Non-modified allogeneic T cells bear functional TCRs and, if injected into a patient, can potentially recognize the patient&#8217;s tissue as foreign and damage it. This reaction, known as GvHD, is mediated by intact TCRs on allogeneic T cells. To reduce the risk of GvHD, all of our product candidates undergo the inactivation of a gene coding for </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">TCR&#945;, a key component of TCRs. The engineered T cells lacking functional TCRs are no longer capable of recognizing peptide antigens presented on major histocompatibility complex proteins and thus incapable of attacking the patient&#8217;s normal tissue. This could mitigate the risk of GvHD that can occur when allogeneic TCR-positive T cells are infused into patients who are unrelated to the healthy donor, as shown in the figure below.</span></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g7.jpg" alt="allo-20191231_g7.jpg" style="height:265px;width:590px;"/></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">CD52 knockout: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The patient&#8217;s immune system is expected to recognize allogeneic T cells as foreign and destroy or reject them. To delay this rejection, we use anti-CD52 antibody to deplete lymphocytes, including T cells, in patients. Anti-CD52 antibody recognizes CD52 protein expressed on many immune cells, including T cells. CD52 protein is expressed in both donor and patient immune cells. To selectively deplete a patient&#8217;s immune cells while sparing the therapeutic allogeneic T cells, we use TALEN gene editing to inactivate the CD52 gene in allogeneic T cells, thus protecting allogeneic T cells from the anti-CD52 antibody mediated depletion.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">By administering anti-CD52 antibody prior to infusing our product candidates, we believe we can reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which our engineered allogeneic T cells can expand and actively target and destroy cancer cells. We also believe our approach is unique and differentiated. To capitalize on this differentiation and to secure our own source of anti-CD52 monoclonal antibody, we are developing ALLO-647. We are currently utilizing ALLO-647 in the ALPHA trial and UNIVERSAL trial, and plan to utilize ALLO-647 in the ALPHA2 trial.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Step 3. Purification, Formulation, and Storage</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Once the allogeneic T cells have been engineered with CARs and gene edited to remove the genes encoding TCR&#945; and CD52, they are cultured for several days to increase the cell number and then harvested. The allogeneic cells then undergo a purification step to remove residual TCR positive cells that have not undergone TCR&#945; gene editing. We believe this purification step is essential as none of the currently available gene-editing nucleases can completely inactivate the target genes. After overnight recovery, the cells are formulated in a cryopreservation media and filled into closed, stoppered vials prior to controlled-rate freezing and long-term storage in the vapor phase of liquid nitrogen. This inventory is securely stored and then shipped to oncology centers as needed.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The figure below illustrates the steps in a manufacturing run for our engineered allogeneic CAR T product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><img src="allo-20191231_g8.jpg" alt="allo-20191231_g8.jpg" style="height:250px;width:534px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Pipeline and Development Strategy</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Using our proprietary allogeneic T cell platform, we are researching and developing multiple product candidates for the treatment of blood cancers and solid tumors. Our product candidates are allogeneic T cells engineered to be used as off-the-shelf treatments for any patient with a particular cancer type. Each product candidate targets a selected antigen expressed on tumor cells and bears specific engineered attributes.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the near term, we are progressing multiple product candidates directed at promising targets for blood cancers, including ALL, NHL, multiple myeloma and AML. We are also conducting earlier-stage research programs focused on targets associated with solid tumors, such as renal cell carcinoma, small cell lung cancer and other common epithelial cancers.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our product pipeline is represented in the diagram below:</span></div><div style="text-align:center;"><img src="allo-20191231_g9.jpg" alt="allo-20191231_g9.jpg" style="height:415px;width:684px;"/></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">1</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Phase 3 may not be required if Phase 2 is registrational.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Servier will hold ex-US commercial rights. Servier is the sponsor of the UCART19 trials.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">3</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Allogene is the sponsor of the ALLO-501 trial and plans to sponsor a trial for ALLO-501A.</span></div><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">4</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> ALLO-647 intended to enable expansion and persistence of allogeneic CAR T product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">5</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;"> Allogene sponsored trial in combination with SpringWorks Therapeutics, Inc. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to the allogeneic CAR T cell product candidates we are developing for the treatment of blood cancers and solid tumors, we are developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing our other product candidates as part of the lymphodepletion regimen. As illustrated below, we believe ALLO-647 can reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which our engineered allogeneic T cells can actively target and destroy cancer cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;"><img src="allo-20191231_g10.jpg" alt="allo-20191231_g10.jpg" style="height:277px;width:292px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">UCART19</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We, in partnership with Servier, are developing UCART19 to be a potential first-in-class allogeneic CAR T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. There are currently two ongoing Phase 1 clinical trials in adult and pediatric R/R ALL. Servier is the sponsor of the UCART19 clinical trials and is also responsible for manufacturing UCART19. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">UCART19 targets CD19, an antigen expressed on the surface of B cells, including malignant B cells. In addition to these indications, CD19 targeting CAR T therapies have shown preliminary efficacy in chronic lymphocytic leukemia, mantle cell lymphoma and low-grade NHLs, such as FL or marginal zone lymphoma.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">UCART19 is manufactured to express a CAR that is designed to target CD19 and gene edited to lack TCR&#945; and CD52 to minimize the risk of GvHD and enable a window of persistence in the patient. In addition, UCART19 cells are engineered to express a small protein on the cell surface called RQR8, which consists of two rituximab recognition domains. This allows for recognition and elimination of cells in the event that silencing of CAR T cell activity is desired. The figure below depicts the construct of UCART19.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><img src="allo-20191231_g11.jpg" alt="allo-20191231_g11.jpg" style="height:241px;width:237px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Target Indication: Acute Lymphoblastic Leukemia (ALL)</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALL is characterized by the proliferation of immature lymphocytes in the bone marrow. Approximately 6,150 new cases and 1,520 deaths in the United States are estimated in 2020, according to the American Cancer Society. Approximately 80% of cases of ALL are B-cell ALL, which we plan to address with UCART19.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The risk for developing ALL is highest in children younger than five years of age. From age five until the mid-20s, the risk declines slowly and begins to steadily rise again after age 50. Overall, about 40% of all cases of ALL are in adults. Though most cases occur in children, approximately 80% of deaths from ALL occur in adults.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Over the past four decades pediatric cure rates have reached greater than 80% in developed countries. This progress can be attributed, in part, to a deeper understanding of the molecular genetics and pathogenesis of the disease, advances in combination chemotherapy, monitoring of minimal residual disease, and use of tyrosine kinase inhibitors for Philadelphia chromosome&#8211;positive ALL. Allogeneic stem-cell transplant (allo-SCT) offers the potential for cure in some individuals, however, the option is available only to approximately a third of patients due to the lack of compatible stem cell source, general health, or the high risk of complications. Furthermore, allo-SCT carries a high rate of treatment-related mortality which can occur in approximately 20-30% of patients undergoing allo-SCT. In patients with R/R ALL after two or more lines of therapy, the median disease-free survival is less than six months. The five-year overall survival in adults over the age of 60 is approximately 20%, highlighting the high unmet need despite the recent advances in the treatment of ALL.  </span></div><div style="text-indent:45pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Clinical Data</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">UCART19 is being studied in two ongoing Phase 1 clinical trials, CALM and PALL, sponsored and conducted by Servier, our collaboration partner. Initiated in 2016, CALM is an ongoing Phase 1, open-label, dose-escalation clinical trial in adult patients with R/R ALL to evaluate safety, anti-leukemic activity, and determine the maximum tolerated dose.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Post-therapy allo-SCT was allowed at the discretion of the investigator. Initiated in 2016, PALL is an ongoing Phase 1, open-label, clinical trial in pediatric R/R ALL patients to evaluate safety and anti-leukemic activity.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prior to the initiation of CALM and PALL, UCART19 was administered to three patients with CD19 positive B-cell ALL (two children and one adult) under a compassionate use license granted by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom. The patients had previously failed multiple lines of prior treatment. UCART19 for these patients was manufactured at an academic site, the University College London. The two pediatric patients achieved a CR and received allo-SCT, and the one adult died within the first month following UCART19 infusion due to disease progression.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:91%;">Pooled CALM and PALL Interim Clinical Findings</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2018, interim results from 21 patients in the CALM and PALL clinical trials were presented at the 60th ASH Annual Meeting. As of the October 23, 2018 data cutoff, 21 patients enrolled had been treated in the CALM and PALL clinical trials. In the CALM trial, six patients were treated at the first dose level of 6 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> total cells (approximately 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">5</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells per kilogram) and six patients were treated at the second dose level with 8 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">7</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> total cells (approximately 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells per kilogram). Two patients were treated at the third dose level of 1.8 to 2.4 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">8</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> total cells. In the PALL trial, all seven of the patients enrolled had been treated at a weight-banded cell dose equivalent to 1.1 to 2.3 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells/kg. Patient characteristics are presented below.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.940%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">All (N=21)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Median age in yrs (range)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 (0.8-62)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No of prior treatment lines</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 to 3</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8805;4</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Median (range)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (1-6)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Previous allo-SCT</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time of relapse following previous allo-SCT</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 6 months</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#8805; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">6 months</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bone marrow blasts prior to lymphodepletion</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt;5%</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-25%</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;25%</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Median (range)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8% (0-96)</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interim Safety</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The table below summarizes the adverse events by grade related to UCART19 infusion as well as those related to the lymphodepletion regimen as of October 23, 2018. Grade 1 represents mild toxicity, Grade 2 represents moderate toxicity, Grade 3 represents severe toxicity and Grade 4 represents life threatening toxicity. Grade 5 toxicity represents toxicity resulting in death. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.460%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">Worst Grade</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">N=21</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">G1<br/>n(%)</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">G2<br/>n(%)</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">G3<br/>n(%)</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">G4<br/>n(%)</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">G5<br/>n(%)</span></td><td colspan="3" style="background-color:#003da6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#003da6;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#ffffff;background-color:rgb(255,255,255, 0.0);">All Grades<br/>n(%)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AEs related to UCART19</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cytokine release syndrome</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;(19.0)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;(57.1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9.5)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1*(4.8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;(90.5)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Neurotoxicity events</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;(33.3)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;(38.1)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acute skin graft-versus-host disease(1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9.5)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9.5)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AEs related to lymphodepletion and/or UCART19</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prolonged cytopenia(2)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6+&#160;(28.5)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;(28.5)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viral infections(3)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9.5)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (19.0)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;(38.1)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Neutropenic sepsis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1* (4.8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9.5)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Febrile neutropenia / septic shock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td><td colspan="3" style="background-color:#e5ebf6;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#e5ebf6;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pulmonary hemorrhage</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1+ (4.8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (4.8)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_______________________</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:26.24pt;">GvHD confirmed by biopsy in 1 out of 2 cases.</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(2)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:26.24pt;">Persistent Grade 4 neutropenia and/or thrombocytopenia beyond day 42 post UCART19 infusion, except if &gt;5% bone marrow blast.</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(3)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:26.24pt;">Viral infections: CMV, ADV, BK virus, metapneumovirus.</span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%;">*                   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">One dose limiting toxicity at Dose Level 1: Grade 4 CRS associated with Grade 5 neutropenic sepsis (death at D15 post-infusion).</span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">+              </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">One dose limiting toxicity at Dose Level 2: Grade 4 prolonged cytopenia associated with infection and Grade 5 pulmonary hemorrhage &#160;&#160;&#160;(death at D82 post-infusion).</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The most common UCART19 related adverse event was CRS, reported in 19 patients. Grade 3 or 4 CRS was observed in three patients. Six patients developed prolonged cytopenia, defined as persistent Grade 4 neutropenia and/or thombocytopenia beyond day 42 after UCART19 infusion. Seven patients experienced mild, or Grade 1, neurotoxicity events and one patient experienced Grade 2 neurotoxicity events. Viral infections were attributed to lymphodepletion and/or UCART19. Two patients experienced Grade 1 GvHD adverse event of the skin, which resolved with steroids.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As previously presented, there were two treatment-related deaths in the CALM study, one at day 15 post infusion as a result of Grade 4 CRS associated with Grade 5 neutropenic sepsis and one at day 82 post infusion with Grade 5 pulmonary hemorrhage in the post allogeneic stem-cell transplant setting. Since the data cut-off, one additional CALM patient was treated </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">at the third dose level and died of a treatment-related multiple organ dysfunction syndrome. Grade 5 adverse events have been reported in other autologous anti-CD19 CAR T cell therapy trials in part due to advanced stage of disease and accompanying confounding conditions.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Of the 21 evaluable patients, thirteen deaths have been reported that were not attributed to UCART19, but due to progressive disease or allo-SCT related complications. </span></div><div style="text-indent:45pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interim Efficacy</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of October 2018, 67% (14/21) of patients achieved a CR/CRi. Eighty-two percent (14/17) of patients who received a lymphodepletion regimen consisting of fludarabine, cyclophosphamide and an anti-CD52 monoclonal antibody (FCA) achieved a CR/CRi. In the four patients who received fludarabine and cyclophosphamide (FC) only, there was no evidence of UCART19 cell expansion and no response. Seventy-one percent (10/14) of patients achieved MRD- CR. Three patients received a second dose of UCART19, two under compassionate use (as a deviation from the clinical trial protocol) and one under amended protocol, and two achieved cell expansion and MRD- CR. MRD- CR occurs when a patient achieves a CR and there is no evidence of ALL cells in the marrow when using sensitive tests such as polymerase chain reaction or flow cytometry. CR or CRi rates are the typical regulatory standard, but studies in both children and adults with ALL have demonstrated a strong correlation between minimal residual disease (MRD+) and risks for relapse.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe these data suggest an anti-CD52 antibody is an important addition to the lymphodepletion regimen for allogeneic CAR T cell expansion.  We therefore believe that an anti-CD52 antibody is important to the success of our allogeneic CAR T platform. Going forward, the PALL and CALM trials will require the use of an anti-CD52 monoclonal antibody in the lymphodepletion regimen.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR T cell expansion was detected in blood from day 7 after UCART19 infusion, reaching the peak expansion between day 10 and day 17. One patient treated in the CALM trial at the second dose level showed the highest peak linked to a long persistence up to 4 months.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The four patients on the FC regimen showed no evidence of CAR T cell expansion. A similar lack of CAR T cell expansion was seen in two out of 10 patients on the FCA regimen. The following table illustrates response, duration of remission and re-dosing of UCART19 in the CALM and PALL trial as of the October 2018 data cutoff.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;text-align:center;"><img src="allo-20191231_g12.jpg" alt="allo-20191231_g12.jpg" style="height:308px;width:604px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Development Plan</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We, in partnership with Servier, plan to continue to advance UCART19 in CALM and PALL in order to determine the recommended Phase 2 dose level and the optimal lymphodepletion regimen, specifically testing the benefits of anti-CD52 monoclonal antibody, alemtuzumab or ALLO-647. Subject to the continued advancement of the Phase 1 trials, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">we expect UCART19 to be advanced to potential registrational trials, CALM2 and PALL2, in 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">ALLO-501 and ALLO-501A</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALLO-501 and ALLO-501A are our other allogeneic CAR T cell product candidates targeting CD19. ALLO-501 is identical to UCART19 in molecular design, however several modifications have been introduced by us to the manufacturing process for ALLO-501. These modifications are designed to facilitate more efficient manufacturing scale-up for the larger patient population targeted by ALLO-501. Like UCART19, ALLO-501 also co-expresses a small protein on the cell surface called RQR8, which consists of two rituximab recognition domains. This allows for destruction of the CAR T by rituximab. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prior treatment with rituximab is typical for patients with NHL and, depending on the lag time between the rituximab administration and planned ALLO-501 infusion, prior administration of rituximab may interfere with ALLO-501. As a result, we have removed RQR8 in the next generation of ALLO-501, known as ALLO-501A, as illustrated in the figure below. We believe ALLO-501A will have the potential to facilitate treatment of patients who were recently treated with rituximab. ALLO-501A has been manufactured from several donors under non-cGMP conditions and has been compared to the current version of ALLO-501 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vitro.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> In this study, we found that ALLO-501 and ALLO-501A exhibited similar characteristics and killing activity.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;"><img src="allo-20191231_g13.jpg" alt="allo-20191231_g13.jpg" style="height:407px;width:684px;"/></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALLO-501 and ALLO-501A are jointly developed by us and Servier. We are the sponsor of the ALLO-501 and ALLO-501A trials and lead the clinical development program.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Target Indication: Non-Hodgkin Lymphoma (NHL)</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">NHL is a hematologic cancer originating from malignant lymphocytes. It is the most common hematological malignancy in the United States, with 77,240 new cases estimated to be diagnosed and 19,940 deaths estimated in 2020, according to the American Cancer Society. Over 60 NHL subtypes have been identified, and each subtype represents different neoplastic lymphoid cells (T, B or NK cells) that have arrested at different stages of differentiation. The most common subtype is B-cell, which represented over 90% of all new NHL cases in 2016.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">B-cell NHL itself represents a group of different neoplasms that not only differ in pathology, but also response to therapy and prognosis. NHL can be rapidly growing (aggressive) with short survival, such as large B-cell lymphomas, which include diffuse large B cell lymphoma (DLBCL), or it can be slow growing, or indolent, such as FL. Despite recent therapeutic advances, more than 50% of patients with aggressive B-cell NHL are incurable using existing approved therapies.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The R-CHOP chemotherapy combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) introduced in the early 2000s remains the standard of care for newly diagnosed DLBCL, and five-year survival can be achieved for 55-60% of patients. Unfortunately, approximately 30% of DLBCL require second-line therapy, and subsequent therapy is dependent on whether the patients are candidates for high-dose therapy followed by autologous stem-cell therapy. A retrospective analysis of patients with R/R DLBCL, who were not treated with autologous CAR T therapy, found that outcomes in this population are poor, with an objective response rate of 26% (CR: 7%, partial response: 18%) and median overall survival of 6.3 months.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Despite availability of multiple active agents, high response rates, and long progression-free survival with first-line therapy, FL remains an incurable disease. Most patients treated today eventually relapse, and subsequent responses and durations of responses become increasingly shorter. Ultimately, patients become resistant to chemo-immunotherapy, clinically defined as relapsed within 12 months. In these patients, the toxicity commonly outweighs the benefit of treatment with chemotherapy. Therefore, there remains a high unmet medical need for newer treatment options, especially for those patients with cancer that is resistant to chemo-immunotherapy.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Clinical Development Plan</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The ALPHA trial is an open-label, Phase 1, single arm, multicenter clinical trial evaluating the safety and tolerability of ALLO-501 in adult patients with R/R large B-cell lymphoma, including DLBCL, or FL. Cell kinetics and pharmacodynamics of ALLO-501 will be evaluated as secondary and exploratory objectives, respectively. The trial is a dose-escalation study for ALLO-501 with three separate dose cohorts, from 40 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> to 360 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> total cells. Prior to ALLO-501 treatment, all patients undergo lymphodepletion with a regimen of fludarabine, cyclophosphamide and ALLO-647. We have recently completed enrollment of the three cell dose escalation cohorts, and we are currently exploring the optimal dose and schedule of ALLO-647 in additional cohorts as well as re-dosing of certain patients. We expect to report initial data from the ALPHA trial in the second quarter of 2020. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We plan to initiate an open-label, Phase 1/2, single arm, multicenter clinical trial (the ALPHA2 trial) evaluating the safety and efficacy of ALLO-501A in adult patients with R/R large B-cell lymphoma, including DLBCL, or transformed FL.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Cell kinetics and pharmacodynamics of ALLO-501 will be evaluated as secondary and exploratory objectives, respectively. In December 2019, the FDA cleared our IND to initiate the ALPHA2 trial and we plan to initiate the trial in the second quarter of 2020,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">subject to completing the manufacturing of ALLO-501A. The Phase 1 portion of the ALPHA2 trial is designed to assess the safety and tolerability at increasing dose levels of ALLO-501A, and identify the recommended doses of ALLO-501A and ALLO-647 for use in the Phase 2 portion of the trial. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also expect certain patients to be eligible for re-treatment.  We expect to dose approximately ten patients in the Phase 1 portion of the trial, subject to the results of the ALPHA trial and ALPHA2 trial including safety data.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">All patients treated with ALLO-501 and ALLO-501A will be followed in a long-term follow-up study.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">ALLO-715</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALLO-715 is an allogeneic CAR T cell product candidate targeting BCMA. BCMA is a member of the tumor necrosis factor receptor family and is selectively expressed on immunoglobulin-producing plasma cells, including malignant plasma cells (myeloma cells). We initiated a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715 in adult patients with R/R multiple myeloma in the third quarter of 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALLO-715 is manufactured to express a CAR that is designed to target BCMA and gene edited to lack TCR&#945; and CD52 to minimize the risk of GvHD and enable a window of persistence in the patient. In addition, rituximab recognition domains, as an off-switch, has been incorporated in between the scFv and the linker domain. The figure below depicts the construct of ALLO-715.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><img src="allo-20191231_g14.jpg" alt="allo-20191231_g14.jpg" style="height:274px;width:214px;"/></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Target Indication: Multiple Myeloma</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Multiple myeloma is a hematological malignancy that is characterized by uncontrolled expansion of bone marrow plasma cells. There will be an estimated 32,270 new cases of multiple myeloma and 12,830 deaths from multiple myeloma in 2020 in the United States according to the American Cancer Society. Multiple myeloma predominantly affects the elderly, with 14 times more patients diagnosed at age 65 and over than those diagnosed under the age of 65.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For patients less than age of 70 with no comorbidities, autologous stem cell therapy is the preferred option to provide a durable response. For transplant ineligible patients, immunomodulatory drugs (Revlimid, Pomalyst, Thalomid) and proteasome inhibitors (Velcade, Kyrprolis, Ninlaro), often used in combination with one another, have displaced older cytotoxic agents as the mainstay of treatment. In the past five years, several new drugs with novel mechanisms (Darzalex, Empliciti, Farydak) have been approved for multiple myeloma, however none of these novel treatments is considered as curative.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Despite the introduction of newer therapies, a majority of patients are expected to relapse and the unmet need in patients with R/R myeloma remains high. In clinical trials, only 3% of patients who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs), or who were refractory to both proteasome inhibitors and immunomodulatory drugs, achieved a complete response to Darzalex. Median survival in such patients was just 17.5 months. Trials of autologous CAR T cell therapies such as bb2121, currently being developed by bluebird bio, Inc. (bluebird) in partnership with Celgene Corporation, have shown significant promise in multiple myeloma with complete response rates of 31% at doses of 150 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">to 450 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> CAR T cells.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical Development Plan</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The UNIVERSAL trial is an open-label, Phase 1, single arm, multicenter clinical trial evaluating the safety and tolerability of ALLO-715 in adult patients with R/R multiple myeloma. The safety of ALLO-647, cell kinetics, pharmacodynamics, and efficacy will be evaluated as secondary objectives. The trial is a dose-escalation study for ALLO-715 with three initial planned dose cohorts, from 40 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> to 320 &#215; 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> total cells. Prior to ALLO-715 treatment, patients undergo lymphodepletion with a regimen of fludarabine, cyclophosphamide and ALLO-647. Up to 24 patients are expected to be enrolled in the dose finding stage of the trial. We also expect to explore different lymphodepletion regimens where the chemotherapy components, specifically fludarabine and cyclophosphamide, will be stepwise removed, and we will also explore the optimal dosing and schedule of ALLO-647. Additional patients may also be enrolled for further dose expansion.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect to report initial data from the trial in the fourth quarter of 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, in January 2020, we entered into a clinical trial collaboration agreement with SpringWorks to evaluate ALLO-715 in combination with SpringWorks&#8217; investigational gamma secretase inhibitor (GSI), nirogacestat, in patients with R/R multiple myeloma. We plan to initiate this combination trial in the second half of 2020, subject to regulatory clearance.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future Opportunities</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Moving forward, we plan to utilize our allogeneic platform to pursue additional targets of interest. These include the additional targets currently in our pipeline as well as other targets that might be validated in the future. For example, we are developing allogeneic CAR T cell product candidates targeting CD70 for the treatment of hematologic malignancies and renal cell carcinoma (ALLO-316), FLT3 for the treatment of AML (ALLO-819), and DLL3 for the treatment of small cell lung cancer (SCLC).</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Renal Cell Carcinoma and ALLO-316.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Analysis using proteomic and immunohistochemistry techniques have demonstrated a high level of CD70 expression in clear cell renal cell carcinoma (ccRCC) cell lines and in more than 80% of human ccRCC tumor samples. ccRCC is the most common subtype of renal cancer. Approximately 73,750 new cases of renal cell carcinoma are estimated to be diagnosed in the United States and 14,830 deaths are estimated in 2020, according to the American Cancer Society. While the median survival for patients with stage IV disease was a little over one year when cytokines were the predominant systemic therapies, analyses from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based upon more than 2,200 patients treated with targeted therapies report a median survival of 28 months in patients who were eligible for clinical trials. Another contemporary trial using targeted therapy reported a median survival of 28 to 29 months in patients treated with sunitinib or pazopanib, mirroring the IMDC results. We have selected an anti-CD70 CAR T candidate, ALLO-316, and are progressing IND-enabling studies, with the goal of submitting an IND by year-end 2020.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Acute Myeloid Leukemia and ALLO-316 and ALLO-819</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. AML is a high unmet medical need with few treatment options. It is a cancer of bone marrow stem cells and is the most common type of leukemia in adults. The American Cancer Society estimates 19,940 new diagnoses and 11,180 deaths in the United States in 2020. Patients have a poor prognosis despite improvements in chemotherapy regimens and supportive care. CD70 is expressed on AML bulk cells and leukemic stem cells and we expect our planned clinical trial of ALLO-316 to allow for the treatment of patients with AML. In addition, FLT3 is a receptor tyrosine kinase that is overactive in AML blasts. We have conducted </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">in vitro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> studies of our anti-FLT3 CAR T candidate, ALLO-819, that show anti-tumor activity against blasts present in bone marrow from AML patients and in mice. We are currently advancing an IND-enabling data set for ALLO-819. </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Small Cell Lung Cancer and DLL3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. DLL3 is a target which is being pursued for SCLC using ADCs, bi-specifics and autologous CAR T therapies. According to the American Cancer Society, approximately 228,820 new cases of lung cancer are expected to be diagnosed in the United States in 2020 and SCLC comprises approximately 10-15% of all lung cancers. SCLC is responsive to chemotherapy, but recurrence arises rapidly, with less than 7% of patients surviving over five years. SCLC has shown to be responsive to immunotherapy with approximately one-third of patients responding to PD-1/PD-L1 therapy and achieving a median overall survival of approximately thirteen months for patients who received PD-L1 and platinum-based chemotherapy. We believe an allogeneic anti-DLL3 CAR T cell product candidate could be used alone or in combination with PD-1/PD-L1 therapy. We are currently testing and refining constructs for an anti-DLL3 CAR T candidate, and following completion we plan to progress to IND-enabling studies.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also plan to enhance our platform using next-generation technologies such as TurboCARs, switch technologies, including small-molecule induced off-switch, site-specific integration and multi-specific CARs.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.15pt;">TurboCARs and ALLO-605</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Mimicking cytokine activation signaling within a CAR T cell could enhance the proliferative potential, migratory behavior, and killing activity of cells. Such modulation may enhance the anti-tumor activity and durability of CAR T cells without affecting non-engineered immune cells. We are investigating multiple constructs designed to mimic cytokine signaling selectively within CAR T cells, a technology platform that we call &#8220;TurboCARs&#8221;. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are progressing our first TurboCAR, ALLO-605, which targets BCMA and uses a constitutive cytokine signaling domain and a rituximab-mediated off-switch, with the goal of submitting an IND in 2021.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Renewable Cell Source. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">In November 2019, we entered into a Collaboration and License Agreement with Notch (the Notch Collaboration Agreement), pursuant to which Notch has granted to us an exclusive, worldwide, royalty-bearing,  license to certain Notch intellectual property to develop and commercialize gene-edited T cell and/or natural killer cell products from iPSCs directed at certain CAR targets for initial application in NHL, ALL and multiple myeloma. We believe iPSCs may provide renewable starting material for our allogeneic CAR T cell product candidates that could allow for improved efficiency of gene editing, greater scalability of supply, product homogeneity and more streamlined manufacturing. We commenced the research collaboration with Notch in late 2019.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Site-Specific Integration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">. Using a combination of gene-editing technology and homologous recombination technology we can potentially integrate the CAR expressing DNA into specific target genes within the T cell DNA. Such site-specific integration may allow the CAR or other transgenes to be introduced into T cells in a more homogeneous manner, allowing a more uniform and controlled expression of the proteins, with the goal of generating CAR T cell products that behave in a more consistent and predictable manner.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:13.8pt;">Multi-specific CARs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> We are investigating the utility of a single cell product targeting multiple antigens. This may be accomplished by including two antigen binding domains with different specificity in a single polypeptide encoding the CAR or in two separate polypeptides each encoding a CAR with different antigen specificity.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we continually survey the scientific and industry landscape for opportunities to license, partner or acquire technologies that may help us advance current or new T cell therapies for the benefit of patients.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Manufacturing Strategy</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have invested resources to optimize our manufacturing process, including the development of improved analytical methods. We plan to continue to invest in process science, product characterization and manufacturing to continuously improve our production and supply chain capabilities over time.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our product candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The process is gradually developed from small to larger scales, incorporating compliant procedures to create cGMP conditions. Although we have a platform-based manufacturing model, each product is unique and for each new product candidate, a developmental phase is necessary to individually customize each engineering step and to create a robust procedure that can later be implemented in a cGMP environment to ensure the production of clinical batches. This work is performed in our research and development environment to evaluate and assess variability in each step of the process in order to define the most reliable production conditions.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Servier is responsible for UCART19 manufacturing and is working with a CMO in Europe to provide clinical supply for the CALM and PALL clinical trials. ALLO-501 is identical in molecular design to UCART19, but is produced using a modified manufacturing process, optimized by us. ALLO-501, ALLO-501A and ALLO-715 are manufactured in the United States by a CMO, and we will manage all other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The CMO that is manufacturing the clinical supply of ALLO-501, ALLO-501A and ALLO-715 is subject to cGMP requirements, using qualified equipment and materials. We also utilize separate third party contractors to manufacture cGMP raw materials that are used for the manufacturing of our product candidates, such as viral vectors that are used to deliver the applicable CAR gene into the T cells. We believe all materials and components utilized in the production of the cell line, viral vector and final T cell product are available from qualified suppliers and suitable for pivotal process development in readiness for registration and commercialization. </span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, in February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. We plan to phase the build-out of the facility, and expect to complete the build-out of the majority of the facility in the second half of 2020 and initiate cGMP manufacturing operations in 2021. However, we expect to continue to rely on our CMO and may rely on CMOs and other third parties for the manufacturing and processing of our product candidates in the future. We believe the use of contract manufacturing and testing for our first clinical product candidates has allowed us to rapidly prepare for clinical trials in accordance with our development plans. We expect third-party manufacturers will be capable of providing and processing sufficient quantities of our product candidates to meet anticipated clinical trial demands. We also utilize a CMO in the United States for the manufacture and supply of ALLO-647.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We plan to create a robust supply chain with redundant sources of supply comprised of both internal and external infrastructure.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Strategic Agreements</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have also entered into multiple additional strategic agreements and collaborations, including an Asset Contribution Agreement with Pfizer (the Pfizer Agreement), a License Agreement with Cellectis (the Cellectis Agreement), an Exclusive License and Collaboration Agreement with Servier (the Servier Agreement) and the Notch Collaboration Agreement. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For additional information regarding our significant agreements, see Note 7 to our financial statements appearing elsewhere in this Annual Report.  </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intellectual Property</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and applications related to our technology, inventions, and improvements that are important to the development and implementation of our business.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of using and manufacturing the same.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are actively building our intellectual property portfolio around our product candidates and our discovery programs, based on our own intellectual property as well as licensed intellectual property. Following the execution of the Pfizer Agreement, we are the owners of, co-owners of, or the licensee of multiple patents and patent applications in the United States and worldwide. These licensed assets include rights to the Cellectis TALEN gene-editing technology to engineer T cells that lack functional TCRs and to inactivate the CD52 gene in donor cells. We have exclusive worldwide rights to these patents for certain antigen targets, including BCMA, and have U.S. rights to these patents for CD19. Our patent rights are composed of patents and pending patent applications that are solely owned by us, co-owned with Servier, co-owned with Cellectis, exclusively licensed from Pfizer, exclusively licensed from Servier, or exclusively licensed from Cellectis.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our patent portfolio includes protection for our lead product candidates, UCART19, ALLO-501, ALLO-501A and ALLO-715, as well as our other research-stage candidates. With respect to UCART19, ALLO-501 and ALLO-501A, we have an exclusive license from Servier in the United States to patent rights covering composition of matter and methods of making and use covering UCART19, ALLO-501 and ALLO-501A. With respect to ALLO-715, we have an exclusive license from Pfizer to patent rights covering ALLO-715 in the United States and in foreign jurisdictions. These rights include composition of matter protection for ALLO-715 and methods of making and using ALLO-715. More generally, our patent portfolio and filing strategy is designed to provide multiple layers of protection by pursuing claims directed toward: (1) antigen binding domains directed to the targets of our product candidates; (2) CAR constructs used in our product candidates; (3) methods of treatment for therapeutic indications; (4) manufacturing processes, preconditioning methods, and dosing regimens; and (5) reducing GvHD, and methods for genetically engineering immune cells suitable for allogeneic use.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Competition</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If successfully developed, our products will compete with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Novartis and Kite were the first to achieve FDA approval for autologous T cell therapies. In August 2017, Novartis obtained FDA approval to commercialize Kymriah, the treatment of children and young adults with B-cell ALL that is refractory or has relapsed at least twice. In May 2018, Kymriah received FDA approval for adults with R/R large B-cell lymphoma. In October 2017, Kite obtained FDA approval to commercialize Yescarta, the first CAR T cell product candidate for the treatment of adult patients with R/R large B-cell lymphoma.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the promising therapeutic effect of T cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogeneic T cell therapies. Potential cell therapy competitors include, but are not limited to:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Allogeneic T cell therapy competition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">: Atara Biotherapeutics, Inc., Celyad S.A., CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc. (acquired Kite), Intellia Therapeutics, Inc., Poseida Therapeutics, Inc., and Precision Biosciences, Inc. Additionally, Cellectis has several fully-owned allogeneic CAR programs that could compete with programs that fall outside our agreement with Cellectis.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Autologous T cell therapy competition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">: Adaptimmune Therapeutics PLC, Autolus Therapeutics plc, bluebird bio, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson &amp; Johnson, Iovance Biotherapeutics, Inc., Mustang Bio, Inc., Novartis International AG, TCR&#178; Therapeutics Inc., Tmunity Therapeutics, Inc., and Unum Therapeutics Inc.</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Competition may also arise from non-cell based immune oncology platforms. For instance, we may experience competition from companies, such as Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, MacroGenics, Inc., Merus N.V., Regeneron Pharmaceuticals, Inc., and Xencor Inc., that are pursuing bispecific antibodies, which target both the cancer antigen and T cell receptor, thus bringing both cancer cells and T cells in close proximity to maximize the likelihood of an immune response to the cancer cells.  Additionally, companies, such as Amgen Inc., Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, ImmunoGen, Inc., Immunomedics, Inc., and Seattle Genetics, Inc., are pursuing antibody drug conjugates, which utilize the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, pre-clinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, convenience, and cost of manufacturing.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, and investor capital, as well as for technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Government Regulation and Product Approval</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">U.S. Product Development Process</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act (FDCA), the Public Health Service Act (PHSA) and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices (GLPs) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before the trial is commenced;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (GCPs) and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices (GTPs) for the use of human cellular and tissue products;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt;">FDA review and approval, or licensure, of the BLA.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Certain clinical trials involving human gene transfer research also must be overseen by an Institutional Biosafety Committee (IBC), a standing committee to provide peer review of the safety of research plans, procedures, personnel training and environmental risks of work involving recombinant DNA molecules. IBCs are typically assigned certain review responsibilities relating to the use of recombinant DNA molecules, including reviewing potential environmental risks, assessing containment levels, and evaluating the adequacy of facilities, personnel training, and compliance with the National Institutes of Health Guidelines. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Phase 1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Phase 2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt;">Phase 3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vitro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">U.S. Review and Approval Processes</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Within 60 or 74 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and cellular and tissue based products (HCT/Ps), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, under the Pediatric Research Equity Act (PREA), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Orphan Drug Designation</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Expedited Development and Review Programs</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any product, submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Regenerative Medicine Advanced Therapy (RMAT) designation was established by FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Fast Track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Post-Approval Requirements</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physicians deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product&#8217;s approved labeling.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">U.S. Marketing Exclusivity</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Biologics Price Competition and Innovation Act (BPCIA) amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Other U.S. Healthcare Laws and Compliance Requirements</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services (CMS), other divisions of the U.S. Department of Health and Human Services (HHS) (e.g., the Office of Inspector General, the U.S. Department of Justice (DOJ), and individual U.S. Attorney offices within the DOJ, and state and local governments). For example, our business practices, including any of our research and future sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of the Health Insurance Portability and Accountability Act (HIPAA), transparency requirements, and similar state, local and foreign laws, each as amended.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and other individuals and entities on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For example, pharmaceutical and other healthcare companies have been, and continue to be, investigated or prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, imposes requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Coverage, Pricing and Reimbursement</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Healthcare Reform</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP);</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and added new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">expanded of the entities eligible for discounts under the 340B Drug Discount Program;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">expanded healthcare fraud and abuse laws, including the Anti-Kickback Statute and the Foreign Corrupt Practices Act (FCPA), created new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">required reporting of certain financial arrangements with physicians and teaching hospitals;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to physicians;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">created a licensure framework for follow on biologic products.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There remain legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the current U.S. President has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care Act-mandated health insurance, commonly known as the &#8220;individual mandate&#8221;, as part of the Tax Cuts and Jobs Act of 2017 (Tax Act). In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#8217;s mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Bipartisan Budget Act of 2018 (BBA), among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In December 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2029 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President&#8217;s administration&#8217;s budget proposal for fiscal year 2020 contains further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the U.S. President&#8217;s administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. While some of these and other measures may require additional authorization to become effective, Congress and the U.S. President&#8217;s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We anticipate that these and other healthcare reform efforts will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">The Foreign Corrupt Practices Act</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Additional Regulation</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Europe / Rest of World Government Regulation</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit an MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">European Union General Data Protection Regulation</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">California Consumer Privacy Act</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">California recently enacted legislation, effective January 1, 2020, that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.  Known as the California Consumer Privacy Act (CCPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.  The CCPA requires covered companies to provide new disclosures to California consumers, provides such consumers new ways to opt-out of certain sales of personal information, and allows for a new cause of action for data breaches. As our business progresses, the CCPA may impact (possibly significantly) our business </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of February 24, 2020, we had 206 total employees and 205 full-time employees. Of our full-time employees, 65 hold Ph.D. or M.D. degrees, and 151 are engaged in research, development and technical operations. Substantially all of our employees are located in South San Francisco, California. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate Information</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We were incorporated in Delaware in November 2017. Our principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650) 457-2700. Our corporate website address is www.allogene.com. Information contained on or accessible through our website is not a part of this report, and the inclusion of our website address in this report is an inactive textual reference only.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_19"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:45pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this Annual Report. The occurrence of any of the following risks could harm our business, financial condition, results of operations and growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Business and Industry</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have a limited operating history and face significant challenges and expense as we build our capabilities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We were incorporated in 2017 and acquired certain rights to multiple allogeneic CAR T cell therapy assets from Pfizer in April 2018. We have a limited operating history and are subject to the risks inherent in any newly-formed organization, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. Several support services were provided by Pfizer through a Transition Services Agreement (TSA), including certain research and development and general and administrative services, which terminated in September 2019. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. If we are unable to build and manage our support services in a timely manner, our operating and financial results could differ materially from our expectations, and our business could suffer.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a company, we have not progressed any product candidates through clinical development to commercialization. Our collaboration partner, Servier, conducts the CALM and PALL clinical trials of UCART19, and we cannot be certain that our ongoing and planned clinical trials of our other product candidates will be completed or begin on time, if at all.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a clinical-stage biopharmaceutical company and investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have only recently acquired rights to an allogeneic CAR T platform of primarily early-stage product candidates and have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. For the year ended December 31, 2019, we reported a net loss of $184.6 million. As of December 31, 2019, we had an accumulated deficit of $396.1 million.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our engineered allogeneic T cell platform, including UCART19, ALLO-501A and ALLO-715. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells to express CARs and are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">manufacturing our product candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner and treat certain patients;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related to cytokine release syndrome (CRS), neurotoxicity, graft-versus-host disease (GvHD), prolonged cytopenia and neutropenic sepsis;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">using medicines to manage adverse side effects of our product candidates which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">conditioning patients with chemotherapy and ALLO-647 or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">obtaining regulatory approval, as the U.S. Food and Drug Administration (FDA) and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The gene-editing technology we use is relatively new, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Cellectis&#8217;s TALEN technology involves a relatively new approach to gene editing, using sequence-specific DNA-cutting enzymes, or nucleases, to perform precise and stable modifications in the DNA of living-cells and organisms. Although Cellectis has generated nucleases for many specific gene sequences, it has not created nucleases for all gene sequences that we may seek to target, and we may not be able do so, which could limit the usefulness of this technology. This technology may also not be shown to be effective in clinical studies that Cellectis, we or other licensees of Cellectis technology may conduct, or may be associated with safety issues that may negatively affect our development programs.  For instance, gene-editing may create unintended changes to the DNA such as a non-target site gene-editing, a large deletion, or a DNA translocation, any of which could lead to oncogenesis. The gene-editing of our product candidates may also not be successful in limiting the risk of GvHD or premature rejection by the patient.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render our technology obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our program. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at a cost that is acceptable to us. If we are unable to maintain technological advancements consistent with industry standards, our operations and financial condition may be adversely affected.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are heavily reliant on our partners for access to key gene editing technology for the manufacturing and development of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A critical aspect to manufacturing allogeneic T cell product candidates involves gene editing the healthy donor T cells in an effort to avoid GvHD and to limit the patient&#8217;s immune system from attacking the allogeneic T cells. GvHD results when allogeneic T cells start recognizing the patient&#8217;s normal tissue as foreign. We use Cellectis&#8217;s TALEN gene-editing technology to inactivate a gene coding for TCR&#945;, a key component of the natural antigen receptor of T cells, to cause the engineered T cells to be incapable of recognizing foreign antigens. Accordingly, when injected into a patient, the intent is for the engineered T cell not to recognize the tissue of the patient as foreign and thus avoid attacking the patient&#8217;s tissue. In addition, we use TALEN gene editing to inactivate the CD52 gene in donor T cells, which codes for the target of an anti-CD52 monoclonal antibody. Anti-CD52 monoclonal antibodies deplete CD52 expressing T cells in patients while sparing therapeutic allogeneic T cells lacking CD52. By administering an anti-CD52 antibody prior to infusing our product candidates, we believe we have the potential to reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which the engineered allogeneic T cells can actively target and destroy the cancer cells.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We rely on an agreement with Cellectis for rights to use TALEN and electroporation technology for 15 select cancer targets, including BCMA, FLT3, CD70, DLL3 and other targets included in our pipeline. We also rely on Cellectis, through our agreement with Servier, for rights to UCART19 and ALLO-501. Pursuant to our agreement with Servier, we are also dependent on Servier for us to obtain rights to ALLO-501A from Cellectis.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We would need an additional license from Cellectis or access to other gene-editing technology to research and develop product candidates directed at targets not covered by our existing agreements with Cellectis and Servier. In addition, the Cellectis gene-editing technology may fail to produce viable product candidates. Moreover, both Servier and Cellectis may terminate our respective agreements in the event of a material breach of the agreements, or upon certain insolvency events. If our agreements were terminated or we required other gene editing technology, such a license or technology may not be available to us on reasonable terms, or at all, particularly given the limited number of alternative gene-editing technologies in the market.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, under the Servier Agreement, Servier is responsible for conducting the two clinical trials of UCART19, CALM and PALL. We plan to support Servier in advancing the CALM and PALL trials, and we expect Servier to support our clinical trials of ALLO-501 and ALLO-501A for the treatment of patients with R/R NHL. Other than the agreed-upon global research and development plan for UCART19, we have limited control over the nature or timing of Servier&#8217;s clinical trials and limited visibility into their day-to-day activities, including with respect to manufacturing and sourcing of raw materials. In addition, we rely on Servier for access to data from the UCART19 trials, and as a result at any given time we may not be aware of one or more significant trial developments. If UCART19 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed. Additionally, other clinical trials being conducted by Servier may at times receive higher priority than research on our programs. Moreover, if Servier does not provide its share of support for the UCART19, ALLO-501 and ALLO-501A clinical trials, our expenses may be greater than we currently expect and we may have difficulty progressing our ongoing and planned clinical trials in a timely manner.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have concentrated our research, development and manufacturing efforts on our engineered allogeneic T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, since we are in the early stages of clinical development, we do not know the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose for our cell therapy product candidates as well as ALLO-647 may delay our anticipated clinical development timelines. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">T therapies, such as Kymriah and Yescarta, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability and the use of healthy donor material may create separate variability challenges for us. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T therapies that have previously been approved. For instance, allogeneic product candidates may result in GvHD not experienced with autologous products. Even if we collect promising initial clinical data of our product candidates, longer-term data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our business is highly dependent on the success of UCART19, ALLO-501A and ALLO-715. If we are unable to obtain approval for our lead product candidates and effectively commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced product candidates, UCART19, ALLO-501A and ALLO-715. UCART19 is in the early stages of development and has only been administered in a limited number of patients in Phase 1 clinical trials. The results to date may not predict results for our planned trial or any future studies of UCART19 or any other allogeneic CAR T product candidate. Because UCART19, ALLO-501, ALLO-501A and ALLO-715 are among the first allogeneic products to be evaluated in the clinic, the failure of any such product candidate, or the failure of other allogeneic T cell therapies, may impede our ability to develop our product candidates, and significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies, particularly if high or uncontrolled rates of GvHD are observed. If significant GvHD events are observed with the administration of our product candidates, or if any of the product candidates is viewed as less safe or effective than autologous therapies, our ability to develop other allogeneic therapies may be significantly harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are also dependent on Servier to oversee the manufacturing of UCART19 and conduct the UCART19 trials in a timely and appropriate manner. Servier has experienced UCART19 supply issues that limited its ability to recruit new patients. Significant delays in enrollment, due to supply issues or results from the CALM and PALL studies or other reasons, could affect the progress and success of the CALM and PALL clinical trials, our leadership position in the allogeneic CAR T industry and the ability to progress additional product candidates.  In addition, we expect Servier to submit a revised pediatric investigation plan for UCART19 to the EMA. The EMA could reject the revised pediatric investigation plan, which would affect Servier&#8217;s ability to progress the PALL2 clinical trial on the timeframe currently anticipated or at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">All of our product candidates, including our lead product candidates, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because our other product candidates are based on similar technology as our lead product candidates, if any of the lead product candidates encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T therapies and those under development have shown frequent rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. We expect similar adverse events for allogeneic CAR T product candidates. Our allogeneic CAR T cell product candidates undergo gene engineering by using lentivirus and TALEN nucleases that can cause insertion, deletion, or chromosomal translocation. These changes can cause allogeneic CAR T cells to proliferate uncontrollably and may cause adverse events. In addition, our allogeneic CAR T cell product candidates may cause unique adverse events related to the differences between the donor and patients, such as GvHD or infusion reactions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the PALL and CALM clinical trials, the most common severe or life threatening adverse events resulted from CRS, prolonged cytopenia and neutropenic sepsis. Multiple patients have died in these trials, including deaths that were attributed to UCART19.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the future, patients may experience additional severe adverse events related to the lymphodepletion regimen as </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">well as UCART19, some of which may result in death. As we treat more patients with UCART19 in our clinical trials, new less common side effects may also emerge.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As an anti-CD19 CAR T cell therapy, we expect ALLO-501 and ALLO-501A to cause similar toxicities as UCART19. Other of our allogeneic CAR T product candidates may also cause similar or worse toxicities. For instance, because ALLO-715 may require a higher dose than UCART19 and could be used in a more elderly patient population, it is possible that the risk of GvHD or other adverse events for ALLO-715 could be greater than UCART19. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If unacceptable toxicities arise in the development of our product candidates, we or Servier could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We have trained and expect to have to train medical personnel using CAR T cell product candidates to understand the side effect profile of our product candidates for both our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including UCART19, ALLO-501A and ALLO-715, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, for ongoing and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">From time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For instance, we and Servier have published preliminary data from the CALM and PALL clinical trials, however such results are preliminary in nature, do not bear statistical significance and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in ongoing or future clinical trials of UCART19 or our other product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim and preliminary data should </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We plan to submit INDs for additional product candidates in the future, including an IND for ALLO-316 by year-end 2020 and an IND for ALLO-605 in 2021. We also plan to submit an IND amendment to initiate the combination trial of ALLO-715 and the SpringWorks&#8217; compound, nirogacestat, in the second half of 2020. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The manufacturing of allogeneic CAR T cell therapy remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, will be a focus of IND reviews, which may delay the clearance of INDs. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical study can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">difficulty sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in obtaining required institutional review board (IRB) approval at each clinical study site;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in recruiting suitable patients to participate in our clinical studies;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">difficulty collaborating with patient groups and investigators;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">failure to perform in accordance with the FDA&#8217;s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">transfer of manufacturing processes to any new contract manufacturing organization (CMO) or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">patients dropping out of a study;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For our clinical trials of UCART19, ALLO-501 and ALLO-715 and in our planned clinical trials of other product candidates, we and Servier contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:&#8232;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the patient eligibility criteria defined in the protocol;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the proximity of patients to study sites;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the design of the trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to obtain and maintain patient consents; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Since we only need to conduct a limited number of manufacturing runs to generate clinical supply, the diversity of our supply is limited during clinical trials. As a result, some patients may have antibodies to certain donor specific antigens that may interact with our product candidates, which would render the patients ineligible for treatment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, prior treatment with rituximab may interfere with ALLO-501 as ALLO-501 contains rituximab recognition domains.  Since rituximab is a typical part of a treatment regimen for a patient with NHL, patient eligibility for the ALLO-501 trial may be limited. Patients may also undergo plasmapheresis to remove rituximab prior to infusion of ALLO-501, which may cause separate adverse effects. We have removed the rituximab recognition domains in the second generation of ALLO-501, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">known as ALLO-501A, which we believe will potentially facilitate treatment of patients who were recently treated with rituximab. However, we may have difficultly manufacturing or otherwise advancing ALLO-501A.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our clinical trials will also compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation or autologous CAR T cell therapies, rather than enroll patients in our clinical trial. Patients eligible for allogeneic CAR T cell therapies but ineligible for autologous CAR T cell therapies due to aggressive cancer and inability to wait for autologous CAR T cell therapies may be at greater risk for complications and death from therapy.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our allogeneic T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf product, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with R/R cancer and to treat potential side effects that may result from our product candidates can be significant. We also have less control of costs incurred by our development partner, Servier, for the clinical trials of UCART19. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FDA often approves new therapies initially only for use in patients with R/R metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as autologous CAR T therapies and may only be approved for patients who are ineligible for autologous CAR T therapy.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our projections of both the number of patients who have the cancers we are targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect UCART19 to initially target a small patient population that suffers from R/R ALL. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">One of our core strategies is to pursue clinical development of additional product candidates beyond UCART19, ALLO-501A and ALLO-715, including ALLO-316 and ALLO-819. Developing, obtaining regulatory approval and commercializing additional CAR T cell product candidates will require substantial additional funding and is prone to the risks </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Even if we receive FDA approval to market additional product candidates for the treatment of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We utilize an anti-CD52 monoclonal antibody as part of a lymphodepletion regimen to be infused prior to infusing our product candidates. While we believe an anti-CD52 antibody may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which such engineered allogeneic T cells can actively target and destroy cancer cells, the antibody may not have the benefits that we anticipate and could have adverse effects. For instance, our lymphodepletion regimen, including using an anti-CD52 antibody, will cause a transient and sometimes prolonged immune suppression</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">that is associated with an increased risk of infection.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the ongoing CALM and PALL trials, we use a commercially available monoclonal antibody, alemtuzumab, that binds CD52. Alemtuzumab is known to have risk of causing certain adverse events.  The EMA recently completed a pharmacovigilance review of alemtuzumab in the context of the treatment of multiple sclerosis following reports of immune-mediated conditions and problems affecting the heart and blood vessels, including fatal cases. The EMA has recommended that alemtuzumab should not be used in patients with certain heart, circulation or bleeding disorders or in patients who have autoimmune disorders other than multiple sclerosis. The EMA also recommended that alemtuzumab only be given in a hospital with ready access to intensive care facilities and specialists who can manage serious adverse reactions. We are reviewing the final EMA&#8217;s recommendations with respect to the use of our proprietary anti-CD52 antibody in our clinical trials, which are currently conducted at specialized centers. If the EMA or other regulatory agencies further limit the use of alemtuzumab or anti-CD52 antibodies, our clinical program would be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To secure our own readily available source of anti-CD52 antibody, we are developing our own monoclonal anti-CD52 antibody, ALLO-647.  We are using ALLO-647 in our clinical trial of ALLO-501 and ALLO-715. Subject to regulatory acceptance, Servier may also use ALLO-647 in the Servier sponsored clinical trials of UCART19. However, we may be unable to agree with Servier an appropriate arrangement for the use of ALLO-647. ALLO-647 may also cause adverse events, including but not limited to those events that alemtuzumab may cause. In addition, we are exploring various dosing strategies of ALLO-647 in our clinical trials, and higher doses of ALLO-647 may increase the risk of adverse events.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we are unable to successfully develop and manufacture ALLO-647 in the timeframe we anticipate, or at all, or if regulatory authorities do not approve the use of ALLO-647 in combination with our allogeneic T cell product candidates, we may be unable to source alemtuzumab and our engineered allogeneic T cell product candidates may be less effective, which could result in delays in our product development efforts and/or the commercial potential of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We intend to operate our own manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or at our CMO, including mass-producing off-the-shelf product to satisfy demands for any of our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in T cells that will be safe and effective.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. The facility requires substantial improvements and there can be no assurance that we will complete the build-out of our manufacturing facility in a timely manner or at all.  We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose will affect our ability to scale and our costs per dose. For instance, because ALLO-715 may require a higher dose than ALLO-501, it is possible that it may be more difficult to scale ALLO-715 production.  As a result, we may never be able to develop a commercially viable product. The commercial manufacturing facility we build will also require FDA approval, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with current good manufacturing practices (cGMPs), and other government regulations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such supply may have to be discarded and our manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We or our CMO may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or in other markets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The CALM  and PALL clinical trials are currently being conducted in the United States and multiple countries in Europe, and we plan to globally develop our future product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">differing regulatory requirements in foreign countries;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">differing standards for the conduct of clinical trials;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">import and export requirements and restrictions;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">foreign taxes, including withholding of payroll taxes;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">difficulties staffing and managing foreign operations;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">business interruptions resulting from natural or man-made disasters, including earthquakes, tsunamis, fires or medical epidemics, or geo-political actions, including war and terrorism.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These and other risks associated with our international operations and our collaborations with Servier and Cellectis, each based in France, and with Notch Therapeutics Inc. (Notch), based in Canada, may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Specifically, engineered T cells face significant competition from multiple companies. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Executive Chairman, our President and Chief Executive Officer, our Chief Financial Officer, our Executive Vice President of Research &amp; Development and Chief Medical Officer, and our Chief Technical Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conduct substantially all of our operations at our facilities in South San Francisco. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of February 24, 2020, we had 205 full-time employees. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we have rapidly expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants.  In September 2019, we terminated support services previously provided by Pfizer, and our internal build-out of such services may disrupt our operations and be more expensive than we expect. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we mis-classify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our product candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our agreements with Servier, Notch and SpringWorks require significant research and development that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not realize the benefits of acquired assets or other strategic transactions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including our acquisition of CAR T cell assets from Pfizer, licenses with Cellectis, Servier and Notch, and any future strategic transactions depends on the risks and uncertainties involved including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">unanticipated liabilities related to acquired companies or joint ventures;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">retention of key employees;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect to spend a substantial amount of capital in the development and manufacture of our product candidates, including UCART19, ALLO-501, ALLO-501A and ALLO-715. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December 31, 2019, we had $588.9 million in cash, cash equivalents and investments. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our operations, and those of our CMO, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. Our corporate headquarters and planned manufacturing facility are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information. The U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully, offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that may be alleged to be intended to induce prescribing, purchases or recommendations, include any payments of more than fair market value, and may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act and the civil monetary penalties statute;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">federal civil and criminal false claims laws, including the federal civil False Claims Act and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services&#8217; (HHS) Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, we may be subject to state, local and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope. For example, we may be subject to the following: state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of who receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The collection and use of personal data in the European Union (EU) are governed by the General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.  Known as the California Consumer Privacy Act (CPPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.  The CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As our business progresses, the CCPA may significantly impact our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">decreased demand for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">injury to our reputation;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">initiation of investigations by regulators;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">costs to defend the related litigation;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a diversion of management&#8217;s time and our resources;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">loss of revenue;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">exhaustion of any available insurance and our capital resources;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the inability to commercialize any product candidate; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a decline in our share price.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The global credit and financial markets have experienced extreme volatility and disruptions in the past, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Legal, regulatory, political and economic uncertainty surrounding the exit of the U.K. from the European Union may be a source of instability in international markets, create significant currency fluctuations, adversely affect operations in the U.K. and pose additional risks to our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the formal withdrawal arrangements agreed between the U.K. and the EU, the U.K. will be subject to a transition period until December 31, 2020 (Transition Period), during which EU rules will continue to apply.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Negotiations between the U.K. and the EU are expected to continue in relation to the customs and trading relationship between the U.K. and the EU following the expiry of the Transition Period.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Such a withdrawal from the EU is unprecedented, and it is unclear how </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the U.K&#8217;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The uncertainty concerning the U.K&#8217;s legal, regulatory, political and economic relationship with the EU after the Transition Period may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise). It could also lead to a period of considerable uncertainty in relation to the regulatory process for drug development and approval in Europe, and make it more costly or difficult to advance our product candidates in the EU and U.K.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. As a result of our private placements, IPO and other transactions that have occurred in 2018, we may have experienced, an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Reliance on Third Parties</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We rely and will continue to rely on third parties, including Servier, to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us. In addition, we depend on our collaborator, Servier, to sponsor and lead the conduct of the CALM and PALL clinical trials.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (GCPs), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Servier is responsible for UCART19 manufacturing and is working with a CMO in Europe to provide clinical supply for the CALM and PALL clinical trials. Servier has experienced UCART19 supply issues that limited its ability to recruit new patients. ALLO-501, ALLO-501A and ALLO-715 are manufactured in the United States by a CMO, and we will manage all other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. There can be no assurance that we or Servier will not experience additional supply or manufacturing issues in the future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While we have leased space to build a manufacturing facility, we must currently rely on outside vendors to manufacture supplies and process our product candidates. We do not have long-term agreements in place with CMOs for the manufacture of our cell therapies or of ALLO-647.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we are unable to contract with CMOs on acceptable terms or at all, our clinical development program would be delayed and our business would be significantly harmed. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. For instance, our CMO has certain responsibilities for storage of raw materials, and the damage or loss of such raw materials could materially impact our ability to manufacture and supply our product candidates. Each of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We rely on donors of T cells to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unlike autologous CAR T companies, we are reliant on receiving healthy donor material to manufacture our product candidates. Healthy donor T cells vary in type and quality, and this variation makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates, but our screening process may fail to identify suitable donor material and we may discover failures with the material after production. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have strict specifications for donor material, which include specifications required by regulatory authorities. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate specifications, or address variability in donor T cells, there may be inconsistencies in the product candidates we produce or we may be unable to initiate or continue ongoing clinical trials on the timelines we expect, which could harm our reputation and adversely impact our business and prospects. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our product candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and electroporation technology, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. We do not have contracts with many of the suppliers, and we may not be able to contract with them on acceptable terms, or at all. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, many of our suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also face competition for supplies from other cell therapy companies.  Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such qualification, could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Government Regulation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">obtaining regulatory authorization to begin a trial, if applicable;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the availability of financial resources to commence and complete the planned trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">obtaining approval at each clinical trial site by an independent IRB;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">recruiting suitable patients to participate in a trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">addressing any patient safety concerns that arise during the course of a trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">adding new clinical trial sites; or</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">manufacturing sufficient quantities of qualified materials under cGMPs and delivering product candidates for use in clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more of our clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Because we are developing novel CAR T cell immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (OTAT), formerly known as the Office of Cellular, Tissue and Gene Therapies (OCTGT), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Also, the FDA department that reviews ALLO-647 is different than the department that reviews our CAR T cell product candidates. As we are concurrently developing ALLO-647 to be used as part of the lymphodepletion regimen for our CAR T cell product candidates, mapping a path for dual approval of ALLO-647 and any of our CAR T cell product candidates and coordinating concurrent review within the FDA create additional regulatory uncertainty for us and may delay the development of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. In this regard, on May 28, 2014, the EMA issued a recommendation that UCART19 be considered a gene therapy product under Regulation (EC) No 1394/2007 on ATMPs. We believe this recommendation is likely to be </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">applicable to our UCART19 product candidate; however, this recommendation is not definitive until UCART19 obtains regulatory approval for commercialization.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If and when our ongoing and planned Phase 1 clinical trials for UCART19, ALLO-501A and ALLO-715 are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for UCART19, ALLO-501A and ALLO-715 to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative, two-stage, pivotal, multicenter, single-arm clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Given the molecular similarities between UCART19, ALLO-501 and ALLO-501A, we may have additional difficulties progressing any clinical trial of ALLO-501A, if emerging data from the clinical trials of ALLO-501 or UCART19 have safety or other issues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe our accelerated approval strategy is warranted given the limited alternatives for patients with R/R cancers, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ALLO-647 will also require regulatory review prior to its use in new clinical trials and the FDA may not accept the use of ALLO-647 in our clinical trials in a timely manner or at all. In addition, we cannot be certain we will be able to successfully obtain regulatory approval of ALLO-647 in a timely manner or at all. Any delays to ALLO-647 approval could delay any approval or commercialization of our allogeneic T cell product candidates. Additionally, regulatory authorities may seek to understand the contribution of the lymphodepletion regimen, including the use of an anti-CD52 antibody, to any treatment effect.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may seek Regenerative Medicine Advanced Therapy (RMAT) designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">fines, warning letters or holds on clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President&#8217;s administration may impact our business and industry. Namely, the current U.S. President&#8217;s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect physicians in the large bone marrow transplant centers to be particularly important to the market acceptance of our products and we may not be able to educate them on the benefits of using our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the clinical indications for which our product candidates are approved;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the prevalence and severity of any side effects;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">limitations or warnings contained in the labeling approved by the FDA;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the cost of treatment in relation to alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the effectiveness of our sales and marketing efforts.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a covered benefit under its health plan;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">safe, effective and medically necessary;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">appropriate for the specific patient;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">cost-effective; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">neither experimental nor investigational.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. We are still unsure of the full impact that the Affordable Care Act will have on our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There remain legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the U.S. President has signed two Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care Act-mandated health insurance, commonly known as the &#8220;individual mandate&#8221;, as part of the Tax Cuts and Jobs Act of 2017 (Tax Act). In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#8217;s mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018 (BBA), among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In December 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2029, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President&#8217;s administration&#8217;s budget proposal for fiscal year 2020 contains further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current U.S. President&#8217;s administration released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While some of these and other measures may require additional authorization to become effective, Congress and the current U.S. President&#8217;s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:&#8232;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to set a price that we believe is fair for our products;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the availability of capital.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We depend substantially on our license agreements with Pfizer, Servier and Cellectis. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">harm our ability to commercialize our product candidates. For example, we are dependent on our license with Cellectis for gene-editing technology that is necessary to produce our engineered T cells. In addition, we are reliant on Servier in-licensing from Cellectis some of the intellectual property rights they are licensing to us, including certain intellectual property rights relating to UCART19, ALLO-501 and ALLO-501A. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have an exclusive collaboration with Servier to develop and commercialize UCART19, ALLO-501 and ALLO-501A, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier gives us access to TALEN gene-editing technology for all product candidates under the Servier Agreement. Certain intellectual property which is covered by these agreements may have been developed with funding from the U.S. government. If so, our rights in this intellectual property may be subject to certain research and other rights of the government.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">if and when patents will issue;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties relating to certain CAR compositions of matter and their methods of use. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when UCART19, ALLO-501A, ALLO-715 or another CAR-based product candidate is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Ownership of Our Common Stock</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prior to our IPO in October 2018, there was no public market for our common stock. We cannot assure you that an active, liquid trading market for our shares will develop or persist. You may not be able to sell your shares quickly or at a recently reported market price if trading in our common stock is not active. The trading price of our common stock following our IPO has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the commencement, enrollment or results of our ongoing and planned clinical trials of our product candidates or any future clinical trials we or Servier may conduct, or changes in the development status of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our or Servier&#8217;s decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">adverse results or delays in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our failure to commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">adverse developments concerning the manufacture or supply of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our inability to establish collaborations if needed;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">additions or departures of key scientific or management personnel;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates or pre-conditioning regimen;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">introduction of new products or services offered by us or our competitors;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to effectively manage our growth;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the size and growth of our initial cancer target markets;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to successfully treat additional types of cancers or at different stages;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">actual or anticipated variations in quarterly operating results;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our cash position;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in the market valuations of similar companies;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">overall performance of the equity markets;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">sales of our common stock by us or our stockholders in the future;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">trading volume of our common stock;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in accounting practices;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">ineffectiveness of our disclosure controls or internal controls;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">disagreements with our auditor or termination of an auditor engagement;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in the structure of healthcare payment systems;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">significant lawsuits, including patent or stockholder litigation;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">general political and economic conditions; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">other events or factors, many of which are beyond our control.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We currently anticipate that we will retain any future cash flow or earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to various compliance initiatives.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), which requires, among other things, that we file with the Securities and Exchange Commission (SEC) annual, quarterly and current reports with respect to our business and financial condition.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies are permitted to implement many of these requirements over time, however we are no longer an emerging growth company as of December 31, 2019 and expect to incur additional compliance-related expenses as a result. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect the rules and regulations applicable to public companies to continue to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations make it difficult and expensive for us to maintain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Failure to comply with the rules and regulations applicable to us could have serious consequences, including civil and criminal penalties. In addition, our reputation and our ability to raise additional capital would be harmed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the 2018 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. For instance, we have sold equity securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">through at-the-market offerings</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and may do so in the future. We may also sell our common stock as part of entering into strategic alliances, creating joint ventures or collaborations or entering into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the 2018 Plan, our management is authorized to grant stock options and RSU awards to our employees, directors and consultants. We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. Additionally, the number of shares of our common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year and continuing through and including January 1, 2028, by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have broad discretion in the use of our cash reserves and may not use them effectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our management has broad discretion in the application of our cash reserves. A number of factors will determine the ultimate use of our cash reserves, and our management may not be able to apply these funds effectively. Pending their use, we may invest these funds in short-term, investment-grade, interest-bearing securities, which may not yield a favorable return and may lose value.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_22"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1B. Unresolved Staff Comments.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_25"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Properties.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our corporate headquarters are located in South San Francisco, California, which consists of approximately 68,000 square feet for office and laboratory space. The lease for our headquarters commenced March 1, 2019 and has an initial 10-year term expiring on June&#160;15, 2023. We entered into an additional lease in October 2018 for approximately 14,943 square feet of office and laboratory space in South San Francisco near our headquarters. This lease has an initial term of ten years and four months and commenced on November&#160;1, 2018.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. The lease has an initial term of 15 years and eight months. We expect the lease to commence in March 2020.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our existing facilities and other available properties will be sufficient for our needs for the foreseeable future.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_28"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Legal Proceedings.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_31"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_34"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_37"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#8220;ALLO&#8221; since October 11, 2018. Prior to that date, there was no public trading market for our common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Holders of Common Stock</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of February&#160;27, 2020, there were approximately 74 holders of record of our common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock Performance Graph</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or incorporated by reference into any of our filings under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following graph shows the value of an investment of $100 from October 11, 2018 (the date our common stock commenced trading on The Nasdaq Global Select Market) through December 31, 2019, in our common stock, the Standard&#160;&amp; Poor&#8217;s 500 Index (S&amp;P 500), the Nasdaq Biotechnology Index, and Nasdaq Composite Index. The historical stock price performance of our common stock shown in the performance graph is not necessarily indicative of future stock price performance. </span></div><div style="text-indent:45pt;text-align:center;margin-top:12pt;"><img src="allo-20191231_g15.jpg" alt="allo-20191231_g15.jpg" style="height:336px;width:604px;"/></div><div style="text-align:center;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"></td><td style="width:21.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.110%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative Total Return date ended</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/11/2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/31/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S&amp;P 500</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Biotechnology</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Composite</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Dividend Policy</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Proceeds from Initial Public Offering of Common Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, we completed our initial public offering, and sold 18,000,000 shares of our common stock at a price of $18.00 per share pursuant to registration statements on Form S-1 (File Nos.&#160;333-227333 and 333-227774) that were declared or became effective on October 10, 2018. Additionally, the underwriters exercised their option to purchase additional shares for an additional 2,700,000 shares at $18.00 per share. As a result of our IPO, we raised a total of approximately $343.3 million in net proceeds after deducting underwriting discounts and commissions of $26.1 million and offering expenses of $3.2 million. Upon completion of our IPO, (1)&#160;all outstanding shares of our Series A convertible preferred stock, were converted into 61,655,922 shares of common stock and, (2)&#160;we issued 7,856,176 shares of common stock as a result of the automatic conversion of the $120.2 million aggregate principal amount of convertible promissory notes sold in September 2018.&#160;&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt, the net proceeds from our IPO were held in cash, cash equivalents and investments. As of December 31, 2019, we have not used any of the net proceeds from our IPO. The net proceeds from our IPO will be used, together with our cash and cash equivalents, short-term and long-term investments, to fund continued advancement of our product pipeline, with the balance to be used to fund working capital and other general corporate purposes, which may include licensing, acquiring or investing in complementary businesses, technologies, products or assets.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_40"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6. Selected Financial Data.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The selected statements of operations and comprehensive loss data for the periods presented and the selected balance sheet data as of the dates presented are derived from our financial statements appearing elsewhere in this Annual Report.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our historical results are not necessarily indicative of the results that can be expected in the future. The selected historical financial data below should be read in conjunction with the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and related notes appearing elsewhere in this Annual Report.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period from November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statements of operations and comprehensive loss data:</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,842&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202,008)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192,842)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (expense) income, net:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible note payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other (expense) income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,780)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,925)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,594)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,505)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(183,755)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,199)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to common stockholders-basic and diluted &#185;</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.83)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.31)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average number of common shares used in net loss per share applicable to common stockholders basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,061,149&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,948,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,249,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#185; See the statements of operations and comprehensive loss and Note 17 to our financial statements for further details on the calculation of net loss per share, basic and diluted, and the weighted-average number of shares used in the computation of the per share amounts.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.678%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance sheet data:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">588,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">721,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital &#178;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">511,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">438,523&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">717,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,691&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(396,122)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,528)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">703,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#178; We define working capital as current assets less current liabilities. See our financial statements for further details regarding our current assets and current liabilities.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_43"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with &#8220;Selected Financial Data&#8221; and the historical consolidated financial statements and the notes thereto included in &#8220;Financial Statements and Supplementary Data&#8221;. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the &#8220;Risk Factors&#8221; section of this Annual Report. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_46"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. In collaboration with Servier, we are developing UCART19, ALLO-501 and ALLO-501A, CAR T cell product candidates targeting CD19. Servier is sponsoring two Phase 1 clinical trials of UCART19 in patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL), one for adult patients (the CALM trial) and one for pediatric patients (the PALL trial). </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are sponsoring a Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R non-Hodgkin lymphoma (NHL). We expect to report initial data from the trial in the second quarter of 2020. We plan to use the clinical data from ALLO-501 to accelerate the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. In December 2019, the FDA cleared our IND to initiate a Phase 1/2 clinical trial for ALLO-501A (the ALPHA2 trial) and we plan to initiate the trial in the second quarter of 2020, subject to completing the manufacturing of ALLO-501A. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the FDA cleared our IND to initiate a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715, an allogeneic CAR T cell product candidate targeting B-cell maturation antigen (BCMA), in adult patients with R/R multiple myeloma. The UNIVERSAL trial was initiated in the third quarter of 2019 and is ongoing. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have had significant operating losses. Our net loss was $184.6 million for the year ended December 31, 2019. As of December 31, 2019, we had an accumulated deficit of $396.1 million. As of December 31, 2019, we had $588.9 million in cash and cash equivalents and investments. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_49"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Research Development and License Agreements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, we entered into an Asset Contribution Agreement (Pfizer Agreement) with Pfizer pursuant to which we acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis and Servier as described below, and other intellectual property for the development and administration of CAR T cells for the treatment of cancer. See Notes&#160;6 and 7 to our financial statements included elsewhere in this report for further description of the Pfizer Agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2014, Pfizer entered into a Research Collaboration and License Agreement with Cellectis S.A. (Cellectis). In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In March 2019, we terminated the agreement with Cellectis and entered into a new license agreement with Cellectis. See Note 7 to our financial statements included elsewhere in this report for further descriptions of the prior agreement with Cellectis and the new license agreement with Cellectis.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Exclusive License and Collaboration Agreement With Servier</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2015, Pfizer entered into an Exclusive License and Collaboration Agreement (Servier Agreement) with Servier to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR products, including UCART19, in the United States with the option to obtain the rights over certain additional allogeneic anti-CD19 CAR product candidates. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. See Note 7 to our financial statements included elsewhere in this report for further description of the Servier Agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration and License Agreement with Notch</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, we entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted us an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in NHL, ALL and multiple myeloma. In addition, Notch has granted us an option to add certain specified targets to our exclusive license in exchange for an agreed upon per-target option fee.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to our exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. In connection with the execution of the Notch Agreement, we made an upfront payment to Notch of $10.0 million. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. See Note 7 to our financial statements included elsewhere in this report for further description of the Notch Agreement.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_52"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transition Services Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the closing of the Pfizer Agreement, we entered into a Transition Services Agreement (TSA) with Pfizer in April 2018, pursuant to which we obtained from Pfizer certain (i) research and development services, including services relating to testing, studies, and clinical trials, project management services, laboratory equipment and operations services, animal care services, data storage services and regulatory strategy services, and (ii) general and administrative services, including business technology services, compliance services, finance/accounting services, and procurement, manufacturing and supply chain services, with respect to the assets that we purchased from Pfizer. Under the TSA, Pfizer also provided us with certain facilities and facility management services. The services were provided by certain employees of Pfizer as independent contractors of Allogene. We believe that it was helpful for Pfizer to provide such services to us under the TSA to help facilitate the efficient operation of our business after the asset purchase. Pfizer began providing the services in May 2018 and the TSA was terminated in September 2019.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_55"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Components of Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, our research and development expenses have related primarily to discovery efforts, preclinical and clinical development, and manufacturing of our product candidates. Research and development expenses for the year ended December&#160;31, 2019 included costs associated with our clinical and preclinical stage pipeline candidates and research into newer technologies. The most significant research and development expenses for the year relate to costs incurred for the development of our most advanced product candidates, UCART19, ALLO-501, ALLO-501A and ALLO-715, which include:</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expenses incurred under agreements with our collaboration partners and third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">costs related to the production of clinical materials, including fees paid for raw materials and to contract manufacturers;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies; and</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">other significant research and development costs include overhead costs.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expense all research and development costs in the periods in which they are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of the project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, milestone payment obligations are expensed when the milestone results are achieved.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are required to reimburse Servier for 60% of the costs associated with the development of UCART19, including for the CALM and PALL clinical trials. We accrue for costs incurred by monitoring the status of the CALM and PALL clinical trials and the invoices received from Servier. We adjust our accrual as actual costs become known. Servier is required to reimburse us for 40% of the costs associated with the development of ALLO-501 and ALLO-501A. Collaboration expenses and cost reimbursement are recorded on a net basis as a research and development expense in our statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase in the future as&#160;our UCART19, ALLO-501, ALLO-501A and ALLO-715 clinical programs progress and as we seek to initiate clinical trials of additional product candidates. The cost of advancing our manufacturing process as well as the cost of manufacturing product candidates for clinical trials are included in our research and development expense. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">per patient trial costs;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">biomarker analysis costs;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost and timing of manufacturing for the trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of patients that participate in the trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of sites included in the trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the countries in which the trials are conducted;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the length of time required to enroll eligible patients;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the total number of cells that patients receive;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the drop-out or discontinuation rates of patients;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the duration of patient follow-up; and</span></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the efficacy and safety profile of the product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the case of UCART19, we are also dependent on Servier&#8217;s ability to manage the CALM and PALL clinical trials. In addition, the probability of success for each product candidate will depend on numerous factors, including safety, efficacy, competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because our product candidates are still in clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative&#8232;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist primarily of salaries and other staff-related costs, including stock-based compensation for options and restricted stock units granted. General and administrative expenses also include stock-based compensation expense related to the modification of shares of common stock issued to our founders to include vesting conditions. Other significant costs include costs relating to facilities and overhead costs, legal fees relating to corporate and patent matters, insurance, investor relations costs, fees for accounting and consulting services, information technology, and other general and administrative costs. General and administrative costs are expensed as incurred, and we accrue for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from our service providers, and adjusting our accruals as actual costs become known.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, potential commercialization of our product candidates and the increased costs of operating as a public company, including additional compliance-related expenses as a result of no longer being an emerging growth company. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other (expense) income, net: </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of 2018 Notes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In September 2018, we sold and issued an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV81NS9mcmFnOjJiOGI1OTdhZjI5YjQxOTY5ZDNiMGQ0MjY0OTAxOTgxL3RleHRyZWdpb246MmI4YjU5N2FmMjliNDE5NjlkM2IwZDQyNjQ5MDE5ODFfMzg0ODI5MDcxNDA2Nw_9022b838-e7d1-4b8c-9008-dbd2d0bdffab">120.2</ix:nonFraction> million in convertible promissory notes (2018 Notes) and received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV81NS9mcmFnOjJiOGI1OTdhZjI5YjQxOTY5ZDNiMGQ0MjY0OTAxOTgxL3RleHRyZWdpb246MmI4YjU5N2FmMjliNDE5NjlkM2IwZDQyNjQ5MDE5ODFfMzg0ODI5MDcxNDA4Mw_fefa648b-fb02-4290-ac22-651f795c6d63">116.8</ix:nonFraction> million. We elected on issuance to account for the 2018 Notes at fair value until their settlement. In the prior reporting period, the change in fair value of the 2018 Notes was recognized through the statement of operations. The 2018 Notes settled on the closing of our IPO in October 2018.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense consists of debt issuance costs we incurred to issue the 2018 Notes. The debt issuance costs were expensed on issuance because we elected to record the 2018 Notes at fair value.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest and Other Income, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net consists of interest earned on our cash equivalents and investment gains and losses recognized during the period.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other expense consists of non-operating expenses, including our share of equity investments' net losses for the period.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_58"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the period from November 30, 2017 (inception) to December 31, 2017, we incurred $2,000 in start-up costs to establish our company. Principal operations commenced in April 2018 when we acquired certain assets from Pfizer and completed a Series A and A-1 preferred stock financing.  Due to our limited operations in 2017, the following discussion does not contain a comparison of the results of operations for the period from November 30, 2017 (inception) to December 31, 2017.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Years Ended December 31, 2019 and 2018</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following sets forth our results of operations for the years ended December 31, 2019 and 2018 (in thousands):</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.970%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,325)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,842&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,166&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202,008)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192,842)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,166)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (expense) income, net:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible note payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,358&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,780)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,925)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,594)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,505)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses were $144.5&#160;million and $151.9 million for the years ended December 31, 2019 and 2018, respectively. The net decrease of $7.3 million in research and development expenses during this period was primarily due to $109.4 million in expenses related to the acquired in-process research and development assets with no alternative future use, acquired from Pfizer in April 2018. This was offset by a $102.1 million increase, driven primarily by increased external costs related to the advancement of our pipeline candidates of $44.6 million, increased personnel related costs of $40.8 million,  including an increase of $18.0 million in stock-based compensation expense,  and increased allocated building rent and facilities costs of $19.2 million, offset by a decrease of $4.0 million in Pfizer TSA costs. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses were $57.5 million and $41.0 million for the years ended December 31, 2019 and 2018, respectively. The net increase of $16.5 million was primarily due to a $18.6 million increase in personnel related costs, including an increase of $9.7 million in stock-based compensation expense, and increased legal and professional services of $2.7 million. This was offset by a $5.1 million decrease due to a greater proportion of facilities costs being allocated to research and development expenses and a $1.5 million decrease in expenses incurred under the Pfizer TSA.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of 2018 Notes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in fair value of convertible notes was zero and $21.2 million for the years ended December 31, 2019 and 2018, respectively. The decrease of $21.2 million was due to the accretion of the 2018 Notes to their fair value from the date of issuance at $120.2 million to the fair value upon settlement of $141.4 million which occurred in 2018. There was no comparative transaction in the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense of $3.4&#160;million for the year ended December 31, 2018 consists of debt issuance costs that were expensed on issuance of the 2018 Notes. There was no comparative transaction in the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest and Other Income, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net was $17.4 million and $5.8&#160;million for the years ended December 31, 2019 and 2018 respectively. The $11.6 million increase was due to interest earned on our cash equivalents and investments as our combined cash, cash equivalents and investments interest earning balance was higher on average during the 12 months ended December 31, 2019 compared to the 12 months ended December 31, 2018.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_61"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity, Capital Resources and Plan of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have incurred significant net losses and negative cash flows from operations. As of December 31, 2019, we had $588.9 million in cash, cash equivalents and investments. We believe that the aggregate of our current cash and cash equivalents and investments available for operations will be sufficient to fund our operations for at least the next 12 months from the date this Annual Report on Form 10-K is filed with the SEC.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">operations have been financed primarily by net proceeds from the sale and issuance of our convertible preferred stock, the issuance of the 2018 Notes and net proceeds from our IPO. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In connection with our IPO in 2018, we sold an aggregate of 20,700,000 shares of our common stock (inclusive of 2,700,000 shares of common stock pursuant to the over-allotment option granted to the underwriters) at a price of $18.00 per share and received approximately $343.3 million in net proceeds. In November 2019, we entered into a sales agreement with Cowen and Company, LLC (Cowen) under which we may from time to time issue and sell shares of our common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0 million. From November 2019 to December 31, 2019, we sold an aggregate of 1,965,082 shares of common stock in ATM offerings resulting in net proceeds of $54.2 million, after deducting commissions and offering costs of $1.6 million.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capital Resources</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary use of cash is to fund construction projects for our manufacturing facility and operating expenses, which consist primarily of clinical manufacturing and research and development expenditures related to UCART19, ALLO-501, ALLO-501A and ALLO-715; other research efforts; and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are still in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain.&#160;&#160;Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. If, and when, we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.245%;"><tr><td style="width:1.0%;"></td><td style="width:67.642%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.880%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.395%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(137,350)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,653)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(632,798)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">771,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase in cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2019, cash used in operating activities of $137.4 million was attributable to a net loss of $184.6 million, substantially offset by non-cash charges of $54.1 million and a net change of $6.9 million in our net operating assets and liabilities. The non-cash charges consisted primarily of stock-based compensation of $46.1 million, non-cash rent expense of $6.8 million and depreciation and amortization of $4.4 million, offset by net amortization and accretion on investment securities of $3.6 million. The net change in operating assets and liabilities was primarily due to a $6.4 million increase in accrued and other current liabilities, offset by an increase in prepaid expenses and other current assets of $5.4 million, an increase in other long-term assets of $4.4 million and a decrease in other-long term liabilities of $2.4 million. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2018, cash used in operating activities of $44.7 million was attributable to a net loss of $211.5 million, substantially offset by non-cash charges of $154.8 million and a net change of $12.1 million in our net operating assets and liabilities. The non-cash charges consisted primarily of acquired in-process research and development expense resulting from the asset acquisition from Pfizer of $109.4 million, change in fair value of convertible notes payable of $21.2 million and $18.6 million of stock-based compensation. The net change in operating assets and liabilities was primarily due to a $12.1 million increase in accruals and other liabilities driven by increased professional fees and an $8.8 million increase in accounts payable resulting from the timing of payments made to our collaboration partners and Pfizer accrued services. This was partially offset by a $8.6 million increase in prepaid expenses and other current assets and a $0.2 million increase in other long-term assets. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the year ended December 31, 2019, net cash provided by investing activities of $164.1 million was related to proceeds from investment maturities of $472.6 million, offset by cash used for investment purchases of $252.6 million, cash used in purchases of property and equipment of $50.8 million and cash used in connection with our investment in Notch&#8217;s series seed convertible preferred stock of $5.1 million, inclusive of transaction costs. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2018, cash used by investing activities of $632.8 million was related to the purchase of investments of $649.3 million, cash transaction costs of $2.1 million incurred in the asset acquisition from Pfizer and the purchase of property and equipment of $3.2 million. This was offset by cash inflows from maturities of investments of $19.2 million and cash inflows from sales of investments of $2.6 million.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2019, net cash provided by financing activities of $59.0 million was related to net proceeds from the issuance of common stock in ATM offerings of $54.2 million, proceeds from the issuance of common stock upon the exercise of stock options of $3.0 million and proceeds from the employee stock purchase plan of $1.8 million.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2018, cash provided by financing activities of $771.2&#160;million was related to net proceeds of $299.3&#160;million from the issuance of our Series A and A-1 convertible preferred stock, $116.8 million from the issuance of the 2018 Notes, $343.7 million in net proceeds from our IPO and $11.4&#160;million from the issuance of common stock in connection with stock option exercises.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_64"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our commitments and contractual obligations as of December 31, 2019</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.859%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments Due by Period</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021-2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024-2026</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2027 and After</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Obligations:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease obligations &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#185; In August 2018, we entered into an operating lease agreement for our headquarters in South San Francisco. The lease term is 127 months beginning August 2018 through February 2029. In October 2018, we entered into an operating lease agreement for additional office and laboratory space in South San Francisco near our headquarters. The lease has a term of ten years and four months commencing on November 1, 2018. In December 2018, we entered into an operating lease agreement for office space in New York, and another operating lease agreement for office space in Los Angeles. The lease terms are 79 months and 36 months, respectively, with the leases commencing on December 1, 2018 and December 19, 2018, respectively. In February 2019, we entered into a lease agreement for manufacturing space in Newark, California. The lease term is for 188 months beginning October 2019. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commitments primarily consist of obligations under our agreements with Pfizer, Cellectis, Servier and Notch. Under these agreements we are required to make milestone payments upon successful completion of certain regulatory and sales milestones on a target-by-target and country-by-country basis. The payment obligations under the license agreements are </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of December 31, 2019, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we have entered into an agreement with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have a Change in Control and Severance Plan that require the funding of specific payments, if certain events occur, such as a change of control and the termination of employment without cause.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_67"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_70"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the assumptions and estimates associated with accrued research and development expenditures, research and development expenses, stock-based compensation and leases have the most significant impact on our financial statements. Therefore, we consider these to be our critical accounting policies and estimates.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Research and Development Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We accrue liabilities for estimated costs of research and development activities conducted by our collaboration partners and third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. We recorded the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in the accrued and other current liabilities on the balance sheets and within research and development expense on the statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We accrue for these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, we adjust its accrued liabilities. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expense research and development costs as incurred. Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development; is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable alternative future use.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses also include costs incurred for internal and sponsored and collaborative research and development activities. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf. Costs associated with&#160;co-development activities performed under the various license and collaboration agreements, including milestones achieved, are included in research and development expenses.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize compensation costs related to stock-based awards granted to employees and directors, including stock options, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Black-Scholes option-pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include:</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8209;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair value of common stock</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;For grants before October 2018 when we were private and there was no public market for our common stock, the fair value of our common stock underlying share-based awards was estimated on each grant date by our board of directors. In order to determine the fair value of our common stock underlying option grants, our board of directors considered, among other things, valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. For all grants subsequent to our IPO in October 2018, the fair value of common stock was determined by taking the closing price per share of common stock per Nasdaq.</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8209;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Expected term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8209;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Expected volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as we do not have sufficient trading history for our common stock. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8209;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8209;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Expected dividend</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;We have never paid dividends on its common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December 31, 2019 and 2018, stock-based compensation was $46.1 million and $18.6 million respectively. As of December 31, 2019 and 2018, we had $148.6 million and $87.4 million of total unrecognized stock-based compensation relating to options, restricted stock units and founders stock.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We early adopted Accounting Standards Update (ASU) No. 2016-02,&#160;Leases&#160;as of January 1, 2018 in accordance with ASC 250,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Changes and Error Corrections</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;For our long-term operating&#160;leases, we recognized right-of-use assets and lease liabilities on our balance sheet. The lease liabilities are determined as the present value of future lease payments using an estimated rate of interest that we would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.&#160;The right-of-use assets are based on the liability adjusted for any prepaid or deferred rent. For each lease, the lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We elected to exclude from our balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for our long-term real estate leases.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_73"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 2 to our financial statements for a discussion of new accounting standards updates that may impact us.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_76"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cash, cash equivalents and investments of $588.9 million as of December&#160;31, 2019, consist of bank deposits, money market funds and available-for-sale securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. A 10% change in the interest rates in effect on December&#160;31, 2019 would not have had a material effect on the fair market value of our cash equivalents and available-for-sale securities.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Exchange Rate Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaboration agreement with Servier requires collaboration payments for shared clinical development costs to be paid in euros, and thus we face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. An adverse movement in foreign exchange rates could have an effect on payments due and made to our collaboration partner as well as other foreign suppliers and for license agreements. A 10% change in the applicable foreign exchange rates during the periods presented would not have had a material effect on our consolidated financial statements. As of December&#160;31, 2019,  we had $2.4 million of liabilities denominated in foreign currency.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_79"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 8. Financial Statements and Supplementary Data.</span></div><div style="text-indent:27pt;text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the year ended December 31, 2019 and 2018</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:86.286%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_82">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_82">89</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_85">Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_85">91</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_94">Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_94">92</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_97">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_97">93</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_103">Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_103">94</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_106">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_106">95</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_82"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the Stockholders and the Board of Directors of</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div style="text-indent:63pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have audited the accompanying balance sheets of Allogene Therapeutics, Inc. (the Company) as of December 31, 2019 and 2018, the related statements of operations and comprehensive loss, statements of convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for each of the years ended December 31, 2019 and 2018 and the period from November 30, 2017 (inception) to December 31, 2017, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the years ended December 31, 2019 and 2018 and the period from November 30, 2017 (inception) to December 31, 2017, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-indent:63pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 27, 2020 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="text-indent:63pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Audit Matter</span></div><div style="text-indent:63pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-indent:63pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.148%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued Research and Development Costs</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of the Matter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As discussed in Note 1 liabilities are recorded for estimated unpaid costs of research and development activities conducted by the Company and its collaboration partners and third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. Total research and development expenses were $144.5 million during the year ended December 31, 2019 and include the estimated costs of accrued research and development activities for services provided but not yet invoiced. The accrual for these costs is determined after consideration of several factors, including budgets and estimates of the work completed in accordance with agreements established with the Company&#8217;s collaboration partners and third-party service providers. Auditing accrued research and development costs was complex due to significant judgments and estimates made by management in determining the required accruals.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.148%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We obtained an understanding, evaluated the design, and tested the operating effectiveness of relevant controls over the Company&#8217;s determination of accrued research and development costs, including controls over the determination of significant assumptions and the completeness and accuracy of the data used in determining accrued costs.<br/><br/>Our audit procedures included, among others, examining, on a test basis, evidence regarding the estimated accrued amounts through comparison of expenses incurred to budgeted amounts and to expenses incurred in prior periods and obtaining an understanding of the reasons for changes. We verified that accrued amounts were in accordance with key terms and conditions through review of the underlying agreements with the Company&#8217;s collaboration partners and third-party service providers. We verified expenses incurred by obtaining confirmation from the Company&#8217;s collaboration partner and further validated accrued amounts based on information provided by third-party service providers.<br/></span></td></tr></table></div><div style="text-indent:63pt;"><span><br/></span></div><div style="text-indent:63pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have served as the Company&#8217;s auditor since 2018.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Jose, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 27, 2020</span></div><div style="text-align:center;"><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_85"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMy0xLTEtMS0w_d4d68e5b-0205-41a7-abbc-b397ca3692dc">175,126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMy0zLTEtMS0w_3e123dc3-0676-4d16-b8fc-41337405f9b6">92,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNC0xLTEtMS0w_523ee80f-ab1f-48a5-a9f3-bc186268a6ad">355,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNC0zLTEtMS0w_70914674-35b3-4e8a-9891-f836785fae0f">366,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNS0xLTEtMS0w_4f7a2b6e-4d10-4af3-9c56-6a8cf9582127">14,043</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNS0zLTEtMS0w_52918415-903a-4d70-99bf-20a9edab9471">8,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNi0xLTEtMS0w_066ce9da-c71a-463e-a81d-ed6635540ac5">544,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNi0zLTEtMS0w_c6784ef4-d5a6-4b6f-a367-1746d9cc4fd7">467,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNy0xLTEtMS0w_f82cabfa-a1da-4911-a2da-d4864216e54b">58,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNy0zLTEtMS0w_16617bf8-64bc-4626-be55-00bbcc415598">261,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOC0xLTEtMS0w_ac5d4b93-3cb3-4cef-b2b0-d60406acfe1d">44,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOC0zLTEtMS0w_ec7bf0c3-f50f-4653-b996-170e45079c55">33,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOS0xLTEtMS0w_c3088c78-c3ba-41b6-a198-190e64ece667">56,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOS0zLTEtMS0w_16b172c7-2ee1-4421-93c0-caf4949108d6">8,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTAtMS0xLTEtMA_f409c450-97b3-4d00-8f6c-3545c849081b">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTAtMy0xLTEtMA_19425ddf-a079-4e71-9969-0a8d05b0c347">754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTEtMS0xLTEtMA_2b217ba5-73b8-42b3-a4da-5b2fd45cebb8">4,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTEtMy0xLTEtMA_2e8a12fa-34e9-48ab-a0ac-fca628ff653c">1,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTItMS0xLTEtMA_b67ee99a-31fd-498d-a62e-da31ac855075">4,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTItMy0xLTEtMA_bfa2e1ad-2f65-46b4-accc-af7be571a96d">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMS0xLTEtMTQ5Mg_4d5042a8-5124-47d6-96e1-40c5194383f7">4,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMy0xLTEtMTQ5NQ_0662da6e-380c-41ea-984e-d62d3437119e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMS0xLTEtMA_7ae45f27-4745-4ce0-a2c6-284775ffea08">717,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMy0xLTEtMA_e3bf1730-404d-421e-b2e7-8eecc7d99628">773,855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities, convertible preferred stock and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTYtMS0xLTEtMA_462f8959-c957-42b0-bbd7-60ecdd066d4d">9,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTYtMy0xLTEtMA_3bd32363-64ed-403d-8ff3-28d67e6e3283">12,338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTctMS0xLTEtMA_bc0133bf-50b0-4765-8a7f-67976873ed93">23,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTctMy0xLTEtMA_060b9f5d-e693-485e-9305-b1949b0f42e4">17,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTgtMS0xLTEtMA_3cafa5db-816f-4653-8a5a-6095308a082e">33,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTgtMy0xLTEtMA_c41f0adb-50de-4489-b984-95c97ebf0877">29,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTktMS0xLTEtMA_32aa3b84-731f-44ee-a22a-886034457fdf">51,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTktMy0xLTEtNjIw_8834d78f-2491-4f01-a97c-3994dfe49aae">34,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjAtMS0xLTEtMA_f23d0171-3607-4ce4-b448-c05a32a90bd0">4,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjAtMy0xLTEtMA_aa9678de-d2ba-49d0-a24d-ca5fb5daf91e">6,776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjEtMS0xLTEtMA_d12d3c39-2e15-4b88-a8d0-34b7432b1077">88,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjEtMy0xLTEtMA_b163c89d-287e-4f39-8874-4282b30235ed">70,691</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies (Notes 6, 7 and 8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjItMS0xLTEtMA_55ce3590-b4f0-4500-9dba-4ee29b22ab78"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjItMy0xLTEtMA_b07f95b9-3af6-48a3-8013-56f59999514a"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2019 and December 31, 2018, respectively; no shares were issued and outstanding as of December 31, 2019 and December 31, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjUtMS0xLTEtMA_72207e99-fe11-4fdd-8817-7aa673d66fc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjUtMy0xLTEtMA_e4b77cf9-5c13-4ee8-b1b8-62ad0d0cf9fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $0.001 par value: 200,000,000 authorized as of December 31, 2019 and December 31, 2018; 124,267,358 and 121,482,671 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjYtMS0xLTEtMA_daf652be-0d3e-42f8-84ce-2d41107b5816">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjYtMy0xLTEtMA_1d09363f-9014-457c-b283-cc9e120e9705">121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjgtMS0xLTEtMA_f910f39e-8503-44c5-b22b-29859daf1983">1,023,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjgtMy0xLTEtMA_ea326ef3-15ee-4a9a-bbd5-3bbbaec9718d">914,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjktMS0xLTEtMA_7ecc802b-0890-4c77-9051-5a6d7bc8e09b">396,122</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjktMy0xLTEtMA_b7aa2496-c965-4cff-b279-c8ce5669d4c5">211,528</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzAtMS0xLTEtMA_8ff51377-f904-40c7-a27c-24c5d1db7558">1,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzAtMy0xLTEtMA_403baee9-b0f4-4fe2-9e3c-f20ff641e57b">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzEtMS0xLTEtMA_3fdf8ed0-0e8c-4860-8bd6-767388c68c3b">629,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzEtMy0xLTEtMA_11aa066c-2d6c-4fdc-afac-57845c3ae9f1">703,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzItMS0xLTEtMA_ee72ae0e-370d-412d-ac57-fa90a5dcaa6e">717,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzItMy0xLTEtMA_27de7aa6-4263-4eb7-bb96-ad4e1d38160b">773,855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_94"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:51.508%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.058%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.058%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.062%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period from November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0xLTEtMS03MjM_e0391cad-96f0-4a73-ba52-fa0512c83085">144,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0xLTEtMS0w_02102a47-22b7-4a07-823e-083d632bdf1f">151,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0zLTEtMS0w_3cbef4b7-e1f1-4611-8aca-12167501a0a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0xLTEtMS03MjM_34d70ea1-84e1-4ba1-9417-175802cae8ba">57,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0xLTEtMS0w_75e4c2fa-4b53-41b7-a2d7-4496139094d9">40,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0zLTEtMS0w_f83b305e-7ab4-45e8-87d9-29990ee503a4">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0xLTEtMS0zMDY_caae18ae-28c2-4d58-b4b7-e0d61c5f6a9e">202,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0xLTEtMS0w_f6b5e8b2-e948-43e9-901f-5f723604c2dd">192,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0zLTEtMS0w_8b079d46-ad05-4eeb-a5f3-1809333d4157">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0xLTEtMS0zMDY_aca6a86f-e19b-4ce0-8ade-381dba4195e0">202,008</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0xLTEtMS0w_9274f9d0-8bbb-48bf-ae5c-c920abb769fd">192,842</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0zLTEtMS0w_9262710f-d1da-43e3-8f16-be8e94022772">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible note payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0xLTEtMS03MjM_225990fd-4492-4d21-a191-bea9ebb6abd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0xLTEtMS0w_869b532b-3d07-4d10-991d-4bfe1bf49088">21,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0zLTEtMS0w_bfb05cdd-1811-4a4d-a0a2-3522134bb29d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0xLTEtMS03MjM_48acede7-9086-43d5-94d8-c3467bce7917">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0xLTEtMS0w_4fd0fad8-f43b-440b-b323-379d1c712df8">3,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0zLTEtMS0w_220f9363-3a3a-49b7-9e1a-d881cdfc0724">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0xLTEtMS03MjM_6579b4bd-a5c8-464c-af03-eed376871ce4">17,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0xLTEtMS0w_c6570a91-4d8d-4946-b843-a19d866dbd59">5,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0zLTEtMS0w_449afd1f-25b4-438a-be3f-159ec3476ae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMTYzMA_5b3bca8d-fd46-4ca7-9ea7-88e66a7ea8aa">268</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMy0xLTEtMTYzNg_b3c181c5-4174-4134-85cf-d8f38dd1eaca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtNS0xLTEtMTY0MQ_ba2637b0-4d73-4796-b5c9-3cc66787c972">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMS0xLTEtMzA2_2eb287cd-9606-40e1-a0fa-11f7a6da0e0d">17,083</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMS0xLTEtMA_50b2a7dd-4b61-49a9-8506-22e31bea0d82">18,780</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMy0xLTEtMA_b65fb0dc-2229-441d-a599-bc633c5aafc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMzA2_32122f0c-a005-4a43-bf84-746a8c5c5191">184,925</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMA_ff1bee91-67e8-4990-a847-0105ab71d248">211,622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMy0xLTEtMA_28ea006c-d863-4c97-8c62-9bab8c5a3ffc">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMS0xLTEtNzIz_3676ac77-fbe0-4ee4-983c-0517280469d7">331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMS0xLTEtMA_3e8272f7-f16f-4efe-8e91-3a85aa6bca1a">117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMy0xLTEtMA_494abe85-58b2-4c4f-bae4-b8c9a8922fba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMS0xLTEtMzA2_8b541334-1d3c-4642-8903-2f030d0586dc">184,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMS0xLTEtMA_eb5d8e8d-c3e9-40d3-83fc-40abc11c355c">211,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMy0xLTEtMA_df73949a-6dfb-4835-9ea7-f39fa83135e3">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized gain on available-for-sale investments, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMS0xLTEtNzIz_b7314dc6-3491-4751-aa6d-c92bbdb96018">839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMS0xLTEtMA_65f276d1-166c-4d9c-9068-87d0169c02f5">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMy0xLTEtMA_00bccda5-cc47-4cb8-9756-5b52b1f1486b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMS0xLTEtMzA2_16239e63-12df-42cc-a40b-9a2a826cafe7">183,755</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMS0xLTEtMA_0ea3b0db-5657-46ab-baea-991ae050e104">211,199</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMy0xLTEtMA_377a001d-8752-4e45-a859-f58ebbac3d3e">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMS0xLTEtNzIz_1e00bcf6-e969-4ca9-a3a7-86c894445e2b">1.83</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMS0xLTEtMA_21473459-b8ac-45af-8b8e-c0c42854547d">7.31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMy0xLTEtMA_0217b1dc-4a38-4315-a7bd-99575b11ef3b">0.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average number of shares used in computing net loss per<br/>share, basic and diluted </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMS0xLTEtNzIz_bf8b1058-aad0-4f2b-8969-2fb1b9aa0e31">101,061,149</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMS0xLTEtMA_df607a9f-ec1d-493e-a4dc-c7c6611cddf3">28,948,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMy0xLTEtMA_60c5e074-398c-4248-b569-34ceb57e205f">26,249,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_97"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">92</span></div></div></div><hr style="page-break-after:always"/><div style="height:23.22pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.346%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.034%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.467%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.034%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.792%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.359%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.116%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.689%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A Convertible<br/>Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subscriptions<br/>Receivables<br/>from<br/>Preferred<br/>Stockholders</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notes<br/>Receivable<br/>from&#160;Common<br/>Stockholders</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity&#160;(Deficit)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Balance &#8212; November 30, 2017 (Inception)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i99decb5567534b8497dffa86e0b1023e_I20171129" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xLTEtMS0w_3a74e5db-d15a-4278-a76f-ca24ab7a0ae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99decb5567534b8497dffa86e0b1023e_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0zLTEtMS0w_9b99029f-883f-44f4-981f-28b44a4c7d5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3201ab4ab1724c7ea1125d924e0873ff_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi01LTEtMS0w_6d7db709-e2ae-49f8-96b4-4d558845d859">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i84465143443f4cf0ad45c2485bf6f687_I20171129" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi04LTEtMS0w_b08b12e1-6543-4fba-b2f7-b1198a989557">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84465143443f4cf0ad45c2485bf6f687_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xMC0xLTEtMA_33e6912f-51b5-4c9d-a904-a38a95e2fb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i450d417e37254e0ab2024cc5cdb97eeb_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xMi0xLTEtMA_bcf10dbd-6cda-41be-8a93-7cefa8debf80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbe813e0d64c4e969856a6e3723ab181_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xNC0xLTEtMA_f16cefa0-17c1-46f1-8dba-4de4cbbcbee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ed9b242005d4eda9f7a3d5117e787a4_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xNi0xLTEtMA_3e239318-34d9-41b1-8dad-dcba7f4af1cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia97c507021ed4124b41826a307eef5b4_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xOC0xLTEtMA_4e6ceadb-b4ae-4b08-8e0d-90bf4899e52b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic178392ea1bb4a2d8265ba3c454059e5_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0yMC0xLTEtMA_4c717147-8057-4286-a5e6-f0f4da8d020c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy04LTEtMS0w_03e2d4d6-3c01-4b44-9056-51c6725b45b3">26,249,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0xMC0xLTEtMA_08a487fb-64fc-4afe-b008-98d93b1a78be">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0xNi0xLTEtMA_dade7612-257a-43ff-9568-e1e6d58229ea">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0yMC0xLTEtMA_e7026d0f-653e-4b3b-81d8-8fec595c6fa4">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Notes receivable from common stockholders</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5a7717940ad443ac959da4945a7df7df_D20171130-20171231" decimals="-3" name="allo:NotesReceivableFromCommonShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNC0xMi0xLTEtMA_851b7626-98ea-458a-831e-1434dc70d4c6">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" name="allo:NotesReceivableFromCommonShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNC0yMC0xLTEtMA_12fbddb4-e34c-4385-ac9b-62d227b899a2">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNS0xNi0xLTEtMA_6644f228-b2ae-47ff-ae94-462d9e1970d1">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNS0yMC0xLTEtMA_46175fc6-397d-4976-96e1-64d63642061b">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance &#8212; December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xLTEtMS0w_db600994-309c-449f-ad0d-ff369148e183">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0zLTEtMS0w_bd0d77d5-4483-4364-b091-98fe30485cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8da636562f1e4692894fbc13c7c7b15c_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi01LTEtMS0w_350cd115-1d0d-4488-a6a9-e4f09ceb80d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi04LTEtMS0w_cdaa8eb7-683e-4df4-89b1-5318210108e7">26,249,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xMC0xLTEtMA_f2fa78ce-d761-4339-bcf5-341f32e60b13">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9a3039ba156d4b1da1b438ddb91e2eda_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xMi0xLTEtMA_ef513294-8f19-4da4-a3cb-971f5251b61b">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371f0794baf348b8a900545a9f712728_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xNC0xLTEtMA_f055fb4f-21fc-4f69-a418-dabbcbc910f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idd581e624e4c4c0ca42cf1cf3eaa1f3f_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xNi0xLTEtMA_7dc239c9-b2a2-4afb-9eb3-f143d3f8ec0e">23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c398c33948642ec8719c3f9f261004c_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xOC0xLTEtMA_d4e0b3fb-f346-4017-9c74-7a7f7f9a5807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0yMC0xLTEtMA_f809f191-a8b4-4509-ac60-e9250443cf36">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance&#160;costs of $635</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNy0xLTEtMS0w_b41d99da-3682-4707-9837-93cb8a974820">7,557,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNy0zLTEtMS0w_56b4adc4-18a6-4040-885e-a6f5e1d1fc00">264,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOC0xLTEtMS0w_36f43ef4-bc0f-4ab1-90a8-72f114ddb050">3,187,772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOC0zLTEtMS0w_14d35912-13a8-43a7-9795-7779b121bd39">111,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of Series A-1 convertible preferred shares at $35.06 per share, net of issuance costs of $84</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOS0xLTEtMS0w_a37c3a38-247c-40df-8d7b-ff3eac3df491">998,225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOS0zLTEtMS0w_bc5ce861-0eb0-40a5-91c1-3ce4a8b49db0">34,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Proceeds received from common stockholders for issuance of founders' stock at inception</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idfdd74767fd7438889e77589cf703193_D20180101-20181231" decimals="-3" name="allo:StockIssuedDuringPeriodValueCommonStockIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTAtMTItMS0xLTA_dea784c6-44ce-4748-bdeb-1c2484bbbb6f">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="allo:StockIssuedDuringPeriodValueCommonStockIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTAtMjAtMS0xLTA_ee8ed7a8-592f-4e72-8ab2-1f3668f7d5c5">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Subscriptions receivable from preferred stockholders</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:SubscriptionsReceivableFromPreferredStockholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTEtNS0xLTEtMA_6c76c887-7311-4c9b-96bc-e46fc3821474">150,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:SubscriptionsReceivableFromPreferredStockholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTEtMjAtMS0xLTA_0e861dbd-3ecd-4a4c-bf57-2b4f298a6413">150,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Proceeds received from preferred stockholders</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:StockIssuedDuringPeriodValuePreferredStockIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTItNS0xLTEtMA_8853323d-3d9f-4467-83cf-869cbd525b22">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:StockIssuedDuringPeriodValuePreferredStockIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTItMjAtMS0xLTA_03d2ef3e-46f4-4ec9-826c-0293f36e038b">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of common stock for early exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtOC0xLTEtMA_f6b0b8eb-d66c-4ce0-8555-8986e8ee3b7c">5,020,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtMTAtMS0xLTA_c7817d69-add3-4576-b70f-13353f9c8ae7">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtMjAtMS0xLTA_8a6abc56-6555-480e-9a90-a49af7abdfc1">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of common stock upon initial public offering, net of issuance costs of $29,272</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtOC0xLTEtMA_0c10c4be-cd37-4a9f-a642-f0390c814182">20,700,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMTAtMS0xLTA_14d9d5de-1520-476c-aeac-ac372a28c9ff">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib660932f6bce4ad6b6fba62272a8c8a4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMTQtMS0xLTA_b423db72-3040-4d9e-a486-226d4d1cbad0">343,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMjAtMS0xLTA_a831a2d7-12f3-4f0e-8ec0-6842d78f3e3b">343,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Conversion of Series A convertible preferred stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMS0xLTEtMA_ce88729f-6726-4cd1-b9ae-5b3204247f03">11,743,987</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMy0xLTEtMA_697797e7-8f5c-467d-96cc-440b7fe91a95">411,052</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtOC0xLTEtMA_deee3474-65bc-468e-ae4a-27cf99819136">61,655,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMTAtMS0xLTA_d8c6ff08-ca2b-4043-8dea-4016f80840ac">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMTQtMS0xLTA_422d612e-9d96-4334-afab-b86a565f3792">410,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMjAtMS0xLTA_6fefb1df-c062-4251-9454-a566ab7efbe5">411,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of common stock upon conversion of convertible notes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtOC0xLTEtMA_c97a7405-0dea-4b39-b6c6-e50f030932c4">7,856,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMTAtMS0xLTA_c1a4ea3f-8093-466a-b036-08eb843c97c8">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMTQtMS0xLTA_f89976ab-da6d-4bb3-b306-29a34a59fb40">141,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMjAtMS0xLTA_b44dd25e-4f04-4c55-a3af-41440af848e5">141,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Adjustment for fractional shares from forward stock split</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTctMTQtMS0xLTA_92e3fc0d-c72e-41cb-a6d6-7a983703a7bf">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTctMjAtMS0xLTA_6025b47e-c676-4cf2-92e4-399f5357ca2f">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTgtMTQtMS0xLTA_8314e294-ab75-4ad3-bce4-22eb2a48f02c">18,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTgtMjAtMS0xLTA_ed276a47-7e34-462d-9344-e1a048141b4c">18,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if03e9aad02914725a696c4b00ae00db6_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTktMTYtMS0xLTA_5cae7d8e-546d-4069-acc5-afedcb3d52e5">211,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTktMjAtMS0xLTA_380c314a-3079-4cbb-b1c2-fbe3d4913481">211,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Net unrealized gain on available-for- sale investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i824f05079e344862807f10de3ec47704_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjAtMTgtMS0xLTA_c6b143fd-c34a-43c1-8acd-901dae864b23">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjAtMjAtMS0xLTA_2daf1771-ed7b-492e-94ed-7cd96ccc258e">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance &#8212; December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMS0xLTEtMA_f2c936a1-367e-4a93-8e17-c88538997ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMy0xLTEtMA_64ef687c-45a2-4f35-be46-fcab812bb9ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57ba1414023a4bb6a54a2fe2c91369ac_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtNS0xLTEtMA_f671a479-e6e7-41e2-a3b2-3c08e1c5e385">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia0e44d1416c24d019f4334743e7793bf_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtOC0xLTEtMA_2c167520-695b-4b27-a6e8-e74cd4724f52">121,482,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0e44d1416c24d019f4334743e7793bf_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTAtMS0xLTA_965c80d2-ded0-42dc-a9c3-fbf0773cefd5">121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i894cb9f424d847fd87d8fcba20ed1e12_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTItMS0xLTA_6273ecb6-457b-4405-ad20-714a688d6f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee1bc4e91f584f8a829f502e3581da80_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTQtMS0xLTA_7967a458-2b40-40b4-8f58-9f5cfefd3746">914,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6bc6daa75634ee18f23d67b4d5b10be_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTYtMS0xLTA_75a1f0db-db4c-4960-b17d-44c90ccfeb1e">211,528</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d942c4c69d247dc94894cc3832f4f13_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTgtMS0xLTA_42d40bd9-556b-441b-a31a-57977f4e139f">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMjAtMS0xLTA_9392de7e-dce7-4391-a2df-539b307b0e6f">703,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and vesting of RSU's</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItOC0xLTEtMTc1NA_ea89db35-c239-4d37-9540-ca2ddc81cf66">711,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMTAtMS0xLTE3NTQ_e52d01b3-1653-4bd0-9438-209edceb69a6">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMTQtMS0xLTE3NTQ_05b93da1-51de-426b-9e5b-5ccf39aa6b89">2,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMjAtMS0xLTE3NTQ_ceea548a-e2f1-4d89-bb14-0a84a85fcabc">2,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Vesting of early exercised common stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjMtMTQtMS0xLTE3NDk_d58631c3-e48d-4932-ae3d-2cacb414389b">4,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjMtMjAtMS0xLTE3NDk_d0bbb9c6-968a-4946-8159-048126a6fec6">4,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjQtMTQtMS0xLTE3NDk_57d3ca08-2728-4051-b4cb-74de074bc265">46,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjQtMjAtMS0xLTE3NDk_2dac44ee-e912-4664-82e7-da01ae2906fa">46,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtOC0xLTEtMTc0OQ_e59729a2-b925-4728-a486-e74f3de31d46">107,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtMTQtMS0xLTE3NDk_d14157fe-147b-487e-ae54-d86e24e367b0">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtMjAtMS0xLTE3NDk_4b6ed7d5-3a3a-47e1-bb71-a4a0a0fa7490">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Issuance of common stock from public offering, net of commissions and offering costs of $1.6 million</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtOC0xLTEtMTc0OQ_97623d33-936e-4806-bb7b-efe4ff536d2d">1,965,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMTAtMS0xLTE3NDk_c2926b18-a226-4526-9bcc-81e753d3b1d1">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMTQtMS0xLTE3NDk_fb79dce2-8af3-4aae-a90e-9758b03b0a80">54,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMjAtMS0xLTE3NDk_cd4f9fc9-1b1b-4c81-8edd-e0787fc79f4e">54,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Net Loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4504b4d5097a4954858c46286aa5dba4_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjctMTYtMS0xLTE3NDk_200ecf10-d329-4e0f-b3c0-5c71b91a70a8">184,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjctMjAtMS0xLTE3NDk_a39bf041-cde2-4729-b615-fe362dfd6660">184,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;">Net unrealized gain on available-for-sale investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdef23c610c643cd98f536491957b5ef_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjgtMTgtMS0xLTE3NDk_90dcc1ee-0abe-4752-a794-c6a636bdd301">839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjgtMjAtMS0xLTE3NDk_50284aec-3439-4ef7-8074-1704b7dbb504">839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance &#8212; December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMS0xLTEtMTc0MQ_441fb90b-08f2-4b92-a883-fd228774cd65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMy0xLTEtMTc0MQ_1cc559dd-1a4f-4190-aa77-5cd1c4e9ec75">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd1910421c5c43d585972f790a229f83_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktNS0xLTEtMTc0MQ_66cbd61a-bd0f-4421-91b2-23ee4dcf1d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8800095a2bb4f63b85032f31ca50e7f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktOC0xLTEtMTc0OQ_6e26a96e-3ad4-43ca-bfec-888d384ef6ee">124,267,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8800095a2bb4f63b85032f31ca50e7f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTAtMS0xLTE3NDk_9a51930c-dc3d-4e2a-8091-e0a3526c7043">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea539b4757a94514a3201e3bef9d08e6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTItMS0xLTE3NDk_b2a64daa-8fb6-4c11-9c5d-84ac345904e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07b75e8befc040d38153c0e4e0ed8a06_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTQtMS0xLTE3NDk_1bfdac8d-59b7-48c0-96f7-3130471eaff4">1,023,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56d6273dcf9f4ca4b6c7f19445ea045d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTYtMS0xLTE3NDk_ea2bdd79-8661-41ad-a2cb-77cd903810fe">396,122</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658fd51e478545beb0ee00eed9c4872f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTgtMS0xLTE3NDk_a4d7c6be-4ccd-49cb-bec0-0d63680bada4">1,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMjAtMS0xLTE3NDk_fc90567b-c078-48ab-8336-b0ec6e7ea4a3">629,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_103"></div><div style="position:relative;width:100%;height:23.22pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">93</span></div></div></div><hr style="page-break-after:always"/><div style="height:28.35pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:63.161%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.225%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.316%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.225%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.445%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.228%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period from November 30, 2017 (Inception) to December 31, 2017</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMS0xLTEtMzIy_bbdd21c7-f72b-4622-8215-20249430778f">184,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMS0xLTEtMA_e8e0d5a2-3cd8-49ba-a7de-387f024c6c3d">211,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMy0xLTEtMA_9e109efd-86d4-4a9f-9793-ce79df557258">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash (used in) operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMS0xLTEtMzIy_0aae5ec7-3a37-4544-b542-158449c020ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMS0xLTEtMA_06fdd018-3219-42ee-9063-3ed3c7d30a4b">109,436</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMy0xLTEtMA_eb6a47e6-7113-4db0-9d96-ae643db7650f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMS0xLTEtMzIy_e5f65064-ee25-4f2c-898e-58f5ce74efdf">46,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMS0xLTEtMA_c63338b9-c7f8-4a75-8d73-009eb8389a14">18,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMy0xLTEtMA_ee27384f-584e-489d-a0f8-7e18f516f868">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of other intangible assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMS0xLTEtMzIy_9738bfc9-97d2-48e3-9729-fb088631dbab">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMS0xLTEtMA_baa7e3b6-4a3f-4db0-bfd0-efd4f7d75bfc">452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMy0xLTEtMA_05bcffee-cd99-4646-9321-325e6d26d09a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMS0xLTEtMzIy_e52a336b-e99d-4e4b-b71d-5c751f1d5773">4,424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMS0xLTEtMA_e2d45357-da05-4809-ab79-717aff5694a2">1,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMy0xLTEtMA_cb8d3dd1-a479-41c5-ae8f-a80e169b2d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amortization/accretion on investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMS0xLTEtMzIy_0701e3a1-b367-4365-895c-6adddcd39490">3,596</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMS0xLTEtMA_e9e823cc-688e-4b6a-bd26-22a761ed6d47">1,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMy0xLTEtMA_5bf1dde6-30b3-4360-9984-76426d1e6a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash rent expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMS0xLTEtMzIy_2ca96d52-8c30-4ecb-918e-9336588b89db">6,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMS0xLTEtMA_cb7d098b-473e-4a10-ae26-ee17b2f65d98">1,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:LeaseAndRentalExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMy0xLTEtMA_8ae9bb75-ab21-4d76-9bf1-e47aea1c3ed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible notes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTEtMS0xLTMyMg_1548b33e-7d42-401b-9b42-d3ccbb9d7507">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTEtMS0xLTA_fcae7cb7-8835-4234-8a73-5783946daaa4">21,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:ChangeInFairValueOfConvertibleNotePayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTMtMS0xLTA_7cc70ac0-26cc-4bf9-b119-d351b8272a9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt issuance costs on convertible notes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTEtMS0xLTMyMg_26bf60c8-a5a9-4a3c-9f3c-aad0d3844e3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTEtMS0xLTA_005a2f9f-053d-485a-a872-bd5cb071a500">3,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTMtMS0xLTA_86cab2ab-b976-4cee-9d2a-c008f0331c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTEtMS0xLTMyMg_7c30b8bb-d730-4307-996d-a1a10b4648c0">331</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTEtMS0xLTA_9b4a56c5-2fa2-456d-9f03-52a33d836f7d">117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTMtMS0xLTA_dfdc8bb6-fe48-45d3-bbaf-ada346320c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share of losses from equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTQwNTg_b4c7ed8e-7568-41cf-9cf5-29e8e16a2d7b">182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTMtMS0xLTQwNTg_11ad062e-126a-43f3-8410-cd39d5b019d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTUtMS0xLTQwNTg_418523de-727a-4a21-bec2-262629348b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTMyMg_31b83b5f-53bf-4209-99fa-cfe2f789dd58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTA_37e70ec7-b6c3-4b83-b834-9787f1d8b5fd">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTMtMS0xLTA_9b896dad-8763-4259-b6ca-1edd65a70265">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTEtMS0xLTMyMg_9250ca9d-59ed-4857-b7da-a26e10d35ee8">5,445</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTEtMS0xLTA_e175303d-39a1-4c5f-a584-a78231465dc5">8,598</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTMtMS0xLTA_96b3091f-25c5-4426-9796-90ef5f303f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTEtMS0xLTMyMg_d85d591d-bfe8-446d-9dc8-f0927b76225e">4,374</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTEtMS0xLTA_f74c7ed4-874e-497e-abea-7fa54c1bd57f">244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTMtMS0xLTA_6f97172b-76fa-4d95-8c66-691ab0548f12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTEtMS0xLTMyMg_aa1dc621-4c8e-41d1-b4c3-055e1065605e">985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTEtMS0xLTA_8f15c5fe-3c7f-4737-a0c7-483d61edf87f">8,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTMtMS0xLTA_64a9a593-028a-4fb2-8adb-27d9256c2484">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTEtMS0xLTMyMg_a7e220df-0e57-4291-b5d9-97e3d0690df9">6,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTEtMS0xLTA_a4d2518a-a01c-4fbf-9346-b69d2f2e4eab">12,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTMtMS0xLTA_9e46b5cd-e900-417b-a030-cb4df472ad47">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTE4MTE_dd018a01-7ace-410b-ae35-38473b603916">2,425</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTMtMS0xLTE4MTE_5f5fa2c6-537f-4a06-b384-b57feed51faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTUtMS0xLTE4MTE_2775e149-c23b-408e-8b6a-c4bd94500dc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTMyMg_f5773399-00ab-4227-acb8-0eefe620ec5e">137,350</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTA_7f9cb1a9-9675-476c-a4e6-c0002fbc8f73">44,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTMtMS0xLTA_ac1a5432-4bce-49d0-9588-93dc2f8ecc4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTEtMS0xLTMyMg_38112332-df80-4961-ac57-bede8a4cd4d4">50,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTEtMS0xLTA_54bed89e-eb92-4a27-80de-55534dbaef95">3,234</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTMtMS0xLTA_6421598a-1af2-4780-bd29-630797981152">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of stock in equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTE4MzE_a0ac62e9-f197-465f-923b-33edc7b9dc0f">5,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTMtMS0xLTE4MzE_d0c7b862-11f4-415e-96bb-de54281ea6bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTUtMS0xLTE4MzE_e705c8e5-9cfb-4907-9549-44d21b7046a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTEtMS0xLTMyMg_28af1bd2-dd30-4abc-a2f3-55f887533f3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTEtMS0xLTA_e6095f0f-700d-446a-90f6-15ba6215387c">2,606</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTMtMS0xLTA_1d2d55ce-d6f4-46d7-a9ff-aed622062d3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTMyMg_df99ef2d-f68e-4372-ba3a-d56b4c990766">472,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTA_dd0d2da7-826f-4e74-9c4a-64f30ae71c40">19,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTMtMS0xLTA_fe2992db-f727-4a53-b660-7a30e75f353c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTEtMS0xLTMyMg_47b3658e-6c63-4976-bb0b-9153c2f3dd94">252,628</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTEtMS0xLTA_62904ef3-9622-42d2-b086-5d124a63bcab">649,307</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTMtMS0xLTA_5fb64eb5-06f4-4051-ac4b-d33175f55c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for acquisition of assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTEtMS0xLTMyMg_90fc15e8-b6c2-4095-bd18-330ac83e63d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTEtMS0xLTA_53e240c1-12e5-4a3f-b706-4dc7ef7e6cda">2,098</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTMtMS0xLTA_31c04a0c-93d4-4dd5-adf3-94f58567799a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTEtMS0xLTMyMg_a69c3444-8925-449c-8b79-afe9c3fc1db8">164,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTEtMS0xLTA_3161242c-1bf7-4392-bffb-7315cb999460">632,798</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTMtMS0xLTA_11250e56-77f5-410c-9be3-c9b41a839f66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTEtMS0xLTMyMg_d03a9ab7-1603-4823-8411-4b7c7a1fd5bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTEtMS0xLTA_90d3a903-65e2-4d14-b2bc-38c9adb35e45">299,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTMtMS0xLTA_1f8923a5-e6a7-499f-a4fb-2f10036419c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of convertible notes, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTEtMS0xLTMyMg_a010be8f-1af9-40b6-baa3-70aec9809eab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTEtMS0xLTA_05a0eea9-4cf6-4143-bba6-c47a206509c7">116,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTMtMS0xLTA_06759bd1-06dd-4e9f-9dff-1f8a669c6924">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from early exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTE4NTE_c3a2df97-dc92-423c-9278-4d9372e3bb38">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTMtMS0xLTE4NTE_493f46e4-b9f4-4dc7-a4de-2ec7910716ff">11,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTUtMS0xLTE4NTE_c2be1778-90cc-4e20-b274-914528cfbbcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of commissions and issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTEtMS0xLTMyMg_332e1ca2-aca6-4154-ba32-89831cf0876a">54,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTEtMS0xLTA_905dee94-cea8-49bb-84ab-bc1e6ad30451">343,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTMtMS0xLTA_5463d416-e627-432c-a8c3-86377f149c5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock and upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTEtMS0xLTMyMg_c261a705-1e7d-4792-b573-2e041db1a937">2,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTEtMS0xLTA_6588f17e-0b99-4bac-8e46-92c3a038ddc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTMtMS0xLTA_de2a0123-a12c-4afb-8256-fa7fb379c6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTEtMS0xLTE4Nzk_75bdb6fc-6170-49f8-8da5-21fade897b1a">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTMtMS0xLTE4ODQ_a7907e42-99fc-432b-b95d-a4705ae6ea17">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTUtMS0xLTE4ODY_279b5ee4-df5e-4a25-bd9a-d45a55a0ab47">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTEtMS0xLTMyMg_d538cc84-6779-4cf7-a017-8be84391d409">58,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTEtMS0xLTA_aa323445-1b51-4410-9a93-36fcedb7960c">771,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTMtMS0xLTA_cc24c8d6-bc1c-47a3-a12f-e60cf3288436">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTMyMg_ddc81fd0-f2fa-414a-85fc-1688e78ad765">85,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTA_45bd7c24-52a5-4f06-9e42-ecbd64f7527e">93,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTMtMS0xLTA_aa64df9f-c031-4260-9d9f-5c4371429816">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash &#8212; beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTEtMS0xLTMyMg_02b2d7bc-9129-4d7e-8303-23c427d35be0">93,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTEtMS0xLTA_d5c3b25d-9616-4394-9705-1dec5c8721e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic178392ea1bb4a2d8265ba3c454059e5_I20171129" decimals="-3" format="ixt:zerodash" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTMtMS0xLTA_3bb5d287-9c61-4f7b-a278-0783b0d697c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash &#8212; end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTEtMS0xLTMyMg_fa728899-b428-45a9-ba78-b0800d552cc2">179,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTEtMS0xLTA_c570e122-4d56-4c34-804d-56cee542e5f2">93,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTMtMS0xLTA_c72694eb-4e8f-4adb-b096-b4b61f985392">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash operating, investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued on conversion of convertible preferred stock</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTEtMS0xLTMyMg_a4a87d34-a14b-4f9b-a06b-2c34d64989f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTEtMS0xLTA_6b3b961c-28f7-422b-819f-0b005572650c">411,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTMtMS0xLTA_2d7cb66f-f96e-4f97-b95c-7bc3b93861da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued on conversion of convertible notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTEtMS0xLTMyMg_4bd922f0-7d5b-4d7f-9627-235db23ca887">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTEtMS0xLTA_47def943-8a17-4298-a6d7-4ce4c3e8ae94">141,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTMtMS0xLTA_a84d8af1-9113-4c10-8986-90711f0fdd4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A-1 convertible preferred stock issued in asset acquisition</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:ConvertiblePreferredStockIssuedInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTEtMS0xLTMyMg_21e62158-24c2-40c7-bdac-b868557ebc26">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:ConvertiblePreferredStockIssuedInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTEtMS0xLTA_629b29f3-b4b4-4611-bdff-6da87d8b4c3b">111,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:ConvertiblePreferredStockIssuedInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTMtMS0xLTA_ec64097b-39ce-47ae-af29-2eb70d67f320">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PP&amp;E and other assets acquired in asset acquisition</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTEtMS0xLTMyMg_f0e2c665-6686-4b8d-bac1-5bf9a0d87584">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTEtMS0xLTA_65ac2d49-a686-4da2-b930-7a36da70c643">111,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTMtMS0xLTA_09c7e0e0-bed2-419d-b77c-f91453c430a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset obtained in exchange for lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTEtMS0xLTMyMg_626d0a20-e8dd-48c5-b844-8a5d6703c0ff">13,827</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTEtMS0xLTA_540ea758-f7ca-4e33-8406-16e3b559e122">33,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTMtMS0xLTA_f446770a-e389-4747-974c-e8b6b989b000">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment purchases in accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTEtMS0xLTMyMg_018e250a-6c68-4865-b4a1-2cf54607a559">4,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTEtMS0xLTA_c8aa2ed9-fe3b-4fcc-8ce6-c7e72e86ba2d">3,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTMtMS0xLTA_b1e7767c-6351-42d0-8e6c-8e451ecdec99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred offering costs included in accounts payable and accrued and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTEtMS0xLTMyMg_0091971a-11a9-40df-ad00-fb140e4f1de8">135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTEtMS0xLTA_b23daa81-65c3-4653-af35-0e61e0477f83">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTMtMS0xLTA_ce06c8b4-1fca-4baa-a551-67e227f896ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTEtMS0xLTMyMg_c92f523c-7ecb-481f-abc8-4c7aad1adda7">3,563</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTEtMS0xLTA_b7d67770-e4e7-42c7-9242-6af5a5aad703">31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTMtMS0xLTA_f2d0d5fd-2251-4cf4-b93b-b0edecbb876e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash received for amounts related to tenant improvement allowances from lessors</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTEtMS0xLTE4OTk_ac13351c-2171-4f96-8739-79e85876f7d4">4,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTMtMS0xLTE5MDM_ab0f3190-e777-4758-a44c-2d33db4da0bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTUtMS0xLTE5MDY_027124b4-155c-435c-93d0-744b998b140a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_106"></div><div style="position:relative;width:100%;height:28.35pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">94</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Financial Statements</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_109"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 1. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDUyNTU_72dd42f0-0106-4028-9550-7a4bf8c93071" continuedAt="i05f8e176266e49deaea85a3b6909c0f7" escape="true">Description of Business and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i05f8e176266e49deaea85a3b6909c0f7" continuedAt="i8e6081190cff45dc87ba1e9e7960dddc"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the period from November&#160;30, 2017 (inception) to December 31, 2017, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:numdotdecimal" name="allo:StartUpCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzYzNw_c3a40f8a-5fe2-40be-98b3-9320c11e4d20">2,000</ix:nonFraction> in start-up costs to establish the Company. Principal operations commenced in April 2018 when Allogene acquired certain assets from Pfizer Inc. (Pfizer) (see Note 6) and completed a Series A and A-1 preferred stock financing (see Note 11).</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offerings</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEwNTM_70eb9a89-e99c-411c-ba27-5fc7cb81a536">20,700,000</ix:nonFraction> shares of its common stock, which included <ix:nonFraction unitRef="shares" contextRef="ic3f77038b1af4fb8b9344a23d6e30de4_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEwOTk_56546acb-6e4d-45c9-ba9b-10aeae679612">2,700,000</ix:nonFraction> shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyMzE_1a8bdc27-d793-4894-90df-93d770f8c00f">18.00</ix:nonFraction> per share. As a result of the IPO, the Company received $<ix:nonFraction unitRef="usd" contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyOTA_77336f67-2145-428e-ae82-a133aa38eb55">343.3</ix:nonFraction> million in net proceeds, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForUnderwritingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEzNjg_9add02b8-6759-411d-8df4-f8f7fd1f369b">26.1</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEzOTY_4dde47cd-6f06-4c6f-bc27-b28d6ab1fd8b">3.2</ix:nonFraction> million payable by the Company. At the closing of the IPO, <ix:nonFraction unitRef="shares" contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE0NTA_5b0020ee-0324-4263-bc34-a811b79a03b4">11,743,987</ix:nonFraction> shares of outstanding convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i5ba5824b8755458399cf44363881b72a_I20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE1Mzc_e8e11903-7619-475b-a871-3aa7cce9da87">61,655,922</ix:nonFraction> shares of common stock and the 2018 Notes (see Note 10) were automatically converted into <ix:nonFraction unitRef="shares" contextRef="iee39b6265afd4c15bb48df2ab24035ac_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE2MzA_26659cc6-fb8d-45d8-aeaf-306a81a82ea0">7,856,176</ix:nonFraction> shares of common stock. Following the IPO, there were <ix:nonFraction unitRef="shares" contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE2ODc_b8f2bc91-21a0-48d0-b14c-454cf7e07d49">no</ix:nonFraction> shares of convertible preferred stock or preferred stock outstanding.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i08444efecc9e4a61b85b99875e786078_I20191130" decimals="-5" format="ixt:numdotdecimal" name="allo:StockIssuanceMaximumValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5Njg_edc2785a-e39a-4fdd-99f9-869a0318950e">250.0</ix:nonFraction>&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to <ix:nonFraction unitRef="number" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="3" name="allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5ODQ_400b3036-dae9-4ef8-a6c4-7afe96801109">3.0</ix:nonFraction>% of the gross sales price of the shares sold through it pursuant to the sales agreement. Beginning November 2019 and through the year ended December 31, 2019, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQzOTgwNDY1NDE1MDY_e18d0ffa-34f7-4494-9f0c-8fd2574a0700">1,965,082</ix:nonFraction> shares of common stock in ATM offerings resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQzOTgwNDY1NDE1MTk_8153c20a-679d-407f-814e-0f622ce3b565">54.2</ix:nonFraction> million, after deducting commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5OTA_47d243f2-3019-450e-9b65-3180ac5ed228">1.6</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU1_f3233ce6-fde1-4922-b2ef-6f2c3b724451" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Offering Costs</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Offering costs, including legal, accounting and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO. Upon the completion of the IPO in October 2018, $<ix:nonFraction unitRef="usd" contextRef="i821e501b07404b9a9c7d2c5ca11840c7_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMDU_534bc644-e409-4123-bbb4-cd8def8b68ce">3.2</ix:nonFraction> million of deferred offering costs were reclassified to additional paid in capital. Offering costs, including legal, accounting and filing fees related to the ATM offerings were incurred. Upon the issuance and sale of common stock in ATM offerings in November 2019, $<ix:nonFraction unitRef="usd" contextRef="ic58cfdcb98b24158bdd7223f565fcd2b_D20191101-20191130" decimals="-5" name="allo:DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyMDk0NjI3OTM4Mjg0_56a2f412-43cf-4f07-98b4-70f1aa2c9aaf">0.5</ix:nonFraction> million of deferred offering costs were reclassified to additional paid in capital. There were <ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM4NDgyOTA3MzQ5NTk_a9a9985a-2172-4c6a-9564-5ef4d98ab074"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM4NDgyOTA3MzQ5NTk_e0068cfe-09c4-4e79-ab64-f13d9213a2c7">no</ix:nonFraction></ix:nonFraction> deferred offering costs capitalized as of December&#160;31, 2019 and 2018.</span></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Forward Stock Split</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 1, 2018, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a 1-for-5.25 basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Need for Additional Capital</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">95</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i8e6081190cff45dc87ba1e9e7960dddc" continuedAt="i599ea263fd5b4f80bff530cf94134cc0"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to commercialize the Company&#8217;s product candidates. The Company had cash and cash equivalents and investments of&#160;$<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM1Mzc_d45f468a-c611-4d00-b2b6-ea1a5bd06b0c">588.9</ix:nonFraction> million as of December&#160;31, 2019. Since inception through December&#160;31, 2019, the Company has incurred cumulative net losses of $<ix:nonFraction unitRef="usd" contextRef="ic88cc8410c2e4057a11268c203ce1002_D20171130-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM2Mjg_690f99ca-3175-4d45-b28b-fff46127204f">396.1</ix:nonFraction> million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the Company&#8217;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ1_fb88e8ee-bea7-4e42-a32d-5cdefae97f26" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ2_3511ff3a-399a-4716-a964-c46850d1a221" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjUx_14162bc1-ea8c-4943-b784-0fca1148a224" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit and other Risks and Uncertainties</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ3_e40507b5-80fc-4939-9b10-55a5c8c5363c" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</span></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ4_da17b049-7faf-4c97-b9b5-64f3252609d8" continuedAt="ife52617fa06b48f7afe43b099adfd559" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">96</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i599ea263fd5b4f80bff530cf94134cc0" continuedAt="iaa9cd8e6dc6045f797b3d576efa156b3"><ix:continuation id="ife52617fa06b48f7afe43b099adfd559"><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has issued letters of credit under separate lease agreements which have been collateralized by restricted cash. This cash is classified as long-term restricted cash on the accompanying balance sheet based on the terms of the underlying leases.</span></div></ix:continuation><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ5_8c241b62-395c-4902-9fdf-6a6ab7c6e866" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as current.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest and other income, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQy_cdfaa128-a6c6-47bc-8da1-291e30f807bb" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM3_6c290b0d-a355-47ae-8213-1969d70dc290" continuedAt="i062dcd741d0c414a819483752926dfdf" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally <ix:nonNumeric contextRef="i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NTI_13dcedf7-8ea6-4851-ab43-5825f8f6c8af">three</ix:nonNumeric> to <ix:nonNumeric contextRef="i0b21a198f1184844a973ffb0f8eb7de1_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NjU_be56973c-a92e-4b27-a3d2-7e3cd1c94423">seven</ix:nonNumeric> years. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in other expense.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:EstimatedLifeOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjUy_9505cd03-cacc-4249-9939-6bb614c53a20" continuedAt="i99f3e64bb08e434595e347424ea4308d" escape="true">The Company has determined the estimated life of assets to be as follows:</ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="text-indent:45pt;margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">97</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="iaa9cd8e6dc6045f797b3d576efa156b3" continuedAt="i890666d045d74edeb10ecdab102540c9"><div style="margin-bottom:6pt;"><ix:continuation id="i062dcd741d0c414a819483752926dfdf"><ix:continuation id="i99f3e64bb08e434595e347424ea4308d"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:68.717%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.283%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i31559d28138348d0ab6ce2d61e8edf3e_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90YWJsZTo1OWY5M2MyM2UyNDc0MjM3OWY1Mjc0YTUwMWQzZTU3Zi90YWJsZXJhbmdlOjU5ZjkzYzIzZTI0NzQyMzc5ZjUyNzRhNTAxZDNlNTdmXzAtMS0xLTEtMA_4eb3b43f-24d8-437a-94c9-1f2c520f2e91">5 years</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and purchased software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 - 5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixtures and furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iccc4fa5d70e04dcaa95ad41bc1ee441d_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90YWJsZTo1OWY5M2MyM2UyNDc0MjM3OWY1Mjc0YTUwMWQzZTU3Zi90YWJsZXJhbmdlOjU5ZjkzYzIzZTI0NzQyMzc5ZjUyNzRhNTAxZDNlNTdmXzItMS0xLTEtMA_47f12178-02bd-4b5d-8895-a6ad7a933c81">7 years</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDY4NzA_5d68d37f-159a-4b15-b852-e6b15679624f" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Update (ASU) No. 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> on January 1, 2018. For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDY4NzE_f446f409-1c06-4cbe-ad62-c75b58b0d58b" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company's proportionate share of the net income or loss of these companies is included in other expenses in the statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For entities in which the Company has variable interests, the Company focuses on identifying if one of the entities is the primary beneficiary through having the power to direct the activities that most significantly impact the variable interest entity&#8217;s economic performance and having the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company&#8217;s financial statements. For the year ended December 31, 2019, the Company did not consolidate any variable interest entities because the Company determined that it was not the primary beneficiary.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:AccruedResearchAndDevelopmentCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM4_db6582aa-bd0c-4aab-a527-2819ce97a00b" continuedAt="ib2c8ddcb81a2496ca8d8fa5be327a335" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Research and Development Costs</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records accrued liabilities for estimated costs of research and development activities conducted by collaboration partners and third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities on the balance sheets and within research and development expenses on the statements of operations and comprehensive loss.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its collaboration partners and third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">98</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i890666d045d74edeb10ecdab102540c9" continuedAt="i574505cc1db94baeb15bc1defb3a2159"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib2c8ddcb81a2496ca8d8fa5be327a335">become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</ix:continuation></span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM5_4dd0d90c-7326-4ac8-8646-b3411ad9b7cd" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQw_12020cde-93e0-4b41-bea0-1c6db5dbe7ee" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures its stock-based awards granted to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense&#160;is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as&#160;they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU2_b4dc4af5-9ec2-42c0-9f1d-dd1045340b92" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:ComprehensiveLossPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQx_f35272fa-3722-4870-bc99-6b06c547269f" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss. For the years ended December&#160;31, 2019 and 2018 this was comprised of unrealized gains and losses, net of tax, on the Company&#8217;s investments. For the period from November 30, 2017 (inception) to December 31, 2017, comprehensive net loss was equal to net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU0_f363d4d0-167a-4895-bd06-c198d702bc4d" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Definite-Lived Intangible Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable intangible assets consist of in-process research and development and workforce associated with the Pfizer asset acquisition. Intangible assets with finite lives are amortized over their estimated useful lives on a straight-line basis, generally two years. Acquired in-process research and development intangible assets with no alternative future use are charged to research and development expense when acquired. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible assets. Intangible assets are carried at cost less accumulated amortization. Amortization of intangible assets is included in research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQz_7a833e21-ed00-4d0e-b78e-8945f005fc4a" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were impairment losses related to equipment disposals of $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NzI_fc089c2f-8483-49c4-9649-a00334c9a315">0.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0ODY_37755907-9e46-4f21-a85a-3e2891051814">zero</ix:nonFraction> for the years ended December 31, 2019 and 2018, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">99</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i574505cc1db94baeb15bc1defb3a2159"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ0_700736ff-aa4c-4ccd-87fb-f3a382b677b4" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development expenses also include costs incurred for internal and sponsored collaborative research and development activities. Costs associated with co-development activities performed under the various license and collaboration agreements are included in research and development expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses for the year ended December 31, 2018 primarily consisted of acquired intangible assets pursuant to the Asset Contribution Agreement with Pfizer (see Note 6) as, at the time of acquisition of the asset, the technology was under development, was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing, had not reached technical feasibility, or otherwise had no foreseeable alternative future use. For the year ended December 31, 2018, the Company recognized expense of $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDUyNTc_3767db29-e3e8-4d76-bbe5-2d3150a3f115">109.4</ix:nonFraction>&#160;million related to the acquired intangible in-process research and development.</span></div></ix:nonNumeric></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_115"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 2. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTUvZnJhZzplMDBiZmJiNGI2ODM0YWNjOTUxMDA3ZTRkOGFlY2FlNi90ZXh0cmVnaW9uOmUwMGJmYmI0YjY4MzRhY2M5NTEwMDdlNGQ4YWVjYWU2XzQ5NDc4MDIzMzE4MDc_dead2541-43a5-4af5-a2c9-1aeac84ffc69" continuedAt="ia1f12ca7f96d4fc080fd6f4494dd77c9" escape="true">Recent Accounting Guidance</ix:nonNumeric></span></div><ix:continuation id="ia1f12ca7f96d4fc080fd6f4494dd77c9" continuedAt="i3fd2349887f948ba8bc83bef7664cc42"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January&#160;2017, the FASB issued Accounting Standards Update, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU&#160;2017-01). ASU&#160;2017-01&#160;clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This new accounting guidance is effective for public or private companies for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The new accounting guidance should be applied prospectively on or after the effective date. The Company adopted this guidance on January&#160;1, 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued Accounting Standards Update No. 2018-07, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU&#160;2018-07). ASU&#160;2018-07 simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Some of the areas of simplification apply only to nonpublic entities. For all entities, the amendments are effective for annual periods beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2020. Early adoption is permitted for any entity in any interim or annual period for which financial statements have not been issued or made available for issuance, but not before an entity adopts ASC 606. The Company early adopted this guidance on January&#160;1, 2018. As a result, the accounting for share-based payments to nonemployee consultants is consistent with employees.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the FASB issued Accounting Standards Update No. 2016-18,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Statement of Cash Flows: Restricted Cash</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;This ASU&#160;requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.&#160;&#160;This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all periods presented.&#160;The Company adopted this guidance on January 1, 2018.&#160;The adoption of this ASU&#160;increased&#160;our ending cash balances within the statements of cash flows. The adoption had no other material impacts to the statements of cash flows and had no impact on the results of operations or financial position.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued Accounting Standards Update No.&#160;2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU 2016-02), which provides revised accounting requirements for both lessees and lessors. Lessees will recognize a right-of-use asset and a lease liability for virtually all leases (other than short-term leases upon election). The liability is recognized at the present value of future lease payments. The asset is recognized based on the liability. For statements of operations purposes, ASU 2016-02 requires leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. ASU 2016-02 is effective for public companies for fiscal years beginning after December&#160;15, 2018. Early adoption is permitted. The standard requires a modified-retrospective transition method and </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">100</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i3fd2349887f948ba8bc83bef7664cc42"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">provides for certain practical expedients. The Company early adopted the new lease standard on July 1, 2018 with the adoption reflected as of January 1, 2018 in accordance with ASU No. 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842) &#8211;Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. There were no lease arrangements prior to August 2018 and consequently, the adoption of the standard did not have any impact on periods prior to August 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include but not limited to trade receivables and available-for-sale debt securities. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In January 2020, the FASB issues Accounting Standard Update No. 2020-01, Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323),  which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_118"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 3. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90ZXh0cmVnaW9uOjcyZmE0MGQ0ZTc1ODRkMzA5MzJhMjZmMzY0OGYwODAyXzQ5NDc4MDIzMjY5MTU_7c0cef86-fb89-4253-b9d3-8da9075dc700" continuedAt="i04bf5b46de7e4524ab2d236ce6bf881a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i04bf5b46de7e4524ab2d236ce6bf881a" continuedAt="i4ef904ad27ea49638ae384002e18c2a6">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received </ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i4ef904ad27ea49638ae384002e18c2a6"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and reports its cash equivalents, restricted cash, investments and convertible notes payable at fair value.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no Level 3 assets or liabilities at December&#160;31, 2019 or 2018.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90ZXh0cmVnaW9uOjcyZmE0MGQ0ZTc1ODRkMzA5MzJhMjZmMzY0OGYwODAyXzc2OTY1ODEzOTcxOTM_c510c159-24df-42cf-96a3-68e8660e74b4" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dddefdb7f0347409c74598e8d7213a9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtMS0xLTEtMA_d06def68-bac5-40f1-9ccf-45b6917a42aa">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad4580516611428ea09e371d04ecdcf0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtMy0xLTEtMA_3196d493-7d3a-4999-ab1f-f05a72ee858b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41321b51b20b4ec3807a67d0a72c0075_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtNS0xLTEtMA_6190f8b0-4958-4944-9786-d421d6cb5511">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f9280b34fd4edca10d8753f9795f1d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtNy0xLTEtMA_5828739c-5c85-41e2-a468-eed48e5b8397">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b5d88729cac494eb409276d41aad939_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtMS0xLTEtMA_779c0b8b-d74f-4e90-9734-b8eae7fbe664">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i910ae198636f445ab767fe7a98e42da1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtMy0xLTEtMA_4ce96b2b-0d13-4941-bc29-92eb1debdee2">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10fdb61401b746fca53090e64340f864_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtNS0xLTEtMA_978d8c55-23f9-4888-89e9-7e53ca74f48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf7a233f74f545049d9e8aa6b0476dc6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtNy0xLTEtMA_587ff1c4-b01a-4feb-855f-0213e1c805ad">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaec915df35d44a74a0e37fe81e953ea8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctMS0xLTEtMA_b223f9b5-15b0-498a-809f-b3f259107bc6">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06c178fec4d743b7a556aec06c2f821d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctMy0xLTEtMA_03cc2cb1-afb6-4a78-984a-e0335370892c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic91027a1351f40f6a6ce39d721284794_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctNS0xLTEtMA_f8e00bb2-cd55-49c7-8ae5-8720f2034358">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab948e17826146478ea922d2d145b16a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctNy0xLTEtMA_2c5b7df2-5720-405d-9d00-44f9a44b3d0b">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied8402dc6dc845bc9113f9d66ed86178_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtMS0xLTEtMA_415f58df-8a48-4e5a-82e7-ebf8fcadab02">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25faef9ff3c64269b6c008b1dc92e476_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtMy0xLTEtMA_430c95f4-b511-40e2-9dba-47c101d41f1f">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86abab37a4774a968808425797205a1d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtNS0xLTEtMA_c1342ec3-62b9-4e87-8088-4907dfceff1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic67152294c6942b9ba899ab8f21e9ab8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtNy0xLTEtMA_1802a52b-09ac-49d5-adc2-bb300330f042">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0968abaaa5f7440c8eff4d639ac876db_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMS0xLTEtNzEwMg_26d08a91-dab3-40e1-8cba-f0d5cf1eb0f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i689d4094b8024bcc8d34927e5f90f7c5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMy0xLTEtNzEwMg_beaf6e19-c973-44ed-88f7-a11da217d337">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0364d3024ca74ee5b4ea651c2620ca3f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNS0xLTEtNzEwMg_aa363721-bac8-4670-bc5f-db8b5025aa5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb123eb6e34d4fb79ca3d24126047e63_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNy0xLTEtNzEwMg_bc57e533-19ba-4207-8527-4a6368c8ee7d">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9990cf0b9413469cae5b763d89e229c3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMS0xLTEtMA_61bc171d-e30e-4c8d-862c-b208e1fdadb0">304,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i413973bdc4c8478484b252834be4455d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMy0xLTEtMA_48a24f3e-c9ce-495a-ac61-4715f58bc22c">231,835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d00b3947da248a9aa0a662b95549a62_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNS0xLTEtMA_f9bb9262-03cc-4319-829f-d9520f6174a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i131f8341b44741a8be5ad09784c38587_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNy0xLTEtMA_7b8e6840-0042-43e7-b524-dc8da150756a">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:49.104%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.783%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6af031995e6847efaf03df708bb7eb62_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtMS0xLTEtMjI1OA_9e6383fe-2571-4dce-9c0f-6c9a0d246336">61,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if29d551d20ae4eb8962e30ebfd31ed44_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtMy0xLTEtMjI1OA_16024f24-cfe1-46ec-b6ef-be72036ec64d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibeaa87c3871d4b7494311fa64fdb63ec_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtNS0xLTEtMjI1OA_642f2a2e-a86d-4bbb-9e90-8406763104ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd83064e20c54412994b903a9de5ffd4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtNy0xLTEtMjI1OA_d4bb61b5-a39f-4596-bb49-4f69272d9367">61,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9a0862545c944c7970f75cf79d47b8d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtMS0xLTEtMjI1OA_6912d8c0-6ad6-4df3-a441-29dec26eb4a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdeb525a74b740d4b778fb321271ccce_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtMy0xLTEtMjI1OA_e66a6137-f4f9-4727-ab9a-142dab63df64">4,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia306dfbbd94f4a72aa4930728fb27045_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtNS0xLTEtMjI1OA_079fbbaa-3c60-47cf-aa2a-0e382635bfed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i769efc364d1b49ad9f1e5c3e1e33a712_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtNy0xLTEtMjI1OA_84b9faf2-4be5-428f-8c79-8fa8c78d59db">4,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i985e7490d1a549e8a0feb30d7a02d3b1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtMS0xLTEtMjI1OA_43ca30c3-aefe-41a0-8059-a4be2393f25e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f6a1cfe504a41018e8e5e0de30f51d4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtMy0xLTEtMjI1OA_e9487a94-6e44-423e-871a-5d58b1beb4d1">244,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40117c0bb4854d40a4fa2a481a673eec_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtNS0xLTEtMjI1OA_7415b5b8-d3b3-4e4b-948e-0e6a323bbaf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d9f4a396a4241bda2a780ca2c70f3be_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtNy0xLTEtMjI1OA_046c0137-c596-4c6f-8e74-e757a8aecbdc">244,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14e9bfa620a94645901e0e79295a81c2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctMS0xLTEtMjI1OA_9460c78b-f612-4dbe-8d72-c38f03950e94">342,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieea078f2b943446d87c87029de76019d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctMy0xLTEtMjI1OA_d679db00-05c9-4160-a571-cc1377af8b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae09226ae44c493cbda2c9500466d142_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctNS0xLTEtMjI1OA_a02a066a-c89b-4eda-8ec3-dfeeb4ed47c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b4b10265f764f3ab736b5d47b1f9502_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctNy0xLTEtMjI1OA_c309078f-498a-403f-bc44-3a58a3d9ceb6">342,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic98c546ec02943d0a92444708d47ad3b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtMS0xLTEtMjI1OA_9741d6b6-4ffd-4483-838f-741938f6355e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i576dbba691a54312ae4f7f7b9fa27f72_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtMy0xLTEtMjI1OA_a2b6fe02-3132-4095-b0ac-987953c7e579">62,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b15926b27844890b92923069fc998a2_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtNS0xLTEtMjI1OA_b8656f7d-7420-4574-acee-a5c00a529cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c7eaa563c1f4ebc81ea162cae253d1e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtNy0xLTEtMjI1OA_47be238a-aff2-44e6-aedb-4b99ad230d5c">62,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e6bcfc30bc543409ce74f21a01801ac_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktMS0xLTEtMjI1OA_feed3ee3-f6e5-48c1-845a-c12074cd07fd">403,024</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7af350b1cafc4cd1a2cbfc361f70255a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktMy0xLTEtMjI1OA_68379e91-3c63-4b68-be27-a2424010cc12">311,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i712f2cfe4d6b404ab9882f4089185418_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktNS0xLTEtMjI1OA_99d04f65-cc77-4ac1-9188-48c5386b5daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice5f2d0234854debb1249a5a134c8a88_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktNy0xLTEtMjI1OA_9a587b3a-ed1c-472b-9df1-91cd1bb55d16">714,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no transfers of assets between the fair value measurement levels during the years ended December&#160;31, 2019 or 2018.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_121"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 4. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzQ5NDc4MDIzMjU4ODY_009fefc5-bdf3-430e-b3e7-71a976b8338e" continuedAt="id4270c32c0b6447da10ce0b8676e2226" escape="true">Investments</ix:nonNumeric></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">102</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="id4270c32c0b6447da10ce0b8676e2226" continuedAt="ib41bc4a4250746eabc3c138e8d1d63c8"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzc2OTY1ODEzOTYxNzc_c378bc40-4ef7-4d00-9c3c-34d6352a5ba0" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92883258851343719809a457e47461f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtMS0xLTEtMA_8f6c62c2-4ba9-4510-8241-a7f415fd242c">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92883258851343719809a457e47461f3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtMy0xLTEtMA_99796be5-231a-4b61-8998-485953c7ae7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92883258851343719809a457e47461f3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtNS0xLTEtMA_e6577c6f-2072-4099-8788-1fe4f508eb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92883258851343719809a457e47461f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtNy0xLTEtMA_5205c1a5-076a-4d07-814b-c5cb35c88b17">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0083451548d0466897483be2bafb4bd4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtMS0xLTEtMA_9ad76fee-1aff-4806-b11b-c394c1c3935e">204,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0083451548d0466897483be2bafb4bd4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtMy0xLTEtMA_53ea05ae-21fa-45dd-9c10-e2a997d5b919">871</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0083451548d0466897483be2bafb4bd4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtNS0xLTEtMA_4eda28e4-0e6b-423a-8aa9-854a794f460b">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0083451548d0466897483be2bafb4bd4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtNy0xLTEtMA_28f8211f-3404-4e59-b845-bb6f953c0e9c">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtMS0xLTEtMA_c88e37db-7036-4939-98e1-02f297a61367">181,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtMy0xLTEtMA_2957081c-3625-4a2d-9771-0b9fe4618719">557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtNS0xLTEtMA_07d18673-3f0c-47bc-8e50-bf3887f6a4fa">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtNy0xLTEtMA_2647c308-d973-4c7f-81a9-48f6536a3d4e">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctMS0xLTEtMA_4ed8912d-a0fd-44ef-8711-8a44a56fec8d">25,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctMy0xLTEtMA_1b129015-fcea-4bec-a450-bcf34a64d3b0">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctNS0xLTEtMA_44a53506-3a01-45c9-8725-0f33574c1f99">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctNy0xLTEtMA_60fef9a4-fc35-48b7-a3f8-606f417612ee">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedec35042c304a2d90f0918f919f1531_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMS0xLTEtMjQ3OQ_652e84aa-07b5-495a-9130-1f66271abc31">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedec35042c304a2d90f0918f919f1531_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMy0xLTEtMjQ3OQ_2cc2dfc9-5df0-414e-8de1-0b8a41f1d81d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedec35042c304a2d90f0918f919f1531_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNS0xLTEtMjQ3OQ_bf9597bf-2f8e-45e3-b7aa-75ca41c4d73d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedec35042c304a2d90f0918f919f1531_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNy0xLTEtMjQ4Mw_a12cf680-17c0-4dcd-81d1-f79c50ccd009">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMS0xLTEtMA_d3c7d5d5-0e69-414a-8b65-bc944f03be4f">535,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMy0xLTEtMA_67050d68-193a-4b2e-9307-c41dfe363060">1,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNS0xLTEtMA_90ec9bd0-c182-45c0-8b09-7ec06fb5a7b5">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNy0xLTEtMA_ff9e6f9c-be20-4141-80d2-7ad7947784e6">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzExLTctMS0xLTA_d1557b70-7692-481b-a3b0-27b85b546deb">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzEyLTctMS0xLTA_c54b47c8-bd83-4ba9-bc3c-afeb5086e632">355,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzEzLTctMS0xLTA_c82d3ff4-a769-4002-8c5b-962babb4e953">58,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzE0LTctMS0xLTA_289a6887-2826-4ad0-a4ce-7695aa3a364d">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.248%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.387%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.387%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.387%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.750%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec77988e07a84ed997297aea9582d919_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtMS0xLTEtMjM2OA_e886b070-6edd-4876-b70e-c7cd7547fe76">61,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec77988e07a84ed997297aea9582d919_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtMy0xLTEtMjM2OA_9e4bbad9-0789-46b7-ac12-10282252d23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec77988e07a84ed997297aea9582d919_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtNS0xLTEtMjM2OA_0718987f-6ac0-4482-9b85-9378befc236a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec77988e07a84ed997297aea9582d919_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtNy0xLTEtMjM2OA_bf4e130c-c993-4f64-abb0-0a77f0d7dffa">61,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial Paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtMS0xLTEtMjM2OA_51bff37a-7c7c-47a2-a6e5-0271a749f803">4,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtMy0xLTEtMjM2OA_a5c48463-1c15-45fc-b055-014a7a57f433">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtNS0xLTEtMjM2OA_13596d09-e29a-41e9-82f2-92e24d58af74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtNy0xLTEtMjM2OA_fd913def-cfad-45ac-8859-2d3a4b1e6422">4,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtMS0xLTEtMjM2OA_45fdef25-b251-48f0-a03c-b7e02a28bc3b">244,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtMy0xLTEtMjM2OA_6f9ebed7-aa2a-4045-998a-74245d3543f0">220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtNS0xLTEtMjM2OA_54ab3954-910f-487f-9450-08609e71c14f">280</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtNy0xLTEtMjM2OA_a45707c3-c566-4f91-b8bc-68c8f3e4314b">244,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtMS0xLTEtMjM2OA_6486c817-176c-4196-b368-3f376cf71308">341,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtMy0xLTEtMjM2OA_9e1ed135-adda-47c3-84bf-ebcc819d8178">342</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtNS0xLTEtMjM2OA_e8cfee06-9085-4e51-81a0-2db0ce099c42">37</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtNy0xLTEtMjM2OA_20ff8e60-766a-43b8-ad2a-eeaed03f71a6">342,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctMS0xLTEtMjM2OA_7db4b6e0-cf2d-4db0-b7fd-e6e4326f944a">61,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctMy0xLTEtMjM2OA_381ecdfc-a68d-4408-845f-858222d54067">181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctNS0xLTEtMjM2OA_971db7fe-5447-4021-acfd-343f3136cb24">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctNy0xLTEtMjM2OA_46527ef9-c340-4d36-a8e3-f39d91a3c5a1">62,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtMS0xLTEtMjM2OA_7c2a1954-ba41-4118-8b63-91582af016ec">713,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtMy0xLTEtMjM2OA_596cc5f0-26f7-4000-9022-7315862eae95">743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtNS0xLTEtMjM2OA_f5ad8442-2935-4f97-8f3d-09b32ed318c5">320</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtNy0xLTEtMjM2OA_7014f5d0-67e8-419f-8179-37ef944c262e">714,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzExLTctMS0xLTIzNzE_f4423b4d-02da-4dbe-9d3c-c45da987b9fe">85,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzEyLTctMS0xLTIzNzE_2b8a8edd-aab2-4319-a9dc-bf8670807651">366,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzEzLTctMS0xLTIzNzE_b5ae39cf-9ffb-4c1e-8d02-32310b51e518">261,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzE0LTctMS0xLTIzNzE_784e36d0-5b4d-4835-b887-f47b95276bf9">714,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzg5Mw_92c22b34-aac3-48f6-8aa9-6c425f4d2486" continuedAt="ifd6ed47682ef4afaa866a52ddf8c75be" escape="true">The fair values of available-for-sale debt investments by contractual maturity as of&#160;December&#160;31, 2019&#160;and 2018 were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">103</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="ib41bc4a4250746eabc3c138e8d1d63c8"><div style="margin-bottom:6pt;"><ix:continuation id="ifd6ed47682ef4afaa866a52ddf8c75be"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:63.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.815%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzItMS0xLTEtMA_3062a76b-cdf1-474b-92d5-292ecc96af60">355,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzMtMy0xLTEtMjQ0Mw_da977735-0e04-4726-9146-519d17e46386">375,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 - 2 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzMtMS0xLTEtMA_0148a092-6476-4565-b380-90589f65bc67">58,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzQtMy0xLTEtMjQ0Mw_cff87a53-bbc4-4fd0-85c2-0037fd44bc72">240,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 3 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:zerodash" name="allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzQtMS0xLTEtMA_3df12920-babf-4003-8aa7-71d1fdb1817a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzUtMy0xLTEtMjQ0Mw_2a309e53-1c58-4cac-b491-bdd1f4d43413">36,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments not due at a single maturity date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzUtMS0xLTEtMA_12abb871-221c-4f6a-ae8a-61d4ccd0412d">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzYtMy0xLTEtMjQ0Mw_c46714ac-59e5-4ba9-a423-711a42b18932">61,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzYtMS0xLTEtMA_f66153e9-7447-43dd-bdcc-040dc3f3dddd">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzctMy0xLTEtMjQ0Mw_0219a527-56e4-4526-bcce-cdd1d55b0b93">714,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018,&#160;the remaining contractual maturities of available-for-sale securities were less than <ix:nonNumeric contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzM4NDgyOTA2OTg4MzI_8165c7d7-e7db-45a5-bfa2-0bbfa01a80ba">two years</ix:nonNumeric> and <ix:nonNumeric contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzM4NDgyOTA2OTg4MzY_b497cc87-7d8c-4787-98fd-df8e8e29f037">three years</ix:nonNumeric>, respectively. There have been no significant realized losses on available-for-sale securities for the years ended December&#160;31, 2019 and 2018. Based on the Company's review of its available-for-sale securities, the Company believes it had&#160;<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzU3Mg_c9a41c7b-2333-4a68-bc3a-e07c33536f3f"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzU3Mg_f3dc7e94-20aa-4e20-b950-33c0b12192a8">no</ix:nonFraction></ix:nonFraction>&#160;other-than-temporary impairments on these securities as of&#160;December&#160;31, 2019 and 2018, because the Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the years ended&#160;December&#160;31, 2019 and 2018.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_124"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 5. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjU0Njk_a9fbfa40-38bf-4079-b063-62072e0410f3" continuedAt="i385a5a5625cc4efd97c45652b0abef60" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i385a5a5625cc4efd97c45652b0abef60" continuedAt="i331ccc40904840b3990b30750b756e6a"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3Mw_7090560b-4397-4aec-b2e6-9a7c8d48f2f0" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:PrepaidResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMS0xLTEtMjU2Ng_8ce585e7-d9e9-4186-a612-9e568d7f4231">6,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:PrepaidResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMy0xLTEtMjU2Ng_83f852ae-4b7c-4b0e-9d58-05405617a514">2,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzQtMS0xLTEtMjU4MQ_a407ce1d-f76b-44b8-9f89-2f1370540551">2,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzQtMy0xLTEtMjU4MQ_a24c5a82-987e-4c91-8781-6b5f8259afae">2,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest on short-term marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedInterestOnShortTermMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzItMS0xLTEtMA_bd28b54c-6311-47a6-a463-ae9d3fd63c81">2,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedInterestOnShortTermMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMy0xLTEtMjUyNw_c4c2a123-4515-4fce-b618-320e4026f74a">3,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzUtMS0xLTEtMA_22219a23-8ac0-4b4d-98e0-35a88ce4a637">2,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzYtMy0xLTEtMjUyNw_ba2b6ed7-78d9-478b-bf64-4efe495c9388">758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzYtMS0xLTEtMA_38dbf494-5151-415d-a7b8-33c773a11364">14,043</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzctMy0xLTEtMjUyNw_aa288b01-d2db-4638-a8df-360f83c5f071">8,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3NA_6821d4d0-6e34-4f50-8f55-7ab353ba3b26" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f3ba3d3dc894efaacd3513306d920ab_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMS0xLTEtMjYxNQ_2d219b35-6c30-46b9-9b69-b438994c8004">29,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ebbf8f4f5bf4febac60e511f7aa4329_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMy0xLTEtMjY1Ng_f793308d-e77b-4622-8dbe-44b45a705688">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib08b0bba7d634a958a96f0964cbad763_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzItMS0xLTEtMA_0e9640f4-b364-412c-a031-3119de16554d">13,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3db3a0119c79483e94242db1f548282c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMy0xLTEtMjU0OA_e9195159-6bd2-462f-ad8e-12841b07d36f">5,534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5852e80f853444996e612e6a78b2caa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMS0xLTEtMjYzMA_73a53295-e5a2-4e66-829d-3225aae006cb">12,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38b72e2f0d4e48588b008f53598ce7d2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMy0xLTEtMjY2Mg_baa85288-7829-45ef-bf3f-3b8b9b7e70cf">2,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5647d962561c44b8b5b291742b6f3eb6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzQtMS0xLTEtMA_f9e7ae35-c5f1-47e3-a27b-5459f7fa05ec">3,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb2d346af52d45db8ca2a02108d6fb0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzYtMy0xLTEtMjY2NQ_3e95c5fb-d054-4461-9598-e16846eb9e3e">1,327</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if797f590c7f0479a9a697558f2de76e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMS0xLTEtMA_8a01c3b3-0d8f-44a8-b744-7b07a9d83ce3">2,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23478e60d4914559b5221e0ebd4c4fa8_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzctMy0xLTEtMjY2NQ_dadfdf4a-e887-4112-aa4c-e8d33a19481a">64</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzctMS0xLTEtMA_08d8e530-2abd-43f8-a6d8-6fb7bae73947">61,921</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzgtMy0xLTEtMjY2OQ_b60baa8f-f34f-40f8-87bc-050a583a31c2">9,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzgtMS0xLTEtMA_c3c76439-9c48-4013-bbd9-d2ab0ee18407">5,472</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzktMy0xLTEtMjY2OQ_92f6d7df-6180-4f75-908e-842b257e8775">1,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzktMS0xLTEtMA_4757ff34-c1b6-42b7-8357-f26e16022f43">56,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzEwLTMtMS0xLTI2Njk_9a53be12-2a35-4dd5-96c5-4a6659326988">8,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense for the years ended December&#160;31, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzU0OTc1NTgxMzk1Njc_da8e227e-631e-4455-a1e2-52461efe7bc5">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQzOTgwNDY1MTE3NDk_21ec939e-968a-4ad7-8944-9c9395983f48">1.0</ix:nonFraction> million, respectively. Disposals of property and equipment were $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjYwNzQ_e0389fee-d30c-424f-bd4d-e0faa4599a53">0.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjYwOTM_02b008a6-6c2e-4dcb-a929-24eeccb0c3ac">zero</ix:nonFraction> for the years ended December 31, 2019 and 2018, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">104</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i331ccc40904840b3990b30750b756e6a"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzE1MzkzMTYyNzg5NTIz_0cc95959-0971-4ca6-a496-a31260073f3e" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.678%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Amortization</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic080d00e479b47cb866477893266680a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtMS0xLTEtMA_f2c411ef-d074-42ec-b6c4-cbeaa114af51">1,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic080d00e479b47cb866477893266680a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtMy0xLTEtMA_ad3f3e58-5e30-4308-be29-d75678b61099">1,055</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic080d00e479b47cb866477893266680a_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtNS0xLTEtMA_823af234-55fb-4b92-b24a-903c9df5e9a4">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:45pt;"><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.970%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtMS0xLTEtMjczMg_2c4e3ec9-94aa-4bae-b439-36dab0bd4f19">1,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtMy0xLTEtMjczMg_cb79a805-a78e-4151-ab97-5cef1b8e34da">452</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtNS0xLTEtMjczMg_357f2b25-b622-4ab5-a757-37122c234139">754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the weighted-average remaining amortization period of the assembled workforce was <ix:nonNumeric contextRef="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzI5Nw_7067a047-ca33-4cba-a9b9-7008994e0499">0.26</ix:nonNumeric> years. Amortization expense related to the assembled workforce intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzM3OQ_ed17dd0c-0a5a-40ff-a5e6-bbc9ed1b8d3e">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i109b33bc252c4867bdf458174acbbebf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzU0OTc1NTgxMzk2Nzk_d3fc682a-cf05-44df-8f61-21993d9f4143">0.5</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3Ng_d48aee9f-957c-4cfc-b76e-04a7298f81c5" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and related benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedCompensationAndRelatedBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMS0xLTEtMjY5MA_9cb7975d-ac69-4e93-af4b-0d7285f49328">9,560</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedCompensationAndRelatedBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMy0xLTEtMjY5MA_58c5d4c4-1cc1-405c-8fc8-26e6c8e6c643">4,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMS0xLTEtMA_8e44fc84-741a-4771-b7df-478f4630acb0">4,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMy0xLTEtMA_256a2803-18f8-4118-8ce7-9c4e79d52346">7,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMS0xLTEtODQwOQ_5a1dbd3b-47ba-4c87-adae-d2e9da19d991">3,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="allo:AccruedPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMy0xLTEtODQwOQ_ac55d903-4861-4105-a41e-2528da15a5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:UnvestedSharesLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzMtMS0xLTEtMA_d3138651-6bbe-4d65-9ab6-526d4139f81d">2,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:UnvestedSharesLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzMtMy0xLTEtMA_7d8578c2-0534-4356-954a-0661f02eab70">4,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMS0xLTEtMA_2d70cc3b-ea57-4ba6-b58f-5cc724db3959">3,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMy0xLTEtMA_c1130557-92bc-46c8-8b06-43d25afafe03">612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzYtMS0xLTEtMA_6b9da7ce-39a7-4eb8-b2d4-04951b4db85e">23,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzYtMy0xLTEtMA_9f837af7-1745-46fe-86c7-59971f11f1db">17,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_127"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 6. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ5NDc4MDIzMjk2MDI_511dbc47-922a-4a8b-8adc-dfc1e3ed1d4c" continuedAt="ie84a54868b6d4693ba74f6410017fade" escape="true">Asset Acquisition</ix:nonNumeric></span></div><ix:continuation id="ie84a54868b6d4693ba74f6410017fade" continuedAt="i8060250c12d34ded98269bf41cb32a1e"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts described in Note&#160;7, and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As consideration for the purchased assets, the Company issued Pfizer <ix:nonFraction unitRef="shares" contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ0OA_cce836b4-419f-47d4-bed6-480bd21715a6">3,187,772</ix:nonFraction> shares of its Series&#160;A-1 convertible preferred stock with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzUzNg_adb89426-ad52-4df6-a3d6-73b9edba98e3">111.8</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzU0Mg_e073f257-7786-4c4b-a2b4-28b5032a9634">35.06</ix:nonFraction>&#160;per share. The Company also incurred $<ix:nonFraction unitRef="usd" contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzU4Mg_5b8179f0-c13c-4b13-b918-7c7d4c0c3f3d">2.1</ix:nonFraction> million of direct expenses related to the asset acquisition, bringing the total consideration to $<ix:nonFraction unitRef="usd" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzY3NA_77504cf6-1ae5-465a-9e97-8cd9ec8d87cb">113.9</ix:nonFraction> million. The fair value of the Series&#160;A-1 convertible preferred stock was established using the price per share paid by third-party investors in the concurrent closing of the Series&#160;A and A-1 convertible preferred stock financing at $<ix:nonFraction unitRef="usdPerShare" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzkwMg_35085585-a615-4850-a317-c66cd4b7228c">35.06</ix:nonFraction>&#160;per share as well as the price per share paid by Pfizer to purchase additional shares of Series&#160;A-1 convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzEwMzY_053e27c3-509f-4d67-b134-0362247efaf5">35.06</ix:nonFraction>&#160;per share at the same time and at the same price per share as the rest of Series&#160;A and A-1 shares sold in such financing (see Note 11 for additional details). The Series&#160;A-1 convertible preferred shares issued to Pfizer had the same rights, preferences and privileges as the Series&#160;A convertible preferred shares issued to the third-party investors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, anti-CD19 CAR T&#160;cell therapy, thus satisfying the requirements of the screen test in ASU 2017-1. The assets acquired in the transaction were measured based on the fair value of the Series A-1 convertible preferred stock issued to Pfizer and direct transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzE4NDk_29cf9347-c499-403d-8b74-00d2d2aeb006">2.1</ix:nonFraction> million, as the fair value of the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">105</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i8060250c12d34ded98269bf41cb32a1e"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">equity given was more readily determinable than the fair value of the assets received. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ2MDk_ee23baf3-cc17-4d3c-8f86-958c719e058b" continuedAt="ia662153fccf0413d9bf392d88e4bea7e" escape="true">The following table summarizes the fair value of assets acquired (in thousands):</ix:nonNumeric></span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><ix:continuation id="ia662153fccf0413d9bf392d88e4bea7e"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:86.286%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzAtMS0xLTEtMA_33a98d25-2089-4d76-be54-fafd3a09eff8">3,258</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development (IPR&amp;D):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-CD19 CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i418f7561acb7456a9cd8ab2b0b615390_I20180430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzItMS0xLTEtMA_66f5d67c-a9cb-41f6-9589-498a12593f73">103,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-BCMA CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4c667c41352411c9e3641748894a942_I20180430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzMtMS0xLTEtMA_d172bceb-d681-4f0c-89bc-7d4b44481c4a">5,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie103799a43e847da97be9090d9658fdb_I20180430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzQtMS0xLTEtMA_dc57bbcb-d7e5-4123-b888-518bf5276b47">1,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec3f1d9861bc4aec8c55821fb2f64337_I20180430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzUtMS0xLTEtMA_7cef7f11-daa7-4dcb-81d6-8dc902372a1d">113,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy were determined using a risk-adjusted discounted cash flow approach, which used the present value of the direct cash flows expected to be generated by anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy during their estimated economic lives, net of returns on contributory assets such as working capital, property and equipment, and the assembled workforce. The discount rate of <ix:nonFraction unitRef="number" contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430" decimals="3" name="allo:DiscountRateForValuation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzI1Mjg_cc5d5c2b-0be4-4215-a3dc-82829f2d8e21">16.5</ix:nonFraction>% was based on rates of return available from alternative investments of similar type and quality as of the valuation date. The remaining IPR&amp;D targets were determined to be more conceptual in nature with nominal value being attributed to them. The estimate of the fair value of the assembled workforce was determined using a replacement cost approach, based on the estimated cost of recruiting and training an equivalent workforce as of the acquisition date.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amount allocated to intangible IPR&amp;D assets was charged to research and development expenses as these assets had no alternative future use at the time of the acquisition transaction. The remaining intangible asset relates to the assembled workforce which was capitalized and is being amortized over its estimated economic life of <ix:nonNumeric contextRef="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzMzMjM_4e54153f-4a27-4354-8aa8-76f881d9cb21">two years</ix:nonNumeric> to research and development expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the terms of the Pfizer Agreement, the Company was also required to make milestone payments to Pfizer of $<ix:nonFraction unitRef="usd" contextRef="i209e07dad467461eb9a9d4bec5f07fe7_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM0ODc_273b5383-bcf5-4ed7-804a-b914ee3c2d4a">30.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="id04f9a07e6ef4653bc71b89352bc570b_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM0OTM_451d3d59-8079-4278-9cea-d505adcbe57f">60.0</ix:nonFraction> million per target (depending on the target, and up to $<ix:nonFraction unitRef="usd" contextRef="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregateMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM1NDM_03ed091c-e246-4393-951d-d07ef4ea3d22">840.0</ix:nonFraction> million in the aggregate for all targets) upon successful completion of certain regulatory and sales milestones for certain targets covered by the Pfizer Agreement. <ix:nonFraction unitRef="usd" contextRef="if4c18293923046afb816ad6ab2d44ca8_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM3MDM_0df7331b-5773-4bd0-98ea-b16e16d40ef4"><ix:nonFraction unitRef="usd" contextRef="i7db1990140824815a537851541246079_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM3MDM_4a17e599-91b3-40ff-8c7b-2b992bbce32d">No</ix:nonFraction></ix:nonFraction> milestone payments were made or became due in the years ended December&#160;31, 2019 and 2018. These contingent payments were not part of the consideration for the purchased assets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the asset acquisition, the Company also assumed licensing agreements Pfizer had entered into with two third-party entities holding certain intellectual property. Both agreements cover use of the intellectual property held by the parties and certain research collaboration activities. See Note 7 for additional details on these agreements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Pfizer Agreement, the Company was required to use commercially reasonable efforts to develop and seek regulatory approval in and for the United States and the European Union for certain products covered by the Pfizer Agreement and to commercialize each product covered by the Pfizer Agreement in the applicable royalty territory in which regulatory approval for such product has been obtained.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_130"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 7. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="allo:LicenseAndCollaborationAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ5NDc4MDIzMzUwMzU_e9241351-9d93-4ee1-ba92-a140eec593f8" continuedAt="i6ac714b7b3b249d99720cadb2cba2ab4" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i6ac714b7b3b249d99720cadb2cba2ab4" continuedAt="ib3fd6c61c2e54dcd8e412bedc5c7ecd8"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Pfizer Agreement (see Note 6), the Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $<ix:nonFraction unitRef="usd" contextRef="i506e30c449204baba23fb44c640ebef6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzUzOQ_47958978-5fa6-47ba-bd8c-0e01ad1143d7">30.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="i6017f1fd2aeb4f5dae24a3f6a824c26d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzU0NQ_835c0461-69a9-432f-8f9b-adc559f72dda">60.0</ix:nonFraction> million, depending on the target, with aggregate potential regulatory and development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i9427490ef4a44d8f9b59d11282662b76_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2MDI_92959fd2-db39-45b7-8002-157b2291d599">840.0</ix:nonFraction> million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $<ix:nonFraction unitRef="usd" contextRef="ifff9430c2ddd4802ba7887cb075336c9_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzExMDA_a7835cd3-7572-41d3-9f24-cfd0c7d53fe1">325.0</ix:nonFraction> million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the years ended December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">106</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="ib3fd6c61c2e54dcd8e412bedc5c7ecd8" continuedAt="i9b873f8c5cc54ad9917407f8b835f447"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for which an IND is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis. In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement. The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzMyNjU_8f73aa46-f78d-46d0-bf67-92df90df2c5f">185.0</ix:nonFraction> million per product that is directed against an Allogene Target, with aggregate potential development and sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i61808ff845034c22af5a68f40821c91c_I20191231" decimals="-8" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MjU_1ebc36ce-d37b-44b4-a550-29acc78e8c91">2.8</ix:nonFraction> billion. Cellectis is also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i) the expiration of the last to expire of the licensed patents covering such product; (ii) the loss of regulatory exclusivity afforded such product in such country, and (iii) the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">107</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i9b873f8c5cc54ad9917407f8b835f447" continuedAt="i473a8cdaeeda41f9883c1c1b0daa3355"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses. For the year ended December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i6c06fbacca5f491d8f5469bd4fb315fd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU1Njg_2ddc0211-1211-433c-afd3-8ae3b643f4f8">5.0</ix:nonFraction> million of costs were incurred related to the achievement of a clinical development milestone under this agreement, which was recognized in research and development expenses in the statement of operations. No clinical development milestones were achieved for the year ended December&#160;31, 2018. For the years ended December&#160;31, 2019 and 2018, <ix:nonFraction unitRef="usd" contextRef="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU1OTc_c25a17c5-6656-4a5f-bd91-50e46b28a472">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i75364e669b7b45f1a7aef2c29529fead_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ1MTY_ddf67665-ca45-4e37-be4d-e98ca487a332">0.4</ix:nonFraction> million, respectively, of costs have been incurred associated with research services performed by Cellectis. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License and Collaboration Agreement with Servier</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In October 2019, the Company agreed to waive its rights to the one additional target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for <ix:nonFraction unitRef="number" contextRef="i9047b22f877746d385f33c4ed54f6267_D20190101-20191231" decimals="2" name="allo:PercentageOfDevelopmentCostResponsibleFor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzY5MzI_85fd04bb-1bfd-4ccb-ae72-3b860590803b">60</ix:nonFraction>% of the specified development costs and Servier is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231" decimals="2" name="allo:PercentageOfDevelopmentCostResponsibleFor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzcwMTU_13e41c4e-1fe3-4af9-8584-ac66b682d41e">40</ix:nonFraction>% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i2d0e971edbd54b578a622c44aadb4b6e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzc3Mzk_46549ab3-ed11-44fb-b08f-1817feffd8f1">137.5</ix:nonFraction> million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i026e57edd43d4beb8496539196c89a2a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzc4NzE_7953fbbe-adff-44dd-83e4-06d612afe69f">78.0</ix:nonFraction> million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $<ix:nonFraction unitRef="usd" contextRef="i4b9afa63ed9142d29e23a8cc70154a6c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzg1NTk_c76f8396-efb9-4889-872d-8a843e498d63">42</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="if9165b13a059438f9d7dce0930c8b3e1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzg1NjY_6714cf52-e83b-46a2-b2aa-6eb69f19b960">70.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="if9165b13a059438f9d7dce0930c8b3e1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2MzY_2c84607d-1f16-4369-b0f7-8e52cb50ae2b">79.1</ix:nonFraction> million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">108</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i473a8cdaeeda41f9883c1c1b0daa3355" continuedAt="ie4b4baa2a7ee49b38b1eea88be1a0ded"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2NTU_a7b6eb30-37f7-49f4-840d-103d01c2e1f0">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0156b166fd0646f1a182d6801df909d7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzk5MTg_52a15e32-4cd5-4dab-a88c-8ac73b5f9353">4.2</ix:nonFraction> million, respectively, of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. As of December&#160;31, 2019 and 2018, amounts due to Servier of $<ix:nonFraction unitRef="usd" contextRef="ib9b1db0a202a4ae19712fb80c6cd0e22_I20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2NzE_475ab953-ea8e-41f5-b135-bdb30f0daa7f">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i191222ceb5b4462cb69b763179a7d5b9_I20181231" decimals="-5" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2ODY_a0734792-3ef9-438b-b80c-21077a9ba420">4.2</ix:nonFraction> million were recorded in accrued and other current liabilities in the accompanying balance sheets. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Notch</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $<ix:nonFraction unitRef="usd" contextRef="i14f6805421204eae85b427c2f3c6052a_I20191101" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3NDM_3663d14c-91ae-4bb4-9352-269a722fc570">10.0</ix:nonFraction> million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i0d5aa740645543fbb3c41bb7edf9788d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ5NDc4MDIzNjU0NDY_df019476-e87e-4969-ac37-3f45810697b6">10</ix:nonFraction>&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $<ix:nonFraction unitRef="usd" contextRef="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3NjA_e13ea92c-699b-487a-992c-69d40b5ee949">5.0</ix:nonFraction> million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a <ix:nonFraction unitRef="number" contextRef="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3Njg_a2291156-ed99-4d0f-ad4d-7084602efc86">25</ix:nonFraction>% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Notch Agreement, Notch will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ibcc9be9dbd394b6582ca42b028bc5605_I20191231" decimals="-4" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3ODM_6df29491-db05-49f5-ada1-6807176a21a0">7.25</ix:nonFraction> million upon achieving certain agreed research milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i3adabcdd37fd4a4c9feddc86618ac41d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MDA_df46fde6-57c4-448b-a540-e7ad6828c9ec">4.0</ix:nonFraction> million per exclusive target upon achieving certain pre-clinical development milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i46a7d0cfcf8146eb94cd73bc47ddd879_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MTk_eeba042a-db79-4c1d-9b6c-806ceff0bbb9">283.0</ix:nonFraction> million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has determined that Notch is a variable interest entity as of December 31, 2019. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the year </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">109</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="ie4b4baa2a7ee49b38b1eea88be1a0ded">ended December 31, 2019, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary.</ix:continuation></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_133"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 8. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQ5NDc4MDIzMjgyNjI_99d91a05-9d73-4666-80db-c47dd99a75af" continuedAt="i0c98328290794444b3515cb28d9de920" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0c98328290794444b3515cb28d9de920" continuedAt="i39faa459386d4328a277751f537b7f0c"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately <ix:nonFraction unitRef="sqft" contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY1MzM_7fc944d4-85b0-4f3a-bb2a-f2c2219108f9">68,000</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzIzNQ_cd9eeb18-4896-4f09-a648-42880fdd08ad">127</ix:nonNumeric> months beginning August 2018 through February 2029 with an option to extend the term for another <ix:nonNumeric contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzMxNw_977d24df-bfc9-405a-9194-d8aebd901b7c">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831" decimals="-5" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzUwMA_3507e65e-8a48-40b9-a2d2-7f6dea5b8f30">5.1</ix:nonFraction> million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzY5Nw_bd7d87d6-7840-4e16-966c-11055a8f177e">1.0</ix:nonFraction> million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ic0412b597de74f279eae527af0469dbd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwMTA_373441f4-f63c-4fcb-92e4-7c2933e4082d">23.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwMTk_015c12bd-86f8-452d-b416-1e419ca1347c">24.6</ix:nonFraction> million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="ic0412b597de74f279eae527af0469dbd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwNTk_e44805b0-870c-480b-9dd7-5cb51b14f0c2">30.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwNjg_2a4e5672-5105-444e-9032-9d6400d5e491">26.3</ix:nonFraction> million, respectively, on the balance sheet. The remaining lease term is <ix:nonNumeric contextRef="ic0412b597de74f279eae527af0469dbd_I20191231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMTM_f23bd6a7-93fa-4d23-969e-02e5e0c12442">9 years and 2 months</ix:nonNumeric>, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="ic0412b597de74f279eae527af0469dbd_I20191231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxMDg_688b73c9-c558-4119-bcc1-7d9c3d33a2b0">8.0</ix:nonFraction>%.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately <ix:nonFraction unitRef="sqft" contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031" decimals="INF" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzExMTA_4ea8d027-99ae-484d-86e4-72bc3aedbecf">14,943</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzExODc_79c1efa2-e97b-40b6-b8bb-2079a93fec32">124</ix:nonNumeric> months beginning November 2018 through February 2029, with an option to extend the term for another <ix:nonNumeric contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzEyNzI_56bab084-c7a3-47c8-be51-9042361d2a0e">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031" decimals="-5" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzE0NzQ_558a8388-703d-495c-b09a-24caf23c01ca">0.8</ix:nonFraction> million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzE2NDE_d15dc885-d1ef-4248-b0eb-612c495da22d">0.2</ix:nonFraction> million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxMTU_76aae00e-a345-4524-8631-b6377f84e70d">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia4a231e4e72e4029ac07d4f130b3076f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNTM_b8fada93-3110-4e3e-bb91-3283dbc4d3fb">6.2</ix:nonFraction> million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNDY_655cfe09-f9f8-4a50-8a59-b041d800adee">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia4a231e4e72e4029ac07d4f130b3076f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNTY_600971a9-3860-41d4-85ad-becd831e373b">6.3</ix:nonFraction> million, respectively, on the balance sheet. The remaining lease term is <ix:nonNumeric contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYyMTA_f662cbaf-86d1-43e4-b8b9-a42f34d9e777">9 years and 2 months</ix:nonNumeric>, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY1MzA_efff4a71-39be-4165-9b2d-21d0907b18d3">8.0</ix:nonFraction>%.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into <ix:nonFraction unitRef="operatinglease" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="allo:OperatingLeasesNumberOfLeaseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMTg_b93416f2-172b-4e8a-b803-caf38b26ddf1">two</ix:nonFraction> operating leases for office space in New York and Los Angeles for approximately <ix:nonFraction unitRef="sqft" contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMjI_1f69a1da-37c1-4112-bcbd-5cc3fbb950c1">4,358</ix:nonFraction> and <ix:nonFraction unitRef="sqft" contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMjU_7b0160cd-4911-4f23-b7a5-623d1c0798b2">1,293</ix:nonFraction> square feet respectively. The Company recognized operating lease right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="ifd2210c6df794207907be5b74981ad04_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3Njc_f2524ca4-3084-4b32-b99d-23c71d289830">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3NzA_01b580f6-cd5e-4472-8db6-078342c3263f">2.0</ix:nonFraction> million for New York and $<ix:nonFraction unitRef="usd" contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3ODE_d280cbab-5012-4523-ad72-1ebc53153c72">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3OTI_70e829e7-f217-4949-ae91-35aaa95a109a">0.2</ix:nonFraction> million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The Company recognized aggregate lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ifd2210c6df794207907be5b74981ad04_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MDE_cc372e12-4f5c-46a1-9ffc-68af1319e7a4">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MDQ_e0a4f57c-2cee-4595-b829-9b7c4711da0c">2.0</ix:nonFraction> million for New York and $<ix:nonFraction unitRef="usd" contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MTU_e72a4cfa-a0a4-44ad-9526-bc14fc72f82c">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MjY_52077835-76e9-44f9-a52c-3bdf94d81a31">0.2</ix:nonFraction> million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The lease term for the New York operating lease is <ix:nonNumeric contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY5OTk_8bad4b5c-457e-4ed8-a24a-aa140347cb27">6 years and 7 months</ix:nonNumeric>, with no option for renewal. The lease term for the Los Angeles operating lease is <ix:nonNumeric contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMDQ_43eae74e-820a-47c4-8677-17912d21902b">3</ix:nonNumeric> years with an option to extend the lease term for another <ix:nonNumeric contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMDc_54191ad0-06ab-4da5-8b81-22a3f1859184">2</ix:nonNumeric> years which is not reasonably assured of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintained a letter of credit for the benefit of the landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="ifd2210c6df794207907be5b74981ad04_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMTM_5cb854b9-484c-4030-b327-ddceafa6168b">0.1</ix:nonFraction> million. The remaining lease terms were <ix:nonNumeric contextRef="ifd2210c6df794207907be5b74981ad04_I20191231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMzg_cc544c4d-b49e-48c3-b3f7-74b6edcf0083">5 years and 6 months</ix:nonNumeric> for New York and <ix:nonNumeric contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNjM_67e679ed-4929-4816-9741-c17f46d5891c">1 year and 11 months</ix:nonNumeric> for Los Angeles at December&#160;31, 2019 and the estimated incremental borrowing rates applied were <ix:nonFraction unitRef="number" contextRef="ifd2210c6df794207907be5b74981ad04_I20191231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNjg_4d89285a-2e8f-42f3-a77c-954d120f0575">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNzI_dcd1b0f7-a96e-48c1-9f40-1279a492002e">7.5</ix:nonFraction>%, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwODE_da94ee9a-cd53-44b7-ae86-63dc8966ff02">118,000</ix:nonFraction> square feet of space to develop a cell therapy manufacturing facility in Newark, California. Upon certain conditions, the Company has <ix:nonFraction unitRef="option" contextRef="i54c6044221fa4585b6ea5a3c74e488dd_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="allo:LesseeOperatingLeaseOptionToExtendNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNzg_10ec3085-f7bb-484f-831e-fe5a2d8a92f5">two</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNjc_5253a5b3-7a0c-4331-8539-db7f2e8159f7">ten</span>-year options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$<ix:nonFraction unitRef="usd" contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTczNzQ_eb43ecef-f024-4059-b335-ed3caa6950bf">2.9</ix:nonFraction> million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company will maintain a letter of credit for the benefit of the landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTczOTE_094c0949-0d3f-4955-9cd2-009847019e40">3.0</ix:nonFraction> million. The Company started accounting for this lease in October 2019 when tenant improvement work commenced, and recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3Mjg_295ead7e-62bb-4a1f-a10f-9e490b16885c">13.6</ix:nonFraction> million as of December 31, 2019 and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3NDE_a30734ba-f04b-4694-a7c3-d96999dd5c1a">14.0</ix:nonFraction> million on its balance sheet. The lease term is <ix:nonNumeric contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQ5NDc4MDIzOTQ4MzQ_96da8ee0-683e-4e80-9345-1ee834416be0">188</ix:nonNumeric> months, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231" decimals="4" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3ODY_f0faf4bf-aab8-4a67-83d5-975dec6d9edc">9.25</ix:nonFraction>%. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">110</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i39faa459386d4328a277751f537b7f0c"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzMyNjQ_245d94d8-c046-47b9-bcd3-fb59c6b5396f" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future non-cancellable lease payments under our operating leases as of December&#160;31, 2019 is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:84.032%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.226%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzEtMi0xLTEtMA_2d577189-f414-46a8-9bb4-b636832c2508">5,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzItMi0xLTEtMA_f3bfc496-e117-43a6-ab01-75b72135e9a4">7,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzMtMi0xLTEtMA_c9f8ebb6-a4e2-44fa-806f-015ec18109b9">7,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzQtMi0xLTEtMA_d3080040-2410-4037-b4b2-8ce643a94744">8,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzUtMi0xLTEtMA_389f26c2-989d-4ffa-a24b-c5783f541123">63,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzYtMi0xLTEtMA_b589d735-5dd8-4aef-ae04-eefabb6c4d1e">93,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzctMi0xLTEtMA_c2d33209-3aef-4fce-80c8-8ed601ee289c">35,920</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzgtMi0xLTEtMA_39c4c785-572e-4888-b4a9-d2122f336b8e">4,367</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzktMi0xLTEtMA_df080e30-1512-4df7-929f-4c149804b788">53,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the Company&#8217;s operating leases was $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3OTc_b10eca25-84be-4912-aa7d-f91fecb82841">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4MzA_7ab6ef57-1d5f-4d4c-bb14-635adb9a9322">1.9</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively, net of lease incentives recognized. Rent expense for short-term leases was $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:ShorttermLeaseRentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4MzI_78184b45-74c6-475b-9151-1fe814f5b059">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="allo:ShorttermLeaseRentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4NDA_61bd31a0-9429-428a-8ce9-fc966cf3f896">2.6</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively. There was a total commitment of <ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4Nzg_d50874a5-3aa0-4202-91b3-1005eb171b94">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4ODM_18e05d9a-8ed5-44f6-8657-93229eaaac1f">1.6</ix:nonFraction> million at December&#160;31, 2019 and 2018, respectively, related to short-term leases. Variable lease payments for operating expenses were $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeasePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc5OTY_0cb163c1-b7df-46af-b78f-f66fa0d21967">1.1</ix:nonFraction> million and immaterial for the years ended December&#160;31, 2019 and 2018, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain lease agreements require the Company to return designated areas of leased space to its original condition upon termination of the lease agreement. At the inception of such leases, the Company records an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. To determine the fair value of the obligation, we estimate the cost for a third-party to perform the restoration work. In subsequent periods, for each asset retirement obligation, the Company records interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Asset retirement obligations were $<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-5" name="allo:OperatingLeaseAssetRetirementObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzYwNDczMTM5NjA1ODA_0fec5484-6d24-4f74-b4a6-a25c8f116fdc">0.4</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="allo:OperatingLeaseAssetRetirementObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTkyNTA_483b1696-2f31-4598-ba03-303be368efa8">zero</ix:nonFraction> as of December&#160;31, 2019 and 2018 respectively.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_2053"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 9. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDEz_34bac431-ff0e-47c8-95b4-f68589849841" continuedAt="i82473330d1eb4d6689c83186c08c19f6" escape="true">Equity Method Investment</ix:nonNumeric></span></div><ix:continuation id="i82473330d1eb4d6689c83186c08c19f6"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the execution of the Notch Agreement (see Note 7), the Company also entered into a Share Purchase Agreement (&#8220;Notch Investment Agreement&#8221;) with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $<ix:nonFraction unitRef="usd" contextRef="id582a2792aa240b5b2ce2ac625929e33_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDMy_b139054d-f77f-41be-a21e-3b183457c90b">5.1</ix:nonFraction>&#160;million which includes transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:CostMethodInvestmentTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzUy_1d112a8d-b5d1-4cfb-aa32-a0a0d84e8010">0.1</ix:nonFraction> million, resulting in a <ix:nonFraction unitRef="number" contextRef="i245b301a06c44689b7b0147fb93ad43b_I20191231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzU4_09f86116-3d77-4d2f-bae7-d927c7072945">25</ix:nonFraction>% ownership interest in Notch. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s total equity investment in Notch as of December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i245b301a06c44689b7b0147fb93ad43b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDQ0_ba948523-b7cf-4c6b-8466-9d51f1bbbc99">4.9</ix:nonFraction>&#160;million and the Company accounted for the investment using the cost method of accounting. During the year ended December 31, 2019, the Company recognized its share of Notch's net loss under the other expenses caption within the statement of operations. The Company's share of Notch's net loss was $<ix:nonFraction unitRef="usd" contextRef="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:IncomeLossFromCostMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzM3_d9958f96-b708-47fb-afc5-93db9c76a74b">0.2</ix:nonFraction> million for the year ended December 31, 2019.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_139"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 10. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzkvZnJhZzo2N2Q4ZmQzNDFhMzU0MTE4YmMzNjNmMWMyZGY1ZjIwMi90ZXh0cmVnaW9uOjY3ZDhmZDM0MWEzNTQxMThiYzM2M2YxYzJkZjVmMjAyXzQ5NDc4MDIzMjY1OTY_9cf9403b-0b30-4526-9acf-8261b3a202f9" continuedAt="i90d5ab8b1379489d84b40631f0252d4e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i90d5ab8b1379489d84b40631f0252d4e" continuedAt="ib3d6aa13a30e41b092dfd06290b7c36c"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchase Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, and we have entered into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.&#160;The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made.&#160;The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">111</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="ib3d6aa13a30e41b092dfd06290b7c36c"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with the Company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity.&#160;There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_142"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 11. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5NDc4MDIzMjYyNzQ_33ed97bb-ef3c-421c-a611-88cf6503e707" continuedAt="i456038cd2713451c9dba18d3feb0e441" escape="true">Convertible Notes Payable (2018 Notes)</ix:nonNumeric></span></div><ix:continuation id="i456038cd2713451c9dba18d3feb0e441"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzE3Ng_9022b838-e7d1-4b8c-9008-dbd2d0bdffab">120.2</ix:nonFraction> million in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzI4Nw_fefa648b-fb02-4290-ac22-651f795c6d63">116.8</ix:nonFraction> million. On issuance, the fair value of the 2018 Notes was determined to be equal to $<ix:nonFraction unitRef="usd" contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzM2Nw_0c9fb127-f713-4bff-909a-35070e7a72a2">120.2</ix:nonFraction> million, which is the principal amount of the 2018 Notes.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2018 Notes did not accrue interest. The 2018 Notes were settled in <ix:nonFraction unitRef="shares" contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5MQ_6169e23a-7418-4764-af1a-58e02c43fe39">7,856,176</ix:nonFraction> shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price equal to <ix:nonFraction unitRef="number" contextRef="ie63f9c3516964c56af3104a004c46f95_D20181001-20181031" decimals="2" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5NDc4MDIzMjYyNzY_3d4d59de-089a-4246-b803-a8391833af17">85</ix:nonFraction>% of the IPO price per share.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in estimated fair value being recognized through the statements of operations and comprehensive loss until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be $<ix:nonFraction unitRef="usd" contextRef="i821e501b07404b9a9c7d2c5ca11840c7_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzkyNA_eb5bb814-19f0-4d47-9745-5911071e845e">141.4</ix:nonFraction> million upon settlement. For the years ended December&#160;31, 2019 and 2018, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncreaseDecreaseInNotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQzOTgwNDY1MTI1Njk_91838a71-7de7-42f6-aaa8-b0dfcbdf8a64">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInNotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzk5MA_2569ef73-acc4-4969-b5a7-3da1fc9c74c7">21.2</ix:nonFraction> million, respectively, of expense in the accompanying statements of operations and comprehensive loss for the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzExNjI_74e89e0a-3309-47f0-b8f0-6e94f462cd22">3.4</ix:nonFraction> million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_145"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 12. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQ5NDc4MDIzMjcxNjM_4d79557c-7871-49e1-89f3-5b3c39e1edc6" continuedAt="icc1a1dce818a42b7b826f36aa6c618db" escape="true">Convertible Preferred Stock and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="icc1a1dce818a42b7b826f36aa6c618db" continuedAt="iaef800af134e41649eb0edec886969c5"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note&#160;6, the Company issued <ix:nonFraction unitRef="shares" contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE0OA_23a6dabd-0cb3-41c2-9623-a01766f19de6">3,187,772</ix:nonFraction> shares of its Series&#160;A-1 convertible preferred stock to Pfizer in connection with the Pfizer Agreement entered into in April 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="ia3471d8f101c4d3ba94220c7aad9494d_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzMxNg_d6e58a1d-4421-407a-904e-aa908c91c50d">7,557,990</ix:nonFraction> shares of its Series&#160;A convertible preferred stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia3471d8f101c4d3ba94220c7aad9494d_I20180430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzM5NA_71091379-62a8-4fa4-bbfd-4767b834b84f">35.06</ix:nonFraction> for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3f92a81d50e2447da3666732666bc702_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQyMg_52d985d6-95e4-4cdb-8802-dcc7cd986f36">264.4</ix:nonFraction> million and issued <ix:nonFraction unitRef="shares" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzNg_ebf8ae23-6d4a-4de3-ab9c-9f98e95b5a72">998,225</ix:nonFraction> shares of Series&#160;A-1 convertible preferred stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzUxMg_ca1f6c08-5e91-4bf1-b54d-05a7cbd6650f">35.06</ix:nonFraction> for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzU0MA_93b9b6e6-a714-453d-801f-8cf4f8eaa87c">34.9</ix:nonFraction> million. Fifty percent of the aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePurchasePriceSharesValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzU5Mw_686f65b2-c4dc-4147-a28c-5db6a9c19730">300.0</ix:nonFraction> million was paid in April 2018. The remaining subscriptions receivable of $<ix:nonFraction unitRef="usd" contextRef="if780bd54cfd745968c9507e6e347e804_I20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzY2Mg_4dc02908-bf09-47c6-b2eb-c423505c9859">150.0</ix:nonFraction> million was received in July and August 2018, at the election of the Company&#8217;s board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the completion of the IPO (see Note 1), all outstanding shares of convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="id87618dee4474bd9a48ad4abc969f130_I20181010" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5Xzg4Nw_95633ee6-5525-48d7-8d5c-7e72b7404e5e">61,655,922</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of <ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEwODE_4cb46eed-d35a-4993-a43c-c0bb9ae77635">10,000,000</ix:nonFraction>&#160;shares of preferred stock, of which <ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_07923c8a-5c54-4c66-9ed1-e9c820717518"><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_2fdb570b-2bb8-4efa-973b-ea0ef2624cfe"><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_36cbb2a8-9344-425a-8a23-f3190087009c"><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_b885b8ea-d875-4fc4-a6a9-9afb4d700026">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding at December&#160;31, 2019 and 2018.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of <ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzMzA_14ad3dcd-e472-462f-8406-ef1a8c75a793">200,000,000</ix:nonFraction>&#160;shares of common stock, of which <ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzOTgwNDY1MTMzMDA_1b34abc4-f34b-4a48-94c9-2eb867de49ad"><ix:nonFraction unitRef="shares" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzOTgwNDY1MTMzMDA_2e9c5775-ff92-4b13-83da-8387305dfb3c">124,267,358</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzNjY_1e4a2731-e048-4ad7-aadc-ff339f39dd07"><ix:nonFraction unitRef="shares" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzNjY_ae239ed7-3955-4b2d-832e-3dabedb2679e">121,482,671</ix:nonFraction></ix:nonFraction> shares were issued and outstanding at December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Company&#8217;s Series A convertible preferred stock in April 2018, the Company&#8217;s founders agreed to modify their common shares outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the <ix:nonFraction unitRef="shares" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="allo:ModificationOfConvertiblePreferredStockForCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE3MDc_a6ed6530-fd73-45b0-a4f6-2693b948d142">26,249,993</ix:nonFraction> modified shares of common stock became compensatory upon such modification. The total compensation cost resulting from the modification is approximately $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4NjM_12f86bc5-6ba7-4041-b683-36adbb418312">59.5</ix:nonFraction> million and is being recognized over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4OTk_9cc142d9-55cb-4a93-93b8-502c7e750f35">four</span> year vesting term.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">112</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iaef800af134e41649eb0edec886969c5">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors subject to the prior rights of the preferred stockholders. As of December&#160;31, 2019 and 2018, <ix:nonFraction unitRef="usdPerShare" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzIwODg_0664c6ab-3118-4c62-8350-6b21b36cc473"><ix:nonFraction unitRef="usdPerShare" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzIwODg_4832c564-fb08-4e52-b880-67625215b3d5">no</ix:nonFraction></ix:nonFraction> dividends on common stock had been declared by the Company&#8217;s board of directors.</ix:continuation></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_148"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 13. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzMyOTY_3bf83780-390c-4006-bab4-2fbc9879ab34" continuedAt="ib6d3ea5109bb4153a7997d63b6780e1e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ib6d3ea5109bb4153a7997d63b6780e1e" continuedAt="i387d356797224248ab73d0c687e1aa78"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Equity Incentive Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to <ix:nonFraction unitRef="number" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="INF" name="allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NjY_437e91bd-ef1b-4ca3-9ce5-dc783ec1c50e">5</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">st</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed <ix:nonNumeric contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231" format="ixt-sec:duryear" name="allo:StockOptionGrantedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1Njk_ef1b4889-4637-4ca9-8e6b-6aa9b39a8726">10</ix:nonNumeric> years. The Company generally grants stock-based awards with service conditions only. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzEwODk_5e3a8163-9ab6-4322-bca2-e60302945177">four</span>-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc1MzQ_e0c6a459-876a-4698-840d-09c9bbd3a86c">four</span>-year period but may be granted with different vesting terms. Options shall not have an exercise price less than <ix:nonFraction unitRef="number" contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231" decimals="INF" name="allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NzI_6f8b6a0e-76ed-4ef1-921d-94860f865cba">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the grant date. If the individual possesses more than <ix:nonFraction unitRef="number" contextRef="i2fe5e85d46bc42af97edd8a33aeb5fac_D20190101-20191231" decimals="INF" name="allo:CombinedVotingPowerByIndividual" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NzY_e2c79f6b-7315-4e54-9e9e-9450fc8eaf89">10</ix:nonFraction>% of the combined voting power of all classes of stock of the Company, the exercise price shall not be less than <ix:nonFraction unitRef="number" contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231" decimals="INF" name="allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODA_2ed44749-d4cd-4f80-b8a5-6fad9e6f5984">110</ix:nonFraction>% of the fair market value of a common share of stock on the date of grant. This requirement is applicable to incentive stock options only.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, there were <ix:nonFraction unitRef="shares" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODQ_42715812-fd2e-4b5d-9939-32ea85d738f3">9,642,503</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODc_4560a6c1-d5ea-4aab-8181-327a2f3dc985">8,176,125</ix:nonFraction> shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDA_936dd60c-ca9c-4d21-938f-9565529795eb" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Contract</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtMy0xLTEtMA_11cce863-96d1-4a03-a899-7db7a6bc9913">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtNS0xLTEtMA_07777e30-d793-4dd7-ac37-8e39529ebc39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonNumeric contextRef="ia43d81dd97134b1c840f4d8375d51b36_D20170101-20171231" xsi:nil="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtNy0xLTEtMA_292731fa-1b53-4798-9791-854039898395"></ix:nonNumeric></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtOS0xLTEtMA_11f2d267-6c68-4b2a-a4b7-9c68ca1d7ec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzUtMy0xLTEtMA_39cec952-86c0-48eb-a1fb-cd8007011672">12,336,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzUtNS0xLTEtMA_8c1e088b-8ca9-4665-8735-2375db3f0fb7">5.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtMy0xLTEtMA_984fd4f7-d137-48d3-a63c-63aeecad475c">5,020,580</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtNS0xLTEtMA_b9785488-0557-459b-8404-5fd4eec3c478">2.27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtOS0xLTEtMA_706058a9-420b-4fb5-a617-d4c018cdae0b">123,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzctMy0xLTEtMA_548ddeb4-4244-4d5d-bdc3-4812b0edf89d">80,850</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzctNS0xLTEtMA_fab0c0d3-69f0-4e4e-9adb-757f24491b65">2.27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMy0xLTEtMA_89a5e2fb-fa20-46a1-8fdb-e59f57ea7b7c">7,235,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtNS0xLTEtMA_a417224c-1513-40f2-83c3-3a16d53259d6">7.72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtNy0xLTEtMA_2eeb4ed7-5e6a-46bb-89ce-c4b98573d797">9.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtOS0xLTEtMA_56470ed2-299c-40e9-8c30-db472a916023">139,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMS0xLTEtMzk5Nw_be8578ce-8ee7-4162-920f-040e14d47d03">3,052,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMy0xLTEtMzk5Nw_a8555ac9-97cc-4339-bfb8-3e7c0fd1b0da">27.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMS0xLTEtMzk5Nw_f435a04e-257c-4388-b728-6cafbc1981f8">711,123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMy0xLTEtMzk5Nw_1daa2f54-c2f4-4e31-9340-dca1eddba555">4.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNy0xLTEtMzk5Nw_1235df4a-aad9-464e-a03a-5ce8cc16b129">17,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTEtMS0xLTM5OTc_c9f73571-f6fd-4348-a6a3-5cddf11dc0a4">386,716</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTMtMS0xLTM5OTc_b70c2841-4255-415f-b8fb-cebfb12e4b10">8.79</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTEtMS0xLTM5OTc_b3d735bf-c6d9-4901-8829-8b1dc5156bd5">9,190,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTMtMS0xLTM5OTc_3d6c340c-15db-4931-9f79-7f704fb36b0a">14.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTUtMS0xLTM5OTc_75787419-562a-4ca7-9dea-cdc738ff2a12">8.82</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTctMS0xLTM5OTc_3f40ffd5-86ef-4bc3-9244-6964ad2665b9">110,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMy0xLTEtMA_fe8e1d3a-1326-45cb-bd44-b5023560e9a5">4,660,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNS0xLTEtMA_0d15bfe8-3c49-4137-b4e1-cb401b1143ea">11.33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNy0xLTEtMA_8597da05-03f8-44db-b8fb-7e4bc75e4f64">8.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktOS0xLTEtMA_b86d2c1a-290d-4e89-88c1-a73034caedd1">69,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTMtMS0xLTA_8aaac948-3e5d-42cc-8450-9f637c7e92ee">9,190,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTUtMS0xLTA_2b899c4c-379e-4252-9a76-834c87466b78">14.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTctMS0xLTA_ee8536b3-6463-426a-80f4-bf7793df279f">8.82</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTktMS0xLTA_272d83e3-ca77-41a3-a465-818562c9bb9b">110,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on December&#160;31, 2019. During the years ended December&#160;31, 2019 and 2018, the estimated weighted-average grant-date fair value of employee options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjUyNTY_0ae8228e-b4b3-41d4-b915-b625d78079db">18.42</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1OTk_b3adb1d0-5d0e-4362-b162-cb4fff84e4b0">3.75</ix:nonFraction> per share, respectively. As of December&#160;31, 2019 and 2018, there was $<ix:nonFraction unitRef="usd" contextRef="i79699a85746047d8bd631f0242942e41_I20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2MDI_043831f4-25f4-4f8d-ba72-f9692163cd9c">74.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i11a2bcc9c898478cbaded2c1853112a5_I20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2MDU_c19e9c08-b541-4ebd-bdd5-d75abc0e6a9c">42.8</ix:nonFraction> million, respectively, of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2OTc_7f84e95b-df49-41d1-8850-4419e3abda14">3 years, 15 days</ix:nonNumeric> and <ix:nonNumeric contextRef="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2NzU_193c59a6-61c5-4c70-a85e-c9f47ddec67d">3 years, 6 months</ix:nonNumeric>, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">113</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i387d356797224248ab73d0c687e1aa78" continuedAt="i6cf26fbc2c174651846463e730df9ca7"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDE_cf201f26-4df6-4ba8-9ee7-73b136809d06" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:66.274%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.497%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.645%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$25.94 - $31.99</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$2.27 - $26.52</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.27 - 6.08</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99&#160;-&#160;6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.14% - 74.92%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.2% - 77.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54% - 2.62%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.74% - 2.99%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToxZmM0YzYxY2Y4NDM0MWVkYjU3MjgyMmQwY2I0MGUwYS90YWJsZXJhbmdlOjFmYzRjNjFjZjg0MzQxZWRiNTcyODIyZDBjYjQwZTBhXzUtMS0xLTEtNjM1Ng_c6a8701e-f32e-417c-9a94-a01900a99198">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToxZmM0YzYxY2Y4NDM0MWVkYjU3MjgyMmQwY2I0MGUwYS90YWJsZXJhbmdlOjFmYzRjNjFjZjg0MzQxZWRiNTcyODIyZDBjYjQwZTBhXzUtMS0xLTEtMA_d8328448-cb7e-4f94-b7b4-9c529ad6ad2c">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value of common stock</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;For grants before October 2018 when the Company was private and there was no public market for the Company&#8217;s common stock, the fair value of the Company&#8217;s common stock underlying share-based awards was estimated on each grant date by the Company&#8217;s board of directors. In order to determine the fair value of the Company&#8217;s common stock underlying option grants, the Company&#8217;s board of directors considered, among other things, valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. For all grants subsequent to the Company&#8217;s IPO in October 2018, the fair value of common stock was determined by taking the closing price per share of common stock per Nasdaq.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to stock options was $<ix:nonFraction unitRef="usd" contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3MjE_9ae7eb88-6dd7-44f3-8acb-106979ce731a">21.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3MjQ_e47f36da-378c-4d30-b7b5-ea039a18f9a7">3.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc2MDM_f31156a3-4c90-470e-a0db-cc3945f87996" continuedAt="i1f0dceb93faa4f0b8969028a8c1f1696" escape="true">The following summarizes restricted stock unit activity under the 2018 Plan:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">114</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i6cf26fbc2c174651846463e730df9ca7" continuedAt="if812957f7b374b97a9adf7e1ee7947ae"><div><ix:continuation id="i1f0dceb93faa4f0b8969028a8c1f1696"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted- Average Grant Date Fair Value per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItMS0xLTEtNjI5NQ_d95bdbbe-acef-448c-a2e0-756735fff62f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItMy0xLTEtNjI5NQ_ee445b1a-0c95-4ab4-9dc3-0658741c4212">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItNy0xLTEtNjI5NQ_37ba1e2c-832e-43b8-809f-898c8647851a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtMS0xLTEtNjI5NQ_5562315a-6b28-4a5d-9b30-f80763cdf00f">1,982,855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtMy0xLTEtNjI5NQ_69189a86-c9da-4984-babc-fe4f359ca41a">27.45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtNS0xLTEtNjI5NQ_27dffa76-4574-4709-a62a-59a044ab73a4">1.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzQtMS0xLTEtNjI5NQ_4dab5410-de11-41d9-a747-83617b691b3c">500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzQtMy0xLTEtNjI5NQ_4e64d498-ac12-4f6f-a066-58e4f4ed9736">25.94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzUtMS0xLTEtNjI5NQ_7d32c774-8230-452c-bfe7-530d7882cefa">41,200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzUtMy0xLTEtNjI5NQ_e539cb51-ebcd-4e70-b992-04f53fa69777">27.48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtMS0xLTEtNjI5NQ_e5c65a62-4113-4c7a-9a35-c1e41e5acae2">1,941,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtMy0xLTEtNjI5NQ_860d3fe7-4998-462b-99c0-a6ea589f1c57">27.45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtNS0xLTEtNjI5NQ_3aba0a37-5ccc-4503-af10-4c840a9e6b0c">1.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtNy0xLTEtNjI5NQ_608337c0-a416-4bcf-ab03-fb4529b21b55">50,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="INF" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctMS0xLTEtNjI5NQ_a1e561a6-ccba-424d-a568-4fcdf5bb1cd7">1,941,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctMy0xLTEtNjI5NQ_2f1c70be-799a-469c-b74f-b072b0eb8fe0">27.45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctNS0xLTEtNjI5NQ_058ea1c1-2458-444f-928c-07400c5e681c">1.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctNy0xLTEtNjI5NQ_0ea47fcb-8eb4-4659-81af-6cf811b75049">50,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#160;In September 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3Mzg_2646c02b-ec15-402b-a6dc-49c5ebae4ccc"><ix:nonFraction unitRef="shares" contextRef="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3Mzg_582d6c6c-19e0-4639-aaa4-99cbde2fa1d4">57,361</ix:nonFraction></ix:nonFraction> performance based restricted stock units to a certain executive officer pursuant to the 2018 Plan. These performance awards are subject to the holder's continued service to the Company through each applicable vesting event. Through December 31, 2019, the Company believes that the achievement of the requisite performance conditions for these awards are not probable and as a result, no compensation expense has been recognized related to these awards in the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3NDY_5c7f98ac-e34f-4254-b542-376b49e2c0fc">8.8</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i363161bd29bc4e10850ef908f85ad126_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzM4NDgyOTA3MDkyOTE_d20435de-4917-4318-be9e-5502a9621f9a">zero</ix:nonFraction>, respectively. As of December 31, 2019 and 2018, there was $<ix:nonFraction unitRef="usd" contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjQ1MDc_25f8671d-c0f4-48c9-8b0b-9f65e10cfb83">43.0</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjQ1MTQ_9f463151-d140-47b7-9c1d-dbacb9010643">zero</ix:nonFraction>, respectively, of unrecognized stock-based compensation which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzcxNDY4MjU1OTMxMTE_673cb693-3314-4a8b-8034-a9a144bbdd2f">1.98</ix:nonNumeric> years.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2018, the shareholders approved the 2018 Employee Stock Purchase Plan (ESPP), which initially reserved <ix:nonFraction unitRef="shares" contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031" decimals="INF" format="ixt:numdotdecimal" name="allo:InitiallyReservedCommonStockForEmployeePurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzUwNTY_d25e63b5-8258-499c-9f16-f43e6a6e373e">1,160,000</ix:nonFraction>&#160;shares of our common stock for employee purchases under terms and provisions established by the Board of Directors. Effective January 1, 2019, the number of shares authorized under the ESPP for employee purchases increased by <ix:nonFraction unitRef="shares" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="allo:InitiallyReservedCommonStockForEmployeePurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzc2OTY1ODE0MDcwMzM_7acedb32-f119-43ff-a108-21880f3b1b17">1,214,826</ix:nonFraction> shares. The ESPP is intended to qualify as an &#8216;employee stock purchase plan&#8217; under Section 423 of the Internal Revenue Code. Under the current offering adopted pursuant to the ESPP, each offering period is approximately <ix:nonNumeric contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031" format="ixt-sec:durmonth" name="allo:CurrentOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzUzODc_634d37f8-5b29-4073-b06f-c25207c09943">24</ix:nonNumeric> months, which is generally divided into four purchase periods of approximately six months.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employees are eligible to participate if they are employed by the Company. Under the ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031" decimals="INF" name="allo:PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU2NDg_b207c955-4bca-4145-882e-d23a22ff7dfb">85</ix:nonFraction>%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the purchase date. The ESPP provides for consecutive, overlapping&#160;<ix:nonNumeric contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031" format="ixt-sec:durmonth" name="allo:CurrentOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU4MjY_ae7b2037-3f8d-4d32-a716-60039ef8142c">24</ix:nonNumeric>-month&#160;offering periods. The offering periods are scheduled to start on the first trading day on or after March 16 or September 16 of each year, except for the first offering period which commenced on October 11, 2018, the first trading day after the effective date of the Company&#8217;s registration statement. Contributions under the ESPP are limited to a maximum of&#160;<ix:nonFraction unitRef="number" contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031" decimals="INF" name="allo:PercentageOfEligibleCompensationContributionByEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYxOTI_baa0276e-44f9-4160-8c35-14e854345e76">15</ix:nonFraction>%&#160;of an employee&#8217;s eligible compensation.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDI_1426a6b1-dedd-480e-b714-0a6baab797e9" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of the rights granted under the ESPP were calculated using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:67.610%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.548%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.4% - 76.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.7%&#160;-&#160;81.8%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.72%-2.49%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.37% - 2.83%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5ODkzY2NjYWRiZWI0NjgyYjc1NDMxODUzMzk2MzY2Mi90YWJsZXJhbmdlOjk4OTNjY2NhZGJlYjQ2ODJiNzU0MzE4NTMzOTYzNjYyXzUtMS0xLTEtMTAzMDA_093bfc47-1df6-4f9b-a180-67d5b4c16fec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5ODkzY2NjYWRiZWI0NjgyYjc1NDMxODUzMzk2MzY2Mi90YWJsZXJhbmdlOjk4OTNjY2NhZGJlYjQ2ODJiNzU0MzE4NTMzOTYzNjYyXzQtMS0xLTEtMA_3731581d-ec2f-4a3c-b19b-4a604623b4db">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to ESPP was $<ix:nonFraction unitRef="usd" contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5MTk_d114a71c-b583-4c0d-be50-5ab15ade18e9">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk4OTU_e2edac92-e33e-4d80-9b25-1e2565afca6f">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Founders&#8217; Stock</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">115</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="if812957f7b374b97a9adf7e1ee7947ae"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense is recognized for shares of founders&#8217; stock as vesting conditions are met. In relation to the modification described in Note 12, <ix:nonFraction unitRef="shares" contextRef="i3835f781ec444d7e9271140857371e43_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzY2MDM_8fa22dc2-5d9e-4ae0-ad33-1112011ba158">24,230,750</ix:nonFraction> shares of founders&#8217; stock remained unvested at the modification date in April 2018. For the years ended December&#160;31, 2019 and 2018, $<ix:nonFraction unitRef="usd" contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5Njk_098cd825-7fdd-42cd-b207-f9375e2815f3">13.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5Nzc_d1b9312a-2064-4e19-b5cd-418271f4c566">14.9</ix:nonFraction> million of stock-based compensation expense was recognized related to the vesting of <ix:nonFraction unitRef="shares" contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMDc_f8040516-4296-47a7-813f-774db3e5f146">6,057,684</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMTE_0cbf6102-e10e-473e-9b1a-736fa02220d3">6,562,506</ix:nonFraction> shares, respectively, of founders' stock. At December&#160;31, 2019 and 2018, there was $<ix:nonFraction unitRef="usd" contextRef="i1e27365619214bc59bfb299e39609936_I20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMjM_b299b62e-3d4a-4a9d-8791-d8c536a23211">30.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64b1551f5cd34b7ca95dd312bcae049d_I20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMzk_61ba24c2-8955-41a5-b92c-5a1bd29dd8d7">44.6</ix:nonFraction> million of unrecognized stock-based compensation expense related to <ix:nonFraction unitRef="shares" contextRef="i1e27365619214bc59bfb299e39609936_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNTU_61d3e7fe-e37b-493b-bddb-59391c6f7aa6">13,629,803</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i64b1551f5cd34b7ca95dd312bcae049d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNjM_cf951550-25ba-4ae1-8318-c0356fba9794">19,687,487</ix:nonFraction> shares of unvested founders&#8217; stock which is expected to be recognized over <ix:nonNumeric contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNjg_36b07457-ca89-4f9b-86e4-e8de49d2e4ae">2 years, 3 months</ix:nonNumeric> and <ix:nonNumeric contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwODE_300e9949-1df6-4fea-8376-8892e76c7fbf">3 years, 3 months</ix:nonNumeric>, respectively. The weighted-average fair value at grant date for founders&#8217; stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwOTA_4baff455-5ec0-40d4-b5d0-007c356215ce">2.27</ix:nonFraction> per share.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDM_09d5f63a-eca1-4233-9405-48493a259036" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense related to stock options, employee stock purchase plans and vesting of the founders&#8217; common stock was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.469%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.471%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6af2cfd2ff1d4e4a9d19b9a090f83467_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzItMS0xLTEtMA_71127d31-e91c-4477-8fed-7b1888c0b67c">19,429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ebdfee99c3d44bbba77e1538670e241_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzMtMi0xLTEtNjExOQ_2d4bdabe-b5a1-4c25-8f1d-74a45e551924">1,657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf7d6e8325894802b105e402db61b959_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzMtMS0xLTEtMA_86258010-818d-4a5d-86b2-87b3765eac96">26,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic335635d76f5410592d7071e11926b5d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzQtMi0xLTEtNjExOQ_4fc71f97-5e6a-4946-a0f5-39f88349335f">16,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzQtMS0xLTEtMA_c32c1b2e-400e-4cd4-9899-ab32fc59f6c8">46,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzUtMi0xLTEtNjExOQ_c2016340-8783-4329-8721-412849e4a484">18,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercised Options</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the years ended December&#160;31, 2019 and 2018,  <ix:nonFraction unitRef="shares" contextRef="i5284d2ec96844b179d5bb270bb5844ab_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA0ODc_0061f2f4-0032-4fcd-b61e-a561beb5da79">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e4ee5f686274fdeb535ec2690bb50dc_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA0OTY_3c6b86c9-4372-420e-85b2-cc4a0e20c2c0">5,020,580</ix:nonFraction> options were early exercised. As of December&#160;31, 2019 and 2018, there was $<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-5" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1MDk_cad96a0c-e54c-4847-8212-27c1e083924d">2.8</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-5" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1Mjg_b205c5c7-ba1d-4107-bf94-bb2e7b876c39">4.6</ix:nonFraction> million recorded in accrued and other liabilities and $<ix:nonFraction unitRef="usd" contextRef="ifa574b7418b34ab89121de3fef9eb09d_I20191231" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1NDM_b6a386d3-0a16-49c8-96dc-49f7b23f2504">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc3716dab85d4812af96ca87413ed4aa_I20181231" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1NTA_3ee0d7f8-d966-4f63-a88d-367b5140f572">6.8</ix:nonFraction> million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the financial statements since the exercise date.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_154"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 14. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQ5NDc4MDIzMjgyNjk_03c56612-9fd9-4540-90e1-89576f4ec7fc" continuedAt="i9c856e4e45c74cf8851ee9ab1a9e59ba" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i9c856e4e45c74cf8851ee9ab1a9e59ba" continuedAt="i7f7e14b454344fa19ac142df00c27549"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, Pfizer held <ix:nonFraction unitRef="shares" contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzYz_9196c1a0-ac0c-46b8-ab9a-f3ecd04881e1"><ix:nonFraction unitRef="shares" contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzYz_95f55b7b-78a7-45d9-93f3-31dce39303d2">22,032,040</ix:nonFraction></ix:nonFraction> shares of Common Stock and had appointed <ix:nonFraction unitRef="director" contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="allo:NumberOfMembersAppointedToBoardOfDirectors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzEwNw_3ac3b754-a73e-4e50-8898-ac52a15f1520"><ix:nonFraction unitRef="director" contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="allo:NumberOfMembersAppointedToBoardOfDirectors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzEwNw_b294e403-e4a8-4019-9572-5ac5dc54ac0e">one</ix:nonFraction></ix:nonFraction> member to the Company&#8217;s Board of Directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the years ended December&#160;31, 2019 and 2018, the costs incurred under the Pfizer TSA were $<ix:nonFraction unitRef="usd" contextRef="i0f25012c47684987b5c8de4583d7013a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTQ3OTI_80d24eb7-3a72-4a41-ac1f-f7690ede898c">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice6c8adf2175476b82e13eba7aa65e3b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQ3Mw_9a64c093-f549-4cba-b1a8-78e9d3980aaf">10.1</ix:nonFraction> million, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also purchased certain lab supplies and services from Pfizer in connection with its research and development activities. For the years ended December&#160;31, 2019 and 2018, total lab supplies and services purchased from Pfizer were $<ix:nonFraction unitRef="usd" contextRef="i2ed333deb19e4f8aa30fd212e8437454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTUyMDA_0c58beef-29f6-483a-a468-a2c33faf5d47">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia54626e66f62444da7a1a1a1bd878fa1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzgwMg_05971c6e-95c6-4cc8-9151-85735f5fec59">10.4</ix:nonFraction> million, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, the Company had amounts payable to Pfizer of $<ix:nonFraction unitRef="usd" contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTUyNzY_65187ea9-fa2f-42ec-9c10-034779f5e852">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzkxOA_448f7c44-67a9-410c-9022-3da73bf830b7">5.7</ix:nonFraction> million, respectively, which were recorded in the accompanying balance sheet.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consulting Agreements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $<ix:nonFraction unitRef="usd" contextRef="i3b3b4b6820d34ffe8a18270f928c827b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU1Mjk_3860ee60-0ca8-454d-a7d4-a75fbc0627ed"><ix:nonFraction unitRef="usd" contextRef="i46512246cc53487190bb23e1f83b9f1e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU1Mjk_4c61bb12-25fd-425e-843d-c82eb7d033c5">0.6</ix:nonFraction></ix:nonFraction> million for the years ended December&#160;31, 2019 and&#160;2018.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">116</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i7f7e14b454344fa19ac142df00c27549"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018 the Company entered into a consulting services agreement with TPG Capital &#8211; FO LLC (TPG FO) a firm affiliated with a beneficial owner of more than <ix:nonFraction unitRef="number" contextRef="i937aa356e7d74904be670337e39f839f_I20190630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzE2NzI_3c30e564-012c-460d-ae80-18aceba1f4a5">5</ix:nonFraction>% of the Company&#8217;s capital stock. The costs incurred for services performed under this agreement were <ix:nonFraction unitRef="usd" contextRef="iebe223e780a54b2e9611b6aa31c1b596_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTYxNTE_c6dae3cc-6d56-46cb-a79b-bb7d8583b536">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic44e3cf19d214ae795601add9e69e7eb_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzE3NzQ_d7cef854-ec8c-4f7d-972e-353fdada61dc">0.3</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $<ix:nonFraction unitRef="usd" contextRef="i22b5cfb3c05f4d6b822f58dea1aab477_I20180630" decimals="0" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI1MjA_9cd64586-3a06-48dc-91bc-d306ed37f384">26,250</ix:nonFraction> per month in arrears commencing June 2018. Beginning January 2019, the Company paid Bellco $<ix:nonFraction unitRef="usd" contextRef="ice415ea64e2243bc968eb2884b47ca78_I20190131" decimals="INF" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzcxNDY4MjU1ODk4MTc_fc208e76-17b1-4a09-94eb-2da231d06581">33,333.33</ix:nonFraction> per month in arrears and, at the Company&#8217;s discretion, may pay Bellco an annual performance award in an amount up to <ix:nonFraction unitRef="number" contextRef="id14c29c033be4cfbb4eb48f42b7d40c5_D20180801-20180831" decimals="2" name="allo:RelatedPartyTransactionCompensationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI2NTQ_2e44aae9-f6aa-4236-852b-f8bc8883e3b4">60</ix:nonFraction>% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided, bonus and out-of-pocket expenses incurred under this consulting agreement were $<ix:nonFraction unitRef="usd" contextRef="i3fdaf74dec9d4787bdf514649b2cd27f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU5OTA_5dede70f-4bf8-491d-ab72-e88596ca9bef">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b77ef1f61024c568c150dd64f256116_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI5NDQ_d47a088e-c9f7-4f2f-b60b-0f5c8c0d04d1">0.5</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sublease Agreements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a sublease with Bellco for <ix:nonFraction unitRef="sqft" contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMwOTM_f8ccb13a-7ffb-4d49-92db-c3137e77c383">1,293</ix:nonFraction> square feet of office space in Los Angeles California for a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMxNTY_6ef0bf0c-3a55-4439-89b6-05ebb3b69460">three</span> year term. The total right of use asset and associated liability recorded related to this related party lease was $<ix:nonFraction unitRef="usd" contextRef="ibb66cca6e6e14fb0b660ef62239b32cc_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzM4NDgyOTA3MDI5NTg_6d02d56a-7c02-48c0-85c9-8fe2dd4d373c">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMyNjg_e93e031b-7d3f-40ba-98b7-b2b3fa6b89d2">0.2</ix:nonFraction> million at December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company subleased <ix:nonFraction unitRef="sqft" contextRef="ie27792aefa4b465fa4c423f1df05599c_I20190228" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTk5ODQ_eb5236dd-f465-4cd4-a2c7-195fcbdd50e2">2,180</ix:nonFraction> square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart). ByHeart is a development-stage infant formula company. Two of the Company&#8217;s board members have beneficial ownership in ByHeart and one serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to <ix:nonFraction unitRef="sqft" contextRef="ief267c01c710405abd30252861e3e24c_I20190930" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTk5OTE_fab83634-67c4-4a1b-a537-760afd31f342">2,907</ix:nonFraction> square feet. Sublease income for the year ended December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i2b8b5580156846e28ce6eb93624129e1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MjAwNjc_2fedb7d4-4524-44db-bce8-1a96236dd1e2">0.3</ix:nonFraction> million and was recognized as other income.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_157"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 15. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzQ5NDc4MDIzMjUzODc_c57846e1-e96d-4190-a45b-120fb223ea47" continuedAt="i80a1776699294d5c9d34d6eb9ae0a2e5" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i80a1776699294d5c9d34d6eb9ae0a2e5">In April 2018, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. All employees are eligible to participate, provided they meet the requirements of the plan. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzQzOTgwNDY1MTE1MDI_b29cdf80-f7cb-4542-a432-9a82f3284533">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzMzNw_1543ecc7-bcc7-42c3-8279-b41b1664eb27">0.4</ix:nonFraction> million related to matched contributions for the year ended December&#160;31, 2019 and 2018, respectively.</ix:continuation></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_160"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 16. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQ5NDc4MDIzMjkwMjc_a6735697-909c-48c7-8445-97a6a9c31ca9" continuedAt="id56f576aab55495388333ebd0eb84d56" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="id56f576aab55495388333ebd0eb84d56" continuedAt="i4a7ea3c9a3cc4a53bda8e4d30b3c57bc"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company recorded income tax benefit due to the intraperiod tax allocation of deferred income taxes on unrealized gains on available for sale securities recorded in other comprehensive income. The Company has incurred net operating losses for all the periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzA_d14588d5-f9b7-4e89-8960-d9c9342d21d2" continuedAt="ic224ba4d43504d958d9ce2e0c7930708" escape="true">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">117</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i4a7ea3c9a3cc4a53bda8e4d30b3c57bc" continuedAt="i6204c9cbec8f455d901f145513a1bc65"><div style="margin-bottom:6pt;"><ix:continuation id="ic224ba4d43504d958d9ce2e0c7930708"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:55.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.600%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMS0xLTEtMjk5NA_c7632ed1-7cfa-49d8-9692-6ca04abd84d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzItMS0xLTEtMA_54ffd1c3-18e3-4294-b9ed-76a85ab7cbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzItMy0xLTEtMA_a4f6dac8-35bc-4b1d-a5a8-5b596384d706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMS0xLTEtMjk5NA_7d7bdcd3-4ba3-41f6-84c3-766b3fb044df">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMS0xLTEtMA_15f09dcc-9741-4b27-a021-c3b6aa765de2">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMy0xLTEtMA_1bfd5a81-9ce0-4191-9f78-d1e9a36cdf5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzUtMS0xLTEtMjk5NA_c3f9039e-e827-4735-9dc5-2f022ef59f80">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMS0xLTEtMA_98df97ec-0627-4a43-97c3-f786580ea53e">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMy0xLTEtMA_96a80d89-ee73-493e-b811-0164aa3e9f58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMS0xLTEtMjk5NA_701c6b63-0e97-4a1a-8f34-8175ddb781b7">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzYtMS0xLTEtMA_491ec7c0-1c89-4124-9eae-62f0d46a6236">89</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzYtMy0xLTEtMA_0776bbe2-0a30-4037-8029-9728da500846">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMS0xLTEtMjk5NA_47327859-6b73-41b5-9d46-c13cf605be56">81</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMS0xLTEtMA_0ac15766-cfad-4e7f-bd31-22166c5fdbd1">30</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMy0xLTEtMA_db9e80d6-98c1-402d-8bcb-90e020b798de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMS0xLTEtMjk5NA_c47d012a-d8a1-4694-b722-76f9d68f1583">332</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMS0xLTEtMA_79fb3b07-e4fa-4faf-8317-0073b9ac93a5">119</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMy0xLTEtMA_34124933-3b95-463a-8047-008a21834972">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzEwLTEtMS0xLTI5OTQ_92fab677-43d8-4726-ae08-c100b9f0c5f4">331</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMS0xLTEtMA_678333b9-e3d6-4378-bdf8-95d20abc113d">117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMy0xLTEtMA_8099fb31-f5a4-4db7-a2a9-0a26cfac207d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzE_7e1d83fe-93e8-437b-8430-0d3845a3cbe7" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reconciliation of the benefit for income taxes calculated at the statutory rate to our benefit for income taxes is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:55.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.600%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMS0xLTEtMzA4MQ_d5d03bfb-dabd-49d3-9701-f96eaa6690b3">38,834</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzItMS0xLTEtMA_7920564c-77d8-4125-b8ba-255e31f764bf">44,441</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzItMy0xLTEtMA_c8dd102a-8c7f-477c-b44f-85086d7ae11f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMS0xLTEtMzA4MQ_9a1f11b8-06d3-48be-9248-862cfc3fba58">12,951</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMS0xLTEtMA_aab9afa6-f6f0-41f9-b1c0-6baa693e8007">10,652</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMy0xLTEtMA_5b6fcfde-fa5a-41fa-97a6-bb682310d32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMS0xLTEtMzA4MQ_4f846148-fd39-4719-8fdc-cd845b7ac828">2,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMS0xLTEtMA_f6a97a39-9462-4f50-9e98-240e1c68f151">3,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMy0xLTEtMA_8fa5ddfb-9c5e-44e5-a0d0-5df89732c1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMS0xLTEtMzA4MQ_677e5fb2-7836-46ee-9a3c-a342332c7554">1,714</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMS0xLTEtMA_df39ecf4-b3a9-4927-909c-37c47350abc3">708</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMy0xLTEtMA_bb70ccd7-d723-4041-88f2-a1d852a144a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-off of in-process R&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMS0xLTEtMzA4MQ_2b9c780d-b9c9-404c-bee9-32fb3a190b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMS0xLTEtMA_db565199-f5ba-47ff-9baa-60e6e43f17f0">5,247</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMy0xLTEtMA_66e61c11-f8e2-4219-a2a8-625cf65fc4a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMS0xLTEtMzA4MQ_c1f7ed96-1467-4d8c-90c3-92b5b8fbd20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMS0xLTEtMA_ff62d9cd-8989-41fa-a4f0-81f78b7ab439">4,454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMy0xLTEtMA_5cc14b5f-12f5-46f5-82cd-70efa377aff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMS0xLTEtMzA4MQ_c967f5e7-30f2-4cfa-9420-f3b392de5a97">49,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMS0xLTEtMA_45b47cd1-65a9-42e4-9964-460ed34fb40f">41,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMy0xLTEtMA_d752e328-9665-437a-99eb-4e7605730b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTEtMS0xLTMwODE_e1b43622-5e32-452b-8f32-dd043ddd1cf4">1,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMS0xLTEtMA_11f9cb03-f872-4d2f-8410-fdaee394139d">438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMy0xLTEtMA_9422a8f1-560a-4402-b097-c9b49933d951">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for incomes taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzExLTEtMS0xLTMwODE_64f61c67-ca51-4744-9910-2b5d20382781">331</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTEtMS0xLTA_eb8415c4-aa21-4037-ab27-0f5e9a623d4e">117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTMtMS0xLTA_9c3e7ed1-f4f2-4a32-8070-657303b1311f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzI_a9543a3c-8c71-4ce0-8d90-c34857b50367" continuedAt="i20604fda65bc4d36b79166cdb3500dde" escape="true">Significant components of our deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">118</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="i6204c9cbec8f455d901f145513a1bc65" continuedAt="id92b2916361844349ae65bbef5373fb1"><div style="margin-bottom:6pt;"><ix:continuation id="i20604fda65bc4d36b79166cdb3500dde"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:56.040%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.600%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMS0xLTEtMzA5NA_0263e612-6032-4e90-ab6e-9ddbfd0d70fa">54,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzMtMS0xLTEtMA_f094c0cf-79e1-4029-b5a1-1efdfde5c131">16,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzMtMy0xLTEtMA_3320f686-c81a-4a7c-b1cc-bb052460bc36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMS0xLTEtMzA5NA_f60217ad-1725-4a26-a344-d486e56347e7">4,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMS0xLTEtMA_ea00539d-49c0-4a07-84d0-562d9cf15512">1,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMy0xLTEtMA_adac6589-a220-4711-9658-0a5b732080e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMS0xLTEtMzA5NA_326c64df-3525-4191-9df9-12ac9ccfae8b">22,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMS0xLTEtMA_ef8a3e7c-f9f3-4fcc-96a9-dc591949b856">23,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMy0xLTEtMA_abae2e0c-8706-4c0e-8ad6-9af5ba9f1c29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMS0xLTEtMzA5NA_554a5243-a6b9-4538-ac8b-0be5f3ab918b">2,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMS0xLTEtMA_2ad7aaa8-2057-44d7-9a54-3f164c48fe5c">952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMy0xLTEtMA_a8098a92-354c-4c54-b0e1-15f1f900760d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMS0xLTEtMzA5NA_a0649164-4175-4f7b-9d2e-d88640a36381">14,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMS0xLTEtMA_145a09ae-1127-4a65-bfb6-113e089520cc">9,730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="allo:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMy0xLTEtMA_cb40b0c9-e5e9-4279-91e8-3d643f743900">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMS0xLTEtMzA5NA_5bd6f116-2ea2-415a-8f95-63eccaa9d8f0">6,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMS0xLTEtMA_8cdcf81f-6fed-4cde-86a6-8731bd7cd2a2">360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMy0xLTEtMA_d3b9274e-9d7b-47ba-9d46-99a72a43d6cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTEtMS0xLTMwOTQ_1777abfc-f079-4eb1-8749-5fa18c77dcfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMS0xLTEtMA_83f16962-8653-4823-ae23-ccb87bddd95a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMy0xLTEtMA_87ff140d-c6cd-407f-abac-7779e38f0872">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzExLTEtMS0xLTMwOTQ_36d4dbf3-7016-471f-9457-823294e168e3">105,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTEtMS0xLTA_4b6fa9ae-277c-4a25-9529-fec4b2f7e2d2">51,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTMtMS0xLTA_0893aab5-1da5-4aed-bc8a-b9c5972476f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTEtMS0xLTMwOTQ_7b2b0e7e-51fe-450e-a205-3db9bdca473b">361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEyLTEtMS0xLTA_5e7ce2ff-e41b-4e35-ab64-57a2a5baa6d8">531</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEyLTMtMS0xLTA_67d30c9b-d859-40ad-bcd4-c5bdc49e75ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use leased assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxLiabilitiesRightOfUseLeased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTEtMS0xLTMwOTQ_fa00281c-5782-4d0c-99e7-c9a090bee9c4">12,453</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxLiabilitiesRightOfUseLeased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTEtMS0xLTA_0feb7971-d278-43c3-953e-36a4e29efd3e">9,239</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="allo:DeferredTaxLiabilitiesRightOfUseLeased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTMtMS0xLTA_af863590-89b1-4334-a7c7-b2c3c11598ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTEtMS0xLTMwOTQ_d52c579a-32c0-42ee-857e-b4f063a01846">393</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTEtMS0xLTA_07ccdcf5-d746-48dd-b7f3-c8dd8f331626">118</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTMtMS0xLTA_2c8a7851-197c-4b2b-a75a-705f7cd92461">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTEtMS0xLTMwOTQ_86d9fcc3-a1d2-471a-ac3b-4f117321b979">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTEtMS0xLTA_bf998f07-9adf-4d9f-8356-3efb92d3a499">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTMtMS0xLTA_43e23676-cbc3-4a34-93ae-ac9a430d1837">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTEtMS0xLTMwOTQ_3589c647-3b3c-46fd-9ed4-ee5ac49ec082">13,207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTEtMS0xLTA_fce58d97-98a8-4e90-9365-5aff2d839bf9">9,888</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTMtMS0xLTA_1b33f599-6bd8-4c9c-b082-03c2077f7b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTEtMS0xLTMwOTQ_d7842c0e-4b95-42cd-9a9b-b26a4ef60978">91,904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTEtMS0xLTA_082bbd8c-83e2-4b2a-95e1-4e37e42be3b7">41,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTMtMS0xLTA_c43e29aa-3166-41ab-b8e1-5c2aa8478820">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTEtMS0xLTMwOTQ_6901c662-f171-4623-9351-04c19fc135a2">91,904</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTEtMS0xLTA_c4590046-d196-49c6-bf3a-a76d38183d92">41,916</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTMtMS0xLTA_c42abcf4-454c-4003-b369-f8cd90d6785a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzIwLTEtMS0xLTMwOTQ_5a4e0bab-d395-47a6-8712-435868dcfe35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTEtMS0xLTA_1539bcd1-a878-411a-b790-29b2a59a5b5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTMtMS0xLTA_b43f63e7-a045-4207-819d-01a4cf6b6e84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.&#160;&#160;Due to the lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQzOTgwNDY1MTUyNjc_8396a5c1-6b1e-43ca-b4aa-b9b493ae901a">50.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzE0NzY_4021f068-fc7f-4a5d-a233-502f0f62981a">41.9</ix:nonFraction> million during the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzM_c4087438-2e67-4e48-9b25-d5b93c112e85" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our federal and state NOL carryforwards and federal research and development tax credits as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16c74cfa985346f494f9d5736c6a5fe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzItMS0xLTEtMA_41c57a73-bfe2-4e53-933e-a3211f2c29a8">193,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7523fadedd6b4e51ab3614c36301ac25_I20191231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzMtMS0xLTEtOTczNg_efc18cef-c6b1-4c88-8a35-ea9a74f9dc0d">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2037</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib540aeb004f94ffc9bfe1a2e2bed3e89_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzQtMS0xLTEtMA_ee451d2f-0d58-4416-8c3d-6d49d26b6dc0">190,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2037-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib08658a06a8a40aaa3b3aa34badf31cf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzUtMS0xLTEtMA_0d02e0ee-5035-4f29-9048-cb4c1189468d">4,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2038-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c2150c8f59c49ea84c39db5a3d27693_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzYtMS0xLTEtMA_3291c273-e05d-45d6-a6a5-ca9f4dff456e">3,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Indefinite </span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax credit carryforwards may be limited as a result of such ownership changes. Such a limitation could result in the expiration of carryforwards before they are utilized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income.&#160;&#160;An exception is provided in ASC 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year.&#160;&#160;In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets.&#160;&#160;In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale investments recorded as a component of other comprehensive </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">119</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><ix:continuation id="id92b2916361844349ae65bbef5373fb1"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets.&#160;&#160;For the years ended December&#160;31, 2019 and 2018, the Company recorded a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQzOTgwNDY1MTU1MDk_6b08874e-b2ff-4768-9727-360f59ef1e3f">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzMxMDY_9b343fcb-2663-48ad-bfe2-ed0721927351">0.1</ix:nonFraction> million, respectively, in other comprehensive income, related to available-for-sale securities.</span></div><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzQ_868783e0-2469-44a2-8f2a-d5d05fc78c09" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply the provisions of ASC Topic 740 to account for uncertain income tax positions.&#160;&#160;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:55.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.600%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of the year:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzItMS0xLTEtMTE1OA_6237013a-a83f-4ed3-8788-22070e5b225a">920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzItMy0xLTEtMTE1OA_6094c04f-97c0-42ea-b03f-132f1fbfc257">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6c735ffeb0e4728ab0cf9f8a68323c0_I20171130" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtNS0xLTEtODExNQ_5c2d75c0-b8f4-4616-a5f0-dff037148317">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtMS0xLTEtMA_e4ae372c-5735-4130-a98f-3d66d2517e7b">2,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtMy0xLTEtMA_481a473a-55e4-4fdb-ac98-05df35d0c500">920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtNS0xLTEtMzE1Nw_09bb57e9-606f-4031-94e8-14b732aef7bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to tax position of prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtMS0xLTEtMA_a9d0f031-74d9-430f-8528-0615dcc0b10f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtMy0xLTEtMA_530dfc70-b65a-4429-a1c4-ddfd9d6e0d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtNS0xLTEtMzE1Nw_6b576afa-b32c-4676-a8b0-6bf539bfa2af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions to tax position of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtMS0xLTEtODExMg_d894ec1f-12e2-4b6f-8a9d-788522e2aa99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtMy0xLTEtODExMg_27f4cfe4-c6f9-40d3-95a7-01529c341526">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtNS0xLTEtODExMg_89efea1c-a048-486d-a1ee-36a2da1f2d4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lapse of the applicable statute of limitations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctMS0xLTEtODExMg_d9b59b99-db47-4812-bb5a-444e93b2ae37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctMy0xLTEtODExMg_f7dea57e-f1f6-45f0-8b2c-77b4fd8e9f32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctNS0xLTEtODExMg_b2e2cc55-04b9-4af8-8c03-bc72eae79b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtMS0xLTEtMA_39b59065-2d29-4dbb-94f5-100c58d2ffcd">3,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtMy0xLTEtMA_c2934f4e-c844-4e71-a5f0-99724db8040b">920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtNS0xLTEtMzE1Nw_7a60c866-c36a-42b0-af9e-0cbeff5a5890">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as a component of interest and other income, net, as necessary.&#160;As of December&#160;31, 2019 and 2018, there were <ix:nonFraction unitRef="usd" contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzM1NDg_8358aac7-ab45-424c-a4b3-796416056ecb"><ix:nonFraction unitRef="usd" contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzM1NDg_f03a20e3-27ab-4874-9f0f-fec741a28609">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties related to uncertain tax positions.&#160;The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.&#160;Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business.&#160;&#160;We are subject to examination by U.S. federal or state tax authorities for all years since inception.</span></div></ix:continuation><div id="i4bbd891a4ae94fb1b6070b8f551a6549_163"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 17. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzQ5NDc4MDIzMjU1NTA_9891f674-9400-447c-b38b-3ec3d9d393f6" continuedAt="i6820e03c019346e49ba66ee62357fa3b" escape="true">Net Loss and Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i6820e03c019346e49ba66ee62357fa3b"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzU1Ng_3cc459c9-97c7-4a23-86c3-b77892d776bd" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.970%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtMS0xLTEtMA_460ae5e1-e99d-441b-9f77-d037b66d6f2f">184,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtMy0xLTEtMA_6be146dd-3dac-46cc-806f-e3da4d12bc80">211,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtNS0xLTEtMTMxMg_780bff73-3c63-4749-ad41-a16c200cdd10">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtMS0xLTEtMA_1fd9afd2-218e-44e7-8a62-04583cf9d3fb">101,061,149</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtMy0xLTEtMA_ce539bae-894e-41e4-a550-bc18718a32e2">28,948,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtNS0xLTEtMTMxMg_5104be35-5932-446e-8d35-ffe4e87a0234">26,249,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtMS0xLTEtMA_7826bbb2-9678-41d4-9932-bdaa2c270037">1.83</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtMy0xLTEtMA_2c0cc0c2-0d29-45c5-a88d-3d7b642892a9">7.31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtNS0xLTEtMTMxMg_03ec3598-60ee-42d5-a537-28c54010d43a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities would have been anti-dilutive. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzU1Nw_cbbdc320-5d81-4b54-8774-52ee2e0a7314" continuedAt="i5703691c89b54356833ef62f964a85d1" escape="true">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="i5703691c89b54356833ef62f964a85d1"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.970%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1685cab5677b4214acd1e61778618c7a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItMS0xLTEtMA_bda0dc72-731c-4482-b69e-0cba004016c7">9,190,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3db00b97645d4dfcb5199164cd300fd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItMy0xLTEtMA_8164e200-dc51-42b4-9bad-4308f5a48a5b">7,235,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i07955f1bc4d842309fb7054451349500_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItNS0xLTEtMTM4NQ_7f65e760-23de-4861-ad2e-159e393189bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i98d07f8ad8e24589b9cd7e9093f0cdb3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMS0xLTEtMTM4Nw_e09faecc-5a61-47bd-8cab-576caaaf4340">1,941,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i96ced67d40264f25905f485ca894893f_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMy0xLTEtMTM4Nw_16004a13-11f4-45ca-8f78-a17c078793f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6e63cc94d1614433bc6dbbf8f222c887_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtNS0xLTEtMTM4Nw_b5157296-3af7-44b0-b896-bb11ec27011a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3b6803e703b349ab84305332583a3b58_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMS0xLTEtMTM4Nw_c43b4aad-43a6-4f9a-bfc5-ad9a0efae74c">195,161</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i68b6c63c353f4630aed12ad8c7160e52_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMy0xLTEtMTM4Nw_42d27602-84de-464c-9f1c-68eac16027aa">144,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iff8a1d2d642b449f977d62cd68697248_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtNS0xLTEtMTM4Nw_831db36e-4ecf-4dfe-8f06-202a7354c93f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder shares subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8943b433f73e48b1b575b63c35b128bc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMS0xLTEtMA_84845bc6-a623-47d2-ba44-34e32448a588">13,629,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id55c9b66b5bc4d93aaa9151719a26f75_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMy0xLTEtMA_0919bc12-5ae2-4e60-a8d2-cae2c3776827">19,687,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8f3a4d9d806b414bbbbd1501a52e6766_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtNS0xLTEtMTM4NQ_a8e379d5-39bb-4ba4-bb71-3ebaa502e859">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b519b46465449bf8e62e676785a0c8f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMS0xLTEtMA_c3a5938f-8758-4247-b159-75e410f95c35">2,992,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa11e1394d8e429a82692ed6d10cf29e_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMy0xLTEtMA_aaa25905-dbc8-43d3-b3e9-5ca14132725b">5,020,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3d1db84ffd5f434f9c56d87b4cbf3f69_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzYtNS0xLTEtMTM4NQ_5be60166-762a-42ff-aa66-737617309d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtMS0xLTEtMA_8b664294-d490-4fb6-87a4-419b3e2787a5">27,948,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtMy0xLTEtMA_45a3916d-ecd6-4c5c-882c-3bf38a3b36d9">32,087,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzctNS0xLTEtMTM4NQ_8a348c80-db02-4fd8-a57c-d7ee3b2fcc3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_166"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">120</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 18. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MzQ_7e1515f0-a51e-4509-a2c0-84ecf091d8d7" continuedAt="i66fed2bb44ab4c15bf72ec1cba14affb" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i66fed2bb44ab4c15bf72ec1cba14affb">From January 6 to January 17, 2020, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MTE_07d6f27e-6843-47bf-b9c5-899f7a5a0db3">570,839</ix:nonFraction> shares of common stock in ATM offerings resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MjA_50801495-1e17-4bd0-91a9-73b7343f8753">14.8</ix:nonFraction>&#160;million.</ix:continuation></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_172"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 19. <ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90ZXh0cmVnaW9uOjViZGYyMzBiNDk0MDQ0ZjA4NGU3YWY3MjkyNzliNmYzXzQ5NDc4MDIzMjU0NjE_8da92301-68a1-4d0d-826c-e55eb8ca5149" continuedAt="if643e1cd2ef549779dc1c7c55a64c8a8" escape="true">Selected Quarterly Financial Data (unaudited)</ix:nonNumeric></span></div><ix:continuation id="if643e1cd2ef549779dc1c7c55a64c8a8"><ix:nonNumeric contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90ZXh0cmVnaW9uOjViZGYyMzBiNDk0MDQ0ZjA4NGU3YWY3MjkyNzliNmYzXzQ2Nw_0c2d4e04-5c47-484b-9e1e-e5e9877665c0" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2019 (in thousands, except per share amounts):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.859%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItMS0xLTEtMjkxMQ_5d0b0064-4398-47b9-a135-f2c8f4e17257">36,461</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItMy0xLTEtMjkxMQ_bd4363ae-53cd-4560-b587-cd37202a87b8">45,961</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItNS0xLTEtMjkxMQ_a80c0a8b-5413-4f23-a9cf-207b50b4aa05">55,011</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItNy0xLTEtMjkxMQ_3e2bae8e-6241-4c70-968a-2ac7aac3660e">64,575</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtMS0xLTEtMjkxMQ_22a19920-0c6a-4228-b372-3f73f95fac0c">31,586</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtMy0xLTEtMjkxMQ_97fcf47f-fa80-42c8-9803-61ba2e45a44a">41,243</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtNS0xLTEtMjkxMQ_22100965-a258-4170-8c32-b4a559dfb76c">50,735</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtNy0xLTEtMjkxMQ_12b45808-39da-43e0-b1d2-dfa778d4421e">61,030</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtMS0xLTEtMjkxMQ_b20142e1-3844-4eec-afd5-48cc84467ade">0.32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtMy0xLTEtMjkxMQ_4e8f08b1-b2d5-4421-81f4-5ac44dcaddb5">0.41</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtNS0xLTEtMjkxMQ_c9d416a7-c3c2-4401-99aa-432c410a319d">0.50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtNy0xLTEtMjkxMQ_db5df723-a3b2-4df7-8e63-d899abebcd56">0.58</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2018 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.859%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItMS0xLTEtMA_c771eea8-6557-4d46-8eb8-144f81727a18">2,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItMy0xLTEtMA_7f97493f-a55f-4880-8d19-0320512e0675">135,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItNS0xLTEtMA_e4cc0c9d-0667-4b3c-b9ff-e2fa978ab271">22,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItNy0xLTEtMA_21e53976-e0f9-4e07-b5d7-88ae0171e0ad">33,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtMS0xLTEtMA_a5250d72-fc5e-4297-9dfc-d60534654dd6">2,597</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtMy0xLTEtMA_0ad945db-4846-4936-9593-b76395850b36">134,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtNS0xLTEtMA_ce0a5236-6970-441d-b40e-2a21b62d17fa">43,497</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtNy0xLTEtMA_08d35c5c-0eff-4bbc-9361-bb04b9d6108c">30,509</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtMS0xLTEtMA_dff36e18-9e54-4814-8a70-7043c5e2334f">0.10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtMy0xLTEtMA_af72da34-5d4b-42f8-bbc3-afe5fb1fe7d4">43.82</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtNS0xLTEtMA_ad0dce79-2f6e-4f54-9d11-76e1ddf3bcb7">10.71</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtNy0xLTEtMA_b6853353-e8bf-4e18-8d5e-2ec91a26cf17">0.37</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:45pt;margin-top:12pt;"><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_175"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_178"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019, management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December&#160;31, 2019, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Management&#8217;s Annual Report on Internal Controls Over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">121</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management has assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The effectiveness of our internal control over financial reporting has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report herein, which expresses an unqualified opinion on the effectiveness of our internal control over financial reporting as of December&#160;31, 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inherent Limitations of Internal Controls</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes. There were no changes in our internal control over financial reporting that occurred during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_2069"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the Stockholders and the Board of Directors of Allogene Therapeutic, Inc.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have audited Allogene Therapeutic, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Allogene Therapeutic, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 financial statements of the Company and our report dated February 27, 2020 expressed an unqualified opinion thereon.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">122</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">San Jose, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">February 27, 2020</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_181"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9B. Other Information.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None. </span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_184"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">123</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART III</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_187"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item and not set forth below will be set forth in the section headed &#8220;&#8212;Election of Directors&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our definitive Proxy Statement for our 2020 Annual Meeting of Stockholders to be filed with the SEC by April&#160;29, 2020 (our Proxy Statement) and is incorporated in this Annual Report by reference.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have adopted a code of ethics for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">http://www.allogene.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;under the Governance section of our Investors page. We will promptly disclose on our website (i)&#160;the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (ii)&#160;the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver. Shareholders may request a free copy of the Code of Business Conduct and Ethics from our Compliance Officer, c/o Allogene Therapeutics, Inc., 210 E. Grand Ave, South San Francisco, CA 94080.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_190"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 11. Executive Compensation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item will be set forth in the section headed &#8220;Executive Compensation&#8221; in our Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_193"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item will be set forth in the section headed &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Information regarding our equity compensation plans will be set forth in the section headed &#8220;Executive Compensation&#8221; in our Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_196"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item will be set forth in the section headed &#8220;Transactions With Related Persons&#8221; in our Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_199"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 14. Principal Accounting Fees and Services.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item will be set forth in the section headed &#8220;&#8212;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; in our Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_202"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">124</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART IV</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_205"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(1) Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The response to this portion of Item&#160;15 is set forth under Part II, Item&#160;8 above.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(2) Financial Statement Schedules.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All schedules have been omitted because they are not required or because the required information is given in the Financial Statements or Notes thereto set forth under Item&#160;8 above.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(3) Exhibits.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exhibits listed in the Exhibit Index below are filed or incorporated by reference as part of this Annual Report.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_208"></div><div style="margin-top:18pt;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit Index</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.459%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reference is made to Exhibits </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">3.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">3.2</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex43.htm">Description of Common Stock.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex42.htm">Investors&#8217; Rights Agreement, dated April&#160;&#160;6, 2018, by and among the Registrant and certain of its securityholders, as amended September 5, 2018, (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018)</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex101.htm">Form of Indemnity Agreement by and between the Registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex102.htm">Indemnification Agreement, dated April 6, 2018, by and between the Registrant and John DeYoung (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex102.htm">Allogene Therapeutics, Inc. Amended and Restated 2018 Equity Incentive Plan (Prior Plan) and Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise and Early Exercise Stock Purchase Agreement thereunder, as amended (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518306372/d642001dex992.htm">Allogene Therapeutics, Inc. Amended and Restated 2018 Equity Incentive Plan and Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement thereunder (incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227965), filed with the SEC on October 24, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518306372/d642001dex993.htm">Allogene Therapeutics, Inc. 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227965), filed with the SEC on October 24, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex106.htm">Allogene Therapeutics, Inc. 2018 Change in Control Plan and Severance Benefit Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-2019x1231xex107.htm">Non-Employee Director Compensation Policy.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex1012.htm">Employment Agreement by and between the Registrant and David Chang, M.D., Ph.D. (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">125</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.459%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex1013.htm">Employment Agreement by and between the Registrant and Eric Schmidt, Ph.D. (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex1014.htm">Employment Agreement by and between the Registrant and Alison Moore, Ph.D. (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex1011.htm">Employment Letter of Agreement, dated July 29, 2019, by and between the Registrant and Rafael G. Amado, M.D.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019016480/allo-ex10_104.htm">License Agreement, dated March 8, 2019, between the Registrant and Cellectis S.A. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38693), filed with the SEC on May 7, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518275199/d548088dex107.htm">Exclusive License and Collaboration Agreement, dated October 30, 2015, by and between the Registrant (assignee of Pfizer Inc.) and Les Laboratoires Servier and Institut de Recherches Internationales Servier (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 17, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex108.htm">Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc. (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex1015.htm">Collaboration and License Agreement, dated November 1, 2019, by and between the Registrant and Notch Therapeutics Inc.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex1011.htm">Lease, dated August 1, 2018, by and between the Registrant and Britannia Pointe Grand Limited Partnership. (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), originally filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1017_446.htm">Lease Agreement, dated October 25, 2018, by and between the Registrant and HCP, Inc.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1017_446.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1017_446.htm">(incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38693), filed with the SEC on March 8, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1018_447.htm">Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1018_447.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-ex1018_447.htm">(incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38693), filed with the SEC on March 8, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000173728719000020/allo-20190930xex101.htm">First Amendment, dated September 4, 2019, to the Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38693), filed with the SEC on November 5, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000173728719000022/allo-20191106xex12.htm">Sales Agreement, dated November 5, 2019, by and between the Registrant and Cowen and Company, LLC (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-234516), filed with the SEC on November 5, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_211">Power of Attorney. Reference is made to the signature page hereto.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20191231xex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">__________________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">+&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">126</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted as the Registrant has determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to the Registrant if publicly disclosed.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Item 16. Form 10-K Summary</span></div><div style="text-indent:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">None.</span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_211"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">127</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7">Table of</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i4bbd891a4ae94fb1b6070b8f551a6549_7"> Contents</a></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on February&#160;27, 2020.</span></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.877%;"><tr><td style="width:1.0%;"></td><td style="width:8.344%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.656%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics,&#160;Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;/s/ David Chang, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Chang, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer and Member of the Board of Directors</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Principal Executive Officer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">)</span></div></td></tr></table></div><div style="text-align:right;"><span><br/></span></div><div id="i4bbd891a4ae94fb1b6070b8f551a6549_214"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">POWER OF ATTORNEY</span></div><div style="text-indent:72pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Chang, M.D., Ph.D. and Eric Schmidt, Ph.D., and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.900%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:52.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.816%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Signature</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer <br/>and Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Principal Executive Officer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Eric Schmidt, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Schmidt, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Principal Financial and Accounting Officer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Arie Belldegrun, M.D., FACS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Chairman of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arie Belldegrun, M.D., FACS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David Bonderman</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Bonderman</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ John DeYoung</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John DeYoung</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Franz Humer, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Franz Humer, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Joshua Kazam</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Joshua Kazam</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Deborah M. Messemer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deborah M. Messemer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Todd Sisitsky</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Todd Sisitsky</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Owen Witte, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Member of the Board of Directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Owen Witte, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">128</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>allo-20191231xex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_26"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 4.3</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF COMMON STOCK</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this &#8220;Description of Common Stock,&#8221; you should refer to our amended and restated certificate of incorporation (the &#8220;Restated Certificate&#8221;) and amended and restated bylaws (the &#8220;Restated Bylaws&#8221;), which are included as exhibits to our Annual Report on Form 10-K, and to the applicable provisions of Delaware law. Our authorized capital stock consists of 200,000,000&#160;shares of common stock, par value $0.001 per share, and 10,000,000&#160;shares of preferred stock, par value $0.001 per share. Our board of directors has the authority, without stockholder approval, except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock.  In addition, our board of directors has the authority, without further action by our stockholders, to designate the rights, preferences, privileges, qualifications and restrictions of our preferred stock in one or more series.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Voting Rights</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Dividends and Distributions</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidation, Dissolution or Winding Up</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event of our liquidation, dissolution or&#160;winding up,&#160;holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Rights and Preferences</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fully Paid and Nonassessable</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All of our outstanding shares of common stock are fully paid and nonassessable.</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transfer Agent and Registrar</font></div><div><font><br></font></div><div style="text-indent:22.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC.</font></div><div style="text-indent:22.5pt;"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock Exchange Listing</font></div><div style="text-indent:22.5pt;"><font><br></font></div><div style="text-indent:22.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;ALLO.&#8221;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Anti-Takeover Provisions</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="padding-left:22.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Delaware Anti-Takeover Law</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prior to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the interested </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">on or subsequent </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to the consummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Section 203 of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the DGCL defines a business combination to include&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any merger </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or consolidation involving the corporation and the interested stockholder&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59; and</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the receipt</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In general, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Section 203 of the DGCL defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="padding-left:22.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws Provisions</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions of the Restated Certificate and the Restated Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, the Restated Certificate and the Restated Bylaws&#58;</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control)&#59; </font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66 2&#47;3% of the voting power of all of our then outstanding common stock&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">divide our board of directors into three classes&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice&#59;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose)&#59; and</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2&#47;3% of our then outstanding common stock. </font></div><div><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Choice of Forum</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Restated Certificate and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf&#59; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders&#59; (iii) any action or proceeding asserting a claim against us or any of our current or former directors or officers or other employees arising out of or pursuant to any provision of the DGCL, our Restated Certificate or Restated Bylaws (including any right, obligation, or remedy thereunder)&#59; (iv) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware&#59; and (v) any action asserting a claim against us or any of our directors or officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </font></div><div style="text-indent:24.5pt;"><font><br></font></div><div style="text-indent:24.5pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, our Restated Certificate and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>allo-2019x1231xex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iae3d314a2292489aaf663f98aa3ec909_1"></div><div style="height:36pt;width:100%;"><div><font><br></font></div></div><div style="padding-right:17.75pt;text-align:right;margin-top:3.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.7</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:115.9pt;padding-right:115.9pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">LLOGENE </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">T</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">HERAPEUTICS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">, I</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">NC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">.</font></div><div style="padding-left:115.95pt;padding-right:115.9pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">N</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">ON</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">-E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">MPLOYEE </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">D</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">IRECTOR </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">OMPENSATION </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">P</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">OLICY </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">DOPTED</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58; S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">EPTEMBER </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">26, 2018</font></div><div style="padding-left:115.95pt;padding-right:115.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">MENDED</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;  A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">PRIL </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">16, 2019</font></div><div><font><br></font></div><div style="padding-left:5.8pt;padding-right:5.65pt;text-align:justify;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each member of the Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of Allogene Therapeutics, Inc. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) who is a non-employee director of the Company (each such member, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Non- Employee Director</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) will receive the compensation described in this Non-Employee Director Compensation Policy (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Director Compensation Policy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) for his or her Board service following the closing of the initial public offering of the Company&#8217;s common stock (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">IPO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:5.8pt;padding-right:5.7pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A Non-Employee Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:5.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Cash Compensation</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5.8pt;padding-right:5.7pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Commencing January 1, 2019, each Non-Employee Director will receive the cash compensation set forth below for service on the Board. The annual cash compensation amounts will be payable in equal quarterly installments, in arrears following the end of each quarter in which the service occurred, pro-rated for any partial months of service. All annual cash fees are vested  upon payment.</font></div><div><font><br></font></div><div style="text-indent:-36.05pt;padding-left:41.8pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.05pt;">Annual Board Service Retainer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.73pt;">All Eligible Directors&#58; $40,000</font></div><div><font><br></font></div><div style="text-indent:-36.05pt;padding-left:41.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:27.05pt;">Annual Committee Member Service Retainer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#58;</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.73pt;">Member of the Audit Committee&#58; $12,500</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt;">Member of the Compensation Committee&#58; $7,500</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.73pt;">Member of the Nominating and Corporate Governance Committee&#58; $5,000</font></div><div><font><br></font></div><div style="text-indent:-36.05pt;padding-left:41.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.05pt;">Annual Committee Chair Service Retainer (in lieu of Committee Member Service Retainer)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.73pt;">Chairman of the Audit Committee&#58; $25,000</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt;">Chairman of the Compensation Committee&#58; $15,000</font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.73pt;">Chairman of the Nominating and Corporate Governance Committee&#58; $10,000</font></div><div><font><br></font></div><div style="padding-left:5.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Equity Compensation</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:5.8pt;padding-right:41.65pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Equity awards will be granted under the Company&#8217;s Amended and Restated 2018 Equity Incentive Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), adopted in connection with the IPO. All stock options granted under this policy will be Nonstatutory Stock Options (as defined in the Plan), with a term of ten years from the date of grant and an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of the Company on the date of grant.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:-36.05pt;padding-left:77.8pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.07pt;">Automatic Equity Grants.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:60.64pt;padding-left:5.8pt;padding-right:5.55pt;text-align:justify;margin-top:3.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:30.25pt;">Initial Grant for New Directors. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Without any further action of the Board, each person who, after the IPO, is elected or appointed for the first time to be a Non-Employee Director will automatically, upon the date of his or her initial election or appointment to be a Non- Employee Director (or, if such date is not a market trading day, the first market trading day thereafter), be granted (i) a Nonstatutory Stock Option to purchase shares of common stock of the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Initial Option Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and (ii) a restricted stock unit award covering shares of common stock of the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Initial RSU Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), whereby the Initial Option Grant and Initial RSU Grant shall together have a total grant date value of $850,000 (with the shares covered by the award rounded down to the nearest whole share). The recipient shall designate the proportionate share between the Initial Option Grant and Initial RSU Grant prior to or on the date of grant. The grant date value will be calculated in accordance with the Black-Scholes option valuation methodology or such other methodology as the Board or the Compensation Committee of the Board may determine prior to the grant of such award. Each Initial Option Grant will vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant. Each Initial RSU Grant will vest in a series of three successive equal annual installments over the three-year period measured from the date of grant.</font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="text-indent:57.31pt;padding-left:5.8pt;padding-right:5.45pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:30.25pt;">Annual Grant. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Without any further action of the Board, at the close of business on the date of each Annual Meeting following the IPO, each person who is then a Non- Employee Director will automatically be granted (i) a Nonstatutory Stock Option to purchase shares of common stock (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Annual Option Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and (ii) a restricted stock unit award covering shares of common stock of the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Annual RSU Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), whereby the Annual Option Grant and Annual RSU Grant shall together have a total grant date value of $425,000 (with the shares covered by the award rounded down to the nearest whole share). The recipient shall designate the proportionate share between the Annual Option Grant and Annual RSU Grant prior to or on the date of grant. The grant date value will be calculated in accordance with the Black-Scholes option valuation methodology or such other methodology as the Board or the Compensation Committee of the Board may determine prior to the grant of such award. Each Annual Option Grant will vest in a series of 12 successive equal monthly installments over the one-year period measured from the date of grant. Each Annual RSU Grant will vest on the one-year anniversary of the date of grant.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:5.8pt;padding-right:5.5pt;text-align:justify;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15.6pt;">Vesting&#59; Change in Control. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All vesting is subject to the Non-Employee Director&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Continuous Service</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (as defined in the Plan) on each applicable vesting date. Notwithstanding the foregoing vesting schedules, for each Non-Employee Director who remains in Continuous Service with the Company until immediately prior to the closing of a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Change in Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (as defined in the Plan), the shares subject to his or her then-outstanding equity awards that were granted pursuant to this policy will become fully vested immediately prior to the closing of such Change in Control.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:5.8pt;padding-right:5.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.95pt;">Remaining Terms. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The remaining terms and conditions of each award, including transferability, will be as set forth in the Company&#8217;s Director Option Grant Package or Director RSU Grant Package, as applicable, in the forms adopted from time to time by the Board.</font></div><div><font><br></font></div><div style="padding-left:5.8pt;margin-top:10.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Expenses</font></div><div><font><br></font></div><div style="padding-left:5.8pt;padding-right:5.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company will reimburse Non-Employee Director for ordinary, necessary and reasonable out- of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Non-Employee Director timely submit to the Company appropriate </font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:36pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:5.8pt;padding-right:5.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">documentation substantiating such expenses in accordance with the Company&#8217;s travel and expense policy, as in effect from time to time.</font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>allo-20191231xex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.11</font></div><div style="text-align:right;"><img alt="allogenelogo5.jpg" src="allogenelogo5.jpg" style="height:36px;width:150px;"></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">July 29, 2019</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rafael G. Amado, M.D. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Re&#58;      Employment Letter of Agreement (&#8220;Agreement&#8221;)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Dear Dr. Amado,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Allogene Therapeutics, Inc. (&#8220;Allogene&#8221; or the &#8220;Company&#8221;) is pleased to offer you employment on</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the following terms and conditions.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Title&#59; Reporting&#59; Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">When you commence employment with Allogene, you shall be employed in the position of Executive Vice President of Research and Development and Chief Medical Officer, shall report directly to David Chang, Chief Executive Officer and President, and shall perform the duties and responsibilities that the Company assigns to you.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">You shall devote substantially all of your business time, attention and energies to the business and affairs of Allogene and shall not during the period of your employment be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, that will materially interfere with the performance of your duties or your availability to perform such duties or that will adversely affect, or negatively reflect upon, Allogene.</font></div><div style="padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">Your duties will be performed from 210 E. Grand Ave, South San Francisco, CA 94080. Reasonable out of pocket travel expenses incurred for visiting Allogene&#8217;s offices prior to relocation to the San Francisco Bay Area as described in Section 5 will be reimbursed by Allogene.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You shall receive base salary paid at the rate of five hundred thousand dollars ($500,000) per year, payable in accordance with Allogene&#8217;s payroll practices.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19.84pt;">Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You will be eligible to earn an annual performance bonus at the sole discretion of the Company in an amount equal to a target of forty percent (40%) of your base salary (the &#8220;Annual Bonus&#8221;). The Annual Bonus will be based upon the Company&#8217;s assessment of your performance and the Company&#8217;s attainment of targeted goals as set by the Company in its sole discretion. Following the close of each calendar year, the Company will determine whether you have earned an Annual Bonus, and the amount of any such bonus, based on the achievement of such goals. No amount of Annual Bonus is guaranteed, and you must be an employee on the Annual Bonus payment date to be eligible to receive an Annual Bonus. No partial or prorated bonuses will be provided (except that for calendar year 2019, any bonus will be based upon the time of your employment with the Company in 2019). The Annual Bonus, if earned, will be paid no later than March 15 of the calendar year after the applicable bonus year.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Allogene shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable under this Section 2.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Options and RSUs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Subject to the approval of the Board of Directors (the &#8220;Board&#8221;), or an authorized committee thereof, you shall be granted a stock option having an aggregate grant date value of $2.75 million for the purchase of shares of Allogene&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) on your employment start date. The grant date value will be calculated in accordance with the Black-Scholes option valuation methodology or such other methodology as the Board or the Compensation Committee of the Board may determine prior to the grant of such award (with the shares covered by the award rounded down to the nearest whole share). Such grant shall be evidenced by an option agreement </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(the &#8220;Option Agreement&#8221;) to be entered into by and between you and the Company. In the event of a conflict between this Agreement and the Option Agreement, the terms of the Option Agreement shall control. The exercise price per option share will be equal to the fair market value per share of the Company&#8217;s common stock as of the date that such Option is granted by the Board. The Option shall have a 10-year term and shall vest and become exercisable as follows&#58; (i) 25% upon the first anniversary date of your employment start date (the &#8220;Initial Vesting Date&#8221;)&#59; and thereafter (ii) the remaining unvested options shares shall vest in 36 equal monthly installments following the Initial Vesting Date and measured from the first anniversary of the Initial Vesting Date.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19.84pt;">Restricted Stock Units</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#58; Subject to the approval of the Board, or an authorized committee thereof, you shall be granted a restricted stock unit (&#8220;RSU&#8221;) in the amount of a number of shares equal to $2.75 million divided by the closing price per share of the Company&#8217;s Common Stock on The NASDAQ Global Select Market on your employment start date (with the shares covered by the award rounded down to the nearest whole share). Such grant shall be evidenced by a Restricted Stock Unit Agreement (the &#8220;Award Agreement&#8221;) to be entered into by and between you and the Company. In the event of a conflict between this Agreement and the Award Agreement, the terms of the Award Agreement shall control. The RSU shall vest in four (4) equal annual installments as of the annual anniversary of the last calendar day of the month of your employment start date.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Performance RSU</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Subject to the approval of the Board, or an authorized committee thereof, you shall be granted an additional restricted stock unit (&#8220;Performance RSU&#8221;) in the amount of a number of shares equal to $1.5 million divided by the closing price per share of the Company&#8217;s Common Stock on The NASDAQ Global Select Market on your employment start date (with the shares covered by the award rounded down to the nearest whole share). Such grant shall be evidenced by a Restricted Stock Unit Agreement (the &#8220;Performance Award Agreement&#8221;) to be entered into by and between you and the Company. In the event of a conflict between this Agreement and the Performance Award Agreement, the terms of the Performance Award Agreement shall control. The Performance RSU shall vest in three (3) equal annual installments, with (a) the first installment to vest upon initiation of a Phase 2 clinical trial of ALLO-501, (b) the second installment to vest upon the filing of a biologics license application with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for ALLO-501, and (c) the third installment to vest upon FDA approval of ALLO-501. Any unvested portion of the Performance RSU shall lapse after seven (7) years.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Sign-On Advance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You will receive a sign-on advance in the amount of seventy- five thousand dollars ($75,000), subject to standard payroll deductions and withholdings, payable within thirty (30) days after your employment start date (the &#8220;Sign-On Advance&#8221;). The Sign-On Advance will be considered earned only if you successfully complete one (1) year of continuous employment with the Company. If within your first year of employment with the Company&#58; (a) you resign your employment, or (b) the Company terminates your employment for Cause (as defined below), then you agree to pay back the entire amount of the Sign-on Advance within ten (10) days after your employment termination date. For purposes of this Agreement, &#8220;Cause&#8221; will mean any one or more of the following&#58; (a) commission of any felony or crime involving dishonesty&#59; (b) participation in any fraud against the Company&#59; (c) material breach of your contractual, statutory or common law duties to the Company (including violation of any provision or obligation under this Agreement)&#59; (d) your failure to satisfactorily perform your job duties as assigned by the Company&#59; (e) intentional damage to any property of the Company&#59; or (f) misconduct or other violation of Company policy that causes or reasonably could cause harm. </font></div><div style="text-indent:-13.5pt;padding-left:27pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Relocation Advance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. We understand you will be relocating to the San Francisco Bay Area. In connection with that relocation you will receive a relocation advance payment in the amount of one-hundred fifty thousand dollars ($150,000), subject to standard payroll deductions and withholdings, payable within thirty (30) days of your start date (the &#8220;Relocation Advance&#8221;). The Relocation Advance will be considered earned only if you relocate to the San Francisco Bay Area on or before December 31, 2019 and you successfully complete one (1) year of continuous employment with the Company. You may use the Relocation Advance to pay for relocation expenses or for any other purpose. If within your first year of employment with the Company&#58; (a) you resign your employment, or (b) the Company terminates your employment for Cause (as defined above), then you agree to pay back the entire amount of the Relocation Advance within ten (10) days after your employment termination date.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Allogene will reimburse you for all normal, usual and necessary expenses incurred in furtherance of the business and affairs of Allogene upon timely receipt by Allogene of appropriate vouchers or other proof of </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">your expenditures and otherwise in accordance with any expense reimbursement and approval policy as may from time to time be adopted by Allogene.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. As a regular full-time employee, you shall be entitled to participate in the employee benefits made available to similarly situated employees, in accordance with the terms of such benefits plans and programs and company policies. Information regarding these employee benefits is available upon request and in the official plan documents, summary plan descriptions, and applicable summaries. The Company, in its sole discretion, has the right to amend or terminate any benefit plan, program or Company policy at any time and without prior notice.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You hereby represent and warrant as follows&#58;</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">By accepting the Company&#8217;s offer of employment, you represent that you have no agreements, relationships, or commitments with any other person or entity that conflict with your obligations to the Company.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">You have the full right, power and legal capacity to enter and deliver this Agreement and to perform your duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the parties, enforceable against each in accordance with its terms. No approvals or consents of any persons or entitles are required for you to execute and deliver this Agreement or perform your duties and other obligations hereunder.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">You represent and warrant to the Company that you have not brought and shall not bring with you to the Company, or use in the performance of your duties, any materials or documents of any former employer that are not generally available to the public, unless you have obtained written authorization from the former employer for their possession and use and provided the Company with a copy thereof.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Conditions to Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. This offer of employment is contingent upon, and your employment shall be subject to&#58;</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">completion of reference checks and background check, and may be contingent upon a drug screen, each to the reasonable satisfaction of Allogene&#59; and</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">satisfying the requirements of the Immigration Control and Reform Act, which may be accomplished by showing your proof of right to work in the U.S. within three days of commencing employment, and you agree to assist as needed at the Company&#8217;s request to meet these conditions.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">execution of Allogene&#8217;s form of Employee Confidential Information and Invention Assignment Agreement attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which prohibits unauthorized use or disclosure of Allogene&#8217;s proprietary information, among other obligations&#59;</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">Notwithstanding the foregoing, this offer may be withdrawn by Allogene at any time prior to its execution by the parties.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Employment-at-will and Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Your employment shall be at-will. Accordingly, you may terminate your employment with Allogene at any time and for any reason whatsoever, with or without advance notice, simply by notifying Allogene in writing. Similarly, Allogene may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This at-will relationship cannot be changed except in a writing signed by the Company&#8217;s General Counsel and you. The employment terms contained in this Agreement supersede any other agreements and promises made to you by Allogene or any representative on its behalf, whether oral, written or implied.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">No Reliance by You on Promise or Representation Not in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. In accepting employment with Allogene and signing this Agreement, you agree that you are not relying on any representation, promise or inducement that has been made by Allogene or any representative on its behalf that is not explicitly stated in this Agreement. Allogene is not bound by and will not be liable for any representation, promise or inducement that is not explicitly stated in this Agreement.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The terms of this offer letter shall be governed by, and construed and interpreted in accordance with, the laws of the State of California without regard to such State&#8217;s principles of conflict of laws, except as provided in Section 13.</font></div><div style="padding-left:27pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. To the maximum extent permitted by law, any dispute between the parties, including but not limited to those arising out of, or relating to, this Agreement, shall be exclusively decided by binding arbitration in accordance with the terms of the Arbitration Agreement, which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and incorporated into this Agreement. The Federal Arbitration Act shall govern the interpretation, enforcement and all proceedings pursuant to the Arbitration Agreement. To the extent that the Federal Arbitration Act is inapplicable, the terms of the Arbitration Agreement shall be construed in accordance with California law.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. </font></div><div style="text-indent:-13.5pt;padding-left:27pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">This Agreement, and your rights and obligations hereunder, may not be assigned. Allogene may assign its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets, provided the assignee entity which succeeds to Allogene expressly assumes Allogene&#8217;s obligations hereunder and complies with the terms of this Agreement.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto. The Company&#8217;s signatory must be an officer who is authorized by the Company to enter into such an amendment.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">This Agreement, including its </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Exhibits A and B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter of the Agreement. This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Certification of Qualifications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. By accepting employment, you certify that the information you provided to Allogene about your experience, education and other qualifications for employment has been accurate and complete.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If you wish to accept employment at Allogene under the terms described above, please sign and date this Agreement, and return it to me. If you accept this offer, we would like you to start employment on Tuesday, September 3, 2019.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We look forward to your favorable reply and to a productive and enjoyable working relationship.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This offer will be deemed withdrawn if not accepted by August 2, 2019.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Sincerely, </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:29.239%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics, Inc.</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Understood and Accepted&#58; </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:44.883%;"><tr><td style="width:1.0%;"></td><td style="width:63.146%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.514%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.340%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Rafael G. Amado</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 30, 2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rafael G. Amado</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</font></td></tr></table></div><div><font><br></font></div><div id="i_0_554"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo4.jpg" src="allogenelogo4.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee Confidential Information and Invention Assignment Agreement</font></div><div id="i_0_548"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo3.jpg" src="allogenelogo3.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIAL INFORMATION AND </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INVENTION ASSIGNMENT AGREEMENT</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-right:5.76pt;text-align:justify;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In consideration of my employment or continued employment by Allogene Therapeutics, Inc., its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Company&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), and the compensation and benefits provided to me now and during my employment with Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Agreement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">1.   CONFIDENTIAL INFORMATION PROTECTIONS.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.1   Recognition of Company's Rights&#59; Nondisclosure. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#8217;s written approval before publishing or submitting for publication any material  (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns. I  will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.2   Confidential Information. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Confidential Information&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Confidential Information&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know- how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">)&#59; (b) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers, and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential Customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names&#59; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with any federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.3   Third Party Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I understand, in addition, that Company has received and in the future will receive from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Third Party Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of </font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Company in writing.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.4   No Improper Use of Information of Prior Employers and Others.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.   ASSIGNMENTS OF INVENTIONS.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;2.1   Definitions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As used in this Agreement, the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Intellectual Property Rights&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Copyright&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Moral Rights&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.2   Excluded Inventions and Other Inventions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Attachment 1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Excluded Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Other Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> means Inventions in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.3   Assignment of Company Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Inventions assigned to Company, or to a third party as directed by Company pursuant to Section 2.6, are referred to in this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Company Inventions.&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> Attachment 1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights. I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.4   Unassigned or Nonassignable Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Specific Inventions Law&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), as detailed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Attachment 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.5   Obligation to Keep Company Informed. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;2.6   Government or Third Party.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.7   Ownership of Work Product.  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;(a)     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">(b)     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.8   Enforcement of Intellectual Property Rights and Assistance. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.9 Incorporation of Software Code.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">3.   RECORDS.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">4.   DUTY OF LOYALTY DURING EMPLOYMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">5.   NO SOLICITATION OF EMPLOYEES,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">CONSULTANTS, OR CONTRACTORS. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.   REASONABLENESS OF RESTRICTIONS.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;6.1   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests. I represent and agree that I am entering into this Agreement</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">   In the event that a court or arbitrator finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, Company and I agree that the court or arbitrator will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.3   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the court or arbitrator declines to enforce this Agreement in the manner provided in subsection 6.2, Company and I agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">7.   NO DISPARAGEMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that, during my employment with the Company and after the termination of my employment for any reason, I will not disparage the Company, its officers, directors, managers, employees, consultants, shareholders, or agents, in any manner likely to be harmful to it or their business, business reputation or personal reputation. Notwithstanding the foregoing, nothing in this Agreement shall prohibit me from making truthful statements or disclosures required by applicable law, regulation or legal process&#59; or requesting or receiving confidential legal advice. Nothing in this Agreement shall limit my right to make truthful statements in the proper performance of my job duties for the Company, discuss my employment, or report possible violations of law or regulation with the SEC, EEOC, DOL, NLRB, OSHA or other federal government agency or similar state or local agency, or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the NLRA, or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to &#8220;whistleblower&#8221; statutes or other similar provisions that protect such disclosure.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">8.   NO CONFLICTING AGREEMENT OR OBLIGATION.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">9.   RETURN OF COMPANY PROPERTY. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide the Company access to any such personal systems as reasonably requested to search for, copy and&#47;or delete such information, and upon my employment termination I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed. I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#8217;s Termination Certificate&#59; however, my failure to sign and deliver the Termination Certificate shall in no way diminish my continuing obligations under this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">10.   LEGAL AND EQUITABLE REMEDIES.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">10.1   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">breach of this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;10.2  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">11.   NOTICES. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">have been given on the delivery date reflected by the courier or express mail service receipt.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">12.   NOTIFICATION OF NEW EMPLOYER.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.   GENERAL PROVISIONS.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.1   Governing Law. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.2   Severability. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.3   Successors and Assigns. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.4   Survival. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.5   Employment At-Will.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree and understand that </font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.6   Waiver. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">adherence to all terms of this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.7   Export.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.8   Advice of Counsel. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.9   Entire Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The obligations pursuant to Sections 1 and 2 of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant (except Subsection 2.4 and 2.7(a)) or employee if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</font></div></td></tr></table></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall be effective as of the first day of my employment with the Company. </font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.911%;"><tr><td style="width:1.0%;"></td><td style="width:6.888%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.305%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.605%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.888%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.114%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EMPLOYEE&#58; </font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COMPANY&#58; </font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT AND HAVE BEEN GIVEN THE OPPORTUNITY TO REVIEW IT WITH INDEPENDENT LEGAL COUNSEL. I HAVE ALSO COMPLETELY FILLED OUT ATTACHMENT 1.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ACCEPTED AND AGREED&#58; </font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Rafael Amado</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Signature)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Signature)</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rafael Amado</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EVP of R&#38;D and CMO</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General Counsel</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 30, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 26, 2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Address&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Address&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210 E Grand Avenue, South San Francisco, CA 94080</font></td></tr></table></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;"><font><br></font></div><div id="i_0_562"></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ATTACHMENT 1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRIOR INVENTIONS</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:59.935%;"><tr><td style="width:1.0%;"></td><td style="width:18.053%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.791%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.156%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TO&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FROM&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DATE&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SUBJECT&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior Inventions</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:3.365%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.642%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.617%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.162%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.617%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.020%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:28.5pt;">Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Allogene Therapeutics, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No inventions or improvements</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">See below&#58; </font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;     Additional sheets attached.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:28.5pt;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Invention or Improvement</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Party(ies)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Relationship</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;     Additional sheets attached.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div id="i_0_568"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">ATTACHMENT 2</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIMITED EXCLUSION NOTIFICATION</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:67.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:67.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">Result from any work performed by you for Company.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div id="i_0_574"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo2.jpg" src="allogenelogo2.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">EXHIBIT B</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arbitration Agreement</font></div><div id="i_0_580"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo1.jpg" src="allogenelogo1.jpg" style="height:36px;width:150px;"></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Arbitration Agreement</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I recognize that disputes may arise between Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) and me during or following my employment with the Company, and that those disputes may or may not be related to my employment. The parties understand and agree that by entering into this Arbitration Agreement (the &#8220;Agreement&#8221;), they anticipate gaining the benefits of a speedy, impartial, final and binding dispute-resolution procedure.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and I mutually consent to the resolution by arbitration of all claims or controversies (&#8220;claims&#8221;), past, present or future, whether or not arising out of my employment (or its termination), that the Company may have against me or that I (and no other party) may have against (1) the Company&#59; (2) the Company&#8217;s officers, directors, employees or agents in whatever capacity&#59; (3) the Company&#8217;s parent, subsidiary and affiliated entities&#59; (4) the Company&#8217;s benefit plans or the plans&#8217; sponsors, fiduciaries, administrators, affiliates and agents (except claims under an employee benefit or pension plan that specifies a different claims process&#59; and&#47;or (5) all successors and assigns of any of them. The Federal Arbitration Act (9 U.S.C., Sections 1-16) (&#8220;FAA&#8221;) shall govern the interpretation, enforcement and all proceedings pursuant to this Agreement. To the extent that the Federal Arbitration Act is inapplicable, or  held not to require arbitration of a particular claim or claims, the arbitration law of the state in which I work or last worked for the Company shall apply.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Arbitrable claims include, but are not limited to&#58; claims for wages&#47;other compensation due and any related claims&#59; claims for breach of any contract or covenant (express or implied)&#59; tort claims&#59; claims for retaliation&#59; claims for harassment&#59; claims for discrimination (including, but  not limited to, race, sex, sexual orientation, religion, national origin, age, marital status, physical or mental disability or handicap, or medical condition)&#59; claims for benefits (except as noted above)&#59; and claims for violation of any federal, state, or other governmental law, statute, regulation, or ordinance. The following claims are not covered by this Agreement&#58; claims for Workers&#8217; Compensation or Unemployment Insurance benefits&#59; claims pending against the Company at the time I sign this Agreement in any forum&#59; and claims that as a matter of law cannot be subject to arbitration.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Both the Company and I hereby waive the right to a trial by jury or judge, or by administrative proceeding, for any claim or dispute covered by this Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Both the Company and I agree that neither of us shall initiate or prosecute any lawsuit in any way related to any claim covered by this Agreement to arbitrate, except that this Agreement does not prohibit the filing of or pursuit of relief through the following&#58; (i) seeking temporary or preliminary injunction relief as is otherwise available by law, (ii) an administrative charge to any federal, state or local equal employment opportunity or fair employment practices agency, (iii) an administrative charge to the National Labor Relations Board, or (iv) any other charge filed with or communication to a federal, state or local government office, official or agency.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The  arbitration  will  be  held  before  a  neutral  arbitrator  under  the  auspices of JAMS.    The arbitration shall take place in the county (or comparable government unit) in which I am or was last employed by the Company, and, except as provided above, no dispute affecting my rights or responsibilities shall be adjudicated in any other venue or forum. The arbitration shall be held in accordance with its then-current Employment Arbitration Rules &#38; Procedures (and no other JAMS rules), which are currently available at </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. I understand that the Company will provide me a written copy of those rules upon  my request. The Arbitrator shall be either a retired judge, or an attorney who is experienced in employment law and licensed to practice law in the state in which the arbitration is convened (the &#8220;Arbitrator&#8221;), and shall be selected pursuant to the JAMS rules.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Arbitrator shall apply the substantive law (and the law of remedies, if applicable) of the state in which the claim arose, or federal law, or both, as applicable to the claim(s) asserted. The Arbitrator is without jurisdiction to apply any different substantive law or law of remedies. The Federal Rules of Evidence shall apply. The Arbitrator shall have the power to award any types  of legal or equitable relief that would be available under applicable law, shall have the authority to compel adequate discovery for the resolution of the dispute, and shall render an award and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">written opinion, which shall include the factual and legal basis for the award. The arbitration decision shall be final and binding upon the parties.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Questions regarding the enforceability, interpretation, scope, applicability or coverage of this Agreement (including whether an issue is subject to arbitration under this Agreement) shall be decided by the arbitrator. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. Pursuant to the FAA, issues of contract formation and enforcement relating to this Agreement shall be governed by and decided under the internal laws of the State of California, without regard to conflict of law rules.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company will be responsible for paying any filing fee and the fees and costs of the Arbitrator. Each party shall pay in the first instance its own litigation costs and attorneys&#8217; fees, if any. However, if any party prevails on a claim which affords the prevailing party attorneys&#8217; fees and&#47;or litigation costs, then the Arbitrator shall rule upon a motion for attorneys&#8217; fees and&#47;or litigation costs under the same standards a court would apply under the law applicable to the claim(s) at issue.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the maximum extent permitted by law, all claims, disputes, or causes of action under this Agreement, whether by me or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, collective, or representative proceeding&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">provided, however, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">that this Agreement shall not apply to any representative action under the California Private Attorney General Act (&#8220;PAGA&#8221;). The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative, collective or class proceeding. If a court adjudicating a case involving the Company and me were to determine that there is an unwaivable right to bring a class action, any such action shall be brought only in court, and not in arbitration.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and I agree that any arbitration, including, without limitation, discovery, documents produced and&#47;or entered into evidence, hearings, legal briefing and the final award, shall be confidential, although the final award may be disclosed as necessary to confirm the award and obtain entry of a final judgment by a court of competent jurisdiction. The Company and I further agree that we will execute written confidentiality agreements in order to ensure arbitration remains confidential.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall survive the termination of my employment and the expiration of any benefit plan. It can only be revoked by a writing signed by both the Company&#8217;s General Counsel and me specifically stating the intent to revoke this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This is the complete agreement of the parties on the subjects covered, and supersedes any prior or contemporaneous oral or written understandings on the subjects addressed in this Agreement&#59; provided, however, that if this Agreement is held to be unenforceable for any reason, then any prior arbitration agreement between the Company and me shall survive. No party is relying on any representations, oral or written, on the subject of the effect, enforceability or meaning of this Agreement, except as specifically set forth in this Agreement. This Agreement only can be modified in a written agreement signed by the parties.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If any provision of this Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, such adjudication shall not affect the validity of the remainder of the agreement. All other provisions shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I understand that nothing in this agreement affects the at-will nature of my employment with the Company, and that my employment may be terminated by either party, at any time, with or without cause or advance notice.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I acknowledge that I have carefully read this Agreement, that I understand its terms and that I have entered into the Agreement voluntarily and not in reliance of any promises or representations by the Company other than those contained in the Agreement. I understand that by signing this Agreement, I am giving up my right to a jury trial. Finally, I further acknowledge that I have been given the opportunity to discuss this Agreement with my own legal counsel.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.365%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.326%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.957%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 30, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Rafael Amado</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee Signature</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rafael Amado</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Printed Name of Employee</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 26, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COMPANY</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri, General Counsel</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>allo-20191231xex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i55f8e32f7dea432292ac06b577aa5dae_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.15</font></div><div style="margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Confidential &#8211; Execution Version</font></div></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK &#34;&#91;***&#93;&#34;.</font></div><div style="text-align:center;margin-bottom:8pt;"><font><br></font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COLLABORATION AND LICENSE Agreement</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Collaboration and License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), effective as of November 1, 2019 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is made by and between </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene Therapeutics, Inc.,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> a Delaware corporation with its principal place of business at 210 East Grand Ave., South San Francisco, CA 94080 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notch Therapeutics Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a corporation organized and existing under the laws of Ontario, Canada with registered address at 40 King Street West, Suite 2100, Toronto, Ontario M5H 3C2, Canada (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Allogene and Notch are sometimes referred to herein individually as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Allogene is a clinical-stage biotechnology company engaged in the research, development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer&#59; </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Notch possesses certain technology and expertise relating to the use of pluripotent stem cells to manufacture T cell therapies&#59; </font></div><div style="text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties desire to collaborate in relation to research and development of the use of Notch&#8217;s proprietary technologies for generating and manufacturing cells of T cell or NK cell lineage in connection with Allogene&#8217;s cellular therapies, and potential commercialization of pharmaceutical products arising from such research and development activities for the treatment of certain hematological malignancies&#59; and </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties have entered into that certain stock purchase agreement of even date herewith&#59;</font></div><div style="text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">DEFINITIONS </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Academic Use Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a non-exclusive license to Research Program Inventions granted by Notch or its Affiliate to a non-profit academic or research institution solely for such academic or research institution&#8217;s internal, non-commercial, non-clinical research. Such license shall not permit the publication or disclosure of any Research Program Invention or data related thereto without Allogene&#8217;s prior approval, not to be unreasonably withheld.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, as to a Party, any entity directly or indirectly controlling, controlled by or under common control with such Party, where &#8220;control&#8221; means (a) beneficial ownership of greater than fifty percent (50%) of the voting equity interests in such entity or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">management and policies of an entity, whether through the ownership of a voting equity interest, by contract or otherwise. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Alliance Manager</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;Allogene Background Technology&#8221; means Background Technology Controlled by Allogene or its Affiliates.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;Allogene Indemnitee&#8221; has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) Background Technology Controlled by Allogene, and (b) Allogene&#8217;s interest in any Research Program Inventions, excluding any Joint Technology.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Applicable Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all applicable laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">&#8220;Available&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and its cognates mean, with respect to a Target, that (a) Notch has not granted any Third Party any license, or option to acquire a license, under the Notch Technology to Exploit cellular therapy products Directed Against such Target (excluding licenses granted to service providers solely to provide services to Notch), or if Notch has granted such a license or option to acquire a license, such license or option to acquire a license has expired or terminated&#59; and, if the requirement in clause (a) is met, (b) Notch, together with its Affiliates and any Third Party to which Notch had previously granted a license or option as described in clause (a), have not (i) expended an aggregate amount in excess of &#91;***&#93; dollars (US$&#91;***&#93;) directly in the research and development of a cellular therapy product Directed Against such Target, or (ii) initiated any IND-enabling GLP toxicology studies for a cellular therapy product Directed Against such Target.   </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#34;Background Technology&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means Patent Rights and Know-How (a) Controlled by a Party prior to the Effective Date or (b) Controlled by such Party during the Term, but not generated in the performance of the activities under this Agreement.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Bankruptcy Code&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">B-Cell Malignancies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the hematological malignancies or cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system and  affect B cells. These include B-cell lymphomas and some leukemias. For clarity, B-Cell Malignancies shall for example not include Multiple Myeloma, chronic myelogenous leukemia, acute myelogenous leukemia, or T cell malignancies.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Biologics License Application</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BLA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Biologics License Application (as more fully described in U.S. 21 C.F.R. Part 601.20 or any successor regulation) and all amendments and supplements thereto submitted to the FDA, or any equivalent filing in a country or regulatory jurisdiction other than the U.S. with the applicable Regulatory Authority, or any similar application or submission for Regulatory Approval filed with a Regulatory Authority to obtain marketing approval for a biologic product in a country or in a group of countries. </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Bi-Specific Product&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means a CAR Product which is directed against at least two Targets, both of which are Exclusive Targets.  For clarity, a Bi-Specific Product may include a single CAR or two independent CARs, as long as they are intended to be expressed in the same T Cell or NK Cell.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a day other than Saturday, Sunday or any day on which commercial banks located in the San Francisco, California, USA, or Toronto, Canada are authorized or obligated by Applicable Laws to close.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Calendar Quarter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31&#59; provided, however, that (a) the first Calendar Quarter of the Term or following First Commercial Sale of Product shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter&#59; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.17</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Calendar Year</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) for the first year of the Term, the period beginning on the Effective Date and ending on December 31, 2019, (b) for each year of the Term thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31, and (c) for the last year of the Term, the period beginning on January 1 of the year in which the Agreement expires or terminates and ending on the effective date of expiration or termination of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.18</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CAR</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a chimeric antigen receptor.  For clarity, a CAR does not contain a TCR binding domain.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CAR Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a pharmaceutical or biological product comprising an Engineered CAR Cell. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;&#91;***&#93;&#8221; means the &#91;***&#93;, located at &#91;***&#93;.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.21</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#34;CEOs&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means the Chief Executive Officer of Notch and the Chief Executive Officer of Allogene, or a named designee of either of the foregoing. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.22</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Cell Type&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means either a T Cell or an NK Cell.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.23</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Change of Control&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means with respect to a specified Party&#58;  (a) the acquisition, directly or indirectly, by a Person or &#8220;group&#8221; (whether in a single transaction or multiple transactions) of more than 50% of the voting power of such Party or of beneficial ownership of (or the right to acquire such beneficial ownership) of more than 50% of the outstanding equity or convertible securities of such Party (including by tender offer or exchange offer)&#59; (b) any merger, consolidation, share exchange, business combination, recapitalization, the sale of substantially all of assets of, or similar corporate transaction involving such Party (whether or not including one or more wholly owned subsidiaries of such Party), other than&#58; (i) transactions involving solely such Party and&#47;or one or more Affiliates, on the one hand, and one or more of such Party&#8217;s Affiliates, on the other hand, and&#47;or (ii) transactions in which the stockholders of such Party immediately prior to such transaction hold at least 50% of the voting power of the surviving company or ultimate parent company of the surviving company&#59; or (c) the adoption of a plan relating to the liquidation or dissolution of such Party.  For purposes of this definition, the terms &#8220;group&#8221; and &#8220;beneficial ownership&#8221; has the meaning accorded in the U.S. </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Securities Exchange Act of 1934 and the rules of the U.S. SEC thereunder in effect as of the Effective Date. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.24</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Claims&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means all liability, loss, damage, claim, injury, costs or expenses (including reasonable attorneys&#8217; fees and expenses of litigation) of any kind arising from Third Party demands, claims, actions and proceedings (whether criminal or civil, in contract, tort or otherwise).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.25</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Collaboration Product&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means a T Cell or NK Cell created pursuant to the Research Program that expresses one or more CARs that are Directed Against one or more of the Exclusive Targets.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.26</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Collaboration Term&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.27</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Combination Product&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning set forth in the definition of Net Sales.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.28</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Commercially Reasonable Efforts&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means, with respect to either Party in relation to this Agreement, such efforts (whether undertaken by such Party directly or by such Party&#8217;s Affiliates or Sublicensees) that are consistent with the efforts and resources used by a biopharmaceutical company of similar size and resources in the exercise of its commercially reasonable business practices relating to an exercise of a right or performance of an obligation under this Agreement, including the research, development, manufacture and commercialization of a pharmaceutical or biologic compound or product, as applicable, at a similar stage in its research, development or commercial life as the relevant Product, and that has commercial and market potential similar to the relevant Product, taking into account issues of intellectual property coverage, safety and efficacy, stage of development, product profile, competitiveness of Third Party products in the marketplace, supply chain, proprietary position, regulatory exclusivity, anticipated or approved labeling, present and future market and commercial potential, the likelihood of receipt of Regulatory Approval, profitability (including pricing and reimbursement status achieved or likely to be achieved), alternative therapies and legal issues.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.29</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Competing Products&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.5(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.30</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Competitive Indication&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means B-Cell Malignancies and Multiple Myeloma.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.31</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Confidential Information&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.32</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Control&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Controlled&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means, with respect to any Know-How, Patent Rights or other Intellectual Property Rights, a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or right to use (as applicable) under such Know-How, Patent Rights, or other Intellectual Property Rights to the other Party on the terms and conditions set forth herein at the time of such grant, in each case without breaching the terms of any agreement with a Third Party.  Notwithstanding the foregoing, Know-How, Patent Rights and other Intellectual Property Rights licensed by Notch under a New Notch Third Party In-License shall only be considered to be Controlled by Notch if Allogene elects, within &#91;***&#93; days after notification thereof from Notch, to be bound by all terms and conditions thereof applicable to sublicensees thereunder (which terms and conditions shall be fully included in Notch&#8217;s notification to Allogene) and to pay the share of the license fees, milestone payments and royalties payable thereunder and reasonably allocated to such sublicense rights (which share that is paid by Allogene is subject to offset against Notch&#8217;s royalties to the </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">extent permitted under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.9(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) based on Allogene&#8217;s sublicense rights thereunder relative to the rights thereunder retained by Notch, which share shall be negotiated by the Parties in good faith. For clarity, Notch shall provide such notification for election to Allogene as described in the proceeding sentence for any Third Party license that includes any Intellectual Property Rights that would, if Allogene were to make the election set forth in the immediately prior sentence, fall within the definition of Notch Technology.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.33</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Cover&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#8220;Covering&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Covered&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means, with reference to a Patent Right and a product, composition, article of manufacture or method, that the manufacture, practice, use, offer for sale, sale or importation of such product, composition, article of manufacture or method, would infringe a Valid Claim of such Patent Right in the country in which such activity occurs without a license thereto (or ownership thereof) (or if such Patent Right is pending, would infringe such Valid Claim if it were to issue as then being prosecuted in good faith).</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.34</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any of the milestones described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.35</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Directed Against</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, as used in connection with a Target, that the product or agent at issue is designed to interact or bind with such Target as its primary mechanism of action.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.36</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Dollars</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the U.S. dollar, and &#8220;$&#8221; shall be interpreted accordingly.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.37</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EMA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the European Medicines Agency, and any successor entity thereto.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.38</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Engineered CAR Cell</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an engineered T Cell or NK Cell that expresses one or more CARs Directed Against a Target.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.39</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EU</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all countries that are officially recognized as member states of the European Union at the relevant time.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.40</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exclusive Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) any Initial Target for which no Substitute Target has been selected by Allogene pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, (b) any Substitute Target selected by Allogene pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to replace any Initial Target, and (c) any Optioned Target.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.41</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exclusivity Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.5(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.42</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Existing Notch Third Party In-License&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means &#91;***&#93;.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.43</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#34;Exploit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, a product.  Cognates of the word &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exploit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have correlative meanings.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.44</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Field</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means the treatment, prevention and palliation of all human and animal diseases and disorders, including, without limitation, the Competitive Indications.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.45</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;First Commercial Sale&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means the first arm&#8217;s length commercial sale for monetary value by Allogene, its Affiliates or Sublicensees of a Product in the Territory to a Third Party who is not a Sublicensee for end use or consumption by the general public of such Product in any country following the receipt of Regulatory Approval for such Product by Allogene, its Affiliates, or its Sublicensees&#59; provided, however, that the following shall not constitute a First Commercial Sale&#58;  (a) any sale to an Affiliate or Sublicensee unless the Affiliate or Sublicensee is the last entity in the distribution chain of the Product&#59; (b) any use of such Product in clinical </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">trials, non-clinical development activities or other development activities with respect to such Product by or on behalf of a Party, or disposal or transfer of such Product for a bona fide charitable purpose&#59; and (c) compassionate use, in each case for which no payment is received by Allogene, its Affiliates or Sublicensees.  For purposes of clarification, except as otherwise provided in the previous sentence, any first arm&#8217;s length commercial sale to a distributor or wholesaler under any non-conditional sale arrangement would be a First Commercial Sale.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.46</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Full Time Equivalent&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;FTE&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means the equivalent of a full-time scientist&#8217;s work time over a twelve (12)-month period (including customary vacations, sick days and holidays).  The portion of an FTE year devoted by a scientist to the Research Program shall be determined by dividing the number of eight (8)-hour days during any twelve (12)-month period devoted by such employee to the Research Program by the total number of working days during such 12-month period.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.47</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Funding Minimum</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.48</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;FTE Rate&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means an annualized rate &#91;***&#93; dollars (US$&#91;***&#93;) per year for FTEs performing activities under the Research Plan.   </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.49</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#34;GAAP&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means United States generally accepted accounting principles applied on a consistent basis.   </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.50</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Governmental Authority&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means any federal, state, national, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).    </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.51</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Improvement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means an advancement, modification, development or improvement. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.52</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Indemnify&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.53</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Infringe&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Infringement&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means any infringement as determined by Applicable Law, including, without limitation, direct infringement, contributory infringement or induced infringement. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.54</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Initial Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any target set forth in Exhibit A.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.55</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Intellectual Property Rights&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means rights in and to all (a)&#160; U.S. and foreign patents and patent applications, including&#160; all provisional, utility, divisions, substitutions, continuations, continuations-in-part, reissues, re-examinations and extensions thereof</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">,or inventor certificates, or equivalents thereof, (b) copyrights, whether registered or unregistered, (c) Know-How, (d) software, (e) trademarks, service marks, trade names, trade dress, domain names and similar rights, including goodwill therein whether registered or not, and (f) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction, including the right to bring a claim with respect to any of the foregoing for past, present or future infringement, and any applications or registrations thereof.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.56</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Inventions&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means any process, method, composition, formulation, article of manufacture, method, discovery or finding, whether or not patentable or copyrightable, including all rights, title and interest in and to the Intellectual Property Rights therein. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.57</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">iPSCs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means induced pluripotent stem cells.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.58</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Joint Development Committee&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;JDC&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.59</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Joint Know-How&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means the Know-How included in the Joint Technology.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.60</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Joint Patents&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means the Patent Rights included in the Joint Technology.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.61</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Joint Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#34; has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.62</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any information and materials, including discoveries, improvements, modifications, processes, techniques, methods, assays, designs, protocols, formulas, data, databases, know-how and trade secrets (in each case, patentable, copyrightable or otherwise), but excluding any of the foregoing to the extent claimed by any issued Patent Right.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.63</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.64</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Member</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.   </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.65</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Multiple Myeloma&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means a cancer that forms in a type of white blood cell called a plasma cell.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.66</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Necessary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.9(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.67</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Negotiation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.7(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.68</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Net Sales&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means, with respect to any Product, the gross amounts invoiced by Allogene, its Affiliates and Sublicensees (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Selling Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to Third Party customers in an arm&#8217;s length transaction for sales of such Product, less the following deductions actually incurred, allowed, taken, paid, accrued or allocated in its financial statements in accordance with GAAP (as applicable to the Selling Party), for&#58; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">discounts (including trade, quantity and cash discounts) actually allowed, cash and non-cash coupons, retroactive price reductions, and charge-back payments and rebates granted to any Third Party (including to Governmental Authorities, purchasers, reimbursers, customers, distributors, wholesalers, and group purchasing and managed care organizations or entities (and other similar entities and institutions))&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">credits or allowances, if any, on account of price adjustments, recalls, claims, damaged goods, rejections or returns of items previously sold (including Product returned in connection with recalls or withdrawals) and amounts written off by reason of uncollectible debt&#59; provided, that if the debt is thereafter paid, the corresponding amount shall be added to the Net Sales of the period during which it is paid&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">rebates (or their equivalent), administrative fees, chargebacks and retroactive price adjustments and any other similar allowances granted by a Selling Party (including to Governmental Authorities, purchasers, reimbursers, customers, distributors, </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">wholesalers, and group purchasing and managed care organizations and entities (and other equivalent entities and institutions)) which effectively reduce the selling price or gross sales of the Product, as well as costs of distribution and wholesale&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">insurance, customs charges, freight, postage, shipping, handling, and other transportation costs incurred by a Selling Party in shipping Product to a Third Party&#59; and</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">import taxes, export taxes, excise taxes, sales tax, value-added taxes, consumption taxes, duties or other taxes levied on, absorbed, determined and&#47;or imposed with respect to such sales (excluding income or net profit taxes or franchise taxes of any kind).</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.83pt;">Sales of Product(s) between or among Allogene and its Affiliates, licensees or sublicensees shall be excluded from the computation of Net Sales and no payments shall be payable on such sales except where such Affiliates, licensees or sublicensees are end users.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For the avoidance of doubt, sales of a Product for an invoice price less than or equal to Allogene&#8217;s or its applicable Affiliate&#8217;s, licensee&#8217;s or sublicensee&#8217;s cost of goods sold (reasonably determined consistent with GAAP and customary manufacturing cost accounting principles) for (x) use in conducting clinical trials of such Product in a country in order to obtain the Regulatory Approval of such Product in such country or (y) any compassionate use or named patient sales shall be excluded from Net Sales calculations for all purposes.    </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If a Product is sold in combination with other pharmaceutical or biologic active ingredients that are not themselves Products (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Combination Components</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;, and taken together (whether co-formulated, co-packaged or for co-administration) with the Product, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Bundled Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) for a single price, the Net Sales applicable to such transaction will be the product of (i) Net Sales of the Bundled Product calculated as above (i.e., calculated as for a non-Bundled Product) and (ii) the fraction (A&#47;(A+B)), where&#58; </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;A&#8221; is the gross invoice price in such country of the Product as the sole therapeutically active ingredient&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;B&#8221; is the gross invoice price in such country of all of the Combination Components contained in the Bundled Product.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If &#8220;A&#8221; or &#8220;B&#8221; cannot be determined by reference to sales other than in connection with a Bundled Product as described above, then Net Sales will be calculated as above, but the gross invoice price in the above equation shall be the relative value contributions of the Product and Combination Components to the Bundled Product gross invoice price, as reasonably determined by the Parties in good faith.  Notwithstanding the foregoing and solely for calculating Net Sales under this Agreement, if the Combination Component is a pre-conditioning antibody, the Parties shall assign relative value contributions of the Product and such Combination Component to the Bundled Product gross invoice price, as reasonably determined by the Parties in good faith.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.69</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">New Notch Third Party In-License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any license of Third Party Know-How, Patent Rights or other Intellectual Property Rights entered into by Notch after the Effective Date.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.70</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NK Cell</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a natural killer cell, or an innate lymphocyte that does not express a TCR, and recognizes target cells through a balance of signals from activating and inhibitory receptors.  For clarity, NK Cells do not include T Cells.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NK cells may express CD56 and CD16. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.71</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Non-Publishing Party&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.7(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.72</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Background Technology&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means Background Technology Controlled by Notch or its Affiliates.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.73</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Indemnitee&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.74</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Know-How&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means all Know-How that is (a) Controlled by Notch or its Affiliates as of the Effective Date or during the Term, (b) solely with respect to such Know-How arising after the Collaboration Term, is directly related to any Notch Technology utilized in the Research Program (or to any Notch Technology that existed during the Collaboration Term and was suitable for use in the Research Program) and (c) necessary or useful for the Exploitation of any CAR Product Directed Against one or more Exclusive Targets, including, to the extent necessary or useful, methods for (i) generating progenitor T Cells from donor material&#59; (ii) generating and manufacturing cells of the T Cell lineage, including mature T Cells, hematopoietic stem cells, embryonic stem cells and&#47;or iPSCs via a soluble or insoluble, bead-based system&#59; and (iii) generating and manufacturing cells of the NK Cell lineage.  Notch Know-How includes Notch&#8217;s interest in the Joint Know-How.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.75</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Microbeads&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means a surface, such as a microbead, which creates an engineered thymic niche for three-dimensional presentation of immobilized proteins, such as delta-like ligand 4 and VCAM-1, in suspension cultures in order to instruct expedite progenitor and mature T-Cell differentiation from stem cells, such as hematopoietic or induced pluripotent stem cells.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.76</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Microbead Technology&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means all Know-How and Patent Rights Controlled by Notch during the Term that relate to the production or use, as produced or used by or on behalf of Notch, of Notch Microbeads for the Exploitation of CAR Products directed to one or more Exclusive Targets, including the Patents and Know-How described in Exhibit B.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.77</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Patents&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means any Patent Right that is Controlled by Notch or its Affiliates as of the Effective Date or during the Term, and Covers the Exploitation of any CAR Product Directed Against one or more Exclusive Targets.  Notch Patents existing as of the Effective Date are listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notch Patents include Notch&#8217;s interest in Joint Patents.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.78</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notch Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Notch Know-How and Notch Patents, and includes the Notch Microbead Technology.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.79</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Notch Third Party In-Licenses&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means (a) the Existing Notch Third Party In-License and (b) any New Notch Third Party In-License pursuant to which Allogene receives a sublicense of rights under this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.80</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Optioned Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.81</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all US patents and provisional and non-provisional patent applications (which for the purpose of this Agreement shall be deemed to include certificates of </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, revalidations, extensions, registrations, patent term extensions, patent term adjustments, and supplemental protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.82</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.83</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Phase 1 Clinical Trial&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means a human clinical trial of a CAR Product, the principal purpose of which is a preliminary determination of safety, pharmacokinetics, and pharmacodynamic parameters in healthy individuals or patients, as described in 21 C.F.R. 312.21(a), or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.84</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase 2 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a human clinical trial of a CAR Product in any country that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate evidence of clinical safety and effectiveness for a particular therapeutic indication or therapeutic indications in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.85</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase 3 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a human clinical trial of a CAR Product in any country that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(c) and is intended to (a) establish that the Product is safe and efficacious for its intended use, (b) define contraindications, warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed, and (c) support Regulatory Approval for such Product, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.86</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Pivotal Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Clinical Trial of a CAR Product in a sufficient number of subjects that satisfies both of the following ((a) and (b))&#58;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">such Clinical Trial establishes that such CAR Product has an acceptable safety and efficacy profile for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such CAR Product in the dosage range to be prescribed, which Clinical Trial can be used to support Regulatory Approval of such CAR Product, or a similar clinical study prescribed by the United States, Canada or EMA&#59; and</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">such Clinical Trial may be a Phase 2 Clinical Trial or Phase 3 Clinical Trial that satisfies the requirements of any of the expedited development and review pathways available at the FDA or its foreign equivalent.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For the avoidance of doubt, a Clinical Trial may become a Pivotal Clinical Trial after the commencement of such trial based on the statistical significance of the data generated in such trial.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.87</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prior Confidentiality Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that certain non-disclosure agreement between the Parties dated January 11, 2019.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.88</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a CAR Product that (a) expresses one or more CARs that are Directed Against one or more Exclusive Targets&#59; and (b) the manufacture, use or sale of which is Covered by a Notch Patent or which was developed or manufactured through use of the Notch Technology.  For clarity, a Product may be a Bispecific Product.      </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.89</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Product Infringement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.5(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.90</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prosecuting and Maintaining</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;, and its correlates, means preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof) and maintaining a Patent Right.  For these purposes, &#8220;prosecution&#8221; shall include any post-grant proceeding including supplemental examination, post grant review proceeding, inter parties review proceeding, patent interference proceeding, opposition proceeding and reexamination.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.91</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PSCs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means pluripotent stem cells.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.92</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Publishing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.7(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.93</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Regulatory Approval&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means all approvals, licenses, registrations, and authorizations by the Regulatory Authority necessary for the commercial sale of a CAR Product in the Field in a given country or regulatory jurisdiction, including pricing and reimbursement approval where required as part of obtaining such regulatory approval.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.94</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">&#8220;Regulatory Authority&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means any applicable Governmental Authority or other authority responsible for granting Regulatory Approvals for a CAR Product, including the FDA, the EMA and any corresponding national or regional regulatory authorities.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.95</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Regulatory Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Product, other than Patent Rights.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.96</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Remainder</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.5(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.97</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Budget</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.98</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) the costs of Notch FTEs performing activities under the Research Plan at the FTE Rate and otherwise without mark-up, (b) out-of-pocket costs directly incurred by Notch in performing activities under the Research Plan without mark-up, and (c) costs incurred by Notch for the Research Facility and cGMP manufacturing capacity in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> without mark-up.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.99</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Milestones</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any milestone described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.100</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Milestone 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the first to be achieved of Research Milestone &#8220;T-3A&#8221; and Research Milestone &#8220;N-3A&#8221; as described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.101</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.102</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.103</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Program Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Inventions discovered, conceived or created during the Collaboration Term by either Party or its Affiliates alone, or by the Parties jointly, in each case as a result of the activities conducted under the Research Plan. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.104</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROFN Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.105</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROFN Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Target listed on Exhibit D&#59; provided that Allogene may replace each Target listed on Exhibit D with an Available Target once.  Allogene shall provide Notch with a written request for such replacement that names the new Target and describes its primary applicability to a Competitive Indication, and Notch shall respond in writing within &#91;***&#93; days of receipt of such written request confirming the replacement or, if such Target is not Available, stating the new Target is not Available, in which case no replacement shall take place (for clarity, Notch shall not be required to disclose the identity of any Third Party that holds a license or option to such Target). For clarity, Allogene shall not have any ability to increase the number of aggregate Targets listed on Exhibit D or to replace any Target listed on Exhibit D with a Target that was previously an Exclusive Target. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.106</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">&#34;Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.107</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning given in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.108</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Selling Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has the meaning set forth in the definition of Net Sales.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.109</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sublicensee(s)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Third Party to which Allogene has granted a sublicense under this Agreement.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.110</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Substitute Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.5(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.111</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Success Criteria</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.112</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Supply Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.113</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">&#8220;Target&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means an antigen expressed on or in a tumor cell.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.114</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">T Cell</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any lymphocytes that naturally contain a TCR and includes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">alpha beta T cells, gamma delta T cells, natural killer T cells and any other cell type naturally containing a TCR, whether variable or invariant.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">TCR may be genomically rearranged at alpha and beta loci, expressed on cell surface or intracellularly. T Cells may express both alpha and beta, only alpha or only beta chains, or neither.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.115</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TCR</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a T cell receptor. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.116</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.117</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means worldwide. </font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.118</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any person or entity other than a Party and its Affiliates and their respective employees, agents and representatives.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.119</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.120</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Useful</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.9(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.121</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Valid Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) an issued claim of any issued patent within the Notch Patents that has not expired, or been revoked, cancelled, become abandoned or disclaimed, been declared invalid and&#47;or unenforceable by a patent office or a decision or judgment of a court or other appropriate body of competent jurisdiction&#59; and (b) a claim included in a pending patent application included in the Notch Patents that is being prosecuted in good faith and that has not been cancelled, withdrawn from consideration, finally determined to be unallowable by the patent office or applicable governmental authority (from which no appeal is or can be taken), or abandoned or disclaimed&#59; provided, however, that, if a claim of a patent application has been pending for more than seven (7) years, such claim will not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent issues with such claim&#59; provided, further, that, for purposes of the foregoing proviso, any newly filed claim which claims priority to any earlier filed claim shall be considered pending for the same period of time as such earlier filed claim has been pending.</font></div><div style="text-indent:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.122</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.13(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-align:justify;margin-bottom:13.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:30pt;">RESEARCH PROGRAM</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:13.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">Research Program.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">The Parties will conduct a research program directed to the use of the Notch Technology to discovery, generation and manufacturing of Products for oncology applications, pursuant to a research plan mutually agreed to by the Parties (such plan, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and such program, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Research Plan shall include the following&#58;  (i) a timeline for the conduct of research activities, on an Exclusive Target-by-Exclusive Target basis as applicable (it being understood that, unless otherwise agreed by the Parties, the Research Plan shall be limited in scope to the activities for the Exclusive Target(s) specifically set forth in the Research Plan)&#59; (ii) the deliverables to be provided arising from such research activities&#59; (iii) the personnel and other resources Notch is required to apply to the performance of the Research Program, which resources shall not exceed the Research Costs set forth in the Research Budget, (iv) any biological or chemical materials to be provided by a Party to the other Party in order for such Party to conduct its activities under the Research Plan (the providing Party&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and timing therefor&#59; (v) any Know-How to be provided by a Party to the other Party in order for such Party to conduct its activities under the Research Plan and timing therefor&#59; (vi) the criteria for determining whether each Research Milestone or Development Milestone has been successfully completed (with respect to each such milestone, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Success Criteria</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (vii) Notch Affiliates, contractors and service providers expected to perform services pursuant to the Research Plan&#59; and (viii) a budget for the Research Costs (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Budget</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), which, excluding the Research Costs incurred pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, shall not exceed &#91;***&#93; dollars (US$&#91;***&#93;) for the duration of the Collaboration Term, unless otherwise agreed in writing by the Parties, or be less than &#91;***&#93; dollars (US$&#91;***&#93;) per Calendar Year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Funding Minimum</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), pro-rated for partial Calendar Years, unless otherwise agreed in writing by the Parties. The initial Research Plan is set forth as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to this Agreement.  The Parties hereby agree that the T Cell-based Collaboration Products Directed Against any Target listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to be researched, developed, manufactured and potentially commercialized shall utilize a chimeric antigen receptor construct produced using technology Allogene has licensed from Cellectis SA. </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Notch shall provide reasonable, good faith, non-binding estimates for the Research Budget that is intended to fund Notch for the activities to be performed by Notch as set forth in the Research Plan and intended for the achievement of the goals set forth in the Research Plan, and shall provide supporting documentation therefor to Allogene upon request.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch shall not be required to provide resources or to perform activities under the Research Plan the aggregate cost of which (including Notch FTEs at the FTE Rate, material and equipment purchases, costs pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> below, and other Third-Party costs as specified in the Research Plan) exceeds the funding provided by Allogene for such activities.     </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Subject to the foregoing provisions of this Section 2.1, each Party shall use Commercially Reasonable Efforts to conduct its respective obligations set forth in the Research Plan.  For clarity, neither Party guarantees that any timeline, deliverables or Success Criteria will be achieved or provided, within the Research Budget or otherwise, and any failure by a Party to achieve any of the same shall not constitute a breach of this Agreement provided that such Party has fulfilled its obligations to use Commercially Reasonable Efforts as set forth in the preceding sentence.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Each Party shall perform, and shall require that its applicable Affiliates, licensees, sublicensees and Third Party contractors perform, all research activities in a good scientific and ethical business manner and in compliance with the terms of this Agreement, and in compliance with all Applicable Laws. Any breaches of the foregoing by an Affiliate or Third Party shall, as between the Parties, be the responsibility of the Party that engaged such Affiliate or Third Party. No agreement between Notch and its Affiliates, licensees, sublicensees, or Third Party contractors that perform services pursuant to the Research Plan will conflict with the terms of this Agreement or impose any obligations on Allogene, except as approved in writing in advance by Allogene.  Each Party shall use Commercially Reasonable Efforts to maintain materially complete, current and accurate records of the activities conducted by or on behalf of such Party under the Research Program and all data and other information resulting from such activities.  Such records shall properly reflect all work done and results achieved in good scientific manner and with intention to be appropriate for regulatory and patent purposes.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.83pt;">Notch shall keep accurate records of the Notch FTEs involved in the performance of the Research Program, including time sheets tracking the time such individual spent working in support of the Research Program.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, with respect to each Exclusive Target, Allogene shall have the right to specify whether the Research Plan shall at any particular time be directed to T Cells, NK Cells or both T Cells and NK Cells.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">The term of the Research Program shall commence on the Effective Date and expire upon the earlier of (i) the fifth (5</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) anniversary of the Effective Date, (ii) at Allogene&#8217;s election, following the JDC&#8217;s determination that for each Exclusive Target, Notch has met the Success Criteria for all Development Milestones for at least one Product (irrespective of cell type) Directed Against such Exclusive Target, or (iii) the JDC&#8217;s determination that the Research Program cannot be reasonably pursued against any Exclusive Target due to technical infeasibility or safety issues (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Collaboration Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Allogene </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall have the right to terminate the Collaboration Term by written notice if Notch materially fails to perform its obligations under the Research Plan, subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 2.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and does not cure such failure within &#91;***&#93; days following Notch&#8217;s receipt of Allogene&#8217;s written notice of such failure.  In such event, at Allogene&#8217;s request, Notch shall perform the technology transfer described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.49pt;">During the Collaboration Term, each Party shall report to the JDC each Calendar Quarter summarizing the results and data obtained from the conduct of the Research Plan.  If reasonably necessary for Allogene to perform its work under the Research Plan or to Exploit a Product or exercise its rights under the Agreement, Allogene may request that Notch provide more detailed information and data regarding such results reported by Notch, and Notch shall promptly provide Allogene with such reasonable information and data responsive to such request to the extent in Notch&#8217;s possession or control, provided that, without limiting Notch&#8217;s obligations to perform the Research Plan as set forth in this Article 2, Notch shall not be required to perform any additional work in responding to such request beyond transmitting such existing information and data in the form it exists unless Notch and Allogene agree upon reasonable additional funding (including Notch FTEs at the FTE Rate) in accordance with an agreed budget that Allogene will pay to Notch for such additional work.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Notch Research and Manufacturing Facilities.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch will use Commercially Reasonable Efforts to maintain access to laboratory and process development facilities at &#91;***&#93; or similar facility approved by the JDC (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Research Facility</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) at its own cost. Notch will use Commercially Reasonable Efforts to negotiate a fee-for-service agreement with the Research Facility to maintain access to cGMP manufacturing resources for cGMP master cell line generation and banking to perform the Research Plan as necessary during the Collaboration Term.  Such agreement shall not conflict with the terms of this Agreement or impose any obligations upon Allogene, except as expressly approved in advance in writing by Allogene.  Allogene shall reimburse Notch in accordance with the Research Budget for its actual, out-of-pocket costs of the Research Facility specifically incurred for the conduct of manufacturing activities pursuant to the Research Plan.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">In addition, Allogene shall fully reimburse Notch in accordance with the Research Plan budget for its actual, out-of-pocket costs for Notch&#8217;s costs of maintaining cGMP facility manufacturing capacity required for Notch&#8217;s performance under this Agreement (which shall be paid on a pro rata basis if such capacity is also used for other Notch programs).  If the Parties enter into a Supply Agreement, then such costs shall be addressed under the Supply Agreement.  For clarity, Allogene shall not be responsible for any legal or advisory costs incurred by Notch in contracting for such capacity.  Such agreement between Notch and the manufacturer shall not impose any obligations upon Allogene, except as expressly approved in advance in writing by Allogene.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Transfer of Know-How and Materials for Research Program. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Each Party shall use Commercially Reasonable Efforts to transfer to the other Party any Materials and Know-How specified in the Research Plan for use by such other Party in conducting the Research Program and performing its obligations under this Agreement in accordance with the timeline for such transfer set forth therein.  Each Party shall use the other Party&#8217;s Materials and Know-How in compliance with Applicable Law and the terms and conditions of this Agreement.  </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as otherwise provided under this Agreement, all Materials and Know-How shall remain the sole property of the providing Party, and shall be returned to such Party or destroyed, in such Party&#8217;s sole discretion, upon the termination of this Agreement or, solely with respect to Allogene&#8217;s Materials and Know-How, expiration of the Collaboration Term, whichever is the earlier.   </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Technology Transfer for Collaboration Products.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">For each Collaboration Product, upon the date that is &#91;***&#93; days following Notch&#8217;s completion of its activities under the Research Plan for such Collaboration Product or upon Allogene&#8217;s written request, the Parties will agree in writing on a plan for the transfer of Notch Know-How relating to such Collaboration Product to Allogene, or its designee, including the manufacturing process therefor (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Technology Transfer Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), subject to  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and the Supply Agreement, if and when in force. If the Parties do not execute a Supply Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Allogene may engage a reputable Third Party manufacturer located in the United States, Europe or Japan and transfer or instruct Notch to transfer the applicable Notch Microbead Technology (including any reagents or other factors necessary to use the Notch Microbead Technology) in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Parties do not execute a Supply Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Allogene may not engage a Third Party manufacturer located outside the United States, Europe or Japan without Notch&#8217;s prior written approval, not to be unreasonably withheld.  Prior to any transfer to a Third Party manufacturer, Notch may require that the Third Party manufacturer execute an agreement with Notch, to be negotiated in good faith by Notch, that includes reasonable industry-standard measures to protect Notch Know-How relating to the applicable Collaboration Product and manufacturing process therefor, including reasonable confidentiality and non-use provisions.</font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">The Parties intend that each Technology Transfer Plan encompass the transfer to Allogene of all Notch Know-How (including tangible materials) Controlled by Notch as of the date of such transfer and that is necessary or reasonably useful to enable Allogene&#8217;s Development and manufacture of such Collaboration Product, excluding any inventory of Notch Microbead cGMP raw materials, work in process and finished Notch Microbeads, which shall be supplied solely to the extent set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or a Supply Agreement.  As soon as practical and pursuant to such Technology Transfer Plan, Notch shall commence disclosing and making available to Allogene or its designee the Notch Know-How and materials listed in the Technology Transfer Plan, according to the timeline set forth in the Technology Transfer Plan.  Notch shall use Commercially Reasonable Efforts to complete such transfer within such reasonable period as the Parties shall agree in writing in the Technology Transfer Plan.  The Parties shall cooperate with each other in good faith to enable a smooth and successful transfer of such Notch Know-How to Allogene.  Upon Allogene&#8217;s reasonable request, Notch shall provide reasonable technical assistance, including making appropriate personnel available to Allogene at reasonable times, places, and frequency, and upon reasonable prior notice, for the purpose of assisting Allogene to understand and use the Notch Know-How in connection with Allogene&#8217;s Development and manufacture of Collaboration Products, provided that Notch may reasonably condition such provision of assistance on Allogene&#8217;s funding of any Notch resources needed to respond to such Allogene request (including Notch FTEs at the FTE Rate) in accordance with an agreed budget.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch shall, at Allogene&#8217;s request, use Commercially Reasonable Efforts to make such introductions and facilitate discussions with contract manufacturers, contract research organizations and other Third Parties that have performed services related to each Collaboration Product on behalf of Notch in order for Allogene to evaluate and potentially contract for such Third Parties&#8217; services.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Substitution of Initial Targets.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">During the Exclusivity Term, Allogene shall have the right to substitute each Initial Target with one (1) substitute Target.  To exercise such right, Allogene shall provide Notch with written notice of its intent to substitute an Initial Target with a different Target, which notice shall identify the proposed substitute Target.  Notch shall notify Allogene within &#91;***&#93; days following its receipt of such notice as to whether such Target is Available or, if such Target is not Available, a brief description of why such Target is not Available (for clarity, Notch shall not be required to disclose the identity of any Third Party that holds a license or option to such Target).  If such Target is Available, then it shall become an Exclusive Target (and shall be deemed to be a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Substitute Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and such Initial Target shall cease to be an Exclusive Target and thereafter Allogene shall have no further rights under this Agreement as to such former Exclusive Target.  If such Target is not Available, then Allogene shall retain the right to substitute another Target for such Initial Target as set forth above.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, promptly following the substitution of an Initial Target with a Substitute Target, the JDC shall update the Research Plan to reflect such substitution and the activities to be performed with respect to such Substitute Target, provided that Notch shall not be obligated to undertake such additional work unless and until the Research Budget has also been modified as necessary to cover any expansion to the scope of activities to be required of Notch, which modification may increase the aggregate funding to be paid by Allogene to Notch above &#91;***&#93; dollars (US$&#91;***&#93;).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Solely with respect to any Substitute Target that is not a substitute for &#91;***&#93;, neither Allogene nor any of its Affiliates shall conduct (and shall not facilitate any Third Party to conduct) any clinical development of any Product Directed Against such Substitute Target for an indication that is not a Competitive Indication unless and until Allogene (or any of its Affiliates or Sublicensees) has submitted a BLA for a Product Directed Against such Substitute Target in a Competitive Indication.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Target Option.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch hereby grants to Allogene an option to add &#91;***&#93; additional Targets as Exclusive Targets under this Agreement, as follows&#58;  From the Effective Date through &#91;***&#93;, Allogene shall have the right, but not the obligation, to propose in writing to Notch from time-to-time additional Targets to be added to this Agreement.  Notch shall notify Allogene within &#91;***&#93; days following its receipt of such notice as to whether each such Target is Available or, if such Target is not Available, a brief description of why such Target is not Available (for clarity, Notch shall not be required to disclose the identity of any Third Party that holds a license or option to such Target).  If such Target is Available, then Allogene shall within &#91;***&#93; days following its receipt of Notch&#8217;s notice of Availability notify Notch whether Allogene is exercising its option with respect to such Target.  If Allogene exercises its option with respect </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to such Target, then such Target shall become an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Optioned Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and Allogene shall pay to Notch an option exercise fee therefor in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, promptly following Allogene&#8217;s exercise of its option with respect to an Optioned Target, the JDC shall update the Research Plan to reflect such substitution and the activities to be performed with respect to such Optioned Target, provided that Notch shall not be obligated to undertake such additional work unless and until the Research Budget has also been modified as necessary to cover any expansion to the scope of activities to be required of Notch, which modification may increase the aggregate funding to be paid by Allogene to Notch above &#91;***&#93; dollars (US$&#91;***&#93;). </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Neither Allogene nor its Affiliates shall conduct (and shall not facilitate any Third Party to conduct) any clinical development of any Product Directed Against an Optioned Target for an indication that is not a Competitive Indication unless and until Allogene (or any of its Affiliates or Sublicensees) has submitted a BLA for a Product Directed Against such Optioned Target in a Competitive Indication.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Right of First Negotiation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  During the Exclusivity Term, Notch hereby grants to Allogene a right of first negotiation with respect to each ROFN Target to acquire an exclusive (even as to Notch and its Affiliates), royalty-bearing, world-wide, sublicenseable license under Notch&#8217;s Intellectual Property Rights to Exploit CAR Products Directed Against a ROFN Target (a &#8220;ROFN License&#8221;), as follows&#58; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">During the Exclusivity Term, neither Notch nor its Affiliates shall (i) initiate any IND-enabling GLP toxicity study for any CAR Product Directed Against any ROFN Target (such product, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROFN Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and such study and any further studies conducted by Notch or its Affiliates, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notch Internal R&#38;D</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), nor (ii) initiate or participate in negotiations for any agreement with a Third Party for a license, an option to acquire a license, or the sale or other transfer under Notch&#8217;s Intellectual Property Rights to Exploit any ROFN Product, unless and until the procedures set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> have been fulfilled.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">If Notch or any of its Affiliates desires to undertake any activity described in subsection (a)(i) or (a)(ii) above, then Notch shall provide Allogene with written notice thereof, which notice shall specify</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i) the ROFN Target, (ii) a summary of the Intellectual Property Rights and data Controlled by Notch and its Affiliates relating to such ROFN Target and ROFN Product(s) and (iii) whether such notice is triggered by subsection (a)(i) or (a)(ii) above (such notice, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROFN Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Allogene may exercise its right of first negotiation with respect to such ROFN Target at any time during the &#91;***&#93; days following its receipt of such ROFN Notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notification Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), by providing to Notch a written notice of exercise during such Notification Period.  If Allogene exercises such right of first negotiation, then for &#91;***&#93; days following Notch&#8217;s receipt of Allogene&#8217;s notice of exercise (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Negotiation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Parties shall engage in good faith negotiations regarding the commercially reasonable terms for the ROFN License. During the Negotiation Period, Notch shall provide Allogene with such reasonable additional information regarding such ROFN Target (and any existing ROFN Product(s) Directed Against such ROFN Target Controlled by Notch) and related Intellectual Property Rights as Notch may have in its possession or control and Allogene may reasonably </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">request, provided that Notch shall not be required to perform any work in responding to such requests beyond transmitting such existing information and data in the form it exists.  The Negotiation Period shall be commensurately extended by any period of delay in Notch&#8217;s transmission of such information.    </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">If Allogene does not exercise its right of first negotiation with respect to a ROFN Target during the applicable Notification Period, or Allogene exercises such right of first negotiation and the Parties do not reach execute an agreement for such ROFN License in accordance herewith prior to the expiration of the applicable Negotiation Period, then, in each such case&#58;</font></div><div style="text-indent:60.69pt;padding-left:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)    If the ROFN Notice was triggered by subsection (a)(i) above, then Notch and its Affiliates shall thereafter be free to conduct Notch Internal R&#38;D with respect to such ROFN Target, subject to subsection (a)(ii) above&#59; and</font></div><div style="text-indent:57.36pt;padding-left:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)    If the ROFN Notice was triggered by subsection (a)(ii) above, then Notch and its Affiliates shall thereafter be free to grant a Third Party a ROFN License with respect to such ROFN Target.  Notwithstanding the foregoing, prior to Notch accepting any offer to grant such ROFN License (or any other sale or transfer) to any Third Party on terms that are substantially similar to (or less favorable to Notch than) those last offered by Allogene, Allogene shall have a one-time right of first refusal whereby Notch shall offer such ROFN License (with the same terms and conditions offered by such Third Party) to Allogene in writing, and Allogene shall have &#91;***&#93; days following its receipt of Notch&#8217;s notice to accept such offer in writing, in which case the Parties shall promptly execute a definitive agreement on reasonable and customary terms reflecting such offer and acceptance.  Notwithstanding anything to the contrary in this Agreement, Allogene&#8217;s right of first refusal does not apply where a Third Party has offered Notch terms and conditions for a license to a New Target Product that are substantially better for Notch (considering the entire economic consideration to be received by Notch under such offer) than the terms and conditions last offered by Allogene.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Option under Existing Notch Third Party In-License.&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If Notch receives a notice from &#91;***&#93; pursuant to Section 4.5(a) of the Existing Notch Third Party In-License regarding any Licensor Improvement (as defined in the Existing Notch Third Party In-License) that relates to the Notch Technology, then Notch shall notify Allogene of such Licensor Improvement within &#91;***&#93; days of Notch&#8217;s receipt of such notice.&#160; If Allogene wishes to include such Licensor Improvement in its licenses granted under Section 4.2(a) of this Agreement, then (a) Allogene shall so notify Notch within &#91;***&#93; days of its receipt of Notch&#8217;s notice&#59; (b) promptly following its receipt of Allogene&#8217;s notice, Notch shall notify &#91;***&#93; of its interest in exercising its option under Section 4.5(a) of the Existing Notch Third Party In-License with respect to such Licensor Improvement (unless Notch has already provided such notice)&#59; and (c) the Parties shall discuss in good faith the terms for such license to such Licensor Improvement.&#160; For clarity, this Section 2.8 shall not prevent Notch from exercising such option with respect to any Licensor Improvement that Allogene does not wish to include in its licenses hereunder.</font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:30pt;">GOVERNANCE</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Alliance Managers.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Each Party shall by written notice to the other Party appoint a principal point of contact to be its project manager (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Alliance Manager</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) who shall coordinate and act as a liaison with such other Party with respect to this Agreement and the Research Program and who shall have the authority to act on behalf of their respective Parties.    Each Party may from time to time change its Alliance Manager upon written notice and reasonable consultation with the other Party. The Alliance Managers&#8217; responsibilities shall generally include overseeing and supervising its Party&#8217;s fulfillment of its obligations under the Research Plan, understanding the obligations of the other Party under the Research Plan, discussing the progress of the Research Program, and identifying barriers to success, key issues and issues-resolution options with the other Party&#8217;s Alliance Manager.  The Alliance Managers shall not have any authority to amend or interpret this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Joint Development Committee.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Promptly following the Effective Date, the Parties shall establish a joint development committee to oversee, coordinate and review the activities to be conducted under the Research Plan during the Collaboration Term (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Joint Development Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The JDC shall be comprised of at three (3) members from each Party with appropriate relevant expertise (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Member</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Each Party may replace any appointed Member at any time upon written notice to the other Party. Each Party shall designate one (1) of its Members as co-chairperson of the JDC. Each of the co-chairpersons shall be responsible, on an alternating basis, with the Allogene co-chairperson having responsibility with respect to the initial meeting, for working with the Alliance Managers to schedule meetings, prepare and circulate an agenda in advance of each meeting. Any JDC member may add topics to the draft agenda. The following shall apply to the JDC and its members&#58;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">During the Collaboration Term, the JDC shall meet at least once every Calendar Quarter at times mutually agreed upon by the Parties, or more frequently as the Parties deem appropriate.  At least one (1) such meeting per Calendar Year shall be held in person, and all other such meetings may be held by teleconference or videoconference.  The location of the meetings to be held in person shall alternate between sites designated by each Party, or as otherwise mutually agreed upon.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">The presence of at least one Notch Member and one Allogene Member shall be required to constitute a quorum at any meeting of the JDC.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">In addition to its Members, the Parties&#8217; Alliance Managers may attend any meeting of the JDC.  Each Party may invite other of its relevant employees or consultants to a JDC meeting as non-voting observers, provided that (i) such Party must provide the other Party with advance written notice identifying each such observer and such other Party has no reasonable objection to such observers, and (ii) such Party shall ensure that such observers are bound by written obligations relating to confidentiality and intellectual property that are consistent with this Agreement.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Each Party shall be responsible for all travel and related costs and expenses for its Members and other representatives to attend meetings of, and otherwise participate on, the JDC.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Responsibilities of the JDC.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The responsibilities of the JDC shall include&#58; (a) overseeing, reviewing and coordinating the Parties&#8217; implementation of the Research Plan, including reviewing data provided by Notch to evidence its achievement of the Research Milestones and Development Milestones&#59; (b) making key decisions as designated in the Research Plan, including determining whether or not the Research Milestones (as applicable) have been met, as set forth in Section 3.4&#59; (c) subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, amending the Research Plan, including following the substitution of an Exclusive Target pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or the addition of an Exclusive Target pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; (d) undertaking and&#47;or approving such other matters as are specifically provided for the JDC under this Agreement&#59; and (e) serving as an initial forum for resolving any disputes between the Parties.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Milestone Achievement.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Promptly following Notch&#8217;s determination that it has achieved a particular Research Milestone or Development Milestone with respect to a Collaboration Product of either Cell Type, Notch shall provide the JDC with a data package that includes the data and information required under the Research Plan and reasonably necessary for the JDC to determine whether the Success Criteria for such milestone has been achieved.  The JDC shall have &#91;***&#93; days to meet and consider such data package, and to determine in writing whether such Success Criteria have been achieved.  The JDC may request that Notch provides additional data and information to assist in such determination, which Notch shall promptly provide.  If the JDC determines that the applicable Success Criteria have been achieved, then Allogene shall pay the applicable milestone payment in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as applicable.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Decision-Making. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All of a Party&#8217;s Members whether present in person or by other means (e.g., teleconference) at any JDC meeting shall vote collectively counting as one vote.  Decisions of the JDC shall require the unanimous vote of both Parties.  If the JDC is unable to reach a unanimous vote with respect to a particular matter, then the matter shall be escalated for resolution by the CEOs in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All decisions of the JDC within its authority shall be documented in meeting minutes prepared by Allogene&#8217;s Alliance Manager.  Other communications between or among any members of the JDC outside of a JDC meeting shall not be deemed to constitute a JDC decision unless incorporated in meeting minutes, nor shall any decision of the JDC outside its authority be deemed binding on either Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Scope of Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The JDC shall have no authority to amend or modify any term or condition of this Agreement, or to determine or waive any compliance therewith.</font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">LICENSES&#59; EXCLUSIVITY</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Research Program License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the terms and conditions of this Agreement&#58;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Allogene hereby grants to Notch, a non-exclusive, non-sublicenseable (except as set forth in subsection (b) below), non-transferable license during the Collaboration Term (i) to use and practice the Allogene Technology, solely to the extent necessary for Notch to carry out its obligations under the Research Plan, and (ii) to use Allogene&#8217;s Materials transferred to Notch pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, solely for performing activities under the Research Plan.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">The license set forth in subsection (a) shall include the right for Notch to sublicense such rights to its Affiliates, contractors or service providers (but solely to the extent that they are identified in the Research Plan and are performing services solely related to the Research Plan), provided that Notch shall remain fully liable for the acts and omissions of, and for any breach of this Agreement by, such Affiliate(s), contractors and service providers.  Except as set forth in this subsection (b), Notch shall not have the right to sublicense to any Third Party without Allogene&#8217;s consent. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;"> License to Allogene</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Subject to the terms and conditions of this Agreement, Notch hereby grants to Allogene an exclusive (even as to Notch and its Affiliates, provided that Notch shall retain such rights as are necessary to carry out its obligations under the Research Plan), worldwide, royalty-bearing, sublicenseable (through multiple tiers) license under the Notch Technology to Exploit CAR Products Directed Against one or more Exclusive Targets for use in the Field.  Allogene shall remain fully liable for the acts and omissions of, and for any breach of this Agreement by any of its Affiliates or Sublicensees.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Allogene shall not exercise its rights granted under subsection (a) above with respect to the Notch Microbead Technology to make or have made Notch Microbeads, except (i) if the Parties do not enter into a Supply Agreement in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> during the Supply Agreement Negotiation Period, (ii) if the Parties do enter into a Supply Agreement and Allogene terminates the Supply Agreement for Notch&#8217;s material breach thereof or Notch otherwise fails to fulfill its obligations to supply Notch Microbeads sufficient to support the development and commercialization of the Products in the Field throughout the Territory, or (iii) as otherwise set forth in the Supply Agreement or agreed in writing by the Parties.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Notch Third Party In-Licenses.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Allogene shall comply, and shall cause its Affiliates and Sublicensees to comply, with all terms and conditions of the Notch Third Party In-Licenses applicable to sublicensees thereunder, provided that such terms and conditions have been provided to Allogene. </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Allogene shall be responsible for the payment of all license fees, milestone payments, royalties and other amounts payable under the Notch New Third Party In-Licenses based on Allogene&#8217;s sublicense rights thereunder, which Allogene shall pay to Notch or directly to the Third Party licensors, as mutually agreed by Notch and Allogene, in time for Notch to satisfy its payment obligations to the applicable Third Party licensors.  Notch shall be responsible for the payment of all license fees, milestone payments, royalties and other amounts payable under the Existing Notch Third Party In-License.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch shall, and shall cause its Affiliates to&#58;</font></div><div style="text-indent:96.69pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)    subject to Allogene&#8217;s satisfaction of its obligations as a sublicensee thereunder, maintain each Notch Third Party In-License in full force and effect and not terminate such Notch Third Party In-License if the failure to do so would adversely affect, or would </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">reasonably be expected to adversely affect, Allogene&#8217;s rights under this Agreement, without Allogene&#8217;s prior written consent, not to be unreasonably withheld&#59; and</font></div><div style="text-indent:93.36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)     not amend or waive, or take any action or omit to take any action that would alter, any of Notch&#8217;s or such Affiliates&#8217; rights under any Notch Third Party In-License in any manner that adversely affects, or would reasonably be expected to adversely affect, Allogene&#8217;s rights under this Agreement without Allogene&#8217;s prior written consent, not to be unreasonably withheld&#59; and </font></div><div style="text-indent:90.03pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)   Notch shall promptly notify Allogene in writing of the receipt or delivery of any notice of any default under, or any termination or amendment of, any Notch Third Party In-License.   If Notch fails to cure any such default and the failure to do so would adversely affect, or would reasonably be expected to adversely affect, Allogene&#8217;s rights under this Agreement, Allogene shall have the right to cure any such default and subtract any reasonable amounts paid to the counterparty under the applicable Notch Third Party In-License in connection with such cure (other than amounts with respect to Notch New Third Party In-Licenses for which Allogene is responsible as set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) from any amounts due to Notch hereunder.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">At Allogene&#8217;s request, Notch shall use reasonable efforts to obtain the written agreement of the counterparty to any Notch Third Party In-License that, in the event of any termination of such Notch Third Party In-License, which termination does not result from any failure by Allogene or its Affiliates or Sublicensee to comply with the applicable terms of this Agreement or of such Notch Third Party In-License, such counterparty shall grant to Allogene a direct license under the Intellectual Property Rights covered by such Notch Third Party In-License that are equivalent in scope to the sublicense under such Intellectual Property Rights granted to Allogene hereunder, under the same terms as are in such Notch Third Party In-License (adjusted for any differences in the scope of such direct license from the license granted to Notch under such Notch Third Party In-License), and provided that such counterparty shall not be required to accept any obligations greater than those provided for in such Notch Third Party In-License. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">No Other Rights. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  All rights that are not specifically granted herein are reserved to the possessing Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">During the Exclusivity Term, neither Notch nor any of its Affiliates shall sell, license or otherwise transfer any Notch Technology to any Third Party for application to products in the Field the primary mechanism of action of which is modulation of any Exclusive Target.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">During the Exclusivity Term and other than as set forth in the Research Plan, neither Notch nor any of its Affiliates shall, itself or with any Third Party, research, develop, manufacture or otherwise progress &#91;***&#93;.</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">During the Exclusivity Term and other than as set forth in the Research Plan, neither Notch nor any of its Affiliates shall, itself or with any Third Party, research, develop, manufacture or otherwise progress &#91;***&#93; (such products, together with any products described in subsection (b) above, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Competing Products</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exclusivity Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the period commencing on the Effective Date and expiring on &#91;***&#93;.  Notwithstanding the foregoing, for each Exclusive Target for which Allogene is conducting (itself or through an Affiliate or Sublicensee) development or commercialization of a Product Directed Against such Exclusive Target at the end of the period set forth in the immediately preceding sentence, the Exclusivity Term with respect to such Exclusive Target shall be extended until the earliest of &#91;***&#93;.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Rights in Bankruptcy.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All rights and licenses granted under or pursuant to this Agreement by Notch to Allogene, are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Article 101(35A) of the Bankruptcy Code. The Parties agree that Allogene, as a licensee of such Intellectual Property Rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.  The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Notch under the Bankruptcy Code or analogous provisions of applicable Laws outside the United States, Allogene will be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to Allogene and all embodiments of such intellectual property, which, if not already in Allogene&#8217;s possession, will be promptly delivered to it (a)&#160;upon any such commencement of a bankruptcy proceeding upon Allogene&#8217;s written request therefor, unless Notch elects to continue to perform all of its obligations under this Agreement or (b)&#160;if not delivered under clause (a), following the rejection of this Agreement in the bankruptcy proceeding, upon written request therefor by Allogene. The Parties further agree that, upon the occurrence of a bankruptcy event, each Party shall have the right to retain and enforce their rights under this Agreement. </font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">DEVELOPMENT&#59; COMMERCIALIZATION</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:21pt;">Generally</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">. Following the completion of the technology transfer described in Section 2.4 with respect to a Collaboration Product, Allogene shall have sole responsibility for the development and commercialization of such Collaboration Product.  In any event, following the Collaboration Term and for the remainder of the Term, as between the Parties, Allogene shall have sole responsibility for the development and commercialization of Products. Following the Collaboration Term, Allogene shall use Commercially Reasonable Efforts to develop and commercialize at least one (1) Product for each of (a) the treatment at least one B-Cell Malignancy and (b) the treatment of Multiple Myeloma, in each case ((a) and (b)) in the United States and in the European Union. The timelines for Allogene&#8217;s development and commercialization of the two Products set forth in the foregoing clauses (a) and (b) may vary based on the factors set forth in the definition of Commercially Reasonable Efforts relating to such Products (e.g., in some circumstances, one of such Products may progress further in development at an earlier point in time based on such factors).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:21pt;">Reports.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">On an Exclusive Target-by-Exclusive Target basis, following the disbanding of the JDC, and until the First Commercial Sale of the first Product Directed Against such Exclusive Target, Allogene shall provide Notch with a written report providing a status of Allogene&#8217;s development (including registration) of Products Directed Against such Exclusive </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">Target annually.  Such report shall cover the previous twelve (12) month period and shall be provided by Allogene no later than &#91;***&#93; days after each Calendar Year.  Each such update shall summarize Allogene&#8217;s (either by itself or through its Affiliates and its Sublicensees) activities with respect to Exploitation of such Products.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:21pt;">Supply of Notch Microbeads. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For &#91;***&#93; days following Allogene&#8217;s request therefor, the Parties shall seek in good faith to negotiate the commercially reasonable terms of supply agreement pursuant to which Notch would supply to Allogene, its Affiliates and its Sublicensees the Notch Microbeads sufficient to support the development and commercialization of the Products in the Field throughout the Territory (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;">Supply Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#8221;), provided that Notch shall not be obligated to negotiate a Supply Agreement after &#91;***&#93; months after the Effective Date.  If the Parties do not enter into a Supply Agreement within such &#91;***&#93; day period and prior to &#91;***&#93; months after the Effective Date (or such longer period as the Parties may agree in writing) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;">Supply Agreement Negotiation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#8221;), then Notch shall transfer to Allogene or its designee applicable Notch Microbead Technology (including any reagents or other factors necessary to use the Notch Microbead Technology) in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration: underline;">Section 2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">, subject to Allogene reimbursing Notch for the cost of any tangible materials included in such transfer that were not acquired or generated using Research Budget funding previously paid by Allogene.  If the Parties execute a Supply Agreement that relates to the supply of Notch Microbeads for a particular Product and Allogene thereafter requires Notch Microbeads to be supplied for an additional Product, then the Parties shall follow the procedures set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;"> to amend the existing Supply Agreement for the supply of Notch Microbeads for any additional Product. For clarity, to the extent the Parties were previously unable to negotiate a Supply Agreement or amendment thereto as set forth above, Allogene shall have the right to request Notch to transfer to its designee the Notch Microbead Technology (including any reagents or other factors necessary to use the Notch Microbead Technology) in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration: underline;">Section 2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;"> for Product, subject to Allogene reimbursing Notch for the cost of</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">any tangible materials included in such transfer that were not acquired or generated using Research Budget funding previously paid by Allogene</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;">.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:27pt;">PAYMENTS </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Initial Consideration&#59; Option Exercise Fee.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">In consideration for the rights granted to Allogene under this Agreement, Allogene shall pay to Notch a one-time-only, non-refundable, non-creditable payment of ten million Dollars ($10,000,000) on the Effective Date.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">On the Effective Date, Allogene shall purchase &#91;***&#93; shares of Notch&#8217;s Series Seed convertible preferred stock at $&#91;***&#93; per share, pursuant to the stock purchase agreement and related agreements entered or to be entered into between the Parties of even date herewith. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Option Exercise Fee.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  For each Optioned Target, Allogene shall pay to Notch an option exercise fee of &#91;***&#93; Dollars ($&#91;***&#93;) within &#91;***&#93; days following its receipt of Notch&#8217;s invoice therefor, which invoice shall not be sent until Allogene has exercised its option with respect to such Target in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Payment of Research Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Advance Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Within &#91;***&#93; days of the Effective Date, Allogene shall pay to Notch an amount equal to Notch&#8217;s estimated Research Costs to be incurred under the Research Plan in accordance with the Research Budget (as set forth in the initial Research Plan) for the then-current Calendar Quarter.  Thereafter, for each Calendar Quarter in which Notch is anticipated to activities under the Research Plan, Notch shall submit to Allogene an invoice setting forth Notch&#8217;s estimated Research Costs to be incurred based on the then-current Research Budget for such Calendar Quarter, no later than &#91;***&#93; Business Days following the first day of such Calendar Quarter (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Advance Invoice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).    </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">True-Up</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Within &#91;***&#93; days after the end of each Calendar Quarter in which Notch has conducted activities under the Research Plan, Notch shall submit to Allogene a reasonably detailed reconciliation report setting forth the actual Research Costs incurred by or on account of Notch to conduct such activities in such Calendar Quarter and any credits or deficits from the corresponding Research Advance Invoice previously provided for such Calendar Quarter (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">True-Up Report</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  If the estimated Research Costs paid by Allogene pursuant to subsection (a) above for such prior calendar quarter are less than Notch&#8217;s actual Research Costs for such quarter, then Allogene shall pay the deficit to Notch as described in this subsection (b) to the extent such amounts do not exceed the corresponding amounts in then-current Research Budget (exclusive of Research Costs incurred in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">).  If the estimated Research Costs paid by Allogene pursuant to subsection (a) above for such prior Calendar Quarter are more than Notch&#8217;s actual Research Costs for such Calendar Quarter, then the excess shall be credited toward the Advance Invoice for the current Calendar Quarter (except where such invoice is the final such invoice to be provided by Notch, in which case the excess shall be refunded by Notch to Allogene within &#91;***&#93; days after the delivery of such invoice).  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Timing of Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For ease of administration, Allogene shall pay Notch a single payment reflecting the amount due under the Advance Invoice for the current Calendar Quarter plus any deficits (or less any credits) reflected in the True-Up Report for the prior Calendar Quarter within the later of (i) &#91;***&#93; days of Allogene&#8217;s receipt of such Advance Invoice, or (ii) &#91;***&#93; days of Allogene&#8217;s receipt of such True-Up Report. Notch shall provide Allogene with sufficient detail and supporting documentation of the costs for which payments are sought hereunder, and the periods for payment set forth above shall be commensurately extended for any delay in the provision thereof or for the resolution of any good faith dispute relating thereto.  In no event shall Allogene be obligated to reimburse Notch for any amounts in excess of the corresponding funding amounts set forth in the applicable Research Budget, unless otherwise agreed in writing by an authorized representative of Allogene.       </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Research Milestones.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In consideration for the rights granted to Allogene under this Agreement, Allogene shall make the following non-refundable, non-creditable milestone payments to Notch within &#91;***&#93; days from Allogene&#8217;s receipt of Notch&#8217;s invoice after Notch&#8217;s achievement of the Success Criteria for the applicable milestone&#58;</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:13.359%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:60.418%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.223%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Research Milestone</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:6pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the milestone payments set forth in the table above shall be payable only once, the first time the Success Criteria for the applicable Research Milestone is achieved by Notch and irrespective of the number of Exclusive Targets with respect to which such Research Milestone is achieved.  The aggregate amount payable by Allogene for all Research Milestones shall not </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">exceed seven million two hundred fifty thousand Dollars ($7,250,000).  The determination of the achievement of each Research Milestone shall be made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Development Milestones</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In consideration for the rights granted to Allogene under this Agreement, Allogene shall make the following non-refundable, non-creditable milestone payments to Notch within &#91;***&#93; days from Allogene&#8217;s receipt of Notch&#8217;s invoice after Notch&#8217;s achievement of the Success Criteria for the applicable milestone&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:6.169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.039%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.732%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.060%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Development Milestone</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the milestone payments set forth in the table above shall be payable only once per Exclusive Target, the first time the Success Criteria for the applicable Development Milestone for such Exclusive Target is achieved by Notch, and irrespective of the number of times a Development Milestone is achieved with respect to an Exclusive Target.  If any Development Milestone is achieved for an Initial Target which is subsequently replaced by a Substitute Target, then such achieved Development Milestone shall not be paid for such Substitute Target&#59; however, Allogene shall pay for any Development Milestones achieved by Notch for such Substitute Target that were not paid for such Initial Target.  The aggregate amount payable by Allogene for all Development Milestones achieved by Notch with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively) shall not exceed four million Dollars ($4,000,000).  The determination of the achievement of any Development Milestone shall be made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, Allogene shall only be required to pay one set of Development Milestones relating to any Bi-Specific Product that meets a Development Milestone and that is Directed Against two (2) or more Exclusive Targets (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Bi-Specific Excluded Target</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)&#59; provided that Allogene shall thereafter pay any additional Development Milestones that are achieved for any further Product that is Directed Against a Bi-Specific Excluded Target, subject to the limitations that each milestone payment be payable only once per Exclusive Target and that the aggregate amount payable by Allogene for all Development Milestones achieved by Notch with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively) shall not exceed four million Dollars ($4,000,000).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For example, if a Development Milestone is first achieved by a Product Directed Against an Exclusive Target and then such Development Milestone is achieved by a Bi-Specific Product Directed Against such Exclusive Target and a second Exclusive Target as to which no Product has previously achieved such Development Milestone, the applicable milestone payment shall become payable based on such achievement by such Bi-Specific Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">   </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Clinical and Regulatory Milestones</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In consideration for the rights granted to Allogene under this Agreement, Allogene shall make the following non-refundable, non-creditable milestone payments to Notch following the achievement of the following milestones by Allogene or any of its Affiliates or Sublicensees&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.397%;"><tr><td style="width:1.0%;"></td><td style="width:11.355%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.485%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.662%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due for First T Cell Product</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due for First NK Cell Product</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the milestone payments set forth in the table above shall be payable only once per Exclusive Target per Cell Type, the first time such milestone for such Exclusive Target and Cell Type is achieved, and irrespective of the number of times such milestone is achieved with respect to an Exclusive Target and Cell Type.  If any milestone above is achieved for an Initial Target which is subsequently replaced by a Substitute Target, then such achieved milestone shall not be paid for such Substitute Target&#59; however, Allogene shall pay for any milestones above achieved by Allogene or any of its Affiliates or Sublicensees for such Substitute Target that were not paid for such Initial Target.  The aggregate amount payable by Allogene under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for all milestones achieved by Allogene, its Affiliates and its Sublicensees with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively) shall not exceed &#91;***&#93; Dollars ($&#91;***&#93;) per Cell Type.  Allogene shall notify Notch within &#91;***&#93; days following the achievement of any milestone above (or, if achieved by a Sublicensee, within &#91;***&#93; days following its receipt of notice of such achievement) and shall pay the corresponding milestone payment within &#91;***&#93; days following its receipt of Notch&#8217;s invoice therefor. </font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, Allogene shall only be required to pay one set of clinical and regulatory milestones relating to any Bi-Specific Product that meets a clinical or regulatory milestone and that is Directed Against two (2) or more Bi-Specific Excluded Targets&#59; provided that Allogene shall thereafter pay any additional clinical and regulatory milestones that are achieved for any further Product that is Directed Against a Bi-Specific Excluded Target, subject to the limitations that  each milestone payment be payable only once per Exclusive Target and that the aggregate amount payable by Allogene for all clinical and regulatory milestones achieved by Allogene, its Affiliates and its Sublicensees with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively shall not exceed &#91;***&#93; Dollars ($&#91;***&#93;) per Cell Type.  For example, if a clinical or regulatory milestone is first achieved by a Product Directed Against an Exclusive Target and then such clinical or regulatory milestone is achieved by a Bi-Specific Product Directed Against such Exclusive Target and a second Exclusive Target as to which no Product has previously achieved such clinical or regulatory milestone, the applicable milestone payment shall become payable based on such achievement by such Bi-Specific Product. </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">  Commercial Milestones</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In consideration for the rights granted to Allogene under this Agreement, Allogene shall make the following non-refundable, non-creditable milestone payments to Notch following the achievement of the following milestones based on cumulative annual, worldwide Net Sales by Allogene or any of its Affiliates or Sublicensees&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:11.301%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.756%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.078%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due for First T Cell Product</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Milestone Amount Due for First NK Cell Product</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the milestone payments set forth in the table above shall be payable only once per Exclusive Target per Cell Type, the first time such milestone for such Exclusive Target and Cell Type is achieved, and irrespective of the number of times such milestone is achieved with respect to an Exclusive Target and Cell Type.  If any milestone above is achieved for an Initial Target which is subsequently replaced by a Substitute Target, then such achieved milestone shall not be paid for such Substitute Target&#59; however, Allogene shall pay for any milestones above achieved by Allogene or any of its Affiliates or Sublicensees for such Substitute Target that were not paid for such Initial Target.  The aggregate amount payable by Allogene under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for all milestones achieved by Allogene, its Affiliates and its Sublicensees with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively) shall not exceed &#91;***&#93; Dollars ($&#91;***&#93;) per Cell Type.  Allogene shall notify Notch contemporaneously with its provision of its royalty report under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for the Calendar Quarter in which such milestone was achieved and shall pay the corresponding milestone payment within &#91;***&#93; days following its receipt of Notch&#8217;s invoice therefor.</font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, Allogene shall only be required to pay one set of commercial  milestones relating to any Bi-Specific Product that meets a commercial milestone and that is Directed Against two (2) or more Bi-Specific Excluded Targets&#59; provided that Allogene shall thereafter pay any additional commercial milestones that are achieved for any further Product that is Directed Against a Bi-Specific Excluded Target, subject to the limitations that each milestone payment be payable only once per Exclusive Target and that the aggregate amount payable by Allogene for all commercial milestones achieved by Allogene, its Affiliates and its Sublicensees with respect to an Exclusive Target (including an Initial Target and its Substitute Target, collectively) shall not exceed &#91;***&#93; Dollars ($&#91;***&#93;) per Cell Type.  For example, if a commercial milestone is first achieved by a Product Directed Against an Exclusive Target and then such commercial milestone is achieved by a Bi-Specific Product Directed Against such Exclusive Target and a second Exclusive Target as to which no Product has previously achieved such commercial milestone, the applicable milestone payment shall become payable based on such achievement by such Bi-Specific Product. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Royalties.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 6.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, following Regulatory Approval, on a an Exclusive Target-by-Exclusive Target basis and Cell Type-by-Cell Type basis, Allogene shall pay to Notch non-creditable, non-refundable royalties on aggregate annual Net Sales of all Products Directed Against such Exclusive Target in the Territory, as calculated by multiplying </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the applicable royalty rate by the corresponding amount of incremental Net Sales of all such Products in the Territory in each Calendar Year as follows, provided that, in the case of Bi-Specific Products, such Products shall be deemed to be Directed Against one (but not both) of the applicable Exclusive Targets for such Bi-Specific Product (i.e., royalties for such Product shall be calculated as though the entire Product were of a single Cell Type).  Notwithstanding the foregoing, if (a) there are Net Sales of Products Directed Against one of the Exclusive Targets a Bi-Specific Product is Directed Against, such Bi-Specific Product Net Sales shall be aggregated with such Products, and (b) there are Net Sales of Products Directed Against one of the Exclusive Targets of a Bi-Specific Product and Net Sales of Products Directed Against the second Exclusive Target of a Bi-Specific Product, the Net Sales of the Bi-Specific Product shall be allocated equally between the Exclusive Targets.  </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:51.267%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.366%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.367%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Annual Net Sales</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Royalty Rate for T Cell Products</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Royalty Rate for NK Cell Products</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For that portion of annual aggregate Net Sales of all Products of such Cell Type Directed Against a particular Exclusive Target in a Calendar Year that are less than or equal to &#91;***&#93; Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For that portion of annual aggregate Net Sales of all Products of such Cell Type Directed Against a particular Exclusive Target in a Calendar Year that are greater than &#91;***&#93; Dollars ($&#91;***&#93;) and less than or equal to &#91;***&#93; Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For that portion of annual aggregate Net Sales of all Products of such Cell Type Directed Against a particular Exclusive Target in a Calendar Year that are greater than &#91;***&#93; Dollars ($&#91;***&#93;) and less than or equal to &#91;***&#93; Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For that portion of annual aggregate Net Sales of all Products of such Cell Type Directed Against a particular Exclusive Target in a Calendar Year that are greater than &#91;***&#93; Dollars ($&#91;***&#93;) and less than or equal to &#91;***&#93; Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:1.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">For that portion of annual aggregate Net Sales of all Products of such Cell Type Directed Against a particular Exclusive Target in a Calendar Year that are greater than &#91;***&#93; Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-right:-0.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#91;***&#93;%</font></div></td></tr></table></div><div style="text-indent:36pt;margin-bottom:6pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;">Royalty Floors and Offsets. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">If, on a country-by-country and Product-by-Product basis, there is no Valid Claim in such country that Covers the manufacture, use or sale of such Product in such country and, solely with respect to countries outside of the United States, there is no applicable Regulatory Exclusivity that covers the Product in such country at the time of sale, then the applicable royalty rate under Section 6.8 shall be reduced by &#91;***&#93; percent (&#91;***&#93;%), subject to Section 6.9(c).</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">If it is Necessary or Useful for Allogene to license one or more Patent Rights from one or more Third Parties in order to Exploit any Product, whether directly or through any Allogene Affiliate or Sublicensee, then Allogene may, in its sole discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license, or any such Third Party, referred to herein as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Any royalty otherwise payable to Notch under this Agreement with respect to Net Sales of any Product by Allogene, its Affiliates or Sublicensees will be reduced by &#91;***&#93; percent (&#91;***&#93;%) of the amounts paid to Third Parties pursuant to any Third Party Licenses, provided that in no event will the total royalty payable to Notch be less than &#91;***&#93; percent (&#91;***&#93;%) of the royalty amounts otherwise payable to Notch and provided that if any portion of any such reduction is limited by the immediately preceding proviso, the portion that is not permitted to be deducted may be carried forward for reduction in subsequent Calendar Quarters, subject to the limitation in the immediately preceding proviso, until such amounts have been expended. For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.9(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, (i) &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Necessary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that, without a license to use the Third Party&#8217;s Patent Right, the Exploitation of any Product in the form such Product exists at the time that the Third Party License is executed would, in Allogene&#8217;s reasonable opinion, based on written advice from counsel, infringe such Third Party&#8217;s Patent Right, and (ii) &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Useful</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that Allogene has determined in its discretion that use of such Third Party&#8217;s Patent Right would enhance the commercial potential of any Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, a Third Party License may include a license for Patent Rights and Know-How and all payments thereunder shall be subject to the offset set forth in this Section 6.9.</font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notwithstanding subsection (a) above, in no event shall the royalty rate on the sale of any Product in any country be reduced below &#91;***&#93; percent (&#91;***&#93;%). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;">Royalty Term. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Royalties shall be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, on a country-by-country and Product-by-Product basis, commencing on First Commercial Sale of such Product in such country and continuing until the latest of (a) the date upon which there is no Valid Claim of the Notch Patents (including Joint Patents) in such country of sale, (b) the expiration of applicable data or other regulatory exclusivity in such country of sale or (c) the tenth (10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) anniversary of the First Commercial Sale of such Product in such country (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Following the Royalty Term, Allogene&#8217;s license rights under any Notch Technology with respect to such Product and country shall be perpetual, irrevocable, fully paid up and royalty-free. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;">Royalty Reports and Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Within &#91;***&#93; days after the end of each Calendar Quarter, commencing with the Calendar Quarter during which the First Commercial Sale of the first Product is made anywhere in the Territory, Allogene shall provide Notch with a report that contains the following information for the applicable calendar quarter, on a Product-by-Product and country-by-country basis&#58; (a) the gross sales and Net Sales of each Product, (b) a summary of the deductions from gross sales applied in calculating Net Sales, (c) the basis for any adjustments to the royalty payable for the sale of such Product and  (d) the royalty due hereunder for the sale of such Product.  Concurrent with the delivery of the foregoing applicable quarterly report, Allogene shall pay in Dollars all royalties due to Notch with respect to Net Sales by Allogene and its Affiliates and Sublicensees for such Calendar Quarter.  </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;">Currency&#59; Exchange Rate.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All payments to be made by Allogene to Notch under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from Notch.  The rate of exchange to be used in computing the amount of currency equivalent in Dollars shall be made at the average of the closing exchange rates reported on the Oanda website (http&#58;&#47;&#47;www.oanda.com&#47;currency&#47;historical-rates&#47; ) with Interbank +&#47;- 0%, or such other source as the Parties may agree in writing, for the first, middle and last business days of the applicable reporting period for the payment due.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;">Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any Applicable Law requires Allogene to withhold taxes with respect to any payment to be made by Allogene pursuant to this Agreement, Allogene will notify Notch of such withholding requirement prior to making the payment to Notch and provide such reasonable assistance to Notch, including the provision of such standard documentation as may be required by a tax authority, as may be reasonably necessary in Notch&#8217;s efforts to claim an exemption from or reduction of such taxes.  At Notch&#8217;s request, Allogene shall delay making any payment otherwise due hereunder in order to provide time for Notch to provide to Allogene documentation necessary to claim an exemption from or reduction of such taxes prior to withholding&#59; for clarity, no interest shall apply during such period and Allogene shall not be required to pay any such payment to Notch on less than &#91;***&#93; days&#8217; notice from Notch following such delay request that such payment is to be paid.  Allogene will, in accordance with such Applicable Law withhold taxes from the amount due, remit such taxes to the appropriate tax authority, and furnish Notch with proof of payment of such taxes within &#91;***&#93; days following the payment.   If taxes are paid to a tax authority, Allogene shall provide reasonable assistance to Notch to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All payments due to Notch from Allogene pursuant to this Agreement shall be paid exclusive of any value-added tax (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) (which, if applicable, shall be payable by Allogene upon receipt of a valid VAT invoice).  If Notch determines that it is required to report any such tax, Allogene shall promptly provide Notch with applicable receipts and other documentation necessary or appropriate for such report.  For clarity, this Section is not intended to limit Allogene&#8217;s right to deduct value-added taxes in determining Net Sales.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;">Interest.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any undisputed payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement will bear interest at a rate equal to the lesser of&#58; &#91;***&#93;, in each case calculated on the number of days such payment is delinquent.</font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">TECHNOLOGY OWNERSHIP</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Background Technology.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As between</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Parties, each Party will own and retain all right, title and interest in its Background Technology.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Ownership of Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ownership of all Inventions shall be assigned based on inventorship, as determined in accordance with the rules of inventorship under United States patent laws.  All jointly owned Inventions shall be referred to as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Joint Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and each Party shall own an undivided half interest in the Joint Technology and any Patent Rights claiming such Joint Technology (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Joint Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Subject to the licenses granted to the other </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Party under this Agreement, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.5(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> with respect to enforcement of such Joint Technology, neither Party will have any obligation to obtain any approval or consent of, nor pay a share of the proceeds to or account to, the other Party to practice, enforce, license, assign or otherwise exploit Inventions or intellectual property included within Joint Technology, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or accounting.  Each Party agrees to execute all papers and otherwise agrees to assist the other Party as reasonably required, to perfect in the other Party the rights, title and other interests owned by such Party under this Section and Intellectual Property Rights relating thereto, as applicable. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Disclosure of Research Program Inventions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party shall promptly disclose to the other Party, in writing, no later than the occurrence of the first JDC meeting following such conception, all Research Program Inventions, including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates&#8217;, employees, agents or contractors relating to such Research Program Inventions, and shall respond promptly to reasonable requests from the other Party for additional information relating to such Research Program Inventions.  </font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">PATENT PROSECUTION AND ENFORCEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Notch Patent(s). </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">As between the Parties, and subject to subsection (b) below, Notch will be solely responsible, at its own cost, for the Prosecution and Maintenance of all Notch Patents, excluding all Joint Patents. With respect to any Notch Patents, Notch shall consult with Allogene and keep Allogene reasonably informed of the status of such Notch Patents and shall promptly provide Allogene with material correspondences received from any patent authorities in connection therewith.  In addition, Notch shall promptly provide Allogene with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Notch Patents for Allogene&#8217;s review and comment prior to the submission of such proposed filings and correspondences.  Notch shall confer with Allogene and shall give good faith consideration to Allogene&#8217;s comments in relation to such Prosecution and Maintenance, and shall use reasonable efforts to implement any reasonable changes requested by Allogene towards the objective of optimizing overall patent protection with respect to the Notch Patents.  Allogene shall provide any such comments within &#91;***&#93; days of receiving the draft filings and correspondences from Notch.  If Allogene does not provide comments within such period of time, then Allogene shall be deemed to have no comment to such proposed filings or correspondences.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Subject to the terms of any applicable Notch Third Party In-License (provided that such terms have been provided to Allogene), if Notch wishes to abandon or cease Prosecution and Maintenance of any Notch Patent, Notch shall provide reasonable prior written notice to Allogene of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91;***&#93; days prior to the next deadline for any action that must be taken with respect to any such Notch Patent in the relevant patent office).  In such case, upon Allogene&#8217;s written election, Allogene shall have the right, but not the obligation, to assume Prosecution and Maintenance of such Notch Patent at Allogene&#8217;s expense.  If Allogene elects to assume the Prosecution and Maintenance of such Notch Patent, then Notch shall promptly </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">transfer to Allogene&#8217;s patent counsel all relevant files and materials and Allogene shall have the right to deduct &#91;***&#93; percent (&#91;***&#93;%) of the reasonable costs of Prosecution and Maintenance against milestone payment and royalty amounts payable to Notch hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Allogene Patents.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  As between the Parties, Allogene will be solely responsible, at its own cost, and at its discretion, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Patent Rights included within Allogene Background Technology and any Patent Rights Controlled by Allogene, excluding Joint Patents (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Joint Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Subject to subsection (b) below, Allogene shall be solely responsible, at Allogene&#8217;s cost, and at its discretion, for the Prosecution and Maintenance of the Joint Patents.  Allogene shall consult with Notch and keep Notch reasonably informed of the status of the Joint Patents and shall promptly provide Notch with material correspondences received from any patent authorities in connection therewith.  In addition, Allogene shall promptly provide Notch with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Allogene Prosecuted Patents for Notch&#8217;s review and comment prior to the submission of such proposed filings and correspondences.  Allogene shall confer with Notch and shall take into consideration Notch&#8217;s comments in relation to such Prosecution and Maintenance, and shall use reasonable efforts to implement any reasonable changes requested by Notch towards the objective of optimizing overall patent protection for such Joint Patents prior to submitting such filings and correspondences, provided that Notch shall provide such comments within &#91;***&#93; days of receiving the draft filings and correspondences from Allogene.  If Notch does not provide comments within such period of time, then Allogene may proceed without obtaining or considering such comments in order to continue the Prosecution and Maintenance of the Joint Patents on a timely basis in Allogene&#8217;s reasonable discretion.  In case of disagreement between the Parties with respect to the Prosecution and Maintenance of the Joint Patents, the final decision shall be made by Allogene with the objective of optimizing overall patent protection for such Joint Patents.</font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">If Allogene wishes to abandon or cease Prosecution and Maintenance of any Joint Patent, Allogene shall provide reasonable prior written notice to Notch of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91;***&#93; days prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).  In such case, upon Notch&#8217;s written election, Notch shall have the right, but not the obligation, to assume Prosecution and Maintenance of such Joint Patent at Notch&#8217;s expense.  If Notch elects to assume the Prosecution and Maintenance of such Joint Patent, then Allogene shall promptly transfer to Notch&#8217;s patent counsel all relevant files and materials and Notch shall keep Allogene reasonably informed regarding the Prosecution and Maintenance. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Collaboration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party shall provide the other Party all reasonable assistance and cooperation in the Prosecution and Maintenance efforts under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, including providing any necessary powers of attorney and executing any other required documents or </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">instruments for such prosecution.   The Party assuming such Prosecution and Maintenance responsibilities shall have the right to engage its own counsel to perform such activities.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">          </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Enforcement</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">The Parties hereto shall inform each other promptly in writing of any alleged or threatened Infringement by any Third Party of any Patent Right included within the Notch Patents, Joint Patents or any Allogene Patents, where such infringement  adversely affects or is expected to adversely affect any Product in the Field, including any &#8220;patent certification&#8221; filed in the United States under 21 U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or similar provisions in other jurisdictions and of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Notch Patents, Joint Patents, or any Allogene Patents (collectively &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Parties shall consult with each other regarding any actions to be taken with respect to such Product Infringement, including sharing all information available to such Party regarding such alleged Product Infringement.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Allogene shall have the exclusive right to bring and control any legal action in connection with any Product Infringement in the Territory that relates to any Allogene Patent, at its own expense as it reasonably determines appropriate. </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Subject to the terms of any applicable Notch Third Party In-License and provided that such terms have been provided to Allogene, for Product Infringement in connection with a Notch Patent or Joint Patent, Allogene shall have the first right to bring and control any legal action in connection with such Product Infringement at its own cost and expense, and Notch shall have the right to be represented in any action by counsel of its choice.   Allogene shall have a period of &#91;***&#93; days after its receipt or delivery of notice under subsection (a) to elect to so enforce the applicable Notch Patents or Joint Patents in the Field in the Territory (or to settle or otherwise secure the abatement of such Product Infringement). If Allogene fails to commence a suit to enforce the applicable Notch Patents or Joint Patents, or to settle or otherwise secure the abatement of such Product Infringement within such period, then Notch shall have the right, but not the obligation, to commence a suit or take action to enforce such Notch Patents or Joint Patents, as applicable, in the Field in the Territory at its own cost and expense. In such event, promptly after the expiration of the applicable &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day period, or Allogene&#8217;s notice to Notch that it does not elect to enforce such Notch Patents or Joint Patents, the Parties shall meet to discuss in good faith the strategy for enforcing such Patent Rights. Notch shall reasonably consider Allogene&#8217;s views with respect to such enforcement. </font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">The Party enforcing a Patent Right under subsection (b) or (c) above shall keep the other Party reasonably informed as to the status of, and all material developments in, such action, and reasonably consider and incorporate such other Party&#8217;s input regarding the strategy and handling of such enforcement activities.  Such other Party shall provide the enforcing Party reasonable assistance in such enforcement, at the enforcing Party&#8217;s request and expense, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required or if reasonably beneficial for the action.  Such other Party shall have the right to be represented in any such action by counsel of its choice, at its expense.  In connection with any such proceeding, the Party bringing the action shall not enter into any settlement admitting the invalidity of, or otherwise impairing the other Party&#8217;s </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">rights in, the Patent Rights that are the subject of the applicable enforcement action without the prior written consent of the other Party.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch shall have the exclusive right to enforce the Notch Patents, other than Joint Patents, for any Infringement that is not a Product Infringement at its own expense as it reasonably determines appropriate.  Allogene shall have the exclusive right to enforce the Allogene Patents for any Infringement, other than a Product Infringement, at its own expense as it reasonably determines appropriate.  With respect to any Infringement, other than a Product Infringement, relating to any Joint Patents, each Party shall have the right to enforce such Joint Patents as its cost and its sole discretion, provided that the enforcing Party shall notify the other Party in writing promptly upon becoming aware of such Infringement.</font></div><div style="text-indent:72pt;padding-left:7.2pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.83pt;">Any recoveries resulting from enforcement action relating to a claim of Product Infringement shall be first applied pro rata against payment of each Party&#8217;s costs and expenses in connection therewith.  Any such recoveries in excess of such costs and expenses (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Remainder</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be shared by the Parties as follows&#58; </font></div><div style="text-indent:60.69pt;padding-left:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)   if Allogene is the enforcing Party, the Remainder shall be allocated &#91;***&#93; percent (&#91;***&#93;%) to Allogene and &#91;***&#93; percent (&#91;***&#93;%) to Notch&#59; and </font></div><div style="text-indent:57.36pt;padding-left:36pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)     if Notch is the enforcing Party, the Remainder shall be allocated &#91;***&#93; percent (&#91;***&#93;%) to Notch and &#91;***&#93; percent (&#91;***&#93;%) to Allogene. </font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">CONFIDENTIALITY</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Confidentiality&#59; Exceptions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, each Party (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Receiving Party&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) agrees that it shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Confidential Information of the other Party (the</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#8220;Disclosing Party&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">).  The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> will mean all information and materials of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available to the Receiving Party by or on behalf of the Disclosing Party in connection with this Agreement or the Prior Confidentiality Agreement, including any of the foregoing of Third Parties.  The Joint Technology and the terms of this Agreement shall be the Confidential Information of both Parties, such that each Party shall be deemed to be a Receiving Party with respect thereto.  Results, data and other information arising from the Research Plan or related to any CAR Product Directed Against an Exclusive Target that is Controlled by Notch and licensed to Allogene hereunder shall, subject to the licenses granted hereunder, be the Confidential Information of both Parties. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Exceptions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Notwithstanding the foregoing, the Receiving Party&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not apply to information or materials to the extent that the Receiving Party can establish by competent evidence that such information or material&#58;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">was already rightfully known to or possessed by the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality, at the time of disclosure hereunder&#59;</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party or any of its Affiliates&#59; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">became generally available to the public or otherwise part of the public domain after its disclosure hereunder other than through any act or omission of the Receiving Party or any of its Affiliates in breach of this Agreement or the Prior Confidentiality Agreement&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">was independently developed by employees, agents or contractors of the receiving Party or any of its Affiliates without use of or reference to the Disclosing Party&#8217;s Confidential Information as demonstrated by documented evidence prepared contemporaneously with such independent development&#59; or</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">was disclosed to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality, by a Third Party who had the right to disclose such information without restriction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Authorized Use and Disclosure.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  In addition to the rights granted in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Receiving Party may use and disclose the Disclosing Party&#8217;s Confidential Information as follows&#58; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">to its and its Affiliates&#8217; officers, directors, employees, agents, contractors and advisors who are under legally enforceable obligations of confidentiality and non-use at least as stringent as those herein and who reasonably require access to such information for purposes of this Agreement&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">complying with Applicable Laws, orders of a court, or the securities laws and regulations applicable to the public sale of securities&#59; provided, however, that the Receiving Party shall, to the extent legally permissible and practicable, give reasonable advance notice to the Disclosing Party of such disclosure requirement and, shall use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed&#59; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">such disclosure is reasonably necessary (i) to comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of a Product, (ii) to Prosecute and Maintain Patent Rights hereunder&#59; or (iii) for prosecuting or defending litigation as contemplated by this Agreement&#59; or </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">as expressly agreed by the Disclosing Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Prior Confidentiality Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  As of the Effective Date, this Agreement terminates, supersedes and replaces the Prior Confidentiality Agreement with respect to information disclosed thereunder. Nothing herein shall release either Party for any liability incurred under the Prior Confidentiality Agreement prior to the Effective Date.   </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Agreement Terms.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Each Party agrees not to disclose to any Third Party any non-public terms and conditions of this Agreement without the prior written approval of the other Party, except to advisors (including financial advisors, attorneys and accountants) and to potential and </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">existing investors, collaborators, partners, licensees, acquirers, lenders, or investment bankers under circumstances that reasonably protect the confidentiality thereof, and except as permitted pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Allogene and Notch agree to issue a press release mutually agreed upon by the Parties, and either Party may publicly disclose the information contained in such press release without the need for further written approval by the other Party.  Allogene shall have the sole right to disclose the Exclusive Targets, provided that Notch shall be permitted to disclose to any Third Party, without identifying Allogene, that an Exclusive Target is unavailable for the grant of rights to such Third Party. </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the U.S. Securities and Exchange Commission (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SEC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or other applicable entity having regulatory authority over such Party&#8217;s securities or the exchange thereof, as a material agreement of such Party.  Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available, and to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed.  In the event of any such filing, the filing Party will provide the other Party with a copy of this Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s timely comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed.  The other Party will as promptly as practical provide any such comments.  Each Party recognizes that Applicable Laws and SEC policies and regulations to which the other Party is and may become subject to may require the other party to publicly disclose certain terms of this Agreement that such Party may prefer not be disclosed, and that the other Party is in all cases entitled hereunder to make such required disclosures to the extent necessary to comply with such Applicable Laws and SEC policies and regulations, as determined in good faith by the other Party&#8217;s counsel.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Term of Obligations of Confidentiality and Non-use. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> The obligations of confidentiality and non-use under this Agreement shall expire &#91;***&#93; years from the termination or expiration of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Publication.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  If either Party wishes to publish the Confidential Information of the other Party, the Party desiring to publish such information (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Publishing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall notify the other Party (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-Publishing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) in writing at least &#91;***&#93; days prior to any proposed disclosure.  During such at least &#91;***&#93; day reviewing period, if the Non-Publishing Party notifies the Publishing Party that it wishes to (a) remove its Confidential Information from such proposed publication or presentation, then the Publishing Party shall remove such Confidential Information from such proposed publication or presentation&#59; (b) request a reasonable delay in publication or presentation in order to protect patentable information, then the Publishing Party shall delay the publication or presentation for a period of no more than &#91;***&#93; days to enable patent applications to be filed in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> protecting Inventions disclosed in such publication or presentation, or (c) in the case that Allogene is the Non-Publishing Party, prohibit the proposed publication or presentation from proceeding, then </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Publishing Party shall comply with such request.  For clarity, if the Non-Publishing Party fails to notify the Publishing Party during the &#91;***&#93;-day reviewing period as provided under this Section, the Publishing Party shall be free to proceed with the proposed publication or presentation of such Confidential Information.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Authorship of all publications and presentations of data, results or information arising from the Research Program will be based on contributions to the Research Program in accordance with industry standards and journal requirements.  Each Party agrees to work in good faith with the other Party with respect to any such publication or presentation reasonably requested by such other Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Injunction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party shall be entitled, in addition to any other right or remedy it may have, at law or in equity, to seek an injunction, in any court of competent jurisdiction, enjoining or restraining the other Party and&#47;or its Affiliates from any violation or threatened violation of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">WARRANTIES&#59; </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party represents and warrants to the other Party as of the Effective Date that&#58; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">it is duly organized and validly existing under the laws of the jurisdiction of its incorporation, and it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder&#59; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it&#59; and </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform activities under the Research Plan pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign Inventions in a manner consistent with the provisions of this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Notch Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notch represents and warrants to Allogene as of the Effective Date that, except as set forth in Schedule 10.2&#58; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">Notch has full legal or beneficial title and ownership of, or an exclusive license to, the Notch Technology (excluding the Joint Technology) as is necessary to grant the licenses (or sublicenses) to Allogene to such Notch Technology that Notch purports to grant pursuant to this Agreement.  Exhibit C is a complete and accurate listing of all Notch Patents existing as of the Effective Date.  </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Exhibit G is a complete and accurate listing of all Notch Third Party In-Licenses pursuant to which Notch or its Affiliates have obtained rights to the Notch Technology as of the Effective Date, and Notch has shared with Allogene a complete and </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">accurate copies of all such agreements.  Each such agreement is in effect and is valid and binding on Notch or its Affiliates, enforceable in accordance with its terms, and neither Notch nor any of its Affiliates, nor to the knowledge of Notch, any other party thereto, is in material breach of, or material default under, any such agreement, and no event has occurred that, with the giving of notice or lapse of time or both, would constitute a material breach or material default by Notch or any of its Affiliates thereunder&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">None of the Notch Technology is subject to, any liens or encumbrances, and Notch has not granted to any Third Party any license or other right with respect to any Notch Technology that would conflict with the rights and licenses granted to Allogene pursuant to this Agreement. No patent application or registration within the Notch Patents is subject of any pending interference, opposition, cancellation,  inter partes review, ex parte reexamination, post grant review, invalidity proceeding including nullity actions or patent protest&#59;</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">Notch is not a party to any current or anticipated legal action, including inventorship disputes, suit or proceeding relating to the Notch Technology&#59; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.5pt;">All employees and contractors of Notch or its Affiliates involved in the creation of any Notch Technology have assigned all right, title and interest in and to the Intellectual Property Rights relating to such Notch Technology to Notch or to an entity that is obligated to assign such Intellectual Property Rights to Notch&#59; </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.83pt;">Notch has not received any communication from any Third Party claiming that&#58; (i) any of the Notch Patents are invalid or unenforceable&#59; (ii) any of the Notch Know-How has been misappropriated&#59; or (iii) the manufacture, use, import, offer for sale, and sale of Products intended to be developed under the Research Program infringes or misappropriates or would infringe or misappropriate any Intellectual Property Rights of any Third Party&#59; and</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.82pt;">to Notch&#8217;s knowledge as of the Effective Date, the practice of the Notch Patents and the use of the Notch Know-How as contemplated under the initial Research Plan as of the Effective Date, will not infringe a Third Party&#8217;s Intellectual Property Rights&#59; provided that, for clarity, Notch gives no representation or warranty as to non-infringement with respect to any derivation of stem cell lines or any genetic engineering or gene editing of stem cell lines.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Notch Covenants.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notch covenants that all individuals and entities that conduct any portion of the Research Plan, prior to conducting such work, shall have entered into written agreements requiring that such individual or entity shall assign all right, title and interest in and to, or grant to Notch an exclusive (even as to such individual or entity), sublicensable (through multiple tiers), world-wide, fully paid-up license with respect to Products under, the Intellectual Property Rights relating to all Know-How and Inventions arising from such work to Notch or to an entity that is obligated to assign or license such Intellectual Property Rights to Notch, provided that Notch may grant Academic Use Rights to such an entity with notice to Allogene. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Mutual Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">No Debarment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the course of conducting the Research Program and the Exploitation of Products hereunder, neither Party nor its Affiliates shall use any employee or consultant who has been debarred by any Regulatory Authority, or, to such Party&#8217;s or its Affiliates&#8217; knowledge, is the subject of debarment proceedings by a Regulatory Authority.  </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party shall notify the other Party promptly upon becoming aware that any of its or its Affiliates&#8217; employees or consultants has been debarred or is the subject of debarment proceedings by any Regulatory Authority.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party and its Affiliates shall comply in all material respects with all Applicable Laws (including all anti-corruption and anti-bribery laws) in relation to the conduct of the Research Program and performance of its obligations under this Agreement, including (in the case of Allogene) the Exploitation of Products hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Warranty Disclaimer.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXCEPT AS SET FORTH IN THIS </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, NOTCH AND ALLOGENE EXPRESSLY DISCLAIM ANY WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">INDEMNITY&#59; LIABILITY&#59; INSURANCE </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Indemnification.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Indemnification by Notch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notch hereby agrees to defend, hold harmless and indemnify (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnify</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) Allogene and its Affiliates, and its and their respective agents, directors, officers and employees (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Allogene Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) from and against any Claims against any Allogene Indemnitee to the extent arising out of any negligence or intentional misconduct of any Notch Indemnitee or breach of this Agreement (including of any representation or warranty) by any Notch Indemnitee.  Notch&#8217;s obligation to Indemnify the Allogene Indemnitees pursuant to this subsection (a) shall not apply to the extent that any such Claims arise out of (A) Allogene&#8217;s breach of this Agreement or any negligence or intentional misconduct of any Allogene Indemnitee, or (B) any activity set forth in subsection (b) below for which Allogene is obligated to indemnify the Notch Indemnitees.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">Indemnification by Allogene</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Allogene hereby agrees to Indemnify Notch and its Affiliates, and its and their respective agents, directors, officers and employees (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notch Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) from and against any and all Claims against any Notch Indemnitee to the extent arising out of&#58; (i) Allogene&#8217;s Exploitation of Products or the exercise by or under the authority of Allogene of the rights and licenses granted to Allogene under this Agreement&#59; or (ii) any negligence or intentional misconduct of any Allogene Indemnitee or breach of this Agreement (including of any representation or warranty) by any Allogene Indemnitee. Allogene&#8217;s obligation to Indemnify the Notch Indemnitees pursuant to this subsection (b) shall not apply to the extent that any such Claims arise out of (A) Notch&#8217;s breach of this Agreement or any negligence or intentional misconduct of any Notch Indemnitee, or (B) any activity set forth in subsection (a) above for which Notch is obligated to indemnify the Allogene Indemnitees.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;">Procedures.  To be eligible to be Indemnified hereunder, the indemnified Party shall provide the indemnifying Party with prompt written notice of the Claim giving rise to the indemnification obligation pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim&#59; provided, however, </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">42</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that any failure or delay to notify shall not excuse any obligation of the indemnifying Party except to the extent the indemnifying Party is actually prejudiced thereby. The indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified Party&#8217;s written consent, such consent not to be unreasonably withheld or delayed. The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party, provided that the indemnifying Party shall have no obligations with respect to any Claims resulting from the indemnified Party&#8217;s admission, settlement or other communication without the prior written consent of the indemnifying Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall maintain in full force and effect during the Term, and for a period of not less than &#91;***&#93; years thereafter, valid and collectible insurance policies providing reasonable liability insurance coverage to protect against potential liabilities and risk arising out of activities to be performed under this Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Limitation of Liability.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> EXCEPT WITH RESPECT TO (A) A BREACH OF EACH PARTY&#8217;S CONFIDENTIALITY OBLIGATIONS UNDER </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, OR (B) THE PARTIES&#8217; INDEMNIFICATION OBLIGATIONS UNDER </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, INCLUDING LOSS OF PROFITS OR ANTICTIPATED SALES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24pt;">TERM&#59; TERMINATION</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Term of Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in the remainder of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, shall continue in full force and effect, on a country-by-country and Product-by-Product basis, until the expiration of all of Allogene&#8217;s payment obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), after which time Allogene shall retain a perpetual, irrevocable, exclusive license, sublicenseable through multiple tiers, to any Intellectual Property Rights licensed to Allogene pursuant to the terms of this Agreement during the Term, solely within the scope of the licenses granted to Allogene herein during the Term.    </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Termination by Allogene.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Allogene may terminate this Agreement for any reason at any time in its entirety or on a Product-by-Product basis upon ninety (90) days&#8217; written notice to Notch.  Upon any termination by Allogene for convenience, all licenses and other rights granted to Allogene pursuant to this Agreement shall terminate as of the effective date of such termination, provided that if such termination is only with respect to a specific Product(s), then such licenses and rights shall terminate only with respect to such Product(s).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Termination for Material Breach.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Either Party may terminate this Agreement by written notice referencing this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and specifying the breach to the other Party if the other Party is in material breach of its material obligations under this Agreement and has not cured such breach within ninety (90) days (or thirty (30) days in the case of payment breaches) after notice requesting cure of the breach&#59; provided, however, that in the event of a good faith </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">43</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">dispute with respect to the existence of a material breach, this Agreement shall not be terminated unless it is finally determined under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that this Agreement was materially breached, and, the breaching Party fails to cure such breach within thirty (30) days after such determination.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Termination for Insolvency</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If, at any time during the Term (i) a case is commenced by or against either Party under Title 11, United States Code, as amended, or analogous provisions of Applicable Law outside the United States (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Bankruptcy Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and, in the event of an involuntary case under the Bankruptcy Code, such case is not dismissed within sixty (60) days after the commencement thereof, (ii) either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (iii) either Party assigns all or a substantial portion of its assets for the benefit of creditors, (iv) a receiver or custodian is appointed for either Party&#8217;s business, or (v) a substantial portion of either Party&#8217;s business is subject to attachment or similar process&#59; then, in any such case ((i), (ii), (iii), (iv) or (v)), the other Party may terminate this Agreement upon written notice to the extent permitted under Applicable Law.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Effect of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Accrued Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Expiration or termination of this Agreement for any reason shall not release either Party of any obligation or liability which, at the time of such expiration or termination, has already accrued to such Party or which is attributable to a period prior to such expiration or termination.  In addition, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">4.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (solely with respect to Research Costs incurred prior to the effective date of termination), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (solely with respect to Product sales occurring prior to the effective date of termination), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Articles 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, shall survive any termination or expiration of this Agreement. </font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">Non-Exclusive Remedy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything herein to the contrary, termination of this Agreement by a Party shall be without prejudice to other remedies such Party may have at law or in equity.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:15.5pt;">Consequences of Certain Terminations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:99.03pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">If this Agreement is terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> by Allogene, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> by either Party, or Section  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  by either Party, all licenses and other rights granted to Allogene pursuant to this Agreement shall terminate as of the effective date of termination, provided that if a termination by Allogene pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is not for this Agreement in its entirety, then the scope of such termination shall be limited to the particular Product(s) terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:99.69pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">If Allogene has the right to terminate this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, then in lieu of exercising such termination right Allogene shall be entitled to retain all licenses and other rights granted to it pursuant to this Agreement subject to all financial provisions and other obligations set forth herein, provided that in such event Allogene may also seek any other remedies that Allogene may have at law or in equity in respect of the applicable breach hereof by Notch.</font></div><div style="text-indent:72pt;padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.82pt;">Return of Materials&#59; Regulatory Documents&#59; Reversion License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon termination or expiration of this Agreement, each Party shall return to the other Party or destroy </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">44</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:7.2pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">all Confidential Information and materials (including any Materials) provided to it by the other Party and all copies and embodiments thereof, other than such Confidential Information and materials to which such Party retains an ongoing right to use.  Notwithstanding the foregoing, each Party may retain one copy of the other Party&#8217;s Confidential Information in its confidential files solely for archival purposes.  In addition, upon termination, other than for termination by Allogene pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and at Notch&#8217;s request, Allogene shall exclusively negotiate with Notch for a period of &#91;***&#93; days following the date of such termination for a sale or license to Notch of one or more of the Products developed hereunder. </font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">DISPUTE RESOLUTION</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Disputes.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">13.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, if the Parties or the JDC are unable to resolve any dispute arising out of or in connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to the CEOs of each of Notch and Allogene or their respective equivalents, or designees for attempted resolution by good faith negotiations within &#91;***&#93; Business Days after such notice is received.  In such event, the Parties shall cause their respective officers or their designees to meet (face-to-face or by teleconference) and be available to attempt to resolve such issue. If the Parties should resolve such dispute, a memorandum setting forth their agreement shall be prepared and signed by both Parties at either Party&#8217;s request.  If the Parties are unable to resolve any dispute that is related to the Research Plan, Allogene shall have the final decision-making authority with respect to such dispute.  Notwithstanding the foregoing, Allogene shall have no authority to require Notch to incur costs that are not included within the Research Budget or otherwise subject to reimbursement by Allogene, without Notch&#8217;s prior written consent, and Allogene shall have no final decision-making authority to determine whether or not any payment due hereunder (including any milestone payment hereunder) has been earned or is payable, which payment disputes shall be subject to resolution in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Arbitration.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">13.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">all disputes arising out of or in connection with this Agreement, including any question regarding its formation, existence, validity or termination, shall be finally settled by arbitration pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any arbitration under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be held in San Francisco, California, and administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by three (3) arbitrators appointed in accordance with such Rules.  The arbitrators shall allow reasonable discovery, in an amount determined by the arbitrator to be necessary in view of the issues in dispute.  The Parties shall use good faith efforts to complete arbitration under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> within &#91;***&#93; months following the initiation of such arbitration.  The arbitrators shall establish reasonable additional procedures to facilitate and complete such arbitration within such &#91;***&#93; month period.  The costs of such arbitration shall be shared equally by the Parties, and each Party shall bear its own expenses in connection with the arbitration&#59; provided that the arbitrators shall have discretion to award all or any part of the costs of the arbitration, including reasonable attorneys&#8217; fees, to the prevailing Party.  Judgment on the award may be entered in any court of competent jurisdiction. The existence of and proceedings in the arbitration shall be considered the Confidential Information of both Parties and shall be subject to the terms of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Article 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Patents&#59; Injunctive Relief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any dispute, controversy, or claim relating to the scope, validity, enforceability, or infringement of any Patent Rights covering the manufacture, </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">45</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">use, or sale of any Product shall be submitted to a court of competent jurisdiction in the country or jurisdiction in which such patent or trademark rights were granted or arose.  Nothing herein shall prevent either Party from seeking at any time a preliminary injunction or temporary restraining ord</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">er in any court of competent jurisdiction in order to protect its interests.</font></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">MISCELLANEOUS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be governed in all respects by the laws of the State of New York exclusively without regard to any conflict of law rule that would result in the application of the laws of any jurisdiction other than the State of New York. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Force Majeure.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except with respect to payment of money, neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, terrorist acts, strike, flood, or governmental acts or restriction, or other cause that is beyond the reasonable control of the respective Party.  The Party affected by such force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and shall use commercially reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable.  If the performance of any such obligation under this Agreement is delayed owing to such a force majeure for any continuous period of more than &#91;***&#93; days, the Parties shall consult with respect to an equitable solution, including the possibility of the mutual termination of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Relationship. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Parties agree that the relationship of Notch and Allogene established by this Agreement is that of independent contractors.  Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish an employment, agency or any other relationship.  Except as may be specifically provided herein, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Neither Party shall report the relationship between the Parties arising under this Agreement as a partnership for United States tax purposes without the prior written consent of the other Party unless required by a final &#8220;determination&#8221; as defined in Section 1313 of the United States Internal Revenue Code of 1986, as amended.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Assignment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  This Agreement shall not be assignable by either Party to any Third Party without the written consent of the other Party and any such attempted assignment shall be void.  Notwithstanding the foregoing, either Party may assign this Agreement, without the written consent of the other Party, to its Affiliate or an entity that acquires all or substantially all of the business or assets of such Party to which this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms and conditions of this Agreement.  No assignment or transfer of this Agreement shall be valid and effective unless and until the assignee&#47;transferee agrees in writing to be bound by the provisions of this Agreement. The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the Parties, provided that, the exclusivity provisions applicable to Notch pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not apply to any acquiror or successor-in-interest to Notch or any Affiliate of any such acquiror or successor-in-interest, in </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">46</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any case that was not an Affiliate of Notch prior to an applicable Change of Control transaction involving Notch (but, for the avoidance of doubt, the exception from the exclusivity provisions set forth in this proviso shall not permit the use of any Notch Technology for activities that would otherwise be restricted by the exclusivity provisions applicable to Notch pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">).  Except as expressly provided in this Section, any attempted assignment or transfer of this Agreement shall be null and void.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Change in Control. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Notch shall provide written notice to Allogene upon its intention to sell all or substantially all of its business or assets (whether by merger, reorganization, acquisition, sale or otherwise) (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CIC Transaction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) at least &#91;***&#93; days prior to entering into a binding agreement for such sale or exclusivity agreement regarding the negotiation of such sale. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Representation by Legal Counsel</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof.  In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Waiver.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Neither Party may waive or release any of its rights or interests in this Agreement except in writing.  The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.  No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any notice required or permitted to be given under this Agreement shall be in writing, shall make specific reference to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable overnight delivery service, (b) on the day of sending by email (with receipt confirmation), or (c) three (3) days after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested.</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Notch, addressed to&#58;&#160;  </font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notch Therapeutics Inc.</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attn&#58;  President</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">40 King Street West, Suite 2100</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Toronto, Ontario M5H 3C2</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Canada</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Allogene, addressed to&#58;&#160; </font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc.</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attn&#58; General Counsel</font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">210 E. Grand Avenue</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">South San Francisco, CA 94080</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">USA</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58; </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any term or provision of this Agreement that is held to be invalid, void, or unenforceable in any situation in any jurisdiction will not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the invalid, void, or unenforceable term or provision in any other situation or in any other jurisdiction.  If any term or provision of this Agreement is declared invalid, void, or unenforceable, the Parties agree that the authority making such determination will have the power to and shall, subject to the discretion of such authority, reduce the scope, duration, area or applicability of the term or provision, to delete specific words or phrases, or to replace any invalid, void, or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the original intention of the invalid or unenforceable term or provision.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Interpretation. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement and references to this Agreement include all Exhibits hereto.  Unless context otherwise clearly requires, whenever used in this Agreement&#58;  (a) the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating, also, &#8220;but not limited to&#8221; or &#8220;without limitation&#59;&#8221; (b) the word &#8220;day&#8221; or &#8220;year&#8221; means a calendar day or year unless otherwise specified&#59; (c) the word &#8220;notice&#8221; shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement&#59; (d) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Exhibits)&#59; (e) the word &#8220;or&#8221; shall be construed as the inclusive meaning identified with the phrase &#8220;and&#47;or&#59;&#8221;(f) provisions that require that a Party, the Parties or a committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise&#59; (g) words of any gender include the other gender&#59; (h) words using the singular or plural number also include the plural or singular number, respectively&#59; (i) references to any Applicable Laws, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement Applicable Laws thereto&#59; and (j) neither Party or its Affiliates shall be deemed to be acting &#8220;on behalf of&#8221; or &#8220;under authority of&#8221; the other Party under this Agreement.   </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may be executed in two or more counterparts (whether delivered by email via .pdf format, facsimile or otherwise), each of which will be considered one and the same agreement and will become effective when counterparts have been signed by each of the Parties and delivered to the other Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Entire Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Agreement with its Exhibits and Schedules (a) constitutes the entire agreement and supersedes, as of the Effective Date, all prior and contemporaneous agreements, negotiations, arrangements and understandings, both written and oral, between the Parties with respect to the subject matter hereof, and (b) is not intended to confer upon any person or entity, other than the Parties, any rights, benefits, or remedies of any </font></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">48</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">nature whatsoever.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#93;</font></div><div id="i55f8e32f7dea432292ac06b577aa5dae_4"></div><div style="position:relative;width:100%;height:50.4pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">49</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties have caused this Agreement to be duly executed by their authorized representatives as of the Effective Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="padding-right:-18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.&#160;&#160;NOTCH THERAPEUTICS INC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="padding-right:-18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#47;s&#47; David Chang&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#47;s&#47; Timothy Key&#160;&#160;&#160;</font></div><div style="padding-right:-18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;David Chang, M.D., Ph.D.&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Name&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;Timothy Key, PhD&#160;&#160;&#160;</font></div><div style="padding-right:-18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;CEO and President&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Title&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;Director&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-right:-18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">List of Exhibits</font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit A &#8211; Initial Targets</font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit B &#8211; Notch Microbead Technology </font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit C &#8211; Notch Patents</font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit D &#8211; ROFN Targets </font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit E &#8211; Initial Research Plan  </font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit F &#8211; Cellectis Technology Targets </font></div><div style="padding-right:-18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit G &#8211; Notch Third Party In-Licenses</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>allo-20191231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4edb2648496541e98ca9bd98cb61b341_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 23.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;">Registration Statements (Forms S-8 Nos. 333-227965 and 333-230164) Amended and Restated 2018 Equity Incentive Plan, and 2018 Employee Stock Purchase Plan of Allogene Therapeutics, Inc.</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt;">Registration Statement on Forms S-3 No. 333-234516, of Allogene Therapeutics, Inc.&#894; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">of our reports dated February 27, 2020, with respect to the financial statements of Allogene Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Allogene Therapeutics, Inc. included in this Annual Report (Form 10-K) of Allogene Therapeutics, Inc. for the year ended December 31, 2019.</font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:18pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Jose, California</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 27, 2020</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>allo-20191231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David Chang, M.D., Ph.D., certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this Annual Report on Form 10-K of Allogene Therapeutics, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; &#47;s&#47; David Chang, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">David Chang, M.D., Ph.D.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>allo-20191231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Eric Schmidt, Ph.D., certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this Annual Report on Form 10-K of Allogene Therapeutics&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#47;s&#47; Eric Schmidt, Ph.D</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Eric Schmidt, Ph.D.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>allo-20191231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Annual Report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit 32.1, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:-45pt;padding-left:90pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-45pt;padding-left:90pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#47;s&#47; David Chang, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">David Chang, M.D., Ph.D.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Allogene Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>allo-20191231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Annual Report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit 32.2, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Eric Schmidt, Ph.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:-45pt;padding-left:90pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-45pt;padding-left:90pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#47;s&#47; Eric Schmidt, Ph.D</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Eric Schmidt, Ph.D.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Allogene Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>allo-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:allo="http://allogene.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:element id="allo_OperatingLeaseAssetRetirementObligation" abstract="false" name="OperatingLeaseAssetRetirementObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_RelatedPartyTransactionCompensationPercentage" abstract="false" name="RelatedPartyTransactionCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_TaxExpiration2037Member" abstract="true" name="TaxExpiration2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AreaOfNewOfficeBuilding" abstract="false" name="AreaOfNewOfficeBuilding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_CostMethodInvestmentTransactionCosts" abstract="false" name="CostMethodInvestmentTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ConsultingAgreementsMember" abstract="true" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostResponsibleFor" abstract="false" name="PercentageOfDevelopmentCostResponsibleFor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" abstract="true" name="TwoRiverConsultingLimitedLiabiltyCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_DeferredTaxLiabilitiesRightOfUseLeased" abstract="false" name="DeferredTaxLiabilitiesRightOfUseLeased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" abstract="false" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_LeaseTwoMember" abstract="true" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AssetContributionAgreementMember" abstract="true" name="AssetContributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayable" abstract="false" name="AggregatePotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_BalanceSheetComponentsLineItems" abstract="true" name="BalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="allo_CombinedVotingPowerByIndividual" abstract="false" name="CombinedVotingPowerByIndividual" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_StockIssuedDuringPeriodValuePreferredStockIssues" abstract="false" name="StockIssuedDuringPeriodValuePreferredStockIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NumberOfMembersAppointedToBoardOfDirectors" abstract="false" name="NumberOfMembersAppointedToBoardOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_NotesReceivableFromCommonShareholders" abstract="false" name="NotesReceivableFromCommonShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TwoThousandEighteenPlanMember" abstract="true" name="TwoThousandEighteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SeriesAConvertiblePreferredSharesMember" abstract="true" name="SeriesAConvertiblePreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CashEquivalentsAndShortTermInvestments" abstract="false" name="CashEquivalentsAndShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" abstract="false" name="StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_UnvestedSharesLiabilitiesCurrent" abstract="false" name="UnvestedSharesLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_BellcoCapitalLLCMember" abstract="true" name="BellcoCapitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_StockOptionGrantedPeriod" abstract="false" name="StockOptionGrantedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_TaxExpiration2037To2039Member" abstract="true" name="TaxExpiration2037To2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SeriesA1ConvertiblePreferredSharesMember" abstract="true" name="SeriesA1ConvertiblePreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_EarlyExercisedStockOptionsMember" abstract="true" name="EarlyExercisedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ByHeartMember" abstract="true" name="ByHeartMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SubscriptionsReceivableFromPreferredStockholders" abstract="false" name="SubscriptionsReceivableFromPreferredStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_OperatingLeasesNumberOfLeaseAgreements" abstract="false" name="OperatingLeasesNumberOfLeaseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_IncomeLossFromCostMethodInvestment" abstract="false" name="IncomeLossFromCostMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" abstract="false" name="StockIssuanceMaximumCompensationDueToThirdPartyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_EstimatedLifeOfAssetsTableTextBlock" abstract="false" name="EstimatedLifeOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ComputerEquipmentAndPurchasedSoftwareMember" abstract="true" name="ComputerEquipmentAndPurchasedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AssetAcquisitionLineItems" abstract="true" name="AssetAcquisitionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="allo_FoundersMember" abstract="true" name="FoundersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_EarlyExerciseOfStockOptionsMember" abstract="true" name="EarlyExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AllowanceForTenantImprovements" abstract="false" name="AllowanceForTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AccruedInterestOnShortTermMarketableSecurities" abstract="false" name="AccruedInterestOnShortTermMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" abstract="false" name="PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_ClinicalRegulatoryAndCommercialMilestoneMember" abstract="true" name="ClinicalRegulatoryAndCommercialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_DiscountRateForValuation" abstract="false" name="DiscountRateForValuation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" abstract="false" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_LosAngelesMember" abstract="true" name="LosAngelesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_NotchTherapeuticsIncMember" abstract="true" name="NotchTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CellectisSAMember" abstract="true" name="CellectisSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PreClinicalDevelopmentMilestoneMember" abstract="true" name="PreClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" abstract="false" name="IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AccruedAndOtherLiabilitiesCurrent" abstract="false" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="NumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" abstract="false" name="DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AssetAcquisitionTable" abstract="true" name="AssetAcquisitionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_ConvertiblePreferredStockIssuedInAssetAcquisition" abstract="false" name="ConvertiblePreferredStockIssuedInAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" abstract="false" name="IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" abstract="false" name="ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" abstract="false" name="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" abstract="true" name="ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_StartUpCost" abstract="false" name="StartUpCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AccruedPropertyAndEquipment" abstract="false" name="AccruedPropertyAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AggregatePurchasePriceSharesValue" abstract="false" name="AggregatePurchasePriceSharesValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LesseeOperatingLeaseOptionToExtendNumber" abstract="false" name="LesseeOperatingLeaseOptionToExtendNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_AccruedCompensationAndRelatedBenefitsCurrent" abstract="false" name="AccruedCompensationAndRelatedBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AggregateMilestonePayments" abstract="false" name="AggregateMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_StockIssuedDuringPeriodValueCommonStockIssues" abstract="false" name="StockIssuedDuringPeriodValueCommonStockIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AssembledWorkforceMember" abstract="true" name="AssembledWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_StockIssuanceMaximumValue" abstract="false" name="StockIssuanceMaximumValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TaxExpirationYears2038To2039Member" abstract="true" name="TaxExpirationYears2038To2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" abstract="false" name="PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AntiBCMACARTCellTherapyMember" abstract="true" name="AntiBCMACARTCellTherapyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RegulatoryAndSalesMilestoneMember" abstract="true" name="RegulatoryAndSalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" abstract="false" name="AccruedResearchAndDevelopmentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_LicenseAndCollaborationAgreementsTextBlock" abstract="false" name="LicenseAndCollaborationAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_LeaseOneMember" abstract="true" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ComprehensiveLossPolicyPolicyTextBlock" abstract="false" name="ComprehensiveLossPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_FounderSharesOfCommonStockMember" abstract="true" name="FounderSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" abstract="false" name="IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_CurrentOfferingPeriod" abstract="false" name="CurrentOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NewarkMember" abstract="true" name="NewarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_InitiallyReservedCommonStockForEmployeePurchase" abstract="false" name="InitiallyReservedCommonStockForEmployeePurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PercentageOfEligibleCompensationContributionByEmployee" abstract="false" name="PercentageOfEligibleCompensationContributionByEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" abstract="true" name="AffiliatedWithPresidentAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SubscriptionsReceivablesFromPreferredStockholdersMember" abstract="true" name="SubscriptionsReceivablesFromPreferredStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ModificationOfConvertiblePreferredStockForCommonStock" abstract="false" name="ModificationOfConvertiblePreferredStockForCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_PrepaidResearchAndDevelopmentExpensesCurrent" abstract="false" name="PrepaidResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ResearchCollaborationAndLicenseAgreementMember" abstract="true" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AntiCDNineteenCARTCellTherapyMember" abstract="true" name="AntiCDNineteenCARTCellTherapyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ChangeInFairValueOfConvertibleNotePayable" abstract="false" name="ChangeInFairValueOfConvertibleNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShorttermLeaseRentExpense" abstract="false" name="ShorttermLeaseRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_FoundersStockAwardMember" abstract="true" name="FoundersStockAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_BalanceSheetComponentsTable" abstract="true" name="BalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_RelatedPartyTransactionMonthlyPaymentsInArrears" abstract="false" name="RelatedPartyTransactionMonthlyPaymentsInArrears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TPGCapitalFOLimitedLiabilityCompanyMember" abstract="true" name="TPGCapitalFOLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ClinicalDevelopmentMilestoneMember" abstract="true" name="ClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="allo_PfizerIncMember" abstract="true" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" abstract="true" name="NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" abstract="false" name="MaximumPaymentsRequiredPerProductAgainstSelectedTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" abstract="false" name="DeferredTaxAssetsNetOfDeferredTaxLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayments" abstract="false" name="AggregatePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://allogene.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://allogene.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://allogene.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005006 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://allogene.com/role/StatementsofCashFlows">
        <link:definition>1006007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails">
        <link:definition>2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingGuidance" roleURI="http://allogene.com/role/RecentAccountingGuidance">
        <link:definition>2106102 - Disclosure - Recent Accounting Guidance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://allogene.com/role/FairValueMeasurements">
        <link:definition>2107103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://allogene.com/role/FairValueMeasurementsTables">
        <link:definition>2308302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2409403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2410404 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://allogene.com/role/Investments">
        <link:definition>2111104 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentTables" roleURI="http://allogene.com/role/InvestmentTables">
        <link:definition>2312303 - Disclosure - Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" roleURI="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
        <link:definition>2413405 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" roleURI="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail">
        <link:definition>2414406 - Disclosure - Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentAdditionalInformationDetails" roleURI="http://allogene.com/role/InvestmentAdditionalInformationDetails">
        <link:definition>2415407 - Disclosure - Investment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://allogene.com/role/BalanceSheetComponents">
        <link:definition>2116105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://allogene.com/role/BalanceSheetComponentsTables">
        <link:definition>2317304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2418408 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>2419409 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>2420410 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofIntangibleAssetsDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails">
        <link:definition>2421411 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails">
        <link:definition>2422412 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisition" roleURI="http://allogene.com/role/AssetAcquisition">
        <link:definition>2123106 - Disclosure - Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisitionTables" roleURI="http://allogene.com/role/AssetAcquisitionTables">
        <link:definition>2324305 - Disclosure - Asset Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisitionAdditionalInformationDetails" roleURI="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails">
        <link:definition>2425413 - Disclosure - Asset Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" roleURI="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails">
        <link:definition>2426414 - Disclosure - Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://allogene.com/role/LicenseandCollaborationAgreements">
        <link:definition>2127107 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsDetails" roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails">
        <link:definition>2428415 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://allogene.com/role/Leases">
        <link:definition>2129108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://allogene.com/role/LeasesTables">
        <link:definition>2330306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2431416 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" roleURI="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>2432417 - Disclosure - Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestment" roleURI="http://allogene.com/role/EquityMethodInvestment">
        <link:definition>2133109 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentDetails" roleURI="http://allogene.com/role/EquityMethodInvestmentDetails">
        <link:definition>2434418 - Disclosure - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://allogene.com/role/CommitmentsandContingencies">
        <link:definition>2135110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable2018Notes" roleURI="http://allogene.com/role/ConvertibleNotesPayable2018Notes">
        <link:definition>2136111 - Disclosure - Convertible Notes Payable (2018 Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable2018NotesDetails" roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails">
        <link:definition>2437419 - Disclosure - Convertible Notes Payable (2018 Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquity" roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity">
        <link:definition>2138112 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersDeficitDetails" roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails">
        <link:definition>2439420 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://allogene.com/role/StockBasedCompensation">
        <link:definition>2140113 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://allogene.com/role/StockBasedCompensationTables">
        <link:definition>2341307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2442421 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" roleURI="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails">
        <link:definition>2443422 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>2444423 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>2445424 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>2447426 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://allogene.com/role/RelatedPartyTransactions">
        <link:definition>2148114 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2449427 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://allogene.com/role/A401kPlan">
        <link:definition>2150115 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://allogene.com/role/A401kPlanDetails">
        <link:definition>2451428 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://allogene.com/role/IncomeTaxes">
        <link:definition>2152116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://allogene.com/role/IncomeTaxesTables">
        <link:definition>2353308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2454429 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofValuationAllowanceDetails" roleURI="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails">
        <link:definition>2455430 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxReconciliationDetails" roleURI="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails">
        <link:definition>2456431 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2457432 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" roleURI="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails">
        <link:definition>2458433 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2459434 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossandNetLossPerShare" roleURI="http://allogene.com/role/NetLossandNetLossPerShare">
        <link:definition>2160117 - Disclosure - Net Loss and Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossandNetLossPerShareTables" roleURI="http://allogene.com/role/NetLossandNetLossPerShareTables">
        <link:definition>2361309 - Disclosure - Net Loss and Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>2462435 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails">
        <link:definition>2463436 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://allogene.com/role/SubsequentEvents">
        <link:definition>2164118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://allogene.com/role/SubsequentEventsDetails">
        <link:definition>2465437 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataunaudited" roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited">
        <link:definition>2166119 - Disclosure - Selected Quarterly Financial Data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataunauditedTables" roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables">
        <link:definition>2367310 - Disclosure - Selected Quarterly Financial Data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataunauditedDetails" roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails">
        <link:definition>2468438 - Disclosure - Selected Quarterly Financial Data (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>allo-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20191231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheets" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_71015654-ce33-407f-ba74-9aa6d93bc365" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40c76d2d-7995-4b48-bfe3-1a9861017405" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71015654-ce33-407f-ba74-9aa6d93bc365" xlink:to="loc_us-gaap_Liabilities_40c76d2d-7995-4b48-bfe3-1a9861017405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_81c0338a-a508-431d-bb3b-96ede77888cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71015654-ce33-407f-ba74-9aa6d93bc365" xlink:to="loc_us-gaap_CommitmentsAndContingencies_81c0338a-a508-431d-bb3b-96ede77888cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3121249f-7451-4c2c-b847-6a6e1f9db1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71015654-ce33-407f-ba74-9aa6d93bc365" xlink:to="loc_us-gaap_StockholdersEquity_3121249f-7451-4c2c-b847-6a6e1f9db1c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_27072c14-38cd-4617-bcf7-54b105ee208d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e9df06db-5982-4c43-b8f4-c6cb5bfd6ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_27072c14-38cd-4617-bcf7-54b105ee208d" xlink:to="loc_us-gaap_LiabilitiesCurrent_e9df06db-5982-4c43-b8f4-c6cb5bfd6ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9c5eed6-df59-42e2-a6df-b4a6b6ca3dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_27072c14-38cd-4617-bcf7-54b105ee208d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9c5eed6-df59-42e2-a6df-b4a6b6ca3dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_56883bee-5c7a-49c8-8c58-22da9e65a9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_27072c14-38cd-4617-bcf7-54b105ee208d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_56883bee-5c7a-49c8-8c58-22da9e65a9c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ce99a24-2c51-4378-862a-0f7ef99fce1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b042f29a-033d-48c4-bdc5-9ba376e3a854" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ce99a24-2c51-4378-862a-0f7ef99fce1b" xlink:to="loc_us-gaap_AccountsPayableCurrent_b042f29a-033d-48c4-bdc5-9ba376e3a854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_c1eb8e99-0f39-472a-aeda-1cadf3fc9018" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ce99a24-2c51-4378-862a-0f7ef99fce1b" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_c1eb8e99-0f39-472a-aeda-1cadf3fc9018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdc7f265-50a0-4cfa-9ae9-70263c6dcdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdc7f265-50a0-4cfa-9ae9-70263c6dcdfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_44cede1e-be07-497e-afb1-c964ecb180bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_44cede1e-be07-497e-afb1-c964ecb180bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_906ee6af-1cb3-4f85-b67a-37c8a8b10bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_906ee6af-1cb3-4f85-b67a-37c8a8b10bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae49691-a6d1-434c-93b7-42648dbf9045" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae49691-a6d1-434c-93b7-42648dbf9045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7006d5f0-c4f9-4329-88c7-8fe455fdffe1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7006d5f0-c4f9-4329-88c7-8fe455fdffe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6237a6d2-be7d-4fe7-829c-6584b96b3499" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_AssetsCurrent_6237a6d2-be7d-4fe7-829c-6584b96b3499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_343e34ae-cb4a-4168-9781-aa4f9f89bee4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_343e34ae-cb4a-4168-9781-aa4f9f89bee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_36d85e07-ce3e-4d85-8094-e970f6546b44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68547e82-b56a-464a-af9f-bfba6f34c072" xlink:to="loc_us-gaap_OtherLongTermInvestments_36d85e07-ce3e-4d85-8094-e970f6546b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3fa36b41-12b8-4ad9-8fe7-329e806d870a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:to="loc_us-gaap_PreferredStockValue_3fa36b41-12b8-4ad9-8fe7-329e806d870a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7685ce28-450d-44e9-8ab6-53244b53d3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:to="loc_us-gaap_CommonStockValue_7685ce28-450d-44e9-8ab6-53244b53d3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_454a4f30-3b43-485b-9c70-6f7a263589ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_454a4f30-3b43-485b-9c70-6f7a263589ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_610e658e-3489-467a-815d-bb36f45258e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_610e658e-3489-467a-815d-bb36f45258e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d91f7ded-675b-44f7-ba78-c737d4f22c99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d28c50d-e947-417c-a84e-dd674df8f16b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d91f7ded-675b-44f7-ba78-c737d4f22c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aa34f55c-fa11-43c6-b489-4145ba5f2ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64b32083-622b-4345-b7fd-1c0ac2072e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aa34f55c-fa11-43c6-b489-4145ba5f2ce4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64b32083-622b-4345-b7fd-1c0ac2072e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9bed78d0-a1d1-4667-a628-9520196a4a74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aa34f55c-fa11-43c6-b489-4145ba5f2ce4" xlink:to="loc_us-gaap_ShortTermInvestments_9bed78d0-a1d1-4667-a628-9520196a4a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bbb9d214-1efe-4b76-9470-93002ab85a23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aa34f55c-fa11-43c6-b489-4145ba5f2ce4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bbb9d214-1efe-4b76-9470-93002ab85a23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20191231.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dd45504e-4806-4d99-a96b-a1a7ac10b81a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0877970f-2230-4901-9811-d54eb0e3e0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dd45504e-4806-4d99-a96b-a1a7ac10b81a" xlink:to="loc_us-gaap_InterestExpense_0877970f-2230-4901-9811-d54eb0e3e0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_b7a1097b-15f0-4adc-9195-e031150141d8" xlink:href="allo-20191231.xsd#allo_ChangeInFairValueOfConvertibleNotePayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dd45504e-4806-4d99-a96b-a1a7ac10b81a" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_b7a1097b-15f0-4adc-9195-e031150141d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cf64adde-eea9-42ad-88a2-44084ca43848" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dd45504e-4806-4d99-a96b-a1a7ac10b81a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cf64adde-eea9-42ad-88a2-44084ca43848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_a56baec5-74a0-46f5-8826-9437477a98c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dd45504e-4806-4d99-a96b-a1a7ac10b81a" xlink:to="loc_us-gaap_OtherExpenses_a56baec5-74a0-46f5-8826-9437477a98c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ba21f00b-8f66-45d9-a505-0cccb2debc81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_217a9ca8-0451-42cf-bfc6-2feb230014b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ba21f00b-8f66-45d9-a505-0cccb2debc81" xlink:to="loc_us-gaap_OperatingExpenses_217a9ca8-0451-42cf-bfc6-2feb230014b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c0e44ca-8ed6-4185-9b39-b881db8d5a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e30d8dd6-33aa-4bfa-8a4c-bb11e83f6be7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c0e44ca-8ed6-4185-9b39-b881db8d5a0e" xlink:to="loc_us-gaap_OperatingIncomeLoss_e30d8dd6-33aa-4bfa-8a4c-bb11e83f6be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_755853ee-d837-4a46-a4f4-4d3ca87ae7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c0e44ca-8ed6-4185-9b39-b881db8d5a0e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_755853ee-d837-4a46-a4f4-4d3ca87ae7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_da60a6a8-0615-4d59-a145-ae6123df2602" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dd333f2b-5454-4dcf-9723-1ab2c3292506" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_da60a6a8-0615-4d59-a145-ae6123df2602" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dd333f2b-5454-4dcf-9723-1ab2c3292506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3724cfe2-eff0-4d1b-b20f-6ab6f7e12cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_da60a6a8-0615-4d59-a145-ae6123df2602" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3724cfe2-eff0-4d1b-b20f-6ab6f7e12cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e63cabd-ddcb-455c-b7d7-dd160fab3318" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a40ce1fa-3385-42a6-b4da-61099ec165ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e63cabd-ddcb-455c-b7d7-dd160fab3318" xlink:to="loc_us-gaap_NetIncomeLoss_a40ce1fa-3385-42a6-b4da-61099ec165ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_060a24fd-69c8-494e-9eb2-27294b7fc228" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e63cabd-ddcb-455c-b7d7-dd160fab3318" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_060a24fd-69c8-494e-9eb2-27294b7fc228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d770d3fd-f9b2-4234-9556-601904d47c83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3abe7377-2cb0-42d7-89ec-385ca1fe5da5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d770d3fd-f9b2-4234-9556-601904d47c83" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3abe7377-2cb0-42d7-89ec-385ca1fe5da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4e1f8ed9-38fd-4fa1-a0e4-e3cb1e52db26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d770d3fd-f9b2-4234-9556-601904d47c83" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4e1f8ed9-38fd-4fa1-a0e4-e3cb1e52db26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ab3214-da4a-43bb-b258-c4a32ef40981" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e628a822-9137-4876-b2d9-6aba15fefcdc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ab3214-da4a-43bb-b258-c4a32ef40981" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e628a822-9137-4876-b2d9-6aba15fefcdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31e783fc-526e-4124-bc8e-509286bc7e91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ab3214-da4a-43bb-b258-c4a32ef40981" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31e783fc-526e-4124-bc8e-509286bc7e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe1d3537-2266-4d74-97bd-e722524785b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ab3214-da4a-43bb-b258-c4a32ef40981" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe1d3537-2266-4d74-97bd-e722524785b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2f2b2505-f4d6-4715-887b-058a7b489a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_us-gaap_ProceedsFromStockPlans_2f2b2505-f4d6-4715-887b-058a7b489a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_e7220623-35c3-4504-a024-a02e8ee5ee67" xlink:href="allo-20191231.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_e7220623-35c3-4504-a024-a02e8ee5ee67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_bb323454-6b91-4b1b-a46a-1cd48a05d54b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_bb323454-6b91-4b1b-a46a-1cd48a05d54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b6910c11-b64f-426f-94b1-d03508f83309" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b6910c11-b64f-426f-94b1-d03508f83309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2d10fee3-67b6-4169-9315-5db88cc5632a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2d10fee3-67b6-4169-9315-5db88cc5632a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_e3b8479e-4ec9-4cc6-aba0-2b6c01d016b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4b8a162-2ffc-45de-86b3-68a51ff118f2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_e3b8479e-4ec9-4cc6-aba0-2b6c01d016b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_26a34647-9b7d-4421-858c-e0e57865eeef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_26a34647-9b7d-4421-858c-e0e57865eeef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f22b009b-6bfb-47ff-8260-00ff2078386c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f22b009b-6bfb-47ff-8260-00ff2078386c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_eeab8309-5ade-42f3-8fd5-5963b5c2757b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_eeab8309-5ade-42f3-8fd5-5963b5c2757b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_59c5abc6-e8c1-4e15-9fda-089272dfc6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_59c5abc6-e8c1-4e15-9fda-089272dfc6aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_022ea833-8d1e-4d1a-ac8a-ce86f84ee256" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_022ea833-8d1e-4d1a-ac8a-ce86f84ee256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca444561-0bac-49a8-927c-3fc58ce92b62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_817c39c6-8e0d-4531-b4d0-650184f45931" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca444561-0bac-49a8-927c-3fc58ce92b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_52a77fdf-5549-4a4b-addf-3904857ac98a" xlink:href="allo-20191231.xsd#allo_ChangeInFairValueOfConvertibleNotePayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_52a77fdf-5549-4a4b-addf-3904857ac98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_78ecb512-4a00-467d-9374-c6f6749ee540" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_LeaseAndRentalExpense_78ecb512-4a00-467d-9374-c6f6749ee540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_bda8a665-c922-4248-86c6-e421f1a7e4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_bda8a665-c922-4248-86c6-e421f1a7e4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bdf1263e-6970-4f0f-bf8c-1b48d0e8f526" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bdf1263e-6970-4f0f-bf8c-1b48d0e8f526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d73bcbf-52ab-4437-a3c1-23c4a2f68b30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d73bcbf-52ab-4437-a3c1-23c4a2f68b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7d27e0bc-5ce4-4faa-a0a2-b3c10d78751f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_ShareBasedCompensation_7d27e0bc-5ce4-4faa-a0a2-b3c10d78751f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_839ec651-28f0-456b-9389-5cebe347d1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_839ec651-28f0-456b-9389-5cebe347d1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_2b81f32a-edab-40a2-a452-d81003f67a1e" xlink:href="allo-20191231.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_2b81f32a-edab-40a2-a452-d81003f67a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21fb21cd-bc13-4ac9-a864-af02e3d9db90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21fb21cd-bc13-4ac9-a864-af02e3d9db90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2baedad9-1c14-4a7b-aa43-a02edf9654b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2baedad9-1c14-4a7b-aa43-a02edf9654b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9a78f9a6-9d94-4462-9b46-29bf259c5b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9a78f9a6-9d94-4462-9b46-29bf259c5b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98e3ec21-969b-4aaf-af82-d2502f61f059" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98e3ec21-969b-4aaf-af82-d2502f61f059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_364f9151-0761-43c2-9e0f-3faab7dbba71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_364f9151-0761-43c2-9e0f-3faab7dbba71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9234d63f-5ac4-4afc-9497-ada57df1bfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9234d63f-5ac4-4afc-9497-ada57df1bfa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_863c0db0-827d-4593-b3b7-44b4d3546cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_863c0db0-827d-4593-b3b7-44b4d3546cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_138c4b15-02b5-49c1-91aa-cbcc42bff829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_ProfitLoss_138c4b15-02b5-49c1-91aa-cbcc42bff829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5a48830a-9749-47c7-aa40-74f586c0349e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8608cce0-a505-48ba-a9ae-acdda367f965" xlink:to="loc_us-gaap_Depreciation_5a48830a-9749-47c7-aa40-74f586c0349e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RecentAccountingGuidance" xlink:type="simple" xlink:href="allo-20191231.xsd#RecentAccountingGuidance"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RecentAccountingGuidance" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/Investments" xlink:type="simple" xlink:href="allo-20191231.xsd#Investments"/>
  <link:calculationLink xlink:role="http://allogene.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentTables" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/InvestmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_12b2e3ab-d208-4b67-be4d-bdfd645d5770" xlink:href="allo-20191231.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_fe334c02-ab11-45cc-8375-fe86e09ad3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_12b2e3ab-d208-4b67-be4d-bdfd645d5770" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_fe334c02-ab11-45cc-8375-fe86e09ad3a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5624d601-b8bf-4a3e-9ce8-c8c96ff20ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_12b2e3ab-d208-4b67-be4d-bdfd645d5770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5624d601-b8bf-4a3e-9ce8-c8c96ff20ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_60094629-eb4a-444d-bffd-9e340b31bf55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_12b2e3ab-d208-4b67-be4d-bdfd645d5770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_60094629-eb4a-444d-bffd-9e340b31bf55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_223a337d-ba63-4909-ac24-da066595ae22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74e71e3a-6093-477d-9976-6160d508409d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_223a337d-ba63-4909-ac24-da066595ae22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74e71e3a-6093-477d-9976-6160d508409d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d30b995-967b-4c64-88ae-d7bf99509823" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_223a337d-ba63-4909-ac24-da066595ae22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d30b995-967b-4c64-88ae-d7bf99509823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b86f8b5-f0d4-4f90-b5cc-7bff36ddb70b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_223a337d-ba63-4909-ac24-da066595ae22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b86f8b5-f0d4-4f90-b5cc-7bff36ddb70b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13db074f-7d03-4763-b367-975f8da044b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f83a4dae-bda1-4993-9957-eb6b7042f29a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13db074f-7d03-4763-b367-975f8da044b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f83a4dae-bda1-4993-9957-eb6b7042f29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_48e472bd-39f7-4ac7-ba30-109f0ce4cee8" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13db074f-7d03-4763-b367-975f8da044b6" xlink:to="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_48e472bd-39f7-4ac7-ba30-109f0ce4cee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_9fa8dd8b-8b13-4412-9953-7fb5e4d4e74a" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13db074f-7d03-4763-b367-975f8da044b6" xlink:to="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_9fa8dd8b-8b13-4412-9953-7fb5e4d4e74a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_9b96527b-83d2-4115-a762-2e913c106668" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13db074f-7d03-4763-b367-975f8da044b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_9b96527b-83d2-4115-a762-2e913c106668" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedPropertyAndEquipment_e4d639ac-140d-4aae-9c37-8e597a3d0ebe" xlink:href="allo-20191231.xsd#allo_AccruedPropertyAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:to="loc_allo_AccruedPropertyAndEquipment_e4d639ac-140d-4aae-9c37-8e597a3d0ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_e4b44e80-c913-4658-9b1e-d1cad85d3924" xlink:href="allo-20191231.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:to="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_e4b44e80-c913-4658-9b1e-d1cad85d3924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3185dac4-b2d3-4d68-a7d3-4b8cad50b647" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3185dac4-b2d3-4d68-a7d3-4b8cad50b647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent_895e8e06-48c6-464e-aed3-085fb6af117b" xlink:href="allo-20191231.xsd#allo_UnvestedSharesLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:to="loc_allo_UnvestedSharesLiabilitiesCurrent_895e8e06-48c6-464e-aed3-085fb6af117b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_e749d30c-7422-4776-9669-54e9dd783049" xlink:href="allo-20191231.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_d16c2805-7b46-4014-a932-78bfa0d59b57" xlink:to="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_e749d30c-7422-4776-9669-54e9dd783049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5877e2e-e10e-41a4-8347-4e548f0c8a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedInterestOnShortTermMarketableSecurities_8cf53ab8-5ccc-4734-adaf-b17fc896df0a" xlink:href="allo-20191231.xsd#allo_AccruedInterestOnShortTermMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5877e2e-e10e-41a4-8347-4e548f0c8a5d" xlink:to="loc_allo_AccruedInterestOnShortTermMarketableSecurities_8cf53ab8-5ccc-4734-adaf-b17fc896df0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_4e3ea4c8-9928-45a0-91b5-43fea8768bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5877e2e-e10e-41a4-8347-4e548f0c8a5d" xlink:to="loc_us-gaap_PrepaidInsurance_4e3ea4c8-9928-45a0-91b5-43fea8768bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_fcc2ddcd-8955-45be-bc4c-9ec546df1df8" xlink:href="allo-20191231.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5877e2e-e10e-41a4-8347-4e548f0c8a5d" xlink:to="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_fcc2ddcd-8955-45be-bc4c-9ec546df1df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_cc9bfb68-ece4-4227-ab15-370a42f47ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5877e2e-e10e-41a4-8347-4e548f0c8a5d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_cc9bfb68-ece4-4227-ab15-370a42f47ff7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55a505f6-ef39-4985-a2f3-18da37b92c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8cf2854e-8867-4c98-a5d7-04f090fddaa2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_55a505f6-ef39-4985-a2f3-18da37b92c7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8cf2854e-8867-4c98-a5d7-04f090fddaa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8773ca8-ff28-4a78-83f0-980afbc187b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_55a505f6-ef39-4985-a2f3-18da37b92c7c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8773ca8-ff28-4a78-83f0-980afbc187b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bd116ef0-e334-4f08-9f0f-467b51232a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e31d8b4c-3210-45dc-8cff-780d79a5ffe4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bd116ef0-e334-4f08-9f0f-467b51232a4c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e31d8b4c-3210-45dc-8cff-780d79a5ffe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_11f127c5-1a13-40be-9d5e-b95f67950bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bd116ef0-e334-4f08-9f0f-467b51232a4c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_11f127c5-1a13-40be-9d5e-b95f67950bd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisition" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisition"/>
  <link:calculationLink xlink:role="http://allogene.com/role/AssetAcquisition" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionTables" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/AssetAcquisitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:type="simple" xlink:href="allo-20191231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_fb181485-9d73-4b60-96c4-703e32983595" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_fb181485-9d73-4b60-96c4-703e32983595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8e867f3-0a07-45a5-905e-0840cf7d983e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8e867f3-0a07-45a5-905e-0840cf7d983e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_458838db-6f15-4000-a1e6-2ab0df0b2479" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_458838db-6f15-4000-a1e6-2ab0df0b2479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a6564763-58d5-4cdf-a131-8d19de037f24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a6564763-58d5-4cdf-a131-8d19de037f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_514e8cfa-cc51-48e7-9521-8c721fee8809" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2c180-d4bf-4279-94ac-0e09ebc54b4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_514e8cfa-cc51-48e7-9521-8c721fee8809" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestment"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestmentDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20191231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018Notes"/>
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018NotesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersEquity"/>
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersDeficitDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlan" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlan"/>
  <link:calculationLink xlink:role="http://allogene.com/role/A401kPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlanDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/A401kPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3dccd714-9ab4-47b1-b6a8-a188f6f46a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b81a2015-7e29-42fd-baee-1d7856718b69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3dccd714-9ab4-47b1-b6a8-a188f6f46a2e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b81a2015-7e29-42fd-baee-1d7856718b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f466f3c9-0a98-4c7a-949d-523756b78d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3dccd714-9ab4-47b1-b6a8-a188f6f46a2e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f466f3c9-0a98-4c7a-949d-523756b78d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4c040513-1af2-459d-ace3-90ddefe6fcbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b1b181ec-744b-4f82-b5b3-df95ebe90953" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4c040513-1af2-459d-ace3-90ddefe6fcbf" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b1b181ec-744b-4f82-b5b3-df95ebe90953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c25fde53-5d71-4823-8b39-34b2f46bb91e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4c040513-1af2-459d-ace3-90ddefe6fcbf" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c25fde53-5d71-4823-8b39-34b2f46bb91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3b49060-2087-4f64-830f-d8fd412efdee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7dadf532-5fbd-4968-a8e4-a7f3fd98500e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f3b49060-2087-4f64-830f-d8fd412efdee" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7dadf532-5fbd-4968-a8e4-a7f3fd98500e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_59670e27-5512-4106-a454-6ed6e7632593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f3b49060-2087-4f64-830f-d8fd412efdee" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_59670e27-5512-4106-a454-6ed6e7632593" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_742cbccd-1299-4ed7-8c88-80f4b1f0b01f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_742cbccd-1299-4ed7-8c88-80f4b1f0b01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_710da7cd-e1f9-417f-a2c0-8be3e14c6716" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_710da7cd-e1f9-417f-a2c0-8be3e14c6716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bc461500-26d6-4c73-9daf-bb732a1e6e79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bc461500-26d6-4c73-9daf-bb732a1e6e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_86009a48-927b-4293-af75-9ecbf225ec8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_86009a48-927b-4293-af75-9ecbf225ec8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_10aee15c-dd44-4ca8-a9ef-20e55a0756b4" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_10aee15c-dd44-4ca8-a9ef-20e55a0756b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_7b6658ad-b447-4328-9f21-0b13cbe2a18d" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_7b6658ad-b447-4328-9f21-0b13cbe2a18d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7613790-d339-4b16-a671-d5e6ab9de226" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7613790-d339-4b16-a671-d5e6ab9de226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4c847e8a-52ee-4c6d-80af-6081c9f4f86c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e2802ee-40c8-4396-9395-80569398fa55" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4c847e8a-52ee-4c6d-80af-6081c9f4f86c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_0c97bf1f-5d29-4c79-9a93-e2580c62e387" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cab06852-6228-4b17-b8e2-2d54bcaa8fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_0c97bf1f-5d29-4c79-9a93-e2580c62e387" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_cab06852-6228-4b17-b8e2-2d54bcaa8fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_627d5908-8bd1-426b-90e8-abab1fe4dc00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_0c97bf1f-5d29-4c79-9a93-e2580c62e387" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_627d5908-8bd1-426b-90e8-abab1fe4dc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_664766e8-cda3-45de-82df-d39417283f41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_664766e8-cda3-45de-82df-d39417283f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_17554f39-a451-489d-b28e-dd41e39684f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_17554f39-a451-489d-b28e-dd41e39684f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_091a6f6d-749d-45f4-92a3-20daae350ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_091a6f6d-749d-45f4-92a3-20daae350ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_85210a0d-7342-41ed-8697-90c4db6e8a54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_85210a0d-7342-41ed-8697-90c4db6e8a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsLeaseLiabilities_40589879-b806-4fcb-8798-488c4b9fb6f7" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_allo_DeferredTaxAssetsLeaseLiabilities_40589879-b806-4fcb-8798-488c4b9fb6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6d0a4b85-a7d1-4fb5-aeed-d45aad311d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6d0a4b85-a7d1-4fb5-aeed-d45aad311d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_520dd3fd-2139-4873-a63b-32ced9bb1eef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cdc846dc-6d54-4b92-b298-db71612b2574" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_520dd3fd-2139-4873-a63b-32ced9bb1eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0488b6d9-4488-4116-90b0-86ee43507a40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dedbcd76-122a-4a71-b46c-a8e316a80430" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0488b6d9-4488-4116-90b0-86ee43507a40" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dedbcd76-122a-4a71-b46c-a8e316a80430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased_8c15a706-5f70-45b5-b201-7570738d4d8b" xlink:href="allo-20191231.xsd#allo_DeferredTaxLiabilitiesRightOfUseLeased"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0488b6d9-4488-4116-90b0-86ee43507a40" xlink:to="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased_8c15a706-5f70-45b5-b201-7570738d4d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_73ac160a-102d-4fb1-b46c-ad8537dd4286" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0488b6d9-4488-4116-90b0-86ee43507a40" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_73ac160a-102d-4fb1-b46c-ad8537dd4286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f8bfa985-0260-4f9d-80d2-e01002587de0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0488b6d9-4488-4116-90b0-86ee43507a40" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f8bfa985-0260-4f9d-80d2-e01002587de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a731def-159f-46ed-ac8a-8a6f0594113c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_6cf23fe3-9e0a-4783-b860-ce4b0b4799fb" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a731def-159f-46ed-ac8a-8a6f0594113c" xlink:to="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_6cf23fe3-9e0a-4783-b860-ce4b0b4799fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_913cd9c3-a565-4111-840c-9abfd5697eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a731def-159f-46ed-ac8a-8a6f0594113c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_913cd9c3-a565-4111-840c-9abfd5697eeb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShare"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunaudited"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>allo-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20191231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended" id="i536cd14736824285b680b125190316c3_39a2c550-e4dc-4762-9e08-b91609f40fcc"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheets" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheets"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheets" xlink:type="extended" id="ib4a849af919a49dda3edffa5a2f3da9b_a0667e7f-82ac-42fc-abec-cf293971cfb5"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="extended" id="i995477a1335143a194b87cae80c341fb_a6739ff1-01e4-457b-b78c-476fe42d7341"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20191231.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i17e3fbfa540e41a89e068e3b0f5b9338_8021ebf9-e40a-470d-afeb-bfec8ce7a508"/>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="ic9d54808ab534fd998593059633f1d8c_5bd6d3bd-3ae8-46b6-92f8-da029e90617d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e55c47c-d541-4230-9c1e-7a6ccdbd2979" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockholdersEquity_4e55c47c-d541-4230-9c1e-7a6ccdbd2979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1414625d-f9c7-4823-90ae-131ace6c69f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1414625d-f9c7-4823-90ae-131ace6c69f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4bb2cfea-4e5f-4b90-81e2-6fcd5038381b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4bb2cfea-4e5f-4b90-81e2-6fcd5038381b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_a99493df-4729-4e8a-8f60-fc62c9ced364" xlink:href="allo-20191231.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_a99493df-4729-4e8a-8f60-fc62c9ced364" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_90ae9e75-87c5-4d3d-9bb8-eb846760ca2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_90ae9e75-87c5-4d3d-9bb8-eb846760ca2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d8f18538-49e0-4e2c-9102-5a991eeb028d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d8f18538-49e0-4e2c-9102-5a991eeb028d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_b5833cd7-2af5-4d40-a390-1512da167b66" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_b5833cd7-2af5-4d40-a390-1512da167b66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders_9f6c9935-4e4a-4aa1-93dc-982a09016e70" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivableFromPreferredStockholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_SubscriptionsReceivableFromPreferredStockholders_9f6c9935-4e4a-4aa1-93dc-982a09016e70" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues_126ccc62-7ff1-468c-bd12-2d6ba1b6768d" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValuePreferredStockIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues_126ccc62-7ff1-468c-bd12-2d6ba1b6768d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_73b77142-7697-4725-9566-24f3b3f222c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_73b77142-7697-4725-9566-24f3b3f222c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1f6d1c0-8a6f-44a7-8114-73a8093c7cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1f6d1c0-8a6f-44a7-8114-73a8093c7cd6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_df048c51-7dde-4fd2-b9b7-5d50d4dbe558" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_df048c51-7dde-4fd2-b9b7-5d50d4dbe558" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_155657d9-7c21-47dd-b34c-6bb014ecdeec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_155657d9-7c21-47dd-b34c-6bb014ecdeec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6d6476ce-d781-4b0c-bf7b-0fd9440f71db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6d6476ce-d781-4b0c-bf7b-0fd9440f71db" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ecb55b-c4b7-4432-a0f7-577b0803506f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ecb55b-c4b7-4432-a0f7-577b0803506f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotesReceivableFromCommonShareholders_abcd5cc0-f020-4e75-ad16-bd82d050416d" xlink:href="allo-20191231.xsd#allo_NotesReceivableFromCommonShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_NotesReceivableFromCommonShareholders_abcd5cc0-f020-4e75-ad16-bd82d050416d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_65589c48-15b8-4317-8710-4f95a17509a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_65589c48-15b8-4317-8710-4f95a17509a1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_357bb0c2-5e8a-4196-a456-8d7648764005" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_357bb0c2-5e8a-4196-a456-8d7648764005" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_18085cf3-096a-43f2-b3f1-1fe70504e217" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_18085cf3-096a-43f2-b3f1-1fe70504e217" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5b4442f0-27bf-4b1e-84eb-22eb10be793a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5b4442f0-27bf-4b1e-84eb-22eb10be793a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_4fdf71e5-99fa-43b7-b15c-743f4f65e2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_4fdf71e5-99fa-43b7-b15c-743f4f65e2b4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_6f2ec054-170e-416f-bfaf-adfb3df6c1a3" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_6f2ec054-170e-416f-bfaf-adfb3df6c1a3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18701802-247c-4abe-a85a-0ea9b523d0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18701802-247c-4abe-a85a-0ea9b523d0fd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30e6e893-ebb5-43de-814c-1056c7a9abef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_NetIncomeLoss_30e6e893-ebb5-43de-814c-1056c7a9abef" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1128881-408c-419e-939d-d4391da53fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1128881-408c-419e-939d-d4391da53fd1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71885bb6-2264-4f2c-8510-35bcf0dd272d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_175ca358-8d57-446e-8518-68843eaca415" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14efa92e-580d-4cb3-9b6a-eec3d7139fd5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:to="loc_us-gaap_EquityComponentDomain_14efa92e-580d-4cb3-9b6a-eec3d7139fd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:to="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_cb2671d4-c1bc-440e-960b-77622de24132" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivablesFromPreferredStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_cb2671d4-c1bc-440e-960b-77622de24132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_20ea2163-55d5-4f96-a886-274abe71c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_CommonStockMember_20ea2163-55d5-4f96-a886-274abe71c98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_a8b5dc38-e2b2-4588-aca5-f5ae6cdbc1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_a8b5dc38-e2b2-4588-aca5-f5ae6cdbc1c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a33328c3-f8fc-4952-806d-ebeb220dae02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a33328c3-f8fc-4952-806d-ebeb220dae02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90ce590d-2939-4f08-8129-abcc70757da5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_RetainedEarningsMember_90ce590d-2939-4f08-8129-abcc70757da5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a5f67192-f7f6-4a69-9740-89fdb8fd8dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a5f67192-f7f6-4a69-9740-89fdb8fd8dd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8eb9aad3-5f1b-4916-81fc-b9557e7e2967_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:to="loc_us-gaap_ClassOfStockDomain_8eb9aad3-5f1b-4916-81fc-b9557e7e2967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:to="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0f26e04f-967f-40f6-9c26-6331279a63e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0f26e04f-967f-40f6-9c26-6331279a63e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dcb20c32-a917-4283-961f-1fc031a58770_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dcb20c32-a917-4283-961f-1fc031a58770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_c381a701-ee59-4c8f-b28b-3698a89cf30d" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_c381a701-ee59-4c8f-b28b-3698a89cf30d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_efed06a5-5131-4484-b638-edc263e14f48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:to="loc_us-gaap_IPOMember_efed06a5-5131-4484-b638-edc263e14f48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="i32a6464125a64218822091ee28a49a27_7b7c8e8b-8f8e-4369-bce1-d6fe0fbde577">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_753b3dd1-ddeb-432b-8572-075a00800752" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_753b3dd1-ddeb-432b-8572-075a00800752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d77141e5-08b2-4e98-9236-48d6087bf259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d77141e5-08b2-4e98-9236-48d6087bf259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:to="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8507be68-6132-4b59-b056-f2dbd4d42d9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:to="loc_us-gaap_ClassOfStockDomain_8507be68-6132-4b59-b056-f2dbd4d42d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:to="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f8948446-9cc5-435a-8836-9a913baafe51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f8948446-9cc5-435a-8836-9a913baafe51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4493c384-47eb-4d4e-847b-2e30c75bf14d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4493c384-47eb-4d4e-847b-2e30c75bf14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_e3478d1c-8e64-449d-a4a7-9977ec692c1c" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_e3478d1c-8e64-449d-a4a7-9977ec692c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_de44ab29-2f63-4baf-ba24-ecbca4d9d24d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:to="loc_us-gaap_IPOMember_de44ab29-2f63-4baf-ba24-ecbca4d9d24d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StatementsofCashFlows" xlink:type="extended" id="ie0ecf72c43054e1fb192475e096a41b6_bd8d19e5-a41b-446d-a180-6655dcf6e4e3"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i03b448e5456746508da0bb29ede2d578_3b4b040e-2d5a-4d91-8c30-2efd47ecfda9"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i6977b604fb864f2faf3e83ebbcaf5986_cbae31f2-5ed6-45a1-be15-8d5b15ab47a2"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i34ae2cc8cafb42adbff3a566712c257c_8e28cedc-8170-4d07-939a-70e73a89b768"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ia338abfde8764ee0b9adcc80b3c6076a_940c1995-dd17-43a2-9735-98afdcb6df3b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StartUpCost_15422257-8606-4ce0-83ae-f50c775fdc77" xlink:href="allo-20191231.xsd#allo_StartUpCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StartUpCost_15422257-8606-4ce0-83ae-f50c775fdc77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d257e2e6-8d1b-46ea-aadf-4859e10f72ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d257e2e6-8d1b-46ea-aadf-4859e10f72ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_651c3283-0763-412c-bef9-544b57d8bcc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_651c3283-0763-412c-bef9-544b57d8bcc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_fdac86af-7c4c-4ce9-8792-1a0108ae8018" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_fdac86af-7c4c-4ce9-8792-1a0108ae8018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_249235d0-a61b-4fb8-9f7b-4323e09e6df8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_249235d0-a61b-4fb8-9f7b-4323e09e6df8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0572d002-88d2-4c17-bc76-5f45708a58b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0572d002-88d2-4c17-bc76-5f45708a58b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27e997e3-b8bb-4563-a7d6-56a014b077f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27e997e3-b8bb-4563-a7d6-56a014b077f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7235c6d-eca0-4e41-855a-5934b2f976e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7235c6d-eca0-4e41-855a-5934b2f976e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7ba7203d-0163-44a6-808b-fe3024267eac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7ba7203d-0163-44a6-808b-fe3024267eac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumValue_f3f140e1-53fb-4724-a186-e5a9402dd82a" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StockIssuanceMaximumValue_f3f140e1-53fb-4724-a186-e5a9402dd82a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_3d1abf06-d7de-4d5e-aab8-d835d15d3416" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_3d1abf06-d7de-4d5e-aab8-d835d15d3416" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a7d5c9fd-846e-4b6c-b51a-55a6df42c543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a7d5c9fd-846e-4b6c-b51a-55a6df42c543" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_c7ecf313-0805-4523-819b-3d7c21430e49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_DeferredOfferingCosts_c7ecf313-0805-4523-819b-3d7c21430e49" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_c52785e8-9166-4064-a66b-c19980633bd1" xlink:href="allo-20191231.xsd#allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_c52785e8-9166-4064-a66b-c19980633bd1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_528df8b7-91ea-4333-814d-85582f318bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_528df8b7-91ea-4333-814d-85582f318bb1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_452faba0-ce2f-4cfc-863b-14ee2600bfab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_452faba0-ce2f-4cfc-863b-14ee2600bfab" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8169ff2-777e-4279-aa63-160c79aca229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8169ff2-777e-4279-aa63-160c79aca229" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f955c2f5-3683-4e85-9604-52ff807b4d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_NetIncomeLoss_f955c2f5-3683-4e85-9604-52ff807b4d9f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_93ed6fcb-852c-43d8-ae2f-041e7c6fc789" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_93ed6fcb-852c-43d8-ae2f-041e7c6fc789" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f942b881-d3f2-468e-9a1d-93b085593f31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f942b881-d3f2-468e-9a1d-93b085593f31" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62967415-3905-48a1-855a-d5c961912dcd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:to="loc_us-gaap_EquityComponentDomain_62967415-3905-48a1-855a-d5c961912dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:to="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_78152770-e851-4b69-8ca5-f8d5cb367ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:to="loc_us-gaap_CommonStockMember_78152770-e851-4b69-8ca5-f8d5cb367ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b13c77ac-2b86-434d-8a6e-996865094bf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b13c77ac-2b86-434d-8a6e-996865094bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_649fdf19-441b-49fc-94e2-160fc3682380" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:to="loc_us-gaap_IPOMember_649fdf19-441b-49fc-94e2-160fc3682380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_80aa3237-5b47-4074-8085-0e004061b179" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:to="loc_us-gaap_OverAllotmentOptionMember_80aa3237-5b47-4074-8085-0e004061b179" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="extended" id="iaca4d56c446d4134b75a033189a4a3a9_4b47120b-ef42-43aa-b500-ae7266b4cce7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16e5f2d4-9092-4856-9ede-054aac04ec6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16e5f2d4-9092-4856-9ede-054aac04ec6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fc86c56-7525-46ba-8d25-1706806afb68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fc86c56-7525-46ba-8d25-1706806afb68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_aaf2c537-9841-4d17-95d0-6158105e35e3" xlink:href="allo-20191231.xsd#allo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_allo_LaboratoryEquipmentMember_aaf2c537-9841-4d17-95d0-6158105e35e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_743d18a8-db78-4fb7-bd63-36aeb509759e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_us-gaap_ComputerEquipmentMember_743d18a8-db78-4fb7-bd63-36aeb509759e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_180db5ee-3f04-43bc-9b9d-d84b70ce9b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_180db5ee-3f04-43bc-9b9d-d84b70ce9b6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:to="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c485740-eb4d-446a-aa4d-457f77ad5790_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:to="loc_srt_RangeMember_0c485740-eb4d-446a-aa4d-457f77ad5790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:to="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_38ce2196-a414-46b3-8c93-915259fd14e6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:to="loc_srt_MinimumMember_38ce2196-a414-46b3-8c93-915259fd14e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9aa66b5-dc5a-4794-95b4-bbac7e5756a6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:to="loc_srt_MaximumMember_d9aa66b5-dc5a-4794-95b4-bbac7e5756a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/RecentAccountingGuidance" xlink:type="simple" xlink:href="allo-20191231.xsd#RecentAccountingGuidance"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RecentAccountingGuidance" xlink:type="extended" id="ic9220ede367a4f88b8e52ad26a53492c_2fff2914-86ed-44e6-97c0-721ae076f944"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended" id="ib5ab50d3d66549f89730e653bd121c7e_0d973b9c-592e-473b-b8a7-81dea268629a"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i36b238944d4041e89f9c9322c2e79111_d9b28ff9-8e6e-4672-8631-6c9305cf7a31"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="icacbfa0df43843efa003617e5bc7b308_bc101aa0-5410-46de-8df5-a047f3f23fe6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_852ba9b6-52f2-49a6-a4f1-27d22704cc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_852ba9b6-52f2-49a6-a4f1-27d22704cc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d043f70-2437-4949-8a74-52c736c824c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d043f70-2437-4949-8a74-52c736c824c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_009890b6-4bcd-4101-9c65-6617c6ac6dad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_009890b6-4bcd-4101-9c65-6617c6ac6dad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f12b8154-9023-463a-a989-af399cb1f436_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f12b8154-9023-463a-a989-af399cb1f436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_88f6a7f6-dd30-4958-938d-fb05d4a45a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_88f6a7f6-dd30-4958-938d-fb05d4a45a7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i92b6bc76393d4832b0786c88b5dc26f9_a3be34e1-aaa0-444a-a671-ff1094a24f11">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_224ec0fa-5480-4a1f-8463-2fefe0836808" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_224ec0fa-5480-4a1f-8463-2fefe0836808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_19ec192a-71e2-4a88-bd9f-6a72ebe4170d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_19ec192a-71e2-4a88-bd9f-6a72ebe4170d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1315ac63-0c46-451f-86df-5f9a73abb957" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1315ac63-0c46-451f-86df-5f9a73abb957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_878692d9-c713-402f-b472-f22bc732c6b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_878692d9-c713-402f-b472-f22bc732c6b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_da853a50-b4ae-46fa-a541-4282e3b22f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_da853a50-b4ae-46fa-a541-4282e3b22f6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_69c7c383-c6ed-43ee-b476-55ec0b846c73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_69c7c383-c6ed-43ee-b476-55ec0b846c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc4bb502-cb0d-4f33-b429-eec071825b05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc4bb502-cb0d-4f33-b429-eec071825b05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_297e827f-801f-4365-a60a-9d8d30786b36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_297e827f-801f-4365-a60a-9d8d30786b36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a3cc63e6-29d4-4d45-8beb-e03e5790edb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CommercialPaperMember_a3cc63e6-29d4-4d45-8beb-e03e5790edb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8878cab6-4a0b-4841-8e94-53dacb61e9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8878cab6-4a0b-4841-8e94-53dacb61e9d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4bcdd009-a5e7-41fb-8d54-fe883c4e701c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4bcdd009-a5e7-41fb-8d54-fe883c4e701c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9ef2ebc3-fb33-4efc-917b-7a993813a41c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9ef2ebc3-fb33-4efc-917b-7a993813a41c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_51be9ba4-4c74-466d-b228-b03f6a139eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_51be9ba4-4c74-466d-b228-b03f6a139eb3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/Investments" xlink:type="simple" xlink:href="allo-20191231.xsd#Investments"/>
  <link:definitionLink xlink:role="http://allogene.com/role/Investments" xlink:type="extended" id="i20731e34b69e4a04868bbe9171dbf6ec_007094a3-8e7e-4329-b07e-8fc9f1d8a7c6"/>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentTables" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/InvestmentTables" xlink:type="extended" id="i381f62e03f644d4fa092753e436b8550_5c5a73b8-7caf-4f44-8749-3489fe855056"/>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i14a36bc457e247149eb756e7dff12c82_faaeb5bd-1b58-4dcd-a74a-b6e98ff6cf7b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a45a631d-942c-400f-901c-021f34dc118a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a45a631d-942c-400f-901c-021f34dc118a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3febdb0f-37fc-4233-9c3d-cf8d51862212" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3febdb0f-37fc-4233-9c3d-cf8d51862212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9ada326-f07a-400c-bf67-9c7f8d122451" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9ada326-f07a-400c-bf67-9c7f8d122451" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aae75292-6071-4456-94a3-250a5481a321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aae75292-6071-4456-94a3-250a5481a321" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7da79cb2-4ccf-4e9f-937c-24a82da3092d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7da79cb2-4ccf-4e9f-937c-24a82da3092d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcdf981-875c-4fc6-b963-275ac6da3420" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcdf981-875c-4fc6-b963-275ac6da3420" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fde1ad14-f709-41f6-a2a1-6ab9b57e21af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fde1ad14-f709-41f6-a2a1-6ab9b57e21af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_c7b4a83a-7383-4c84-b8a2-ba9b9d9ecbf3" xlink:href="allo-20191231.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_c7b4a83a-7383-4c84-b8a2-ba9b9d9ecbf3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:to="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bd7bd1f7-1271-47a5-8f8e-70f0e83de556" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bd7bd1f7-1271-47a5-8f8e-70f0e83de556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_72fa6432-ca80-4f04-8765-bef43151686a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CommercialPaperMember_72fa6432-ca80-4f04-8765-bef43151686a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_110f07c5-14a1-46fa-b34f-83934f37b4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_110f07c5-14a1-46fa-b34f-83934f37b4b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ccaeb7ff-3400-4573-80f0-76ed27a6d7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ccaeb7ff-3400-4573-80f0-76ed27a6d7ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abadb3fe-01bb-4fb6-8d56-d31413a188f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abadb3fe-01bb-4fb6-8d56-d31413a188f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2d3c7e0b-4a41-4e28-a08d-27e44bfe4332" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2d3c7e0b-4a41-4e28-a08d-27e44bfe4332" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="extended" id="i9297a694e66d450eaa2a94b7883c7a8d_9183139b-9a20-4948-980d-461fd9838f1d"/>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="extended" id="i887eb50c14f744e3ab8b528a3ce54481_5956f066-01b0-4829-ac08-ac57636f864b"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended" id="if55745484f994629800ef1287e541b1e_9c63e799-a851-40ea-a41d-67cfe9044c07"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="idac0732869f14b22aaf54f8fbfb7db32_56e23d5b-a0a4-4346-9468-22c26bcc8416"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i613261a553464776992efe1fd47766b5_ffa26658-fe45-4403-885e-9c47fab8bb06"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="iac75dd4e436e4b4fbfb0f320bc9a3c47_66cd47bb-ecf7-4a37-9572-64e49c26d6e1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_80c38046-ef41-41e4-a4b7-5a848f891886" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_80c38046-ef41-41e4-a4b7-5a848f891886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae472426-57bd-4e9c-a16a-e485dec7b5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae472426-57bd-4e9c-a16a-e485dec7b5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b74a4e69-e018-4e74-a555-51742585cf49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b74a4e69-e018-4e74-a555-51742585cf49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_906aadc3-148d-48c0-8c65-f24abd7e3120_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_906aadc3-148d-48c0-8c65-f24abd7e3120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_a84a57d6-00d7-490a-8a42-5baac4029a8a" xlink:href="allo-20191231.xsd#allo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_allo_LaboratoryEquipmentMember_a84a57d6-00d7-490a-8a42-5baac4029a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_db55ba52-a9f0-4ebb-b689-1d9c434c0bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_db55ba52-a9f0-4ebb-b689-1d9c434c0bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_db175ab7-094d-4f97-ade3-0c29dc14d777" xlink:href="allo-20191231.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_db175ab7-094d-4f97-ade3-0c29dc14d777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0719a24b-f0f7-41f2-8477-3500d5067b64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0719a24b-f0f7-41f2-8477-3500d5067b64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae3090fc-0ceb-4f7c-a4f8-31398a9ee5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae3090fc-0ceb-4f7c-a4f8-31398a9ee5f7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" id="i8080552c5dd94256b0c90bf769e752af_96f4611b-991a-4f9c-9279-90142175ffd7">
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89476707-6230-4bce-8283-1f011f7304ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89476707-6230-4bce-8283-1f011f7304ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_77977cc7-9405-4200-bbb4-e904cc98b6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_77977cc7-9405-4200-bbb4-e904cc98b6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2d56a939-af5c-43b7-9051-4a3e096515a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2d56a939-af5c-43b7-9051-4a3e096515a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eb5a5a3e-9564-4396-9d9c-fddd0213a989" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eb5a5a3e-9564-4396-9d9c-fddd0213a989" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68d8f839-a982-49af-b549-c33f7caa3e7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68d8f839-a982-49af-b549-c33f7caa3e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_c7b2f039-04c2-4f96-910d-54c62613a9ef" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:to="loc_allo_AssembledWorkforceMember_c7b2f039-04c2-4f96-910d-54c62613a9ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i367ca3d7e89c42e293cd1d79a4720ac5_bc04fc82-a421-46fc-8fb4-437fae5b3ac4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b82202fa-9f2f-4f7e-96cb-95d236e90c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b82202fa-9f2f-4f7e-96cb-95d236e90c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_390f98c2-95c3-4ed9-b9bd-9dc132f2dcce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_390f98c2-95c3-4ed9-b9bd-9dc132f2dcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f1c155c-f598-44f3-b568-225925c2eee0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f1c155c-f598-44f3-b568-225925c2eee0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_a889273d-d998-48d8-8bed-f9aa4c419bd5" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:to="loc_allo_AssembledWorkforceMember_a889273d-d998-48d8-8bed-f9aa4c419bd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended" id="i6740441d840f411682fd58bdeda57886_90302567-c1e4-4860-bc9c-3ef8c1ee83e5"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisition" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisition"/>
  <link:definitionLink xlink:role="http://allogene.com/role/AssetAcquisition" xlink:type="extended" id="i17748cbd49064edf97879306365e001a_4f151d1e-3447-4606-bbac-2587158314aa"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionTables" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/AssetAcquisitionTables" xlink:type="extended" id="iabbfa45e57994a31b38578ca7f9517f2_91226fb6-8c4b-403d-b560-43126a477b67"/>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="extended" id="ie970d43719f348b385a1db62bfdcf4cb_87af49cc-8f9c-410c-b5c0-d8c8a36d1c52">
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_66721c97-0458-4d13-a387-55f9bae80526" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_66721c97-0458-4d13-a387-55f9bae80526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_fd1a8625-82be-41a6-9e6b-82a4d08650f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_fd1a8625-82be-41a6-9e6b-82a4d08650f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9f9068f5-a0bc-4b6d-bad5-d30b9caa1f88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9f9068f5-a0bc-4b6d-bad5-d30b9caa1f88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_4b0ab22c-b87d-4228-85da-ee34f21e47f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_4b0ab22c-b87d-4228-85da-ee34f21e47f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f0f0187b-1acb-4f1a-a14c-53bb95acadba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f0f0187b-1acb-4f1a-a14c-53bb95acadba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DiscountRateForValuation_cb53f600-137b-4825-9176-f4d84a27d3d1" xlink:href="allo-20191231.xsd#allo_DiscountRateForValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_DiscountRateForValuation_cb53f600-137b-4825-9176-f4d84a27d3d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_03daebb0-f20b-439e-ac29-551886ada117" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_03daebb0-f20b-439e-ac29-551886ada117" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_2c94df45-5a2d-481f-a64a-f031692bde7e" xlink:href="allo-20191231.xsd#allo_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_MilestonePayments_2c94df45-5a2d-481f-a64a-f031692bde7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregateMilestonePayments_4486e41c-8014-4c7b-b015-810cd8aa7804" xlink:href="allo-20191231.xsd#allo_AggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_AggregateMilestonePayments_4486e41c-8014-4c7b-b015-810cd8aa7804" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_536e2537-c5e2-4965-9084-d6d95627db2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:to="loc_us-gaap_ClassOfStockDomain_536e2537-c5e2-4965-9084-d6d95627db2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:to="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_00cf34a1-3c3b-4ba3-be9b-68067299fd2e" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_00cf34a1-3c3b-4ba3-be9b-68067299fd2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:to="loc_us-gaap_RelatedPartyDomain_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:to="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_c6c0b37d-e694-4f45-ba71-5057d40ecb81" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:to="loc_allo_PfizerIncMember_c6c0b37d-e694-4f45-ba71-5057d40ecb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2811e81-80dc-4d69-9ab7-e601cf632099_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2811e81-80dc-4d69-9ab7-e601cf632099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_1021dd04-16a2-47c3-bb92-2419c6664a76" xlink:href="allo-20191231.xsd#allo_AssetContributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:to="loc_allo_AssetContributionAgreementMember_1021dd04-16a2-47c3-bb92-2419c6664a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c8a367c-9c73-46e7-b6b5-133978274199_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:to="loc_srt_SegmentGeographicalDomain_8c8a367c-9c73-46e7-b6b5-133978274199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:to="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_85c14cb6-8df1-42cc-b525-a38369cd75f4" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:to="loc_country_US_85c14cb6-8df1-42cc-b525-a38369cd75f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_fad85498-3bc3-4b52-a652-45e46ca49f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:to="loc_us-gaap_EuropeanUnionMember_fad85498-3bc3-4b52-a652-45e46ca49f4d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="extended" id="id8470a2a0e864883b60be635ca63ea7a_72131489-8984-4a10-b30f-78ab135ce25d">
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a24d7526-cd4f-4515-9548-8458749ec7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a24d7526-cd4f-4515-9548-8458749ec7d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3e2dcfd9-ab25-4468-aed3-d05562f3eff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3e2dcfd9-ab25-4468-aed3-d05562f3eff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:to="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_31b4f595-ccc2-4eaf-8609-a13d465cb7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_31b4f595-ccc2-4eaf-8609-a13d465cb7d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f29698fa-ecd8-466c-b56c-2f6b521885ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f29698fa-ecd8-466c-b56c-2f6b521885ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiCDNineteenCARTCellTherapyMember_64de05d9-72eb-47e5-b7f2-9b4ad9a75cd5" xlink:href="allo-20191231.xsd#allo_AntiCDNineteenCARTCellTherapyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AntiCDNineteenCARTCellTherapyMember_64de05d9-72eb-47e5-b7f2-9b4ad9a75cd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiBCMACARTCellTherapyMember_892a9289-93a1-4547-a533-21638db7d7f1" xlink:href="allo-20191231.xsd#allo_AntiBCMACARTCellTherapyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AntiBCMACARTCellTherapyMember_892a9289-93a1-4547-a533-21638db7d7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_cf7fae3a-a299-4c6d-8750-699d76e2cb8b" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AssembledWorkforceMember_cf7fae3a-a299-4c6d-8750-699d76e2cb8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i5a02cfd1d5434dc3857053757df90d16_504e9326-ef52-4db7-bb9d-8d38843ff1c2"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended" id="ifde7706124ef45b6adf0673e35c3921f_97a92287-5c0e-4f1c-8ec3-8d8c659b2699">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_a106e91e-85d5-4171-8100-43c39ef650d0" xlink:href="allo-20191231.xsd#allo_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_MilestonePayments_a106e91e-85d5-4171-8100-43c39ef650d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_63f079da-83a6-4984-9fc2-ff87402ab551" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AggregatePotentialMilestonePayments_63f079da-83a6-4984-9fc2-ff87402ab551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_e286d951-6eb2-4ede-902d-13ec5bbcccc2" xlink:href="allo-20191231.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_e286d951-6eb2-4ede-902d-13ec5bbcccc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9176e589-09bf-48ed-8f7e-1b7dbdcabc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9176e589-09bf-48ed-8f7e-1b7dbdcabc3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostResponsibleFor_7edd0201-3ffb-4d99-b4fa-5d56b148bfb8" xlink:href="allo-20191231.xsd#allo_PercentageOfDevelopmentCostResponsibleFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_PercentageOfDevelopmentCostResponsibleFor_7edd0201-3ffb-4d99-b4fa-5d56b148bfb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_a2ef4175-0387-4342-bf7d-2d6333897fc0" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AggregatePotentialMilestonePayable_a2ef4175-0387-4342-bf7d-2d6333897fc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_4582bf83-6ef6-4a59-8647-61f865c65530" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_4582bf83-6ef6-4a59-8647-61f865c65530" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_03c1bbe0-c304-4bf4-892b-fb4b85205e6d" xlink:href="allo-20191231.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_03c1bbe0-c304-4bf4-892b-fb4b85205e6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4170b530-a4ac-4e83-b1a2-124956c0d1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4170b530-a4ac-4e83-b1a2-124956c0d1d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d61351-cd38-41f4-abdd-4e74e882a8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d61351-cd38-41f4-abdd-4e74e882a8bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_442697c5-ad47-4dc5-a624-a2fbec542d98_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_442697c5-ad47-4dc5-a624-a2fbec542d98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_b7e933f8-0db2-4758-b69b-b6aa520c8f29" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:to="loc_allo_NotchTherapeuticsIncMember_b7e933f8-0db2-4758-b69b-b6aa520c8f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b8228b9b-096d-49b8-95b2-4a273c50aed5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:to="loc_us-gaap_RelatedPartyDomain_b8228b9b-096d-49b8-95b2-4a273c50aed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:to="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_6ed727ba-f1a2-416c-9ebf-00914da18572" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_PfizerIncMember_6ed727ba-f1a2-416c-9ebf-00914da18572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_02a10d71-cbc2-4014-b329-bc1b42292cb7" xlink:href="allo-20191231.xsd#allo_CellectisSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_CellectisSAMember_02a10d71-cbc2-4014-b329-bc1b42292cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_f764183e-98a4-41e5-b43c-e86e27700f2e" xlink:href="allo-20191231.xsd#allo_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_ServierMember_f764183e-98a4-41e5-b43c-e86e27700f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_f302ce39-7248-4e1a-a3b2-8635a46c3081" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_NotchTherapeuticsIncMember_f302ce39-7248-4e1a-a3b2-8635a46c3081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_29e735c5-72c3-4342-96ba-45dc15908aa5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_29e735c5-72c3-4342-96ba-45dc15908aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_e7d4560a-d587-4b59-968a-a2ba628f69e3" xlink:href="allo-20191231.xsd#allo_AssetContributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_AssetContributionAgreementMember_e7d4560a-d587-4b59-968a-a2ba628f69e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_1e28c5b8-0216-4687-9e2a-cddb18f0bf27" xlink:href="allo-20191231.xsd#allo_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_RegulatoryMilestoneMember_1e28c5b8-0216-4687-9e2a-cddb18f0bf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_0dc543cc-34de-4a21-bb5e-8c68129ac7cd" xlink:href="allo-20191231.xsd#allo_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_SalesMilestoneMember_0dc543cc-34de-4a21-bb5e-8c68129ac7cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryAndSalesMilestoneMember_73d272c5-ec49-4e0a-b335-ad6b4a473843" xlink:href="allo-20191231.xsd#allo_RegulatoryAndSalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_RegulatoryAndSalesMilestoneMember_73d272c5-ec49-4e0a-b335-ad6b4a473843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_e1697cc9-ac71-4f0a-a08b-ab24f8aeef5b" xlink:href="allo-20191231.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_e1697cc9-ac71-4f0a-a08b-ab24f8aeef5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_98123db4-b13f-4364-be50-1250be690a61" xlink:href="allo-20191231.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_98123db4-b13f-4364-be50-1250be690a61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:to="loc_srt_RangeMember_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:to="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79dcd9d3-fd64-4cc1-af2f-e7e1b582b526" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:to="loc_srt_MaximumMember_79dcd9d3-fd64-4cc1-af2f-e7e1b582b526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f2765e4-6261-4cd4-a26e-e512465d8ec4_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:to="loc_srt_SegmentGeographicalDomain_8f2765e4-6261-4cd4-a26e-e512465d8ec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:to="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9cb8085-4302-4255-80ec-cb4d9bb9acb0" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_country_US_a9cb8085-4302-4255-80ec-cb4d9bb9acb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_98195597-548e-49bf-a1a8-61b6f2029a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_us-gaap_EuropeanUnionMember_98195597-548e-49bf-a1a8-61b6f2029a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_2ab6c9d9-28f4-4976-9986-ef578a3e1c48" xlink:href="allo-20191231.xsd#allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_2ab6c9d9-28f4-4976-9986-ef578a3e1c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f17d714b-6152-44bd-b28d-f8c08ae27373_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f17d714b-6152-44bd-b28d-f8c08ae27373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_97f80c80-0ea7-4e19-baff-a58c10c75073" xlink:href="allo-20191231.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_97f80c80-0ea7-4e19-baff-a58c10c75073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_2ea2d929-de76-4ca8-aab8-498ffaf6a825" xlink:href="allo-20191231.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_2ea2d929-de76-4ca8-aab8-498ffaf6a825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalDevelopmentMilestoneMember_f957d15f-ba4d-4072-9690-6ebf215db907" xlink:href="allo-20191231.xsd#allo_ClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_ClinicalDevelopmentMilestoneMember_f957d15f-ba4d-4072-9690-6ebf215db907" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:type="simple" xlink:href="allo-20191231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended" id="i0f91806d1a094c82a266900dd0a97332_df0b0e52-971a-4e4e-8296-7a1e6d53f033"/>
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended" id="ib547d4fbc044444581b868d47ecd58b8_85ce71b7-03b9-4f42-a820-e1b2ffbd8ed0"/>
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="icc247024dfdb4ac28ad046b5cb16cbe6_b0eee5c9-6f35-4604-9e81-15480ae632c6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_dcc3a9d0-0d7f-418f-8d84-347a40febc4f" xlink:href="allo-20191231.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_AreaOfNewOfficeBuilding_dcc3a9d0-0d7f-418f-8d84-347a40febc4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd974311-947f-4cf0-9be7-156b43d1abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd974311-947f-4cf0-9be7-156b43d1abd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseOptionToExtendNumber_26ede094-e58a-4ca9-87d3-85b92f751ae3" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseOptionToExtendNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_LesseeOperatingLeaseOptionToExtendNumber_26ede094-e58a-4ca9-87d3-85b92f751ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_660362ed-0803-412f-9906-aa5f39051c72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_660362ed-0803-412f-9906-aa5f39051c72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_6b28f155-7f84-462e-838a-5ededf76e556" xlink:href="allo-20191231.xsd#allo_AllowanceForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_AllowanceForTenantImprovements_6b28f155-7f84-462e-838a-5ededf76e556" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7de97945-4264-4e0f-adae-1f736699a227" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7de97945-4264-4e0f-adae-1f736699a227" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_debd7c18-8666-4df2-aca5-85ec6d770772" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_debd7c18-8666-4df2-aca5-85ec6d770772" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc0db1b6-5c13-4101-b813-469e56ea03b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc0db1b6-5c13-4101-b813-469e56ea03b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9fd42c1d-471a-4c66-a666-8257d74099ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9fd42c1d-471a-4c66-a666-8257d74099ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_fc68b17f-630e-4095-a1fc-ad07c81599fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_fc68b17f-630e-4095-a1fc-ad07c81599fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeasesNumberOfLeaseAgreements_9c5c6d9c-698b-402d-abd5-0b46ac8bd38e" xlink:href="allo-20191231.xsd#allo_OperatingLeasesNumberOfLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_OperatingLeasesNumberOfLeaseAgreements_9c5c6d9c-698b-402d-abd5-0b46ac8bd38e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9b46e05d-c431-4301-a2d9-df7c537fa060" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9b46e05d-c431-4301-a2d9-df7c537fa060" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShorttermLeaseRentExpense_d1acdf38-5256-425b-a1db-dae5707d7d03" xlink:href="allo-20191231.xsd#allo_ShorttermLeaseRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_ShorttermLeaseRentExpense_d1acdf38-5256-425b-a1db-dae5707d7d03" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_b1f0a5f9-877f-4c9d-9d2e-1178ec32ba5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_b1f0a5f9-877f-4c9d-9d2e-1178ec32ba5c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment_9e46ef4d-f402-404f-9251-7633189bbe92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_VariableLeasePayment_9e46ef4d-f402-404f-9251-7633189bbe92" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeaseAssetRetirementObligation_f449c4f2-21d5-4846-b1cb-8ff74c7ccbf8" xlink:href="allo-20191231.xsd#allo_OperatingLeaseAssetRetirementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_OperatingLeaseAssetRetirementObligation_f449c4f2-21d5-4846-b1cb-8ff74c7ccbf8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_25462aad-9840-4948-882a-ca914f1f065e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_25462aad-9840-4948-882a-ca914f1f065e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember_6a080182-6451-41e7-a23a-19b45a4702a4" xlink:href="allo-20191231.xsd#allo_LeaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:to="loc_allo_LeaseOneMember_6a080182-6451-41e7-a23a-19b45a4702a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_e1fd254f-d468-4dbb-b264-27dc81e3b24d" xlink:href="allo-20191231.xsd#allo_LeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:to="loc_allo_LeaseTwoMember_e1fd254f-d468-4dbb-b264-27dc81e3b24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:to="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e4466271-986a-4ed3-a01a-adbda35e18f8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:to="loc_srt_SegmentGeographicalDomain_e4466271-986a-4ed3-a01a-adbda35e18f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:to="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_801cb3bf-6815-4795-a279-8e844bcfac5b" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_stpr_NY_801cb3bf-6815-4795-a279-8e844bcfac5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LosAngelesMember_11146c0c-e6a3-4de9-8c67-d028413ed46c" xlink:href="allo-20191231.xsd#allo_LosAngelesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_allo_LosAngelesMember_11146c0c-e6a3-4de9-8c67-d028413ed46c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_dc970d58-c9c6-4ef9-8181-0bf23742769a" xlink:href="allo-20191231.xsd#allo_NewarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_allo_NewarkMember_dc970d58-c9c6-4ef9-8181-0bf23742769a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="extended" id="if54b0b0ca5eb4507b4972c44a594938e_69c60838-0091-4024-85ca-76746c712068"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestment"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended" id="ic25c223f673f44f2bcc8d758a144756c_48a3aeb2-0f74-4418-9ad2-3bd5f14f2589"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended" id="iac1e0d3e891f4986940bb6b26a0c92ec_6ff2ab23-947f-4ead-aeba-9af5f63fd295">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_9451b4a3-3f51-4ede-8a8a-93ae0637070b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_9451b4a3-3f51-4ede-8a8a-93ae0637070b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_d041f944-442a-4cba-9b73-647d2c73c1c0" xlink:href="allo-20191231.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_d041f944-442a-4cba-9b73-647d2c73c1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e3ce22ec-88d2-4c0b-85a2-cc5fe9b2d5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e3ce22ec-88d2-4c0b-85a2-cc5fe9b2d5e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dc3677d0-f623-4b1e-b14c-c470d86eda58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dc3677d0-f623-4b1e-b14c-c470d86eda58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_0407a5c1-e5ce-483f-b09c-ac5fc8a5574e" xlink:href="allo-20191231.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_0407a5c1-e5ce-483f-b09c-ac5fc8a5574e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_182481f6-75b5-4f0d-9451-e3e64bccfd83_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_182481f6-75b5-4f0d-9451-e3e64bccfd83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_d991ee0a-ad39-4137-87cd-095505a52fc5" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:to="loc_allo_NotchTherapeuticsIncMember_d991ee0a-ad39-4137-87cd-095505a52fc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20191231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended" id="i4e984f2559fa4c5fb13358bf81970a92_5f096ca2-ca90-4cc3-9a12-0b16a08d1354"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018Notes"/>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="extended" id="i5769fe014c0841c388f69c07f815b2a9_a56bddb5-cf05-4a0a-886a-58f92b2f1962"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018NotesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended" id="i607fe47c09cc4a20b7ef4177a742d2dc_7fbe2adc-185b-489b-8f6f-339a30ed3af1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f355639a-aa28-4416-8568-9c792eeeca99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f355639a-aa28-4416-8568-9c792eeeca99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_2f8b1989-8918-48f3-8dfa-ec1a56824abe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_2f8b1989-8918-48f3-8dfa-ec1a56824abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5460f50c-d527-4de3-9d08-b2f96c572915" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_LongTermDebtFairValue_5460f50c-d527-4de3-9d08-b2f96c572915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_91810142-208b-4bde-b585-057ada359713" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_91810142-208b-4bde-b585-057ada359713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_05d44361-1d27-4c9b-a486-a4675386e038" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_05d44361-1d27-4c9b-a486-a4675386e038" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_f38920b7-33dc-4204-aac8-21b0519302fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_f38920b7-33dc-4204-aac8-21b0519302fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_57f8d8a3-1e21-4e72-9a4d-df414b6c4541" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_57f8d8a3-1e21-4e72-9a4d-df414b6c4541" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cfbadd1-cd6f-46b4-9891-634b170a2b38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cfbadd1-cd6f-46b4-9891-634b170a2b38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_3cbad27e-6b27-438c-b9e4-b11b506efcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:to="loc_us-gaap_IPOMember_3cbad27e-6b27-438c-b9e4-b11b506efcf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended" id="i61bf1bcd46084e68ac3b855a7e1b2dd3_a3452e21-b69d-4e35-923a-1a751aedd5ab"/>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersDeficitDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="extended" id="i91e519b9160344e1b55f1b12ded24cff_f5f81ee6-0b21-43de-ab71-ba7a71edfcba">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ffedfb5e-abae-4ef8-bb01-fed838c3f4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ffedfb5e-abae-4ef8-bb01-fed838c3f4b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_6e9bc467-6b43-4c00-a96d-bb5a4ae3d455" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_6e9bc467-6b43-4c00-a96d-bb5a4ae3d455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_748a0094-bb3c-41fc-8f37-54bc6d116895" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_748a0094-bb3c-41fc-8f37-54bc6d116895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_930864cf-679b-4029-8ff1-a7775cfafb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_930864cf-679b-4029-8ff1-a7775cfafb3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePurchasePriceSharesValue_0d65b3a4-6966-41ea-815b-061eda792215" xlink:href="allo-20191231.xsd#allo_AggregatePurchasePriceSharesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_allo_AggregatePurchasePriceSharesValue_0d65b3a4-6966-41ea-815b-061eda792215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_635bc50c-2b09-441b-9b32-d416f48d5a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_635bc50c-2b09-441b-9b32-d416f48d5a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_744d1060-6e55-410e-82e5-8bfef7b038bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_744d1060-6e55-410e-82e5-8bfef7b038bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12af3785-1e39-405f-8664-954ca725f856" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12af3785-1e39-405f-8664-954ca725f856" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9c8751c0-1e70-40c5-accb-99d6071519b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9c8751c0-1e70-40c5-accb-99d6071519b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3c777ed-5ed4-4c07-b47a-7515bbdd52dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d3c777ed-5ed4-4c07-b47a-7515bbdd52dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_51f4a984-5a4c-424e-91fd-41f1adce41b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_51f4a984-5a4c-424e-91fd-41f1adce41b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e5e64d8f-22ed-47b0-a304-26eb780de061" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesIssued_e5e64d8f-22ed-47b0-a304-26eb780de061" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ef3ef0a-2e95-4f05-a2a4-e6ace6aa480b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ef3ef0a-2e95-4f05-a2a4-e6ace6aa480b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock_2b1fcf70-3149-49be-9d74-f65422af2096" xlink:href="allo-20191231.xsd#allo_ModificationOfConvertiblePreferredStockForCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock_2b1fcf70-3149-49be-9d74-f65422af2096" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_d4bd9c91-ad3c-4fb9-b291-4481c1f2ef80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_d4bd9c91-ad3c-4fb9-b291-4481c1f2ef80" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54930f5d-38fa-429e-b2bd-9ab0882c4721" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54930f5d-38fa-429e-b2bd-9ab0882c4721" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_182cc866-adda-4465-8192-6b8143ea98e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_182cc866-adda-4465-8192-6b8143ea98e4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0d81856-78fb-456e-a57e-7f8190381087_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:to="loc_us-gaap_ClassOfStockDomain_b0d81856-78fb-456e-a57e-7f8190381087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:to="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_f9d13489-cac3-4ab9-b62e-4567d90e0e54" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_f9d13489-cac3-4ab9-b62e-4567d90e0e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesAConvertiblePreferredSharesMember_a829cb09-bf30-404a-bf05-83ae7472efe4" xlink:href="allo-20191231.xsd#allo_SeriesAConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:to="loc_allo_SeriesAConvertiblePreferredSharesMember_a829cb09-bf30-404a-bf05-83ae7472efe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2270d4c-6043-4399-b300-69622deed09f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:to="loc_us-gaap_EquityComponentDomain_f2270d4c-6043-4399-b300-69622deed09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:to="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_58ee3653-be3b-4d94-98cb-8772537df0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:to="loc_us-gaap_CommonStockMember_58ee3653-be3b-4d94-98cb-8772537df0f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac1974ff-132a-4c2a-9f35-1a866fd58f2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac1974ff-132a-4c2a-9f35-1a866fd58f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9564982e-36e3-4c37-8412-a655b9030e37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:to="loc_us-gaap_IPOMember_9564982e-36e3-4c37-8412-a655b9030e37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended" id="iaadaba02d958414ab6016fb171c59877_a5cb5845-b236-48e8-b726-bbc2a090f1ff"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended" id="ib3d85b3b4ce743449718f915f2d95136_c6152440-2bad-42df-8239-74fe11d85717"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="icafa258959dc4d6db6be5b72a82670ce_3a0e3312-412e-4005-b449-6a0b8cfb9fba">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_3c4ec717-7ce1-4563-adaf-1ce1cade5e7d" xlink:href="allo-20191231.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_3c4ec717-7ce1-4563-adaf-1ce1cade5e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_810c6ee6-bf91-474a-8610-355733eb8e6d" xlink:href="allo-20191231.xsd#allo_StockOptionGrantedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_StockOptionGrantedPeriod_810c6ee6-bf91-474a-8610-355733eb8e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6ce62de4-fdcf-448d-a628-8bcf0091d26b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6ce62de4-fdcf-448d-a628-8bcf0091d26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_89d68d82-d435-42e3-b4f1-812d50589d3f" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_89d68d82-d435-42e3-b4f1-812d50589d3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CombinedVotingPowerByIndividual_3bdbd502-0812-4e66-8267-b2c252d98dc7" xlink:href="allo-20191231.xsd#allo_CombinedVotingPowerByIndividual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_CombinedVotingPowerByIndividual_3bdbd502-0812-4e66-8267-b2c252d98dc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_51bb04d8-c61f-410d-8314-36d86796c8e7" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_51bb04d8-c61f-410d-8314-36d86796c8e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ef6f9e67-843f-442c-bc62-7c38cabd2158" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ef6f9e67-843f-442c-bc62-7c38cabd2158" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108d0054-4a3d-4d4a-802a-694aadbb5d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108d0054-4a3d-4d4a-802a-694aadbb5d1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6888b577-8454-4a1d-9484-576c99709043" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6888b577-8454-4a1d-9484-576c99709043" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7e99f80-ab99-49f4-bb40-eef94c2a81af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7e99f80-ab99-49f4-bb40-eef94c2a81af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_21416a98-e620-445b-af97-906cbe07dab0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_21416a98-e620-445b-af97-906cbe07dab0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3114dffb-c8c0-4ee5-a7fb-21a2deef9534" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3114dffb-c8c0-4ee5-a7fb-21a2deef9534" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_InitiallyReservedCommonStockForEmployeePurchase_40e501e4-003b-4e63-b12c-36a4f0fff9db" xlink:href="allo-20191231.xsd#allo_InitiallyReservedCommonStockForEmployeePurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_InitiallyReservedCommonStockForEmployeePurchase_40e501e4-003b-4e63-b12c-36a4f0fff9db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentOfferingPeriod_03516932-7d79-459f-805b-d5b73c79a549" xlink:href="allo-20191231.xsd#allo_CurrentOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_CurrentOfferingPeriod_03516932-7d79-459f-805b-d5b73c79a549" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_066cf418-b1dd-4601-ace2-ce0703ec9cae" xlink:href="allo-20191231.xsd#allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_066cf418-b1dd-4601-ace2-ce0703ec9cae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfEligibleCompensationContributionByEmployee_4a192187-fd46-4196-b4ec-3397369aa3c0" xlink:href="allo-20191231.xsd#allo_PercentageOfEligibleCompensationContributionByEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_PercentageOfEligibleCompensationContributionByEmployee_4a192187-fd46-4196-b4ec-3397369aa3c0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_91a020f5-8682-4f32-9a20-ff78e5e5bc76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_91a020f5-8682-4f32-9a20-ff78e5e5bc76" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90da640a-07b5-4033-889d-08708d06ff34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66b3e5c7-edcf-4195-bb45-57a50d8c16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66b3e5c7-edcf-4195-bb45-57a50d8c16c7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60f8983f-01fb-43e2-8d03-12ae0371e627" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60f8983f-01fb-43e2-8d03-12ae0371e627" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_e53eefcd-8878-49e7-a965-6bc4b4c4be4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_e53eefcd-8878-49e7-a965-6bc4b4c4be4f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_77f1f5a3-54c7-48ff-a39e-26ffb27544a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_77f1f5a3-54c7-48ff-a39e-26ffb27544a4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_698a378d-d7e5-48dd-bf05-683d99bd5ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_698a378d-d7e5-48dd-bf05-683d99bd5ae5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97fc2535-0653-492e-b3e0-e1add5443f5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97fc2535-0653-492e-b3e0-e1add5443f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_b024742c-bf62-4e93-bf26-fe37fac7afa8" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenPlanMember_b024742c-bf62-4e93-bf26-fe37fac7afa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f6f8f97-a77d-4368-b5b0-59d22c332f21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f6f8f97-a77d-4368-b5b0-59d22c332f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_933dd662-6dc8-442c-8169-159551ed5a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_933dd662-6dc8-442c-8169-159551ed5a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_a2afc942-db8c-47a9-98e7-c81953f23a9d" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_a2afc942-db8c-47a9-98e7-c81953f23a9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_59701eec-9dba-4f6b-ac65-4040aa8d8149" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_59701eec-9dba-4f6b-ac65-4040aa8d8149" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersStockAwardMember_0a42ed26-7c59-48ae-bc42-c491c73f33ad" xlink:href="allo-20191231.xsd#allo_FoundersStockAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_FoundersStockAwardMember_0a42ed26-7c59-48ae-bc42-c491c73f33ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExercisedStockOptionsMember_a24dd8f4-dca8-4ef6-92fb-c4ad767dfb95" xlink:href="allo-20191231.xsd#allo_EarlyExercisedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_EarlyExercisedStockOptionsMember_a24dd8f4-dca8-4ef6-92fb-c4ad767dfb95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8175622c-6dfb-4d16-b5a9-545dc0e1464d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:to="loc_srt_RangeMember_8175622c-6dfb-4d16-b5a9-545dc0e1464d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:to="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_113c87a2-bbea-4157-a2b1-0aede6532ebc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:to="loc_srt_MinimumMember_113c87a2-bbea-4157-a2b1-0aede6532ebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfbedc04-9268-432c-98af-7b4bdf85d0a2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:to="loc_srt_MaximumMember_bfbedc04-9268-432c-98af-7b4bdf85d0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_78925e5c-a21a-46a8-b860-2b152bbbb0d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_78925e5c-a21a-46a8-b860-2b152bbbb0d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersMember_d1f5c5b6-edb1-4b9e-8656-9f2de44b1e40" xlink:href="allo-20191231.xsd#allo_FoundersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:to="loc_allo_FoundersMember_d1f5c5b6-edb1-4b9e-8656-9f2de44b1e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExecutiveOfficerMember_f9d0890e-c9c9-4999-8041-fdd07a106d71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:to="loc_us-gaap_ExecutiveOfficerMember_f9d0890e-c9c9-4999-8041-fdd07a106d71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="extended" id="i148f668f498e482caf0e9fdeb8d20717_2ac60cc2-95cd-4352-a86d-a4febdfeca63">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b64df32-e46f-46a4-8b55-0b273ed3c3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b64df32-e46f-46a4-8b55-0b273ed3c3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_df6176c9-6c74-43dd-b397-8ea8b9cfcdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_df6176c9-6c74-43dd-b397-8ea8b9cfcdb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d7b130-fc0d-4189-b80e-040d97ed1c15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d7b130-fc0d-4189-b80e-040d97ed1c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7a63b8a4-889e-4acd-b974-0afb94119c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7a63b8a4-889e-4acd-b974-0afb94119c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8dbd8e69-c46b-49cc-b101-d444017322a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_94394fab-5e36-4686-b0ee-4de43e0d22c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_94394fab-5e36-4686-b0ee-4de43e0d22c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3e72a313-1d5a-431e-8e6a-4c64dc0efe23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3e72a313-1d5a-431e-8e6a-4c64dc0efe23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0688873-642d-4b98-8f0e-b4335f664b56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0688873-642d-4b98-8f0e-b4335f664b56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f99adb09-52ac-42c8-b422-6e64e9c5a886" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f99adb09-52ac-42c8-b422-6e64e9c5a886" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36bf33cb-e818-4419-87bd-64e47ae5662c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36bf33cb-e818-4419-87bd-64e47ae5662c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0c396d01-43bc-4112-93c9-a2b07b700a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0c396d01-43bc-4112-93c9-a2b07b700a07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e5d2c54-abe0-4c74-aa13-432a821d5442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88c72325-32c8-4c7f-ab37-5af4c7c44660" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88c72325-32c8-4c7f-ab37-5af4c7c44660" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2372ab00-8641-4427-b3a0-1cc9d39cb468" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2372ab00-8641-4427-b3a0-1cc9d39cb468" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_68e543e9-13ce-451d-8843-ce1c5553357a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_68e543e9-13ce-451d-8843-ce1c5553357a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0ed853b0-9ee8-4c46-b479-eeacc3b6568e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0ed853b0-9ee8-4c46-b479-eeacc3b6568e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd00fba5-8bf5-4e5c-8007-758d73296a37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd00fba5-8bf5-4e5c-8007-758d73296a37" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a620cd1-a37e-4d93-b430-d086c9b07d34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a620cd1-a37e-4d93-b430-d086c9b07d34" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25a4a48c-8f94-486e-93ed-f1c329d79c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25a4a48c-8f94-486e-93ed-f1c329d79c4e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1e6a3b9d-528e-4266-b52f-a56c7bd90c14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1e6a3b9d-528e-4266-b52f-a56c7bd90c14" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2b38cd2d-255f-41fd-b2b5-58b480dde236" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2b38cd2d-255f-41fd-b2b5-58b480dde236" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:to="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80a9c405-a57a-4585-af23-d76acf888248_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80a9c405-a57a-4585-af23-d76acf888248_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_6e8fc1f3-e774-421d-947b-bf7c97aa8de8" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:to="loc_allo_TwoThousandEighteenPlanMember_6e8fc1f3-e774-421d-947b-bf7c97aa8de8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended" id="i4899ce82f6024f869622ef6bf6714155_ec4ad12b-ac9d-40aa-872b-a983d9c523b6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5c265510-50e5-47be-b2f8-a747fc064792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5c265510-50e5-47be-b2f8-a747fc064792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48bef6cb-92bf-4997-85d2-4fa82c925f82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48bef6cb-92bf-4997-85d2-4fa82c925f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_69664d16-ae28-4d20-9f02-87afc235b52d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_69664d16-ae28-4d20-9f02-87afc235b52d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c646113e-e12a-4a10-82f0-d63f3563244f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c646113e-e12a-4a10-82f0-d63f3563244f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b511ec4b-3771-40c7-be06-39b6143c98ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b511ec4b-3771-40c7-be06-39b6143c98ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0030aed3-c375-4716-89b3-94f08af5414f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0030aed3-c375-4716-89b3-94f08af5414f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_266bb501-0c1b-4a76-b091-5c01a0389b93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_266bb501-0c1b-4a76-b091-5c01a0389b93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:to="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0efadd92-d24c-424f-9bfd-8883e6a12332_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0efadd92-d24c-424f-9bfd-8883e6a12332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_69729468-922a-4bb6-987f-1c59d595a448" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:to="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_69729468-922a-4bb6-987f-1c59d595a448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:to="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a2d141e-58cd-4dad-89a9-1016dc986ce0_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:to="loc_srt_RangeMember_8a2d141e-58cd-4dad-89a9-1016dc986ce0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:to="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fbabc5e-3252-4c39-9ea2-909a59ea40a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:to="loc_srt_MinimumMember_8fbabc5e-3252-4c39-9ea2-909a59ea40a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ae6a035-f6c8-4535-869a-c77d8400e8c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:to="loc_srt_MaximumMember_5ae6a035-f6c8-4535-869a-c77d8400e8c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="i2b90a7425d5e468481fa9bcc5cffcd00_3e71af8a-9252-4382-b74a-c0c4371c08ab">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9266e4a8-127d-4754-9d17-ff415151870f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9266e4a8-127d-4754-9d17-ff415151870f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db394c5-f41b-4cc1-8728-84ac0f66569f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db394c5-f41b-4cc1-8728-84ac0f66569f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00dea312-55e5-42d2-8ce8-417de1334593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00dea312-55e5-42d2-8ce8-417de1334593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24b5e11d-ce44-45e3-b9bb-cba3e8ff9729" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24b5e11d-ce44-45e3-b9bb-cba3e8ff9729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_750b7f98-90b5-40c7-8c7e-0f87a00900df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_5dfdca5a-74b1-4428-b081-198952e61010" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_5dfdca5a-74b1-4428-b081-198952e61010" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c5bed458-374c-442c-a83b-f49bd4b747b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c5bed458-374c-442c-a83b-f49bd4b747b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c795b686-079b-411d-9896-a6a44f205f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c795b686-079b-411d-9896-a6a44f205f4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e542a27-1574-4a99-91fb-eaf7b80191f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e542a27-1574-4a99-91fb-eaf7b80191f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_24442fa2-66ff-458e-817a-20442e9be406" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_24442fa2-66ff-458e-817a-20442e9be406" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a01f6e3-2c7a-4271-be55-89cbf62c767f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_08ded9c3-db88-4b01-8006-2391f7646221" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_08ded9c3-db88-4b01-8006-2391f7646221" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_1446b129-a209-45c7-9e9e-a18e9eae76b6" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_1446b129-a209-45c7-9e9e-a18e9eae76b6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f7f74206-a615-4ac1-b006-5b7187ba023f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f7f74206-a615-4ac1-b006-5b7187ba023f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_23284854-cea4-4f32-be31-82b76d7c611d" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_23284854-cea4-4f32-be31-82b76d7c611d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_aaca4787-f4ff-4e82-a367-fccf2996ff04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_aaca4787-f4ff-4e82-a367-fccf2996ff04" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6d5233fa-61d1-43fb-a579-6776b61ba77a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_9d16370c-e908-4404-b05a-73368a94361d" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_9d16370c-e908-4404-b05a-73368a94361d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:to="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068c1a60-e785-4f52-8ad8-1808433a1d48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068c1a60-e785-4f52-8ad8-1808433a1d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_450046ab-ac27-43b4-8f24-9ecc979060e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_450046ab-ac27-43b4-8f24-9ecc979060e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="extended" id="ia5ef8761612a4b36bbaa73079b164b2c_f8f89794-4266-4bb5-966a-314e3f1a1e0c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d2f3e3e6-cd33-4e49-9d2c-0d0059c93698" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d2f3e3e6-cd33-4e49-9d2c-0d0059c93698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ae3ac02e-5b2b-4383-8af3-cf2fccfb460e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ae3ac02e-5b2b-4383-8af3-cf2fccfb460e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bcaf2456-d3ad-41cc-9f84-a999d7c3e806" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bcaf2456-d3ad-41cc-9f84-a999d7c3e806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a01bb7b0-631f-4cd6-9030-1741410cdf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a01bb7b0-631f-4cd6-9030-1741410cdf0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bcd96dc8-6795-47ff-a3b2-fa60bb2139e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bcd96dc8-6795-47ff-a3b2-fa60bb2139e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e62c135-023d-4d3b-a9ee-81761cee8b70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e62c135-023d-4d3b-a9ee-81761cee8b70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:to="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_791a34e7-ea47-436c-bda2-63809dedb7c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_791a34e7-ea47-436c-bda2-63809dedb7c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_3a364163-8371-4bf5-aa91-3534510152d6" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:to="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_3a364163-8371-4bf5-aa91-3534510152d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:to="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa5f9f5d-a2db-4bef-9637-e590d02e2034_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:to="loc_srt_RangeMember_aa5f9f5d-a2db-4bef-9637-e590d02e2034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:to="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd73d2c3-a79e-43cc-b837-9ba5bf601bb3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:to="loc_srt_MinimumMember_fd73d2c3-a79e-43cc-b837-9ba5bf601bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4609b13c-d71e-4b01-b9f3-af5f0dc5d061" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:to="loc_srt_MaximumMember_4609b13c-d71e-4b01-b9f3-af5f0dc5d061" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i88aed3eba3e44fef9adf3e715ba8256a_57c45205-54cb-4267-9a4c-b8bd3e62baf3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e97057e-25e1-473c-9210-1f33f2d888f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e97057e-25e1-473c-9210-1f33f2d888f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3516498b-67af-4cea-a9a1-e1170ba86c59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3516498b-67af-4cea-a9a1-e1170ba86c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4f6d8d6-39d4-4c96-a734-209e4d0a82d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4f6d8d6-39d4-4c96-a734-209e4d0a82d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended" id="i4b3aaf555ab045ffa610886a6f113f50_7282d362-cb6e-461e-9a4a-523c30e45d74"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i2f9eac35d5ce43fa911ab005ba4d075f_e25ae4b6-37c9-41f2-a2e6-a757717f0f5d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4265beb6-729b-4421-a9cc-99289fbccbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4265beb6-729b-4421-a9cc-99289fbccbc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_11a40877-9d6e-4248-8390-0931ac9b07f3" xlink:href="allo-20191231.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_11a40877-9d6e-4248-8390-0931ac9b07f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_e24f7410-327d-4a94-90b0-952da61d4a88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_RelatedPartyCosts_e24f7410-327d-4a94-90b0-952da61d4a88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f0ff8a99-c8c7-42ab-8ec3-d64c956382b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f0ff8a99-c8c7-42ab-8ec3-d64c956382b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_b239dd9b-6ea7-470e-8a2a-1e746fb1e3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_SuppliesExpense_b239dd9b-6ea7-470e-8a2a-1e746fb1e3f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_dbface2a-675b-4044-84ad-16bd30656bad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_dbface2a-675b-4044-84ad-16bd30656bad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5fe526a6-e067-4ea4-99ea-17f3e68b8f68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5fe526a6-e067-4ea4-99ea-17f3e68b8f68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_e1cfba9e-a8b2-43b9-8954-ae715ab778d7" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_e1cfba9e-a8b2-43b9-8954-ae715ab778d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_29432ea9-aefc-489a-b516-4029de75b03a" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_29432ea9-aefc-489a-b516-4029de75b03a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_69f5ab01-7007-4356-b123-3aa4a2174c93" xlink:href="allo-20191231.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_AreaOfNewOfficeBuilding_69f5ab01-7007-4356-b123-3aa4a2174c93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2170bd87-7f31-4999-8256-18a973546426" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2170bd87-7f31-4999-8256-18a973546426" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cfd29d95-ac58-463e-b422-7f3e15c6783f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cfd29d95-ac58-463e-b422-7f3e15c6783f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e7ac554d-ee07-4f9b-8945-50bec85a428a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_SubleaseIncome_e7ac554d-ee07-4f9b-8945-50bec85a428a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc7e736e-f398-4110-b8df-ae4ea87ff2cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:to="loc_us-gaap_RelatedPartyDomain_cc7e736e-f398-4110-b8df-ae4ea87ff2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:to="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_bb191796-d5f8-44a3-94d6-da618fdbca56" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_PfizerIncMember_bb191796-d5f8-44a3-94d6-da618fdbca56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_554b15c8-26e0-408f-847e-17b25285ef04" xlink:href="allo-20191231.xsd#allo_TwoRiverConsultingLimitedLiabiltyCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_554b15c8-26e0-408f-847e-17b25285ef04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember_5a529865-d127-42d3-8946-262e28680aa0" xlink:href="allo-20191231.xsd#allo_TPGCapitalFOLimitedLiabilityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember_5a529865-d127-42d3-8946-262e28680aa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_29fd80f6-ab28-4a59-b8f2-022ae77edc85" xlink:href="allo-20191231.xsd#allo_BellcoCapitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_BellcoCapitalLLCMember_29fd80f6-ab28-4a59-b8f2-022ae77edc85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartMember_c985b644-c91e-4a44-bf64-385103f8e93c" xlink:href="allo-20191231.xsd#allo_ByHeartMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_ByHeartMember_c985b644-c91e-4a44-bf64-385103f8e93c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_98ab5d8b-b78c-4284-8036-440b52532969" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_98ab5d8b-b78c-4284-8036-440b52532969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31bdb0e5-4311-4483-976e-c5f9bb84f057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31bdb0e5-4311-4483-976e-c5f9bb84f057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1f2c9040-7dbe-4837-857d-165a3889ad65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1f2c9040-7dbe-4837-857d-165a3889ad65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember_6323ad25-0df7-41b2-9de4-756257c77fba" xlink:href="allo-20191231.xsd#allo_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_TransitionServicesAgreementMember_6323ad25-0df7-41b2-9de4-756257c77fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_a3c4edb1-983e-4893-b916-9bf0e7fea048" xlink:href="allo-20191231.xsd#allo_ConsultingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_ConsultingAgreementsMember_a3c4edb1-983e-4893-b916-9bf0e7fea048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_3dc101c0-26a2-43b5-82a9-519657f81adb" xlink:href="allo-20191231.xsd#allo_TwoRiverConsultingLimitedLiabiltyCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_3dc101c0-26a2-43b5-82a9-519657f81adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_4782b5d6-ae0c-4786-9b76-19f78010402f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_4782b5d6-ae0c-4786-9b76-19f78010402f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_248f46ba-ab4e-4153-bf6a-e1fc4b16b3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_248f46ba-ab4e-4153-bf6a-e1fc4b16b3ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9315b483-00c6-4c9d-a046-a2a55c0b11c8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:to="loc_srt_OwnershipDomain_9315b483-00c6-4c9d-a046-a2a55c0b11c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:to="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_bf109c54-7ff6-419b-ae4b-c39248a6acd2" xlink:href="allo-20191231.xsd#allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:to="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_bf109c54-7ff6-419b-ae4b-c39248a6acd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_684095e7-4033-46c5-94d2-bcd2861599b4_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:to="loc_srt_RangeMember_684095e7-4033-46c5-94d2-bcd2861599b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:to="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca7b2f3a-ef74-4fc1-8348-1e6399af74bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:to="loc_srt_MaximumMember_ca7b2f3a-ef74-4fc1-8348-1e6399af74bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7646edf4-344b-4531-8b7c-0e4043f024fb_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:to="loc_srt_SegmentGeographicalDomain_7646edf4-344b-4531-8b7c-0e4043f024fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:to="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_d63afb27-5ae3-43c3-a4b4-ebea5361e3a3" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:to="loc_stpr_CA_d63afb27-5ae3-43c3-a4b4-ebea5361e3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_03784ca2-7721-46d2-8380-f822c2d03ddf" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:to="loc_stpr_NY_03784ca2-7721-46d2-8380-f822c2d03ddf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlan" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlan"/>
  <link:definitionLink xlink:role="http://allogene.com/role/A401kPlan" xlink:type="extended" id="i5388d2fd64304ed583127690763176fb_c77fe361-844e-490f-913c-df781ae0f6d1"/>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlanDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/A401kPlanDetails" xlink:type="extended" id="i87c8bff603a142bb9dbf80dcd95f75a3_a5563542-ae30-46ce-b801-4810e0ca30ca"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended" id="id7c4fa73b8a746798864f48efd4cee6a_79a91268-884e-4a95-bf18-130ac4b3c55f"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesTables" xlink:type="extended" id="i3776eac7053e4fe9be8c6efd06a4e962_c9c95e11-90ed-41bc-8ae8-4da05a957652"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i41c7af027a7d469dbaedc748d3b2b101_81b6bb31-5a49-40d2-b17e-046019d9a86c"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended" id="i54b5a634dd7e48fc8c504f264ace7812_c3441b8f-16da-4a17-bf23-bcbd6a2abcaf"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofIncomeTaxReconciliationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="extended" id="ieddbb615ccf449169e207dc847e9e7e0_b66795b8-8d10-4340-99d8-23803147e36d"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i0460b88e8d11498e8f4df68285ff9625_a3c15309-a941-4c44-8b59-f9fadcf12dfc"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="extended" id="i62b8d05f03bf4b309d19b201ca6035f4_fb5cd853-95da-4323-a2ca-201bc1df811c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0afc804b-4cc1-4757-8309-20157ee92cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0afc804b-4cc1-4757-8309-20157ee92cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_be76f7b5-1ddd-4a09-920a-86d41fb47c14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_be76f7b5-1ddd-4a09-920a-86d41fb47c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_388d7224-982e-43a8-8503-a6c50df5b688_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_388d7224-982e-43a8-8503-a6c50df5b688_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_10e04b7a-327f-4d84-a097-6077aad05284" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:to="loc_us-gaap_DomesticCountryMember_10e04b7a-327f-4d84-a097-6077aad05284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_19ace807-f490-43dc-9de9-bbda4716825d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_19ace807-f490-43dc-9de9-bbda4716825d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:to="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_8cd8fa0c-157d-4b3c-be46-889574503735_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:to="loc_us-gaap_TaxPeriodDomain_8cd8fa0c-157d-4b3c-be46-889574503735_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:to="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IndefiniteMember_862a1782-029b-4b39-8370-cab520aa6bd5" xlink:href="allo-20191231.xsd#allo_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_IndefiniteMember_862a1782-029b-4b39-8370-cab520aa6bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037Member_5c04d7ed-a3d6-4d45-b434-aaff482064df" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpiration2037Member_5c04d7ed-a3d6-4d45-b434-aaff482064df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037To2039Member_cdc3496c-b397-4c1a-8e4d-195bc4571428" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037To2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpiration2037To2039Member_cdc3496c-b397-4c1a-8e4d-195bc4571428" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpirationYears2038To2039Member_e6107906-8576-47c7-8d7f-c9847c2b745a" xlink:href="allo-20191231.xsd#allo_TaxExpirationYears2038To2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpirationYears2038To2039Member_e6107906-8576-47c7-8d7f-c9847c2b745a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i3a7960a41419450a9b163b1a5cf0e9bc_0bc526b1-8ad8-4020-b02a-c26ce630352e"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShare"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="extended" id="i477abb2db50c4f1395e2c5970818960a_cc8e3dc9-af9a-4e4f-8a23-adc3b0db701a"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="extended" id="ifcda79038cf345c6b50ac8e6242fe335_1e9364bd-eb90-432b-85ec-abe5dd9c5821"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended" id="i8e671a00f02f4e3292a35c7c25358a8b_5bd0731e-3082-45d7-a2bc-dfb018433a6c"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended" id="ieb353f44e9a640e68c8c957f829d44e5_4722759d-07e5-414c-8767-7b944a675698">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0174be9-2bdc-4893-a97b-ab7a1181aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0174be9-2bdc-4893-a97b-ab7a1181aae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_426277f3-bb85-428b-8b68-940e8fbae593_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_426277f3-bb85-428b-8b68-940e8fbae593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f83702e1-866a-405e-a36d-3d47e24e5570" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f83702e1-866a-405e-a36d-3d47e24e5570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ef7f81e-4d91-45af-a698-ac0a0faaf9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ef7f81e-4d91-45af-a698-ac0a0faaf9bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_e19b183f-88c1-4309-944d-32a33f11ad00" xlink:href="allo-20191231.xsd#allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_e19b183f-88c1-4309-944d-32a33f11ad00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_e928bc61-f521-4c32-94c8-1403e46348c3" xlink:href="allo-20191231.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_FounderSharesOfCommonStockMember_e928bc61-f521-4c32-94c8-1403e46348c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_441f0176-d374-4902-b7be-21de8e7e2aae" xlink:href="allo-20191231.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_441f0176-d374-4902-b7be-21de8e7e2aae" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended" id="ic1ae9ccd15914a99ab6c2a01f66860f6_baa134a5-c0cb-46bd-9b44-9b3db0254ed8"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended" id="i2173f9e7783d4906847ba2fd8313092f_dea22c7e-1a10-408b-92e8-e6d9a23010b3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5eac0c57-5260-4f81-b7c0-2b5034f8c3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5eac0c57-5260-4f81-b7c0-2b5034f8c3cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de5cb580-3595-435f-adb2-95aa7414c062" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de5cb580-3595-435f-adb2-95aa7414c062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:to="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a91c5455-552c-47f2-80be-6f8ba72bd71a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a91c5455-552c-47f2-80be-6f8ba72bd71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3cf18fd0-a264-44a4-b760-af141985c5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:to="loc_us-gaap_SubsequentEventMember_3cf18fd0-a264-44a4-b760-af141985c5e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunaudited"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="extended" id="ie1acc8859606494684089c5664a5f412_34a1be89-4645-4226-8056-1c8b22021294"/>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="extended" id="i42f8b012051a4e8aa52c4a9b3a573c3d_b2bd6f5c-47f7-4b57-904b-7cdd6124b983"/>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="extended" id="i32849e31dfbf444cae4b5ae4936b998c_5361a09b-16ef-483d-a76a-b43b5a54ab5c"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>allo-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_2e495c62-0b6e-4fc1-8a1f-d284358498c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_87967b38-25e9-40a2-a9b4-4f7f424c1e07_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c894ee39-7e9f-4008-8758-6079b159559f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FoundersMember_6ec3b13a-867a-4608-ba64-cc2b3ff5cfe8_terseLabel_en-US" xlink:label="lab_allo_FoundersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders</link:label>
    <link:label id="lab_allo_FoundersMember_label_en-US" xlink:label="lab_allo_FoundersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders [Member]</link:label>
    <link:label id="lab_allo_FoundersMember_documentation_en-US" xlink:label="lab_allo_FoundersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersMember" xlink:href="allo-20191231.xsd#allo_FoundersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FoundersMember" xlink:to="lab_allo_FoundersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01e784ea-405e-4ce9-a960-26b15f6e2034_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_22521b3e-aad3-4640-8a54-616e6a81ef36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining contractual maturities of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_43447065-6607-4642-9616-f9a73fe8a683_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67ac74c8-addb-4860-a28d-c6258002ebcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_93186726-52bd-4f54-b298-60b64a102b79_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_adc64b5c-8b89-49ab-a793-76c5fa1b86cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e66b0a73-e6f0-4fba-b462-87e07418d1ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TaxExpirationYears2038To2039Member_934d92d8-432f-4a92-899f-e073f24cc591_terseLabel_en-US" xlink:label="lab_allo_TaxExpirationYears2038To2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2038-2039</link:label>
    <link:label id="lab_allo_TaxExpirationYears2038To2039Member_label_en-US" xlink:label="lab_allo_TaxExpirationYears2038To2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expiration Years 2038 To 2039 [Member]</link:label>
    <link:label id="lab_allo_TaxExpirationYears2038To2039Member_documentation_en-US" xlink:label="lab_allo_TaxExpirationYears2038To2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expiration Years 2038 To 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpirationYears2038To2039Member" xlink:href="allo-20191231.xsd#allo_TaxExpirationYears2038To2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TaxExpirationYears2038To2039Member" xlink:to="lab_allo_TaxExpirationYears2038To2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7b9a39dc-5217-43fb-ace8-d9425b1ca9ef_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a9efb63-d259-4db5-8857-6e1451117d42_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a44ac8b-1926-4979-af26-04075d61f416_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0bb233ab-f26b-40f5-9765-b13c5b626571_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of recognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_592a6088-cf5a-4101-abe1-8246f5433d0d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_394e4287-a822-408d-985a-89b61fdc33d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_378c5edc-c326-4acb-ac4b-a6c0d73211f6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4dc9b3b4-079c-4f2a-9c1b-81029a6d4c90_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad9ff32c-4e85-497f-89e6-5f79e0e873bc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e32d6df5-a60d-41f5-978f-eecfa851a710_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b9164dc6-a453-428f-95f4-fda738087198_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_618024ac-027f-4d23-8bd9-31aa0cc54fca_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b2df2cd9-8d32-4f34-b75d-b5d81c432e16_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PfizerIncMember_2c77af60-e228-4b8d-b87f-67aea7728558_terseLabel_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_allo_PfizerIncMember_label_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_allo_PfizerIncMember_documentation_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PfizerIncMember" xlink:to="lab_allo_PfizerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_83704e72-12ec-4d6a-9aa5-9808b83623b4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6479891b-62fc-4bb6-9fbe-d1b5788e9583_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to tax position of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d1f9db6b-5e7d-4d0c-9700-ab2dcb843487_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7fe3a983-2c0e-491f-a86c-ab8d7ca5bb09_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d7f9064d-d7e0-422a-ac25-086c6246b8ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d3961471-020f-40c2-bbaf-e61084a512d2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_efc5e611-ba13-428a-bed3-2588044fd8b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_d5a4ebd0-523f-4bb2-bd56-5c932c9e31a8_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_d4de3399-5408-476e-8061-c66613b8f5f0_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8b012649-2435-4f98-92c3-d0b19354769b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e6cfe993-995f-4362-a7da-7dea29acebb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_9443377b-d23b-4b26-8515-b95fe6ff2893_terseLabel_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Of Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:href="allo-20191231.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:to="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6de8b0d1-4981-4fa4-9e42-e456fcbc67ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_7ad83ed3-de19-4f31-af9a-b0b15f4dd0ea_terseLabel_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares liabilities</link:label>
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_label_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Shares Liabilities Current</link:label>
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_documentation_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares liabilities, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent" xlink:href="allo-20191231.xsd#allo_UnvestedSharesLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UnvestedSharesLiabilitiesCurrent" xlink:to="lab_allo_UnvestedSharesLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f60e4f75-8e5c-4240-9a9a-ac72947aca98_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_972db8f5-a613-4d52-87f2-038e64bf9671_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_142dc3da-2aba-46b6-bfbc-de99600beff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_a7b415b0-8277-45d5-9811-e141d71d50d7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1cbb8078-1d07-4704-bfff-7dfc87b2d34d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4e0ffd9d-9587-4ee2-903b-4d451ef1b83f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6c19d5bd-a3e7-4c5a-8345-d5f06f4fc889_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseTwoMember_46f48a57-8ff0-4da2-88f1-fcbc51764f1a_terseLabel_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">124 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseTwoMember_label_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two [Member]</link:label>
    <link:label id="lab_allo_LeaseTwoMember_documentation_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember" xlink:href="allo-20191231.xsd#allo_LeaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseTwoMember" xlink:to="lab_allo_LeaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d283c6af-19a2-4466-9d8e-479ddc80c2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_69896f78-00d5-47ea-818f-c2e0675857d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_b72d595c-d151-43c4-9a25-0fe6b6833627_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b9560aac-94f8-4835-b252-88ff7c4d3ffc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b86398d1-b7c2-4a39-a5e6-e9d9b594cc53_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_04058611-9b84-449e-9fe3-d20f33b319c2_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b9e92bbb-9100-417e-b211-496405f460da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_01e4c651-0bad-4d0c-958b-704d7027e8a0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_6733c883-fe92-4f3a-aabe-4bb5061e421c_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9dc6b10-4f0e-455f-b2c4-ba0e54808ab0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae7559c2-54b9-4817-8d05-6c8f63ddaeab_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_368be417-3d1e-42bb-8b85-3602fb45596c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_07754310-a836-417a-8a9b-7e20921bbd34_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_798a2490-0143-4265-b7df-ade7ec24f1bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa51038a-67ef-4dc5-b73c-f88629b166b9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_d972cfe0-bbf3-418b-9457-1d463d601f2b_terseLabel_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:href="allo-20191231.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:to="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_eae28279-2604-4be2-902e-b275690a2416_terseLabel_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five And After Year Five</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five And After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d973089b-fea8-47d7-9dac-cbb9eee86fc6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_ad042566-4efd-4a98-b9ef-1b6793cd4bbb_terseLabel_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers equipment and purchased software</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_label_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Purchased Software [Member]</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_documentation_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and purchased software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:href="allo-20191231.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:to="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_049e6b7b-1dbd-42a3-8f68-a57f2f7e6180_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_c5ea0441-4b9b-433e-b08d-bdafce2720f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_86320818-c524-442a-b374-2059822a5921_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment" xlink:href="allo-20191231.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementUpfrontPayment" xlink:to="lab_allo_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_28e371b7-284f-4a7b-a50f-faf511131d5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_710ab109-4fae-4d16-95f2-d0b1380314d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_40f72aff-4c44-4bf5-9fe9-81417994bd95_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockOptionGrantedPeriod_8ee96bc5-3920-4d03-9d97-2091a7be568f_terseLabel_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_label_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Granted Period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_documentation_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod" xlink:href="allo-20191231.xsd#allo_StockOptionGrantedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockOptionGrantedPeriod" xlink:to="lab_allo_StockOptionGrantedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_cb7dc97d-07f2-4151-87e7-a4d48d3d1daa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2abfeff6-9aa2-43f0-b6a9-6f09135defeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_5257aed6-a933-41d4-ad9e-a5d6c7b25528_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c16aeaf9-a483-45d3-9565-9f2aa4ac2f7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b6e41b0-226e-471d-8ef9-a60f33ed50bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_1fba557d-a41b-4df4-8242-36067619dc14_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6995829c-9013-4b40-b700-d21b303a3281_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs from issuance of preferred shares</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssembledWorkforceMember_a918f96d-b33a-4dea-8e7b-5c8c584a66c0_terseLabel_en-US" xlink:label="lab_allo_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled workforce</link:label>
    <link:label id="lab_allo_AssembledWorkforceMember_label_en-US" xlink:label="lab_allo_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_allo_AssembledWorkforceMember_documentation_en-US" xlink:label="lab_allo_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled workforce.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssembledWorkforceMember" xlink:to="lab_allo_AssembledWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c0554d9a-e7b3-4928-9bac-e1e37d1b14d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_42e57737-2b55-4699-9437-6d2f3805eeda_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3ffd18d7-f2b9-42bc-b9b0-96ea9a6abe3f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_7950c9d0-774f-49ec-a6aa-ed425d276b0c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BellcoCapitalLLCMember_788af4d4-3ffe-46cd-a2c1-a20fab129b0b_terseLabel_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_label_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital L L C [Member]</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_documentation_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember" xlink:href="allo-20191231.xsd#allo_BellcoCapitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BellcoCapitalLLCMember" xlink:to="lab_allo_BellcoCapitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StartUpCost_b7da8c74-4641-4f41-b2d2-522731383760_terseLabel_en-US" xlink:label="lab_allo_StartUpCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start up costs</link:label>
    <link:label id="lab_allo_StartUpCost_label_en-US" xlink:label="lab_allo_StartUpCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start Up Cost</link:label>
    <link:label id="lab_allo_StartUpCost_documentation_en-US" xlink:label="lab_allo_StartUpCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StartUpCost" xlink:href="allo-20191231.xsd#allo_StartUpCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StartUpCost" xlink:to="lab_allo_StartUpCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_80bde9d6-1122-4dce-8a6e-6e58cedabf29_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8d9da611-a034-487a-a3cc-3f180c14193e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostResponsibleFor_3355b9ea-b61e-49b1-9e97-b21220f7770e_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development cost responsible for</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostResponsibleFor_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Responsible For</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostResponsibleFor_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development cost responsible for.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:href="allo-20191231.xsd#allo_PercentageOfDevelopmentCostResponsibleFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:to="lab_allo_PercentageOfDevelopmentCostResponsibleFor" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_6bb96593-c84a-421e-ae86-e76e81e7dd3c_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested and expected to vest, weighted average remaining vesting life</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe16a0b2-a670-4a5a-9790-4aeca4a91582_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenEquityIncentivePlanMember_151cdc78-847d-48eb-97ed-1318b14ad653_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_allo_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_7ecc512d-4a95-4cc8-bf27-52b901599b41_terseLabel_en-US" xlink:label="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected shares purchased under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Shares Purchased Under Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Shares Purchased Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:href="allo-20191231.xsd#allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:to="lab_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_a138b868-0e04-49e0-b3a7-5f4110795d84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b1b2a085-0337-4dfe-be5d-1c24abbea04c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9e36db7a-cc9c-4733-b53c-951b4e7f3b58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_f1ad7dd1-89be-40a8-80e1-6cb1bde64703_terseLabel_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_label_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_documentation_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Vesting Of Early Exercised Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:to="lab_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aa10ecd5-6dc6-4929-a6e6-b2f82e518666_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 200,000,000 authorized as of December 31, 2019 and December 31, 2018; 124,267,358 and 121,482,671 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4f429870-e817-449d-8a7d-431320588417_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5612a435-5c2d-44aa-995b-aa7024103c49_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_9cf9e532-1e60-4040-91f3-32ca4d408f15_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vested shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44539321-3718-4873-b7b0-f50a76e16c56_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8f93b68f-637a-41f8-bdec-c0f04e941990_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_e0045727-827f-4d7e-93f3-218507a3214a_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayable" xlink:to="lab_allo_AggregatePotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_454ed79f-555e-47c3-a4da-17a0a43e5f5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_f045cc9f-b489-4dc4-b40b-fc0034bb5b69_terseLabel_en-US" xlink:label="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock through payroll deductions to equal price of lower fair market value</link:label>
    <link:label id="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_label_en-US" xlink:label="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Common Stock Through Payroll Deductions To Equal Price Of Lower Fair Market Value</link:label>
    <link:label id="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_documentation_en-US" xlink:label="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock through payroll deductions to equal price of lower fair market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:href="allo-20191231.xsd#allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:to="lab_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_fcfb87c2-3601-4aa2-8632-f27acab10ccf_terseLabel_en-US" xlink:label="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America, Europe, Asia, Australia and Oceania</link:label>
    <link:label id="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_label_en-US" xlink:label="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America Europe Asia Australia And Oceania [Member]</link:label>
    <link:label id="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_documentation_en-US" xlink:label="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America, Europe, Asia, Australia and Oceania.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:href="allo-20191231.xsd#allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:to="lab_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_c92a2906-0c75-47aa-8b3c-72cdf417f4dd_terseLabel_en-US" xlink:label="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting LLC</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_label_en-US" xlink:label="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting Limited Liabilty Company [Member]</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_documentation_en-US" xlink:label="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting Limited Liability Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:href="allo-20191231.xsd#allo_TwoRiverConsultingLimitedLiabiltyCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:to="lab_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_c12e1ff9-0880-459d-a9b7-89eec45ee98a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2d558d1f-dc6d-41ea-ad16-b3cbb5e644d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SeriesAConvertiblePreferredSharesMember_5f0e24d5-24d7-4491-ad75-3e972931a4af_terseLabel_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Shares</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredSharesMember_label_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Shares [Member]</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredSharesMember_documentation_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A convertible preferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesAConvertiblePreferredSharesMember" xlink:href="allo-20191231.xsd#allo_SeriesAConvertiblePreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SeriesAConvertiblePreferredSharesMember" xlink:to="lab_allo_SeriesAConvertiblePreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_acdb10f9-9879-44eb-a41a-c40918092fd9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5ec172e7-b42c-4612-b2e6-77c57fd9fa84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6dedbe90-e0ae-4c27-9df4-fbd5bd0a7015_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, grants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2257ac44-9744-4299-874c-c5a7ab1b1a6c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances from lessors</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b59cc972-2cfd-4b97-8f87-a68f92089c1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e5dc1ec-749f-45e6-bc41-5e9296f5ef36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecd330c6-55aa-4ac9-83e9-c307acf487b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_45898e99-b2bb-4f11-a325-4335f3aaa014_terseLabel_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members appointed to board of directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_label_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Members Appointed To Board Of Directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_documentation_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members appointed to board of directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:href="allo-20191231.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:to="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_123ff8d4-1f81-49b3-8b32-000f05aee7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b58d4df0-efe5-4a28-8ff8-fbb29968dfc5_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7b8d8918-90d4-44d3-926b-7d3ada695664_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_3b26b18e-609b-4d86-98d4-fd23c9751eb4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedPropertyAndEquipment_776d5dd9-a760-4b7f-9a2b-b1ebd5f6f502_terseLabel_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment</link:label>
    <link:label id="lab_allo_AccruedPropertyAndEquipment_label_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment</link:label>
    <link:label id="lab_allo_AccruedPropertyAndEquipment_documentation_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedPropertyAndEquipment" xlink:href="allo-20191231.xsd#allo_AccruedPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedPropertyAndEquipment" xlink:to="lab_allo_AccruedPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ad5deb9-60a2-4294-b4c7-5b8c09265955_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_63a29ab5-86bc-4509-8458-69fe7be104f4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3f2ddd79-ae18-40eb-918c-9230d36a5bd3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_692d0fd2-e4b1-4a53-a16e-2ed62c57cfb3_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e6fa4cb7-69c0-43d4-80fd-3520e28c0ce2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_2e2a1f6d-a376-4846-bd2f-19d45b0f1d37_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_19fd8b82-3dc3-47fd-9a7b-b89951d379d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_df0c58d5-a112-4175-9aca-e0d6d817fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_964c9baa-7292-4618-80cb-c3efcbab87ae_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments per target</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments per target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayments" xlink:to="lab_allo_AggregatePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_39d555e0-47b4-4c72-ba15-bb7e39dfb88f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit and other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_a67a5158-c416-490e-a77a-bb206014e3b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_49dbee5f-7b38-46fa-9a95-c0e4ff62e8a2_terseLabel_en-US" xlink:label="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs reclassified to APIC</link:label>
    <link:label id="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_label_en-US" xlink:label="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified To Additional Paid In Capital</link:label>
    <link:label id="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified To Additional Paid In Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:href="allo-20191231.xsd#allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:to="lab_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfEligibleCompensationContributionByEmployee_686a2585-e862-4a2a-a44c-6622b40eaffb_terseLabel_en-US" xlink:label="lab_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible compensation contribution by employee</link:label>
    <link:label id="lab_allo_PercentageOfEligibleCompensationContributionByEmployee_label_en-US" xlink:label="lab_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible Compensation Contribution By Employee</link:label>
    <link:label id="lab_allo_PercentageOfEligibleCompensationContributionByEmployee_documentation_en-US" xlink:label="lab_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible compensation contribution by employee percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:href="allo-20191231.xsd#allo_PercentageOfEligibleCompensationContributionByEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:to="lab_allo_PercentageOfEligibleCompensationContributionByEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1c5b21af-c9bb-42a9-8e76-8aeeb1c77950_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_48c978da-a99b-424e-9b53-b8e5ee15a4bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_183b68e4-775c-4c80-abf5-cf63858dbf69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, extended term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_a3c5b760-f9fa-437e-b08e-1fb9d94248cc_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions receivable</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Subscribed but Unissued, Subscriptions Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:to="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_dfe8652f-919a-4c26-8837-9f60f6490e7e_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aceba73b-b54d-46de-ab61-63ce74cb48b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_c99fffd1-5f93-4dcc-b6f4-2cb6e185ef3a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cbec7442-5539-4ed7-aa8b-b6bc58aed5f8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bb8fd0c0-96d0-40d0-9e33-51266a91e3db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available For Sale Debt Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e23b2b65-c294-427c-bc87-4de89084a94e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_afc26260-ab8d-473a-ab74-823c2c05b153_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_54755f98-e221-47b1-8277-a86729a59fed_terseLabel_en-US" xlink:label="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated with President and Chief Executive Officer</link:label>
    <link:label id="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated With President And Chief Executive Officer [Member]</link:label>
    <link:label id="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated with President and Chief Executive Officer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:href="allo-20191231.xsd#allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:to="lab_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_5b90caab-9f1c-469e-9f05-c13511d64091_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_058d1d44-8b87-4d26-8bab-15f7402c89a0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4324880d-ecb7-4625-8b7a-9dd4cca6535c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureTextBlockAbstract_5ce240a9-367a-45d0-94b1-b2f2f52c29b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureTextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed451f82-be63-4f49-828e-9b1519308a1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_9793f250-75d4-431d-b738-9a58f41c3a46_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Compensation Percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:to="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1fbbae2a-dec8-4e54-aecf-625a0746d047_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_19cd5bd8-35fe-40f1-be47-c1c99caeced2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_92deb005-b2c5-4245-8495-f36c91d91893_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_06f26ba5-e267-4f7f-959e-0f5361a89549_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d7bae459-909f-45af-a4eb-75e5e35406a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_12e858f4-16ae-4474-96b4-ed6730d917fd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_fc84e6b2-ee40-4fc2-8853-120548836d2e_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_27f3bedd-8829-4781-9a40-79d6921d9ef8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_66162eb9-804d-49a7-96fc-d87e35d896e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4b38561d-aea5-4132-b41e-8dd2365bc65f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of convertible stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_86bd66e2-9e02-4b44-a429-58f82aa7fe3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of 2018 Notes converted into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_e59ee9c4-98a6-442f-a482-4ec3d83a8dda_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_646bc705-9082-4388-afdb-cb426872b54c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_08b804ee-074d-4e8b-8a3d-46e19c6f98b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issued in connection with asset acquisition, fair value</link:label>
    <link:label id="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_62e658e2-5b22-412f-b8b6-36874bc800dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_36ccb29f-8d98-4c10-8650-226ec83911e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e75a38cf-5ef1-4ede-8a79-25fb38f68751_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_f0776b26-7501-4a2a-9d6e-e99d1decaf96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3415f23-28cc-4bc0-bd2f-8057e4a260da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4cf3e6ab-3d6c-41f8-ad2e-b97ced33901b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues_01373926-bbf8-4e3b-a641-ce13a71de93a_terseLabel_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from preferred stockholders</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues_label_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Preferred Stock Issues</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues_documentation_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value preferred stock issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValuePreferredStockIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:to="lab_allo_StockIssuedDuringPeriodValuePreferredStockIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_7a6efbbc-797e-4c96-bb8b-b54483e4152d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6879a967-e5e7-4b7e-8002-811240caabca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_e7f5a60c-2934-423f-b7c7-d2aa0a6b5bb7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5ed24bc3-deda-4601-804b-625f73fdecca_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal, state and local, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0687f242-1d4c-41d2-aaff-5966a86a1842_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9db80dc-e975-421b-88e1-9318789dd391_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d3588a54-8e78-464c-8075-a7a884c89183_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_6cdff172-c7ee-45ac-a137-9322713a609f_terseLabel_en-US" xlink:label="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes</link:label>
    <link:label id="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_label_en-US" xlink:label="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Change In Fair Value Of Convertible Notes</link:label>
    <link:label id="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_documentation_en-US" xlink:label="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation change in fair value of convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:to="lab_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_392b81bc-13ac-4ef6-a49d-93d078f909f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8a53d814-e0e5-4dd0-8ad9-227d0a611f0f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance of cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d41721ce-d8fc-4254-b7ce-aa74ad337f3a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_194e1812-3f73-4586-8821-f30078107c4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_03288628-8c3d-4254-a1fa-36392bb046b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_69030fbe-8fdd-4339-bfcb-76adda02f864_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20ecd02a-4d1a-46be-b6bd-f3dac4a706b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ad8af9ad-ab67-4e9e-ab56-55795ea2da47_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of other intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e3242021-bb9f-46de-8a99-6226f5dd461f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_69ec8ed6-18c9-4a1a-a066-21fd16d5ac77_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_1aa37595-76c9-4a26-9035-840da5eb29d0_terseLabel_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_label_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_documentation_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotchTherapeuticsIncMember" xlink:to="lab_allo_NotchTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_03aadf09-e977-45ae-9c33-8bde0057bb87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4f012160-a876-4f9a-b425-32f1ea11e7e1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a9585089-c0b8-4395-9356-eb2ddbb8fb1f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7109b8ed-7727-4d1f-9ed8-4b7a750ddc73_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_70aa2abd-b92b-421d-9687-f2090fd936c1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_baa7db69-db40-4dda-9258-ba24f5944a94_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8445f3ee-2d8f-4c15-8c89-8e1f051caeb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeasePayment_71359bbf-9e9a-4b78-8a8c-7d128c499034_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease payments</link:label>
    <link:label id="lab_us-gaap_VariableLeasePayment_label_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment" xlink:to="lab_us-gaap_VariableLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_1a048bcb-f185-424c-a5c8-2c3c549c8a83_terseLabel_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="allo-20191231.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4358d95d-7136-4801-b508-d1ec774aaad7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ec6d3ae4-cb3d-4a4d-a2f8-5da3a5337e85_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_69b8b346-8df9-45f3-89b5-77d261d3d8d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_dcf0c58e-eef5-4f86-95e4-9c4d7dee5448_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_e9f2d83f-2e50-44a4-bd40-20c87d5f7191_terseLabel_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_label_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of New Office Building</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_documentation_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of new office building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding" xlink:href="allo-20191231.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfNewOfficeBuilding" xlink:to="lab_allo_AreaOfNewOfficeBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b27effe0-6d88-45d9-89de-e777fa2cc8ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_64cd7d10-0b61-45af-a8b4-cf83dbb8a32f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_915b7973-54d4-4273-8565-434ee30a7c54_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ccf2baea-699e-49dd-839b-7e56c06b7efd_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_b6c91eb3-5c0d-4f2c-8846-e342e7e8d8c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_dac099da-29f5-4e95-a0af-186ed14b14dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable (2018 Notes)</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0353c0f5-bdad-4ec7-a784-123d634b1300_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased_ad24e8dc-361e-4341-8418-1999e28837ac_negatedLabel_en-US" xlink:label="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use leased assets</link:label>
    <link:label id="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased_label_en-US" xlink:label="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Leased</link:label>
    <link:label id="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased_documentation_en-US" xlink:label="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities right of use leased assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:href="allo-20191231.xsd#allo_DeferredTaxLiabilitiesRightOfUseLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:to="lab_allo_DeferredTaxLiabilitiesRightOfUseLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_cb3a841e-2cd9-40ac-a9f5-58023af057ef_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_427a27cb-a932-4a71-8cb6-98b1e445d6d0_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_49670d49-3264-4f70-80b8-480531151ab5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BalanceSheetComponentsTable_5c9604f8-32d8-4e41-8ce5-c248c20e75ad_terseLabel_en-US" xlink:label="lab_allo_BalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Table]</link:label>
    <link:label id="lab_allo_BalanceSheetComponentsTable_label_en-US" xlink:label="lab_allo_BalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Table]</link:label>
    <link:label id="lab_allo_BalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_allo_BalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet components.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsTable" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BalanceSheetComponentsTable" xlink:to="lab_allo_BalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_07d37463-6a80-4293-b96a-80cea81ddd6e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fcb9ca04-d67c-4b17-b8b7-54639fe9a2b6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_103c5fb6-3f58-4f41-88d4-2139e45d53d3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1531323b-2b86-4d52-a775-bc128a374265_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_644d0d1b-1f5e-4e88-a91c-e33a1dfe58a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d5a6055d-7952-4fd6-be3b-fe021fc9cd58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss and Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_0d1ff11b-dfb7-4a46-9622-4fc7ad2cdedb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_86817bcd-9068-45ee-bcee-71cfba80885b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_InitiallyReservedCommonStockForEmployeePurchase_0835f766-bdbd-4b80-80b8-91496655721f_terseLabel_en-US" xlink:label="lab_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initially reserved common stock for employee purchase (in shares)</link:label>
    <link:label id="lab_allo_InitiallyReservedCommonStockForEmployeePurchase_label_en-US" xlink:label="lab_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initially Reserved Common Stock For Employee Purchase</link:label>
    <link:label id="lab_allo_InitiallyReservedCommonStockForEmployeePurchase_documentation_en-US" xlink:label="lab_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initially reserved common stock for employee purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:href="allo-20191231.xsd#allo_InitiallyReservedCommonStockForEmployeePurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:to="lab_allo_InitiallyReservedCommonStockForEmployeePurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5f7c4244-6538-4826-afc0-01c8ccec73ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_748a2745-73b5-4680-a21f-10e39dd46565_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_32a85247-384f-4a1c-bfb6-37d1e1fbc0d4_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_bcadec06-96cf-4080-b5e8-3c014a9045d1_totalLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Liabilities Current</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1182de2e-c9d9-4db2-822c-cd241f943039_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, carrying value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_11f30bee-83eb-4a37-909e-01e30485ad8d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock_fd05582d-c6ae-4d20-928b-8b1d4b5a3533_terseLabel_en-US" xlink:label="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-Lived Intangible Assets</link:label>
    <link:label id="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Definite Lived Policy [Policy Text Block]</link:label>
    <link:label id="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-Lived Intangible Assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:href="allo-20191231.xsd#allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:to="lab_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_91309b0e-dbcb-4e65-8743-fffa4d6c8868_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Leasing Costs, Commissions, and Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:to="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_10d27dde-dd56-408b-831f-63dbdb9600b3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dfeccea1-9e96-4ccd-975a-ba29d624856a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0586520c-de4a-481e-9629-1fdc9d9c3b1c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1dfbc8ef-0a6b-492f-bd63-4b66247d0288_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_c19e25c2-bbb6-4c75-984f-3a5080c750bc_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_a1ee6930-39ec-40c8-9a8a-d797db2a0a9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_7d7302a5-825e-4c56-850a-6ff9d25e59fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54cdf1d7-128a-4219-8941-487444b18660_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31521122-5b11-40e6-9882-0b0beac564e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_befe37c5-5bd1-428a-aa58-07876c8eadc3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Underwriting Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_717c3e80-0ee7-442c-9444-6d6515a489bf_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3b2351a8-75c0-4b02-9c33-3bcc6979649c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_6a945298-ee67-4d8a-a83a-46c41858e9ff_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cd74526d-57f1-4e16-86c5-1f1ec6f96cfa_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetContributionAgreementMember_b024d33b-35e4-441f-874d-6cbcaac89ab2_terseLabel_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_label_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement [Member]</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_documentation_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset contribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember" xlink:href="allo-20191231.xsd#allo_AssetContributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetContributionAgreementMember" xlink:to="lab_allo_AssetContributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b57bd13-e8c8-4fbe-a8f1-19319b4e6af7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_57d7e20f-da3b-4408-8dfd-261540ad6361_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_167ac8fa-9488-4f77-a246-2aca2c7c7507_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45319167-fef5-48df-b9f6-1397d7ac3693_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e1136874-f363-4a24-af1d-e9b91dc63641_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_42766d5b-53ca-444e-847d-3a87066c8534_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9691a153-c992-4089-8713-d2118b0f5019_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_5e478f7d-01f1-47d0-b8e0-d2fe05f043c9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred federal, state and local, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DiscountRateForValuation_183e1dec-140d-4ad6-b68d-96b23ec4be67_terseLabel_en-US" xlink:label="lab_allo_DiscountRateForValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for valuation</link:label>
    <link:label id="lab_allo_DiscountRateForValuation_label_en-US" xlink:label="lab_allo_DiscountRateForValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate For Valuation</link:label>
    <link:label id="lab_allo_DiscountRateForValuation_documentation_en-US" xlink:label="lab_allo_DiscountRateForValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for valuation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DiscountRateForValuation" xlink:href="allo-20191231.xsd#allo_DiscountRateForValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DiscountRateForValuation" xlink:to="lab_allo_DiscountRateForValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ce8c8cd1-aedc-4860-9ad7-8345b5a4af7b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_6bcefe29-d27f-491c-bb9c-ffbba07706ef_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1970d1c5-c567-4002-b613-192a052b1b81_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_2324d6ae-94e1-4881-bd38-5fe489660875_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_affced31-a612-4709-b317-f956535c3351_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EarlyExercisedStockOptionsMember_c5b79ba5-b9cb-452f-8cea-284dae762ad1_terseLabel_en-US" xlink:label="lab_allo_EarlyExercisedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercised Stock Options</link:label>
    <link:label id="lab_allo_EarlyExercisedStockOptionsMember_label_en-US" xlink:label="lab_allo_EarlyExercisedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercised Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExercisedStockOptionsMember_documentation_en-US" xlink:label="lab_allo_EarlyExercisedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercised Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExercisedStockOptionsMember" xlink:href="allo-20191231.xsd#allo_EarlyExercisedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExercisedStockOptionsMember" xlink:to="lab_allo_EarlyExercisedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6e59cecc-e86a-4866-990a-f65c32de1b37_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_92c08dcb-d5f6-4d7c-abf7-8b23dfb39e47_totalLabel_en-US" xlink:label="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_label_en-US" xlink:label="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Net Of Deferred Tax Liabilities</link:label>
    <link:label id="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of deferred tax liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:to="lab_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_f91c907f-53e0-4c08-a460-addc32e499f7_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payment in arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Monthly Payments In Arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payments in arrears.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:to="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_126f97f0-e31c-4660-8030-553d88e600f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_64c1f15e-7d6f-4fab-830b-180e196f9ac5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a875eeea-6839-4dfb-ab8d-917520df7019_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_03435be0-0e6d-4ec1-b17b-f20c8e469557_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyCosts_dda1b23e-bbe8-4a22-9e47-1e14d00dd71d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party costs</link:label>
    <link:label id="lab_us-gaap_RelatedPartyCosts_label_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts" xlink:to="lab_us-gaap_RelatedPartyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9f24dd5a-a7e1-4aad-a9da-39b5143c2799_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cfd91b7a-8172-4a1d-bc48-ab7971aa6cfa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ee00e74-d681-455b-a706-9b6df593f8f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_1974ec44-5f92-4b51-8edd-7be660e6e2b3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7de5511a-5e32-4378-b879-fc9ebcde58f6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_61dd1be0-62ce-46b1-b05e-a263201dc3db_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of the applicable statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_676ffd9f-c13e-45c4-be1d-fc4c30eadd2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Forfeitures [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_653da5d6-d4d4-4fd8-9429-f6df7e7fa69e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_85749a27-ba00-4d0d-b50d-acbfd9edb37b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bf12fd1d-b02a-413c-a49c-7e9c113c7c38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2019 and December 31, 2018, respectively; no shares were issued and outstanding as of December 31, 2019 and December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_11a1d626-3c7a-4d20-882d-5ebd06662840_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_67b8bc8d-ed63-4475-9626-4cb16e40ae68_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_115ff3f2-3544-4c11-8dc7-fef6a10850c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0d567a9f-274b-4c9e-93e9-ba28740168c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d1fc4f74-a057-4962-935e-9746e19b4e17_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_558ed198-9b85-45b7-8a9c-e9dfe4aed758_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5c872428-8594-4586-8abd-c1238bd1a150_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2cd89b46-7dd5-4571-bc0a-b25a9bf6a825_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_533e0dc8-e425-49f1-8fc2-7fbdad14a436_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable to related party, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuanceMaximumValue_f283dfb9-c438-4ea1-a0ba-9eeabfc4429d_terseLabel_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, maximum value</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumValue_label_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Value</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumValue_documentation_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumValue" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuanceMaximumValue" xlink:to="lab_allo_StockIssuanceMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_585ee566-4767-46cd-86ce-1c27d800a9e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on conversion of convertible notes payable</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_59616f47-abcb-4b62-9d1f-809679b2c508_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eb6252ed-859f-4ac2-9881-4a3029b2dcd3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IndefiniteMember_c11df4f3-8fcd-460e-b2ac-79b024e725f0_terseLabel_en-US" xlink:label="lab_allo_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_allo_IndefiniteMember_label_en-US" xlink:label="lab_allo_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_allo_IndefiniteMember_documentation_en-US" xlink:label="lab_allo_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IndefiniteMember" xlink:href="allo-20191231.xsd#allo_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IndefiniteMember" xlink:to="lab_allo_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_ac3729bb-d472-428d-afa1-85fdc46bdf90_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_8493f522-4f87-4824-93d8-a8a6f66446c7_terseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember" xlink:href="allo-20191231.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_36f5bd40-de1b-44f1-beed-e6365a803618_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e8e750a5-c50c-4678-812f-bef39f49ffd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fc20af8e-c9f9-40fc-b3ca-2b73f6e8004a_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2679260c-9b05-45b5-af51-8c47a932246b_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ConsultingAgreementsMember_5c69363c-7e59-4eb4-8f80-1ea5455d5b9c_terseLabel_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreements</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_label_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_documentation_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember" xlink:href="allo-20191231.xsd#allo_ConsultingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConsultingAgreementsMember" xlink:to="lab_allo_ConsultingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_11251d4c-5fd2-49e3-82df-798d5e81b32e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TaxExpiration2037To2039Member_fb1a86a6-b47c-402c-978c-ae597d290db2_terseLabel_en-US" xlink:label="lab_allo_TaxExpiration2037To2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037-2039</link:label>
    <link:label id="lab_allo_TaxExpiration2037To2039Member_label_en-US" xlink:label="lab_allo_TaxExpiration2037To2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expiration 2037 to 2039 [Member]</link:label>
    <link:label id="lab_allo_TaxExpiration2037To2039Member_documentation_en-US" xlink:label="lab_allo_TaxExpiration2037To2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand thirty seven to two thousand thirty eight expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037To2039Member" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037To2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TaxExpiration2037To2039Member" xlink:to="lab_allo_TaxExpiration2037To2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SalesMilestoneMember_eb91a73d-17cb-4e49-8371-c6d10ab5e191_terseLabel_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_label_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_documentation_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember" xlink:href="allo-20191231.xsd#allo_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SalesMilestoneMember" xlink:to="lab_allo_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_230117f7-64cb-440b-badf-c347bdc4614b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_75710d9d-89df-4da7-9956-9e994addac99_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_816debae-5a0d-4ad6-8a81-53800e9a1978_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6b7fa833-9128-4c01-bbea-6ef90b23cea8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3da4e159-2f9e-48ce-a61f-e69805f9dc99_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2044f7c9-fc63-435a-bab3-9e891f50a2a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePurchasePriceSharesValue_d7c85ab8-8847-46e9-a66d-ff4cfe96bcc0_terseLabel_en-US" xlink:label="lab_allo_AggregatePurchasePriceSharesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price, shares value</link:label>
    <link:label id="lab_allo_AggregatePurchasePriceSharesValue_label_en-US" xlink:label="lab_allo_AggregatePurchasePriceSharesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Purchase Price Shares Value</link:label>
    <link:label id="lab_allo_AggregatePurchasePriceSharesValue_documentation_en-US" xlink:label="lab_allo_AggregatePurchasePriceSharesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Purchase Price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePurchasePriceSharesValue" xlink:href="allo-20191231.xsd#allo_AggregatePurchasePriceSharesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePurchasePriceSharesValue" xlink:to="lab_allo_AggregatePurchasePriceSharesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_4c47563c-46a8-42ac-9b3d-12871de87028_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution expenses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5319fd40-51b6-417e-8d1d-65d1b75111e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_3eef0a66-b8a1-486b-8f51-c3c487380ae0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_7f7e6df6-12c6-4272-be76-39c677ed1692_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_f86beb39-bed5-4459-8e54-def2848034e1_terseLabel_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84 (in shares)</link:label>
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of new stock classified as temporary equity issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="allo-20191231.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2dd0ec02-d7c3-4c2e-9088-68f7df0770df_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2d1f4d47-a1b1-4e78-9163-2e1a1a042aab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_17db870a-9ddc-4cab-844c-4211ee9440cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a1256a21-ef52-4c5c-9cfc-1a211db4bee4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e067e7ef-694f-4703-8e23-b70accc45fd6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c3315182-29f7-4f85-912b-acd6689513bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred stock per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_49eb6d21-585e-4e14-b722-9765df6f32da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetAcquisitionTable_a98ccc0f-4475-4be0-acda-695ca403b620_terseLabel_en-US" xlink:label="lab_allo_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_allo_AssetAcquisitionTable_label_en-US" xlink:label="lab_allo_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_allo_AssetAcquisitionTable_documentation_en-US" xlink:label="lab_allo_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information about asset Acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionTable" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetAcquisitionTable" xlink:to="lab_allo_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50945368-63e6-4892-986b-0124dc79078d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_a5434b47-cbc0-4408-9123-4f410974584a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable from&#160;Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_label_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from Stockholder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFromStockholderMember" xlink:to="lab_us-gaap_ReceivablesFromStockholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_68c4813e-5c60-4e4e-8a87-8fece17a6bdd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_c47176c3-e026-4bd9-ae0c-606766c297c0_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_fb39bc25-3b77-4189-9a57-aba867c952ec_terseLabel_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_label_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Payments Required Per Product Against Selected Target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_documentation_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:href="allo-20191231.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:to="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f64bfab1-cebf-440b-8a3d-32967b5ade04_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SeriesA1ConvertiblePreferredSharesMember_9af60346-8bda-4123-922c-e7e33e78c20f_terseLabel_en-US" xlink:label="lab_allo_SeriesA1ConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A1 Convertible Preferred Shares</link:label>
    <link:label id="lab_allo_SeriesA1ConvertiblePreferredSharesMember_label_en-US" xlink:label="lab_allo_SeriesA1ConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A1 Convertible Preferred Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SeriesA1ConvertiblePreferredSharesMember" xlink:to="lab_allo_SeriesA1ConvertiblePreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8cc462a9-630f-4d04-8748-8b4fd044d419_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_55c6b92e-3c94-41c2-b392-7c949aa57dce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_59cb85a0-2a6c-4644-a6dc-d6fa3b6f1409_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseOneMember_03d4f9df-ebe1-42ae-9979-15971b4c2830_terseLabel_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">127 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseOneMember_label_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease One [Member]</link:label>
    <link:label id="lab_allo_LeaseOneMember_documentation_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember" xlink:href="allo-20191231.xsd#allo_LeaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseOneMember" xlink:to="lab_allo_LeaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_35f5c58b-8101-45f7-bee2-b1ea1b52b443_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_8e06e1b3-55e6-4ee1-8fd6-2e8aa4627be7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_8240c9c3-f1af-4894-9de3-10b537756264_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_73bfe66a-6a06-46bd-a25b-8e7d083200dc_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_8af8fdae-bddb-498e-a6df-2e85b2273400_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_32f9e2aa-7413-4476-a5e5-5888415d327d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_22aa1061-3b8b-4fa1-9e78-217744fdd547_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7e9ce061-6d0e-409b-b2b0-e3ca15ee6d5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf9e3fb9-8de8-48ae-9f19-3c0031b8c7ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d6406ad-a41d-481d-bb26-af19b6ca9794_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b61e2519-2c12-40ee-90a0-d2e41e4cb1ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_76ba70ac-d0d3-4b20-b7d6-98da9adadd20_negatedLabel_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions receivable from preferred stockholders</link:label>
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_label_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions Receivable From Preferred Stockholders</link:label>
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_documentation_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions receivable from preferred stockholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivableFromPreferredStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:to="lab_allo_SubscriptionsReceivableFromPreferredStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_30b22f2f-d821-466a-920e-113573f368aa_negatedLabel_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses from equity method investments</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_dab77abe-0d01-4afc-82d5-20f907958332_terseLabel_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_label_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_documentation_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment" xlink:href="allo-20191231.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeLossFromCostMethodInvestment" xlink:to="lab_allo_IncomeLossFromCostMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_f089792f-8606-4b6e-a622-3cc89e399781_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fd73454d-2f3e-4d56-8ad9-94c8e8d0fe8c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_146d59d6-cf25-48f8-9e94-5125877c7fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_2ca0c18b-ee41-43aa-a3e6-179f837e7ac4_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_915c6767-2879-456e-9c66-5158452e932a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_65e34d83-32c0-40a2-a129-ea7d961e2ebd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7810798d-4dd7-470f-92e4-ce81edce56bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_85cd94f0-36f5-4c0b-a6eb-e7c77ac96da1_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a07ec72a-0876-49b6-966d-5cc1499001ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_945c53b1-c92e-4824-a46a-cd9e98dc40dc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Assets Acquired Other than Through Business Combination [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Assets Acquired Other than Through Business Combination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7718dfd5-f8d3-4c2c-86b7-53240e1b59c4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_69be8020-64ed-4b07-b4f8-aa6a3ed426a2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09e71d88-5b88-42f7-bf45-fa7164b0fbd4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fed445ec-c5af-41da-9133-39e4a5fd7caa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c11a79ff-b06c-4c8c-be06-ac6c1ae4cf35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5385fa07-44db-4100-8ed0-2d878ee1ff40_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd86ef1e-f060-4c96-9725-a15218586a11_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, weighted average grant date fair value, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ComprehensiveLossPolicyPolicyTextBlock_f77e5660-a5dd-4372-b38a-b0e41971de9a_terseLabel_en-US" xlink:label="lab_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_allo_ComprehensiveLossPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss Policy Policy [Text Block]</link:label>
    <link:label id="lab_allo_ComprehensiveLossPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="allo-20191231.xsd#allo_ComprehensiveLossPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="lab_allo_ComprehensiveLossPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_8d4067cb-df9f-4381-93be-1365cd942290_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetAcquisitionLineItems_d813c44f-5633-414f-a650-837e63c2e787_terseLabel_en-US" xlink:label="lab_allo_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_allo_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_allo_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_allo_AssetAcquisitionLineItems_documentation_en-US" xlink:label="lab_allo_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionLineItems" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetAcquisitionLineItems" xlink:to="lab_allo_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a88e0497-4585-4e32-bf41-93144459c4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6a96f46e-e214-424e-8f61-b67e75e9d3c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_34589c51-a66f-4d4a-be48-3cfe2e32d192_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ac39b87c-b585-4d04-8309-18572f269a09_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5f8b587a-f971-49d8-9ba3-f05ee265be32_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b0e9652a-8bfb-43a7-840f-f40f08b0c855_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LosAngelesMember_821a67cc-a795-4d44-ad40-099d0ba1050e_terseLabel_en-US" xlink:label="lab_allo_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_allo_LosAngelesMember_label_en-US" xlink:label="lab_allo_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_allo_LosAngelesMember_documentation_en-US" xlink:label="lab_allo_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LosAngelesMember" xlink:href="allo-20191231.xsd#allo_LosAngelesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LosAngelesMember" xlink:to="lab_allo_LosAngelesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f7fbb65b-15b8-47b3-ad75-d9228485ca7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_c7d10849-5b61-433a-a54b-0e2c70974590_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_76c458fa-71a6-4423-a768-9b5e374d9f5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_22b67527-4a07-4371-8472-a7f3321c9223_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of convertible preferred stock converted to shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_61ff0bc4-8f59-4010-b353-af5fc6171de6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_ff21c0a7-5e62-4196-a6b7-b3a1a639b472_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Supplies</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_7f91ea6a-5006-491f-8a29-aaee41af8cc4_terseLabel_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder shares subject to future vesting</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_label_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Shares Of Common Stock [Member]</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_documentation_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder shares of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember" xlink:href="allo-20191231.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FounderSharesOfCommonStockMember" xlink:to="lab_allo_FounderSharesOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregateMilestonePayments_9a5bdd6e-ab5a-48be-992f-ad95f236bea7_terseLabel_en-US" xlink:label="lab_allo_AggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments</link:label>
    <link:label id="lab_allo_AggregateMilestonePayments_label_en-US" xlink:label="lab_allo_AggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Milestone Payments</link:label>
    <link:label id="lab_allo_AggregateMilestonePayments_documentation_en-US" xlink:label="lab_allo_AggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregateMilestonePayments" xlink:href="allo-20191231.xsd#allo_AggregateMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregateMilestonePayments" xlink:to="lab_allo_AggregateMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_fbaf420e-432c-4004-844f-ca979508c6e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_484db054-a699-4172-9f4f-b6c5f9c63933_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_807317fd-380c-4464-819c-b88e6b1f0396_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on conversion of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f87c931d-1ffb-42b3-b9d4-808bad7110c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_3fe6f27c-6a52-4b88-9e00-5ff7a11f7d75_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, aggregate intrinsic value, ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_57fa3e62-d672-4b91-9c07-73fd1ed19b92_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on investment securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb7f0958-a115-4213-84ba-74e175c50ec0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_935990f6-d3b3-4ba9-8de4-db605aafc1aa_terseLabel_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_label_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_documentation_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:href="allo-20191231.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:to="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c4a4f5c0-5649-472a-942e-380fd027b301_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0ee1dbdb-a955-4fe7-8b10-b4892999fd7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BalanceSheetComponentsLineItems_29c3616a-0552-4e38-8b28-ca5c339e43d7_terseLabel_en-US" xlink:label="lab_allo_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_allo_BalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_allo_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_allo_BalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_allo_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet components line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsLineItems" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BalanceSheetComponentsLineItems" xlink:to="lab_allo_BalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c7b2038a-95e5-47a5-b248-b1e8a17b5b59_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_44e96276-5aa5-4ea0-8d97-33be3b2331cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b2d65dc4-739a-4c0c-91e3-98e0fcdb98f2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7adae7df-c718-4d88-ae37-387eeb50ce95_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_bbdb5eb6-fdc1-4433-99b2-9c73eed9787f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_8066a88c-4701-4160-a20c-c339552db676_terseLabel_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:href="allo-20191231.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:to="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f829ad77-cc27-4366-af33-8bc436a87b46_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to tax position of prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_92c7eff1-4304-44c0-a07a-b1a5841f4902_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock_706636b1-76c6-4cfb-95b5-d00f067dc942_terseLabel_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock_label_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs Policy [Text Block]</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:href="allo-20191231.xsd#allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:to="lab_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2c20ee81-0790-4e18-bbd1-323eaf22fd08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_420a9a5b-0514-45d3-bb76-5d8272ad5e8c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9502dead-e98c-4ec4-8abf-c2abc5c2b040_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_11ca742e-45fe-4162-98ac-8afec32015db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, weighted average remaining vesting life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aa7d575a-861e-4ab8-b924-6e7ae0014042_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b9e7f5cb-ec13-457c-a57d-f7979932cdea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3c93de38-2dd0-4761-8f08-fb3dff4c5178_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_e0f48d94-9937-488a-9e20-3d41a6675750_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d62c7d4f-2dbd-42a9-b011-6980c5c05094_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d43a31b5-c8c4-426d-a531-3faac6c73c95_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a04548dc-1e86-44c0-b33f-014ecde324f2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_38155e59-8364-4aad-9dd6-61b2cf013950_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_530709fe-706e-416b-989b-d0ab4c9e63ba_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_53aaa827-469e-4284-beb2-26c10dedf67b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_aaa8f387-3451-4a44-b18d-4897086d7b51_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c221c1b1-5dd1-4e3e-8574-e9d978d7080d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c03ba69e-4efa-4aac-b6c8-b30094bdcb97_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1c847c8d-3f0e-4596-83a8-3b63f73f62b9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CurrentOfferingPeriod_133fe682-6582-46fa-8ecf-4b92395f0c3c_terseLabel_en-US" xlink:label="lab_allo_CurrentOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current offering period</link:label>
    <link:label id="lab_allo_CurrentOfferingPeriod_label_en-US" xlink:label="lab_allo_CurrentOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Offering Period</link:label>
    <link:label id="lab_allo_CurrentOfferingPeriod_documentation_en-US" xlink:label="lab_allo_CurrentOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentOfferingPeriod" xlink:href="allo-20191231.xsd#allo_CurrentOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CurrentOfferingPeriod" xlink:to="lab_allo_CurrentOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bb9ff74b-6a5e-44ef-8e0c-9b2d173744b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0190dd1a-eeec-4989-884d-759cb93ad444_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a27f1352-9f0d-4e1e-b3bc-ff6253e0e32f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_0cda102e-bffb-4ce7-a3cf-8a63865c0027_terseLabel_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 - 2 years</link:label>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_label_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_documentation_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39e3fe85-d440-4fa6-8708-5e0478fa49d1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_c03eea06-49ad-4bd6-b581-416cea414838_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_052393d7-9a13-4a36-9741-d916555743cb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7c2d122e-e987-44c9-95dc-339b4f8341e6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_dd28436f-ea5d-4c3c-a35e-743a684e3115_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c8c8eb34-4f12-4fa0-bd44-1f82269be77e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_291392a2-d974-427a-b803-f643af56a4cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4986db13-ee57-421d-817b-1406c00817f7_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_49100ab7-93d5-49ca-ab9a-08d577a24eca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_7174f694-7fd5-4d59-98db-e89de556ce79_terseLabel_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related benefits</link:label>
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_label_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation And Related Benefits Current</link:label>
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_documentation_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and employee related benefits current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:href="allo-20191231.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:to="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8771bbb2-f3f1-49a1-8560-ec47fb599834_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TaxExpiration2037Member_7d258fba-ef95-4674-a865-d5af26aff409_terseLabel_en-US" xlink:label="lab_allo_TaxExpiration2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037</link:label>
    <link:label id="lab_allo_TaxExpiration2037Member_label_en-US" xlink:label="lab_allo_TaxExpiration2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expiration 2037 [Member]</link:label>
    <link:label id="lab_allo_TaxExpiration2037Member_documentation_en-US" xlink:label="lab_allo_TaxExpiration2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expiration 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037Member" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TaxExpiration2037Member" xlink:to="lab_allo_TaxExpiration2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ByHeartMember_078f2524-929d-4eae-9b6b-744913bbf5da_terseLabel_en-US" xlink:label="lab_allo_ByHeartMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ByHeart</link:label>
    <link:label id="lab_allo_ByHeartMember_label_en-US" xlink:label="lab_allo_ByHeartMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ByHeart [Member]</link:label>
    <link:label id="lab_allo_ByHeartMember_documentation_en-US" xlink:label="lab_allo_ByHeartMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ByHeart</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartMember" xlink:href="allo-20191231.xsd#allo_ByHeartMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ByHeartMember" xlink:to="lab_allo_ByHeartMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EstimatedLifeOfAssetsTableTextBlock_d4efa357-776a-42c6-87fd-8e28cd7cb48a_terseLabel_en-US" xlink:label="lab_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Life Of Assets</link:label>
    <link:label id="lab_allo_EstimatedLifeOfAssetsTableTextBlock_label_en-US" xlink:label="lab_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Life Of Assets Table [Text Block]</link:label>
    <link:label id="lab_allo_EstimatedLifeOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated life of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:href="allo-20191231.xsd#allo_EstimatedLifeOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:to="lab_allo_EstimatedLifeOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a543a707-71e0-4cb8-a905-9650d457c7c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5f2aaefb-4e6d-4153-be8e-742b27c67d50_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net issuance cost on equity</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_dc997540-fd6a-4af2-b5c4-d65470bdf6bd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0ad259b8-5763-472c-a1dc-04ee557a44a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50a5d366-c234-4122-8279-c1a51194a780_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_960be8d2-be58-4010-b329-03b7e0c825d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ca5d4e6-1cf0-4196-bc1a-f169d664dc00_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for early exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NewarkMember_d9318a66-1a29-4fc4-84fd-66f613a310f2_terseLabel_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark</link:label>
    <link:label id="lab_allo_NewarkMember_label_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:label id="lab_allo_NewarkMember_documentation_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember" xlink:href="allo-20191231.xsd#allo_NewarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NewarkMember" xlink:to="lab_allo_NewarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LaboratoryEquipmentMember_6ed33d3d-9259-4049-9d2b-03d6c68e7ddf_terseLabel_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember" xlink:href="allo-20191231.xsd#allo_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LaboratoryEquipmentMember" xlink:to="lab_allo_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a2094a5a-7770-4147-b3b1-e50e8aeb3ea4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_40a1c23b-ec5f-49d3-815a-8ecdc0ff092c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_4cc688e7-6714-407f-9c49-f6a5e86fb8d6_terseLabel_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from early exercise of stock options</link:label>
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_label_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Early Exercise Of Stock Options</link:label>
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_documentation_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Early Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:href="allo-20191231.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:to="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_4312e552-7f66-4fe9-a76e-d00fc174bfe1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bdaf65a7-1d4d-40b1-9ba1-b25f1980d49e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OperatingLeaseAssetRetirementObligation_435c6159-7afb-4841-9441-4639d1119129_terseLabel_en-US" xlink:label="lab_allo_OperatingLeaseAssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_allo_OperatingLeaseAssetRetirementObligation_label_en-US" xlink:label="lab_allo_OperatingLeaseAssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Asset Retirement Obligation</link:label>
    <link:label id="lab_allo_OperatingLeaseAssetRetirementObligation_documentation_en-US" xlink:label="lab_allo_OperatingLeaseAssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Asset Retirement Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeaseAssetRetirementObligation" xlink:href="allo-20191231.xsd#allo_OperatingLeaseAssetRetirementObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OperatingLeaseAssetRetirementObligation" xlink:to="lab_allo_OperatingLeaseAssetRetirementObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6df08429-6c97-49ae-a113-00972813dfeb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_a16d7cc9-7e29-45ab-95c7-aea9970b1be6_terseLabel_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_label_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_documentation_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts" xlink:href="allo-20191231.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CostMethodInvestmentTransactionCosts" xlink:to="lab_allo_CostMethodInvestmentTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b9067321-66fc-4da8-9971-fb7c7c117359_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_845a0c2b-3f3f-41b0-9899-e8603ac29fd8_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6bbe5794-bbe7-4078-9645-304b1c1ca539_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedInterestOnShortTermMarketableSecurities_71418cb4-4a33-4467-87bc-b2cac9b0a6c9_terseLabel_en-US" xlink:label="lab_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on short-term marketable securities</link:label>
    <link:label id="lab_allo_AccruedInterestOnShortTermMarketableSecurities_label_en-US" xlink:label="lab_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest On Short Term Marketable Securities</link:label>
    <link:label id="lab_allo_AccruedInterestOnShortTermMarketableSecurities_documentation_en-US" xlink:label="lab_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on short-term marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:href="allo-20191231.xsd#allo_AccruedInterestOnShortTermMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:to="lab_allo_AccruedInterestOnShortTermMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RegulatoryAndSalesMilestoneMember_6fb2c4d2-e13e-4409-b989-656a998dd9c1_terseLabel_en-US" xlink:label="lab_allo_RegulatoryAndSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Sales Milestone</link:label>
    <link:label id="lab_allo_RegulatoryAndSalesMilestoneMember_label_en-US" xlink:label="lab_allo_RegulatoryAndSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryAndSalesMilestoneMember_documentation_en-US" xlink:label="lab_allo_RegulatoryAndSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and sales milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryAndSalesMilestoneMember" xlink:href="allo-20191231.xsd#allo_RegulatoryAndSalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryAndSalesMilestoneMember" xlink:to="lab_allo_RegulatoryAndSalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_ef5eb4bf-3c63-4fe3-b39f-b0c1c702af9b_totalLabel_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents, and investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_documentation_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:href="allo-20191231.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:to="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_e5bcf643-2749-4dd5-9ec4-57b69dec05bd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8c405ea2-08bd-4d54-ba49-1521bca619c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_492f240a-076b-4cbc-a72f-f6bfe2706bcc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_c5aeaf26-23c0-42b8-bdc6-a3360ae15eba_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0332055e-416c-44b7-acc2-712ce7305ad4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, convertible preferred stock and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3d41b0a6-7915-4645-973b-bae12f8cadbb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a9344525-d35f-438f-a095-9fe16be74bda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_501d1ea3-3c7e-4021-8206-8b753c058969_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0fa89e10-1f07-4cfa-8810-df0a51b8a67e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumeratorAbstract_683da281-7920-4df0-b6af-b39e8c504469_terseLabel_en-US" xlink:label="lab_allo_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_allo_NumeratorAbstract_label_en-US" xlink:label="lab_allo_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_allo_NumeratorAbstract_documentation_en-US" xlink:label="lab_allo_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumeratorAbstract" xlink:href="allo-20191231.xsd#allo_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumeratorAbstract" xlink:to="lab_allo_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShorttermLeaseRentExpense_138791c1-e7d5-4a68-9db0-a6264f032eb6_terseLabel_en-US" xlink:label="lab_allo_ShorttermLeaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense for short-term leases</link:label>
    <link:label id="lab_allo_ShorttermLeaseRentExpense_label_en-US" xlink:label="lab_allo_ShorttermLeaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shortterm Lease Rent Expense</link:label>
    <link:label id="lab_allo_ShorttermLeaseRentExpense_documentation_en-US" xlink:label="lab_allo_ShorttermLeaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term leaser rent expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShorttermLeaseRentExpense" xlink:href="allo-20191231.xsd#allo_ShorttermLeaseRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShorttermLeaseRentExpense" xlink:to="lab_allo_ShorttermLeaseRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_9a69cb57-78d0-4809-bced-4ded99891cc1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_fde9530b-57b4-4692-af0b-d2046a2b4dd5_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_a9035528-aa29-4b08-9e8a-49ce8f1563cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_1d341755-f8dd-4376-bdec-9083e6daaf09_terseLabel_en-US" xlink:label="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of in-process R&amp;D</link:label>
    <link:label id="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Write Off Of In Process Research And Development</link:label>
    <link:label id="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation Write-off of in process research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:to="lab_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef82cf8d-4019-4596-ae34-6b15b40142fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_a19d55f4-21b7-4697-88fb-4655bb1e9d3a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_55020e27-239c-48b8-b1d6-3b1092a25312_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_56d6c007-a66b-4d1c-8323-4e6c7536c8a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short tem lease total commitment</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_61f5241e-df95-44a7-9fdc-1f27918ec8be_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures and Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ce8c2a7d-097e-406f-a883-c55f5f24a390_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9f2730f9-b8c9-41a6-9b9c-fb3a72dd0a90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3eec360c-b3e3-444c-995e-481771444d37_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c008016b-7abd-4b25-bfb6-030a9ef4013c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Notes 6, 7 and 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock_f5cc9d1f-9a0a-47e0-b449-54c6993cc2c2_terseLabel_en-US" xlink:label="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepayments and Other Current Assets</link:label>
    <link:label id="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepayments And Other Current Assets Table [Text Block]</link:label>
    <link:label id="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the prepayments that will be charged against earnings and carrying amounts of other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:href="allo-20191231.xsd#allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_14d2958c-ccd9-4988-b1c6-7a8464d3e9a1_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_50a733de-c0f3-4f9f-8c1d-05e00470cbb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_35bb13bc-b6de-4a5f-9861-c4437953828d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_4e3ee717-9060-4780-b54e-a06af39a0308_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_5ad07e6c-7329-42b0-800a-da989ae7e4dc_terseLabel_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_label_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember" xlink:to="lab_us-gaap_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_726f8529-f5d2-4052-8d41-3ef8d01a7a00_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_72be7ddc-7872-43ff-9b04-b83cd68e9f56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_90d33ae1-ab7f-43fa-90ef-71aa273e1d68_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f1ea69fe-8f6e-4013-b4c0-2fc6b09f8df8_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_f7ab6e90-3744-41da-82ce-5c2232efc199_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f0ee2afd-dd56-47a9-8b3b-6a0c4ee3c269_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating, investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7a2bed71-0b1c-41b9-a2d8-f33ae99ad3a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7956f194-ef6e-4229-b741-484cc026ca8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_66378bf3-b50d-455d-bae8-1f6ae6fc82f7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2ad1cbbc-9dbb-43df-9434-f47b7d2d7509_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cfe56438-06ae-44ec-b750-887c734f2e76_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementsTextBlock_f06a87cf-855b-486c-83e2-546ca5638a8e_terseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementsTextBlock_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Text Block]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementsTextBlock_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:href="allo-20191231.xsd#allo_LicenseAndCollaborationAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:to="lab_allo_LicenseAndCollaborationAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_bc3c890c-2ab5-4b4e-8ae9-6236a364af75_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenPlanMember" xlink:to="lab_allo_TwoThousandEighteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_c611492d-bb2d-4929-9ca2-9628c2a1dff9_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date1</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date 1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d2bc2435-3870-4a8d-80bb-d865db12cad8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60d7eedc-52b5-4042-b7d9-f481e48a4dea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b8a6bd18-3c67-41b5-ac25-22bc5fc63caa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bf4da0c0-1abb-49fa-bbf6-20f304d864e1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8ee6a3cc-46a4-4cae-b5b9-507b4fb907f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f26be6cc-7b01-4625-bca0-35f52e3b8357_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments not due at a single maturity date</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4a3fa013-2d73-492a-9aa6-e5546a4bc8bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_ad1d1bf8-b57e-4456-8904-86c5877ae949_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_011e067d-bfc7-432c-8afe-7527d5dc60fd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f67d66d1-2854-4599-8143-01f797268330_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_11587604-9e12-46e2-b6b3-551cf6255ef7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition of assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Assets, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:to="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cde8061b-d973-4364-8d5a-137c094de6e9_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, weighted-average remaining amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_50703e24-ccae-4cdb-8442-58f6f368104c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d996bfd9-f80c-4aeb-aef7-8f2d193f3cee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FoundersStockAwardMember_6bcd36d3-2b85-4ea6-9043-f735facf0f6e_terseLabel_en-US" xlink:label="lab_allo_FoundersStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders Stock Award</link:label>
    <link:label id="lab_allo_FoundersStockAwardMember_label_en-US" xlink:label="lab_allo_FoundersStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders Stock Award [Member]</link:label>
    <link:label id="lab_allo_FoundersStockAwardMember_documentation_en-US" xlink:label="lab_allo_FoundersStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders Stock Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersStockAwardMember" xlink:href="allo-20191231.xsd#allo_FoundersStockAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FoundersStockAwardMember" xlink:to="lab_allo_FoundersStockAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CellectisSAMember_a0f7719d-0a0e-4bc3-8d89-68186f50bab2_terseLabel_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis</link:label>
    <link:label id="lab_allo_CellectisSAMember_label_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S A [Member]</link:label>
    <link:label id="lab_allo_CellectisSAMember_documentation_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S.A..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember" xlink:href="allo-20191231.xsd#allo_CellectisSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CellectisSAMember" xlink:to="lab_allo_CellectisSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_f1b63c2c-b50e-40e7-a2e1-e73145d5fbe0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fd2094a9-f2af-4d73-9521-66e3585a62a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2d5fd3bd-94ad-4a04-807d-b0118dd10a82_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d591c1da-5651-423f-96e9-b35dfddd52d6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeOperatingLeaseOptionToExtendNumber_b1f98588-13d6-434e-8227-8e47a0e0637f_terseLabel_en-US" xlink:label="lab_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, options to extend term</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseOptionToExtendNumber_label_en-US" xlink:label="lab_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Extend, Number</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseOptionToExtendNumber_documentation_en-US" xlink:label="lab_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Extend, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseOptionToExtendNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:to="lab_allo_LesseeOperatingLeaseOptionToExtendNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_a99cfa4a-e512-495f-94ba-959781715901_negatedLabel_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible note payable</link:label>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_fbeeabb7-1af5-44c6-b522-5e50a2936869_terseLabel_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_label_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Convertible Note Payable</link:label>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_documentation_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:href="allo-20191231.xsd#allo_ChangeInFairValueOfConvertibleNotePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:to="lab_allo_ChangeInFairValueOfConvertibleNotePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_80fbe138-4ac9-41c3-9cd0-9eb4e9460cff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4d83776b-f829-4c8e-b71a-130d6138a2f5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d134ab8f-b9fc-44fb-b801-f021666fee9b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d5327ac0-2589-4a2c-92ba-70d9d2397a9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_c877e2f2-627c-4bf1-a5bd-dafc2bfa0565_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_00be77b3-8186-4add-8584-696035f37d5f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e41fdb69-8ca3-4f02-92e3-931932548fa4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_96c515b9-bac2-47e5-8b64-bdcb1a5bfebd_terseLabel_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, maximum compensation due to third party (as a percentage of stock sales)</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_label_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Compensation Due To Third Party, Percent</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_documentation_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Compensation Due To Third Party, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:to="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e13aabef-6f1f-4e5e-b28b-1d344213af2d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4eed66bb-a223-4092-aafd-2a548fe8a066_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_540dc061-d6b6-49f2-abb4-a4b8bdfdcc00_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock_4533c1e0-3830-445e-8a5c-cddd52172ae6_terseLabel_en-US" xlink:label="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Acquired</link:label>
    <link:label id="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock_label_en-US" xlink:label="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Fair Value Of Assets Acquired [Table Text Block]</link:label>
    <link:label id="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock_documentation_en-US" xlink:label="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:href="allo-20191231.xsd#allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:to="lab_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e59a53a6-6937-495f-b2d7-4c66cc335601_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issued in connection with asset acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_38c00275-e888-46e6-8fe2-83d91590a256_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833f9a1b-9add-4ca0-b9cf-8c81247ef107_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8047e912-4050-4374-a048-c26847da50c5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in Notch</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_af7589fe-43a7-4675-8936-7587f1d025b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_51a9dd81-17a2-4a9c-a3c8-1a2912b41a54_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35146508-320a-4d0e-a3b1-365e14d3ad93_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c5f32fd0-763c-49a8-97a4-04db0a8dc1f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_45530048-1cd4-4df3-bd2d-eba854da09ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40503f98-0132-475a-8caa-6d3bac8e1daf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average grant date fair value of employee options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_0a126292-5747-461e-816e-e59cf582d6c6_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="lab_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4c3d8cb-ebc2-4887-829d-f44f8c2774c7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8054f6e4-f863-4576-ac25-b322ce75965a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_6e16ee6c-3897-4469-a2a7-0160e898c4ba_terseLabel_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from common stockholders for issuance of founders' stock at inception</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_label_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Common Stock Issues</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_documentation_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value common stock issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:to="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TransitionServicesAgreementMember_2c629a75-46ed-4fda-8876-3c54ec1b8fd0_terseLabel_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement [Member]</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember" xlink:href="allo-20191231.xsd#allo_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TransitionServicesAgreementMember" xlink:to="lab_allo_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AllowanceForTenantImprovements_a84745ec-e771-4512-b45a-32139b6c93f4_terseLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_97ab2479-303d-47f9-a877-cfe10f1541fd_negatedLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_label_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_documentation_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements" xlink:href="allo-20191231.xsd#allo_AllowanceForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllowanceForTenantImprovements" xlink:to="lab_allo_AllowanceForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6ca1f75b-4498-486d-9ba0-c870e3730016_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_59692083-43a4-4769-82eb-29fdc63d207f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f07f3cf-df3e-41a2-a4c5-fc59740c92fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_81e0791f-00cd-47b4-9a3e-0b76018b34cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_32bb2ac7-d2ab-4d8c-b7b7-d9a40c29cd78_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, granted, weighted average remaining vesting life</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_82fab127-5892-405d-ba99-60394a92e80c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_537c90e7-5cbd-414e-abbb-e1edba2a29da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2e7e6ac1-a74e-40b5-b482-b8ef75c0eb9d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4547168e-01f8-4b08-ade7-607faccca628_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_4bd0ddea-1dc8-442e-a6bd-8e23fcae896c_terseLabel_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 3 years</link:label>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_label_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities Within Three Year Fair Value</link:label>
    <link:label id="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_documentation_en-US" xlink:label="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities debt maturities within three year fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:to="lab_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_73d3e9a4-0508-45a7-b32d-05b0414b1089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_bec817c8-c0b4-43f8-907f-cb57b51ef498_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_93115b24-ecd7-44fb-ba43-77cbefdecfde_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b57c28e4-24a7-4087-b3eb-f03a8ee8781c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_37957df7-d46d-4ed8-8881-763f008d7c11_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_750f0387-fb8c-42e8-8098-43d5753f7268_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_919fc3b8-8c5c-418c-a453-19bc07ace93b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88d1479c-cac2-49ad-9b77-d176464cb8dc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_790406cb-2291-4ee2-8e88-b3e8d6ada5c0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_e5dd6382-8384-4bbc-96a4-c37b45b1d76f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0da90b76-df5e-4965-92f7-ceb4e949266f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_f3af7b58-f0e5-4829-b5af-1ac174485cd1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_18ae4ad7-287f-49c4-83f8-9ea4dfacd5f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_71fb9da5-a1bc-48c3-bafc-e5501cfbfa86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b260adc5-50a1-4f61-800c-0d05f45dbf1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_34ec5d1e-d664-4935-9855-06316a9e2aa0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_232743bc-0621-449f-803d-88d669ef87aa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of stock in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fd99deb6-27ed-433b-b167-94822d9e26e8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_ff5b3a23-431f-4120-8f25-48dc4e4eb729_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DenominatorAbstract_62a79ff9-6071-48b8-bc6b-b2202d743441_terseLabel_en-US" xlink:label="lab_allo_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_allo_DenominatorAbstract_label_en-US" xlink:label="lab_allo_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_allo_DenominatorAbstract_documentation_en-US" xlink:label="lab_allo_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DenominatorAbstract" xlink:href="allo-20191231.xsd#allo_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DenominatorAbstract" xlink:to="lab_allo_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_596abda0-7370-4d2a-ac18-56d976331f98_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_73ea0af4-c20c-46d5-a0b8-ce534c7403c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units subject to vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_15493c3e-11da-44ff-be60-4f86977788c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of commissions and issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestonePayments_2a7bbe89-b775-4a12-8ea8-68358a53dc02_terseLabel_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, per target (in usd per share)</link:label>
    <link:label id="lab_allo_MilestonePayments_label_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_allo_MilestonePayments_documentation_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments" xlink:href="allo-20191231.xsd#allo_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestonePayments" xlink:to="lab_allo_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DeferredTaxAssetsLeaseLiabilities_84835d57-a5e4-4de3-8c57-487231d0da11_terseLabel_en-US" xlink:label="lab_allo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_allo_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_allo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label id="lab_allo_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_allo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsLeaseLiabilities" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_allo_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e1c4b5d8-fc3f-41e3-9a90-6314abb78261_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06f87ae8-0d96-4aff-987a-df3491e39f1f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c6175ad6-90c0-4044-b22f-3ffd243fea47_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_36d4772f-c7e0-417f-a4c3-739b16843886_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b1e13fa5-8a2a-4b35-ad04-9db0d8ba48ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock forward split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e182ae09-13e2-4a9c-96f3-ff888df286bc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f78108e6-4916-4203-bb75-b7ec35b2dfc0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_444b83d2-4cb1-4d1d-b30f-9aefb520d0a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_42cf4436-74f9-40f6-a7c5-437e3bd59d3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AntiCDNineteenCARTCellTherapyMember_4268b97a-ade0-44a8-87ea-79e6985d1c46_terseLabel_en-US" xlink:label="lab_allo_AntiCDNineteenCARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-CD19 CAR T cell therapy</link:label>
    <link:label id="lab_allo_AntiCDNineteenCARTCellTherapyMember_label_en-US" xlink:label="lab_allo_AntiCDNineteenCARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti C D Nineteen C A R T Cell Therapy [Member]</link:label>
    <link:label id="lab_allo_AntiCDNineteenCARTCellTherapyMember_documentation_en-US" xlink:label="lab_allo_AntiCDNineteenCARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-CD19 CAR T cell therapy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiCDNineteenCARTCellTherapyMember" xlink:href="allo-20191231.xsd#allo_AntiCDNineteenCARTCellTherapyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AntiCDNineteenCARTCellTherapyMember" xlink:to="lab_allo_AntiCDNineteenCARTCellTherapyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_acca7dd8-9468-45bb-8540-aba88a10517e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_461f30fd-311f-453c-9d10-6cd27e1af358_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_9e39f022-de7a-476c-9d58-65b8fbbfa729_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion settlement price as a percentage of IPO price per share</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d18b3fb9-aa9f-47c3-8618-f13df55a5d4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dd3db1b1-1629-4b1e-8f0e-f1ef07af7b7f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_1954ecb2-77e0-41d8-ba43-b757a4f32321_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for fractional shares from forward stock split</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd02a3da-3e91-4d63-be06-6915fb8aa3a0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_598bd39e-c438-4219-97cb-45ea096009e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition_f6d17007-d2a3-49b6-bac2-f3749f86e6e4_terseLabel_en-US" xlink:label="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PP&amp;E and other assets acquired in asset acquisition</link:label>
    <link:label id="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition_label_en-US" xlink:label="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant Equipment And Other Assets Acquired In Asset Acquisition</link:label>
    <link:label id="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition_documentation_en-US" xlink:label="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant &amp; equipment and other assets acquired in asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:href="allo-20191231.xsd#allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:to="lab_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_edd086db-9cb4-4ac0-ad5b-4314ed7e8df8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d4cc7468-3f10-4586-b6fe-d61dc8861603_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3346de0-6931-4afe-a74e-91cbe29695a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3a0a67a5-bad6-4475-b571-0fe33639a0f8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CombinedVotingPowerByIndividual_8cde3965-abf1-49cb-a7d2-aad88685cd5f_terseLabel_en-US" xlink:label="lab_allo_CombinedVotingPowerByIndividual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined voting power by individual</link:label>
    <link:label id="lab_allo_CombinedVotingPowerByIndividual_label_en-US" xlink:label="lab_allo_CombinedVotingPowerByIndividual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined Voting Power By Individual</link:label>
    <link:label id="lab_allo_CombinedVotingPowerByIndividual_documentation_en-US" xlink:label="lab_allo_CombinedVotingPowerByIndividual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined voting power by individual.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CombinedVotingPowerByIndividual" xlink:href="allo-20191231.xsd#allo_CombinedVotingPowerByIndividual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CombinedVotingPowerByIndividual" xlink:to="lab_allo_CombinedVotingPowerByIndividual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_26804c7a-5b71-4f0b-8e86-9a671a2db7bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8c0e897c-7bd4-40d7-800c-6b05cf3e52d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_ac1b463b-5b9a-41ec-8248-7c48aca9e9ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_36e62603-9676-4088-84d6-77f690c453bf_terseLabel_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 convertible preferred stock issued in asset acquisition</link:label>
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_label_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock Issued In Asset Acquisition</link:label>
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_documentation_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 convertible preferred stock issued in asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:href="allo-20191231.xsd#allo_ConvertiblePreferredStockIssuedInAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:to="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_2ffd0b2f-e034-4163-a242-679eacd31074_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a045ae5-e111-4423-b6f5-13f817b60fa9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OperatingLeasesNumberOfLeaseAgreements_c96af5c5-a6b5-4c61-b5c7-7755f32beb7c_terseLabel_en-US" xlink:label="lab_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating Leases for office space</link:label>
    <link:label id="lab_allo_OperatingLeasesNumberOfLeaseAgreements_label_en-US" xlink:label="lab_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Number Of Lease Agreements</link:label>
    <link:label id="lab_allo_OperatingLeasesNumberOfLeaseAgreements_documentation_en-US" xlink:label="lab_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating lease agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:href="allo-20191231.xsd#allo_OperatingLeasesNumberOfLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:to="lab_allo_OperatingLeasesNumberOfLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_97ac7e76-7473-4e89-be8b-c8ca109662a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ClinicalDevelopmentMilestoneMember_ce22f2c0-5a32-4807-8916-d1c97774ac98_terseLabel_en-US" xlink:label="lab_allo_ClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Milestone</link:label>
    <link:label id="lab_allo_ClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_allo_ClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_allo_ClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalDevelopmentMilestoneMember" xlink:href="allo-20191231.xsd#allo_ClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalDevelopmentMilestoneMember" xlink:to="lab_allo_ClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_05dff15b-e6a9-4606-aae8-f9459a07c856_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_8238a714-655d-48a8-9070-7c715cb385e6_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_609a5366-f64f-40b4-bb3a-e50fb9b33e98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impairment losses of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2f33c00c-5738-439a-9b6b-2f2521cedeb4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_88c90e70-1062-4229-bd1e-8a929cfcfd4f_terseLabel_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="allo-20191231.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_98d280a6-9d02-4bcc-918c-d9c3261e4d57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated incremental borrowing rate of lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0aee1250-cf12-4f6f-8b0b-0b525b55f43e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and purchased software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock_0e6b2104-985a-4eef-b2dd-086b05299b5b_terseLabel_en-US" xlink:label="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modified shares of common stock (in shares)</link:label>
    <link:label id="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock_label_en-US" xlink:label="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modification Of Convertible Preferred Stock For Common Stock</link:label>
    <link:label id="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock_documentation_en-US" xlink:label="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modification of convertible preferred stock for common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:href="allo-20191231.xsd#allo_ModificationOfConvertiblePreferredStockForCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:to="lab_allo_ModificationOfConvertiblePreferredStockForCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8150eb22-4353-40fd-b253-470c93ccb070_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_d214f914-1f39-4cc0-95cc-d693a86f5364_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_5c484474-b327-4ede-8638-7caee7f73733_terseLabel_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Expenses Current</link:label>
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Expenses Current</link:label>
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:href="allo-20191231.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:to="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3d7aea9a-36d0-49e3-9c50-382bffc1013d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a3bceaa-b73b-4b78-acdf-6a850f9bcc6c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ServierMember_a78d8309-244e-44cc-9d1a-8fc26275c33c_terseLabel_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_allo_ServierMember_label_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_allo_ServierMember_documentation_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember" xlink:href="allo-20191231.xsd#allo_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember" xlink:to="lab_allo_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AntiBCMACARTCellTherapyMember_2549e2ef-f671-4c42-ad4b-3faf53edb15e_terseLabel_en-US" xlink:label="lab_allo_AntiBCMACARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-BCMA CAR T cell therapy</link:label>
    <link:label id="lab_allo_AntiBCMACARTCellTherapyMember_label_en-US" xlink:label="lab_allo_AntiBCMACARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti B C M A C A R T Cell Therapy [Member]</link:label>
    <link:label id="lab_allo_AntiBCMACARTCellTherapyMember_documentation_en-US" xlink:label="lab_allo_AntiBCMACARTCellTherapyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-BCMA CAR T cell therapy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiBCMACARTCellTherapyMember" xlink:href="allo-20191231.xsd#allo_AntiBCMACARTCellTherapyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AntiBCMACARTCellTherapyMember" xlink:to="lab_allo_AntiBCMACARTCellTherapyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_195917e0-40c7-427f-8fcf-e51a12baf73c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e0801d27-6792-4d34-893d-c62c9c403ad4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_f184e385-4e24-4a1e-ac75-cf2602ad07aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_dc2c7e5d-fe79-4d24-8a62-ac49adb865a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8d2ca837-ecab-4edb-b801-b3136088bbdd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_d4c4f085-c6a3-4f0e-8ee2-25822916831d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c85d729e-e889-48c6-b3a0-158d279c1bd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost resulting from the modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_f75344ac-0ade-4d01-8f34-c76d4334729a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bce95e07-cff6-4138-a89f-14515fcad8e1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember_37f9aeb7-bcc3-46cf-a8ab-9261f9387a69_terseLabel_en-US" xlink:label="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TPG Capital &#8211; FO LLC</link:label>
    <link:label id="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember_label_en-US" xlink:label="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">T P G Capital F O Limited Liability Company [Member]</link:label>
    <link:label id="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember_documentation_en-US" xlink:label="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TPG Capital FO Limited Liability Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:href="allo-20191231.xsd#allo_TPGCapitalFOLimitedLiabilityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:to="lab_allo_TPGCapitalFOLimitedLiabilityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f4e553a4-a345-4c1a-8248-d778018fedf2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7010764f-6185-4d4d-9724-83daf5d71a49_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NotesReceivableFromCommonShareholders_0b29c677-1789-47ec-bf65-3b25fa4c1027_negatedLabel_en-US" xlink:label="lab_allo_NotesReceivableFromCommonShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable from common stockholders</link:label>
    <link:label id="lab_allo_NotesReceivableFromCommonShareholders_label_en-US" xlink:label="lab_allo_NotesReceivableFromCommonShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable From Common Shareholders</link:label>
    <link:label id="lab_allo_NotesReceivableFromCommonShareholders_documentation_en-US" xlink:label="lab_allo_NotesReceivableFromCommonShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable from common shareholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotesReceivableFromCommonShareholders" xlink:href="allo-20191231.xsd#allo_NotesReceivableFromCommonShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotesReceivableFromCommonShareholders" xlink:to="lab_allo_NotesReceivableFromCommonShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_060d6b2d-5850-4df6-b391-23f4457f2038_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_2892f7d2-64c8-4b08-8efe-8c69595276ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d5d87dcd-15ec-4dff-b2f4-feccd836685d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b28b0dd8-379b-4d53-beae-93b527b2844f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_530e1ff8-0cc2-4197-8fab-a2df09e07b00_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cdc5b158-7df4-46fd-889c-91f918991ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_830d3375-326a-47d1-941c-5d303c69d56d_terseLabel_en-US" xlink:label="lab_allo_SubscriptionsReceivablesFromPreferredStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions Receivables from Preferred Stockholders</link:label>
    <link:label id="lab_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_label_en-US" xlink:label="lab_allo_SubscriptionsReceivablesFromPreferredStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriptions Receivables From Preferred Stockholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivablesFromPreferredStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember" xlink:to="lab_allo_SubscriptionsReceivablesFromPreferredStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_faa2a05a-a919-4ed6-88ce-85d4e7e98c62_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_b136a76d-1a1b-448e-af1d-ae72c97ba043_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RegulatoryMilestoneMember_f8025b48-554a-465d-9d26-707f0ff7c9a1_terseLabel_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember" xlink:href="allo-20191231.xsd#allo_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryMilestoneMember" xlink:to="lab_allo_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9e25f305-350b-4489-9615-a7183f47c1bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>allo-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d8d6a139-183d-4f81-94ee-c4cf0b6788b2,g:9c6cf07c-217c-443c-8f84-66f2c90fa5e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20191231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_16d3aed4-15c1-41cb-892e-55f2633a4f71" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentType_16d3aed4-15c1-41cb-892e-55f2633a4f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_93e003f5-d723-4ffc-af25-73101a9c5e63" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentAnnualReport_93e003f5-d723-4ffc-af25-73101a9c5e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_84f60520-363c-4743-8858-9bd19b4d27a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentPeriodEndDate_84f60520-363c-4743-8858-9bd19b4d27a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6fe4eb27-82aa-4c23-a7ed-c34dde759964" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentTransitionReport_6fe4eb27-82aa-4c23-a7ed-c34dde759964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cc9d251a-ec47-4e40-9939-d8a1dbdfe3fe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityFileNumber_cc9d251a-ec47-4e40-9939-d8a1dbdfe3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc5cc0a7-3501-46d6-86dd-d9e2ce1f3b45" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityRegistrantName_bc5cc0a7-3501-46d6-86dd-d9e2ce1f3b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_98c4555a-8a55-42b5-a542-5ac19e7c7dcd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityCentralIndexKey_98c4555a-8a55-42b5-a542-5ac19e7c7dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_25b5cfa3-1c18-49f1-bd92-c10438c9cc80" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_CurrentFiscalYearEndDate_25b5cfa3-1c18-49f1-bd92-c10438c9cc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f805a823-814f-4c48-a5bc-daf8b778c7aa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_AmendmentFlag_f805a823-814f-4c48-a5bc-daf8b778c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0f3ef1d3-d063-4345-a747-59e2a08a5e32" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentFiscalYearFocus_0f3ef1d3-d063-4345-a747-59e2a08a5e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7f79e348-873a-45fe-8efd-5c19d6a97cb4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7f79e348-873a-45fe-8efd-5c19d6a97cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0cbac776-3c30-4e11-82ac-2670d2c7173f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0cbac776-3c30-4e11-82ac-2670d2c7173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e4268a8e-81a0-4199-8a88-26aed3d82095" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityTaxIdentificationNumber_e4268a8e-81a0-4199-8a88-26aed3d82095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7c525f85-0c87-4375-be2f-56c47b2b524c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityAddressAddressLine1_7c525f85-0c87-4375-be2f-56c47b2b524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_08f87935-c5b5-4707-8e83-811be933f6d6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityAddressCityOrTown_08f87935-c5b5-4707-8e83-811be933f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d8365133-2fbe-42d1-a7f2-da51aca5be30" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityAddressStateOrProvince_d8365133-2fbe-42d1-a7f2-da51aca5be30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_43455429-d513-4fc9-bb6a-0a5df1974891" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityAddressPostalZipCode_43455429-d513-4fc9-bb6a-0a5df1974891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5097ca3b-a360-43cb-b473-bc183a4c3aa9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_CityAreaCode_5097ca3b-a360-43cb-b473-bc183a4c3aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_30bab70e-e91b-49e4-87a4-b0ca18d1b004" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_LocalPhoneNumber_30bab70e-e91b-49e4-87a4-b0ca18d1b004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_605d8068-0773-4b48-a876-121f3c59bcfb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_Security12bTitle_605d8068-0773-4b48-a876-121f3c59bcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0e9ba4c2-49e6-4b3a-ab3f-364d53d29324" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_TradingSymbol_0e9ba4c2-49e6-4b3a-ab3f-364d53d29324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a8102301-174b-4483-9599-6d73873df72c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_SecurityExchangeName_a8102301-174b-4483-9599-6d73873df72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bf715a78-9ef6-49d8-b511-bb3489f87427" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bf715a78-9ef6-49d8-b511-bb3489f87427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_24065754-146e-4f9b-a582-71d9d55ba820" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityVoluntaryFilers_24065754-146e-4f9b-a582-71d9d55ba820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ea982e29-03d8-429d-af0e-e35b4e4deaa3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityCurrentReportingStatus_ea982e29-03d8-429d-af0e-e35b4e4deaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_92edef34-3353-4ae7-a56d-52ea2bd41d86" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityInteractiveDataCurrent_92edef34-3353-4ae7-a56d-52ea2bd41d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c44c031c-1d17-4e68-8779-677f2f3f2a65" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityFilerCategory_c44c031c-1d17-4e68-8779-677f2f3f2a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_36f953cb-d5ce-4dfa-ae28-5f1f66dc6300" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntitySmallBusiness_36f953cb-d5ce-4dfa-ae28-5f1f66dc6300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7316e398-8b15-4d53-9171-e035cb44d6d4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityEmergingGrowthCompany_7316e398-8b15-4d53-9171-e035cb44d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_26f9521d-16fb-48a8-a9a4-e6c7561c2fdd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityShellCompany_26f9521d-16fb-48a8-a9a4-e6c7561c2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4b46d9c9-2b0f-4f1a-8b6e-5ad036812423" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityPublicFloat_4b46d9c9-2b0f-4f1a-8b6e-5ad036812423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4d04b099-7dd2-48d6-80d5-bc021f46bd50" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4d04b099-7dd2-48d6-80d5-bc021f46bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9de4e83a-1fd1-45cb-a2d7-fd52e1164693" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_54b01890-6793-4f63-b07a-d5dd1ac712cf" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9de4e83a-1fd1-45cb-a2d7-fd52e1164693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheets" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e838a7b1-9d50-4e6b-8af0-4669b59f667d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e838a7b1-9d50-4e6b-8af0-4669b59f667d" xlink:to="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e12c600d-cec2-48ca-a64e-28f3cebd13fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e12c600d-cec2-48ca-a64e-28f3cebd13fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_cfebf0b4-64a4-4eb0-9ae0-c322e0c8c1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:to="loc_us-gaap_ShortTermInvestments_cfebf0b4-64a4-4eb0-9ae0-c322e0c8c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eab06595-4b66-4122-bb1c-0e4f25c39c69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eab06595-4b66-4122-bb1c-0e4f25c39c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1b43b9e-82ca-40c4-b8f6-3d8f79a424f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7610e6d2-14bd-4df7-aafa-256d3d00d5a9" xlink:to="loc_us-gaap_AssetsCurrent_d1b43b9e-82ca-40c4-b8f6-3d8f79a424f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_9838b9a3-5976-4377-b978-b5e25dcc1d52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_OtherLongTermInvestments_9838b9a3-5976-4377-b978-b5e25dcc1d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2443c0d-077d-4da4-9a55-96315255ad75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2443c0d-077d-4da4-9a55-96315255ad75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46d872fc-f43f-44b5-8662-59beb584bf3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_46d872fc-f43f-44b5-8662-59beb584bf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4e503c2f-b102-4622-bfc8-63d555fe8773" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4e503c2f-b102-4622-bfc8-63d555fe8773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_41176ff0-bc7d-4e1e-8076-039c738981a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_41176ff0-bc7d-4e1e-8076-039c738981a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_753c3930-13bc-47eb-a981-e83b7d111e17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_753c3930-13bc-47eb-a981-e83b7d111e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d837bfc5-e33a-42cf-9bef-8b81270e25cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d837bfc5-e33a-42cf-9bef-8b81270e25cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66721c75-6214-42f3-9b0f-8df845ad8829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8caae10c-0396-46a0-b5d2-322b069940ee" xlink:to="loc_us-gaap_Assets_66721c75-6214-42f3-9b0f-8df845ad8829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e838a7b1-9d50-4e6b-8af0-4669b59f667d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dcd1cbb9-a532-4128-8cce-34945108d3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dcd1cbb9-a532-4128-8cce-34945108d3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5fcb7a11-5a5a-4f0d-afc1-75a8381d4db0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcd1cbb9-a532-4128-8cce-34945108d3cb" xlink:to="loc_us-gaap_AccountsPayableCurrent_5fcb7a11-5a5a-4f0d-afc1-75a8381d4db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_840ae83f-4b7c-45ea-9c8c-26857ce52a90" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcd1cbb9-a532-4128-8cce-34945108d3cb" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_840ae83f-4b7c-45ea-9c8c-26857ce52a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dce2dc3-7089-493c-879e-2e4156fcec73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcd1cbb9-a532-4128-8cce-34945108d3cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dce2dc3-7089-493c-879e-2e4156fcec73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df0fd594-fac8-4b71-be85-4f9c0f56cb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df0fd594-fac8-4b71-be85-4f9c0f56cb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9e1ce907-33b3-4fe2-ac8f-e795db3971b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9e1ce907-33b3-4fe2-ac8f-e795db3971b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_15078a71-82e7-4cb7-97df-14708975fd31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_Liabilities_15078a71-82e7-4cb7-97df-14708975fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_653686f0-a3f3-425b-adca-ea1d31161197" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_653686f0-a3f3-425b-adca-ea1d31161197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3f441db1-f949-4b04-9873-1431a8293c78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_PreferredStockValue_3f441db1-f949-4b04-9873-1431a8293c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a9192342-8618-4058-959a-554bb4b1583c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_CommonStockValue_a9192342-8618-4058-959a-554bb4b1583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_88cf2cb5-5966-41da-9c71-8a4201de5721" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_88cf2cb5-5966-41da-9c71-8a4201de5721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440de215-c99a-43d0-b326-e968d8d07eda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440de215-c99a-43d0-b326-e968d8d07eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8d3e27c-90ae-43bb-9ea5-bfcb0c3b3499" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8d3e27c-90ae-43bb-9ea5-bfcb0c3b3499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ada58ee4-100b-483e-be33-5dd1b074aba1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a4f100af-39b7-432b-8cc7-3d73ec4df251" xlink:to="loc_us-gaap_StockholdersEquity_ada58ee4-100b-483e-be33-5dd1b074aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_93a53b1f-ba04-4d20-a7ef-9f0707fd940f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f30bf1b7-6aaa-467f-b707-a09733eeb19f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_93a53b1f-ba04-4d20-a7ef-9f0707fd940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cc0ffbf0-a88a-4e39-997e-f2186cf94bee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cc0ffbf0-a88a-4e39-997e-f2186cf94bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3bd59022-1cd3-4ba2-966b-529d22dff54e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3bd59022-1cd3-4ba2-966b-529d22dff54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b924169e-ead1-4cea-af31-06d45398a018" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b924169e-ead1-4cea-af31-06d45398a018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_424be549-a8b4-4cdf-bb13-c95af3c9317b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_424be549-a8b4-4cdf-bb13-c95af3c9317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c920184f-37af-497c-bfd5-83d95e4a56b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c920184f-37af-497c-bfd5-83d95e4a56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19f2d7b3-fddd-4567-b176-15a734317474" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_19f2d7b3-fddd-4567-b176-15a734317474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4cd8846f-9549-44f9-b4de-0500a874acff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_CommonStockSharesIssued_4cd8846f-9549-44f9-b4de-0500a874acff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e96e7afe-5c50-4f5e-9ea7-7ab54035707e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c4401783-605f-438c-9294-1acee9b06433" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e96e7afe-5c50-4f5e-9ea7-7ab54035707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20191231.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_21e11da2-6fd4-44fa-b4c2-08a13f1a6743" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_OperatingExpensesAbstract_21e11da2-6fd4-44fa-b4c2-08a13f1a6743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1ee4335b-6e07-4897-92c5-52860e17350e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21e11da2-6fd4-44fa-b4c2-08a13f1a6743" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1ee4335b-6e07-4897-92c5-52860e17350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6dd01f4d-3a1d-4f6e-bd49-78dc4bc46c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21e11da2-6fd4-44fa-b4c2-08a13f1a6743" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6dd01f4d-3a1d-4f6e-bd49-78dc4bc46c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_679b4a88-fe12-4c4f-aa88-864cc79d1cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21e11da2-6fd4-44fa-b4c2-08a13f1a6743" xlink:to="loc_us-gaap_OperatingExpenses_679b4a88-fe12-4c4f-aa88-864cc79d1cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4dea00ca-d85f-4e94-ab9b-e55c624aaf18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_4dea00ca-d85f-4e94-ab9b-e55c624aaf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_a8260379-d0ad-4951-b9a2-f3ca8025744a" xlink:href="allo-20191231.xsd#allo_ChangeInFairValueOfConvertibleNotePayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_a8260379-d0ad-4951-b9a2-f3ca8025744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c8cd5aa2-115b-4124-83fd-4bcda803e4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:to="loc_us-gaap_InterestExpense_c8cd5aa2-115b-4124-83fd-4bcda803e4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a17fe70-6db0-4446-b37c-9d74d5e07d31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a17fe70-6db0-4446-b37c-9d74d5e07d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_e9a8cde8-7ede-46f6-92f4-583085e83229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:to="loc_us-gaap_OtherExpenses_e9a8cde8-7ede-46f6-92f4-583085e83229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_23a87bb8-24e4-4430-a70b-bc929eba8458" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_644f057b-b6f3-471f-bbb7-96a203b869a6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_23a87bb8-24e4-4430-a70b-bc929eba8458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_63e4e488-2456-46ab-9a6a-772bc65b7551" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_63e4e488-2456-46ab-9a6a-772bc65b7551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab4c0afa-1da2-4b4e-a954-9408487039bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ab4c0afa-1da2-4b4e-a954-9408487039bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa3a286b-ad11-47cd-840a-83feded8868c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_NetIncomeLoss_aa3a286b-ad11-47cd-840a-83feded8868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1e4763be-be5c-4efe-8f05-440b6302600b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1e4763be-be5c-4efe-8f05-440b6302600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9aed5fd6-7fb0-465e-9d03-842eb5fbc7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1e4763be-be5c-4efe-8f05-440b6302600b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9aed5fd6-7fb0-465e-9d03-842eb5fbc7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_746612fc-a37b-4d09-977a-eea4d59689ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1e4763be-be5c-4efe-8f05-440b6302600b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_746612fc-a37b-4d09-977a-eea4d59689ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a8be8e27-92ee-4e03-bb35-75e5359b241d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a8be8e27-92ee-4e03-bb35-75e5359b241d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6ee70ba6-455a-487d-ac70-e29cae513a47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ac6046f5-ec29-4586-93d8-e36ca99c54bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6ee70ba6-455a-487d-ac70-e29cae513a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e6e27f9d-55d5-4971-81bb-f033ec304c96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e6e27f9d-55d5-4971-81bb-f033ec304c96" xlink:to="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14efa92e-580d-4cb3-9b6a-eec3d7139fd5" xlink:to="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_cb2671d4-c1bc-440e-960b-77622de24132" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivablesFromPreferredStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_allo_SubscriptionsReceivablesFromPreferredStockholdersMember_cb2671d4-c1bc-440e-960b-77622de24132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_20ea2163-55d5-4f96-a886-274abe71c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_CommonStockMember_20ea2163-55d5-4f96-a886-274abe71c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_a8b5dc38-e2b2-4588-aca5-f5ae6cdbc1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_a8b5dc38-e2b2-4588-aca5-f5ae6cdbc1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a33328c3-f8fc-4952-806d-ebeb220dae02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a33328c3-f8fc-4952-806d-ebeb220dae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90ce590d-2939-4f08-8129-abcc70757da5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_RetainedEarningsMember_90ce590d-2939-4f08-8129-abcc70757da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a5f67192-f7f6-4a69-9740-89fdb8fd8dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d577c1e-18a9-472f-9683-d720a6038b08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a5f67192-f7f6-4a69-9740-89fdb8fd8dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8eb9aad3-5f1b-4916-81fc-b9557e7e2967" xlink:to="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0f26e04f-967f-40f6-9c26-6331279a63e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_08dbc2b3-761d-4474-9b87-3d917ca7baeb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0f26e04f-967f-40f6-9c26-6331279a63e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dcb20c32-a917-4283-961f-1fc031a58770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_c381a701-ee59-4c8f-b28b-3698a89cf30d" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_c381a701-ee59-4c8f-b28b-3698a89cf30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_efed06a5-5131-4484-b638-edc263e14f48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bc4ed0e-6073-4106-bedf-20d37896ed75" xlink:to="loc_us-gaap_IPOMember_efed06a5-5131-4484-b638-edc263e14f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd486043-96fc-4037-859a-61e70718e45f" xlink:to="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e55c47c-d541-4230-9c1e-7a6ccdbd2979" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockholdersEquity_4e55c47c-d541-4230-9c1e-7a6ccdbd2979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1414625d-f9c7-4823-90ae-131ace6c69f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1414625d-f9c7-4823-90ae-131ace6c69f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4bb2cfea-4e5f-4b90-81e2-6fcd5038381b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4bb2cfea-4e5f-4b90-81e2-6fcd5038381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_a99493df-4729-4e8a-8f60-fc62c9ced364" xlink:href="allo-20191231.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_a99493df-4729-4e8a-8f60-fc62c9ced364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_90ae9e75-87c5-4d3d-9bb8-eb846760ca2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_90ae9e75-87c5-4d3d-9bb8-eb846760ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d8f18538-49e0-4e2c-9102-5a991eeb028d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d8f18538-49e0-4e2c-9102-5a991eeb028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_b5833cd7-2af5-4d40-a390-1512da167b66" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_b5833cd7-2af5-4d40-a390-1512da167b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders_9f6c9935-4e4a-4aa1-93dc-982a09016e70" xlink:href="allo-20191231.xsd#allo_SubscriptionsReceivableFromPreferredStockholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_SubscriptionsReceivableFromPreferredStockholders_9f6c9935-4e4a-4aa1-93dc-982a09016e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues_126ccc62-7ff1-468c-bd12-2d6ba1b6768d" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValuePreferredStockIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValuePreferredStockIssues_126ccc62-7ff1-468c-bd12-2d6ba1b6768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_73b77142-7697-4725-9566-24f3b3f222c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_73b77142-7697-4725-9566-24f3b3f222c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1f6d1c0-8a6f-44a7-8114-73a8093c7cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1f6d1c0-8a6f-44a7-8114-73a8093c7cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_df048c51-7dde-4fd2-b9b7-5d50d4dbe558" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_df048c51-7dde-4fd2-b9b7-5d50d4dbe558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_155657d9-7c21-47dd-b34c-6bb014ecdeec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_155657d9-7c21-47dd-b34c-6bb014ecdeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6d6476ce-d781-4b0c-bf7b-0fd9440f71db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6d6476ce-d781-4b0c-bf7b-0fd9440f71db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ecb55b-c4b7-4432-a0f7-577b0803506f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ecb55b-c4b7-4432-a0f7-577b0803506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotesReceivableFromCommonShareholders_abcd5cc0-f020-4e75-ad16-bd82d050416d" xlink:href="allo-20191231.xsd#allo_NotesReceivableFromCommonShareholders"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_NotesReceivableFromCommonShareholders_abcd5cc0-f020-4e75-ad16-bd82d050416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_65589c48-15b8-4317-8710-4f95a17509a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_65589c48-15b8-4317-8710-4f95a17509a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_357bb0c2-5e8a-4196-a456-8d7648764005" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_357bb0c2-5e8a-4196-a456-8d7648764005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_18085cf3-096a-43f2-b3f1-1fe70504e217" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_18085cf3-096a-43f2-b3f1-1fe70504e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5b4442f0-27bf-4b1e-84eb-22eb10be793a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5b4442f0-27bf-4b1e-84eb-22eb10be793a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_4fdf71e5-99fa-43b7-b15c-743f4f65e2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_4fdf71e5-99fa-43b7-b15c-743f4f65e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_6f2ec054-170e-416f-bfaf-adfb3df6c1a3" xlink:href="allo-20191231.xsd#allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_6f2ec054-170e-416f-bfaf-adfb3df6c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18701802-247c-4abe-a85a-0ea9b523d0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18701802-247c-4abe-a85a-0ea9b523d0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30e6e893-ebb5-43de-814c-1056c7a9abef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_NetIncomeLoss_30e6e893-ebb5-43de-814c-1056c7a9abef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1128881-408c-419e-939d-d4391da53fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1128881-408c-419e-939d-d4391da53fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71885bb6-2264-4f2c-8510-35bcf0dd272d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_StockholdersEquity_71885bb6-2264-4f2c-8510-35bcf0dd272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_175ca358-8d57-446e-8518-68843eaca415" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10c1beba-9265-4800-aa20-7a37f0ed10d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_175ca358-8d57-446e-8518-68843eaca415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e53b78a-b6c0-4567-93b6-570a7f4d6c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e53b78a-b6c0-4567-93b6-570a7f4d6c6f" xlink:to="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8507be68-6132-4b59-b056-f2dbd4d42d9b" xlink:to="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f8948446-9cc5-435a-8836-9a913baafe51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_148a9b31-7050-4aee-9fb6-6c9fb1ed333d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f8948446-9cc5-435a-8836-9a913baafe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4493c384-47eb-4d4e-847b-2e30c75bf14d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_e3478d1c-8e64-449d-a4a7-9977ec692c1c" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_e3478d1c-8e64-449d-a4a7-9977ec692c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_de44ab29-2f63-4baf-ba24-ecbca4d9d24d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338581fc-a932-45f4-882f-dfbaedf2123e" xlink:to="loc_us-gaap_IPOMember_de44ab29-2f63-4baf-ba24-ecbca4d9d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec16e590-1ba6-47d7-ad88-72d0ad0a676e" xlink:to="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_753b3dd1-ddeb-432b-8572-075a00800752" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_753b3dd1-ddeb-432b-8572-075a00800752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d77141e5-08b2-4e98-9236-48d6087bf259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69d24042-8dd8-4db8-8b74-7fdf768d0af7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d77141e5-08b2-4e98-9236-48d6087bf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="allo-20191231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b9205761-af19-49b7-ad3c-bc47897f97b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:to="loc_us-gaap_ProfitLoss_b9205761-af19-49b7-ad3c-bc47897f97b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a38e64e8-d602-412c-8299-fd4a88453d27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a38e64e8-d602-412c-8299-fd4a88453d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e955eed1-22d0-45c2-846e-1427a591c6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_ShareBasedCompensation_e955eed1-22d0-45c2-846e-1427a591c6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1c5cd10c-dd1e-48a9-ac59-7a25eb614269" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1c5cd10c-dd1e-48a9-ac59-7a25eb614269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_64a6e0ec-3692-4454-97e6-c150f85a3f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_Depreciation_64a6e0ec-3692-4454-97e6-c150f85a3f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d41f6618-064c-4654-944b-891d6f810f45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d41f6618-064c-4654-944b-891d6f810f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_826202fe-244a-4392-a0c4-9f243a93d60b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_LeaseAndRentalExpense_826202fe-244a-4392-a0c4-9f243a93d60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_8c5b969a-5b7a-4771-82bc-7992c4db93f8" xlink:href="allo-20191231.xsd#allo_ChangeInFairValueOfConvertibleNotePayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_8c5b969a-5b7a-4771-82bc-7992c4db93f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e81b39bc-839c-4e48-a4d8-efb6a2be4bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e81b39bc-839c-4e48-a4d8-efb6a2be4bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_af0361d5-173d-401b-b1b9-bd048881e996" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_af0361d5-173d-401b-b1b9-bd048881e996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_29211e88-b688-41f8-87e4-4f8e88ccc5dc" xlink:href="allo-20191231.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_29211e88-b688-41f8-87e4-4f8e88ccc5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d3613e56-32c9-4830-9521-82a767fa4f61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_484609f6-62a3-403d-b7d9-80c92bf342aa" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d3613e56-32c9-4830-9521-82a767fa4f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e0f9e1c-281e-46ed-a11e-ebee103f3987" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e0f9e1c-281e-46ed-a11e-ebee103f3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f1584eeb-20e0-41ac-9586-c148ec59e685" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f1584eeb-20e0-41ac-9586-c148ec59e685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a9532e1f-5ad1-4155-84eb-5d9f335f95c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a9532e1f-5ad1-4155-84eb-5d9f335f95c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d59e4a4d-1b29-4332-8af0-dad12ef98ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d59e4a4d-1b29-4332-8af0-dad12ef98ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fcfae31b-8c4e-44db-bb89-59499fbca28e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b9e4d24-3062-4b30-990c-9e84c7a5ac16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fcfae31b-8c4e-44db-bb89-59499fbca28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_888d20e7-6127-4c75-9785-e56281863778" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6428e8e5-1cab-4b79-bad6-539d88c3517c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_888d20e7-6127-4c75-9785-e56281863778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_415ff097-091c-41af-b07f-5fce2993b898" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_415ff097-091c-41af-b07f-5fce2993b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_41e868ac-0a9d-44d3-a7e8-9b25b4b7ebfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_41e868ac-0a9d-44d3-a7e8-9b25b4b7ebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_bf7403ac-8082-4462-b2a9-3c09345dc76e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_bf7403ac-8082-4462-b2a9-3c09345dc76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_5c685789-fa42-465c-a4a2-8583b77e8670" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_5c685789-fa42-465c-a4a2-8583b77e8670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c6e430ea-63e3-496b-9669-b411e027d2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c6e430ea-63e3-496b-9669-b411e027d2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_3ad7a567-69ec-47e9-b3f4-664c96b7c828" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_3ad7a567-69ec-47e9-b3f4-664c96b7c828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69729edd-5169-4d5f-b2d9-74fbea66d351" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0dbd5dc-5387-4b78-8e60-0ffef13b66dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69729edd-5169-4d5f-b2d9-74fbea66d351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f84cc49c-e24b-46fb-b7c5-6f9a0faef4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f84cc49c-e24b-46fb-b7c5-6f9a0faef4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_04c7cd75-9fed-415e-bc85-414a436840bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_04c7cd75-9fed-415e-bc85-414a436840bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_818d6cdd-42e2-48ac-885f-679401746c5d" xlink:href="allo-20191231.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions_818d6cdd-42e2-48ac-885f-679401746c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_62fc22ea-7951-4b2b-a9fd-bad02879d810" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_62fc22ea-7951-4b2b-a9fd-bad02879d810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9d5410ed-222e-4cf5-8581-9e1c8009ef33" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9d5410ed-222e-4cf5-8581-9e1c8009ef33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_447c0142-52c6-4d72-a613-659d722127d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_ProceedsFromStockPlans_447c0142-52c6-4d72-a613-659d722127d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a99e5462-86e9-423b-816c-c17e0eee08e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f0d49b5-a21b-4f92-a040-2db71d0eec58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a99e5462-86e9-423b-816c-c17e0eee08e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64c3f7c4-218c-44ac-abbd-e4c451f80c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64c3f7c4-218c-44ac-abbd-e4c451f80c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2609e77f-7586-4b2d-8ba9-79b615695dee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2609e77f-7586-4b2d-8ba9-79b615695dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf7abb1a-cfa1-4772-bdc7-ef120a45ad06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf7abb1a-cfa1-4772-bdc7-ef120a45ad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_09379a7b-b1b7-4b2f-ba4c-deaaa233eeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_09379a7b-b1b7-4b2f-ba4c-deaaa233eeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d3dedd85-113f-4b06-87ba-ae293c4dda7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d3dedd85-113f-4b06-87ba-ae293c4dda7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_36303872-1863-4f0f-8828-81a0877a2391" xlink:href="allo-20191231.xsd#allo_ConvertiblePreferredStockIssuedInAssetAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_36303872-1863-4f0f-8828-81a0877a2391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition_0614daea-ead4-4ca2-a9a5-0364d530cb53" xlink:href="allo-20191231.xsd#allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition_0614daea-ead4-4ca2-a9a5-0364d530cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f424ad7-5515-47a4-864c-fcf67b4f9680" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f424ad7-5515-47a4-864c-fcf67b4f9680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a7e23e61-fb17-468a-867f-f5a82ca5b892" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a7e23e61-fb17-468a-867f-f5a82ca5b892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_6cf2f8f4-8bfe-402a-8cb8-dfcc0cd3b206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4212b380-6a65-44cd-b20f-0a2931292ce1" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_6cf2f8f4-8bfe-402a-8cb8-dfcc0cd3b206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_eea9bd9f-ddac-4b3a-a22c-d83a361250ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e6ee288-6dfb-42d6-9b31-5d67b473b5c7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_eea9bd9f-ddac-4b3a-a22c-d83a361250ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_69c3ee56-7c50-419f-9d86-96088aca65d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_eea9bd9f-ddac-4b3a-a22c-d83a361250ad" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_69c3ee56-7c50-419f-9d86-96088aca65d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_33fd73d8-e595-4814-ba04-4f3d7a7c505b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_eea9bd9f-ddac-4b3a-a22c-d83a361250ad" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_33fd73d8-e595-4814-ba04-4f3d7a7c505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_afd7ec59-7254-4d43-bf4d-9563fe44fa1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_17448f4e-719a-48c5-b74b-17c5c1a71655" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afd7ec59-7254-4d43-bf4d-9563fe44fa1b" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_17448f4e-719a-48c5-b74b-17c5c1a71655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_da562583-146b-4ba0-b5e7-18432f53551c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_da562583-146b-4ba0-b5e7-18432f53551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4cc802ce-4e63-41c5-9297-617b2b23083c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4cc802ce-4e63-41c5-9297-617b2b23083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_469158c4-8a66-45eb-b8f5-cf7aa0727f12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_UseOfEstimates_469158c4-8a66-45eb-b8f5-cf7aa0727f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4c3fc90f-1830-4ebf-8e66-9a7452d920a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4c3fc90f-1830-4ebf-8e66-9a7452d920a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5deb7af7-8b8b-44d2-845b-6d37e232707b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5deb7af7-8b8b-44d2-845b-6d37e232707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5d900ec8-c268-4c47-beff-69b67f9aa9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5d900ec8-c268-4c47-beff-69b67f9aa9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_f94016da-6f07-4b72-848d-6bc0d84e0e50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_f94016da-6f07-4b72-848d-6bc0d84e0e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_339681f1-ecc6-433d-b299-2adcd812e29b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_339681f1-ecc6-433d-b299-2adcd812e29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_081f9731-4895-43aa-85f4-305b321c6bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_081f9731-4895-43aa-85f4-305b321c6bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e5286e12-b42b-4548-866c-330484454d37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e5286e12-b42b-4548-866c-330484454d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_55be933a-074a-4768-a627-b37b0f40e9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_55be933a-074a-4768-a627-b37b0f40e9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock_80d2544d-b04e-4329-9e45-5859f01b61b0" xlink:href="allo-20191231.xsd#allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock_80d2544d-b04e-4329-9e45-5859f01b61b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c13581bd-5fdc-433d-bf83-83e5d69e59b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c13581bd-5fdc-433d-bf83-83e5d69e59b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_4e9a09ed-aec4-47ee-b039-5e74ee9947fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_4e9a09ed-aec4-47ee-b039-5e74ee9947fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e4157fe8-2922-43dd-b883-7d724ca50844" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e4157fe8-2922-43dd-b883-7d724ca50844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComprehensiveLossPolicyPolicyTextBlock_4ad05cc1-a5eb-40c0-8d1a-a4ccb316e179" xlink:href="allo-20191231.xsd#allo_ComprehensiveLossPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_allo_ComprehensiveLossPolicyPolicyTextBlock_4ad05cc1-a5eb-40c0-8d1a-a4ccb316e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock_0c9aa3c6-72d0-4134-a21a-bd225b22486c" xlink:href="allo-20191231.xsd#allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock_0c9aa3c6-72d0-4134-a21a-bd225b22486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1b8bad60-2e7b-4bce-9ca8-e7e6bba41b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1b8bad60-2e7b-4bce-9ca8-e7e6bba41b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_664a23be-f85f-494d-a6b3-2b117e5b0834" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_afe5a387-e46e-42e2-acdc-7c7fefe43d71" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_664a23be-f85f-494d-a6b3-2b117e5b0834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_39ffae51-89d1-468f-89ba-6718c0f86eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EstimatedLifeOfAssetsTableTextBlock_e95fc675-3737-4042-a5e4-c556d352c747" xlink:href="allo-20191231.xsd#allo_EstimatedLifeOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_39ffae51-89d1-468f-89ba-6718c0f86eeb" xlink:to="loc_allo_EstimatedLifeOfAssetsTableTextBlock_e95fc675-3737-4042-a5e4-c556d352c747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_281a7daa-a2f7-4230-a7f5-1287f4823091" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_281a7daa-a2f7-4230-a7f5-1287f4823091" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62967415-3905-48a1-855a-d5c961912dcd" xlink:to="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_78152770-e851-4b69-8ca5-f8d5cb367ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0f58377-47e1-4a01-bba9-0cf484ba6b5b" xlink:to="loc_us-gaap_CommonStockMember_78152770-e851-4b69-8ca5-f8d5cb367ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b13c77ac-2b86-434d-8a6e-996865094bf9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_649fdf19-441b-49fc-94e2-160fc3682380" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:to="loc_us-gaap_IPOMember_649fdf19-441b-49fc-94e2-160fc3682380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_80aa3237-5b47-4074-8085-0e004061b179" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e92c106-ac34-4fe2-a5aa-70036a849c84" xlink:to="loc_us-gaap_OverAllotmentOptionMember_80aa3237-5b47-4074-8085-0e004061b179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7c058e50-d5e0-4701-afa7-6b93b797b8c8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StartUpCost_15422257-8606-4ce0-83ae-f50c775fdc77" xlink:href="allo-20191231.xsd#allo_StartUpCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StartUpCost_15422257-8606-4ce0-83ae-f50c775fdc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d257e2e6-8d1b-46ea-aadf-4859e10f72ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d257e2e6-8d1b-46ea-aadf-4859e10f72ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_651c3283-0763-412c-bef9-544b57d8bcc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_651c3283-0763-412c-bef9-544b57d8bcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_fdac86af-7c4c-4ce9-8792-1a0108ae8018" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_fdac86af-7c4c-4ce9-8792-1a0108ae8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_249235d0-a61b-4fb8-9f7b-4323e09e6df8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_249235d0-a61b-4fb8-9f7b-4323e09e6df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0572d002-88d2-4c17-bc76-5f45708a58b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0572d002-88d2-4c17-bc76-5f45708a58b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27e997e3-b8bb-4563-a7d6-56a014b077f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27e997e3-b8bb-4563-a7d6-56a014b077f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7235c6d-eca0-4e41-855a-5934b2f976e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7235c6d-eca0-4e41-855a-5934b2f976e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7ba7203d-0163-44a6-808b-fe3024267eac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7ba7203d-0163-44a6-808b-fe3024267eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumValue_f3f140e1-53fb-4724-a186-e5a9402dd82a" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StockIssuanceMaximumValue_f3f140e1-53fb-4724-a186-e5a9402dd82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_3d1abf06-d7de-4d5e-aab8-d835d15d3416" xlink:href="allo-20191231.xsd#allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_3d1abf06-d7de-4d5e-aab8-d835d15d3416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a7d5c9fd-846e-4b6c-b51a-55a6df42c543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a7d5c9fd-846e-4b6c-b51a-55a6df42c543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_c7ecf313-0805-4523-819b-3d7c21430e49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_DeferredOfferingCosts_c7ecf313-0805-4523-819b-3d7c21430e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_c52785e8-9166-4064-a66b-c19980633bd1" xlink:href="allo-20191231.xsd#allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_c52785e8-9166-4064-a66b-c19980633bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_528df8b7-91ea-4333-814d-85582f318bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_528df8b7-91ea-4333-814d-85582f318bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_452faba0-ce2f-4cfc-863b-14ee2600bfab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_452faba0-ce2f-4cfc-863b-14ee2600bfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8169ff2-777e-4279-aa63-160c79aca229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8169ff2-777e-4279-aa63-160c79aca229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f955c2f5-3683-4e85-9604-52ff807b4d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_NetIncomeLoss_f955c2f5-3683-4e85-9604-52ff807b4d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_93ed6fcb-852c-43d8-ae2f-041e7c6fc789" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_93ed6fcb-852c-43d8-ae2f-041e7c6fc789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f942b881-d3f2-468e-9a1d-93b085593f31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c3764ea6-143b-44c7-a3fe-3b8479b00bb5" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f942b881-d3f2-468e-9a1d-93b085593f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_83aa0347-1f34-461e-9df1-34af26748632" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_83aa0347-1f34-461e-9df1-34af26748632" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fc86c56-7525-46ba-8d25-1706806afb68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_aaf2c537-9841-4d17-95d0-6158105e35e3" xlink:href="allo-20191231.xsd#allo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_allo_LaboratoryEquipmentMember_aaf2c537-9841-4d17-95d0-6158105e35e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_743d18a8-db78-4fb7-bd63-36aeb509759e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_us-gaap_ComputerEquipmentMember_743d18a8-db78-4fb7-bd63-36aeb509759e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_180db5ee-3f04-43bc-9b9d-d84b70ce9b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_269bd455-60c6-42ce-bfc3-635cb76ebb62" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_180db5ee-3f04-43bc-9b9d-d84b70ce9b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:to="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c485740-eb4d-446a-aa4d-457f77ad5790" xlink:to="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_38ce2196-a414-46b3-8c93-915259fd14e6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:to="loc_srt_MinimumMember_38ce2196-a414-46b3-8c93-915259fd14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9aa66b5-dc5a-4794-95b4-bbac7e5756a6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc388e58-e477-4ce9-be37-d87e0b0f1bef" xlink:to="loc_srt_MaximumMember_d9aa66b5-dc5a-4794-95b4-bbac7e5756a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e484a06-1f6e-488a-a522-50ccc35338f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16e5f2d4-9092-4856-9ede-054aac04ec6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0326d674-d092-4545-adcc-dffe78cd1206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16e5f2d4-9092-4856-9ede-054aac04ec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RecentAccountingGuidance" xlink:type="simple" xlink:href="allo-20191231.xsd#RecentAccountingGuidance"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RecentAccountingGuidance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f8a94c5b-cf93-4677-8c7f-d820f1abe3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a99f6b75-8fef-41c3-af58-b9a520269ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f8a94c5b-cf93-4677-8c7f-d820f1abe3f1" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a99f6b75-8fef-41c3-af58-b9a520269ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7dbe18b4-68df-47e9-a28e-28584a1da47e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_40bb1ea9-139c-4e57-adb7-cd54070a37dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7dbe18b4-68df-47e9-a28e-28584a1da47e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_40bb1ea9-139c-4e57-adb7-cd54070a37dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e313f3b-06aa-40a3-b3af-d8fcc7648865" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_dba0dc34-a691-41e4-bb94-9e85ca33bc16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e313f3b-06aa-40a3-b3af-d8fcc7648865" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_dba0dc34-a691-41e4-bb94-9e85ca33bc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_203b0792-15a5-4d17-893e-bfadf1f86bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_203b0792-15a5-4d17-893e-bfadf1f86bc8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3d043f70-2437-4949-8a74-52c736c824c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_009890b6-4bcd-4101-9c65-6617c6ac6dad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8887-b2a2-4ca8-8b64-f881262e27b6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_009890b6-4bcd-4101-9c65-6617c6ac6dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f12b8154-9023-463a-a989-af399cb1f436" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_88f6a7f6-dd30-4958-938d-fb05d4a45a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2549c4ad-e0d9-4d22-b10a-bd61f88c5f13" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_88f6a7f6-dd30-4958-938d-fb05d4a45a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_08316227-37b9-4f66-99a2-b76ecd2f9fb7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_852ba9b6-52f2-49a6-a4f1-27d22704cc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fac7eb29-eb47-47a0-a758-ccbfe911b835" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_852ba9b6-52f2-49a6-a4f1-27d22704cc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_6576afb2-2971-46a1-910e-451e0e75c6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_6576afb2-2971-46a1-910e-451e0e75c6c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_19ec192a-71e2-4a88-bd9f-6a72ebe4170d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1315ac63-0c46-451f-86df-5f9a73abb957" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f503bc44-4f04-438f-b85f-7a9ca7c2c7cf" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1315ac63-0c46-451f-86df-5f9a73abb957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_878692d9-c713-402f-b472-f22bc732c6b6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_da853a50-b4ae-46fa-a541-4282e3b22f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_da853a50-b4ae-46fa-a541-4282e3b22f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_69c7c383-c6ed-43ee-b476-55ec0b846c73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_69c7c383-c6ed-43ee-b476-55ec0b846c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc4bb502-cb0d-4f33-b429-eec071825b05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be3e24a-777e-4762-9355-3db65b9c2c6c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc4bb502-cb0d-4f33-b429-eec071825b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ba78ea32-8cd8-428b-88d2-40eb5d4d02b6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_297e827f-801f-4365-a60a-9d8d30786b36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_297e827f-801f-4365-a60a-9d8d30786b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a3cc63e6-29d4-4d45-8beb-e03e5790edb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CommercialPaperMember_a3cc63e6-29d4-4d45-8beb-e03e5790edb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8878cab6-4a0b-4841-8e94-53dacb61e9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8878cab6-4a0b-4841-8e94-53dacb61e9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4bcdd009-a5e7-41fb-8d54-fe883c4e701c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4bcdd009-a5e7-41fb-8d54-fe883c4e701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9ef2ebc3-fb33-4efc-917b-7a993813a41c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9ef2ebc3-fb33-4efc-917b-7a993813a41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_51be9ba4-4c74-466d-b228-b03f6a139eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b0ea04e3-1d01-45aa-8703-e2283cb8eda6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_51be9ba4-4c74-466d-b228-b03f6a139eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9c60fe-1c8b-4cfe-86d3-a34841d2b5db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_224ec0fa-5480-4a1f-8463-2fefe0836808" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebea916d-d0bb-47f8-b02e-586ac1c22cf0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_224ec0fa-5480-4a1f-8463-2fefe0836808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/Investments" xlink:type="simple" xlink:href="allo-20191231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://allogene.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0571baaf-935f-466a-a812-e3648d4b7b56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_81b8084e-ae29-4e5d-83ff-48e8124252ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0571baaf-935f-466a-a812-e3648d4b7b56" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_81b8084e-ae29-4e5d-83ff-48e8124252ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentTables" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/InvestmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cb76731d-a0d9-45a5-8c3b-05b33c4dea15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7c6c92b9-d853-41a1-8a03-a453fb12c51b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cb76731d-a0d9-45a5-8c3b-05b33c4dea15" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7c6c92b9-d853-41a1-8a03-a453fb12c51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c6106940-9dba-4ba5-9d92-4398292e848c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cb76731d-a0d9-45a5-8c3b-05b33c4dea15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c6106940-9dba-4ba5-9d92-4398292e848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b739bd4-5194-461e-aa4e-3dcba9f08ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b739bd4-5194-461e-aa4e-3dcba9f08ef7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:to="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_116ba1b6-e474-4ed1-8f6b-3c7cf984ee63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bd7bd1f7-1271-47a5-8f8e-70f0e83de556" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bd7bd1f7-1271-47a5-8f8e-70f0e83de556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_72fa6432-ca80-4f04-8765-bef43151686a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CommercialPaperMember_72fa6432-ca80-4f04-8765-bef43151686a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_110f07c5-14a1-46fa-b34f-83934f37b4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_110f07c5-14a1-46fa-b34f-83934f37b4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ccaeb7ff-3400-4573-80f0-76ed27a6d7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ccaeb7ff-3400-4573-80f0-76ed27a6d7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abadb3fe-01bb-4fb6-8d56-d31413a188f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abadb3fe-01bb-4fb6-8d56-d31413a188f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2d3c7e0b-4a41-4e28-a08d-27e44bfe4332" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fcfbe287-4775-487d-a11f-3607b2f820b0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2d3c7e0b-4a41-4e28-a08d-27e44bfe4332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1c5eae14-229c-4f3a-bb67-4fbf3208dde8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a45a631d-942c-400f-901c-021f34dc118a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a45a631d-942c-400f-901c-021f34dc118a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3febdb0f-37fc-4233-9c3d-cf8d51862212" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3febdb0f-37fc-4233-9c3d-cf8d51862212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9ada326-f07a-400c-bf67-9c7f8d122451" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9ada326-f07a-400c-bf67-9c7f8d122451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aae75292-6071-4456-94a3-250a5481a321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aae75292-6071-4456-94a3-250a5481a321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7da79cb2-4ccf-4e9f-937c-24a82da3092d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7da79cb2-4ccf-4e9f-937c-24a82da3092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcdf981-875c-4fc6-b963-275ac6da3420" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcdf981-875c-4fc6-b963-275ac6da3420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fde1ad14-f709-41f6-a2a1-6ab9b57e21af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fde1ad14-f709-41f6-a2a1-6ab9b57e21af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_c7b4a83a-7383-4c84-b8a2-ba9b9d9ecbf3" xlink:href="allo-20191231.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b977845-0510-41ef-b425-6a0f7ef9fd95" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_c7b4a83a-7383-4c84-b8a2-ba9b9d9ecbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_642ec492-55d6-44c0-b20c-a9ca09b65130" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_642ec492-55d6-44c0-b20c-a9ca09b65130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_119ec827-acab-4a93-8cd0-1dec615ea7b7" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:to="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_119ec827-acab-4a93-8cd0-1dec615ea7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_ba239692-19ea-48ab-a785-674f85474fd5" xlink:href="allo-20191231.xsd#allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:to="loc_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue_ba239692-19ea-48ab-a785-674f85474fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_ab48309a-9bf9-4ad9-888e-f46d5aa9c606" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_ab48309a-9bf9-4ad9-888e-f46d5aa9c606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cafc965-1dfa-440b-94ea-d94fac3cac39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_419397af-3a40-4164-a99d-b5eb0f02400d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cafc965-1dfa-440b-94ea-d94fac3cac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#InvestmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/InvestmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0cd9862e-78c6-4b4c-8c41-2b81ae3d4612" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b70fa62a-a147-4ad4-95cb-e5c66362e06f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0cd9862e-78c6-4b4c-8c41-2b81ae3d4612" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b70fa62a-a147-4ad4-95cb-e5c66362e06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_3a0b07fb-02b6-42b8-aaa2-d585f167232e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0cd9862e-78c6-4b4c-8c41-2b81ae3d4612" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_3a0b07fb-02b6-42b8-aaa2-d585f167232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c830026-a322-4891-beab-a883fff50c37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e41f0e47-ccf5-4d1d-af18-0f5938ef4753" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c830026-a322-4891-beab-a883fff50c37" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e41f0e47-ccf5-4d1d-af18-0f5938ef4753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a4938d5-8de5-4939-8674-0a61f968de30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock_1e6fb0cd-6228-44be-8e09-0f7902e2034f" xlink:href="allo-20191231.xsd#allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a4938d5-8de5-4939-8674-0a61f968de30" xlink:to="loc_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock_1e6fb0cd-6228-44be-8e09-0f7902e2034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1d055bd-db22-473f-bcce-906a551e5cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a4938d5-8de5-4939-8674-0a61f968de30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1d055bd-db22-473f-bcce-906a551e5cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_144b8abd-77e7-4b1f-ae95-12114c29b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a4938d5-8de5-4939-8674-0a61f968de30" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_144b8abd-77e7-4b1f-ae95-12114c29b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_23eb5525-b56d-4c9a-aa8e-2233fd052aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a4938d5-8de5-4939-8674-0a61f968de30" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_23eb5525-b56d-4c9a-aa8e-2233fd052aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedInterestOnShortTermMarketableSecurities_638526ce-3979-476d-9196-44beec0d3a23" xlink:href="allo-20191231.xsd#allo_AccruedInterestOnShortTermMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:to="loc_allo_AccruedInterestOnShortTermMarketableSecurities_638526ce-3979-476d-9196-44beec0d3a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_a47813af-a1c8-458d-9d09-bd64f714c903" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:to="loc_us-gaap_PrepaidInsurance_a47813af-a1c8-458d-9d09-bd64f714c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_9a047315-3bdf-41ae-a702-faa4814df755" xlink:href="allo-20191231.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:to="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_9a047315-3bdf-41ae-a702-faa4814df755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_e7c500af-27fd-405c-9181-1276861a3920" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_e7c500af-27fd-405c-9181-1276861a3920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_547afea6-1c09-427f-a8ee-716f43d4e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f2dcda-afe0-4baf-a790-07581f65e73b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_547afea6-1c09-427f-a8ee-716f43d4e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_535048ef-acb7-4ad9-91fc-9ba93763c4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_535048ef-acb7-4ad9-91fc-9ba93763c4e8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_906aadc3-148d-48c0-8c65-f24abd7e3120" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_a84a57d6-00d7-490a-8a42-5baac4029a8a" xlink:href="allo-20191231.xsd#allo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_allo_LaboratoryEquipmentMember_a84a57d6-00d7-490a-8a42-5baac4029a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_db55ba52-a9f0-4ebb-b689-1d9c434c0bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_db55ba52-a9f0-4ebb-b689-1d9c434c0bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_db175ab7-094d-4f97-ade3-0c29dc14d777" xlink:href="allo-20191231.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_db175ab7-094d-4f97-ade3-0c29dc14d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0719a24b-f0f7-41f2-8477-3500d5067b64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0719a24b-f0f7-41f2-8477-3500d5067b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae3090fc-0ceb-4f7c-a4f8-31398a9ee5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_112a1a20-6d3a-44ef-b0e9-699aeb355a42" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae3090fc-0ceb-4f7c-a4f8-31398a9ee5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2f3c680-b33b-45ed-bf8c-9a21c3de7564" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_80c38046-ef41-41e4-a4b7-5a848f891886" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_80c38046-ef41-41e4-a4b7-5a848f891886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae472426-57bd-4e9c-a16a-e485dec7b5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae472426-57bd-4e9c-a16a-e485dec7b5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b74a4e69-e018-4e74-a555-51742585cf49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63b37e2c-79bc-46f3-957c-84a24bba7ab5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b74a4e69-e018-4e74-a555-51742585cf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f02d8f8-92dc-4d77-8bb5-c8d4ca40802f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f02d8f8-92dc-4d77-8bb5-c8d4ca40802f" xlink:to="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d8f839-a982-49af-b549-c33f7caa3e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_c7b2f039-04c2-4f96-910d-54c62613a9ef" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0fa0660b-6d31-4260-a185-1e0604d00b9e" xlink:to="loc_allo_AssembledWorkforceMember_c7b2f039-04c2-4f96-910d-54c62613a9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:href="allo-20191231.xsd#allo_BalanceSheetComponentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsTable_7c981faa-03d8-46b7-a6e5-e8e902ff091e" xlink:to="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89476707-6230-4bce-8283-1f011f7304ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89476707-6230-4bce-8283-1f011f7304ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_77977cc7-9405-4200-bbb4-e904cc98b6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_77977cc7-9405-4200-bbb4-e904cc98b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2d56a939-af5c-43b7-9051-4a3e096515a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2d56a939-af5c-43b7-9051-4a3e096515a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eb5a5a3e-9564-4396-9d9c-fddd0213a989" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_BalanceSheetComponentsLineItems_be040c6a-2db0-42af-b119-2258b1bca987" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eb5a5a3e-9564-4396-9d9c-fddd0213a989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811412ee-2b64-4f06-9025-0ca7119f7a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811412ee-2b64-4f06-9025-0ca7119f7a9d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7cc9d4df-2b7b-4ad9-85e0-c003bf3b7960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_a889273d-d998-48d8-8bed-f9aa4c419bd5" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646ad046-2e12-4bd7-98bf-ef2ad2e24ec8" xlink:to="loc_allo_AssembledWorkforceMember_a889273d-d998-48d8-8bed-f9aa4c419bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_243d6e7b-a08e-49da-b176-3bc76c22adfb" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b82202fa-9f2f-4f7e-96cb-95d236e90c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b82202fa-9f2f-4f7e-96cb-95d236e90c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_390f98c2-95c3-4ed9-b9bd-9dc132f2dcce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_390f98c2-95c3-4ed9-b9bd-9dc132f2dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f1c155c-f598-44f3-b568-225925c2eee0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_d2c247fd-273d-4a63-b581-db9482c2777d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f1c155c-f598-44f3-b568-225925c2eee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_d80966d1-b1c7-4ebe-95e2-b1aab89f913c" xlink:href="allo-20191231.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_d80966d1-b1c7-4ebe-95e2-b1aab89f913c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_49c6a576-82c9-4d8d-baab-6c6ceb5504ae" xlink:href="allo-20191231.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_49c6a576-82c9-4d8d-baab-6c6ceb5504ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedPropertyAndEquipment_5202483f-3162-4782-8ece-7e3e585915fa" xlink:href="allo-20191231.xsd#allo_AccruedPropertyAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_allo_AccruedPropertyAndEquipment_5202483f-3162-4782-8ece-7e3e585915fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent_72361f9d-c4f6-4984-ba6d-1f098dea0ce3" xlink:href="allo-20191231.xsd#allo_UnvestedSharesLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_allo_UnvestedSharesLiabilitiesCurrent_72361f9d-c4f6-4984-ba6d-1f098dea0ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4c664b36-b496-4f84-88e6-ed3f43ef2a83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4c664b36-b496-4f84-88e6-ed3f43ef2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_a9d1f072-f3a6-4c0d-9734-f614ff870f1f" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7993afc3-abc5-4a5c-a44d-badce924aaaf" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_a9d1f072-f3a6-4c0d-9734-f614ff870f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisition" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisition"/>
  <link:presentationLink xlink:role="http://allogene.com/role/AssetAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fa97f644-0a60-45f0-88d0-f94929214a48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7a4646e0-c60e-4481-b37e-10944f3103ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fa97f644-0a60-45f0-88d0-f94929214a48" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7a4646e0-c60e-4481-b37e-10944f3103ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionTables" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/AssetAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a06211df-c868-4e85-9eb9-1bbae8b462f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock_a9b090d4-9769-4adb-a2de-21690d03d389" xlink:href="allo-20191231.xsd#allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a06211df-c868-4e85-9eb9-1bbae8b462f0" xlink:to="loc_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock_a9b090d4-9769-4adb-a2de-21690d03d389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_df976493-50f3-4a57-bc81-6ad1ca1b7ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_df976493-50f3-4a57-bc81-6ad1ca1b7ce3" xlink:to="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_536e2537-c5e2-4965-9084-d6d95627db2a" xlink:to="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_00cf34a1-3c3b-4ba3-be9b-68067299fd2e" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_492f5ffc-19c6-408b-bbaa-476270522eac" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_00cf34a1-3c3b-4ba3-be9b-68067299fd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_343b10fd-23be-4ed0-a6bb-9cdf5e7a0b29" xlink:to="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_c6c0b37d-e694-4f45-ba71-5057d40ecb81" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7211b89f-348a-4f07-a8cc-ba021f9a5d0a" xlink:to="loc_allo_PfizerIncMember_c6c0b37d-e694-4f45-ba71-5057d40ecb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d2811e81-80dc-4d69-9ab7-e601cf632099" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_1021dd04-16a2-47c3-bb92-2419c6664a76" xlink:href="allo-20191231.xsd#allo_AssetContributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f86f5-77e9-4dbd-82a2-316aec1c9692" xlink:to="loc_allo_AssetContributionAgreementMember_1021dd04-16a2-47c3-bb92-2419c6664a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8c8a367c-9c73-46e7-b6b5-133978274199" xlink:to="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_85c14cb6-8df1-42cc-b525-a38369cd75f4" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:to="loc_country_US_85c14cb6-8df1-42cc-b525-a38369cd75f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_fad85498-3bc3-4b52-a652-45e46ca49f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b2a87fdd-cb1c-49f3-9e0a-3375d4ffed02" xlink:to="loc_us-gaap_EuropeanUnionMember_fad85498-3bc3-4b52-a652-45e46ca49f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_2a7d7d05-017c-4ee7-b6a8-9c5b0ac6d28c" xlink:to="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_66721c97-0458-4d13-a387-55f9bae80526" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_66721c97-0458-4d13-a387-55f9bae80526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_fd1a8625-82be-41a6-9e6b-82a4d08650f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_fd1a8625-82be-41a6-9e6b-82a4d08650f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9f9068f5-a0bc-4b6d-bad5-d30b9caa1f88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9f9068f5-a0bc-4b6d-bad5-d30b9caa1f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_4b0ab22c-b87d-4228-85da-ee34f21e47f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_4b0ab22c-b87d-4228-85da-ee34f21e47f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f0f0187b-1acb-4f1a-a14c-53bb95acadba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f0f0187b-1acb-4f1a-a14c-53bb95acadba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DiscountRateForValuation_cb53f600-137b-4825-9176-f4d84a27d3d1" xlink:href="allo-20191231.xsd#allo_DiscountRateForValuation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_DiscountRateForValuation_cb53f600-137b-4825-9176-f4d84a27d3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_03daebb0-f20b-439e-ac29-551886ada117" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_03daebb0-f20b-439e-ac29-551886ada117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_2c94df45-5a2d-481f-a64a-f031692bde7e" xlink:href="allo-20191231.xsd#allo_MilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_MilestonePayments_2c94df45-5a2d-481f-a64a-f031692bde7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregateMilestonePayments_4486e41c-8014-4c7b-b015-810cd8aa7804" xlink:href="allo-20191231.xsd#allo_AggregateMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_d44087fe-6771-4138-b5c3-75172280f35d" xlink:to="loc_allo_AggregateMilestonePayments_4486e41c-8014-4c7b-b015-810cd8aa7804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5e9d5925-02eb-45bd-8df9-a1dedffa2ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5e9d5925-02eb-45bd-8df9-a1dedffa2ddd" xlink:to="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a5862d3-4b53-44c4-ab8c-dbd689eeacaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_31b4f595-ccc2-4eaf-8609-a13d465cb7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_623e5de8-1cfe-4676-8d10-d7879ab35542" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_31b4f595-ccc2-4eaf-8609-a13d465cb7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f29698fa-ecd8-466c-b56c-2f6b521885ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiCDNineteenCARTCellTherapyMember_64de05d9-72eb-47e5-b7f2-9b4ad9a75cd5" xlink:href="allo-20191231.xsd#allo_AntiCDNineteenCARTCellTherapyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AntiCDNineteenCARTCellTherapyMember_64de05d9-72eb-47e5-b7f2-9b4ad9a75cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntiBCMACARTCellTherapyMember_892a9289-93a1-4547-a533-21638db7d7f1" xlink:href="allo-20191231.xsd#allo_AntiBCMACARTCellTherapyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AntiBCMACARTCellTherapyMember_892a9289-93a1-4547-a533-21638db7d7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssembledWorkforceMember_cf7fae3a-a299-4c6d-8750-699d76e2cb8b" xlink:href="allo-20191231.xsd#allo_AssembledWorkforceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_82c1f269-d6af-471e-a323-560e65cad298" xlink:to="loc_allo_AssembledWorkforceMember_cf7fae3a-a299-4c6d-8750-699d76e2cb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:href="allo-20191231.xsd#allo_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionTable_c4cdd29c-3b45-4001-a4d5-fc22ef74d48e" xlink:to="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a24d7526-cd4f-4515-9548-8458749ec7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a24d7526-cd4f-4515-9548-8458749ec7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3e2dcfd9-ab25-4468-aed3-d05562f3eff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_AssetAcquisitionLineItems_0b990e12-bc2c-489e-9b73-5c2eca31e23a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3e2dcfd9-ab25-4468-aed3-d05562f3eff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0f93586e-946b-4aa8-8ff5-f29cf1d55ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementsTextBlock_bca4dd17-c4f5-47ff-be68-7a096f356bb5" xlink:href="allo-20191231.xsd#allo_LicenseAndCollaborationAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0f93586e-946b-4aa8-8ff5-f29cf1d55ad9" xlink:to="loc_allo_LicenseAndCollaborationAgreementsTextBlock_bca4dd17-c4f5-47ff-be68-7a096f356bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_26f0e32a-a4e1-4beb-a20a-30e379628142" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_26f0e32a-a4e1-4beb-a20a-30e379628142" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_442697c5-ad47-4dc5-a624-a2fbec542d98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_b7e933f8-0db2-4758-b69b-b6aa520c8f29" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9bc923bb-b7e4-4855-b89c-4ed702763ae7" xlink:to="loc_allo_NotchTherapeuticsIncMember_b7e933f8-0db2-4758-b69b-b6aa520c8f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8228b9b-096d-49b8-95b2-4a273c50aed5" xlink:to="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_6ed727ba-f1a2-416c-9ebf-00914da18572" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_PfizerIncMember_6ed727ba-f1a2-416c-9ebf-00914da18572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_02a10d71-cbc2-4014-b329-bc1b42292cb7" xlink:href="allo-20191231.xsd#allo_CellectisSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_CellectisSAMember_02a10d71-cbc2-4014-b329-bc1b42292cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_f764183e-98a4-41e5-b43c-e86e27700f2e" xlink:href="allo-20191231.xsd#allo_ServierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_ServierMember_f764183e-98a4-41e5-b43c-e86e27700f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_f302ce39-7248-4e1a-a3b2-8635a46c3081" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8dcc0698-cca4-4944-8a82-e6f8107ea1e8" xlink:to="loc_allo_NotchTherapeuticsIncMember_f302ce39-7248-4e1a-a3b2-8635a46c3081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29e735c5-72c3-4342-96ba-45dc15908aa5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_e7d4560a-d587-4b59-968a-a2ba628f69e3" xlink:href="allo-20191231.xsd#allo_AssetContributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_AssetContributionAgreementMember_e7d4560a-d587-4b59-968a-a2ba628f69e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_1e28c5b8-0216-4687-9e2a-cddb18f0bf27" xlink:href="allo-20191231.xsd#allo_RegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_RegulatoryMilestoneMember_1e28c5b8-0216-4687-9e2a-cddb18f0bf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_0dc543cc-34de-4a21-bb5e-8c68129ac7cd" xlink:href="allo-20191231.xsd#allo_SalesMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_SalesMilestoneMember_0dc543cc-34de-4a21-bb5e-8c68129ac7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryAndSalesMilestoneMember_73d272c5-ec49-4e0a-b335-ad6b4a473843" xlink:href="allo-20191231.xsd#allo_RegulatoryAndSalesMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_RegulatoryAndSalesMilestoneMember_73d272c5-ec49-4e0a-b335-ad6b4a473843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_e1697cc9-ac71-4f0a-a08b-ab24f8aeef5b" xlink:href="allo-20191231.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_e1697cc9-ac71-4f0a-a08b-ab24f8aeef5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_98123db4-b13f-4364-be50-1250be690a61" xlink:href="allo-20191231.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55dcb44f-821c-4138-8de1-3643df919157" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_98123db4-b13f-4364-be50-1250be690a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fa5d71cb-5fae-43b7-83de-ea5bdea7ad7b" xlink:to="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79dcd9d3-fd64-4cc1-af2f-e7e1b582b526" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fdb877ca-2318-4d6c-9a11-b9678f412921" xlink:to="loc_srt_MaximumMember_79dcd9d3-fd64-4cc1-af2f-e7e1b582b526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8f2765e4-6261-4cd4-a26e-e512465d8ec4" xlink:to="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9cb8085-4302-4255-80ec-cb4d9bb9acb0" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_country_US_a9cb8085-4302-4255-80ec-cb4d9bb9acb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_98195597-548e-49bf-a1a8-61b6f2029a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_us-gaap_EuropeanUnionMember_98195597-548e-49bf-a1a8-61b6f2029a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_2ab6c9d9-28f4-4976-9986-ef578a3e1c48" xlink:href="allo-20191231.xsd#allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e9d728f-9467-43b0-8144-e44328ebb642" xlink:to="loc_allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember_2ab6c9d9-28f4-4976-9986-ef578a3e1c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f17d714b-6152-44bd-b28d-f8c08ae27373" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_97f80c80-0ea7-4e19-baff-a58c10c75073" xlink:href="allo-20191231.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_97f80c80-0ea7-4e19-baff-a58c10c75073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_2ea2d929-de76-4ca8-aab8-498ffaf6a825" xlink:href="allo-20191231.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_2ea2d929-de76-4ca8-aab8-498ffaf6a825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalDevelopmentMilestoneMember_f957d15f-ba4d-4072-9690-6ebf215db907" xlink:href="allo-20191231.xsd#allo_ClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e350b10f-78ed-41dc-aba0-03f6c126e86e" xlink:to="loc_allo_ClinicalDevelopmentMilestoneMember_f957d15f-ba4d-4072-9690-6ebf215db907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_517e94f1-aa3e-401a-8730-08c03fd76c4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_a106e91e-85d5-4171-8100-43c39ef650d0" xlink:href="allo-20191231.xsd#allo_MilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_MilestonePayments_a106e91e-85d5-4171-8100-43c39ef650d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_63f079da-83a6-4984-9fc2-ff87402ab551" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AggregatePotentialMilestonePayments_63f079da-83a6-4984-9fc2-ff87402ab551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_e286d951-6eb2-4ede-902d-13ec5bbcccc2" xlink:href="allo-20191231.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_e286d951-6eb2-4ede-902d-13ec5bbcccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9176e589-09bf-48ed-8f7e-1b7dbdcabc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9176e589-09bf-48ed-8f7e-1b7dbdcabc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostResponsibleFor_7edd0201-3ffb-4d99-b4fa-5d56b148bfb8" xlink:href="allo-20191231.xsd#allo_PercentageOfDevelopmentCostResponsibleFor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_PercentageOfDevelopmentCostResponsibleFor_7edd0201-3ffb-4d99-b4fa-5d56b148bfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_a2ef4175-0387-4342-bf7d-2d6333897fc0" xlink:href="allo-20191231.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AggregatePotentialMilestonePayable_a2ef4175-0387-4342-bf7d-2d6333897fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_4582bf83-6ef6-4a59-8647-61f865c65530" xlink:href="allo-20191231.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_4582bf83-6ef6-4a59-8647-61f865c65530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_03c1bbe0-c304-4bf4-892b-fb4b85205e6d" xlink:href="allo-20191231.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_03c1bbe0-c304-4bf4-892b-fb4b85205e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4170b530-a4ac-4e83-b1a2-124956c0d1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4170b530-a4ac-4e83-b1a2-124956c0d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d61351-cd38-41f4-abdd-4e74e882a8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_765addac-28b9-4b40-b4b2-9aa557af868e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d61351-cd38-41f4-abdd-4e74e882a8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:type="simple" xlink:href="allo-20191231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45b93557-69c0-4b8f-817d-7a0d8e3d8e72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_57327f5d-cc5e-4cc0-8c8c-50d662f5469e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45b93557-69c0-4b8f-817d-7a0d8e3d8e72" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_57327f5d-cc5e-4cc0-8c8c-50d662f5469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2003adc0-976b-4ad8-8ca2-a2738b1ff9da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6b273120-7216-4c7a-a58d-185985c74b58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2003adc0-976b-4ad8-8ca2-a2738b1ff9da" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6b273120-7216-4c7a-a58d-185985c74b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2a152f7-cd66-4a75-b08b-5101921f5dca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a152f7-cd66-4a75-b08b-5101921f5dca" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_25462aad-9840-4948-882a-ca914f1f065e" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember_6a080182-6451-41e7-a23a-19b45a4702a4" xlink:href="allo-20191231.xsd#allo_LeaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:to="loc_allo_LeaseOneMember_6a080182-6451-41e7-a23a-19b45a4702a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_e1fd254f-d468-4dbb-b264-27dc81e3b24d" xlink:href="allo-20191231.xsd#allo_LeaseTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_9808bae5-79f0-4ff1-bf17-a4ff100d5522" xlink:to="loc_allo_LeaseTwoMember_e1fd254f-d468-4dbb-b264-27dc81e3b24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:to="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e4466271-986a-4ed3-a01a-adbda35e18f8" xlink:to="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_801cb3bf-6815-4795-a279-8e844bcfac5b" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_stpr_NY_801cb3bf-6815-4795-a279-8e844bcfac5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LosAngelesMember_11146c0c-e6a3-4de9-8c67-d028413ed46c" xlink:href="allo-20191231.xsd#allo_LosAngelesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_allo_LosAngelesMember_11146c0c-e6a3-4de9-8c67-d028413ed46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_dc970d58-c9c6-4ef9-8181-0bf23742769a" xlink:href="allo-20191231.xsd#allo_NewarkMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa98978a-1b1d-4b50-b1a1-8352baa82ec7" xlink:to="loc_allo_NewarkMember_dc970d58-c9c6-4ef9-8181-0bf23742769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_94ec676f-8b71-451e-806a-3306253624c4" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_dcc3a9d0-0d7f-418f-8d84-347a40febc4f" xlink:href="allo-20191231.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_AreaOfNewOfficeBuilding_dcc3a9d0-0d7f-418f-8d84-347a40febc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd974311-947f-4cf0-9be7-156b43d1abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd974311-947f-4cf0-9be7-156b43d1abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseOptionToExtendNumber_26ede094-e58a-4ca9-87d3-85b92f751ae3" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseOptionToExtendNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_LesseeOperatingLeaseOptionToExtendNumber_26ede094-e58a-4ca9-87d3-85b92f751ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_660362ed-0803-412f-9906-aa5f39051c72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_660362ed-0803-412f-9906-aa5f39051c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_6b28f155-7f84-462e-838a-5ededf76e556" xlink:href="allo-20191231.xsd#allo_AllowanceForTenantImprovements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_AllowanceForTenantImprovements_6b28f155-7f84-462e-838a-5ededf76e556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7de97945-4264-4e0f-adae-1f736699a227" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7de97945-4264-4e0f-adae-1f736699a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_debd7c18-8666-4df2-aca5-85ec6d770772" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_debd7c18-8666-4df2-aca5-85ec6d770772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc0db1b6-5c13-4101-b813-469e56ea03b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc0db1b6-5c13-4101-b813-469e56ea03b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9fd42c1d-471a-4c66-a666-8257d74099ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9fd42c1d-471a-4c66-a666-8257d74099ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_fc68b17f-630e-4095-a1fc-ad07c81599fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_fc68b17f-630e-4095-a1fc-ad07c81599fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeasesNumberOfLeaseAgreements_9c5c6d9c-698b-402d-abd5-0b46ac8bd38e" xlink:href="allo-20191231.xsd#allo_OperatingLeasesNumberOfLeaseAgreements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_OperatingLeasesNumberOfLeaseAgreements_9c5c6d9c-698b-402d-abd5-0b46ac8bd38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9b46e05d-c431-4301-a2d9-df7c537fa060" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9b46e05d-c431-4301-a2d9-df7c537fa060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShorttermLeaseRentExpense_d1acdf38-5256-425b-a1db-dae5707d7d03" xlink:href="allo-20191231.xsd#allo_ShorttermLeaseRentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_ShorttermLeaseRentExpense_d1acdf38-5256-425b-a1db-dae5707d7d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_b1f0a5f9-877f-4c9d-9d2e-1178ec32ba5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_b1f0a5f9-877f-4c9d-9d2e-1178ec32ba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment_9e46ef4d-f402-404f-9251-7633189bbe92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_us-gaap_VariableLeasePayment_9e46ef4d-f402-404f-9251-7633189bbe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OperatingLeaseAssetRetirementObligation_f449c4f2-21d5-4846-b1cb-8ff74c7ccbf8" xlink:href="allo-20191231.xsd#allo_OperatingLeaseAssetRetirementObligation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_408a0f50-e7e8-432a-87b4-d2e6c82ace77" xlink:to="loc_allo_OperatingLeaseAssetRetirementObligation_f449c4f2-21d5-4846-b1cb-8ff74c7ccbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d787857c-7b7b-4938-91ae-eddac98e1db1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d787857c-7b7b-4938-91ae-eddac98e1db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f401da0d-be61-4d92-be5a-52c4fee18274" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f401da0d-be61-4d92-be5a-52c4fee18274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3577ebc6-5cc4-440c-bab4-45245b1d9db1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3577ebc6-5cc4-440c-bab4-45245b1d9db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bdb3b885-6b22-4e7a-b1f1-1a724f0f41ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bdb3b885-6b22-4e7a-b1f1-1a724f0f41ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_7f5b3acb-1737-482b-82b1-a4fc407df4cf" xlink:href="allo-20191231.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_7f5b3acb-1737-482b-82b1-a4fc407df4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ac038663-f9c6-44df-8d12-6bd46d3bd11f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ac038663-f9c6-44df-8d12-6bd46d3bd11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dd4b0ea6-2970-40ab-9fa6-2f460ee84bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dd4b0ea6-2970-40ab-9fa6-2f460ee84bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_d777d9ee-91ab-499a-a356-8b9a2ebf258f" xlink:href="allo-20191231.xsd#allo_AllowanceForTenantImprovements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_allo_AllowanceForTenantImprovements_d777d9ee-91ab-499a-a356-8b9a2ebf258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_575fade8-2295-4a2c-8c09-6ec90ac88804" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1291997b-10a1-4fda-b6c4-5019034d587f" xlink:to="loc_us-gaap_OperatingLeaseLiability_575fade8-2295-4a2c-8c09-6ec90ac88804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestment"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2f6e83a3-fc9f-4d2a-9386-b898de67f2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b1d50278-cfd2-4cfb-8ad3-a778eccfd3df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2f6e83a3-fc9f-4d2a-9386-b898de67f2c0" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b1d50278-cfd2-4cfb-8ad3-a778eccfd3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#EquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_41d6c6ad-aa96-45e1-9914-5e319b0f6d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_41d6c6ad-aa96-45e1-9914-5e319b0f6d9e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_182481f6-75b5-4f0d-9451-e3e64bccfd83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_d991ee0a-ad39-4137-87cd-095505a52fc5" xlink:href="allo-20191231.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2557eaf3-a601-4c90-94f5-b4764211ab0d" xlink:to="loc_allo_NotchTherapeuticsIncMember_d991ee0a-ad39-4137-87cd-095505a52fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2dd6435c-e3fc-4a92-b24b-4ed69bd81da3" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_9451b4a3-3f51-4ede-8a8a-93ae0637070b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_9451b4a3-3f51-4ede-8a8a-93ae0637070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_d041f944-442a-4cba-9b73-647d2c73c1c0" xlink:href="allo-20191231.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_d041f944-442a-4cba-9b73-647d2c73c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e3ce22ec-88d2-4c0b-85a2-cc5fe9b2d5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e3ce22ec-88d2-4c0b-85a2-cc5fe9b2d5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dc3677d0-f623-4b1e-b14c-c470d86eda58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dc3677d0-f623-4b1e-b14c-c470d86eda58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_0407a5c1-e5ce-483f-b09c-ac5fc8a5574e" xlink:href="allo-20191231.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2679ef55-1429-4083-a2eb-2e1c8a14a7b8" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_0407a5c1-e5ce-483f-b09c-ac5fc8a5574e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20191231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_664c0ee3-8661-47c0-b02e-ad20cfe2cd65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bddd6478-864f-4096-be7d-7b1a648383f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_664c0ee3-8661-47c0-b02e-ad20cfe2cd65" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bddd6478-864f-4096-be7d-7b1a648383f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018Notes"/>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f87e5c2e-ce01-4450-8c4a-4fda05b5be3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5fe17ec8-7302-4661-9722-d95d4f58302a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f87e5c2e-ce01-4450-8c4a-4fda05b5be3a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5fe17ec8-7302-4661-9722-d95d4f58302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertibleNotesPayable2018NotesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ff061289-7283-4ee1-abed-bc068cfc3650" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ff061289-7283-4ee1-abed-bc068cfc3650" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6cfbadd1-cd6f-46b4-9891-634b170a2b38" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_3cbad27e-6b27-438c-b9e4-b11b506efcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d13fbfb-3fc6-4844-8520-b17eda2e6894" xlink:to="loc_us-gaap_IPOMember_3cbad27e-6b27-438c-b9e4-b11b506efcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_075c921a-a367-41da-b0d7-449ffdfa7c7f" xlink:to="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f355639a-aa28-4416-8568-9c792eeeca99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f355639a-aa28-4416-8568-9c792eeeca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_2f8b1989-8918-48f3-8dfa-ec1a56824abe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_2f8b1989-8918-48f3-8dfa-ec1a56824abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5460f50c-d527-4de3-9d08-b2f96c572915" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_LongTermDebtFairValue_5460f50c-d527-4de3-9d08-b2f96c572915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_91810142-208b-4bde-b585-057ada359713" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_91810142-208b-4bde-b585-057ada359713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_05d44361-1d27-4c9b-a486-a4675386e038" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_05d44361-1d27-4c9b-a486-a4675386e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_f38920b7-33dc-4204-aac8-21b0519302fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_f38920b7-33dc-4204-aac8-21b0519302fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_57f8d8a3-1e21-4e72-9a4d-df414b6c4541" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_80d00aa9-24ad-4840-9aa5-c3165809cd32" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_57f8d8a3-1e21-4e72-9a4d-df414b6c4541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_33f967c8-025e-430d-bb23-acefc6cd0683" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0e6d4b3f-b5a9-49ee-87e9-ee40d54a1a93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_33f967c8-025e-430d-bb23-acefc6cd0683" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0e6d4b3f-b5a9-49ee-87e9-ee40d54a1a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#ConvertiblePreferredStockandStockholdersDeficitDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2fb045e-6e8f-4457-bb1a-c26fb8d872ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2fb045e-6e8f-4457-bb1a-c26fb8d872ee" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0d81856-78fb-456e-a57e-7f8190381087" xlink:to="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesA1ConvertiblePreferredSharesMember_f9d13489-cac3-4ab9-b62e-4567d90e0e54" xlink:href="allo-20191231.xsd#allo_SeriesA1ConvertiblePreferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:to="loc_allo_SeriesA1ConvertiblePreferredSharesMember_f9d13489-cac3-4ab9-b62e-4567d90e0e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SeriesAConvertiblePreferredSharesMember_a829cb09-bf30-404a-bf05-83ae7472efe4" xlink:href="allo-20191231.xsd#allo_SeriesAConvertiblePreferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7a7fe5f-5b34-4301-8782-ca569e97d068" xlink:to="loc_allo_SeriesAConvertiblePreferredSharesMember_a829cb09-bf30-404a-bf05-83ae7472efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2270d4c-6043-4399-b300-69622deed09f" xlink:to="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_58ee3653-be3b-4d94-98cb-8772537df0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a8a0201-73ef-48af-a21a-dc2987a03f2a" xlink:to="loc_us-gaap_CommonStockMember_58ee3653-be3b-4d94-98cb-8772537df0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac1974ff-132a-4c2a-9f35-1a866fd58f2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9564982e-36e3-4c37-8412-a655b9030e37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40b56c87-c76e-4f98-863a-0c0dc7675e49" xlink:to="loc_us-gaap_IPOMember_9564982e-36e3-4c37-8412-a655b9030e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_af8cd8db-1be0-470a-b681-52317ea75dde" xlink:to="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ffedfb5e-abae-4ef8-bb01-fed838c3f4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ffedfb5e-abae-4ef8-bb01-fed838c3f4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_6e9bc467-6b43-4c00-a96d-bb5a4ae3d455" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_6e9bc467-6b43-4c00-a96d-bb5a4ae3d455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_748a0094-bb3c-41fc-8f37-54bc6d116895" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_748a0094-bb3c-41fc-8f37-54bc6d116895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_930864cf-679b-4029-8ff1-a7775cfafb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_930864cf-679b-4029-8ff1-a7775cfafb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePurchasePriceSharesValue_0d65b3a4-6966-41ea-815b-061eda792215" xlink:href="allo-20191231.xsd#allo_AggregatePurchasePriceSharesValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_allo_AggregatePurchasePriceSharesValue_0d65b3a4-6966-41ea-815b-061eda792215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_635bc50c-2b09-441b-9b32-d416f48d5a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_635bc50c-2b09-441b-9b32-d416f48d5a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_744d1060-6e55-410e-82e5-8bfef7b038bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_744d1060-6e55-410e-82e5-8bfef7b038bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12af3785-1e39-405f-8664-954ca725f856" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12af3785-1e39-405f-8664-954ca725f856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9c8751c0-1e70-40c5-accb-99d6071519b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9c8751c0-1e70-40c5-accb-99d6071519b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3c777ed-5ed4-4c07-b47a-7515bbdd52dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d3c777ed-5ed4-4c07-b47a-7515bbdd52dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_51f4a984-5a4c-424e-91fd-41f1adce41b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_51f4a984-5a4c-424e-91fd-41f1adce41b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e5e64d8f-22ed-47b0-a304-26eb780de061" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesIssued_e5e64d8f-22ed-47b0-a304-26eb780de061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ef3ef0a-2e95-4f05-a2a4-e6ace6aa480b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ef3ef0a-2e95-4f05-a2a4-e6ace6aa480b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock_2b1fcf70-3149-49be-9d74-f65422af2096" xlink:href="allo-20191231.xsd#allo_ModificationOfConvertiblePreferredStockForCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_allo_ModificationOfConvertiblePreferredStockForCommonStock_2b1fcf70-3149-49be-9d74-f65422af2096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_d4bd9c91-ad3c-4fb9-b291-4481c1f2ef80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_d4bd9c91-ad3c-4fb9-b291-4481c1f2ef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54930f5d-38fa-429e-b2bd-9ab0882c4721" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54930f5d-38fa-429e-b2bd-9ab0882c4721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_182cc866-adda-4465-8192-6b8143ea98e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0ade93a-0aa3-4431-a484-33a1ceba7dd0" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_182cc866-adda-4465-8192-6b8143ea98e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4f00c01-f34d-4fe8-8e66-775788647786" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f97b10ae-8685-4e34-9da9-22a3d7e97ede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4f00c01-f34d-4fe8-8e66-775788647786" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f97b10ae-8685-4e34-9da9-22a3d7e97ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6a890d63-fa7e-43d6-a825-d0bb7b1ef589" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6a890d63-fa7e-43d6-a825-d0bb7b1ef589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc9b5abd-8734-4a5d-a990-b3f139bacc91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc9b5abd-8734-4a5d-a990-b3f139bacc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_87e9e13c-578f-405f-8123-a77c0772728f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_87e9e13c-578f-405f-8123-a77c0772728f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_facd7690-cb8e-4c67-b87a-43c92d70c03e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_facd7690-cb8e-4c67-b87a-43c92d70c03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0818a97c-01be-4219-9d45-ee89a19bd20a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1bbefa-4f7b-4408-a2cc-cd7dea4c7256" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0818a97c-01be-4219-9d45-ee89a19bd20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84a9ace1-a329-40aa-abb1-076670de8372" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84a9ace1-a329-40aa-abb1-076670de8372" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_97fc2535-0653-492e-b3e0-e1add5443f5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_b024742c-bf62-4e93-bf26-fe37fac7afa8" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenPlanMember_b024742c-bf62-4e93-bf26-fe37fac7afa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f6f8f97-a77d-4368-b5b0-59d22c332f21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f6f8f97-a77d-4368-b5b0-59d22c332f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_933dd662-6dc8-442c-8169-159551ed5a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_933dd662-6dc8-442c-8169-159551ed5a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_a2afc942-db8c-47a9-98e7-c81953f23a9d" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_a2afc942-db8c-47a9-98e7-c81953f23a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_59701eec-9dba-4f6b-ac65-4040aa8d8149" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_59701eec-9dba-4f6b-ac65-4040aa8d8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersStockAwardMember_0a42ed26-7c59-48ae-bc42-c491c73f33ad" xlink:href="allo-20191231.xsd#allo_FoundersStockAwardMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_FoundersStockAwardMember_0a42ed26-7c59-48ae-bc42-c491c73f33ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExercisedStockOptionsMember_a24dd8f4-dca8-4ef6-92fb-c4ad767dfb95" xlink:href="allo-20191231.xsd#allo_EarlyExercisedStockOptionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1006b9f-4d92-4e41-bfc7-bd2358945ae2" xlink:to="loc_allo_EarlyExercisedStockOptionsMember_a24dd8f4-dca8-4ef6-92fb-c4ad767dfb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8175622c-6dfb-4d16-b5a9-545dc0e1464d" xlink:to="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_113c87a2-bbea-4157-a2b1-0aede6532ebc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:to="loc_srt_MinimumMember_113c87a2-bbea-4157-a2b1-0aede6532ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfbedc04-9268-432c-98af-7b4bdf85d0a2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adf421c6-ec59-41bd-8f77-3b134de2134f" xlink:to="loc_srt_MaximumMember_bfbedc04-9268-432c-98af-7b4bdf85d0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_78925e5c-a21a-46a8-b860-2b152bbbb0d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FoundersMember_d1f5c5b6-edb1-4b9e-8656-9f2de44b1e40" xlink:href="allo-20191231.xsd#allo_FoundersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:to="loc_allo_FoundersMember_d1f5c5b6-edb1-4b9e-8656-9f2de44b1e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExecutiveOfficerMember_f9d0890e-c9c9-4999-8041-fdd07a106d71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_340686c9-947e-44f0-8ccd-fcda4407822e" xlink:to="loc_us-gaap_ExecutiveOfficerMember_f9d0890e-c9c9-4999-8041-fdd07a106d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d44d828-038f-425e-aa29-99afd6511a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_3c4ec717-7ce1-4563-adaf-1ce1cade5e7d" xlink:href="allo-20191231.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_3c4ec717-7ce1-4563-adaf-1ce1cade5e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_810c6ee6-bf91-474a-8610-355733eb8e6d" xlink:href="allo-20191231.xsd#allo_StockOptionGrantedPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_StockOptionGrantedPeriod_810c6ee6-bf91-474a-8610-355733eb8e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6ce62de4-fdcf-448d-a628-8bcf0091d26b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6ce62de4-fdcf-448d-a628-8bcf0091d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_89d68d82-d435-42e3-b4f1-812d50589d3f" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_89d68d82-d435-42e3-b4f1-812d50589d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CombinedVotingPowerByIndividual_3bdbd502-0812-4e66-8267-b2c252d98dc7" xlink:href="allo-20191231.xsd#allo_CombinedVotingPowerByIndividual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_CombinedVotingPowerByIndividual_3bdbd502-0812-4e66-8267-b2c252d98dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_51bb04d8-c61f-410d-8314-36d86796c8e7" xlink:href="allo-20191231.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1_51bb04d8-c61f-410d-8314-36d86796c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ef6f9e67-843f-442c-bc62-7c38cabd2158" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ef6f9e67-843f-442c-bc62-7c38cabd2158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108d0054-4a3d-4d4a-802a-694aadbb5d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108d0054-4a3d-4d4a-802a-694aadbb5d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6888b577-8454-4a1d-9484-576c99709043" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6888b577-8454-4a1d-9484-576c99709043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7e99f80-ab99-49f4-bb40-eef94c2a81af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7e99f80-ab99-49f4-bb40-eef94c2a81af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_21416a98-e620-445b-af97-906cbe07dab0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_21416a98-e620-445b-af97-906cbe07dab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3114dffb-c8c0-4ee5-a7fb-21a2deef9534" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3114dffb-c8c0-4ee5-a7fb-21a2deef9534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_InitiallyReservedCommonStockForEmployeePurchase_40e501e4-003b-4e63-b12c-36a4f0fff9db" xlink:href="allo-20191231.xsd#allo_InitiallyReservedCommonStockForEmployeePurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_InitiallyReservedCommonStockForEmployeePurchase_40e501e4-003b-4e63-b12c-36a4f0fff9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentOfferingPeriod_03516932-7d79-459f-805b-d5b73c79a549" xlink:href="allo-20191231.xsd#allo_CurrentOfferingPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_CurrentOfferingPeriod_03516932-7d79-459f-805b-d5b73c79a549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_066cf418-b1dd-4601-ace2-ce0703ec9cae" xlink:href="allo-20191231.xsd#allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue_066cf418-b1dd-4601-ace2-ce0703ec9cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfEligibleCompensationContributionByEmployee_4a192187-fd46-4196-b4ec-3397369aa3c0" xlink:href="allo-20191231.xsd#allo_PercentageOfEligibleCompensationContributionByEmployee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_allo_PercentageOfEligibleCompensationContributionByEmployee_4a192187-fd46-4196-b4ec-3397369aa3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_91a020f5-8682-4f32-9a20-ff78e5e5bc76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_91a020f5-8682-4f32-9a20-ff78e5e5bc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90da640a-07b5-4033-889d-08708d06ff34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90da640a-07b5-4033-889d-08708d06ff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66b3e5c7-edcf-4195-bb45-57a50d8c16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66b3e5c7-edcf-4195-bb45-57a50d8c16c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60f8983f-01fb-43e2-8d03-12ae0371e627" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60f8983f-01fb-43e2-8d03-12ae0371e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_e53eefcd-8878-49e7-a965-6bc4b4c4be4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_e53eefcd-8878-49e7-a965-6bc4b4c4be4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_77f1f5a3-54c7-48ff-a39e-26ffb27544a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_77f1f5a3-54c7-48ff-a39e-26ffb27544a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_698a378d-d7e5-48dd-bf05-683d99bd5ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b8860c4-5b81-44e9-809f-d77290b3fd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_698a378d-d7e5-48dd-bf05-683d99bd5ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d20bf25f-37dd-4e49-94f5-11b227a244c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d20bf25f-37dd-4e49-94f5-11b227a244c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:to="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80a9c405-a57a-4585-af23-d76acf888248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_6e8fc1f3-e774-421d-947b-bf7c97aa8de8" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a44db5fa-d859-450a-a092-bc3f21eb0032" xlink:to="loc_allo_TwoThousandEighteenPlanMember_6e8fc1f3-e774-421d-947b-bf7c97aa8de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5315299e-7da4-4521-b2b9-dec772bbd4ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b64df32-e46f-46a4-8b55-0b273ed3c3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b64df32-e46f-46a4-8b55-0b273ed3c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_df6176c9-6c74-43dd-b397-8ea8b9cfcdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_df6176c9-6c74-43dd-b397-8ea8b9cfcdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d7b130-fc0d-4189-b80e-040d97ed1c15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d7b130-fc0d-4189-b80e-040d97ed1c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7a63b8a4-889e-4acd-b974-0afb94119c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7a63b8a4-889e-4acd-b974-0afb94119c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8dbd8e69-c46b-49cc-b101-d444017322a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8dbd8e69-c46b-49cc-b101-d444017322a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_94394fab-5e36-4686-b0ee-4de43e0d22c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_94394fab-5e36-4686-b0ee-4de43e0d22c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3e72a313-1d5a-431e-8e6a-4c64dc0efe23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3e72a313-1d5a-431e-8e6a-4c64dc0efe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0688873-642d-4b98-8f0e-b4335f664b56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0688873-642d-4b98-8f0e-b4335f664b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f99adb09-52ac-42c8-b422-6e64e9c5a886" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f99adb09-52ac-42c8-b422-6e64e9c5a886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36bf33cb-e818-4419-87bd-64e47ae5662c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36bf33cb-e818-4419-87bd-64e47ae5662c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0c396d01-43bc-4112-93c9-a2b07b700a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0c396d01-43bc-4112-93c9-a2b07b700a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e5d2c54-abe0-4c74-aa13-432a821d5442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e5d2c54-abe0-4c74-aa13-432a821d5442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88c72325-32c8-4c7f-ab37-5af4c7c44660" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88c72325-32c8-4c7f-ab37-5af4c7c44660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2372ab00-8641-4427-b3a0-1cc9d39cb468" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2372ab00-8641-4427-b3a0-1cc9d39cb468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_68e543e9-13ce-451d-8843-ce1c5553357a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_68e543e9-13ce-451d-8843-ce1c5553357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0ed853b0-9ee8-4c46-b479-eeacc3b6568e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0ed853b0-9ee8-4c46-b479-eeacc3b6568e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd00fba5-8bf5-4e5c-8007-758d73296a37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fd00fba5-8bf5-4e5c-8007-758d73296a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a620cd1-a37e-4d93-b430-d086c9b07d34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a620cd1-a37e-4d93-b430-d086c9b07d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25a4a48c-8f94-486e-93ed-f1c329d79c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25a4a48c-8f94-486e-93ed-f1c329d79c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1e6a3b9d-528e-4266-b52f-a56c7bd90c14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1e6a3b9d-528e-4266-b52f-a56c7bd90c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2b38cd2d-255f-41fd-b2b5-58b480dde236" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24e768d8-e2c5-4b8c-9bd2-4bd917f6417c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2b38cd2d-255f-41fd-b2b5-58b480dde236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d218326e-7be2-4156-922e-bb53b8641903" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d218326e-7be2-4156-922e-bb53b8641903" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:to="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0efadd92-d24c-424f-9bfd-8883e6a12332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_69729468-922a-4bb6-987f-1c59d595a448" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25b13cc5-28ba-4512-bd25-13c7ce4f517f" xlink:to="loc_allo_TwoThousandEighteenEquityIncentivePlanMember_69729468-922a-4bb6-987f-1c59d595a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:to="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8a2d141e-58cd-4dad-89a9-1016dc986ce0" xlink:to="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fbabc5e-3252-4c39-9ea2-909a59ea40a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:to="loc_srt_MinimumMember_8fbabc5e-3252-4c39-9ea2-909a59ea40a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ae6a035-f6c8-4535-869a-c77d8400e8c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5cf9fb6-879e-40f6-99e1-6961c99a38d2" xlink:to="loc_srt_MaximumMember_5ae6a035-f6c8-4535-869a-c77d8400e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737b8450-1400-409f-9334-cf5c470c2a82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5c265510-50e5-47be-b2f8-a747fc064792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5c265510-50e5-47be-b2f8-a747fc064792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48bef6cb-92bf-4997-85d2-4fa82c925f82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48bef6cb-92bf-4997-85d2-4fa82c925f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_69664d16-ae28-4d20-9f02-87afc235b52d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_69664d16-ae28-4d20-9f02-87afc235b52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c646113e-e12a-4a10-82f0-d63f3563244f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c646113e-e12a-4a10-82f0-d63f3563244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b511ec4b-3771-40c7-be06-39b6143c98ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b511ec4b-3771-40c7-be06-39b6143c98ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0030aed3-c375-4716-89b3-94f08af5414f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0030aed3-c375-4716-89b3-94f08af5414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_266bb501-0c1b-4a76-b091-5c01a0389b93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc31dcf1-08cf-4344-a967-ca9960cc7f6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_266bb501-0c1b-4a76-b091-5c01a0389b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b684447b-2581-43c9-adfe-b77e26a3b71d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b684447b-2581-43c9-adfe-b77e26a3b71d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:to="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_068c1a60-e785-4f52-8ad8-1808433a1d48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_450046ab-ac27-43b4-8f24-9ecc979060e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a356e80-dec3-4b49-9251-6eccb1941f55" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_450046ab-ac27-43b4-8f24-9ecc979060e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e7b53fc-da10-4965-a115-4d0893749094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9266e4a8-127d-4754-9d17-ff415151870f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9266e4a8-127d-4754-9d17-ff415151870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db394c5-f41b-4cc1-8728-84ac0f66569f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db394c5-f41b-4cc1-8728-84ac0f66569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00dea312-55e5-42d2-8ce8-417de1334593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00dea312-55e5-42d2-8ce8-417de1334593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24b5e11d-ce44-45e3-b9bb-cba3e8ff9729" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24b5e11d-ce44-45e3-b9bb-cba3e8ff9729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_750b7f98-90b5-40c7-8c7e-0f87a00900df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_750b7f98-90b5-40c7-8c7e-0f87a00900df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_5dfdca5a-74b1-4428-b081-198952e61010" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_5dfdca5a-74b1-4428-b081-198952e61010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c5bed458-374c-442c-a83b-f49bd4b747b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c5bed458-374c-442c-a83b-f49bd4b747b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c795b686-079b-411d-9896-a6a44f205f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c795b686-079b-411d-9896-a6a44f205f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e542a27-1574-4a99-91fb-eaf7b80191f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e542a27-1574-4a99-91fb-eaf7b80191f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_24442fa2-66ff-458e-817a-20442e9be406" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_24442fa2-66ff-458e-817a-20442e9be406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a01f6e3-2c7a-4271-be55-89cbf62c767f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a01f6e3-2c7a-4271-be55-89cbf62c767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_08ded9c3-db88-4b01-8006-2391f7646221" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_08ded9c3-db88-4b01-8006-2391f7646221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_1446b129-a209-45c7-9e9e-a18e9eae76b6" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_1446b129-a209-45c7-9e9e-a18e9eae76b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f7f74206-a615-4ac1-b006-5b7187ba023f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f7f74206-a615-4ac1-b006-5b7187ba023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_23284854-cea4-4f32-be31-82b76d7c611d" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_23284854-cea4-4f32-be31-82b76d7c611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_aaca4787-f4ff-4e82-a367-fccf2996ff04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_aaca4787-f4ff-4e82-a367-fccf2996ff04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6d5233fa-61d1-43fb-a579-6776b61ba77a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6d5233fa-61d1-43fb-a579-6776b61ba77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_9d16370c-e908-4404-b05a-73368a94361d" xlink:href="allo-20191231.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e68f572c-8017-4547-b473-d6c7ad2e060e" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_9d16370c-e908-4404-b05a-73368a94361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d01317a-0d5d-424d-ad60-1eb6e2499c08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d01317a-0d5d-424d-ad60-1eb6e2499c08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:to="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_791a34e7-ea47-436c-bda2-63809dedb7c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_3a364163-8371-4bf5-aa91-3534510152d6" xlink:href="allo-20191231.xsd#allo_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8540af30-05ae-4fff-8e31-5de62955ed76" xlink:to="loc_allo_TwoThousandEighteenEmployeeStockPurchasePlanMember_3a364163-8371-4bf5-aa91-3534510152d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:to="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa5f9f5d-a2db-4bef-9637-e590d02e2034" xlink:to="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd73d2c3-a79e-43cc-b837-9ba5bf601bb3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:to="loc_srt_MinimumMember_fd73d2c3-a79e-43cc-b837-9ba5bf601bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4609b13c-d71e-4b01-b9f3-af5f0dc5d061" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d48b672e-301a-44c0-aa46-ffe1467dc3e4" xlink:to="loc_srt_MaximumMember_4609b13c-d71e-4b01-b9f3-af5f0dc5d061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf4e2eda-ea3e-4ff5-be11-06d417aeb709" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d2f3e3e6-cd33-4e49-9d2c-0d0059c93698" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d2f3e3e6-cd33-4e49-9d2c-0d0059c93698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ae3ac02e-5b2b-4383-8af3-cf2fccfb460e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ae3ac02e-5b2b-4383-8af3-cf2fccfb460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bcaf2456-d3ad-41cc-9f84-a999d7c3e806" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bcaf2456-d3ad-41cc-9f84-a999d7c3e806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a01bb7b0-631f-4cd6-9030-1741410cdf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a01bb7b0-631f-4cd6-9030-1741410cdf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bcd96dc8-6795-47ff-a3b2-fa60bb2139e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bcd96dc8-6795-47ff-a3b2-fa60bb2139e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e62c135-023d-4d3b-a9ee-81761cee8b70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4820406c-85a0-4474-8bd2-1cc3e8cc817e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8e62c135-023d-4d3b-a9ee-81761cee8b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f96336-e78a-45cc-8714-3a3740b5e1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f96336-e78a-45cc-8714-3a3740b5e1ff" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe2ab304-2f0e-4dbd-985e-0cd08fa4aa25" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3516498b-67af-4cea-a9a1-e1170ba86c59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3516498b-67af-4cea-a9a1-e1170ba86c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4f6d8d6-39d4-4c96-a734-209e4d0a82d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1af4cf9-2f30-4c6d-96aa-8c97cbeee706" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4f6d8d6-39d4-4c96-a734-209e4d0a82d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abbd456a-7019-4e21-a65b-3d967dcb9071" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e97057e-25e1-473c-9210-1f33f2d888f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e5ae531-ab61-4c6f-bc47-f556bbcef67f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e97057e-25e1-473c-9210-1f33f2d888f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_02e7fc40-d024-4684-92c1-439bdd531121" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d94e7a37-6284-4cae-80ca-76230d46cec7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_02e7fc40-d024-4684-92c1-439bdd531121" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d94e7a37-6284-4cae-80ca-76230d46cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bd14982f-6104-47f4-8772-237731cda93b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bd14982f-6104-47f4-8772-237731cda93b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc7e736e-f398-4110-b8df-ae4ea87ff2cc" xlink:to="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_bb191796-d5f8-44a3-94d6-da618fdbca56" xlink:href="allo-20191231.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_PfizerIncMember_bb191796-d5f8-44a3-94d6-da618fdbca56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_554b15c8-26e0-408f-847e-17b25285ef04" xlink:href="allo-20191231.xsd#allo_TwoRiverConsultingLimitedLiabiltyCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_554b15c8-26e0-408f-847e-17b25285ef04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember_5a529865-d127-42d3-8946-262e28680aa0" xlink:href="allo-20191231.xsd#allo_TPGCapitalFOLimitedLiabilityCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_TPGCapitalFOLimitedLiabilityCompanyMember_5a529865-d127-42d3-8946-262e28680aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_29fd80f6-ab28-4a59-b8f2-022ae77edc85" xlink:href="allo-20191231.xsd#allo_BellcoCapitalLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_BellcoCapitalLLCMember_29fd80f6-ab28-4a59-b8f2-022ae77edc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartMember_c985b644-c91e-4a44-bf64-385103f8e93c" xlink:href="allo-20191231.xsd#allo_ByHeartMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_48643b90-232d-4837-94d9-7052899524fc" xlink:to="loc_allo_ByHeartMember_c985b644-c91e-4a44-bf64-385103f8e93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19a1e6ad-d746-446e-ba8b-f94a04ccaf6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_98ab5d8b-b78c-4284-8036-440b52532969" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_98ab5d8b-b78c-4284-8036-440b52532969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31bdb0e5-4311-4483-976e-c5f9bb84f057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_176261b0-e3ea-4ed3-8ed9-be9a5db1fa25" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31bdb0e5-4311-4483-976e-c5f9bb84f057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2c9040-7dbe-4837-857d-165a3889ad65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember_6323ad25-0df7-41b2-9de4-756257c77fba" xlink:href="allo-20191231.xsd#allo_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_TransitionServicesAgreementMember_6323ad25-0df7-41b2-9de4-756257c77fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_a3c4edb1-983e-4893-b916-9bf0e7fea048" xlink:href="allo-20191231.xsd#allo_ConsultingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_ConsultingAgreementsMember_a3c4edb1-983e-4893-b916-9bf0e7fea048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_3dc101c0-26a2-43b5-82a9-519657f81adb" xlink:href="allo-20191231.xsd#allo_TwoRiverConsultingLimitedLiabiltyCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4b252086-766e-458e-9c7c-d7820f4a37bc" xlink:to="loc_allo_TwoRiverConsultingLimitedLiabiltyCompanyMember_3dc101c0-26a2-43b5-82a9-519657f81adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_4782b5d6-ae0c-4786-9b76-19f78010402f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_248f46ba-ab4e-4153-bf6a-e1fc4b16b3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f15fc737-b5c9-4d4f-a073-176edf78ddbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_248f46ba-ab4e-4153-bf6a-e1fc4b16b3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9315b483-00c6-4c9d-a046-a2a55c0b11c8" xlink:to="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_bf109c54-7ff6-419b-ae4b-c39248a6acd2" xlink:href="allo-20191231.xsd#allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b224b155-144a-4e4d-921c-bca97b29bcb7" xlink:to="loc_allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember_bf109c54-7ff6-419b-ae4b-c39248a6acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_684095e7-4033-46c5-94d2-bcd2861599b4" xlink:to="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca7b2f3a-ef74-4fc1-8348-1e6399af74bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c793400-aeb5-4c94-bd72-6aa997101d1b" xlink:to="loc_srt_MaximumMember_ca7b2f3a-ef74-4fc1-8348-1e6399af74bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7646edf4-344b-4531-8b7c-0e4043f024fb" xlink:to="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_d63afb27-5ae3-43c3-a4b4-ebea5361e3a3" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:to="loc_stpr_CA_d63afb27-5ae3-43c3-a4b4-ebea5361e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_03784ca2-7721-46d2-8380-f822c2d03ddf" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e5cce58-85cb-4036-b408-6b818f08d60f" xlink:to="loc_stpr_NY_03784ca2-7721-46d2-8380-f822c2d03ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b9e60343-7ec6-4d47-9b95-76953eab621c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4265beb6-729b-4421-a9cc-99289fbccbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4265beb6-729b-4421-a9cc-99289fbccbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_11a40877-9d6e-4248-8390-0931ac9b07f3" xlink:href="allo-20191231.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_11a40877-9d6e-4248-8390-0931ac9b07f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_e24f7410-327d-4a94-90b0-952da61d4a88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_RelatedPartyCosts_e24f7410-327d-4a94-90b0-952da61d4a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f0ff8a99-c8c7-42ab-8ec3-d64c956382b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f0ff8a99-c8c7-42ab-8ec3-d64c956382b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_b239dd9b-6ea7-470e-8a2a-1e746fb1e3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_SuppliesExpense_b239dd9b-6ea7-470e-8a2a-1e746fb1e3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_dbface2a-675b-4044-84ad-16bd30656bad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_dbface2a-675b-4044-84ad-16bd30656bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5fe526a6-e067-4ea4-99ea-17f3e68b8f68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5fe526a6-e067-4ea4-99ea-17f3e68b8f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_e1cfba9e-a8b2-43b9-8954-ae715ab778d7" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_e1cfba9e-a8b2-43b9-8954-ae715ab778d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_29432ea9-aefc-489a-b516-4029de75b03a" xlink:href="allo-20191231.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_29432ea9-aefc-489a-b516-4029de75b03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_69f5ab01-7007-4356-b123-3aa4a2174c93" xlink:href="allo-20191231.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_allo_AreaOfNewOfficeBuilding_69f5ab01-7007-4356-b123-3aa4a2174c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2170bd87-7f31-4999-8256-18a973546426" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2170bd87-7f31-4999-8256-18a973546426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cfd29d95-ac58-463e-b422-7f3e15c6783f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cfd29d95-ac58-463e-b422-7f3e15c6783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e7ac554d-ee07-4f9b-8945-50bec85a428a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b525247b-47da-461c-ade0-6c03f007c43c" xlink:to="loc_us-gaap_SubleaseIncome_e7ac554d-ee07-4f9b-8945-50bec85a428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlan" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://allogene.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_667825cb-a296-466a-8b13-b505c4ad2c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7597c2c-9dab-4715-81f9-6497b41f46bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_667825cb-a296-466a-8b13-b505c4ad2c8f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7597c2c-9dab-4715-81f9-6497b41f46bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fa8463b5-c152-42ce-8e19-56885c086690" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_539da0af-18a5-4d5b-8488-5c63556a5b48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fa8463b5-c152-42ce-8e19-56885c086690" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_539da0af-18a5-4d5b-8488-5c63556a5b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_26d2ef27-3204-4e6b-9a9f-2ac5c19969f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f7e36e73-f2ff-4ea2-8af0-46b1675550f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_26d2ef27-3204-4e6b-9a9f-2ac5c19969f5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f7e36e73-f2ff-4ea2-8af0-46b1675550f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_5ae7d3a5-a0df-4407-8ae0-1a2dd7750ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_5ae7d3a5-a0df-4407-8ae0-1a2dd7750ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_713ae6cb-667a-4b62-89d3-68f38b6b93c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_713ae6cb-667a-4b62-89d3-68f38b6b93c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1b49e542-1138-4823-b249-d0d4d1db30e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1b49e542-1138-4823-b249-d0d4d1db30e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_83ab81e9-84a0-4abb-a14b-dccdc6c046a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_83ab81e9-84a0-4abb-a14b-dccdc6c046a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4b8c3c21-94e2-4d8a-b123-242c6148576c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_385bcfc4-af4d-4305-8e06-e0773d0bb3f3" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4b8c3c21-94e2-4d8a-b123-242c6148576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27c7dd4a-b49e-4010-8718-6d177b4e21ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_2e40f3df-078c-4b54-ba04-d8cd66d54c07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c7dd4a-b49e-4010-8718-6d177b4e21ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_2e40f3df-078c-4b54-ba04-d8cd66d54c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_31ddc0e3-28d1-416b-8054-bc19b4b7230f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c7dd4a-b49e-4010-8718-6d177b4e21ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_31ddc0e3-28d1-416b-8054-bc19b4b7230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_78d73f72-a2b7-4441-80bc-63f768857f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c7dd4a-b49e-4010-8718-6d177b4e21ee" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_78d73f72-a2b7-4441-80bc-63f768857f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_28c005af-86d0-4524-9c1a-129fc663f5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1b76a185-4f62-4edd-8a68-f44a45565edd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28c005af-86d0-4524-9c1a-129fc663f5c8" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1b76a185-4f62-4edd-8a68-f44a45565edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4a8cce04-56e9-43a4-8808-18476a3392c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1b76a185-4f62-4edd-8a68-f44a45565edd" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4a8cce04-56e9-43a4-8808-18476a3392c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_56ccc75b-6499-4fdf-832a-1a2b347df5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1b76a185-4f62-4edd-8a68-f44a45565edd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_56ccc75b-6499-4fdf-832a-1a2b347df5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4c11c2ae-42b5-4d81-9044-b7d999e71d40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1b76a185-4f62-4edd-8a68-f44a45565edd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4c11c2ae-42b5-4d81-9044-b7d999e71d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cd97c684-3253-40e7-9aa7-9bf603a1d7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28c005af-86d0-4524-9c1a-129fc663f5c8" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cd97c684-3253-40e7-9aa7-9bf603a1d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dedfee24-c4a6-4aa8-9d8c-fcfc78796c59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cd97c684-3253-40e7-9aa7-9bf603a1d7b4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dedfee24-c4a6-4aa8-9d8c-fcfc78796c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4a4f827f-6e18-417b-ab59-67ac8ba42dea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cd97c684-3253-40e7-9aa7-9bf603a1d7b4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4a4f827f-6e18-417b-ab59-67ac8ba42dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0ae492e0-fbbc-4c11-b27b-90f994046f12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cd97c684-3253-40e7-9aa7-9bf603a1d7b4" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0ae492e0-fbbc-4c11-b27b-90f994046f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6a95f36-192b-4c57-a264-6da8f1adb513" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28c005af-86d0-4524-9c1a-129fc663f5c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c6a95f36-192b-4c57-a264-6da8f1adb513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d5497d89-33db-4687-b4e5-9641d411ffd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d5497d89-33db-4687-b4e5-9641d411ffd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ad43e4d7-fc38-464b-9b4a-849c8c620abb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ad43e4d7-fc38-464b-9b4a-849c8c620abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_b540675c-5898-4be0-a79d-a8683ff8027c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_b540675c-5898-4be0-a79d-a8683ff8027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_cb2f5e4b-1c93-4892-a1db-cd3f2440bdc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_cb2f5e4b-1c93-4892-a1db-cd3f2440bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_a9acf669-7687-413d-bc07-a83235e0c42c" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment_a9acf669-7687-413d-bc07-a83235e0c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_c6416ca8-2dfc-4598-bf40-d803752ff6e6" xlink:href="allo-20191231.xsd#allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_c6416ca8-2dfc-4598-bf40-d803752ff6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1a18d2c8-4884-461f-991c-4433a5819d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1a18d2c8-4884-461f-991c-4433a5819d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_dae3fb13-b8ef-45db-8e3d-f7ad5f67fe6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_dae3fb13-b8ef-45db-8e3d-f7ad5f67fe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20f51d87-eec6-424b-827b-6d05fc3ad0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b64d324f-8268-4ed2-8d92-9254cb35b57e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20f51d87-eec6-424b-827b-6d05fc3ad0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bdb81e11-338d-4834-a9d3-271f9112e56d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bdb81e11-338d-4834-a9d3-271f9112e56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1a6cbf22-4e16-4425-b077-fc195a12779d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1a6cbf22-4e16-4425-b077-fc195a12779d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ecc08b9e-9bb3-437f-ad8d-62234e55db7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ecc08b9e-9bb3-437f-ad8d-62234e55db7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a4294064-6909-45d3-bbd1-a83dbbf5055e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a4294064-6909-45d3-bbd1-a83dbbf5055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsLeaseLiabilities_5c509741-6252-41fa-a64b-3caac65ede84" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_allo_DeferredTaxAssetsLeaseLiabilities_5c509741-6252-41fa-a64b-3caac65ede84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3c95bf54-eb61-4a37-9ff8-0d73ea835485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3c95bf54-eb61-4a37-9ff8-0d73ea835485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a89a3c82-7181-423a-94ec-3ede39a6722f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a89a3c82-7181-423a-94ec-3ede39a6722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3fa0ceea-7076-4d1c-83a6-e858126b762c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b66ed503-b6f9-4414-aaf1-37c9a0865e57" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3fa0ceea-7076-4d1c-83a6-e858126b762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_950df9bf-0877-47c0-a3a1-2ba39c123971" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_950df9bf-0877-47c0-a3a1-2ba39c123971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased_65fa7791-63f6-48c6-847f-f171feb9083d" xlink:href="allo-20191231.xsd#allo_DeferredTaxLiabilitiesRightOfUseLeased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:to="loc_allo_DeferredTaxLiabilitiesRightOfUseLeased_65fa7791-63f6-48c6-847f-f171feb9083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_163935c2-818b-4de8-82d8-1eef9f30d8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_163935c2-818b-4de8-82d8-1eef9f30d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_a376c72b-0389-43af-a5e9-d33f83d8983d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_a376c72b-0389-43af-a5e9-d33f83d8983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_31c1f630-77bf-47db-985c-d2d725546cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18472751-2778-4775-9b01-193718453417" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_31c1f630-77bf-47db-985c-d2d725546cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_d12505a1-1210-4ff5-bbc6-a033991b09d3" xlink:href="allo-20191231.xsd#allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:to="loc_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities_d12505a1-1210-4ff5-bbc6-a033991b09d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_8b5a8e94-1fce-4d30-aefa-d3db9d60d529" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_8b5a8e94-1fce-4d30-aefa-d3db9d60d529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fb04452e-905e-4d37-9c6b-5485d181e1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44381d34-6807-4021-8462-06f4226bc791" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fb04452e-905e-4d37-9c6b-5485d181e1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bbc73ba1-2849-49e4-ae81-a2f7764520b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bbc73ba1-2849-49e4-ae81-a2f7764520b9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_388d7224-982e-43a8-8503-a6c50df5b688" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_10e04b7a-327f-4d84-a097-6077aad05284" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:to="loc_us-gaap_DomesticCountryMember_10e04b7a-327f-4d84-a097-6077aad05284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_19ace807-f490-43dc-9de9-bbda4716825d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3f3fd8de-5714-423d-b0cf-10d37a6d8454" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_19ace807-f490-43dc-9de9-bbda4716825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:to="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_8cd8fa0c-157d-4b3c-be46-889574503735" xlink:to="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IndefiniteMember_862a1782-029b-4b39-8370-cab520aa6bd5" xlink:href="allo-20191231.xsd#allo_IndefiniteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_IndefiniteMember_862a1782-029b-4b39-8370-cab520aa6bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037Member_5c04d7ed-a3d6-4d45-b434-aaff482064df" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpiration2037Member_5c04d7ed-a3d6-4d45-b434-aaff482064df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpiration2037To2039Member_cdc3496c-b397-4c1a-8e4d-195bc4571428" xlink:href="allo-20191231.xsd#allo_TaxExpiration2037To2039Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpiration2037To2039Member_cdc3496c-b397-4c1a-8e4d-195bc4571428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TaxExpirationYears2038To2039Member_e6107906-8576-47c7-8d7f-c9847c2b745a" xlink:href="allo-20191231.xsd#allo_TaxExpirationYears2038To2039Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_b34e257e-21e0-47a4-ae4a-ca983fa8f2bc" xlink:to="loc_allo_TaxExpirationYears2038To2039Member_e6107906-8576-47c7-8d7f-c9847c2b745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e134295f-bc23-4ff3-9986-56a96198a6a7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0afc804b-4cc1-4757-8309-20157ee92cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0afc804b-4cc1-4757-8309-20157ee92cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_be76f7b5-1ddd-4a09-920a-86d41fb47c14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_78f841bb-a4bc-4195-b897-044d9bfdbef0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_be76f7b5-1ddd-4a09-920a-86d41fb47c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b22ec0b0-feae-4c07-814c-1f179b69baaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b22ec0b0-feae-4c07-814c-1f179b69baaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a05b84de-760b-4b76-b9f3-1ca4b7cdbfd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a05b84de-760b-4b76-b9f3-1ca4b7cdbfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_48b65d64-173f-4600-9bf5-a490d405064d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_48b65d64-173f-4600-9bf5-a490d405064d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d6322418-655c-4f03-9c48-1645c2dcc90c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d6322418-655c-4f03-9c48-1645c2dcc90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_0e929d0d-293e-48ab-8d7c-2790a7f326cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_0e929d0d-293e-48ab-8d7c-2790a7f326cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9e5ef370-2067-439b-8fbf-be9eb2b6e3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92396052-1920-4fed-bacc-eb5d951b295b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9e5ef370-2067-439b-8fbf-be9eb2b6e3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShare"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7fac21a1-3f50-4a6f-98d1-01b84a1331e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bb41d285-f396-4d3e-876e-59ee89f8a187" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7fac21a1-3f50-4a6f-98d1-01b84a1331e1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bb41d285-f396-4d3e-876e-59ee89f8a187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0c419e72-3114-4bd3-92be-be77514cee71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_175ba1ea-6b3b-4794-8cd4-dac3e3a9bf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c419e72-3114-4bd3-92be-be77514cee71" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_175ba1ea-6b3b-4794-8cd4-dac3e3a9bf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_42f6555f-795b-4c65-9a7a-08f854743c25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c419e72-3114-4bd3-92be-be77514cee71" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_42f6555f-795b-4c65-9a7a-08f854743c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_413e007c-988a-4e34-8e97-e5640d3d1a67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumeratorAbstract_ced105a3-9a29-4e23-b3c2-edca2ac05375" xlink:href="allo-20191231.xsd#allo_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_413e007c-988a-4e34-8e97-e5640d3d1a67" xlink:to="loc_allo_NumeratorAbstract_ced105a3-9a29-4e23-b3c2-edca2ac05375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_32c5fe5f-c690-4e02-b8bf-461bdc34b41a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_NumeratorAbstract_ced105a3-9a29-4e23-b3c2-edca2ac05375" xlink:to="loc_us-gaap_NetIncomeLoss_32c5fe5f-c690-4e02-b8bf-461bdc34b41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DenominatorAbstract_8029b18e-fd0a-4464-9722-25d8f8fbf83d" xlink:href="allo-20191231.xsd#allo_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_413e007c-988a-4e34-8e97-e5640d3d1a67" xlink:to="loc_allo_DenominatorAbstract_8029b18e-fd0a-4464-9722-25d8f8fbf83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_25fd5045-c82c-440b-8f92-a5cc273a7383" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_DenominatorAbstract_8029b18e-fd0a-4464-9722-25d8f8fbf83d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_25fd5045-c82c-440b-8f92-a5cc273a7383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_69bdb2e6-47a3-499f-8961-a34cd0f2d48b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_DenominatorAbstract_8029b18e-fd0a-4464-9722-25d8f8fbf83d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_69bdb2e6-47a3-499f-8961-a34cd0f2d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36ea9b50-0bab-44bb-9453-0db4bfaf2b35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36ea9b50-0bab-44bb-9453-0db4bfaf2b35" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_426277f3-bb85-428b-8b68-940e8fbae593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f83702e1-866a-405e-a36d-3d47e24e5570" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f83702e1-866a-405e-a36d-3d47e24e5570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ef7f81e-4d91-45af-a698-ac0a0faaf9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ef7f81e-4d91-45af-a698-ac0a0faaf9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_e19b183f-88c1-4309-944d-32a33f11ad00" xlink:href="allo-20191231.xsd#allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember_e19b183f-88c1-4309-944d-32a33f11ad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_e928bc61-f521-4c32-94c8-1403e46348c3" xlink:href="allo-20191231.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_FounderSharesOfCommonStockMember_e928bc61-f521-4c32-94c8-1403e46348c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_441f0176-d374-4902-b7be-21de8e7e2aae" xlink:href="allo-20191231.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4bb7740-127b-4622-9403-c4739a177889" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_441f0176-d374-4902-b7be-21de8e7e2aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_219dbe41-e05c-4172-aa9d-7591550617ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0174be9-2bdc-4893-a97b-ab7a1181aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd724d38-ab49-4335-9cc3-6e1007ec36c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0174be9-2bdc-4893-a97b-ab7a1181aae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b4895497-a76d-4a53-ae0f-ccc222cefe6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_bac0a1f0-7562-4503-91c9-4b87a9091b70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b4895497-a76d-4a53-ae0f-ccc222cefe6b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_bac0a1f0-7562-4503-91c9-4b87a9091b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_96b68fa1-fda6-4e5b-b254-8aa4c47892a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_96b68fa1-fda6-4e5b-b254-8aa4c47892a7" xlink:to="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a91c5455-552c-47f2-80be-6f8ba72bd71a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3cf18fd0-a264-44a4-b760-af141985c5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_86e6614b-e18a-4c81-932a-59a1a476a6a4" xlink:to="loc_us-gaap_SubsequentEventMember_3cf18fd0-a264-44a4-b760-af141985c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_575f85aa-9f75-4ed0-bf5e-2221dc398424" xlink:to="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5eac0c57-5260-4f81-b7c0-2b5034f8c3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5eac0c57-5260-4f81-b7c0-2b5034f8c3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de5cb580-3595-435f-adb2-95aa7414c062" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_477d35fc-2c2c-41de-8ca6-0f462b0fc1fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de5cb580-3595-435f-adb2-95aa7414c062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunaudited"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_dbf1b05f-f0a0-41a9-beef-5a9bd66f3f79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_d2aaa3a6-23c3-4c3c-8a3c-a90e677f38a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_dbf1b05f-f0a0-41a9-beef-5a9bd66f3f79" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_d2aaa3a6-23c3-4c3c-8a3c-a90e677f38a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_6b898a43-1cd4-4b5f-9aa4-f867624b7796" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_734e830d-b004-451a-9d75-c157267bdfe4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_6b898a43-1cd4-4b5f-9aa4-f867624b7796" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_734e830d-b004-451a-9d75-c157267bdfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="simple" xlink:href="allo-20191231.xsd#SelectedQuarterlyFinancialDataunauditedDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_e9825984-7fef-4639-a20c-e22e8e545e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_344db656-b359-4c14-8323-6b4040470454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_e9825984-7fef-4639-a20c-e22e8e545e2e" xlink:to="loc_us-gaap_OperatingIncomeLoss_344db656-b359-4c14-8323-6b4040470454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02c588f1-645a-44a4-bf07-698480771ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_e9825984-7fef-4639-a20c-e22e8e545e2e" xlink:to="loc_us-gaap_NetIncomeLoss_02c588f1-645a-44a4-bf07-698480771ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_cefa9540-9685-4ca5-b9e5-a96575775f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_e9825984-7fef-4639-a20c-e22e8e545e2e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_cefa9540-9685-4ca5-b9e5-a96575775f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>allo-20191231_g1.jpg
<TEXT>
begin 644 allo-20191231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M?^8?\1"S[_G]_P"2Q_R/UG_XBA6_Z(N?_"F'_P CT?\ $4*W_1%S_P"%,/\
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M[%P?\GXO_,/^(A9]_P _O_)8_P"1^L__ !%"M_T1<_\ A3#_ .1Z/^(H5O\
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M._P,D\:?\*BQY?B)=!^R?\)$.<VK7'F[_(_V=NW'?.>U?CA7JD/_ "8M<?\
M91(O_35)45,EP:2M'JNK_P SJPG'V>3Y^:MM%OX8[KY'Z)#_ (.AFQ_R1?\
M\N8?_(]'_$4,W_1%O_+G'_R-7Y,T5?\ 8F#_ )/Q?^9R_P#$0L^_Y_?^2Q_R
M/UF_XBAF_P"B+?\ ESC_ .1J/^(H9O\ HBW_ )<X_P#D:OR9HH_L3!_R?B_\
MP_XB%GW_ #^_\EC_ )'ZS?\ $4,W_1%O_+G'_P C4?\ $4,W_1%O_+G'_P C
M5^3-%']BX/\ E_%_YA_Q$+/O^?W_ )+'_(_6;_B*%;_HBW_ESC_Y&H_XBA6_
MZ(M_Y<X_^1J_)FBC^Q<'_+^+_P P_P"(A9]_S^_\EC_D?K-_Q%"M_P!$6_\
M+G'_ ,C4?\10K?\ 1%O_ "YQ_P#(U?DS11_8N#_E_%_YA_Q$+/O^?W_DL?\
M(_68_P#!T,P_YHM_Y<X_^1Z]X_97_P""U[?M+> =0US_ (5S_8_V'4GT_P G
M^V?/W[8HI-^?)7_GKC&/X?>OPAK[S_X)6?\ ) ]>_P"QDF_])+2L,1D^$C"Z
MC^+/4R?CK.J^(Y*M6ZL_LQ_R/WAK\N/^#H'_ )(S\)?^P_>?^DU?J/7Y<?\
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M7Z ?\(%H%_H/QR\+:+I-G\6KB:'P5*_A;7_'",VDSQ1W0FL8]226+[2EE\J
MJQ&&"G)%?$O[6OPUNOAO\1[>WN?A_I/PUCOK%)8M(T[7?[8A8!F5I?.\V4AF
M(P5+#&W@<UKAL7*I/E=MOT7G?\#AS;)*&$P_M(7;N];W2]YK^5+HMY)^1QNJ
M_"_Q%H7P[T?Q9>Z-?VGAKQ!<SVFFZC+'LAOY80IE$>>6"[E!8#;GC.00,&OH
M_P"/7QGUCXP?\$^_A>_B+Q#)K>K:9XRUJTBBFF4R65FEEIZ0QI&N/+B&U@H
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MYNS9_M5T7[8_PEN_AEJ.AW%Q\*M!^%MK>0RQBVTSQ+_;:Z@Z$$R,QGE:,J&
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MO_GQ#_P!?Y$G_#E3]E__ *)-I/\ X,;[_P"/4?\ #E/]E_\ Z)-I/_@QOO\
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M3_X,;[_X]1_PY3_9?_Z)-I/_ (,;[_X]7U-11]<Q'\\OO8?V'EO_ $#P_P#
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MWBG_ ,'!_P#DNOS[HH_L+#=Y?^!/_,/^(<\._P#0+'[E_D?H)_PV_P#L+?\
M1JWBG_P<'_Y+H_X;?_86_P"C5_%/_@X/_P EU^?=%']A8;O+_P "?^8?\0YX
M=_Z!8_<O\C]!/^&W_P!A;_HU?Q3_ .#@_P#R71_PV_\ L+?]&K^*?_!P?_DN
MOS[HH_L+#=Y?^!/_ ##_ (ASP[_T"Q^Y?Y'Z"?\ #;_["W_1J_BG_P '!_\
MDNM+5?\ @H=^Q1K?AK2-'NOV8?%DVFZ#Y_V" ZN +;SW$DN"+K)W, >2?;%?
MG312_L'#=Y?^!/\ S*7AUP\M%AH_<O\ (_03_AM_]A;_ *-7\4_^#@__ "71
M_P -O_L+?]&K^*?_  <'_P"2Z_/NBG_86&[R_P# G_F3_P 0YX=_Z!8_<O\
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MK'N8LW+$GDDGD]ZWJ**P\S0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M6?\ HD&A_P#@;>?_ !ZC_7+"?R2_#_,/]<\)_)+\/\S^;^BOZ0/^')G[+/\
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M;:O<X;_Y&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH
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M2_S/K^%\EHXI2KXC51=DOQU/T+/_  <L_M 9_P"0'\,__!9=?_)%)_Q$L_M
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M _\ !,G_ (+0^#_V_=6_X1/5-+/@KXBPP-.NF/<>?:ZK&HR[VLI )*]3&P#
M<C< 2/Y[ZZ[]G[XA:K\)OCUX)\3:'-)#JVAZ[975JT9^8L)E!7Z,I92.X8BN
M/'\-X.I1E[*/+*VC7ZG#F'#>#J46J4>65M&K_D?U<K]VEIL9ROI[>E.K\M/R
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\F_^#IW_D3O@I_V
M$=6_]$VU?K)7Y-_\'3O_ ")WP4_[".J_^B;:O<X;_P"1C3^?Y,]SAO\ Y&5+
MY_DS\>Z***_6#]<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LA_=MQN
MX/'K7W1K_P"T[\3/@%XH^"'AO19/B/XS\.S>%]+NID@D0KXI%S"NVWL)$MF,
M*VN?(4 NQ>$[\#BOAFN_\ _M6_%#X4^#)/#GACXB>-/#^@3%V;3]/U::"W!?
M[^U5;Y-W?;C-<.-POMDM$[7T?FK'#C<+[9+1.U]'YJW0^K/V-M$N/#/_  7Z
MTO3[O7;WQ/=6?C+4HI=5O61KJ\86MQDS%,(95^XQ4 ;D. *_;']IW]E3PW^U
MMX8T+0_%DVJ-H>C:U;:W+86TJQPZI) 2R0W 927AW')08S@<U^ ?_!&+][_P
M5"^$C.[;FU*Y8LV6+-]CN#R?4^IK^D@'-?!\51=/$TU?507YM'Y_Q=3Y<13@
M];02^YL^<_B;_P $N/A3\0/%DFL:?IDG@B:\\.ZAX7O[?PQ'!IUMJ5E>+B03
M1K$0SJ?F1N""!G(&*H>&/^"8FD>'_ NI>%;KXJ?&37O"NI>'Y_#9T;5->CGL
MK>UEB$0,<?D@*\:CY#R%]#7TW17S7MJEK7/D?9Q['S9X _X)F^'_  CX>F\/
MZM\0?BIXW\&7&C2:#)X8\1:XEUI+6K((U B6)"K1JHV,&!4@$=!53X4?\$J_
M!/PT\>^%=;U#Q7\1_&]OX!?S/"ND^)=<-[I_A]\;5>*,(NYD7 4N6V@#'05]
M/44>VGW#V<>QY%\<_P!BWP?\:O#-I9VQU+P+J.FZE'K%GJ_A25=,OK>Z0,%<
MLJE9!AV!616!STSS7FVI_P#!)+X>S> ="TO3=?\ 'FA:_H=_J&I?\)58ZL%U
MN_GU!=M\9Y60JXF7 (VC 48QSGZFHI1K32LF-TXO5H\4\6?L$^ _$_[-/A3X
M3PKJFD^$?!MWI][IR6=P!.'LIEFCWNRMNW.,OQEMQY&:U/VW_P!GF3]JC]EC
MQCX'MKB*SU+5[,2:9<2?<@O876:W9O\ 9$L:9]B:]7HI>TDFG?9W&X)JQX!I
M'[$7AWXGV7C?7?'FGW4FO?&'PUINC^+M*-VD]E;-;0%!]G95X97=F#Y/*J0!
MBD^#7_!.7P1\#M5^%-YI&H>))YO@]INI:5HOVJZC<3Q7S%IC/B,;V!/RE=H'
M<&OH"BG[:=K7_JUOR#V<;WL?,WQ#_P""6/@7XAIXB9O$'C;2;SQ'XXC^(,EY
MIVH1PW%EJ<<)A0P,8CLC"G(!R=P!SVK"^+W_  3_ /$7B#P)H?@6W\=>.?''
MAW7/%^FZQXEOO%VMI>3:?86+&X\BV58U.9YDB4CH!DGI@_6U&*I5Y]R?9Q#J
M* ,445B:!1110 4444 %%%% !1110 4444 %%%% !1110!S?Q?\ A9I/QM^%
MOB'P?KT'VG1?$VGS:;>1CAC'*A4D'LPSD'L0*_FX_;E_X)O_ !(_8-^(=YIO
MB+1M0U+POYS#2_$MK;-)8ZA#GY2[*"(I0,;D?!SG&1@U_374-S:0WEO)#/''
M-#*,.CJ&5AZ$'K7L91G57 2?*KQ>Z/:R?.JN D^5<T7NC^1@WL(_Y:Q_]]4?
M;8?^>L?_ 'U7]8__  ISP>QS_P (KX;/_<,A_P#B:/\ A3OA'_H4_#?_ (+(
M?_B:^D_UTC_SZ?\ X%_P#Z3_ %VC_P ^OQ_X!_)Q]MA_YZQ_]]4?;8?^>L?_
M 'T*_K'_ .%.^$?^A3\-_P#@LA_^)H/P<\(?]"GX;_\ !9!_\31_KI#_ )]/
M_P "_P" '^NT?^?7X_\  /Y.?ML/_/6/_OH4?;8?^>L?_?0K^L;_ (4WX0_Z
M%/PW_P""R#_XFC_A3?A#_H4_#?\ X+(/_B:/]=(?\^G_ .!?\ /]=H_\^O\
MR;_@'\G'VV'_ )ZQ_P#?5'VV'_GK'_WT*_K''P=\(C_F4_#?_@LA_P#B:/\
MA3?A$_\ ,I^&_P#P60?_ !-'^ND/^?7_ )-_P _UVC_SZ_\ )O\ @'\G'VV'
M_GK'_P!]4?;8?^>L?_?0K^L<?!WPAC_D5?#8_P"X9#_\32_\*=\(?]"KX;_\
M%D/_ ,31_KI'_GT__ O^ '^NT?\ GU^/_ /Y-_ML/_/6/_OJC[;#_P ]8_\
MOJOZR1\'/"!_YE7PW_X+(?\ XFC_ (4WX0_Z%7PW_P""R'_XFC_72/\ SZ?_
M (%_P _UVC_SZ_'_ (!_)M]MA_YZQ_\ ?5'VV'_GK'_WT*_K)_X4WX0_Z%7P
MW_X+(?\ XFD/P9\($_\ (J^&_P#P60?_ !-/_72/_/I_^!?\ /\ 7:/_ #Z_
M'_@'\G,=Q'.X6-ED9N J_,3^ K]"?^"-7_!)'QE\=_C=X<^)'CK0;[P]\.?"
M]W'JENFHP-!/XAN(R&A2.-@&\D. S.0 VW:N<DC]PK/X3^%]-N4FMO#?A^WF
MC.4DCTZ%64^H(7(K>V\UQ8[BZI6I.E1ARWTO>[^6B./'\75*U)TJ,.6^E[W?
MRT0J=*6@<"BOCSXT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\F_^#IW_ )$[X*?]A'5O_1-M7ZR5^3?_  =._P#(G?!3_L(ZM_Z)MJ]SAO\
MY&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /I[_@C%_RD_P#A%_V$;G_TBN*_I(9MM?S;_P#!&+_E)_\
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M10 4444 %%%% !1110 4444 %?DW_P '3O\ R)WP4_[".K?^B;:OUDK\F_\
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MU_H&BWS:LL:WQN+&*4W@CYC$I93O"?P[L[>V*;_P@W_4:U[_ ,"A_P#$T?\
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M Z5_12*^%XNE?$P?]U?FSX/B^5\33?\ <7YL,4;:**^5/DPQ1110 =****
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MQ=J(U/3H&W1:?*MK<)Y*-D[E1550V3N !SS7[0_MT?LJWG[9OPET_P #?\)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DW_P=._\
M(G?!3_L(ZM_Z)MJ_62OR;_X.G?\ D3O@I_V$=5_]$VU>YPW_ ,C&G\_R9[G#
M?_(RI?/\F?CW1117ZP?K@4444 %%%% !1110 4444 %%%% !1110 4444 (Z
M[T*^HQ7TS'_P4$\.ZIX!NM#U_P""GA?7I-5TC1='U6]?Q%J5M)J,>DJ%LV*Q
ML%C88R=F V>:^9Z*PK8>G5MSK;S:_(PK8:G6M[1;>;7Y'V5_P36^*UQ\>?\
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M;:O<X;_Y&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH
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M 5-7YO*S=T?F<K-W04445)(4444 %%%% !1110 4444 %%%% !1110 4444
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MLVU"6_:8?9UME3S#-OZ; GS9Z8YHY7U0<R(O^$DU'_H7]0_[_P!O_P#'*/\
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M))J7_0OZA_W_ +?_ ..4?\))J7_0OZA_W_M__CE;5% &+_PD>HG_ )E_4/\
MO_;_ /QRC_A)-2_Z%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QR
MC_A)-1_Z%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QRC_A)-2_Z
M%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QRC_A)-2_Z%_4/^_\
M;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QRC_A)-2_Z%_4/^_\ ;_\ QRMJ
MB@#%_P"$CU'_ *%[4/\ O_;_ /QRH[O6+S4+9H9_#-Y-#(,,DDMLRL/0@OBM
MXG KSCXH_M2^$_A7J#V-U=37VHQ\/:V:"1HCZ.<A5/L3GVJH0E)VBM2Z<)2=
MH+4N'P1HQ/\ R3C3_P#P%L?_ (JC_A!]%_Z)OIW_ ("V/_Q5>>?\-_\ AL_\
MP37?_(7_ ,52_P##?WAS_H!Z[_Y"_P#BJZOJV)[,Z?J^)[,]"_X0?1?^B;Z=
M_P" MC_\51_P@^B_]$WT[_P%L?\ XJO/?^&_O#G_ $ ]=_\ (7_Q5'_#?WAS
M_H!Z[_Y"_P#BJ/JV)[,/J^)[,]"_X0?1?^B;Z=_X"V/_ ,51_P (/HO_ $3?
M3O\ P%L?_BJ\]_X;^\.?] /7?_(7_P 51_PW]X<_Z >N_P#D+_XJCZMB>S#Z
MOB>S/0O^$'T7_HF^G?\ @+8__%4?\(/HO_1-]._\!;'_ .*KSW_AO[PY_P!
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M\F_^#IW_ )$[X*?]A'5O_1-M7ZR5^3?_  =._P#(G?!3_L(ZM_Z)MJ]SAO\
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MWAG_ (1Z#Q%<(P$LT$<L2R+$ O#2$NJ #@L17CGP^_X*=7UUXS\#VOC[X/\
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MBBB@ HHHH **** "BBB@ HHHH *^'_\ @ML2GP[\ X)'_$UN?_1%?<%?#_\
MP6Y_Y)WX _["MS_Z(%?%>(G_ "3F*]%_Z5$^LX&_Y'N']7_Z2S\\?-;^\WYT
M>:_]YOSIM%?R!8_J =YK_P!YOSH\UO[S?G3:*+ .\U_[S?G1YK_WF_.FT46
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MU;V^M>)+?P=I^J&.1?*AN;VYBA4,P7&U/-E#$+C@$#%>3^(OBS\>_P!CJ_\
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MX@_Z!^D?^!TG_P :K:HH Q?MGB#_ *!^D?\ @=)_\:H^V>(/^@?I'_@=)_\
M&JVJ* ,7[9X@_P"@?I'_ ('2?_&J/MGB#_H'Z1_X'2?_ !JMJB@#%^V>(/\
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M_P /'/C9_P!#Y>_^ =M_\;H_X>.?&S_H?+W_ , [;_XW1_Q&;)_^?53[H_\
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M-->7]WL@8$$E\16\1)=L;GF&,X-?2PZ445G*;EN5&*6P4445)04444 %%%%
M!1110 4444 >/_M\W=]8_L=?$*33O,6Z_LEURGWA&642?^0RU?C>!@<=.U?O
M)KNAVOB71;O3[ZWCNK.^A>WN(7&5EC=2K*?8@D5^7O[3G_!+;QU\*?%%U<>#
M=-N?%WA>9R]L+4AKVS4GB.2/(+;>@=<Y'4 U^&^+G#>/QE2EC\)!SC&+BTE=
MK6][+6SOK;L?KWAEGV#PL*N"Q,E"4GS)O1/2UK[>EWU/EVBN\/[+'Q-!_P"2
M>>-/_!3-_P#$T?\ #+/Q,_Z)[XT_\%,W_P 37X=_8^/_ .?,_P#P&7^1^O\
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M'4/)^P3>+]!CN1,=L9B-]&'#'^[MSGVK^HO!F'/DO+WJ2_*)_._BI+ES>_\
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M"2?J_P#X)UWTGAOXP_M'>!;7'_"-^$_'K7.DQJ/W=G]NMH[N>!!T"K,[L%'
M\PT5,/RIVZ>7G8(5.:Q]3T4"BN8V"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'_^"W!Q\// '_85N?\
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MI[;=GI?JK'X_48K](O\ ARIX%_Z&[Q?_ .2__P ;H_X<I^!?^AN\7?\ DO\
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M\3?%;X<_%"W\!^#=;@\'Z+\:+2[UKPA#&FK7$>EI8*%@:W6=4N5BD9&:V6;
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M+T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P" \O\ \31_PLO1?^?J3_P'E_\
MB: -ZDQS6%_PLO1?^?J3_P !Y?\ XFC_ (67HO\ S]2?^ \O_P 30!O8YHK!
M_P"%EZ+_ ,_4G_@/+_\ $T?\++T7_GZD_P# >7_XF@#>HQ6#_P ++T7_ )^I
M/_ >7_XFC_A9>B_\_4G_ (#R_P#Q- &]BDVYK"_X67HO_/U)_P" \O\ \31_
MPLO1?^?J3_P'E_\ B: -T#%+CBL'_A9>B_\ /U)_X#R__$T?\++T7_GZD_\
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MW)/^^:_<;_A*_"_]V#_P!?\ ^(H_X2OPO_=@_P# %_\ XBC_ (@D_P#H+_\
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MZ+_S]2?^ \O_ ,31_P ++T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P" \O\
M\31_PLO1?^?J3_P'E_\ B: -ZBL'_A9>B_\ /U)_X#R__$T?\++T7_GZD_\
M >7_ .)H WJ*P?\ A9>B_P#/U)_X#R__ !-'_"R]%_Y^I/\ P'E_^)H WJ*P
M?^%EZ+_S]2?^ \O_ ,31_P ++T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P"
M\O\ \31_PLO1?^?J3_P'E_\ B: -ZBL'_A9>B_\ /U)_X#R__$UH:7XEL]9M
MVEMI&DC5MI)C=>>/4#UH O5^8G_!S3_R1[X3_P#8>O/_ $F%?IW7YB?\'-/_
M "1[X3_]AZ\_])A7F9S_ +E4]/U1^A>%/_)5X/\ Q/\ ](D?D_IGPUUO6?AU
MK'BRVL3)X?T"\MK"_N_,4?9Y[D2&%-I.X[O*?D @;><5@&50&^9?EZ\]*^C_
M -F7P5/\6?V*?BUX3TG4?#EOK][XF\/7]M:ZKK5KI?VB&%+T2LC7#HK;=Z9
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MOWA6T<MBVTIWMY>NVOD>34X\KTE&5;#**DTDW-I:J#]Y\FFD_/5->9^>NH^
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M/D\'_'BVM=$G@M+*T&FZ#,ETDRQ^6@S:?+$2YR%)W!@3FOBOX_+JR_'+Q?\
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M>F**F'C%?%_6O^01K-]/ZT/>_#G_  4_^!GBWXN0>"=/\?:=<:U>7S:9:O\
M9YUL;R[!P;>*[*""23/&U7.3P,FJ7_#U[X!Q>/IO#=QX^M['4K?4WT:5KO3K
MNWM8KM)#&T+7#Q")6WC'+XKYS_9%^+]QX#^ OP>^ ]]^SQXJUWQUX/U2VL]8
M@U?0_)T71O*D<R:PE\Z/"Y /F(4^9BQ (."?,9=;UFZ_8]_: ^!L7PM^)7B#
MQS\0O'>NS:(/^$8N%TP)<W2>5=O=R*(D10ADW9[#'7-:?5H7:U^]??ML3[:5
MK_I^!]__ !N_X* _"+]G+X@6_A7QEXQMM'\075M%>1V8L[FX<Q2.4C8F*-@
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MS_XW7X(44?ZS8KM'[G_F'_$ ^'O^?M7_ ,"C_P#('[W_ /#^O]FK_H;-:_\
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M &A,>M4?%7A;3_''AG4-%U:SAU#2M6MI+.\M9EW1W$,BE'1AW!4D'ZUH44;
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0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>allo-20191231_g10.jpg
<TEXT>
begin 644 allo-20191231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S<S  "2D@ "
M S<S  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8E98R"H(Z8I38VY,1,2YB.4./NFJYC)4VGN3(<BG4BKM'%+4&X4444 %%%%
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MM:DL76"\;? 3A7[K[5U*.'4,IR",@CO2&.HHHH **** "BBB@ HHHH ****
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M(IU9UMBTWL')B/.#VJ[%*LR!XSD&NF%13,I1L24445J(**** "BBB@ HHHH
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M-+2 **** "BBB@ [U5OU=K-A'][(Q5KO4-RQ2W=E&2!42^%C6Y2DD:.$R+U
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MSN3=1+F"0Y8#^$T 265P-2L'M+@_OT&,^I]15FPOB/\ 1+K*W"# Y^^/7FL
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M7QQ9+<0+ CR))*8V?& A!QSFNF1PR@CH1D4--*Y<HN.X^BDR?2DS2)'4444
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M@X7Z5V^A>%+;2F%Q*3/=GEI6_I2<4D3*$(1MU.AI::/ZTZLCF"BBB@ HHHH
M**** "BBB@ HHHH **** "BB@]* $-<GJ=W#IVI31PSQG=AG1CC9GO75UY9X
MGDWZQKDBYR$C /KT%7%7-*5/G;3/0M'M5CMS-YOG&;G>/2L?Q$(X?$5C=ZA
MTUBL3(PV[E5^Q(_2MS1T$>CVR@?\LQQZ<5;=5*X."/<9J6[,RE'H<'++8+>:
M?<OIIM[$LX D3(;IS@]!5!K&)[?[3<075M;O</+:(L8(08. 5(/K7I)C##YE
MW>Q%*5!'(!'IBJYC+V=]SSJ>XBO6M+"_M1!<,@:>Y\O#  \!?3BO1XAB)0.F
M*0HIR2H)]<4]<]ZENY<8<HM%%%(L**** "BBB@ HHHH **** "BBB@ HHHH
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M5G2],CTO3H[2(_*@Z^IJ[BBG=E<S:L(!BEHHI$A1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4448H **,44 %%%% !1110 4444 %%%% !1110
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M+F3S&CE*!L 9  _QIJ5Q6-*BBBK$%%%% !1110 4444 %%%% !1110 4444
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M,?['JG_/Q#_WQ1]CU3_GXA_[XK7Q1BCD0^9F1]CU3_GXA_[XH^QZI_S\0_\
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MI:7+*9_]-@C52"5PYRF>,4VS\:7MU;AS9QQJ"Q9F)("@ ]N_-=J;:$]8D/\
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>allo-20191231_g11.jpg
<TEXT>
begin 644 allo-20191231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S V  "2D@ "
M S V  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1FBF[A0 [-&
M:3- 8&@!<T4F1BD# ].: '44W(HR/6@-1U)FC.>E(3P<4 !; Z5G7?B#3[*0
MQRS!G!P53DBL+6-;N+ZZDL-+D,<:'$TX_DM8FE:#9MXLB23S6S$SN6E;YVZ>
MM58YW67-RG:VWB33[F41I(5)&06&!6JK;JY?6_#]O%9-<V<>QHQDKG@CUK1\
M-73W.E@2,6:([-QZG%(Z-C8HHHI %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BC-&: "BBB@ HHHH **** "BBC- !11FC-
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MTCQ_N"@!ECK5EJ+;(7_>#^%^,UHUQ^NZ*M@HO;(LBJ<E0?NGUSVKH-'O&O\
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ME]!:6U@4<!NK5W/A7Q@]]/\ 8-3PEQ_ _9ZS>+A*7*CU,1@:L:?.BM()8?\
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M1/*DEA/5'P/I23Y$+%>J_,/;% 'H(YYI:KV,WGV,,G]Y!5BD,**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD9Q1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>allo-20191231_g12.jpg
<TEXT>
begin 644 allo-20191231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" $T
M EP# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#]_**9,3Y?7'TK*O?%MCI5_!9W6H65O=W0)@AEG1))L?W5)!;\
M : T-263 ]:YOX3_ !5TOXR^#(]=T7SS8RSS6P\Y-C;XI&C?C_>0UMO<>8I
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MM%C''+*".,/G;C\C5V(8MU^@_E7*>&!_Q=[Q-_UZV?\ *2@#L**** "BBB@
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M#_G]4^Z7^9RS3^*ED/[SQ)N[_--2-<^*&'S2^(_E[;IJZEOVL?&>=WVK3O\
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M-'_$5,F[2^X/]>,M_O?<8@D\2!S^^\0;N_S2@T/)XD;;NF\1'GC+2]?:MO\
MX:W\:J[-]LT_<V,_Z&O^-#_M<>-7QF\T_P"4Y'^AC_&C_B*F3?WON#_7C+O[
MWW&+YGB8=9?$G/'WI::LGB0K\LWB+;G PTM;H_:]\;C_ )?+#_P#'^-(O[7/
MC9>EWI_7/_'HO^-'_$5,F_O?</\ UXR[^]]QA[_$A=?WWB(.1D'=+R*)+KQ(
M 6:X\1XZ$EI:VU_:W\:;]WVS3]V,?\>B\#\Z23]KGQM(-IO=/*^GV5>?UH_X
MBIDW:7W!_KQEO][[C'W^)QC]]XDV]1S+38YO$IW,LWB/T.&EK<_X:\\;!?\
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M-;S_ +X'^%'M,W_GH?\ E,=\Q_FI??#_ "&_\+G\ _\ 1/[7_OM?\*;'\9?
M*A@?A_:XR3]]?\*D'PT^%^T?\5I>?]\#_P")I(?AS\+V#?\ %:7G#$9\L?X4
M>TS?^>A_Y3%?,OYJ7_DG^0A^,G@ LO\ Q;^V_P"^U_PH;XR> &'_ "3^V_[[
M7_"G2?#KX7HZ_P#%:7G/^P/_ (FFR_#KX7@,?^$UO.G]P?\ Q-2ZF;?ST/\
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MC\U7L\N_Z *G_@3_ /D1^SPCWPL__ G_ )'9?\,?^)ATNM%_[_\ _P!:B/\
M9#\3.F[[5HI_[;__ %JY#_A!?%V?^09XB]?N/3$\#>+'12NF:]MQV5Z/9Y=_
MT U/_ G_ /(C=/";K"U/_ G_ )'9+^R)XF9V7[5HO3/^O_\ K42_LA>)HQDW
MFBXR.L__ -:N-/@;Q8K?\@WQ!N_W'S0W@GQ8(SNTWQ!M[Y1^*/9Y;_T 5/\
MP)__ ")/L\%UPM3_ ,"?^1V:_L>^)2?^/K1/^_\ _P#6I$_9!\329_TK1>#@
M_O\ _P"M7&KX$\79_P"07XB_[Y>FCP-XN<$KIGB#D]E?K1[/+O\ H J?^!/_
M .1#V>%_Z!9_^!R_R.R?]D#Q,C*/M6AY/_3?_P"M3I/V0_%$>6:\T;Y>>9__
M *U<8? _BY'7.FZ_N]TD-*_@;Q<H??IOB ?+GE)#1R9?_P! -3_P)_\ R(>S
MPG7#3_\  G_D=FO['_B8C/VG1<_]=_\ ZU!_9#\3.[#[5HF,#_EO_P#6KC!X
M(\78W+I?B#GOM>@>"?%I#+_9OB#/4_*]'L\N_P"@"I_X$_\ Y$KDP7_0-4_\
M"?\ D=DO[(/B:-U_TK1/FX_U_P#]:G-^R%XF8Y^UZ+_W^/\ A7%MX)\7 J/[
M-\0;F^[\KTO_  A7B]3_ ,@OQ%Q_LO2]GEO_ $ U/_ G_P#(B]E@WMAJG_@3
M_P CL5_9#\32H&^U:+S_ --__K4X?LB>)MVW[5HOW2/]?_\ 6KBU\$^+B %T
MOQ$<#^Z_%">"/%C/_P @W7RV,'Y'I^SR[_H!J?\ @3_^1#V6#ZX:I_X$_P#(
M[)OV0/$T:'-UHO\ X$8_I3C^R!XE*!?M6B_]_P#_ .M7&2>"/%H7YM+\0!?=
M7I?^$(\7G_F&Z_\ @DE'+EZVP-7_ ,"?_P B/V>#Z86?_@4O\CLH?V/_ !1<
M,%CN-%9L[<"<G-./[&WBQ)5C+:7N;G*S$=/PK%^&_@WQROBR!M/M=5M;I0X2
M:X#"%#C^+->GR>&?C2CQ[]5L6(! ^9/_ (FO:RS)\MQ-)U)82LO35?>>I@LM
MP5:GSO#U%Z-M?H<#8_LL:[JMS-';WV@W$MN2LJI<$^41V8>M7(_V-/%DJ!A)
MI>UNF)2?Z5B+H7C;4OB+-_9LC7&M02?Z1<V \N)3W$AP 3]:^J/A=:>(++PQ
M OB*XM;B\P/FMT*@#'0^I]Q7I\/\)Y3F$Y0J8>I&W5L[<IR/ XQN,J,X6_F;
M7ZGS@?V./%;2M'NTO*X/^M/^%=+X,_8]UF/2YH-1U@Z6&F61?L4G^LX(PV:^
MB+)?^)A<?1>:=J@Q%%_UU6OM<'X=Y11GSQ4GZMGT.'X/RZC/GC?[SP/6/V1[
M[2]/FFM_$FM7TD:EE@1P&?V!)KF?!?[(7B#7-16[U"[?24R2,2A[G_OH<"OJ
MKRUVM\O:H-)&;,?[Q_G716X%RJ>(CB.5WCYLZ*G#.#J5%5UT\S)\$^&V\'Z;
M:Z?)=75YY:MB6X??(?J:U]7.-*F^G]:;,V=6A'8H]/UE<:7-]/ZBOL*=.-.*
MA'H>[3@HI11/#P!],_RJOIW2Y_ZZM_2K$75?]VJ^G=+G_KJW]*T+"7_D(V_T
M:IM0_P"/*;_<-0R_\A&W^C5-J'_'E-_N&@!+3_CUA_W5_E5:V_Y"-U_NI_*K
M-I_QZP_[J_RJM;?\A&Z_W4_E0!)JG6'_ *ZI_.K:?=JIJG6'_KJG\ZMI]V@"
MIHO_ !Z?BW_H1HD_Y#?_ &Q_K1HO_'I^+?\ H1I)/^0W_P!L?ZT /U+_ (\)
MO]VK$?\ JU^E5]2_X\)O]VK$?^K7Z4 5=-_X^KG_ 'Z-2_X^[7_KH?Y4:;_Q
M]7/^_1J7_'W:_P#70_RH FG_ -1)_NG^5-TK_D&P_P"X*=/_ *B3_=/\J;I7
M_(-A_P!P4 1Q?\AF?_<6FZM_QXM_OK_Z$*=%_P AF?\ W%INK?\ 'BW^^O\
MZ$* +9Z56TK_ %,W_79_YU9/2JVE?ZF;_KL_\Z '2?\ (9C_ .N3?S%&K?\
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M^@?,A7B8TU?V0]6\PK_PD&@_*!QYU9?V3FMK?V7'[O\ [8^&^I8[_H#C^/\
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M.K"_ZMOQJOI'_'HO^\W\Z $F_P"0S;_[C_TIVM?\@N;Z?UILW_(9M_\ <?\
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MNKLBU??#?08K.1AH^FY"_P#/NG^%/3X;:#)&K?V1IW('_+!?\*V-3_X\)O\
M=J6#_4)_NBO4^HX;_GW'[D=GU6C_ "K[CG;3X?:%)<W"?V/IW[ML#,"^GTJU
M#X8T_06C^QV=K:M)( 3%&%)'X"KVG_\ (0O/]X?RIVI?ZRV_ZZBJCA*$9<T8
M)/T0XX>E%WC%?<1ZGH\=_8S02+YD,R%'7.,@BLGP/X!TGPIH\<>FV,%HI'.U
M>2?<]3^-=%+]P_0U7T7_ )!T?T_K52P]*4U.44VNKW*E2@Y*4E=KJ0VT7DZK
M*./]6.@I=5_X]6^H_F*>/^0Q)_US'\Z9JO\ QZM]1_,5L:%WM^%5=-_Y>/\
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M% OBY\#-2LM!\9>$_P#A(]:U#Q#-9%;FY@M9K&VB\E/+,J!(YII3)YD80'*
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M"\_WA_*G:E_K+;_KJ* +$OW#]#5?1?\ D'1_3^M6)?N'Z&J^B_\ (.C^G]:
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MR#(P?6N=F_X(X^&)O&5YJTWC+Q'<7&I0RV#;K6V&ZU99P4)VY9\3,-_4[5H
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M?^0;#_US'\J ([3_ )"MU]%IVK?ZN+_KHM-M/^0K=?1:=JW^KB_ZZ+0!.O\
MJV_&J^D?\>B_[S?SJPO^K;\:KZ1_QZ+_ +S?SH 2;_D,V_\ N/\ TIVM?\@N
M;Z?UILW_ "&;?_<?^E.UK_D%S?3^M $T75?]VJ^G=+G_ *ZM_2K$75?]VJ^G
M=+G_ *ZM_2@ E_Y"-O\ 1JFU#_CRF_W#4,O_ "$;?Z-4VH?\>4W^X: $M/\
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M]*M=OPJKIO\ R\?]=F_I0 7_ /R$K7_@?_H-.U/_ )!TW_7-J;?_ /(2M?\
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M:5_J9O\ KL_\Z '2?\AF/_KDW\Q1JW_'A-_US/\ *B3_ )#,?_7)OYBC5O\
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MVF>9IFJ:<74&9Y=ASE2S%MPQBOJC_@FKK/B(^"OVB%FNM;^SVKZFVG*9)3%
M_GSY\CMPW&5K]H\5WG#R_*/[5G0E'V*]G[)KF4;?\O+=;6UV/,P+I1E*--/?
MJ=MK_P"Q-\0+W_@GIX1^'<.D6I\4:3K O;FT:ZCVK%YN[=OZ=/2NV_:9_9'\
M5?%+]I+P9X@L]/AET72?#+Z?=7'GH&@N K;< \GGH17C/B'Q-XS3_@EWX&NE
MO_%7_"0/KH2>99)OMIC\WHQ^_C'X5Z9^TSXA\2V7[5W@V&QO=>AT^;P>SS)
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M\$:#KG@4ZCK]]H37NGZLT@ L($1W,6,\\ BOS4[BF/VMO%Q(Q_8_W@,?9/\
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M56MO^0C=?[J?RH DU3K#_P!=4_G5M/NU4U3K#_UU3^=6T^[0!4T7_CT_%O\
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MJOJ7_'W:_P#7;^E6+G_CWD_W30 VQ_Y!\/\ NBH[;_D*W/\ NI4EC_R#X?\
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M_CZN?]^C4O\ C[M?^NA_E0!-/_J)/]T_RINE?\@V'_<%.G_U$G^Z?Y4W2O\
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M1OYTZZ/_ !-+;Z-0 _4_^/";_=J6#_4)_NBHM3/^@2_[M2P?ZE/]T4 5=/\
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M#I^GQ6[W/VF625D%E#;&S2 C8D:O$91)N+$MC% 'T4?A]K!D5SXNU7Y00/\
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MWB#M.Z%F2,$;PG/RN1D!NV:\V_X)Z>)=<U6U\26,U^+K0=,F2*Q@FWR3V[E
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>allo-20191231_g13.jpg
<TEXT>
begin 644 allo-20191231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSV\L2RQRP2(>DB2H\; $C<IP2,$\=_P3PTJ73OA1KC2 C?K'DCW,-I;0N?\
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M)%5T8'G#*"05(R"">NH=UHR8SC.*E%W3ZA11104%%%% !1110 4444 %%%%
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MM)>7]U+>7MX[J4CC:61F<Y=E 7. 3P!7U7XUM8-'LF^ZN!7/_L9_!*3]I?\
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M1114'L!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 5R?QE^+VF_!7P6^K:A'-=222+;65G!CSK^X;.V),\<X)+'A55F/
M-=97RS^W/'_PE7QK\%>'[J1X].N($B<JVW NK^VMYF!['RMRY["0^M %'1?&
M7QK_ &E=VHZ'<'1]#D8B&2SFCL;'@XQ'.\4D]QCH9%1(R0<58O1\?O@P/M;S
MWOB"QA^:0*8=9C(_VD6."ZQ[Q[OI7U/8V,.EV4-K;0QV]O;HL444:A4B11@*
MH'     '2I: /!_A/^WKX;\562)XG5/#5SN\LW@D,^F2OT(\[ ,+9SE)U0CI
MENM<%\6?%>E>,?VU_"-]X:U"SU9//TJ">>QF6:,RB2[9UWJ2"PMW9B >%(SU
MKW?XE_LR^#OBIJ#W]_IK6>KNNTZEITS6ETP]'="/,'M(&'M5'X3?LI>%?@]X
M@_MBU;4M2U*%'CM[G4;@2?8U;[_EHJJBEAP6V[B.,X)% 'IE%1V]W%=*3%)'
M(%X)1@V*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M9?VTOC]JWPR^._@G0%\?:MX!\/ZKH6J:E=W>F>&EUR>:>WFLUC4IY$S1QA)I
M26"@9"@GI6!\(OVL_&-SX T?4;V]U3Q=!K6N:M#X1U"/2[;2SXQT^#2);R*6
MXCDQY"F6.5$>/R]_E1L556.?HS5?A%9ZM\;]%\=->7:7VAZ/>Z-';+M\F6.Z
MEMI69N-VY3:H!@XPQR#QC@O#_P"Q#X?\+^+HKRQU35K?1[/Q!?\ B*QT9?+%
MKI\U]8S6MU%#\NY(7:>2<(#A9&;&%.VOI*&-P'U6-*I!<RB];+5WEU24KZQU
M<FK7V:1\IB,OS+ZY*M2F^5R5ES/16A=V<G&VDM%%.]MTVC ^!G[;MUXE^#%M
MJ?BKP[?6?B#3_AO:^/M16&2%HKJ*47&!%M<[2_V9G56/RK*@8[@V-FR_;@TZ
M]^(VA^$5\*^)/^$B\41V%]H]N$C,5[IUQ")9K[S=VU([;YTE5OF#^4%#><A/
M,R?\$Z7_ .$-TO1H?B=XNLDA\(GP+J<]M9V2R:MI"-*;>(YB(BEB69T\V,!F
M!)/.".E@_88T:W\:Z7XH7Q%XA'BCP])I\6CZB'C!TRPM8A$^GHFW:;>X4RM,
M"-SM*&R#%%LJM_9+G.2>][)<UD]+;]+W?5\OGM-'^VU"$)+:UVW&[6M]OM6L
MNBYO[NKX;3/^"BG]B> ;2ZMO"/C'QHMCX8D\8:QJ!:QM'L]-2[NH)'9 ZJ\J
MBV9EBC&74=0<Y[#3OVVKNXL/%BW/PW\46>L>'[73]2L].DN[/=J-C?22QP7+
MR^;Y=LJF&0RB5AY2KGYL@4S3?V$_"_@KX>^(-,D\1:M#IVI^")_!US<SM"OV
M:T::[G:XW;0 Z_:W&3\N$7(ZDP?'']COPC\8+&ZNKKQ=)IK:I;:!9VLK?9;B
MT9["XN);3=#*ICN%F:Z8&)P5?";0" :J4LIG.T8V5][2VO'HG;;F5DO34B$<
MZIT[SE=J/PWAORR6[3>_*[MM7O?0Y&;]O[Q!X^U#P1)X0\*W%]?2>+K_ ,,Z
MWH%IJ5A>+>21:1)>1F*^5S"(EWPNT@8,-KH5W?*?H#X$?&:U^.G@'^V(=/OM
M&O+6\N=,U+3+W8;C3;RWE:*>%BA9&VNIPRDJRE6'6O(=#_X)X1^$[*WGT?XA
M^)M-\06GB&3Q-!J<%A8(L5W)IRZ>\8MU@$/V<Q*#Y048_O9YKV#X&?!NS^!?
M@%=%M;[4-7N)[NXU+4-2OBIN=2O+B5I9YY-@506=CA54*JA5   KES2>7.DE
MA4KKMS7WDW>^C6J2^UWT.O)Z>:1K-XQOE=]^6VT4K6U3T;DOAUNM6SQ7_@HY
MK5TEEX5TOS@FEW0NKN>-UWPRRQ-;I&9%Z.L8FDDV-P612?NBF^/?^"?\VDPP
MZEX-\07DNL6(WQKJ4BP3,P[PW=NB20-[$.AZ%0*T_P#@HUX<74_AUX?O!_K(
M[^>Q'TN+.<?^AI'7MOPQ\0-XM^&WA[56.YM3TRVNR?4R1*W]:\$^E/GWX5?M
MDZQ\.M;D\-?$ZUO(Y+$ 2:A);A+RS7. ]S%'\DD1[7,&4/\ $J\M7TMIVKVN
MKZ?;W=I=6]U:WB"2":&0/',I&058<,".01VKF_BU\%= ^-&BQVNM6S^?:DO9
MWUNWE7E@YXWQ2=5]U.5;&&##BOB/X2_ 72_&6J>(K77IFOM1TO6+RPCMWS -
M(\J9E7RHE;%O)(%69FCVEFDW XVX]'+\"L1S.<N6,5J[7>NVEU]]_P!#R<VS
M1X-0C"'-*3LE>RTWUL_NMKZ)GZ$45\U>"OCSXH_9X:/3_&[7_BCPBN%BUY(S
M-J6EI_T](HS<1C_GL@\Q0/G5^7'T3X?\0V'BS1+74M+O;74=/OHQ+;W-M*LL
M,Z'HRLI((/J*RQ6!J4'=ZQ>S6S_R?D]?D;8',J6*5HZ26\7NO\UYJZ^=RY11
M17&>@%%%% !7R-X[75OV.?VD9O$=O9M>>&_$4TQC4,(X[E)W\V6U#MA$N(YM
M\D0<A9$D= 002/KFJNMZ%8^)M)GL-2L[74+&Z79-;W,2RQ2KZ,K @CZT >:V
M/[:GPXN;)9+C79=-GQE[2\L+B*YC/]TILR3_ +N0>Q-<GXY_X*$>&_#R,NEZ
M/JVH.3B.6^*:5;R?0S'S3_P&(UUDG[%OPY,N8]%O+6+.3!;:O>0P?0(LH4#V
M  KJ/ WP*\&_#202:'X:T?3[@?\ +PELK7#?65LN?Q- 'SVWQ1^-?[0@\O0=
M-N=!TN8?ZZTA-A$4)ZF[NE\QOK! #[U;TW_@G5>:^IO/$OBBUEU&;YI/+T_[
M>P/O/=N[O]=J?2OJ6B@#X_\ %_P6\=?L=Q?\)#X;UY+C0;9@UT\,3QV\(SC-
MU9[VC:'G#2PE)$!W8V@D?27P0^+5M\:/A[:ZU# UG<[WMKZS9MS65S&=LD9/
M\0!Y5N-RLK<9K,_:/^-_@OX,_#36)_&&KZ7:6\UA,JV,\R_:-2!4KY447WY&
M8G;A0>M>2?\ !+;5QXM^#>LZY:274NCWVHI:VLTT$D(NI;:WBM[B5!( 60RQ
ML@?'S&(FJY7;FMH7[.7+SV=N_0^G****D@**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO"?VY?@O??$#PE8Z]I$-U<:AX?$J3PVJ[KF6UDV,SQ#^*6*2**55ZML8#)8"
MO=J* / _@_\ MW>&]=\*6O\ PEEQ_8^I1H$DO8H))M-OF'!DCD0'R\XR8Y-K
M(21\V-QVO$G[<W@/1[9I-/EU?Q!MZFPL'$2_6:7RXA_WW72>-?V7O OC[6YM
M3OM ABU*X.9KNQGEL9ISZNT+(7/NV35;0?V2/AUX?O%N5\+V>H7"?=DU.234
M&7W'GL^#],4 >.7W[;7C7XJ7#V?@/PQ&I/RF:"-M8G3)X)*;+:(^[S,!Z4RV
M_9!^(GQGG^V>._$0M%;YA!>3'4I5/H((S':1?\!$GUKZIM+2*PMDA@BCAAC&
MU$C4*JCT ' J2@#Y7UK_ ()Z:EX4@_M#PGXDMSJEN-T2-:_V7(Q']RXM2K(?
M3<CCU&*ZG]D_]HW6/$'B.X\#^,O._MZR$@M;BX1([B5HL>;;3A?D,R!E<.GR
MRQL' X)/NVL:S9^'M,FO=0NK:QL[==\L]Q*L442^K,Q  ]S7QII?QM\+_''_
M (*26%EX'U#^UIK-H[R\O+&&26S:.UMIHKB;SPOE%2;FW@!#'<RD#A<U2BWJ
MD7&G*2;BF['VI1114D!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?"OCWXV_$CP_P#!J'Q)%XWU6=_&OQ%U'PM-)-=V&EV?AZPM;W4HX4@GDMW2
M&:4V\,)FF$F2P"A7*FCP'^T#XM\;P^$_#/C#XM6O@[P_=7FO+_PE.EZMI]U<
MW[67V3[/82WS6ZVOGH)[EY&CB'F+:@<$25]M:AX1TG5M!N-+NM+T^YTN\W>?
M9RVR/;S[F+-N0C:V6))R.2<UX_)\=?A!XP\<:+\+=.B\%^*-.\J_EN+6T:SN
M;#06L/*8K-#R(S^^.T[0 8WZ$5]90S*E5BU##)M.3NDM%9VZ6]U;76MNY\7B
M,IK4)QE/%-)J,4FY>]*\;[._O/=IZ7['SSXK_:JUR[\*>,O$4?QNDM=4\"Z1
MIESX2T]-+MK&'Q]YUI'*+J6TEC,TRWD[/;HD#((S'E>36I??M*^()/BKI-U=
M?%:XT?Q9>_%.#PI<_#PI9F.#2OM6Q1Y31FXW20!;@W(?:PEVC VX^D]*^+GP
M;^)EG_PEEKXA^'.MP^$9EMAK"W=I.NCR.0J*)LGR=QP%P1N[9KR[3-!^#OQ,
M^.WA[Q"OQFA\32:MJ[:OH7A]M=L)X)[V$M@0N$^U21Q/N9+<S&-'&0GR@#HI
M8JBTU/#N/*G]E/HO=TA;6W,V[-7=FEORUL'B(N+IXE2YFK>_):<S][6HV[74
M$E=.RNI/;R71OC;\1-+^$?@WQ?J/Q"U+7G^(GAWQ5]MTV]LK(Z?:FRLKJ>U>
M!%A!W)Y(5][.L@9LJ. *_@3QKJGA[XH^)M6C\1M>:EKNL?#@2:7/!9M"L-TM
MHKM%'Y68P=S1HX^[N."& (^LV^.GPOU*?7-$T?7/ NM:UX1LKJXFT:#4;02V
MJHC"96!;;$O)5V;"KN._'-,7XP?">T\6Z);ZIJ_P^TOQAK$%I;6UE+?6;7QR
MJ3P0(0<L 71HPORDE2N<BL_[2?O+ZM:ZV22TYU-:*.RBDK_\,:?V2O=;Q=^5
MK5MO7D<'JY/5R;E;N[>9\LZ#^U5XIMO!/AOQ1;?%:37_ !7XQTK7I_$/A1H;
M3RO"C6NG7=PKQ1+&)K<VEQ##;OY[.)3+S\Q6O7/V5/%OC+3OC=X=T?7_ !UJ
MWC"T\9?#F#Q9<QZA;VT8L[X3P1N;80QILA99_P#5MNP4!W9)SZQX<\:?"K4O
MB_KWA_2=0\"3>.KB-EUFQM9+8ZG.B@;EG5?WCA01D-G&1G&:[N#1[.UN(YH[
M6VCFAA^SQNL05DBX.P'&0N0.!QP*XL=F5)Q=-4.7F7513UNU;W5HKI)K=)>B
M]#+\IK*2J/$.?*ULY-:64KWD]79MI[-NW=_,7[6D6L?&OXX'P,-4OM+\/Z#I
M]GJS1V+B*:ZNY9)PKM)@L%C6+A5P"78MG  Z3]C+5-<\(>)M<^'^I:G=:OI/
MA_3;*ZTB2[VM<6D3--$8"X ,B+Y*E2V6&2"2 ,5O% S^V?XH_P"Q?TO_ -#O
M:U_@<-O[4?BS_L7+ _\ DS=UI6Y/JCIJ*LH1=[*]WRMN^_5_+0Y</[1Y@JKG
M+6I*-KNUDI)*VW1=-]=SW2O,/C=^S%IOQ3U$:]I5TWAGQG;H$BU>WCW"Y1>D
M-U%D">+T!(=?X'7G/I]%?/4,14HSYZ3L_P"M'W7DSZS%86EB*?LJRNOZU3W3
M[-:H^7]/^(=]X8\0Q^$_B!IJ:+KDVX6DJN9+'5U7J]K,0-V!R8V"R)GE<88\
MOXC\0WW[)UU?>*O!MU'_ &+\]]JWAZ5O]!U!0-TDD0_Y=[@J"0Z#:YQO5N&'
MU;\0OAQH?Q6\+3Z+XBTVWU33;@AFBE!^1A]UT889'4\AU(93R"#7S9\5_P#@
MGCK&O>%;^UMO&U]KVFVO[^TT74+5%?40AW+:W-TK LC8QN"*V=I<N P;Z+!Y
MEA&FZWNK[4;-J7IV?KL]5+M\GCLGQT9)8;WG]F=TI1_Q=UWM>ZT<>_U/I>H)
MJVF6]U&LBQW42RJLB[6 8 @$=CSTJ>O$_P!B'XTW?Q/\ 76EZG<7%YJ/A\Q!
M+JX_U]U:2J3"TOK*I22)SW:(L>6->V5\N?:+S"BBF7%Q'9V\DTTB111*7=W;
M:J*.223T ]: 'TV:=+:%I)&6..,%F9CA5 ZDFO _B=^W1I]I+-8^!K&/Q-=1
MDH^I3.8M+@8=<./FG(](QM_VQ7A'C?Q'KWQ6N#)XMUN\UM,[EL5_T?3HOI I
MPV/60N?>@#Z<\;?MJ^ _"5S):V=_<>)KZ([6M]%A^U!3Z-+D1+^+BO-/$?[<
MOB[5RRZ)X9T?18CD"75+MKN;Z^7#M4'V\PUY+!"EM L<2)'&@PJ(H55^@'%.
MQ\I/8=3Z4 =)J_QX^(_B$-]J\;75JC?\L],L+>U4?1F5W_\ 'JYO5M3U[7;6
M6.Y\9>-I))$9%D_MN=3$2" P56"Y!Y QC(K-G\8Z3!<^3_:%K)/T\J%O.D_[
MY3)_2M*#1M8\1V4BV/ACQI=),C)YMMHMPFT$$95F4 $9R#V- 'R/K_PKC^%-
MW=KK_BJ;QYJ<:#[9&U^;RYN"!@M<01B&0%N2PFNG7)."!@5[Y^S-\0+[QY\(
M]-U6S'BKP?!&\EI:V=OJMS:P^3$VQ)88UE94B8#Y5!8#!PS##'YXN?!.D_LV
M7DFEPOJ7B*\TQ]K"^"7312+P1(+A+BUCFR/F"RPL6R<*37T[\$+[X@>//AE:
M:UXC^&_C/1[BXDD\K9I$CK<6X.(I]J%]F]>=N2.X."*]#%ZP4M_/;\#W<RO*
MC&;][7XGITZ1_4[S2_B?XXT%PUEX\\3KMZ+=R17J_B)48_K76>'_ -L#XC>'
MRHNSX9\20@\B:WDL)R/]^,NG_CE>6WWBBST>7R]0^U:4_P#=U"TEM/\ T8JB
MKEE>PZE!YEM-#<1_WXG#K^8KSSPCZ&\*_M\:#.RQ^)M!USPVQ.&N$0:A9K[E
MXLN![M&*]B\%?$+0OB/I*WV@ZOI^L6AZR6DZRA3Z-@_*?8X-?#8.#55-(CM-
M774K&6ZTG5$^[?:?,UM<#ZLN-P]FR/:@#]!J*^4/AS^V7XJ\#&.W\46H\7:6
MO!O+2-8-2A'JT7$<V/\ 9V-[$U]&_#7XL>'OB]H/]H^'=4M]1MU.R55RLML_
M]R2-L-&WLP!H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **\\^,G[3?A?X+R_8[R:;4]>D3?#I%@
MHFNG'9F&0L:?[4A4>F>E?.GQ#_:.\=?%1I(Y-0_X1/29.!8Z1*?M3KZ2W1 ;
M/M$$^IH ^GOB3\??!_PD98]>UZQL[IQE+-6,UU)_NPH"Y^N,5Y'XH_;XDN"R
M>&?!]]<+CY;K6+A;&/ZB-0\A'U"FO!=+T.ST3S#:V\<,DQS))]Z24^K.<LQ]
MR35H#)H [37/VI/B9XA=MNN:/H<;?\L]-TP2,/\ @<[/^>T5S.H>-O%FLEC>
M^./&,^[J(]1^RJ?PA5*QM4UZQT3_ (_+VTM,]!-,J$_@3FG:7J+Z^?\ B5Z;
MKNK9Z&QTFYG4_P# E3'ZT >*?M-?".^U_P 6P^(=4^(NJ1Z2L444&F:KKNU8
MY4W;V@:>*?>TFY2P0(X*##X.!F_LR^/(;?XLWGAG2M%US3VN+)KN\UNTFN;*
M3]V5$:SR?:&>4,78)N6/!!PI&2+O[5GP2CTOX@VOC+Q OBS1;J>S2R@TR^6>
MV6=8RY+0Q1EG;/F?.&@E4D*3BK'[*GCKQAXT\63:%H'P[US4/"=G!)+=:CIV
MF6X2RG&WRT/V=(@S2?,"KPI(-NXDC->AO0[V7I;_ #/<UG@?YDE_A2_23^>I
M[W8>+/%&D;?L7C;QG;;>@.JO<*/PEWBNET7]I?XF>'77;XFL-8C7_EGJFEQG
M</\ ?A,9_'!KBM4FNM _Y">B^)-+ ZM>:/<Q*/JVS'ZU7TSQ-INLOMM-0L[B
M0=4292X_X#U_2O//#/=O#'[>FI615/$G@UY$_CNM$O%G_'R90C?DS&O6/AO^
MTUX(^*MTMKI6NVZZDW_,/O%:TO ?3RI K-]5R/>OC\C:>:KZII%KKEOY5Y;0
MW48.0)4#;3Z@]0?<<T ?H)17Q'\/?C;XV^$AC32=8;6-+CX_LO6I&GC"^D<_
M,L?MDNH_NU]$?!O]KCPW\5KZ'2KI9O#?B23[NFW[*/M!_P"F$H^28>RG=ZJ*
M /5**** "BBB@ HHHH **** "BBB@ HHHH I^(]+?7/#U]8QW$EI)>6\D"SQ
M_?A+*5#CW&<_A7Q#/^QK\2/B!\/O#O@V;P/X;\'?\(A\/=7\%'78M4BFBUJ:
M:*U2)UCC42K;2F!V<2?O 9F^4\LWW517I9?FE7"7]DEWUOH[-=&ELWO='DYE
MD]''6]LW9*UE;573L[IM:Q6S3/C7QY^S1X[_ &@M?O-;OOASHG@:V6R\/Z*=
M#;4[:[&J16FN6M]/*YB'E>3###(D2M\[>8X*H" >L\2_LE:Y<^)/%VH6.AZ+
M'/JWQ6T'Q7:S!HT=K"TCTX2N2!D,K07&$ZG)Q]^OIZBNC^WL0K**22V6O]WN
MV_LK=]_*W+_JWAM93;;>[TN_B72*2^-[)=/._P !:3^R%\:/%.KZ2=;T&.R3
M1]$\1Z;)!'J.EV^C13WUC/%%_9UK:PK(D#2,FYKAS)\P)4X9J[J[_8K\5W'P
MG^*%B=%T=M<\3'PK_9LIN(][C3K33TER^/E\N6"<IGJ>1]ZOL.BMJG$F)E)-
M1C&UM$G;22GW[HYZ7">$A%QE*4KWU;3>L'#MTB]/,^3?A9^SS\0/!W[74>J6
M>@W&B>$(]?U;5;[[7J]GJNDS)=+,1/IT;1?;K.[FED1IEWB$ S*-X*U]9445
MYF.QT\5*,II)I6TOKN[N[;;UW/8R_+J>#A*%-MJ3OK;31*R2226FUCYM\9W\
M=C^V?XF\Q@H;0-+'_C]Y6Q\ ;^.__:@\7-&P8+X>L!Q_U\W==-\;OV5]/^+_
M (MMO$%KKFL>&==AMA8RW-B(I$NX%9G19(Y49249W*L,$;V!)!P-'X#_ +.F
MG? PZI=)J6IZ]K6M&,7FHWYC$C1Q[O+B1(U5$C7>YP!DL[$D\8].KC,/+"Z2
M]]QC&UGTMK?:UEZ^1XM'+\7''7<5R*<I<UULT[*V][OT\ST.BBBOGSZH*KZI
MJEOHFF7%Y>31V]K9Q---*YPL2*"S,3Z  FK%?._[>7Q1N+;2M/\  NFPR75U
MX@"S7T$1Q)<0&58X;5?>XG(0G_GFDN>M &+_ ,$]+6;6/$OC#7/*>&WN(K>,
M*1@!Y9KF[V?5([B+([;Z^HJXOX!?"=?@S\,[+2'DCN-1D9KO4KE!@7-W(=TC
M#_9!PJCLB*.U9'[17[1]C\$-+BM+:%-6\4ZDA.GZ:'VC:.#/,W\$*GJ>K'Y5
M!/0 V_C'\<-!^!_A]+S6)Y&N+IC'96%NOF7=_)_=C3OCNQPJCDD"ODSXJ_%;
MQ%\>KIO^$AD6QT/=N@T"UE)MP.QN'&#._L<1@]%/6L6^NM0\1^(KG7-<OI-6
MUV]&V:[==JQIG(BA3I'$.RCKU)).:9>7L.G6DEQ<2QP00KNDDD;:J#U)H D5
M0B*JJJJHPH P /0"J\^J1Q:E!8QI<7FI77^HL;2%KBZG_P!V-06Q[G 'K7=_
M"#]FWQ-\;%BOIFN/"?A>3#+=RQ8U#4$]88F&(D/:20$G.0G>OI_X6?!/PS\&
M=,:W\/Z7#:R38^T73DRW5V?[TLK9=S]3@=@* /F[P+^R+X\\=K'-J36/@O3W
MYQ.!>Z@P_P"N:D11G_>9R.XKU?PI^POX$T79)JT&H>*[I<$OJ]T9(L^T*[8@
M/;::]DHH S?#G@W1_!UKY&D:5INEP@8\NTMDA7\E K.^+/C_ ,-_#/X?ZEJW
MBW5[/0]!CB,=S=7$_DJ PV[5(^8N<X 7YB>G-=&6Q7YG_P#!0;XB7WQ^_:^O
MO#4DS-X=^'ICL[6U!_=O>21+)/<,.[@2+&I_A"MC&\Y\G.LT6 P_MK7;=DO,
M^NX+X9_MO'^PJ2Y*<(N<VM^5-*RZ7;:6NVKL[6?CIU+P[\ ?$-C_ ,,\:QXJ
MM8[.Y!.I:WHT3N(%0A4C:X9RV3M)/V>(G!)8DG/V'^Q-_P %,-1^(?C/3_ O
MQ-MK&RU[4V\G2M:M$,-MJ4N,B"6,D^5,V#M*G8Y^4!6VAO'O"OP4C33%80CI
MZ5Y7^T;X0;POH]Q>VKM:W5B/M5O,IVM#+'\Z.#V*LH(/J*^"J<29DL0L76E=
M:7CTMZ=_/<_=?]6\@S'#_P!DQI^]KRU'K44GLW))<R3^R_=MLD]3]?KBWCO(
M6CFC26-QAD=0RM]0:\]\9?LI_#WQM(TUUX7TVUNV'_'UIZFQN ?7?"5)/US7
M4?#GQ)/XN^'>@:M<IY=QJFFVUW*H&-KR1*[#'U)K8S7Z?&5U='\QU:;IS=.6
MZ=ON/FWQE^PMJ>EJTWA/Q0;I5Y%AKT>_/LMQ& P_X&CUY!XOTG5_AE?+:^+-
M'O/#TDC;([B8B2QN#V"7"_)D_P!UMK>U?=Y>JVJ:?;:SI\UI>V\%Y:W"[)8)
MXQ)'*I[,IX(]C5JYERGPM4=G]JT+Q!%K6CW]UHNN6X 2^M2 [J/X)%/RRQ_[
M+@CTP>:]L^*?[%"V*RZA\/IX]/89=]"O)";&;U\F3EK=CV',?LO6O$1<2VVK
M76FWUI=:7J]B0+JPNTV3P9Z''1D/9U)4]C3)/I#X"?MAP>,-0M?#WC"*VT7Q
M%<'R[6ZC)%AJS>D9;F.4_P#/)CD_PENWN5?G[J.G6^KV,EM=0QSV\PPZ.,@^
MGXCJ".0:]>_9T_:INO 5Y:^&O&E])=Z-,RP:;KEPV9+1CPL%VW=3P%F/L'Y^
M8@'U)11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***S?%WB[3? 7AJ\UC6+R'3]-T^,RW%Q*<+&H_4DG  ')) &2: +FI:E
M;Z/I\UU>7$-K:VR&2::9PD<2@9+,QX  [FOEWXR?MCZE\0&ETWP)-)I.B\I+
MKSQ_Z1>#H?LB,/D7_IJXR?X5Z-7&_&GXTZI^T5J?^EQW&F>$8'#V6CO\LEY@
MY6>[ ZGNL/W5X+9;ISO4T 5]-TF#25D\E6\RX<R3S2.9)KASU>1VRSL?5B:?
M>WT.F6CW%S-%;P1C+R2N%5?J35WP=X8UOXI>(Y-'\*Z>-2O(&"W=S*QCL=-S
M_P ]I #\V.1&F7/H!S7TE\'_ -C7P]X N;?5->;_ (2SQ%$=Z7-Y$!;6;?\
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M_P#$BWV\7&H6MX/I+96[?SS7Z6EL5^>/[4<0C_X*)>*C_P ]+#2W/N?(*_\
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MEBD:.1.1U5U93[BOS\\#^-]0\5/XDTNQU"[U?PW,?"&I1)!X@U3Q);&\7Q%
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MX11_,GDDGDDDGDUIDXII>FDYJ>8KE'%Z;12%\5)0N::7II.:0MB@!2:^7?\
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MD4BAT=3E6!Y!!]#3 ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;NC?ME_!OX?6=KX7TKQ!%9V^@1OIMC8V6E7LD>ZU;R7L[;;$1-/'MP88RT@
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M.4;HY 4<'NIX(_+-0S7559;C)ZTK@?,_AFQ;1;&?2Y"3)HMW/IQSZ12,J_\
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M^N9_Q2SGQ_.N(\ #;X(TM>ZVZJ?J,C^E=S\"I1!^T?X$9NC75W&/J;.;'\J
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MJ]G9$?[#3*TGY(KFJ,C[L\#:1_PCW@G1]/QC[#8PV^/39&J_TK4HHH ****
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M,_4"BOG7]CG]C?QM\&O'.J^//B7\6/$7Q$\<:_9"RN;=6^SZ'81[Q($M[;&
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M=#CN-02^AEN-/U*,82]M)/*G4>A/1E_V6!'M4\H'NLD^:@DGQ7EVE?%WQ!H
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M4G+')/'I5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7-_$_X1^'OC'H']F^(=-BOH8VWP29*3VK_WXI%PR-[J
M1[Y'%=)10!\A_$S]DOQA\-'DN-%\SQKHB\A%"QZM;+Z%>$GQZKM<_P!TUYKI
MVM6VJ3S0Q2,MU;G;/;2H8KB ^CQL RGZBOT&KD?B;\"/"7QAB7_A(-%M;RXB
M&(KM<PW4'^Y,A#K] <4 ?&(.#6;J/A#3-4N?/ELXEN.T\689A_P-"&_6O=O&
M'["&KZ6S2>%?%2W</\-EKT.\CV%Q$ W_ 'TC'WKS;Q'\(/'O@QC_ &GX+U::
M-<_O])=-1B(]=J$2C\4H Y:&QU73Q_H?B36(5'1+@I=H/^_BEO\ QZIEUOQ5
M /\ D(Z+=?\ 76P>-C_WS)C]*JW/C#3=/N##>7!TV=>#%?1/:./PD"U:M=7L
M[Y=T%Y:S#UCF5OY&@!K>(_%3?P>&S[_OQ4;ZGXHN.L_A^#W6WFD/ZN*O#D=O
MSIDMS% ,R2Q1CU9PM &;)IFM7W_'SXAFC7^[9V<</ZMN-,3P'I[S"2Z%UJ4J
M\AKVX>;'_ 2=OZ5)<>-M'M9-KZKI_F?W%G5V/_ 5)-;.@:%KWC';_8?A7Q/J
MRN<+(FGO;P'_ +:S;$_6@#"\2_#SP]XTLA;:QH.C:K;@8\NZLHY !Z#(R/PQ
M7P7^T_\  70?A/XUC\.Z+97&GZYJE[LM)+:>15:Q;YFE= <, A*D#J4:OU,T
M7]DCQQJ5C+>Z]?>'_!>FVZ-+/)))_:%Q%&HRS'&R)< $Y+,!7Q3X=^!.K_M
M^%O'G[1MO=:E?>$]'U?^P?#27R*)I](C8QS7V% "CS64X48"^=G[H->+FM"E
M6<:'*G*;WLKI+=W_  7FT?IWA[G&897&OF\:\XT,/&_(IR4*E65U2IN*=FKW
MG)-:PA)=3S#PY\-O&7P$\6*O@_Q]''9Z>WDVSZKIV^TDLY2I$X&"3$5PY*@\
MHV,D5]A_#FW_ &BOV6/$@\0>+OV?]#^+S1.7M-8\+^(%:2U0@8-O:R [3WW!
M QSC=BO.]>/_  M;]FO3]3;]]K?PKDCT2_W?,UQHERY-G(<GD03;X>G"ODU]
MI?\ !,SX]+\3_@5'X;OKH2:]X)*V#J[YDFL\?Z-+[@+^[)_O1'UK99:H*U"<
MH>5[K[I7_ \N7'57%2<\WPE#$MZN4J:IS;>[<Z+IMM]Y<QU7[('[95M^UM9Z
M\O\ P@_CSP+JGAF2&&_LO$NF?8VWRAR!$V3Y@ 0Y.!C(]:]FHKG_ (DQ>*IO
M#H7P?<>'[;5O.4E]8MYI[?RN=PVQ.C;NF#G'7BO0HQG&"527,^]K?@?)YE7P
MU;$RJX2E[*#M:/,Y6T5_>:3=W=J^R=KNUSH**^9? ?[5?Q&N/@#HWC36=/\
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MEP[C^.W-=A10!YR_[(GPQ=LGP+X;_"S45:L/V7/AOICAH? OA4,O0MIL3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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6Q$9 H:7YD:0R2EG9I6RV  "B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>allo-20191231_g14.jpg
<TEXT>
begin 644 allo-20191231_g14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S0V  "2D@ "
M S0V  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"*8X^4L./K6I%<QW$*S02+)$PR'4Y!'KFN$\+-HPTW4_[8,(O?M#_:?/^]C
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M<@'LM8TU)RW)BFV=0/NBEI*6O1-PHHHH ****8!1110 4444 %%%% !1110
M4444 )535+Y=.L7N70R!.=J]35OO56_LH[^V:"7(5NXH5KZB=[:&%+XSMH+B
M.&> HS!2X:0?N\] >*F_X2J#]ZXM93;(VU9AR&;TJ2Z\,V\^H_;//=2=N]>S
M8]:K#PQ:W;2%;N5[<L2(0?E5O45O^[.?]ZAY\5(H>.>QECNP1LMV.6<'OTJ(
M>+M^%BTV9IMS*T?==O7M4>H>&IDM6FAFEN[W<-LKM@J!V!J30O#LL"M<:@[F
MX=F/)R0&&.M'[NPKU&QEUXHD\Z+[#"TR2.BGG& 0QX_*I1XH2*([;:2?8K22
MN#_JU#$<\>U/7PS:8\F&XD5HRF<'H #C^9I9?"L#+MBNYX@RE)-I^^I))!_.
MG+V=M 7M+A;^*(YK[RUM)/(\[R%GS\I;&<8JWX@O)+33B(E!:;,?/;/%$?A^
MV2-8PSX6X%P/][&*FURV%SI,P/5%W@X[CG^E9W@YHTM)0?,<U8)?Z%Y4AN6E
M@D?#H0,"NQDCCNK<K*H>-A7/.!?Z'QP2OZBM70[D76D6[_Q*H0Y]1Q55$MT*
MG=;LP;S[;X69Y[4&>T;@(>QJQ#JNL[1(T,4J-R4 .X5NW]C'J-E);3$A6[BL
M3^S]6T\D0,MU$!@*3M-*FXM:CJ<W0MQ>([?S!'>1O;2>CC(_.M2&YBN4#P2+
M(OJIXKFVU*$*8]0MFA]=RY6LR2]BT[5;>73]S+UE1,XVXZ_RJG235T0JLEH=
M[B@C%9-OXDT^51ND,6?[XQ5M=5L7Y6Y0CZUS[,Z?,SO$Y_T>W7LTH!'J*KQ/
MM3TXI?$5]92V(V7"O+$P=57DGFLRWN;FZ@3[/;2%I.FX8 KCK1ESZ$,;K5XR
M0^5%]^3J?05F23?9;%;"VR)IANG?NJ=A_.K>L0#3RJ2D//M\R4GI]!6?8*7D
M,LO+.=Q)]?\ .*EOD5B6S3TZT$48&!5BYG6&/C' J%KI8DZ]JJV%G<:_?;(\
MK;(?GD_I644Y:(G?1$^BZ8VMZ@)I,_9(CG_?-=ZJ*BA5& !@ 5!:6<-E;K#;
MJ$C3[H%6:[J=-01K%6"BBBM2@HHHH ****8!1110 4444 %%%% !1110 444
M4 )B@CGBEHI <WXIEEC2V#RRP6I8B:2$9(X.*YKSYH;"!3<W<,&',#JIS(V>
MAX^E>C2*KKA@#]13/)0XS&N%^Z".E:QJ)*UC"5-MWN</*FJW4;3RW5S%*LD<
M91.A!X)JKJ5[=VL,EFUQ=9AE<)+GEN 1]>M>B;%QT'Y4ABC8_,BGZC-5[:/8
M7L7W.%AEU'4'MHI)KB+SS'YCHNTCY6SS^55[^ZU&VL8 US<D1R.J@\%\,0.:
M]"V*,85>OI2&)&QE%P#TQFCVT>PO92[C+20R6<3D$%D'![5,PW*0PR#P0::T
MD<*Y=@@]SBDCN89?]7*K?0UB][HZ(W2U.<TT^3)=6DAR89"1]#5GP[)Y=U=V
MG78VX?0TFL:-.\SWVGW'E2[>1C@U#X/5#;S22,7NRV)6-;N2<3!1E&1THZG%
M*1F@4M<YT$<D$<J[98U<?[0S5>'2[2W9FBMXP6X/':KE%.[%9%";1K&XR9+9
M"3WQ5-_"UBQ^7>H] :VZ*0S)M_#MA P;RMY'=JTUC5%PBA1Z 8I]%#U \[\;
MQ31WC2%&925(/MW%8\%\JK\K;VQT7K^5>JS6T5PNV=%<=<,*KIHUA%)YD=I$
MK>H%<]6CSRN9RA=W.+TO0+[62LDX:WM<Y)/#-7=V=E#8VZ0VZ!$48X'6ID4*
M,*,#TIU:0IJ!25AN#VIU%%:%!1110 4444 %%%%, HHHH **** "BBB@ HHH
MH **** "BBBD 4444 )12T4[B$JGJM^NG:?)</U4<#U-7:P/&*,^BY4' < X
M[9- RC:Z/=:V#=ZE<2(C\I&#T%6)?"83YK*ZDBD'3!*@_7%;5@Z2V$+18V%!
MC%6J U.535M3TEO*U.%IX0,>:JTGAUVFUFYGMH]L$G+>E=/,T0CS-MV=]U9,
MGB+3+5BD1WD=1$M S:48Z\TM8UMXFL9Y0A+Q$]-XQFM=6W $'([$=Z0AU%%%
M !1110 4444 )12XHHL@"BBB@ HHHH **** "BBB@ HHHI@%%%% !1110 44
M44 %%%% !1110 4444@"BBB@ HHHH *AN[:.[M7@F&4<8-39I.O2@#E4MM8T
M-BEJHNK?/RKGI3_MWB&\^6&T%J?4X(KICQUXH9E098@#U)H YI/#=W>NLFJW
M;-C^$'=_.M:UT.PM/]7 K-_><9-++K5A#UN4/LIS51_%%D.(TD?G'"D4P+&H
MZ)97L+*T2JV/E8#&#6?X7NI1YVGW!+-;]#^E8FH_$=1-):Z;82/,AQF0':/Q
MIGA357MVNKS4&\Z2=^/+((4=3TJK:%<FEV>@YHK'C\26,G#;T/NAJ[!JEE<'
M$5S&3Z;N:FQ);HH!S12 **** "BBB@ HHHH **** "BBB@ HHHH ****8!11
M10 4444 %%%% !1110 4444 %%%%( HHHH ***KW=W#9Q&2=PH]^] $YQWK/
MO=9M++*O)O?LBU@WVMW-]N2VS#">_P#$:H(@7W8]VZF@#4N?$%W. +9! I[G
MDUFRM+.V^XEDD/H3@4UI G!X/H.<U-;V5Y=<V]NV/5^E,"%8U'0 ?04X<-ZY
MXK5B\-3R*#<7(4^B<5<7PS:*/G>5C[N:+AJUH>8ZI>R3:A);2VBQ1*<"0=7-
M:/AFWBMK:0QW1F9F^8-_#3/%%C?6NJ2/=(+>PC^X\;;F/X5L^$++PU<0M'9;
MUGD^9UE8AR?7%)U(_#?4[73J.ES6T)3SU&:1D3TY_(UOR>&+=L^7-*K?[U5)
M?#MY$N89DF'HPP:9PK:Y0@N+FUYMIV4_W7.16I;>)98U O(=V.KJ:R9X9[0_
MZ5 T?^UU%-# C*D'^M SL[/4;:]4&"0'_9/!JU7 8VMOC8QN#]Y:VK#Q#)$R
MPZBN1VE'2@#I:*9'*LJ;HV##U!I]( HHHH **** "BBB@ HHHH ****8!111
M0 4444 %%%% !1110 4444 %%%%( HHJAJNIIIUMN/S2-PB^II@)J>JQ:='E
MCND;[J"N5GGFO+@RW+;F_A0]!37>2:9IYVW2/Z]AZ4UF*[452S,?E4#K0 I9
M44EN!Z^E6K+3+K4"#&ODQ=W?J?I6GI>@?,MQ?C<_4)V%;RJ N , =!0!GV6B
M6EG@[/,?N[\UHA0%P!@>U+BC-(!M<YXPUYM&L56WYN9SM3VKH^U<#\0%W:II
MV_E22,?@:QK2:IZ'7@Z:J5HIG.K:7.H,9+R9Y6S_ !'I4-Q;2Z;,ES;,4DC.
M0174V%LIA'':LO7T"0MQ7E--QYCZ.-:+FX6T/0]'O/M^DV]R?^6B"KU97AV+
MR/#UF@XQ%Q^)S6IFO9B_=1\K424W81T5QAU##N"*R+[P_;SYDM3Y,G;'2M<G
MGBD/-40<7<6UQ82;;M,#_GH!P:C(SU'';/>NUFCCFC*3*'4\8(KF=1T:2Q!F
MLP7@_B3J5^E $-AJ,VF2#R\R0_Q1YZ>XKK+2\AO(!+ VX'MZ5Q2LK#Y>AZ^U
M2V=Y+IMQYL7*$_.G;ZTQ'<45!:74=Y;K-"0485/2 **** "BBB@ HHHH ***
M*8!1110 4444 %%%% !1110 4444 %&:*0]1FD!#=W*6EL\TG11G'K7&3W$M
M[=M/,<[ON#T%7]>O?M=X+=&_=1'YL=S68Q"J<\ 4P$8GC;\[DX4#O73:-HPM
M$$]Q\\[<\]%^E5= TS)^VW"_-C$2^@]:Z.@!,4M(31FD M)110 A/%<3X]0&
MXT]S_"Q_D:[6N+\>MBXT]?5S_(UC7_AL[L O]H0[3N;=<^E8GB0?N2/4_P!:
MW-/_ ./<?2L3Q+_J_P 1_.O/E90/5I?Q6>@Z:NW2[7VB7^56,U6L75=)MF)
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MD0N+.2,]UX^M<U&3Y?/4#'XYKJ,\USDZ>5?S1CINW+^-49EO1[C[-K2 G"S
MJ?<UV%<$'\J:*7ND@/\ 3^M=U&V]%;U&:0#Z*!THH **** "BBBF 4444 %%
M%% !1110 4444 %%%% &-XF8C2R@_B<#]:YP#! ].*W_ !0<6L ]9/Z5@#I]
M* -WPN@%G-)W:0C/TK<S6-X9&W2OJYK7S2&*33<T4E "YH-)030 &DHS24 +
MFL;Q5=-:Z#*4ZR86M<FLW7+6.\T>>.7@!=P/H16=7^&S6C;VJOW.,L1MAP>M
M1K<&TUFVN$ZAP/SX_K3;&7]UST Q4UA"EYX@MXI3A0<X^@S7BPOS(^DGRI2;
M['H"ME 1W&11FDS@<?2FDU[JO9'R[U8[--8TTFFDTQ"DTA-(332<4 .)II:F
MEJ:33 5F]*Q=2&-4R.Z"M?/-9.J?\?<)]0:!%23_ %9]N:[;3V+Z?;N><H*X
MN3_5O_NFNQT@YTBW]D%("[1110 4444 %%%%, HHHH **** "BBB@ HHHH *
M*** ,+Q0O^APL>TE<^?NFNE\3(6TEF'\+J?U%<VO(4^O- &_X;;.F./[LA%:
M]8?AJ3]Q<1#^%]WYUMYZ>E(849QS^0/>DYK)N;A]0N7L[9RD4?\ KY1W]@:3
M=AHGN-7B20Q0*UQ,.J1CI^-1&YU=_FCM[=%_NR.01^0JQ;VT=K&$B7:!^M2X
MKGE4=QV*/VC5UY>WMF ZA)#D_I3X=6C=A'<(UM*W&R0<'Z&K?/K4<]O#<QF.
M9 ZGUY(_&FJ@$V??/O534X7N=,N(8_ONAVU7@DET^Z%M</OADXBD/4'T-7]V
M.V/6M?CC8%+DDI'ER3-:GR)@5=>"#Q6AX?@FO=>CFC!V0DEF(]J[*\TFQOVW
M75NCGUQBIK>WAM(Q';(L:CL!UKBAA+3N>M4Q\9TW&VI8)ZX[4S-(33<UZ"5E
M8\?WK:CB:;FD+4PM3 <6IA-(332:0#B::32$TTF@0[.*R=3.;N$?W0:TB>OO
M65=OYFI'@X"#!]Z U(I3^[;_ '379Z2N-(M_]P5QDG^J_'%=M8IY>GPJ>R"F
MP+-%%%( HHHH ****8!1110 4444 %%%% !1110 4444 5-2C$VG3IC/[MB/
MJ!7%QG,2^PQ7?-SP>AKA[B+[-?3P'^%LCZ&@"YH4ODZL\6<"5>*Z4GM7%+(8
M+B&X'6-@3_*NR259(@X_B /% %?4;@P6,K*?G/RK[FH;.*.SLT5R S?,V3U)
MY-4O$R//9P6\3^6Q?<&SCE>:R(;\WEO-?WV#Y8\F*,'[S=S6,]2EY'6"5&;:
M'5F] >M-DN(HG"RR*C-T#'%<4T4UKH<Z.WDWUH1."3]\>E8S7<NKZ-+J%RJR
M7NHMY-K$#G8.F?;GFL&TF=U'#.I'FOI^IZ>DT<C$(ZL1U /2D^TPB389%#>A
M-<)-<2Z3X=6ZC!2]L& F3@;QCK[U4 EO--MSQ-J>J/YHPV1$G7\.*3>MA1PK
M<7*YW]Y%%?6<D2.I<<J0>A]:98W1NK*.1N6^ZWU%<])>&QL(+RV&V7!AF0G^
M+UK2T")[>TEBE?>RR$DYSR:Z('&]K&MFD)IN< 4TM6I(I:FEJ0FFDT .S32:
M3/%-)H 7=32::3BFEJ8AV<TTMSCO4-Q.L-N\L@+*@S@5C0WNI:L-VG+';0]G
M<;B:0G))FAJ]])I^ES744?F-&,[36?8W/VV'[6.!*,@>E1W\^HPV$\-[;BX2
M2-E$B?3TJAX3N4FT=;?.'A)0J3SUK/FM*QU147AW+JF;T2>;=P1?WW''ZUW"
MC" #L,5R&E&)=1:ZN76*.%,[G. ":U=,\3V6K:E+96+-(8QDRA3M/X]*TDTF
M8*$FKVT-S=2YK-U'6[+2F1;N0AY#\J*I8G\!5>3Q1ID:0/YS-]HSY:I&2>.O
M %.Q%T;6:,UCGQ'IPT]+M92T<C[%54)8MZ8ZTEQXFTVT\O[1(ZF10P_=M\H]
M3QQ18.9&SFBFQR++&KH=RL,@TZ@84444 %%%% !1110 4444 %%%% "&N;\2
MVOESQ7:#AOD?_/XUTN*JZA:+>V<D+_Q#@^AH XQAD$'D&MK0KOS+5K:0_O(>
M,^H-8BJZ,T4PVNAVFGQ3M9W*W"=CAAZB@#;UR(3V\3E<A906(]*G33K--LB0
MJ .1Z9]:>XBO;%E!!CE7 /H:K:;<D(]I<<3PG:1_>';'X5C436I2>FA+>:=:
MWJ_OX@[8YYZ^WTK!TLV$NL?9K73U6X@)\P \18Z$?6NI;T!P>?F]*R+70DM=
M1%TDS&X;/FDG_6#L#]*YFKLZJ4U&#3+5]IMK=)(\EN)6(R5_O'WK(T&2RFU"
M1;.R$3P K*Y_Y9GT%=%(K/&P5]I(QN]#63I^CP:5>&6*8J\B_O5<_?;UIM)N
MX0E%0<;EZ33K-][/"I'WB#6?I6TPS21Y"RREAGZU9U6Z/DK;6[J9ICA<'[H]
M:(HOL\*1(I 1<9SUK>%SF9(6S32:3..F::2?>MB12::3368+U;'UJ"6\MX1^
M^F1/JU $Y:FEN]9-SXETVVSFX$A'9!FLV3Q+>7;;=+T]V!Z._ I@=#<W45M&
M)+APBGN:KP:G:7,NR"<.?:L!]&U;58R=4N0JXXC4UJZ3I,&DVP6, RG[S8Y%
M C1D421M&XRK@BLC0[Z.RWZ?<'RY$8A=W\0K4+^]<WKVK0";[''9-=71&%('
M"_C42=API>TE8ZV22)(V>5D" =SP*\T$JGQ#J%MI,+W$LCAXFC. O^35T:#J
MUQ;1F_N_,13G[*#@8],T^WNK;3?%-C)%;&S0QF)T/3.?7\:YYN4FCUL/"E1<
MH2]YM7\B>WT/45N$E\1-+<V[??@A.,'WKT#0KG2&MQ%I0BC"\&,##"JH9)%)
M5E89ZBLG6+...W:]MP4FA&\,O'3M6\8I:GF5*]2;LWH:>IP7%AXH74Q:/>P/
M!Y15!DQGCG\<52>2Z@UJRU"?2S'"$D'E1IDKG."1ZFNKL+@7MA#-E6\Q03BK
M0 Q6ES&QP4FE2S6+7-[ITNV6Z,BQQ.5:+@X/'UILAU 6-MI]Y9RB-P?.GV;B
M8]QPA/KC KO\#&,<4;1G.!3N+E(K5%CMD6-=J!0%!["IJ,8Z44BPHHHH ***
M* "BBB@ HHHH **** "D-+12 YKQ#8&.07\(RO20#^=8^0R\\YKN98UEA9'&
M588(KCK^Q?3+K8P)A8_(U,!VEW_V23[/,3Y3GY&/8UJ75K]H*2P2".>/[K^O
MUK 90R[3_P#JJ]I^HF)OLUVV5_@E_I2W&G8OQ:J(L1:@A@?/#X^4U8N MTFZ
MVG02CD%6!S3'"2KAU##'<9S5-M-M6SM5HO=&Q63IW'<F@UJ'[0;6_*V\^?NL
M<!OI3+S48)MT5K%]JE)/(SM7ZFJLVB6,Z;9T:3W9N1^-9QLM4T=3_9<BW-MG
M_4-P5_'O3C30719'A^)B99)Y4F;JRN?E]A43Z)> _N=7F [ X-1Q^*X4;9J5
MO):2#[V5R*T(=7L+E<Q7<9!Z9.*TV$V9S:1K&/EUAB/]T?X5$=&UAOO:RX^@
M'^%;JW$3?<E4_1J1Y%"EBPP.O-,1SY\-W+_\?&KS/]#3T\(V(.Z:6:7V9R:V
M(KJ";_4RJ_K@]*4MZ>M %*#1M.M?]5:QY]2,U<4*@PJA1Z 8I'<("7. .I/:
MH8KJ*X4F%PV.N.U ;$Q..E,+?_7]Z:6S_.HWD"KDG ]:-G8!SN%4EC@"J4:K
M-,;@H!_=XY-+\UU)EN(AT']ZIC@#T &30QJ32LA&?8I)_ >IJ#Q/HRV_A>*_
MFB\R:.=9&SV6MS0M--Y.+R=?W2?ZL'N?6M^\L(;^U>VN4WQ.,,/6HDKHTHS]
MG-29S7_".N(%N]#NF42+N$3G<I_.FIH&L:A^[U*6."'^)8CDL*ZNWMDM;=(8
M1M1%VK["I=OYTTK(RDDWH5=-L(M.L([:#)2,8!/4U; Q28I13"P4444 %%%%
M, HHHH **** "BBB@ HHHH **** "BBBD &JM[9Q7UJT,PRI[XY7W%6J#0!P
MUW:S:=/Y-QT)_=OV(^M1.@="K@<?I7;7EG#>P&*= 1V/<5R5]IT^FN=^9(/X
M9 .GUH 9:W\EIA)B9(NQ')%:T<J31[XV!'UZ5AJ0W3G/6D4-"V^!C&?0\BF!
MO$\=?QII;'W<CW%9T>J8P+I-A[..AJT)DD7=&P/XT $\,-PI%Q&L@;^\H-9-
MQX7TR8[A#Y9]5.*UB::6H P&\)0CF*]N4'IO-1-X6?:0-1N",="YYKHBU,+4
M <]IGA?[+*)KFXD)!XC5N#]:Z'.._':FEJJW5];V;*+F41[^@:C1(J,92=HF
M)->7/VZ:"XD/ER'81Z9Z&F:7.;.^,9/RN=IS^E2ZR()&CGB=#N^4E6_(UG.S
M2*LF,;>&/H?6DI)H<H2BU&1L:_JKZ;:H+8;KB5@B+WZU8A2>>*,W?RMMRZBL
M'0D;5]8>^G^:*W_=Q@],],UU!< '+9YZ8Y-9T[M\S.C$1C"*CUZAP%(^ZJU=
MTO2WU.0-("MLIST^]4NFZ))>%9;T&.$<J@ZO[UU$4:11A8P%4#  [5J<@11K
M%&$C4*J\  =*?112 **** "BBB@ HHHH ****8!1110 4444 %%%% !1110
M4444 %%%%( HHHH ,<TQT61"KJ&!Z@]Z?28H YV_\.$;I-/;;W\H]/PK$??#
M)Y<\9B<=F']:[W%0W%I!<H5GB60'U% '$]>WXGO4?D*'W1Y1O53BM^X\,@$M
M93%1_<?D?XUF3:=?6N3+;%E'\2<_I3 KB2Z7[LH<>C#%+]LN!]Z$'Z&D+ ?Z
MQ64_[0(I!(C='!^E "_;I.\#4TWDA^[ <^YI^<]#2%@.I_.@!GFW#=%5?J:J
M7>EQ:C&%U +,!T&W&*M^='G[ZT_YF/[N-WSZ+0-.2U3L8$OA"R9?]&DE@8C
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M8!1110 4444 %%%% !1110 4444 %%%%( HHHH **** "BBB@!"*-N?I2T4
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M<$&F6]M%:Q>5;H$4=A4U% !1112 **** "BBB@ HHHH ****8!1110 4444
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>allo-20191231_g15.jpg
<TEXT>
begin 644 allo-20191231_g15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M.BD!F?\ "%:/_P! G3/_  %3_"C_ (0K1_\ H$Z9_P" J?X5IUSOQ<^*NA?
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MW_X0K1_^@3IG_@*G^%'_  A6C_\ 0)TS_P !4_PK3HI 9G_"%:/_ - G3/\
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M_P !4_PK3HH S/\ A"M'_P"@3IG_ ("I_A1_PA6C_P#0)TS_ ,!4_P *TZ*
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M>-/B>+G28X/#MW#!K>AW=S8>25FL_+GU"SCD:XN);.WD92(9DG$8D^;SNP^
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M>H TZ*S/LNL_\_\ IG_@ _\ \>H^RZS_ ,_^F?\ @ __ ,>H TZ*S/LNL_\
M/_IG_@ __P >H^RZS_S_ .F?^ #_ /QZ@#3HK,^RZS_S_P"F?^ #_P#QZC[+
MK/\ S_Z9_P" #_\ QZ@#3HK,^RZS_P _^F?^ #__ !ZC[+K/_/\ Z9_X /\
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M/LNL_P#/_IG_ ( /_P#'J -.BLS[+K/_ #_Z9_X /_\ 'J/LNL_\_P#IG_@
M_P#\>H TZ*S/LNL_\_\ IG_@ _\ \>H^RZS_ ,_^F?\ @ __ ,>H TZ*S/LN
ML_\ /_IG_@ __P >H^RZS_S_ .F?^ #_ /QZ@#3HK,^RZS_S_P"F?^ #_P#Q
MZC[+K/\ S_Z9_P" #_\ QZ@#3HK,^RZS_P _^F?^ #__ !ZC[+K/_/\ Z9_X
M /\ _'J -.BLS[+K/_/_ *9_X /_ /'J/LNL_P#/_IG_ ( /_P#'J -.BLS[
M+K/_ #_Z9_X /_\ 'J/LNL_\_P#IG_@ _P#\>H TZ*S/LNL_\_\ IG_@ _\
M\>H^RZS_ ,_^F?\ @ __ ,>H TZ*S/LNL_\ /_IG_@ __P >H^RZS_S_ .F?
M^ #_ /QZ@#3HK,^RZS_S_P"F?^ #_P#QZC[+K/\ S_Z9_P" #_\ QZ@#3HK,
M^RZS_P _^F?^ #__ !ZC[+K/_/\ Z9_X /\ _'J -.BLS[+K/_/_ *9_X /_
M /'J/LNL_P#/_IG_ ( /_P#'J -.BLS[+K/_ #_Z9_X /_\ 'J/LNL_\_P#I
MG_@ _P#\>H TZ*S/LNL_\_\ IG_@ _\ \>J6R@U*.X4W%U8RP\Y6.T:-C^)D
M;^5 %ZO(/C__ ,CE:_\ 7DO_ *')7K]>0?'_ /Y'*U_Z\E_]#DH ],\%?\B;
MI/\ UY0_^@"M.LSP5_R)ND_]>4/_ * *TZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ#4M4MM&LI+F\
MN(+6WB&7EFD$:(/4D\"A)MV0$]%>4>.?VZ?@[\."ZZM\2/",<D9P\-O?I=S(
M?>.'>P_$5XYXU_X+8_!/PT[1Z7-XH\42'Y8QIVE&-7;M_P ?#1'GZ$^U>OA<
M@S+$?P:$VN_*[??L<-;,\)2_B5(KYJ_W'UU17Q&?^"I7Q,^)'R_#[]G7QEJ4
M#\QWU_YR0D>X6'9_Y%[?D?\ "3?MP?%@XM]#^'_PXADRJ2RM%,Z#LS O<G(_
MW!]*[O\ 57%0_P!YG3I?XJD;_<FW^!S_ -M49?P8RGZ1?YNR_$^W**^(S_P3
MX_:$^* W>./VCM5L%D&9;;08IEB?_9^1K=<?5#].]#_\$<+SPY_I?A7XY?$;
M0=9?YI;PR,_FMZXCDB8?BYH_LC+(^[4QT;_W83:^^R_!,/KV+>L,.[><HI_=
M=_BT?;E%?$?_  SI^V+\)3GPY\7O#?C*SC/_ ![ZQ"//E Z<R0N1[_OA^/6D
M7]KG]K/X38_X2[X$:?XHMX^3)X?F9I95'M#)<<_\ 'TH_P!6W4_W7$4JG9<_
M*_NFHA_:RC_&I3C_ -NW7WQN?;M%?%.F?\%L/"_AZ]CL_'OPY^('@J\DX*R6
MRS(GUWF)\?1#]*]4\!_\%2O@3\0!&L'C[3]-F<<Q:I;S6.SV+R((_P F(KGQ
M'#.:T5S3H2MW2YE]\;HTI9Q@JCM&HK]F[/[G8^@J*P_!OQ-\-_$:V\[P]X@T
M/7H=N_?IU]%=+M]<HQ&/>MRO$G"4'RS5GYGH1DI*\0HHHJ2@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KR#X_P#_ ".5K_UY+_Z')7K]>0?'_P#Y'*U_Z\E_]#DH ],\%?\
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M8];RB]XMK_P%M:>3MIY#J*S/M>L_\^&F?^![_P#QFC[7K/\ SX:9_P"![_\
MQF@9IT5F?:]9_P"?#3/_  /?_P",T?:]9_Y\-,_\#W_^,T :=%9GVO6?^?#3
M/_ ]_P#XS1]KUG_GPTS_ ,#W_P#C- &G169]KUG_ )\-,_\  ]__ (S1]KUG
M_GPTS_P/?_XS0!IT5F?:]9_Y\-,_\#W_ /C-'VO6?^?#3/\ P/?_ .,T :=%
M9GVO6?\ GPTS_P #W_\ C-'VO6?^?#3/_ ]__C- &G169]KUG_GPTS_P/?\
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M&)$<>A!X->5>/?V"_@U\2_,;5OAOX5:2;[\MI9BQF?W+P;&S[YS7I/VO6?\
MGPTS_P #W_\ C-'VO6?^?#3/_ ]__C-=&'QE>@^:A-Q?DVOR,JE"G45JD4_5
M7/E'QG_P1)^#VN7!N-#N/%WA.Y5MT1L-2\U(S_VV5WQ]'!]ZP_\ AVW\;?A<
M=WP__:,\1&%3^ZLM929H8P.G625#[XB%?97VO6?^?#3/_ ]__C-'VO6?^?#3
M/_ ]_P#XS7MPXLS1+EJ5.==IJ,__ $I-GG2R3!WO"'*_[K<?R:/C4:O^W%\(
MC^^T[X?_ !,AC/SO&88791UP UJ<GM\I/L>E'_#TOXF?#(;?B-^SQXPTN&/F
M6_T_S7@P.N T6SC_ *ZU]E?:]9_Y\-,_\#W_ /C-'VO6?^?#3/\ P/?_ .,U
M7]O86I_O6#IO_#S0?_DKM^ ?V;6A_!KR7K:2_%7_ !/ESP)_P6I^"/BQD34K
MSQ'X7D;AAJ6E,X0^F;<R_G^>*]I\!_MG_"?XF;%T7XB>$;N:096!]2C@N"/^
MN4A5_P!*T_'7P<T7XH(R^)/ G@C7O,&"=01+EOS>W)&/4=*\5\>?\$H?A!X\
M\Q_^%>Z7HUQ)_P MM+UVZMMOTCV&+_QRGS9#6WC5I/R<9K\5%_B'+F4-G"?J
MG%_A='U%!.ES"LD;K)'( RLIRK ]"#5.Z\3Z;8W#0S:A8PRIPR/.JLOU!-?$
M<W_!"?X<22LRZEXTC5B2%77[;"^PSIY/YDU<M/\ @AU\,;:W5';Q1<,O623Q
M#&&;Z[;(#\A2^H9*O^8N;_[A?_;A]9S#_GQ'_P #_P#M3Z\F^+_A.VF:.3Q1
MX=CDC8JRMJ4(92.H(W=:RI?VF?AO"&+_ ! \$($R6+:[:C;CU^>OFN#_ ((L
M_">*%5;1=4D90 7;Q++N;W.+<#\@*U8O^"/7P;CV[O! DVXSN\4WWS?7"C]*
M7U?(EO7JOTIQ_68>US)[4X+_ +>?_P B>U7'[:'P?MH6D;XJ?#DJ@R0GB.S9
MOP D)/T%9EY^W]\%+&V:5_B?X-95QD1ZBDC=<<*I)/X"O/(/^"3GP3MYED7X
M7:260A@&\5:JR_B"V#]#6I:?\$RO@]97"R)\*?"S,O02:O>2+^*LI!_$4<O#
MZ^U6?_;L%_[<PYLT[4_OE_DC;OO^"EOP)TZ'S)/B5H++G&(A+*WY*A/XUEZA
M_P %7/V?],16D^(EJP8X'E:7?3'\0L)Q^-7;'_@GS\*=.G\R/X1^ F;&,2RR
M2K^31$?I6II_[%'PSTV1FC^#OPN8L,'S;**8?DUN0/PHYN'UTK/YP7Z,+9IW
MI_=)_JCB]0_X+!_L_697R_&EU=[LY,6B7PV_7?"OZ9K+O_\ @M%\";.8+'K&
MO7:E<[XM'F"CV^;:<_ACFO7-/_9:\"Z2&^R_"7X6VOF8W>5IMNF['3.+7WK4
ML/@CX?TJ)H[7X>^ ;:-CN*Q6\: GUP+:CV^0K:E5?K.*_* >SS-[S@O^W7_\
MD?/=Y_P7!^"EK<%(X_&5PH_Y:1Z6@4_]]2@_I4^B_P#!;7X'ZI<;)Y_%6FKD
M#?<Z5N7O_P \W<\?3O7TC9>"(=-MQ%;^%?"MO$#D)&P51^ @JOK/PUL?$=OY
M.H>#?!M_%@C9<!95YZ\-;GK@?E1]<R-Z?5JGK[17_P#2+![#,=_:Q_\  '_\
MD>7>'O\ @JE\ _$JKY/Q#L;=F'*W=C=VVTXS@F2(#\B1GUKO/#W[87PG\5G;
MI_Q*\"W,A_Y9C7+99.P^X7#=P,X[USWB+]B+X:>*2S7GPA^&NZ0Y9X+=;=F.
M<Y+1P*<D]^]<'XA_X)-?!GQ -W_"M]-L9/[]IXDU"/U_AP5[^F>!1;()]:T?
M_ )?_(A_PIQ_Y]R_\"7^9]+:)XHTWQ-#YFFZA8ZA'C.ZVG65<9QU4GN"*O5\
M0ZU_P1!^'%[-YVG3>)]%G4[HVMO$*L$;'!_>6;-UYX8'W%41_P $CO&WA?\
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M7,SY8 ]U7"^PKU&BBOGL1BJV(J.K7DY2?5MM_>SU:5&%*/)322[+0****P-
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MB@#3HK,_X2VU_P">.I_^"VX_^(H_X2VU_P">.I_^"VX_^(H TZ*S/^$MM?\
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M=I))99YF>6::21W=Y97:21W9F9F8D]%113E)MW8)):(****0!1110 5E^(/
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MI6ZS6\T-Q$W1XW#*?Q%35\^WO_!.[PW9W#7&@^(O%&A7!Z-'<*ZKZ=%5N/\
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M* "BBB@ KR#X_P#_ ".5K_UY+_Z')7K]>0?'_P#Y'*U_Z\E_]#DH ],\%?\
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M/_T%M,_\"D_QH_X371_^@MIG_@4G^- &G169_P )KH__ $%M,_\  I/\:/\
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M^@MIG_@4G^- &G169_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C0!IT5F?\
M":Z/_P!!;3/_  *3_&C_ (371_\ H+:9_P"!2?XT :=%9G_":Z/_ -!;3/\
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M:*-FCD0LD;$HO>4VK?.S79IJZ:?5-:IK1K5!?IV;7S3LUZIZ,****0!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0?'__ )'*U_Z\
ME_\ 0Y*]?KR#X_\ _(Y6O_7DO_H<E 'IG@K_ )$W2?\ KRA_] %:=9G@K_D3
M=)_Z\H?_ $ 5IT ?,/[;O[/'Q0_:"^,WPRC\-V?@NW\+^&=;MM=;Q+<:I<VN
MM^&9H94,OV:V2)DN3/;B6WR9H5"7$JR)+&S*_F]S_P $MO$WC);SPQJTW@G0
M_#/A6/Q,/"&OZ3+--K%^=9N%N$6_M6@CBB6U9(@Q2><W1@B<^1@H?N:BI4;*
MWK_Y,DOP25O36X/5W]/POIZ.[NMNUCY]^%?P.^(5Q-XPUKQWI7@E=<^*MQ%I
M_B.RT7Q#=2V>@Z5!826\7V2:2R1[N=Y69V62.W55N" [^0#-YCIG[!GQ0U71
MM-U77+_P/_PF'PMT_1M(\"K:7]RUCK46EW0N#<:DS6P:U>]5(XGBA2X6VPSH
M\Y(0?:%%4M)^TCHTTT^SC=1?JN:6]T^9WOI8E%2A[.6JU37=-IM>CM'S]U:[
MW\S_ &5OA'K7PG\!:I+XGDTQO%?B[6[SQ)K46F3//8V=Q<N"+>"22.-Y(XHD
MBC$C1QM(4+E(]^Q?2I8Q-$RMNVL"#M8J?P(Y'U%.HHZ)+1)))=DE9+Y))"ZM
MO=MM^;;NW\V[F9_PB5K_ ,]M3_\ !E<?_%T?\(E:_P#/;4__  97'_Q=:=%
MS,_X1*U_Y[:G_P"#*X_^+H_X1*U_Y[:G_P"#*X_^+K3HH S/^$2M?^>VI_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU/\ [XM__C5:=% &9_8-U_T&M3_[XM__ (U1_8-U_P!!K4_^^+?_ .-5IT4
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M8-U_T&M3_P"^+?\ ^-4?V#=?]!K4_P#OBW_^-5IT4 9G]@W7_0:U/_OBW_\
MC5']@W7_ $&M3_[XM_\ XU6G10!F?V#=?]!K4_\ OBW_ /C5']@W7_0:U/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y!\?_\
MD<K7_KR7_P!#DKU^O(/C_P#\CE:_]>2_^AR4 >F>"O\ D3=)_P"O*'_T 5IU
MF>"O^1-TG_KRA_\ 0!6G0!\*_MV>/_"'P!_;R^'OB"PUK2]2\=>,)]+T35/
M&J%9&\460O-EM>Z="R&4WEI)<22^9&7@"0NLJQMLN(.-_:,^+?P7_:P\7_$:
M'X0^,/">O>,_ ?@#6O!(\/>%=0M;C4-9MIKBTN]006UNQF$$"6AA20JL;S7L
MD:L6*[OT5GTRVNKVWN9+>"2XM=WDRM&&>'<,-M/5<C@XZU/4QNK/JN>S_P 2
MY5ZI)R376ZLXVUIVZ:7Y;_)W?S;2L^EM4WJOD?X&?&;PW\1_$?QF\0?#[QAX
M<D\,_$:XL](\"W]KJ<,=EX@UJ#12L_V!MVV9XTAA1O*SM-E*I ,+X^<]*\7Z
M!XDT'P'K?AVY@_X5_P#"CPWX+TOXHA) +?0KFPU59I+74!G"S6!$\]RC_-"C
M[Y/E<9_42BJC[E95H[IQDD]5>"DE?;1\\KK1Z1UT=\YQ4Z3HRV:DM-':3BW;
M?5<L4GLO>T=U;PO]@+5(_%'PT\7>(--N%N_"7BCQMK.L^&;F-]]O>:?/<;A<
MP'H89Y_M$R./ED2977*N#7N4I81-L56?!VACM!/;)P<?D:=11HHQC':*C%=[
M122;[MVNW97=]$/6\I/>3;^<FV[>6NGD9GVO6?\ GPTS_P #W_\ C-'VO6?^
M?#3/_ ]__C-:=% S,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^
MUZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\
M_&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^
M![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_
M ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/
MM>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__
M !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&
MF?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_
M\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM
M.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\
M@>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F
M?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#
M,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__
M ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![
M_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZ
MS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H
M^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#Q
MFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX
M:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS
M_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B
M@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^&F?^![__ !FM.B@#,^UZS_SX:9_X
M'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^UZS_ ,^&F?\ @>__ ,9H^UZS_P ^
M&F?^![__ !FM.B@#,^UZS_SX:9_X'O\ _&:/M>L_\^&F?^![_P#QFM.B@#,^
MUZS_ ,^&F?\ @>__ ,9J6RN-2DN%%Q:6,4/.6CNVD8?@8U_G5ZB@ KR#X_\
M_(Y6O_7DO_H<E>OUY!\?_P#D<K7_ *\E_P#0Y* /3/!7_(FZ3_UY0_\ H K3
MK,\%?\B;I/\ UY0_^@"M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4AF\L-M!!.!6C;^.=$N]5U>QBUC2Y+[P^L;ZI;I=QM+IJR(9$,ZYS&&0%@7
MRHR.*&TES/;_ "W^X%J[+^K["_V]=?\ 0%U/_ONW_P#CM']O77_0%U/_ +[M
M_P#X[69\)?C1X.^/O@J'Q)X$\6>&?&OAVYD>*'5=!U2#4K*5T;:ZK-"S(2K
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MOKII?4^#?A#XL^"^K_L;_M>:7;:E\+[KP+H_BOQ+_;%G%<6+Z38^;;1LWVA
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M4?W=-4UTC&/W1A%OUE[.'HE9;R;JI[\W+^]*7WRFTO\ MWVDEYWN]DD4444
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M *\E_P#0Y* /3/!7_(FZ3_UY0_\ H K3K,\%?\B;I/\ UY0_^@"M.@ HHHH
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MFC^\C&:VD^7YV3:?:UU>^]UR\PY>ZI]XI/U4IJ":>VK;MZ-2L?HY17Y]Q?\
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M4>:6FWWM\J7FVVDK76MVTBI1:3?^+[H).3^2:WL^R/N2BOS<A_X*B_'3PO\
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MZC.G[\>:/9/Y2OR_?:5O*+O;2Y6_=SY'_-**_P"W7:7I;2_2[5KZGTI1110
M5Y!\?_\ D<K7_KR7_P!#DKU^O(/C_P#\CE:_]>2_^AR4 >F>"O\ D3=)_P"O
M*'_T 5IUS?A'Q=I-KX4TN.35-/CDCM(E=&N4#*0@!!&>"*T?^$UT?_H+:9_X
M%)_C0!IT5F?\)KH__06TS_P*3_&C_A-='_Z"VF?^!2?XT :=%9G_  FNC_\
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MR>>M=!_PFNC_ /06TS_P*3_&C_A-='_Z"VF?^!2?XT7?]?+_ "7W+L#UU?\
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MM,_\"D_QIW=[_P!;W_/7UUW%96M_6UORT]-#D+S]DCX4ZA_PFGVCX8_#V?\
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?SXWZE;ZOXKMY+2XANHUM%4O"X=0=[G&1WY'YT ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>allo-20191231_g2.jpg
<TEXT>
begin 644 allo-20191231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" $&
M JP# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@#P^+XI:EI_P#P40USPS>Z
MTUOX:@^&EGK<-A-(J0+.-3O(KBY&>?EC$"N<X4%,XR,_,_[*/C+Q=^U]X0T^
MU\;?&#QMX('A7X6>&O%%M>:5J,&G3:C+?P74MQK-T[1D30QM"D:QM^X'ER%U
M;>-OVC\9?V:OA[^T1'IZ^//!/A?Q@NE,S6?]KZ;%=FVWXWA2ZG"OM7<O1MHR
M#@5!\4OV5/AG\;_['_X3#X?^#_$W]@)Y6G#4](@N?L<?RYB3<IQ&=JY3[IVK
MD' H ^-?C#_P4*UWPK\=_ NM:/XB\4^*?AK\.])T1O&6LZ3X9E.@^(?[8C1K
MB]NIT5DLQ96CV>H*FX?)=L#D8KDKKXS?%5_CS?WD.O?$K1[>^^-ESX3TWQ+J
M'B.R?P9:6T6HA/[.GT\*TZF:!)+6(E%#W,D6)D+H3^BH^$_A<>']?TG_ (1W
M1?[+\5-,^M6ALH_)U8RQ+#*9TQB7?$JQG<#E%"] !56?X&^#+KP1J'AJ7PKX
M?D\/ZK<&[O-->PB:UNIRZR>:\>-K2>8JON(SN4'.0#0,^;?@%\,/$EC^VK\7
MM)@^)_Q'U:W\"6&DW&AV&NZTU[IJSWUK>%S<1*$::,.D;!=X(V\$5Y^WQ(^*
MFK?!?P=INM>-_&VOJ_Q*\6:%XDU+P?%9V/B/48K.]OX[-;2W<D);1M%'YBQ;
MY$CC0NQC$SU]U:=X/TG2/$>I:Q:Z;8V^K:PL*7]Y% JSWBPAA$)' RX0,P7)
M. QQUKF?'?[,OP[^*'@U_#OB+P/X5UO0Y-1DU=K"]TR&:#[9)(\DEQM9<>:[
MR2%GZMYCY)W'(!X3\,?VB?&GQ>_X)_\ P7U2\O+K3?'WQ5FTG37O;5(EE"NY
MFN[I0H,88V-O<R@I\F2"ORXKB_\ @H=^W%XH^#'[2>AV_A-?&=UX=^$MC!XI
M\<PZ'H;ZE9WUM=3B%K2\E5"+80Z>E_>@DJ2\=L?NY!^SAX*T<2:0PTK3U;P^
M"-,Q;H/[.!C,1\GC]W^[)3Y<?*2.AQ4=O\/]!M9]<ECT;2UD\3N)-886J9U1
MA"L ,_'[S$*)'\V?E4+T&*!'SMX.^-7B#6O@W^U/JB^(KBZD\*:[JT?AVZ1T
M8:?;IH%A<PB$@8*B25Y%)SDOGD8K.^)OQA\37?[)/[.]O_PE]]X9E^*M[H6B
M^(O%4)B%Y9QW&F2W#&.1U,<4]U<0Q6RR%3M:[&T!]E>O6/[#OP;TSQ=#K]O\
M+? <&M01)!'?1Z);K.J+;BV5=P7.! !$!V0!>@Q3_"/[$?P=\ ^%M;T/1?A?
MX#TO1?$EO'::K86^B6Z6NHPQDF..6,+M=5))4$8!/&* /(OA;\:;K]F?]H3X
MB?#V^U[XA?%'PKH%CH=]9S)IUQXCUC0+R_:_66QN)+:-I6B$=K!<*\P+1BYP
MSE&B \(^*'[2GQ.^#5QXRU[4?%E\[>/I?$47A'4],\6VFLZ/H5K:ZM#;-))8
MK:*L$EK9ON\PSSJLT<B3*A8+7W]\)O@MX1^ _A8Z'X+\-:)X6TEIFN'M=,LT
MMHY)6P&D8*!N<@ %FR2 .>!65I?[+?PUT3Q1XGUNT\ ^#[?5O&D$EMKUTFD0
M>9K$4O\ K8YSM_>+(>75LASRV30,^3O$?Q ^)OPTUG5?"^B_$S5[_P ,^ /C
M#X4T"XO]6MX;_6-8LM2;1WETZ2[ 151'O9RS^6TI1XH]R@%F^[:XOP7^SGX!
M^'/@.S\+Z#X-\-:3X<T^^CU.WTVUTZ*.VBNXY5F2X" 8\U945P_W@R@YR!7:
M4""BBB@ HHHH **** "BBB@ HHHH **** "OAO\ ;8_;I\0?"+]L/36T63Q@
MW@/X11V,WCA=+T&:]TJ[74I-EQ]MNE0K;?V=8^7?C++N$RYR*^Y*PC\,/#9T
MKQ!8G0=':R\622RZW ;2,QZN\L2P2-<+C$I:)$C._.415Z "@#Y>M_CIXN?]
MA[]J[Q$?$5\=<\&:KXWAT*]RGFZ7':0RM:B/C&(B 5R#TYS76?M._$37I?!G
MP/\ #=OXKU#P?9?$_7K;1M<\26;QQWEO&=+NKI((97!6*:ZN((H%DP6'FL$Q
M(R$=]%^PY\&X?%=WKJ_"WP&NL:A%+!=7HT2W\ZY26$V\JNVW+!X28VSG<I(.
M14WAK]BSX0^#? ^N>&=*^&?@?3_#OB81+JVF0Z- MKJ(BR8O-CV[7V$Y7(^4
M\C!H&>0_!;XZ77[/_P <_B5\.]2UOQ]\3O#/AFXT1=+OH]+N/$&J:-<W\5R\
M]A=S6T;,T<2P03B6<;D2]17<CRZ\!O/VD?B=\.-%UJ[U[QA?#5/B?#=W>@:Y
MI/B^SUW1-%TT^)K&QFFCMEM4CM9+>TU"'RY#+<1EHY!(0PPWZ#?"OX/>%?@;
MX230?!OAW1?"^C)*T_V/3+1+:%I&QND(4#<[8&6.2<<FL+1?V3OA?X<O/%5Q
M8_#SP7:S>.8WB\0M'HUNO]M1R%C(EP-N)%<LS,K9#,S$@DDD ^49OB3\3? ?
MCO2_#>G_ !-U+5/"/@[XV:=X.N+C4+:&[U;7[2ZT^SNS:3W@VJ$@EN94)$?F
MOY<:LXVOOM67[=FOC_@HZSR2^,/^%1WFNM\+X=VA2KX?CU".,.NI"_V;&G?4
M_.TLQ[\;ECXSFOK3PA^SSX$\ >"])\.:)X/\-Z7H.@WHU+3K"VT^*.WLKH,7
M%PB@867<S-O'S98G.35P_!KPD? B^%_^$9T+_A&TN!=KIGV&/[()A<?:A+Y>
M-N\7 $V[&?,^?.[F@#I:***!!1110 4444 %%%% !1110 4444 %%%% !111
M0 5\[_\ !2OXWZM\+O@;I_AWPO>>)K#QA\2-7A\.Z9=^'--.I:OI<+!IKZ^M
M[8*QD>"SBG=?E(#F//!Y^B*S=0\':3JOB;3=:NM,L;C6-'CFAL+V6!6N+-)M
MGG+&Y&4#^6F[!&[8,]* /DO]BW]KWQ-^T7\;/AK'JUQJ&ERR?#G6X_%&A7$/
MV=K?7].U?3K*=Y(6 >)QNE94;!$=PN1R#74?#OX^^+]+^$/[47B".2X\4:Q\
M/?%&O+X=TZ9=^5M=*M;B"S54 8J96;@?,?,//2O4/B+^Q7\(?B[K$NH>*/AG
MX&U^_GFDN9+B^T6WFEDED2))'+,N2SK!"K'J1$F<[1B?3_V/OA5I/Q0C\;6O
MP[\&VWC"*59TUF+284OED6(0A_-"[MPB 3.<[0!TH ^:O#7C/6O@/=? /QEI
M_P 7/&7Q5/Q=F9->TN>:+4+?6;4Z1=7\NH:;:0QAK?R)(8@$MQL*3B-E:1HV
MKI/V@M1U?X]_%WX0P>!_&GQ>\"ZEXZN)+N\L6C.DQZ;HVF2"2]GFL;JW\T33
MO+;6J[P!B[60 [ &]\^''[+?PU^#WC34O$?A3P'X1\.:]JX9;S4-.TJ&VN)U
M=M[J7100K. S 8#,,G)YKK9?"VFS^*(-;?3[-M8M;62QAOC"IN(H)'C>2)7Q
MN",T4;%0<$QJ3T% 'Q9XT^(/Q@FN/VAO"B_$+39?$L?BSPMI7AV?[5;^'+;1
M[:_%HTMI:RRK.?.:)Y55W6622:0;$^Y&/=OV"_B#<^-O@WJEAJ3Z_)KO@_Q'
MJ7AW5WU76$UAFNK>;YO*O%AA$T.UU"DQ1LN"C*&1A7H7BSX'>#?'FE^(K+6O
M"OA_5K3Q<(EUN*[L(I5U7RE"Q>>&!\PH%4*6R5VC&,"M'X??#O0?A/X.L?#W
MAC1M-\/Z'IJ&.UL-/MEM[> $ECM10 ,L2Q/4DDG))- &S1110 4444 %%%%
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MGW_0\M\&?\%'?#NI_!35_%_B"S7PS?6&@1Z[!X=O;J*/4;PM8M>&"$EMLSE
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M-WRK\YRW'WN,<_@!1'&L2*JJJJHP !@ >E='MH_R_P!?<>5'+ZJ37M7KZ_\
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MOV@?B;X?\=^,_A;JGAS6++5+RUUZ-/)@D_?)'))$&WI]Y,E57# 'YJ /-?\
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M^*M+U/\ :>^%>M:'J5CJCWAN+.4VDZS#RB, G:3@?O9#S_=/H: :3T9\]_\
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M& 8,8]A(8 Y)SSFG9VN5RR2YK:'<4444B0HHHH **** "BBB@ HHHH ****
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M\US3X([(ZDVMS.UB@71&D9D.!-O-C> @@EC(K'[Q*V?$_@OXS>$])OK>QO\
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MY=XY_9Z\:?#Q'FN-*76+&/DW>D%I]H]6@($H_P" AP/6N@^//IOX9_';PO\
M%D-'H^I(U]&NZ6PN%,%W$/>-L,1_M#*^]=A7Y]QM;ZLL-Q%)O:W?=%/#(4DM
MW'=74AD8>Q!%>R?"']K[5/!CQ6'BYIM9T@85=32/-Y:#UF11^^0=W4!QW5N3
M0!]0455T76[/Q'I-O?Z?=07ME=H)89X7#QRJ>A!'!%6J "BBB@ HHHH ****
M "BBB@ HHHH ***\G^./[5&F_#*YFTC2(8]<\2*,20B3;;V&1P9W&<'N(URY
M_P!D'=0!Z=K>NV7AO3)K[4;RUL;.W&Z6>XE$<<8]2S$ 5XSXU_;AT6P9H?#.
MFWGB*0<"Y<_8[/\ !V!=_JB$'UKP'QCXJU?XE:PM]XBU";5KE&W0QLNRUM3_
M -,H1\J_[QRY[L:9X5\/:M\0-0>U\/Z7>ZW<1MLD:W4>1"?229B(U/L6W>U
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M;W%];K7OS,\7\4?L$?#SQIX6@T74[75;K3[>/7HEC-^ZDC6;K[7=MN7#!A,
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MO O#/A*X^(GB[2_#UN[QRZU<>1)*GWH(0"TT@]Q&&Q_M%: -'PK^P-#^T_\
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M 6Z@'@W4P5Y6_P" Q^4OMEZB_96^'B^/OBXEY<1^9IOA5$O7!^[)=/D0*?\
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MKG[#X:?".PDTCPE9Z]HK:E?7%OX@TO3YM72>6]:+3DL891$7W30FVB&5'RN
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MG".0.0&!HO[*>@^'],:VCU369O,FENI9)&BWRS2V$]E)(<( "RW,LF   Q
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MU@^.]873?!FL7!/^JL9V_'RVQ^M*UP/)=#_>>&['=_%:1Y_[X%?;'[/LK3?
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MS;;/2[66\G.[;\D:%VY^@KAO#OB'2?AOHL)\2:UI=CKVN#^U=2>XN%C\R63
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MM2GA ](I3Y\?_HQA_P !-<3^V'X0;PU\98]45<6WB:S5\]OM%OA''XQ-$?\
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MJ'Q)\76?A_2BR7NH9:2?;N6Q@!'F3M_NY 4'[SLH]<85*#J.TY/E[+3[WO\
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M%$4\&K2?V7"6U".=S).DA*_,LCG<Z]&;!.2 :[70="L_"VAV6F:=:PV6GZ=
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M^B6[37UU;V4:C)>XE6)1^+$"O*_&O[:/PY\(W#6__"1PZQJ&<"ST>-K^=CZ
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M":\EE(6*!2>-[.P7GI@D]*L_;[KQG;QYCFT_3Y$!E#';-.2.4&/NH.A;JW;
M.3\Z? ^&;XJ_'FWT2_NO.T'X;-)J26F[?!<:H_R@+CY66$,T@Z_-*N.*^L/!
MG@_6/B9XA.E^'[/[?>(0+B5B5M;$'^*:3!V^H09=NPQR)H5)5)2E]E:+U6[^
M_3Y>9MFN!HX/#T*,E^_DN>?]V,TG3A;:_+^\;WM4479Q90TS3+C4-0LM*TJQ
M:\U"\;R+*R@ 4R$#\E11RS'A0,GL#]=_L_? NW^"WAJ0321WNO:EMDU&\5<*
MQ'W8H\\B),D*#R22QY8TOP,_9^TSX+:?)*LG]I:]>H%O-1D3:S@<^7&O/EQ
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MKX^5:6D?R@XZDGHD:CEF/ 'J2 ?L#X#?!2U^"OA)K;S%O-7OV$VI7NW;]HD
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M(QY9V[L>?P %;==1X@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFZ'Y._#K]FC2_ GP]\-^*EO-9LWM-0&F:[)H&HRV5W%(5\[<IR4'G0F54^7
M-LP.>E?I9\%?V;OBC\*;3PW)X'^-EGXD\ R207)T[Q)X7MI;B:R<JS&*[M3
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M2CM=4U:[N-/N[J9[2V6[FN'BGM(_NQ3JDOEL,;2LTN"#@GV:@ HHHH ****
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ME?$'XL^&_A1;6TWB36K'1H;QS'"]T^Q9&&. ?7Y@,=R0*J+\>/!K>(K'2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSNM,O8OD%Q(!*LFZ+),<@41!N2#A2">0/HJBBJ **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *X7]I[Q9=^!OV=?&VK6+,E[8Z+=20.IPT
M;^6P##_=)S^%=U5'Q+X=L_%_AR_TG4(5N+#4[>2UN8CTDC=2K#\030!^4O[*
M'P[\4>./C3HL/A'3XM0N=+D6>\%R^RT2S.8IEG;!^22-I(\ %FW' ."1]0I_
MP1]T5;.Z5?'&L1S-(_V3;8Q&."/)V*X)+.0N 6#+D@G S7J?[%7[*-Y^RHWC
M*QN+RUU.SU:_AFTZ]7(N)+=(RJI,N,!U8MRI(;<3QD@>Z4K >)_L)_!GQ/\
M 'X6:QX7\3-#)]AURX?3I89-\4]LZ1.'0=5#2&0[3R&W=1@GVRBO/_%W[4?@
M/P+\3[/P=JOB"WM/$%[L"6YBD98R^-@>0*4C+;EP&8?>7^\N6!Z!17F_BO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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3[(HV"HI=F(')P1N9VR[%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>allo-20191231_g3.jpg
<TEXT>
begin 644 allo-20191231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S(T  "2D@ "
M S(T  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#VB"_P!,T9]K#4+4%;N//W\]:+0[ O;K7G,K_A;/BSH;U>/]GK2'XL^+<?\
M'Z@]?EK,U273+;Q7%#;VRFRM9!&^<_O/4FNK/AC2]+U$?:8$ECU*[46@+<"+
M!)(]1Q0U%"BZLW[LC'_X6SXL[WJ_]\T?\+8\6$X^V+_WS6Q+I^C77BB'38X[
M-X_,962(,'& ,=34UGX1TC4K73# J+=C>\T>[_61_P#UCCI2]TKEQ"^T8/\
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MHH *.]%% ",<#-?/_B[XD^)-+\8:C9VEVJ00R;4&W/85] -R*^5O'_\ R/\
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MBA7##(('3BF7/B35;Q;A;F[>1;D!90>X!R /3D"O7/\ A0^G_P#02F_(4?\
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M3P'!X+53SXL^WDKY_P!JP<[F_<[-HQCWSFC7N#Y$_A.FN/"\%SI-G8RW$O\
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M]>2?'?\ Y ^G?]=3_2M*7QHY<7_!9:^!/_(KWG_78?UKU*O+?@3_ ,BM>?\
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M7_<N_P#OU_\ 6H_MOXE_\\[O_OU_]:CV?F'UQ?RL^AMU&ZOGG^V_B7_<N_\
MOU_]:C^V_B7_ '+O_OU_]:CV?F'UQ?RL^AMU&ZOGG^V_B7_<N_\ OU_]:C^V
M_B7_ '+O_OU_]:CV?F'UQ?RL^AMU&ZOGG^V_B7_SSN_^_7_UJ/[;^)?]R[_[
M]?\ UJ/9>8?7%_*SZ&)XKR7X\?\ (&T\CM(W\A7)_P!M?$O/^KN_^_7_ -:L
MS6H?'.OPI%JMG<S(ARN8SQFKA3497;,,1B?:4G%19Z3\"N/#-X.WG#^M>I5Y
MM\%]-O=,\.W<6H6[P.TV0'&/6O2:QG\3.[#*U)(****@Z IA13U _*GT4!HQ
M@1>RC\J78/[H_*G44!H-VKZ#\J-J^@_*G44 -VKZ#\J-J^@_*G44 -VKZ#\J
M-J^@_*G44 -VKZ#\J-J^@_*G44 -VKZ#\J-J^@_*G44 -VKZ#\J-J^@_*G44
M -VKZ#\J-J^@_*G44 8/C)0/!^I\#_4'M7FWP3_Y%S4,\G[1U_ 5Z7XR_P"1
M.U/_ *X-7FGP3_Y%O4/^OG^@J)-IG=32>&F>E?YZ4GY444[LXNMQ?\]*/S_*
MDHSCGC\3BG=@+^?Y4?G^50O=01G;)*@/H#31=V_:>,_\"HU)YD3G&.#UHSZ<
M'-1?:8,9,J8^M0R:K9Q YF!QZ=J5FQ\T8F/XG\PRQKDA#QQ3O"^]!-&<E0>*
MAU;4EU!56V!(3DDBC1-8M[2W,,RNO).X+UK:SY3CYDJCU.HI*I1:M9S'"SJK
M?[1Q4_VNW_Y[1^_S5ERL[%*+6C)J*@.H6@X^T1Y[?-3TN(9#\DJ-ZX:E9A==
MR6DH&",@Y^AHH&%%%% !1110 5A^)/%EAX;M\7+&2X892!>IK6O+E+&QGNI/
MN0QLY_ 9KYTNM;GUS5KJ\EG EDEPF_IL]!56?*VC.<K'HJ?$+5KV3,5O%;KG
M(4GG%=!IGC%Y2%OXEQ_>6O+5N;=[Z";>5D0;2JG@UT6F7"ROD\9-33YI;JQR
MRF^AZS#-'<1++"VY2*?7*>&+YHKW[*Q^1QD?6NLQC\ZJ2L['7"3E&XE%%%2:
M6T"BBB@04444 %%%% !112%T7EG7'<ENE 70M%0?;;8=9H^3UW4[[3 .!.A_
M&G9BNNY+39,^2Y'4*<?E3'N[>,9>9 *I3Z[9Q%E#EVQT HL[DRG%1W.4F$PN
M6<D^8IR.:[F EK9"W7:,UQ<UPR7HGE0L-^X#';TKI8O$%G(@R6C. ,%>E:3B
MVCEHSC=W9IT5 M]:R*&$\>#_ +6*4WEJ.#-&/^!5G9G8Y+N38HZYSW.>E0)?
M6CYVW*$YQP:F#JPR'7'J&HLT%XM6'?YZ4?YZ4GUY]#12U'9"_P">E*OWQSC\
M*;2K]]?J*3N.-DSR_P"&//Q8\0Y'\5>U[5_NC\J\5^%__)6/$/U/]:]LH@]#
MHQ45&:2[#=J_W1^5&U?[H_*G459RV&[5_NC\J-J_W1^5.HH"PW:O]T?E1M7^
MZ/RIU% 6&[5_NC\J-J_W1^5.HH"PW:O]T?E1M7^Z/RIU% 6&[5_NC\J-J_W1
M^5.HH"PW:O\ ='Y4;5_NC\J=10%ANU?[H_*C:O\ ='Y4ZB@+#-@SPJ_E2%!_
M='Y5)10 U  >./PIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!A^,O\ D3M3_P"N#5YI\$_^1;U#_KY_H*]+\9?\B=J?_7!J
M\T^"?_(MZA_U\_T%9SW1WTO]VD>DT4453W.$*AN;2.Z4"0'CT-3447L&YGC0
M[,2$@/\ 3-0MX=M"28WD!/K6M0<GO].:KF(=-,Q!X?95(%UGZKT_6N6\0ZMI
M>AH\1O1=3_\ /*,=/J:SOB+\1&AEDT;19,$?+-,O4'N!7F<,K.S,Y+,>I)R3
M753B^IR58PMHCK/^$[ED.R*U" >K5/#XMD9@7M^.^#7%1C][CK^%:]D \D:=
M!N&<5UJ,>6YXLYR4K(]0T81ZF$D,ZPNW17[UN+X8W;BUUC<<X KD+;B-0."H
MX/I73:%KC1LMK=N2AX4D\BN";=]#UJ+BTE(TX_#EDNUGWL5'KUJ0:!9B?>2^
M,?=S6F.>3S[FD^G%8<S._P!G!;$-O:QVJE8L[?<U-112;N6E8**** "@\444
M 9WB.%Y_#&HQ0C+M;R;1ZG::^68B8I&7/(8@_P!:^MR P8,,AA@BO!/B)X N
M]$U:75-.@:6PG;<PC&?*/?BNFC)*Z9C5BV<U8S;2"2>*ZFQU.&TC$EQ($3]:
MX0WRV<)D?Z '@DU9TZ<7%O)?7@,BJ<*O:M:DE37-T.*46]$>A:?XZC35HA8V
MC3,O\1.!75IX\OB^9;- N>S_ /UJX.UT^/\ LF2YT_:L[)\A4\#VJWH<MS_9
M&W4$9)%R&+_Q&O,EBU.?NHNFI1CJSTJQ\803L%N(C$3W'-;\%Q%<IO@?>OM7
ME=G)GCM[5L6&H3Z?,'A<[>I4G@UUR@BHUVWJ>@456L+V.^M%EC//\8'8U:^G
M>L7H=L7S*Z$HHHH&%%%%(-A>Q![\50ETBVF8EMQ)]ZO4M,3BF9C:!9-'L(<>
MX:H'\.QC'ESLN#W'6MKMT'Y5G:WK=KX?TJ6_O6PD2DJ,_>/8"J4FW8R=*G:]
MC+U#2X+. W%]?K%$O5F'\A7G^M>-K2UNBM@AN@.DG0$5RGB#Q;?^)]0::YE=
M8<_)$#\H'TK-EP44GUKLI0_F.&O&*C>!UB^-;B89\A0.P+5KZ1X@^VS"%X6C
M+?>(.0*X&U(W?, 1VR*ZSPVOSR2$\]..*Z)J/*>7"I5<[7/1[714N[;]S>JR
M^N.E7(?#$2MF6=GX[5S%K=S6,HEMG*L.V>#7;Z5J4>I6H<?ZP?>'O7GRNCW*
M:@]'N0+X>L4C95$@)_BS4D&BVL"C:'W Y#%JT,?C2_R^E9\S.I02&@84 '.*
M6@#%%24%*OWU^HI*5?OK]12'U1YA\+_^2L>(?J?ZU[97B?PO_P"2L>(?J?ZU
M[91#8ZL9_$^2"BBBK.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/U->V40V.K&?Q/D@HHHJSC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS^)\D%%%%6<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_[X/^-'_"Z?%'_3K_WP?\:/8R'_ &A1/HRBOG/_ (73XH_Z=?\ O@_XT?\
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MX4OX7S]V;_OJO1/QJGJ@OO[/E_LORS=;?W?F?=S1SR#ZM1_E.&/P8\+J,D3
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M!=O_ -\5-X7_ .18T_\ ZX+_ "K5)]ZARE<UA3AR)M&)_P (9X?_ .@7;_\
M?%+_ ,(9X?\ ^@7;_P#?%;@HI<TC3V<.QA_\(9X?_P"@7;_]\4G_  AOA_\
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M0V4-VLBR03, KJ<@Y[T>^'+2Z6*W_"'>'_\ H%V__?%'_"'>'_\ H%VY_P"
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M\J%8)*I?0$\::#-;_:4FW@/Y8VI\X."?Z5+I7B2PU6]O;:WA:,V@5F=EP#D
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MKVFKJ?&<^#_@H7O11WHK,[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8Y1QDX)K*\2>%CX@U&TDEF:."!'5MAPQ+# K!'@&^:YMFGE@>../8P#$;?\
M:'')JK*Q#G-2V.SM=6TZ]A$EM-$R;R@Y .5.,?F*G^TVB1E_,B";L$Y'WO\
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MX (SC%<3<>"M2GTC[&%LH\.,[2>>#SG'7FG:=X$NK.6":6>)IH98F#@G)55
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MKQ;X"?ZW4_H*]IJJGQF&#_@H7O11WHK,[ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &2_ZMOI7R3XA_P"1HO\ _KY;^=?6TO\ JV^E?)/B'_D:+_\ Z^6_G6]$
M\K,=D?47AC_D5]._ZX+_ "K5K*\,?\BMIW_7!?Y5J^E8O=GI4_A0M#<THHJ2
MR-88T=F1%5F^\0.M/I:2F%CD_%_B&ZTB:*UMO)C\^)W\V;/! X ]ZR;/QS<0
M6<44T:27 **%)^9P58DC_OD5UNJ7VF6LD:ZH\*LY^17&23[51CUSP\SS2-)"
MAMG\MG9._M5K8YY7YMRGX8\57>O?:_,BB3RURA0YVGT(]:P;'QQJ<%BOVEK>
M25 7+-D&3YL;%'K767?B3P]I*&1IXDW%<B)>3N(Q^>13(M:\/FW2:<P0+O(7
M<O)/'/ZT?(5I?S&=XJUF[M9K)X-R+)#N=.G.1Q6>OC76&5/(MK;86*J7SG(
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M>,,??U+/_ J^I/LL'_/&/_O@4?98/^>,?_? H]LNP?49?SGRW]L\8=I-2_\
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M9W.VC3]G#E%%%%%2;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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4Y5KC!./K6M10 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>allo-20191231_g4.jpg
<TEXT>
begin 644 allo-20191231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S(R  "2D@ "
M S(R  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?*SE_P#A:WBA>/MO-'_"U_%/_/Y7%#I179R1N>!]8JJ*U.U_X6QXI_Y_*/\
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MC^M54\*:?=B^$-K<6DMLB!$D<GDDCG\J5H#O7_G*W_"T/%>2?[2DP.V>*/\
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M.E=/_P *Z\3?] V3_OH4?\*[\3?] V3_ +Z%5S1,'2JR>J.9HKIO^%=^)O\
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MD/\ WP*/[.L_^?2'_O@5/O4_Q@_C4<UW! NZ29 .GWJ-0]WL,_LZS_Y](?\
MO@4?V?9_\^D/_? I(K^&XW"&094C.32#4;9K_P"QB4>=MSCVHU"R[#O[/L_^
M?2'_ +]BC^S[/_GTA_[]BG1WD$LCHDRDKUYZ5(TJ)$9&<;!U.:5V%H]B'^S[
M,=;2'_O@4O\ 9UG_ ,^L/_? IT5U#/'OBE5@?>I=Z\_.O'7GI1=A:/8KG3[,
M?\ND7_? I?[.L_\ GUA_[X%++>6\+())D4N<+SUJ;(QD'-%V'*NQ!_9ME_SZ
MP_\ ?L4ATZS'2UAS_N"K&]3G!!QUYJ.YN8[:W::9PD:#)8^E&H6B1_V?9?\
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M8K.:8KTR6 !_PH]X(^S1)JO@BZN]4G>&X1;>:19"&'.0<GO56V^'4T%U(3=
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MQKV..^*/_(@WGU'\Z^>_"?\ R-^E?]?*U]"?%'_D0;SZC^=?/?A3_D;M*/\
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MQ$^LX?\ 4I_NBG"FP_ZA/]T5)7,]SV([ ****104444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &/XJ_Y%>_\ ^N1KY9\/?\C#I_O<(/\ QX5]
M3>*O^17O_P#KD:^6O#QQXBT\CK]I3_T(5TTO@9X^._BQ/JC!FOX(C]R.,$_D
M*U#QTK,@(355!XW1#'Y"M/M7.]SU^AY]XP$O]K'=G9CY<]JCT;^QWC*W^4D[
M,>E=7J<VEW<QM+XC>.F>U<]?^&+986EL[Q#CHNX5I$YI*S-73O#^G"^2[MIA
M*HZ#-=(?O9)_"O+]*O9[+48Q"_REL%1WKTU7+VX<\$KGZ5#T-*<KHHWRF*[A
MN(ASG#8[BM)3D UYUJ&MZA'?SHMQ)M5^ #6SX1U&ZOKB=;F9I0J\9[4W'0%/
M6R.L;I7+>-["\U*TLX[!$+BY5B'Y&!FNHK$\2:V^A6D#0VQG>:81J,]"<_X5
M,2YZQLSG)_ 5[/:;?MD2RRR&250#MQMQBFVWP^N;10B7,0C:V6%^#G@'&/SJ
M:T^($[W,,5QIYC69VC#>9W"EO3VJ ?$H^9/&]B25*>7AL@[C@=JT]XY;41;;
MX=/;7\3M<))"&#'.=V1VJRO@$BUCB$L>5R&;![YJ6T\</)(D-W9F&5I1&QW9
M'/X5D7_BS4-2U*TCT\-# 7.]EEV[L G^E'O!:CT+%Q\/KRXM[5?M,'FVW DV
MG( ]*Z'4_#CZC8VD#RJ3!C+N.3Q6'%\1L7%U%-9,HB \LALAR<]\4V[\7ZS]
MJT^-;&.+[1(-X$P8E:7O%?NET++^!Y%TCR(KB-;A9O,1]O#<=#38_ DK/Y]U
M<1M*Y=G 'R@GIBI_^$X3[*LAMSN+%=@;G(&:H)XTNY)8+NXMI(8FB=U0/@-@
M9H]X35(U-'\(OI>IVURLZ'R8GC?8.NY@?Z53N_!-W=^)!J+W,)C\[S ,'<.,
M5&/B&\,<K7=@8L0&:,!L[@"!Z>];&@^)9M5N[BWN+;R6AC#C#[LT>\->S;L5
M/$O@V;6]2ANH98T9  6;.1CTJ"+P',EQ%))=))MD#DXYX&*5?'%RUPQ:PVVP
MNQ:B7S!RV[!.,4D_CN7SXX;2R:5W=E'. <''7%'O#:IWL8NN^&;[2)(9=/C:
M=B&1MH^5<@]OQJ>R\!75YI<374@@E-NL93L"!7::!JXUS2(KSRVB+=5S6JO-
M+F8+#TWJ<[X6\.MH5LZRLI=R.(^E='114O4Z(QC%60M!I**11\W?&+_D>I/^
MN8_F:]3^#'_)/8O^NS_SKRSXQ?\ (]2?]<Q_,UZG\&/^2>Q?]=G_ )UT2_AG
MD4/]Z9W]%%%<YZX5X?\ 'G_C^L/H?Z5[A7A_QY_X_K#Z'^E:4_B.+&_P6;?P
M27?X8NU]9/Z5Z19L?+:%^J<8]J\X^!__ "+=U_UU'\J]'N$:*83Q#..&'K15
M^(O#?PD>4^/-$DTW5I+J-28)CN! [FJMCJ=CI&F[[$>;J$HP7<?<^E>MWEE:
MZS8-#.H96X]P:\UUOX>WU@SOIH\Z(\X[BJC(RJ4>IR4TS7-PTURY=SU+>M-Y
MVX<<GGIUK:TW2F@N9EU2PD*;/DPO\506WAW5+V8I;V#@,>&;C J^9&#A)Z&9
MC+8 .XG@"O7? >A/I6C^;.-LTXR?I5'PUX!2PE2ZU(B1P,[.P-=?//MQ#;C+
ML,<=A42E<[*-/EU",F:^WH?D3@U98+P7"G'0D=*;;PB"(*.IY-2&L6=*T1GM
MI-HVK+J97-P$V!\]O\FLV]\&Z7?ZC]KN$=I-P8#>1R*Q?%M]K46MRQ:9<211
M) C\+P22:RI==URTBF@FNYF=HT=)@A^4D9QTK17Z'-*4;ZHZY?!6D?:)I3&S
M-(NP@L>!44O@W18?(W[D\O@?.?FKDH_%>O6>DVUS<S,YN"80&'.[)YQ]!71>
M()-0M-%T[<YDG#_O& /M3]X%*F^AT>G:/9Z7$ZVJ,JN<G+$UGCP;I8F9RC$,
M^_&XX!Q7&+J/B668,+Z4([.,;3Q@_2H%\3:O)=-#<:A-$Z0ED4*<LV[&.E+E
MD+VD.QWT?A73(X5C6-MJH4'S'H1@U#'X-TF*^AN8XV5H0, ,0#MZ9%<DFJ^)
M94NKB262)H54-$%X&3@L/PIT&N:U!9SW4%Q->6UHZ/N9<&08)88Q1RR%ST^Q
MVVH>'K+5+JWN;D,9(00O.,CGK^=,TGPKI^CW#SVJN9&7;EV+8'H,]*X:]UOQ
M/']C<S-$+E?,&5)P<XV\>W-;OBC6+^Q\/Z:_VK[/+,X$LF"?2ERR+4H&U<>%
M=.N+YKJ16\QF#$*QP2.G%07/AG13J9O[CY9LY(WD G&.E<3=>)-;&F>7'<SJ
MQ9RDX0\@'CM4,MYJDDDMS<7$WF- ,1E20QW#VJN61#JI?9.X3P+HNZ255=FE
MZG><?@,U,OA'2H89%*OAEPSLQZ5Q\6M^(CJWDK*88D0D1%#\W![U&^H>(9K,
M-+=38N!(IC"_=P<#M1:2&JB?V3LY_!NCWP9BK%GP0ZL<C''6K$?A338B-L;<
M1&/[QZ$8J'P2SOX6M!++)+(%.XR#!!W&NAJ&Y&\8QDMC'L_#5C8:@MW;!D=4
MV8W'!'^16L!@<4XTWM2>Q:5D<A\4O^1"O/J/YU\]>$_^1OTK_KY7^=?0OQ2_
MY$*\^H_G7SUX4./%VE$\#[2O/XUT4O@/'QG^\1/K.'_4)_NBI#4$,L8@3,B_
M='\5/\Z+_GHO_?5<SW/8BGRHDHIGG1?\]%_[ZH\^+_GHO_?5!5F/HIGGQ?\
M/1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^
M^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//
MB_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ
M+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU
M0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/
MHIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGG
MQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\ /1?^^J//B_YZ+_WU0%F/HIGGQ?\
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M!_XJC3>/^7A<?G7535Z;/&QDN7$Q=K['5?V/\2L#$D^,=F-']C_$K_GI<?\
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MV/\ $K_GI<?]]&O<LGU/YT9/J?SI\@UCF_LH\-_L?XE?\]+C_OLT?V/\2O\
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M?\^D'_?7_P!:C_A>>M?\^D'_ 'U_]:H]E(V^O43W^BO /^%YZU_SZ0?]]?\
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M"^!O_(TZID?WOYU[O1&M-[F^+P%"%3E43R7_ (4-IO\ T$I_R%'_  H;3?\
MH)3_ )"O6L48J_:2.3ZI0_E/)?\ A0VF_P#02G_(4?\ "AM-_P"@E/\ D*]:
MQ1BCVD@^J4/Y3R7_ (4-IO\ T$I_R%'_  H;3?\ H)3_ )"O6L48H]I(/JE#
M^4\E_P"%#:;_ -!*?\A1_P *&TW_ *"4_P"0KUK%&*/:2#ZI0_E/)?\ A0NF
M?]!*?\A1_P *&TW_ *"4_P"0KUK%&*/:2#ZI0_E/)?\ A0VF_P#02G_(4?\
M"AM-_P"@E/\ D*]:Q1BCVD@^J4/Y3R7_ (4-IG_02G_(4?\ "A=,_P"@E/\
MD*]:Q1BCVD@^J4/Y3R7_ (4-IO\ T$I_R%'_  H;3?\ H)3_ )"O6L48H]I(
M/JE#^4\E_P"%#:;_ -!*?\A1_P *&TW_ *"4_P"0KUK%&*/:2#ZI0_E/)?\
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M_P#:%@K$_,.&KFDK:GJ4:G-HR_TXI#SVZ49R>.W%%0G<ZNM@HHHI!9A1110
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MYW:)6M5DC7<GR>XKI=(UY@1#>\@\!JZ&WT*PCCV&/<<UFZUX:2.%KBSS\O\
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MW=B*-)V=F3:+KGFN+6^.U^FZM6^0><NUN.Q%<7=H5N&\LX;.172Z)>_VE!'
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M$"'(],5+B<[;.NAUVU;5(KH(P51M$>?E/O70#5TN+5HU0C)R"37FUHV)USR
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M!-?07UY&UN""N=V:AMK7[3KL29PN[<15#2G_ -,+'H."*ZO1--(O?MD@(#<
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M)>IYC\#/^1JU3_@7\Z]ZKP7X%_\ (U:I_P "_G7O5%/8Z\?_ !_D@HHHK0X
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M8WEB+*Z> ,#G:?I7L]>'_'G_ (_]/'L?Z5I35Y''C9.-!V/,CKVKKTU.<_\
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M)GRRYMV<Q_;VKG&-1N#Z@-2G7=8R,W]P/0;J[OPU8Z9J)U6]BL$A\J/<J7!
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M,FL+B1[738(XY5V21[]V[\<4?\*^\4?] N3]/\:/^%?>*/\ H%R?F/\ &B\
MOB.I4UGQ/<:S;)9K;QVMLARL2'C/J3BIM)\63:;IXLIK:.[MT.Z*.3^ _E4A
M^'WBC_H%R?F/\:3_ (5_XH_Z!4GYC_&G> FJU[DD'CF[BFNC-9P3Q7"D-%]P
M >G IMGXS.GWCSV.F0QAEVF/?P?TI/\ A7WBC_H%R?F/\:/^%?>*/^@7)^8_
MQHO +UR2S\:_V?=-+9:5;Q!T*2('X<$8]/>LC5=6BU)HS#816FW.=ASG]*U/
M^%?>*/\ H%R?F/\ &C_A7WBC_H%R?F/\:.: I1K/=&=J_B"[UB"TCE_=+:Q^
M6JHY ;G/(_&KVF^,9K#34L9[.&]MXWW1++QLZ>Q]*?\ \*^\4?\ 0+D_,?XT
M?\*^\4?] N3\Q_C2YH@E570KOXMOY/$D&M.%:X@_U<71% Q@?IZ4NF>++C3-
M2OKM;6.4WO$L;-@'IWQ[58_X5]XH_P"@7)^G^-(?A]XH_P"@7)^G^-.\!<M;
ML1Q>+3:S^;9Z;#:ML*$)(7SD8[CWI#XSU,Z"NE%E,:S><KGJIR3_ %J3_A7W
MB?\ Z!<GZ?XT?\*^\4?] N3\Q_C2YHEI5WT)9_'ES/!(IL+?SY4V/<8&XC\J
MR(=;F@\/S:0JJ8)75BW\7!R*TQ\/O%'_ $"Y/S'^-+_PK[Q/_P! N3\Q_C33
M@)TZSW.9S[T#DX%=+_PK[Q1_T"Y/S'^-(?A_XG YTN3\"/\ &CFB1]7G?8YP
M\=:T_#'_ "-&FX_Y^%JU=>"?$-C;/-<Z=(L*#+,2./UK.TJ^33]8M;Z52R02
MJQ5>O%-RCRMCITY1JI6/J)>8D_W12XKS8?&C2%4 Z?."HQU'^-+_ ,+JTC_G
MPG_,?XUY;<;W/LUA*S5E$](Q25YO_P +ITC_ )\)_P Q_C1_PNG2/^?"?\Q_
MC2YD/ZI7_E/2*6O-O^%TZ1_SX3_F/\:/^%TZ1_SX3_F/\:.="^J5_P"4])I*
M\X_X75I'_/A/^8_QH_X75H__ #X3_F/\:?.@^J5_Y3T>BO./^%U:/_SX3_F/
M\:/^%U:/_P ^$_YC_&ESH?U2O_*>CT5YQ_PNK1_^?"?\Q_C1_P +JT?_ )\)
M_P Q_C1SH/JE?^4]'HKSC_A=6C_\^$_YC_&C_A=6C_\ /A/^8_QHYT'U2O\
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M_P"%U:/_ ,^$WYC_ !HYT'U2O_*>CX-&#7G'_"ZM(_Y\)_S'^-'_  NK2/\
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M'_?!H_LO4?\ GQN/^^#1> G.LU9E7Z=,<#TI:L_V5J/_ #XW'_?!H_LK4?\
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MJ:A9RL%CN8F)Z ,"37"R>$;Y].E$D9:Y>^WDASRF5_\ KTFG^$=0M-3AN &
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:A<VEQ'J7VEW1@1)." WTS7<4Q J#" !<< "G9Y&*ANYT15D.HJ-GPI).T
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M^Z*EKE>Y[D=D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC,TI1AG@KMK9T6UO['P+=PVT$BWBL^U7/)XK!_X7SI/7^SI\'D_-_P#6I/\
MA?6DCIITX[XW?_6HY9![:C_.26CZ_%HLZ26UPX8C>N>>G.#GUJL!XB_LZ(-#
M<DQS?)"3QMQZ]:F/QZTCH=-GVGK\W_UJ/^%\Z0?^8;/@=/F_^M1:787M:/\
M.3ROXDEUNV=K>:,$1X"GY5Y^:O4(MQB3?][ W'\*\H/QZTH\_P!FS9'^W_\
M6I?^%]:3U&G3D_[_ /\ 6J7&3-(8BC#[1ZW17DG_  OS2O\ H'3_ /??_P!:
ME_X7YI7_ $#I_P#OO_ZU3R2-?K='^8]:HKR7_A?FE?\ 0.G_ .^__K4?\+[T
MG_H'3_\ ??\ ]:CDD'UNC_,>M45Y+_POS2O^@=/_ -]__6I/^%]Z5_T#I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9,&:%PGWBI ^N*?01F
M@#S>6&:WOY4N[:6>1@V& Z<\5M:K<KI?AZU%Y:M/<8PH52=N>YQ76%%)S@9]
M<4-&&7!P1[C- 'G,<$=M&[21R3+<1GRCL/RN1^G:MHV!CU+3KORW:3R C#T.
M!_A76>6.,@<>U&WG)Y/:@9Y]X9@N(M:65U<E582H5(V<DYSW[47\6J-K<FM)
M;LXAD\M,=X\]<?2O0?+&<]#[4% >G'M0%SRRV-_'+/<1)/&)9\EPIRJ\YK0D
MU&[60I-=W$>G1QDQ3D?O&;T/']*]#$:XQ@?E5.^TBUU!56X4X7^Z<9H"YYO!
MJNNW%NDKW5PO_/)MN=P]^*U=VMP+!<+/<22O]]<?*!7=064%O D,: (@P!CI
M4VT=NW2@#C/"$^HR7C_;)II5<9(D7&TYZ5+<V"_\)!>2+;\>2<$#^+!KK50+
MV&?4"EVC\: /-BFKZ7;>7:3W)62-W;(SL.?I[T^V?5KAH$>\N6A\UF9@N&8!
M,XY'K7HGEC&#@CZ4>6HQP..G% 'F3ZIJ44Y=9KQ(75MZN.4].<5)+?:N8Y/L
MEQ<O:%DS)M^897GMZUZ+-9PSQ&.1 0?:GI B1A%  'M0!P4&K:E:P(US-<2J
MT0"G8>6S]/2J6GMJ<'G-&UQYTLKOAAT4FO2S&IP" 0.@Q2[ .0!GZ4 >>7%U
M>#3I/LE[=K+G]X70G'TXKIO#>H^=91Q3B5)F_AD'6MSRE_NK@]>.M)]GC+JY
M52R]#B@1P-Q!>MXDOTA>X@221/GC'7DT0W=^\L:ZC/=HL:MM,:_>PV!GBO0-
M@Z\9^E(8Q[?E0!%:W"SQ\$G;P<BK%-"!<XXR<TZ@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>allo-20191231_g5.jpg
<TEXT>
begin 644 allo-20191231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S@T  "2D@ "
M S@T  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M )[K1]OM/^>ZT<DA^TB=#Y\7_/5/^^A1Y\7_ #U3_OH5SWV^T_Y[K1]OM/\
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M\^+_ )ZI_P!]"CSXO^>J?]]"N>^WVG_/=:/M]K_SW6CDD'/'N=#Y\7_/5/\
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M@J#[8G_/.3_OFC[8G_/.3_OFC0"?:/04;1Z"H/MB_P#/.3_OBC[6O_/.4_\
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M6#$,6\61CY<5O5P2W/3C\*(+S_CT?\/YUEUJ7G_'H_X?SK+I#"BBB@ HHHH
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M+!D^_P"='/J?SHHHY@L,GD,4+N.JC-92W]ZP!#1X(STK2N_^/.;_ ':R(O\
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M"W;/>M_Z^IJ77GW"[)?MU[_>B_[YH^W7O]Z+_OFHJ*7UBIW%=DOVZ]_O1?\
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M-_LE_P#G]?\ [YH_LE_^?U_^^:TJ*/8P[!R(S?[)?_G]?_OFC^R7_P"?U_\
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M/F-3Q3PSDB&5)-OWMISB@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR)')YQQ@5B^')X[?6$,H!#]"?7% '8Z7"]OID,4GWE'(JY0??KG-% !1110
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M2^=>71\N.-1RH]:OW(AT+P=Y$Q+;;<1#:.7;&!5?0?"<>FWC:G?.EQ?OU=%
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MK6\.W!NI\[0H#'^E4GMXI,AD!./3%2>&YU&MO;1)M"\UL2=?G-7M&_Y#%O\
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MS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYTA]B,_6F!R7C'_C]A'^S_45U-M_QY0?]<UKEO&/-]"./N_U%=3;?\><&?\
MGFO\J'L(EHHHI#"BBB@ HHHH **** "CZ44AH HW&GV"^==21I&77:\I[#UK
M"DT#3943=J2A(MI4#'WE& >M:6OZAI8TRXM]1NXXU8;'1'^;VX'-<O-HF@FS
M%VVJ300WIWIE>S<=QQUIH#:GT[3KFVBTLZDGF1AI"=N=X;VS[51E\.:?&T>G
MMJC(_EKM8*.%'J<]32CPI8-'';V.IQR,R*@&]=VP$DG(Y[U<U.PT62YC$U_'
M')A8^JMC QS3 @B\'6MR7\C5&E(D#Y R5QVSGVKKD4(BQ[LE5 )QUKG+*71/
M">FM&MZCB20L2K!B2?7%=%#,MQ DL9^5AD'&*0#ATI:**0!1110 5ROQ"9O^
M$=B0?=:ZB5_H7%=56;K^E+K6A7%B>&=<J?1AR/U I@7K=5%K"J<+L7 QTXKB
M?$US=1^/M*2.V$D7(4FKVA^*D327MM01SJ-AA)+<#YW Z,!WK)\0ZM>WUUI]
M[8:5=(]G)O;?&1N7!JD(]!5%&"$4'L/2O,-*TV35?B/J\4P>VB'4Q-CO6Q<?
M$ZVMK7SSIL[.3M"C&2_ICK6+X?O=4T75;O6M1L+EHK[YI!Y9X';GM3L!?C\-
M0#4=:MEFFW0Q[XL/U^7OQZUS%C-YL'WL,C%6-3S^)=9U/6[RYT=9(?MB^6D:
M("2!QD_E69:1W5E +F2VD\N4D,P7(W@\\U:$=5=Z<J^!UU"%Y#(C#<"_&,XZ
M55MSNAC<,0&P>M4H[C5;BTFMUA<6D>#*IZ8) _K4VVZM3]F%I)D_<)& 1^-(
M#H/$=DMG/I\D+N4F'S$MFK&E1@ZE%$SMM8\D&L>T74=0BA>^5]@RD0;L13VE
MOMP-M;2(\)&XXP:0&W=6[6VM2PAB4(R"36MI,>]G5B2J\KS61#!=%7:Y#23@
M!L]3CTJ6T^VM>(T<3)&6P:E[#.J].U7*ICA0#U JY3@#&2_ZLYJC=B7[(_DD
M!^V:O2_ZH\XJG<6Z7-NT4H^1^O/(J9[@CGM$3R]:=63]X$.[;+N Y'MQ6Y>2
M>7;''.:K:=I1TRX;R)B867E"/ZU)J'W%4=_6L]D6M64[2(27* ].]%Y#Y=TP
M'3M5G3X\S%O2H[SYKAJCI<OK8I[:-M2;:-M04.M(?,N4!Z9I;R'9=,.QYI]I
M\MPM3ZBG[Q6_O5:5U<6SL36#E[49ZK5JJ.GG&Y*O5I'8SEN%%%%,D**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!/Y^HI:** "BBB@ HHHH **** "BBB@ HHHH /7BN>\0Z/=ZE=Q26
MRH55<$$XKH:2FG8#CAH.L_W_ &QYE']A:U_?_P#(E=CSZT<T^85CCO["UK^_
M_P"1*/["UKIO_P#(E=CS1S1S!8XM_#>JR,&EVM@]6?-=E"GEV\:'[RH :=2T
MF[CL%%%%( HHHH **** "BBB@ HZ44=.GZT <M>Z+I#7KW%[>A09&(#$=<#(
M/Z?G2IH.ASK%;V]R,VZ L%;)*C!R0>G2I[SPK!>73323MR[2*IZ(3@?TIUCX
M3M-.:X> EVDC9,GJ2W)I@95KIGAR#5I)5O2WE_._SX"@\8_2B#2?#S75VXO@
M-C;64GH<]:L6/@QDGFN[JX N7 ";>BKBIF\$VS!U%PP!<NH]">M%P,N+0?#]
MS>^6MX[&1_-0E@%./_U5VT6SR4\L@IMPN.G%<P_@BV2UAAM)"K1MPY/*C/)K
MJ418XE0<!0 /H*0#J*** "BBB@ I,9Z\G//]*6B@#&UCPQ8:RZS2;X;I/NSP
MG:P_QK+_ .$;\2)\D7B5C'ZO"-P%=;13N!Q47PWMDD^UMJ$[ZANW^:<8W>N,
M5>?P]K-PAANM:WPL,,HCY(_.NGHHN!P\?P\?3;AWT+59;59%PV] Y.>N#QCF
MKT7@YCIJZ=>WSS6J_P *J 23WSZUU5%%V*QR4/@NXMXS;0ZJPM=^3&8\EL=,
MFM"[\-"_B47EV[/&,1%1C;6[11=A8Q+;0[B*:-Y[SS1$/D&S&*FGT;S9A<),
MRW&,%B.#^%:M%%V.Q1MK!X=[O-O=^K8Y^E2BT,;%HWZGO5FB@! ,#GD^M7*J
M5;JX"8R7_5&J]6)?]6:KU,]P051O>9%SZ5>JM=+DJ:CH4MPLTV0D]S568;IF
M-7H?E@&*IE<D_6E;2Q=];D.VC;4VVC;4V&,B&) ?>KEXF^'/IBJX7'/O5R09
MMS5):6);UN5;,?OF/;%7JJ6P"!F/  R:@;7[$$C]YP<9"U44R)22W-*BLS_A
M(+'UE_[X_P#KT?\ "06/K+_WQ_\ 7JN5D>TCW-.BLS_A(+'UE_[X_P#KT?V_
M8^LO_?'_ ->CE8>TCW-.BLS_ (2"Q]9?^^/_ *]'_"06/K+_ -\?_7HY6'M(
M]S3HK,_X2"Q]9?\ OC_Z]'_"06/K)_WQ_P#7HY6'M(=S3HK,_M^Q]9/^^*/[
M?L?67_OC_P"O2LQ\\>YIT5F?V_8^LO\ WQ_]>C^W['UE_P"^/_KT<K%[2/<T
MZ*S/[?L?67_OC_Z]']OV/K+_ -\?_7HY6'M(]S3HK,_M^Q]9?^^/_KT?V_8^
MLO\ WQ_]>BS#VD>YIT5F?\)!8^LO_?%']OV/K+_WQ_\ 7I\K#VD>YIT5F?\
M"06/K+_WQ_\ 7H_X2"Q]9?\ OC_Z]'*P]I'N:=%9G_"06/K+_P!\?_7H_P"$
M@L?67_OC_P"O1RL/:1[FG169_P )!8^LO_?'_P!>C_A(+'UE_P"^*.5A[2/<
MTZ*S/[?L?63_ +XJ>+4[::TDN48^7'PV1S2LTKC4XOJ7**SCKME_TTQ_NT'6
M[0?\]/\ OFH4DQ\R-&BL[^V[/_II_P!\_P#UZ!K=IW\SIS\O_P!>GS(.9&C1
M6?\ VW9_]-/^^?\ Z])_;=IZ2_\ ?/\ ]>ES(7,C1HK..N68'(E_[Y_^O0=;
MM/\ IK_WQ_\ 7HYD',C1HJK!J5M<!RA8!!N.1VJ#^W+/_IH?^ TVT@YD:-%9
MW]MV?_33_OFC^V[3_II_WQ1S(.9&C16=_;=I_P!-/^^*/[;M/^FG_?-+F7<.
M9&C16=_;=I_TT_[YH_MNT_Z:?]\4<R[AS(T:*SO[;M/^FG_?-']MVG_33_OF
MCF7<.9&C16=_;=I_TT_[YH_MRS_Z:?\ ?-',@YD:-%9W]MV?_33_ +XH_MNS
M_P"FG_?%/F7<.9&C16=_;=G_ --/^^*/[;L_^FG_ 'Q1S+N',C1HK._MNS_Z
M:?\ ?%']MV?_ $T_[XHYEW#F1HT5G?VW9_\ 33_OBC^V[/\ Z:?]\TN:/<.9
M&C16=_;=G_TT_P"^:/[;M/\ II_WS1S+N',C1HK._MNT_P"FG_?%']MVG_33
M_OBCF7<.9&C16=_;=I_TT_[XH_MNT_Z:?]\4<R[AS(T*7OGO6=_;=I_TT_[X
MH_MNT_Z:?]\4<R[AS(T:*SO[;M/^FG_?%']MVG_33_OFCF0<R-"EK._MRT_Z
M:?\ ?-/AU:UGG6)"X9CQE:?,KV#F3+U%%%,H**CGG2!0TF<$X&!FH/[1@_NR
M?]\U+G%.S9239;HJK_:,'I)_WS1_:,/]V3_OFI]I#N'*RU157^T8?[LG_?-'
M]HP_W9/^^:/:P[ARLM455_M&'^[)_P!\T?VC#_=D_P"^:/:P[ARLM455_M&'
M^[)_WS1_:,/]V3_OFCVD.X<K+5%5?[1A_NR?]\T?VC#_ '9/^^:/:0[ARLM4
M55_M&'^[)_WS1_:,/]V3_OFCVL.X<K+5%5?[0A])/^^:0ZC#QPX^JT>UAW'R
MLMU;JF"" 5.015RNB!FQDO\ JS5>K$O^K-5Z4MP05%/RHJ6FLNX5!1'%Q&:A
MV5:"X4TS92 @VT;:L;*-E%AW*^WM4\F?* HV4\KE<4"(, 6LQ_V#_*N20?)_
MP(DUV$HVVLO^XW\JX]/N?B:WI'#B]KCZ,TE%;V.#<7/O1DTE%%D,7)HR:2BB
MR CN+F*VCWS2!1[]Z;]MMC )O/3RR-V2><>N.M0W]I)<M!+"4\RW8LJN/E.?
M7\JRV\/W,S$S7"C=DL0.I/;'I2LP2B;J7$4D?F)(I3&[.X#CUI%NX'8JD\9P
M,D[AQ7.6_A:>VZ7)<JI"[FX/L1Z5*/#<ZRF1)D''*=B?\*-2K1.B#JQ(61"P
MZ@,#BD\U,9$J$9Q]X5D6.BR63,XN-SNI!)JFGAB?YR]SR0VT ]&/>C45HG0&
MZ@!?,Z?NR _S=,]*=YT?:9#QG[PK$BT"1-/NK>252\Y3YAS]T]:@G\,W$K*%
MN@B["I(]Z-0M$Z(2QDX\U/\ OH4V.XBF5FBE5PIP<,*P)/#5P9R\-QL!Z#/0
M>E-3PW=Q[A'<*BR2%V /3V%%V/E\SH1=0&01B="Y_AW"G":)L!9D)(R,,#FN
M>;PU.]Q#-YZQM&I!V\YJ>WT"2*=9WE&\8^53PO/:GJ#21N\_K1S03GCKCN>]
M)1ZDBY-&324460"Y-&:2BC00HJU8_P#(!OC_ +9YJJ.M6K'_ ) %]_OFLJOP
M,VHVN-5L*/7&>?I7*)XEO8[>XGDPWE2,NP+R0&Q70:E>?8-.:XQG: ,'O7/I
MKZ%#,NFJ%<A#QQG&<GVKR(I':2'Q7-):R21V/EN@&=YZYZ8J63Q/-$KM-: "
M/).#][''%,EU=;718+F>TB>1@YP.F >E,_MM;A2J::N VT$]A@YJK(5EU)!X
MK+!L6GW45S@]01D8IMQXKFB7Y;/#/'E><XQ_^NG:;JL%S#/LTT)';QED!'.1
MU'XXJG-XA,L*M%I\:/O 8L/O*<\#WHL@LNA<7Q6Z0*\EIDL$7_@38_QK;TZ\
M:]M/-DB,;*Q5@?6N=BUF7SI<V<;,DFQ<KPJ>OUQ6EI6N?;[W[.(!$I0L!GD8
M]:322#4Z*Q'_ !^8_P">-58_]6O/:K5@>;S_ *XU5C_U:_2G.W*F*[%_&EI*
M6L;H HI**+H!:*2BBZ 6DHHHN@"H'O8([E;=I,2MT7!J>LBZT0W%[<W*3&.2
M6+RXSGA3ZU2L%D:OF( "9%P>1\PI?,7&0ZD \G<.*YR/PW<DN9;G[S9"@_=&
M#Q37\.7R*XMKL8D0(VX].>2*=EW"R.B^TP[-_G+C.#STIPE1@2LBX^N*Y=O#
M%^]PIDNE,2,&V@_>QZTY/#5]YRM+=[DWLQP>2#G@_3-%EW#W3J R\$N #T)-
M-,T:J6,B@#KE@,5AZGHM]=:?;6]K=!/+4AB3WSUJ.;PY<MPMSO5C\RL>/K19
M=P]TWS/&L8=Y552,@EA3MZ$X\Q.N#\PXKG]0\/W=U*OE3*(A;^4RL>IQ@?A4
M<7AR^5QF[ V)M4]=Q]319=P]TZ3>FT-YBX/3##FE!SG:P.#C@UQLN@:O$@MT
M;S#+G]ZK<19.:Z#0].GTVU9+J;SG)'.:4DK;A[IIT4E%3= +124470"T4E%%
MT M)111= +^-/LQG5K//7)J.I+,_\3:T^IK2%G-#CN=/111VKO.HI:ET@'K)
M_0U'U/U/%2:E_P L/]_^AJ('O[UY&*M[74Z:=^4IPZQ83W#01W"^8A(8'C'X
MU:$\)&?-CQZ[Q6+>^'FNEN1',L9FDW A>0/2J-SX0DDP8;EE&\DIN^\.WY5S
MVCW--3IS<0K)L:5%;;N(9P,#UH-S KA6F125W#+=JPK_ ,.RW-S#-'*"8H/*
M8,?]8??Z4MWX<>Y:W+3Y,:!7;H3QVHM'N+WC=\^(*"98\?[XXIJW=NXRMQ$1
MG'WQUKDG\&W;1-&EYM5B<_-[YS5N+PF5W>9-\V\,K ]  1_6GRP[A[QTIEC'
M62,<X.7'%-CN(9E)AD5\==K9Q7+6W@Z:*1FFNFD)5\Y?[Q(.#^&?TK4L]&EM
M;.YMQ(%,GW95Z]*5H]PU-;SHN,2QG)PN''/TIK74"3")YHU<\[2PS6!!X9E6
M99FE",I)15.0G.?Y5'J7A:XOKF61;@ $@HV<,<=C[46CW#4Z7SX@0#+&"1G!
M<=*!-$3_ *V/DX'SCDUS47A%DC.;EM^25);.W/05%;^$+K>[7-YEF3:-IX5O
M[U/ECW#WCJ4N(I)C$DBM(HR5#=*)S^Y;L:RM(T633[V6:1U8. !SR?>M288M
MV';%))*6C#4TXN(4_P!T5>JE'_JD_P!T?RJ[7T-+X3B>XR7_ %9JO5B7_5FJ
M].6X(****@84444 %%%% !1110 R8%H) O4H?Y5R(M+I&(^S29[8'6NQHJE)
MHRJ4E4./^SW/_/M+^5'V>Y_Y]I?RKL**T]JS'ZJK;G'_ &>Y_P"?:7\J/L]S
M_P ^TOY5V%%'M&'U5=SC_L]S_P ^TOY4?9[G_GVE_*NPHH]HP^JKN<?]GN?^
M?:7\J/L]R?\ EVE_*NPHH]HP^JKN<?\ 9KG_ )]I?RH^SW/_ #[2_E7844>T
M8?55W./^S7/_ #[2_E1]GN?^?:7\J["BCVC#ZJNYQ_V>Y_Y]I?RH^SW/_/M+
M^5=A11[1A]57<X_[/<_\^TOY4?9[G_GVE_*NPHH]HP^JKN<?]GN?^?:7\J/L
M]S_S[2_E7844>T8?55W./^SW/_/M+^5'V>Y_Y]I?RKL**/:,/JJ[G'_9[G_G
MVE_*C[/<_P#/M+^5=A11[1A]57<X_P"SW/\ S[2_E1]GN?\ GVE_*NPHI>T8
M_JJ..\BY'_+M+^57K&TG&AWBO$RL[9"XKHZ*F4G)694:"B[HY1K661 LEHS+
MW!3/---DVW'V'C^Z$KK<T5S^Q\R_9/N<9=:1'=P+'<6+F-#E5V]ZF2R:+[EE
MM8#LG>NMHI>Q\P]D^YR:V;H3MLL%N#A.N:;]@S@&PX!R/W===11[%=P]D^YR
M?V-P^X61!)R<)WJ"#2%MKJ2X@L9$EDX=L?RKLZ*/8KN'LC!T^VG*W+R1LH:+
M S5-8;E5 :WD) QTKJJ*?LE:P_9HY40W&/\ CWD_*E\FY_Y]Y/RKJ:*GV,1>
MS.6\FY_Y]Y/RH\FY_P"?>3\JZFBCV,0]F<MY-S_S[R?E1Y-S_P ^\GY5U-%'
ML8A[,Y;R;G_GWD_*D\FY_P"?>3\JZJBCV,0]F<KY-S_S[R?E2^3<_P#/O)^5
M=311[&(>S.5\FY_Y]Y/RI1#<_P#/O)^5=311[&(>S.6,-S_S[R?E2>3<_P#/
MO)^5=511[&(>S.5\FY_Y]Y/RH\FY_P"?>3\JZJBCV,0]FCE?)N?^?>3\J7RK
M@?\ +O)^5=311[&(>S1RWE7'_/O+^5)Y-S_S[R?E759HH]C$/9HY;R;G_GWD
M_*D\FY_Y]Y/RKJJ*/8Q#V9RWDW/_ #[R?E1Y-S_S[R?E74T4>QB'LSEO)N?^
M?>3\J/)N?^?>3\JZFBCV,0]F<KY-S_S[R?E2^3<_\^\GY5U-%/V,0]F<KY5R
M/^7>3\JFLK>X;4K=FA940G.X5TE%$:23N-4T'TH[445L:%/4E9DB*J6VMDX^
ME5B[Y_U4F/I6K17-4PRJ2YF:1FTK&7N;_GC)^5&YO^>,GY5J45G]2CW*]HS+
MW-_SQD_*C<W_ #QD_*M3//)P.U1"ZA*LRRKA3AB#TH^I1[B]HRAN;_GC)^5&
MYO\ GC)^57Q=0=1,AP<?>ZTHGC^0[Q\V0O/6E]27<?M&9^YO^>,GY4;F_P">
M,GY5HB1'&5D4@^].#J>C+ST.>E'U)=P]HS,W-_SQD_*C<W_/&3\JOM=P12!)
M955F&1DT_>H'++ST.:/J2[B]HS-W-_SQD_*C<W_/&3\JT]XP,.,'T-(9$#E"
MZ[P,XS1]27<?M&9NYO\ GC)^5-<NZ%1"_/J*U"Z^66+A5[MGI2A@3PP)I_4T
MM0]HQ(AMB13P0O-7:J>XZ]#5NO1@K*QC+<9+_JS5>K1 88/2F^4GI^M$HML1
M7HJQY2>GZT>4GI^M+E87*]%6/*3T_6CRD]/UHY6%RO15CRD]/UH\I/3]:.5A
M<KT58\I/3]:/*3T_6CE87*]%6/*3T_6CRD]/UHY6&A7HJQY2>GZT>4GI^M'*
MPT*]%6/*3T_6CRD]/UHY6&A7HJQY2>GZT>4GI^M'*PT*]%6/*3T_6CRD]/UH
MY6&A7HJQY2>GZT>4GI^M'*PT*]%6/*3T_6CRD]/UHY6&A7HJQY2>GZT>4GI^
MM'*PT*]%6/*3T_6CRD]/UHY6&A7HJQY2>GZT>4GI^M'*PT*]%6/*3T_6CRD]
M/UHY6&A7HJQY2>GZT>4GI^M'*PT*]%6/*3T_6CRD]/UHY6&A7HJQY2>GZT>4
MGI^M'*PN5Z*L>4GI^M'E)Z?K2Y&%RO15CRD]/UH\I/3]:.1@5Z*L>4GI^M'E
M)Z?K1R,"O15CRD]/UH\I/3]:.1A<KT58\I/3]:/*3T_6GRL+E>BK'E)Z?K1Y
M2>GZT<C'<KT58\I/3]:/*3T_6CD87*]%6/*3T_6CRD]/UHY&%RO15CRD]/UH
M\I/3]:.1A<KT58\I/3]:/*3T_6CD87*]%6/*3T_6CRD]/UHY&%RO15CRD]/U
MH\I/3]:.1A<KT58\I/3]:/*3T_6CD8KE>BK'E)Z?K1Y2>GZT<C"Y7HJQY2>G
MZT>4GI^M'(PN5Z*L>4GI^M'E)Z?K1R,=RO15CRD]/UH\I/3]:.1A<KT58\I/
M3]:/*3T_6CD87*]%6/*3T_6CRD]/UHY&%RO15CRD]/UH\I/3]:.5BN5Z*L>4
MGI^M'E)Z?K1RL+E>BK'E)Z?K1Y2>GZTN1A<KT58\I/3]:/*3T_6CD"Y5=!)&
MZ'.",'%8B^&\6D]NMV<S_P 6SH,]*Z7R4]/U- A0 @#@^YHY N<JOA.+R?+^
MTMGC:VSIBG-X322&%1>2 P@E#CN?6NH\I/3]31Y*>GZFGR,+G&'PC=VZK]CU
M-R,D'>.U31>#VC@=/[3N"[=6_N_K76B)!V_6CRD]#^9HY&%SG[CP]#<V\<;S
M/N2'RA(1DGD<_I54>$RJ*HU.?Y>_J*ZKRD]/U-'E)Z?K1RL+G'P^$;A9&,VK
M38SE HQBI4\*2BY:=]4E+D8^[_\ 7KJ_*3T_4T>4GI^M'*PN<ZF@RKITUF;Q
MW20[@VWE33[;1'M=0^T)?2,FT#8PX/'6M_RDSG!S]30(D';]:.1A<K]OK5NF
M>4GI^M/JHIH HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>allo-20191231_g6.jpg
<TEXT>
begin 644 allo-20191231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S(Y  "2D@ "
M S(Y  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM:_]?"?SK;3_ %:_05B^(_\ CVM?^OA/YUM)_JU^@H 6BBBF(**** "BBB@
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MQ7,(DA8$'K[5-D<#UKO331S;;A2XHHH$&**** "BBB@ HHHH Q?$?_'M:_\
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M(EH/_0+MO^^!1_PB6@_] NV_[X% %[^TK+_GZB_[Z%']I67_ #]1?]]"J/\
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M *^$_G6S'_JU^E" =1113 **** "BBB@ HHHH P/&7_(#'_7:/\ ]#%;<?\
MJE^@K$\9?\@,?]=H_P#T,5MQ?ZM?H* *5[>SV]S'!;PK*SC.&;'%,-SJP/%E
M#C_KH?\ "BZ_Y&"V_P"N1_G6I0!E_:=6_P"?*'_OX?\ "C[3JW_/E#_W\/\
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MDM%% K0@**** "L#PE_R#9/^NC?S-;]8'A+_ )!LG_71OYF@#?HHHH ****
M"BB@T )N''/7I52_U"&PA\R9@,]!ZU-<2I!"TKG"J,US$2OJ=PUW<9*'(C0T
M$RV(I==U#4+T06\+0J02"1V]:R%=CJ!N'RS@X;=6Z=NGZQ%+(/E8>6WMWK(U
M)#9ZK<1R#Y97S$1TQFLJFJ(3N;]NZ2VZO&, U(P&,/5/3#NM2,]*N9Y.>PXK
M"R+5C$UW3UELS(N 1S5CPKX?MYK..\N&,CY/RGIUIVKS(EF^X]5P!6MX4C:/
M0XBXP22<?C13BG,A)<QKJ@50JC"CH*:UNC2%S&A)')QS4M+799&MB 0HF5CB
M5<\\*.:<L:;]XC4$CKCFI*6BPK(.E%%% PHHHH **** ,7Q+_P >]K_U\)_.
MME/]6OT%8WB7_CWM?^OA/YULI_JU^@H 6BBBF 4444 %%%% !1110!@>,O\
MD!C_ *[1_P#H8K;B_P!6OT%8GC+_ ) 8_P"NT?\ Z&*VXO\ 5K]!2 S[K_D8
M+;_KD?YUI]ZS+K_D8+;_ *Y'^=:E  1D8K)UM+=88VFA1R6V_,,UK&L?Q!A;
M%;AL[86RWL*!:&A;6\5M"%@C5!CH!5'6%:1K6/&4>4!Q[9J]:7,=Y9QW%NP9
M'7(/J*J:E83W5U:RPR[$BD#./4"@=D:*QJB!5& HP,4H449%&10%PQBEI* 0
M>AH 6D/M1FBF A?"YZ5S]B/[5\137C?-#;_)'Z9]?UJ[KU]]BTYA'S+*=J@=
M:ET>Q&GZ;%"!\V,N?>@74NX[=C7-Z*QCOM1A?C]_E1[;173$?+Q7-:KNTO6H
MK\#]U-^[?T'?/Z4":-?DJ-IQ].]9=_>23W*V.G_-,PPS@9"?6DN]1>YF^Q:8
M-TK#YF'\ ]:U-,TV/38 J?,[<NYZDTA)!IFFQZ?!@?-*W,CGJ35X #ITHP>U
M+04C(3CQ0^/^>8_D*V*QU_Y&A_\ KF/Y"MB@84444 <[;?\ (\7/_7 ?SKHJ
MYVV_Y'BY_P"N _G714 %%%% !1110 4444 %'-%&:+ %%)G-%,!:2BC(%( K
M!U^Z9VBLHNK\OCTK=9L*<]A7*"87-Y<7F<@_</L*QK2M$TIQNR*93*\-E#\I
M8?-CTK8A@2WA6-!A5XQ[^M4M&@,@FNVY,OW#Z"M7&0,]A7+3AU-I2UL8=[FX
MU5(SRD*Y<>]3=<?2HYOW.MW&[CS1Q4@'&*RG\1I%:!SZG\Z4J#D$<$<BDZ=:
M7^*IO<JQ'IF([N6T3A?O+]36GM_,5F6$9EUB0C^!1SZUL;< ^GK71%:&+>I%
MBC;[5)BC;56%<CQC-17%NEQ T;CC&1CM5K;2!><XI<H7,&$%X9;6XY8'@>HK
M8T"Z9XFM93EX3@?2J&JQ>3=1W2C /R/[>])!*+76()L[4D^1S_6E!\LQR2<3
MJ:6D!!/%+7><H4444 %8'A+_ )!LG_71OYFM^L#PE_R#9/\ KHW\S0!OT444
M %%%% !F@]**9+((XV<]%&: ,/79FN)8M/C;EOGDQZ=JMVT"I&B@8^7'TK,T
MT?:[^>[;YO,;*'_9'(K7QCYL]*#/=F9K 3[&Y89QU)JAJ=HBZ#:K.2\_57SS
MVJSJKF:ZAM1R)&^?V Y_I32IU+6ECCYMX","E9"4=3*@O+C3T"W,,BAA]_;Q
M4S>(8CE4Y;&.>]:^OZ[:Z7%Y0C2XF(PL>,XK C\1WFW+:-:YZ@XYK"5%WO<&
M]">STZ[UJZ7ST:*U3DL1][Z5V\$20PJD8PJC KS&;7-6EU>UED?R%5P/)C^Z
M:]/A8O C'JR@FM8TU%#IV:'T4459H&**** "BBB@ HHHH **** ,7Q+_ ,>]
MK_U\)_.ME/\ 5K]!6-XE_P"/>U_Z^$_G6RG^K7Z"@!:***8!1110 4444 %%
M%% &!XR_Y 8_Z[1_^ABMN+_5K]!6)XR_Y 8_Z[1_^ABMN/\ U:_04@,^Z_Y&
M"V_ZY'^=:E9=WQK]K_US(_6M,,.^/SH #5#4;IH=B*@?S.-IJ^6'J*S=54[5
MD4 A>]!+3956]N88MJ+&JH,XQTHBU6ZFC\Q1&!G'(-0,P9 B-EGXQFDCC-JW
MDSD(>M!#;6@W4->N;"-=RHSR'"D U4_X2'55Q\L1]>#_ (T[4+1[^U,D(R(3
MG.:S/M,84$M\_0J/6@R;D7D\67USN6!(\H</P:)O%.H6:-+.D3QCC"@YJA]A
M?3OWDPV+<'*G/^?6AK8ZJ6MK<AR>6(H)YIFDOB'5)/F1(5##*Y!Z?G6CI6O&
M5)!J+)$R#)(8<_A7.^8D7[J9L/$<%36IHFAV]ZS7MXN03A5[4RZ;DV6[)&US
M5_[0D1EMX.(-W\7O_.NC'2HT2.*,)&%55Z <8I^X>HH.D=56\M(K^V:&X7*.
M,?2K&X>HI..>>OO0!1TO2;;2K?R[=?FS\S'J:T![4 @T8X%(!:0]J6D- &0O
M_(T/_P!<Q_(5L5CK_P C0_\ US'\A6Q0 4444 <[;?\ (\7/_7 ?SKHJYVV_
MY'BY_P"N _G714 %%%% !1110 4=Z**0 :R]9UF+2;?>_+G[J^M:;?=KA_$+
M--XC6*;YHT7(&/>IJ2<8D2&'Q/K1/F+ HCZX]OSK0'C>T^S@-&S3]"@'>F>3
M'Y((YXS_ /6KF9(HUUU"@^]U KC]I(AMHZ?_ (2N[?YH[3Y/0]:M67BNWEE$
M=S$UNQZ,>E1V\*"$?*.15#5+.)X^0,]?I3YY;L+NUSJKZ<1Z;+.AR F0V>M<
MR5$.FL4[X _$UA2:CJJ:'.8WWVT;>7C&355]6O8X([:4?ZL M\O4=J*TN:2.
MBG425ST2Q@%O8Q1+V458VU2T666YTJ&>;[SC(XQQ6ABMDM"[\VJ,K5+%YE%U
M;C]^G;VJE%<+.-K85Q]Y3US71XJG<Z5;71+,FU_[R\&LYT[[&D9VW,T>C J!
M4,MS@[8?WLS< #M5[^P(3UN)OH9#5RUTZVLQ^[7+?WCR:SC1:>HW4N0Z;9_9
M(,R'=*YRQ]/:K9'Y5)M]J N!738SN1X]J-M2X%&!18"+;1MJ7 HP*+ 9^J6_
MVC3W1>"O-8KYGL$8<%3U^E=-< ?8Y?\ =-<W$/\ B4X]B?UKGJ+WD:0V9U=L
M_FVL<GJN:G%4=(.=(MB>\8J\*[8[',PHHHJA!6!X2_Y!LG_71OYFM^L#PE_R
M#9/^NC?S- &_1110 4444 (>M96O77DZ:54_O)2%7\ZU&^\,=:P=<_?:A9Q+
MU0^81[<B@F3T+%E;K;6P5?X>!4TS!$)[XXI4X09K+UR^%K9N4/S$C;[F@S>Q
ME2W;&[DDC.XCY(_I_P#KJ6?4/[!L%AA42:C-U'78#ZUFPSQZ=;M<3C<^<QKZ
MG_"I-+L);J8WUZ29I>Y]* NQ=,THO(UU=DRS,=QW5K/#&L9( Z<BI^% P, <
M'%9&LWYA @B&9I.% [U([::E2PM%U3Q-#&@_=Q'S">WKC]*]&3A0,8Q6'X:T
M8:98;YAF>7ECZ5M\CIS56*A&R'44F32$G SQ06.HIH)IU !1110 4444 %%%
M% &+XE_X][7_ *^$_G6RG^K7Z"L;Q+_Q[VO_ %\)_.ME/]6OT% "T444P"BB
MB@ HHHH **** ,#QE_R Q_UVC_\ 0Q6W'_JU^@K$\9?\@,?]=H__ $,5MQ_Z
MM?H* ,#Q'+Y%_;2;]@V'G\:R8[R65PD5PSL>P-3^.NMO_NG^=8GA3YM>0'D<
M\&@#3>_DCD*27!#*<$$T[[1.]N9#,S0=V["L'Q#QKMR"Q7YN,5MV>!X'E8<G
M/6@".*=#(!%+EB?E&>:DN)F5\7,A5_\ :-<_HQ/]LVOS$Y?D5J^-!MUD*#M&
MWM0*R+D,TC1.8&9D7[P'2JH-KY@D#*6Z_6K7A,9TB^+_ # #^E<H&/GC:YSN
MZ4!9(ZFX<^4JW;?(XRN_T]J;9D*Q%BPW$9^3KBG>+ %TO3B."4&?TJGX,^;5
MG#G</+.,_6@":8V[R,9BIE'4MUJT+B:* .KLD&.".F:YO5=PU:Y&3PQQ727/
M'P_#?Q<9H&K(8E^\D@2.Y+,>@!ITEY+#*8Y9RKCJ":P="S_;-OR<$]ZM^+L#
MQ!)C/W1R* -2.YGFB:2*9F13@D'I4?\ :+'_ )>OUIWAD9\+W^.>O7\:Y>%O
M]*0$G[_3\: /3]#$WV,F;))8X)K2%16@Q:1X&/EJ:D 4AI:0T 9"_P#(T/\
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MA/YULI_JU^@K&\2_\>]K_P!?"?SK93_5K]!0 M%%%, HHHH **** "BBB@#
M\9?\@,?]=H__ $,5MQ_ZM?H*Q/&7_(#'_7:/_P!#%;<?,:_04@.4\;1/*T C
M!)"$X'UK(\(VDYUH2B-M@')(QBNSO[6=[V*YA4.$4@H>_-0M<7D+?+:*@/\
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MRQ\6-Y9;9C:^UO8U/:>()KN^^S)'\Y&<>U "VO\ R.]U_P!<!_.NBKG+//\
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M/"4B4XR1U]ZZC^*F!C>)?^/>U_Z^$_G6RG^K7Z"L;Q+_ ,>]K_U\)_.ME/\
M5K]!0 M%%% !1110 4444 %%%% &!XQ_Y 8P>?.C_P#0Q2>)([:328_M;E1D
M=*7QC_R!!Z^='_Z&*9KUC=:I:+!%'\HP<T 9;6VF_:9O](?_ % _+BFV]MIO
M_$OQ</GRSM_(T_\ L"\,C2&/AX_+Q_GZ4D?AV^C:VP@_T=2H_'_]= $0MM,-
MD0+A\?:./KFI#:Z9YMV//;[@S^E"^&[Q8/+\O@3>8/SS2_\ ".7I,K;.9>M
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MME/]6OT%8WB7_CWM?^OA/YULI_JU^@H 6BBBF 4444 %%%% !1110!@>,O\
MD!C_ *[1_P#H8K;B_P!6OT%8GC+_ ) 8_P"NT?\ Z&*VXO\ 5K]!2 DHHHH
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MH :,=N:=1BB@ HHHH **** "BBB@ K \)_\ (-D_ZZ-_,UO'K6!X3_Y!DO\
MUU;^9H WJ0FC--)YH&+FDS2&B@ )H[=,TE%(3^$Y3QB8Y5CM%7?*S=?05SX\
M-.T6XS,5'O6UX@#+XDC9Q\F %K15<Q$>U>;6]ZH>[1J2ITHM&;X0*6-Q+8NN
M7ZASWKL/QKC;(;O$R"+/R\G%=@W4\%<],UUX?2)P8Q*56_<4FD+8ZTA//?TR
M*3=D< XZ5T'$DS-LPCZU=S.,F/ 3VSFL#5M0T.'6)8Y[:1Y&&)'6///;'O6]
M8'_B87?L1_,U5N_"]A>7#S2!@SG) )ZT 9ESJWAL6B6CP3%-G.(N1SWIBW?A
MA[R&U6%O-CC\U4*?+M R/QK7C\-:=&L@V,3( &)YS40\)Z8M_P#:MK;L$ Y]
M:8C'DUCPM<6,CW$,BQ+)SF+ECST-;$7A[1[N%+B.%2'&X'OCWJ.7PCI;P1PF
M/Y8V)&2>YS6M;V\=I:I;P\HG3VH YNYTV&&\8>4NU> OM35MXX+[[:BX90
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M)9&?[5N^>WR\?I3NUL"LBX=WI^M-^;T_6JW_  B1_P"@I=_DO^%)_P (D?\
MH*W?UPO^%(+EDAO3]::0?3]:@_X1+/75;L?@O^%)_P (EGC^U+L?@O\ A0!,
M0?3]:0@^GZU$?"7IJ=WZ=%_PH/A =/[4N_K\O^% #CG^[^M-Y[C]:4>#QC_D
M*77Y+_A1_P (>O\ T%+K\E_PIB*=^2T(4 G<?6JH4[0NT^_-:I\&(V-VIW1Q
MTX7_  I/^$+C_P"@E=?DO^% $OAF-E>=W_BZ5T%<['X1\E=L>JW2CV"_X4__
M (19_P#H+W?_ ([_ (4 ;]'T_G6!_P (L_\ T%[O_P =_P *#X6?'_(7O/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D!C_KM'_P"ABMN+_5K]!6)XR_Y 8_Z[1_\ H8K;B_U:_04@)**** "BBB@
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M;*/3[5+>'E$Z9[4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNT?_ *&*VXO]6OT%(#/.@6C$E@23U/K1_8%GQ\G3I[5J44 91\/6?]W]*/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^13%N(W7*-N&<9% $M%)N'UI@GC9]BN"V,XH DHIN\8!_2D\Z/8S!@57J:
M'T56.HV@ )G0 KN'/4>M);ZE9W2[K>XCD&<94]Z +5%&:*0!1110!SMM_P C
MQ<_]<!_.NBKG;;_D>+G_ *X#^==%0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 4/[$T__GV3\J/[$T__ )]D_*K]% %#^Q-/_P"?9/RH_L33_P#GV3\JOT4
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M2%[>%49A@D>E6J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>allo-20191231_g7.jpg
<TEXT>
begin 644 allo-20191231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S W  "2D@ "
M S W  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM3_Y[I_WR:/;1%RG0T5S_FZI_P ]T_[Y-'G:G_SV3\C1[:(<IT%%<_YVJ?\
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M44606#\3^='XG\Z**+(+!^)_.CM@Y_.BBBR'<C@)_P"$A@YX\MOY5NUA0?\
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MN 6VFNNT C^P;51'Y;)&%9<< @5+07-+)]J3'//6BBH*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H-%%("KJ'^J3_?%=!#_J$_W16!J'^J3_?%;\/^
MH3_=%=5#8SEN/HHHKH("BBB@ HHHH **** "BBB@ HHHH #1VH-':@#&UG_C
MZMZ*-9_X^K>C%<=;<TB%%%%9%A1110 4444 %%%% !1110 4444 %&<444
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MA_SI?[%/_/P_YTO92#F1!*@DA9&!97&TCVJ.TLH+&(16R!8\] .<U:_L4_\
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M_#4>SF',B/ X&T;3PRD##>]+SVP?P& *=_8S?\_!I?[&/_/PWYT>SF*Z(_E
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M+11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0BC%+11<!****+L
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MP(@^TL?E)XS6KG/2N7U;3K-]%2XLU4,H!1_;%;6E2M+IL)8Y;&#2-"]10**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH PO$VJZEI5MYVG6(NN/F)/W?UK'\/^
M,M1U.QFU&_TY;6SCB+!\_>(./6NIU0%M,N H).P\#O7G4]MJMQX'T[1+*)HY
M;N9EE8J<(FYFR?Q H Z71/&D>L^'+O41 4EM0Y>$\$A1FM6PU@7_ (;35"@
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M5VQ]XUI_=.2?QI6.B$;(?129I:9H%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!#< LIPI/TK#N[6=MVV%V]A70FC'M0!PEWIMX^=
MMG,?PK/_ +(U#_GQF_*O2\"CBF!YI_9&H?\ /A-^55YK>:U9?M$#1@]-PZUZ
MF1FLS4-&CU&YADF)"PG./6@#'\(6=W&7F<E8&^ZAKK,TQ%6- H  [ "G"@!:
M***0!1110 4444 %%%% $%[/]FLY9<9VJ37-Z+IL>K!M0O\ ,@=CL4GI7374
M(GM9(CP&&*Y?3;Y]"GDL;Q&\G=F-\<"F!K77AVQGCP%,;=F4UERZ1K,"&&UN
M!)">#NZXJ]/XHM$7]TCRGMM%5#J&LZD"MK!Y"-T<]J -C2K3[!8K;NRE\EC^
M-7NG'>N:.BZMY.[[;F;K4^CZI<"[:PO^95Z-ZT ;X].AH*@T ]O2EH 3;Z4!
M0*6BD FWU_"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%%, HHHI %%%% !1
M12;J %JO<6D%T,3QHP_VA5:^UFULE(9M[X^ZM85SK]Y/_J<1(?;)I@= EM86
M(^5(8ORIDNLV4"G,H/LO-<F_F2?--([9]33?D3H5_.@#7U;QSI6DP"2=W);[
MJ[<5@:+XGCU3Q&UZ\310*N!MY)ZUE>)[AQ8+]B@BN26PVX<K69X0>T6\N&>Y
M8W!49CQA5JXIVU-4HJ'O;GK<>NV$F-LI&3_$N*N17D$W^KG1O8&N(!B8<8^8
M9-*J;?FB++]#4:]3([S.>"#2_K7&6VK7UJWR2"5!U5C6W8^(K:Y(68>5)G'/
M2@#9HI%=64,IR#T(I:0!1110 4444 %%%% !1110 4444 %%%% !1129H 6D
M-075VMK"7<%O8552]DNK=L1^7NX!--)LGF2+^Y0W457EO[>)]I<EL]%JC# Z
M.7>5G/H>E.\J-'+C;GN2<UIR(GG9:N=1BM54N&8-_=&:6/4(Y+<S88 >J\U4
M6>WD?;&ZLW<4UKBW1]CR*I]*.5"YF7(-3@N)-L8D![Y3%3&ZBW[!(F[TW527
M8.1@9[BHFM86;>5^;U!HY$',S7XXZ_A3A63.]T0OV:3:5_A(ZU:BO@MN&N?D
M(X-2XV+4KERBHXY4D4/&0RGH13R<=:@H6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HI,T9H 4U!/;17"XGB24>XJ"]U:VLU.]\M
M_='6L"Y\075UD6ZB)?7UI@;Z6EA9\K'%'^0ILFK6, /[T?A7)2F29B9YF8]^
M>*9MC3_ZYS0!M:IXVTG3+?SIWD]@J]:YW3?%::OXF6Y,1AM@N58#DU0\1W#+
MII%K;Q7![AATK!\)O:?VJSS3.+DC'DG[JU<8Z:FL5'EUW/8(=>L)CA92/]]<
M5=BO;>;B.96/L:XA2D@ &#^E CVG*,R'U!K/7J9:G? TM<7;:I>VF-LOF(.S
M5M67B*"X95G'E/[]*8&U135=7 *'(]:=2 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBD8@#F@!::?J*0R*N<G'K6#J/BJUMG\JT'VJ?H%3D ^]4HM
MDN21O'I_]:JUQJ%I:$"YN8HSZ,P!KEY)-9U0[IY?LL7>./K^=,CT:S5LS,UP
M_?S&-;1H]S"5;L;DWBG3+;(:5Y,=T7=FJW_"::<WW([AO^V1JIBRLUY$48'8
M\XJ,ZMI7>YMP?3;C^E:*C$R=:1?7QKIV<-%<C_MB:L0>*M,G)_>21CUD0K_.
ML<:KI3' N8/R_P#K5,%L;Q?D\J0?SH]C$/;R.B@U*UNF M[F*3_95@35D<\U
MQCZ):,VZ'? W]Z-C3X9-8T\EK>X6ZA7^!^M9NC;8TC7;W.R'%%8&G>*K>X80
MWBFUGZ%9.A/M6XL@<9'3U]:QE%HZ%),D%%(#14E !S2T44 %%%%, HHHI %%
M!J"YN([6)I96P@&: 'RRI#&7E( 'J:YG4=>ENBT-G^[CZ%ZJZA?S:E-\QV6X
MZ*/XJJ_>(CB3+?PJ/ZTP$P(_F)RQZLW>I(8;BZ8+:QEO]HBMC3O#Q?$U_P G
MM'VK?BACA4)&@51Z4 <[!X9ED -U-CU45H0Z!8PKG9N/J:U:BNF*VLC+U"\4
MF[*XTKNQP/CZ+2Y;5+6.X\B6-MVR(<GBL/PMK5KILR0W=A&$E./-(Y/UJE\]
M]?7%Q.<R%RH_.B_MPD;8ZBO+GBIMW1]32P-/V:A+6YZN-(T^[A618P5<9!6J
M<WA=02UI.4_V35GPP7;PY:%^OEC^5:V:].+;1\S4CRS:.+N;&\LR?/CRH_B4
M56RLHY'^-=VXW+@@,#U4UD7^A0W.7M_W,O4 =S3,S(LM3NM/( ;S8_[I[5U5
ME?0WT DB8$]"O<&N-F26TF\JZ7#=FI89I;.;SK9L$<LH[TP.ZHJCIFI1ZC"'
M4X<?>3TJ]2 **** "BBB@ HHHH **** "BBFNP1=S' [F@!68*I)('UK.OYI
M64)9L 3U:F7N;W"I)MB'4_WJ%V!E3A<#A3WK51,W(1%(558ESW)J*:X*/Y<,
M;.WTZ5*EG<S7&Z5O+C4\!:TEC53G: ?4=Z.:PN6Y1DL9+B%?WAC)'(%36U@D
M$6QCO]2:N4AJ.9E\J*\=C!"VZ.)0WK1)96\C[GA5F]:L44KL=D5I[*&XCV.I
M4#TJ-=/CBA*1%LD<$GI5VBB["R,B&*\$Q6=!M'1@:<7BEW(<,>A4UIXV^X-5
M)M/@DF$@RC^HJU*Y+C8KPC[%&QA'7HAJU97Z78*X*R+U!%4Y[A;><1RJWS<!
MJ><J6>( /C(/K1))LE2:-0'BEJAI]ZUP#',A61>M7>XJ&K&B=QU%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%!XJ*>9((3)*0JCJ: %DE2)2TC
M!5 ZDUS>HZ_),6BL054<%ZJZEJ4FI3%%.V!3Q[U3SC"@9/\ "@[TP$( /F2/
MN;NS=JDABGNOEMXR??'%:NG^'S-MFU#H>1'70PP1V\82%  * .=@\-SRJ&N9
M@GJ@K0B\/64.,H7/J36MFF3,5@=AU"DTKV#<X7QW'I9TO[&DX@D!^['U-<QX
M9U>UTB=5N;%2C':9&'S4VYW7^L7$\WWO,8?K4=Y:@0,#Z9%>7/$SY]#ZFG@J
M4:?++5M'J::7I][ CQQ#8PW J:JS>&8\DVTS(?0TG@DN?"]J9>NVN@S7I0ES
M13/FZL.2;B<;<Z=>V63)$)4'=157*3#GYO4=,5W9(.1U]0>]9-_H<%V2\/[F
M3V[U1D8EEJ5UIQ!5C+%GE3VKJ;#48;^,-&<-W&>17(3PS6DQBN5P>Q[&DB>2
MVD\ZV?:PY(_O4P.\HK.TK5$U& =I5^\M:'?%(!:* <T4 %%%% !1110 4444
M %%%% !1124 +FJ>I:C;:=:M-=2!0. .Y/I4.JZK!I=LTDIRY^XG=C[5R\-M
M<:E<"^U;YF)S'!V4?XUK"FWJ8U*BCH.GN-1U_.XM9V0/W1]YA5B**STR(LI2
M%<?,Y^\U1WNI"&5+6S3[1=,,)&.WUJU8>&&G9;C6I3-(>?*'W4]JZ/=BCEM*
M3**WUWJ$FW2+1G&>)9!@5<3PS?W9#:A?,$/6)*ZB*%(4"Q*$5>@7@4^L95F]
MCHC02W9A0>$M-@(S&S_[QJY_8&F#_ERB_*M&@UGSON:J$5T,T^']*_Y\HORJ
MI<>%=.F/RQM'_N'&*W**.9]PY%V.4?PS?6K$Z=?G8.D;\YJH]]=V4FS6+,KS
MQ+&,BNVJ.:))XS'*H=3U!K2-5K1F<J*:T.6DBL]3@!.V0$<'/S"J\-Q?Z WR
M.UW9Y^96Y9![5=U#PR8)#<:+(89>IC)^5JJV>I>=*;:\C$%ROWD8?>]Q6R<9
M',U*#.FT[4[?4;<2VT@8=QW%7<UP\UK/ID[7VD-MD)R\1^ZP_P :Z?2=6AU2
MT$D)^<??1NJFL*E.QU4ZB>C-*BD'WC2UB;!1113 ***,T@&R/L4DD  9-<AJ
MFI-J%P5C.($/;O6GXCU!HT%K;G]ZX^;'I7/-^Z0;1R!@#U- "[79ECB&9&^[
MBNITG1TLHQ)(-TS?>)[5#H>F"VB%Q.-TS\C/:MD4P%V_E1]***0!45R,V[CV
MJ6HK@@6[Y]*3V*C\2/'[%<74XQ_RT;'YT_5%_P!'QW'?UIMDW^E3_P#71OYT
M_4SF$D>U>')?F?8QDTXH]-T ;-!LQ_TR'\JT:SM#.=#LR/\ GDO\JOYKVX['
MR57^)+U ]:3H<YHHS5&17O;&&^C*2CYL?*W>N4NK=[&X\F08*\AO45V)Y.2:
MJ:A9I?6Y23[PY0^],1S-M<O8W0N8AQGYE/>NSM+N.[MUEC.0P_*N(*O%,T-P
M/G7]16CH=\;*\,$I_<R_<]C2 ZWZT4@/'6EH **,T4 %%&:* "BB@].: &Y]
M:SM0/VI56.0A ?FVU9O"QMV5& 8U2MX1;P[0<[CDD^M:15R)2Z#E58PD?&#P
MJDT^WTXBY,]PY8_PCTI(+$O="XF;(7[@K2.,=*4I6",1,4M%%1<L,T444 %)
MFEI* #-%%% !28YYY'I2TA-,!DL,<JXE4,/>LZZD^SW:H4.QNC>E:=,:,. )
M/F/:J3$XZ%%VD52;<@R=O<59T^\^V0;B"&4X;ZU3\_\ TQH'78PY7W%.>Z:S
MVLJ 1DX;%7)71FG9FM134<2(K+T(IP]JQ-0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 0D#.>/6N1UG4C?3F*-OW"G''>M7Q#?M;VXMX3B23]!7-#;$F
M0,C^M !R2J1+ESQMKIM(T9+5!-.-\QYY[5#H&E^6OVJY&96^[["MZF  8HHH
MI (::XS&P]C3J1SA&SZ4GL-;GD)7&NWP[><P _&C4!_H[4K-_P 3Z^/_ $W;
M^=&HG,+8KQ)?$S['6R]#T7PNGE>'K9?]FM;-9/AMP^@VQ!XVUJU[-/X$?*5_
MXLO4,^O-&:0T'VJS$@N;2*]A:.50?0]Q7*7EI+I]P(Y?F4GY'KKR05ST-5[V
MU2^MVB?DXX/I3$<M%*]K<+- ?F4_,.S5V-C>I>VJS1L,8^;V-<88GMYF@DZJ
M>">XJ[I%Z;&^V$_N)3T]#2 [ =**0$%01TQ2T %%&:* "BBB@ HHHH ****
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M0T9HH **2DS0!!=)&%\\KEH^:JQNES'D#Y&[5H-AN",@CD506%+:0Q(V<_,
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M44V,YC4^HHKA/06PZN)U'/\ ;5T?<?RKMJXO5%(UJX]R/Y4#)_#X_P")T_\
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M%93>8UY#&@(53DD5L+G'-1)ZEQV%HHHJ"PHHHH **** "BBB@ HHHH ****
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MM8X6W'+R#^-NM3%L=. >H]33"WO36; IDMCB:8S8IA:FEJH0XM3"U-)J-FH
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M\\8CU3W-3W\\D\JZ=8?--*?G(_@'^-.OK]XW6TLHQ-=R\*J\A!ZDUM:'H?\
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M#^-,=_I^=9WV9>S$?C2_9E[EC^- %EI4'5@/QJ![N,<+EC[4W[-&.2I^I-.
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MYYI6F'- UHX(H@3$BJ>Y J3J..15.XU.VM8$EGD"*XX![U$VMV*O&IN$&\9
MS2Y9,?/$TOPI:PK/Q''=ZP+$1D':6#>O-;M2XN.Y2DGL%%%%(84444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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@+^8 $]-W6GV>@VEA(K6XD&TY.6SFM6B@ '2BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>allo-20191231_g8.jpg
<TEXT>
begin 644 allo-20191231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,CD
M  60 P "    %   $*"0!  "    %   $+22D0 "     S4S  "2D@ "
M S4S  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]!WKZ>G;D1\36=ZC$X]ORHX_R*7:P'"L1WXZ4#..V>]6FF9O3H)Q_D4<?Y%
MYZ<_UHYY]0.<\=:+I;BWV0<>WY4<?Y%+TSG(^HI!TR:%KJ#N@X_R*./;\J4*
MW96;U(4D4F<8]>X'-)2BW8;C)*X<?Y%''M^5&>?_ *] [TQ=+AQ[?E0,9_\
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M'N91_!?J***!17GGLA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_\ (='_  I$_P#05_\ (=/Z[1[A_9N(_E/)*.Q^E>M_\*1/_05_\ATA^"+
M?\A7V_U=+ZY1ON']G8I?9.+^'W_(]:=_UU_I7TD#D5YGX>^$YT37;;43J'F&
M!LXV=:], P*\O%U(U)WB>YE]"I0I\LQ11117&>F%%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449YH
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M P#^)KQ75=.DTG5;BQE&&@<K]1V_2KBU+1G-4IRHOF@]#W?P3\6[+76CL]7
MM+QL '/RN?Z5Z2K _,._<5\: E6#)D.#P0<8KVGX5_$A[AX]#UR;<X&VWF8]
M1_=-8U:-M4>AA<:Y^[,]ES13 <C(_2G5S'KBT4"B@ Z49H/(I"* #<*S=:UV
MPT&Q>[U*X6*-1GD\GZ4W7M:M- TB:_O7"I&O S]X^E?,OB[Q=?\ BW5FGNG8
M6ZM^YAS@*M:PAS,X\3B525EN=7XL^,>I:I(]OH9-G;9P)/XV_P *\\N+FZO[
M@M<SRW$CGJQ))-5\X^A&,'M7H'@GPVB^&[WQ!<KB2*-A;Y7."/XJZK*"/#4Z
MF(EJ]#,TKX::]JD"RK%';(PR/-."15J\^%&O6T+/$89PO\*MS^5=M:WUWH\V
MF3-J#W27D9>6*1\A2.X]!4]IXVN+B.Y+VBG[.%=BI( 0D<\_6H<G>YU1H4;:
MGB=Q!=Z;=M#,LEO.IQ@94BNL\-?%'7]!EC6:<WEJ.L4IYQ[&NN\2Z9'XWT"[
MU"VM4BFM6VP2 #,HP"3^N/PKQTC&>>AQ6BM41RRYZ$KQ>A]4>$O'&E>++-7L
MI/+F4?/"Y^93_6NFW"OCW2M5N]&U"*\TV9H9T;.0>#]:^D_ 7C6V\7Z.'R%O
M(>)HSZ^H]JY:E-QU1[&%Q:J^[+<["BC% K$] **** "BCI24 &>:Y_Q3XQTO
MPM9&:_F!?'R1*?F:J_CCQC:^$='>YEP\[_+%%W8_X5\T:UK-]X@U22]U.4R2
MN>%+<*/05M3I\VYY^*Q2I*T=SJO$_P 5=<U^9TM7-E:_PHA^;'N:XP"ZU"Y"
MCS+B9SQDELFHN_/7OCM7I>C^&_[$\'V^JAVBOKRX5!(IP44]ZZ7:.AXRY\1+
MWF9&G_"S7[V)99A%;*PR$=OFJ/4_AAK]A"942.Z0=HVR:]#CU:ZT34;ZT:[^
MVQI$KI)*V2K''&>O>DM/';/;^;=6Z11*YCD<!@ 1R.OUK+GE?0ZXT:-K=3Q.
M.6ZL)\Q/+;R(>0I*D5WOA7XO:QH\B0:NQO[7NQX91_6KOCKP^-7\.Q^);>V6
MVN?^6L:<;E/>O+OPR.H]JU2C):G,Y5*$M&?6_A_Q'IWB/3TNM-G$BL.5[J?>
MM?-?)7ACQ/?^%=62\L96*_\ +2,GY7'TKZ;\,>([/Q/HT6H63##J-Z9Y1O0U
MRU*?*>SA,4JL;/<VQ10.!161W!1110 49HII[\4 *<8KCO&?Q%TSPG"8V;[1
M>$<0H>GUJC\2_B GA6P-I8L'U&9?E](QZFOG>\NYKZ[DN;J5II7.YG<Y)/?\
M*WIT^;5GFXK&*G[L=SI/$/Q%U_Q%*PFO&@MV/$,7R@?6N?L=/O=8NQ#:0R7$
MCGL<X^M000FXG2*,$O(0!7KEGX=&@7>DZ;;7+6LMTC&XFCX).">M=#:CT/)@
MJE=WDSF;;X3:[)%OD>WA.,[2YS_*LO6OA_KNBQ&:6!9HAU:,YQ]:])@\4W>G
M:7-'(R7,L,[Q)(^6WJ #GCGO4J>-O,LXVGLU#W,:F%2,^:3@$?K4<[.IT*#T
MZGBMGJ=[ID_F6-S+!(IXVMT->G^$/C/<VTD=IXE7SXCQ]I7@K]1WK!^)/A5-
M'N8=2LXQ'%=*#+$O2-JX4\U?*IHY.>IAY;GV%I^HVNJ6D=U93+-$XR&4Y%6P
M>*^8O /CR[\(ZDD<C-)ITS@2QDYVD]Q7TII]]!J5C%=VD@>*5=RD5R3IN+/>
MP^(56/F6J*0<T=ZS.L6BBB@ S29%&*:0,4 *SJ%R3@"O-O&WQ:L=!9[/2@+N
M\Z$@_*GUK'^*GQ(-HSZ'HDN)B,3S)_"/2O$R23\[,S$Y+9S^==-.E?5GD8O&
M\GNP-S6_&&MZ_,S:C?2,I/$2G"C\*KZ1X=U/7YV33[<S8Y9VX"_C3=!TB37=
M:MK"(?ZQ@K^R]S7JT>F&RUN?2["^:Q@L[59%P<!F^;D^O2MFU'1'GTXRJOFF
M]#E4^$>N>5EIK</C.W<?\*YS6_".L>'_ )KZW_=_\]$Y'YUZ?%XXNH='LY9(
MEG=E4RER<D$@9P.G6M"3Q(FH7/\ 9%W8J[32!/*."/+(!W?J:S51WU.F6'IM
M>[N>,:7XAU;19Q)IE]+"1V#9%>O>"OC+#>/'9>)5$,I.U;A3\K'W]*\Q\;^'
M?^$;\120(O[B3]Y$1_"/2N=(!QW[^X-:."FKG-"O5H3LV?94,\<T"RQ.&1AD
M,#D&G@@]*\!^%_Q'GTJ\CT?69B]E(=L4C')C/H?:O>XRK(&0@JW(([UQSBXL
M^@H5HUH76Y)1114&X4444 %(3Q13)I$BA9Y2%11EB3P!0&VXD]Q%;0M-<2+'
M&@RS,< "O%?'GQUCM))=/\*1K-*.&NG/RK]!WKEOBQ\4;C7[Z72-%E*:=$Q6
M21#@RG_"O*@,9QT_B.>3753H]6<%;$/:)JZOXDUC79S-JE_+<,3P,D 5:\/^
M"=;\2D-IML?+)_UTG"U8\ ^%_P#A*?$RVT@/V:)?,FQQD>E>DJ;K3['5+RPU
M*2W73[H10VN[Y67=C&*UE*VQSQ3DKR.6?X*^(%AW)/;%\<KO//XXKC];\-:M
MX<N FI6KQ9Z29^4U[E+XYN(M6M;);:)UF*1E@3E68 ]1P.M*NJ6_C@_V-=6"
MDM$QN2QYA88 'Z_I4J;V9I*E&UXGBV@>./$/AN97TO4954-_JW;<K>V.U>[^
M ?C-IWB-DL-8"V.H,<*<_)(?Z&OGOQ'HTOA[7[O3I^/*8[#_ +/8UF@E7!3.
MX'(P<<^WO52IJ2,X59P=F?="L"N0<CM3J\/^#OQ3>\:/P_XAGW3*N+>=C]__
M &3[U[>OMTKBE'E=CU(34U=#J***DL**** "BBB@ HHHH **** "D/2EI&Y4
MT ><_%WQ:="\/"QM)-MW>?*,'E4[FOG@G)R>377_ !0UDZOXYN\.6AM_W4>>
MV.O\ZX^N^G%*)\QC*OM:COL@QR#7K?P<$?\ 9=^3CS/,&<^F#7DG^&*[#X=>
M)H] U_9=G;;7("NWH>U5-.Q.&FH5=3UZ+POH\5T+E+8F3=YG+G;NZYQ3!H6D
M?VA)/;1H+Q#Y@ <G:_J16PC"6,-$X=&&5=3D$5S.AV/V+QGJP4RLDB(VYLG<
M><C/I7(I-'M22Z;&CX=T3^Q8;@R2+)/<RF21U&!7D'Q.$0\:7'E[=Y0%]OKB
MO:=6U6VT?39;R]D"(B[@&ZL>P%?.NM:E)K.L7-_-]Z=\CGH.WZ5K33O<XL9*
M*@HHH]_UI\,LEO.DL#%)%8%6'K3*.XKHZ:GD_"[H^H?AUXG3Q-X5AF9LW$/[
MN8?[0_\ K5UW:OGOX)ZR]EXJDTYV_=W29 _VA7T'UK@JQY9'U&$J^TIIBBBF
M;L-C/X4 D]",5F=-QQZ4C>IZ"EK(\3:H-&\-WM\_2&(D?E3CJ*4N6+D>(?&'
MQ6^K>(#I5K+_ *+:'#8_B>O-ZEGGDN;B2>9MSR,68GN:BKT81LM#Y6M-U)\S
M#UXS7T%X.MK:Z\!64+ -%+%MD'N1S7S[^@[UZM\*O$\(M6T6\D$;JQ:$N<!L
MG-145SHP4HQJ:]3N;;POI%H&$-MC>NP[G+8'MGI51O#M@--N[?0C'')*ODR,
M6W )GI^E:6N27L.D3G3(_-N&&%"GFN>^'\=S!;:A!=P21XG+%I#DGFN=-GI2
M47*QT6G:=#I6AQV4>#'%'AF]?4U\XZ@$&I7 B^YYAQ^=>Y^._$T6@Z%*BN#>
M3J4CC!Y ]37@>26)/)SS6U%'GXV2>B"M[P9XCF\,>)+>]B)$98),F?O+6#1V
M_E[5JU=6.&$G&2DC['M+J*]M8YX&WQR*&4CN*L"O//@[K)U+P4EO(VZ2T8QM
MGT[5Z"#\M>?*/*SZJC/GIJ0ZBF[L]"#ZTH.34FP5#<3I;6\DLI 2-2S$U-7#
M_%;6O[&\%7(1MLMS^Z7\>OZ9JH*\K&5:?)#F/#_'GBB;Q/XFGN"V;:)C%"F>
M@'>N9],]:#SUHKT$K+0^6JRYY-CDQYBAN 2 :^CTTNRU3PY:6UW#YD'EHRJK
M8.:^;L9[X]*]Q^'/BF#5]%CLI7"W=N-NUCC<*SJIM7.O!2BI69MMH&BVEC+'
M-"(X'/SL[\DYSUJE>^%;2^TY+;2VCBM)9 \S [BQ'_UJC\>P326%ELRL(GS*
MP4L%&#R0/>M'PD[MH$.Z+R]LA"A01N'K@]*Y[NQZ=E*5FB37XH8_"=[%M'E)
M;D+7S>,;0/RKV3XG>*HK32SI%M('N9QA]ISL'I7C8& !Z<5T4D[:GEXR:D[(
M*[OX5>+7\/\ B6.TN)"+.\?RV![-V-<)2H[))YD?WE(8'Z&M)Q4D<M*;IS4D
M?9J,&0%>0>E+7/>"-7_MKP;I]YGYFB"MGU'']*WR2,Y-><U9V/JX24H*7<=1
M3 ^[!!!%.SFD7NKH6L[7-5AT71[G4+AL1PH6/OBM&O)OCGK1M]%MM+C8AKE]
MS 'JHJHQYG8QK3Y(.1XUKNLW&OZQ/J%VQ+3,6 /85GCK29SUHKT4K+0^4DW.
M3D]S8\)A&\4Z>)1\AD&2:]]U+1-/U9XY+^$NT7"LC%:^;[:=K6YBGC)#1.&'
MX5]#>%O$4'B+1H;B%QYF,2)GE3]*PJW1Z6"DOA876CZ#%#;V]TD<2(Q\L%R#
MS[U7;PI$VJ:=(A1+*P!,40Y)8CUK%\=122ZM%]Z," [/D+"1LG@8Z'WKM;(G
M^SX"Z[3Y8RK=4]R:Q=['<N5RU6QR7Q5"-X/8O@'S1CV/%>'=OH*]#^*7B:+4
MKM-+LG#Q0',K@\%O:O/!Q7325HGDXN2E4T"O8?@KXN<7,F@7DF0PWV^3T]17
MCU:&AZE)I&N6E]"Q5H90V1Z551<T2,/4]E431]>+3LU6LKE;NSAN(SE)5#@_
M6K#$ 9R!]:\ZUF?4IWU'44P-G\.M.!H"X'O7*?$'Q,OACPK<7 8"XD&R$?[1
MKJCUKP#XWZR;OQ+!IJOF.V7<RCLQK2FKLY<55]G2]3S6>:2XG>:=M\DC$LWN
M>:CI2,4E>@M-CYAZMMG<?"@+_P )@2_WA"=ON=M>LWOAO3=2OOM=U [3;0I8
M.0"!V_6O O#FL/H6O6M^G(C;#CV/%?0EK=6VN:2);6?=#<)C<AY2N:HFG='K
MX.2]GRLH7&B>'YQY\ZQA(@(CM? &T]/TIFG:(C>(&UEI8I5$?EP"/LM<Q/:-
M;>'[N"))1&-18>8P)VKD_,?6NC\'2"T\,E[EO+B21B96!4,N>O-0W<Z(M7N<
M=\90@_LX_P#+0AMWTXKRZNG\>^(AXA\1O) ?]&A_=QGU]ZYBNB&D3Q\0^:I<
M4'!!SAAWKZ%^#_BQM;\/FPO9,W=GA?=E[&OGKT]JZWX9:R^C>.+/!Q'<GRG'
MKGI2J1YHFN$J>SJ:;'U OM2TP'H?6@OCJ?8>]<!]+=#Z*;DTHZ4#$)KR?XX^
M,VT304TBS?;=7XY(/W4Z?XUZPY 4D] ,U\A?$[7&U[X@:A-O+1PMY48[ "MJ
M,;LYL1-QC8Y'IW.3P312Y/K17>M#RCUSX%A ^J-_RU^7'^[S7HS^$M#%W)>R
MVQWEC*Y,AVYSG)'2O"?AUXG7PSXH22=BMK<#RIL?P^]>^ZW!!K/ARX\J8M$T
M1=6A;[PZ]:Y:B:9WT))QL4Y]%\.)=)J4WDI)*XDCD,GREAP#C\*D\.Z =)N;
M^\N)8Y;J_E\QV0?+[8KAM6M/*\)Z:2K%_L\L:Q,A/))Q^-=S87PT/P9;7.KR
MB(Q0@OD]2!T^M1JS71:L\?\ C,$_X3564#<8EW?E7GU:WBG77\1>([G4&SM=
M\(/1>U9%=4;I'G5&G(D@GEM;B*>W8I+&X9&'8BOKCX9>+4\6^#[>Y9@;F']U
M,/\ :%?(F3VKU?X :Z]CXNGTR1RL-W'D*>FX5G6@FKHVP\^65CZ5HIN3Q3JX
M3U0HHHH **** "BBB@ HHHH *ANY/*LYI/[B%OR%357U!#)IMR@ZM$P'Y4(3
MV/D/5)#-K-Z['.ZX<Y_&JGH1T-6-04IJERA_AE<?K4 4E@!R2<#->DM(H^0F
MFY/U$Y/0'\J.#QWK6N/#&I6UNTSQQNJH'95;YE!Z<50%E<D']PXP1GCI5)KJ
M')*^AT/A_P >ZSH*+$D@G@'_ "SD/3Z5T,GQCO&AQ#I4"2D8,FX_XUQ0\/:@
MPF81C;"NYSG[M4/LER7V?9WW8R0!V]:SM%LW52NO=6QHZYXEU/Q#/OU&X)&<
MA!PH^@K)/^<5:ATV\G<)%;LQQGD=J9)9W$3.#"Q" ;B!P*K1&+YYZR(*.E2/
M!-$@:6)D5NA(ZU&.2!3(:9T'@6[:R\;Z9(AQF8+^9YKZM4Y45\F^#H&G\9:7
M&H)_TA3QZ9KZR7A17'B-SW<MOR,\G^,'B#4_#NJZ3=:7=-"PR2G\+\]ZL>$/
MC)I^I[+37 EG<XQOSA&-9_QMTR]U74M(M].MGN)6! 51[FF>#_@JB&.[\3OY
MC#YA;KT!]S3]SDU!NNJ]H;'L$4L<\2R1,'1AE64Y!%<-\8;HVW@"X"_\M7"'
MW%=O;6T=G;1P0)LCC7"J.PK@_C/"9? ;L/X)0364+<VAW8C^#(^<Z*.U7M,T
MJXU:8Q69B#^DC8S7?LCY1)LHFG12/%(KQ.4=3E6!Y%6)]-NK:5D:/>0VTE.1
MFHS:7/S9MY/E^]QTIZ,I1DMCLM'^*FLZ;"(KQ$O4484N,$?B*MW_ ,7M2F@*
M6-C!;.W5^N:X'[+/A"(7^<X7CJ:EN=.N[-XEN(2I<<8'6IM$V]K52L%_?W>J
M737-_.TTC'DL>@]JJ]>E6K;3+RZD5(+9SOS@XZTQ[&Y5F41,VP9) Z"FK+8Q
M:G+<@HI[V\T2J\D;*K="1UIE-"LSV+X"W!$^J6Y/#!7_ *?UKVG'YUXC\!82
MVH:E+V6,#^5>X9KAJ_$?28+^#J>!:G\1M8\*_$#4H8Y/M-D)N89#T^AKU#PI
M\1-%\4H%@G6&ZZ-!(<$'V]:\AUSP9K'BCXB:DNGVY$)G^:9QA17I_@WX7:9X
M9:.[F_TJ_'65N I]JN2ARZ&-!U_;-/8[S/I7CGQ[N6%KID /#2%B/P->QX/'
MZBO&/CW#@Z7+V+,OZ&LZ7Q&^,NJ+/&:"".WYU8LK.74+V.UME5I9#A03BK<O
MA^]@\S(BD\M"[;&S@9 S^M=]TCYF,6UH9G&:GM;NXL+A9[25HI$.5932?9;@
MR*@@?>PR !VJ233;R*-'>W<"097CK2;3T*2DGH=MI_Q;U2V@$6H6<-Y@8W,,
M9^M1ZM\6-7O+<PV,$=FI&,J.1]*XD6ER653!)N89 QU%-%M.=^(I#Y?WOEZ4
MK1-W6K6LQ;BXENIFFGD:25CEF8Y)J+_&IA:7!X%O)G&>G:II-*O8K99Y(2%;
M&WU.3BFFD8\LY:M%.D_^O4XM;DNR"!]R]1CI4.#D\4[DM-;GT'\$+II_!<L3
M'/E7#*/88!KT'4B5TNZ93@B%R".W!KSCX%0F/PC=2$'Y[DD?]\K7H^I<Z7=
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MR^O:?Y'VOSF02.[?9E7ID$8^@S7%T5/*C7VWD=J?%NFQVC1PH2^Q@A,1^4D
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ML*AL-/MM,M([6QA6&&,85$& !5D#!KBJ3YF>K3IJFK#J***S-0HHHH ****
M"BBB@ HHHH **** $I:** &.H8$-S]:Y77?AQX>U^1I+JS6.9AS)%\I/UKHM
M1U"'3+-[JY)$:=<#K[5GKXGLE16N=]NSG"I*,9JHW,YQ@_B1YO?_  %MV?.G
M:FR#L)$S6>/@+?%^=4BQ_N&O8SK.G*P$EY CD<J9!FI9-1MHK=IFF0H!G(:J
MYYG*\)AY=#RW3_@381LIU'49)@.JHNW-=SH7@?0?#RC[!8H''_+1QEOSK037
M=/:V$QN8U!C$FTM\P7&<XJ>#5+.X\H17$;-,H:,!AEA0YR>YI3HT(;(M "G
M<]*1>G%.K,Z@HHHH **** "BBDH ,TTCVH9MJD]A5"'6[&9$8W,<9D8JJLV"
M<,1Q^(HL*^I8NK."]A,5U$DL;#!5QD&N'UCX.>&M3D:6VB:RD;KY0X_*NO@U
MW3;B,.EY#@D@ N,Y%.EUFPAL7NC=Q&)0?G#C!(JDY+8RG3I3^)'DES\!) Q-
MKJRE>P>.HX?@)=;QY^K1JO<(A->R6^I6MQ:I.DR>6XR#NI/[5L?),@O(=@.-
MV\8%7[29S?4\/>]CSW3/@AH5JP;4)I+OU4_*#]?6N]TS1=/T:!8=-M(K= ,
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MN<]1FM%>QSMPDS0M_")C8--Y;D,Q)/?*D?UJO+X6U$HMND\?D@AF8YR#D_\
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M01$/NOCUIZ$WE_*=+;SZ;9QI;V\D,2MRJ ]<UHK7'V_@Z:-)VE:-Y9'5T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D[TM% "'KS2T44 %%%% !1110 4444 %(:6DH S=?D>'P_>O$Q1UA8JP[<5
M\T-XKUX.W_$VN?O'H>.M?2OB/_D6[_\ ZX-_*OE-^9' X)8@5QXB4D]#Z7)*
M<)QFYJYK?\)7K_\ T%;G_OJC_A+->_Z"MS_WU5;3/L32O'?(Q:7"QD?PGUK<
M33M.N+Z;3S:/ MNH8W&[._U_"L%SOJ>Y/V4-X_@9G_"5Z_\ ]!:Y_P"^J/\
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M0G"\4M,F+B!_+QOQ\N>F:!/1"AC_ )[THS7#>%+C5#XRUJWU6Z\\QA"J@85
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M."5=16WE)<X<<]./:CDD)UX(]4R:3->;3>-6T>34R(F>Y-VL*K))\H)5>>G
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MY3..GY5H+XBM9YOGG\D(B8;R@<@ ;AUJ[+N<=ZB;]TPFN]2U.S>/<94C!9^
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M9_B!JES9ZG;PPQ17,-N9HY5Y7'/^%'+)%2J4GNCH'^'FCB*!(3/ (%\L,DK
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MW/EFZ\D,V?NFL_PKXSN]=U3[-.EN%";LQDT79I^[?0Z#4?#UCJ.AC29DQ:@
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M>UU326T^Z4F!@!UZ8[UIX%)M%#DV-02V.4T[P#IMAJ\>J"6:6\08\YVY*XP
M?PJ_KWA>PU_RGN-\5Q"<QS1':Z_C6YM%&!Z47=PY(I62.7@\":7!IDUF/,?S
MW62:5FRSD'(S^5:5GH-I9ZM+J$6[S9HUC;)XP!Q6M@>E&T478E3BMCE-1\!:
M=J&K7%^\]Q&]SCS41L!@.WZT^\\"Z5=QVJ(K6_V5/+C:,\E>XKJ,"EQ3YF#I
MQ;O8YK_A"M,5I\!P)X%A< ]0"?\ &EN/!>EW*;)E9E-J+;&?X 1C^0KH\"C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JM_#)<6$T<+;79< U:HH X?
M2-,O%O8XY-/: QR;FN<]1Z4FM6UUJFL75L--N(8U!\J>,#$CXX)/8=:[FB@=
MSAUTB>^L+Y9;&2-3;)&L;?+OD7JPJ.\TF^?5+=OL\V0L80*OR$#J&/8UWE%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>allo-20191231_g9.jpg
<TEXT>
begin 644 allo-20191231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M?^8?\1"S[_G]_P"2Q_R/UG_XBA6_Z(N?_"F'_P CT?\ $4*W_1%S_P"%,/\
MY'K\F**/[$P?\GXO_,/^(A9]_P _O_)8_P"1^L__ !%"M_T1<_\ A3#_ .1Z
M/^(H5O\ HBY_\*8?_(]?DQ11_8F#_D_%_P"8O^(AY]_S^_\ )8_Y'ZS_ /$4
M*W_1%S_X4P_^1Z/^(H5O^B+'_P *8?\ R/7Y,44?V+@_Y/Q?^8_^(A9]_P _
MO_)8_P"1^L__ !%"M_T1<_\ A3#_ .1Z/^(H5O\ HBY_\*8?_(]?DQ11_8N#
M_D_%_P"8?\1"S[_G]_Y+'_(_6?\ XBA6_P"B+G_PIA_\CT?\10K?]$6/_A3#
M_P"1Z_)BBC^Q<'_)^+_S#_B(6??\_O\ R6/^1^QWPI_X./9/B;<^)(_^%1_8
M_P#A'_#M_KV?^$B$GG_9D#>5_J!C=G&[G'H:Y<?\'0S$?\D6//\ U,X_^1Z_
M.W]E/_D(?$;_ +)WKO\ Z)2O*ZSCD^$<VN7MU?\ F=5;C[/(T*<U6U=[^['H
M_0_6?_B*%;_HBQ_\*8?_ "/1_P 10K?]$6/_ (4P_P#D>OR8HK3^Q<'_ "?B
M_P#,Y?\ B(6??\_O_)8_Y'ZS_P#$4*W_ $18_P#A3#_Y'H_XBA6_Z(L?_"F'
M_P CU^3%%']BX/\ D_%_YA_Q$+/O^?W_ )+'_(_6;_B*%;_HBW_ESC_Y&H_X
MBAF_Z(M_Y<X_^1J_)FBC^Q<'_)^+_P P_P"(A9]_S^_\EC_D?K-_Q%#-_P!$
M6_\ +G'_ ,C4?\10S?\ 1%O_ "YQ_P#(U?DS11_8N#_D_%_YA_Q$+/O^?W_D
ML?\ (_6;_B*&;_HBW_ESC_Y&H_XBAF_Z(M_Y<X_^1J_)FBC^Q,'_ "?B_P#,
M/^(A9]_S^_\ )8_Y'ZS?\10S?]$6_P#+G'_R-1_Q%#-_T1;_ ,N<?_(U?DS1
M1_8N#_D_%_YA_P 1"S[_ )_?^2Q_R/UF_P"(H9O^B+?^7./_ )&H_P"(H9O^
MB+?^7./_ )&K\F:*/[%P?\OXO_,7_$0\^_Y_?^2Q_P C]9O^(H9O^B+?^7./
M_D:C_B*%;_HBW_ESC_Y&K\F:*/[%P?\ +^+_ ,Q_\1"S[_G]_P"2Q_R/UG_X
MBA6'_-%C_P"%,/\ Y'H_XBA6'_-%C_X4P_\ D>OR8HH_L7!_R?B_\Q?\1"S[
M_G]_Y+'_ "/UG_XBA6'_ #18_P#A3#_Y'H_XBA6'_-%C_P"%,/\ Y'K\F**/
M[%P?\GXO_,/^(A9]_P _O_)8_P"1^L__ !%"M_T1<_\ A3#_ .1Z/^(H5O\
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M._P,D\:?\*BQY?B)=!^R?\)$.<VK7'F[_(_V=NW'?.>U?CA7JD/_ "8M<?\
M91(O_35)45,EP:2M'JNK_P SJPG'V>3Y^:MM%OX8[KY'Z)#_ (.AFQ_R1?\
M\N8?_(]'_$4,W_1%O_+G'_R-7Y,T5?\ 8F#_ )/Q?^9R_P#$0L^_Y_?^2Q_R
M/UF_XBAF_P"B+?\ ESC_ .1J/^(H9O\ HBW_ )<X_P#D:OR9HH_L3!_R?B_\
MP_XB%GW_ #^_\EC_ )'ZS?\ $4,W_1%O_+G'_P C4?\ $4,W_1%O_+G'_P C
M5^3-%']BX/\ E_%_YA_Q$+/O^?W_ )+'_(_6;_B*%;_HBW_ESC_Y&H_XBA6_
MZ(M_Y<X_^1J_)FBC^Q<'_+^+_P P_P"(A9]_S^_\EC_D?K-_Q%"M_P!$6_\
M+G'_ ,C4?\10K?\ 1%O_ "YQ_P#(U?DS11_8N#_E_%_YA_Q$+/O^?W_DL?\
M(_68_P#!T,P_YHM_Y<X_^1Z]X_97_P""U[?M+> =0US_ (5S_8_V'4GT_P G
M^V?/W[8HI-^?)7_GKC&/X?>OPAK[S_X)6?\ ) ]>_P"QDF_])+2L,1D^$C"Z
MC^+/4R?CK.J^(Y*M6ZL_LQ_R/WAK\N/^#H'_ )(S\)?^P_>?^DU?J/7Y<?\
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M7Z ?\(%H%_H/QR\+:+I-G\6KB:'P5*_A;7_'",VDSQ1W0FL8]226+[2EE\J
MJQ&&"G)%?$O[6OPUNOAO\1[>WN?A_I/PUCOK%)8M(T[7?[8A8!F5I?.\V4AF
M(P5+#&W@<UKAL7*I/E=MOT7G?\#AS;)*&$P_M(7;N];W2]YK^5+HMY)^1QNJ
M_"_Q%H7P[T?Q9>Z-?VGAKQ!<SVFFZC+'LAOY80IE$>>6"[E!8#;GC.00,&OH
M_P"/7QGUCXP?\$^_A>_B+Q#)K>K:9XRUJTBBFF4R65FEEIZ0QI&N/+B&U@H
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MYNS9_M5T7[8_PEN_AEJ.AW%Q\*M!^%MK>0RQBVTSQ+_;:Z@Z$$R,QGE:,J&
MQP#GN:^A/#O[/'Q ^%W[/'_"66;Q^/OB5\1O!H\/17LOB&R-CX%T">-8A;%7
MF$DUVT.%$:KY<",<;GZ;SQ;C3C)-7;_K9V7WGEX?)85,35I.,K05_-:=4XIN
M[V7*N[:2N?,7P_\ V-OBA\4[6QN/#_@[4M2M]0L$U."9988HFMY)I((F+R.J
MJ9)8I%1"0[E#M4CFL>3]GGQE;> O%7B6ZT*[T_2/!>H1:3K$EWB"2UO'D\L0
M>6Q#LZL1N 'R@C.,C/T_?^'-4^)O[0?B*W\%V_ACXC>$_A3?Z1X=M_ &I:^^
MGPZW#86[6T>J "2-)(XYUF8L')7S\E2A;/F7[:/Q>TVQ_:1^/^FZ'J4?BW3/
M'^KV\IUC[0K+&\4Z7,@C,:A)4$N^$.  50,,YHIXBK.?*K='Z:K1Z]G_ )=2
ML5E.$HX?VTG+=QW5FTG9K3;F5GOYVT;^>#UK[S_X)6?\D#U[_L9)O_22TKX,
M/6OO/_@E9_R0/7O^QDF_])+2NC%?PSAX?_WOY/\ 0_>&ORX_X.@?^2,_"7_L
M/WG_ *2U^H]?EO\ \'/_ /R1CX2?]A^\_P#245\+D_\ OM/U_0_HCCK_ )$6
M(]%_Z4C\<Z***_0C^6PHHHH *1D5CDJ#CI[4M%  !B@#':BB@!&16ZJI_"@H
MK+@JI'H12T4 &T!<8X]*18U5<!5"^@I:*  KD48YHHH **** "BBB@#U3]E/
M_D(?$;_LG>N_^B4KRNO5/V4AG4/B-_V3O7?_ $2M>5@YK*'\27R/0Q'^ZT?^
MWOS04445M9GGA11119@%%%%%F 444468!2*JH,*H49SQ2T468 J*H.-J[N3@
M=::8(]@7RTVKT&.!3J*7*5=B"-1'LVKMZ;<<4BP1H"!&J[N#@8S3J*.45V->
M)9$VLJLOH1D4&)63:54K_=(XIU%'*&HT1*,85>#N''0^M.50@^4!>_%%%'*P
MU"BBBBS$%%%%.S ****+, HHHHLP"O5/AKQ^R!\6/^PSX<_]#OJ\KKU3X;\?
MLA?%C_L,>'/_ $.]K*M\*]5^:.[+_P"(_P##+_TEGE==1\$?'-K\,/C3X.\3
M7UJ;ZR\.:Y9:I<6P )GCAN$D=0#U)53CWKESUHK24;JS.6C4E3FIQW3O]Q]5
M?&?]GW0[SXO?$OXF3?&OPE#X+UPZKK.E:CHVLI<>(-:DNO,>&P^PAEGCD8R"
M.;S0J*H;EABK7[;'PH7X@_&$_$K2/&?PQOO#L>D:#(8(?%EHVHY@L+2&9!:[
MO,+JZ,-N,_*37R6%56W8&[UQ0(U!^ZM<<<)--/FV5MNA[E3.J,H2A['XGS?$
M_BUUUOIKM^)^B?QM_;<\-_"O5OB-?:;J6B^-/#GBCXS:G_;WA^&\61/$GAZX
MTF"*1@ >5WKF.4<++&I!X-8WQM\?_#7PC'XZT?PCXVTGQ)X?M_@)INA:+<3W
M"1S:C,FK13"T=,\7*Q??CZC:QP*^!0@'- 7V6LXY;%6LW_GL==3BRO/F4H+7
M;?2][V\G>_JO6_V=\?/AIX;_ &COVL-6^-5K\8/!_A?X>^(C'KD]_'K*+XDT
M K;*K6$>GAEN&N4=#%&$&QEP=P%=)\%OVHOA#^REX8^$G@?5(]?\507-O=ZM
MXPN]'U:V739&UN,VLUO>1F-VFDM;(1Y5)%VON&<\U\&[1NW?Q=,XH QZ4WE_
M-%0E)V6W0RAQ%*G5=>C22G)W;=W>[3>CT2=O7?6Q]F?'/]G"Q\;_ +/WPU\&
M^$_B3\)M1/PYU3Q-8SSWWC"RL3<03:B)+6=!(XW+)" V1T)Q7QO=VYM+N:%F
MC9H79"R,&5B#C((X(XX(ZCFHO+7^ZOY4N*Z*%&=-<K=UZ=SR\RQU/%34X4^5
MV2WNK))+TT05ZK\6_P#DU?X+_7Q!_P"ET=>58KU3XMG_ (Q8^"__ ','_I='
M55+\T?7]&9X/^'6_PK_TJ)Y711BC%:\K.$$41C"@*.N * J@-\H^;D\=:,48
MHY0NP1%C^ZJKGT&*:]O&X&8T(!)QMXIU&:+#NQCVT,B*K11LJ_=!4<?2EBA2
M 81%3/7:,9IU%%F.[V#: V[:NXC&<<T44469(5ZI#_R8M<?]E$B_]-4E>5UZ
MI"W_ !@M<?\ 91(O_35)65;1+U1Z& _Y>?X)'E=(J!"=J@;CDX'4TM%;69YX
M !22!R>I]::D2QG*JJGID#%.HI<H]1IAC;.8T.XY.1U-(;:-H]OEIM'(&W@4
M^BCE8^9C8X4@/[M%3/7 Q3?LD);<8X]W7.P9S4E%'*%V-DB21=K*K#W%. P/
MIQ111RBU"OO/_@E9_P D"U[_ +&2;_TDM*^#*^\O^"5AQ\ M>_[&2;_TDM*Y
M\5_#/;X?_P![^3_0_>*OR@_X.EKZ:#P'\%X4D989-4U21D'1F6&  GZ!F_.O
MU?K\F_\ @Z=_Y$[X*?\ 81U;_P!$VU?&\.I/,::?G^3/[*R/"T<1C84<1!2B
M[W32:>CW3NF?C^+J0?QM^='VF3^\U1T5^L>SCV/T3_57)?\ H#I?^"X?Y$GV
MJ0?QM^='VF3^\U1T4>SCV#_57)?^@.E_X+A_D2?:I#_&WYT?:Y/^>C?G4=%'
MLX]@_P!5<E_Z Z7_ (+A_D2?:Y/^>C?G1]KD_P">C?G4=%'LX]@_U5R7_H#I
M?^"X?Y$GVN3_ )Z-^='VN3_GHWYU'11[./8/]5<E_P"@.E_X+A_D2?:I#_&U
M'VJ3^^U1T4>SCV#_ %5R7_H#I?\ @N'^1)]ID_O-1]JD'\;5'11[./8/]5<E
M_P"@.E_X+A_D2?:I/[[4?:Y/^>C?G4=%'LX]@_U5R7_H#I?^"X?Y$GVN3_GH
MWYT?:Y/^>C?G4=%'LX]@_P!5<E_Z Z7_ (+A_D?1W_!)_P ,V?Q-_;[\">$]
M<B:^\.^+3>:1K%GYC1K?VDEI*SPL5(;:Q12<$'CK7[:?\.4_V7_^B3:3_P"#
M"^_^/5^+?_!&+_E)_P#"+_L(W/\ Z17%?O9^VO\ M4C]CWX-6_BXZ&WB#S];
MT[1_LJW7V;;]KN$A\S=M;[F[=C'.,9%?G_%52I#&1C1;5XK9VZL_.^,,@RJE
MB81AAJ:7+LH12W?9'F__  Y4_9?_ .B3:3_X,;[_ ./4?\.4_P!E_P#Z)-I/
M_@QOO_CU=+\<OV^='_9[_:'U+P=XATN2+1=&\ W7CR]UI+@%HHH)_),"P[?F
M9NQWCD@8[USOP)_;K^)7Q+\9^"_^$C^ ?B;PSX-^(D9FT?7+;4XM3>Q0Q^9&
MVH01H#;+(I!#%B 2 >^/F_;8NW-SNWK_ ,$^1_L?*[V]A#_P!?Y#/^'*G[+Y
M_P":3:3_ .#&^_\ CU'_  Y3_9?_ .B3:3_X,;[_ ./5,_\ P4WT)/\ @H&/
M@8=#N?LI_P")?_PD_P!I'V3^UOL_VG^SMFW_ %GD\YWYW<8[US/Q-_X*<>,O
M"WQ6^+&A^&_A'9^)=&^#\L:ZQJ4_C&VTR21&M1<[HX98\L0NX8#')4=R!5*I
MC+VYGM?=_P"8O['RO_GQ#_P!?Y'0?\.4_P!E_P#Z)-I/_@QOO_CU'_#E3]E_
M_HDVD_\ @QOO_CU<CX__ ."J7C+1O"/PY\6>'?@NVN>#?BM+IMCX<OKKQ3!8
MW,][>1EA;RP&)C&%977S"VT@ ]#75?&;_@I;/\ ;KX<^'?$_P_U*W^(/C74K
M&SU/2+6\^TZ?X<ANKEX(Y9;]8_*D9MA*1J S8;.T#)/:8S3WW_X%_P $/[(R
MO_GQ#_P!?Y$G_#E3]E__ *)-I/\ X,;[_P"/4?\ #E/]E_\ Z)-I/_@QOO\
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M3_X,;[_X]1_PY3_9?_Z)-I/_ (,;[_X]7U-11]<Q'\\OO8?V'EO_ $#P_P#
M8_Y'RS_PY3_9?_Z)-I/_ (,;[_X]6E8?\$@_V<=*\*:IH=O\,-,CTO6IK>>]
MMQ?7F)W@+F(DF;(VF1^A'WN<U]*45+QE=[S?WL(Y)ERVH0_\!C_D?+/_  Y5
M_9?'_-)M)_\ !A??_'J^4OVU='_X)[_L0>))O#NN?#B'Q)XNMP#-HNA75Y<S
MVF0"//=KA8XB1SM9MV.=N*^[_P#@H#\?;W]F#]C#XD>/-,56U3P[HLLMB6&5
M2X<B*)B.X61U..^*_F#U?5[SQ!JUUJ&HW=QJ&HZA,]S=W4[EY;F5R6>1V/)9
MF))/O7T_#^7U<;S5:U27+'31O5_Y'TW#O N58[FJUJ$.6.EE&.K^X^_#^V[^
MPJ#_ ,FK>*O_  <'_P"2Z/\ AM_]A;_HU;Q3_P"#@_\ R77Y]T5]9_86&[R_
M\"?^9]=_Q#GAW_H%C]R_R/T$_P"&W_V%O^C5_%/_ (.#_P#)='_#;_["W_1J
MWBG_ ,'!_P#DNOS[HH_L+#=Y?^!/_,/^(<\._P#0+'[E_D?H)_PV_P#L+?\
M1JWBG_P<'_Y+H_X;?_86_P"C5_%/_@X/_P EU^?=%']A8;O+_P "?^8?\0YX
M=_Z!8_<O\C]!/^&W_P!A;_HU?Q3_ .#@_P#R71_PV_\ L+?]&K^*?_!P?_DN
MOS[HH_L+#=Y?^!/_ ##_ (ASP[_T"Q^Y?Y'Z"?\ #;_["W_1J_BG_P '!_\
MDNM+5?\ @H=^Q1K?AK2-'NOV8?%DVFZ#Y_V" ZN +;SW$DN"+K)W, >2?;%?
MG312_L'#=Y?^!/\ S*7AUP\M%AH_<O\ (_03_AM_]A;_ *-7\4_^#@__ "71
M_P -O_L+?]&K^*?_  <'_P"2Z_/NBG_86&[R_P# G_F3_P 0YX=_Z!8_<O\
M(_03_AM_]A;_ *-7\4_^#@__ "71_P -O_L+?]&K>*?_  <'_P"2Z_/NBC^P
ML-WE_P"!/_,/^(<\._\ 0+'[E_D?H19?MM?L'S7<:W'[+?BR"%C\\B:J9&4>
MNW[6,_G7VE^QU^RA^P=^W5X6N-2^'O@71[VXT\*;_2[N\OK;4=/W=/-A:;.T
M]G4LAZ!LU^$M>K?L0_M':U^R?^U5X*\;:'<RPR6.I0VU]$K82^LI9%2>!QW5
MD)(ST95(Y%<6.R%>R;P]22DMO>;3.+'>&N2.DY8:A&,EM[J:?EL?O8/^"*G[
M+Y_YI-I/_@QOO_CU'_#E/]E__HDVD_\ @QOO_CU?4D9!0$=#R*=7YU]=Q'\\
MOO9^<?V'EO\ T#P_\!C_ )'RS_PY3_9?_P"B3:3_ .#&^_\ CU'_  Y3_9?_
M .B3:3_X,;[_ ./5]344_KF(_GE][#^P\M_Z!X?^ Q_R/EG_ (<J?LO_ /1)
MM)_\&-]_\>K2'_!(/]G%?!;>'?\ A5^E_P!BM?C5#;?;KS:;D1F(29\[.=A(
MQG'MFOI2BI^N5WO-_>PCDF7+:A#_ ,!C_D?+/_#E/]E__HDND_\ @QOO_CU'
M_#E/]E__ *)-I/\ X,;[_P"/5]3457US$?SR^]A_8>6_] \/_ 8_Y'RS_P .
M4_V7_P#HDVD_^#&^_P#CU'_#E/\ 9?\ ^B3:3_X,;[_X]7U-11]<Q'\\OO8?
MV'EO_0/#_P !C_D?+/\ PY3_ &7_ /HDVD_^#&^_^/4?\.4_V7_^B3:3_P"#
M&^_^/5]344?7,1_/+[V']AY;_P! \/\ P&/^1\L_\.4_V7_^B3:3_P"#&^_^
M/4?\.4_V7_\ HDVD_P#@QOO_ (]7U-11]<Q'\\OO8?V'EO\ T#P_\!C_ )'R
MS_PY3_9?_P"B3:3_ .#&^_\ CU'_  Y3_9?_ .B3:3_X,;[_ ./5]344?7,1
M_/+[V']AY;_T#P_\!C_D?+/_  Y3_9?_ .B3:3_X,;[_ ./5VWPS_P""</P4
M^#FASZ;X:\!Z?I=C<W!NY(DNKB0-*51"V7D)^ZBC'3BO<**F6+KO>;^]E4\G
MP$'S0HP3\HK_ ""OR;_X.G?^1.^"G_81U;_T3;5^LE?DW_P=._\ (G?!3_L(
MZK_Z)MJ]3AO_ )&-/Y_DSZ[AO_D94OG^3/Q[HHHK]8/UP**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBN^\$?LH_%+XF>#_ /A(O#?PX\<:]H)SC4+#
M19Y[9\$@[75<-@@CY<\C%1.I&"O-V]29U(P5YNWJ>P?\$8O^4G_PB_["-S_Z
M17%?NS_P4,_9@U?]KG]F/4/"?A_4+'3/$%O?V6L:7->JQM6N+2X2=$EVY8(V
MTJ2 2,YQ7X4_\$9;>2+_ (*B_"6-XY$DBU.Z61&4JT9%G< @@\@@\$'D5_2/
M7YYQ=)QQL)+^5?FS\VXTBI8J*?\ +^K/AK4_V"_BE^V+\1/'GB3XTKX-\(?\
M)!\/)_ .G6/AJ\FU QF6<3M>2/(B?=<#$8ZC@GN>K^"?PY_:LTC5_!.C^)-4
M^&^C^$_A[9/;W4FBRRW%SXX,4'E6T<BS18M$)"L[(2P.<<<5]=8HKYAXB35F
ME;\CXY44G='YMR?\$<OB=/\  A]>;XH:@OQE;Q,?'HTT7,?_  C8USS]WF>9
MY'VC_4_N]V?;;CBNB^*7_!'B;]I/Q;\=/$OC&V\/Z;XJ\;76G:GX,U2VG>Z?
M1KB"S198YE9 K0O.@!4AMR<X!P*_0+%%7]<JWO?^OZ1/U>&Q\G_%?]E_XG?'
M7X)? "SUJT\'Z5XJ^'?C#2=<\0PZ?<,FGM!:"1'-J!$,%@598RJA<E<X SWG
M[>?[.GB#]I'P3X%T_P .MIL=QX=\=Z/XDN_MDS1*UK:2L\H4JK9?!& < ^HK
MW2BLO;2NGV*]FK6/@7]KS_@F%XN_:9_:AU"^BT?P!I?A+7]7TO5+SQ%:ZA?6
M^J+#:;3)%-8!C;7%R^W8EP=I6-L8SS7K'_!1'0+G0?B5^S_\1/)EFT3P%XZC
MCU?9&7^RV]_ ]FMPP'\,<LD>3V#D^M?472D9=XY ([@U7UB7NWZ?J'LEK;J?
MGEXU_P""0/COX^^&OB]X@\8?$;4M"\;?$76)=4M])TBYCFT4"U/_ !*5G>2'
MSB8L+DH1MR<9.<]-X-^ /[3OPJ_:-U[XEZ7H?PK\0:SXR\*:)I&L1ZEK]U;K
M'>64++-)&8[<[E=V+#."!7W115?6IM6>J_X;_)$JC%.Z/BMO@=^T=\//VNO&
M'Q4\+^&_A5JEQX]\.:-I^HV6HZ_=P1V-S:1$2B(I;L7C\QV +8) !P.E.L_@
MLG[7O[?/B(_$'PUINH:+X5^&FG^&O$MG&TDNFW.K7-V+]K>-V"F5(51&R0,>
M8F0#Q7VE2! IX'O4_6);];6*]DOU,+X;?#/0_A'X.M-!\.Z?'I>CV.XP6R.[
MK'N8LW+$GDDGD]ZWJ**P\S0**** "BBB@ HHHH **** "BBB@ HHHH ****
M//?VK?@+9_M0?LX^-/A_?3?9K?Q9I4U@L^,_9Y&&8Y,=]L@5L>U?S"_'3X%>
M*OV:/BIJO@KQMI-QHOB+1Y3%-%*I"3KGY9HFZ21..5=<@@^N17]7A&:\]^._
M[+7PY_:=T>/3OB!X+\/>++> GR/[0M%DDM_7RY.'3/\ LD5[^1YX\ W&2YH2
M^]/R/H,CSV6 ;C)<T)?>GW/Y61S17]'_ /PY,_99/_-']"_\#;S_ ./4O_#D
MS]EG_HD&A_\ @;>?_'J^G_URPG\DOP_S/J/]<\)_)+\/\S^;^BOZ0/\ AR9^
MRS_T2#0__ V\_P#CU'_#DS]EG_HD&A_^!MY_\>H_URPG\DOP_P P_P!<\)_)
M+\/\S^;^BOZ0/^')G[+/_1(-#_\  V\_^/4?\.3/V6?^B0:'_P"!MY_\>H_U
MRPG\DOP_S#_7/"?R2_#_ #/YOZ*_I _X<F?LL_\ 1(-#_P# V\_^/4?\.3/V
M6?\ HD&A_P#@;>?_ !ZC_7+"?R2_#_,/]<\)_)+\/\S^;^BOZ0/^')G[+/\
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M;:O<X;_Y&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1ONG/3'.*^__  ;%\3-8^#>AZI;_  <\8-J7B3P=I_AF
M/5+?XA6UAI-WH]O)$RW5C:,P,%XRPJHD#%8Y"\@7>2*^ 6;:I/H,U]->+M'^
M$'PK\%_#WX?_ !.N?BOXFOI-*MO$!FTB_LK?3?"@U5(YS':V\T3O<$1F-Y,R
M1JSY"@'+'S,R@I<JM?5]&]+>37EU/+S*"DHJU]7WV^37ENST#]@;Q7JWCS_@
MN?X;UK7M)M]!UK4_%5_<7NG0SK<)92FTGS'YBDB0C W.#\S%F[U_0=FOYX?^
M";?PFD^ W_!:OP;X*DO(]0;POXFO].6[CC\M;I$M;C9(%_AW*5..V<5^ZW[7
MG[0=C^RO^S5XS\?W^UH_#6F27,$1_P"7BX(VP1#_ 'Y61?QKX?BF*EB*:I[<
MBM][/A.+915>FX[<B^[4](#9HS7YF_LU?M^?$:7]D']H+P_XL\=:7XA^*?P_
M\+MXMTC7=,DMKB/[-<V8E5!Y:^66MI\QL""06 .:^H/B)\:?%.B_\$HKSX@6
MNK30^,8_ALFMKJ0B0N+PV"RF;:5V9WDG&W'M7ST\/*+L^]CY&-:,E='TEFDW
M5\Q?%[]K/Q#\"_\ @E)'\7-L6L^*K7P5IVH![E (YKVXB@3S9 H VB27>0,#
M QQ7D7B?Q1\:OV);[X,^-/$7Q@OOBAI?Q(\1:?X>\1:#?:5:P00O?(66:P:%
M5=1$P/#%@R@9]IC0E+\ON'*JD??>>*3=7QU^V+^VEJ'Q?^#7V']FCQ%=>,O%
MEGXIL=,UV7PE;P:E=Z':L93,SI-^Z0GRB@,A"YZD=:\5\,_M6_$?XV7'PY^&
M7A?XN>,-+UO5I?$]UXEUS6/#UA;:YIEQI<:%-,>!5: *LC99UR60CD<U4<+-
MQYOZ1,JT4['Z89HK\V?B'^W;\=O&7["/P1^(VCW&@Z!I_B+4-)M?$^LQ<WU]
M=/J9M'M[> J8XXG5/,=R<X?:H')KZ]_X*%?'[4OV9OV0/&7BS0_+_P"$@AMX
M[#2#(NY8[RZF2VA<CN$>4/@]=N*F6'DFH]6[%1JIIOYGM.<49K\X_$?[<?Q$
M_9)_;[UCPQXP\0:AX@^$NAZ#H6AZSJES%$6T/4[RT)AU&1E4-MFGC=7SE1Y@
MP!@ X_P9_P""AGQ"\-VO[*VL>)-0\9>,[/QIH'B2X\1:=H>DQWU]K,T%P8[:
M011J#B(8)*$# R<UI]3J6OT_X%R/K$;V/TT!S1FOS(T3]OSXF>,/$%W?6FO>
M(M'T^\_:$TSPM;Z;JFFQ6]Y8Z/-:EWL98F0LA+#)R=X_O5]:?\%#_B[XA_9U
M^'OA'X@:)J4UO8^'?%FG0:]8?*8=4TV[E%I*C9!(9#*DB,",%.X)%3+#RC)1
M>[*5:+3?8^@]U&:^3/V&/'.M>,/CC\6)I-<^)MQX?M6$&G6/BNTN?/NI4FF\
MV_MS)#'##"^Y(HK>(GY(5D<*7K6_X)U^(O$VLZ]\38=4OOB#JWAF'4[230KO
MQ9!/#=1AX/\ 2+<B=$?S$E7+A!Y ,BB/@&LY4VK^12G<^G:***S+"BBB@ HH
MHH **** "BBB@ HHHH **** &EP*_,#]O7_@XSTGX,>/]1\(_"'P]I_C2^TB
M9K:]UW49W33%F4D,D"1X>;:1@ON5<@XW#FOK_P#X*I?$C5OA'_P3Q^+FOZ'+
M);ZI:Z!+%!+']^#SF6%G![%5D8Y[8S7\S"((D55^ZHP*^NX9R>CBE*OB-5%V
M2_S/K^%\EHXI2KXC51=DOQU/T+/_  <L_M 9_P"0'\,__!9=?_)%)_Q$L_M
M?] /X9_^"RZ_^2*_/:BOL/[#P'_/I'V?]@Y?_P ^D?H3_P 1+/[0'_0#^&?_
M (++K_Y(H_XB6?V@/^@'\,__  677_R17Y[44?V'@/\ GT@_L'+_ /GTC]"?
M^(EG]H#_ * ?PS_\%EU_\D4?\1+/[0'_ $ _AG_X++K_ .2*_/:BC^P\!_SZ
M0?V#E_\ SZ1^A/\ Q$L_M ?] /X9_P#@LNO_ )(H_P"(EG]H#_H!_#/_ ,%E
MU_\ )%?GM11_8> _Y](/[!R__GTC]"?^(EG]H#_H!_#/_P %EU_\D4?\1+/[
M0'_0#^&?_@LNO_DBOSVHH_L/ ?\ /I!_8.7_ //I'Z$_\1+/[0'_ $ _AG_X
M++K_ .2*/^(EG]H#_H!_#/\ \%EU_P#)%?GM11_8> _Y](/[!R__ )](_0G_
M (B6?V@/^@'\,_\ P677_P D4G_$2S^T!_T _AG_ ."RZ_\ DBOSWHH_L/ ?
M\^D']@Y?_P ^D?H?I_\ P<O_ !ZMKR.2X\-_#.ZA4Y:+[!=1[QZ;A<''UQ7Z
M _\ !,G_ (+0^#_V_=6_X1/5-+/@KXBPP-.NF/<>?:ZK&HR[VLI )*]3&P#
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M%/PW_P""R#_XFC_A3?A#_H4_#?\ X+(/_B:/]=(?\^G_ .!?\ /]=H_\^O\
MR;_@'\G'VV'_ )ZQ_P#?5'VV'_GK'_WT*_K''P=\(C_F4_#?_@LA_P#B:/\
MA3?A$_\ ,I^&_P#P60?_ !-'^ND/^?7_ )-_P _UVC_SZ_\ )O\ @'\G'VV'
M_GK'_P!]4?;8?^>L?_?0K^L<?!WPAC_D5?#8_P"X9#_\32_\*=\(?]"KX;_\
M%D/_ ,31_KI'_GT__ O^ '^NT?\ GU^/_ /Y-_ML/_/6/_OJC[;#_P ]8_\
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M\F_^#IW_ )$[X*?]A'5O_1-M7ZR5^3?_  =._P#(G?!3_L(ZM_Z)MJ]SAO\
MY&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /I[_@C%_RD_P#A%_V$;G_TBN*_I(9MM?S;_P#!&+_E)_\
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M10 4444 %%%% !1110 4444 %?DW_P '3O\ R)WP4_[".K?^B;:OUDK\F_\
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MU_H&BWS:LL:WQN+&*4W@CYC$I93O"?P[L[>V*;_P@W_4:U[_ ,"A_P#$T?\
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M Z5_12*^%XNE?$P?]U?FSX/B^5\33?\ <7YL,4;:**^5/DPQ1110 =****
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MQ=J(U/3H&W1:?*MK<)Y*-D[E1550V3N !SS7[0_MT?LJWG[9OPET_P #?\)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DW_P=._\
M(G?!3_L(ZM_Z)MJ_62OR;_X.G?\ D3O@I_V$=5_]$VU>YPW_ ,C&G\_R9[G#
M?_(RI?/\F?CW1117ZP?K@4444 %%%% !1110 4444 %%%% !1110 4444 (Z
M[T*^HQ7TS'_P4$\.ZIX!NM#U_P""GA?7I-5TC1='U6]?Q%J5M)J,>DJ%LV*Q
ML%C88R=F V>:^9Z*PK8>G5MSK;S:_(PK8:G6M[1;>;7Y'V5_P36^*UQ\>?\
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M;:O<X;_Y&-/Y_DSW.&_^1E2^?Y,_'NBBBOU@_7 HHHH **** "BBB@ HHHH
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M 5-7YO*S=T?F<K-W04445)(4444 %%%% !1110 4444 %%%% !1110 4444
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MLVU"6_:8?9UME3S#-OZ; GS9Z8YHY7U0<R(O^$DU'_H7]0_[_P!O_P#'*/\
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M))J7_0OZA_W_ +?_ ..4?\))J7_0OZA_W_M__CE;5% &+_PD>HG_ )E_4/\
MO_;_ /QRC_A)-2_Z%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QR
MC_A)-1_Z%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QRC_A)-2_Z
M%_4/^_\ ;_\ QRMJB@#%_P"$DU+_ *%_4/\ O_;_ /QRC_A)-2_Z%_4/^_\
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MOB>S/0O^$'T7_HF^G?\ @+8__%4?\(/HO_1-]._\!;'_ .*KSW_AO[PY_P!
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M\F_^#IW_ )$[X*?]A'5O_1-M7ZR5^3?_  =._P#(G?!3_L(ZM_Z)MJ]SAO\
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MWAG_ (1Z#Q%<(P$LT$<L2R+$ O#2$NJ #@L17CGP^_X*=7UUXS\#VOC[X/\
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MBBB@ HHHH **** "BBB@ HHHH *^'_\ @ML2GP[\ X)'_$UN?_1%?<%?#_\
MP6Y_Y)WX _["MS_Z(%?%>(G_ "3F*]%_Z5$^LX&_Y'N']7_Z2S\\?-;^\WYT
M>:_]YOSIM%?R!8_J =YK_P!YOSH\UO[S?G3:*+ .\U_[S?G1YK_WF_.FT46
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MU;V^M>)+?P=I^J&.1?*AN;VYBA4,P7&U/-E#$+C@$#%>3^(OBS\>_P!CJ_\
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MX@_Z!^D?^!TG_P :K:HH Q?MGB#_ *!^D?\ @=)_\:H^V>(/^@?I'_@=)_\
M&JVJ* ,7[9X@_P"@?I'_ ('2?_&J/MGB#_H'Z1_X'2?_ !JMJB@#%^V>(/\
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M_P /'/C9_P!#Y>_^ =M_\;H_X>.?&S_H?+W_ , [;_XW1_Q&;)_^?53[H_\
MR0?\0JS3_GY3^^7_ ,B?K/\ ;?$7_/AH_P#X'R?_ !JC[;XB_P"?#1__  /D
M_P#C5?DQ_P /&_C9_P!#Y>_^ =M_\;H_X>-_&S_H?+W_ , [;_XW1_Q&;)_^
M?53[H_\ R0?\0JS3_GY3^^7_ ,B?K3]M\08_Y!^C_P#@=)_\:H^V^(,?\@_1
M_P#P.D_^-5^3-O\ \%(?C9;S*_\ PG5T^TYVO96Q4_4>77U)^P[_ ,%1[KXJ
M^-++P;\0H;&WU/4V$.G:M:IY45S*>D4L>2%9NBLO!/&!D5ZN3^*638_$QPJY
MJ<I.R<DK-OI=-V^9YN:>'>:X*A+$/EFHZOE;NEWLTKV\C["^V>(/^@?I'_@=
M)_\ &J/MGB#_ *!^D?\ @=)_\:K93[M+7Z0?!F+]L\0?] _2/_ Z3_XU1]L\
M0?\ 0/TC_P #I/\ XU6U10!B_;/$'_0/TC_P.D_^-4?;/$'_ $#](_\  Z3_
M .-5M44 8OVSQ!_T#](_\#I/_C5'VSQ!_P! _2/_  .D_P#C5;5% &+]L\0?
M] _2/_ Z3_XU1]L\0?\ 0/TC_P #I/\ XU6U10!B_;/$'_0/TC_P.D_^-4?;
M/$'_ $#](_\  Z3_ .-5M44 8OVSQ!_T#](_\#I/_C5'VSQ!_P! _2/_  .D
M_P#C5;5% &+]L\0?] _2/_ Z3_XU1]L\0?\ 0/TC_P #I/\ XU6U10!B_;/$
M'_0/TC_P.D_^-4?;/$'_ $#](_\  Z3_ .-5M44 8OVSQ!_T#](_\#I/_C5'
MVSQ!_P! _2/_  .D_P#C5;5% &+]L\0?] _2/_ Z3_XU1]L\0?\ 0/TC_P #
MI/\ XU6U10!B_;/$'_0/TC_P.D_^-5<TZ7498&-W!:0R;N%BF:12/7)5>>O&
M*O44 %?#_P#P6Y_Y)WX _P"PK<_^B!7W!7P__P %N.?AYX _["MS_P"B*^*\
M1?\ DG,5Z+_TJ)]9P-_R/</ZO_TEGYWT445_(!_4 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'T=_P2A_Y/8T/_L'7W_HJOT-_:S_90T?]L/P7
MHOAOQ)J&IV_A[3=:M=9O;"UV"/61 Q9;:<L"?)+8+!<$[1S7YY?\$H?^3U]#
M_P"P=??^BJ_6(=*_J#P=DUD;:_Y^2_*)_//BDD\X2?\ )'\Y'RSX^_X)(?"[
M7?%%UJ7A6VD^&\>K>&M1\*ZM8^&[:"VM-5M;Q0"TL90@R1L RL.X&<BCPU_P
M31OM*^&VI^"]4^-GQ1\1>#]1\-S^&%T>_-A]GMH)(1"CIL@5M\2@;<DCU!KZ
MFHK]:]O4[GYK[*'8^7_ _P#P3072/!D_A'Q3\6/B-X_^']QH;Z!)X8UEK-;$
MVYC5(R&B@217B"J48-P0#S5?X8?\$LM)\(>//!VK>)_B1\2/B-I?PXF%QX4T
M3Q!>PO9:/*B[8I#Y<:M,\:X"&0G&!7U111[>?</9Q['B/QA_82\)>/=!M8_"
M<UW\*-<L=436(-9\'10:?.]PH=?WZ!/+N4(D?*2JPR<\&L>R_P""<?A/3_V-
M/%OP9CUCQ%)8>.7NKK6]<GFCDU.^O+F023W+$KY>]F4<!=H  QWKZ&HJ?:SM
M:X_9QW/FW]H+_@FWH?QSUO2=6L_&/C'P3K%GX:;P;J-YHDT*OKFCMC?:SB2-
ME&3DAU 9=QQVQM?M3_L<6GQ,_8-U;X1^$ECTW^S]&M[7PX)7^6">R,<EH&8]
MM\*!F/8DU[Q11[:>FNP>SCV/E[Q]^P'-\=O$5C\1K?Q;XZ^#?Q$\1>'[;2_%
M8\.7UNZZ@JQC,4N]9$+QDLJRQX. ,&JWB'_@E-X;M['X91>"_''CKX>W'PIT
MV\TS2;S2YX)KJ9+ME:=Y7GC?<[D$D@ ?,< <8^JJ*KV\ULQ>SCV/F@?\$P/!
MJ_LU>*?AQ_;OBRX/CS5X=;\3>(+RZ2XU;7+E)HI6\YV3;M;RE3:% "D@<G-=
MC^U5^QMI_P"TV_A/4+?Q)XB\"^*? ]Q-/HFNZ$T2W-DLT7DSQ;9%9&1X^,$<
M$ BO9J*GVL[WN/V<;6L?-'@#_@F!X+^&W@CQ%X=TW5-<73==\#KX#C\QHWFL
M;4O<23SJVWYIIIKEI'+#;E5   Q6CJ/_  3H\,F?X.:EI>O>(-%\3?!:T@TW
M3-:M&B%SJ=BD0C>TNP4VR0N!DJ ,$G;C)KZ&HH]M4[A[./8^1_$W_!(3PGKN
MJZQIUKXZ^(FB_#7Q'K']NZKX$L-0CCTB[NC()7PVSSHXGD4,T:. 2.W&-GXS
M_P#!,/1OB3\1/$WB#PWX^^('PU7QY;1V?BO3_#EW#'::]'''Y2LRR1L8Y/+R
MA=""0?<Y^GZ*KV]2][B]E#L?-.@?L>SZ!^UE\+)M+TQ=+^&?P2\(75AH9DN1
M-->7]WL@8$$E\16\1)=L;GF&,X-?2PZ445G*;EN5&*6P4445)04444 %%%%
M!1110 4444 >/_M\W=]8_L=?$*33O,6Z_LEURGWA&642?^0RU?C>!@<=.U?O
M)KNAVOB71;O3[ZWCNK.^A>WN(7&5EC=2K*?8@D5^7O[3G_!+;QU\*?%%U<>#
M=-N?%WA>9R]L+4AKVS4GB.2/(+;>@=<Y'4 U^&^+G#>/QE2EC\)!SC&+BTE=
MK6][+6SOK;L?KWAEGV#PL*N"Q,E"4GS)O1/2UK[>EWU/EVBN\/[+'Q-!_P"2
M>>-/_!3-_P#$T?\ #+/Q,_Z)[XT_\%,W_P 37X=_8^/_ .?,_P#P&7^1^O\
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M'4/)^P3>+]!CN1,=L9B-]&'#'^[MSGVK^HO!F'/DO+WJ2_*)_._BI+ES>_\
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M"2?J_P#X)UWTGAOXP_M'>!;7'_"-^$_'K7.DQJ/W=G]NMH[N>!!T"K,[L%'
M\PT5,/RIVZ>7G8(5.:Q]3T4"BN8V"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'_^"W!Q\// '_85N?\
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MI[;=GI?JK'X_48K](O\ ARIX%_Z&[Q?_ .2__P ;H_X<I^!?^AN\7?\ DO\
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M\3?%;X<_%"W\!^#=;@\'Z+\:+2[UKPA#&FK7$>EI8*%@:W6=4N5BD9&:V6;
MR%R=E4L'%ZJ6G]>8OK#3M8_6;QQ\>/"GPX\6^$]!UC5[>UU;QS=/9Z';8+M?
MR)$97VE00%5!DL2!R!U(%=1!J=O=7,D,<T,DT./,C5P7CSZCJ/QK\J?#/[%_
MB/PW8_ 7Q%KGPN\=>*-&T/QWK$TVDRZ9'%?Z)IEPBM9H+9+A_(M5N@9E1GS$
M.O& >A_X)]?LV?$+X,?MOZ/=?\*]\2+HX;5TUS6O$^E+9ZAIJ2,S1_\ $RMY
MS%JWF/MVEXB44Y^7&:F6&A:ZE_P1QK2OJC]/:*%^Z**XSH"BBB@ HHHH :S[
M:^2?VO\ _@J9I/P'\577ACPIIL/B;Q!8MY=[--,4L;&3O&2OS2..X& O0G.0
M/I7XN:_=>%?A;XFU2RR;S3=*NKJ  ?QI"S+^H%?ADUW)J#M<32---<,99)&.
M6D=CEF)]2237Y3XG<88O)Z=+#8%\LZEVY6O9*VU]+NY^C>'W"^&S2I4KXS6%
M.RY;VNW?>VME;YGUD_\ P62^*3,2ND^#5'8?9)CC_P BTG_#Y#XJ?] OP9_X
M!S?_ !VODZBOP[_7SB#_ *"Y_A_D?K_^I>2?] T?Q_S/K'_A\A\5/^@7X,_\
M YO_ ([1_P /D/BI_P! OP9_X!S?_':^3J*?^OG$'_07/\/\@_U+R3_H&C^/
M^9]8?\/D/BI_T"_!G_@'-_\ ':]=_9K_ ."PMKXO\46NC_$31K/0?MD@BBU:
MQD8VL;$X'FHV612?X@Q [@#D?GE2,H==K#(/4'O77@?$;/\ #UHU95W-+>,K
M-/RVO\UJ<V,X#R6O2=.-%0;V<6TU^-OOT/WOBD66-64AE89!!R"/6G5XK_P3
MU\77_C3]C?P+>ZE))-=+9-;>8YRTB12O$AS_ +J+S[5[57]7Y=C%B\+3Q459
M3BI6]5<_FW'85X;$5,/)W<)-?<[!11178<H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\/\ _!;4&3X=^ <#/_$U
MN>G_ %PK[@K\R_\ @Y<U*YTWX0_"EK>XN+=FUV\#&*0H6_T8=<5\SQA@'C<G
MKX6+MS):_P#;R9]MX<X5XCB3"T4[7D]?^W9'R+Y+?W6_*CR6_NM^5?(?_"4Z
MI_T%-2_\"G_QH_X2G5/^@IJ7_@4_^-?SQ_Q#RK_S^7_@+_S/[$_U3J?\_%]Q
M]>>2W]UORI?);^ZWY5\A?\)3JG_04U+_ ,"G_P :/^$IU3_H)ZE_X%/_ (T?
M\0\J_P#/Y?\ @+_S#_5.I_S\7W'U[Y+?W6_*CR6_NM^5?(7_  E.J?\ 04U+
M_P "G_QH_P"$IU3_ *"FI?\ @4_^-'_$/*O_ #^7_@+_ ,P_U3J?\_%]Q]>^
M2W]UORH\EO[K?E7R%_PE.J?]!34O_ I_\:/^$IU3_H*:E_X%/_C1_P 0\J_\
M_E_X"_\ ,/\ 5.I_S\7W'U[Y+?W6_*CR6_NM^5?(7_"4ZI_T%-2_\"G_ ,:/
M^$IU3_H*:E_X%/\ XTO^(>5?^?R_\!?^8?ZIU/\ GXON/KWR6_NM^5'DM_=;
M\J^0O^$IU3_H*:E_X%/_ (T?\)3JG_04U+_P*?\ QI_\0\J_\_E_X"_\P_U3
MJ?\ /Q?<?7ODM_=;\J/);^ZWY5\A?\)3JG_04U+_ ,"G_P :/^$IU3_H)ZE_
MX%/_ (T?\0\J_P#/Y?\ @+_S#_5.I_S\7W'UYY+?W6_*CR6_NM^5?(?_  E.
MJ?\ 04U+_P "G_QH_P"$IU3_ *"FI?\ @4_^-'_$/*O_ #^7_@+_ ,P_U3J?
M\_%]Q]>>2W]UORH\EO[K?E7R'_PE.J?]!34O_ I_\:/^$IU3_H*:E_X%/_C2
M_P"(>5?^?R_\!?\ F'^J=3_GXON_X)^I/_!*-&3]M;0\JP_XEU]U'_3*OU@Q
MDU^#'_!"3Q%>S_\ !2+PV+J_O9H%T;56=9)G=>+?.<$G-?N4/B7HN/\ CZD_
M\!Y?_B:_<O#K)Y9;E3P\I<WOMW2MT7^1_+GC)E[P>?1I2=_W<7^,C>QQ01FL
M'_A9>B_\_4G_ (#R_P#Q-'_"R]%_Y^I/_ >7_P")K[P_*#>/-8MW\.=!OO'=
MKXHFTC3I?$=C:/86VIM INH+=V#/$LF-P1F )4'!(%1_\++T7_GZD_\  >7_
M .)H_P"%EZ+_ ,_4G_@/+_\ $T+38#>QQ0*P?^%EZ+_S]2?^ \O_ ,31_P +
M+T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P" \O\ \31_PLO1?^?J3_P'E_\
MB: -ZDQS6%_PLO1?^?J3_P !Y?\ XFC_ (67HO\ S]2?^ \O_P 30!O8YHK!
M_P"%EZ+_ ,_4G_@/+_\ $T?\++T7_GZD_P# >7_XF@#>HQ6#_P ++T7_ )^I
M/_ >7_XFC_A9>B_\_4G_ (#R_P#Q- &]BDVYK"_X67HO_/U)_P" \O\ \31_
MPLO1?^?J3_P'E_\ B: -T#%+CBL'_A9>B_\ /U)_X#R__$T?\++T7_GZD_\
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MW)/^^:_<;_A*_"_]V#_P!?\ ^(H_X2OPO_=@_P# %_\ XBC_ (@D_P#H+_\
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MZ+_S]2?^ \O_ ,31_P ++T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P" \O\
M\31_PLO1?^?J3_P'E_\ B: -ZBL'_A9>B_\ /U)_X#R__$T?\++T7_GZD_\
M >7_ .)H WJ*P?\ A9>B_P#/U)_X#R__ !-'_"R]%_Y^I/\ P'E_^)H WJ*P
M?^%EZ+_S]2?^ \O_ ,31_P ++T7_ )^I/_ >7_XF@#>HK!_X67HO_/U)_P"
M\O\ \31_PLO1?^?J3_P'E_\ B: -ZBL'_A9>B_\ /U)_X#R__$UH:7XEL]9M
MVEMI&DC5MI)C=>>/4#UH O5^8G_!S3_R1[X3_P#8>O/_ $F%?IW7YB?\'-/_
M "1[X3_]AZ\_])A7F9S_ +E4]/U1^A>%/_)5X/\ Q/\ ](D?D_IGPUUO6?AU
MK'BRVL3)X?T"\MK"_N_,4?9Y[D2&%-I.X[O*?D @;><5@&50&^9?EZ\]*^C_
M -F7P5/\6?V*?BUX3TG4?#EOK][XF\/7]M:ZKK5KI?VB&%+T2LC7#HK;=Z9
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MOWA6T<MBVTIWMY>NVOD>34X\KTE&5;#**DTDW-I:J#]Y\FFD_/5->9^>NH^
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M/D\'_'BVM=$G@M+*T&FZ#,ETDRQ^6@S:?+$2YR%)W!@3FOBOX_+JR_'+Q?\
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M>F**F'C%?%_6O^01K-]/ZT/>_#G_  4_^!GBWXN0>"=/\?:=<:U>7S:9:O\
M9YUL;R[!P;>*[*""23/&U7.3P,FJ7_#U[X!Q>/IO#=QX^M['4K?4WT:5KO3K
MNWM8KM)#&T+7#Q")6WC'+XKYS_9%^+]QX#^ OP>^ ]]^SQXJUWQUX/U2VL]8
M@U?0_)T71O*D<R:PE\Z/"Y /F(4^9BQ (."?,9=;UFZ_8]_: ^!L7PM^)7B#
MQS\0O'>NS:(/^$8N%TP)<W2>5=O=R*(D10ADW9[#'7-:?5H7:U^]??ML3[:5
MK_I^!]__ !N_X* _"+]G+X@6_A7QEXQMM'\075M%>1V8L[FX<Q2.4C8F*-@
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MS_XW7X(44?ZS8KM'[G_F'_$ ^'O^?M7_ ,"C_P#('[W_ /#^O]FK_H;-:_\
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M &A,>M4?%7A;3_''AG4-%U:SAU#2M6MI+.\M9EW1W$,BE'1AW!4D'ZUH44;
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0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>allogenelogo1.jpg
<TEXT>
begin 644 allogenelogo1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
MLLCS\U)Z/_\ O>9X<O1RY>KZ]6I_OID?=G]6?T7DW\)]W\[Y_P"WY>JIPO/?
M7-D6+QZ6L=?MY1Y&P.QJ%8]G-(E-==576\:>6*\</&[98BJL7$VMQ$/G1NQ8
MB"+8RZA2II'53K)W BR9-N/]'N561&>WW O>_J#=)/.P%_"X[8_!1GZ!@=],
M;\^-&F1/@9,6(SD #*?HZ0I(L'>$3QH+J69PBDLP5J)E<AY^PV&#@:I'2DO:
M)F7CHNN14&W<NYJ2G'[Q%K%,8EJS*=VXDG3Y4A$") *AE# !?CTR XDDDD6.
M$%I6(  XDD\@+>-^5=G,_*P<'!FS=3DCBTZ&)WE>0A8TC5279RWNA H)8G@!
M>_"NHSJQG;8[6.N(^_NO>WMC0Z@SNKWU3+^[MK:O1R-C=>N=18ZWN)@BQ^\3
MG$W7J(C^7+58BS+BQ+D&^0(U#'TM8=7U[U_G(W)+I<^XL^?1%Z-%?-G;'6UN
MF RL8A:PM:/I%K"WHJJ/]3#"70-G\7K&Y([4UVI0[U"0Z@$5.Q971*PQC^R$
M44 3(H.Y.#6BA(4P%,J1H80[@3-V1+W/CG^E8DIO]&\MP/0&N"WU1T_4]5=+
MO\/;,T@[=W'@1E1KPS<>207'4V.8G6*PYE4D$USQ"EQ>W4+UA,BRNBE7Q? -
M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
M@@@CTU]O7E_M^J;W3]ET":=5R[4.QP]LJTXS$GN(R<@GR,A'.BIJ%.BNF1P@
M7U$E"G263$Q#E,0QBC^,B"+*@?&G4-"ZE6'I!%C7HTS4LW1M1@U;39#%J&-*
MLD;CFKH0RGT'B.(/ C@00:Z+?C=\C6J_(!J".G(E_$5S=M9BVR.W=3^\*64@
M91'T&KBS5]FY5,^DZ#-NU2J,W9?5!L98&C@X.$S=U?=Q;>RM!RRC MA,?Q;^
M!'H/@&'B/'F.%=0^U?=+1^Y6AKD0LD6X(4 R<>_O(PL#(@/%H7/%6X]-^ACU
M#C(]FO5*=,4IBE5D?/+Y/ZW0=>67A+HVSM9;9]]:JPN])^">E72UU1ERE"2U
M^HY;@=#[WWA PMG[?U!.PB!6363*J\1,E)&Q]M23Y"ZSFJ1C1F\8(^>W@WWJ
M\P?%K6X WJ7\1O=S%TW3)=@;>F#ZODCIRW0W\B$_.AN.'FRCW7%[I'U!A=U(
MIAY,%4.IBE=,?QG?A\\-O[N^L/XL,<KCN3^OLS^D/]DUUC[3_JST+^R\?_5B
MMX\PM2%5+/ZCCAO(4/=U7YBU2*64I6Z6D93=D.6Z)S-X3:=4AR,()X\.7HDV
M1N='BDB(%*7[3F&='.;N6( S%V]U=9\)M(E/XZ$ED]:,;G]ZQX^IAZ*H5\4N
MQ9=-W!#OG#0G SU6*<@<$R(ULA/H$L2BW[:)R3=A5:')&JI]6(O!YY4H+BI.
M/.,7(6?^5:$OLX>8I5XD5CGC]2WR2%NW?(32AS#\NU];O2(=RN7\S%2)?<J$
M*BZ>N$M WIMA]40:E@+?.1;,HYNHY6]++X#[8<.8 -G_ (?.\6-LW(;:6YI.
MC;>3)U12L?=QIFL"&^YADYL>4;^^0%>1EN_,7S*39,Y*->-9".D&K=\P?L7"
M3MD^9.TB+M7C-T@=1!RU<H*%.FH0QB'(8! 1 <A=E96*L"&!L0>8-= XY(YH
MUEB8-$P!!!!!!%P01P((X@C@17ZL_E?NF*5YRWW"J:_J\[=KS9(2H4^KQKF9
ML5GLDFTAX*$BF9!4=/Y.3?JH-&;5$@?$YS@'7H'Y1#/I##+/*L,"L\S&P4"Y
M)]  KRYV=AZ9AR:AJ,L<&#"A9Y'8*B*.99B0 !ZZTGXJ>3?AGS(FY2IZ8VRR
M4N\=)2[-M1+DS7IENL,?%.5TD['5(B9%(UDA))FA[M/VAU'C9L<OO&[53N3+
MF=4VWK&D()<R(^20/>7WE!/@Q'(CEQX$\B>=:!LWNUL3?60^%H.:OYP5V AE
M!BE=5)]^-6^>C =0Z2653^,5#<#?O,%4DTQ2F*556^J%_@+P[_6W<WZ'UUDG
M]M/X;+^]C^R]4Z^+O^KM#_+Y7X,%4_LEFJ/U<!^EZ_@+S$_6W3/Z'V+D3=R_
MX;$^]D^RE7@^$3^KM<_+XOX,]6J<C"KBTQ2F*4Q2H9_/I^&3N3];M/\ ])]8
MS;]B_I)#]Y)^ :@GXD?U2Y_Y?&_WB.N?;D\US0J<3Z>?\1ZL_LEVI^BF6:7O
M[]'F_*I]FK"?#)^M.+^A9'X(J_-D%UTAK!/)S0U8Y/\ '[;>@;>8J,)M&ERM
M:^8"B#D\%,*$*\K-F;-S'(1=[5K*T:2*!##V&6:E W4O4,]VFYTNF9\6?%\^
M)P;>D<F7]T+@^VM=W;MS$W=MK-VUG<,?,QVCZK7Z&YQR >)CD"N!Z5%ZYB&W
M=57?1NS[WJ#9$0I!7G7-FE:I98T_>9-.1BG)T#.6*YTTO>Q4BB!'+-R4OINF
MBJ:Q!$ARB-DL3*AS<9,O'/5!(H8'U'T^@CD1X'A7)#6]&U#;VKY.AZJACU'%
MF:.1?VRFUP?%6%F5N3*0PX$5\2BW>UZTN=5V%19Q]6KG29^*M%7GXU7T7T1.
M0CU&0C7[8_02B=NZ0*/:8#$.'4I@$HB _N>&+)A;'G4-"ZE6!Y$$6(KX:=J&
M9I.?#J>G2-%GX\BR1NO JZ$%2/81[#R/"NA?XQO*#JWG_K=HP>/(BE\C:G%H
M%V1JU9\BDM)^V321<7R@(N%"NIJF22Y@,L0@*.(9PH#9SU(9LY=P'N3;63H.
M06 +Z>Y]Q[<OVK>AA]1AQ'B!TV[2=W='[E:4L4C)C[IA0>?CD@%K<#-"#Q:)
MCS N8F/2_ H[RHYK%3%3%*8I4;_,3RJ<1.$5XI&NMO6R5D[A;)!,LW T"/:V
MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
MM*[  #F238 >TU4/+R\; Q)<[,=8\.&-I'=N 5$!9F/J502?4*J9;<^IPL+/
M94@TTAQPK4OJ>,E'#5E+;%LTVQNENBT>\B4JFR@T BZ6=X?H<C=7YN8B8?;,
M!S"5.5,3MO&<8'-R&&41R0 JI]''BWM]VJ7ZW\6N4FJLFW]*B?1D<@-/(XED
M4?;60=,5^84^98<S<V%A3@;SCU?S[T8UW)KED^KC^/EUZM?J#,ND'DS1[<S:
M-'RT:J];I-T9B(>L7Z+EA()I)$=('Z&31<)KMT=!US1<G0LTX>00RD=2L.3+
MRO;P-Q8CP]8()LUVY[A:1W)V\NNZ6K12*YCFA8@M%( "5N+!E((9'  8'B%8
M,J_=YG<T=-\&M1+[8V\\?N2O7Y8*FTROD:N+7>+(H@JY)%PS5VY:-D6K1LD9
M=Z\74(W:(!\1,JHBBKIVMZWA:#A_3,PDW-E4?.9O0/LDG@!Z[ V.[2]I-U]X
M]T#;.UD12B>9//+<0X\0('7(5#$EB0L<:@L[<K*KNL U9^IH;+7!HG<N)*\;
M05WXIOGM9VRG-7",C#*AT>-(R5H\!"SC]% !ZMCNXY-4X_X=, ^,>Q=T 9@)
M\.V/?B5DNP'IL5 )]5U]M7;U'_#SD32F;2=SB36PEU6;",<#O;YK.F1+)&I/
MVX24@?:-4\]]LM:YO<#]MR''R?:V>)Y$<<=NU77<J;N8 :=M]%M%.:L)1%T9
M!6*D8BR+F:/451(9LX14(80[1')=V]JN%/D8>KPMU87G1O?U*X+"WI%B"/2+
M5S4[O[ W/M_%W!V[UF X^YUPLG&*$@CKE@81LK V:-PZ.C@V9&##@:YF,S#2
M]<F):O6"+D(2>@9)]#3<++-%X^4B)>+=*L9*+DF#I-)TRD&#Q Z2R*A2J)*$
M$I@ 0$,M&CI(@DC(9& ((X@@\00?0:XP3P3XL[XN2C1Y,;E75@5964V96!XA
M@000>((L:WS\5FI+KN'R"\5(FDQKIZI2MRT+;=H>)(+J,X2E:KM,1=;))2CE
M(HIL&KAK$@Q145$J:KYXW0 1.L0IL'N?+AQ-!RGF( >%HU];.I4 >GG?V GP
MJ1NSNBZAKG<S1H=/0L<?/AR9" ;)%CR+*[,1R!"] )X%V5>; 'I2Y76NK-<J
M7=FI+KH;;>Q--[%C745=-<VR7JT\W=(+MQ7<1SHY&\JT!P4IW$5.LC)/63@.
MJ;IFX263,8ARF&S^%EPYV)'F8Y!AD0,/E\/:#P(\""*XY:_HNH;<UK*T+5$*
M9^+,T;@@BY4\&%^:N+.C<F5@P)!!K^>F=47;>FU]?:?UQ&.)>[[%M415J\S;
M)JG['DDZ(F>1=G1*8S6+AVH*.WC@W1-JT0464,4A#&#^YF5#A8LF7D&T$:EC
M[!X>T\@/$FU?G0=&U#<6LXVAZ6A?4,J98T OS8_.-N2J+LS<E4%C8 UTQ^5O
M*S4G##2\ONG<\N_3@(M=I#1,5%-VCNU7:TOD5U(VLUJ.46C63N:D$F:RQN]1
MNV;MT55U3IHI',6IFKZOAZ+A-G9I(B!L .+,QY*H)XGGS/  DFPKN?VQ[9[I
M[L;JAVAM2-7SW4O))(2L4$*V#S3,JDJBEE'NJ69V5$4LP%5X67U-)#7 A)'B
M,=&@&DQ24<LMO YN",,)_3!^1DO06D*YDRI?G?:"X12$WYKW(!^>&.%[H?CO
M>P__ "]_"3WK>FW1:_JOZK^-7MF_P\V&E$X^Z =;\NX#8-H#):_3U#):0)?A
MU]+&WO>7]I5D;CIR(U9RHU#4]W:=G#SE*MK=<4 =H RFH248KG:2]<L<7ZJQ
MHN>AGJ9DETN]1,X=JJ*BK=1)922]-U+$U;#3.PFZH''L((X%6'@0>?U02"#5
M M^[$W)VVW3E;/W7"(=7Q6%^D]4<B,.I)8GL.N.12"IL".*NJNK*NG'DO\F>
MN?'1K^M2$K6U]C[7V,I*H:[UPTE20J"[6%(T"8M%IFO9R*D-7(M:1;I$ C=5
MR_<*>DB4"$<+M]SVYMO(W!.RJWEXL=NM[7Y\E4<+DV/C8#B? &NO=CNSI?:[
M3(I9HCE:SE%A! &Z00ENJ21K-THI8#@I9V-EX!F6(_B7]2,EL';M=U_R=TW5
M-;TNY3B,(RV;1;#,+LZ4O)N@:Q"]P@K F[.^@RJK)E?2+9XW,T3 RX-5"=2$
MVO5>W9@Q&GTV9Y)D6_0P'O6Y])'(^@$&_*]0KLOXJ1J>MQ:;NW AQ<">0()X
M78B(L;*94>]TN1UNK+TB[=!' 6ILC"KB57I\P7B)V-S)OU?Y"<>IFM%V0QJK
M&F76B6R2-!L[3&PSMXO SM=G/:.6C:?:(R2C5T@],@V7:HHF35343,1>.MY;
M.R=:R%U'3F7Z2$"LC&P8 FQ!Y7XV(-@0!QN.-Z/A7^*+0>U&B3[&WU%D?F!\
MEI\?)A3S&A>15$D<L?4&,;% Z-&&=79PRLK IX+Q&^&S;'%G=+;DUR5D:M'V
MVK0,W%ZUU[5)@+$[BI:UQ#FOSMCM4XV0)#)':5N2>,6S-DJ\*L9X=8ZR8(D3
M6\VS]E9>DYPU34R@F12$13>Q86+,>7S20 +WO>XMQS?Q0_%?MGN1M%NWG;Z/
M)DTS)GC?+RID\I72%Q+'%#&3YAZI4CD=Y!'TB,*$;K+)93R3JY^4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5J=S%YBZOX0ZVK.V]PL[(M19S9-<U
MS)R-88)2SZNJ62-GWZ%A=Q9G#=S(14>,$(.4VOJ._3/W))*G*"9LKI&D9.M9
M#8F(5\]8RX#&P-B!:_@3?A?AZ2.=:9OG?.D=O]*BUO7%E.G29:0,T8ZBGF*Y
M#E;@LJ]'O!;M8W4$BQRCI;D#I+D74V]XT;M"F;/K*Y$C*/ZG--9!:-56)ZA&
M4[%@8DO790I!ZG:/T&SI/_G)@.>7,P,W3Y?(S8GBD]#"U_6#R(]8)%9?0=R[
M?W1A#4-O9D&9B&W&-PQ6_@Z_.1O2KA6'B*S!GDK.4Q2F*5!IY>/+-1>'^NK/
MI;3EGCK)RIN40^@VR$&_0>%T@QDV@)+7.U*M53^QMR+-WZD)&'_/"X]-VX(#
M8A4W6Z[3VK/JV0N9F*5TM"#Q'\(1]JOI7[H^C@./*O7>WO1IVQ]+FT'0IEEW
MC.A0!"#]$#"QED(Y2 &\49X]5G8=  >A"8QCF,8QA,8PB8QC"(F,81ZB8PCU
M$1$1^(Y.=<X"23<\ZV(XE\?+'RIY(:>T#6$71WFR+I%Q$H\:$!0\'4VYS2=T
MLR@& 2^A6:FQ>OS@/43%;]H )A !\&JY\>F:=-GRVM&A(];<E'RL0/EK9]E[
M9RMX[JP=M8@/7E9"JQ'VD8]Z63V1QAG/LMSKJ(QL='046PB8QLA'1,/'M8Z/
M9H@";9C'1[=-LT;) (]$T&K9$I2]1^!2Y6=F9V+N;L3<GUGG77F"&.&),>!0
ML2*%51X "P ]@X"H>+3YY_';5[).ULU[OD^>!EG\0I-5K7DM)UZ35CW*C59Y
M"R9UFP248LJD(HN"D!-=/H<@F(8IATF7N!MN*5HO,D;I)%U0D&WH/B/0?&K:
MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>allogenelogo2.jpg
<TEXT>
begin 644 allogenelogo2.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
MX  < !RK %_Y=<5M4V]OK_9O)#1NO[PY.F0M3N.TJ57; @*Z9%6POXN5FFKN
M,(\(H7T#.2I%7$0!,3"/3/?!I.J947GXV//)#]TJ,1\A X^NW*M9U+>VSM&S
MAIFK:KI^-J!_[N7(B1Q?E=68%;^'5:_A>L_LWC20:-7[!TV?,'S9!XR>LUTG
M+1XT<I%6;.FKE$QT7#9PB<IR'(82G*(" B YX""I*L"&!XBMF1TE021D-&P!
M!!N"#Q!!' @CB".=:X<L.6VF.&&I9'<&[)QQ'P:#M&)@H*'00?VRYV)TFJLT
MKE4B7#MBD_DU4$%%3F461;-VZ1U5E4TR"8,5J^L8.B89S,YB([V '%F/H4<+
MGY0 .)(%2)VR[8;M[M;GCVKM"%7S"I>21R5A@B! :69PK%4!(4 *S,Q"HK,0
M*@DK/U,&J7UW3C+9Q;O5=UXH_(A]\(C9$)9K2@P.8"B_<T1>IUV.*HD ]QD4
MIU8>T![3&'H4=!B[GXC3],V)(N-?YP<,UO3T=('R==7.U#_#WW+#HYR-,W)A
M3ZZ$)\A\62*$M]R,@32M8^#''7CS '&K&>J]IT#=NNZCM?5EF87'7]YB$9NL
M6*.!<C>08JG414*HV=HMGT>_8NT%&[IJY22=-'22B*R9%4SD"2L3+Q\[&3+Q
M'#X\@NK#Q'V00>!!X@W!%ZH7N7;>N;/U[*VSN3'?$US#E,<T3VNK"Q%BI*LK
M*0R.I9'1E=&96!.0,]%8.JL/U,M/NKN XGWQLB\<Z]@I3:M7EU4B']C$VZRM
MJ1)P8O3E#L]>;B:P^!OW#]D&*H!T[QZQ1W0AG:/$R!<XRF13Z S=)%_:%-O8
M:Z1_X>NJZ1%G;FT60HNNS1X<R _.>"(Y"2=/JC>:/JMS\Q;\N%2[(AKIS5W_
M .G6I]UK?!RUS=D1>-*Y>M[6ZQT%N[(<I'4(RJ]+JTI-,#' !%@]LE?=M@ H
M]OK,E# '4PB,Z=MX9XM">26XBDR&9/8%521ZBP(^0UQZ^/#5=(U#O%C8>GE&
MS\+18(LDKX2--D3)&UOMEBE1_3TR*/#A/AD@U2BL#<E.2FH^)FH[%NK=5B&O
MTVOBW:))-&XR$]8YZ0$Y(BKU>((=-66GY95,WII]R:2*2:CAPHBU1773Q^IZ
MGAZ1AMG9S=,"_*6)Y*H\2?V22 "1NO;_ +?[H[G;H@VCM&#S]6GNQ+'ICBC7
MY\TS\0D2 BYL69BJ(KR.B- #'_4R:K5NX1\GQ5OS'7 NSI_>UGLFO2-T*R];
MM3<FU^K6(V$]R+?[9D0L@E*;[(*&#[61ZO=#$,_2^)(,:_S@X+6^\Z0/DZ_E
MJ[L_^'KN1='\_'W+@OK_ $W\EL25<?JMQ'TD3/):_ -]%N1QZ1RJQ!I#=VL^
M1>KJEN/4-F:6RA72/!_$2C8#)+(J)J';R$3*LE>CF+FX=\DHV>-5@*JW73,0
MP?#J,CX&=BZEB)FX;!\=Q<'[((\"#P(\#5$]X;/W#L/<>5M3=..V+K6))TNA
MX@@BZNC#@\;J0Z.MPRD$5[RR66N4Z"D[1;[!"56LPC4[Z9L5DE6$'!1#),2E
M.\DY>37:Q[!J0Q@ 5%5"$ 1#XY[HXY)G$42LTC&P !))]0'$UJ.5EXN#COF9
MTL<.)&+L[L$11Z69B% ]9(%8DU/RAXW;WD)*)TMOK4&UI>'*JI*1.O\ 8E4M
M<JR;(J$1.^7C8:4=O2QAE5 *1UZ8MU!'[)QSUY6F:C@J'S()HD/(LC*/9<BU
M_5SK"Z-N_:NXY7AT#4L',GCOU+#/'(P X7*JQ/3Z&MTGP-93M]/JFP*O.TF\
MUN$M]/M$:YAK%6+)&-)B"FXIX04W3"3C'Z2[1XU6(/Q(<@AUZ#^4 SRPS2P2
MK- S),IN&!L0?2"*S&=@X>IX<FGZC%'/@S(5>-U#(ZGF&4@@@^NL1:)XJ\<N
M,;6=::!TU1-5DLZS5:Q.*I"HLY*;%@54K!&4EE17E'K2/]=46Z"BQD4#K*&(
M0IE#B;UYVJ:AJ14Y\SR]/+J/ 7YV'(7\3XUA-N[.VMM))$VW@8V&)B"YC0!G
MMR#,;L0+FP)L"20 2;[ 9X*V6F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5#[YN.8'
M]5/A/;8JNR'M-H<@#O=/47V[KT)"+BYB-7/L&W-RIJHNR$@JH91JBX1,!VTI
M)LCC\.H#MNS-)_.FLH\@OC0?C&]!(/N+\K<;>*JU0?\ $!OC^YNP)X<5NG5]
M3OC0V-F564^=(.1]R.Z@CYLDD9JLAX'>8G]6CF1&ZWM$S\OU9R71CM;SQ'*G
M;'1^P$G*RFK+"J(G(5)89I\O#"H8?3(C-'4.'1,IB21OC2/SEI!R(A?*QKN/
M25^W'U &]JU4OX<]\_W3WTFE9DG3H^K!8'O\U9KGZ._J/63%?D!*2>5Q?QR"
MJZ24Q2F*4Q2F*4Q2F*5S-_)A^(+S)_O$[1_C0_RQVW/ZAP_Z.GX(KDYW8_69
MKO\ :F1_K#6CN9JH]KIC^,[\/GAM_=WUA_%ACE<=R?U]F?TA_LFNL?:?]6>A
M?V7C_P"K%;QYA:D*N?9Y]/Q-]R_JEI[^B^KY/.Q?T;A^^D_#:N:/Q(_K:S_R
M&-_N\=0T9M]01702\!?X9.F_UNW!_2?9\@;?7Z23?>1_@"NE_P -WZI<#\OD
M_P"\25,QFH5.U,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE:V\Q]C7#4'$WDGM37
MZ0*7;7FC]G7&K*';^[393=?I\M)1\HLT[3@Z0B%VX.E$A#M4(B)1$ $1#(Z1
MCPY>JXV+D?P,DZ*WL+ $?+RK5=]:IG:'LO5=8TP7U#%T^>6/A>SI$S!B/$*1
MU$>(%<OR=G9NT3<O9+)+R4_89^2?3,[.S+YS)R\S+R;E1Y(RDI(O%%G;^0?N
MUCJK+*G,HHH83&$1$1RRJ(D2".,!8U   %@ .0 \ *Y%Y&1D9>0^7EN\N5*Y
M9W8EF9F-V9F-R6))))-R>)JZM]-?N+95[XR;BUM<'\I,TW3VQ()GK61E%G+K
MY5&VZ$>24Y2XQ=;JFG$04A&D?)-RF$4#RY_@4ADP"'.XN)C0:E#DP@"::,]8
M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
M@C6.-%%E5%%E4>H >WT\:]1GRKV4Q2F*57!^I8T['6GB?J3="35,UBU+M]*N
MF=CT*<E/V; OT9E$# 8!4,:S52%$I1 >TO>("'Q[I#[<Y;1:I+AD_BY8;_ND
M(M]9FJK/Q7:'%F;,PM> 'TK"SNB__A3H0P_E(XOKU23R9:H!5CWZ9Z]+P_+[
M=.OE'"B4==^/SZ=!$#JBBYG*/?::E'%.BF@<GJ)1%LDCE5.<A2 !B!W&4  C
MWN/ 'TF&?[9,@#Y&5K_745:?X3M1:#>^?IA)$61IA>W@7BFBZ>%ON9'-R1;B
M.)-7;<AFK_5!Y]0)R!<Z9X"S5(A7QVECY"7:OZK3%NIZ;Q"I(IN[C=G1>H@4
MS%[&UM*(<A]HPIR_0 ^(F+NFP\ 9FNB9Q>/'0O\ NOFK\MSU#[VJ^?$MN5]"
M[;R:? W3E:GD)C\.8C%Y93["J")O5)\HH,9.E<W:E^\(_$6(Y7\W*P:Z1B,K
MK/1T0IN*XQKUJ1U&3[Z#DXYA2JL_36*HU7;2=JD$';ANL0Z3N/CW2)@Z'$0U
M/>>K/I>BMY)MDSGRU(Y@$$LP]B@@'P)!J;^P&R8-Y]P(3GH'TG3T^DRJ1=7*
M,HBC-^!#2,&92"&1'4\ZZ%F0'73:F*4Q2F*5KURLXY4KEGQ]V?H&^((_)]@U
MIY',94[8KES5[,@4'E5M\:0PD'YC6+ W;O$R]P%5](4C]4U#E'(:7J$VE9\6
M?!\^-KD?=+]LI]3"X^O6L;RVM@;TVSE[:U(#R,F(J&M<QR#C'*O[:-PK#TVL
M>!(KF!WFF6#7-VN&O;:R-&6JB6FP4RS1QA[C1]@J\L[A)ED8P@7N,TDF*B8C
MT#KVY92":/(A3(B-XG4,#Z0PN#]0UR-U# R=+U"?3,U>C,QIGBD7T/&Q1A\C
M BO><=MS3W'?>VI-XUD5AE]6WZM7))JBKZ RC.(DT%Y>"64Z" -+!$>NQ7#_
M )R+@X?NY\-0PX]0P9<*3YDL97V7' _(;$>L5DMKZ]D[7W%A;AQ+^?AY,<MA
MPZ@K LA]3K=#ZF-=/;^676_^4S/_ .6'\LO[U7_Y;_Y3?O/^I_\ )^__ .3*
MU_0\C[D_POE_N_N?;77#\^Z5_&K_ .C^E?\ X/XSV5["U6NLT:MS=PN<_$5:
MJ5N-=3%@L4_(-HJ&AHMDF*SI_(R+Q1%JT:H)EZF.<P!_^>>*6:*")IIV5(5%
MR2;  >))K9=-TW4-9SX=*TF"7)U+(D"111J7DD=C8*BJ"6)/@!6@6JO+5X_-
MS;-;:CHO(6%6N4I))P]=)8*U=:?!6F555%NE'5^T6NN0]?>/W3L2HM4#N$E7
MZJA"M"KB8,U[$W?MW-RAAX^2OG$V%U90Q] 9@ 3X 7X^%ZFW<OPQ=\-I[>;=
M&LZ%,-)CC+R^5+CSR0H!<O+##+)*JA;L[!2L:@F4I:I',V6H$K4/FAS6TQP8
MU.?:>WWL@Y-(OC0E*I=>20=6J\6+T#.?ED.W=+M6C9HR;E]9Z]<*)MVB/3J)
MUE$$5</K>N86@X?TO,)-S95'SF/H'J',D\![2 92[2]HMV]Y-S?W;VLD:B-/
M,R,B4D0X\5[=;D L68^['&H+.W@$5W6"VF_4R4M]=TV-]XI6*MZ[</R(FL=8
MVFPM=MBX\#"0SY6JR-(JD7*KJ@(*&0)*MO1#J0#KCT,.A0]T(&GZ<C$9<8GF
ML@9@/3TE5!]G4+>DU<K5O\/75H=',VB[F@R-=5+^5-AM#"[?<B9<B9T Y=1A
M?JX$JG*I/N??&BD>5O@O'L],7FOR+N2<0>Y-"7@ZJZ=:D+%&,)>*"(L"A6:L
MK&Q\S#S4A&O$S(E<QD@)#KHF.T.W--VS]R8^GYD>JP'S=/F2S%>91B#< V]Y
M2!P-CP*FQY<J_B [.ZUKNDYNPM9B.#N_3LKK1)> 2>,,O0Y7JO'+&[!73J4A
MDE7K4"]':W^.;GC2+H>@3G$;D O9 =K,FY:YK&TW&$DU&_Q77A;548Z;JTVQ
M03^VHX:/%D$R?:,<  1R=XMPZ'-#YZ9<'EVOQ=5(]JL0P/J(O7,_.[7=QM/S
M_P VY&B:F<KJ('1CR2HUN962-7C<#F65B .)-6WO!SXQ]@<+JO>=V;[9-X3=
M&W86+KD91D';=^ZUY0&;X)APSGWT>X<1JMEM<LBT7<-D3K%8(,$""IZZCA%*
M*MZ[D@UB5,+!/5AQ$DMRZVM;@#QLHN ?$D\+ $W5^'OM+J>PL/(U_<BB/7LV
M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>allogenelogo3.jpg
<TEXT>
begin 644 allogenelogo3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
M@( (984$,+CB#7+1T>-S'("KJ2""+$$<""#R(\15AGZ<_C7L"[<N'W)(L5(,
M-6Z6J%MAE[,LU.2+G;Y=H7[NL:?'.50(1X]8P$NZDG@HB<69$VQ5NSW:/?H'
M<'48(=*&G7!RIG4V\0JFY8^T@ 7Y\;<C5G/A=VIJ>H;V;=01ET? @D4R$>Z\
MTJ= B4^)",TC6OT@+U6ZUON5]3-7+LH[XGV[L=KZX9M]HUP5$TU!8Q5VDE:C
M)@1ZJ!Q2*[GX**$6I1*!C$C5Q 1 ! *==T(IR<.;C]& D7U!CTGC[0.'WIK_
M $<_X>F?HZQ;FTNZKK[MARV)'4^.@G3W1SZ8Y']\WM>5/2*JH9$U=*JO-?3Q
MUVX0? )^_LZ+Q&)M>^=AV*@^[%7TU:>2OT2N+K,2*D*";-2ZUZ9^!.I#*]YN
MO4P])X[<Q31[>+2WZ'R'9/O;(O#U=0:N-_QU9^E9G>Y(=.*'*QM%Q8LGIM<3
M^;DR@-;FPQY8.?$"P\*G5S?:IG3%*_PHHFDF=54Y$DDB&4444,4B::9"B8YS
MG,(%(0A0$1$1Z &.? <Z_A(47/ "M1-0\^^&F^]ER&GM/\B=<7W9$<204"L0
MTHN"\NG$IK+R9ZJ_>M&D3<R,&C91PL,0X>@FV3.L/1(ICAELO0M8P<89>7CR
M)C&WO$<K\NH#BM^7O <>'.M)T3N3L3<FK-H>AZIBY.JKU?BU8W;IN6\LD!9;
M $GRR]E!;YHO6WV8FMWIBE,4IBE,4IBE,4K3'R!\JHWAGQ+VYO5=5 ;)"P)X
M+7$>NF1<LMLRS@:(I;4[90!*Z9,I1<'STG_=[-<P=>G3,QH.EMK&JQ8(_@RU
MW/H1>+?5' >LBM#[E[QBV)LO-W$Q'TJ./H@4\>J>3W8A;Q 8];C[A6KF9R\O
M*6"6E)Z<D'<M-3<B]EY>5D%U'3^3E))RJ\D)!ZZ6,95R[>.UCJ**&$3'.81$
M>HY8Y$6-0B !%%@!R '("N3<\\V3,^3D,SY$C%F9C<LS&[,2>)))))\36WOC
M[XMR',?ESIS12:#HU;G;&E-[&?-O4(,5K2K%^>75T+LB2I&#I]$,S,&2J@>F
M,D\;D'XG !Q6O:FND:5-G&WF*MD'I=N"^VQXGU UN_;39\N^M[8.W0#]%DEZ
MYR/M8(_?E-_ E1T(3PZV4>-6=/J+N&3"U: UORBU_ -6<GQZ+':YN+**:E;H
MDTY8GZ+*M&1;-R"FDRHMR=))((ID(1-M-.%##VH@ 1MV^UAHL^33)V)7(NZW
M_C />^5EYGTJ/35MOBBV)'F;:Q=WZ;&%ETSI@E"BP^BN0([ >$,I  %@%E8G
M@M4OLF"J&U9B^G!YA!K_ '/=^(%LD!3K.[4%[MK?W#@P-X[:-2B%#SL6W2.<
MB"8W2D,!4.H/4YEX)LD0!%;X1SW#TCS\--6B'XV'W7]:,>!_<L?J,3X5;'X6
M=\?FS7LC9&:UL34 98+G@N1&OOJ/#\;$+D^F)5'SJND9#M7TIBE,4IBE,4KF
MR>6;\1[EY^UN1_1<5EB=K?H]B?DA]DURI[T?K3UO^FM^"M1X9GZC"NF/XSOP
M^>&W]W?6'\6&.5QW)_7V9_2'^R:ZQ]I_U9Z%_9>/_JQ6\>86I"J@+]01%IQ_
MDIV$[(J=0TYKG4LHJ0P% J"B50:PH))B'Q,04H@I^H_'N.(?D ,G;8;=6W(Q
M]S(X_P Z_P#EKFQ\2\(B[K9+@W,F+C-[+1A?_MO\M0GYN50#702\!?X9.F_U
MNW!_2?9\@;?7Z23?>1_@"NE_PW?JEP/R^3_O$E3,9J%3M3%*@M\MWF!@N#[%
M72FEDX>X\GK##IO5E'9V\C6M-1,@4IF,W:V!#F&3MDFT,*T9#J"0I43$>O/\
M7,W0>[MM3:3ZTWTW,NFFJ?89".84^"CQ;]R.-RM>.]7?#'[?1G0- \N?=TJ7
M-[-'BJW)I%^VD8<8XC;A:1_=*K)1AV5L[86X[M/['VG<K#?;U9WIW\[9[/).
M)25?+G'H0@K+F,5NR:)=$F[9$$V[5 I4D2$3*4H39C8V/B0KCXJ+' HL% L!
M_P!O$\R>)KGEJNK:GKNH2:KK$\N3J,S7>21BS$^T\@.2J+*HL%   KPN?:L=
M6;]:<9>1^YFY'FHM!;GV>Q./3YC0-876W1B8>X!J91>2@85\Q;()N# 0ZBBA
M2$-^^$,\63J6G89MESPQ-Z&=5/U"0:V'2=I;IUY>O1--S\R/[J''ED7G;BR(
M0!?@238>-?MV5Q4Y.Z;9KR6V>.^[];13<YR*3-WU9=ZS!B*9A*8Z,W+PC6*<
M(]2CT.FL8@_N".?S&U33<P].+D0R/Z%=2?J WK]ZKLW=VA(9=:TO4,2$?;2X
M\L:?([(%(]8-JP'GNK6Z]52+U<]:6N#O6O;5/TFYUI\E)0%HJ\J]A)R(?(]>
MQRPDH]9!TW.)1$INANAR&$I@$HB _*:"')B:#(57A86*L 01ZP:]NGZCGZ3F
M1ZCIDTF/GQ-U))&Q1U(\0P((_P HX'A5WSQ"^9)AS"]AQZY%.8BO<EF3%0U6
ML#1NC%0&[(V*8&=2"[5DB";&%V"P:-57+R/0*FU=H%.X9D3*15NC#&[-H-I-
M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
M(H<5Q9/M=.(H2*=H)>N1=(@CZ)ND!;ST]L#7YFM^*G/F*?3U?.^4/U?)8^-=
M._A_W1#N7MG@Q=0.;IR_1)5OQ7RN$7KL8#'8\KAE'S34M^:I4U4Q2F*4Q2HT
M?+QR*C>-O +?=A5D 9V;8E6>Z7H:":Q$7SRT;.8O*\LK'"<Y!]U7ZPK(RW4O
M4Q4X\P@ CT =CVGI[:CKL$8%XXV$C>BR&_'VM9?EJ)^]NZ(MJ]MM2RBW3EY4
M)Q81>Q,F0"A*^M(^N3V(:YP>6%KEE4CGB0U&YW-Y%>+%=2:BY95G9+':DPH8
MBAVS6.U*V<[$(H\%,2@5!W)UQNT*!_L*+."$,!@/VCK^ZLL8>W\J0GBT90>V
M3W/L$GY*E/LIHCZ]W0T?%"WCARQD-Z N,#/Q]19%7T$L >==([*[UU2JL5]3
MAJ=U.Z)XW;H:-3K)ZXV;:Z%*K(E,8S=EM*NL)=JY=@0! &B4AK(B)5#_ &2+
M.BD#H*O09)[;Y03.R,,GC)&K#]P2/L/];U54GXM=&?(V[I6O(MQBY<D+$> R
M$# GU=4 %SR+ >-4RLE^J(59'^FQY&Q^O^2FU..\\\1:,]_4R.G*F+A8I?7O
MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
MA0<"QZ0Y^Y4VXGU\%'(D5%F^>\>R>W^H8^EZW,[YTS>^D*B1H$(X2S*&!52;
M647D8$LJ, :W,TYO#47(.D1VQ]*;$JVRJ5*  -YVK2:+]%!QV$44CI1K]B0A
M)AJ4X NR>I-W;<P]JB9#?#,1F867@3''S(VCF'@PM\H\"/01<'P-;WH6X-$W
M-IZ:KH&5#EX#\GC8$ _<L/G(P\48!AR(%94SRUF*8I5"6_>6SR50W/&Q.&-W
MMR,C";N>T.-XP Q03H[U@RN7W?8ZQ7JAF:QEY2711(Q-* )I<RZPK(N2G$HA
M.<&U=N/H:AD3I:$,9K^]<K?KZO0.?3\VW BN<.I=ZNZT'<:5H\B<2QZ@85P+
M#RB!+T#',=C=F ">9_"7/4K VJ^UD&5T>J!#S0^*&[<[#4/=&B)*!1W;KNN*
MT:3JUHD1AXR^40)9_/Q#.,FU$U6418:W-S4@HD5UZ;5XB_4 ZZ)D4P5WK9^Z
M8=$\S#S@WT*1NH,HN5:P!N.9! '+B".1OPKAWY[,ZAW$.-KVW7C&X,6(PM'(
MW2LT/474*_)71W<CJLK!S=E*B\1/!GZ?WE3)[PI%NY:UZOZFU+1[-%6:>KI+
MM5KE;;\2!D$)%M6(PE G)Z+B8J=6; B]>.'[=RW:G,**1E1+V;7K>_-+7">+
M2F:7+=2 >EE5;BW4>H DCP !!/,VJ$NWGPU;QEW#CYN](HL+1<>99'3S8Y9)
MNA@PC7R7=55R+,S.K*I/2"UK6[.2G)34?$S4=BW5NJQ#7Z;7Q;M$DFC<9">L
M<]("<D15ZO$$.FK+3\LJF;TT^Y-)%)-1PX41:HKKIP5J>IX>D8;9V<W3 ORE
MB>2J/$G]DD@ D=,>W_;_ '1W.W1!M':,'GZM/=B6/3'%&OSYIGXA(D!%S8LS
M%417D=$: 5C]3'J96[%CY#BSL)GKH778:UM=B5Q]<B,Q6,7W T%2O,845P0Z
M&%(+'T[A$H'$  PQZO=##,_2V)(,:_SNM2UOO+ ?Y]7;F_P]MSKI!G@W)@OK
MW3_ G%E6#JMR^DB5I+7X7^B\N-O 6$-,;7U%R/U]2-[:HE8:YU.SQBSRKVA-
MD0LDR**CAA+12Y7:))*$EHYZFNT?-#^FJBN0Z9R_ >LDX&H8^HX:Y6$_7BR"
MXM?P\"/ @\"#Q!%4/WALO6]C;GR-M;JQ/HVX<%^AU8 D BZLCBX:.1&#(ZGI
M=&!' UY/DIRYXY\0JDUN?(?:=?US%2:CE"!9/0?2EFLSEH" NV]8J4$TD[-/
MBS%TC[A1LU41: L0RYTRF V9K3M)U#5I3#I\32,.9X #VL; 7\+GCX7J-=U[
MVVMLC"&?N?,BQ87)" W:20BUQ'&@:1[7'454A;@L0#4=$ERO\1GE?)'\=+1=
MZ]>+*X?*+T2$N,%=M671&<<H$2];6MMFXNO>K..P(4IXYF]55?%1 %FJR10#
M/QN3M_F38)_/6)UXB\>I6!*'TW0]2^L_-/C>LMV5^+33MM[I$_;#7SB:[, C
M0RQND>4H-Q&T<Z"*8W)Z5%Y5))CZ2;UXVF_3P\!*M9VM@EY+?FP8YLY!P:FW
M+85;;UAT4%@5*U=*TB@TRU&; 4.SH64(<Q/WQA'XY&<';C;T4HD<Y$B@_-9U
MZ?\ -16_SJO#JWQU][=2TYL'%CT3!R&6WGP8LIF'"UP,C)GAOX\82+\A;A4V
MU2J-6H-9@Z72*["U*HUF-;0]>K5=C6D1!PL6S(";9A&1K%)!HS;(D#X%(4 Z
M]1_*(YO4,,6/$L$"JD*BP4"P '@ .55!U35-2UO49M6UB>;*U3(D+RRRNSR2
M.W$L[L2S$^DFJCOU"_-'8CS;L7PUIT](5[7%6JD!;=GM(IZNR5O-KM!%9.'A
M9\6ZA1>UFN5\&;I%H8?16?/#*K$.9NU,G#_<;6\DY@T6%BN,B!GL;=;-Q /I
M518@>)-SR%=0/@7[2:%%M>3NQJL$<^OY.3+#B,ZAACPPV1Y([CW999>M&<>\
ML:!5($D@:LID75T-JXK]/-S0V%MBJ;)XL[-GI*UGU%!0MPU9.3#E9_+,*&Z?
M%K\S3'3]<3++Q%8DUF!XH%#**(H/56Y3%;-VR2<S]N=;R,N&72<IB_DJ&C)X
MD)>Q6_H4VZ?0"1R  Y4_'3VET+;.IZ?W(V[!'C+JDTD&9&@"HV2%\V.<*. >
M9!()K !FC60@R/(S6#]NZ<U?ON@3NKMQ4F"V!0K(@",M7)]L95LH=,1,V?,G
M2"B$A$2[!7\XU?,UD'C14 415(< ,$B9F%BZACMB9L:R8[<P?LCQ!'@001S!
MJC.U]U[CV5K<.X]J9DV#K>.;I+&;$7YJP(*NC#@\;JR.MU=6!(J&9;Z=;@.K
M9PGB6#D0WB@?%=_<E'8=2-6!0*;J,8+MQKA>Y^Q.'P$P2X.>GY%0'XYI1[;[
M?,OF=62$O\WK7I]GS.JW[J_KJV2?'AWL73OH1@T%LGHZ?I!Q9O.O]WTC*$'5
MZO(Z/VM9!B_)9XB."#%'C9KK9E9J\-27;MM(0FJJ9?M@0K*:%1-&2<SEX@X2
M=96JR+*(]CQR,C(/0,CZ:YP,0I,EK1]@:K!@)'IN((<.UU!95)OXD,W42?2W
M$\.-<].Y'Q5[3W!NS(U+?6X)-2W(QZ9)%CDF1 O*-##'Y*(ES:.'W4-_=!)O
M*'HW?^F>2M!8[0T3L2N[*HS]RNQ)-5]PMW,I)J5)1S$S<4^09S5>FFZ*Z:AV
M3]LV=$253.*8$4(8V/S<#,TZ<XV=&T<X%['Q'I!' CU@D5G=O;ET'=>FKJ^W
M<J++T]B1UH3P8<U=2 R, 02KJK6(-K$5COE%R?T-PBU1/;HVX\1K\*XDRM&<
M37(QDO;=@7!^DZ=-8. C058$EYYZDW66.JX62001346<+)I$.<,%K&M8FC8?
MTS4'/E#@H'%F/@JB_/AZ@ +D@5+/;#M9N?NINE=K;,QHVSY 9)9&]R&&,$!I
MYW"DA06 X*SNS!45F8 P;5?ZE_43^ZEC;?Q?V!6Z H\(B6W0VP8&T6=)F<YB
MB]=T=Q6ZU'D,D7M,=)*<7-T[NT3"  ;0(NY^&T_3-BR+CW^<'#-[>GI4?YQJ
MZ.H_X>^Z(=(^D:7N/!R-<"7\B3&DAA+?<KD"65C?B 6QU\+V!-K!E8M6I.4V
MD$+%4YF/V%IO=-'E&2,DP.[;M9^JV5@]@IE@LFLFTDXM\FFJX9NVRR:#MDY3
M415(FLF8I9-T_4(LB.+4L!PT9LZ,/4;C@>1!'$$7!!!%ZH'O+9^IZ!J.?LK=
M^*^/J,77CY,#VN RV8=2DJRNC!D=&*NC*Z,5()I/;X^GHYTT?9TM!Z1KU9W7
MJ]S,+_=>[DOM'ITLR@%EA%B-UK]QFJZZ;S#-N8"N0BRR*"ABB=(>ANPLZ8._
MM$FQ@^:S0Y('O+TLPOX])4'AZ.JQ]-<UMQ_#)W$T_5GQ]OQ0ZAI!<^7+YT43
M!">'FI*R$,!\[R^L'F.=A90\0OC<?^/335O1OLY#V+=FXY6"F=A.*XH[7KE>
MB:PSD4*E2XIX\2;*RRL.K/2+EV^!!N5=P^%(A3I-TUE8ZW9N)=?S$,"E<*$$
M)?F2UNICZ+V  N; 7YD@6L[(]JY.V6A3KJ4D<NOYSHTQ2Y1%C#".)2;=727=
MF>RW9^D A0QDCW=:[;0]+[=O% KOWPO=-UA?K72JEZ:RWWHMM=JDM+UNN^DW
M41<*_.YEFBV[2'*<WJ]"B ]!S7<***?,B@G;H@>559ON5+ $_(.-2IN#,S=.
MT'.U#38O/U&##FDBCXGS)$C9D2PL??8!>''C5,GQ>>3[GYM;R ZLIUSVO;MP
MU'<MK>1%]H<RU9NJW"5Y6.?/Y"S5:+8M&K6D$IJ#3WO5@#=!1% Z:Q% 4'K,
M&Y=M:%BZ#+-#$D,L*75AS)N  Q/SNKEQN>/"J(]H>[G<G6>Y6'@Y^;/G86?,
M5FA8 HB%23)&H $7E =7N6! (8&]7A<A:N@M,4IBE,4JN+]1?S!_DJX\U;BO
M4Y(Z%TY"N_G%T%HX]-Q%ZCJ$@W76:N 3,1PC]][:FW;)F 1379QL@BH @<.L
MA=OM)^E9[:I*/Q..++ZY&'_VK<^TJ:JU\46^/S-MB'9V$]L_4VZI;'BN-&P)
M!\1YLEE'@5253SJD?DS5S_J63PO\1PY8\X*"C/Q9)'66EO3W)L4CI(BK!\A5
MW[7[H5IRFL MWA+'=%F1'#4_7UXU%V/:)2&S5MX:K^:M%D,9MDS?BT](ZA[Q
M^1;V/@;5-'8;97]\^X.,N2G5I.!_YJ>_(B,CRHS?@>N4H&7QC#^@UT1L@"NG
MM,4IBE,4IBE,4J(WS6\1OZUO""\+P$:#W9NBA7W+03(I)&?OD*Y'.@O5814[
M1<JISU,4=*)-4AZN9-DR 0$2ES:]FZK^:]:02&V-/^+;T"Y]UOD:W'P4M4*=
M_-D_WR[?9#8R=6K:=?*AMS(13YT8\??BZB%'SI%C]%<\?)]KF+6XG ?E1*\,
M^5^I-]-#/58&NSP1.P(ED8PGGM<61,8:YQOMP$$GCI&)=&>,B*=2%D6K=3X"
M0!#$Z[IBZQI<N";=;+=2?!QQ4_5X'U$BMY[;[QFV)O/"W&G4<:*3IF4?;P/[
MLJV\2%/4H/#K53X5TU(69BK%#Q-@@I!K+0D[&L)F&E&*I5V4E%2;5)['R#-<
M@B19J\:+D43.'P,0P"&5O=&C<QN"'4D$'F".!%=9X)X<J!,G'8/CR(&5AQ#*
MPNI!\0001ZJ^EGYKZUS9/+-^(]R\_:W(_HN*RQ.UOT>Q/R0^R:Y4]Z/UIZW_
M $UOP5J/#,_485TFO$Q^'#Q#_9+'_I66RN^ZOTAR_P J?L"NJW9?]5FB?T)?
MPFJ1#-?J3ZH,_4,?B/6;]DNJ_P!%/<G38/Z/+^5?[-<WOB;_ %IR_P!"Q_P3
M4'>;I5>ZOW?3WO73KQN4Q!PL*B4;M':[)B02D &[52PDD3HE$I0$P&>OUE.I
MNH]3B'7H  $%[]4#<3D<S$A/U+?8%=)/AFD=^U<"L;JF9D >H=?5;ZI)^6IO
M,TNK U\2RUN N5=GJC:XB/L%8M$/)5^Q04JV3>1DS"3#-:/E(N0:+ 9)RR?L
MG!TE2& 0,0P@.?N.22&198B5E4@@CF".((]8->?+Q,;.Q9,+,19<29&1T875
MD8%65@>8()!'HKGE>5+QG7?@%MYV^@V,K8.-E^F'BVI[XHF=U\H,OZSX=:W%
MV45 ;6ROMBF*W75["3+)'W2( H5VW:S[MC<D&NX@5R%U&,>^OI\.M?VI\1]J
M>!\">8_>+M/J';;6VDQU>7:F2Y.--SZ;W/D2GPD0<B;"51UKQ#JD4N;14-5O
M?PQ\C_*G@I+*GTI=TW%(DI LC8]371JK8M;V!SVI$6=GA_=,W\!*N$D$RJ/X
MAU'O52)$(HJ=,H$S":QM[2];3_SB?C@+!UX./EY$>I@1ZKU(VP^Z>\>W<Y.@
M9 .GNW4^-*"\#GQ/3<%&-@"\;(Q  )(%JL5:J^IWU.]8-$MW\9-B5N43(BF^
M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>allogenelogo4.jpg
<TEXT>
begin 644 allogenelogo4.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>allogenelogo5.jpg
<TEXT>
begin 644 allogenelogo5.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
M:1EN.*D>[4].K-6:_P!)Z_J^K-65>-IM"IL:6*KM=BBJ@U8M054<*F,JX46=
MO'CQVLHNX<+J*+N%U#J*',<QC#(&)B8^#CIB8B!,=!95'A_E))XDGB3Q-4KW
M)N37-WZYD[DW)DR9>MY<G7+*]KL; #@ %554!550%50%4  "M6^=OC^T5Y =
M<15&V^C,0\W4GKV4U]L2J*LVULIDA(HMT9-%J9^U>L)*!G",D"OV#A,4W ()
M'(9)=)%9/8M$U[.T'(,^)8HX 9&^:P'+EQ!'&Q'*YY@D5$/<7MIMWN7I2:?K
M8>/(@8M#/&0)(F8 ,!<$,CV'6A%C8$%656$:O%'Z>3CCQ]VQ7-L;'V?;-^.Z
M5*Q]@J51EZQ$TZF)6"+<$>1TE9HUK*6)[:$XYZBFLBT,Y;,U%" 5RDX2$R8[
M'JF_]0S\5L7&B6 ."&8,6:QYA38!;CA>Q/H(/&HHV;\,>UMLZS%K6JYDVI/C
MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
M]U%L6(^V=N+.WI9RS'Q-9BSR5G*PMOKCOI?D[KV5U?O37T!L*G2J*I/9S#;H
M_B'2A/3)+UJ;;&0F:S.-P_P3UBNW<D_(!^T1 ?9@ZAF:;D#)PI&CF'HY'U$<
MB/4016!W'MC0=VZ8^D;AQH\K!<<F'%3]U&XLT;CP9"&'IKG>>27@Q8^ O)2=
MU*Y=OI[7TXT+<-17%\1('5BHT@Y7;HMY4[9%!H%EK;]NJPD"ID2*HHD5P1--
M%PD7)_V[K<>NZ<N4 %R%/3(H\&'H]1'$?4Y@US"[J]O,KMMNN3179I-,D7S<
M:4VN\+$@!K #S$(*/8"Y 8 *RBM <SM1K5YGZ<_DL^VUQ$MFC[%(J/[!QLN2
M$7#F75,JNGK78:<E/U-LHHIU5.$=88R=:I!U$J+-%!(O:4A0"%.X.G+B:LF;
M&+1Y*7/WZ6#?5!4^VYKH9\+N[)-:V3-M[*8MDZ5.%6YN?(FZGC'[EUF4>A0H
M' 581S0JLS7P[/9H"EUJPW&URK2"J]3@Y:S62<D%/280T! L'$I,2KU4 -Z;
M2.CFJBRAN@]"$$<_<4<DTBPQ M*[  #F238 >TUY\O+QL#$ESLQUCPX8VD=V
MX!40%F8^I5!)]0KFF^0CF;;N=')J[[HG%7S2I%<*5G4U3='#TZ=K2(=. K\:
M*)%%4B2\H*RDC*'*8X*23Q;L$$2I$)8S0='BT334PTL9>;M]TYYGV#DOJ \;
MURB[F;[S>X>[<C7L@LN%?R\:,_\ =0*3T+;[IKEY#XNS6]VP&D>9FH_JW?XG
M/!;4E:M5>2G-NM#896Q,FD_K[CS-MU6\+"13CN7C9[;3$_8M-3$FW])=O J=
MK-HW/VR)'"RAVK.*-T[VE$K:=HK=*J;-*.9/B$/@!R+<R?FV N;M=F/AXPFP
MX=U]P(O-FE4/#A."%13Q5\D<V9A8B$^ZH/XT,Q*):IAH6'KL5'P5?B8V"A(E
MJDQBX:&8-8R*C62!0(@SCX]DD@T9M42!T(FF0I"A\ #(P=WD8O(2SDW))N2?
M635QH((,6%<?&1(\=!954!54#D HL !Z +5]+/S7UK7WD7Q6X_\ +"E+4'?^
ML*UL.#$BWRUU)M1;V.M.EB]AI&IVE@=K8:S(]/@*K)RB*A.I%.],QB#[]/U3
M/TJ;S\"5HW\;<CZF4\"/:*UG=&SMM;SP#INY<2+*Q^/26%GC)^VCD%GC;UJP
MN.!N"15$'RF^+*[^/2[QL[!24I?N.U^E'C.A7UXS LK7I4H.7J5 OZK)LA%D
MM!(M ZS5TB1!O+MT%E4D43(KH(S?MC<\.OPE' CU",>\O@1]TOCTWYCB5) )
M-P3SI[P]GM0[9:@F1CN^3M?)<B&8CWD;B?)FL OF=()5@ ) &954JRK$KFU5
M"U6R_IS>>,B>3G."&QYE1VS793-[X^N7RPG48K,".)?8.N6QCF,HHU<,05GF
M"12E*W]M)B8P@HB0D6=P=#7I77,<6:X66WC?@C_5]T^FZ^@U=#X7.XTIFD[=
M:K(6C*M-A$GD1=IH!ZB+S(/#IEN>*@6W\BJKJTQ2F*57P\V?BDV9S<?4+?/'
M@T-)[BH54/K^PT.>F&M?+>J6C,R,_7S5N<E5VM>C;%79B?D143D%6K=ZU>=?
M<I':IHN-]V;NC&T428.H7&)(W4& OTM8 W XD$ <KD$<C>XK-W^[-:MW DQM
MQ[8\M]<QH?)>%V">=$&9TZ'8A%=&=[ARH=6^>"@5H>>"W@6Y;7+=](L?*"B-
M=,Z7IMFB;':VTU:*U,VN\LX-\VD35"N0]0FYI=B$ZHD5NX?O56:39J=55'UU
MB$1/MVM[YTJ'">/3',V8ZD+92%6XMU$L!>W, 7N; V'&H.[>?#CO7/W!CY6[
ML88&@P3*\@>2-I)@A#>4BQ.Y'7\UG8J%4DKU, IO*Y"E="JA@\ZO+'8?%?A9
M_P#Y3+R%9O.Z+[&ZH;V^*6,UEJI77L!8;%:).%?)G*LPFWL? A'H.$P!9L5Z
MHNB=-=)(X;ALG2L?5-8_\T T$,9?I/)C<!01X@$W(\;6-P34#?$1O/4]G;"_
M_HSM%J.?DKCB539HT*.\C(>8<JG0".*]192& -<_A995PJJX<*J+KKJ'6666
M.955954PG4554.)CJ**',(F,(B(B/4<G@  6'*N:K,S,68DL3<D\R:MN_39<
MO-AVF5VQP]ND_)V6K5*BI[<U6$L[=/EZ;&1EAK].N%7CG+GUQ0KCMS:8IRT9
M%.FBS7(Y.D0?<JB6*NXFDX\21:O"H65W\M[<.HD%E8^OW6!/,BU^0JZGPJ;V
MU/,FS=CY\CRX<./])Q^HDF)5=(I8U)O9"9(V5+@*0Y ]XVBP\UE\MUW\CV_F
MEI6<E;45>GT>I1BR_K-XBJQU+@9-F1B4%UR((34A,.94Y0$!]=^H(E*(B4M)
M-\9$T^Y<@2WM'TJH]"A01;VDEO::_P!2WPBZ+I>C]@]$ETT+YF:)\B=P+%YF
MR)$;JX"YC6-(0?N8UL2.)BHS4JLK5NSZ9J\VJ4U]RQUT_?.5Z=3K5J2U5IBJ
M94[=A.7R,V%'6LS03B*:8.VM#BS'(3H &+W"'4_49A[7SROCY>,Q/DH\;*/0
M7#AOP%KEU_B%:-IN/KFV=>@15U7+QLV&5A:[1XSXK0]7B>DY,P!/@;>%2I<T
MO+/P]X//U:GL6V2MWVF1 JYM3ZN9,K);8XBJ1%&RMH=/)*)K=236*LF<$G[Y
M)\H@?U4&RQ0R=]'VKJ^M+YN.@3%^[<D*?O>!+?(+7X$BN2&_>]&Q^WTAPM4F
M?(UBU_H^. \B^CS"65([W!L[AR#=485$/%_4J\>D;@I,..&%MC$W*@)N[=%V
MZD.K@LV$ZHF.HS4K445=0 =KCZ9I7M$3F^T'>80V4]L)EO*F1#](/_AD?YUR
M?K5$P^,K#E5=/R=-U'\TJ>"_2E8#EQ$154OP'VPY#CPX3A<./(SQ3YT1;I71
MM\4^]T6U![/ZNNC).L[)@FO5(#/%X$SM\SF(U(RY"J/8EW(L4U#@F=8JGV<U
M+5]O:IHC#Z:GXHG@Z\4/R\+'U, ?54W;%[I;-[APD[>R3]-07?'E'ESH/24N
M0R\1=XV= 38M?A5;7ZE*\VIYR>T3K1P^<_<FO:&0O,3&=RI686JY;"O,!8'P
MEZ@BJY-$42,3 >@F3( _D X]:]=S9Y6U7'Q23Y"X_4!X=3.P)^HBUVF_P_=&
MTV+MUK6X$1?SQ/K1QW?AU>3!BX\D2^D#KR)CZ"?95<'(TJ_-6!/IS;];8/FA
M>:!&*NUZA>])6.0M,:54P,4']/L%;<UNQ+(>JF0SN//+.F"1^TXE)**!T^/<
M60^VV1-'K<F.E_)D@)8>%U*])^2Y'[JJ/_'IHFEYG:7#UO("C5<+6(EA>WO%
M9XI1+$#8^ZW0DA%QQA7CPL?F_41<OMBWCE.[XE1MAE(C4NE("FOI^JL7CMK'
M6[8ESKD3? L%B02]!O,D@ZW/1K>-26!<C%7W2B1BG<J%+=K8&DX\&F#564'*
MF9@&/-44E;#T7()/*_ 'D*_S ?$]O?5-0W@VRXI731=/BB+Q@D+)/*BS=;C@
M&Z$=%0&X0]9!!<@5ZJ_89ZISD39ZM-2M<L<#(-96#GX*0=Q4S#R;)4J[.0C)
M)BJ@\8O6JQ .FJD<IR&#J AF_21QRH8I5#1L+$$7!!\"#SJLF-DY.%D)EX<C
MQ94;!D=&*LK W#*PL00>1!N*Z2GB^Y+6KEKP=T?NB^B56^R<5-U>ZOR((-DY
MJQ42RR]0=V(J#8"-D5;(C#IOUDTR))).'"A$R%(4H97?<NG1:5K4^'!_  AE
M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
M@C6.-%%E5%%E4>H >WT\:]1GRKV4Q2F*57!^I8T['6GB?J3="35,UBU+M]*N
MF=CT*<E/V; OT9E$# 8!4,:S52%$I1 >TO>("'Q[I#[<Y;1:I+AD_BY8;_ND
M(M]9FJK/Q7:'%F;,PM> 'TK"SNB__A3H0P_E(XOKU23R9:H!5CWZ9Z]+P_+[
M=.OE'"B4==^/SZ=!$#JBBYG*/?::E'%.BF@<GJ)1%LDCE5.<A2 !B!W&4  C
MWN/ 'TF&?[9,@#Y&5K_745:?X3M1:#>^?IA)$61IA>W@7BFBZ>%ON9'-R1;B
M.)-7;<AFK_5!Y]0)R!<Z9X"S5(A7QVECY"7:OZK3%NIZ;Q"I(IN[C=G1>H@4
MS%[&UM*(<A]HPIR_0 ^(F+NFP\ 9FNB9Q>/'0O\ NOFK\MSU#[VJ^?$MN5]"
M[;R:? W3E:GD)C\.8C%Y93["J")O5)\HH,9.E<W:E^\(_$6(Y7\W*P:Z1B,K
MK/1T0IN*XQKUJ1U&3[Z#DXYA2JL_36*HU7;2=JD$';ANL0Z3N/CW2)@Z'$0U
M/>>K/I>BMY)MDSGRU(Y@$$LP]B@@'P)!J;^P&R8-Y]P(3GH'TG3T^DRJ1=7*
M,HBC-^!#2,&92"&1'4\ZZ%F0'73:F*4Q2F*5KURLXY4KEGQ]V?H&^((_)]@U
MIY',94[8KES5[,@4'E5M\:0PD'YC6+ W;O$R]P%5](4C]4U#E'(:7J$VE9\6
M?!\^-KD?=+]LI]3"X^O6L;RVM@;TVSE[:U(#R,F(J&M<QR#C'*O[:-PK#TVL
M>!(KF!WFF6#7-VN&O;:R-&6JB6FP4RS1QA[C1]@J\L[A)ED8P@7N,TDF*B8C
MT#KVY92":/(A3(B-XG4,#Z0PN#]0UR-U# R=+U"?3,U>C,QIGBD7T/&Q1A\C
M BO><=MS3W'?>VI-XUD5AE]6WZM7))JBKZ RC.(DT%Y>"64Z" -+!$>NQ7#_
M )R+@X?NY\-0PX]0P9<*3YDL97V7' _(;$>L5DMKZ]D[7W%A;AQ+^?AY,<MA
MPZ@K LA]3K=#ZF-=/;^676_^4S/_ .6'\LO[U7_Y;_Y3?O/^I_\ )^__ .3*
MU_0\C[D_POE_N_N?;77#\^Z5_&K_ .C^E?\ X/XSV5["U6NLT:MS=PN<_$5:
MJ5N-=3%@L4_(-HJ&AHMDF*SI_(R+Q1%JT:H)EZF.<P!_^>>*6:*")IIV5(5%
MR2;  >))K9=-TW4-9SX=*TF"7)U+(D"111J7DD=C8*BJ"6)/@!6@6JO+5X_-
MS;-;:CHO(6%6N4I))P]=)8*U=:?!6F555%NE'5^T6NN0]?>/W3L2HM4#N$E7
MZJA"M"KB8,U[$W?MW-RAAX^2OG$V%U90Q] 9@ 3X 7X^%ZFW<OPQ=\-I[>;=
M&LZ%,-)CC+R^5+CSR0H!<O+##+)*JA;L[!2L:@F4I:I',V6H$K4/FAS6TQP8
MU.?:>WWL@Y-(OC0E*I=>20=6J\6+T#.?ED.W=+M6C9HR;E]9Z]<*)MVB/3J)
MUE$$5</K>N86@X?TO,)-S95'SF/H'J',D\![2 92[2]HMV]Y-S?W;VLD:B-/
M,R,B4D0X\5[=;D L68^['&H+.W@$5W6"VF_4R4M]=TV-]XI6*MZ[</R(FL=8
MVFPM=MBX\#"0SY6JR-(JD7*KJ@(*&0)*MO1#J0#KCT,.A0]T(&GZ<C$9<8GF
ML@9@/3TE5!]G4+>DU<K5O\/75H=',VB[F@R-=5+^5-AM#"[?<B9<B9T Y=1A
M?JX$JG*I/N??&BD>5O@O'L],7FOR+N2<0>Y-"7@ZJZ=:D+%&,)>*"(L"A6:L
MK&Q\S#S4A&O$S(E<QD@)#KHF.T.W--VS]R8^GYD>JP'S=/F2S%>91B#< V]Y
M2!P-CP*FQY<J_B [.ZUKNDYNPM9B.#N_3LKK1)> 2>,,O0Y7JO'+&[!73J4A
MDE7K4"]':W^.;GC2+H>@3G$;D O9 =K,FY:YK&TW&$DU&_Q77A;548Z;JTVQ
M03^VHX:/%D$R?:,<  1R=XMPZ'-#YZ9<'EVOQ=5(]JL0P/J(O7,_.[7=QM/S
M_P VY&B:F<KJ('1CR2HUN962-7C<#F65B .)-6WO!SXQ]@<+JO>=V;[9-X3=
M&W86+KD91D';=^ZUY0&;X)APSGWT>X<1JMEM<LBT7<-D3K%8(,$""IZZCA%*
M*MZ[D@UB5,+!/5AQ$DMRZVM;@#QLHN ?$D\+ $W5^'OM+J>PL/(U_<BB/7LV
M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
M@@@CTU]O7E_M^J;W3]ET":=5R[4.QP]LJTXS$GN(R<@GR,A'.BIJ%.BNF1P@
M7U$E"G263$Q#E,0QBC^,B"+*@?&G4-"ZE6'I!%C7HTS4LW1M1@U;39#%J&-*
MLD;CFKH0RGT'B.(/ C@00:Z+?C=\C6J_(!J".G(E_$5S=M9BVR.W=3^\*64@
M91'T&KBS5]FY5,^DZ#-NU2J,W9?5!L98&C@X.$S=U?=Q;>RM!RRC MA,?Q;^
M!'H/@&'B/'F.%=0^U?=+1^Y6AKD0LD6X(4 R<>_O(PL#(@/%H7/%6X]-^ACU
M#C(]FO5*=,4IBE5D?/+Y/ZW0=>67A+HVSM9;9]]:JPN])^">E72UU1ERE"2U
M^HY;@=#[WWA PMG[?U!.PB!6363*J\1,E)&Q]M23Y"ZSFJ1C1F\8(^>W@WWJ
M\P?%K6X WJ7\1O=S%TW3)=@;>F#ZODCIRW0W\B$_.AN.'FRCW7%[I'U!A=U(
MIAY,%4.IBE=,?QG?A\\-O[N^L/XL,<KCN3^OLS^D/]DUUC[3_JST+^R\?_5B
MMX\PM2%5+/ZCCAO(4/=U7YBU2*64I6Z6D93=D.6Z)S-X3:=4AR,()X\.7HDV
M1N='BDB(%*7[3F&='.;N6( S%V]U=9\)M(E/XZ$ED]:,;G]ZQX^IAZ*H5\4N
MQ9=-W!#OG#0G SU6*<@<$R(ULA/H$L2BW[:)R3=A5:')&JI]6(O!YY4H+BI.
M/.,7(6?^5:$OLX>8I5XD5CGC]2WR2%NW?(32AS#\NU];O2(=RN7\S%2)?<J$
M*BZ>N$M WIMA]40:E@+?.1;,HYNHY6]++X#[8<.8 -G_ (?.\6-LW(;:6YI.
MC;>3)U12L?=QIFL"&^YADYL>4;^^0%>1EN_,7S*39,Y*->-9".D&K=\P?L7"
M3MD^9.TB+M7C-T@=1!RU<H*%.FH0QB'(8! 1 <A=E96*L"&!L0>8-= XY(YH
MUEB8-$P!!!!!!%P01P((X@C@17ZL_E?NF*5YRWW"J:_J\[=KS9(2H4^KQKF9
ML5GLDFTAX*$BF9!4=/Y.3?JH-&;5$@?$YS@'7H'Y1#/I##+/*L,"L\S&P4"Y
M)]  KRYV=AZ9AR:AJ,L<&#"A9Y'8*B*.99B0 !ZZTGXJ>3?AGS(FY2IZ8VRR
M4N\=)2[-M1+DS7IENL,?%.5TD['5(B9%(UDA))FA[M/VAU'C9L<OO&[53N3+
MF=4VWK&D()<R(^20/>7WE!/@Q'(CEQX$\B>=:!LWNUL3?60^%H.:OYP5V AE
M!BE=5)]^-6^>C =0Z2653^,5#<#?O,%4DTQ2F*556^J%_@+P[_6W<WZ'UUDG
M]M/X;+^]C^R]4Z^+O^KM#_+Y7X,%4_LEFJ/U<!^EZ_@+S$_6W3/Z'V+D3=R_
MX;$^]D^RE7@^$3^KM<_+XOX,]6J<C"KBTQ2F*4Q2H9_/I^&3N3];M/\ ])]8
MS;]B_I)#]Y)^ :@GXD?U2Y_Y?&_WB.N?;D\US0J<3Z>?\1ZL_LEVI^BF6:7O
M[]'F_*I]FK"?#)^M.+^A9'X(J_-D%UTAK!/)S0U8Y/\ '[;>@;>8J,)M&ERM
M:^8"B#D\%,*$*\K-F;-S'(1=[5K*T:2*!##V&6:E W4O4,]VFYTNF9\6?%\^
M)P;>D<F7]T+@^VM=W;MS$W=MK-VUG<,?,QVCZK7Z&YQR >)CD"N!Z5%ZYB&W
M=57?1NS[WJ#9$0I!7G7-FE:I98T_>9-.1BG)T#.6*YTTO>Q4BB!'+-R4OINF
MBJ:Q!$ARB-DL3*AS<9,O'/5!(H8'U'T^@CD1X'A7)#6]&U#;VKY.AZJACU'%
MF:.1?VRFUP?%6%F5N3*0PX$5\2BW>UZTN=5V%19Q]6KG29^*M%7GXU7T7T1.
M0CU&0C7[8_02B=NZ0*/:8#$.'4I@$HB _N>&+)A;'G4-"ZE6!Y$$6(KX:=J&
M9I.?#J>G2-%GX\BR1NO JZ$%2/81[#R/"NA?XQO*#JWG_K=HP>/(BE\C:G%H
M%V1JU9\BDM)^V321<7R@(N%"NIJF22Y@,L0@*.(9PH#9SU(9LY=P'N3;63H.
M06 +Z>Y]Q[<OVK>AA]1AQ'B!TV[2=W='[E:4L4C)C[IA0>?CD@%K<#-"#Q:)
MCS N8F/2_ H[RHYK%3%3%*8I4;_,3RJ<1.$5XI&NMO6R5D[A;)!,LW T"/:V
MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
M L !R  Y"J\9&1/ESOE93O+DR,69W8LS,3<LS$DDD\2222:V)XD[AY3:DW)5
ME.(EJV!"[9M4Q%0<17:&"TF-Y>"Y,:/@)VH*I/8.X1OK*&.+61:N6J8=R@@7
MH)@Q^JXFF9>&WYV6-L5022W#I])#<"I]8(-;1LK7-X:)KL)V3-DQZU-(J*D-
MV\XW]U'BL4E6_P!JZLHXGASKI5\?#;P4TOKE7DF%)3WDM6F:^QV^O&[QM4F<
M^MWJ'81Y7DE+&6<L6IDTGBR*XM%GA%3MBD;F3*%=<_Z%],D&G=?T+J]SK^=;
MTG@.?APO:U^-ZZM;9.X3H.*=U_1_[PF(&<0 B,.?!;LUR!8,0>DL"4 6PK,>
M>.L[6,%=(Z77V.GN);46L%MN)-BLTMIJT&J*;'3:$;E:$:IW<\2-F(V*U(5(
M" Z H)@!>G0.F>D9N8,?Z()9?HGW'4W1^]O;ZU8@[?T%M4&N-@X9UL"WTCR8
M_/M:UO-Z?,M;A;JY<*R?GFK+TQ2F*55Y^IH:7$^ON)+]B5^.OVURVRTLYTR&
M&++<7L)1UJ*5XIZ8E*_/"1]B%L43 )DRKB #T$2Q7W06;Z-ALM_HX>0-Z.HA
M>B_KL'M\M=&/\/.72AKFYX9NC\^-B830W^?Y"R9 R.D7^;YC8O7PX'HXB_&H
MMD/5U$JZG]-ZQNS?B#MAW-%=)TJ0WS**4@'0+ "SIO2ZBVM;J/!4W::+.[3;
M) 9, 3%VBX#J)RG )O[:+.-&F+W\@Y!Z?WJ]5O5>WR@UR-^/N;2).Z>F18A4
MZO'HJ#(M;@#D3F$-;[?I+FQX]#1GD1>M;YB]Q7K;WD.Y&_?-^[58ZUNS_5-(
MAE5ESQ]?J%(,$6R1BVZW0&Q)UZ1>5<=H=%';]4P")1+TN5M'$@Q- Q_) ZI$
M#L?$LW$W]G!1Z@*_SF=\]<U'6^YVJ?3V8QXF0<>);FR11>Z H/+K-Y&]+.3R
MM49C%\]C'K.2C7CJ/D8]TW?,'[%PJT>L7K14B[5XS=('37;.FRZ93IJ$,4Y#
ME 0$!#-C90P*L 5(L0?&HFCDDBD66)BLJD$$$@@@W!!'$$'B".(-=/'@GM:U
M;QX;\:-L7D7*ESO&G*1+VEZZ;E:K2\^$.W:2M@]N0I$DT;$]:G?I@0 )Z;@H
ME "],K;KF+%A:ODXL%O)29@H] OP'R<ODKK?V[UG,W#L72=:U&YS\C!B:0D6
M+/T@,]O0Y!<6X6;APK;#,56YU3T^H:X9WZ+V_%<RZG"/YW6UPK%>I^S7T>@J
M[-1[C6B##04G.%3[C,J[:8 6;5LY[?02?LCIK'(=RU*K#7<;1,A,P:U"I;&=
M KD?:LO $^@,+ 'E<6/,7ZI? KW9T3(VM+VGU.9(=P8N3+/B*Q"_2()?QDB1
MW^=+#)UNRWZC'(&0$1R%:S>1?70JKB/T\7#2_P"K*ILGE1LF"D*N&WH&%J&J
M8F50.RDI*B-7XSTW<G#%4WKHQ-DE&[ D694B9UD&:K@@&;KMU#S-VYT7(Q(9
M=6RE*><H6,'@2E[EK>AC;I](!/(@URJ^.ONQHFY-3T_MMM^:/)_-<\D^8Z'J
M1,DKY<< 8<"\2&0S6)"M(J$AT=19>R3ZY\5%/YJ]QW?2?CIWC8-?.Y"*L-H-
M4];GGXTQTG4!!7JRQ\)9GJ;E(Z:K-1_ *N8])<@@HBL](<@@8 $-HV;B0YFX
M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
MV \6-E4<20*N3>)OP?I<;IRO<DN6:,-8=VQ7H2FOM6LEV4[5]52)T3B6>L<@
MF5S&V?8,<90OLQ:'4CHA<@KHK.G'H+M8BW3O0ZBC:=I5UPCP=S<,X] '-4/C
M?BPX$ 7!O3V8^'U=JY$6ZMZ".77TLT.."'CQVM\]VXK),OVO22D9'4K.W2R5
MK/+-^(]R\_:W(_HN*R1=K?H]B?DA]DU5/O1^M/6_Z:WX*U'AF?J,*Z8_C._#
MYX;?W=]8?Q88Y7'<G]?9G](?[)KK'VG_ %9Z%_9>/_JQ6\>86I"IBE8%Y'\9
M=*<LM82^H][4B.NE1D_\8:BN M9NM3"::B;.QU.=;]LC7Y]@"A@(X0.'J)F.
MBL55!15(_NT[4LS2LD9>"Y24?4(]##D0?0?:+$ UKFZMI:!O32'T3<6.L^$_
M$7X/&W@\;CWD<>!!XBZL"I(-,SG!]/\ \F= /)FY<;B/N2NI$3KNT8N);MT-
MT5I@4IU?0EZ<@"*%V]N'8D5Q >L[='ZJ#&MDP'I+^B[[TW/ AU&V-E^D_P &
M3ZF^U]C<!]T:HCW!^&O=FVGDSMJ]6K:*+D*H RHUYV:(6$MN75#=F/'RD%0*
MS4)-5N5?P-BB)2 G(IR=G*0TTP=Q4K&NTO\ "-7\<^20>,W*?7[1%"%,'[H9
MO*.DBAXR&0C@0;@^PBJXY&//B3-C92/'D(;,KJ593Z"I (/J(KYF?JOC3%*]
MQKO66Q=N6EA2-646V[%M\H<",*U2Z_*62:<AW !U2Q\2U=."MT>[JHJ8H)I%
MZF.8I0$<^.1DX^)$9LITCB',L0!]4UD=+TG5-;S%T_1\>?*SGY1Q(TC']RH)
ML/$\AS)JRIP'^G9O-K>PNR.<[XU%J22B#YOHBKRZ#J[V-'H19)&[6Z$>+1]-
MC%RB *M(Y9S*G(8Q#+1ZQ/C'6N]P((E./H@ZY>7FL/='WJGBQ]9LOJ85:WMO
M\,&HYDD>J]PV^CX0((Q(V!E<<[2R(2L2GQ5"TA%P6B85;QH="I6KJ?7M?:ZJ
MT'2J15(Y*)KE6K<<VBH6'CTC'.#=DQ:$313]190ZBA^@G55.90XF.8QAB>>>
M;)F;(R&9YG-RQ-R3[:NUIVFX&D8,6F:7#'CZ?"O2D<:A451X #ASXGQ)))N2
M37K<^5>VF*556^J%_@+P[_6W<WZ'UUDG]M/X;+^]C^R]4Z^+O^KM#_+Y7X,%
M4_LEFJ/U;?\ I<7KH[+F_''5$6;5UQP>MT.A>U-T_2WJ@[5 P%[Q%9*-0 0$
M1 /3#H =1ZQ5W, OA-XD3?6\K]FKK?"#(YCW!$3^+!P2!ZR,L$_*%'U*MEY%
ME7/IBE,4IBE0S^?3\,G<GZW:?_I/K&;?L7])(?O)/P#4$_$C^J7/_+XW^\1U
MS[<GFN:%3B?3S_B/5G]DNU/T4RS2]_?H\WY5/LU83X9/UIQ?T+(_!%7YL@NN
MD-,4IBE0T>1?PQZ$YQK26R:JY0TGR(50$RU_A(I)S6[ZNDF4K9+9M:;F:FE'
MI4TP1)+M5$9)-,2@M[Q)%% NW[?WAG:*!C2CSM/^Y)XK]X? ?M3P]%B2:@GN
MCV'VWW"9]5PR-/W.1QF104F(Y>?&+=1\!(I#@6ZNL*JBG)RH\9/-#A\]DE=K
MZ:GWU)8JK AM2A(+7;6[UFD*GIOW$_#(JK5DC@J1C$0FV\8\$I1-Z/;T$9=T
MO<FCZLH&+,HF/VC>ZX]5C\[VJ2/75&=X]I=^;'D=M9P)&T]2;9$(,L!'I+J+
MQWMP$HC;]K:M!\SE1M3%*_Z4ICF*4I1,8P@4I2@(F,81Z 4H!U$1$1^ 8K^@
M$FPYU*)Q)\/O-_EJ^B9"'U?(ZJUF^60.[VIMYJ\IT$6..?\ ./*[ O4"VVYG
M41(H"!H]DHR,L4"+.FX&[PUK5=VZ+I2E7E$N2/M(_>-_61[J^NYOZ :E[978
M_N#O61)8,-L/26(OD9(,2=/I1"/,EX7MT(4OP9UYU<S\??BQX[^/^"^8U1J?
M8>ZY:.*QM>Z[5'-$IY9!4B?O86F1:9W:%%JKA<G>=J@LN[<]" [=N@21].(-
M>W/J&O/TRGR\,&ZQJ>'M8_;-ZS8#P N;WM[:=GML=M<?S<,?2M?=;294BCK(
M\4B7B(8R>/2"6;AUN]EM)EFMU+-,4IBE,4JHEY)_.)R2H?)/8VCN+<A6]>5+
M3=MD*).6^0JD);K3;[A5W8QMQ2.A;&$K!0T!&S[5Q'H)(-#.EBMS.!<E]8B*
M$/;GWWJ>/J<N!I16.&%RA8J&9F7@WS@0 #<"PN;7OQL.HOP__!WV_P!:[?X&
M\>X\>1GZIJV*N3' LTD$,$$R]<!O"R222O&5E8LX12PC\L]!9Y.?#EY-KKSO
MK6Q:)N6'A6>X-4(0<NM8ZPP/%0=VJ4\J[8HOUXGW#I&*L4/)L1(\!$R35PFZ
M1.@DF)52AM&R]T3Z_%)CYJJ,V&QZE%@RFXO;P((X^!N+#G5=_BM^'C2.R^H8
M&L[3EF?:NIF1!%,W7)CSQA6*A[ O$Z-=.J[J4<.S74F5/?&A=4\E]86+3VZ*
MDSN5$LR:'O8URHX:.F;YFJ#B.F(:49*MY&'FHQP4#H.6ZA%"_:(/<F<Y#;9J
M&GXFJ8K86<@?';F/01R((X@CP(JMFR]Z[F[?;B@W5M+*?$UK')Z7 #*RL+-'
M(C K)&XX,C @\"+, 1!DQ^FTXJ-[B65>[KWI(4I-^+HE0%2DM955H4P'3C7=
MM1K0@H@8P=JJB4>@L9(1 ADS]% T->V>DB;K:?(,%_F^[?V%NG_(#[.=7)F^
M/_N4^E?1H=(T9-7*6\^V04#<BZP&7@?$!I64'F&'NU/;JK56OM(Z]JNJM5U>
M/IM!I<82)KE=C/6,W8M"J*+JG4<.E7#U\^>.EE%W+EPHJX<N%#JJG.H<QAD#
M$Q,;!QDQ,1 F.@LJCP_RDGF2>)/$U2C<NY=<WAKN3N7<F3)EZWER=<LKVNS6
M %@ %55 "HB@*B@*H"@"J]?EP\)%LY4;-?\ )GBU)5EAL^RM626T-;6E^%?B
M;B^B(UO%QMJJ<V1HLPC;,Y8,D&[]J^%!H\%,'/N$E_6!Q)VU-YQ:9C#3=3#'
M&4GH=1<J";E6',B_$$7(Y6(M:FW>OL!F[QU9MV;/>%=7E &1!(>A92JA5DC>
MQ"R$ !U>RM;KZ@W5U1C\:_IT>75VV)%)<DG53TMJM@]:N;,]AK= W:\SL:10
M#N8JGL*ZI+PK&0>)D%(7DDX329]_K%;NQ)Z!]EU'N#I,..3IW5-E$<+J54'T
ML38D>H#CRN.=1+M3X7=[:AJB#=30X&CJP,A61)977Q6()U(&/+JD("WZNE[=
M)NK1,91]-ZWC8:.3CZ?K;55(9QC!$RATXJK4>C0*;5JF954RBA(^$@8LH"8P
MF,":741$<AMFFS,@NUWR)7N?2S,?LDFK[PPZ?H6E)!$%@TK#QPH'VL<426'R
M(B_4%4R>6'U%W)RV[*FF?%!K5M3:CAY-RTK4K8JC%V^_W%BV57;ISEB"R)R$
M# H2R8$<)1S1GZ[+KZ:CMP/4<F#2^WVFQ8X.J%I<LCB Q55/H%K$VY7)L?0*
MHCO/XHMVYNJR1[,$.%HD;D1L\:RS2@7'6_7=$#<"$5;KR+M6]7BJ\W]MY-[0
MBN+',&#I[JR;%;NX77NRJ_#$AXVT37L3G5I%_JO<Z@O<V5HFX*T>LRM&IUP3
M9G:"*Y5BX+=6R,?!PVU#3.HXZC\9&WO64\"5)XD#Q4WX7-^%JDGLI\16J[BU
M^#;.[1&FJRM_Y;*A!C)E7WE210;*[6)CDCZ &"IT78,)T8G@9PG@K,C<8?B;
MQXC;(V>!(M)1IJ*CI*,9 IP5(^8(%A?:,7B2I0.15%,ATS_:*(#\<A]-OZ''
M+YZ8>,)0;W\M>!](X6!]E= LGO3W>S=..E9>Y]=DT]DZ61LW((9>72Q\SJ92
M.!#$@C@>%5M/(A]03M^O[CMVHN%Z-2KU,U]./JS*[<L4 VML]=;!"NP:3"]6
MB9@#UN&J2#]!=LBHNU?N9!(A72:C8IRI!.&W]AXDF(F7K'6TTB@B,'I"@\NH
MCB6M8FQ '*QYUS4[G_$OK>-KL^B;#$$6!BR&-LET$CRNALQC5O<6,$%02KLX
M <% ;5_'QZ_4&[AF]PU#4O,YO3['2M@3\?66&W8"%:TR=HLS-O!:1CVT1<20
MM9FZD+U=!NN=%M'N6")C.CJN03%(?[K^PL1,1\K1^M9HU),9/4& YA2?>#6N
M1Q()X6'.OSVR^)C7,C7(-%WX()<#)E6,9**(GA9S93(J_BWCN0"0J,@NY+6Z
M:M-\B-$43DYI+9&A=EMEW-,V97%X"5.S,D20C7!5V\C"S\4==)=NG,5N>8M9
M!F91-1,KILF)BF* E&,=/SI]-S8\[&/XZ-KCT'P(/J()!]1JX6Z-N:=NW;^5
MMS5@3@9<11K?.4W#(ZWN.I'"NMP1U*+@U2@VO].[SYIUVDX76C+7>X:45PH:
M#NT?=X&EKNHXRIBMOGE9N#^/?1$N5'H9=!LK(MB&^";E7\N3)B[_ -"FA#Y)
MDAFMQ4J6X^HJ""/038^H5076?AA[D8.H/!I*XN=@7]R42I$2OAUQRE2K6YA2
MZCP<U/GX@_$0MP,-8=R;FG8"V\A;A!JU9JTK!UW]2UM4'3QG(/HV*DY!@P=S
M%HG7$>A[YZ5%%)!%+VK?O3,LLXT7=F[!KG3AX:LF C=7O<&=N0) )LHN;#QY
MGP LAV1[)-VY,NNZ])%-N>>,Q@1W,<$1(8JK, 6D<J.M[  #H6X+,TKG(_C5
MIWE?JZ7U!N^J)6JGRBJ3Y "+JL)B FVB2Z4?8JY+-A!S$S<<5RH":I>I#D.=
M)4BB*BB9HYU/3,+5\0X>>G7">/H(/@RGP(_^AN"15O-@]P=U]L]QQ;IV?DG&
MU6,%3P#))&Q!:*5#P>-K"X/$$!E*NJL(3ZO]-SQ1B+HVF;%N+=MMI;1\+HM*
M<*U*&=2+9-4JB$;,VJ(@D7:K10A1(X.R;1[A0IA%)1 W0P:/%VSTA)P\DT[P
M _-]T7]18#ZM@#Z"*MYJ/Q^]S,K2&Q,#2M'Q=69+?2 )Y I(L7CA>0J&'-1(
M\B@_.5QPJ?J@T*FZMI=8UUKVN1E2I--AF4!6:Y#H>A'Q,2P2!)NV0*)CJJG$
M $RBJACK+JF,HH<ZAC&&0L?'AQ($QL90D"* JCD /^WM/,U2/6];U;<>KY&O
M:[D296L9<K232N;L[L;DGP'H  "J %4!0 *__F/\MVV>(>QZ]QUXXMH"+O:]
M2CKM>=B6&';6,T$VG'4BW@JU6X.2 T0,H=K&B\>.GB#M$$'*":1 4]4Q(\WI
MO#,T?)73=,"C(Z S.1U6O>RJ#POPN2018@#QJ[_PI?#!MCNEH$^_-_-/)HHR
MFQ\?%B<Q>88U4R2RR)[_ $7?H1$9&ZD=F;IZ0<?>('S$[MY+[R9<8>39Z_:;
M!<8&PRFN-CPD!'U>9=3M4AW=EEZY9H:!;LJTX:/*O%O7;=VU:LCH*LQ2.1<'
M!3(>?9N\\[5,\:5JG2\CJ2C@!3=1U%6 LOS02" +6MQOPS?Q3?"IM#M]LY^X
MG;P3XV#B31)E8LDC31B.9UB26*20M*&69XT9'>0,'Z@4Z"'LWY*-<\:8I3%*
M8I3%*\3LG7=0VY0+CJ^_QKB9H]_KLK4[;#M9F<KRTM79QHHPEXOYS6I*'G6*
M,@R6.BH9LZ14,F<Q>[H(@/VQ\B7$G3)@($T;!E-@;$<0;$$&Q](K'ZKI>#K>
MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
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MUY"Y7T/??@V9^S7T[=>0N5]#WWX-,QJV[]>0N5]#WWX-Y_:_77]?#0
M             , */IX                     */4 \"B"R!L#@J$
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797375952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 3,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">113,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Anti-CD19 CAR T cell therapy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">103,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Anti-BCMA CAR T cell therapy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">$ 1,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AntiCDNineteenCARTCellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AntiCDNineteenCARTCellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AntiBCMACARTCellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AntiBCMACARTCellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=allo_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804838784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th">
<div>Series A Convertible Preferred Stock </div>
<div>Series A1 Convertible Preferred Shares</div>
</th>
<th class="th"><div>Subscriptions Receivables from Preferred Stockholders</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th"><div>Notes Receivable from&#160;Common Stockholders</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 29, 2017</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Nov. 29, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NotesReceivableFromCommonShareholders', window );">Notes receivable from common stockholders</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 29, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Nov. 29, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(396,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 629,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,023,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(396,122)<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,365<span></span>
</td>
<td class="nump">$ 34,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,557,990<span></span>
</td>
<td class="nump">998,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuedDuringPeriodValueCommonStockIssues', window );">Proceeds received from common stockholders for issuance of founders' stock at inception</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_SubscriptionsReceivableFromPreferredStockholders', window );">Subscriptions receivable from preferred stockholders</a></td>
<td class="num">(150,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuedDuringPeriodValuePreferredStockIssues', window );">Proceeds received from preferred stockholders</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for early exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Series A convertible preferred stock</a></td>
<td class="nump">411,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (411,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Series A convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,743,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes</a></td>
<td class="nump">141,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustment for fractional shares from forward stock split</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(211,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments, net of tax</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 703,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">914,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,528)<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for early exercise of stock options</a></td>
<td class="nump">$ 2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 54,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">1,965,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised common stock</a></td>
<td class="nump">$ 4,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">46,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(184,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments, net of tax</a></td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 629,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,023,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (396,122)<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NotesReceivableFromCommonShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes receivable from common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NotesReceivableFromCommonShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuedDuringPeriodValueCommonStockIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuedDuringPeriodValueCommonStockIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuedDuringPeriodValuePreferredStockIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred stock issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuedDuringPeriodValuePreferredStockIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Vesting Of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_SubscriptionsReceivableFromPreferredStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscriptions receivable from preferred stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_SubscriptionsReceivableFromPreferredStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801917264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,906,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#8217;s fiscal&#160;year ended December&#160;31, 2019, are incorporated by reference into Part&#160;III of this Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807443936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Income (loss) from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in Notch</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CostMethodInvestmentTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Income (loss) from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CostMethodInvestmentTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CostMethodInvestmentTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790534192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Guidance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text">Recent Accounting Guidance<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January&#160;2017, the FASB issued Accounting Standards Update, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU&#160;2017-01). ASU&#160;2017-01&#160;clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This new accounting guidance is effective for public or private companies for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The new accounting guidance should be applied prospectively on or after the effective date. The Company adopted this guidance on January&#160;1, 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued Accounting Standards Update No. 2018-07, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU&#160;2018-07). ASU&#160;2018-07 simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Some of the areas of simplification apply only to nonpublic entities. For all entities, the amendments are effective for annual periods beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2020. Early adoption is permitted for any entity in any interim or annual period for which financial statements have not been issued or made available for issuance, but not before an entity adopts ASC 606. The Company early adopted this guidance on January&#160;1, 2018. As a result, the accounting for share-based payments to nonemployee consultants is consistent with employees.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the FASB issued Accounting Standards Update No. 2016-18,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Statement of Cash Flows: Restricted Cash</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;This ASU&#160;requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.&#160;&#160;This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all periods presented.&#160;The Company adopted this guidance on January 1, 2018.&#160;The adoption of this ASU&#160;increased&#160;our ending cash balances within the statements of cash flows. The adoption had no other material impacts to the statements of cash flows and had no impact on the results of operations or financial position.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued Accounting Standards Update No.&#160;2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU 2016-02), which provides revised accounting requirements for both lessees and lessors. Lessees will recognize a right-of-use asset and a lease liability for virtually all leases (other than short-term leases upon election). The liability is recognized at the present value of future lease payments. The asset is recognized based on the liability. For statements of operations purposes, ASU 2016-02 requires leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. ASU 2016-02 is effective for public companies for fiscal years beginning after December&#160;15, 2018. Early adoption is permitted. The standard requires a modified-retrospective transition method and </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">provides for certain practical expedients. The Company early adopted the new lease standard on July 1, 2018 with the adoption reflected as of January 1, 2018 in accordance with ASU No. 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842) &#8211;Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. There were no lease arrangements prior to August 2018 and consequently, the adoption of the standard did not have any impact on periods prior to August 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include but not limited to trade receivables and available-for-sale debt securities. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In January 2020, the FASB issues Accounting Standard Update No. 2020-01, Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323),  which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802128368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 110,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares)</a></td>
<td class="nump">7,235,545<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted</a></td>
<td class="nump">3,052,816<span></span>
</td>
<td class="nump">12,336,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares)</a></td>
<td class="num">(711,123)<span></span>
</td>
<td class="num">(5,020,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, options forfeited (in shares)</a></td>
<td class="num">(386,716)<span></span>
</td>
<td class="num">(80,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">9,190,522<span></span>
</td>
<td class="nump">7,235,545<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">4,660,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares)</a></td>
<td class="nump">9,190,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted (in dollars per share)</a></td>
<td class="nump">27.47<span></span>
</td>
<td class="nump">5.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised (in dollars per share)</a></td>
<td class="nump">4.16<span></span>
</td>
<td class="nump">2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited (in dollars per share)</a></td>
<td class="nump">8.79<span></span>
</td>
<td class="nump">2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">14.51<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">11.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 14.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contract term</a></td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, exercisable</a></td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, vested and expected to vest</a></td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="nump">$ 17,141<span></span>
</td>
<td class="nump">$ 123,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, balance</a></td>
<td class="nump">110,490<span></span>
</td>
<td class="nump">$ 139,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 69,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6676365968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (61,030)<span></span>
</td>
<td class="num">$ (50,735)<span></span>
</td>
<td class="num">$ (41,243)<span></span>
</td>
<td class="num">$ (31,586)<span></span>
</td>
<td class="num">$ (30,509)<span></span>
</td>
<td class="num">$ (43,497)<span></span>
</td>
<td class="num">$ (134,902)<span></span>
</td>
<td class="num">$ (2,597)<span></span>
</td>
<td class="num">$ (184,594)<span></span>
</td>
<td class="num">$ (211,505)<span></span>
</td>
<td class="num">$ (396,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,061,149<span></span>
</td>
<td class="nump">28,948,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (10.71)<span></span>
</td>
<td class="num">$ (43.82)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (7.31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M77_X785=,'9G_['Q1;"IX===-%]02P,$%     @ X8!;4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MA&HFLLVZ&Z7K"-KTMR48KNS\'U!+ P04    " #A@%M0O:7>1ZH#   0$
M&    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(6846^;,!#'OPKB/86S#9@J
MB=0DFC9IDZI.VYYIXB2H@#-PDN[;SQA*$_M(7@HX_SO_?-AW7*=G6;\U>R&4
M]UX653/S]TH='H.@6>]%F34/\B J_<M6UF6F]&.]"YI#+;*-,2J+@(1A')19
M7OGSJ1E[KN=3>51%7HGGVFN.99G5_Q:BD.>9#_['P$N^VZMV()A/#]E._!3J
MU^&YUD_!X&63EZ)J<EEYM=C._"=X7!%C8!2_<W%N+NZ]=BFO4KZU#]\V,S]L
MB40AUJIUD>G+22Q%4;2>-,??WJD_S-D:7MY_>/]B%J\7\YHU8BF+/_E&[6<^
M][V-V&;'0KW(\U?1+RCRO7[UW\5)%%K>DN@YUK)HS%]O?6R4+'LO&J7,WKMK
M7IGKN??_888;D-Z # 9Z[EL&M#>@GP;Q30/6&[!/ V:BU2W%Q&:5J6P^K>79
MJ[O7>\C:702/3$=_W0Z:8)O?='@:/7J:0QA/@U/KJ-<L.@VYTB37FB6B&12!
M)A@P"(:Q(,@4W)K"U9!KQ<I5Q!%.0=%@4&-/KRA2W %#'3#C@%TZ@-"*9J>)
MC*8R&DNQ=!7 6$0C:[6(+ (>ASAPA )'"#!8P)TFOIC'BOO2540)2ZC%ZZI8
MF'*"X\8H;HS@6C"+^"XNH@AUIK3VV\J504HX&P%.4. $ ;;BLDB<>28V,2;!
MD!'=+6:.,G/W% ##':2H@Q19M+5Y%ZE#:I^"NXJ5JY@0(#"2>"#$$V"(T#H9
M,+R+>U^R0B032B,^PCN2L 'A36Q>N,_K2B"A$=C,KBQ*^$A2!#2Y/P%!D+F-
M3.XCNY()B>TS<-/1-2Y>!8 BN*F-2^_CNA)(0FZG140V 9[P,6B\\@!2>HA=
M>GK1S52#:8"SE-CE!W6FCPX923: 5R! 2A"Q2Q"XM<.)MBNAU-G-KNCR\%SS
MXB4(D!I$[!H$;NUP XUH=*"CE-G0F#.=4<.1;QO 2Q$D;EXG=,0%7AF (VMG
M]MKY_7?E2CA-[66[(GKQ:7K-BQ<B0"J1O8\7O2BZ^:X0#7":1,ZAP)SI3ZIT
M)&,2O"@1I"@1NRCUHEM?DKV$7W$_."D(DR4/=.P+'B],!"E,Q"Y,Q"TG)"8L
M35-JHR/U*=2]B?X6L7<*YI2GC%-N;Y?@HBTJ1;TS+6?CK>6Q4FWC<#$ZM+5/
MI&VKK/&E;G>[YO333=<K_\CJ75XUWJM4NFDSK=562B4T:/B@W]5>M^?#0R&V
MJKU-]'W=]:C=@Y*'OO\.AG\"S/\#4$L#!!0    ( .& 6U -V="XW@8  -TG
M   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC5K;<MI($/T5BG<'S4V7
ME.VJQ238!*I2V=K=9\66;2J 6)#M[-_O2,B8Z3XM\6(N/MW3TSUS3L^(R[=R
M]VO_7!35X/=ZM=E?#9^K:OMY--K?/Q?K?/^IW!8;_Y_'<K?.*_]Q]S3:;W=%
M_M 8K5<C'47Q:)TO-\/KR^:[[[OKR_*E6BTWQ??=8/^R7N>[_\;%JGR[&JKA
M^Q<_ED_/5?W%Z/IRFS\5?Q;57]OO._]I=/3RL%P7F_VRW QVQ>/5\ _U>>&B
MVJ!!_+TLWO8G[P?U5'Z6Y:_ZP]W#U3"J(RI6Q7U5N\C]RVMQ4ZQ6M2<?Q[^M
MT^%QS-KP]/V[]Z_-Y/UD?N;[XJ9<_;-\J)ZOANEP\% \YB^KZD?Y=ENT$W+#
M03O[>?%:K#R\CL2/<5^N]LW?P?W+OBK7K1<?RCK_?7A=;IK7M];_NQDVT*V!
M/AHHU6E@6@-SKH%M#>S1P"2=!JXU<$>#Q'4:Q*U!?#1PMM,@:0V2CSF83H.T
M-4@_#.).@ZPUR(X&5G<:J.B]<M'11'?G21V+_5%MTUUM]5YN]5%OW6/R7G#U
M47&3-<O]L!:;Q3W)J_SZ<E>^#7:'_;G-:QI0G[V5=UY_VVR7YI]^@>_]MZ_7
M2J>7H]?:4XL9'S ZP&0AY@9@3!1B)@BC0LP7A-$AYBO"F! S11@;8FX1QH68
M.X2)0\P,89(0\PUA2)[G"$/RO  8^Y'GD2_VL>(:5UPW'FS@@51A?,"X!K-I
M,+26O8BOO8AI+^*N%S'K1<Q[$8LN1)!1@S-J0$;)FIT<,'%'-KH001061V%!
M%&17C"T;@ZSWJ66YT&2YS[F3"ZUPJ Z'ZD"H9'-.'1M%Q]IF66;P4#$>*@9#
MD3F/8SXA2@.=D"".!,>1@#A(8L<)2"S)?2<DB"/%<:0\#DU2/T[/78D9'B,#
M<R5\.,YZYSK)>BF&.Z&;BON@R_D.1$*J/^L=9XZF0S;?HLM+D-:ZVX!:'8'$
M$A&9M*"NI !(]]Y24O.@SM"2%M01T*2%=)6ZW\NTW\M=OY=9/V3>#UET0L+<
M"C*MD$[3+=*".K/2!0DC$>1-(7VCW*6X?%V8+%:1-)B@8@K)6$8'XRH5ZRRB
M.VX"<&Q=<35C&>1>&&?>]?N9 8CR,:<)%5@ ;'*I-5UEP..IO(49%\18 35V
M$<TXEV.? QTGQC$"XE"6T7.\A<$+\JZ0OE.M:4&G!61B S!LJ? F@$V,>V%Z
M ]PPP>D?:H[<,,GI]!,F6.A;%&I<6,EY6\(RPR$]FB,T, IT,$[1@%)0!VMB
MDN<O &=LIA(A)*'?4:#A<6R!<?E/G$NR+*(Q<6"6I5H+VUH+S8(&S8(CZ^-+
M"PJH3:DDD4Z40A^@01_@+!V+2Z)1:9(D0@.KI?,K$$9'6WK-58^V])V0,!)!
M&#401D>%40-A]/P:191>S@"&40D*JH&".DJ)&B@'#*H7%\8D:(Q&&D.OF317
M!7HZ;2'NC)H)@J&!8+B,#L-ITT4Z<JDT;8$\-2)/L@=O6E#(0<;0&[9;@-.$
M][X)OB)!5;7 L1IP+#V@WVI^3-11$G4L#H$^-:#/F#8@FK.B52IB-*OYB>\"
M :< &!/,# X:G5)V>#TD4+$!5!Q3R3+\4';AJ=B:+"6;=PJ@L8J=R[1 I4;@
M;0-XFR9A;#AO^T.>SP.-BA^_2. SP54DM !&4  #%" FV^K6<'I/4A>KDVX[
M'$RZW ,D'],;$P.XFRZF;DP8BT#M!E [[6G&!E"VGSB]M.Z%A1$)Q&[051Z5
M0,.)_4(KKR,D]/D9P# J@>0-('EVRV4XR9N(A+[H 871""I@@ K0<HP-9^XD
M,FRE30".:K;I[\:!%T7%Y*[?SPQ ,N4/<JRPZ-[2%Y8^:EH H)QO0;T,4*^8
M-D"&JY?/@$W](90Q<]=]:)O/<[R%P0MB:-!9@G9*!EQK9JR+ 2A%Z\<%SCL2
MN@4KR)M%)PT:C.6:E2@O-@+U6T&Q+%*LE(X%9"9*_!E*&$N0&8MDAEY%62XS
M*DF)&,WZ4&$\@A)9= _'GO 8WB%;K5@Y.(SJE>5Z57L2SL96>BJ%[O,H%5N@
M15GLHI0V;6< PZ@$V;) MA+:<EI^V+".'M=GEFM6@ KC$03+ L%BPFZY%MDX
MHHW/K!<61B2(ECWG@94%M*Y2/WU2X/D9P# J@=KM.8^O+"?CE#U'[P&%T0A<
M;=&#+D80Z)P![JH!C@I[/V0*(/RNNM_/#/F!=]4 B.^JD4?QKMH)4N.0U-!]
MZ[C42'?5 $HS>I:W0_"CDU_=U#]\6^2[I^5F/_A95E6Y;GYE\UB65>'=1I]\
M(IZ+_.'X854\5O7;Q+_?'7YP=OA0E=OVQW2CXR_ZKO\'4$L#!!0    ( .&
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MH \OF_K?('H(4G8W882Z\,$60T'CX_$VG.TT9I/AL9]_$%N^<?D+4$L#!!0
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M_E?&>$ IFRL<H08_V&Q(J'PXWN#9CF,V&MYTTP]B\S?.?P-02P,$%     @
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M:A_,#VC;:<TFQYM^?D%L><;%'U!+ P04    " #A@%M03F<_.;4!  #2 P
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MQI_-.&:CX;";?A";OW'^%U!+ P04    " #A@%M09 PP:[0!  #2 P  &0
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M0>=?-O:_1G3@I20W?H1:_\$60T'MPO'>G\TT9I/AL)]_$%N^<?$+4$L#!!0
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M_E?&>$ IFRL<H08_V&PHJ'PX?L:S'<=L-+SIIA_$YF^<_P%02P,$%     @
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M #X#]C$/&Q-%Y5^$$WEJ<"!F['TGPA-O#]SWI@C.V(IXY\5;[[WD_/HF99=
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MKN<-)7/QG^ *"L.C$LQ16>732JK!!ZMG%I2BQ<NT2Y/V<;K9\QFV#> S@"^
MNY2'38F2\G<BB#)W=B1NZGTOXA/OCAQ[4T5G:D6Z0_$>O=>2WV8YNT:B.>8T
MQ?!5S&Z)8,B^I.!;*4[\+SC?AN\W%>X3?/^;PG_D/VP2'!+!X;\E;L7\J9*M
M>JK!M6F:/*GL8-(DK[S+P-ZG1V2_PJ=I_RQ<*XTG%QOP95/_&VL#H)3L!D>H
MPP^V& J:$(^W>';3F$U&L/W\@]CRC<N?4$L#!!0    ( .& 6U!#O!$GM0$
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MO"@RBP.Q8^\[$9]X>^*A-V5TIE:DNR#>!>^MX(>'C-TBT11S'F/X(F8[1[#
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M1JZ!.4IIA-U+_F ]=K8MZCBIQ-%TPZ4=J[Y/ZR=&MD,/FHV-\/8?4$L#!!0
M   ( .& 6U!X1AUWLP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;'53VXZ;,!#]%<L?L X.NZTB0-IL5;52*T5;M?OLP'#1VAYJF[#]^]J&
M4)K2%SPSG'/FXG$VHGFU+8 C;TIJF]/6N?[ F"U;4,+>80_:_ZG1*.&\:QIF
M>P.BBB0E&=_M'I@2G:9%%F,G4V0X.-EI.!EB!Z6$^74$B6-.$WH-/'=-ZT*
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M._@?W<FBQV:54FIHG30ML5!E]#$Y''<!'P&O$@:WL$GHY&S,6W"^E!G=A()
M0>&#@L#C D^@5!#",GY-FG1.&8A+^ZK^*?:.O9R%@R>C?LK2-QG=4U)")7KE
M7\SP&:9^[BF9FO\*%U (#Y5@CL(H%[^DZ)TW>E+!4K1X'T_9QG.8]*^T=0*?
M"/R&P,9$L?)GX46>6C,0.\Z^$^&*DP/'V10A&$<1_V'Q#J.7?)L\I.P2A";,
M<<3P!2:9$0S5YQ1\+<61_T?GZ_3M:H7;2-\NZ7R_+K!;%=A%@=T_+>YO6ES#
M?+Q)PA8SU6#KN$V.%*9OXR8OHO/"/O)X)W_AX[9_$[:6K2-GX_%FX_PK8SQ@
M*9L[7*$&']CL**A\,!_0MN.:C8XWW?2"V/R,\S]02P,$%     @ X8!;4 G\
M8U_% 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&UL=53M;IPP
M$'P5RP\0@[EKHA,@Y5)%J=1*IU1M?_M@ 2O^H+8YTK>O;0BA5_('V^N9V5G;
M2SYJ\V([ (=>I5"VP)US_8$06W4@F;W1/2B_TV@CF?-+TQ+;&V!U)$E!:))\
M(I)QA<L\QDZFS/7@!%=P,L@.4C+SYPA"CP5.\5O@F;>="P%2YCUKX3NX'_W)
M^!595&HN05FN%3+0%/@^/1SW 1\!/SF,=C5'H9*SUB]A\:4N<!(,@8#*!07F
MAPL\@!!!R-OX/6OB)64@KN=OZH^Q=E_+F5EXT.(7KUU7X#N,:FC8(-RS'I]@
MKF>/T5S\5[B \/#@Q.>HM+#QBZK!.BUG%6]%LM=IY"J.X[1S2V?:-H'.!+H0
M[F(>,B6*SC\SQ\K<Z!&9Z>Q[%JXX/5!_-E4(QJ.(>]Z\]=%+F=$D)Y<@-&..
M$X:N,.F"(%Y]24&W4ASI?W2Z3<\V'6:1GJWIV0?Y=YL"NRBP^Z?$]*K$+<P'
M+O>;2?8; ME5DBW,[BH)65V<!-/&)VM1I0<5VV457;KB/KX4\@Z?6NH;,RU7
M%IVU\\\G7G*CM0-O);GQ7CK?Q<M"0./"]-;/S?26IX73_=RF9/E7E'\!4$L#
M!!0    ( .& 6U!3[^9,W0$   $%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;'54ZV[;(!1^%<0#% <G<1?9EII6U29M4M1IW6]B'U]4,!Z0N'O[
M 78\SV5_#.?P7<[!0#I(]:8; (/>!>]TAAMC^@,ANFA ,'TG>^CL2B658,:&
MJB:Z5\!*3Q*<T"C:$\':#N>ISYU4GLJ+X6T')X7T10BF?A^!RR'#&WQ+O+1U
M8UR"Y&G/:O@.YD=_4C8BLTK9"NAT*SNDH,KPP^9P3!S> UY;&/1BCEPG9RG?
M7/"ES'#D"@(.A7$*S Y7> 3.G9 MX]>DB6=+1US.;^K/OG?;RYEI>)3\9UN:
M)L/W&)50L0LW+W+X#%,_.XRFYK_"%;B%NTJL1R&Y]E]47+218E*QI0CV/HYM
MY\=ATK_1P@0Z$>B*0$8C7_D3,RQ/E1R0&O>^9^X7;P[4[DWADGXK_)HM7MOL
M-8_I+B57)S1ACB.&+C";&4&L^FQ!0Q9'^H%.P_0X6&'LZ?&2'F_# MN@P-8+
M;/]I<;]J,81)PB:[H,DN('"_,@EA/H5-]D&3_4>!.%J9A##_^5U)T"0)"-"5
M20@3KTS(X@@*4+6_?!H5\M+YB[_(SO?[@?HC_!<^/@[?F*K;3J.S-/8B^.-:
M26G EA+=V5UM['LT!QPJXZ:)G:OQ5HZ!D?WTX)#YU<O_ %!+ P04    " #A
M@%M07M%@*K8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6QM
M4]MNW" 0_17$!X1=[%RTLBUE4U6IU$JK1&V?67M\4;@X@-?IWV? CNNF?@%F
M..?,A2$;C7UQ+8 G;TIJE]/6^_[ F"M;4,)=F1XTWM3&*N'1M USO05119*2
MC.]V-TR)3M,BB[Z3+3(S>-EI.%GB!J6$_7,$:<:<[NF'XZEK6A\<K,AZT< S
M^)_]R:+%%I6J4Z!=9S2Q4.?T?G\XI@$? ;\Z&-WJ3$(E9V->@O&MRNDN) 02
M2A\4!&X7>  I@Q"F\3IKTB5D(*[/'^I?8^U8RUDX>##R=U?Y-J=WE%10BT'Z
M)S,^PES/-25S\=_A A+A(1.,41KIXDK*P7FC9A5,18FW:>]TW,?I)N4S;9O
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MM.DVUQ.5$!I,*L&=>;K&#+W%8%!INSV:O9Q:?S*TZ.>I1I;1FO\#4$L#!!0
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MY1DX(<NJKI<&I$Y5.JN='CID.0HY$)5<1;8K!0[#)%&$UZ?^T+D7M*N$HT<
M;A(@+26N#>C4.5\X$;8$+ (FL )?*6C(8H%3]):"2N!2(.@=!140)A&"WI-0
M%C*%H-_( PBI8@3]3D&AAC)LK0?2J"'!=0JX27^!1(9*(NR,PG* D&'+SDD;
MJ-IC/6'D& " F "4/0$ '@&H\C<S.(_&"8XI 8@Q026V&-R?@;4V=6KO:-2
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M965T<R]S:&5E=#0P+GAM;(U4[6Z;,!1]%<L/4(/YZ!H!TIIIVJ16BCJM^^W
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M>81\.6C*T_!X/+D^H]_\#U!+ P04    " #A@%M0:<K19F $   $%P  &0
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M!'MOK,G:9=F2+6GNLNTS;4^KN2@.:+W[]P.TIE6V+P6.[WEY#H53]%*]Z0K
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M&J"A,QJZV">9D2P5A*WR) S"@B L ,)F(&RQ38KQ<S*G6<I8FF 2ILF#-'F
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MVP+QID!L!>(;@4^K+FQ@]OZJD"W,?WJ5;":2; BLNE4X3&(QO<6LT_@(X9+
MB_O!0#1VE"0J^:57YD\LO/.T/H3F?JW\A9YB-W1O,NX)^$%$T_42G;G2M]?>
ML9IS!3I!_T[GUNI79S8HU,IL]WHOW.PY0_%A>E;P_+;E_P!02P,$%     @
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M3.=Z\CB:B_]*[Y1IN2'1.4Z<2?L;G6Y2\6YVT2@=>9_&MK?C./L_PL(!: Y
M2P#,_AN0S@&I$P F,EOJ1Z+(KA)\C,3TL@9B[@1\3O5AGLRF/3O[3%<K]>Y]
MEVTV%;@;HUFSGS1HI4%_*VI?4>2+!&B A0(%*9"-3]<9TBQLD 8-4FN0K0SR
M)''*F#2YU?16L\D+1U3[H@Q"&$;)@BA9  4Z*).F6&?!:>J@^*(2)SB,D@=1
M\@"*\^KVN9<ES<O<0?%%29BC"'(4 0ZGVGWAI4 X<X_$%V7YYA\H91"E]% @
MQ@Y*Z1]) AU1[8L*B,(D.$B" X>2.238NXTHQ<CY?]:^"I80N9<6K%J":='?
MB+BVO8R.7.GN8GO A7-%M6/RI,T:_558%HQ>E)F6>BZFWC@M%!_FM@^6;\_N
M#U!+ P04    " #A@%M0407O)- "   9"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6R55NUNVC 4?94H#]#X.I]4@,2'IDW:I*K3NM\N&(B:Q)EM
MH'O[V4Z:AN3"6GZ0V#GWGGNN<^!.ST*^J /GVGLMBTK-_(/6]7T0J,V!ETS=
MB9I7YLE.R))ILY3[0-62LZT+*HN $I($)<LK?SYU>P]R/A5'7>05?Y">.I8E
MDW^7O!#GF0_^V\9COC]HNQ',IS7;\Y]<_ZH?I%D%799M7O)*Y:+R)-_-_ 7<
MKRFU 0[QE/.SZMU[5LJS$"]V\6T[\XFMB!=\HVT*9BXGON)%83.9.OZT2?V.
MTP;V[]^R?W'BC9AGIOA*%+_SK3[,_,SWMGS'CH5^%.>OO!44^UZK_CL_\<+
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M- 02CM9/%VZNNQNZ"ZQJ^M>'#$]@_@]02P,$%     @ X8!;4-%RM&^]!
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MXC@4A?\*X@=,XM<D%44JM&A7VI5&L]K=SRFX!4U"V"0ML_]^\^*AX'OL3;\
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M\#J"UQ.0?Y>PZ B+1PE^1_ ?)00=(9@00)N[*>862YREG#4.;_=#C?6V0\M
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MLJ!=3]K;C?$D%G%H>9)8/R1B?>BHAEDOS=<I*S'K)=@2N!D_#*#)_M-("IR
M)18'"7A/@=VGPKQ7[(K#*::J BST*#2 )B="0A0"0'5A65.8U@K0FASYN!M
MDUG7!^4&#X""JU@$YI;"Y%:(MV[E!(%,*/E N0"0VW#7#P")D!],;06H;83K
M!X$"8J4PK16@M0GL?16FM;J"U@K36@%:^],\]LL1/('SW!< *2]-="P!"DA
M:&>JL03H*R1 8PG0:+5V=P_:9[9DL&\ 4EVLUFBL AJH@+>)0"!#;D0(%%!:
MC=FO$;&]8*0W*XAI0[%R P) 32)8F=18*C0J"GA5/_^LP24\E2"D2BX-7* 6
MB43#+?5HL&F0))+8*T A9$*Q47%H"+$0Z:^<3Q#(GT\(% H&2YI&YQ-W"S>
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M.WKB7%&M,0ITRBZZM>HGC)Z4&<[T6+3]13M1O.YZI[!OX%9_ 5!+ P04
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MA1G%4NAYY@8KX'"'J3<&CFVR9$,"F$ M*F F>R#T^DTFF,^$ 2N8[AIFK#B
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M>]'=V'8?57Y2M]%N?R6^_!]02P,$%     @ X8!;4#^8&A3: 0  9 0  !D
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M2H/<^%:S!#2#PI$$ X8'82P\X(C$.&*L\6X5J[$B"F$*'TR&K^W]FV3$L(,
M=!!H!\&- R.,1:<)M:;6&M<(]*EB]4AQ@QF"F"& .34P.TWT '.L0 ;F6.'!
MF!&(&8TP$]> 6$1/,<<*$W.LN(,9@YCQJ&H2]T[Q)Z"#Y!-5DSR-<ZR8>*$9
M*B!*IC#K%&2=?J)TID]9QXI)8J("&O].E2,7[FTN4$">V=S<I[2 9.+[9O.!
M5 C=22ZZTXT10.R;Q.AI!P$DDMC,,*1"R&QXSM554A%VT-<TM[;T6 O5;*]V
MAZ? JZ>N(F-_J9X(^HJZN.G>%S\P.Q0UMS94R(M.7T=[2@61D.Z+Q,OEDV98
ME&0OU#26<];=Z]U"T*9_LSC#PRG[#U!+ P04    " #A@%M0IR]*,\@"  ![
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970V."YX;6R%EEUOFS 40/\*XCW%
M-N:K2B(U0=,F;5+5:=LS39P$%3 S3M+]^]F&T-2^"7THX)Q[?7SCX#L_<_'6
M'1B3WGM=-=W"/TC9/@9!MSFPNN@>>,L:]<F.B[J0ZE'L@ZX5K-B:H+H*"$)Q
M4!=EXR_G9NQ9+.?\**NR8<_"ZXYU78A_*U;Q\\+'_F7@I=P?I!X(EO.VV+.?
M3/YJGX5Z"L8LV[)F35?RQA-LM_"?\&..B0XPQ.^2G;NK>T\OY97S-_WP;;OP
MD39B%=M(G:)0EQ-;LZK2F93'WR&I/\ZI Z_O+]F_F,6KQ;P6'5OSZD^YE8>%
MG_K>ENV*8R5?^/DK&Q84^=ZP^N_LQ"J%:Q,UQX97G?GO;8Z=Y/601:G4Q7M_
M+1MS/0_Y+V%P !D"R!B@YKX7$ X!X4= ?#> #@'T(X"::O5+,;7)"UDLYX*?
M/=%_O6VA=Q%^I*KZ&SUHBFT^4^7IU.AIF2(Z#TXZT<"L>H9<,1@EGYDUP(Q$
MH Q&#0)IK @P16I-X3+D,Y&[1!S!%B%8C-#$A]<SQ"F<@(()J$E /U4SLJK9
M,Y%A&L,@:Z$N,0O3-+2^EAS J/J[4?<(%(X X=@2[IGXCK!+S##)(FP)0QB*
M(P(+QZ!P[ CCV*YP/"GL$@2%UI;.72B,20;+)J!L E37FF653,JZQ PGV-X-
M )6@&YLW!6U3P-;Z#:[22=M)(G>)B- $-LU TPPPS2S3;-)TDLA=@M*(PJ88
MP>]7Y+IB9+]@T:0L@- L2ZU5YQ"&,QS?<+YQ)F#W1Y;:.V& [CJ[",;4?BL
M% UO;%P,GAY/F  ;(K2%R>2+%T!F8>@( Q3&]@8.KD[@FHF]Z6XZ;\./C=1G
MU-7HV$$]F0;*&E_KSLJ<[!]I^K;L1R'V9=-YKURJ_L"<XCO.)5.2Z$'I'50G
M.#Y4;"?U;:+N1=\.]0^2MT.K%XS]YO(_4$L#!!0    ( .& 6U!%K1$03 ,
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MJ&W;G8;FO!XV7,-%JP_C9M*Y[&B7_P%02P,$%     @ X8!;4-M]M,TH @
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MQZ^B32CVO3;[[^(@<@.W2LP>*YG7[M=;[6LMBY;%2"GX>_/,2O<\MORG,#@
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M0D<HX$)'\2>\@TL=)5.\2VY[-X2@*,&,AE'?/0#)$IH2.G9PX#L&09<,&Z&
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M&<1RJXM7W[QGU5VA&FAUJ*]!3G,7&_X#4$L#!!0    ( .& 6U#-XJ>1I0$
M (\#   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;'U3[8[;(!!\%<0#
M' [I)6ED6^JEJEJIE:*K>OU-['6,C@\72'Q]^RZ8LY(HZA_#+C/#['HI1^M>
M?0\0R)M6QE>T#V'8,N:;'K3P#W8 @R>==5H$#-V1^<&!:!-)*\:+8L6TD(;6
M9<KM75W:4U#2P-X1?]):N+]/H.Q8T05]3SS+8Q]B@M7E(([P$\*O8>\P8K-*
M*S48+ZTA#KJ*?EIL=SSB$^!%PN@O]B16<K#V-0;?VHH6T1 H:$)4$+B<80=*
M12&T\2=KTOG*2+S<OZM_2;5C+0?A86?5;]F&OJ(;2EKHQ$F%9SM^A5S/(R6Y
M^.]P!H7PZ 3O:*SRZ4N:DP]69Q6THL7;M$J3UG$ZX:M,NT_@F<!GPI+_E[#,
MA.5,2!>PR5BJ]+,(HBZ='8F;_M4@XD@LMDOL91.3J77I#(OUF#W7F]6J9.<H
ME#%/]S#K:\QNPO KS&;&,/0P&^%WC? D\.%*X..-D3N8=7%C9,(\)HQ)F.+&
M!KOH31S5'\(=I?'D8 -V.17:61L U8H'%.KQ=<R!@B[$[1KW;IJ1*0AVR.//
MYC=8_P-02P,$%     @ X8!;4(U%X$RUJ0  6;L" !0   !X;"]S:&%R9613
M=')I;F=S+GAM;-2]:W/C1I8V^/G=7X'H*;>E"(C-.ZGRS$3(JBI/]91=M9;<
M';T;^P$B00E=), &2*DT\?[X/;?,/)E(D%39[IDW8J9=DH!$7DZ>^WG.OS;-
M+OFR69?-O_WA8;?;OO[3GYK%0[[)FEZUS4OXRZJJ-]D.?JSO_]1LZSQ;-@]Y
MOMNL_S3L]Z=_VF1%^8=D7Q;_V.?7U;[<_=L?YK/!'_[]7YOBW_]U]^_7U6->
M)Y^R^SRY2'ZY>9.<O3I/7B5%F?Q8K-=%53;_^J?=O__KG_!I?F,P3'ZLRMU#
MD[PME_DR_/.;?-%+1H,T&?8'E^$?W^5WO60XQC\.^^$?_[POX8_S^)L\SRW,
ML]?Z8K78;_)RE]P^;_/6;/L7_]GYPE59[K-U\G.^K>I=^-2NWK=&LV]^RNNB
M6N(.)&^R7?LYV83_ZW_]K]ABW(SKK&R*'6QSQR16V;IIC?ZVW!6[Y^1=L<Z3
MG_:;N[P.G^CW!Q>C^?1RU/'JS_E]T>S@X[ODIVS3^L#5>EW=YV6>W#[D=;;-
M][MBT:1__)?!M/_=^W+1.@$9]1J65,-^O@>Z^)+\9_[<GE9_,!O-AO-9ZWCW
M=8T;\JYH%C#"W_*L[MS<BXO!\&(T:$T:=G1)N_ING=UW;KG^PCOX98N^#QZ8
MO"W''WW_W=\ZM@=VKJKAD#,\[S2YV<':DJI.Z%;6L'W5LDU(;SL&N\V^).^7
M,*5B52QHQ Y2F,->3:;#V:RU83+2U7)9YTV3FG\D'PHX^8]E:R[#03]YFP$[
M^@$(9YE</>9E^X:$@U[C3[#(V^JI#)^]J?:[A^0F*Y-W,.("MK8Z-IS=M$]U
M]5B4B];WKZ^.#?&I:G9PA/]/L8WN^.6X/V^Q)EK%%?#6Z"O32>N%#Q61R4-5
M=EW1\61V,9SU6V_>%CNXUM4J&0S/[LZ3FWRQK^'K;7ZXV<"9W^RJQ6=8$Q#S
M7[+U/D]>]7MPR9! DYN'K&[-%3C.LBCODYOGS5VU;MVA#Q\^MDY)9I"\_;)X
MR$H0%#&6\=/5S9NK_[MC[_^:K]<7GTL@ 5A/UL"F+)/W3;-O[\K?\M9]DC'^
M4JWAFF0U\[VZ]=A/7;1C6 LS6%H[$%'[WMI;N@.>M]@5CSERG\R\?X )PQ4&
MJKROZM8I?<AJV*^KQ2*'I^"9)3_?,=;-)ENOD^_W#5S IFM^;S=Y?8^K^*&N
MGN#Z "%LL[+U93/D VS]D6<^[>_6Q0*X9I5UK=*G-B*L)OFXW\%-*I&<NOAE
MHY@>+/X.)<\JA^UL7]Q/>#B@;B#I[QYR):+^^"_SX6#V79.\R5=%6=#)P/7_
M\LS<@/ARG:\S.MM=16^C?F'$^X^@#>&?8&!:P$.U7@(!I<G30[%X2)Y STGN
M\F0%)[.$GV!/<00A^P(6BMS.$C]N1=$TR'#Q65"4!L,^B\9E]@P/KX!^: 00
M1P<6LR))PB\^HS#*49N"-2YR9!?\!Z-'I0GL."AE_E[69B_A+[!N8 ([D='O
MW_.7BT;(OB6RO\_6&;YY@[IB$^I^MP_5OH%EMXA0:W?S+B&>-0V,^;KUYZQY
MH+U<X#_R?^R+QVR-1-+B. \PXPO8Q@W,Y3%O=IO84Y_J?)L5RR3_ GIP(\=4
MP6[7R<*;2(L%5LC_#S_SH2KOC\[@XQ8O-9+6&KA:GM3%_</NHEI=[.$'&K<]
M9U#::[A0.%?<@2T.G"9E^U'@0T!OQ=U:AFJB3_T,<ZN+!1($[FIKAK0=:[N8
M^&+?PD1@3IM\]P!*C5MP?./B8YBS7Q?97;&F>],B ."#J.HTH,8_9["PR-]!
MYUY&#E*->O@T#SSX@<[(// ,VUF5BSAO#[?MZ.<//$#\@NF'%G8-MA.0#%Q;
M9"UG/U4[^,\T36;TU_EY\#[:?J^;;;;(_^T/8-PU>?V8_^'?D]:548Q-6 S1
MU^ZY=0J?B&W4L,\-LW-1&;; @QY1AWB=#/HIJ.KX_TD&*EI5%_^%QT*\V3 H
M:^/1O,/?@A4'D]WF)$?7S]_!9B<-BXVG'%D92G\Y:2=&7O:)#I6H<U7#_J]?
MUG? [<?I<#I+1Y,Y/3(8#M+Q?)A.9P.SPM]B<?[^M6[*<DE6(Y >\L +8-F+
M;%L *4;NU'ZS7Y/(6(+\7!0M:M>/R+4#?:'.'X"MHJQ%L=-6^)CPFTZZ.WI1
M:-VGOQ\(K#.0=G"G'D"T@Q@]!P'V*OF3'$#[<A@U ?;_75&BK8':>26F]_][
M=8?">;'[_X[>%4M.R1GL^;):K[,:^!GL&7TZO+WM 81$%/WA0/S;D]\6 ON*
M-S4]'GC=OTHO7;3_]HM6''WU^'*CKYV\5E"\0(%8.G62+JI(=U1)F6_K._&A
M:DY7F@8G.\Q:?A&G8A@UI\7/004 ]7'!JM4R!W91;6/2^X>\S-$[@X]ERPUH
MTDCTR%_B5[5J?;JM),$FK.IJ8YZ-> M9E#(+2<YDI'/29=H*(FO8L)6KK# D
M!R>QJ$ E >L =:$2Y&67_D"F&^@N9L*=?W<*!D\LJEKQS+O6+GO4O;KH9MWE
MJZHV'#7995_: W\/Q[0J=KROAQ[\*0=UIVK;B1\[67AKPW&(?5GGV9KNY7T&
M6P_7*'O,BC5N\ 7,]J(!)5UKP;0Z,B^R+[$!_2_'9FAF[EA(FMQE#=B@1,+%
M>K^3ZWZ<U_PU1Z4[7UYD0"+HQ2[)VX+S$S:PQZN- A+FM2=Z+D_^?@?+\!G%
MM2)/QW=)(Z,!M6[V;2+*]MD;%L;G)W,1HK@627^*^&MJE*Y7A^;U->^89P9=
M#\5E[_ZN6=3%EAGISZ#F@-4'+PKC"+XANW3(V77H;Y'=8/W:?9<^RU:R?K/C
MPTK/^B1ZUG6'GM7Y9&126N-Z<UPIXQOM"Z#W4:7,*$G9+OFI>NPEP\NX6#'/
M*1H_^@XZ[.@EXLA:W@H_*,P#BZII&X@O?/W0]>,SK?TS]0;M.$[+>,@+<91/
MJ=T\**0[=O.D=X+G6I&'$\9NO:.WVMYL+42W3CL4Y6R7O!I->OVI9HGQ<X'?
MO)J.)K2%K^;C_\YO'Z*1V#PN!B^>"0N.LD1#3#Q^[ !)L@4P<C8@_CN_?=@(
MJ!9YOC17!3[6=5$2$/1NLV':JVI?LKQJ6([M4(?(M['E^BP^O)9;WQ+IN)D=
M4SWMY2[60JL"W7C]#&I<7B^*AA[AOU7;J+YZ>*RN48[8%W#LY# ^X4[$1=Q+
M1SCU9G@KW&^K4@8UWPHU[].WZ\A@1V=YM?S[GA5.VOD5A61(O,J%(?J /SUE
MM5ETLUVW!2F)]PM0[W)F^<#OLQ@5=S#DEI?I!(;<>N?M9KNNGG.S[.T>S#5T
M1FYAJ$.;<.B]\-F_@'XN40Z?Y)?>P?RNJFSHE'E!+$%TX&XG3GQJLC&69?[O
M0VZ@KU)@46?PQ!!:2.RBPJ\=V4^,=+Q;5T^G.POHE16]HDUK]!^B,[##LVYO
M2X,1,&"B5;G ]!!KZL!O\=\4>CD3D^C\Q,%1VM3TQL46^72#;/HTI\/5!L-Z
M_\4)"K AQF .8ALLT>J8<P0XVZ+@]\ESH0:,'97^^Y^RQ:+.^=.E,F&3QL;V
MVJIE>4%[1-&$#C_"J7Z*SD#'F_QNU])MRM/??V_= LD=NPO:(32\#3 G/'S#
M+?...$_<A1!?=8/+5F0CQP<G<RCR\Y,A/6.,QPCOV$W@"1\AUD_"(^GZ;:/A
MMJY7G%0ORLZ]ZE1<:(KH*Z$O'XQ;ZC<VV<Z$F8^\IF9YX#':-(J+HMC4BB*\
M%P_=V</98D[-DF/+CD?$MOW84:W8R7[DJ+R-*#Q-HE.S.=':/&ULNF1?->(+
MM<I#TXF8P@N;8\!7Z^O7JC0R'(BTLM]XU@E9"ISQ\ )])4IU,;J)"N02&#N.
M3(&OYB%MY130<NO#T?'KD]],*#8U_ [8[7U1EJ)G;2D+\#<853)%XN-9D61Y
M9JKO)+QZTFW3(1(343FHHA\U2EXXWD&)=MQ,UM^!4S]JA'_Z],=LL_WNK7+V
M![K&2</\W,KI2*J[75:4_'YNTH*0VZ[]#(/(=8I((WM+2+)F08H$ZSR2%W$@
MR^"-V:=J!?] 4F"M B[*>K^4M1X:^T4Y%S?[[79-6B[88\NB68"6L:_;\85
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M25N2 R+_!+H0@B?W9>M9\7HP[)BPWWM0XMG=YMUDM83&Y3/CM60Q? &DJLD
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M&E2JU/H89(VLWMXZ!QBAD8!B$^6[V*TGO8S-G*0&O5!?N>RQ U'=#$^Y%.7
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MSG1:+KWD!A5=MY?8#)2*#JBEMXA+.T-E/H6_.V)'42,^U"JX_T'M+!A+&NC
MYS7+V!)6*>IE(I7%I-,W)W(JHD.' ]#&[SKHJ"M@)INR6#U[^IQ<#0H.NWG1
MP;<RO;R&=2 &]RNL[$%M)/5HS_:E$Z<[3B8\6"8Q[@^*;<=]SF8U#5N@<4?.
M%?.8A=C)9-U/A%?'EX>)M23H&?2*KLC-(L33N;'>537[EA[=;[VOGN#]I^SL
M 8;=XLV1'6]K=O^,_9;@J;VARFOTVUU/[6!2-C?;7U&[V_-!T6_M%_F6,@\D
MAY>RK;]C<YQ>P,0KW[EM% ?*+\"8#%HYATQS)D884L;$+Z,[I,3&FDUF"Z&X
ML,^D Y#EKWR:IS@!ODL>JB=LP)Q29D+%?9@QR8W4+H^)WJD3:GM0&.QICTD5
MX2F!6D1[BRMY0M&:QU<37T$8J<'.[(%[.R1SGP6BJU>Z@5#+#?H*ME>%X<EA
MY_^ES.^K76$M3IMP6=F%L;?%?=0YCW68S=>J[/4T/(&6U+J?.A!X5%$E'[8%
ML5]C: .1Y:R?JQ'812[Y"5A,BW-@<O,2Z]!,["$,T*'&X[^!&E>@32$9X8-<
M+"[%U^9:/E%A9K@$"X(6B0%0,R;]@N%-ZV?A3C3;9Y,['=\&$LH4>\5%F>0;
MF.EE'Z[0,XO,MENP93=R;(#728;)@GI8<*9/6[.4?/5FEV<^%GG6.G@\=ZIT
M1=Q!M*>L:V49:\:!2Z44C;13DZ+O&5[V54YB[F_C\4GD"H%_V]OH< =IPUI,
MN^6(O TH@J0-W<J6DRFVU$Q62Q.>\I&*,)->'T\U(C<B@]L1.I_ HF#^ *;3
M $NJ\QVAHQQPI/22M_P:"W'4*8_.+7WA-V37+X\OPLA69MC"02LW/RO-]YC&
MGB]#J=YMI.'"R$RYRS49!I8$S3.8$IH@:&1@[I0W/3([W+?X&F B7_FYWF]W
M;(DTU?I1G-NQP>7*RODR\C9UR<,"7D.?TH6.$G@P#EZM/16G1^ QG-/K.QT<
MG'G;6VM\GJZ.3W=V.I AZ]*L3FB*?)DFK[0Y2TMH3/S(SK#5!_D!ZZL-1T?\
M]X@?U)FLQOS2:]*.3;6RXH16Y;:=@&Y#YWI/473L\(QD?;*.I5?BUM4^VM_/
M4PKAJ,Y2RNG&+FZMZ^-2M^,..L!N>]@OWNZ,A7YR?>*U+ZYWDE.-AC2NM-\V
MM%*^T+]'%KB=B@H1T!P_P$)-V3%!YYLG;ZYN:%C$I"AV8%DLJ:<UL",2T=+V
M@#.A@M?.T,OO3D'^=*[T*6T.Y1'ERH;:729 -#>ZK>EH7_ O\.0M7L-H.H:-
MW @B,,Q.F@Y8:=5PAJ9*^7*SZ%"R)"FQ.W]!O]!R9N&%5E\S ?MH<-O9I"9Z
M\Y118O1.*["TP/BH3C%M44=$WU81#*LVGWZ@<A0.IQGS\DP:_VZ_H<0Z/(A'
M G#8E]5.LMIC9Y>Z6CD[I^@IJDJA,'DO<AQ=63LI0N";/;+H&13_$(.BV0>J
M>!TS\/'Z8ROI^*<-S;.*W: UCVF<AFOXL](N?SQP%S<Z])84I[7PKG$YK>PO
M;E+E]DME_)J](.,:%TDL2(Z@I>%C']Z+@HXF*T6A"7<@]?)X/'51CC-(Z&F-
M8%?>D7A5296;/B86#JW,03OF"^Y(\:NS.&6=?/R46AND3?F+>OE-H@NPHS9]
MS&G,>EML"!D<NRS,JO\)R_.SPB1.6.:V*9W-_-$][$'8<X6;2^8);D"8;2=)
M> $_^0UV4\NJ9<:O!*R_';QPT4&FHPL;J39<^ET5N2Y--"]O45W(CN/^:A4D
M*A6O/GSX>#'I,X2_^>$J0M;-%C/*3>_M:?\;6PEHM[]]JUK4XX_"_D=3:3$^
M;4P7:E 9-/?KZHX2'CLTV^TZ*S%^T/+X&G1Q]GVZM( V"S))"CK[P(1G9+X+
MPXE=NK)F2*=,$LF)^9!G[H$59;NM!J%E->>"'Z2KZ.]T6Q"I98@QZR9]RAQN
MN_G>@3(10PR_*H785A#[O-B/0\8B?UVQ1S4Q%88<S11&QZ](!&8N]JOG,YLK
M,_*TZ;0W[H8KY)1&_L])^O82#+WD'!49-#Z3( &Q?=!\[]BVE"K%D#H8FB"R
MU?2N6KN7PTR+[PQMMB?RZS:%,G3'/G00W+;1=/S=3./#G+V:7;HRY?,(,)[*
MV W&CP2YN+25=Z,(M#22SXW6EEME( >52]H0V2?+.$PW;5(QG:[,@0CZ$O9F
MUESL:^+I+HI>E$H34,W:@09PAWRNYO92<VV.;(8^SH,!><<QW5,AI9L4"SNP
M_]X!4M.1M6<)FDOCQRRA?EXN6Y1Z:N:E-?THJKZC!F<G1].E&<0.+7T<G:3L
MLM[?<T0\#5S(DL$J=),Q/JW@@!=+SU)I!<PO@H"Y7JA*[[6-8/CQKFS?F%\Z
M3/O%2&_6DF]12O <)SIG_;PC>?B%H3J71\P=_C+IJ[-4&?\"2?6B6,(!:Z7-
MQCCJP9V:?I= ;6P#6R?(MKK:LF,A!@F$-"]W'&J>9QOHOIKU1CY(U]CANG5Z
M%:TOT5U>_,,%&II4B:]K;MM;?YJC^3@VJ[EN IROU(=7PP"=3B_+.;YI"YB0
M3L#",I5ZBP7O(G>E4 T"FJ])1/^IVL'C'U4OR<$)>=PG)Y?S\&%6-__VUB5[
MHE]ST4O.Z _1+&I^1:7YVA#AJ3F^J<L5U'F$[9Q ^M3A[-S  W=2QJWOF-NY
MQ5/BTP5V>8:5B>4*K_X)NV51R=TZ^0RD Y,\^^D_SSW+5NH5L$D""I#M>E\7
MK( ES2[?1#*SK=U[];,5C2QWN#VW&'@&YQ+3-?^C6MY_AG^OGS?;AVJ3P<(6
M>U"J^><[3/? NOE\_SG?2('5!KO0;Q$Y^1GV:),%]A,?)II[YD#U:3J/(KQA
M)^SL4S-M,?S:[E'.*N+XE2ER8V?M%K%^6>.5KZQR,:P"2C59],U)6?0>/WEI
M$GV.Z%YYSL!NWGDI,G>:G5VNC:9+T$D @65.<1GEML).F4U@S$3>+W%C'%-%
MFZ Q.1U9\G?J8.A[!S;4R2_ON0.D:=1YL;F#.YP'ERG2\SB8( MN?TIB7J@F
MOQTGHD/U5D<PPEOE+*V*U?$TH( @4LY,@BO4/A)1ME.-+ 0C'-@P^ZX%,F*2
M0BW6:EWA4>N+L\G=719K*%F  H61Z53*FF2U7SF- _N\@*T#NX)45_$_/HN)
MH1.$GULKL$UFL&:![D=1KF"(0IKQH4<X6^4[0?A[0=5/Z[0L05(B;H;V._!*
M!^* T^"7".(O0+P0'!PN"%5AEXQWFE[\ME&U%Y2N4R_9.=]B"V&E0#!;W[6C
M8^)'-169O9U[T#P&/QC181J=DF=P7-"@;7(V.^*8+@$;#[;8C[H[G" !GE1L
MH&%HL2;/_5:" ;88*8 H20@3QGWN(7MD[)WAY)ND>@(VVCP46X=HW?H>VL_8
M/D@!*@EZ&>G=JSVZTI?%FJ""N*2V &&]Q##U^CFXU6YA'=1)F=SFF31Y [-=
M)M<HCM+DQ]Z;7II\>J#_* 7K6P(0;P@Z+H6'BWR5O&4:AQ/XN%K!47%MR/<5
M-D':T(FFC!FSW>(-9WGA+_R.'K:HDU7MY<6U[@S_PG9]C3@#C&.L-PS\=.P:
M\LJU SFCO7,RS#@H.FBQBXZA.R5LZ $T503ST;$O,3@)IA<CD-59T<OA@$09
M R;PTW_2/\^[9F1FDX8>*&6;:G\9[[0J-BQVZWQYT.TB^O^&>YFJM/V$T_;9
M(U&5;?ED"QU:SI5H1C:Y(\0[SPQP1P7C737H4HX5YL2)14H;P%"5J&Y]M<&N
MNAK[V<@,IF5$.TEPSGHRU9=USK%6A/@JEJXB6+% EY4<?AJGEJVE[0)Y21MO
MKJE+6 XR_%RDA-J"8KH:V78=^<Q='[:BW+DI!%H[*%5^X:8ZI:KID*&^C^*K
M<A_EJ%H4>7+*8Q=%4&(1:WI+]$48!DT/N8-(VY\V0N_@Y]2:)(7[+G<E::FN
M1TM%?)#3;<\Q5UW*UM-BLI7HV)$[1(@[%9]^U[[+!B.IET 6U)WF2*:CD0^1
M!$SB0Z=-CG8N&)FF$98[2#!!Y5)21@?MM#R"JBRKDN@KI/1*\1ZWR)T1\X W
MVG,V2:ADOIZ6PVF2(Q>19%D-.8BWW?%HBN[05;8Z!K'LSMY'_N V=86HEMSB
MU1-KB@8HE1P[UCIDUK5!G$#5;V=-10_XN%$_+6B=I,RA&47H]*")HFAX3OTL
MP!80$V9=MZ"6^+<'(-+E 5!^KO;W>YCD<6!TR63$2FO*]'9IH#C!DKKYK"CS
M%:[/VK7C(/PFV0]!TV^$NYI6EK MTSGUI&NP 7V.)OTN,1B(0!@WH/X])#<P
MBW?8#@4+WD'% ED GRZ+C,^*I\5-MK"KQPRVO]P]-.QRIF"Y6BRLM:[V(('?
MY7?U'@W(87]X:4ULY\$@L!S.?*"QV1W!E-D@M8K_E%=H4X*L487 ;[B/L&23
M\7,DRYOC:51 Y+4\T:D(1&ZBQI->$&RXR?.272D(Z)CZU2.?)6,=S8Z)BY 9
M"$<-D@<[1\7=@KQ@C0]VNL,-OS.IKGS#.XT]FD4[-0Z3&!AAS $TH(^X1E>:
M)7QID>"*D\KE&JZ'=:<R:"9944Y'?,E4M+G6)G0ZEXMJ=;$WN)GL(!Z%'N*A
MUR?EJ//9=XTS1JT*>//'79=[ 8F\#+XY=>[WEK>=]\?S,(= G?ZEN51-Q89R
M?1P^K8/:!')B9&N4%%5=L^0F5QB,,N_UOPDS+_];F<M@G%Z.1[\I<QFWF8MU
MOW>SE_3_*/ZRW][7V5+ _DT\X^ YG,)R^JX1 T8[VNRF*/VM_.]F*JI/T>_.
M5";A_9YJ)O-[L)1IR,7^)S,4N_8C' 4A4X,=YQB)4"^3*Q(:<):_5?5G#H!5
M37(%%KC!]O*9R#@=3>;TW" =7OK<I)U:$J&"XR30B!";!3Q>>3YP7MZD@3P'
M_N.ZKQ8^KI?U,A+J=FIVD)2TLGSY$H:_[Q(449K[;V<0'@O0VU11[<Q2K8"4
MV[ 3(36":,K6G1_1\XY\Q_0R/2@4@F&-:!A^I5A0/<X[^323OQ0&DJ0\Q/OL
M3D:8X&_/BUOZ:IOQ2!G51)WBU(CK%O%);UKZYT _Y=%<K(?<2[A8P\XDM(UQ
M:LC0F+IZDV_:3>RTTG DC!]3EP+E9] VK2C_.UOH,A1*J%8M$3S0A03^Q2*#
M>696?_95I%_0>1"#ZPF%,X%9@TZ#9[<O59L("5%@M)HZ2ZVY>0&OS^53DN>[
MVM=M]M[%%XK&:US\-ZFEPS?5PZ_#QFV@KF$OMDDZG0[QAT$R2Z<C^N<0_GDY
M&1#.8C)/A_T1_G-L" (N(=E'TU$ZMZT?O;4&B[H<I:/!4!I"?O)Z8;BLP^1L
M-$DOL3LU/W?;TM^4GG4&PFHZ,TTCL6]QVA].6-L*&T&&"".MC:56?"W%9*!^
M\6M:\=FN&@$WTN67O?;,5;]3/<VAJV@T@F?ZFTS3\DX"4# MO# &:RH]75GE
M0)N!79PCMA.JGK6UOE[R%^/!"LB']!I[:+8:E9ML#@+MX*M;_(;;<2V7/6!
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M<UPHZ2R?('RR2*F8IQO9YKF->8T2 O=TJEM@4+GK4Y[H7KHR;9L<*&=UNGA
MF--RWYBZ:&POT/D]Q?GBO$:$RCST5T]^(V9XL[]CO%5? 3FURT-&[<!I ,T6
M<4[M%@T840Z:/VB$=P=F;B%T,;YP&(O=?!Y6EP[F+8AUAS?6;CB1JG\A<3W_
M!^P@L$ILHD[8NQLT71/"GL-[?H.-PI;)#68'8HD3-UN7UX#KR[^XUYE2GR_
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M.@B.H5P=]%["\@Z9'9;"ZFXQ\P&K*:QLN^%RE6@2KS:K]95QXHHRPXQ#A"]
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M*AN/BJQ3G;03_V75RP:#4=8I3_:)?9#OP\$X*X9P=7&R3]S[8CXF[O?!YY&
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MR[%WZ6%M,!H%+[1R &=D[T2N^XRX-%M]\*MJB$Z5E\.1.1I1AP6=-W+LI=+
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M-JV#KR5.2=VLZ[0'T.JH*.CZ/2499]@>YLF"WI8%HP!U=4 N)+G3>J958NW
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M<',O87!P+GAM;%!+ 0(4 Q0    ( .& 6U!#=:+$[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #A@%M0174SP$$"  "^!P  &
M    @ '%$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MX8!;4+VEWD>J P  $!   !@              ( !/!,  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .& 6U -V="XW@8  -TG   8
M          "  1P7  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #A@%M0(Q?%JQH"  !=!@  &               @ $P'@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ X8!;4-;EC7LC!@  7R0
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .& 6U!L5#QGL $  -(#   9
M      "  8,N  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ X8!;4$YG/SFU 0  T@,  !D              ( !:C   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #A@%M09 PP:[0!  #2 P
M&0              @ %6,@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( .& 6U"M6Q/4LP$  -(#   9              "  4$T  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ X8!;4'8=Q\^U
M 0  T@,  !D              ( !*S8  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #A@%M0US'AD;4!  #2 P  &0
M@ $7.   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .&
M6U"4UZK4M $  -(#   9              "  0,Z  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ X8!;4/-R[WBW 0  T@,  !D
M         ( ![CL  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #A@%M0UTA&#;8!  #2 P  &0              @ '</0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .& 6U!^S[\&M $  -(#
M   9              "  <D_  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ X8!;4%" !>6U 0  T@,  !D              ( !M$$
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #A@%M0R%#F
M#K4!  #2 P  &0              @ &@0P  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( .& 6U 5I7$RLP$  -(#   9
M  "  8Q%  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MX8!;4$.\$2>U 0  T@,  !D              ( !=D<  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #A@%M0Q*$OL;4!  #2 P  &0
M            @ %B20  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( .& 6U#=Q+! K@(  !0+   9              "  4Y+  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ X8!;4'A&'7>S 0
MT@,  !D              ( !,TX  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #A@%M02_/)/K,!  #2 P  &0              @ $=
M4   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .& 6U )
M_&-?Q0$  #<$   9              "  0=2  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ X8!;4%/OYDS= 0   04  !D
M     ( ! U0  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M" #A@%M07M%@*K8!  #2 P  &0              @ $75@  >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .& 6U":8@$LLP$  -(#   9
M              "  018  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ X8!;4)*JRB;I 0  9@4  !D              ( ![ED  'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #A@%M0<AX37NT!
M  !F!0  &0              @ $.7   >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;%!+ 0(4 Q0    ( .& 6U DGG,=P0$  #<$   9              "
M 3)>  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ X8!;
M4 $ P<NX 0  T@,  !D              ( !*F   'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " #A@%M0#9R+QS4%  #0&P  &0
M        @ $98@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( .& 6U#P?0:X20(  +$(   9              "  85G  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ X8!;4,H@B('6 0  W00
M !D              ( !!6H  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " #A@%M0M(Q*W/L$  "O'P  &0              @ $2;
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .& 6U!IRM%F
M8 0   07   9              "  41Q  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ X8!;4/,OH\H9 @  "@8  !D
M ( !VW4  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #A
M@%M0,_N2?>P!  #G!   &0              @ $K>   >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .& 6U#J+"QN#@(  /X%   9
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M970T.2YX;6Q02P$"% ,4    " #A@%M0407O)- "   9"P  &0
M    @ %ZA@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M .& 6U">'[=P'@(   X'   9              "  8&)  !X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ X8!;4-%RM&^]!    !L  !D
M             ( !UHL  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " #A@%M0'VWD54\%  !&'@  &0              @ '*D   >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .& 6U!]#COR)@(
M )@&   9              "  5"6  !X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ X8!;4'4PV5%/ @  [P<  !D              ( !
MK9@  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #A@%M0
MX4\^9J0"   Z"0  &0              @ $SFP  >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( .& 6U ZESD>.00  ),4   9
M      "  0Z>  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ X8!;4%*7\L-;!0  PAT  !D              ( !?J(  'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #A@%M0KV49@<$#   X$
M&0              @ $0J   >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( .& 6U#J4160H (  ,P)   9              "  0BL  !X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ X8!;4)/!<0W!
M @  R@H  !D              ( !WZX  'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " #A@%M0:V3]AG "  "K"   &0
M@ '7L0  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( .&
M6U!4GH5=,0(  (@&   9              "  7ZT  !X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ X8!;4($W\G:#!   'A<  !D
M         ( !YK8  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
M    " #A@%M0/Y@:%-H!  !D!   &0              @ &@NP  >&PO=V]R
M:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .& 6U"N43NJ!P(  ( %
M   9              "  ;&]  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL
M4$L! A0#%     @ X8!;4&-#;CN' @  1 D  !D              ( ![[\
M 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #A@%M0IR]*
M,\@"  !["@  &0              @ &MP@  >&PO=V]R:W-H965T<R]S:&5E
M=#8X+GAM;%!+ 0(4 Q0    ( .& 6U!%K1$03 ,  -T.   9
M  "  :S%  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @
MX8!;4-M]M,TH @  3P<  !D              ( !+\D  'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6Q02P$"% ,4    " #A@%M0B%$P2V$"   F"   &0
M            @ &.RP  >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4
M Q0    ( .& 6U#P5UO=.0,  *H,   9              "  2;.  !X;"]W
M;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ X8!;4-U_DH_3 @
M*PL  !D              ( !EM$  'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6Q02P$"% ,4    " #A@%M0R/6'*@4"  #@!0  &0              @ &@
MU   >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( .& 6U O
M\E/(5P,  )<-   9              "  =S6  !X;"]W;W)K<VAE971S+W-H
M965T-S4N>&UL4$L! A0#%     @ X8!;4,WBIY&E 0  CP,  !D
M     ( !:MH  'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
M" #A@%M0C47@3+6I  !9NP( %               @ %&W   >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #A@%M0TR/'878"  !D#0  #0
M        @ $MA@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .& 6U!BMXQ0
MS04  !DR   /              "  <Z( 0!X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " #A@%M03A&N7VH"  ")+0  &@              @ '(C@$ >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #A@%M0Q>""@1<"
M  !R+   $P              @ %JD0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     50!5 $47  "RDP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790598768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Asset Acquisition</a></td>
<td class="text">Asset Acquisition<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts described in Note&#160;7, and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As consideration for the purchased assets, the Company issued Pfizer 3,187,772 shares of its Series&#160;A-1 convertible preferred stock with an estimated fair value of $111.8 million or $35.06&#160;per share. The Company also incurred $2.1 million of direct expenses related to the asset acquisition, bringing the total consideration to $113.9 million. The fair value of the Series&#160;A-1 convertible preferred stock was established using the price per share paid by third-party investors in the concurrent closing of the Series&#160;A and A-1 convertible preferred stock financing at $35.06&#160;per share as well as the price per share paid by Pfizer to purchase additional shares of Series&#160;A-1 convertible preferred stock at $35.06&#160;per share at the same time and at the same price per share as the rest of Series&#160;A and A-1 shares sold in such financing (see Note 11 for additional details). The Series&#160;A-1 convertible preferred shares issued to Pfizer had the same rights, preferences and privileges as the Series&#160;A convertible preferred shares issued to the third-party investors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, anti-CD19 CAR T&#160;cell therapy, thus satisfying the requirements of the screen test in ASU 2017-1. The assets acquired in the transaction were measured based on the fair value of the Series A-1 convertible preferred stock issued to Pfizer and direct transaction costs of $2.1 million, as the fair value of the </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">equity given was more readily determinable than the fair value of the assets received. The following table summarizes the fair value of assets acquired (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:86.286%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development (IPR&amp;D):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-CD19 CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-BCMA CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy were determined using a risk-adjusted discounted cash flow approach, which used the present value of the direct cash flows expected to be generated by anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy during their estimated economic lives, net of returns on contributory assets such as working capital, property and equipment, and the assembled workforce. The discount rate of 16.5% was based on rates of return available from alternative investments of similar type and quality as of the valuation date. The remaining IPR&amp;D targets were determined to be more conceptual in nature with nominal value being attributed to them. The estimate of the fair value of the assembled workforce was determined using a replacement cost approach, based on the estimated cost of recruiting and training an equivalent workforce as of the acquisition date.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amount allocated to intangible IPR&amp;D assets was charged to research and development expenses as these assets had no alternative future use at the time of the acquisition transaction. The remaining intangible asset relates to the assembled workforce which was capitalized and is being amortized over its estimated economic life of two years to research and development expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the terms of the Pfizer Agreement, the Company was also required to make milestone payments to Pfizer of $30.0 million or $60.0 million per target (depending on the target, and up to $840.0 million in the aggregate for all targets) upon successful completion of certain regulatory and sales milestones for certain targets covered by the Pfizer Agreement. No milestone payments were made or became due in the years ended December&#160;31, 2019 and 2018. These contingent payments were not part of the consideration for the purchased assets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the asset acquisition, the Company also assumed licensing agreements Pfizer had entered into with two third-party entities holding certain intellectual property. Both agreements cover use of the intellectual property held by the parties and certain research collaboration activities. See Note 7 for additional details on these agreements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Pfizer Agreement, the Company was required to use commercially reasonable efforts to develop and seek regulatory approval in and for the United States and the European Union for certain products covered by the Pfizer Agreement and to commercialize each product covered by the Pfizer Agreement in the applicable royalty territory in which regulatory approval for such product has been obtained.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6783395504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchase Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, and we have entered into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.&#160;The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made.&#160;The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with the Company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity.&#160;There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805356336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StartUpCost', window );">Start up costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuanceMaximumValue', window );">Stock issuance, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent', window );">Stock issuance, maximum compensation due to third party (as a percentage of stock sales)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital', window );">Deferred offering costs reclassified to APIC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock forward split ratio</a></td>
<td class="nump">0.1905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">$ (61,030,000)<span></span>
</td>
<td class="num">$ (50,735,000)<span></span>
</td>
<td class="num">$ (41,243,000)<span></span>
</td>
<td class="num">$ (31,586,000)<span></span>
</td>
<td class="num">$ (30,509,000)<span></span>
</td>
<td class="num">$ (43,497,000)<span></span>
</td>
<td class="num">$ (134,902,000)<span></span>
</td>
<td class="num">$ (2,597,000)<span></span>
</td>
<td class="num">(184,594,000)<span></span>
</td>
<td class="num">(211,505,000)<span></span>
</td>
<td class="num">$ (396,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property, plant, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of 2018 Notes converted into common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,743,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of 2018 Notes converted into common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of convertible preferred stock converted to shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of 2018 Notes converted into common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Reclassified To Additional Paid In Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StartUpCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Establishment cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StartUpCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance, Maximum Compensation Due To Third Party, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuanceMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuanceMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6796617520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plan</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.421%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Contract</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,336,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,020,580)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(80,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,235,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.62</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,052,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(711,123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(386,716)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,660,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:66.274%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.645%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$25.94 - $31.99</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$2.27 - $26.52</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.27 - 6.08</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99&#160;-&#160;6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.14% - 74.92%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.2% - 77.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54% - 2.62%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.74% - 2.99%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Unvested Restricted Stock Units Activity</a></td>
<td class="text">The following summarizes restricted stock unit activity under the 2018 Plan:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.421%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted- Average Grant Date Fair Value per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,982,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.94</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of the rights granted under the ESPP were calculated using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"/><td style="width:67.610%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.548%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.822%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.4% - 76.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.7%&#160;-&#160;81.8%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.72%-2.49%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.37% - 2.83%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense related to stock options, employee stock purchase plans and vesting of the founders&#8217; common stock was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.471%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6788606592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">535,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:49.248%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial Paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(280)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(320)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">366,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available For Sale Debt Investments by Contractual Maturity</a></td>
<td class="text">The fair values of available-for-sale debt investments by contractual maturity as of&#160;December&#160;31, 2019&#160;and 2018 were as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:63.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.812%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.815%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 - 2 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 3 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments not due at a single maturity date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6783666096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, Pfizer held 22,032,040 shares of Common Stock and had appointed one member to the Company&#8217;s Board of Directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the years ended December&#160;31, 2019 and 2018, the costs incurred under the Pfizer TSA were $4.5 million and $10.1 million, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also purchased certain lab supplies and services from Pfizer in connection with its research and development activities. For the years ended December&#160;31, 2019 and 2018, total lab supplies and services purchased from Pfizer were $1.4 million and $10.4 million, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, the Company had amounts payable to Pfizer of $0.1 million and $5.7 million, respectively, which were recorded in the accompanying balance sheet.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consulting Agreements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.6 million for the years ended December&#160;31, 2019 and&#160;2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018 the Company entered into a consulting services agreement with TPG Capital &#8211; FO LLC (TPG FO) a firm affiliated with a beneficial owner of more than 5% of the Company&#8217;s capital stock. The costs incurred for services performed under this agreement were zero and $0.3 million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $26,250 per month in arrears commencing June 2018. Beginning January 2019, the Company paid Bellco $33,333.33 per month in arrears and, at the Company&#8217;s discretion, may pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided, bonus and out-of-pocket expenses incurred under this consulting agreement were $0.8 million and $0.5 million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sublease Agreements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a sublease with Bellco for 1,293 square feet of office space in Los Angeles California for a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMxNTY_6ef0bf0c-3a55-4439-89b6-05ebb3b69460">three</span> year term. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.2 million at December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company subleased 2,180 square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart). ByHeart is a development-stage infant formula company. Two of the Company&#8217;s board members have beneficial ownership in ByHeart and one serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to 2,907 square feet. Sublease income for the year ended December&#160;31, 2019 was $0.3 million and was recognized as other income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782725680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsFrom January 6 to January 17, 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790651136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304,794&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">231,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:49.104%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.783%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">403,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6781950528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Intangible Assets (Details) - Assembled workforce - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, cost</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 1,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,055)<span></span>
</td>
<td class="num">(452)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, carrying value</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=allo_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=allo_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6591966144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maximum remaining contractual maturities of available-for-sale securities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other than temporary impairment losses of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6711721120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 536,629<span></span>
</td>
<td class="nump">$ 714,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6621938208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 46,063<span></span>
</td>
<td class="nump">$ 18,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">19,429<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 26,634<span></span>
</td>
<td class="nump">$ 16,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20191231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 301,
   "dts": {
    "calculationLink": {
     "local": [
      "allo-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "allo-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "allo-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 636,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 58,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 63
   },
   "keyCustom": 72,
   "keyStandard": 404,
   "memberCustom": 46,
   "memberStandard": 38,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://allogene.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Fair Value Measurements",
     "role": "http://allogene.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Investments",
     "role": "http://allogene.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Balance Sheet Components",
     "role": "http://allogene.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Asset Acquisition",
     "role": "http://allogene.com/role/AssetAcquisition",
     "shortName": "Asset Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAndCollaborationAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - License and Collaboration Agreements",
     "role": "http://allogene.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAndCollaborationAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Leases",
     "role": "http://allogene.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Equity Method Investment",
     "role": "http://allogene.com/role/EquityMethodInvestment",
     "shortName": "Equity Method Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Commitments and Contingencies",
     "role": "http://allogene.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Convertible Notes Payable (2018 Notes)",
     "role": "http://allogene.com/role/ConvertibleNotesPayable2018Notes",
     "shortName": "Convertible Notes Payable (2018 Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138112 - Disclosure - Convertible Preferred Stock and Stockholders' Equity",
     "role": "http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://allogene.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140113 - Disclosure - Stock-Based Compensation",
     "role": "http://allogene.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148114 - Disclosure - Related Party Transactions",
     "role": "http://allogene.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150115 - Disclosure - 401(k) Plan",
     "role": "http://allogene.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152116 - Disclosure - Income Taxes",
     "role": "http://allogene.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160117 - Disclosure - Net Loss and Net Loss Per Share",
     "role": "http://allogene.com/role/NetLossandNetLossPerShare",
     "shortName": "Net Loss and Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164118 - Disclosure - Subsequent Events",
     "role": "http://allogene.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166119 - Disclosure - Selected Quarterly Financial Data (unaudited)",
     "role": "http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited",
     "shortName": "Selected Quarterly Financial Data (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredChargesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)",
     "role": "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredChargesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:EstimatedLifeOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "role": "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:EstimatedLifeOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://allogene.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://allogene.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Investment (Tables)",
     "role": "http://allogene.com/role/InvestmentTables",
     "shortName": "Investment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://allogene.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:ScheduleOfFairValueOfAssetsAcquiredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Asset Acquisition (Tables)",
     "role": "http://allogene.com/role/AssetAcquisitionTables",
     "shortName": "Asset Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:ScheduleOfFairValueOfAssetsAcquiredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Leases (Tables)",
     "role": "http://allogene.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://allogene.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353308 - Disclosure - Income Taxes (Tables)",
     "role": "http://allogene.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361309 - Disclosure - Net Loss and Net Loss Per Share (Tables)",
     "role": "http://allogene.com/role/NetLossandNetLossPerShareTables",
     "shortName": "Net Loss and Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367310 - Disclosure - Selected Quarterly Financial Data (unaudited) (Tables)",
     "role": "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables",
     "shortName": "Selected Quarterly Financial Data (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:StartUpCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:StartUpCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)",
     "role": "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i131f8341b44741a8be5ad09784c38587_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i131f8341b44741a8be5ad09784c38587_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "if1f9280b34fd4edca10d8753f9795f1d_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "role": "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails",
     "shortName": "Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail)",
     "role": "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail",
     "shortName": "Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Investment - Additional Information (Details)",
     "role": "http://allogene.com/role/InvestmentAdditionalInformationDetails",
     "shortName": "Investment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AccruedInterestOnShortTermMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AccruedInterestOnShortTermMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "ic080d00e479b47cb866477893266680a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "ic080d00e479b47cb866477893266680a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AccruedCompensationAndRelatedBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AccruedCompensationAndRelatedBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "ic178392ea1bb4a2d8265ba3c454059e5_I20171129",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i983a7f491bc342188b274ebaacc4b537_I20180430",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "allo:DiscountRateForValuation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Asset Acquisition - Additional Information (Details)",
     "role": "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
     "shortName": "Asset Acquisition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i983a7f491bc342188b274ebaacc4b537_I20180430",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "allo:DiscountRateForValuation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i983a7f491bc342188b274ebaacc4b537_I20180430",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)",
     "role": "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails",
     "shortName": "Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i983a7f491bc342188b274ebaacc4b537_I20180430",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - License and Collaboration Agreements (Details)",
     "role": "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
     "shortName": "License and Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i9047b22f877746d385f33c4ed54f6267_D20190101-20191231",
      "decimals": "2",
      "lang": null,
      "name": "allo:PercentageOfDevelopmentCostResponsibleFor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AllowanceForTenantImprovements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://allogene.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i931fe0adef2547279e3d242f0f22774d_I20181231",
      "decimals": "INF",
      "lang": null,
      "name": "allo:OperatingLeasesNumberOfLeaseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operatinglease",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)",
     "role": "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails",
     "shortName": "Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Equity Method Investment (Details)",
     "role": "http://allogene.com/role/EquityMethodInvestmentDetails",
     "shortName": "Equity Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "id582a2792aa240b5b2ce2ac625929e33_D20191101-20191101",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i97a7d47bd645462aa3e6c38d02dd4202_I20180930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Convertible Notes Payable (2018 Notes) (Details)",
     "role": "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
     "shortName": "Convertible Notes Payable (2018 Notes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i97a7d47bd645462aa3e6c38d02dd4202_I20180930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Details)",
     "role": "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Deficit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i983a7f491bc342188b274ebaacc4b537_I20180430",
      "decimals": "-5",
      "lang": null,
      "name": "allo:AggregatePurchasePriceSharesValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i98539d3bf6db493eb4bac0723e6ee092_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i98539d3bf6db493eb4bac0723e6ee092_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i6af2cfd2ff1d4e4a9d19b9a090f83467_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Related Party Transactions (Details)",
     "role": "http://allogene.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyCosts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i46512246cc53487190bb23e1f83b9f1e_D20190101-20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RelatedPartyCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - 401(k) Plan (Details)",
     "role": "http://allogene.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://allogene.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)",
     "role": "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails",
     "shortName": "Income Taxes - Summary of Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)",
     "role": "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i539b2ae7956d4b19badf4d751d50af35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Statements of Cash Flows",
     "role": "http://allogene.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i16c74cfa985346f494f9d5736c6a5fe4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)",
     "role": "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails",
     "shortName": "Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i16c74cfa985346f494f9d5736c6a5fe4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i931fe0adef2547279e3d242f0f22774d_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details)",
     "role": "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details)",
     "role": "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails",
     "shortName": "Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465437 - Disclosure - Subsequent Events (Details)",
     "role": "http://allogene.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Selected Quarterly Financial Data (unaudited) (Details)",
     "role": "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails",
     "shortName": "Selected Quarterly Financial Data (unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "role": "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Recent Accounting Guidance",
     "role": "http://allogene.com/role/RecentAccountingGuidance",
     "shortName": "Recent Accounting Guidance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20191231.htm",
      "contextRef": "ia6c735ffeb0e4728ab0cf9f8a68323c0_I20171130",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - allo-20191231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - allo-20191231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 96,
   "tag": {
    "allo_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails",
      "http://allogene.com/role/BalanceSheets",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AccruedCompensationAndRelatedBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "allo_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued liabilities and employee related benefits current.",
        "label": "Accrued Compensation And Related Benefits Current",
        "terseLabel": "Accrued compensation and related benefits"
       }
      }
     },
     "localname": "AccruedCompensationAndRelatedBenefitsCurrent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AccruedInterestOnShortTermMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued interest on short-term marketable securities",
        "label": "Accrued Interest On Short Term Marketable Securities",
        "terseLabel": "Accrued interest on short-term marketable securities"
       }
      }
     },
     "localname": "AccruedInterestOnShortTermMarketableSecurities",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AccruedPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "allo_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Property And Equipment",
        "label": "Accrued Property And Equipment",
        "terseLabel": "Accrued property and equipment"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipment",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsPolicyTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "allo_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued research and development expense, current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliated with President and Chief Executive Officer.",
        "label": "Affiliated With President And Chief Executive Officer [Member]",
        "terseLabel": "Affiliated with President and Chief Executive Officer"
       }
      }
     },
     "localname": "AffiliatedWithPresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate milestone payments.",
        "label": "Aggregate Milestone Payments",
        "terseLabel": "Aggregate milestone payments"
       }
      }
     },
     "localname": "AggregateMilestonePayments",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential milestone payable",
        "label": "Aggregate Potential Milestone Payable",
        "terseLabel": "Aggregate potential milestone payable"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayable",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential milestone payments per target",
        "label": "Aggregate Potential Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments per target"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayments",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePurchasePriceSharesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate Purchase Price.",
        "label": "Aggregate Purchase Price Shares Value",
        "terseLabel": "Aggregate purchase price, shares value"
       }
      }
     },
     "localname": "AggregatePurchasePriceSharesValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for tenant improvements.",
        "label": "Allowance For Tenant Improvements",
        "negatedLabel": "Less: Tenant improvement allowance",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AntiBCMACARTCellTherapyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Anti-BCMA CAR T cell therapy.",
        "label": "Anti B C M A C A R T Cell Therapy [Member]",
        "terseLabel": "Anti-BCMA CAR T cell therapy"
       }
      }
     },
     "localname": "AntiBCMACARTCellTherapyMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AntiCDNineteenCARTCellTherapyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Anti-CD19 CAR T cell therapy.",
        "label": "Anti C D Nineteen C A R T Cell Therapy [Member]",
        "terseLabel": "Anti-CD19 CAR T cell therapy"
       }
      }
     },
     "localname": "AntiCDNineteenCARTCellTherapyMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AreaOfNewOfficeBuilding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of new office building.",
        "label": "Area Of New Office Building",
        "terseLabel": "Area of lease"
       }
      }
     },
     "localname": "AreaOfNewOfficeBuilding",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assembled workforce.",
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails",
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent asset acquisition.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_AssetAcquisitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about asset Acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_AssetContributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset contribution agreement.",
        "label": "Asset Contribution Agreement [Member]",
        "terseLabel": "Asset Contribution Agreement"
       }
      }
     },
     "localname": "AssetContributionAgreementMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through two years fair value.",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "terseLabel": "Due in 1 - 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available for sale securities debt maturities within three year fair value.",
        "label": "Available For Sale Securities Debt Maturities Within Three Year Fair Value",
        "terseLabel": "Due in 3 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_BalanceSheetComponentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance sheet components line items.",
        "label": "Balance Sheet Components [Line Items]",
        "terseLabel": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "localname": "BalanceSheetComponentsLineItems",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_BalanceSheetComponentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance sheet components.",
        "label": "Balance Sheet Components [Table]",
        "terseLabel": "Balance Sheet Components [Table]"
       }
      }
     },
     "localname": "BalanceSheetComponentsTable",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_BellcoCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bellco Capital LLC.",
        "label": "Bellco Capital L L C [Member]",
        "terseLabel": "Bellco"
       }
      }
     },
     "localname": "BellcoCapitalLLCMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ByHeartMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ByHeart",
        "label": "ByHeart [Member]",
        "terseLabel": "ByHeart"
       }
      }
     },
     "localname": "ByHeartMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CashEquivalentsAndShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments",
        "totalLabel": "Total cash equivalents, and investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestments",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CellectisSAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cellectis S.A..",
        "label": "Cellectis S A [Member]",
        "terseLabel": "Cellectis"
       }
      }
     },
     "localname": "CellectisSAMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ChangeInFairValueOfConvertibleNotePayable": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in fair value of convertible notes payable.",
        "label": "Change In Fair Value Of Convertible Note Payable",
        "negatedLabel": "Change in fair value of convertible note payable",
        "terseLabel": "Change in fair value of convertible notes payable"
       }
      }
     },
     "localname": "ChangeInFairValueOfConvertibleNotePayable",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Development Milestone",
        "label": "Clinical Development Milestone [Member]",
        "terseLabel": "Clinical Development Milestone"
       }
      }
     },
     "localname": "ClinicalDevelopmentMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ClinicalRegulatoryAndCommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical, Regulatory, and Commercial Milestone",
        "label": "Clinical, Regulatory, and Commercial Milestone [Member]",
        "terseLabel": "Clinical, Regulatory, and Commercial Milestone"
       }
      }
     },
     "localname": "ClinicalRegulatoryAndCommercialMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Collaboration agreement, upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CombinedVotingPowerByIndividual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Combined voting power by individual.",
        "label": "Combined Voting Power By Individual",
        "terseLabel": "Combined voting power by individual"
       }
      }
     },
     "localname": "CombinedVotingPowerByIndividual",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_ComprehensiveLossPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ComputerEquipmentAndPurchasedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer equipment and purchased software.",
        "label": "Computer Equipment And Purchased Software [Member]",
        "terseLabel": "Computers equipment and purchased software"
       }
      }
     },
     "localname": "ComputerEquipmentAndPurchasedSoftwareMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ConvertiblePreferredStockIssuedInAssetAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A-1 convertible preferred stock issued in asset acquisition.",
        "label": "Convertible Preferred Stock Issued In Asset Acquisition",
        "terseLabel": "Series A-1 convertible preferred stock issued in asset acquisition"
       }
      }
     },
     "localname": "ConvertiblePreferredStockIssuedInAssetAcquisition",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CostMethodInvestmentTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost Method Investment, Transaction Costs",
        "label": "Cost Method Investment, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "CostMethodInvestmentTransactionCosts",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CurrentOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current offering period.",
        "label": "Current Offering Period",
        "terseLabel": "Current offering period"
       }
      }
     },
     "localname": "CurrentOfferingPeriod",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs Reclassified To Additional Paid In Capital",
        "label": "Deferred Offering Costs Reclassified To Additional Paid In Capital",
        "terseLabel": "Deferred offering costs reclassified to APIC"
       }
      }
     },
     "localname": "DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets, lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets net of deferred tax liabilities.",
        "label": "Deferred Tax Assets Net Of Deferred Tax Liabilities",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfDeferredTaxLiabilities",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DeferredTaxLiabilitiesRightOfUseLeased": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liabilities right of use leased assets.",
        "label": "Deferred Tax Liabilities Right Of Use Leased",
        "negatedLabel": "Right of use leased assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseLeased",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_DiscountRateForValuation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate for valuation.",
        "label": "Discount Rate For Valuation",
        "terseLabel": "Discount rate for valuation"
       }
      }
     },
     "localname": "DiscountRateForValuation",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_EarlyExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early exercise of stock options.",
        "label": "Early Exercise Of Stock Options [Member]",
        "terseLabel": "Early exercised stock options subject to future vesting"
       }
      }
     },
     "localname": "EarlyExerciseOfStockOptionsMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EarlyExercisedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Exercised Stock Options",
        "label": "Early Exercised Stock Options [Member]",
        "terseLabel": "Early Exercised Stock Options"
       }
      }
     },
     "localname": "EarlyExercisedStockOptionsMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EstimatedLifeOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of estimated life of assets.",
        "label": "Estimated Life Of Assets Table [Text Block]",
        "terseLabel": "Estimated Life Of Assets"
       }
      }
     },
     "localname": "EstimatedLifeOfAssetsTableTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected Shares Purchased Under Employee Stock Purchase Plan",
        "label": "Expected Shares Purchased Under Employee Stock Purchase Plan [Member]",
        "terseLabel": "Expected shares purchased under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FounderSharesOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Founder shares of common stock.",
        "label": "Founder Shares Of Common Stock [Member]",
        "terseLabel": "Founder shares subject to future vesting"
       }
      }
     },
     "localname": "FounderSharesOfCommonStockMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FoundersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Founders [Member]",
        "label": "Founders [Member]",
        "terseLabel": "Founders"
       }
      }
     },
     "localname": "FoundersMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FoundersStockAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Founders Stock Award",
        "label": "Founders Stock Award [Member]",
        "terseLabel": "Founders Stock Award"
       }
      }
     },
     "localname": "FoundersStockAwardMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_IncomeLossFromCostMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) from Cost Method Investment",
        "label": "Income (Loss) from Cost Method Investment",
        "negatedLabel": "Share of losses from equity method investments",
        "terseLabel": "Income (loss) from investment"
       }
      }
     },
     "localname": "IncomeLossFromCostMethodInvestment",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of convertible notes.",
        "label": "Income Tax Reconciliation Change In Fair Value Of Convertible Notes",
        "terseLabel": "Change in fair value of convertible notes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income tax reconciliation Write-off of in process research and development.",
        "label": "Income Tax Reconciliation Write Off Of In Process Research And Development",
        "terseLabel": "Write-off of in-process R&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite.",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_InitiallyReservedCommonStockForEmployeePurchase": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initially reserved common stock for employee purchase.",
        "label": "Initially Reserved Common Stock For Employee Purchase",
        "terseLabel": "Initially reserved common stock for employee purchase (in shares)"
       }
      }
     },
     "localname": "InitiallyReservedCommonStockForEmployeePurchase",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Definite-Lived Intangible Assets.",
        "label": "Intangible Assets Definite Lived Policy [Policy Text Block]",
        "terseLabel": "Definite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory equipment member.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease one.",
        "label": "Lease One [Member]",
        "terseLabel": "127 Months Lease Term"
       }
      }
     },
     "localname": "LeaseOneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Two.",
        "label": "Lease Two [Member]",
        "terseLabel": "124 Months Lease Term"
       }
      }
     },
     "localname": "LeaseTwoMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Five And After Year Five",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five And After Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LesseeOperatingLeaseOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option to Extend, Number",
        "label": "Lessee, Operating Lease, Option to Extend, Number",
        "terseLabel": "Operating lease, options to extend term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtendNumber",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LicenseAndCollaborationAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LosAngelesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Los Angeles [Member]",
        "label": "Los Angeles [Member]",
        "terseLabel": "Los Angeles"
       }
      }
     },
     "localname": "LosAngelesMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum payments required per product against selected target.",
        "label": "Maximum Payments Required Per Product Against Selected Target",
        "terseLabel": "Maximum payments required per product against selected target"
       }
      }
     },
     "localname": "MaximumPaymentsRequiredPerProductAgainstSelectedTarget",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments, per target (in usd per share)"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ModificationOfConvertiblePreferredStockForCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Modification of convertible preferred stock for common stock.",
        "label": "Modification Of Convertible Preferred Stock For Common Stock",
        "terseLabel": "Modified shares of common stock (in shares)"
       }
      }
     },
     "localname": "ModificationOfConvertiblePreferredStockForCommonStock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_NewarkMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Newark",
        "label": "Newark [Member]",
        "terseLabel": "Newark"
       }
      }
     },
     "localname": "NewarkMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "North America, Europe, Asia, Australia and Oceania.",
        "label": "North America Europe Asia Australia And Oceania [Member]",
        "terseLabel": "North America, Europe, Asia, Australia and Oceania"
       }
      }
     },
     "localname": "NorthAmericaEuropeAsiaAustraliaAndOceaniaMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NotchTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notch Therapeutics, Inc.",
        "label": "Notch Therapeutics, Inc. [Member]",
        "terseLabel": "Notch Therapeutics, Inc."
       }
      }
     },
     "localname": "NotchTherapeuticsIncMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NotesReceivableFromCommonShareholders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes receivable from common shareholders.",
        "label": "Notes Receivable From Common Shareholders",
        "negatedLabel": "Notes receivable from common stockholders"
       }
      }
     },
     "localname": "NotesReceivableFromCommonShareholders",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_NumberOfMembersAppointedToBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of members appointed to board of directors.",
        "label": "Number Of Members Appointed To Board Of Directors",
        "terseLabel": "Number of members appointed to board of directors"
       }
      }
     },
     "localname": "NumberOfMembersAppointedToBoardOfDirectors",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares as percentage of common shares outstanding.",
        "label": "Number Of Shares As Percentage Of Common Shares Outstanding",
        "terseLabel": "Number of shares as percentage of common shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_OperatingLeaseAssetRetirementObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Asset Retirement Obligation",
        "label": "Operating Lease, Asset Retirement Obligation",
        "terseLabel": "Asset retirement obligation"
       }
      }
     },
     "localname": "OperatingLeaseAssetRetirementObligation",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_OperatingLeasesNumberOfLeaseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating lease agreements.",
        "label": "Operating Leases Number Of Lease Agreements",
        "terseLabel": "Number of operating Leases for office space"
       }
      }
     },
     "localname": "OperatingLeasesNumberOfLeaseAgreements",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option exercise price as percentage of fair value of common stock on grate date.",
        "label": "Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date",
        "terseLabel": "Option exercise price as percentage of fair value of common stock on grate date"
       }
      }
     },
     "localname": "OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option exercise price as percentage of fair value of common stock on grate date 1.",
        "label": "Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date1",
        "terseLabel": "Option exercise price as percentage of fair value of common stock on grate date"
       }
      }
     },
     "localname": "OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PercentageOfDevelopmentCostResponsibleFor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development cost responsible for.",
        "label": "Percentage Of Development Cost Responsible For",
        "terseLabel": "Percentage of development cost responsible for"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostResponsibleFor",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PercentageOfEligibleCompensationContributionByEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible compensation contribution by employee percentage.",
        "label": "Percentage Of Eligible Compensation Contribution By Employee",
        "terseLabel": "Percentage of eligible compensation contribution by employee"
       }
      }
     },
     "localname": "PercentageOfEligibleCompensationContributionByEmployee",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PreClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Clinical Development Milestone",
        "label": "Pre-Clinical Development Milestone [Member]",
        "terseLabel": "Pre-Clinical Development Milestone"
       }
      }
     },
     "localname": "PreClinicalDevelopmentMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PrepaidResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid research and development expenses current.",
        "label": "Prepaid Research And Development Expenses Current",
        "terseLabel": "Prepaid Research And Development Expenses Current"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Early Exercise Of Stock Options",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Early Exercise Of Stock Options",
        "terseLabel": "Proceeds from early exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property plant &amp; equipment and other assets acquired in asset acquisition.",
        "label": "Property Plant Equipment And Other Assets Acquired In Asset Acquisition",
        "terseLabel": "PP&amp;E and other assets acquired in asset acquisition"
       }
      }
     },
     "localname": "PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase of common stock through payroll deductions to equal price of lower fair market value.",
        "label": "Purchase Of Common Stock Through Payroll Deductions To Equal Price Of Lower Fair Market Value",
        "terseLabel": "Purchase of common stock through payroll deductions to equal price of lower fair market value"
       }
      }
     },
     "localname": "PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_RegulatoryAndSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory and sales milestone member.",
        "label": "Regulatory And Sales Milestone [Member]",
        "terseLabel": "Regulatory and Sales Milestone"
       }
      }
     },
     "localname": "RegulatoryAndSalesMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory milestone member.",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RelatedPartyTransactionCompensationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transaction compensation percentage.",
        "label": "Related Party Transaction Compensation Percentage",
        "terseLabel": "Related party transaction compensation percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionCompensationPercentage",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_RelatedPartyTransactionMonthlyPaymentsInArrears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transaction monthly payments in arrears.",
        "label": "Related Party Transaction Monthly Payments In Arrears",
        "terseLabel": "Related party transaction monthly payment in arrears"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyPaymentsInArrears",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research collaboration and license agreement.",
        "label": "Research Collaboration And License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales milestone member.",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Fair Value of Assets Acquired.",
        "label": "Schedule Of Fair Value Of Assets Acquired [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfAssetsAcquiredTableTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the prepayments that will be charged against earnings and carrying amounts of other current assets",
        "label": "Schedule Of Prepayments And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepayments and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_SeriesA1ConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Series A1 Convertible Preferred Shares [Member]",
        "terseLabel": "Series A1 Convertible Preferred Shares"
       }
      }
     },
     "localname": "SeriesA1ConvertiblePreferredSharesMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_SeriesAConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A convertible preferred shares.",
        "label": "Series A Convertible Preferred Shares [Member]",
        "terseLabel": "Series A Convertible Preferred Shares"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredSharesMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Servier.",
        "label": "Servier [Member]",
        "terseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms",
        "terseLabel": "Restricted stock units, granted, weighted average remaining vesting life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "Restricted stock units, aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Restricted stock units, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Restricted stock units, weighted average grant date fair value, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Restricted stock units, vested and expected to vest, weighted average remaining vesting life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_ShorttermLeaseRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short term leaser rent expense.",
        "label": "Shortterm Lease Rent Expense",
        "terseLabel": "Rent expense for short-term leases"
       }
      }
     },
     "localname": "ShorttermLeaseRentExpense",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StartUpCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Establishment cost.",
        "label": "Start Up Cost",
        "terseLabel": "Start up costs"
       }
      }
     },
     "localname": "StartUpCost",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance, Maximum Compensation Due To Third Party, Percent",
        "label": "Stock Issuance, Maximum Compensation Due To Third Party, Percent",
        "terseLabel": "Stock issuance, maximum compensation due to third party (as a percentage of stock sales)"
       }
      }
     },
     "localname": "StockIssuanceMaximumCompensationDueToThirdPartyPercent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_StockIssuanceMaximumValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance, Maximum Value",
        "label": "Stock Issuance, Maximum Value",
        "terseLabel": "Stock issuance, maximum value"
       }
      }
     },
     "localname": "StockIssuanceMaximumValue",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockIssuedDuringPeriodValueCommonStockIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period value common stock issues.",
        "label": "Stock Issued During Period Value Common Stock Issues",
        "terseLabel": "Proceeds received from common stockholders for issuance of founders' stock at inception"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockIssues",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockIssuedDuringPeriodValuePreferredStockIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period value preferred stock issues.",
        "label": "Stock Issued During Period Value Preferred Stock Issues",
        "terseLabel": "Proceeds received from preferred stockholders"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreferredStockIssues",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Vesting Of Early Exercised Stock Options",
        "label": "Stock Issued During Period, Value, Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockOptionGrantedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock option granted period.",
        "label": "Stock Option Granted Period",
        "terseLabel": "Stock option granted period"
       }
      }
     },
     "localname": "StockOptionGrantedPeriod",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SubscriptionsReceivableFromPreferredStockholders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subscriptions receivable from preferred stockholders.",
        "label": "Subscriptions Receivable From Preferred Stockholders",
        "negatedLabel": "Subscriptions receivable from preferred stockholders"
       }
      }
     },
     "localname": "SubscriptionsReceivableFromPreferredStockholders",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_SubscriptionsReceivablesFromPreferredStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subscriptions Receivables From Preferred Stockholders [Member]",
        "terseLabel": "Subscriptions Receivables from Preferred Stockholders"
       }
      }
     },
     "localname": "SubscriptionsReceivablesFromPreferredStockholdersMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TPGCapitalFOLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TPG Capital FO Limited Liability Company.",
        "label": "T P G Capital F O Limited Liability Company [Member]",
        "terseLabel": "TPG Capital \u2013 FO LLC"
       }
      }
     },
     "localname": "TPGCapitalFOLimitedLiabilityCompanyMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TaxExpiration2037Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Expiration 2037",
        "label": "Tax Expiration 2037 [Member]",
        "terseLabel": "2037"
       }
      }
     },
     "localname": "TaxExpiration2037Member",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TaxExpiration2037To2039Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand thirty seven to two thousand thirty eight expiration.",
        "label": "Tax Expiration 2037 to 2039 [Member]",
        "terseLabel": "2037-2039"
       }
      }
     },
     "localname": "TaxExpiration2037To2039Member",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TaxExpirationYears2038To2039Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Expiration Years 2038 To 2039",
        "label": "Tax Expiration Years 2038 To 2039 [Member]",
        "terseLabel": "2038-2039"
       }
      }
     },
     "localname": "TaxExpirationYears2038To2039Member",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84 (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transition services agreement.",
        "label": "Transition Services Agreement [Member]",
        "terseLabel": "Transition services agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoRiverConsultingLimitedLiabiltyCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two River Consulting Limited Liability Company.",
        "label": "Two River Consulting Limited Liabilty Company [Member]",
        "terseLabel": "Two River Consulting LLC"
       }
      }
     },
     "localname": "TwoRiverConsultingLimitedLiabiltyCompanyMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 equity incentive plan.",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand eighteen plan.",
        "label": "Two Thousand Eighteen Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenPlanMember",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_UnvestedSharesLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "allo_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unvested shares liabilities, current.",
        "label": "Unvested Shares Liabilities Current",
        "terseLabel": "Unvested shares liabilities"
       }
      }
     },
     "localname": "UnvestedSharesLiabilitiesCurrent",
     "nsuri": "http://allogene.com/20191231",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r123",
      "r189",
      "r190",
      "r380",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Los Angeles California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r33",
      "r97",
      "r319",
      "r321",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Payable to related party, current"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r165"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r53",
      "r54",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets, weighted-average remaining amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r198",
      "r201",
      "r233",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r177",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Adjustment for fractional shares from forward stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r201",
      "r225",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r64",
      "r84",
      "r300"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Debt issuance costs on convertible notes payable"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r84",
      "r151",
      "r159"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of other intangible assets acquired",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r347",
      "r367"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r46"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r132",
      "r134",
      "r361"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Due in 1 year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value",
        "terseLabel": "Instruments not due at a single maturity date"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r126",
      "r129"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total cash equivalents and investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r202",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Convertible preferred stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total asset acquisition",
        "verboseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Costs from issuance of preferred shares"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r27",
      "r86"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r87",
      "r92",
      "r124",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r86",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2014 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r297"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r170",
      "r354",
      "r371"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Notes 6, 7 and 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared on common stock"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 200,000,000 authorized as of December 31, 2019 and December 31, 2018; 124,267,358 and 121,482,671 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment and purchased software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r111",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit and other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Common stock issued on conversion of convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r18",
      "r178",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of convertible preferred stock converted to shares of common stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r266",
      "r269"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r266",
      "r269"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current federal, state and local, tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r266",
      "r269"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Common stock issued on conversion of convertible notes payable"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt Conversion, Converted Instrument, Rate",
        "terseLabel": "Debt conversion settlement price as a percentage of IPO price per share"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes Payable (2018 Notes)"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued and other current liabilities"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available For Sale Debt Investments by Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Maximum remaining contractual maturities of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Other long term liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r267",
      "r269"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Deferred federal, state and local, tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r32",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance of cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r257",
      "r348",
      "r365"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r45",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r267",
      "r269"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r239",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r240",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r262",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r239",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r239",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent": {
     "auth_ref": [
      "r245",
      "r246",
      "r259"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation allowance of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.",
        "label": "Deferred Tax Assets, Valuation Allowance, Noncurrent",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r240",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r240",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contribution expenses"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r84",
      "r163"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r187",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure Text Block [Abstract]",
        "terseLabel": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss and Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period of recognized compensation cost",
        "verboseLabel": "Weighted-average period recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options to purchase common stock",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of equity issued in a business combination.",
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "terseLabel": "Share issued in connection with asset acquisition, fair value"
       }
      }
     },
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r28",
      "r79",
      "r92",
      "r144",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments and Variable Interest Entities"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExecutiveOfficerMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One of the ranking officers of the entity, appointed to the position by the board of directors.",
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r293",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r287",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r196",
      "r288",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r196",
      "r288",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r196",
      "r288",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r196",
      "r288",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r286",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r286",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r152",
      "r155",
      "r158",
      "r160",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails",
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r158",
      "r332"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r152",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails",
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Fixtures and Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r161",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r100",
      "r345",
      "r356",
      "r374"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r120",
      "r271"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Benefit for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails",
      "http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r243",
      "r244",
      "r255",
      "r256",
      "r261",
      "r273",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r242",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r93",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r93",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "calculation": {
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInNotesPayableCurrent": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.",
        "label": "Increase (Decrease) in Notes Payable, Current",
        "terseLabel": "Change in fair value of convertible notes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r150",
      "r156"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r60",
      "r118",
      "r298",
      "r300",
      "r359"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization/accretion on investment securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r92",
      "r136",
      "r141",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets",
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r304",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Estimated incremental borrowing rate of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, extended term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r349",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value of notes"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r55",
      "r57",
      "r62",
      "r85",
      "r104",
      "r357",
      "r373"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RecentAccountingGuidance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating, investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets",
      "http://allogene.com/role/LeasesAdditionalInformationDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r313",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Net unrealized gain on available-for-sale investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r51",
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r67",
      "r375"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r37"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "allo_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r28",
      "r372"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r1",
      "r4"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments, Available-for-sale Securities",
        "terseLabel": "Other than temporary impairment losses of available-for-sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.",
        "label": "Payments for Leasing Costs, Commissions, and Tenant Improvements",
        "negatedLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "PaymentsForLeasingCostsCommissionsAndTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r71",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedLabel": "Cash received for amounts related to tenant improvement allowances from lessors"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.",
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsForUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Net issuance cost on equity"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAssetsInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.",
        "label": "Payments to Acquire Assets, Investing Activities",
        "negatedLabel": "Cash paid for acquisition of assets"
       }
      }
     },
     "localname": "PaymentsToAcquireAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Purchase of stock in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Acquired in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in Notch"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Convertible Preferred stock per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsParenthetical",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2019 and December 31, 2018, respectively; no shares were issued and outstanding as of December 31, 2019 and December 31, 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r2",
      "r4",
      "r147",
      "r148"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of commissions and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r75",
      "r230"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from issuance of common stock and upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of investments classified as other.",
        "label": "Proceeds from Sale of Other Investments",
        "terseLabel": "Proceeds from sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r55",
      "r57",
      "r78",
      "r121",
      "r122",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Disposal of property, plant, and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r92",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r164"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r166",
      "r370"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r92",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Receivables from Stockholder [Member]",
        "terseLabel": "Notes Receivable from\u00a0Common Stockholders"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r65",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Related party costs"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r194",
      "r319",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transaction, expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r194",
      "r319",
      "r321",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "verboseLabel": "Lab Supplies"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Assets Acquired Other than Through Business Combination [Line Items]",
        "terseLabel": "Research and Development Assets Acquired Other than Through Business Combination [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r236",
      "r384"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r92",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r91",
      "r381"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units subject to vesting",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r185",
      "r368"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r133",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r360",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/InvestmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossandNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r201",
      "r224",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r201",
      "r224",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Unvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r95",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures of the amount of capitalized costs of a research and development nature acquired in a transaction other than a business combination, amount of costs charged to expense during the period, and identification of the income statement caption in which the charge is reflected.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]",
        "terseLabel": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r202",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r205",
      "r215",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r96",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r254",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Information [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://allogene.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units, weighted average grant date fair value, grants (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock units, unvested, ending balance (in shares)",
        "periodStartLabel": "Restricted stock units, unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Restricted stock units, weighted average grant date fair value, ending balance (in dollars per share)",
        "periodStartLabel": "Restricted stock units, weighted average grant date fair value, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Restricted stock units, unvested, weighted average remaining vesting life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock units, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units, weighted average grant date fair value, vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Expected risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Expected risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated weighted average grant date fair value of employee options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r207",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "periodStartLabel": "Number of options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost",
        "terseLabel": "Compensation cost resulting from the modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r200",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "auth_ref": [
      "r199",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy election for determining compensation cost for share-based payments by either estimating number of forfeitures expected to occur or by recognizing effect of forfeitures when they occur.",
        "label": "Share-based Compensation, Forfeitures [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "periodEndLabel": "Restricted stock units, aggregate intrinsic value, ending balance",
        "periodStartLabel": "Restricted stock units, aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r222",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails",
      "http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Number of shares unvested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Restricted stock units, weighted average grant date fair value, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of vested shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r13",
      "r350",
      "r351",
      "r353",
      "r366"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-term Lease Commitment, Amount",
        "terseLabel": "Short tem lease total commitment"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r18",
      "r19",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "verboseLabel": "Share issued in connection with asset acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r177",
      "r178",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Number of 2018 Notes converted into common stock (in shares)",
        "verboseLabel": "Issuance of common stock upon conversion of convertible stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r178",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "negatedLabel": "Conversion of Series A convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r185",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, options exercised (in shares)",
        "terseLabel": "Issuance of common stock for exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r44",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of Series A convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock issued, value",
        "verboseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for early exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r125"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Common stock forward split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r311",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails",
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails",
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Summary of Operating Loss Carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Related party transaction, expenses from transactions with related party"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate monetary value of a new issue of securities which have been allocated to investors to buy. When security is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the security to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Subscribed but Unissued, Subscriptions Receivable",
        "terseLabel": "Subscriptions receivable"
       }
      }
     },
     "localname": "TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635 and $84"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r192",
      "r196",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r241",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions to tax position of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions to tax position of prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of the applicable statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r109",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeasePayment": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.",
        "label": "Variable Lease, Payment",
        "terseLabel": "Variable lease payments"
       }
      }
     },
     "localname": "VariableLeasePayment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.M)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4549-113899"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(m)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31928-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918705-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2,12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "305",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r388": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r389": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r391": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790532464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current federal, state and local, tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred federal, state and local, tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (331)<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606567952">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_UnrecognizedTaxBenefits</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782926912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_EstimatedLifeOfAssetsTableTextBlock', window );">Estimated Life Of Assets</a></td>
<td class="text">The Company has determined the estimated life of assets to be as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:68.717%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:27.283%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and purchased software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 - 5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixtures and furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_EstimatedLifeOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated life of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_EstimatedLifeOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001737287-20-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-20-000012-xbrl.zip
M4$L#!!0    ( .* 6U!'BNH+,;4$ +M",P 1    86QL;RTR,#$Y,3(S,2YH
M=&WLO6MW$\FR+?I]_PHN>YQ[[AEC%>0C\L7JQ1EN7H<^V.9A8-E?>D1F1MHR
MLN0ER6#[U]](^8%-0V.#;%4)K;W;2*I252GGS(@9^8CX[7\?[O7O?*31N#<<
M_.NNO"?NWOG?#W_[?YKFW[^_?G'G\3 =[-%@<N?1B'!"^<ZGWF3GSOM,XP]W
MRFBX=^?]</2A]Q&;9OJ=1\/]HU%O>V=R1PDEOC@X>I!]MBAU:*37N8'B91.
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M]$L"M1"SH+S7RGAO&"7M9/ B(!A'X(!=1P<2KSP??*3QI'[IK^6]K[F-Z>=
MF6$N"N$U&&G YSJ1XX,#KR.IB"5"S!THI_!WH/S8(HRV8$,U'UM@QXB,44'%
M,(0B7 0KE)6J WE"_@Z;#B?D!U,2<8>Q8 BDRK4+H9\F_Q$A4@<RE_X],+.+
MPMN"&&5*'+* XJ@74.4@BF"M68(,11K=@8J;?VOF.IR.C9)SK/Y)..Y!E$-P
M*CADNV<\PR1#^Y5<:U3![*2:C3:YD%0I 5A7^Q 4\1NE.&+327<@P/][5=#%
M[3?1*&5S]H0D6*V9H 6'.Z)P],-:S9>N8W+[2FUVV&2KDG%%IF!K2BZ-B@.<
M4K00A;$QHMO8='@%AQ?.IERL@,@A3O"!NXVFXD-)&J+J>*=ICU*;X2A!T1%U
MUCGY %004]9&ZKK).BB!'=#6+T=#_KV3HY=];@*&XLE_#GK[]1J_'_T5PA?<
ML6AGV,_/]_9'#.9T9*<CT@THQN(+%!/Y#[NA9 49*8M#!*TZ(-U:#M4,Q8/P
M4<2(+EL-55MCL!P!64@1L^M"HNPK087]_O#!"XS5$ Y'1^?G=*1#Z1PU"BD#
MBV_PF@(H4#G*PKY+>=6!B=GVHC3#-$O&&T5>%&\T<'@4+%FIR*+S427L0 7/
M:YF]1RPH)J.#5)7%\P%_=7M$XZZX*.VCJZ&KR$#@C6<K*'PQV@2?R.4.K =K
M.U8S7)1JP>5@E;$R 40?351!.E#1EEKD84'ZU=3Z/1KN[1],:'1^!I_]\F"4
M=EABY#?#,OF$(^I('Z.HL@:+Q:@,)D>?4*%04OAL2Q0=&"SJ$FXS]&,NN&*"
M2*X(< $#VN",\475+8G4@3'Q:]G&IP>C06]R,"(^\6GOL+[JBA=3NM8)M^S$
M@@1C0AT*K)N?8X8$!3NPVJ'=2,UP78KPM;H#<7^*X%+TEIV:\T$K:ZT7'="&
M3WO<]O2B]Y'R\P$WPW8O]FFZ8'?\^]$J[@Y'%Q;N3FUB/;C')^7WP]&',ARE
MKC@N*ZV(X-':)&LF"J]EQIQRD:'D;F3N:SM8,URT;##JH'2(-@,@19&5T+HH
M%AO:NO+GX\H-(85LEEWL1U!C9$:3QSBADT[&[2C.<?M\[+Q%\^=3+T%\=N0'
M()8B1*UC4D8E\-;%7,!XC@ PQ4CQ!&)_!O&R8_X<Q/[J$/O902RE5ED63SX#
M&HL)K/.&BE!9^4"G$,,IQ *T:"O$;R;<!M.9EXKD>GDS&:8/%P!]PZU"XQ7)
M,?G'NCZ#L7TYHD*C$4<*.W@CFN9+@.'* /.I6LP X"B4=8)Q=9%C0NW1*&&+
M5!QE!%/2Z83;$M>?\*B7H/JI?)X:7>&0(B8-2GH?E0.*B"E!--K='E3S:@&6
M?,49*]F_.&!C%%+V&%44T4JC@V@_6:_E9SY/*7,XEF@\?DUCJKL#.,YZ7%?_
M#Z\R#'_E9_OZU5=&(W[,DP[&6(PP33:&+VG$+F_OZ7"T/MFAT?@OXRXKW%*/
M'J_U!C0A&CQ:>;WQB/K]#3X7]X\ZTM\X6+?6)9#:<+ A4R!M@=6-]P$PG"70
M6;*M'6S[_='J2C=Y1E)H%P*")E]K3 87*8@@<K#&EQR7/&L-SVX[&)\9Q9(N
M,@=O63MP+)Y\,L8K6:(J%O1M2H<.4:PMX 6!N@2(*>8(0<N0"J-&7@E1MS/X
M#L5@M3^MEPN=[XO.==(9>_&@3HBN;(^(9FL*^APJY)<<5QUM\".,<3KQR@2Z
M>.3"([TLO6,:/1^D18S\E @DV-UDCNC!2HH!0X9(R13A"KD.T&H\FGP._Y[1
M<)N]_DXOX>G&V30\8#8=/7C[YN>YLV1N>YB;!=32:8XL%;!&Q^1D](%E>DS&
MB=@!YLZ75M_I-V</]^2@S@+BX.V O[6D\DU0N4"27H4Z42+JDHSHI<5L,:H,
MD-!W:)9D:2';,S/C<I2!:0/"*_#2H-'.UUWC4H$5+G1H9F9)J_;,!AEA28L$
M$)2 B!&5+I'ME 5!D8KM@+6Z1<GX#>XL^3LWLVB92466K) B%).1%'!L;9&M
M9%(V=Y^_\Y!N2T+/C= !5*WPQV$0 F1?0C0A2ZF\LE9%UP6#O"176\E5:C8!
M=O<JYPQ>J(C.>Y>B<$9KFT('R/4=:SG%<&TXFNRL['&[)#PQFROC'JX<C"<C
M[/.+05Y/;$E[N#2CB\IT("$":J-!9C 2.52"D$EHITDE2!U@^E7"I;-9D$?#
M?O]D-U^EUB"_Z"6^#,V?9'7NEOB<\9N51:29Y9#;E^+!",UZ4V$Q:'U-HZED
M"C*U=[%YM:.O*Z-.P*IO5_&PMW>P-RNN_"*\G:&3>$W;!_WIAEQNBC?8I_%J
MC_],AH/.K.=/PI:(*:&IR]I8OQJP(68H44M3NA".786^C_J]0=4<%V>>KXA4
M&RC;25/+$M4"66:3BV"*1(=45%+!J% (\X(,@"Z09>SD@&@0X*)2Q3OGP&;M
M3=$Z 64#Q2KK%L2"G=%ID"\3[8KTZJ0%*4K&J&MIFECW;%+(D<V'EEX[E++(
M);0W:SG>T.AC[R:2_<V?6BH+"DY2CFPGHG$>K>(P$Q!SA&BI ]2:;T P9])^
M583/7](M<(\1RI)QE#/HND0M>@C6Z""#33Z@PF6/:7>/^5G2SK#'WG2D//_.
M C%@0:LI!PDJJT!*HT_)"6D ;8N'F3K Y%_-]L]JX.=@T#NA)QV,SFFW=U(=
MY6%O/ 0EW8,G;U^???WLT-G[^OVOZ_0@K8E2HS !M"\ANYQ(!"V2C[H+67%:
MS/9?R&[?3+46:6R4UI9:>\(6B=*K;+V0N03!3%V08:B.L[230T\Q1)FC0"44
M I(,M49;]"+9Q.%E%XK-+!EUX_:G$D"I1-%$ *M2K /B5DL7T&43.Y#Q>4F2
M&\_4)*&P2S*LP)0 0O),%N62*CI98=19#C1V4FTER;4!6AM.TL[)+G$ZF/32
M^/L+6]K V)\V*Q?=U,_(FFP0'=1Z6@9TB5$GD#$Z8EGCO._2Q.V2.BT>R1#D
MR*$J4)0&Z60 H5T=-A<ZD4FFO99INO"0[Y@/^HQHS9XY.5JER<XP?ZX/\M=/
MB=9PCWZ.;&VQ$3&E$.NL6=8!HC5>)005A?(Q&?8K[=>GG3$-,UH%T!;1JC%C
M3#EK5S(@I% HY^2ME1[9SRR]RP_L]OUE9QXN+F$>T4\LQ>JD P7+<9Y()14O
MP5(,D++3,8'+.7O7A27\OUA7^CZ-SSA\:?WGYQ*),Y^+6(K2SY,7X_^4R5]F
M+PXFHP?UP+6G+E(L.EO+$50. #$%$4,MRR5LTBKETT(,PK>W4TY+;%V@QI<U
M@^KA]1L>K?>-\+-*!@]211-<)L<AAPN$9)3#(L!6(=M^R=H&/&98K\Y+R9V!
MLA$%T+ /L]$7[74J!3'$]H]>M@&/&19+,(&#;AM-F:YVA9"U- CH4B;MRUEQ
M)M%M/#8^#6\:#S$;/!P%-E8ID<!:+U4@)B0I@A=&*)7"8MBKF\9C=O:*NP*W
M-0$Y12!4P"1<AB*UB%HXVX'BM6W XZ?LU;E2J^5K6(L.MOOUF?^BV:8_Y_R<
MZ>^ZMGRSJ6Y80I^4J_5C4L@232XHC-$178N+2']G6_1XLC]ZL+;91GPO][=H
M%)&24F"$9&-,Q4BDE'PPW!-;7"SP*OO27PS'*]P-^YVII52R4E(DFXL+H(0+
MPD4RT4'P$K. ]KJCN?:'V?D?(XWU)L:,EOL#BJ"<]-JGR#VCEKCO+ "WV1]F
M&+X$47/Z@4TQ@TX48K:! WX9 L<R9^$D*S7?13C6Z!../MPP%$(URO^T$JA#
M4M]2 /78M3V_86\C -C<%03#7<X2&M3)U:*U/I_-4*C38=4EQ'\_AJ>N/(9W
MB0\_,2Z>O.#8*1I=HH$LR(./I&T648A03(O+_K6F:\[*2F;C%2H7%+*'$K6&
M<"*%R2H35""M3_J2/)^B6$[VS[3SR6L,H%\\]:?*QF45BV*OR#HQ&8HR* J%
MI8J5*4,7-DUW&?%Y;'@%$[6H8[D)P/J:E$%(<"4&C2R-8LO-;5> OIEJX5:7
MD+21-ECNK1:+E@*0I6T"6X(YV<(@Q=D6AEL8_;TNYZ<CKE=>GR]FPWG4X&I*
M&S9C";*.M6)4K:J'F ,$R.TON7+%PGJ=KZO'_%;H93:"%-0"3-I:ZZ85H&-R
M0G6HG$ +(6M!CGWG1<VTD$IV8(+U*9AI\0CNH>1/QZ5N99K]V@R?T<1V]LY*
MGXF8WA!S0/#L=S&F8$.=GCB;N)/M)?9!'/=R#T='=1_@)6*?%WMZN3ZK)2_G
MW>C$M3\:[NT/!_SVB_)2=='-<#!]E)N?,90S*:"9DLDB)/ A@(;HE1.U_&NJ
MB6U"Z%*BRQ6.<?,7\U,;GX8;.\.#,0[RD][V3BT]^;*/W\M_W4E)G34&%W(P
M*(%EF0H!5<S20 ZI"-,%)&]^,=VOSA%!'DLBGP3W]<!N+T2!)A#3(4L''>#(
M-Y \3W._M]\?'A%-;?#Z=#!W$8'4-I=@E2E1.W >T29%V5L9*$(VJOM ON:H
M>=1+$]:A%<JW@]YD_/K-VT4$4Q4RY$T&CBY 80DUKY%'K9&B*=A5R]T;+"WW
M[/)*(C(E"E(NR(+=U)U3"61AQ:XI)&KO@%DK +R9U5TZRA@)5<X($LEKYXLO
M,DL;A?,M7FW2-DQFM^1$24S1)6.*54":8A$6*!$H"P%/,ZJ[)2;?Q\3-<!6D
MSE[F')QDU2F3!U$@<V\QV<BH3VK2N#/_M@3G2E[(7=T+N9EY(3(E"$$2K$V@
MM<2:<*9D@2[4'2JR0]F+VH/D? KW4=8@(@BID75GK0691'&@0O0RH>HNDO.+
M!.<")/>\$- ;!U: RSYFJV41BI$$1="!;'?SQ.]F<BQ)5#790?+!<W">(F;*
M*DEOM)0*3>=TX;P@F9TLM,41A"RU)L%R4'A$#62RM<3Z77=XX.M;CNMDHN+Y
M(-4[?J2%C8M-B27Z7%)->B<A.AUR$0XME90L=M>/M0?8^1328&L9LH[%Y@B!
M SF(=?>4TL1=5H3N!=>W/K!Y(X:4M2* L81"U@2",J+Q)HC X+#X"**S<F,>
ML,QP39:3*02@F@X'+&L_2=(9G1)_3-9U.##[.7RN?->-WJ2N(G@^R+V/O7SP
ME^K)AY0.JKE=+Z67%C-_K.; @3MTYA P 4GAC2 .]WWQ!K-4]E?E4"?!A%(2
M6FF<<!*4%QZBMAXP!>5(^3B'19HWK8LN!B<O#T9I!\>WHX[FL);4:@=)H$LB
MVYK'-^2 J99!J9,019L%C&?F!.]\IO<#AZ4AH&!'#MK&Z%EA29TP6(A)BNZ:
MXK;!.Q]/Z[4ISDM* ) =U6VY$MCA<O-+ MW^E>#?D$M3=)\.#P:91M];.?Q3
M##J[Q\FJSWI"1Y:6DT(,4+)U)H)0.=8=3YEE5U"H^48=-]RW@<O\S;,J-NED
MDDK3^F,IR)K%-D!-D5Z4@(Z;YUL'<2Y&6))RVAHK@Y+L5$V():H02 <K0M"V
M<R,9\S",,RS]#5$:(XM)64-T+'5,SEJJF) $A-RY\;[Y^*F9P8%%I9+9GLD,
M!!BR#)$%:1#%:^A4'>/G@S3<H_,='"^&"3\G4+TP-##-F+W"!N5S*N GA_LU
MF^DB^C!),1>B$)+. #%&=(ZDT=ZZNNNM2R.&K0=X+OXM%9<M>:T,*Q,O5)3"
MT%1R5K5INI3I^4H /Z,!C3@0&>25O-<;],:3FLKM(RUP'TY:&ZM-=K888'B#
MRG6\CR1K&AM-7K0^/%^(Y[-.2WG(BE*PGJVT="&;&)43,1K^ &.'>O'7]-$3
M'/6/GAS61.7CTU'YDW4E-[WO>#[#>@1$IEAOE8.2*1IM*"D;*IPBIP[UUU:!
M.9>>6= X#E1 ^JBY(WKN>S*3+E0"11$ZD!M\WAC>2!P9DW;29@;$9. NA"78
MA)YQTI0!L9MQY)Q@F>&^#*430U-\< %L(<\2!;(!CB4QLX9I;V]IS=:V6UGX
M=3,+8J/* 8W4(N5:\0N31S2V+EDQ1LF6)]=KQ8[T#H,/V>7L:R)Z"S*'D)6(
M&;)(4B1O6EQQ]I?M^3,L$$$N<FPJK)$.V"^':)W24=2EUS(EVRWP?XF>/SOP
M10C"25T2)<T4T$$:#G:$Q9!C"7&YK[UM+)A_A%PP!>/(^.@0(FOW1*P:=5;>
MNY) =Y0RBVLXYD^98)5'#KI]<1$X\@O3O**L-%UPV>DN3&3\PE9F+D,W63C-
M=!$9M6))JCSS!!0D;84D'71'*?.+6)FY4$8%)/9(K%R<A.!2S;CD?,DY@0 V
M/AUP3+>T(O/FK%TGW5/-E  .<Q8^@Y76^^R=CD%",<11<0>(TQY;\RNM <]>
M9 ]U*TX*(%%'9%7C?"B 46ER'7!2O[S%F<^4<3*!PRC)* I0,4>A 9%TBL7;
MJ+I G%_>XLQGQ5"0.4=),M=M"3H%C#H314V$QF*+RQ?^<$GXEZ5W3*.;KKTP
MPP*'R*&*<<9 8EGA:ZJSG%+41D5=E.[ ]NN60O13\QWGE<5R;T1I,AQ]O;;8
MV=&SJURYNI@HR@BI$CCK(7@73?*9P'B=74W@U $-^1WX+UKA^FFO?OB&1A][
MB<8KVR.:K@J;E?%O$P?G+S03V>0Q%R6=889%KTAJBN@XQC6D8P?TPI)=K145
MBK+6+".B# 2EYET2)2NIR(-V8+J4>:D5['HQ'&QOT&CO3(S6DA.]:=6IWX\>
M\>-M#T='Z^7YA,[/R%=9"'^AQ'?K^\&5GZ#U&P/F8N_1@%66K*TI<EGHLZ&7
M]?]B]LX7[,*$R;)'+GOD OE('76$:+T264,IY%'6.CPE*)_XQ8(IL$_#U[V/
M-'K$Q#OH3WJ#[1<][B^47_0P]OHGQ95P<+2(0(,U4BFP*1D-WLFZ\%]IDL7K
M&(JDQ1)#[0!Z/HL2-$=/VEARV4$0$,DZH;4C'1CK4$XKO=OV9?BH8ZWKGP8T
M&N_T]B^@N5)*K]^KD+_O379>CF@\O0O;Z$<[/2K73)!V<RYKX^6S1[C?FV#_
MZ?HEOO5ND'"72]3;&:4*B:3J1(\7K-BBHF"EC)9I)9.,)M@.&(LEF3IIO1(
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MHCP)?>FDOHK"*'HM:E-S++)N1:SI?@+\7G.;J1XSR:\F+L=D9^E2#HKXB'Q
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M"M 5,JK'5 *F>887+2;X7"?59*'))XY#Q\O'TINLD+=*@1N&PP:1-1VXI1?
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M;[NW?'_KCV_]LMG>V6VO^N/?:>&\>-@2/(=_O6B]R 42#_+#LC7L-=)_J[/
MCQ8(%(BPY8KNJT49/:<L^29SPP*G^7Q&/CU[,9AT!]6N3/U%Z;\BI^&L-KO;
MR&:UZ3U^"KO7F]^]Q3F6:I5#^K_5]VP/K+ZMTW\U[>W"OCT&^<F.' R["WQ=
M8JDIF4 UF=-$]7]J<GC<C7T$LCSA&@0%;CR+P/>-1#"2VX]%J8L;?2NE/MIN
M[]XE Y92\7VWN-FTMAH[_7JW^>AD7+Z$.XAZXKDN:*?"9G;92OR._5Q=*MQW
M/T_#DEP5)[%6(-H?LV?WDJ._6&B5G:]M[S2_\X ?CV'(IV\M/<OF3Q5 =QPQ
M6T6_>L=ZY=;%C]TF>N$[=FFMZ*AD4]99YCX&3SZ*(=OO-SJOVH_$GW=NY^9S
MJ]W^X>QZYZY5S/NL5*@RZ]?+EM\,<[UM;=GU[N:8ZC^ #A_/5G^OJLZRFJU*
M:SQ8:[0JK;'Y6F.='6LT%GG$,@6YC7K)Z<IL?(NCO>*NK85K_>.D<W]=]=P_
M_>25U55M1958?K"Y4$GES9+*]Y(O9L5!F='UBPH(RHZND';EO+YRU1^I-V>1
M/.Z]P 7QP[G<*N)W)TOM5A&_*N+WJ-;@FQP\Q"*<%F-LZAR:;)5V>0HQ(S0(
M.[]5:9?5=ZQ;">$G((37UD/KU)N/QH_/P#/[\=Q9>6:5QBSLWBAY]7@L^B15
M9N6W/ 65N<Y,^5-2GX^J/M=D(_N_65N-^N[]4J%9OQ L\^=E -9I+;1!OU/%
M_RJ@$8OSW=<4)F))CY*&A+@@>)KG#D%#@";49,+8YG$Z@0.&.S TGW 1"45A
MI\<(^\(3 31*71(N0I,(;']%,'6\!;9 &A??,MF'QYXO($3L6._HB78^WCBV
M8"?P=E\]AY"I^(IFX0IX ('KS5_5,J_"3L\HOX;:WOFRMGD9 M@2S [<,/ (
M-99_H!?7R6]A_,SX#,$V\(>$+2F2\8^?K;&V[4-V RA:M>W=NW^HU=MI]UJ/
MT3_4W>GU[ ?^MK%SRR\;.ZU^^X&__54K[K0>^MMJQ4^7*AYIQ6",MU?N";S#
M>ENEL>R[K:1RN[8_?6ABX[Y=9;]^ 5KI;'POX,_;LY7;)RL27@<2MCL5#2]L
MVL<0\=#(Q%V!D+4-&(2,9+#.EU9,MPY,5^F-2F]4)/P<2/CG '!L/+DC=$1%
M:O?8L'<V1<6"K=]629P\"QKZ]0NH1.;]Z;A9T7%%QT^ CEL5'5=T_ 3HN%W1
M<47'3X"..Q4=5W2\^72,P(H4AX[+Z?G7(BS^FCV\;WG<WF%<4K>S5HWQU?.K
MYU?/KY[_7)^_+C7T/UJI/5[-]_XL":]P'BEH-IJ$%\\"-PHGJR2L?UE'U7IO
MJ0((V;)WX>\U[I2N#O4^8%Q-=:J=WHY=G>H3.=6FM;6[TZF.\XD<I_W?6^V=
M?G6<3^0X__F/?M-N/JB6ISK.]3M.6[4";^TVYF7NAH"#_>H=/)5I%&9=4=Q3
M]O.@?C>? A5J_E:KM=-Z6#S_YSK.U<%E R(>K-BK(]LXY5T=675DU9%51_8T
MCZROC9#^?"!I7:+7&[6=>TZ:2"N^\@*$5A@F=01<2./Z.(P3R_5B#&IOK12Q
MJ]RV*D;V](^S"JI4QUD=9W6<U7%6QUD=Y_>;0D\J=/W3BB?G,<Q$X/X>1C^O
MIO('3)E>8U^[VIQJ<ZK-J3;G&6Y.%4-[@')^'\'7P0A4LS.#G9&!)[::5<BL
M,ONKXZR.LSK.ZCC7^3B[_Z,2:LU^E:9X,J=:,>F3.L[N4AY]4O&SQ]O O[Q(
M^#@C0#H8,(NW5BI@K(HNJ@+"33VR[Z@[J([L%W4^6@]O>JS.K)*,U9%519]/
M\\C6O^BS;.Q?=Z=WSZE_/[47*HDH5NU8L9S&WF-U0CT#[ZQRMJOCK(ZS.L[J
M.-?;X*Z.<PV/\[^K\WQ*Y[E>-9Z;9I6_E8/(\Z459-:YL'Y'^SQ!,WT<.E=5
MU+IR]*LCJXZL.K+JR*HC>SY'5N49GL215>'J!Y98I_XD#$0TL\9R$D;16(PJ
MB-VG&1+[U9OSZQ?PJ ,Z*O*NR+LB[TT^P;4F[^HXJ^-\UL=I_\\Z)S1^]>[\
M^@54VN>1O-K?$S'P)?ROZUV__E_ZC[G6%1]07%7A%2Z]B8RM4WECG8<3$11>
M)M\)NU&R%;X7R/J8_[:;C=_@/3Z7_U_V7OHM]/KI$+W E4'RLM[J&L=#Y]5K
M+A[/][_RXJG=?N2%][0[^)X&>-^O.(Z55EG8R69WI]FFS7QW_<<!<&8P]**)
M=*W!S!IXX32>65Y@V5:8)E8XM)J6(V(9[SR]@VMN[,&]EU'LQ0GL.$]-M-J%
MC*9"JTG&43@9A%G/O#60LS!P+5?,K';3FB("I4*TP<Z=-/;"H&;)KXZ<)I8W
MM/XY2EYU?K,&82"MB8BB\,8:^").GB IM#:6%.8;KUY:^R=_U:R] _C/F_]8
MUUZ4QC5K(A,Q!1*9A/3!\A,L/(5.\(>?UVI[TEOMY/[;6OR_M3_*%Z_/@*7<
M,):6[TV\!#;<RL8FB,0ZP&^.Y;7T+?MEQN'[YQ>6B./0\0BEZL9+QNJ[CL']
MNMK8VG*E@"OP=G:'F+VNF7Q[ \Y_Q8W\G_4Y>KNYVI*?%'TV<_J<+J*T+-!K
M)J=01V74.RU)/EC<D6#^UZ#H?G-EBC9U4KN3$_1KFC1\[Y^MG[G-)W8Y!B6-
M&MT))["9F6+7H';"1>!IR5-9K!L1HSRIP=?3,,+OT>3;M:8B\7!JRXXZFY8%
M=@2+'OQ).(#E7?/58%U(:?S@PON:_66Y2!Q  VX95=3@ZR&\ 2PJMJ8KFC*W
M63)BF,AHP92!)>'+YHN27^%A\$\'G@Q'X-;PY?BA=@V?NC"\AJ@4S1]UC\(M
M^)?-TA_N6/-ZV;J1D03:32)OD*Z$,KAC7=Z$Y:M7B[;(@"^>+%CLR9@!QVO6
MS=ASQG#&<>A?:Q:$O8Y"SUW1H'_"'+,'Q!?):R],8W^&_XQQCCI0!>P?'!6=
M5P(GD$0@=B;P75WS$LFAF)E 6OM[QR?PCJD[JQ&M@'Q"NE1*-R-')':!9Y'Z
M=$H/5.N:(M53E"#,GU+X?:E@5<NFGPG?#T<RD'C_1$[JCO1]>&'8UJDO@)IB
MF:#T1^X&PJ/?N2(1EI,F]7 X5"\,)@/2+] [[85F%I08M'GP6LL-CC"F'[^D
MS?6NY:L;STW&<(J-WUZI VLW.7/^HOR78@#T#3SU2D6.&N8M7BS2* >%'#SM
M:'V)E*,H=K>X<^9_QU%NM8UD?0!;?54G6?A2^#=B%K_XO?#R<[NYL$FW<OGW
M;M-P^'C;1*?J2B>,!!&$!>N2$5Z&;R8V;]$6Z-;AOU[\PVL/!O^?O7=MCMM(
MU@;_"N+,SH04"](B)5GR>/>-H"G+UHQD<27Y>/?3&^CN:C8L--"#"ZF>7[_Y
MY*4N:#0E^<R,*;-/G/"()"Z%JJRLO#SYY.+I-R?%H\)]\V@Y.YE]_>#)@]G3
MY>/')\77CQ]]\[^?T,F/L"!IE/_KJ^*/_['9.;U*^LH5_VMJ:]SBN*@<.Z2X
MH4;[5=DNU,9F2QJ*?5&2JJ2SH9@X=-9T;I0;K'1[25^WV';+H19;VGIB'WO%
MG]@$7;8JKAS93&0,Q?9>@X,N*X:>/OV23D$:0E\>G3\C&XHLD.Q=)J<!751L
MMC2BLJCXT-L4+1T^@X,)0R\JV"3I>IPM-';M:<+?4\S)&J6UV,*#0* 1RZ#_
MEC/C8(:\%H/M](06JZ@&WLQF].4L)CT63FV.B97L5R12;*W433^R,-64S#/Z
MC2T96>279(9T=-;ZQ2*K$Z; T=OS=]YCP-)5Y;R09=I_@N],^+IH+\M:N%*?
MWH8%X!?_M>SIX)]_RJ'[ I9!N<Z^7R[I^^?;NRZB9"G3QGX][YL9*8S3!R=/
M\^SK)W_.[IT\^NKTY#[^Z-V48KXJ'9R-@BS;K\[?E,?9]WC6]@BV-+DPL+OX
MSI,GZ9W7JX9D;^Y*N7OL'+7NDCZJANJ PP@M0G<OJV%1M,6,!IV3ASDGIW/5
M=)L5S<-"=5!M>NWQ*7G(=4/7P%3%+V?-8IO=>WY^=G]JW"_$4":EU>X99?1V
M?M?. .C9])%UM?5>!=G$=4-;G?X*BYH^P?Q6UK;DY=%*68"DQKNZ#7VQ4V^6
MYI']43^/#[XZ>;1G!5Z]>79$'T-^9.*JQY/<N3G[T3B&PE!R]GOXB&8M0.X)
MS/O>90-==X\=&?+P2U8-V9*.'IZH.8D.LJYR5$#/] W)Z'WOL\@3"UK%A40&
M^.\Y_QUO]".?F K_,?J/K)G/AQ;K03)1>)]#']'Q,LJ#>=[+G6D_>_F2W^/]
M.$UQ\ /)ER+Y(H<0+@;IR=YU-''=0-XT8A8-"2>=BC09\U510C8+.8E)CRXK
M>@@B%6O7M]MC'FI+_RTSLGTPL%;\J'Z[X<DBN1Y(X3;DI-$96I,\+41=PZ4L
M'0^/')L5O:JL%JV3Z2@69 YTXNWA2_A<6)"35W=]*P$?>D#;\%G;BF]%XYNY
M_AJ'QYI6:LTO[\K%0/^P@^ >3>__*2O6EMW[CJ2_Y1-A0R)XU_7@+SAZ*\@7
M5K!37[@;+B\=?.E8T7CMPBY[5JYQ6,.C-F<9)S'$8)^:6^J1K-YY9)#Y?7&<
M9;\XD6^Z.AY;<<-HPE!T!"35<S('L">@Z79>NB'9H>>OR;ILL"OHW]<LI+CY
M L(':6'/7VW$Z[*":/UC*%76!U$O'U7%NA/WS,F=E[\I(> 39>%Z-U>K?E8U
MS4*4,@)$3_9$1W-66BL.[2,:Y(KWT4--3W @ZX'X)OCGD^/L=10.M>A.' D3
MY:]>3GR^B)O3K9IK-EI=MJ)OP\;A=]/GOA>;E8Y^J"T?&"9U/6SPAT>0&3*"
M[[P<O-NQ2AI9@.?G7G_H/(\.O6DU<I9U)8VS:+.*OG3?=2QI':0"RTW'M0)$
M2#YVQW'F-VTFHR6M<LW"Q@X.*8A!#JK.6S@Y.2@2'L!36[<N.W_ZM^Z(9$AM
MOB#*0>IP$>LB%;_. N&QU>ICE\UR^>\7HLE88[DFLZ*=_]__Q>X6#>J;D].'
M)__[\N3T^-?-Y7^1]NWW_BT-XSU\\'3S08-X7S]X1/]&N&]G6%^.,_9DVAE[
M)JDDQ$*RBZJH?_?-_Z<E_]]_TNS(+>Q2DU)<E1NQ^]ZZ]JIT;8X3FNT)TK7D
M%R6!F7BSI!L% 2#T-,'%.#_:-;P8;!GR#YJU&ND7*UB%I^- %2YK-CW;D'M.
MZSSK-FY>PH.NJBU;T';8S,B\6)9])S;!#08!N0:56_?#/X=U,8,930-_??3U
M(SJ&W@ZS7^G,,R/&/GUA'[Z.DF'R$2=JGN2_+TK@$Q?]VG'&;QX@6O2E,Q<"
M;HCD- B%EN)$E*Q/)0UC'XH5/_5+?LIB=/K@].23)N _+N>[*OF3-O A@W1S
M!NG)(8-TR" =,DA?4@;ITVTD#=#B6'S\X(15O?UP]KM;2K]WV'IR5C@ !^=)
MTU^3,99-VRP&.GOG=&NY8#>E)T/:L0F##-FQ?R#'5# G$OIL8HMKW51N/L"Q
M6KB.CHP\@U=V1:_M\%^Z?MTLV$02C%#([I1UST,06/[0F9U#LS(LBWD_M!@)
M#9-#-TLSC6@\['!U;O1D?+2,04P'>D99D8#UN)#^YI#J8)\^?4-''^6.R/]>
M,@J+;$!,@_<\R039#!I;E F2 8?!O"S?NQ!7#DM2=;!7C\C&02Z* [8=69,2
M-G8P3L6[X^7HAI:&1#_0!?2"-__/FZ<&;M)T@/A[Y)2V93]\*&$NPHR]K"78
MMB!Q*I'%>K="0 [.J,P:S4G?#G/S.L6?A!C01_A'?4[RZX^YE2[:$NMO26GQ
M/\)4TYQ:.!N3&I(EN.RG'SE""-3?QDGZ5]>V*L@?H''Z<!-['_ZIQ0)A:C-K
M>1?#TX$$A\WGPUD;'N+H'@02_//6!2*,9-PL.1.CH7.5T[. SB+1<K(56[=N
MKE3@+-Q0T])ET!CA%?:4/'M?-]>,]/+J)L=/(=SA8V7+\G*0F&US?9Q%D>6@
MJ#B,RN,0O)89^^GV#8LR3J9Q3AC)GKJ' Z:QNG3ICJ/WD9<DRB>H *>11%-7
M"_+1VDX3.753'\U_>'419?-YD?QS.'?4BL+AO3RT+08*;,)HZFZ)3_;IF6+9
M%[285R5IZN/;,?R/ ,\YH4E[5<&*UQQ%K!5!L.>T=!]6Y:R$X%B,<+XJ6A(.
M&@1Y]'-9\O<DJMC82(/1A&S_/=&U3PZF/;PAF/9P*ICVZ,&3$$Q[NA-,^VR=
M_GM63OP+S*-?FY)U1H!QBQ&"*S7JQ#K+<ID<P"7MJR?HGB=K=@B_K%RQ2'/&
MBRC,QPB58KU?B+[XH.8[MI5H0R[40OMK]A-ITQ^;Q>5[TBDO.:2V+K)[='C>
MO^O&!PP(6&T ,1<,5B-C?8XH&$E<6Y(D%&R7\TFU9B6!]*;$)>=;,MZ/LQ<]
M&RFC(HGH@;#%]=:Y3T3^7+/F>XN#MLOEZ'SR)#]]](#,@&LIC,T0V%P7"KB:
M 5-57-9-AU D23I9O=_0Y0K?"M=*).Y!SABY=B$E-K)[UC1/]'G9N7SBVX8,
M<U*IV6LX#E\_8(.J&V9D<;G$96 G9%D"PHXW([UGUP$M)@#WCL:WA %$,U2[
M9H."3II.F:QRH9"(>^_R[#L$7'_ZN_SFOAP2_+:"3O&.(09]]# & ':" -3?
M"4!$,D#QM-N@:$6^8\AYJ%3P,/RLP==^\^#/'"0F0P@3CB^72>?I._GZSJ<"
M9?YX8LJ^<]4R7NDBPU WR9K8HJ\[65%@!@%0TBLDT="OL"FV@D-A5\V2="JD
MC AE@YQ4-0E[25M,%@>YXXS^7"[HF?1Z3OK=*RX-<GA?JU!63=O#K[LJKPI:
M?X/6L'NI4J%"N2XZDX^RGE?#PO%8@2G0J[/DZNS>LY??G;^\S^4]96]CZH#+
MT0')G^H%N>=U'U[^_.5Q]HP^E#:]VLWZK6[ 'M'0.\II&S[XZ,&/14!3CR=\
M;1:M#PY+^H"AY6B;((S<!X6R%1N:R2M)C&/V/K7@_C-$^Q GOSE._O00)S_$
MR0]Q\L^)DW^IIR8,DC='YS^^OB!OUJT;.]'(/IFQ-4E&RCT?(]D%%N?9HOG0
MM,.LG*/,\HK4.GO# "'+J>@6==DU-1UW4217K4I7M'0VGM(W OS"@4GQHA3^
MB0-ECM,"L30R>_AP-IN2SS9YRY)T^-&6GN;/43OK/) 63WC\^.CK])0Z)L.6
M_M(/P/0"F\RGSP>V3.EE#^5J?I.'\0F2ZZA2D "F2T9!QEQ'UX3#DE&&$NOC
MJ%0-2"W'VCF,Y6'*K8O#ZQ@I &%'C#2P)PEN2/S/J% EJE64"X%A:AU--# '
MC-@MZJ+:HF!RYW1^\]4;FT4?)8,5E 3(HI=)/-A_<Q0R:8:>),8I@KCLXF@X
M/F_3-*UZ#;0N#0,62@XKJC&%B"!S['S]Y^S>^9N_9D_^G#/.0W+Z<M5?LY.G
M?Q9([MJ1(-1L&A<2%I=EIT=\??SP (^3W6TF7'%5E%4Q0Z!TBRGR%52%BLBE
MU-A [-(UZ42T!8=HY3+DGR^!H_>SS@N[+-NN'VV+YR_]O@;VU]M\"K(^SE[!
M&?)2:8+7-\!8,LI_8,R,XJYW]IF-56(IAIKK!#9G?YH!Q<,6)ST>QB8]D*UN
MQ&Y^KGK=[7D8A]X!3'AG &%6CT?E>CW4C?\^"]IPA,A7\NMH90.!3N#4!%(K
M*;JTL,D%3@GQ"^EQM*-X;;L8)\1AI33U$&MM]B\% FU5%G[V96V'>NUZWCQP
M\VNGBI%4JXN3&@ TT=SEY*4#N<3?)VFO)AJZ#D!\<U8#9??1.?M,:,OOO;\^
M-_]\;E&\6P?6^]U4T8,G9FB<O;SX48.?6@V BOXCTDR.'%_%II$3BBV*X,HZ
M%TTE;M.XJD:*!#V4KBN6KA=7G XLUT;J+LJ12;G(Q#DXZ6[GZF?C'7I0TBZ
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MT'D+& >0Q3UK&K# @\Z$OTG.%YA(E=D^F4'WP>V22;3SLFIF WW"D0R'2Q2
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M:/EB71?0+ZT=Z9.Z1 ''O6=%^\^B<A_R['OF:J;ERK/G1;M=%._O1Z5!OKH
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M>:6SC1*W<'.NI<MPQCOGP;=>W/CGDV\/_'?_TI-E%+'&H<(-%?PQD?LM;CW
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M'<=D5L_=K%4VJVGL0<6ES(S336'@)T]S&FO6@7B,+G"N3_+Y2'[W[JA9'I'
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MH3F'(NOZECF:0HI-^ F,%7TDV/F.23 ?Z.PGFY./?8'C)(?^.QSZ=JBKSQE
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MC*$0\;5EY;/'6F.X"\_U4%Q?#BT\GF@8IALXTQ;3WK!"N ;=<7LRT5MAJVW
MD(P\J/PEZM[9D<6W(#O^L,N^E%WV\,O895,)&PY.HALB;R"C /5[0*0SHB4-
M](**.\[C/<7=SN%B%8Q/G]BEC+L"]=S&CJD%F(O;W52W0+6LB?&4C>IQ\#L
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M5NP><GG:.]P3=WC(FK48UZJCR(H+8<J]-J.8-WA>5+S#CS8\4Q1*FV"6S-,
MU)BG+;<\KEK.L:G;U",Z >=Q6=;G*#63\E"%9I%OOL,Z-U7N2@(HD0..KXO9
M1L;\EU$@<Y*PTRV71E[=QPS(M=(2L-7I312L%,-,Q?:P4E^VS9:E#3B7DC_R
MW^AW:*HAX-HZ:CEE6-5+>D&O""L>% K_D >(W?V[OL%^]A5"%R2L\[;<L/ P
M->W/]-#LN3/"V6<_/P<O+=!S:PZE*S8YWE#P=L2_$QAR$M(;\+RE<R'&4BQ^
M';I>/!%^OK]&R@;Q_QRRYG4[UFNB6L,NND;;(.'NI.U+Y <=\^=<%^C#R'$
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MR$BZDG+7-(>I'Q9[#AU=6RRT_[P<"YQZ$@SV\:X\1!5F-DR/&O7'AW6*Y5<
MTZ-GEJQ-4O(MH24V+Q)FRB:&S]8-TY^UW-.KF[?.^9I2#9.-W??9IZBN8 ":
M$FMJYQO*)MSI76)8%%-U@$AC)^0M$YL1F"1!5.SHG'%=.V>G3?DPJ2@DR*X,
M#V8(2.AV8U'0H4TB0*,V/_ CT>B^=IY &P%#Q5T5@'))M;C5GDKKO2QNO>>%
M"@\8]?2[\T?G3TV/!??UU2.'E@N/-?++P";IPQC3G4<>%+DY)3K<<'Y_#H2U
M%T&8,#Z+++RX6_8O(_"K459(]W6SR;E6PD7A6[+FF4W.(O.,1YI"!O.YQ-E.
M-=8ZJX*/!PWMUY)VT0^TEGM<9H4XU[6++A%;?2T$HMX<U$B+?+-\8M1IR3Z?
MA+9D0@?Q##&'8Q.%U501HCE:'.ZTQY),YX*CL#.NC*Y\O;N5IP!8@>;T\ZCE
M)K]=JF7*$?$8SH'TEG"==10J:YQ_6!3WH<#(<E4 W/W)<@5SFJQ+)R;ZNOCU
MAENB:,UHV<;:,4KK[$Z&+)ZE4=0A= OK>A5D+U(Z7#F. @@^?D"LM^/E2F=$
M<V036>0%OV%Y4%F()50/('HO#56;@ULXRA8FMZ:,AA;7!=VW*+JD\L8\[K$U
M_I([K]MXL:*F9(XI=B9ZVOGETM:KVEA4J\_@Y/K=%==\2;E,9SC0$!"7P!'<
M>2Z2QKI?@T<O/-2L/G&'S5DU>;<,(PP+-[+=(]Z76(N%5GELGVE> H=<$8W+
M-VWC00.-50PR8+0=E;T4HYK3.I@D6J9,CC9T;X2'$! 2$#ZGF7:ZE432C$]H
MZ>3&7=X",PLSI7 R5EQQCFU(KSVR=O,8A'^ #7TF;.C) 39T@ T=8$-?$FSH
MYG,N'#!\NH@]R%VHM8 CLE]"B=ST^8$FY!&RY5]0[!<[_%9QJM3:4X <G]-)
MVR9)5JJ6+JO!G9;8P-!>.;*?V7W5''\7$]M9A%UPN#YYD69L.,+-N/YP H,Q
MZ#>"5[\X8RF6C, *>^$698$3/GMC-27?DZ303 KDX\WWC/A@%X,Y@C;:9)C%
M(D2]E69*?*R47'W?0D]5X4LTHRC7;*8$>PM&.]/GJ:^Z\<,F:SL4)/M:?>O[
MH$7X$DM-*'K9=V%*PNE'*<?31.28DQ')UZ26$Z..8-_3]N&^N,*M%+G<QI:.
ME%;<#5=A*<>[ML\?JOGX:P&8,,+HF>)5:&;NNCL3@%CQ!)W-^U23BW@9LB=,
MGVQ(0'WBQ'525L_ET;"Y$3U15X<;()M-;VY+&7<2+B8O5=B=,G$LW;6$+^KL
M],&#G&8J86><ZE6<^P#G9]UF31["WA1VL[J)B1RE4*L( Q7/J^,HN (P33%H
M-CE!?DV\=G=J16$A?+Z5LWARG@R,B! &R((TH-45E=OSA<O&(D&C-QZ;9/ ?
MXK4/Z!F&(00\JV)C?.3Y. N 6D@42U,"%(N?*Y+'H@!14A2&*>X^JJ/G*B2)
M'B(&YC/3^N!!TSHT0_-*D"I,WP9 YBA:M6<H(;I(4WO%X6*0(N$T0%I<&>^[
M%6E]I5A:#)ZD+E=4@H\,&!*GW<$&'*(J<51%+:>] L+P)N&/8YR8QF "YC%!
M7]L);_LD;.-2WL+9_1WYBPF$(("5:#,=DOU5J9&O& NDO8E=$<<)38,FR?=Z
MF_:EUCA*4GZ+8UJR-HW:SB%0/-(&^MM@NWB:L#K;DGT%.K /C&X&^X!&H$;X
M4L,X%!#G:P6@ARS0P"7+C,@*E,D^[9NL5#0GJ>Z(_A VEJ7K,$^LH^*LE8^;
M[].#%CB?/%:2*Z;N3UXP\0C26XR!PU-DO8R0ERDD]T@G<Q\6'[(YJ=U2*=L"
M/ZM1V#)2*@7RPJZ-@\8>N'S7M<-9C#".ISWJGP(=L$\, \#5NVFR_(/U(0&(
ML&V*A=D3:>@UU1GZLL6$.33RA6T(+G)^E8UZ\@RV&#%,AC* @E ,/\W*8+#7
M9=,F(GA=X&&<]ZJD+E8!F*$&?0R@&,2&B>!/PU*2!7U<6CQRGZ";G&HFX)2Z
MA /'I[KWVGZ?Z0?_WF+ZN4[']Q_@Z&&%GX7Z&][[6GYUH8&%N[[#S95E&'"V
M+ ":: N0%FMUA>W2A+!+9S?J8VJD>W$!?>"OKFFT:7R&A==G-C15?)R]->B2
M5$/$MT&2755>,C<@P['#8.,M*-MLN\,R9NZ0H2=O8/%,37I)6<=%UG$+.>Q;
M2?G13EZ[7E&0E>[*L1&4GG+/IS^!SR+G>R0H5?@4],O2WSZEM4]W>K"V%)LM
MCJ$!_R&MM<;K+O5CL0UE@-UH66D>YQ[N:X<HEUZA-SQSI# '6]Q9S!,_Q G:
MJ'U;;CK2T):!D-LS*P;[8Z<.8V)$$<#MLG6*IY%ZLZGQRU+OJGO_<E\2('BA
M,/TZ7F;!J7T =A%5\PP;,:!'@Q;#N4O;!A]:7I+M46^#,$YV!8F3^:D-GYC(
MQ1Y-D8=&=K.1:M':"W+T63SP,A^)GE2$B]$I8Q!],^XW9L/';4])D"KM8AMB
M^F>) Q0/:OP,L:V@N'<TDE$B[@8O,X. 2M/INLF2MM9%1<)?%\F5[D/927U$
M6MY7KMFDXV]6J\HS\N6D\(K+NNE*RTTSAXD2FGAMR,6#FG402RT*Y(]PN@4M
M_WK#EL^"MM8\J3E"@\.AG0>=&=5&:#E"7(['WQ*=+K&9.SG5PHTI<#5D/M)#
M3Z[:8?T8TSXGJSF]^A=VVJF:-FU7MOL#ZYA[S#MK]X\?;EUR!G6:+Q(S?FI0
MHK@*KQ='8;:81TGF2!"-$):AI4TCK607W 3!6Q,^>+>E<;YW3((-*5D -^&=
M7W7ZV*%,VV2F#]0ZXS4]E!&JY.G1^:D>1=E"^%KA%%XW[:Q<: OV-9API)KH
MD\:5?-XG/#:T5MC]HE["D +HG<])[>I)@X?RD,ATY__5[0.BM;F'CZ36">-=
M)*#I^\M7T';,)AGM:-N>@&9U"3#*9](,/S,)12GB.HC=&&E4A",2Q=IX2J8V
MKI7V.09YYR(S5U5'"N5$U ?9RZ.)[*76R^_)?P9"*AUZ)]&5$0AL<E2M"\RH
M4L._;E3#F%?7I6 ?I<<35L)B[NLE(R*!" )4%4--MXXP0/_JD_X F;D9,O/T
M )DY0&8.D)G/@<Q\J4[$&R>933[^7EEAY!D226@2\DY-W'MO7IV]N[\3R?,E
M)@*SYOI7Y"Y/GHR,0+$,-&@7^P*>HP( :FGIJ!Z#KPX7 F,^2GUDQ!K,^;[/
M&B#Y:W;OY#ZL_L $RV<;AA]E<Y6.3\\]E/>H+9\G63PKI*DOZ6IGA6SB<(7B
MI;@TR/_92'FCR(2OFY-&"(.F:XM-Z=0'L)HS]LHL&R+Y$5BBWV;W3N]KK&(G
M<(.RD46YA%W$9I?C,<RE9^7GAG2^Y6^Z]_!^U#YB&QF7\)U@;&DP)8X$\#I-
M^EP?BP)IQ_;I0! 6,!$_'_D([_ ID+A>7'+JRU:R<BP\# CF.8; LKO4S0>%
MYR3"616U#Z=,TBNJRR)&)<=^-+83N;$C7RGR88R09^?C]OK=DU:9<A]).$G(
MG;UCT;12SK%F6$_D:-QHR >F]TE7 S+!Z#/V?!:[Y2D%YQII'I8#K?"PGDDJ
MB2NVTL:@4CO&314Z0VU$K*?2)8&Y)RQ!$JK2C#(R,FV1 (43UB-+N22OV+/?
M)Z3^2967H+\F9];&MQM.V]D+^8[Y/55TG0>7Q_QQKCD"VJEIJT786A888>[+
MMJ$G>[YBKODB;1"/;@Z/P(?(*C1MX?VS+%&ZA,@%EJDCS?FM9!_EUG1:(OYF
MI=D/-?&L,"(.DMY7RI9-&^I_BD.-V7>PB:.UX6E* O"^R>-$H&RL@T*P+")-
M,WW+$?N;E/N8H2(>AA[8W@F\6=6K>[NC!>ETKK0\4PHK_7DGZ7>6=69<XD\Q
M3YB1LCYED/#[)'$SIE<-'FM )=G$,O?;;G4HNBG$=9:J]B(X0<+0YAME6"^E
M9L;T*Q(JX=XO4\TLCK./+C;-B-/3)BIWBK/U^X*ODZ -S]I;;(6]:"I*'R4A
M)A(.48?J*,I5,*\$(ITEYQE"L+B6U !/CS\U&U\T(Z0.2?8A595,PA^-,&$E
M\LVZMZ:I0[EQE!L8<11)+1P8\YE+7@_6NZYX.%GV;E>01@9(+O8&[\:/2>^B
M$8P9%SN* *)TMFC59O-'!XAKN.QOGQ[[)&S9'RK%SGV$/(/IF\CDN.N"&F6N
MNB@+>^U\G#W&R:EN"KQERLLC9K9Q($3 R4A[37.%B05UI%7SH[;U23->WTK'
M=U>*L",QDR@=DU9/+@D9T,]O%FPSI8D)H;]*BLKM4.U0.VPXW(3')QVB[SB]
MQ<5>)_MHK +\:>BDSW>_4-U@\8^2&<+QF.QO220=]0W"SMVPAJ$<GING]9#B
ME6$(P5'VM:&=6@B[;=/T=+,2=JOW'A=F^DH9CY3BI][S+:RY_]Z#;YOE\HAK
M./%W_MW)M_=S<:<+/U#:+0,-?7ND!RH?8:64'<]EJ>BEUL$[;C(E!EGD/RCA
MI ^$AXNC[ND"VT*FP8';J@*[T27<W4  !?5II:(XU;BI?6+SQ*4A!<[6Z$L]
M-, _L%,F0S9X(EB4$9HIWS[-\JKLOL+^ *.=XW,;SH ZZ+\.BTO)6!8I-,L@
M;@H!];/@TH&1Y?EC<XV81*ZQ"_;0M(<EBE-61@(TQ2]*EM'0K^!'8N+Y?657
MN6(AV:'  &P9JH@1:+Q3=T7HT/1NJAYJQ!JB90$[?$Z+H;6>"T:5INJ94U?B
M$YHME]Z?TJPP!#\XW1'[CHN;SOEV#^,2<66+"G0XEI.;4OY3'V>_"RS,4?<3
M<:];83]8")\CNV[6)$0=<BV2%RZFU+QM9I6QY*&3J^^99235K:3K$>8D$\V*
MZIGH@S[M.'L5[;N$]3#T58&B"3ISS(.='":318'8@QZ4$W,%27)]1"8TI@KR
M>[>3<*_V]1-M.3J^I<44:=FA1J>4H99NU,ST(\7YVT]XM("7IVC#PO14Q342
MN<RV2>L&S,$ZF<D=V14^GIB')]]#Q!-YX[;28\EBS$8IA8 \LC#<X^Q9V7$!
MS%8?1'MD;7YB0*^E.T/2S6!0SP2QG9R]13!(XJ_DD-.JJ182@ROJL/B,__JX
MK51(69X1;Q35: .&AI-R%(SRSLJ48L"3Z>XW+"/\.9R7YJT,/U0 9TR2A*')
M_ ?//DKX\UORM+J78U-)S84ZD@+U [L8ZR# _5ZGD*;1J,<;)BI+X-:Y#):)
M2S2E^611KK$)L L1\8EV@=4&![;;A%+^SA](!FV2;GVCDNT(]*"5T7GF[4 K
MS?9_V2F:'M5*^YA/NCO\\3+:JK18S=!5:!0H[]RW>_7Q2S+?^#1KU&C7Z\+9
M&(7A1+TBCLT%VK6[E-0<K!I.88PIU]5!D?HQQL.0P5;.I=@LJ?*]0O2?I'_N
MQ)Q3;A3EUNG"+F87:@TW@*MQY'1B]%/D4HCV#8RE^O5T_J$]J?HH9 ?S,,BD
M77,K*-K(1:5V=.1V'$-LI%VR505RW0"'#X('U;0C9!>G'F+AB'9M\7&K+TU%
M!%YMK#/VLV>/\1R)*;L,;]BQ?+*E;XK% ^PBHM4#+.4WPE*^.<!2#K"4 RSE
MC\/D$O%<*305YCHI5*EL$2+;M610XP!6K+65E0M<C/0SGV&XMX+[4D4P]IF+
MT2J^!)/..G\^;!H<H5KM9O9DC&5<D%[>1G#M*7(U5O9#U()$TLMQTNB/'?;F
M'EZOO'WV?2AV/)BT+OO.\I_9!3D[CO;P>N/Z@%1^01[QE5@-S#CSW<7YB[/[
MUF"(19:[EL+ &4CZ6[1E-6\Y8N'LI!5QQ@AL3;Z5^NPK%Z=A8<4U-1E?WH"F
M/^KMV(YLM&*(7+CMA!PB:2 6KA>'6KNJ)(D^^-:V_9@38=U4;HZ$(;UP1;/$
M"5MYB+:&,&M-AQW!J%-/=<3.BTG&I.7D]&K8<5:T72B*24NYH\'O],(X.94B
M=?/#ZXFQ[$"Z76CF';R44,#P#@P9)Z='>+"&0CP'3EP8;#KK@V($9IB?#_!;
M^I6VN0"S4"^+<')Z_-@*ZJ/Z7*W"3;JEVP=(7ZJM$2-'Q#\^TQT"57'^]M^%
MRO[2MO,S'Y9@&%3 M>>!:T.XO*7TT$_@N 4??J?-,**3(T LE(?,_LX*=E/T
M>A8N#4:63Y;1&(Q0;N .Y")4G)X/S%?,KC.MDR[DUG>X]0T)A+6^A8*"['WS
M]%&D1D9$:7CVCVA4?/1+\0&0R3/K$SC^K2*W.F[[TLOQ&E[& Z>W#1MIW$1*
M3.6]Z$1%U5TH7HJ_EHO6%T,,W]Q!V(0-,^9$L5QU2&+$SXY'J'V?9<=JV=-:
MB+K]Z/VGS=RV8:*%L(4?J;+Q?OBT_PH$"CU#.>WWC$452T)<U$""BVIIDHHH
M6'_ME!XF%, QME%B(>!%]R6< =3AKV"TR89TUO0S]][B:W*275 D/>$ ^Y-1
MVU=&$9/1$;&O(I _S M[]-:DTBV]RG>=]A65'N(F%VY*3Z2CV)7>]QC@O:G[
M!:][UQ8+AV,@>XW,+[)TC+J!O1JAI'S4Q3=%\Z% I8_9J<Y#"GUR2S/VQTN"
M-ABCZ1@0#<Z19#<:<.&&PY,5NQH)D) E^,=SS6?M55  9)')(,$:&AT-P"N:
M3I&<]A0@TTSHL<?U"?%T"IIL)]@KW%6(VG"'*Q_O'3.@^ZB_E&KNYD2T9Z;>
M[[GS#J7$__6_ NUAPDV"60V5OI+J\OI1T[[)#1/4(<?9Y,/3@XL$I8O,&\G$
ME$)Y&;] U)HL=B2>G9I5](0C?L(4^U$[U)%NA?#[L%SRBK;I#4B;G"/^>#74
MMK0!42DE41OJOFA];T)?RAOL*NDP09-TZWR\FZ5CW*Z.1DK*ZDBXWPUV\4L+
M95DSSHGTB (O8F _?_X?W/F5)!*? C\R6ANMVK*7A:KT\Y"O/.#!$O#!CM[(
M^:")L#1%&]63P%N,&UG&*+"K0O#02[> Y9-;XA@];QJ<&.HX:^(\1/T#<T(<
M8@*R$79=X,>7>H-S#IJ+H\B%4QC@7XKUYEO]L:1/<>U5"1#+O?-7;^_GAH:F
M3^IBCXKEA=R)HNT-!2O2PX/^D2N-PJ-^_/'M_>R>.[X\EH&(98&;7D@2G0;T
M@UA]^;['_XV,'-QT[]GKO]W/M<V),4W*#6<]/0B-:!I^?F==M-A9>/TW3:N-
MIC:$[+K[TE?+-\3 <EI77]*R6-EQ+JO>FH&1L)&)Z2(4D7GL5-<Q:.NK&+ E
MK*">DD(U=XQOB%-Q;&#14XZ6;3%(E\=B!H^,@P3)4KUM.+7VULVE":CG(UV2
M$:)DO1T##W(S#J7F#?X]&9)7A;;D[.P)N^_0M7]1&QCE @7SBGW!O6=2#V^_
MXD#1CR\NSL!-+#VR2!;1HF47-FBQ#EZXW#:$<(C2GJQUZ$P%'!I;WWD#";:]
MZI/L#)+R]W+^'H-D;37T+"JK<E;VW32,@NUU4A=B5CAMW\KF".)NC$Z1&O^R
MJJ2W9P,"0.GJ5&SY?SL.4/>:?HT8!)A09SU((2<BWH+;K+8"NK2?<BZGT%_/
M]=_BDA3=2@&:[TMT_F*8$FTH*^QH'>U!]:T'VIB%X#\KI_\@ T$*).&;M"2#
MW!+3U\[)+4YNX&?R#<;83HJ5[*O+IJ$W:]4HC[$3I4=O+]>SH>VD*H!C%J9R
M\Z!M?6F5K=0J',&F"L1-4W\YS!A7+#(;NF]^! L/Q'M2&6?5A#1:7E*,G/N5
MR -OEHW)AWO7"__@&=/DOWG0FU71KHLYEZ)R,#%&+FG9RXIUE?8+9N H(B(V
MW:T$"M?HS:>-2IWEYF6F8GIAQCEY-CU1]'P5?V(KC+5%7,['GP=?(-2H*CS6
M>PE,L$,?,H-'9K8URE\1T)*847S(\X:@RZ =Q7U]QRY@\OCDF<S?UQ;7=5;3
M+#;7NHTL&Z^=9B*@6%FK[($S%5LL,OE1FZD'DQ61L@^9RHI4(<N10J:(NY35
MG*5T:KI]DN8O8>OH!I8N3H(IW&K4P:P:NHWFH-YZPC8MQI#2YJVA@/WD\(8)
M4P/R- \\83:YJ/XH09MH7*KMT;DYQ,&QUR:66$8^M<"!.G7-+:=6+@HN8S-G
M9<6@YBCL.+EA$+3H>E=H8RF^)\)]1KO%TTE;5\*%\N"0]!_-MD?X7^-9,W>-
M_CJL!T%81*5U.CO,BUK,M?M? D4^SEYS>-8DQ #0RL8_9^Z@\4PG7=XBYU*K
M3C]OAN_\.;S;+TV[>5K90B1:-^ODZV#=&.#T0FVUB[!*;&T!^[G@[7 .;:-A
M[],')P_R;/<I:KWQI;C]>S-+R>5#7SXZW)+PN3S'ZG>OG'W8Q&MSP35IJ^<V
M?+22"4B%YLC* (490-1TO=3:6WMKG"4T/3 _*K>X]$A*F[<#3NFWX90>/CC@
ME XXI0-.Z8^#4YH^06!N!599B1,WV5795%Q6U2>6)FM<F'N24BKT.N$V*7IN
M<$AVGM6PU>PSH;3: JG><(L,46E5K89F:QUV\D\X_>A.'>AB@B5NZL2;@UT&
MA(ML4E7<?Y//&PYY9#'E2L?^7!<Y<-T8HA5]__C8F1XP<F9TF@W2>T2"+: X
M1L!FJ##W,@YU4#%SW?C) D=^SO>>2Z"&0R=*_\)=0JKF^OZ=M[+@<\EDH02&
MLQH>N*T&J]..F%WTE^*R*&F5)F,=V?6JF8Z,,!V3,@HO_%;1ML&26YP7W)=>
M?*SP%R][S;B(M;@A!!"P,#I&&$"==DL!R@\_8U0"L;$R2!]<@&S'L0E^'*Q)
MZ1G!K$3,+&6-NQIFL9\0V8.<?7QS_H:PVCBJI@)CW5<A3 S)2*4I]VHE4B3*
M2@$!2\@.MJF.C8"J=%EXL[12RH7Q:^+EZV+!(L'2;:_7ENZ-QF@%':O<FD9&
MOD_[:09C=UQ*9ZK%8^SP,UV800IX)%9WQT'P[T.IB+8%T!H8[[8\^";W6]!K
M?CW C.(;+2"XD@/E)'%.4'K<BTM,"]AOHWVM7\%9B.@33.Q_%XD^_32)SK+?
M=92?2A02YV5&8<80&XQ4IV %H>-]VTAC(0BUDS-&M_C2UH6N+H?R7.28B_F@
M^E7"9]4VXE!8MBYIXT%G,[F("'KZ9,UT/[-P'>OQ&4)#MA5\*FA,YV;]TVQG
M)GD<V:8!"31S?!1%Q+4R+0K1BG)3$\T<ASI0F D4:<"A41_%T>U<2N;O^LG
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M23!VIJ=WR9'2!B*::I@@YO-,*$F9>>05<.1 VU&CO%;ZM8GOD+Y]3].2*39
M92FW_L8<S>":)<FKY-(2HT5?/:,[,22Q/'\B5Z\@0S]I2E'N?53?,SJ=R J<
M1U&K1?N8Z8G)I]YL59 W'I/A6#"\@50> CK<.AL]8)H^S-^-B>WI="+'[Y^J
M1X3J2)G".?VA@%$^'E=.?-_= <M,CZ=+@9TF278*HSZ>@X 1_9)_8>?ZWEB"
M-ZV6VR=,S[C*+X%=FBY *]@+M&P31HQXD,5V#$UB4I/Q"F"T; B$ST&IH.'0
MO8"R_QDQ'M-^$\0+XDF>Z:\(Y:&^WQ@?;U+6IB6OH9@-M!^[K0-T/D,!82!)
MGOP&22PB/=<)W&2^PK$G)<-^AG.&J"E]ULI%#4.Q*I9@E?H]NP:)JJ.4(AJ1
M1;W3!FQ-7BVL89"$?,P&P=%J^K<^OFRG6OD<9YI@1W65]K]@H>!> AV;8A+H
M:(Z<);&U1612(A#UP[OA@Z<_,68<W?D,FQF?[EX$*),M:^BV9%6..WK6$F4S
M"7=@#SN?.JFV.DXD5%GGQ<,$C20OOD^(D!=36L//CVQ07U5:<F!93.EZGY;C
MZ;.J4)/5X^RYT.WGRB>6#D64B4^M?.IXN%N([FA16RK@_'K>:9./2O;XF7U&
MK+W23XHF/NI_"/M9N^0EG29$/:FR[P;?=9F-3+)M_NF\9M .0%K;#V=H:-,$
MRA1AWIW/BSSC!+-X0,'P&UDMC('KQ-*9,"S\H?O]SWG,FH(T7S5HQ\WHK!G%
M2KWNC2+C97O#>-K!0J >14C>A7>CY"#F\[G;=@S68K%>#DQ2R/UD6<,'Z&NG
M_VZZ*"4DZH]#H9TF,GXE)Z1;^#XEZD5(V/%*##[?Y0#'E!^ )%DU"VLOP%Y@
MFLF9=1OA[.%<VD#&7RQ3YZD7V-LB1?"N"39B?'D3S9ZJPD"[*2Z77[P=OO^4
M\VL<GY?4-&+9_O(I'9X<H3OZ5Y#0^_J@LD0)^91D+T/^"/YVDLQ8EA]47*1Y
M!:/Q&).O[=^1'T<[1VV1$0N-D<:J.ZU-9>DYURA#1I"?52((-2*1DL-'EH(=
M9D9H<LU<YY+2A#PU#$ ,#/;>EI$[A6_<XEK!$1DG(PUN:TT;$K,V %"0.1#.
M"6_:S]NFZXYF<@ CQX9<#9M_-&='/#'!-W ?R'MA]]X;\_'GFNQH-J_0]VSO
MO+*$@,@<1MV[/L63^URO"GL2QQW64G34#E)QQQ)%:Y;XQ/<VQ7Y_="16;KU9
M2=_U.G5SIK@0>0NH@#O!N5Y;,8,8#7$]A5VH!\%X:ZDSQ6)WG%DP(I#8CS]Y
MUTR*B>ZS0NKVP.%ZG'VOB>UE<=6TK&8^[J #(--;$WBC"]6NS)_M-X,H"*[7
M[ON3[]OW33,7]W;R!* <]]N_(TE,R04YZIO-7T^>WH:=]>D1*4ES192#;]#G
M:GW7E<_>B \?!49YEE@HXARZCQ4Z&03=HPNN;&MX6;9>1$+/I'VR[9<"5C>_
M-=K18OV8S8# K#6;X+@'&E#LTLK'B(Z8-MQ:Q$7@?&V@Y>\<MS;5X"_S[(3@
MKYSWM!-)Q[JJNEEY3XP/"G(FRL%@S;R1N4;20C\^R+1GT<BA<==8'%LCIGP-
M$4;#>ZG?HHUH;<;+>G>:Q]",!9T9L-@8U,SN%,/.XD*XKA?XN+8/\)TC)4%
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MTRFG\OK7BY_OH,:2CV7*W<51]61N;HWJ\/T]TD(J=UF\H2OJ&=#Q[;:=R--
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MM5H'K\?NZLM>2^];9 8H<YF]#CL^&:+W97BC>K.+_&)5)TD_FFLZL$YL=[D
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ME^VDXZPX[-=?WBR3)NWWL<GJYI9)@O>^^OYD3P(^8<)33!>'*8"WKS,2/RI
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M^3[=FV5HCW F4_&1V7*MAN^@"$$+:9VBK!RN((@$KR%8;>^:\A-ZU/H/BCM
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M]."O#S6\Z4%%H9CWA[<07&65()+5\"4Z>;^".[&6S..-:L\H=Z#X"RTJ!XW
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MI1W7XKAIF=*#YIO5#E!/4OZHXH3T539"!2*E!'8@UL9HBHSA\;)V'MO:R8*
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MBG?W%Y_L_TW]8HNPN(!J%T5-68>YLS*!8"]_-P9;V4>U16FB4 (-<*'L9%H
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MO*[6KS&)R*LAZMJ@HS+C&<;A75%S%CFPM3JNW8E;2=99)&BU5'A7K2JHMSR
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MJ(2.8_/-&7A2SX;Q6NA)&S?E#<MZC2UQWV=L,D/C;<;% 3Z6&U1JJJJ11*M
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MO.Z3X"N+K'#1$,AAA6-D+6G!;W*8@BL^+D],]KG.]L\AX3;2;Q?][YN=%!!
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M-XIUO<]?8IE:G],U3S-.<!9!8UY3'SD1SXUMB\=N\W[N]>@['^/T::44-;;
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MZ7G4_5N\_-OW63Z@KO*"MCT%HE)^0SU!V.;1G<LUVM<WQ4W-[>BZ* 7I0*?
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M<<<^_V:Y>/[TV>^6:73I&NLA5 R6]:=H;]X_^X,<SEAR^.[8PTOB]*ZIP2B
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M4>N#<9!_6;/LKVJ\];^C>UF) N3.X/8QAI AOMM7005'M(5N7W4< T=K'=M
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MYN84[5 O=DM, [M]( 6)FU04F"?[(4ZV*@"ZU#^5?A3C5\_>TV]H,OL26V@
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MH;JLZ:AT_.9Q/^UL!N3EKBI;+(F*MQJ(_A^R,E\^GSFS'AH?$RVM-:K\)YL
M,SZ;D;S#/+$/;6('0/D#^A !_)*D$RE_41FB!$ZOZ2^ 62+DH4]J/[O)Z3PI
M+H&FR#J_7;9SGM:'-JU<H;L)Z!9F_+_N44YWP_U?"WW+3&SX4.=PP-E?H!AW
M/_?X^=>?Y![[GSW,\?J?/UY41U=CA@<Q8#ZWE(@5?$8*T#TF,$)2Q><MFOSJ
MXPQ9J?%.*<7Z3BH./TF29A;S5YO !S)-$VVB;\OV S6C; MI@'\=Q^-E=0A
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MI-3+**.H)HN32ZR$YGB8!:#2X10O,GF@R?7HOC$)[2W1H:KT4LU/SO=-[B"
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MKK!+O?[=JE\^L!V9WL?)#N\!FJ<DW=Y(7Y*LZ'I[^&@TOXV36)K$];"/-H^
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M_(D^[BICOJ:$.)F(1$H^HPD8\]-0Y>.2"_AD0OX*=*1@P RQY-5^-T(L#C0
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M9;:0?A["M,N6\P7>C,%R#:2?2I%1<ZFGPU:W'#Z,\8TKUAL4*1 ;+"/,G 5
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M71V$Z%,.W!+#X.5Y5N%7)L&8Y^P*/!M.()%.1%X<!914\3<V0&2,GAQR#H@
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MG>-:40^896LU9:I&/JC6Z%9#ID9Y8K7246TK@<3+HJ&Z:8A[FV-1Y#^-D2M
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MQLY94N0SYPS>?9MB*;?,3[A:- ] M8;#S/$Z0V<.*YUESD0"Z&*<PUB-D\\
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MY"?4<9=H1>J>HK$C-F!^KU" P*V:M95@H.YK%>9E68+]X67 _$"W\MS=UQ6
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MW_DV2BZMNFA9WUVP/L*Y<<_ROJ:SD:/G?8,G/^&M(<HEWA23L S0,L [88"
M>./^+@;X@G)LUM(WM^1V[IG B[%@F\![W03>D4W@M0F\-H'WQC>,#R)Y<VO9
MAAOF<NU.XVS<]K=UC^%;3*:;K*QJ_;-N//&F;#R!%'#+3.MN]W<:10DV#*)R
MA6)!U7HS%\[:WYZ8W=0CW(+!'Q=A3'>$^*[39BUWCQST0;?:ZS8M9-LUQJ:
M: T+O+XJO\-7T_Y_]K[\J:TC7?M?47&GZB95:D_O2S(?58Q-<KD5P+%)IIQ?
M7+T:.4+B2L(V_NN_[G.TL1@CD,21>%,S&'2DHS[=3S_OTN]R$3JC<<_S4A&@
M:L11MO2U CP9\W< I_5#^?RXC<>/U[*8;RN_6'>DZHY[B"Y43*E][0-^SM]]
M/O5WSRIY#F_Q=\>QOSN,_=WU5Q4?4"H^H"J3KJKV-:Y:?[\2EE.:&+=.J(H9
M'95,P>KMN'J[:OTP;23]8['!KM]/S;<NJV>H5]EK/Y30]4F-R];T24L9Z[J
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M^#YB9HBW 1E9NEE;Q9"S@F:,84&HUPSK4LN>\[9@ZXA8>LQN:A[1-#,'$,0
MB('EY5H8X8-@45-NN*;:4F,3X99X39QUMA(#>B(&'A>Z"F)@!6+@\WM,"::6
M*T2I4UD&8(4T91%AS8)DU(5$4I8!@K2UQ" #0 8\:EC-6IVGD &W%K399!F
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MWVMIG&#4(1:PRHQ(,#*&9()T*1*7N,%:[^Q2TJ:$-,GI!%P(7-@ U7#%-7^
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MOVEVU)-7.GXYKT'-C*F]R;K_TA^\S:O^-OJ+06?4B<.]\/&B7OX,F>-T8K^
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M0<*L0,)DVRM:YG!P2$B1;2]I74F[LL@88B,6.!+,Z[!28FYZ\$&^@'P!^=)
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M-0I>VO/.*+\. -AJ 'A_<7;1M:.QUC-V1L.J/ZM5KTJ:U[M^OMQ1]4I=\P@
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M5GFNA ,!\M0"Y'AF@?"8+1 ;''*\Q$4YK)'.MB,RV"6NC8F".A @($! @(
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M0&N3#1,.*]-^'C9KFT,'#4AX ( #P '@ '  ^,8#'$IYP_:#[0?R!0 .  >
M-_?44UBEB#(<V\ YL]X($RPW/+\>4O[?O1VDMMOM_U0Y.-Y,_1N_#/IGXWX+
M)3QY[-P [^@"WM%2H&ZNRJD6Q"E))3(Z6L2%MD@S$E&I<AZ\PH%[>9MW=*D'
MG<!SP'/-6#H0Y !P #@ '  .  >  \ ;!_!%3+&EQ:J *;8J4VP^4(70Y$)P
M'$7&/>),"Y3-9X<D#90JIXVQ%$RQ!L:H;&\1I:,X:G7[PV'+]LITG9WGC1Y[
MP\ZG6+T,M92:I*)L>W@91-,"P '@ / &+!T ?.,!#K648/O!]@/Y @ '@ /
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M&4NW(A,4 +X^@$,96=A^L/U O@#  >  <  X !P #@ '@ /  >  <  X !P
M#@ '@$-EFFV)H[E1FZ8U*TNC.52EV:8 &JA*LY[CXK=S4326*<\LTXARY1''
M(2$=E"O]OZ/U+"1NR,ZN,;I-*91=@(CE9T^/3QM# S5I5D^.<UV_O?!12X)P
M=#B3HQ7($$\0\Y&7(I,FN!)BR-N&*.!&X,9GPHV0S;$% (>2-+#]8/N!? &
M \ !X !P #@ '  .  >  \ !X !P #@ '  . (>2-$\>2O-ZT,_S$X:M0?2Q
M\RF&5AKTS_+DGYWURYAG3>3*0>(L4J:?\M_Y(?*%_Z[?5B)L.OG2.52?:29Y
M;'L<'@2: L !X #P!BP= 'SC 0[E(&#[P?8#^0( !X #P!L;(!U2"(HKJ5+^
MAVFM351*:..3PHR8^S3MG$L0N2OF^67E$IF] V*?%XE]/CS9&QV>')38YR^_
MG>R]#]$JS;U$G/N(N.(:N1 =(IYRS5W^3Z:=W75DA0#I >DU8^E J@/  >
M<  X !P #@!O', 7L,N$$3X(%C7EAFNJ+34V$6Z)U\19=Y_$5;#+UF67?=R;
MVF4QZAB4U4@8FA"/BB)M'44D,2EU4D%X 7994V-=H&S,7;$N;R_<T \Z58#*
M).#%EF(Q5<C+7,68N:@7J +3/'5HVZ/@(,P3  X !X _^=+]L(#"'_-6P%XZ
MQDCDU(BL]0<6#<4IZ4"T6T:EFMH6F)?B;Z9"_)<LPU]/1/C;.0D.YL!"YL#^
MZ&A2PVOOO?1*>JT54HP0Q+UQR$CG4>0R>9;9CRN^LTL$;F=<W; )?@1.W$Q.
MA/H=F\K8H))LP?8#@ /  >  <  X !P #@ '@ /  >  \.8L'0 < +[% %_$
M[[V$0!?P>S?"[ST?!H-+:?;@ F+1!\0M]\@EH1!U/%&CK>2$@>.[L7$P4//E
MKCB8;]1\>8H F*T.EX1X8(@'!H #P '@FPKP1L:_W!$+?]40@'#X!]@!!_/Q
M+UH+QBC+9D P"7$N%=+,)Z2E\2X(*AREWS8#@!<WF1>A -"FLC:H)5NP_0#@
M '  .  <  X !X #P '@ '  . "\.4L'  > ;S' &QD# [[OU?J^K\3 L$!C
M8A%QF3CBT1NDJ?0(4\,2DQ$S[<#YW>Q &"@(<U<@S,%<-Z/YCD=5JZ-H!]W+
M5OP2![XSK-Y27^O7$7A0&*9YJM.VA\I!_#  '  . &_ T@' -Q[@4.5C4[??
M-TWSX:D=%*OW:F2:L5QSE8PFGA.#G7%6>JDBUT;;*+YCG1\<_7(/\_QBB#Y8
M>_XM"_UM-;#JXG&M/^^/%>LPM=$QV.CWL-$/1\<OI_%I23KL='0HR&R8<Q\Q
MTD((E!=61ATC<\KO[(HVIK@M]#J,="!PT%":L'2+1.X^CA]GI:J_PX&5E_)N
M"@0WY?THL*I:/793>J6)"M*@C$>&N% 2.843(HP)EHS/2ZC64[$:N ^XKQE+
M!]89 !P #@ '@ /  >  <  X !P WE#_P]):98'_86W^A[DP*6VE=5Y()(OG
ME6L<D;$&(\OS,BKK0O($_ ]-#9""2D$/"I"Z.,^_=C*G=6RW=7[ANAV?WY-B
M89MVJQ='Y1.=R:=]?S@:EE?^04V;*@HUA9JG.&U[="6$G0/  >  \ 8L'0!\
MXP$.Q6$V=?LM%CO%6632!\6YI%S+X!Q)TC@5,-=*L;"^V*D\"==RFB!>ZC[&
M^N_S\5+8$^RYB\@'IA"W)B$K.44),X.])IQHNK-+<5MAR&K:/M8&7ER*P_*1
MI+B8P_(F[X&3\GZ\-Q\D17@P082(B* 8<24]LM'F'YXI:JGV)J5,? 0(#PCO
MF1 >V&$ \*T&^ (2W4F)#:-).A^Y#=+)Y*RD-,L&[;7ERRC@ ,)^M<+^]ZFP
M=YRRX!1%#/,L[(.)R&8]#5$J P_$.QOPSB[CK,VP!HD/A/A,"!$D/@ <  X
M!X!O*L 7B:JCE'KM6-#6<XFE53K@%%B02G$5EE*3#%3:E:JT<T%V5C-B:5"(
MT,003S@B'3U&4O/\JDXL,C=6::D!E;:1H790B^RN4+N7_5Z>B6%AM7YJO<TW
MR??>*YQ639#KQNL-^J "V0H:O-YZ"HR]E=;B;%<;R:-*)A'I:2CQO8%)S]9W
M"CQ#R7'Z(X\93H,7DRI_C"5*=1KLH]:*FH2DHA)Q'PARQD8D'*.84ZX2+DU>
M25MEN6*T@CZOD+GRG+GQII+]2&(L2O8PSU3^;4G:]K?Y$;3N>_+CY90?I5'*
MJ*B03L(C+E5 1OK\&\=.I6B(-6)GEV>"Q((".0(Y;C\Y0M[J%@ <"A]NZO9;
M?^'#I:DG8+\M1S^9B^8-,4;&%4=2N**?Z(ALY!91Y9/)BVX(DSN[DK1EAI"A
M-U44H/%-IG$@RLTK?PCVV:/ML[FHWJ"]3 EKY"UUB&/.D [1YM^(3!IKCJW/
M! C$!\3W7(@/##0 ^%8#? ')3HC1@3,N!;&<"FYLL"P*9TARP3NYKA ($/J/
M%_JSZ%Y.:9"$1F2"D8@SQI%-UB&GI152)*8,+5Y9W#8&*KX#,3X78@3)#P '
M@ /  >";"O"&=1P&U78MJNU<E*],,3D2$O)84I1-%H(,%UF_%5):I_+%>$?
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M6\/S;F<$M3F;IT=M>S0OI#D P '@ / &+!T ?.,!#D7R8/O!]@/Y @ '@ /
M >  < #XD_086$+8S-4#@YE3;WC2W\O35+OT7MM...B]M.>=D>U6APIOBR</
M3@@6.B'P5X)A#(TL>9SAH&A$G'B'K P2*6LT4YA9Y4K;>>@= *2W_:0'4AT
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M,)-'J]/[%,=Q=5 EIGF:T;:'LD%4,  <  X ;\#2 < W'N!0)0:V'VP_D"\
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M X@&U U0-Z";T-8O(1 Y$#D0.;  L "P -B-8#>"W0A$TVAH =$ T0#1 -$
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M+4CYI)T$!2D?"BEWTW0-4)R-0A65$8'YPY%VW"#)(\,F*.(XWMHANDO9Y2S
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M.[-6T(R0CZ.+%W#\9G#</?'",4N%1UH2B3C3'.G<2P@.4;A*41+6./Q9H+%
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M#N&DR\GZC2HJ=%#HH-#!QCO&"A/<&Q,L=*"LN*^ S)&&\P+\)QA5NI)(8SC
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M+;'WWEVA<_4 [P?CGYB$)V'AJ91K]%!>HX$E@_9M&(0.J- UG-8$C)T1@/+
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ME&2@QIX+T]=G6/AEK0X./9_XBB1J3Q@GV$MG-2?1&XDE-H8PQ;2KN#W9OU8
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MT^QE>7J&?+LL3\?O3RHBF*/8(*DT6&U81501'A".DE(7F!52;.T(_@6/Y>7
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M)']0>N^"J*:X?M\TY0.I(,"F^%/;Q@H^Y,'>NKC45Z^U_;[&_[-'*7G#<OG
MC96!O'*;CBC&U!VR<5Q>]9QE-PD >#!MOL( 1+1#:.<,I..T;;Z5;R#=^55J
MS.X U,!^Y_>07&O)S/T%H+A#,/J_:<<;%^K,RSBO'<MKWOOD3LW@;;YHFSW7
M^>'UWHO5)ESWW!@U>;&.XDHGU(N2*G7P[C=R$FU5A2J [1N,0CQPB@RC'@GG
M0P0K0D4J-SI5*HM'>FA?-2[$_.1LLC]M:6# 5QRVYW4X-VV#TO2YVF>XSP_\
M0@[)>=,6,%4#-+ZVQ+SP.NBA,^]PYPVHBL$W'5'SAN_FY]UT?OCG[NZK54Q8
MC<'=+T:\&86CN#=JG'NCYXD%](0)0F)DH"[J5*FDB$1&2XX<V"T">V(HW>RT
M21"#))@S0;@1#'#Q)&&@>;1G37^O!()>#O(DXRNI=OFI3\_J5 D:@5(T,PU
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MNLC5)&5+7>6]LQ4QE&OI3.6K:(0-C"K#F-AHX[F5K,Y4M#(.+ A7)TO7<XA
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MU3MEV?4R3W5G=QF9[8ONW,&<5C%MW#!V<)3G>P[5ILF331Q"KQL?L\ZW&*;
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M;9_\N;]]\.EP^V0/QOM^?[OU\GBAI,7!'MO>_?!96&A]D!P$(Q6@F!%@E"-
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M1[SDZNVEF46SLH*_N E?77&"[DJ'*O<O]W\>][\',+L1]9^&-K2!V2WAC3X
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M">348V@9I0@K18V"1"OG60CNBKIJL0(_#+4N*JQ1##(<&08T40%0IC@PABI
M U=88*<(%VVW J\NL]Y+?$<(,-@GZP1]-3@\],,<Y'&DC_SPONH/GY[&YUI_
M6&DH.6:4646I%4K ()@-0CDJC'1%9VH#L']8=N]QA;"3%@*N'0?4!0)T)&>
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M4KCD,;C$J4 U45Q33)%QD4B$A%9C*V @IL1&M8I0%I432+F%*3;*IKP(:GD
MT@L*O&!"2^VM<;8H)ZODXGCJV1$?-MYO=,;#W";GN&F,T_7WY=THGNMI&SKJ
ME0F:8Z@5Y90IB#ST0F'%M$2V>*[; _/V5"4TRJ$5TH# $0;4&0^D$QA8(@,D
MBD&OZ-HFH7@=0E1\UR7"J2@'A2=NR!/>:RADP$910BEW4E@I8$K*$APB5;+I
MVD(12VG27"AG( 20605H1#2@4]E,:Z-Z('20AI=LND(1A2(*1=P^3\)#A3'7
MGE)+%;')9F2C% HIYP[1*ZH2A2+NFR*6O \:8@TYU\!*90#U3@/I+0$N>&_B
MGU1852BB4$2AB$(1M[8V&6H0Q)P%P6D@V@C"#4OU.%"(3%&L3:WBB455PA*H
MD@H(J)(:4$@",)920#23FCAEO>'%VM1N-\+SRI3(3@7]Q??M [@4BA_Y;,BW
M2EJ6"HI#K"AQ4"M,*1501M37CIBB%;0![;^<\BT(BAPW'- 0'*!4$B!)!/_X
MLHH_.6$E8>+Q=802D_0D%8;")6=S"1/<&:.Y2LEW!&'M:1!!I/Q=''\6]:%5
MA+*H/FAL>/ 0 X((CNJ#8L! ;8&20C%BA6="K6URO(X0*WQ2^*3P2>&3>T_
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M3#206BL@&=5"T4 Y-&N;IT7"4Z&/!0,+!JX^!K9;0RZVS[L"P)DLB&60&*$
M"(444,\4,)(R8 P/*4@">F639LS6(2KR8$MMGT\[2/S#QON-SGB8*\(=SY6L
MN"\CZ,W,[T\0XKVA7BN)@XY0'S2.:*X"%"8*19@CC(L1M.U0OS=O!+52>B*<
M 0(2#J@B"BCI$8 X8"4T1X0G-Y=$ZY$+BIOK280[%$QL#286(V@+T'!.\%5,
M0(DL(!PS0#5V0 D1T="HX"E'4B0C*&.B(&%!PF>#A-<Q@CXV%!8CZ&V@<,X(
M"H5#D@L"2("IX8.Q0'H&@0E$2A&XCJN[MDGNUPA:,+!@8#O6KMT:<C&"WA4
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M"'9'N%^J5C=(;QC&W#GIM8=4.J8(U(C X+S1P<A07"AM1_P/RRX4RN+J!<R
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M[Y]%7"7&8=0&B1)1.O(6&.PY4%I8Z:@,47M;WEKGX"%O QSF&[_H1ASJVJL
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M4]7V]OJWXPH/^ATYO/A\JC2GQF."B*8<,>? I<PM_*3SG"M*<A7!*>-TNV?
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MWJ+<?CWS=1+..:CJ8M>J70!:VW,]C-'$DHQU6G>&PQAH+/EBI=U:%)3.S[_
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M\<BA[CQ.%\,A@5"RP)WVA&D:<BT)LR1W#;&?@MC9X?M32;G-6(Y1KK1"C)*
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M0.Q<X%89*6B0\+'E3#NEL&"9"-* T1%8[")_P>CL4?X7*298X[O#@ZB=0F<
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MII/LZSK)[NP,F^LD\\PPHS71PH,_9*@TV'LMI?%89\Z[%]U)=@\]/5-A6)\
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M9/$.B!Q^>&!9^^#=;5S#(7CJ+L!>,Y$C+P5PK<H5TI8*1 /C$F>Y$B:/7+O
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MF3:@9\N)9@\OF"UK.M.DX)F1?L-1/::>0N?%4("4CABE\54)/*_U17=A\])
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M2M/X0N"1_9S>YVA:@;:?EOP=,^X)!\%JG'!2N!P)R< 4\SA'*L\MPCCC7,N
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M*6=+_,I?^T!^L?=D1%Q)VY_[@_I0ONZYEC4\%#T7G*LL-8UP**12!!<RMK'
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M:M!J+S#=4/4"&_/H#.JUJ#^A\Z438B\\&L#<@TK-YU,)VJN!UN82$V12D9M
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M(+@G18QY9/;DI)O'W,GJ?M_'X1"41)B=EIU]$6BB<#0/>F9..[VJ8K_"JC@
MEC1AEO,SG$?4_]J;^U 788QYM;[83C=/_FMB9K]?'5]?Y>U6,[1,4I=D"60)
M6DFI&M?NX\8?0(.#:(=C(-&S..@# 8Y/<LUM5H*S2Z$54\IH=W7-8!:-YS6#
MF:@KP9\)>Y 1!/I%H)^;)O-"?8H0^)IHZM)(Z3.AI@F#.LP>AI@Q:TYLY_QK
MAIF:%EE;8<.'M4NB"P/)#.W$GEY]5V&(@^(#F;/*L_C(.)'GU#1Y3.NT ]9<
MIJM,O<^9JJYQ=-6.G-OA2&9<E<M!C/)D]H9Q%LQH#L/HU@AK]PQ.9R"M&T,6
MO^UV^SX/>WD<YEWU;0U@5H44P]I'[_:-C2HZK9$,02'.$T/:>H<(ED89'Q4C
M=FV3DHV+_2SO#*EVS[A;0Q*/21(?]B-7B<E@$5/:(QX8SF$R@:+%S%BBD\E(
M&6R#W1!"[7(&/,MO]2KPVTNEN+I$,P0M"O3CS"@+=$?K(U!]ZVW^\-G,[]L(
MGID_YS$15ED2/1ELRA0D['SFR\3G>1].YOV5HZ1\$-M;GK>WWI_!L^#:]GYB
MA AI&>*P$(@K')'%P2'OF>$B:66,7,3*(0D''YUAR5J>L--&&DRUU9XD(LT%
MA)7=.>B/X?@8B!A(:)A9P62/3&(NL$=LO595!*:H,26P]1OHA6\N[7C2 (_=
M&WB,-\!CU\Y3 SS6 (]="3QV+9#8 C--H,0:H9)R3'%GE#4V@%U$8E2&*QLG
M^V7IRZ[EQ"\ +XF3#4[OC"]TY4FR(8Q\'+PDP>YZ;S/D51BRQ#>]^1E "5'R
M4JI^G@(E9J;)86NI%7<3#('[ E0]ITN?P0YH )0>9&O<>3LT\%JO@#HF'7%0
MJ^Z)TRI-<5JY*TZKI-Z6.H:2RU5\K@WA-(0S2SA3NIEV$V[]6>=4_:>3&G)I
MR*60R[0Y:&O:';3B++<IT5XMK>2YT&TS:]]]G,^)]\ K7A+C^<<$1.Z?#=K'
MJUKTT6%_#$\*"PO_*"@@-^KGGN?XV4& ?)RT/IM#^[X RON0->UW:C'][$O:
M2PG-<#&U1@MF G-)!L<-BX[#B["B+,H8L:'+NQ662O;9E)J<-Q?L\/#!ZMNK
MBJI<<#88YX/#G5PEMWMH>W6WDVE@?[NNU'_F;57K,G>V=[QWFL>Q=]RF>T<'
M>/N7-M_Y:T_ F''^K[W[8Q>N^=KN+):YA\ZGH_=?]XX..WMGGSH[6W#]V8'X
M=-3M?-KZ'?[[\*W]RY]PS=O3_YZ]GX$'>2^V/^P'(UQP+B+K8T*<:X\LC1@I
M(143*25)TTRY0],&_E9[\CX8(3?B_,\5_VFEQC)9GD;J/*#4N;R5]]U$#UT9
MP?/R6WT_N4PZG9-),7(N'+$(>R,0MQEY)7B&L!1:<>(YR*)&)C4RZ17+I <W
M*^\ADYJ5?)B5;/;;ZJY2HP/>40=\$-T/L5LH?^YZY<_=6OF;!IFF,::BZ4UU
MPD;ENZ7*MSVO\C'E+(G4(UU02IG32&.3D#;::\ESGWG;J'P/#;OWP,[J5/[W
M(IW5Q<B+CX92?7'F7H5\6.J99C(D(ZE(.05>:6NEIS%H20Q(BR#H34"J;USU
M^7CN@D(QP_>]WPK"02,?;B4?VHMN:B$DK+.P2#JJ$;<B(.,81DEC)9D/">.T
MMDG6C:;K6H@GD!!WV[*KRM^N<0K0*XR4%\Z[EI/,2Z>'Q]TIM[%B5VM>_K8J
M+&3U-LKM P'WE/3T>PGS)@#PX-)^WAJ4AFACM43>!(NXT1PYZSQ*D2<FC+>\
M8(VH#=Y(^B=T_]^/D:_ZQ*S46![7_?^@*ML*KN05("-WDCDSYB2,S+\)XT%.
M_)S(']OM]A];^%P(.T^+(G)=>HTKNQL'Q\-&Y-Q(Y&S/&YA4A92LDH@+Q3/R
MB4%64HN$L9ASZQ2S//?X,_Q2S)&&E3YO5MJLTFJM4I-/?:LI_+,$HIH(YIVR
M^I_>1?U4IFM%%HT?^DYJPH=%/S0/U@E., J1$,1) #4!2 !I)HER8+<ZYM<V
M!;[8&^Q"D5 3GGP Y_/+9DLW=CZ_+'IH9%CC@+U2BC4.V <7<_,.6!XE#]QH
M9#VAB">9D,52(J$C3SP&HYA<VZ1BQAQNDG&:_.N7;8\V^=<O>R6;_=:L4K-*
MJ^"E>\&)I#_W!REVFE32Y^.H6X%<TBG1-&Z\.]DW'Q?=>"HPZI7B2%.&$1?4
M(Y>B0H+AH+2F/B:[MLG).GUL3]ZK2BYITDA?>1II(^2>DR?O+I5TBV )BQ*L
M<=T]N&A; $\0S'@G"(K.!\2CPL@90Q'F2;!DI5%*5;F3NLF=;'(G7X>1VN1.
MONR5;/9;LTK-*JV"Z^X%)]A="EAJ5B-AX<XHN\_' %KJY./2<2YDM)C +Y(X
M*[0PV,#K5- &%TR1E?7M-7BF]S%_]A8]>U%X*:RDB!.2VY@JBXQE GD2.8G"
M>AMI*13G9)T\2:'X0V_B566/319?D\5W@\]^1*WB%9:0WX=D5F^CW-[O>3?9
M_X2)BPUJ[.-)_GG'IY8XL!S$X\9HQ"5UR!B/D07J$-HDXH5ZNJ+QE\7+FYS%
M9VKB-SF+JUHT_OBB9Z9S;5,[_J"29Z%VG%EGL64*">\]X@(S9!/!8'UJCJV)
MTF%?:L?U@]2.-QSU.W/4QI)I+)F[6S(/8L$L(B)?[[S\OK#(K)$L-Y,L"T!8
M6#.FLA'#B43<^82L _&2'!?4.$J<$+G<>)TSTA@U]S=JFF3V6\U@5979 AVS
M%;^=Q-()?M1OY;V__G11LMME9%SN8*_/U.]B<#+TQZX;FQC:_6)HCPR/51'A
MVUYX5Y/@;C\?FK%^FLC:'6217XRL61*%)%8B[YU%G/* K) :\>1#$LX1']33
M1M:>=N.O*A-NDA)?IR79P"HWL,J/$1/[[N)ZP5GY[EL<^,XP_C;H^"9(=FLA
M/F]0TD2\PBXB90P(<6D\<HHGY+"B#D>G4\0-LG(CB%^;(&ZJ U8R2'8_671_
MV7-9H*P1/C<2/@MQ,BQTM,3#^G,!=B,'N6.H]@@KH%TOHM3D(>-D#5-MK)N5
MF)[&NEGM.-GWL7@NB9TU(;/;"IEY"P='RU7R#FE0.\#"$09I8A.2/FE"G!*8
MFR<,F;UX$Z>$S/XULJX;-\M\YEW;Z8W+]H$CH?-E\]_P8_(%928ZO0 [Y0V3
M\ W'=G#0Z55^67KQBV\XMOD/NO$\7#.?W4XOHL/J;T(+^\P]:!G]H9J)][W6
M'_%D5,6Y,O]9;\'F;V4.8GNGK8.J<T?K=K&8J(@WAD?K.>&24T,B48)Y#X>C
M5*0HTGJB2%]HEKPJA4TOK 'FI_\>8G_\9\_^9<8[Q^_@^-ZW3[OOQ#9]3]M;
M'\CV\:^=]E^_=K=W?SS:WOKTN7WTX6S[[,_.?\_@O;L>QG  [_[,VF<'^U1R
MZ3%U*'HB$,^_61D\X@:T8&<C]][?-H+74,U+IQJA:9!>>@06-0;)Q@RRUO*<
MY>Y"I,F2P$&RJ74F+TJV"P=:)W%0UKOG8ZMD_K2 J$ 3*5'\X:CO/Q>*&^:(
MOFUYD%=@"K?BM^C'H\Z7V.JGU(&CK9/Q8#B&1<O79>:7J:OU6]?V-EJ[AW$8
MYUYDBUW> M)H#<?N"-2AR6V'_6Z(@_\=MFKYD0<1!U_@%9,K)EQU= CBX."P
M!:1^V+(G)UV0HSE:E],.0'BVXA<@K/SRZK(+>0CS/-K%;@?N@,\\M*-R!AZ;
MCV3RA(\LAP81Z';8&<U_#(PT= K5YIV3+QS.?6&O/VJ=#/JNC"XG25@XGF=Y
MW!VMPUEXP/GF*1D4/7C (5SE8NS!A;Y_T /9E%>F:^ODBKFWP(+DX66722N"
M3%U2F[PQE=8O31+_7,UY^?KAPN=7XGDR!V7R,UW"TO='MEN1-ZJH?NDBS$SX
M);OB*RS3WVYAO]P3H0F)11[\%JP6GP>YG!F_J[YDRD'E*^>@VUM[^\*K9+3U
M*#*>$*>"(R<X14R!<6DB]3B!W-4;%Y&16D# W;S"F9)NM>J,@*T:J'&>1X*U
MP#$9K),6-A J;RF5BX\4)//7/NS^V+LG2;P^H=KF\,[3G5T8_]9G^/?=?J"8
M,Q$BZ%Y$(; )-7+11"0$IA;V*TG&KFV>Q4'_ DVL9]:0+7J0AMW3C=;;8187
M%QCP+/,!72?>FG/<T?,A;J'/O3L^Z?9/8_RCDKC+R6>:U5LYUW<S)YT]_U-_
M.-KNC_8BC'LBN5XQ^X%Q;/FS]FY;;!]](.TMOP_,7X,F#N(3)XZX]@9IAQTR
M20K@#3XYS=8V.=NXB#EZ5_YCM& F,)=D  ['0-0 U6!%690Q8D,+[=R7[3P^
M];P^3K5 /;L?]DT"E9\(@@+AH/XKIY#Q0$P!5M1EQ4%R=B-.M9[9U+@WHUY>
MJ@Y]/>R CMT9SJ7WNCBKFO:_ *^SK:]UX*QEJ\A95I3!@,NO^EZ5=8]&EI5M
M"NIG?2A?1UX=A7IXYQYOP[AW=MO?VB!+I6+>2<,08P3XF]4.:<PXLL82SIT+
M@:;E\;U*A[_<5)FU3/0J6";EQ6\Z0"P=/V>KJ.6VRH066W\4$^*W\<"#G1>+
MG7PG TVNPBQ<9I\1D;_Y?:^UXT?]VC5:J3^MXKNJ;/UA-MX'P#_"N=_@JGEJ
M_>/='[_]]L_U"5?*&\]VNZ>9N<$6O[6?E:?DK21"844XU5ASQZ3FUANJ(M6N
MTLT)GNCF^,[)[^\G0_V]'BEPF.-^KWPCL)')1T^^]A6+O8]?MW?W0"D743(G
MD*8Y4< 8#SH2D2AQT%NLC$RQF%/-P<9?QTL0VBOKOUKT+('ZXT&6:S#EM0F?
MW35Q0FHG];0/@5Z +%NC7 E=%*U,G9UA<?" C+"NVQD> IFYTT*P/_9!8A25
MOP/R<-0'!M9ZEU(E9EN_VM[8#DY;<TZG7JE$R/?4@[/CT6%_4 1I_7*X*I/Y
M94/L]/P@%D$-H[@=O4L0L1Y;Y7&08$=0$PQH#M'IJ)E*3#Q(,X2&WF\G1.G.
M[A[9V8)[MOS7]EE[7UD?@V,4)4(,&*0I(4NP1I1HC1-SQ)%29D$)7]=47K04
MJK4OSM>*DCJ9:D:5?PS4M_\;@]!*I\49V6OE<!:1/TPIK=H?$WIKG0#?+9>H
M'VH"_2-6M,8IFWA'W\/3!SW;;?V>7:_C[%L-<:/U<4K0?CP85-[4!+*D=]"R
MH7^2E<5%WW$>[WKEV)U>6RN2G5I<? -J&X$6>Z5:>2?6OD2M!*(='<Z1]D_5
MI^S4HYN$*5X9V7X\VP%[5C(>@'-H)!P%4L6*(8=E0IX*BH'-&),M$LHO:'ME
M6H?KY^;%0>R!U9!E.:@_G4RH0+%]6)'Q8(86RUP7ACY/"</.M_J1+]?9/>&9
M560A=CL'G1Q5@$DZL3F3H',"<]'JE UY6EU3W3$55W7 8W9?UMMM^NAC>WH^
MW7,"<Q)S.;&G@WZW"V(AC'T5^K C,/].<G)^*V;> F.JTP0NDTZ]NA[OP;6Q
MF7TZD2T[:4;VU"&AWZJ/V)I^PV[_71YYJ3#82?_I?XV##,O5MH//<32?E8/H
MZ]OL%-ZY[_*6-D+D*G2+..&@G6D:4:#,4IJ2"LFM;>J+90-_KZBAEA7=/+D3
MP9%@DH'H\BRWON1ISB?FZ*Y?!;A29S $(3&P.3NF%8!,X<*E8@*TIOJ>*2$'
MV!DSXK H=2%6,3L@P6$=T%POKHPNL!9XW!P%-R+F>U =;Q_M[=NH@/"80BSI
M@$#<4&056 (28V9BTC#U?IF(065:)Y0W1R*U:K1XM(I)>]#OQ]U*40*-?S"Z
M@@)[F=AL MVG!9P":)'(?.0\(2C_79-I]F\ I_WFX>0D6%P_<Y&"*Z&8=T'L
M^>Q@.S>C265,U*;TQ2%5@\GGXM0.R=0_V6^U"*@5NB$8S@>=(3R@L&?XW%$)
M>F^T2K9[QXTK!K]@F.1YZG:..[4WT,(&!DD\/H:7K +?CP,/WV /@)&_JZ7D
MO#_O_--^/)U(U=?,WO?@^>_WG;68*AD1YPET.5A'I#T3B/"H!6=<1"7![+B*
MO8/R-%$EIA0V551FW<H+6MH53%9[2KS!6(#9SZFBAB@JK!2:P!DOW5*3=2%5
MJ=[2.^F2C*2)ESC+FXG6D-U-6>Y7:4W#X?BXRD[:S:D<NS"\'[MP]:LCE8.S
M]M;[?=BFTDI'$"B!P),UCLC!WD48#EKKE%'1K+4B[*B3K'@/0'MZ4:KX[D1S
M*2K+<)HCE*\93G,^%[CFUQSY!1[CQU5BR7B8F79AXZ"*]K\6J_B<T-Y<YPJO
MDXYK-W!)OUVXHA1#V/&H/YG?*JFX'*D1#V#*0-\9QC>37R[46\RN59Z>T!F>
M=.WIFTZO3$QY[P]?.V%T^,:H#2FK"H,:0:<>3W6:;%3G%I*JJY,2[B57G+_R
MYJM/T@U-[WHSWB!7G11<W_'>ZX=,;WCS-8A%-]P[#UDC=:%&R]RKI/+: 6=Q
M'P=/4=:EGB##?F]Y*M\-"N F6Q-D:5RZ#M=<^@PHZ7[%N?>CI#MW5UD]&KL2
MC.N15OR^T]?0PJ/1@EZ1IE#/M1+WW30W)@Z.6__H]*ILA@MMHA]O-N]&K ].
MKT\QV:!UX2IH17YHT8T<_%T-".5FE9]LE;\?2N=S95%_]L'J['0[H].G SYY
M.KW\*690X@W^]Q9J*0G6UZK 432+>,M%5!NJ]E>BZA]--O3?&_WG7K/Z>V?X
M&:5!C"7-))=+M09V%%=$_7EVTTDV%/T[HAO<W(W/O#S=YMDM(=U@*@L+NJ'9
MXW.7EZVZ;)6$H%YHG79B-SP=AOA]*/+YX.PL#<G>,U&4SJ>)YHJ48(>'#X8A
M,.V8-Q.8F]C@$VKY'030\P_JUE Z MYSMD>WC_;^^KWSZ:_W>/OHX'3OR!-X
MUK>=K8]G[;//M U77(32^0S?!/?1[<-/O_S:W3OZ0'>V?NULGWV$=[SCV[OM
MLYW=O3.XXO2_9Q^GB-_MW;=G[:VW^]@PESQ7B(0D$4_&(4LT1E(%X;@G,D5?
M(:(0^D,#IO.L\4(;COJ(')69&*TQ%E-#.)/.:6P<8=X:R9TG^)HR\(:C/D^.
M^N&<H[[=9XH1H4E T=.$N&4>.0(<E5N)0<@RQX-KF.FC(9.5/(I%6-$7E)7R
M1&@H53+++1$,[JE0-M@G]\,^$>W=S_N!$&X5 :8C-$.P' &Y*# 2UA%A0R0Z
MFNQ\6%)1-(L]<"O(F_M)O6;9[[?L\%T?]R.-(>?2HLA81#R ]FX<%8A$*J2P
M.?<VY7@+OW39%V!.7FZ-]L_]DK,WG-2[E8S0^<^]B&\Y,P$G_6&! GA3V"7,
M5IT81S \OGX5IQM*5).S[$[KAOWN>!1_J"4WGGW$DBS*.<7ZNT_XU0**Y.3A
MN<F<^7DX.-=E#B)R@V@_HY+._L9VO]K3X=J_YKY^83HOS%(U%9O_=H-_;5Z@
MV/O.4TJ/-T]E68$']JNL_#=5'FF^+'^9?7Z#;AT.LC#XGTX&@-"&6&ZCX<D1
M)['"3B<AB)6"FWVUMEGRJUO]].]_V9?_L:7,(F-@EJ]=LC46F$TES!+(22-4
M4ADQQ1EEC0U)11*C,ES96^1:KS2$1,4S_KA.,^T,9[%H<F'->=5_6N#G5449
MJ*X3H,@9_,9<U'(<1QNM][U*V\TOJ8N2C_NAD\ B*L="'/I!QY4*U=9V?Q1;
MA*[?LA"?:2:2TB1ZSGE0T5 %RAG60C%%(F<5*!/F#-\3H?4N/7]K'-8I+D[5
M/+&NGAB^XE+]/3C?WM?)4AH\12(8T*=LQ,@&QA A0+*$. LV?BY(6Z<,KRNQ
M!,GK.@(=E)XCI8+@2]U?=;2$#DNY;Z_U]F30Z19K;J-U)Q/P-@I]I-8".PM2
M"<<Q#0Y8C@^2.$,M@Z<U=MSCVG';1Y_WL=$^:-#@5<K5-]2#'4>Q0LDP)2+5
M1"0&RA;;4 ]GR-$D/?/"P\L"9\$;XC#5(&X\38EBWAARC[SN9Q[L=V<8H19F
M6'+$(S%@R</B<Z)!?"3NA<P%>GS#7+[N&7?F.HF:?3N7(@]/1><YK-M-X<GO
MQSJ>5OC]V4B^2XAQ]^W7C&290#O!(K>DIP9^**N0)BPAI7AP+(I$.!"C7,="
MK4N]Q+=P)8SE4@*Z)P]J"&AU"&CWW3[V+DF"*8H$@QJE6$3&$8L4D\EB2BD.
M+!.0D'1=X$M1CI8 6TZ4JO^M6-U&Z^WH!G[P.P'SDDAAO$(20PEW7AB7'#4F
M,B.Q,4Q>#LS;H.\^,<D=M??STCA)(V*!6]#<34!:&8*"]H))2QDE9&V3X:L$
MZ&T5)\D= 9,_@:!FW"EOC0@!I+CS8#AP$Y;#[S84\ATHY.SS?H;6IAQL.UUP
M;H@5"-03CX0M".XAZ-SAGO.K8B0WAM9=$EN[G4"\&_=IO BK1'7;NQ^!Z@*+
M*D44F7*(&^:0"\$A89@A7B9E;5;LV;JD9EUC]A#*U-WX4D,[*T4[(--\,@(6
M$B,J7)9ID2"=6QAXS(1,SAJPLH!V#"CA:IWK)2Z!<V_4U-VTW"UU4RCPJ^!<
M[F0$+L',>FH<^@;P>QGY'>PSZ;#B0B%OM:GR0[6,'$4=(G 1&GF.1]#*(;G>
M8C5*XP4\R!D&MI1N[F3[-72SDG2SL_5NGV$<C>%FDE<<+; M)9'6AD8EO4HN
M@2I^'=TL-F#)P#R3/@1HTH?@'*DG^]$+.D_E/,_!HDM8W75V(*QK(9*']7'1
M[]5E;Z'I>3FY!5,T30MM9.Z$>'??[G-G4^)@((CH,>(XY"92 2.,E0>I2XGP
MF>EMT"72]B36 <KO!(%V(TY7.^?AMYVTR,LREQN^;@"T]CXV023)+(K>$L0I
M8\AP#!:C!NW=4F$PDR\: .W66:,UF&O%?,X1AY>AC5?(^S-QA@HC;9Y/SV'$
M9G9MAS6.VK-$3C,;6K"[(:<I."L?!SF-;'!I'NO)ZJ;H:,\ EDHV &>W!#A[
M]V  9\^ /+XG4M6S(X\;8I-]-\RO^@6/C+&SBLA?J["5OB>G?3J$I:=8_7^4
MUM'],3PIW BJ["[<]V[@$"GAY%\JG$'NB%3 XK.6&^*7V.V?9!/](2O[[C>#
MJS5??WO<B;EYR>/SJ4!>$H:VB?H4:$HD\)A#W\0X8['!23,NU75YF^P689];
MIO:Q9^I#J N)3S\=^6_MOSX=;Q__? 3CQ#M;V\<[>3Q'N0CXPVE[ZR.\_]>C
M[0N%Q+\>;Y^]^_;I>(_N_;7=^;3U@;?IGMC;S67);;J]]?[K=O[6XS;][]G[
MV4)B10A5@1$4#?&(<Z603C$@Y8C6VF,GE2]!'TXOIC(\?!WQ?3;5ZO&;IYB?
MAAN_:FY,H@LI1F,\"[DMKK-*12*8E@I'RLEUV=0--_[.W+@]:G<J;KQ]].[;
MSH=]&K@+UD7D1'8(>RJ (Q/@R-QR$84@AN8P_+H4%V,"#4.^&[##PUH=CV_+
MKM"4_E)U6RPFB W'G5[=!.K+Y9B-]P,#NG9V;T*@SQX9Z*(D\$D%&36C0ANN
M,74$BU@BQSEH+$RCEZ^^)#C7R[6$=83%0IKD7G56!*2EHTCG4ETIHO5&KFU2
MN2[9Q8J(!Q<##[+G5I6#70.=UG"K1^%6C G)1% R"0Z<RM"0F_9% NJ-="(T
M>NN*<ZL/BWHK3UZ19!3*R26(&RZ1Q4D@9I+6C!M8\ 1ZJUPW^ D\":^-8ZV8
M\YQL4/$,E->;)9]\-P?.E5&B^1@B@_.A/\[Y)Y>&D59K[K^C^^=AYO7Y"^$[
MI0,V0GBEA/"YR> 9]<31B(#*X(</'!EM#+*.T>2%2=+KM4TNU[&\6/?SO3U'
M#[DE5X_7?>= P.4MYJZ<V4:"W)Y<;SBCSU]V""-\$"QJ"JJ^IMI28Q/AEGA-
MG'6V,>!67'9\7#3@/*R39!PCK3*H*Z,&?J,$<4(U-Y%;KG/@0:\+>;%F>67E
MQZTVY.KQN'M#43][)-5W=M ];;W[%@>^DRVTNNKHTLS\9XY2F.O.,G.SO=.6
M+44(+0\4;SL%#J S&DX+'JKBAGPD= ;1C_J#82Z/B/5,32HDEC21SPRY]5L7
M)N%DT,DX;_U)C415]U;7\<[47,2R"'&Z"',U& 7P<#AV1S"(";93_0EUC<6P
ME>L:<@W&($X+-,J6:XU/,CAB'!QW>I71#5]9?6'.9&ME$,:JOJB5KUORY!_[
M=A#R75O36:@Q[KIQ"/=.RC[Z\#YX1W>F0F10'CNHROJ 3#['T7EU7[YG!$N;
M[S\?=0%U+!QE,FL%\*5UV._FFI(R%8/X?V,82YFXDT$_MSQHU=B;>>KJSYF?
MJ&KBX6H?8Z@>T\DUGD "IZ4L>A JF$CK_2 _)J]]/U?BM;H=ZW([QDY-$?71
M?F:XN8GL[/E4H_H!L_#CP2#/\$E_D.=]R0#@M5T[''92I_X6VPFPLUK>GN3M
MF^MD\K,N+&FI81ENM+;&@[SDMT81O"7^@ #Q%&CT1FK.'5$F".>HPLX).&"O
MLV(7@0A*?2^H(Y?4]Q84T??#(:Q!]7U5+5N%)U!.[DQZ7M2;I2EXK H>08_Q
M^QA+DFCB"&-&$4\9<5"2B*R0Q$4G@E5F;3,W)7D(: H6>8PB22VIXBG \YF(
MGDJ3B0,'_[ X7PUEW)DR=O?VF9=.2V] \U1 &11'I(6CR'MN<:384X_7-L4Z
MIGA=Z"58J!-I]#7#;RT(K(W6VX)+\4C@78(91VU41LC <R,6&Q(/2I @L,T]
M*6X(WK454P2N/&?=G-L\,\7:P__43/WTIXJ--]A+%2F1]M;G?6^#D19[% 7W
MN9)6H=P(!U'E2<2:&<I#KJK65X-SW8H$#",I8AMBHH(KJDQD@7(*-@RE&<GP
MINA<#0G<GP2.#O8=Q<(+KY"S)..:8O@M&8Y ,XC*:24] SES)?K6[;2NV]!*
MLD)QISC1CH&"HH$SD!!9BLE$AVO$I/NP"W<YK4PUNNVI"M@03DTX\,Y])RW3
M,C"$;88D-5XC(P-P$9.4HPQV-^9KF^PA@?V<9XK( (0@ @<689.1WFJ@#Q8#
MM_;>K*,AA[N1P^[;?18C#BII!!(EH\M(AJS6 3&IG" <)Z'HVJ:\2I3,\I&K
M;+-9B(/* #^,W=!RIPL6_XRU?PAV:E%W9JSO65LUFW151XG3;(G5CRWF^F'_
M:R];</WQ:#B"Q^;SG<K"3F F]WRG1,9A1(5B6F"]9Z,53D\=#!GY9N,F/6T*
M%5W;Q8((OO8<6@%=[:ZJVCCPC2LQJ!X A^7WBEI^LX/1Z2[L[&%%=L.MSM!W
M^\/Q(*X,LLKNA\DV[NSM?A3MXSVQLWO X3J\1_?.]H[\_\_>NS>U=2SMHU]%
MQ?O^SDFJ&#+WB[.+*F*<'.\*$-LD#OQ#S16$A<1/%V/X]*=G+0G$U6! +(G9
M.P:A=9LUT]-/]],]/?#[XY>=SW#^^@>\<Q8.-ZY-X_\>;&Y_.=T]_"*VUO>A
M31\/=P\WVYMG\/N/W(8/?'/]X^$FW<A;)8K-=<\WUM^?@2EP6A6Z9[FD.9B
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M_[DDOD_ )E_&C$_^((91)VZE:TL5UKKASXMAWLYS:AL>_5NGY[_,*9+L_GN
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M:?/_6)IA2CCY19U?O]E.E0]BAU,LW9BVR^&W-[?* GWJ;EVHO8=GL5GIY8#
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M3%S?#L X,2TS(K:I41;J!@W=P(%]PBQ#IMFUG5UF?7+$" W'U@S5)9AQ8)-
M]2(]4&V7T0"FW' HF"=@I'8,YUD2FU\3N]R92[?=H+1R+MU6K0?)8)MGL"AR
MJ1X:H8UYP\2+/,<);2,(;=?V'(.XTK?67O*:\ZVYIA[ZI@V\Q8)()6'$5#?2
M;)A7@SJF10+/;'"Z7-/!2F;$/;E(/Z3"AU:ZUFJ9<-&H&&5,)L2]6 ]1#]TL
MIADY)B.NK_N68_G<#O)UP_4#Z55K-76<U(]SNL0EEA_8*K4-4R5.:*@^)40U
M"3,-@J>+7!=L'K-C&U['U60/HNW-AI, ^UP &UI6X/FV[5MXD,4S*:6>;H'^
M[5'#CAQ+.I;:#K#3\YN:IWM^H!NJ19D!RKFMJ=0%E W@U\!T'-LUL..-U[%=
MIT-<1P*LS/5JCL]IJ]>*M"R>W;*(3 J$%[J:[1.=^/!?J%N:3BV#V8YM2W]4
M6SGO]_GCF]1EIN.%EFIZOJ\2,"I4WW=TU60^I99F,-?R9*Y7F[Q36UYK#&"@
M/U;8#Y8%<3XYIEG5'GMN]]2VUX]8K[X8%KCQB4ULBQ#/CUQF<[YP7(MJ@1M)
MAU2KN>-3W2$5F-3R3#=27<=R56(01_5URU,=BQ%=BSPK,*V=/:/C>4;'\+3&
MU;MI.LQM>0DQ&?R=H":ENLYTTR.ARXCA4=>P/8.%=JAK061X3'J9VHZ:4R\3
MI90?%U5#/P#4-$-3]4WFJ59 =:*;AF-@E3"KHQE:QW*?!36W/?XKDY=D\I+D
MKTT>[@CUT'=)%(46UN2(O,"R0]?Q2>!'9F1[TEG45NKZ.N\LLGQF:[IMJXYM
M4%#ZHTBE%'\U'5MW3,T+'9F\U'#WT-,%J/6N8;7 8729%K3?Q!C"G;7GR@_+
MAYOP>9B.L$G@ZR@@^: VH-(H:@NS_#Z3V^3;-AB^1 V)IZDD\FW5=2A1B>Z!
M<60X\ NZDIR.1]R.9S[#@<$&;.NFHJG,C)+@_EAPMSPK""V3N0:!+6VXU/!H
MI!.J!Z[N4Y]*CU?;P7WJ\2(6-3W=#E46A+9* BM07=<(5!.,0Y>:OFF'WLZ>
M:70TU^FX+I'@WEQPEUE9,BNKT5E9DG3O*,GO!89//9<ZIDN88_MN&$3,<8 X
M(\<((NFF:RO?!O-N.N!5X@:NIH:^9H!!%;HJM9Q #1W&3-^(@N!9SQ@V8$LW
M%427N?QV"PJOL<?G!G=QG(SXCH&_A/'UHK_S/XO;^-GN%)WYW^$?L9&([X>N
MIU-"F0>&MN[;FJ/Y;F19.K4MXOVEV_9._5O5M*=YC,]YE[$^Q;W]RTT<%CT0
M&J!BKY27T74L(>%%WZ0^S-VH8+^4LZ75;S'[G=M]2.=F;47YSD[*RG-YSYKH
MQPE3RW?6#3YX^-^LP.O_]K+IYKEBJI\Q^EVE$;S6.]J_H>-\9W?F[>?$>4M*
M=T[S8^4419N3$Y]68)0TXVOVG2C.AI?AF]'V#5KI94BM?[M_6SD[>Y>XHY4T
M^L<NW?Z750Y0]4B*G+_M@JU16^\#FEW%B4!X]S9"O]A>=Q;O]=.T8(KN=I52
M_3H=#>!.P1.XKV<UJ8N1G[/_C$"(1]<HR4NX^?M^&GQ_<9WH:Z43W9P>[ANG
M/\,^Z$/D[/!*.SO\7?_Z[?.WTV_O>Z<__XC_A.>=#C[W4+_Y\]\]+1C\D= O
MWNCLV[YV<OC5/#5^AV=<P7<_D=/+/^+37T^,DU^/S-,OOWW_^NW*^//7#ZC?
M_#@]_$I.8-QP'>A8G_YRF&[I5J2!6J,SE5B:IU(CT%07BRIHGAZZH2/47R!(
M%NZCTFK;$0L-WR>$^B30+1^T7A;H@4]U0J/(WU$8:)U#I)]LQ';VIO)7Q 14
MBE(YX0LHMDY?,>R<I'AGVK"J:BO<;M "7T)F_YC3+<1RNU=\>ZC<*[]1^%8V
M5FS,P*Y^T9V.8F!*DU+TF((& $W&J,J%"HB!7EUE[(H6"([*>C:-XVF6[H0D
M<C5"HB"B!B&FRUR;1;#=&#^G8FBPS7A]#?A!=^HVS?'IAS5<B;QVZ'&>PX(Z
M!+LFN0*C)4Y#;K?D('S^4=X@7^$+[]/+H[\T)[0CPV&J[1(\M>Y'JN\%ENIZ
M7N10BVJA;^[L68[6<4WOEB%2E9R 95%O(Z[$B;)_>0)_CAA.0Z[ 1:,^)OGC
M1PDKE&&6!HR%_*O_M71)C?+P:=>3:CU^.?U!^R-V>S79KWTU?=O_R])<32>>
MI>I,=U3BAYH*:HBG.J;OF,2,7,<RL>Y;UUUBTP):]N&W[B*SZH'FDF,L,I=:
MJ=)X&U=I/@$;@-G3'W^($YH$,>T?)V*_P!PT1K_Y>5RM=/WKX//@Y-O)S==O
MGRQ8]=KIKU]OS@X_]T^-#P.XSCKY%EA?O_TY.+FUTG$7?!V?P/U/#[_#JO^D
M_?EMGYS^^KOY]0N\S;?OX].?_?AT\/7GOW_BO0-R<GC\$U:[=OKMZ"\WI)YA
M@B1ME^HJ";50=0T[4)EE,=\-0.LAWKQ^$]G$9'H0&BR"E>DX7@CL[ 06S!$)
M7.K>TF]87]3,GLR*,ID6Y9 65'DS2N@HC.&:MW?K/@L5AGO'L[=I!3KHL7#4
M9V?1W>L.[;)7O/B,TYN_M, ("=.(:@4$D-4EONHQT*R9Q3S7<6S;"K3Y];-%
M&N\E:*51VN^G-ZA#<-<;JA#7<0@/094UK_;*?R9[)9KLE1#W"BPG?N68T4QA
M((E0.60!&_@L$]QCZJ@#ZY[R!G24HI>.8,1AWE'8CX -06.I*FPIE+O \[?O
M%OAVQ-!F289'*^BH2"NA"U\G_TOI'P5!]NDP9^^J'VYE7=0G$(46QOFP3\?O
MXH2+BS]WZHGJ:J4WJLQ,+ =4?MX5G\TYCL6'1.^ZEK?\\SN_?/>'>M?R[ =^
M6>OJ=WUHNN2!WY5#;L*0;6W5+]^3;]N(G"9]L_'5TN,^-^9!'(8  4]Z6MQY
MA@!+2?W*$4+R"EEK%?"!7L(6BG^++FW!8M]PJOOBM7Y?Y+%]N^"$9D%/J520
MYT[>?"9!R@X3<N]L0,R_C1*FF%J'QUOE]I';1VZ?=<1\ =8M-X-Q#TGZD?M'
M[I^UQ%QYD19K;R_7*G(3!N%S+-N/:9XK$8:JTR$3:2[Y9H\DWR&]-=9ILZ3X
M7R]PBGMEF34T7?O-&H%HDP2>[1#7U*A+/)M10]-\T]4CRV6^$YESX0_-G$W6
M5A$"0&;PTQH1Z3.Q(9*KXR1(!PQW2G,RL1\8&"DSL7]^_?+)//GVQ_>O7XZL
M$WC6Z>'1CZ]?CF].+\-O<*^?I]^NR-F7$^OT8CX3^[3WYV$P/OWRN??U\ON/
MLTO,;/C0^_IM7S\U3L8G/T^,L\,KZ^O/[_J_?QY/C[5^^_[CY--?5JCYFF83
ME9B>BPD0GDIUTU(C(W CPC"HY>SLF7:'+.B#^;;YFZQYR"2;8[97=Y2\*WGW
M97E7HQ;PK$-#S72(YAF4,=LW*3,-._0-BY6\2RK>M4U-\FXC>'<\P[M^2$P;
MYDVUS"!4B65KJF^YCAJ$IH.=UES'=W?VB-7Q).]*WI6\*WE7\NY+\FYH>*Y+
M74P9]$@0N#2,;-OV(@<LWP ,II)WG8IW/<F[S>#=TUE[E[I:H%'75RVBFRJ)
M#%.E7A#!I#D^:%:$4LW:V8-%HNF2=R7O2MZ5O"MY]P5Y5[<I-4W3]0+3(-2+
MP!R*=,(<%F '65;RKJXM*;,H>??%>'?6WC69X5/F,M4VB*Z2P-%4SW:I:M#
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M679%D_@GG3 87GP) !0"[HAOY6@6*F\.SB[.WB*_S"N,*O[ABEL_RH?)"-Z
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M15+21CF#=?I Z,CQ026XOOD]X9OH DV='%;.^<'^V?NW(G"+<[$X%E0^IWH
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M_!\W%\^U3;;$;CB>F;W*4.1E.V J"W$RM((@GE^;;R><V5L#9V9WLED^UPI
MYC,H=5G+D^B4Y;*%<5@[6_KJG3=KKO2Z4)4OZ-NHQ'TN5/VF+?J%QZ1;N>A)
M%Z1965_U\\^L3'FZ8-EU'#RTJ.UK7=&EV_$SW#+".L6EZ7C!:G[(M<ZB-VL'
M&)HA@Z /"((2&02505 9!'U%0= _'@ZQ]W68:929=*>28:%_JQ?[,1X;FQX)
MFM+71=!C(9X;;5WKD"50_X:^Q=SP!>^ZW8I4>7*:B7 !*!\\'[;4=T  PANO
M6ZBL3%4I$=TXIZ">'!]W:A>Z>+[TNH7ET>Y8%L;"9;'*%FCY^M@'#3JOWE)$
M77G]S)1790DG:<B@58M<?@S_3[1Q,+!K%TS_/M<JY I3I"O=?-'VPQN=I@4_
MP0%:,*S3^76XW<O/?#O!XJU=:;RZ:_F22A\-JTGIB/+=N?'UHTPIP;4F\BJP
M>$7=A*H;2QARQ\Y%(I0V;U<]PI1:IR78*H<N9I0DD&&@PE^Q&>$[T<)GW)CI
M6Z(TS,S1?7NOM!/+5<G[!LY=P7NJTE&15JM8=$/D?_'QC%.&K]VGPYR]JWZX
MU;:UOB/P-?!83I^.W\4)?P'^W-((\[RN:YG<#L->AM.&CZ6-UA4VVEPW2/&A
MTW4U;_G'=WY7Z^IW?6B9Q@._>^=37:=+K%6'S)L[ED();K= ?DA'S,5K]?9&
MF&N0"8]X5,=D=\%27GE+S.ZDE;MEEON"0\#I"$MY/:2M]+T"6]2F6,S BA*[
M8S1RAN^<X4.6!UD\+.I%JE;8-R5\FC#B)YWN$ATY"0T+A9=B5:J7>O1:V-2H
M&SNPIQ+GPM5@-'2/-:YCM]G5%[0=?EQ;YGO%M[!)<UUZ+>K0_&IY9M& 5V>9
M!KO=M3:ZW>\9](SA4QJ#$_=T+1\8+NM>I=>[^UG0BZ]9OLO"*YKMAK2@N[IC
M.H;K[,);Z+IGZH:ENX;GF9:]&]J&8=@6&"BFWNT5@YV]?4R5+5M=?F9E]PY,
M*! 10"9"?I5Q6<LE%;$_S/GD2>5+K,\BG=BN@&!5.N[TNY-J  =8LIR'%*OJ
MAQ^PHINK_DMY\P%+O9^F705>2#5=VS/?=A8=*8 OG05%BL5B=8L7BW7?=A<X
MZ24;/9Z-#,E&DHTD&TDV>AHV,NY@H_=C7K3UX;QC2-[9$MXAT@J2O--.WME4
M[$CD3GV>(%^<BSIB4P3,)U5#)'-N'W.6=AQ85W7&:?):Y>PNE^3V+DFC6I*&
M5((VH@1)XULJ0:U4@B1>-P&O-4+TW= BKN:Z@->D5"&XX8MG+]/! $Q:?K)U
MWA7\( N<W.GYK?[$G<O3S,+*$K]0==Y8FI:N@:E5;IJF:A@._.]>L]P05KDT
MRC?#1Z;D(\E'DH]>,1]A?2(5.P+JAJG_ $XQ!:?44H/FJ46"\6; F$@PEF L
MP?@5@_%CC /'M#12-PY*9\ZD3%NIMRN?<9RYLH]E]5%A[Y2-76M%'<6_MM"]
M.V@>\%Z/P !7\X8$?A"492S*7@9ET\9Q62-LQ@BXP!X<O"NP5=U]55/DKF#@
M)DV1Z9!U4L8(UR' 5B8COPBFZUI7_Q\)Z1+26S;H9_/WZ-J<PP=/+ T2+/\T
M0?,*K'U6W.!IQP5PC1@=SE05GJDR>S\6XT9MAE]HO6P-"<5K0+$AH5A"<=L&
M_8Q0/%&O.01/JBXM5JN5>5WZ#GC^+>TERB'C79U6!^27THXE(#\7()L2D"4@
MMVW0S^;NF #R'=7"E859R@A;RI&HH@I780--;)W1AR7RYAP;"/*?15\$Q,M\
MTBI#.1/^\5\Y=I^F\"36J?Y8(P+Q"7[MZ ?+@CAGHOXYQ;ZKDS^)6YZ/0 (4
M?IUJ]+QP"!?I+$PWG1H6.$XD.VR*'8AD!\D.;1OTIMC!U&SXXVYH$P/^"NS@
M>1M@AZ<DA Y_8A8'D]+TRN\)P'?]3I.!W;YL_P:[12VBC!5IPO,>1Q/N;6KP
M;.M^JT$2PZ:)P9+$((FA;8-^1F(P[R<&P0%E2[1Y/5T8"JN"K"E!=AM!UI8@
M*T&V;8-^1F>YO2+('O1H<H7]$7BI[BSM3S7M"P;KBC>'$ZV%BG60%[>H=)!O
M.0@[$H0E"+=MT*LE9_\HL[-US1%(>IHFZD0CG;2$JC?N4LYYSU )-YN"&U?"
MC82;M@WZ&>-Q>NER%3#%%:IULM0.Z74<"H6PHYQT#[L=Y;P'_ULC1ZTM@:]=
M7LY[0<WQEVYPU>AJ[DN[7ED-Z7I5W60S4I0]L61/K&?NB25;(,@6"*]/S_>D
MGB_U_+8-^CGU?/-1>OY1%@?8C6P V+6^BO^H>)K,;6L' NN:A& )P6T;]'-"
M,'D4!._WXQPP[21-,[8^!!,)P:\ @N7)["V'8-UJ(03?,^BU*A\!C.JW8/0C
M*V 78Z;NK8-]OXWZ8\7P./1XJQSL^TPCROK*KYAI3,-4>+4E8FT*L8R_2\22
MB-6R03^UTFC9Q/( GS3=!G5QEV,>0MU?NE;JC!]CV/?U\V85OIU0N+?B3O!M
M.; =L'Z?!46<*Q?=_354Q[OB<Y]&- ,T HB=:_"A:^JGM3I\G-"QXHBWD KB
MYN#6Q*DSB*S)MMV@*RWU=2QU2_>\&4N]3-\Z^A'T1SF>)*O@E^,HAL+\JEW?
M+4"N,DE-C:.9=9_.^8;F.:P[Q@^:G4<@JHRGVHJCS!]!LA_%T](X@U\N6'8=
MPR7XX7&2%W$Q*I00[QCT&+PQ7'*,B)7PX=%^[2LK([[S\KX"1_H*-DT%1%*!
MI ))!?<X;=WR3$2>LT(<=XC]T5TUA(S5:PC5T'YU<'9?'IP?Y,B5):;7P&;K
M[[+*M*PR+6GL%;N1%CB^+<%%LP8(MQ*6>8=.T^L2LU=W@)^F1=";.?O'&4IB
M_8:PWI90+Z%>0KVT6)XJS:2,CWYD%"L6E;;)Z&J4%R4-K&2<O,_B@B9)3)7S
M- :\Y46.D&H&,=[PG&9%PK*\%P_724/9?$7J%)9YG ![CK<Z(\469UV:#M@X
MYX[$ZZW&ZU>GFC\FPJO9GJ=/([RZ\Q<A=@VPEP<4#&MU\/[GP7EGJK5+\:\B
M?D7*:F59K4[X=[DK]Y-D1/L+4@?^M6;J0"T%0G+Y1KG<E5PNN;QE@WXV@'0!
M()T[N?P#\[,1S<:*OD9&ZD7<CP/ N3_@26RL_ IWNJ%CY9(%O02$>S56#CC.
M=)2/'P\DB:T\1Y+P5Y>5)/Q72OB>)'Q)^"T;]%,#I/@1 5+3C#(]&Z%'\TSM
M1[WA7YSEA2A07R?]J<.15*1?0N2+:0E/TT+PZ;*_)W%*2X+ZYD'=T"2H2U!O
MV: W"NK&%-1U7;,1U,NZ>!<\A7IY8H6U.D(?I#<L*7\:P+H9KP7%C^O\8<Z'
MRTQBZ;;$XY?'8\/LZA*.MQJ.7UU"PWSN&OQ;I:XE.0<FT15[R'CAN!*^ /1"
MY7SD@QZK[ <!"*& 659 JQY(^-D8_! )/Q)^VC?HU<MG&KJ^LW<.NI<H$ $K
M)$O8N N@4ZE9<:X,:,@J_0J/X]%BE#$%R\\JV*2M2"4";0J!@!LD DD$:MN@
MUU* S"HI\P!G=]*&'D_\9F#^Q4/:QR:3P8CWK3R+X J J_-1EH_0>@1@^CQ"
M.U0WJ:J3-U0<#M:ML/R-#TL8<'"3+"YBN/CH1R :]>P'7./2/9/P#,K],!WR
M',[:_2^P- 0,R=0,O);?BF8^35BNGOU CV)Y%P/,90F&&P1#0X*A!,.6#7I-
M,#3N!<,/<4+A1_A)@N'K!4-#:H82#%LWZ/7 T'BL9JB[RN_=B^Y!=P);NFEI
M]V*;I]D2VUX4VZ2B)[&M;8->$]L>J^A);&LCMF%"U/'IA82WQ\-;@V;UW^\_
M?^0EYWA[Y\,T&&&.P<PDRZWS%%OGXN"?<NMLW]:YI#_2)!V,09TO6)+S3)V@
MQP94[J7-[:6#_8]R+[V*O71 ^\&H+S3,CW'RW<?4:KFS-K:S#H\^R)WU*G;6
M(8OB))8;ZYDVUL?]]W)CO8J-]9'ZK"_WU#/LJ?//1W)/O8H]=9XQS#!>60_<
MY1VJ]VZWT:XWME9-NR82+B/3OBV2];VXZPAJ'2^NP2M=_K7TOUFWYW:]]?^(
M(I&/__<X"=%ES3 [-*%7XDA-  - Y[>29O#S8 C+CA9I-E:&?9ITE\IUF.9<
M@WJ7,;11KJN>Z-S?7HZ?& )0=Q9_D_IYVA\5[)<2 +3Z+79NS^(,EL_X[?/1
M8$"S<=,G4C?L1:WNQ;^];(J35TSU,T:_JS2"=WU'^S=TG._LSHAD3L:W1"=$
ML?<//]O=6SJ+FY'BID(Y1AOC3_<->O6\;V=G[Q*Q74FCIA;Z>-*7Y=T)8+?G
M"^):6PCS9?>2IP)[$%X4HSPP%%D FA0<[GLT5WP\SWF%YRVKDY*@8PQ9P$..
M >A2-$X4//\.TY>+N&.<*V5PM*N<#>("OSFYHD>OF;BI.'R9LR'%PY_]<>T<
MYC1SC;=?K[+7#M+!(,Y1T]E."L=#P#M[?W^R6;UG=O#PK2!Y?O*6KRGME__W
M][___?_SG_5?WM:F*RUG$M;$W/%>7"8A _(9P,N$<->W_(KJ"W$2I=E Z*3P
M\"0M0*6 JW&MX?2^B>_XPDTZZH=*/_Z."R2@(U!G>S0;W#X-K,21,N3'Y^#"
M,,Z#?IJS<+E.LL9"N8<7V[3DG,5+[KA@ T6WN[621!>"X%=Z:V(UZ!67[*K3
M-&$+5D,<_M^=%4]12;WV:?1:IR%ZK=1<FZK,2<WU+LUU!@)@RU_%2>46TXT&
M ?$MKA$ <''\Z^G^Y>^?CRY6XA:G2:^T!-/J67BHE63L/Z,XXRX3KG25F7E"
M*]--])[HUIOPK?A#E:NWPG&-LOI_9Z$&-JHTI%!H>659*AB3+X[UP@>H@A6H
MU/=H/T*E#V_$5ZZX@-\Y8Z,$OL5O2$=%+\U &/ 1J)(7*?RN7,!4?,@P<S$/
MT@X&GV/0V)*8=GC1E;* EW@[@S>S-+1[-+%Z:Y;9-5VJ3]Q367VEO(+K5S#"
MM/J*\-?RO_AI!F^%ZZ-/ASE[5_UPRQ]<7VPXWZ [#OMT_"Y.^$SSYY;,8FE=
MUW$XN91!B7(\)?%T!?',-;$1'[I=DY#E']_YW;MO['1MRU[QRPL#*O86>-V=
M9_"Z[_?[Z15+V$Q[J$[E+@VZ*P19JL65I(+)5XER55A#X)6;%:1IPLA>(D2X
M-7&D]^-W*RS:9Y/A6K/?(#&NXHS9S7>50WH=A\H!<GM'.>D>=CO*>0_^MT[,
MNUD(\*S;JZ1T?!:,3 '#&:1935;K%HU<#*\+:S$VSWWLH##W8A8M.-B(WM 3
M47JP- K>IS0+\9=#L">"(LURN3R>=L!/X C:E'$I_%AOJAE_V4'R![^+"Q!Q
ML,JP[SC ^Y(OY*XF]+?+CL;=G3%3MV+O"1ZLZG@FBQS/[?8#E0OD[,O19^7L
M@[)_>7GV^?3HZ^KNH :_[.WUQ*,/_SH]^Z+L?_RHG!]]OC@[O5#>?U4N_WET
M<:2<?X9_3R\OT/-""X71H*<,699C[*N7YO6";'0X9#1#[TT_O<%<G+R(BU%1
M1DGA4VQ5F2_5,D4L-8L#/'DSB,.B_'N'?\ ?+%AGP'U-Z$)*,RP IQ39B/&+
M^O0F&O456I:1RV%60&"!J/!+K]#?U1%WFL1RX?J^,JP*T.4C7PPZ3I..$N']
MXT'U&+Q)G-0?G- !ZV!R4<#P3WG!J/!#T404'*9P\X .:< =9[RT/,IKYG-:
ME:3/A7\N7M**HW3/:>J_A$3@8@Q1BZIX?"#\I?"690 U%]XRN!"O3_$7)2R3
M[7(<)LQ14I[*Y5?B#3KKQ+D[(O0.K*5PGUQ.86KO%O_MR:Q- ;]0N/2*,;YA
M*,8.*PYCKN*+_ [ J2#"\MX@-!@!=VOF<2'6 KP8RW,LU"\\C&&:,#$U\ @_
M'17\%8<9@U?!J8$EA0/AEZ,,8^'U%H\?94-8ZSE?=V*JX7\#W$$BU0R#P#!4
M#&;SO='AA0FQ7#0MXFB,H\/[!)C'@&'H*_X(OJ-6$%G*"^;$&5]VL#PFJU0,
M9?(;7#J@XW(78)@YY:/C4>F:$&!8UW%6C$3UQ#1:+0A=1S94D9H4-E[&\??X
MO1_@UI[ZK2?))Z7K6J!>Z;*.TC[\AO,LUD..F[CT:I</KJ<&B(KD4Z 0^U7\
M->1)CI-,B.63U5BW-,Q&5RN#GFO[I0W2];2'^IZUKG[7AY;YT._>^53+Z+K&
M0WWI+S-DG71=_5%.^A<Y]? $#KEYA?LY'/47E<HDCSULW=Q>QD5?SNOVS>LA
MD.\ZOJU2$S&?.O3T!$[F^R-F3S[JQ@Y,BK.1XMPJ%>-%W/DKQ_,D/;V*V UW
M\ZX=P)&+8RO 8-*SLLIV:_ I]E<817^UN^PIHJ/+8TX-]T[*P.E+2'U1Y+0-
M^Z^A^8NOSL*1 WN- VN.BM16%13MT07!?:D';9DI*NS/6X7#Y3QOV3Q+D_*E
M)"]15%J36VA-3BD#O92U%M/2N)3&I;1(Y,"V=F#-49;:;%SN9S%3WK-^/V17
MV2BIO.T?]@]DKYMM,SZFGN>#'HTSN*N,9[Z:R9>6YTM)?IL@5HZF>:.1YH <
MF!Q8<QBLS>: 2+QYGV+M,+AMZ_A):H%WS[%,8WQE$R[5_I?-86POE,K1-&\T
M4M67 Y,#:PYKM5G5_RWM81_,KW#Y5>O(2:I]4L^7$R[U_ 9(OM4X*D?3O-%(
M)5\.3 ZL.9359B4?^WG\5/XY&K!,)CUOI^8G5?U7-N%2U7\QR;<?3>5HFC<:
MJ?#+@<F!-8>XVJSP_Y;FO1%5_D5_TD'KR$EJ?E+5EQ,N5?T&2+[5."I'T[S1
M2"5?#DP.K#F4U68E_Y !V=*><M)53EB>LX&L%+1UJI_4]5_9A$M=_\4R];<
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M^8B*[1HG?4R"V>5?$:P:!TW=R(6Y]?QP0OWY*EP@"2XH@F_O!'WHLI-9BS^
M>OCFWKXDOK-,-AW"=HB-R'962 EO:XW2=\[59 5F=JCC"!8F\J]D2JH!V^HH
MGU/',;TQ6;"0.#<W8_D:+VO=^$K/"!ALA]$+$$(I%^*- !_D!2= VX2G)Q[\
M^ZQFD#H/U#R'A,'3=S28"O"-#[5<]\F'6 W7^-#.E_]#B5^QAUYKU#C13X#4
M])F8RKP;G=\U5?GA]1&UU27/IRV#9"LEDIAI9D$QZUD.WO2VB\=PJ%^I6;*-
M&A?7:]?TYO3&"P*QT2MFN$KYH@+:6N_KAIG4!?EQK;&')'J""L7 G2ITX^Q-
MW6><TUORQN;1/)LGOXCH!+:^S!?9]#@#4.V-UT3W$1E?]9#8)2"<$Y[HLNF]
MS0/IP03IF="W\-R!,96.6 GVH]@<)EVHQ3,744A]W$/R/"8(YT/DFS-,<CUY
M=O@*;DM5OK<&BL9%F[-B9 *M(H1>&9*6 #0=C+[R(A=MN)P_ZZT:9T'.A[RW
MMW0^-P,V/K@1_.L5]=R5YT^H"\KI>K[PO9<*;Z4*K*7QFY%I CE@NV']@_6^
M=]/HTRWQ?P 6(/F)FI'/(PWEHZ^)IJ6SP?=XYZCVLM9MY,/F?<J;GB]731[(
MDBM+T(Y6<!_.J#^9$3<6YS]XJ 84*>R7J<D3!OC5?13BL+ >ZD_*(\[6"'::
M9$H?*<HG?,]3O3##$7%P_LIM<AMI;3ZND1BN7/W"9 ;XIS.8!1_\M@MJ1;QR
M*YAXEUB*S^L@8&>!23TL@! RRV.-Y55$[]U/P_G#L0,<-8GS2*>10T+/7W(O
M=SY'99W)RE>X$C6Q-*[M+UC *YH?"3_#@;R0U^*6 S3K[.Y>V?.!14.-2S?L
M5D>@%IVJ &"Q7>,2>B.VF;"44O^\8@SE (T/9D/"%8D,E]<N<I*]T*V2MA(<
MC0]Y:SN=# KF@!\K+-CM.*>@:)PE$<?V4-B\_W#GA>9L L,@"PJHS0"D2BZ/
M,HC&I6],'0=\.A8\C2HL=[%AX\0_^#1Q*#*%VHJNB")PXX,4X=0)>7NDIN>:
MS&&\M_$,5]^UF[.M:5:*%^M41&BW0]G69$*\PP1WDBN9&GES!<BV)LY7;K2B
MT$L &A?T)($C$JEY#S)3:19D]IV597FU<#7L@R;G$NYM^"^W?D&("3Z'! $_
M##[Q1I;%0Y2P523,NG;C(HC*HP[;H&QMBF8]7CM9+R"7!7<GJB7CE:RVPB^S
M)7(W>N;AXBU#O!.*!U*)<,;#94E=DY#6._I:49R[);:/BG/S?M3.H!7K*5:T
M7[OK;)248=?&U%:+5F*E__0!*RSH>_O:?? ]DP:PH@-*?',&)BSCRM0U_S40
MMW7*/FZG4A(#38^G7./Y&S=@ICPJV!X"6QIAY_<WH(,RBB>P=%=5;-ATM@YO
MQ+$B)Q_P$IEAKG#XF4.E[/(6F-J0:^9:@UJ\[B.I!DA\L.^8HDPC,+R,>=-2
MP-!,($D#EL?;?T;?;=5[R9H7PTUS\WS<E_.%XRTIY2-)?JJ.HNV$LO&]Q!-,
M7/A]@?ZNI&@ETZ:MG(TWIR#=0$N(V9(T:%NUH=T,T]:M[.J@9R)/F$<0TB>W
MJ0J0;1WT#?A8E.8+&86RF7B7;R%U+;&1+1V[.H(/,H[J99"Q5.;\'M>*[VPY
MIRZU6:@:JU%$TE:VIQ*;/<M<43XB 6GM3EUV2">3"-SAP.D&+*V=#?3?YD"8
MA1<YVIYO5L3JRMNWP+P6ZSTK-C[E$&U=I;G#+/\'^^!@T!^>UCX&4P+9. \3
M]P#]MC!;VLEWEOG-1HT S*YH6[M\U77UOY.*'L&6Z'Q\.QJ/'B>8XA-YRHH;
M@RJ &A?M7'71$\%JC;KID5+ Q@<7NT";0W,\P/_@.<Q<5D<9ML#4ABA#U2&+
MH'KD=5"T8LC<KZ^2WO56C8OJIMU)DEY=)LKQ(J)H(J]$9&9DA]1//M?:]M1#
MW%:G8[,\?E_8ON>&\<@DR0\5X/8.?;[PZ0P6)G (CX\)[:.JS53!V[">?WH:
M()/GKH@HM(&TCSFQJ9R-W%1 N%T0=1M,C6OM^#A17""1K=A5.H8D@6M\:-<N
M2,T4D\-B(W(17Q9S RK#JJ=NMD'5!M43!\>2BI"*&RI*6C=?ACEZ(8R3<.7Y
MZ*BO#@]=T.?PEH3QIS]9.&/N9 :VD!O_))U6[A3OC+BMF54*6KIB">?;-+Y<
M57G!?3MP?./C-:!U>=#E_9A=W4%+F7X-*HG!7TO<Y/DOW*@G6AG&G!BCQ Y)
MM%U-/$U7%&4N^17Z.;='D!U55(!L*;.S18Z7#N/&*>O$92^)/5\F/%.Z![L.
MNH;+*$>VS2N:J(4J^@'$A5DB CF>,6I?OL$:QS( <?M\Q;4<6R)K7'.67!(3
ME-X24W$[R;;H&I^(6\]BP!K>1:Z</4\VZ+",1BN/[&Z'K6EE"-0M""L)].%N
MS VJR^3K(6FIBDRHST=*7"L)"*I=\U(72^.K  /VXXL[!O,$6]#:L?Y*T,8'
M6'UTI>JB\1H8VEHKQ.]4 $=USCV6Q]6RE 1[2B%:.\BT-)(K)!'J3=*+L?JI
M=9//]@C;L)U/[G[AEH;'X=3NBBFV;WP-GV^\&EYZND,*TIXS'B4/4]V" SUS
MTGS%-499<5M9]X&K<CQM#?5/'GZ/SQE=W><>FV&J;]:H(VA<KJ5IUEC?*M:]
MJ>%H*]>W/ZO[;W%0MTZA04MK"YI,_JQ= I"[3J25V2HYP1]TVPL?C<J6SV;_
MXF<>*@[!KS=K7 3OP".=C?C[J>0RPF*R4<#(*$+J'?@#'#.3$I>1JDL7:J)I
M?.!Q461BQ1^IJ)%[H/Z#[^%%4:,I09%YHHZ01_XP='FH8DMT;?7["V'9.QKB
M^WR;WG)3C^U*D;0TAB%_$DNQC%P&V]IBQ0OJ>G/FJAP/W-CT)Q\0)*[KA1P=
M?A-_MU@PU_;$%_ 5/I[])7E!^Y':R5OTA1?F-SQ3SO_S!?Q!W\,QR1H?+D19
M+LAUYIUO@6#F4UM,<"]Y1_Z?X&M]!DJ2)H4.<."K9\#QYT, ,;%XDO$;5)/Q
M)!C$? 5LOG#B&6KS\"UJUQU^_.[,?\+H88W4'3V 4.???N +G]8=.( $F"3;
M@O$(CPJ#Z[>Q!U[D W^7&K___GB=]HPT3JE+/YO>7'2Z:IQ@3'"NI/!;O]_7
MX1^MIUUX)O=QX4\.J2'H;X?K &NH(O"8[]UO_._U4<; <1,)X)I24(;+KZ:-
M8/&7R2Q*YC8;)0I4YC</()ECG<_Q ";V"2:'QI,<@VL"OJL3_4 P&C&C(6[<
M:\]Z'EK. ER-4A9HO^;0_:U#+!E[KH7!(2N=G<"SX\)IV.42?OMJOFY630/5
M1RMGXK#?-]:8F':R^C;0/%M;]:-!1UJN)PV[ZA!_L_-?FH^&6<HFYT7L PL6
M3?35J[F]>R=RWAO]_M$:[_,<SW2JI;UJO#LN MF._UL376N_QIUW:;GOS*G:
M6ON=>Y0+RE&_?_R!@M)A.Y%C(PEF5X[WJF0)-@/*V7C<[Y_(V0B(-(ZI0RRX
MH&F-E6>?1P%S:8"6]"F:SXF_].PG-G5Y^9$;CDQ^R3A_:=H!V:5*O-JQ!PE3
M!WI?U\5F@P6FXP613_'#JD-D:]*E6(JB4_P^TZVVZE=+.M[+@"*'?IXL*,G$
MH __?)!,@*J._^J2EMZ-:;PNXB<(1]R/3#2&_>'PXT1#$+ 7#%6&K>Z O79M
MSY_SP5S0D##G)XB+M'>9$!E]P_@P(>II*[JT#&'H+7+2]N*ERN"DPLZS<Z_F
M>79R<NXG"9HB'7*1.S)XO.]C1"ZA$%NG-&I()'XCR.RD .*9@RQ+?X^8A0$^
M%:$IA97[L\=ZD=$"599Y";(.\2*MD+ZE!.<ESAI7,V(SH)P+)SJ/[>:X@'@T
MCDC+8NHZ"]3=.QFXW&L['18710D[NNB&;9Q8B7^S-;-D..7VZ\Q07E"5/E#G
M67O%7%#^C#C"-,<_621,6WON(YXIQ@*1<Q*P8$>^;]VA5"CTOL&3+XI"D1*1
M>"0)&1H)LV @*"DM&B>FBX*S>O9<23=GFTM-(_ROR+0,=">G6-T&%F"DAD_'
MB$7Y9'?1UF5$+=U^8=P>DRHOQ!%%IU@:A]6E^ /LAC(PX_0-&A*DUS#8Q6L8
ME/>&/Y4>N3H=&CR?6;8R<:.WVA7R7$>&R$_:BDSQ(VXC,^"?M!6M&@FTE-H>
MD-M#>K45P9W<+69%(=WSIQ8R@ W_VKT?>-M'!NAYF7EY,+X%9*ENN3^R>[G@
M&0;/C\H$+Q-A6)EJGG1+J=* +(W+$1*60_"\U#*T:0EQW;;KNX9/%3')67]D
M\)QJF8':AS-+ZM16QT;KUJAE(.6.VK%>- >Y C5MA:KS7%#WX*3P<F_N9%AT
MG<LXTD7?;O/4KHQ9?!=(<NL'V71:OH8"?,_NY%KRU.B?*C,^;RUC(K2$"NZ6
M<3JTF) N!^BK62BNA2>9QVCN:/BN0B+M02X79T;_;&NY$/UR>4A[_J1!WWM)
M2"=M5Q]I"ZQ2C@_ZAMZOP?&]]Z2\U(LWH[[;&B]#+6>U;NB%*@'%Q;WJ<*_<
MR]D2WTZ1.3S[CCPO1R[G.FCU0JI*D>MQEUJFST[RO?@Z2S4["S#2O1'XXL6(
M!4>A97!T>,K5MT,ED-*-T, 8%K>FA>GOX@YH?39W]5]JX9,KMB-#+Z0BBCS;
MNRP2;FX(RWIK[^ONP-L:V.6</C;T0IAB$Z<W!W4S)6-)MYUD?GPK)RE][$>%
MQ]5(Y';N1"^&9V.<\2'&#%9MA7;/I]5<U%B2RKCD"_#4T OF485KW5QG>(>H
M&G=$2_F*.=.+H3H!V+DY57<"<^VEKM^P/RQZW@*\B_Z>&/FN7IX"%JG"&>J&
M7L:4O4-78%=:Y_'=M6#&L":;6E=1"/-VY[ECW.J+"Y]X\^2"*_Z$??[MN%JF
MY8.ZE@O&P-"+_D,B&)EJDBPYFJ!' X)Z&8H$G);0I'&BM)2J5 ET4*S$@?!;
M&LZ\3&V0BE240$I-W'"H%[,.\9ET@2F3P>\\%VHL43D"^4(S#+W@=I3QI)-K
M!%^V8*(<B+O7_!P,=57/'<O Y:OE2"]F;#+88H<\@Z]33,D]51#$;Q4,^OHI
M_ZQXIX\<AYP]QWHQRY*]CH/CT&*DVJ^(5GS7K<4CG^,:2DX5E5S=G1AZP02I
M<:VCRJ_.#3<UV:B"4;X&3_5BSFN;*W'V'"W,?WQ'T'8+M YF^7H],P8;C& =
M#L?==7+Y\IDH7!>O=LW11DCI<C3Z>C%3PQ'U."8MBZKS7% /<DGAI4$O0Q\6
MP_!E'.EB&&SSU.X:%ML"JU0+&EC4H\S&?>"LDL&K^S/P9_$"QL@,V0OX CP\
MA ^4[\SP6KW(!6!H# J.CD0 LI=P<+,H.M>2WN,8&/:_EXH5O](\-G]UY'G]
M#94,&P/,.(M5'0317'RWN\"\$P%R60)UHFREUY+MG*P>IRN)IVJ<LD\Y.0L^
M:2EY6H:^O:P5=</J\*-XHBY>H>^G?"HZD,O*$9B>[?1.YE"G$(U4]^R%0'6]
M)V],<^CDK7%4VHUHGZVHD8O7L3$HU!OLKHH20F/!2TCEYFZOF6H(Y<;?X_-
M[REN*OW(!>G$&!3RR*J"5-8L)J"3HE'R\J82NTMAY<&#4[U8_!>CTC@N+8ML
MSXLZ"K\*A7QQG1F#0A"AG#.=7"\CHZ__0/NB5#^;-I:NB*.^7JS& ]!??_R-
MF[(N3F^=*N5U&*F0'^G&H) 'STQV)Z7ZVH79I!/RIGK%T*JY7++QDH#BY0T(
MK7'P;LYQG<N<UH&D8>"CX;!86YJ=[RZ&?C-SN/N%)FJHY!K(, :%U'2.2?O
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MSC* M?11K=TUTCZ<X>FOPATLRV9;3Z7N9G[Y*\S/)VNW5!P3Z6YY4M= =1^
MW;(%FT?H$//O?F ;AC3(HIQ-/G\>+ML]+I*3B\O78'SL;::['M>5)WM#[<H1
MY/=T7G:5WT[F,,-I79(CQ68N7A_'E@>>V9TWAX!NRZ .DVK?1[=F5Y.)=CWD
M>Z0>IE-('^:3^$>Y.;+\/I^,<,&<+6=^1^;M,T)%'AY,T&E8^1+R, Z[&/DC
M1SH5:W<1V(W%BU%^1N_FUN'E8UBXY4E=6;0/P!8L.'[O:>?SVK"C_M[4YG%J
M[U4=,4H;!IYJ+VOSZ#<7"I=_OUO<./PBSH=?T9XNMF=*77UU-A\T:ANV'T]X
M$S%<EX8L&GR$\O]5K/?BFY^F-9"S4CBRU)P9!J[+]^I+J!*@1L)KP:ZFT^OF
M)L?%!Z\TK=W,>F# QI/J$'(?8SZ]0@Y/+@$6WWY_,8WG95L:9WPO)M=1Z!YG
MIG5G9&/Q;_S_ZB1V2\'N,VYSD1U,?#=AK+H.O??3^>7'J<?QXD+NQS!XZ[.Z
M,FT_D&T8T4'A'GID*[:T* "6E/U1;,11];S77^Y<GKL91B7:NI0LWWU&-4H;
M"//U&/\L5X,=>_WYS=>[]^[> J4:A5VN>;_[D(K4MKCH_?KA]1NY[_?HBOPY
M58B]-N2U)WSC!^''OY5"R#J\VV. BAP\E)Q*!9NK5CG70%:NRZJMX4"D&)-A
MDC@?))$F,!*TM\0S:[/.4GO>I%1L-ZRNF_FKI_\"":9^=)_J8)E'8(H8X(Y(
MGLN-? "$)6.5-LP&W63K_@%<?2K&K*@W]RZ@KRB=:O4?*U ?YNC"O1BG-_B%
M#="0,)U%=(1Z9XF,QA,G72**"Z-T,#:9W%!Q=J/K4SEE>_6I**EJ2O1RM0NT
M4NT'(,I()55,$.8S)U(A.A]!$$=3P@?I'$,393H(9666;%.(P$IE-92VNC(0
MF2TG005!4G8* CCJ5),+D?>#UR?#W$['[DZT!J*K/M-ND;\-8>0J)U""*+0Y
M1%HNB W"$2$#1SL1@F--G)Q#0/;)>)]>Q:J+L9JB;0.319".:HJRMP:UOMSB
M+6@FR>8D&0=$VD2GVGK,VZ@UR:>L!"<JAT2D*W<C6)#$FRQR<E91^NAAPN.:
MY1IZLL73J2&41W)QE-.& C=$*59NU*.:>*DDT9 T&"VX<J=8UI^.W]Q"C=J)
MK%DI]'K>9*U=V^K-WR!.QG$X&E9,I.T]3,V4T%&D54H,;=,T"]Q2CN&VI!$#
M)^$T<<(I8JG2^(?-7C5II=5H8=O"V2VCO9BO39(+?/+ES?=QU@R,Y#%@Z$H8
M=XY(2(;8:"TR)\O ,@V4-0G9JE+Q%);-0[3PKKU[/)'7]SIOD[#938;9P#":
MO$&0P#*"9"83SR-%_Q@$,!FU84WZ\AZ(\RFLM TTKXK86NO6VTE95"[BHIYY
MQ9-%P<J]ZH>SR0RC_B@U0P^3<)UTR:]AP+>XV"48P<O94&ASUK<*^CX=_#VA
M'C84<6OMQ#?.T(4=SF=75X@,K*;4>6F)*U=V2^X$\=FH<DM(R)PKB#:<4 /O
M(SSPH&_;5I\G5+..LJIS]\\6;/^<(IO>Y?P.7>[WTTF$V6SSG30#1CT 4Y&D
M)"5J?]F=<)!1*T I3\LFPGZWM79%TJ?CNS6UZ/1B:JI99^=^_ E>CZ\;$[[+
M=\^O#4S06EF?2)#E\AO!2T-=S@@-3,0 :%1MZJ)3>V#81YOT#Z9-M473>K&[
MPGN5N,$/+'M<WB\=&42CF3".DB3*/1&!:>+1;21)@?;!)>#\E)[_ =#WT43S
M!#7QD83;6BF7MWJE_[E8'G*?#62TTH#U1"T8%'4BY5H0HJEET669K6[2X6U/
M?/NHE_WQU*N3F$Z;S[TW _RX4E_U+L,UR>\>0VK'/.]B0;PW[EN8OUM'LP9B
M0*,S(;-,5"IU5[&T7/'HJ0-7ED;-05BSEW=RR*BU]J.NQUI>7!%]H-HJ3C0O
M-Q<%9DC V49X4C)$[VV&)LOB9CA]R+BVU8=M>TX=Q%)]R_)Z9JX3J;E)RE%+
M;$@,(U,=B*. 043P@660*5+:4E$V@>K%'2&/HR^=951=:^YJ<,+U5*=(-*HL
M:K#C)'!G20J&:<8#5Z9)D[E]#$L%(F^:9N'3S_QT>IDGTW)*$:50FK)I9'M,
M7I2[@(!8GC+ZIDXRPZW(DIV$\NT8^V!G*^K/@T:UDK3:S9GK5.!M<,PH)<N]
MAEXNVJTY#+NYA9+#88!>L)6YJ=%] %^?MJE.H485I-30[$XFZ=MP-'HQOG>1
MU( ZYG7&B,:4TFZILB2.H[ISFKP'H:A/IS%).T#V::_I%,I42UY-C=+5>ZMX
MO.26IU]A5OI]EXNO_&AV_P*L ?JMC'J*Z(4LE5& D;1V!GV1*%- 6^O5:9;^
M(PGH4^/9$YFUYG*NLZ5P#_JMEJ4%DZ3*.HL>=;!4$YEC(/@*0RAK([(I!YV/
MC,WO#M6G[::*6M* SZ>T4.N;\ZB]JP3B;,?NO4[4RU"NC38E:,H!_P)4Y225
M]TDPEGAZ)&MU,#%]VK1Z',O55O[M-'F1CAXH7."3R(EP5O8QK!'$:Q&(X!&2
M"X$!-#WI=AM.GS:>3A(E'BR#TZ3>*!K5H!."P3]PG64:E]A <;$%D.@,&B\?
M.?76:0*L/?7]=(*1^ORR-!"9X_0MS5:7Y0L)4HC):,(X]T1ZPTB0.I:#'()I
M;ZD4K2/A?7#V,;'26:=V3)SJLJON)ZXA_*TP_5W^?;:\&BP-;&3*&_1?5#;E
MUFXT_0'U@!AEJ!$VR72W,NYA9W''>'U,EU13CE9\;['DKF&[Z48_&QCA(]/4
M$T9Y*I[ E9XFJX1)27+;>B]L,[(^ID9.9%6.E4]CM5FZ"MF&[!VZCI1KU./L
M2LE X@0HHY0K:Q*<<%':VV<[=>[B1*IRN$S:N?-KL-X"QAC>")8@$Z9<)E)#
M.?IM/;%>9ZH<4B^:E  ]@*MN+F;7EJ>.F8M<#KL#SE]IK"#!HGPBR$"#-,[E
M@U?: TLF^N&,U="0W:F:6F)H-SGN%_"]G8SC\@SWP"&AR44,NI16Q2XP4N[P
M*PUP<E+:&8 FIQ4.0MF+PH.6JM5>=B<IH;MJ);=]_]>/T\TQC,KM\@X<M44/
MO2Z$UVM0>%W>=[L$LUSA/,5W/HV'_[M0L:ML7>V*Q@.';5+9V(7T;I) &U"D
MCP)?_?4>IHM\Z#'\W?ZPKES;$V8C7AS?;O6A1S;C2_U6K%N'NE'C5WXZ1G-R
M_9^?_6P8\0LOAZ.+.:0.,[?>X,TXWHT-S67S8CP?I@)@^'5Y7+6+(>TTW@DD
ML">Q'5O^7X09_.L"?9M77Q>)F",8>>\9G5OQ[P15E^ NUQ9L>51M\EN('490
M+A3YOQ=^.H?IZ/*7X1A=W:$?O?1S?S'V%^@T03J**WL^NC.7CB'A)%SK<.78
M00.<B(,-+B7;;^ N4_.P$4[$R0<G\BI&+#_*Y3!__]/_!U!+ P04    " #B
M@%M0R#A,LTR$  ",D 4 %0   &%L;&\M,C Q.3$R,S%?9&5F+GAM;.R]:W-;
M1Y(F_'U^A=?S=;-=]TO']&S(DMVK#5E22'+WOI\0=<DBL4T"&@"4K?GU;Q9X
M!P'R #@%@) F>F22HG">RGQ.56967O[C?_UY?O;#%YQ,A^/1WW[D?V$__H"C
M-,[#T<G??OS]TZ_@?OQ?__EO__8?_P/@__[\X<T/K\;IXAQ'LQ]>3C#,,/_P
MQW!V^L,_,T[_]4.9C,]_^.=X\J_AEP#PG_-_]'+\^>MD>'(Z^T$PP1;_=O+7
M[+()7'K@3F90Q7'P"A&22H5%8YV+XG^>_-4G0]_;!(+3'TK)!*XX!<84D3PK
M02.;?^C9</2OO]8_8ICB#[2XT73^[=]^/)W-/O_UIY_^^../O_P9)V=_&4].
M?A*,R9^N?_O'JU__\\'O_R'GO\V]]S_-__;F5Z?#9;]('\M_^K^_O?F83O$\
MP' TG851NGT /3[/;O[A733ZI\N_I%^=#O\ZG?_[-^,49G/U/+F$'U;^1OT.
MKG\-ZH^ "Y#\+W].\X__^6\__' IN3!)D_$9?L#RP]67OW]X_1#I<#3[*0_/
M?[KZG9_"V1DAGG_"[.MG_-N/T^'YYS.\_MGI!,M*]-=+KJ!TA?/O]=-^VAK3
M*0&9I(N(0#_%425XCQB7??KVF&\^"S*6<'$VZQ'QP\_N%>_X/ S[%/"#C^X!
M[?R#X!S/(T[ZA'KO<^_@O :YB) (/C[!$?XEC<]_FD-[.:8]^'TXP:=AU7],
MS^:>B\O7]]]O__&=9Y.2AZ-AW3?>T+=7GU"?M3X*_'.&HXSYQQ^&^6\_#K4T
M*7-EI7%"":>C<2QRH;EGDILD!]('D;1F@"K39FV- (_,0?3<,%\4*REM)J:?
MPUG=2#^>(LZFFXCJ_@=L*:Y'T"R(+*K@E _%<Q^4SSE(S(4.K2"*S,''06#&
M6+0%G @D,E$2A(@)4A%>>LM3B;H'D;T/$SJ[3W$V3*'#COV$_.Y_6I_"? 3G
M@F2]U\I:LB"DYDH&[E5T-@5T+$G%"TG66.E+X< X*E#:1HC6S6E94(ELZ=<V
M?6<)QVB*^>.,+*%J%$W'Y1T="_/3>AI&^>7X_/,$3^L^]@7?C*<;47:3QVR]
M#VRYL@4E<8NR1.*[8JAX<+0;&(<RLJ*CE](-'!,<8_&T8[! JF$90D'25,'D
M$MJ@F=M,27=70,NB_6TVC&?XGH2-DTE=X3C]BQ8T_^_I^"R3*?S+?UT,9U]?
MD>#2L,,)_%!EVS]T2P7VO.H%=2:?M7+,A:BE*ME[I[UDVALI"\\N#73,)LN8
M0=*+",I$ UX4!SDPX=$SP^VET7F]QK-QNO? LVKRCF_.Z#/:"\_F/QU<3.$D
MA,^#FQ624/ U?3D=<)9XQ!CH648# 600@F!@@[2%8>8LNZ4G_/QT+V$:YT?\
MU1/HJ.?N)SR;3:]_4G7L:!NYLIK_?3642_5ML[A%M0P4:IT4^3XD>DX'A&3@
M$T=:G$DIQRR\]6T6MPCE_N)NV?EB<KW,*WMK0X.L>I&]ZGHV[E6ZETJD)?SX
MPWA"G_&W']FV^J;=]'P\FN/Z>$I'W_3=Q:RZC-4+'W#%E1$Z0_')TE*%!,\"
M I<\)#3)^-*$UH^!>O8<Z$WB#]G MV7#)SS_/)Z$R==+<LY!OIY.+S"_NI@0
MOO<X&8[S/\+9!;[%/^9_,QVH&$4J2(<GZ@(J>@:.HP!34M9,.NEX;,&23< ^
M>_8TU]!#5HE-656-@XZ +]^$6\3!>^5E)K!6>(+M KAB&)1D1/()LS3J*5-H
M\\<_6Y;L2.(/.2)[L3M6$/G]Q22=ABF^*R^F4W+1!G5+]&@UD+]%HLDR@X_1
M 4:GC#4L!9&:620=03Y;#C77R$/VJ$;LN>3X [#9%>ZT)/> O$&BNDC@.1.@
MZ1W@B)$)EW=(G^4HCY4_/>CD(8'T5D?48TR_8ZU=;911.RE3MB!"J517)!-)
M)RK77.3 C8W&=#J:UGKLLZ5#8PD_Y(+9C@L7<9HFP\_S:-,'3#C\$N(9_DKB
MN1_"N/+B!KZ8Y+TDG*C(P J! QVCQ%XG O.,&[2L&QW6?/(S9T1+.3\DA6VV
M0=Q'>\5@+LAY)\,); W_*N,2Q,P%B&QBX)%.Q,439H,]8MF3GSDI6LKY(2E<
M2Z-U_G?O+OG]RY\X2<,IYH&5T5JN"+#QMIK:&KPV!H0J,LHB!-G:N[9<ER)]
MMD3:C6X>DLDWM6&7(T9>3.:)O/E@R'%3P9)?SQ58&1SS,MF4S<X-V6^*3GUI
M9TDL;^O0[J.0?SG_?#;^BI>OPK4U_OXLC,@4+TRYI#G8G!%4R0*BCQ9TUBRK
M'%'K1I<9&^$];FKUI*<E_-HZ6/S8#KL2]H!K;;3-'FP2=&03=HA2)3 Q,JXP
M9<2=QVY6HCU6;O6HHR7,VCA@W 7U;<329*.L20C9.D(9&1E_Q49@)7NE6+$\
M-[EW^#8N&OK7P1*FM H;+P:WF<04M8Z0%&V02DD!@<"!MC8RQZ1FINS\2#MZ
MKFRCA25DV3A*//<MWXYGN!!HN(H\593748804]:);+;"1 U#6@TA<T->I1.9
M:::XZ>:X=WK<LU5\(XDN4?K&D=TN^]AE?E+-]'U7?B?1TWY&-I-/R@'7T8&2
MG&QVRPEW\3IPJYD/?-=GR@.4SY8V[76RA$$;QX,[[6X/X4IMR4Q* G2]0U7<
M&PA*&W#9&N7H_QG3.S]KOAD.]:&5)23:.'Z\+N7OI$Q^Q$2_.1O6.*=C3J<B
M@7E#Z&4A5T\6#KR@K7LH"D*XQVUI*>ICI5@#G2UA7*O@],,79#E\'952HC 0
M-M:<(8[@%$80 B-G$:V78:_;V#?%N19:6T*ZK8/8+_+_NYC.YNG?G\8O<IX+
M/YR]#\/\>O0R?![.PMEEZN/GL^%LH$HF%Q$U>%_J.T)N0>0Z@:77116C4435
M@F3KP7SVI&JHE27I@AL'KI^\ _P'3F?TDW?EES Y^WH3:;\;?A^8(C QK8!;
MAG30FP*QA$).1XDR%Y-XD%M?O78 \FQ)LW,M+*'0UK'I3HRO>VJM29Z7%.%H
M.B\Q^H#_=3&<#F>TJTZ^#!->+IS<W/')I0+G,J#3W=+6P@2(FKNO" $$IP,P
M##YJ(3,K37+(6B_LV=+V(#6_A-I;!\??XNSU*(W/Y[5O \G0H/,2,$82E<QT
MX'.5@#-MD@V>_GV3R.8]%,^>-)O+=(F&MPYJOYN=XN1>F>,MN!=?PO!L'FX;
M3SZ&N[;?+?%I->_*I_#G(',NG*N!>5;+3KE'\-)GR$IZGH.6)3>)9O6U@&?/
MJ[UH<@DE^TFPOE^X9KES.D9#OH51H(I(X#1G('5,A>4LK&B71?U(66#?-7!6
MIR"U Y=UO;0P6)?IP#BG)(84%&\2SNM> [>)-J]8_JGR;Y"R<H8I"=X4(A>3
MEI;H QB.EI&:4>E&MV-W8?3XLM_I";,#AWUC62XKX/OALL/'7]/9F,R3O_TX
MFUS@[0_'HQG^.?OE;/[ O_TXQ9/Z16]TN'R=ZGXU'E4#ZL6?0Q*.PA*\0-".
M95 ITMJB"8"89+9<^I(;Q;,?0=4C61YIUO,(>3;0]BKB;"WU!H6@"YA>S4_/
M3J &"^V#^J3$4E1]&@FK>B ]0H3MM3=N)?J=\4+0T6AKT3IWP=?,V4(OA).0
MK6#!,.DB:Y(QN$,^W.LQM7\ZK"/Q'FGP6.G&=&7MQF]SHWN0HC"69P5TV-9&
M>HQL6,,B6&N$R"@4EV*;2IFG .S>F^A!=QUJ9GH5?-L6$U> !,,@N)&@==;U
M'M] <(X\"5O#*98G[Y8W1.O/IG[^E.A'O W.B 5FWB'D%;[@HLY).D 1!2CM
M') ?I:'H@";EF'AJ8E$^!>P8V-"K\'OL!7$;GET:D;T&)Z44+DDHKMK37@MP
MS&1 \LZ$8#D@$RV8\2BJ8Z!%?V)OT/OA \YH?9A_"9/1<'1R?6QYEE![,IAJ
M'T+:QI@#QX6'$%,B[TK;'!IM$\O@' ,+>A!T@^8-+U*Z.+\XJRV=5\5+KWFJ
M"QDR7D"QQ8 *QH.WBH$C SJZDEW.;;:'K@B/@21MU-%CSX8'/M?+LS"=OBOS
MLV[N;SF,/H1,!E#AD?8S;HC0M+-%K[5%B\*;1NER*Q =4[AJ*VDWL"CNXKFB
M?Q=$+>-4#R'M.4BUG<X6'8Y^!-[ \UB"C#DR:4648 W/Y/M:!3XZ"S)[;E.P
M,6"3(K%=4:!K7*HU ]:1<P/-?\1)O3B]'P6Y.J98$0:9JD>@+;3KT5GEDS!@
MI.3"^F DMKG 6(UI]W;"MBI;/ UZDG>#<%.-D@WS,$R^UEOUNY3/*0J6:M49
M+1"4</4@Y 6(]DSRH)U=;-73$Q%6(3H&LZ 7:;=H*'@+YVTXIR\_3<)H&E*5
M[]4+T 5A2S/A:8A[,AOZT>DB4]HHI,5A\C12'Y/"S! ,LQ(49P8BYD*:SM(Z
M;S#;-F?*GBCSE)FQ+\:LHX?>[\$NST"^M,O]/&7G^OY%.AXL*1-1DS>>7($H
M7 1IO O.IR)9QVY@'9^XA[RYGE4U;BWG!H;'Z_?OKH 0N,Q,T*"YY&19.071
MU)![)CM((E=%-;D/OT%P- 383K8KW_C_^&E!,&_HV[W,^-AZ+$[/"/8]_:/[
M^!TI@E%&<:'IOX([)P2KK6*%"\H'80<VVN20WG]7'(*B70!B0@[9%&0E9M36
M]C\*Q/@L%%,"7,X.5(X.7"37RM:B*N,R"Z5M[/%-7Z- [BN-%/-N,G_(53]&
MG,PWWX'5,LJ<2:X9(XE9D,"U%<"L#HPY1O]M$I3O!N\@4LC7X<3BSM= "PW.
MOO?AZ_RMOSH":N58':GU<CRMO9UK6\5:3\A<O7)&[\ +:4"Y;)BSL0C=I.GE
M8Z">/R_ZDG@+!^I^? $3-_6"$7@,IK83LQ"R<V %K9#^9ZQIDNYS,/GEV^AY
M"UD>7'[YPR"T9C:B<6 XN8@JDMD>F3901(Y9926R;]3"[; OZM;2<O>+NC6D
MO9O;F2Z(OO&+NG5TUN&B;@.![X8*7+G@([ETM3D*J( (OD0#)M%_.&8I99-R
MLL._J.N7 >O(><<7=<5Y<N=5O2ZJ0V2D#N <62T^>"YC" 5UF^9K!WY1MY;*
MUKBH6T?>.[VH4\K+))VBDZ\Z,UG5+C8V@D#)DM6Q<-6FM/3 +^JV,@MZD7:#
M_)T.D<,N"+]?U&VLT_6O7391R'XNZJ1T>I[7$GP]/751M,>) KG$@+D(+F0;
MW_.Y7=0U9LPZ>MC;11U*95WF"1S6E@;*9PAU;(/WUF(R7B2^T)O^&"_JUE+5
M1A=UZ\BYZ45=1J5"%!Y$,9)LZU @!J$ 4TQ!Y1JV:6)H'/9%W28$V$ZV.[ZH
M"]/37\_&?TRWOF^[^: ^K\V6HUNX_4*&J5B1E&1:(2<_P ME-=9FHXI',XB9
MWC"/&NJWM6\)O6/<,3!&ZYR*087R+NSNHGR%-U6HX_+SQ70XPNFTWNE=G)_3
MP3(N'X<GHV$9IC":O4AI?#&J[>+>C\^&J7;HW$#F6SYQ2^7TN=X%+3(9E7*H
ME396&<U<#BS2.X,9:PF'&]#?1U8+=NG;0*>RY^"29'0JETP'=2HY^'UH<7_:
M/ RM=M*NH>,L&J9*=$8544*1Z"1&VO^*]LX,$NVGDI?:E#J3/Z<#AXA<UU9#
MD>L0E0UB']J=>YM[T.W5<_>JV65K7\P\4 %%2H[4&)4(.98B@S;&<I&$MFG@
M4+B$F>P;;AF]M<S6;ET!+,,Z_,M':]P^]'I;!?IZ5,:3\WG;PU>U*/!L#]I^
M%,U>.=!=3@O,"&0ZA5@RUH[RB"SZD(DH+,IDF#5AX!5+W'L-.==T2!D$>"LU
M>!=*3M'D(N.V.2G+7+S;N\@D*[1@@"M9[8)D(<B"(".Y>SXR.G_:9*X^"FO+
MEL%A,OO]<[WZ'G"MA*"7$)QAM*4F9.!D0"B:O%BK2<C6=G/A;C]T#T9Z?SI<
M:.N[F:1:1'^[S0S*A! %UD$-U8PU&""$7$ Y[9$S,H%Q][/:]SFYJ7]F--1(
MVYC?^\EEE][+#"BC>9(UOYPVVII>*A(94\6#5BIJFUU,J<TPU!6 CHL;?4B]
MP>7!^\DX(>9YKY/K%*C75<[A[/U%I-/\72E8N3P@3RDY$PK8I%+=[CPXZP7P
MP#AS 1UIMTV:8D>$1\67-GII4"9VG4;WZWCR.QERDS]J"][1R2]_UK;@.!#*
M"ZDS@V#J9D>>'/@ZWU!)(9%Y)(.M#6L>A75<5.E/ PV:DSR:9LETO7EE IS+
M@KA+)GU,UH N2ELBKW91MF3'@22VMN?&UM)OT'YD97G#I<%T:4C]_GD\NIW:
M,Q 6O;<H(;I(LM!T9 :;";*AW4Y%9FUI4H&\ =:CXE%K73VDU^ZF#BX?!!4M
M[9JI]O!*H8[=5!R<U@&TERJ*XJW!)E49SVY\UY[\J7XU^)!_6P\L7/:>W.V+
M;V.P@LE,'*B&OR(9.>8B%)1,*&$LAB9SW)_ =50,ZE,'#RFR\83!^Q.BZH'\
M6_AS>'YQ?CD@I\C"%4,.6I98FX^I>O-H '7PBHF<G5B8'/C4!*[%1QR%DGN4
MXD/=;CS(;R6JNY.27EW@I_&GT^$DOP^3V5?:UQ)9:0.9>8B%&<@V(ZBL$4(@
M>ST[,N"YSE)QL['BGW[^<;.B9_DOB<RU"NG.^7P;/R0C2B=?,K@Z2T5%DR!J
M3N>:#N3+*9&T:N(T=4)W%!QJIX\EK-DZH/OJZHR[C@A=.G>I)C=(+H$YILGZ
M%A(<]Q%DMDF0+!BJ)C6C2]$<%2NVE_<2%FP<R)WO=TLA?<!42R&&98AYY22_
M0=+".HT./#<&%#-T3!H3H=ZR.F:DC(LCSE:<.9MC. IV[%(/2_BS=1SW$YY_
M'D]((I?=)![:REJX7%RT!!#K4%M9":YR]:F<(.:3D]^DN.@I8$?!GB9:6$*3
M!G/LWHYG>.E>U=G'MV[YAVII\0'MA"5$<L 3B@(JE03.D%RX0A2&A$%_V\Q:
M60/H4=&HJ9:6T&K[6'"8GM;_KV"_D#3JX)]1_G@ZGLP^X>3\-<&]FDD[B(X;
M7XH :RV96\)Z,M+)>^>&)>M#"D(T,6RZ0SPJ*C72S!(2;1WQO3^$MGBMDR@:
M9&W<KM#I.K1' 3&].&:CROXH!_NVH\+F\EVB[1[BJ^//6)WWLYJ".,J5H)\K
M$5\-IY_'TW V'7B)V914._F(5.<0.PAU?V.*HTWT-]:UZ9OS)+2CXD7/FEA"
MEHTCK8OWH&1_)T(WP=>C>8;%E*SS*=*S3@GW*_R"9^,Y<F*W$K'."\Z2-C1E
M'((//(.7D9&MY2796BUOIKL"/2XBM=32$EIM'.1]*(MWDTL[ZS><G8[SY:F(
M>$="/W]]^,O7OW99G&X3TPXU@ZR1@:I].$,)%DRDY5AOHTM-4F7Z7,3.>D0U
MM)WWI=.#ZS:U=!2GJ7,-%*=CW]<XEPM7MZHU!FIJ3"BG1OG$ASC->&]<66L6
M\CHZV]G,VRZ@OL]"7E=[G8;?;B+ZG?$"6=%.6EO[*'!0@3078_# 4E%.Q6"B
M;A(P>BZSD/NGPSH2;]'+[,'\5>NX%M8R(*>2UQLU#VX^8M/1(J,T-N<VK<P.
M=;SM6AIZ<KSM.N+=:=NJR&6R-B0@H]Z0EUCCVL&03>^-,YIY%4L3?_WPVE8=
MC%W1BZ[VT_2J"\+O3:\VUNGZ+8PV4<A^FEXYK"UTF(&0I )54$#0H=:?,VF"
M4SXY=4R4V;CI56/&K*.'!DRY[<5CE"^Y< ]JW@S&EP1>$1IN6$G2."%=D[J#
MP^YSM)9Z5O8Y6D>V#<R1=U]P\N+L;#R_Q'HW[WAP!<RQ$*20%G149'HQJVIV
ML :&C"EF>.2VB3FR$M'1D: ?V;=O?K5=-XR/Z13SQ1F.RR_3V?"\SIYX,RST
M[8OI%&?3O?4/Z8AKKYU$-I'=8D^1VBU-FU1;>"DN5:P3/:3DS@<59/ #113C
M@D7 HD3M*1(@:L8@H!7&1)42;COG9N45V6W,FDEA,GGVD)FO3>.4AMK[!'(I
M:%W*A+!)^?W3T)K=U-ZH]/<IEHNS-T-R6P:U0V\168&?R\%I [6=%S"M0DA,
M83)AIW)8AG+W.W'/#.I\A[NUCEI$$*XVA7=E)>Q+U]>@<BK0V<1+3<UV+M#9
M) 1HEE*26DK7IERT*\!=79<U)D\3?1S*==C*)?W\]1-]Q-P-(IO5F41O@=5"
M@S(Q@,OT%;?,.&9"B:95;XRGL.TMA-6$$UUWK0UUT\"'7+UZ^H#KP8X=(+:,
M5'7 N)]05>_Z[<J?+96S)QX)XV-66H-AR8 2"2&2"PU&ZA2MP1A-HTF">^+/
M$W&K0Z#/.CKINV_[FQ#'D_H+7V^07;G7(121-+G7WBD.JO92]+5'C.':<:91
MTO\Z5?VL?,0!6<B;:F/<NR@;V,+UJO!BAI-%6%;)S%UPD*-UM>V/A9B-!&D"
MDG?KK?9-YC:LP',\=.A3\ W.B5\O)B39BPG2DG\=_EF_NIX:P!W+42."+$R!
MDC&!CSY#=BI:EM!'T^1:?36DXV-%3^+O\<9T.ID-/H31R>5QQQ)YZU8QP*AR
M[6I?FT_6K[0MUH:LK>_B$=.'WM$_?;>H^WM//4H?9'.YME#N%<>ZP%C#D^BN
MYO[?YZ>]A"TTL*C#+<37XQZ^""<FZ1QJ!ZAJ[D]M[1B1+(WL+++("H_8I83I
M,+2XPE;O7XGK2*UGY?U&DCJ_.+\"(EU"P;VI$T14=2TDN.0E>$ZNAB^9*^P2
MT>^DOGM/WMVQNI7LQWT(KD>3>@[DLEG,]0@>'VH1OH:<ZO00ZQ79]E'5Y+MD
M45MM0G\:O/OD9ZC!C077_OKV ];V/K>7BW^_&.;:&6B3*]>5G[7E-6DWC M7
MF\D+P3"C-#:HXEPDS8F0A0E:*B_20)12A*>7R!FL^RD:\#8QL(('9-84K]1F
M@S1^#</)O!'.;QBF9.5>5CYO(-#E'[2E-#N@6Q!EU(&\LRRS,5KYXKR5#(VN
M;3<$)\X.6*8?19] >T$V(GT-T04+CF<,PC@C?.A1E)N/D'GLXUJ(M<O %Q.%
M=,2UK&K%I_/%TWXN1!)H/>><]HLH7"F^#K0CX1HK:O\!7B?T2J93L4'R'H7[
MR'R2WB3^V#-:J*'SFA;WD)!B"2P7)9V29-O6O!U.FW1,-DKFZ$3@C(? 0"O.
M2#<9P>6B(3!EBRQ"%CJ-MPQ:7"_H,JN#'+0WPQ"'9_-&GE>+S.]&'VISS]I7
MAW[A[7@TN?[VYS =3M_<7&66>L;4P7DXSQVR!#U8.M$2+12);M'))A-:>EW%
MMG&@2PPWD%X-I_72E! ,G!8Q^&AJI;X Y4.ULPH'8;,0EJF43)/&HRL1[3X*
MM#^^+<:+^E%3@[AR'R*Z#*XP)[DAR"!M]*"*(1O$!P$UE):R*+Y$>ZBOXTZS
M- Z'E?M1_J%D?-RL_N>O-U_^[R%.:@."KV]J^X%YK$)FIF2Q#(0B_TAY1=9+
ML+4!2K+2)"=4:GO,/ IO7S'7/5%G%8'[4V&+NYIE=MQ#O-=3A3N ;9DELA;:
M_>2+M%#[*F8UT]G>B49.;W3.68@BU+D@P8&+1D%QC@LC4-C8)!/Y  CV1$+)
MP?%K'56UY-7KT>>+V70N 7E]E\*\\XSL5Q53!G(=.?AD-!AR+I,)R>30YK9Y
M-:8].AK]:W,5;[9414M7XN>O=\3PZP3_ZP)'Z>O\E2E<1,=US2@7$I21 0*!
MAE"D]RGRHF3;/6<UMN^65)_*:U +ONPENP%X]6IU@;AKXVD!X]Y-IG[TV^$\
MZT,Y.[*2%J$*K7Q2(0.R3*]2%O06<19JBA>G;3KIPIL,7]@;?[I;1'NCSSHZ
MV95Q?;,K7]>SNF*"+09REHQ,0NW 2Y>A1*:S"DK37^[,IEX =QAFT59:[6)$
M;Z.2E591;W?4RRW%X2B,TC"<79H UX=^F-W\]OCV_)\?^#U?8FT,H,4-5S_2
M6+C^\B*:.O52>IF5DR(RZ\A%<U'G)$SQ@R C2H4<0KT#4TK1[F4LAU(X\RH(
M53@_J.LOC!@\-QDRJW,7;7$0F4#0CDQ]GH1(;8H>G\GUEQ *$RL!M'*DS\!+
M'=PC010L2):R<:Q)K=[17G^MP[?NUU_KJ.F@K[]JSHAA!8$G%^MH!01GLH0@
ME5,\"]IHFO0S_,:OO[9AY7Z4?X#77RM->NXQ<2\"6(Z"WDY'TLV^ !E4@B2O
MN&5M@WO''*Y9BS0;A&O64=Z>W.PN$+^':_K0[P;^]B;*V1./BF8R)E7[4LUK
MKER!Z'0!&WP*-HEDT\[<[N<2KFE-GW5TLJ]P#9=<AT3F)DO*@-+5^C2Y@"X^
M6!EB]+IMSM*S"]>LI=5-PC7KJ*3M)=9C5[_..N-%]I LEZ"8(#$H*Z ($9.5
M(IG&=^='GA34DVW4EPIW=)NU^LJX"]CO24&]JWVKI(U-=+;_I*"($H4*5\/]
MK!'@I=8@<S2:7DK1*&O\  C63U+0[OBUCJIVE!3$K^L"@],R:$9+#[7.I]1"
M^]HV13B!,@I1&K6@6(WI,,RIGK39(2EH$U6TM*?N0!/7':$]68O224CSJD6)
M6%\5 UIC8M$I0^_+KE@BODV6;***'2<8EJ1BU$Q BHR@%2D)6JUW(&26.Z$C
M:YM__PP3#'MFR2:J:&DR__QU[F"\/ O3RV%),5B'00IP*;NZM45P+@LZ?I$\
M!969:.Z.W4?TW0/;7E$/&21[ONY;(I"Y!'X?C>,4)U^J(.:O ?WU>)1(C/-J
MV[NKNIYYTF%=._'/>E[8WEVY;?CS^'7??I7?\A#M?7T, U,H@6=BGJI3'YQE
M$E ()U-TF#NU1SER4G=W'Y\%I]?0>0,N_S8>X=??PN1?./OU8I2O>^L);]$)
M6\ Q7LA,-1J"80%\=EG6C*[8IGQ@.9R]9_3L2=WCWG75IF'J.=E-PW#V/I !
M==W%5:9D)!H0/BM066EP$2,@DUB;CF&.35S.I6B^\Z<G33695CKY7#L!X\_C
M4?Y8I7-E0E_E%%N70JVT"HR,X]H1V*%7H&4.*1J./C?9AQY%]9U./6NN@0O[
M^\=/D[F4OCY 5HOV,F,>@D8+BA<R [)64-#1FA5:QIM$WE=#^DZH/G76P)W]
M_>/?QU]P,JK1H&O:T_JKV__B!$?SP5J+D#T6@3%)*%%*4%C'\'$;ZP6^EX[+
MH%K1;&VLW_FW$RT_)*;:^O3$R6P^ZVV&TW?E%7X>3X?7C=,UC^ACH#,]V=KU
MTV2() 6(3!83N/38R 1;C>D[T7K5VD-"Z9ZKJ"XG7V_<B_+N/]^R@FDEDH7Z
M(\&LY"CK%'8DTT,YXR))E%N>8S&8!HS96F<DR1RI,7LI/,F6OG(E^<*S"S:9
MS5HCWD+<O-GD@\_H36Q=VDHZ7HS RK3:6K($YH75$LFGC$YK-M!)!RNC YL"
MN9I%*2*]\B"5\W04TZ_HK64WO1ED^3),3VMC^2_A[#*!;3J;#-,,<_V+,,IW
M_LW\S:17BMZZZ8LO87A6%UO&DSIO]7;/WF(RZ$[Q]?>J[%B6"WSB])J9F)2V
M*)3EBO8NJPW:7 H7R8E!"76&1\S HW;D>Z8,P:H T:!WI9A4;-RR%O!V9L'-
M6GY=7,N;FRH7'KVUCEQ@IFMO3HXUJ41H,($5B\67[)O<@:Z%<NM:OH5'O,(X
MNWW,B_,QG4[_3<P83V?SPW%0:W>-Y!F\$@D48P4\&=S !"^2M,:Y:S)"=%V@
M>YCGW(Q=#RK[6BJM05CP";PI79Q?G-4YJ'^?C*=D?Y'G=U87\'<2^\]UN\%/
MX<^!+!AS).C2DF6M!-G8/LD,J9#[QYT1@C>9P-8+^F^8C@W4VR#VN.DBWM!W
MMXM(/N0@A8'";*@O6@*R-"VMQ-(RN!!*\T/BZ#WTWSG:IWH;!#)7"^G^<@9D
M2EDMO ##+#FDJLZ0KFZ.T"QHY3BM82<T7 7P6V):+TIJ$,=<\ )>S%Z&R>3K
M<'0R#Y$,; [6IUA;Y25R[]"3R2!M J&"$_02D#O8))OX<5C'3)P>%=(@NMB5
MUB\O)A."/\"2<O&.@[.:CO.2#$1?>TQ8/6^**)5HTBEE39S'3*B6*EL9;FS/
ML+?C4;I"7#+RD+F"8IFO5T$&@@B<I!-]K)$&'IJ4(*\/]3O/-E;<0ZJ9K28W
M+^ZSH_SQE#SF3S@YOQ/Y&B0;:6>5 6Q-T5?)J3J32$ ='.&SQQ1+MS'.W9YW
MC 1I)>Z'C+#;;CY=A'&9H\V3QH!$72%\W24)<HSD ZA"" 5S.6.3'E>=$>ZJ
MI]#N-I@VRCF4GD!WKF7H7URVB> F!AY-'12HR-;+="87$T'62G_O%*)I<EW[
M$,K^QPOWJO)QKZ)O$(:ZC^AEF.')>#+\[_G-\W6SA@X(6Y8]/ UQ/P4,VRKS
M46[TIHG]<*:D$E&X.JO(:E#.9@B<%Y"&V2B*$RPV\<;VQ94GZ@)V3Y5U%+"[
MU/Z8;<R\6."BAJ!LT+1HAV!98>AD1JV/.K6_;\5U2])?1^H[2]*WH@2CI( 4
M:D_0VFC(6:,A8E&2:VZ<:7*O>R!)^HV9L+W,=YYNSSG1T28-7)%C/N]A$*4J
MX*2G_TARUUI5;1Q4NGUS8O2E@]TFSJ<4,-I"BU2,J*NM!$=8P1K,P@:3Z>^.
M/7&^,35ZDOZ!I,"'&'*4!4FGM6=P(4O+96T@2ZZX#-RYTB2;ZEFDP#=G4EM]
M[3B9760RRK%6$H7:4X>D H'\?! 6E8H%E91-$H$.*IF]];G4D_QWFI9^'30:
MEYM4_^GX00"I7DK<^4?QZ\OQ:#8):781SGX+L_H:?-U\U$=+.#WF C>5U(,Q
M()[.)*_0F*PTPQ!$\"K:6JYE@\L#SYWDTD?P0=1I,<J!=[79C>$E>R==X7G;
M5/(7.<_%%<Y>C\IX<CY_47I) G_TDWM367?\"])WSF+4+'%5K%(H0W11"Q=D
M0JV4XP/MM2G,F+K3D_2=\! 2HW<Z:6ND*<ZHN)GT?PYG893PXRDBG3OGG\D=
MWK!X9,4G;2G=+O@6I%FTMDHKIXKWR@BB*</":9,E8?+(<>!K ;7U)$.G>6TG
M$8!VR0S&IH*>*968[5.:FY>7//IY323;H>PD$_6L%,[XPE44(H2B57$EEFC)
M'A$#;5#(K",=.;4P2JJ:-64<")&$B2DYQ3<L.UF.^7:G?#_!SV&8?_GS,XZF
M. VC_&YVBI.K[(G+FK(M-I0^']]$>SU(8D'9ADMA>-":M$@VBO%>8$':\^LW
M)NI!*4$8HQV044$6C&+DYSB-X).RI6YDD353]O@SF4!?:6WU\OISW8+?XJRI
M?A]]8G.5=E_O@A9#LCIG52O#4,5Z[199O7F+R=,AH^S F$0:)2\"4R%C-$@+
M7EL!AOZ-I[<V&]QVRM<U_/>TRMF+.VMX<W,!;624%D4"ZV.JL119421P=<Y8
MC,&&V,0!?1K:MK[2RB?,<YD'CB7I&.V36*JYSE'1B10MZ."4*XZ,+]<DR/\X
MK-U[3#US9-%CZE$++4IP;C/<R9F;8!I>&9"T<\W%/LI7=4/SGZ]<S""@LD()
M ]K&7--0$SF5)@ JIS,F6[MG-4FYZVD!1\>[O6BVP6W$2F!T# VB58'\1P]8
MV:'0TMNCM0;-K1+:Z524W^D>1J".CDF]::#!5<1M/M!*E)?I0$$4F8QC$*6,
MH#1FB,6E&EK@26:TVC39G[H"W%5V7F.N--''H63DK5S2SU]O\D4\,R'D)($K
M1[NE2PQ<,AJ*4"%FBY*WJ6_H@&W_.7M]<J+K)K6A;G9YDE6 5RUCND!LF<37
M >-^LOAZUV]7_FRIG#WQB',1>(V:FRP#*%73JAEZ,-X'C%+KH)K<A>V-/T]D
M]AT"?=;128^TF5=;O FQWNZ.)U]OD%U?Z-*QKFTVP%BVH#P+X @(Z!A"4DSX
ML-BX8T4]R\I'')!!O*DVQKV+LH$O_P;#%$_'9_GU^>?)^,OE7(KKR3-1$PHM
M(/C"R$R/$:)Q'GCV24F56(Q-RG8?P70\M.A; 7V__#6P>S'#R<UZ:>WO+R;I
ME.#FC^,R^R-,\ 8GMSI$"\RK.E;$6P@9ZP1(X7/B*EMK.VT':SST>)C05-PM
MIKA<3$C4%Q,DB+\._ZQ?71.66>ZKOP>%E7D[54$.H+4@->UNFAD;VSC,JR$=
M#TUZ%G^++A#CT91<ZE3E^[H&!T\(VDT.&$KF64G$4JPY8#9!4,5!3=9PP2/J
MTF12[V.@CH\<O:E@91I>;[E6RV\1^TZMV> I36Y'-T^Y88YI+9+.V2NA363)
MLUBL\;7C2R@#;XHRG$?PGH=Z&B3PPOK:E$T).BA*R7;#&]'YR;1\/;>1OXA,
ML60"B%Q3?@@21,X]"*%=Y#$%[[H=_D\\:-O=J<N%QL!Y98UE%HR0M)B8$)QP
MY-T5QGFQDBELTER["[C=[5:]ZWUQF^I=%PT\HY5;]:OA]/-X&LZF VN]M2E9
M\(II$@%C$&-44'.S4O(N&MQMP.0&VA%QI6<]M&CWEPC2!,D:(R'CF^$7S*]'
MLS Z&<:SJ_[@_\3AR>D,\XLO. DG^/L4R\79FV'!@<C:!"\]A%(;Y4@RZSVK
MV7Y!(O-&<QV:I))L _J(V+4SW;5HX7=GMWQ7%F$/,-+C"0EX;6IVHS?@,UD'
M)>?,!)<DEB;WW(_#.B;N]"?_'KVQ1Y9]>6-F:4?D)01@LHZK,\3:8% #.MHO
M12G,\R?-ZJ<>TOIFNIEN>Y7>H=Q!/[*Y_?SUM_#_QI/;88;&95=<W=.\$Z!\
M%9I6'I*4Y# &XK-M,_F].\9=WTGWRXG%<$XCW32P<QZ!>@OT;3B_#F1T@=MT
MINYZ>/<T*K>5_KOSK#?E'0#G6 G,&!9K\(P,,6$8!.XT<&2&J<Q8]'BT7'MJ
M@NV!4FT=G?5]S55AG1.\_,_QY%]E/$G7ERRIEK4R$@"YD**&U<AZXRR#5LD(
M4ZTW+)VLI%5/V,/,JI9Z&?<MU)4AG<81Z-LZED4A-2S86?6HQI4ZG5:X.,S)
MT/LOLT7GDQ(HO$R99^N#LH*%I <Q,542[1I!B7FCD02NQ.H!V1)01QF2VK)$
MYP-.D9AQ^F*47^$7/!M?7IG.UW#MT<_+R#Z=AM&GT\GXXN3TYXLI>0;3*<DA
M#D?A2I!7KD(622A;:MVYS.2_&TG;G>.0HU>._L[:-E9OWPMI>-Q>EIY$)P29
MM %\$752ER7WUJ1(/FX6TI"Y2\K?\?FZIQ*@O7)PC2-W?;TU"*8_@N].S<F]
M\+_TK'A'QX37J4[ S!ZBCQEJBH,41>24=FW)K8#ZG7LM=;M;IZ*6I_C"$]<Z
M0=&>W'E5JC#F9>':"YT$(C9)QW\<UG>6]:6SIB5%/0GM,K DE,P&;6U0X)"\
ML!P@<FM QF1-$B+D$ML6(/6YG%V5*QT4;P^ &<\Q#&U3\EGE B+:VAR*3@BG
MD4%B3,8BH_5FUWOPOL/0A\2H+8+8ZVCV  **7>!^#V*WTO^6D<5-E'< G#/*
MA%S[.PCD E3,%KR+!;#06RA0*$Q-QH(<!-=Z#&+ODFKKZ&QG0>S@G)_;+-E7
MJ]AE!RYBAN)#4$EQ\KD6DHN.+HB]EEXZ!;'7$>K^@]CD@I-IE]\,0QR>;3NM
M?O.'-0YD=USE8L\PJYA2/#O%BN+<.%&R=I%^(6CKG!EX)IG0QD*J/7:4,PQB
M\@DD%D<_0B=1WUU:=[7-&3NWT:9S46RBC0>?L:60'\>T(#MNK7(I9N6949B+
MM\YZR8PTM,,R'@:J<,TS1Y!*65"&&8@Q)!#:6:Z=Y"J$?F2W>=O"%9_4LQP[
MM"H,,9:@-&KKZ]Q6'J4C!J9@B]?<%C$@S,+,&R<G14<9H^TG:J*CDER8H*R-
M9L-6D(MH^Z[ 6.OS>Y;\QE47Z"W+2EKNBU2N:B/P'(V():>B4APX&XKRJ5YM
MU4E1O$YOUHE!=LD%:3)/6FQ3=;&XDCO!"*68LP7!V#KQ@TM7GRS!$E&$<*Q(
MG3N?Z4L?L74P;#9._WH]G=*&_.IB,AR=O,?)<)P_GH8)3N\\<#HPQ@J>O 6F
M-!VEF4L(TEG0NO@8T#$MFK23ZXQPQ]FJ_6C]00BJB3X:W!+5U/[9UTNDKT=+
M(A4W#:9?#:<U<G4QP4')/#@C-#@1D203#'@TD;X-*C-G-"M-TIPW 7L4=&JN
MI08>^#7*.\*8T__]9)APX L9,:YH"*PVKXJ&#M>0-63)HD\A\.*:^-N/HCH*
MKO0G]P:7-DNH^Q$_ASI!Y^SK!TSCD]'POS%_FH31-,Q+:J?7;8I?C/*;,4EL
M>OMK Q59B$*0(5"G(R@2#3B= R!*500Y$+8T28WH=QE'1;L]:+9!7?V2U=R"
M>YW)$QZ68;ASZ7X9^:\KN?6'Z>\NSNF'E[4IA14BDXW 0ZJEX#Q X"J!EC%Z
M'5+(L<F$MOZ7<JQ\W:6&>YRY,Q=2/??'%Z/9!WK??AW/;8'+O(\4M2R&,>"R
M!F0=V0.^WC$5E6NC2)MEYIU\EU5/>-9LZ$]V*R?EM+C#N%,0R60.&".#(NI(
M'^D10A*>_(?:DCKDP'F3)A]=P#UK:C33PD.FF*U>_=^&9SB=C4?X/GR=M[(:
MB.15+DJ##J)VR.,%@E$!"I/<>!$SVF[EA@\^^EEKM =I/=2=W>X:Z>1D@B>T
M[SR$I90SJ'@"Q[@"E6@'BHR3-\=9RBX$ZQ;3?E<%G58^X_EKLR?Y/52KV_IV
M\$$X>B""S38S3;NI)=\+T4(TP8%/FJS=9+)PJ9M&EWW\3NI_6ZAP:UD=2K+5
MQQD1<3ZDL5Z(OBOS(.#\5EQ+@T)+"TEC+>TR9$@PIR";[+4A0R**)K;_2D1[
MJ>?M0=,/PJQ]2+Q!\.LNGJM;\2Z(6F8U/82TG\2EGG2VV(6M'X'OA@K*BZ)+
M2<!],D#[9JSWM &4)5A,"X&A2<NK75'@B7RBG3%@'3GWG2#T$2<U0,!?CD=?
MZC!6VNK>DRIQ,L&K:Z#K#I(L%5GG@\M4N^G'("&BCV <,U9X7[+H9JQW?>+N
M$XBV5<VXM5P;7*Q]P'D-SOLPF7V]&_3\^>O=OYFS7BH9.:NY[K)>U&!FY(#$
M2"=@+AIM8%$TN4[K#O%(S(5&.FEP3W(7S]4;TP512_OA(:3]V ^ME/@(5[;0
M0 .#8@DR*SB/SA>0RM6&I,Q"<"E!#$SPXH/.K(E_L2M./&%0[(\2ZPB^;POC
M?1G^-TY>C])UIP>36)0V QJO"(O2!(-\<<VTS8IABJY;I'_A@_=1!;F=H,<]
M2:F!65";3K\K+R;$TI.Y#3QG)1U:G*/CX%BF0RT;#[YVFT?#>"I&"N:;6 !+
MT1S)8;^]I!O<*]^!4Z^]WXY'X?8G=[>NZ[D#'>"V//37Q+L?BZ '32^VF=R!
MFEITQ5T3MG2FT/\T6(N>8,=<D\,$D< $3#QYXYLT4SX(5CUA4^R?5.MHIT5Y
MTXQ<[-ED&"_FLCZ9(-Z9H<3IV,V9*2 P@KSV1-YU] *$J@Z],2I8T\G8>.I)
MN[<^FNKIP<U'7T+NT5:93F:W,;J_X_AD$CZ?#E,XF[\"E]GV=!S[9"4H,S^3
MHP8NI;=.6,+6Q5:AA]S9,.B[Q<WB413/W$;I3\(]YA'-05W>A-V%=&6 =P&U
MAB723?VKT.S6SNA16^-6HN[Q '@<7!3!V9(SI,B)[KY.'4860$JKLRJ%/.HN
M-L,AZG^%1;!K]:\CX1[5/D^!FWP=_/YQX'3B*M7*MUQJ%\KJ9VNA:V&*-#YE
MJQ]+JYYB^LO)^,M/5Q]8U6ROOZE:MG>T?/O0W9WS/4I_O)7H6I3S7-31'6'T
M^XA$=V5%E)"=5M[5MB+$T%B'&QKZ0VE4)@5:HFK2:'$)EN>LY+Y$O/*5[:T^
M?=%.N:W9OBD3&I?[:<T]%INN\;2>2T\W7>="(6IVRK(@ D-GE',R&A;12)V"
MD1ALJ+%(R97SX+Q3H *OD]!9 >M"Y/1[*'1N4XC*HO>L-E6(21!OG4?PD8Z=
MVFTM!<E1R&Y#@)L5HO:95K]R#-$@"$4[J3"0Z&VEMXQK\%HY<$H[JSPFNYC4
M?GBU%"M7=S!9F>NPK65Y13\\:'#:-J@AD2AR*ME#B&0U*&4<!,P2R,'41A2)
MI31IPG;$54*'0N,---PDK/<@@I%4REG4'BM1$2)&[ @J:RA)""Q69>6Z92 =
M8E[R)MKO25:'DI>\3O\N%[0S(L^-6/I#)44\=0ERS(9DAR&%TF+_.> FD'VQ
M88L&CNMHY0":Z76!^[V!8RO];]E5;Q/E'0#GC)"H,SK@J2 H8VL(ACRS7)MD
MA3K#6S6YRSP(KO78P'&75%M'9PTH-I_6GLBZ6][4]_IZCT=5M->04AV@@Z&
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M0'=0[M;ZNNS&D2T4T=C5>@A2$YBH5 $G:A_L.K3=922E&B5S\71JZ"XQX.?
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MN R%K%474%AI98O-8"F:;]3Z[T]#/78+N@9U!T[M ?)V/ JW/[F;HG_M(7>
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M]58R_:+1$,WJ?LAF ZM?(BSQ?_^/_P]02P,$%     @ XH!;4"#[;S"WVP
ME0$! !0   !A;&QO+3(P,3DQ,C,Q7V<Q+FIP9\R["3Q4?_LW?B01:LB^3MG+
M5MD2F39;DBC[,I4D)"%;F"E"U@FA*),ME2V[;),]2;)O66:0G1GK8;;_\5WN
M^_XN]_U;7L__]3R',Z]SYGS.Y_.^UO=US9RA#]#' 8X+.OHZ  ,# W -^@/H
M>."DMJ_3+0 P- 2.  #  C :<P ,T!'#SHLQ)[![YQC8.3[PS^.=C3X,G -V
M,3#L_/^V,3(Q[FQ[=N]F9&+>P\R\L[/L9=O+PL+*PLS,NH^5E8T=VICW[H?M
M8]^_<[PSR<[M.W=!_^PLS"SL_^.-_@G@9&' [LIE9! #=G$R,'(RT!L!.(25
MB>&7[7?(#+L8=S/M@2"QLD$#2CD@^(R,NR"P3+LAT1@"H>O ;DZF X>.G=G#
M97R=6<R=^_BCV#06\;.%=3PFG40)I1L>07M9>?GX!00EI:1E#A]15E%5.Z%^
M\MQY;1U=/?T+5ZZ:FIE;6%K9WW2XY7C;R=GSOI>WCZ_?@^#'(:%A3\(CXN*?
M)20F/7^1G)Z1F?4F^^V[]T7%):5EY14?*^L;&IN:6SZW?NGJ[NGMZQ\8',(3
M)B:G?D[/S,Z15E;7UC<VP:WM';D8 $:&W[>_E8L3DFL79(/=S#MR,>SRV1G
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MDV5HC;]+A_A#*(V1N)70G;QTH.TE>D4%_H<SU,5.W0T%V!:"CP;Y#B>;%AW
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M?_FB_+C(.2A00SRIF T1_36(.,F.'6-E,IEC6$GT=/XQ#'ZSH%Z0W$';"V4
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M5MXQ020)?(R>W+=_^M#I>\?U1.9GC,+&2J7K<0,9=30>EU-7FN%<*H:>S5=
M*"5>[BXU\#>(S#'P2?[VK=\DYFK"\W;&'U^)2V;PVT(Q>BV,A'VRG[!,:XI#
M#0UV0B2=X/>W3])2,MKQ:J$DX3G>CO=G[G\X^,W*XH9KD;3I,57WB,GM7B<-
M2=>\[&2CU<I3%9,@J[O)RX_))C\O&.A^F1+2L+Z:NQ@8:'0*RNGC6-K)GFI9
M^[S6]Q2U[OLU9OX5<@HJ<$&G#1?TAE,4EZ;6S>"O47J9S#;OQF-8<I$,M!91
M)3"$#NS=UYX[RE/X/4 134U"$_89-/*6/9"I5)=E-[^$E_9FO,=Y=PMUEV%/
M;1P8^-X"K-J0 &7?S"8C%Z8)T;H-1!=CYWN^=, FHHMLX.3%&Z<<+?A3C+-[
M>E*8]#G?9*QAV[RYXU&M$(AVRZ&H%)*,ZI>%YK;?I.%S"CA;WLS42I;4W!96
MB=Z@ X<?GY4*$[WF+F"2V651^7YVLVQ8ML:5>O=JD0W7Y6=<?4?,?HZ4\MU<
M=%483;K;]X/4 =Z A6=/G 29 D[&N11D[W.Z90WN?S[D9#LV!'<=FPQ,$MZJ
MVIB.J3;-<]S@ L/?^&+J57G+1N$D)AQ&Q?3[FJ'U^;[%4A&%.?"IUM?^8X5Z
MDP+,=U(NJ0L(]W>)RO>CN(8L?#/P=H\(BBR@D05INJ'-58JPTM]8_@ 7NA9H
M-6RJYO(FCS)5=D:9P?0%+*Y(U%>B%SW(=IE(!Q:<X(^K92=@@KZJ\[8D9)/B
M?I>N8:<'7P5#DD)SE3>2VJL_5D9'<;8JON20N>%]6/[1(X/Y!+^[Y3-Y..SZ
M\-?2I^,)E_01/M:M^E8*<YT^^F7D65R\5@ )MB PT<YXMF?]Q%(U6Z[%S/$6
MW@(I#*%MW^F9+RM/SI<?%@Y)?ZQ79W56-=_OH)D2JF6,(X]V%,SY5'Y2;  ,
MKE/UG+.:'LK/".TV*@EA+&WXP36U=3$WA?^ Q"J'@@'K9@YZ"%:'XZEE#+A+
MG Z]#P]#[*WV]/OY;;-/HTM1>";'XR;VDGZ^@^>^.H>8:^('+_'=W:,^A3J.
MZE4;/0;E*^^ 4Y#P&WU)[@3#<Y<_=@;HD>X(EB[%OMDRRCKCW3!]VSA?>D H
M="4^O\[\4NVA*I6^8=>LY2W:'OZ7Y;)1-GBI+HQJM/+"#QLO_>Q<NQR7TD"!
M51:-T,#;Z1'KL&A6F?2'IZYL7*$#3\,:W<C2#Y9IX1=6*M>-!HUH9^&<N(57
M\[AM2=DO\_SH TCQ[XWH2JBY*L<I<QMKW_'#:W-?9OAMWZ5TQ\3HM)+=-\1X
M*E(PDUC]H!$-\W*)/%RRUGN#P\;:T%TR1T?2,I'IV=>KS3[W7K2<*."K^-EG
M3&LM^%B+0/79,5%3T;<+F,"J\R":+UQ+'/3Y-"KJ N=H)80CBA?ST45BT9:Y
M! Q[Y\V@4!M>^-%%F^<1I3>Z,O-'Z("1LO^+2S!F,ZYW44E'(B.ZOVUV)YJ7
MEG7WPK5 C0T&L(G$6+^M6ISA*[I":V@TR_'/2L 5ZY>R(#7L9*RNB^\Z S"U
MBN_ZH,6#VJE.:E6=!7O+0RG2;VW50J?(6@4J7V,MAF?C)M]&.&7?C):0R]PM
M7_'4MR!?&1N)WG,'=1#5K@K=IBF9-3<4!#)>..9;,>\C:O8H<"/E33G9]J7<
M6V*+:E^LC_BBQP-V49\)\X>:3F3#@/T]U?M< O%4>T+V8YJD2^5FU'T#6Y.A
M$:_5@$-'G<U21NPK0G95 KE6*K&7CNKGZTTXCW;I^^',IPOP.:<^WJ.QQ:<^
M>SDT>GAN)+Z\/G?=[9)+YL*:UHV/5*C\L@IP1(89C7=PP(3U=-KYK7DK8B\L
M'U#0NL)IE/*5^5;GJX$\-R%4$YR[5G2.)E+8JPGWE2(Y;,]:G2\K-]LLV^R/
M.LW;IGQ<\\:=V!4EQK&L0-?KA!KI"T0M+/'21'.J<#"AA7)$%K=7H6(H%WV]
MJ";%S+JG4Q"$R^N7[&-PI5D5+XQ$A&T$@H>R4-^280TG HSW9Q"GF^1)L@U<
MT5+3+696(9@G+Q3X;>;V-'-&W@\]KOIY24="7(+5#6XL6X4ZN97G36X1%6K0
M'Y(?SJDLL4N=[R0/;9K/I'S?,B=(+RB17/!&C[WDT39$P_5:3/I3%:$<_S;K
MINZ588;G9V1+7*JFV@ &0L7(E?&.B!*CQ]O(F/PU(5!3),^N+=MB;BEC85.-
M<]?-Z$N>L:4?#S*6?KBT7ZN9F!VAR4?R;(##*6K$^#J:,!'>U.YA4"7P!D?:
MW?_4-_M\W"9504.WPBM"Z%6].LNA8-VJZ[O-;2>,>"C2(-:!L#R8H4U2_:@T
MJ\47?)HXV1\[I(WOS)_=Y?*F*G2Z?:QRR4F!(/>%Y_%K1P8G71%3)YGYP$#E
M?I^QZ5L\)WR8):8NO(E6$2IUU*B2+16--'6XU9=W"L4!1A+5FL;VRE>KJ84K
MLU&EX/Q.I+E*\2\\H5EWP$$)?_WQR7OW_(0]CBA&XI@#C(E\+4EV_*3$2#\\
M'> 8:.$NY^6S#AA(/+__\:*$1^Y^I6:_@N]N!\#I.BQG];YQ,Y)97D8B-543
MCE\6L;!J\X@:>BF?N5C1S;7[I]$BBUSXI=>:+UFWD#16OXEP+4E4+W:X>X[#
M.:FR/"0 X>GGR9TCUGIOR/9CBJ3O9X]/,:^CS)[;V,P9GLF/H0,H;.BTJ&LL
MGECA9YZMNAYA8)B[54 'W&1E[VOYIT?(=FE=E$F/ '[?97NU!-&MKP.@DNM#
M1QAB36-N)PV%8E=NPWG1"TKX#NK^[:*\HG5DLD81U(8CB% 3K^^8T*E]\L20
M$X^X69SN(=.K=V])/P2$XP*9G.]E#A<)(0W0=2<*U@+5+H+K:D\095 A=P6?
MT#^\!^,N4D.6'EZH")ED,BW&5+,TNSPC(2A<\X2PQP%*.4@[IV0A9U'1[F]Y
M.3.\0U-YS;C,(2;V;J,;,;>T30\]OU;$F+BK>I6@5H_F"#A(PA.;2W<-SA\X
MYW(L5#8D5E#C;4:R<-%+CE:YFS&#T[$VI9*72H3%)?PMK$[DUE:[\SB=4NZU
MM'V#RYH,S")+TWI0G*2R*I=Q6Y@VJ<A7^A.-B?0FQUWU8X&N>Y[S 5NG<4/N
M*Q(W-&[7-^XZDA.P8#'9;TV6=$D5)L&#:YG;B(DMMD@63.0#P_X8>8INWBLC
M,R+M]:.)HI6-]/-EGN*XY01&Y0C.PD=(/M_5C:/@"V)Q7>U1$N^[UR4G=1^N
M0[VM=BDYQ;HQA:RU'FMMOUO]V-,9S;H5AZ!I*:C1:3@&+AL2UT??)AK7V;O@
M933=-=Z\CM")ER/P__QT)W&514B+.!^!3]P?V<=%<9M?[9ONO-QQ;&V1=4W(
M22V]N"S<VO# I-.R%RJ[E-9+!W8Y?J=HO'?F@S.A5"BGNL7[GLV)BO=[#7H9
M:HV.++%617KN/O.B?!<68<.^FKPU,<$<2H'CT9P-L*!J\W>^#0;^]U9&1F?"
M].,.^W#8<PI(_-CUT.>F5_.)@@O=N&L%D309XDANCIN]5-8[I[&A#11_!4FD
M$@S:_GKHJ9'HRRZ_KZS[YJI\BE:X^YEW./4."=L$>YQZG/0M++W5#X\&Y!3S
M1K;>1SM+GK!]VZBTR.CIRGQCY9YL!DSF[,EVITV7LDUT^.3/V((G[[S"G%IM
M;5T<<DKCS,HV#;=>*EZ0S2 IUK_RK$?  A0)D60+0F? 385O\<>_YO;#'9Z=
M4[TJ_*;_H&?_VWR/J@R)#2WO+/4S0\X=NBO.\\M6(0\*FG!;*N@@.H#D0,_>
M]YHRG<-!C>ED+XV-&G"&#F1U]GEIR6S3HN:@QG9_.6A.2^#Z\O86"YL::X9$
MY\6//X>,-HU6\F+XE_SUH*+!+\ %S=:0JTO<-*LHJOA@:R(9]'/(Y86\U;$C
M7\KF#S]_%[6$5XIQM_/+H4B0I((#\2DN[:)SHQ/-WM[;H4^BS$\^X_K<>4[,
MLW/$4F=!.,8=>9WV'5F:] CM.#:D5E>KT!G   ]'01Q=)PIW@7'H_YFC'9G8
M*^2J8WIAD;6:OM(-R=B%!L?<  VB6W2I$7A>64FKW"_/;KCC396S4EQ4XJK$
M!7MIE(CG:L"/&]65ON\W3)[=#ZPY%:CQ .Z E&S[F,7JE4OH7?8N=;H?T1_(
MT[444)R!:A?5(O%%:#JD#_B:FU;WUHH._[ %8_JXS0+%9+T'E5J_:>E\/N1Q
M:;]2L!$H33X&^7YXF'%*72T\Q:RT2U5^<>)'G:/3G2['-IUD'[W-VOT](Q7C
M)*0/F#0QUC VD$. AVN>RW-)IO9]),$)J5F$JN?5QT1>;8_,>)O[\'X?'.%+
M.-ODT?7C\]G)HI 3LZG2#9!W2Q-E0.PXC-4)L4]+W?> $8_UO'<J:X\7>H%Z
MWM+0I;;-K+C*<F)2^W!9 L.-J!<.=>U&&R$&:BZN+K13J FW=4?V;/Y5=;>O
M\>;FA@TW1]^Y9 3&KL)"T=<+(E,524;A)1J(77,Y.;['+:[W+2YE!7V=[3@J
MQ;&H_"3[*^N%!(FC KN#9&/!C\0K37"&:@->#*%=SNGDLPW"["&^RS9+3^+2
MRL\NU5PE7O*=1;Z&$Q_=YMN&M2BRW:XTQ#;EA*<1KQ;@7=$M+.V9'=P^9UWX
MUR42%4NRDKX\S.$,9?70#C @6U%4*D$WDNCHZ#2>%D_LTYCG3I07O]2/+CMT
M32 A:[5Z4.^6.),!N^NXIQ6^T..=EKDK3GL:_0G?7G2!_R*B)&2XJF_38-1E
MRV2F/ ZE*_2>HDCB#2$NZY(<EJ+13O@"#IL.IS=SQUN*A+:NLSIP3B>R?3QS
M374Z:I+CJ,L,'< @!=8Q47"B$2YDF:#(T9HW-^0859JCEY[L<-S2,BLQ]6ES
M;+YF16@?*P"\:HF/1YXPMV6->VF=Y(WA.][0E6%R+'WXTK$'R][Q_GXA#S(1
M*S?ZX1O&8G2@^VK"E-?<4ZA5C[1!#YZ/I .&)J:F@P_2KB&FID$)/XN":T2C
M!692) $1K(SEN&W'U*-R2M:NG&SVG&0[%.Y&^-%6*6-E+#N5\)!!7^*>;$N+
M%5FV!0O7$@Z0 M%DI7G!;,@_P$L46SQFM[6=I:UT1&9AV8=D^4M+>NFI+!FW
M;N0SQOX\=.AAL_H)@G-/2(**-QUHZQ7QTX*Q(8<,^!0LFA3*1K(H1>2\5:TK
M)*,&.(<O5X.55F'NK%KRK90"E2X+PY,A9 .KMLD?"C^6K@AC9?< P;:\L62Y
M@//]-#58:)_6@5Z%:I_BK[3F)^(VKBM,S<LUY:+&L%<C+,M-@3!2PT8:<:F
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M3'I,N="EZ4AL)C<4S@JRA[($6-X>BKGVH23T)F]5=?W<3,-=I95XI&2(J>N
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M\W+=36#5+NR*W"U)#75<3?1-/Q?S[>I?3;/2\=>9_\YWUE6X STY*2OD0>2
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M$)!6!43I(B(B(M)((VU44#HA] 0)B8(TTF6+ @I"1$!Z(M(C$.D1I.^D#4E
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M132-_":%F?,&'I(4G4"7Y,/B+TA7KM@M=_QLDW#MKN#@^/K8WV)HNW3!>6D
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M7]J\YPX,]6(TK,4J4Z-W<F.* 9)85Z.+[%(*()0Y HHFS$T73_[]GHZ@*3%
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M ,<V?4=JVB @5>B6)/6(C(). E7KUJI.59A!W:#$E54/_DX9J[O[9KAR2H4
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M(,CTNK#*F[8BD'JTRQQU,..3RSZ7EI.DX:0G7&4FM\X<,-G?9Z04;4>9>B+
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M_2H]D;*[3L$^*ZP-(8C>UAW,7"_;O3]LJ_&*ON%SQI+FY4Z)V?JP&T^SI\K
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MQ:69 ?IZ<8 !(A]GAI;H3/K1$ 'Z\_HT!NA)!81F$32WE_4LHH?6H(JGA3-
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M+:)!8(<!7V).DV%!%VNG?NU+FS(CL\9V'>V'=T:<DL]0&Y_Y=)Q+GYKTISK
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M(4D;NQ_#NM !N8,:!%O37M"E7.FB79YB-K=.96:YEC\N8;U+G9UX=\(Q>_Z
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M$JV;K.QT,BGB LN)>&N_P (J%ZX)1U>BQ5)9@[,!^1DY]HTZO"Z.XB[@%&2
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M%N]2FD/H.[B0CPV^.I\YSQIPLYVS);:.[X'8A;H3UU'$+^NPK6W L^T!)$L
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M-<L #:34F5&M:-%(F4"H80_B'+Q@E/*J 4?NJ\PO<?] >W_<=/WR-]SAZ*&
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MKEKSB@!P0-N1S1*XFU7EHE(4JJ0MU?(JO"NFW5F%B5YKSTK++JQ@^"+0:/.
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MLI-#.0W-NP@5W-6O(8('R#6(?E&6-"6T4GTLRJX58R71[X_:B=+SG<K4_G/
M7,<KR66/9!+I9UP#?(<F#8,%]R<S/A"W@&8LFV<0H09/L;VE ^)$ASU3]+6O
M-?ITVXD^O6)6CM1(N&W*'GZ:GW&,NSC!K@I8/8&3J2%N)>S%F4&<A.6M;<O
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MUBP8:*HI<V&+GW^&]<#0QRQE$Q'7H0SZ'C_;^[8R&'35_=6;R-)DR@I!F"D
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M]N4U/ZP5(P"VK+;S]=$A.U#MZR<,%7:NDG^2J<0ZH=&YGZNH]0, !<!>PK(
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MA):88.P?1P0 $L&!@:JL .G5]?E"YM_V>"6QS/ABWC2P7I5G?)]CS ]#1B+
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M:N^JO;1VU7_U[GZ9?UD#H$N)28H!(" @ /K@%^!E'7U#U,W<! "0D0'0 @
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M-EWS>9L$$7^L6BP&76]%A\M\(_OHFWEA698WDYQ/I*:? Z)Y!4Y9%F0\^RO
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MXOB"F2,8F7UJIT >4)K8U.PI6;,C*4&8"<K+>9A.N>RS'%_T1=R]45*+$B[
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MX8_]!!D^B>-N5 J/JADW-=1:X28L WT,46PJM=(^VWSD)9BU?HJ@[LW_6(1
M*4B_DL$7ISU1)2@N-LM"95*8TI-*3H YSCQIN*5-0:Y&T+>.<T86+'>M_A"7
M+8G)&@NV^"')GZ'8W(J-PGBK6^#L09Z,SEH%2,87NSVT?,/A])4?GGSVJT,U
MD$ _JJ0+6BG7_/@%,"V=0/S]YQ24<9V89DUO05?8&O %8*84G&WUXV**6$$(
M&TG9:@:B):0H46Y3@>,*ZED3K2L54#W2(Z9;4G?B.],[ZEW\25OFN:K;<J_-
M#%+#)I'[<=@#0KY,A@ZN<>M&]GM&;)\- LYNTZ%:F5-INC2,B*B-1]5:PZ0?
MW3?HN:E0:S')]4QB)S6]0G71PJ70'%W?L(Y6"VDZ'"L2#*%&J.(3GSJ3F.O7
MF(W_Y*,@<%T*C='#&^='C2]LW383U36@)Q64&[4N M6_UU5N$9L!OU'"D?J!
M, >.*@WU>D QJ2&L##@1BY\78C'4\G20QNP,XPZ7KPP29J;M5PF!D2B4J,;2
MHY1CLI63ZN',R%]\?%-2=_Q353*%=52\/_"NZ%*'="B:I>7X5,,_Z5+=U9B6
M7*C1-M]2=BHV46PC_(8W0(\4@)-/*#^3MHES5>9=DKH,3=CB#V=M-N#Z2K(J
M;&5<7[&D27W=)>Q24EZ&/A0BB"M^>?Q@LJO^8S:_BRK*_%Q"G"0+/D[O!B^#
M.'PBN R4 .QF765_4!T_QE4X\$B-/=Y)HQ9;PCWH*N? )N6,&?":5"'YF/$E
MTDSL"R;JW4[HE&'0H7_$PW3BDFQJ &M"!6X.B,X0^E3"TS!=%&#?SCZUBD R
M>\RVLUA/3#A;8]PJPZ53/5<>_4!X$91<*<I/U][2(%VJ01H#U+$3KA2<NAH@
MK"-&62Y%1XA;?,^MNYDZPU?*5O!*EM,TNX=L"*^9H!0Y4*XL$TUS96$?_5L1
M.C#"NO^$3MF.CBU#DP\)7$>B*XAB OY@\$J%B+W(GW_+*E[WR#N+-19R6OZ-
M\Z@!GI=FO;0L%Q/BFR3!UWJJAEBT*8XW>UK%4 =TX[A0$<S]1?BR-;YMUA@O
M #]$0VXKX;T$$ZSGM8KIO1OH2VOBITM9'<8!7BWQNZ(L5 8$Q]#<V+%'.C6&
M*VNQPWB\I<I2YXIO9!*]Y/*YXXBJI!@IT0#C<5B9SR'EY:#6Q\+XF6;$.17$
M+ #@ID)7CT"#H1L)\ET810&GESXI',%.L['=(/R>F"@*>X5VSF;C PVK-PV;
M1.STOWJ( EZ((2+QZAUX9SBJG!(VM+./1/5Z*.EXE") BF8CAH<"O4&=1RLE
M"8(7F,VVA1=8K9:(*X&K.ISBK!B9A9COX\*;."@6IRV:(_7HA>#3Y=ITWU?D
M3P=#%?=:U'TR9RQU;!,!E,"*>5L\C:Q$)1(]-AG6BW32"XT %4/>52B;Q)&
M@.GU?2T"A[+J-IH&,:4XIS*?=2?7&D#N3-:3N.V;V%#. C*N'T$CC*LW&-"9
M]D,17)-I=OMHBWOJCP1BPN2,.T1U^M1793=S3C.I.)%'M)?(O65W]'1"#G1
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M3)X5"8:L-M6T"(6"]S_I.5M!PI1RDMKI_=PW\7SJU]+X^&YK32T!/!@ VDF
M.%&BXFZO)D=U4MQNT$F)K&5TYO?%U.'(MPFN4Q];TO,=(.,7RT379<S'2T1M
M33PQ^?Q*MD-G>*UU:L:M;8Q:&J+<9!5%D5M=B@^B$JWY*]*1N1S"@,(!:T8<
M'M6F;,O@D+W_G_T>$:L-.Y(DP\FFGSNKS@N@+-8C7M6IC96?239JDOPBZ_#
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MV41JST7EHP7*74[T/M@RWW%P77BZ"+:<:%S[-^'W_T$?Y0N ^WG"1IR8##R
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MW#F0*VEE(84D4 ,<>Z_V-;TN$4RJ@[9PNK!VHQ+NV1]I*MZX6^>8RQMH5Y*
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MF$,,G,J(DC0>T' AOP TN1"SD41)],WZV0&UBC:8-G#Y  9,_V_O?)QL<'O
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M.7S[SK4;]YYC?#]))8[&@:$SS+374 !U&(:707$D&;EK=3PW-YO[9"("CTG
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M"M()B[[D?/V*<:!G.-S/SN98Z;;C ZDWW#>,S<NQ%0=\HK=DRN-(J>X1@@\
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M*R7_2;PBK; E#401,#;ZDE3*(R"3<FO-P4MO=(#NZPK2QF^M\SMX\DSL^3/
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M?WZ'\3ASYMS7?2W/^[J>UST'KY<W NPRN6!\ >#CXP/^AG\ WBB@:XAQ=0(
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M[18VL3Q;H6Q ;#%M7-;ISXT7$]44*O(?7O#R,3[8FM HPTIV6>\R-5[R]6Y
M'*T/9!C.K;E<,!(CF)Q*&SQ%RA-J&9 V>)6PE/?S;,]\L:;Q@'T]Y5OGWAO?
M'TP1%RY/_!%YRR;>/0S'BG\H?ZCT(<HI.AGQ4-+ZU.N9+P]X@(5>NUM,LQM7
M%S>A,HGSFKP0:B3<V/H5K;<[>ST"G?(=#%_*L<8V;2L;;"01/;D!5VD*@Z?:
M@DWC8VZ84U^FBPWZ'RO4V?[NY4W/E"INMMPV3W"[W\=;17UE$']_UH=VY)N]
MGZ']23$R[[7:]\WNJ?[0Q0/:QG8CO43:WQ59V+!3D<\0[8^4$V9_W!7F./-+
M'KJGM'"ORZ;+((C4&,PU;TV,\GNWJ7_4\]TMZ?E2$X-VDNLB*5*&M#W$R(&;
M+-W4RP..&R= O<Q%4AY@55YFXV):.B3G.L"XN1)SSX9?/^)-82'CW:;A<<_S
M'I"4:O"'.-/TB%$%9,"E6'+ZV?1CB^D\(#^/,AR9[ZN'\JHE% /6#_OV.+1=
M< FSUU<[P.W>LR?#-DSJ"U@!QA\W4V:?D!=9+^!D;;HX;V'<CZ2>V<9Q2?4&
M;'F Z+><DKO1UV9#VL!XO1L[FK:MD;H)Y\](E8XM-I\0>NPM-;YRX,G7$-^Q
MQU=<ST3NKV8W<Z8VH8M5RJQ:AQT'3Z:7E4FU:46O6N99)"I8AL<4%!_)[^UP
M6@L,8$< 180ROXQ:W>:O:'K*WHM-FL'RQ3;FUZ7[C_4T(QL?J6LW?FIX2TD7
M^_GYW,\ E1\YA6'0K]*U0&VS+"Q3W+M+) !(VO-7;ME#H,.PP37U6+>^,R-K
MSFA=\>1\;DJ0JIX7^4KYV!=0%4AU?[_IR5"#[(WR;SG6,=38*+#)$1'F-KQH
M9-[]2&8S#W Q:UKUB3!H@V+'>8#4$"7T9ENDT.6W VM)_D/<_),\( '5_>BP
MN>Y _:W"Q]/F@O<GNW-F/E'^?LE?;";N$7U!;^<R</[DF[>![ZL_V#R6:'L_
MNW\?J$NX(T-[>-N;%*&A$_2E<RP-/WY&*OV%H<RQJ32M ?_0.J$#R_:QQC[E
M>;]Y (Q75=PE15<ZW6!DX8Q89/KQ(K#NG3BKPS._N_UT<\=^HW+]&[OR?9_S
M@-FD:VX-K:X=D/4A'D .!6PU(NY)"WE%&='CA'?(()])HDR<CIJ2.<7V9Z3V
MCBA2D52ULB"5!%#IA!,[]T>6H^U,&P_H48+N1-M 9Y? ,C/ 2FS3UZK"6TR[
M@Z5$QL&)-WO0159DV2]/3M9.>B(5+._L+D6]@VXV8OX&OP\S=+@!?3S@D K_
MYP\1*L _7YMDABC.>GXK<H&6U5>Q)XI_@1[FD98H::(\ZR59').+ZCB"%<ZR
MGO9QDV)6!)S+*3!2?:%^Z;B@/Y_:V[[)]*!I[/L\*P>_P(">B=90@T/8(%83
M&X,U;<?*4$4DS#ZRI*GQ&6_]F;G)CG1N8GCS!V/?>[]B)XJKU5_W^6]>^:YV
M^Y:XFKIC21*S2YX'C.'DL']]X;Y+[6[4^_Z%?>[C547#=QB?SA3?>G]"*@\8
M2<)1E>@HFN2$<3XWQ2"3F[0G_5BN/YPILUKWM*ZJ32](!?>LILJRFI1P.Q-E
MINF#0G=L$:=_G&S$F=!!EM(D[1BUV6:TM#[ZB'NDN//(MF*]Z-U"CA:/B1UZ
MV$E6?9#[U-+4C6A5^?:XL(CNA_<XYC7Z%S;E(T^LI]I?EQB[N73AP_B-E7ZY
MMN?44_KV/&!G!?W\X515:!BB"/A9X&E$5 HED,7D8O))S(YRQE^(8K 6.;>&
M->2F8O5)KC8..G%WUXC0L$Z0F_FNX$%PUSW2"-Y.G/5<&$H@'NHJ]G;PUK/*
MC&/X?\063+J<7+#+90@RGS$LPMGN'&VZ>O'WU_2%""T'_ZR_NF?N^GN15=<:
M9'=NP:;JB-#H2^\#?=1N(PJI66RW:^F!M^4OE0:KU"_HU 6G%'4>AE1.*S*4
MN2O:?O( -Z_2E> .RNTO*V\?1O*YF;I_#"V^L?BBT7*GSY+LSI5MW$_Z=Q71
MRWG(;/+ZOLD50G4A)%=SM\M!UD*54)4?R0-*D$>;-7-V'[J@/=NR\ 6<N/\!
ME/!OS%-^5E &2@SI]=38:5=PLQ#,FDIZ.OZ9?A#3!AY4:O/8!]GG\%DC;J#"
M0ZC^-(80R"T#1SZ#4CS R?Q9A07^HRLD0_Q,^FR#*QKJT]'TW!]KDB+K_3W0
M\AMZ()&J7-?ZU$".H50L]3+#?6_>ZSB,X3.4BB=21?#%L1"[NXX)[>%%ZUT7
M\*O@"/Y7BD)X/<N_%C]K<2):_X+TL<AT\[>9*J<]#&RFF_(XD<+(YVQ3ZI'7
M[ [9V.%X)\;5>\\K#;_*CC0GS8*CG[".XR.W78..XPH(K XCFOV8AG;)D&OE
M+N18&UA?QBVYJ0SF=;'Q:_B?7:J.2\GX;N5<M#,EXZO?XBFC<H8)+LE<U $Y
MG!3OJ6\!CA.>(T_E9J'[2?5_V><745"L9<386>ZG2D<<:[V#)'0,T@J\E)E_
MA##( WYB^T .E+V*7#KEB/]N146+^I*'DQ);&::Z$+O.YBNVP_OV&6XNQ[$8
M;"]J??-,>2X$U_T*ZB(>'_I>__91 #?*9[V-IHE;%\J%9>R\)_A/8<YEC"NH
M))2HQ\+/P78AO.2N$S^HY_3^;KYM&MQMH*E"F;9&G_,O1(R9\@!AQ[&#LK==
M2:SMR'J<ZROPUTUT.?3E/Z+.>E/3AY[K&_?@DSQ5EC@WO"O,Q7R_K67DYT)[
MR?6HI94,>)6J\("](AMN6^-T@'0),%J^ TYX[Y(H/=Q*V5[$&O?Z/(P9FC>U
M$LQC[.,!CTW_>BBOJK9H3#U=171UST(6)T:U<JK^H<5CMA6K003VU?\J261#
M4N):2J$Y-?T%M%27_)73<4V[-6(WMIV%&Z=5N,W8, L8J0^#<B_S@&]7(2T"
MVY+5A&"L9JS(<E]M"%/YES#I;V#K#/X!Z>=X/RCEP$4_/PVY9N=Y4Z,S[Z4>
MF#^ZUWHFF5G(P'.XTW^4BB>YB^SYP/#/6.$!^+.0EFJ?B1O*.B\S'B8OLKU;
M<O)@"W,U\Y48BG%D=NLN;%;96OILC&L&2MP#3<%$]BR8VO S2QGO%+C'S<<>
M0V'(^K?*-)^Q.YDZ2> EN#:\@SW(-=U&=3(WB7(MU7%T+\YFO@X^WC3=$;4W
M(=7BV'E6BLHFM.@6IJNK%$K,$9=,/4S8'):H70Y'T&?,D0<D-NO)@DVO83$N
MW#R.BQ"8X<H#=%#+QUIG;<"Z&S^^FLYK\P [3<I"4/W^EW51EL<QSV,P,NFS
M)G<9QY"SE<;3T>W=;?!0-Q-\B95<IOXM B)/@Z--CBY8LH-%P6P:#T/WCRCS
M>9&5,75H=?#.1Z+BUA/-U(/7.R827C8S]H,KQ -#L+'-'IFP=7?-/BR9?^,!
MF?! 1/]8?<89RKV.I2(>\$=/)%7U[E#ZJN Z(X$'!,X?LP;%)-<R&**HU0QJ
MB/+S0JBT+J1T.*$$1_,8,Q;H\,^,A?5WAU6HM66-[. 2S-=ESOY3(=/_*)2J
M"-"2ZTQ_"$XDOCS[LBZ4O "O\X(A=0]E&GK,JF>\L@-R*.,![PFHEA"V#:;O
MK0TM"91#_NKAN/" 9]DO_1('$;/U-MR%LCH-ZK53R75&T!9UU2;JU2@SZCX1
M9(!;/[*X)[J !R"20(@/QW@/NN/V?@(9:YG82I'E_U6A;?H79>&U+/.5TQYR
M_@?UPD %6E0>TV3:TU_" T9A=^<W,YN1/@[(*=@T),U[S+(>K<4#7OT&W^,8
M:="!##-8%61/U%<VQ3MR O/:-[$NA;&:GO$I55%ML9FJ7OZMUM0FC5G%@(U*
M;!+A\"/&+I**6Z,3TX?Q/4C&%&G,B&-X*9E-\8*9Q!\IX:2ZT)[5X0,[+YP=
MTCCP_$CE13ZG,H:\KIBU]0"JGU*?O!I4:#X4!9(_T)&ZQDAWO,S%$\E#^H3,
M/DM\-XX5\4;'-:@:JG0D#;.C@B#EW=S5YR=69)O,8M!B;W\68G"_1M/S6EGN
MK3);> !N"!GSI@BUX26XU?$.S,0.IE@36#"K$;VN1-/8,*P45BFL'?/22UCG
M6:1?D^EEUTKC&">&E-YX1EX:VX;5]5IG0&LPA@<XHA@?P?[)^A:_Y"&D<+U!
MXS]-*X)&_@5LS1_4FZ@5HH*=IH%K-KQ.T!Z%F,B'YY=,;1R8Y8P23E"A6;^
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MY%;L]N^^.C%N60HJ,*-N.IM$Y:0'J@V4#W).<U_JWQ[)<QCS;2#^@HML:'2
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M85Z;[[QV93/<]9,KN(*+^==KX 1N66G& ^Q*P$:3&;B<X'S71<9M,T/A#$3
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MZ'5>T%DT/:U6:7<K4SYYU8A3("E'J"$()S?%ZRHEASJ2YXW296/GY!<<)GD
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MMN5WL+\G]2R3&"@6;/8<.<N%LL/@R QJ($"M=JPIVF2X_V"BIM6="=^?8ZR
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M6?NFMG$C%W>=X3RGK1-E(,]1:(.;D(,EI>BPAVI:<4'XAP,EJ8^<QUO4LCI
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M1=_SH]*&P,EEWXJ_D>5MQECP4.[J,M9(NL:M/AY$.,JB$O:U-N:>R+W'RL@
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M2W3CPX=?AX_%IS>!Q?V56[0H[IG*_#3 + ]U^0V3$_<<_(5VC4]L!$\Y5K\
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MW>L0_2H+/RS)+MM49T(CV9Y2JL(5-N9J@"'%$A3[W]QRJ$@Y?YZ#*3?^8-[
M7*JN7#$T+]GO5EW4:-;MJ7(CN^_?=-#\M+H+M)<=YN9R$9B' ^,%Q3;BWR;S
MQEJV5\?2'F7.EI<\NS1\M)/0N7#U2,Y#ET&9KC!$.J[Z82?2X5$KS_7(^;:+
M/W)=\B#?$DSQ)U*@-]TLX*0;H MY?Q,(ND[3]2"@#O1-+VI^NYU?$ YK[1)M
MO'CL.VN9:KC?"?9SV3<,4O*&FZD?^QQ+0T.?\0[K7WI%I:+EW6G((2[! A1)
M)X#YQ:0>^:F$SI6+=,0^.T-#U1FO^^9(26*<3Q@OW1?=<5)^DF65Q8-KJH[Z
MC7+00OMH?L?246">HQ'*+W-8_$;&=+>QDSMOF.I5+D'^+QUFLFVI*[%"E^PZ
M#%559V:6,3'SF\#]M@.#FDDY[A^S\!$[; )6\NHN,(K=5]KQS(X.>'5_R6K:
MT(4P-/6AK_%)T4+[3>#T09"64LO.=X%L!%/SKJ 61*Q>"YO2N-DIA7^;(B'"
M3FD;<?*"//- [T8ZS"*?Q[7FAL^C0?H&#%NV\QVSUD(\Q(8#OL/I/\_95MRL
M829!A[CV?=C( 4V(>]</9(;^ZF7 J!/$EF,^(#H8DG08MB4,C\-#4.9%'I =
MQO6ZL#WFR-X;ZMR_0E2.SBKGCVX_GJT@'#07D$4V6^NO3T#?G]M2&.-UU,0I
M(E,#_/0R].DX#-VWI LIH\[SZ*\,];/N-OZ/NEML*@#Z0XL'03IZL@E,R9+T
MF1<ZD;WR:2-;4;E>)NLFD-A9!%UC!9]M@7M\$GS<#<A&\AI[MM,6 6! ^.-R
M[&5<0LZCQL1S,5M1K&%(\_4=&"QQHI=9;I2\*IZ[2D=L'76^6N@_#IBT8\<$
M(:"U/:<+7138!(HUUCH+X6NL6LO0;YWZ]*!-@/22Z0[\$BV,_ELL47T_>(%F
M[OYQ8$MRA!Z8RPS73MX$,J.8Y=@EV1+DXL&2=3E Y_= 86;'[_'$Q\(@E;S,
M[6UWP)6LE_Y^1*MPF](FD UOS)Z&4*:P"PI+V7N8N5A^3 JRZ<,F4#GR_?%!
M^-K>@4T M.D=[W.1S5+P])4T4#6.Q2-7(>L&19BUG:W+S,)MLI8F#!PFW;UL
MZ^86#/'Z7X9B0"SSHCR(AIE%G+3%>$;=]:^_$E8BRS_ 4X$#N+S KU:._9)M
MCMP*W':!DG,RLP>R/H/^GHO\JO3O^.'EXB:M1,@Q$&?N0/$/-X&Z:CJX8-AE
M'2'DN)SG.2!VTI@;0DN3/A 2:7FRHQJY"00X!Y/ )["7-,+(E5C\*6=.$NC&
MU:H@KG[WX!A\FS^!8,*NV57Y/T'HTI+@9/1G-R>>&RT*,>-<A[+S;4*;&6BF
MFAD"OJ&3FE+L92S.U?X=7[BX6VY]%^OS?-E2O>H;1P3/7_00%KV52A)V"5EP
M0D-""&$)Z/TW6[*L)4/>623KEZM*_!$I].$A#> Y#WE/4G4I>:]&J96P XXQ
MK@.WXC7OON5+46^X^NG=LQ9\,-]$E=N?Y_$QRHP<__/8N<X-%1JFZ<:T<TX+
M_NL!-\&7#[$.SE\J'B:B":R/]1/EUM:HK&T+&^<=D>ST1_BAXVLJK@3+?3W?
M13KR5.2\7+?W.Z;A$WSF%;X,"'O3/RK$6DALZZFN1A\G?(-4E0:@+(N6,$^V
M6D)[]UKF=\PA]J0..F;?V564U>C!EM.#^^X0QUN9FB#B^7KNH5&W.K!W40(^
MBB35)-*]&*D(\U$!Q;EDY)X*QM,99=J$\_5+M1(Y]5A9?\- Z=;5@CA@]>W_
MMM8 O>?H&;^=W?K_HCG SBG)^ZXU32Q4S(M*OPQO!2*:Y$I T329>RV\9PUI
MR(P^AV')'N<BC\['%;@3(==V=L/YA_A,8Z??[4V0($E4U4HWA=(*FKBKMS%
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M!Q/WZ3"YJ/E[U3EY9OJLSI=LW>\UB]N,J[LGU\V9)P)SLKJ$O;.&?T#V8\3
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M5@<=<GL0(=5QVUA4S:J3_]/!,_Z.P'*5<JU90OK] G/:P/72\(*E)JZ*3.&
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MNS<MH,[,/S[-TMQ1X6R-EVKKRJO085.KVNW-B;CF#C9HX"D69T+UCU))JN?
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M6<LDW]AJXEX=S&['.(\"76BXG-B=$&T[;^?NZ]LBM25^[%OVEKY6\".]M$<
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M0O7-BBI,_&;U/Q*L^_7)WS_&>WI&FJ4+V&HB4H%8+OBQU0<G(VG7$3J#*>(
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M W7S2((#2NMC,3B<[>\.*D4C]JTEQ*"OK\UALK/<K<#KC=?8Y]VRD*Q,5-W
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MOF])C(CI?WFP^/]13*=S_PM02P,$%     @ XH!;4%I3("TMS@  \M<  !4
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MS.1'&$.$5CD\RZPY A(?M#I1)7<1&5^3YH:.ZU1?B/9EWV+CC-BHJI3J/ -
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MOS<..\8>:,!0<>:GLXY(Q:7KC0FZJ%'F'C_VVYU<^%JE.-&0 !N5Q<8=&N-
M*R VXSSYIY_RL8>9X>BZU?I,6FSX)NWP=AXUQ9\PD?4U-)S)*Z^%S!GOPGL&
MWW^"#73$6SM>:E62ZP)&-A>$0!4R$$'H6"Z)<;NASX/.'IC4CY73K@)=]'K
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ME<FD^36!K6RU']8>6BRH#NDTK$J'5 O4X?CGJ@NEHU4'@]7M8H?K=C=PST[
MF\\ /:I+;]U+'SO(K":YLSOH/VNWOAF5CI"=H&56;N9<W,_]K$F#<$$2-U>
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MDZ;R=NLF%Z9*?8H9(QF1AK=FFN=$ZS8>V4KLY"=WD.5+",;'X+[EU HPS,&
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MY0$;XRTX4=1:\LP'U+;$W8Y3MU8$S8;"#NJ]6.6L.$N&WZ/$CX.79B/^ #S
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MJZ6E!A___B> 36/!A6P"A7S_B=_47PG^P>#\RTZ"?<;?L[ZSRVO\6Z;FY-Z
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MY]M" 5HG65WP>1-7&=9K_^OCOKMF$^TW<+J)!03+D<61WFD%GRBA^VK,^H$
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M,RA*Y,/[$!%$94A"A(@T,^^^Y9C5A[=9=C=I_NLH0Z-\S_8*-?&._:^P'IG
M8 Q8U8'V<\/4J^@?]8TJ_:\+'D6I/Y?.5C<4GB'*8;B5>U%T[26%-@]V<_Q;
M\KXPIUG#?[U7+F2]9AOT>\K97<(<)$%(S"-<9>.;/H(HB;A_+N#WFU]CG+E6
M2:6F]RQ; R&-/\%J7P"N.W6?2OJ-KZ2HU[PUW3T<@?VIOM^1Q?&AMK=T>=_S
ME_23#VE;U AMKY@RJ85G2DOGSR*+Y:AJEDPBM!L:++Y#HB857G"Q,^L^?1#X
M_MT[/6JJLA>26;--4@N>V4(SNU(MIY(ZTHX)U@P-"T7$)C5XN![QR.X/_/J_
MX^*ZQ#O6$+_JS>9'L6N]OC9@QF8%L6.SFJ&--M:2P[),T5CH"DG)S2TM7>K!
MER\-BN4!3HY;O_7X,BDTBV95"LV1$#<.)-3] Z_J1JYI!W(OH@'.!0MF""]'
MF;L>B_0V^+%WUM0*<%[!/IH5;/NUN(2T2#_.C.BHG-UH%D$<1[24/='6]GR7
MR]#V*)+P^MF0S!_:9,K@)!SG\K?$7Z/7^+] [[5.BN9@Y=/.*_DZ&N^Z>VWD
M7S$)%'JOI DX/2'3?,'QVDZUWX&)X*F1.72+$)[[!".,DIC11.V"-/?X356H
MJ+'J3IXO4S; %K+)$ .F@@G@9Y#"A9=D[\RWR3Y'7'9WA4K;B4QT!_G_A0=<
MM]NV464.EZ=A+K04L[#";9-\E5Q]W11M;2*'2GMDQ[QJMB91,$1AB@Y"3B';
M">=WK$CPP '-4XQPZQ%NZ&D^3N5:A%.6?OL+,EKOW=Y],64?\VM_.0X'!2LC
M^4\4+;U7=!5_:HJ)7(T1+'C[_^BK?+"$53X7L7:1CY^)4^1T090.G0];:3QG
M]GE%?3;;(M)_;?,NFZRLU.&#.U=.3WZX?-HZ;O>F[5%A6[#1TF0J0?*6K%KH
M4>K=G?#A?@!=;?CFD#UR-MR 6K1J'\!F35G].3'ZI$[!<19V*8J2L2$/;(?1
M#'3#T.^$JM2 \JV0OC* K'8XURXW1=F!6# RYC3[3&&4@1#AQFHYL2MIX_G7
M/7D0P^YS <A.DCUUB+L !&B> /!/N=7#0<J:!5$[Q%=5\_NWE5Y3]!0L9GL>
MA2<B!(/5M0[!]>6X\J3F :X8=FXKST:EZ[RA2CW^>9RI)8 RVEOJ%"9*''0J
MG8:UV=R3G#KQ">M5:;!M=@:25_^3E&UVH(K1('63XI2M51S-P8(R9A E"+ZU
MZ6=I14\W52SCZ[0D)%-$O 'GV*Q-9-XD"]8?U,YOVSP7V[,:K+;?3E#'&%,5
M9 0%H6OJ8JULW.]G3-=G%,,CT,RI<,ROL4O:4ML@)WGEMTO'-<6;I4V01"K"
M:U/WHG/Y!P+[5W_6Y<R%K9#S"Q>L.E>4J'JMHC*EFB(&:#_=?M+F]\:=6^U9
M9^6N!=[D1TN/!M<2$A@&8B$(_R#E()M?LGB*8],W+]^/C_+YOLSOD+!KJ.:'
M8EJ/7P48)9DXMB#$"*1SE44B??/$/_ U0ED/A^IO0\T >,&+!S:R)5=42K8;
M;P?&7=DSL*Q]J)(=*)9%3" VB'2OL46M/$XR_(IX\]<^2'B//VVGUJPE4+@^
M:15^2[(E)W2)G3]S1.(^ZN\% &+.Z]T8:KCX1F!&+EUBQW@Z:%&L"QJ5?A:1
M.JH4GL*?7_0IH'EBS= W&%:-QYR/Q13AX<<3!# >\FQBK6Y:]' X2+>Q"[5E
M*FZE@1OX<#]]U;^K\;2YJ,UDO$Z#:+7"SE<[*7E>#!.*]P(F=ZE!V M(>R,W
M..TR&.+>5<M(I7&9T'1T96;DJ]LZ([]4FF,_VY4:8H=OJ"JK3>4,KL//78@.
M7]JY-Q=OXH+';2]EIW%TD?DC41DDY"Z5Q>C),Y6X[-]]=;X=U]MO6A(E<;KA
M^0.K.M"5<Y_0$=03<J([,CT%V,?[Y)%-,],OYF7X3_<D)[PRACJJU>W=?/[8
M77EPI-O<D^J%;\3Y#]OI@T[%].J%P58E+KYG4EG6-CK<K4)/1==+E #<FDKO
M_\V(4I],I(OL'"82S,#G =N;]AO^"#+3XU19=R"S\J+I085DV\P%P-;N;8#.
MY*[>$-#(AK43'L:1@66JD/2MUBLBZ$ZK\.27J?FVC0$#%R=/W(<%5^2NB4P4
M$$3.^;>66%#<VCV?%M^"6%SEG<M?6D:4=AS.<'4RDI=)&/H6:NJM84[5&MQ:
M"M2N"#4_9S[7>S_T^BUU+@VJJZ4) )ZI+>!UE17H3>?%ZSAL=DK!7&?19C/L
M.6>0OYG+B[!<X.^4 ;Z4X;?_+VW;_P?$]! ]", "H@_NT\0>2EMA6UUB$Q5W
M-^ ,-MM[-&JBQ,Y V\K3[9NJ3]T)XL,=(RY+>+*_7W=ZB5/YBT)TLB(IRR@*
M/O26[0BXJ')P;QD?"AFE\-/7O%-5D*11:,/M)QPV>2LPYMP>W='%?1.C'CZO
M.5/Q<DPXH/Z@=]&F)S6_H$IVE2LP@>'Y=3ZS_@Z6=D9"V#+E"ODR::,S(N?J
MY[=Q??52AU8%P"TPJ>/(;:MH-9>V@XIP8DZPXICO2H%D\^A2QH+<=]1)CWV5
MY1E.U]835Y3*)EL?8K#"?9D0&V>9I 5U]GDAS^KYAI,W*A%JQW?-DL.:5&C%
M?_;?_<=HC/"6W96B:(^PBE<VC+,3<^/;+S+8T%,#'YLS8B^AIGD Y')#H"?
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MT\\*&@D6[C]2A) IJYKAV=O(<,F@7W^_N/Y[Y,8':N&$\9TQ5V:""8).2+?
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M_,@6L[Y@/+(+?)Y> ,=QV/Q0T)NH.,P2Q%;8)2PN,GZ,IV*&CR("DZ=O8OW
MM6/>5NQ2;G[ZHW/E?["GZA9OW).ZV_Z2J#2OUH9P$9AL"7,52I'A;AC_NW#1
M _-&0]='2D]Y2=[YY("\91+Z>WL]X0&.287 GC= ];7:9LOLLYN*41/2!BR[
MV_>]F'S'6B@AK 24AXMPVMD\EY\CTH_]:&S\(J5WQR6FR'#2UXV"_L43AN5P
M!3%#SSX^_*;Q_[L&*O^GX05G(C,2@C \'TA9:&YIX0U[-YQF<@JJXP2=]*Y_
M<4N]79UYW. I\![Q)2F9:(<;^]<X!AOEV(CM5[W)4^':'NZOB=]JL;X >,]D
M;J*FZDL4__3PBDPUS2O5%K]N?'^FZ'KMX5D,B:I2'0W]E7@#9A<-7[D[Y@85
MO<\6@_6BFP3NOOPH3[K2 X"]IJ=SW +=FI#2S@%9R:9C:O&.[)%$NNO0Z;;Y
M7N#/"$1AC>8*F%GDKS+2 :'2FFCG<8ON A#,"PP\@#(2[^+WPM@N ,X$,=-,
MJ=&]PPP=M?M*OGFW$WL$KZ5'])E,])T!HZ6BC+VU0S/>*N^ATR\ ?:4.TT23
M2^GQ*2'VDBK9N/)(*Y_\_DP2JAB-DUP +2,#WGG/S80Q'^J]Q> ^B5C63>WL
M97BSIM<PF*^9DM7><RSRXHW@U!&C'7L]:F<Y,:+RHRL$I>E%9X8M-()>'3KR
M1>2W/NW (X-$TW>U5[+XOU2 X7VC48[Q\!8G)R[E,G?);AQ/]L$-T?#I0J%]
MCN.5M3XBQ;>.0DT/C!O/M ZB=)/L=,+BXZN,8^:;'OF0!UE\,D^*7 $S;0VN
MW[SOO >]E+/U-:YZT^\?MVKC#I"+DM4LJ-ZP?)?Z9?NAYNJ$I]2Y_?W$)V!*
M\L0%X(HW\"-9*A'9+)+6FU/IDM$BPE>?K6I:!?U2Z$U->_5V 7TA1X>1)'B.
MMX\C+:ZA^>@DDLCZ8SY?6S%9DY3G<<=%_+=']8-?%/]JKH#O$/R6=1'G3PE6
M?3FU;FW3A<$K2D S<B=N''P_NFB<UYYK9E;_:J)4ZHK:U=.Y\]R9V,P_A1:]
MD4*>68N#FR(+E\IR;>S,+[*IURZMMQW*<1!/JPCM+WI D^;@HY45X^MR\C7%
MLNNVC=YCW#H2R@ZCP+]&A!&#N7P#@P*D1TLWY[%\-:DE3!]"7ZJ^^U>LF&_/
M9S8+IW>[ +Q%S-EWAW7SB))R#I5CAYDR:J<5Q="4SB+Z'\*@D+L*>L&=U[@P
MOL(C1Y@+P$VK8\C$D33IN %7J7&H35J2L'Z;(:KS-5(@B6)^9;.K72>X\ )
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MV?RDN &\]CN6[]HG]AM7W@^F$V(OJQQ.#QYG^V0\'>>ORWW/PO/^E)1@Q:I
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M5+%_.L]C.6NAO6L56]?<^R/EQB/K-'< !AHV I&-+I:*.!SFZCP%(LUS),>
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M9O9S0T?/\1?7F@" LD2+G?%_ %!+ P04    " #B@%M0&P]""7HM   ^2P
M%0   &%L;&\M,C Q.3$R,S%?9S$T+FIP9^VZ!5@<V[8NVHT[(6E<@TMP=PL>
M@KL$Z,;=+4 (EA!<0^/N[DZ"!I?&)8&@C04/FDO66GOOM?==9]][SGOWOO=]
M)W_W__6LJEESU!AC5M4_Y^P?<S^^ !XHRBK( H! (,#D_@/XL?I@3<;+V@(
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MFA$4L\_R80RL9(UU1PU[.#-'  BB.5<SUN'G4A,+5-=<3&L0[HNU_/9,S*Z
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MZPY\ICF/TOE);709*H0UN.65^7FWZ<S!_1?E16O6S7FLSUB?H1(4_,P75$(
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MY7FBH;N^$HI?R Z'LX30$V)'->U+V#U[+J2!&7!VNY-?>P/GCV%>3\/5Y_,
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MG>F2^7WBF7.$<P(B59$=",?U\:-G1$SO_+9*FC>UZ!C >'K#@G?1S9 L8L%
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MK/42SC):6>8>R:_"]7RRSGMAHO\QW5BEBKY?0>":PH(@I-T],N9E2 NN2CG
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MSOZ?=^XK=XQW9[(RUEQKKCGG-^?W_;[?-]<,\R=S"CBBIZ6K!;"QL0%_L#X
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MB:,\/$?",3?I6>Y(/IHL62R:JE15AYT ,<V$A18YMS:+H)"YU;*&O%F&4$*
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MCQ=H.H=@K9@ AI=EI.R33""NC]+@PD H]=(@*(;B]1,^%BZ$;<PN:0!&8L5
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MT]N,>BZ@7T!XA)Z!\YW;&##\X?5D?^:^^I$-?!:7R3=8'5R)$"!,U%ZM\1M
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M5.M^%(JY_Q+[H&HB:/*MM&@"]2%+H00B?7&H&(A+((U2C0Q0:BM]_;R \)Y
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M[E6F:G.D_A#KTCMFZNWW1 TP?UT"EL?[5<FW(.R+ NV >DD!?<9GM5;!Z7I
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M!*@_<&Z3!9.!Y><JYJVM"^<,ZE@.<S]R4QB^M5/E3<U^FL(WERN98$1.9<T
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M?@#[#BTMS8_7H. J,." N@V(2J?RP2.8BCT >H%SZEQ^0EH400_AEWIRP46
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M4\>]876<8\H,,"WU4P1?<T<;ZCA<=4I5G 6B\Z<$,2<'JCC#7J3B]\*Y^3>
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M"2E_R^1O=?A8$PX1M[L;?M1AGC1V+W-^VVY+[]7Z@(I<RF@4)E$N$%?2!DH
M'R \1 LS20-3U,B2"F>8'74C+K6GJ;VHU'MK$!2OF2/MA2GTCOMVDRS[[,I+
MPPN'M!+L,LUBD*#&)(_:].GM42T4Q-EEEQRPQN<RCX(5LN\6OT6&^XS5%5B]
MW[EB&!G!U00'=9B=D\JBK9'G&/AH.EZ5?W041K>?(UTA(,/%6;H5QJY2;6W?
MD\KE&CIDQ&V47[QT?'W] ?BLE!2T(U*-F;5K E?[RI$UIT8$M@)Y.!?LC4L@
M'$&S'G7CX:4-_N,^ZE&; LY.SSX\OP3.]<8;FYQHEU>Z$>P/[NGFYC6SK)4%
M3U^]%9]WHGQ!6W$@"I<+[6P)O2-8SEH^_BA#@2540L/'Y<]/*/XQ&'F*&=T2
M-I-#F_D:]+RRJC(8>GS"R^X0+S(1VU(Y^;+<[V8^UFO:*X_WS NW2IY44O=F
M"AVX.$NU2,A5Q#$AGI,+8,F>PTG3>&9@!3-LIZ,9["W"\(GW?%SVNE)VG\3C
MR '^C(,?$>?8.<_FU6X3!S:'%ZNV@R-T*7Z.#:.ZMS X!Q*GJK-)9 42.N.M
M>T6)W6,(0S?S)^>J$R./33#'[D0;,XI2FBHL_*DW65>*S=T)USW/]GHG.CEM
M]\GZR*VYGBR_T,^95Y,HV0/$OF2 V0(K)SB!"$8"L_<T8[]LYR6SPZ]O^[_K
M*O+JK]15( ^6G"/[()L&]1_R&2>U6V]^"'KC-SP^B?;KLKK=%[3T;C'(+@71
M8@I#<^)#GR.N$)AM0/I KM(>(-^9!NR%<BZY %E&MX7V *AA!#U;< _0=7ME
MPT*=<V\/,-F%8+WF_OXS 5NR.!NQ>Y5ESH0R!#_A(M!/\9=AGB9#T'4IJ^63
MQ^M GIG'O76>E>4^1/HV]^CHN4FAO-8L;Y06!E .PQVIB).1O:!3<'>N>*'>
MXD@P9EO1 ER+ 0GCB[M?,H>7C7"N4)9IBC)Q]SJ3.3-A#RT6Z%%LGX7G;79^
MX"1'M5NWW1\YFS*0D(;SQJJX.$M8V<T,.S!"S,,_TR&6067A.CF+$T@'%MFW
MJ J+R2"SB= //]!?NJ$'P7 S]IM&07KN0K..5OH4*)JCA[/@8UU@)CX^;CLA
MWS\RL#QUNT;; 4X,H3N-S=4<KJVW_7"RK]@MOSHSL:::>9)NO=G"0"RFED/
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MZ-:5&-VWWWMTV=^3N]6"_#(EBO8+[\X3K0#__Z^!"Y1'5_-!%--3H5_@7&-
M4V@4.C;:I1)S@PQD!NRJ6.'">%EIAV(F SX$*W?<*>6#A*<WGGG2>CNBA+E*
M\"NXY!9W%7$:"H=/1M?"1-W455RL.3VN]WA7A0)="W^%#V:EU]V[YD/Z/D00
MQC$J^"!E'D<CSYE5LJ(*(%/>[V;MA8BS QNBI%C8YG9=7"_W#!\DFEL\-G,C
M=K=\44Q[Q$RPK4=HGKWGON0R5OH^SY^W<42'LT6:W&J*GNWB^H\@8TA'NY!Z
M%KW:0=:0!OUU&XS'NVWV*H.6V?"B>]$%-2>R!HI]P<?V'>2X;1KI+G (<]$M
ML![O9QHT+>5&)#]Q0,=AY<86^L>84BU(Z1M&^ 2H'-> =?C5JT:D/SJBC.W=
MMCBZHA'B&&WHE:Y_W2G7/LTI%7-&<;_#:C1TNZ"H'SY G1N%2+(-FDA@EL@#
MM>3("#M:T",MB-Z[0T-5\R^2A#ZW$P$O38L)JIT+'[3YFKZS08.=K)Z-.8W5
M-^5D" 5)R/\XS0=5IS0QI+E7"*S>?*"O06%8GUP3:339;*"B4IMA_Q87^@ B
M]*W6V^%^P>&3F(1,M?-4N11WS@ZN9'?MDPIHWTAG4Z*?TMS^T*@).D1T:DJR
M-4=M"9/Q,E$R0&UC,O.,-1^DK],1KKYIP+K''? V;/02.F*>VKN!9I(_1K97
M&R8B!T*8N=EX)O%/,-9U._8RX/V(KHZ=IYW&.?^CL>-!J[_67[!Z40FO_(23
M+Z^D/;CM*L6JX8F) 274<"R%8R;&-6;_/L('B80&-J?-#*L"2]R3-00<*^BV
MRS#<W/\@57/W_GBWH?-)FG:QF848Q6MH@5GY5ZV#_Q7'W&7" CIWH3(2'KZ,
M?'LS!V'G=KABS7><YIG=S0==2XDS L=SU<N=4:< Y;S*$:7?7X1ZK$M)T6&!
MS/8_'L0-MYU1]/-)T-'^D/!:\<'5G/8NM+N@^$A*P,+]?R*-F2)-&V:6+#SW
M@8/#L%Q5 L-U3:"9Q:U5V]^NW4<.[_@^61&RQ?K2LSC&S[PN.#)>:NDO<O4Y
M]<&GI*1Y%/)V%+S$+SL<WR@8J.J+2Q*TM5XO/]+F'G77#:_M;;L\#,?XQ#\>
MO6R_9]%61O:>+7MI19EM,];)MGK]A"G@W#]\D'3HV-F'E'H2V9^9JV]]<;'U
MG/UQ2]7>1<VNI#3>]+5TG?'7MG]O#X=LS@?5'-]E/D@CRB7<]PW,(F>*%\)=
M-D0J\]J?29(T?/+VTKB($;!(*(G66+FO?J\?W914LI&A>J,L_?1UV(D/OT$^
MOT5F!CJ'J\^: VX4HZ<&=&03&+,>.4X>O. H+PA6G!.)3H#H5S>+<O[@5H]M
M7&7B=RZ@MTCE_8B.-A=\Q!HC8GW C8B1+<AT:.M=\U]%]$]"]_(^\4&2/(G!
M'P#;C/ES;:VZ O;JN[KN#(LO%3<=+R1,G,V>."5\GG2Y0]5G\=A5XX/9'T%]
M_EOMQK3^2*36M?XOY/=OVFL=0:)J4BB=6/)N'%+11T4(\,:.+DB?KJM_@2_Y
MD=U+SRZ6F1O<UR<:;2E]\X)&E="-]9T_S+;XUA2SAPSRL+)F6"N6\QM7#&C-
M<G=_P95C6Y7T3X4WL>/:A@>;]J)..$_?D'-8UW,Z;95:]OS"\U,[=\QO#Q*0
M!WT=@B77$$FE4A0^:!M;I^'-S$.SFU_M*'2UND?XI463@5A1DN=BE/?'R8H@
M\.8Q.,=87N2#U%:U&Y9[^" X'_2$PPB465B) E3R6<E]HVK4:)-#!LU*2N8E
M@Z%YUBI#N"<1'HJ*,K,E3ZM2%Q9W#"[A]^54Y:/D 22&>W<4+.N;)P-\SAU%
M*JA>FJDGOGXH;$#O;B8<5- YAGUT,+U,5:MVG\1.VJ_6%AO!>U!Y?!#:5O":
M[;_J[)0/U# 58GD[0K49E"@Q@(Q%*3,'#=+/ZQ*EK+$VU?>*[LP[*-I?LM+1
MD1%130_3Z]JBY=+\B4Y;]N3NWR#Q9KNX9BR_QAQL'-<^WT?@?><K%-(BBZ=[
M+PT/N%)3@ZTD$C[,I.Y2W)VJ 85$0\5C&HQ"8L< +(;61#=]Y>SD,U-\6I>C
M$7QO[M.),_CV\Y]D+'?;VTK<.3GF)WUW*Q)D95A#"6L+/.2"YX3OBWJT6\$I
M:_3*8;;.*#DVW(:R8<<$4Y2M&L*%)V8N $-]F'+O;MVIB]R/DJ_.NB=U/E;_
M5":U .90M:LW$DF[ID@*+ <L$GC&S"4ECKW+'FNN1T4I5,/=I-O*$:Z+!^0'
MXR2LA(YXB'6ZS&\%ZBF.N+XP.</P4BNNH"$A%ZG; <(*F*T!0"D('.#8)(7A
M2>%8Y_+?]+IWF6AXEE!?#4HW4&Z]:2[P 6;UH8X3)G=N(. K$+9Q)5>C"R4>
M*4!4O!!M8A"XTG&(0F-[M%EK6#W31O5KY1R2M7FL:IQVYE-2I[HI=7/U"EF+
MVC4S[X\;P'+!+<X;,[#OH2$IZ)''# F4.><"'>4#M#QE2$*U+9YY$UEN<9JS
M\DO.M<CENKY+0_"_X!\G0 FT>,P7IQZ9H NE\U'ZO):?K/*-#*9=8:<(T)4T
M2]K8Q,S6X04>M26[PK36.#',9ZEYMO1M1JWT2<L%Q.;0NJO'+_VH6R0'# 4A
MX!%U"B%WIE>7\%$;4$NM=$-CR( Y,^")6=PXGNTW(AYFHE1B7>0C!<96R-4:
M'TTMJJLK@G'B$6(.R:9E#:EGY.13. >XZL JQ=JL,1PML/G88.BN;CW9GEE=
M#;3D0,L+9]>B/ _$N8"J^/1K&9,RQ^(D/QA.$/[E0&'_'6I)2(2 Z(REOCY$
MRS4_-!R^2*.9I[[?2(?*3@N2'EG(3*$,"#JNERQ4:\G$T)L!9&:JE@PN@=<=
MNC_!<@E*R4:]IGS0K!0 L:\[/H229UL%BCO1IS!J0%S>M+^6LTLO8X=FF&WU
M@23HM-SEYU<=!<S>TKN*_W2/B[AN3D;P7+"A7\0R8]*/9S4/$V-6]C\;Z8S1
M2T3 8&P80+7\JNG"JGA=SM7R%.Z=8 4/9=Z-E].IE!E).7YKH#0(W/_S7RL,
MRI!)!%NQ[8!!ZVX3I5+EZY05?=*>ZKA!<Y)J%0&7Y"DN_#T=]:&)9.,R1]ZB
MYN,Y=>-3R,:AR$[[@6E)=?)R)'BXUJ1FS&W6>H01K[*3G02.0QF/V(B&4D:O
M%<#]\O9#96O?1]ZVC3[X-34,&1DP+8%4:BOO^L!TU3] /03,K,CVDO9$=;*X
MQE^6T1A7N2^H,Q%!/$@5@*=0NX+:VPW'G%PEM;OTY!%&L"1HF)=!1%'8OH/S
MVZ+N_4HN_SRJKI*D%I!]<0J.6[^YGO21&#Y$6"8X$%>)]?/U"D%S1@P8;6Y.
MRSV!WMNK%Z?H85LJ<Z2I[%X#" 22T_O%:&&7$3#[J$7-:^M%T^>]#>Y#A4*5
M6MU^KS53\E,1!_(JQLPD+%@^Z\L3:4AH:5%AW*ZZ5<TX)_N8XP<4A=Y.EKY$
MN7.,4*9LS&BNQE]]7+&1H4"7+[C=Y;[U<?D%@PB$[VKCP0<(<XU\GXD!88V)
MHY)UBJVW7B7Q09O6=H&1RY#99SXHCU0?T^<XM4AGW)[,,]V(C1+A7F$%XT>E
M9%%[V7:CUA'-7XKKJDIOY,F\>?^^Q\-\S_EYM?3#8?87CJ>^/K]#E3JD"%7G
M-9D)\?1SP;S?;6+<=J(0@HEE+L$WW'&E+[9<3VJV_2PG&PBK,LB263G;E-Q$
ME/J7./V'H_"]4U1>QWLXW32_RJM'IW,>>F8^6;G,AM\N8>M_MHDC;4OO8WY*
M-(AE(J5<%+G:,W@_I\J'B0Y*CCN4B_Q5HO/[R%[@6-(QEDV"7H<=$TTA6L%9
M+2DK;O'+XI62 QUW*^GN(@/SXS[MW\[%CRFI:I()KM!+R=0M(1&147AN$#J<
M\?:G,U7N^[:,>/R=434YJR0@4;\%Y?*7J+V,F1P(9>:=R@2UT7_%,JA"?M2"
M80)<N,H)K*U(/]?R]</SN23/<_:NGU=7KK+]2E$WZ]A9MX&%AC[P[O+"17^N
M_>&8&_1O8N.U\,L =?+86L#'O]GTYB!51^M?6:ZUO#P7;0X<;6VJVV^\MC#)
M!^U:CARNM$ON,?."Q-*'\\?$"0R,X.F"-NE :RJ[S)=K<%TU[_#9QG,D3Y6
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M-ZY?I[E.34U#3T-#2W=EU#=N,M#3W?RW_>]#_KW]W[NN#KKKU-?I_H_M\B>
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M31V;JLV>)QG.$FI%0B*H3D8X'D'GB%(87NX))F&F);TBVZJ=1"^IS&#*80K
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MG3#'G4'UH VEQ&XI_F0OQ)S9+ZM?V>1>PI:20P.S=$/=D0;"Y.M<'<)$8XQ
MR@F"?OL2P!(H];Q+XR9^M@RDLK+ZM"GFT&)Z7[J!H%KOKKZ,^GHK:^.%L-X&
M(IN[/AG:,9F]/PM-Q=_954O'(TEL?!NM2[3HA:^&'0*I3U/N[5;07N1R!T\0
M]R7[$#Q9&G(YY^-= O4C[]3(EMO%D#EB442ETBT5^JV)AEU:3XT[^WLU41P<
MU[^\=)D?FNO[G26FK.!#Y,:D803QCB2F?%H24T,S!_!;>(QFW8WH/M3[#@?%
M0PZ <1O7L0;X8..MBLV=HG>4K&8/_Z<./KP$4$K@ERK!TGB>,GQPUUF!Z ]L
M;'>R@\#-[>P(WG&3TLIMGQ_N4&CU?F1MVG)]0K#CQ[<;:IB0<\'Z0 9J=Q5H
M?,."Q^Z3VN8I>=!&3!?.BJU&<LRSP*]WS87\KWL;A=>,W-A;#:.+1 APB25B
M%,*CP=U7:>?!;5<'5IY:Q>I&^S+,HI8<QQO#50:"T]G)5GQ;+5Z\8>+K6O.C
M#Q2X2=+ (XSPCPAFH$AE:36S*K Z5A?>P3?^S?ZOK;WXU JMP@NRA,_6S0*R
MQPSJ$A,:@J0>R/4(Z=VK(G_G*GP](T@A)2WI*P0=6(ZU2)J@ 6^]M)%*)TWM
MSF.#O'W.0M.+U XV=TU6(6PC]"I3SX&Z[EH$3+T:>VFTGO:*,?98^V!>D$PN
M;Q\0\(4A!ZZPJ@Y<5I_^J<EUQ:PXU%RP+XCVGS,<QC9SI+27K!M5=":)K3&Y
M[G0OJXGQM^,H8#PT)D(N[MR*-1FXR(E 2"J$(X*Q<QG"#7; 2)>N5L9+'TK:
MR)7T?=M".4<:S6[4ML*.'X_#FZ8JX62)C1_(?U"=C<0*U"TA':,6Y2?@>FA3
M,KP>,@=7P^6M0*]J&(-:"0Q:W+%G9:Q:EB-[.W3?+Z2FR9'6O1Y?1.]Y0E"<
MDO)TKHW!=WU;N2,,6M3/Q#8+R9O5/O5YXF&J]5" '32^PM![HT;3S9M&IEM*
MT9&Y;V6$UMV!KW#?@L3;-+H/[2DV<@=*5BH?YXAEFB^XI!N4\+ <Z*K/X6CQ
M4?ZKWE&AI3$EY\2<PRBB7@4HV#+<TLKX9<[.HG?N -SJ)<NCQHF[LKJ#D4E?
MTZ)#.1(UJ$%*?3F.<56-4!H\Q*(!ZQ,?V%RS)Y@9Z'A7NV<SAGKH#IMV5K]]
M,>?/:H'8I9LG N])-VLQ9S'RGDK(<_Z<&%5;>HU9S_UEBBQ5LX?DDD8L$^D&
M_<)_J'[_K\+[?]?9NL'>^,TR(NNH9PXPI-'8Z<7K1.-QJ1E)6,H7]E=]<2L/
MM4)XHBEN6F?:=I.X08FK8ON4-?@<--C\"]XE0.)345/##]A][5[]]U^Y2HS[
M/.JNK3%VYPF^2ZBQ!.8=<AA8O) Y#"(U:107P4=P'GC$=[#^6&"R7+<BUA:?
MW77V>N 2,,!I$(&Q!O!>,WSP8'E__AXGV7:FV$,S'5; _Y;;B?4>IN9X=P(E
MK$J:FB=/?S^'X"*RWPS4S5/V;O/EKJ>P#1RD-?.\)?OTO9 /[[YZF.+((Y\/
MM*OMP!2DMYI\%4EW]TE548V,2WF8KO\(PC^4WN(BMD9A[M=FMWD^*0/<DSFT
MP6GD%S4[SJZN<N$GEQGV:1/-:R<ERX!2VO.N;_SO4.Q3?[C^CT\(16:_D%AK
MA<JUA#M?_L]<0JY70V:<2(FNK+9]4;B'LP"VS%%^CK\E_CW%^G/<T^)T??(,
MPV<&]GMW#42"W$<=5>V)EMC#WI&X'(?8XAWV#HJKDM.<HV<;")]0U&5-'NH;
MM!"),=?J-1WVC9HB"F,1"6IBV" "^A*0I$ ;[O?Z!W=-6J4P+47VT]@9[*_$
MGRYJ:T'4PFL6G';FDH^5M]HJ9Q+,B\T<Q&K,=-C^N+%:N,8%;HY" SYE*7SP
ML$2XO#)19! WN*]^]#9"H>Q_.];X60C!$;.C$7T:C']DBAOK)V1.@;AT(]N8
MCP)[N\YR2P8"655/BFXQW_*IEA^]]E"TY1(0YX@QBPNPO; 804903\.U1*J/
MK-QA,0?#/'RO=5K&5PO[(0^::?F_LB8,)]28OU6[%A%5V)EC/I(H-%TRON\\
M=;LNPR1E/^-^:4-*"I9\UKI86\\OL2 27KPRTGD)B(( 2-<\IE%+[P/"!*CQ
M$5/6HC%30QDTAO]8S'!D2OZ92_[YMN,9\PMIW3\^HPH52 ?.Q &S'*,CV-+N
MNK/_V26@:0=?B-3@&".*^7X97$6P :/TV,]SU'S<K]OL=XRK&=QVI5)59F-R
M=KROI]5"]@")+=Q_A'5"<L/BJFY? J*?A_@O"]#9X5-M0:C]ZE,!T9UU"ME?
MPI> 1Q^0WEG6%(NV'?=W[K_$%Q,,B$(M%_F!GJ+3/UNA\6J:I?@@;]:F3ZUJ
M6*OM@WCU-0GU 0FIJC$U9A5#N4@S)!B;O4FD0UQ3.*1Q.^.7Q#!$[J.ZN#+T
M8O53",]@'='>4N_3E J!7N-/IK-'99-7P_<5B;4RR:R61WEUU8I[WZ7:9B-,
MH;9_K0[ @007$-+4D=6@%&_2BQH>,<!L5);,S^<FSF;-/6]IC@EK:W-CU:_P
M^I&QUFL]!V3^==-R'/(Z-06!:;L$N.[+].:\O^?N>:\MY3!>,-IF:@,8(F)V
MQU)_IFN8_2&7^5LOK>I#'B(G!M8-4KAS6LT^3""\0BT.[\^P7C'P]9 O/!,Q
MSWGK5+\^HZEGOJZPJ=E0_2UWF2$*Q8 LO#D[MZWH<#LSH'Q?RG+0*%Q%Y%@Z
MZ-ULL1F3NK\/@\T UJ.?CTWD662@JT2/6%G^R25 :"0 F)B:U"$U ?8$I\O@
M?C)MI^G?>W.R+OSST]Z8ZS $5T(#TNGMZZRV.4:?[?.\?.FT/NBT>J<DZNF[
M.CIC3[IT/;_8"=<!%[5[H&'=(27CDNW1[5#%H._$]AA9!V,H:-&3HSM">%+2
MPCI0LPX:'6"UTAG<UBH[&+"]%."3:$Y-."Y7]Q"2:!JA9C#T9KKAN.BU3X+$
MQ%:3^N4@76:K2_$=HK$;XZ?VSK:HYFW!G@T^Y$[=;2)P7F+=-%ZS(3EUSQ@S
M;H /0^<::3*!'RL6K6PL^1+X/QVM)YU)(A3'#)BZ[QU\5S;GZ4L%]9%H&+ U
MJYUC5ON8B-1 X3 >\_KQ=26AR71E$=!H:B4U.:'!KV!*[ 'R3\;[&M0>].A4
M\]$=*,N52@T&C73S:URDJ4E5@-))NQ83?#5HH]VR8VF96RD[5NAT79*H['=B
M7U:OJ6A[789%D.J/TTP;L^\=8Z:'-'>*TG[\#[(T62_I#X0KX!(P>[A\%;^N
M%0V:+G_>Y 0:N!REAY@PWTDLX !7Q6?\E'+0Q!R2:,S0A>P@HRX.#AO11M]R
M8-/H)<!#(TYP0GZ!?7E'S"@ F+^]H8=;=M+5>?7+0OM[B] B\>6RNE@?#L>X
MRVZVI%.ZU%DQ)U1/F;)!O<3ZB8+JSO(]^@^<Y$EO]63%]MJ7N=3,JX%Z2 L(
MRD&P&=8Z\9KA%L?]3OGGW>O!GA1&%"9![UHRQ)25QZ39S](&;13F#XU+JF&%
MD#]'2U203CVP:@61=9+H>$7 ,+]/8][QMU''>GL5I9K!I5Y-QUPW\*Q7?GC]
M[I][DAP?)$'9J].],E3&Z NQYY@1).CTD,-CJDGES0>@Y7W4G&36=,9 ADRZ
MB)3 +-OCA&L&FP'&[WFAT4O<$%?(=1 -&BSG'1A2M)NNF/7G6WS%CNO32$[]
MUX]!:Z[U">SBSD]?/19_GYH)'-&XT8>Q7%%LKW27PS\;T1EOJ Z1!X:=8-?W
M#V# 0/<PWV]6W19*!)W,-OF,N ^&@HYJ]%_Z;?WZ+*^*+_0S<O^[AA7A\5+&
M)>#M>:C5Z1)]Q&S'K<D:-0F@TCOP7.*^MQUF R:5\JU>!PCYIA4BENE6E2CR
MLW#O?85+TBT?SD.>*TI8Y[C?R= W0HOO.'-H' MP5^,! LN7^E_Z*_0T-G P
MJBT^;ZC570&IM3";T[X=G$E/7" *XP,QAW;XE\N$5)KM(+\KT75_AYOVN^%W
M.NQOU@S2\69:J5%\?X@2Q[%1NI$7]#[^-Z8-J7E#GD_FIP9;;=8DV 4,.T>.
MA*B?'%M;5_VC.S9T*);=MO?GNQ>J-IL&\*OJHB_0>Y?$.59M>.).<#>01_"4
M9#:0O'>_CN!#QY_B,ZL]-.Y-"::K&W53VM_*J,EW:R&HEY_,5%ECIZR%-3YM
M(UXOL=B#&%9%*] _:W\7X2.G//UTI1H;9I<9'PD)6*U;)#:+;_5]V/2:5S3X
MYC;KW0X3+CA=167'U[ [LAE\T\,EN_;<[UG>O\WZH5=!T&B:OV<CA@[G+%:4
M][HTK+ZO<RRG1ZOL4+6)9'.Q61?13=8(H<77=_,\"2+=PE+V#-'HO5C>/'ZE
M4>FPX"A-=+^HE+\$S*QVAEHBH=0H%+ZX3]$B?K-[SV+$6.;X\T'"<:NNY"#-
MA[V;!CI(RQ3BTZN)_(%H-05GDRYT+<:[=@4'R_[UVVFJ&PQ4>WCJYI2FK;L8
M3?RI3D\CB9-5[N5^GR<\!ZQ##! <-R(BS1R !#[0H0T^GR"%9^GF%W22;OR^
MA3$-E'T8LY;677*3+) , Q!0XK4L?>8QW/?5L*B"4J'>DM"5<*?$C=5,!_ _
M<[9NTI\EMI%.:#1W3#W#;.ZSURF#QBEHX?2[TAN!"5*[G/?O2]P+OD[[1D^H
M-&C2TFQ4\C0L4;FFVO- >'R#H%.I_RX9WL:E5!.QZQELE^+3'5Q17K(R$? Z
MT.FN5KFJQD4JPZBF9^,44;G$'@5Z??ZW1M*3YUF^:,JBE,K1"C#W!4SVUV.X
M':I5\06KA87R&DVV9E-RMR.90K4?4#5<LY?]_$5P4X[MSS/&S[8FC6TN2SPO
M)\*+DQJ<+Q;G4AMT,$CD!P>'>='HDJKSS*'@;!.IYX'=H[4!:<,:KRU$WJE%
M&NP ?U5%W ?+_AA3,UWVE.D\R\["*15K-_^IEF_.)3QSE/K36\LA((Y\,S_$
MR%G\K"W;78V-S4UDQ P(09R3/F^86R6XWYTT:)A: +>29!S.6>$,!!W0W(I
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M-! ^$YY.! M<U%2/]]K HN'^-:"(I:?CJY% HZW.1J.&C"%*9PO)\AVGX4>
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MU+T:=/B@_/4KFL$5:$HA!YAV)9E#)]5T0D'4V$;@OIN:-';.T49_2E2_WYA
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MJ6,=<?M/R91W0/PS':UOBQ<52(8.M0JGGV>#47B+CU]S1&<&H%$-:1\8WB0
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M4?N';,_$1CN(^[].HB2N@>CT/$C;O2*K"_HV='?B#QU?D.=P#P,.>C*8^V[
M6::EY'S6U*BL&3<+CW;UF^"0OD8^N[KV-Q1GIN\$Z^][Q1IOX!RQ&TG2-.T.
M<-J=EFK!UL,'[VYQ^R29)!-FDM M082;]J%IH#&(N-A=D7OW$P:;Z)%L':HC
M7V9UVTY_L4P0[:>7P]JJ8VZCI_)IS1ODH]Z&3%^^(PZLZSG+)=#,24%]BK>I
M9PI*5R*'Y\0_1SP.?'@W^+MUUC<_P#X ^9[KH=1BZ,:-V1S^T#?G!0.(?*>@
M%YMP^W^[*]:D]KB7.PYB>+A'NEJ$#R8AX5P>O%T3TR1((*% F>IBYW&@*F.6
M@$/7$7+K9WO:\59G,$BU2PS'"-.@DX3ZXB_RT[;DL124B*FJ45VSC,(H*L+Z
M8V6)B/*1>FC2Y'ZCZ 7?W&'6Q+']/6MUKHZJ\R#*"YSZ%>#6\E3\2-<5@)Y-
M=SUQ+:G]1([Z(.;UQH+  W?V#(!7TGFLZF5QB<LRJ9*]R(+;T2M&"=.XIMJ0
MA$!M3?^2NZS?>Y_ TZ^/;X-GG-C',R%&&#QBN@UT95A[;C='I+26Q,P\Z85L
M,G]4MK!M)N\BZUXU(?LY%6?C(V@!?W"XD6V2>#']8,->H*_<GO[<)]L_='<N
MQ6SL\"#ODD(>!43FYF*C7L5^G"H57J:8[1)V'%R>0^P:,$^=T53I4 ;'ZPJP
M&;@M,N6-I\<HL(9.7P$"VU%B<YFU\7L&50TQSO;"="^9UX5TGWE05K=7F?:]
MFA9=\UZ%>I$[QD@U=ND#V^9]#$Q0A&S$ %)->^RD)Q)\::D10Y#F%*^=D_O:
M^=#S.<?Q*I'0BRW!YCN\6-&>5;5O)RKH-<&0.<M@D1;*M]-G.D&:R11@KEF+
M5[E)"JS\.0+W;.??_B8BZIGM>6CD7:9^:@MME7E2IO)KHEE7O22V.IM^X./8
MI&BN2ZT[.#<N<<>8_;)<BC_/:,0>C)D/"Y-8#T4*E&Z6XU[R5T_LB1VR+:!!
MLQRO^O.C4TP9JJ\ 9"8KA0=EI:M-DP<"MELXJ0]RV49-<]]#<@,"*H*/'6@5
MS;6?KPO&*XFWR8 _H[Q7T@**K>=\RDI%,PN4V!V,92__B+V)22SM&0J@J$4>
M\=B.<)JI=OWF+B*(A*U&A4($\Y8\%'KF!!**#(R3C<0TQ,8'-J1BI2>^W7\?
MV0B?4$M.33/,]-1^0"@/UN_K&;L"H)916U(5D"RG<!Y-F*WT%LONF16/U5R?
M=\/NZ(X)->1Y'F'T"D!2M6CZ.DFB+*>6,3[ 8WO4LVB7(G[5SSQ2J_6Q'Z];
M#9'^^<B]XAFAWEC9NE\N(/::([Y/41BC1[[WJT]!'= [^=="*XB1(G"M/@DM
MS'37YG9G-K7:1H8&LF_]IYKF=.&>,3_N+58.(HAF$.&FLTT/B4MMW4Z(_M9"
M("@$7G1O-7M5G=?KB%ZJ!71Y<^@K?[>C@Y0>3)[ Y^;[@*\)@]<ZU@P+0\U)
M".9H3PLGX,AS #V)3_RT/TC>HRR^N*'K!I.%_82:'SY*OP&Q+@]5F#=%F!$&
MZV[ALS[7(Y?W4M'7$E#=Q$0K9?6_3KB3XMY"M.U_F-P_@)4VU4S"Z/6L"M9X
MI\G)Z:,.L@*=]W^XPR*4C'C;$N>\ S7T9O#'AKU#,="YZ,466NM3X-QR#W$W
MB(%)+>),ST.;R"Z#A6RBS5C["N#7LR%88YQU&0=G$8R""W!L=/I:)*]^5)DF
M/NAS.:>\EH(.Q+$SP4, ;_?]$90FX2'7=[+NS$>V"&FSIQ?A?@='#C(JKJ"%
M<&K0W!<D7FOG]D[.YL\:7L_0C0<IXRJ(I*$DL/3[#7++ZW^\DC/7WM(M&" J
MP905IM%@_TE_DO@45L:H?*Y&(+%"@76GJU)O(FB_VYV->?#R!9\:F(&:1(5L
MW!*)T9ZJ+'H*''K!PPM 8+#5L)Z/G*K1-D$I[[K:^"0 )K+O'T75Q(1:.ZHB
MA[B5G^/F5283"2\F5D'DZ^=!S]9@U5:^G4"J0RDZ'.4>8WQRS@+X;(Z\OJ"'
M.0!^*/1EFO<*T%ZVH66^U$:54I1:-.3GJS()!9/:NG>@9N94,0/%I7\Z;G&Y
MQ#12/GQSVL=.[@-&PF:],5^C5A/V\Y;HT!4*F.8OFT;.NA$"@[+O$Q/97U5F
MWX"1=%$=4P4RWR,&,)[[,A>^Q/9]S*WXKK.=7-TBV'I)&B9TX6FAQ2@1>%QZ
M)WNR6VRSHL&MLF9/.V[RP-K# -,]?NCB+2'"YVT0MM<A_$P?ZZOG>D_00BDS
MPC2"17SVT?GLU\V[.W]B2/"3SLJ7%7@@S-"@M$J&^]G"Z\VPP%$+W1BU2NF_
MM?8(FM]?HFM,BU9^*A+WN39#5RE"A9G5A5LHK5\*Y%IZDW8AC)2EWUSL'LA'
M+NT<W%M*(*+F+FVKXV?LH5<MH_HSE\8T!K^SDT91@_7T+!6H?J+$'# 82]J)
M,V_O$4@R$RJ8R19D9_J^3RU4^&6=YE2]2[OYUYJ]2<>%0B]"R+!:T]G#>E<'
M^Y$E9&^HR"HG:3Q1\M N5:L6V;::JGT@8;M:%Z6BNXXSZFJ5<:TJ5QQ@-V!;
M*GE#MAK7G[+&.EF</B_;+GKADD"MYU'/,B-<ZY;_]N?"C$&1+-><1?BC$@X[
MUL?U((ES^>GYCCD#R+VQD\2:P1%3N%M+/;P>KC2:)&R[P7%#[U;QDX=F&CG/
M^+HTL0$K+8%7 "!>*=<J"1C&,69?'=P+#YP;/D:*U6RS?>^-/I/G'\&KA'KJ
M$'T7?@JI&$B2AC^94^8_T;GF @)L(GV_*7/R?1E+\TO]I?>"*N#27PTFU25I
M0Y5_KP!65X" (801D$!-)L,\MQ3$="\[W!R&).)8.W/9&%]V^K=#*U*6*44]
MN\MHU-_A;?7$6'<A4HO=6+UYXKN_9/&S0Q,3PV6ZU!Q<R:!!9#?<$)NX<HJ%
MHND^C']6$U1K ,Z)DKQDUWB^3(]1$B/:+HE#LAT[[U/\:*&R)?#AI<==YUV/
M?&=9./U2JJOZE?L8SG3N2Z/33D>GKRM2N5@D><2:K4G'"QG^T^"6*B21U%,T
M,M(<>/@XI&6%'+P3"MB"_(>O5U:9>P_HB [5<AG0@IE#U)9]PJE611_$@)XK
M'\A6)[ Q$)=G4"3C'UX!;M\<LR>\@+P:K[95Z$"NIMX94(>/!?Q V"IRQK3S
M*XR$2TA8,;FP\AXH+AQ/E4'D+BNE5%=)F\GY8$'&K*@%?7]K)Q.E0I&<,7U9
MVWSI=>>WY0NV"0>KXPZ\Z@GAQ?2'+O^\*X?@<:A96)5WA.3J08*CMTBG?HZQ
M?/HM]6328'M+:CNR)T9UKK&'YC.I ^I+> [L4PA#SK)U"S7'Q--3JTVPM*D&
M.G3P(L7>#D-A4]&(]/CA_("W*>AQR)(*D"Z9JG^LH/&@L;@4KF)+,=X<^:ZH
M.^=/'+5UGWC?\F+,C[B<N#EE)U7E(QU]XTO7=&1$5IA(0%6ST[%VH,'O_*I
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MSWW='=U1MW+;G'@^\.!KQT:4&T>(S/KT4(,[GF;+N&$J?EP?;9',%11W!?#
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MDV#09A0C,PR( :46-LO-X3%&M34#>^&*MA6#8QK!!K^;>__,HQ3C ?/-3?&
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M[-9],FRL\KKZ>GM$,WAN=@(,8RVR85G,:X3$1-#DF/(@GM)ST3EI@K]9HX'
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M4&15+[T?_\]:L=FGR0];6&]F [<?@HO4"TO,KLS8RG(_5GTQO2X$:CK1@1+
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MZ.&\^?VN#-+("+OP4ZJ)(03B5KG<C^K/.,I?N7+87MB M4HBL3BQR_W(_E*
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M7LFG<S!L#\QW[CEHCMJ#?^T2/.+P6&+\-3_B WPHAD'0,840T6Y 'VR';#6
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M_32&1<E2C/ 1_U=WWQG5U-:U&P4% 2G2.P+2JP("0B)(1[H4:4$#A]Y[#45
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MS8A>+GAC1.4"0J#*$!60L)KD,Y,#=62@KCW48/!J:UARUJ2_2$SF5OL>IJ3
MYC)5/A0#ON]?DY^-=%4($R^%5MG)(L8/!.ZI>P1.-\3PJJ]J# MP#CO;WQA(
MW_ZJ1G17ENO+Y.C*0R:648$/,49ILM9,@G6J1XNT!2]'RTN'+9JV*@KMD20H
MTQ;#=,6I%GN296EM$I*U\Q#KCR6:'1[IYNWVV%@1Z':ZP1-=EL'X:4(Q[\=D
M7ZWG'<*(/R*]9!D"PZ-B .42=-4;O0S=WCS=I#Q1S EX!93W/C04_L"C\CQL
M8XC["2Z41E>=@9U]K:#<HTA?E=KP!?,33V?9??G&MS_K\2@]5:HKQJ4T'52-
M-" 6A$H8P&<RWH<6P,8Y?4#2*=FT:)NQ$H>9S!N)*=?Q9!M3-8H[3QBV*GK0
M%;H?Z3?5.IH_.!=3GF@H?=Y;+BVK+_B>.%"=UY&9/&O]+6OM\?G+3]7VM/9H
M-MF(E]WF0T5!R_/XP$O>6!/#8S/2TJ6LZ]M:+9E'A652\L4F\LO&-@^Z:5A"
M!0=BWG)5CQ3JAN@M/VIB?A(D*$KF;48&K1H2]VOOU%E&@!UL%74KA^_5@ 7&
M9I:P](3/9D^.NIMAV0AU4OX@HUVRM#MJRN8!XL7=G)[+(4FZ,&G#$T:TR53Q
M"F-_V#R\?"P^<L>P7,T_?M#]J,K$@][ 3FIM;(D[T!#_JV!FP'':8@H7_9.P
M\S'\A5=/=2OQ$ECW3YVG?,?90*^/;=^-"HAR+^FRE(&SF-(3*'<J_ MY^"^W
M:@EIVDK@J;[#6O[/[Y3>3 _5&<$ 4K69WCHP]EFQ4XJ+>HXL+0]#UF:#,8 #
MC6P,H*S?-,@4N@=&*Z/ QZ.; [S!4')@,0F**Y1"2]/AJF@0R1F7)_-QM^VZ
MRN]:"H_@YTO5U<RO#UT%Y](T @-HK0)8]_S+<@(^O5^>;K U<VJ'WC411'$[
M$C$5/[P\U@\@@W9+?#QO08?9UE+D<[O2:W\==E++Z<-R1E4O\$4E=/89M"UQ
MK^7T#RR?*Q[D*EB-S1\MP "X5Z%[>8W"EQ,MNT6@>54D&.3A>+'11+Y?Y)/9
MC.Y/NA#L>6@$]5SQGQKL9SFO9EX6A^Q!VC;NRWWQO+=./3<;:FPA-<Y4-(?=
MN6#0*L50S;05S6\.<HP>& "5L#$&<)+TPPZZD$&M=^+R]$DOW].? :;7@R7)
MGZ5FZ'!KYU#OP;$T4W@>NC,%G76#MB7MM>3.GHX*;39SOH>X7?9Y )HU9KKM
MTM/;LJ"4FQ6S_+F59/>#JG&9-P/,I,47,IJFC*M ;RHQ  +P5^;I#/1Y#IJB
M)0S4@$5$W=ZQ734_I3CB*?[I3;%V6F&6+O$NZ0WR<N0'JX0!FN"B=+-NO_0F
MKM.&R$3X 0GHIA\?L;"8<ZK#59DAP7FH,A:0<F#U GN<,N6M^M#G<F&";_>[
M:'*!W/N\'?DT6;PK-V?,7Z/W@YBFB*U.&\+Y29;XF$-,J8BND9L?G74(^3'O
MO??/RIW.:%@A&CZZ5-0=D;)X*1@5TI-HMO<:(0<0,G4.F:SBKU+*04:+!'/+
MV=K%%?+]]$RTN_!@T/+VI,N3OPP.1W%#B7S4, !_;>80(#6CWWQZ!LBPI6C3
M,*WE]4KM:T0QW0J-'FN;X]OX0TB,_V8&>G2?N(CE(6R)O>16*$'L ?SM^:"W
M)T7AH*$+'=M<5R@"04ZV-4(2 J1B#^1 ;#Q\Y@.L+3.RU1/3+A;-X=;.9JOS
MC8?5EX%MJ=!<B?RBSZGT8 \$VAXC:+,/=D0)^/UPF??R4+^=!8S4GJ%!;V%7
MRSV H:&A84AW%P,8Q[-XJ>_@/$M91D);N!J;ZW1DWDS>?^579J2RO:WH8W-D
MSCPH_"B#" PVNN7W@W7JO<,9Y>;S,L\NZ &[3<9QUSG,QJ5>5.@HAVI$(Z.1
M#LU[&X1B?0%GZ3%1@D8R3]L,(&]E/-!9GVS*Y*(435AQ7T8F:!#'PZ28H1WP
MG6IZ-)^/J&_?#7K%_$V#"Q$?9F/TAA0]]B.%G*NFW'M2&F0H!M<8@_\1LIDQ
M#7:>^WDE\:?8X/KY8)5/0)6OR)7<!?SF[#YDL."J*9[QP I%YPP?YTQDGJ^>
MZD]YB6$ D4S1"K]:T\,K,7NFC%*F7KQQT.?FQ=9:E,&1S<.KYC3M2LSJZ-+J
MQ I8?SEZRG2[9:$K1^NJT6_<Q@I=6:M8*7/<OU->MX<- 532=-&_VJ;5*[$K
MFZ632<J@[OY=(8[(BK61JV9T]Q%63.'*YJT!?]>+XIW_SR>*5F-(^R]S@;IC
M[86)K<0H,!N/SRF&4"/+JW9NQYP=E8LU'6( 57D75AB \B%)2NRLZ/'%9>?<
M'N]2"VD&LLB=1,=EYG(SGX3>>/^!"GI,N$IO=9")<2\QXF&XG7F2>M#TG/9W
M_<(.&V@;[3P&<'[C)P8P2_DP% -8,AC&LD?LOLXSRCF3]4U?-%3<A6,P @/
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MK;'&.VE3M/Z B'E/LVDM^S^RMV8.X-S# )[-/L$RI/!_,"0$U&U6Y8RSG?E
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M^F^ :[R^,D.U^U$$S;D7?,R'G:"+.:VKR41=3>:G0.LQ+53B8!9K]Z2:*@;
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M;AHOX5YG/&>^%+:PF^_K'+5Q0* P/_G\AL)'QK2%C.[  9K>3*D9*+!"K2N
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M!ED>: =12EIR-&+D,9)J-,.Y_&Z4A!,C)YO%)\P8/8M4+0=H;TQR:UU[A[N
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M>?_Z9RK$A22/-TPLX+Y,NS_H6'%FW6I,+27),>"Z^Q9.%Y7'?OQLY+XLWZ,
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M^V&5QG<[D86$,"CG+AN=G\$BSG"2;HFSZ%W[-VA^?1W;V$:S[N8OU@DK20#
M*,[=T+A@QSVBX:W/D+RXFHF(V0N./4R_:<X:SM[GNPO[H'F6 GJEUB\2TON*
M]SQ$Q[3?VAU/M\U@]#F)<2 AYH4NGF\K)'0^$S^IW@:5K#]?K$K?X.]2'19[
M,\J[.4MP^;4A$)8LL/CY+=E(L$Y 7Y@E9U<5IHS]A<.6P7.D3S/<()!SRFXK
M6@8NL<'>XY3B$Q\*(Q[FDF@5.@_(+LP>E;<R6S1/[4]Z3YK^)7EV4EK8;EV=
M;FQK[_:CGV3TX7*CW MV#YY/V@BK7P'>EUE[X"'N).*7\.IOLR5&!(<$VO+Q
MC3+*W/S)/C%762>:/I"GT*!=&8[?.XDHYP7Z)RL1;#XTN0(X@!K*RRJ+*S4+
M8)J#N/;"XP_CY<1397>4K+<(VH?>^J+=[=GHTC8B/+&2DJ70Q@Y<S C"O&46
MQ/KAKFAIU";:X_$1A_ED#4<&L0#2T%=^US#"\\7MUVS)]]@5PJ*MF0KM4P@\
M[C8PCZ!&3+SMTF[MBEVZ4!P["]L,E=<'IB7S^*N3]'G::AK'KWG(+!0PMPX9
M;1"%V0Y_7?8$92;IKS[- J\&DF\?YXV;GZB-(U,6U3/2*8\?!G^2V69GFFY*
MIM%L84K@^#1+"LI+X@,'1!R4F6)=HJ0*',>';0+?N:N1B)#G][@4B^#@$/]8
MGLBQH,:#E;Z*4XMS-WZ&R2JO&:0Z4QWFWE3# "_,O*.NJ;I<3$%V^*PS<LX"
M(=&<E>66(/V17:Z:SIN(7FG?6V&,OC_UIL]) %^7T,Q&EHSX(]ZE<Y]UA70E
M/PQX[+=GL4U_,AK5\NN7^F@E8T))%HY1VJ&>"S0>=35&Y$#N.*(8-URAWP=.
MR<H5D<0'16Y%F$CB*P"]>LX5X";*:4=597*SXPI O?PQB*7@WB^:_M^_C <H
M3+#MTP]O'7WE-CQ4-;#R0;D5K4G!OUX!DO-.1TJ9XT6[++(;QO O#@WZH64M
MB:[!*06/#/NHELM4#2P#4&[<Z,F&[1YM'>/!3P[HM-FXRUH&=HC#ZH:.LR%K
M:2A'K> OSHQI:>>O@0=#$&&QD3OK=-=%L9YNRTE(''_^-<4SDV*I5_?2HO2>
MZ4QL4/#6&\B VL6/OW[!T?(;@Y$_&/PZJG%=!BLVZ).>N)ML8Q*U90#IP?48
M5^#?$[W!?QY$=1U.G6E<Q&I!-HM1:H<ZNB\K+XU03@>9L5(77$*:X<3](BD9
MYKP#+[%9LOMW4K?[)O;2,\N&'ET!M.L]+7&'H*=6C4G*"AT85DL_,EV'UBZM
M4(ZN0Y !U8L?I3BIK0B8Y?/-UY$NWX'U!OW9 ^]@*&WN-87>9-.9L@E!4<L"
M1^'DAJ//)^PI1\&G([@;DW:/'R;>B+?B#!#14*9^H%!$83/JCRC[N2-='+RZ
M9$=772^.,]WS]?&CQR %PB?B])3/-U6WC8EWH@M,%)$R/?>^\ T')YH\&A!E
MCT -U/CO;#V@B 29ZG7?G'>G&*)5&8K?? >@>:O2UE%O',!')SN571X6G,#.
M(LKV!JP57LU4U/J.]08CH9+TU[]DX(8E3UA9.6$]"\#R>;;V@C%I[H@05FYI
MO*7NZT%0Q.9K 8,MH]+@>$NP8G2RL>)6Z%3VN1:P32L!6D#^:4<M&TS_1L^X
M4:QLT1%?EZQKSM/R9>*P!3?8E O[]6@>"U](Y(.Y@N;E858>:8KA48?$D0W)
MOS<,RZ+?8&A5C,H_)ISZ')3*X>_+/EEC"]AY+:#9?^_&YHY6*#V9_&I.:QPM
MW^:'LW=%0+=\2^(0WFS[&3=UI@RBE9G<B#TJM[%IP7@<WL PDGL.VMR^31[6
M>4YL,@CI4Y)^>4<[QU<F17,=I(7*FXK5YS)5OA];OA98,$1U4YG/=? FYV"*
M/N2<=(UX/=P74IDAML]J7B-C9+A_V*=.\)AY.#/LY4A\%$B?J8Y#^TDM:9NT
ML!J+[LF"<QX.K\X+@L+;2_'!NK49U9R$ \+<IQLI252.!@=C0.'W1FM0AT,5
MD1^-:[E>CJ[%*=?"P_YX%>IP)/7KC>W:KS>V\PG4%T=H<=D$2USZN 82HM9K
MJ*W(/#*CEPOK%7E^J;="WF_U5EN 8.BIM D7(K#G1"Y!LZB1VYMHR?Z:%);H
MB-C4$_-%*Z*5+Z1' JTRJM0'8Q#AX5[$ZJOKT3_JB=;EX-,A,XJ>:DXBXK]4
M&ZV?P+7<7QJ"5D^!QSX^=&N;_Z@R6.K?YOY65"WH%X(A)<]<ZM.-7UIW#5[B
M,_A:Z\M?H/52XP"V]>8*<*V]OW7YTTRS<"=L#[:%#F4&)/Z,_JWAJG]I^+]9
MB#'L:\H$/_ZU!,L P0-BH+:;<.=3WP>)#A*?69F_;;"DA3?7&2]YP=R-78TX
M"I,!W]<LSS1*)P(N7*\ T$L1]^LCLQH1':%1H=C&O6'U>47R"F T,=.O +X^
M&K]W[4[&E+KZJ$.=!?-2@%N9P5> :7C3@I6*]V8-=.O20 @U7&7MV)1_;,TE
M)'( E3V\I)8K@S:I:\AA?HDW?Q:_..IVV)7MD5TE,V!F3SU]5K.0) EY;?O#
M C4_CD&$&DJAQR:O9Z\=<N3DUA@\HG>B<)@AY6]^\U' 03UUUS.WV]KV;=@S
MOQ*C_2< <SMMW2'^8Z=GI?V02B?#4'CT2D)*?1OK1'G(0?8 5'YLS*KA85!/
M<X4E^4L')P>7^W)WL'%\.JAEA_:<?6UL+@1P8_G;F$N<= )0*&GJ\>#6@+M)
M4\UX[NHB>)(+]Z:L@)5'1JZCMD\%!6UCUBNI<$9LBWB_6"\I=^&:;7"MV6/3
M'^7K]'CR-)^9:,AGX51S9]CBOWK3YG"$B$&H9*G4"@YL7>I"3^\H2%GS44_#
MOY,(^[6[);MKN"\6 %\W!*C5A36S>)3P,_8 'J9XJ'!P6AMH-D2NCL,-Z";<
M\@79%$0E+>JDNOAJS7$NZ_,B_$:9.Y1BTU'S8]^7E!*3D58_ZEZ C+-=)/%L
M^P=^1@;>%7F[.Y.RFV,-&ZD373CG5 8]\$1KOZ2@4@>UON4<DT?)ZFQBQ_%Q
MH4.HY,+9A]$LO?&G/!![4:R-[0L^XTPK9K7ZH";:?=A,COUSP,*)8.;T^KAS
M35^W[@MKCUJCKN/WN#?.0H9<X@55M_NIS]W5!RY\F=>^X@TG7#;FH;UI>#3R
M"N!6(8*?I;U!L,$.IMHC*JUQ&-P"+NIVK;YV^/ .DQ=AS&V17&)Z!4!*\WF=
MQ;0KUF,8C.U#$,9"]$-YHP\EAF$C90=@&UM.IDINCOSOCS>'J\\_'4)Q+?B=
MP]<1R'F9"/9WM8(+^/IE @\-S+:\WCN@1>^L\9853Z0+ABC;UZHOM@V#)<+]
M]^1.F.K9YEIDB_<R_'+7FW4\97D]B\9P  YG(V6:O'T:K?!\@ZG=5Q4LXG;M
M/!$3!QDN,22*IU-K6=IC"E+366L1 U:*6P5O[G&O#A1N'.)QM2C4[[U^;/#"
MBF9?,[:2)N3MF1FL9E<^_9'M5RQ_Q.;]@4E6YB!N CW6G?Y^G',[U27B@P>3
M:_6LXT<O#LC7O46(!C;U; O<8>L3E6X,;NR"WL^U8EPY/X!',K1'#K>P3IY#
M6U4D";4[5@;P3U(HO#*#6Y-E@[=*/Z'@8\(0"_G384ICY1T(ZX55W3Y')8%T
M<+%6E]KAK</L 3Z/[ ZXXFDP! [WO@+$34&$&U.M-/9!QPX)7:14:K<>:I9G
M+!;7MIY97 &R_-+'_49RN)R<P3_P2[])4+H0IIA;36B^D%C*#1+QUO?<HE]'
MU(^:>";E2%07V-$H?\)DCS%FT2&+X'1=U]:7SKH]^@93<V%:/<*>=9*P#!"M
M)$'[]]8ZWX1]EO(@)BM-5VZ?-4CU@Z4?B[C9BPK>$6M/=MUF/.9PUAGUIV*]
M<]&>7VJ#)O<QF</QB'%(Z2;/5/R*#PL4:53JBM<E.HR%;!0SM()PU;Y^3 00
MZG+P8<&=")5)_OF7CM+S!W)4&YG'4P5DXE\'?7O]R^G+'T]3RTY:>*_+[V,^
M"VH'3L&AI>6@TYM0&B6'R<[S9[\>8$"C?'HS.*C="!X%SPR;)O(TPB@0I*%D
MJ?II F(9<O':"X]Q"ED(.AT%:7]1N@(\O.-].&L@C?QDW!)7M70BV6#4#\H-
M45I:Y8DVT44S!?B#5N#R2 $%'[T"_/JH"B%["H+%.(D4V3PC5BC/\:[:>/C6
MK9QZ6CNU2>  8V8[SXMXJ+^RL TCU47EJ2SVB11PN*;/KN5,+2"$MVM\UC_&
M1:1"?>G66ZIY[10G<@GU1$?S^T[UBFBV*22(-EB1:X\N8S+4A_N3&-:&:.B!
M%Q/DZ17'LNJ"P;S>'$VB+SK6YO+G79ANU]TB("$_5V X6#$29)-2'!RNDU7=
M=#;'L','&_T<!Y=Q7?#0MDMHH>;&^1>L>,Z3QF8FD2"Y^/:N91\\1A@/Y?=W
M3W0- AP;MZ $+RV^EG $V$_W8UG.,73SQ11.$6R>-3RNB6Z]MY(#7*09J]T
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M(?YV(->/9RRK-7WNS36>14%E.39O#3-G*$/2P1%-J#)]6I)QAQF$?V.>SQ6
MEO73MH C&ADU"DH%C^3SO$$G_%N6%1-PO[X:[!(V_G!P>=7"F'/)(&R4MX_.
MAG>[SN].M&!WU'P& T*#\56EH ':7>Q=ICXYP9-#TR>R:M2<_G+C&R]S5%N
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M/U\=9>8 ^5<N A=5T&+B@;V.(H(K27%(_8]/\32J/. )_A?(UR>>4IH;#Q:
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ML/FX!PYE?16N1D^$]R$.VHD6/4!Z+O;42[5U<X:;87-UG,,R/.DY\*^W)YB
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M)X-;;Z!QZFBCO^7;OO]+!<3K_2=02P,$%     @ XH!;4,/28='.9P  +Y(
M !0   !A;&QO+3(P,3DQ,C,Q7V<U+FIP9^R[!5C53=<W^B<$! 110+J1;ND6
M:9'N$C;=W4A)2'=)=VVZ01&ENSNDNV$C?;9QQWG>^XGW>\_UG7.=[QZ=:^8_
MLV:M]5LSLV;-;+V;NOL*/)02DQ0#8&!@@-?0/\#=TL-E41=3(P"0D0%H 0!
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M\K>0OX7\+>1O(7\+^5O(_[>$_!'G&EI!@UMG:!1[-PN( (CW[B'<@T=$N(>
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M!\8WQ5+!(-5*^P"3@:2KTU#S,95Q69),?(:O:H#?#.?:UIBVBJ&ZC>3I<U[
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MXTH''4Q5'C5UOI6LZ--ZVEW$F7#[PMJ?NY4 KRQ[.V!O9N:UQQK\JD,[2'_
M:N!PQJPNS.+]8+(=1W*(5C.G%=$Z63 B0+-<NL4JCE#ANE&NNY#RB%80LU'G
MY;VJDO=BLM:?:S<E&1.*9*V-"C'I2,@/+,TZX@TYA[L^O?.8X*(USQNVVAM]
M";.&W-/B$!XW,.A7+"[86]5O)0.8+6['].=6,UG7L)S7)F^=SGD9:H)N78,[
MQYD8WC\W4 <Q?O%9J-G%-XJQL(5ZL?:7$'C-#I>.-[%ON/A/U)+3"NG-\F"J
M]+JI6FJ4)FJ<T[\<:LVL<T2_CDCNIXNSSSX!,51+O+T#/KSB<UBYG"1+]IR+
M#V,F%<(=< 6#85T-AJ(E!S;FQ%=-ZZN?L L-OHI5$<@M;'RN<F]FVS[:A=U:
M>DQ5H>9$&3F.5U.@&IS[J9$G=))N&?QFYU6#M";K8[KH-F/V<6/$6MZ4T]+'
M'0GQYYSEK=8G,KA?\&Q5]8T&_1V[STS6@@\0U"X?LK0;F7\D:3IAU OS%6N
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MZ O-*]S,@3Z*^$(@)*"?82U:WU\0;%EAQ) H:8'+E/<AVC8\X10022K4$)#
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M+&%E^*OFO.&:/2X.+FVFT;!:@N3=!B0KNQ3CHC:(X9V^!)*C7,!CJ@]J->[
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MXNOVUNPM\+%,V]MR%HF=VPO;PV#I](HY!DB,DM2P7YE9ER1(MO,ZZ!Z)#J!
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M.NTBOPSB@ZON<T.OFLOQF'8#A3/*X]Q_&4+R1TX!'075, <2Q16@FZKCXU/
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M1][\ASWPI[_D7_XJ?_@C_L2/X?_%._UMIN<I@.TO0MQV8ZH-1X<M^TJ_".N
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MV?]<9D7J,CG$CK]I%CSB[]"CO <#8NRS3\8[4G.P+YAR Q%=9N+I9D(OBRC
M6:][[D=J/#.<,\57YU+G\%W]JH8F';LCZ[^3G=Y[X:[!8YEN3L"&!DPN]J;9
ML?JM[O8[UE:&63EN+"15O_63,R]*:9_H?5S6YK:E?8)+J/>YDLC]W7F 6>F%
M.6CF=4Z-X-A,C4>+4^W6MT[+/-'D[^67)B1;D\_C[I,/MJ3B&B3A$MAZ>;VR
MB:,24 ]L+$G,#WJ0JDCBMTG0K\']8X)^T72:MM'DQ.FPG7FB^Q1;5LE36#_
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MNY=/IV(7[)SO/K%,GZ.PBYG<X\VNK[X(]ZYM4='9AUPRMBF6<*V^RFVG3GN
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M2=M@-67JR[VU6A6B?<ZIF:S%81W+%U;&9@]!07(2==4-P(4O])%.*/NV3+C
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M6&CVO:V-R-TQ%9:LS&5,)KKL82M@V-GEN-*YEL;BF]G.KO8W4N;Y%;9A=!Y
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MF]J_US?%NT<W#)JGK-L6<8C[I-?K1-PIB4:QP]G]A$J9%CH<C^MZ54,YW39
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ME!:&20^S63EKH$M5CX#,+$4OB8IWKN=>F@1U[(V?LI9.+[(EB!B#^Q:;3Q]
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MF,Z^-*;T]"@%NZCTB;]3^/W_8WJ<^S]02P,$%     @ XH!;4$=(?;M+8
M#XD  !0   !A;&QO+3(P,3DQ,C,Q7V<W+FIP9^QY!51=RY+V)@0(! WN'BRX
M.X3@P=U=SL'=+5@@2/!P"!#<(02W0((['#18@KM;\/\D5]Y[=^Z;-?-FULRL
M]=^".KM[=W575_77W=6][Z;OO@&8<E*R4@ <'!Q@#/L#[A8QER0]098 H*
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MPD*.>T0V45WMTV-%)(O$(HD9[7H93[6(=@]VU]G@#W.4R3=VY0;O .SMY3M
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ME]1D[", P97#,WEN*\P$-8W'V#\)ZV"R.B &;C?VMN7IY>/R%"H\:Z\5TN8
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M<90 2A@EW%0%).+39F5HF A@]3M81/,WK3T\GS[-8_ =R6)^QAKJ@-D$N5B
M"K)%#S_RNG&E5[8:#UE%JK(-D_&\M9 #C7UK<*14+-VMVM+EX(;>B'P2R'M
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MGMJ,@=6R,G.K!T7,$D6E8<N'V1]FQZ9E]#O(]2IP4^SJ'8'CBQ_<E#.'B_>
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M<^JV<SGSD9=GA*3Q9BUTP[R(.L1'IKRK"S('L$?G0F)8C"HY=_X()/"_[!7
M+2+7>^#<JO:1&:C5&@/>L6S,+[)TW*B#"1(>FY96#Y-/0#K>"DI%RM.1X#%[
M#MXJ\WI;6I!LBJ5_CD'Y^-_10U8_+#"RW7ZBZ<[I.OT6FTAJ%$YS58PU8VBR
M9CP?##<@B'UQ.(!7>0\0%.I^+!,K'$VU<'CW<APGYV27>%W+_W>8;_;EJ_V>
M,.$OKZTW8>ORE" C>C/BOKS@YGZ"5-FIE7H5">XPY&0$1$ZW*X+EF7#AYB^C
M"23!DY%MOETG._773(H$$C)$XE7.<D3J+#S+@V]N>_((TYD1IS;TY:]:FXXA
M.PWM]+SDTE_:,C[E:HPW-42C!1+R]&2X+</((W!+MC75XPS^-IB%R>@TA!;F
M"341&$TOL390WGWD#$8\$MX_9*^N]-@ZW-/,'$3KE6_C>>$.J'XITO:U<2[M
MJ_1L/JU[VGG3Z^M/F;"D!,[&RM]7]C:5I6JIAQ=]<PMIV!V7XYZ>I&E:W$CA
MMX)PS_>E=B@I;_#<WE&%0\UA/8V5?DMX?%F^9VD.-]S8TVPH6P04F=J\'D";
M=CY8H2D"W3W^IGYW15&A_UHS@W)URM4M.31GE0VWF)@Q6S,GL/_[-(P_IF0Q
M]$?MW0YSX0NB>=4KPC?ARX5P7&EHW?=P4EA9>1,-M.CC38@E$KR(#K]A0;M>
MM?7= ]X8)?PP>2RZ2AF^XC)>D-!2_)LPK<=OQ>^;70M'/M2+>%UO?QK%P.';
MT.2^JI J!W/Z/#EG7NVOE'YW)&*YF[BDQC+IRMK,<0<2Z()4(".7@Q/G=] (
M%WN';C ?3W;/K7JI\L'7*HZY<Z5%C.ZQ&YZ?5Q6-R]3-[6!VE.CY5R6\KGL
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MG. J(>&RA7+( _C\&2&P[N?^#5!+ P04    " #B@%M05_(#8<UX  #DG
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M-J'P43P'A@AM3.05"ER][(SK<"EA#80&WM!O>0! @+!!#YM<5\+E]8Q/B0^
MIM<],8TJ@B(JU6.E.FMPQT NHIL4HKQ=XM+:FL]UM1\U\'E0KR#2_%KG;MG>
MFAF"GL(H<)P6Z?L36'$*PE!(W!H6+*HQZ:[S1HU;5T9L:9 <)QC.U"(29=,7
M*=C&R"#F,)(.<U=-J@@LD07U9B.6HU:SQW&_\%S""A#W?S<\1UVO/Q1SO[L;
MM3,G\?!6MH.+$@EZN>+6\RQ&\IG4FM:/6<HB!"'X"]TSO..='@ 7XVAV?]Z>
MW?#=8>2E0[@\$B*>XF3+">B;-BD45ZCZX=NY!( _ FG3%TJ/,MF*[G-9JG0_
M4:9'<E%&=DW^ "#7R+\KU/GAKC9L  H?+NNOZ>SI"!4'-=GD&ED(48Y7\PCT
MW\4CC@NF22*,$:;$W-W8YY\0XX*YM1DKF19JE["6GC](Q@J%T6IDW+M8+UU$
M0&_P:M8> #<D7'*WUS;;ZIV"/@+GI/N[N_,QY#B?EK)Q?H<$U)L[]\.V1-R;
M3YXC<O:7:K*QC:POPF5$YMYMYX.F(MTN4%)/IL)RZ^MFT1'^(-:EQWE[;T.%
MQVD#(-^/_*).Z1%NY6(N)J1,!% KFA!>'*%SQF<M!JY30_Y(_W("T?8#H.S=
MKX_:++_C^=3D 5 J2MK-5CJ4M'I,?IQFUG8Q<EF6L[\U'+1\*KB+N)H><UI%
M[-S@J-P^D.^]**X\?9G Y?O_XLX Z^GU\ . 2J7NWB/J'F,Z=3K;T^2/8P1O
M@<+]+88L=H[;VL5[UMN6Z/:<0<]6)9TL#O?Q-VN-Q>*-E%?.M-&J&XV.FK+G
MF^86EQ^!A22HYLF6V'IDW*8RBA;- FTJ>73Y.%YMF%",.RZ^]V*\Y6^B?*D.
M_T7BK<*137OT=7>-"C=./'=1V*IP1@O/PN+&ZI>R,7US&[T-"JFL%U#;45NP
M^0.7@PUA72CH=?:!+A&\9BO)^^V4]0B5-(E%,R^V&($=.A7/50$TW,F'2-C^
M_3?/=:C:[CV:T0$C5V93]ZC&3U+9[+K.6^VC[#P-$>:!QK /F].V$6*V: K5
MHYDG9(5V0H66CC?X-'9/#4+8^>Z,RTL\M8O5M;2DG_9UK [$4A48,>_[29*'
M<8E.T#:YJ7ZB!;R]0'WJ^.-00RQUC,VI4&;14G6Z>O@@0M_C'203"^EVK:IH
M*;=0:V]ZT,4=;E@Z@3@H1=\A!71]$+N)JI3-F?,,W[93MJ4'P#0>W+@%U)W<
MDYV]^TPHX?.T_7HJ>=,O';UC-;@8__+M6MO =&W"TQQNJK%F)B6IFMGS64^M
M\N;"V0Q6BR6*2:[^'BL-9VJ<X : AW[+]&H9V:.J==3MT*BN!\!SQXP7V;TQ
MI36C1"\I>N1:S*_EQ)*$C\_Q<7JI7:O.GE^H%+]W' LMUSN>-%.S3VE8)7\!
MWO!"F+I,WM?0N"M$\0#HO2L$MX(2')SV1^'$0B[88"M6>4AV>^*)EGCQ345Q
M0J5] U%[.T2GVM'+_NI]O=OY%>91DSIV=$?:A[F14/MP(S=+4U>YSI R.<?I
MYZ.=%F27F&\&ARVGTJY\#YGC%&)?)3GY+II$N,>DVH+Y^FR(]DH=:9^]],R5
M8OH,]-OC/R]8/;$N?)3)M6#MDQ?5[XB!?'C>K?=3Y<"QZ*N'>214Y-BK0K.8
M>;]U[R?-,L6=?^+NC:I@DC^3R509<XYT&>V<\ M+I&%["S(P@?G5,Z# -7L/
M%8W8FT=V44,Y<L3[&+I7?4O&"X'RXOTC:T&8B_U.Y7.F%FW^CBV"-ENMZ6L2
MI2RJU"\@D@OHUU-?C[>^Y9HV1N1>[E(2*&!L* 0A^:F2D/$U1LDTG+W_Z6''
MUZ<=C<<#M>FHV#IYFV^'6\ATYS]64A8#$^&!.S'BZ2HN?N2;I"H,^H$?YN9M
MDJ[J^U@!]RG*&< >C**2T<&GDA"P.;@Y4+:QX/9X(_R(&AF(#R(T_^G$><@H
M98))JHV$;@H@\48N&BQ;7O@D;<&9DIFHRY64/ZAVL ?)\YX*.DW3*5YY!7Q"
MV[T>\MWPC' E"'5E1<%KI=]*2)KH0.>32KXH>P*:&U1!:W,Z]$*Z7]G73:7V
M\'YKA/!P-VXI Q3.]>EPC)R-ZH/=Z],1EBW2Q[!">^4CLJF 6CZ[E7GF]Z?W
M.6DYZ;RA& 8=*P W"/(>BH4;)Q/F@?UW;IUGENWKS!I+GZ@EJ5BIK/O%'J-/
M$'>GN[%8D[E]K8Y].01MN"@UZS&[&^BI+N2!R/3N9(7.; EJKH!AGGLMUW(=
MC5'!0K13U?P"9F^?[G4^<PCWAP&__E$6^/)'@=/4 33A.:%$ZI]]><K0L6E(
M1*S(5?S\\_VD6.8SF!;,N=WS<JK,<9K'./T2>:%":<6[ASS@KKQE> ,+B''-
M4_PX7V["F,!=09,_8OXKTFG=IO9DB=A2!WU&HD1'W#FN/F-'CD%O"2$3YXZ4
MK)S#5AD!8MNO%H&G.\%\-@%4DLTJ^5#*0-5X9(Q>SE96Q$.Q4PE1N ]A^V_[
M3BV>S!R5IAA6I!9C7AJ4<AELTTY8O+U+CV[$CW_5!39H"EU31 Z66O]Y$V"X
MMX164SDNER20819A8$SW2M>6"#K.-=!=MMQ.LP]E>79R?P)E'C+OAH9Q2:>H
MKR9^&/"PHQ!NVMP=7E5G5&'U2/->"AO-S@,_^J2A.;_\WD@UT#%B/0GUC>#>
M5F[>[A/2@<#)YI-BC':4<.L5+S:MB.$(KK <('7,%W5>QB\O.UO$!#X5H=4_
M^F!G1_^MD^)N99LS5S9[CV<JDRQ( 6)*3#-YF<TGR21CPN3M_N5MP&<^3.BT
M ,WSH+P%[4$.G*V 6L('@'KSQ@. L>\!X!]XZF:MNF5\^@OC[#*R?E<5IK#&
M-=7:;6-9R5R3JD<P .(@VY@4X\)-;"22S:5[E5M8G+_<GPWC"SP=FGL,(=XI
M9(<VV0Y+M95<&\BFPV7$UIU:*C6HQX4QMNV&I38=V_#WW$6#9IF)04"[SQ"?
M+YPS FK%\WL.NLP_S8SE(81&$D3KY!'/XX_F#%0*=P<<Z=KY-)BF8Q<&+VEJ
M-.,[8#,\-W+;'^/:W3U=Y.RMZ>##D;W:>',"G=-18^76 BI%"S7MB;;>HX01
M/[2>99=?KB62XYN7+XKR?&6+?(VAJA4H)W(SOE%LU;,OWQK#1P@CR*WBFE^4
M9=(86/C^8XF7A'RH/B6#ZE#N4GN+>9D67E]JUJQ9+"<PUM+S=-3M(YXMLCM6
M7P7?<QZ46@>-L?#IK@$+J12+&%+6SE\W9.?+MSL6NWPW5:M7L"@-FWM'KO,T
M-YX'P!K9E@*,8(\^RT?4;;L25T$4\%^&Q/2"O+\+_A!XK:@6T9S8/0 RB<^2
MKS)>P?A3NMVKU6)TF"AY.CY'V8-+'4#'.4=M.]095S_+++!"<C'-V4T&](^=
MMC_U <7<C/#V_%;2IN]1X^ WG.".N$;$!!'K+59[N\FRS=%_0M[GIHVWE_$/
M"479JVC0RZB9!T#UB[24*C\9_5T7NCW"A$LYKJP6)3ANPC!"TBE"4.R?@I*F
M&5R85]A "#G(?S @5&7#(L@1$H.T)4&_XF0,Z.>F$2)2/&GD?)?_64_K#3%7
M8,^.;W4?[RDM]#M6A<BS ':GFN9.3CC"][3)17UR&97=:.K3KW,$4*3W)=M)
MIMD6(=#!-D3]\YQH6_I=_B[!V##Z^BF8B$,!S6D/K>4A5:[Q/UULF7,M4O"5
MR6#01 E.$!L3@(1>R%TKNNB>OY3K14Q'F++[<%_)&^+Q_7B/;UXB.+#\A%&=
MPG^N@U8E%\$CDB JZ?WXIJ@]GHS-?R=!"L&I !>+@B@>L1;H@^-/6^EOU8K^
MC$T\..:[)\Z?MD1!%(Y8#V#BI^EJHN[Y, ;^LMO'=!N_QS@:1'\N3(_HZ^00
M:H(NO:ENY(!_1/J/G)W^2\H"PK,7P+/74?_>CC\M%FH0NZIOJSHAN/[/1"1-
MTU^17WK3W8C#L!X 47_T]Y\AP!_>Z$D=.-J<=>_!(!*D<;RYYX'-EA\F]GBI
M=M]P;LKZAM>)-"F]"AXR6_>1Z+2/V5?/KMB+^NJIB[ Z,/\!H#U_,\7E\;;B
MV',O>7+RZC)RN%I"ETQ7*D\(HV*_Z &PP7?%L+8K]OBM9ZE6&S9CI"29M*C[
M,HP!!^&Y+BQ(_!^4VD6?X, #H,J.NXUA(UZM] '0$0,Z1PQFO8[@?U!>]E&V
M\,$N,,-&*IQTYQ;SHNU:D0[NVW;S/.KO1 ;"3>+^"N!!NN1_K B14H^P.VY$
MSF,5=.H0$?SP !A1>P"\'OT7>OSVD&SU/B48KO23_L [81]\G"-WCP8^)7U]
M3?D#W*LV?Z_-"E%H7;U/"]4U7(.3@WLO\L'3NKNZDB@Q.B:KO_RW/TQ;U> 4
MN 4^&GKK5/81!;FY65MB(FT-L=TPXQE.!Q#SL!K1+F+D?H?V7X@8H@#%M5"
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MBG:.J+0869^$5,N(W8Y"X//$'R"Q4K.,4!*3,G=I.=*J^9LZU5U<J2U>DD<
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M$T+>K[XQ8%Q46DCN7H+:;]I/6MKKXKWG]IMI13H3$XS"6UUL]6W!6DL*R9J
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M__ZPHLHGFN-VVFM,R)C-RM38+CE]ZFBM8]6D.B$KYKE*_)A7XDIO 877 3N
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M=[9.+P\#2OD#H%7&4\:#(4.^(:&!E8,$SG596YUR_N3BR&H#>G]JL?9I!.K
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M= 4J_Q.B67=6V>(MG\HS]/_^IM-FXB::7A.T+ZN)66+6AMK^W2>?/I6<];K
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M/_O]S*GG+>X>"UI/2,<(NQQ$N-?XL8%^E?)9R%RZ.4I7UCD!SNER14!_&E@
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M;$.").X;];YJCNR)-J] +/$_T%.7+2^(^9"-_$J1'!<U72U_#=Y=M0Z/8R\
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M*^4,M;+G(9H^^]T[%7&1/,Y%O:8ULBP%K0_<8UOTO+1\4"6LUY9<D<%_K!L
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ME.GK\I?2&/EV?0O"QWP:<@8!T !*P.0.JE1!<BMNS&F;%C9OXT4'Q.1TT^E
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M"_ YIS[>H['%ISY[.31Z>&XDOKP^=]WMDDOFPIK6C8]4J/RR"G!$AAF-=W#
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MVR[E!%0XQ95:KJE&+# #HP/?S%DI1FNJ$S!10]B-S3!\M2578ZIH1=>U"!U
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M5;@#/3DI*^1!Y("?&Y41ZGX8,%MP.:BF_)L0^2-XY!5CW?YC\ [%FK -48B
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M8K<@1^28#D//\/[7,_C^ZPR(#Q]&INC (\0J# S3U(!\O)"<M 5/XT66]2_
M57ZXN)/EP2(6"\J*U/N;#J)5J#ZEK?XA9&'_0AJ9&35BQUO14RL*\NG65'37
MIU 5EE:VAXV[-^^O7G<J+MGPD@M[?:<?+_^@?.$<6=<%681>-!TO$+KM<[Q!
M,B9K7^G:A0&#^<,WKZ8RB_0^C5/J3-";-.?5.&376GU*_[!\S<_N$X6C@I,Q
M\8F"C^TERRN34=;PFF :RSNR(G8K\]]'+50]G]8]]SG;?!II^TODH]S_MVF'
M]O$)S2]P ?%A96R;.8S&"%_1LOR5<NC FGX)EL(_AB;-=?T2_$T!O*,B=" $
M"=67-TK!WGWEPP6J*;$"3_2Q&NH#>LWNB\G;)A'8?'/_=NJ">)Q#FS/'G]*)
MPG_.H:;_CR?!_YN9OW<X0&GGQR(4;E ]K>,-Z/+I 2K)WO/>W<EPA7R)?8>O
MGAWTVTM^FR%RHN!>^AN+RF4_7$V"D?2G,ZMGH[A6(NC P8)6''C2AW9^.0B[
MP=F+6S,L11693XY11*"@$/.I,R*SS.&VI89J+@E!^*,14-^5C\=M"9ALT2Y2
M=KXV7@]>_Y0>(0/\^WVYFI,L0S$!7T"9!M2K5B-.M AN!'E&GVW03O5WK#NX
MZ&6CRB(^U2'.P_6.7[9]N.=%3Q3/S\4Y?V8*9R3-!$V,I-6K(;:UW9%5".+E
MCL%@<VH^^M:I<_4H>(_<_0X.Z[%!%T&;_O?-O?GR"@?NZWM/!:EV93[4^^:.
M#$$0=:S]Q" -I5,DHR=B)2*O5%IR/LO1T7[UZ6#PYX/$,Y/F:QADJOO]E^X?
MXFBF6\6K=Y4C$H] .5AQKB.T%#&@2$A:C"1QM:1*@%VU^XAA% DX3)JX_Y4]
M/J>UE%$@T5W#3F]%++"?D3,F(\@_M6 <VX =*M;KI7!E@/%70;<,T B_&#\\
MH@\Q4E-'#/ME/[/.S\7:D><E9#4.R>UW;^%9[Y,I>.X;KG(K 2<^D<#]JG.K
M7)K"V4:X#R5NN)U;A& 0Q<&-"RX:K6S30@=8!OHUJ:..+R8#,ZA&2YN.PW=/
MY$<2DBB<!+<AHR:<B*;!A) ;;+;V"*FT[]4[4.EJV:LEK$Y%4#NOQ4^STWEL
MWQ[R'"J7/L&\"W>Z4!O9?V1TDX;+-.K%%ZZ@F]"#:()/"S(("<BMYQ@QS]H=
M 7TF]DG;D-A/!C9(I7ZWVLO9_I:3G9?)TOY(FH?Y"<93TXO3Y).^P1NQ1*-'
M$-[]92DB+6$!/AE@W/)BO/*%OK*XXB_<[\N0NZ\),\[)CLCDUI3D8V_4))=B
M'J%=.D IODB<$W8H[')MI"YQ3Q)>'FW>M6[0P6DUQ]>WG=[@5-+*W<<07=K4
MMCB0Q.QD,<S?H3(/)QJ+[)H^ R:0$93S*PXIYXE\,1D8\T$!=-'PV*<-EWN?
MT.P>K:)&UR:W^WML#POXQ)P6KU!!6B15H;!O_27S*K&I=E#Y''0:7)Y8#JU5
M] UNAG.6RK,UCW%ZA7L9!$KK?8QQY6:#>/E PJO)L&]2<@H7.,NE!=0[#,?'
M'B)*ENL+AM3LP*2L&30KY4PNV%:?+!6;J_O.9=-L7F3JF5RQOD#,CR5S;SFE
M(*; 3FWSOC>]J3DT(4KLD:@KE5JR;H_&2GP:.H;FF^$\FHIX7(A55@LF0#W#
M:3LZ,:-@I$XDNCWS_ 6QPW>;)E9%'LH'G69FS#K9,5Z$ZL>5=SS!-,+W.56&
M1N*1H<GHT&H#1R%]A13/')N1R(WRZ('#"8>NZK0RBMZXR=@4F*7'<7C<OX=Z
MPWJ]-&+#8/UHK5" TG<:)WBR^PQQ"2N:E#&P=-1:O"K7_WFQ1V.JOG3\:/G;
M] ^KRCN/H/V[77-S(P]D<R1?1GW34@;1@6J#>13++,-KQ1,(Q]A0^WB1C<\\
MA8O(KXHM1H_LCE"3M8XXU[*2RN+=T\%(W6=-RB;O]IZ<GDJ6FI6XI&YN$P3+
MUT:;/[Y5O3F!6R@E3F^\ZISHKCWHJ]@P*E?^$"M./MMY,VZLORT^["(=*-+V
MWQ+U)>YK-D@^0.Y>T0H6[W!X>/>XS?>D4:SGEJ5P)Q*B>HJZTH8E8E5W39&R
MKWJ'$W#$R8Y!1UKXGC"([,NQ4'F)I7K4HR5PL%6M#*KGKT>(E&W9[=,0OTFA
MVA!K>LJ(WVY&-\0C'+#;$H)PVIY1B.\0_7+2*P;$7^HA&R*V5;&!TO&3%D%[
MBL"W8HLZJ ?V014'HQMBATW^M"QFO6TO)8Z"^(KHU_QU#J4M7#HN$P9Z."Y
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M<1=,K-:4J+CX*B_ ?N<S>=\,@F2D)DJ3./UX77:?F7+'*_N<P7K21;VY7(&
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M_49/).IO@L#DN=4XZ/H_!J>>R !%YM(X&:", 0;HS%[GT<!C])>>'5'(VIO
MO=54>M\WW-PX _3E#LKU!VJ=V=1IYR;\7\6@ =_5?XP,CGJ8&L\-R#I_J?YA
MS@Q+Q(O;(IXAZ@OF(<;)#IWD=2(ZD@E5'FO9-JE/I1:[?A)A7YZSMC#>MA4I
M"!81ZO@ 0W_ 7AP?4E9_TZJ=4DN"F?=THOY#_,8?XG69\0P)##% VD@F!6KX
MR  1Y3;?B?19HV#$VGH2>#.,?W8;U0 YS40V?^V]$NT2E61%^P5 &2#6IKW5
MV>'',G1\2U!( _TC\]E50'J&SK13%C^@,RA(Q%<Z7)[H&/%F\\IBV B'H%1]
M]VXD:CHM!;P<-^=NE5Q Y#XQ=>5N @/4L48HC9TN\SKU5?!+9[HMR.LB-JO$
MH**ZY%*%>.TER8VU2Q3K>JG:2U++M>&F3YG,(B7HWI_RS?^7%_0EBNPW1]O;
M+@59EBA S:>Z[3K]ZT[KX+=,8"DAA()\39_C8H#:.Y)[UISG<,LOJ _UJ KP
M V:EH8UKJY8UE/AP(M\#N:T@#_GAGQJ?7<_[OGE?XW2"Y>Y;8IU9)_WP.?*P
M,>]7QUPXMUT-@/H 5%ZO[2W3D4?-"REBLNVM]3AH0-"SD?T^;T:ENPOQJ@BH
M'C+QMD*&F:?/K=6> 1IZ0';VE:S18$)@\-("77\L?8_/Q %BS"G0PX8OJZSR
M0HT<,^"EUVV;,A92%&JQA=9-G/))24[Z?-XJT+,:DT^[B4C3[_#;;=K\N[@-
MA1LC)I\&%?RTV%K5I:J=N2JCRKJ4S2L31,6'6XF&KS[[ZSY$=K[0O+EVU8?3
MV0O;4_/HHR2PS@.%&35=+ YZP/?*PZB,2EN=<91_GQ"75X$)V<&W4VVW0G?K
M:,*^5'L 8C/@4:[@J ? *&'VE-1)FU?GW"J2U0)Z>"KD=28L)ZL1^P6#&E0=
M"?HT/BL"K G*M; "(V".N>XD;[%BWR\&#*=<2-58%%![OZ"W[J;,ZY=[G,E8
M]-#W]^>PQ$8 L=YZMSN\?AX^LA.TPP"]@8Z>"#S(%J*YB_JVXT2?V%'%M("/
MPQ-&](>$C!P)GLG3[B=^\& 4M[KE#JX[">-(D^E=W:RV1RYVN^<-H#P@8>DG
M=G.+M95<=[B;.[''X)G-;<TV+8E=,SRC\W0GM?TN=P\Q0 OA'UX_"FH,,BT&
MR?M"Q?IL4 _[W,96/'9<<Z9=UCJX;.V+<$8J-.Y2/RQP)CX2W.!Q1+ (8>!(
MXCX"\-3R\*=%O,S:C=@^JE4;*&V2(%47H<P7^:WR9L3)\ ><[F]W/T \4/MH
M;KMIQ0B-(\G$$-\6 =V;1AHFE(-QT5/PAQH/.%108R8>58-FER^<K#9Q=)AY
M"I7MNVU\IJG1S=LF!P6 1V:,-'.XV<^TN*4U1LM@KV^$_K&[?Q^ZXS%2=8>#
M>A[S#%-J!SV,*ME "<$UB#W-1N?EOJO6/5QK_#&AS"G_GJTV0AC^X"X"4][:
MJB?K'?;RU]KT^;-:AQJP=311JM("I SV1%."A(T68Z_IW^2"-(T]J/OQ#G>T
MK Y\8W"9I%<Y((F+=DKXT?+3\6K<X3/'GLEG!*G./%Q#B]_VT+=/WW$I\O?W
M;>_Z%23^82S^L_^ D;"5U24\(-TW"*9SO"!D%L3=<<.3DQ:O;+@EF=R9^M4X
M-@U)8P%7QVT[RX';-9RL5HW;E&)JH%^4PM*E*!\JQ9NR :@1QJQ*DN33&AZ*
MWGK])',BF@;>?:;:PP,DTSE*"=15@04OEW29U):QJ,&->6$_&T2!NU?ZC0NW
M9O4L3$8UGK!ICJQPK_119:>0HSAV/P;H *KQL@KXR*3[A>1T\:M/LU+-2\)I
MK677..NM ]B3+[5.)5+>&CE'9?=4BM?5.;0U>3LBA],J9VP?ES8@]S/=I;&F
M+PDZRDU2BM*\1S 2:$+QT8\OL#D8'7UN.4SL"#[G_T!N_VS[O<1'9V>#>:.W
ME83H S7X"-QTVC94@% R(#E"()\'WEE7H3X)ASV47MM97=L6\>_6&(D!.NF'
M2-GS4W*4@R--:'XHW-F0@@E3Y68#(CHMD^;NN ^E@2K23B>9S=^[>_9-@P/K
M1,I4'^H^=YQ-Y#(#E$]3I$!:L&R+Z9RU9 3]>'G$0*.1NR\L]1[+L3*<B\<X
MJ%.1==74@<OX[B0)WP-K!@"J7A;Z&F5D)0EW"#>-.4KSI+"F5"KK$VRU?#RT
MOZU8%WN*1Q7*V)XV[Y0MOG5=9#UZ[03D$0X- 6WV1*CWM"H=H5V"L=#,AHK\
MS.I%DA;\N3DF[<^X^[_NN'$KBU9HPGG4>UQ]![S,1H&T0@_D ,84)6)@A*8!
MN15UA)L[1D&IB<UX\-3:B^-C#ZJ4JR:%KQ7JW#PG,NBP]UDN$'&#@HFI%VNC
MP(B;V#B:,+F8+FI\K7_9[^# 3U6- O]QF,)&O2/L7+S7.\]+/;>OAB3<VJ(%
M+-Q-+@L6ZZ+>0>A2MI_6BWXM1FC6 C ^&Z&N(*P=O#@XL:*L+%[*9V$+43%M
M/A=X@JT.,4(" V>L6F%[.Y=OC4.CQRH;QX5Q?.Z]=HL5ADX)'UYDNKK._K(*
M;-4_QI8(];D:Z<L*#N1RR*,XTMF?3J>NCBX1V9[2A<?& %;8\Y?C%SX_%B)N
MKWCK>YU^<;BV%G9;%I'%/242UE\GO%6UFXHB,$&24\]QQ+D!V#OR#A!S0\B^
M;D!G3M_I7?' ;&@U2/'LH;QG"W)26.RT>:9:P&>D=#>N D?CFVO&EXZ@D6(
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MEQ4'T,O@&[)OM,WA"S<!/\%U_G_R#G&4S8DHNA#U%$[9W:QT>93]J3R=Q?]
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M]V>[A*-.K;?,'G=(DQ\M+'B8G_Y3 O5*OB L/SU( ZUO<G']?77WS_\CQQP
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M3:YW98_PG7B2<E:T7KIH@'_4P;([I3>N+P:=$OB,=9'@RYP'%VTNL>]8SC-
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M$,A]B\_1WTEWRR;804AJW3.Z>\'OX'8UQX_V 7?Z06.2T?A8(V;/PN!XUX9
M/!NE;R[C];SD"AQ/4:KP4-JP/^?1)9AE+N3>"[G%+C+1OGB+J%-?RT0*:("Q
M#%'DZO/\5 H(3J2'Q<FEL4HXSJLRC1"5K_U#F*>*32$8D^$A_2 FK+2[J/<9
M"WV!I-#Y \NGLZ.?KZ?"<%0UO4<.N=!4(#X_HQ_NT93:X9I-28VM+O4@_(2:
MD91+<J/-\_+@<+$TYA/K/Z[&QI-SYD*;5$XG<YN;'_IT%G0<9):3EE&1,;F=
MJJ?YJ4Z7^_KSOR9&]S#%1</Z1)$F=O=R8_*QJ?M+WW9W2J9KV874"KK<%]0V
M! P]9F*=(AQ=)O7X+,WJ6.:E)J$Q#%"A\V--F5QC+WR5?Y]OT/%B+Y%0'T](
M^87F<8VC[27W!SQ/';W*V363ETPXR8V7X>!^7\5!<5X11'5DY:/&M<#$]E$U
M(&N! F[XZ_V-FA+(-"QH(=@-]:-V+?[?-=7:;1GX_UG#;.E474S96<^UQH^W
MAW!(?!DX3BH7-K""55 S)Z:5)*M-LR$S=I,-2.'TN_3 .)P]R=9+A\S+.3@W
M3]"3/<=Q4I#-[Y!B.^QR6ZGDZU-#+KN_1/P[UY.>/1UH %+"W'Y5FM=/0X/J
M0]9;/E/_K\!S+1@ MD.<Z,-4IH?Z5&-/U+IN2!V, X@RGJC)-Q0F>GT99/N$
M95-@% ,D.BW5B9HST2X*Q4P&1VZ@MHT@FH@^^AK2-ZB -DV=*[9<98Z?WS/J
MS@ %8=0U?WTS>/KSX378SL^MSFG,YJNUS$[=!P& ZHW"V^*5&:#JL3<JT=),
MU;A_(F)R4^A7T_2?J!75&>/W,:"5WUH*NZ, LA[<N7]N;_8O VQKT ^:B**)
M@]:R8R\Q17+DB-M[M*%\!3VA000VU#>(/C!#<Q!*+Q)(L^I.HR;)2I =%AAJ
M]A/M).V3MN8< U3$L7M<'^SVRK@LO+@%?DR1 9+C#'W\7GCEI"YXQ7*#):P0
M+N**:F]!FD#2$*:NS@<QD_$S(ED[SH\A,PU_T ??);%0*2Y YBHDL7OD^ '*
MN9UR&MXD@!Z0FNB-C%,>V3\QP=* 8D?56WX8NZ&S+WG%V<]1(FSRPE31!5F'
M>_JF>]JMMW4(+%@,]RR*:)33'I5<UH&=.%TKE/7X&'%(1$_../J'X^KC@=C)
M-^58-YIGIK")?\@BTIV_TVV6O%(:&$8/W8;060QW#U;_F;= N2;X$),5!9C^
M?=4Q$V*]-;4E!",4B^OVNSC=U7<5-171/&QU7B6: SI'RL>/R-M#"7(Q$&$&
MR %(),+HTB1<8ZP  1))%W4G"POCBB\1J>HH\I6RCU>\!XSX1A<$]AY(U'C0
MCN2^MYH\FE9ZT-Q@QV@I[020'R&? 5E4%XKT27N  ,!8;$3\[Y])D'BT4(&V
M'%6^5Y0B0M*HC_'!VQ3*1<LIO=(EB7]P<,D^Z9*7)R*=Y[OXRMSQN(:-(.XG
M78*&J=6  ?,(Y,WX.X%(CD/#E-2O;NX%@0\MXG@[""7EJX2Q6Q%@SR0#]H/U
MERY(?.36YS@CH]$O9G%F8!N-#"EJ!*_MOI$Y[HNFNL7OB@RAA*(>3F2 8BWK
M,*5P*C<30>Z1MO0LDIU86_,Q\+:6*G[27JEWPPY2#R8^,])L.T^C6NT5.-UK
M-?E,&_6*M8TYA&L'BNSC1>\'J*(MQ[B4@G^*V.)DBS54NCSS1&XY!(4$3>GN
M^UBP%J1G:%Y?IJ''H:2IV5M=9QY34RG<31X[@FK_AU"T1P@<6Z1.(+BK0^G*
M,.&AP+&)%.S*(+0)?9 J15)OKY.G@HGD!.40CW6!D(MKC94E(Y@75L^^QDEY
M%4_J59R;& 1'03@Q+JSH. BH]M@P0I>X$E9M/*'%9%5-$LYY._MYWC] <>"1
M2YIH!2A_"G)V'^B'UU-FR]Y1G!W=HKSFRV+(4SCB/&3J'ZJS?[,1A,+&_<$A
M!76>EJ4MNP!A1<K/U9ZBY+VCJ%K3WFQ4.. 0)NYX%_@IDG!:7RU"K?19?<-9
MS2./'OH_"5#VA<7#BNT_C*\\0++T(5PS*,$$WN8H/SO/!1MMX8>&2L8JHYV>
M)XIWM!&9+\MDR9  ,?TK*1M6 ;"N&O*BW-WXRMHA0##$/P2C/X2XP !I\_^N
M[#GC(7+T0V"2% &W.#0NY&[8D[N.XK:A"#2E29&,AJR:B6V#UC5O"EE/>,3(
M#%B=A93K7Y5*H<7O7E(1/<9#5Z.>[/1%1ZFBN9:K#;D#TLYUR"'84C61_(6!
M3%H] 3<E7N2</)3AY#@AY%:;I:&:B<;-RN7JS8$S_F+R;T<I#S@H_^ 2QH5@
M!;(5??K &(>R7$SM04HL'GQH+JPQ0$4='.8G<U2T>UG:(_\)![FJ[F6?\R'L
MZ;.'08*D+]H25&]: 5V=ZMB-%*;J="*/ R.PK$QTW/7(Z"#T8,J4CX*2K60=
M4UXL;0JEMX*69A+.WL(/^GNX8I[9]_I>V6%:J@5,#\T.6#M3QNZK"[MJO\[1
M!?F-+>U9(,&N/4E5HN73N2A&6-Y!F2ET$\>!$;&FVA<5184XZ;T_I9-7%:+8
M%'5."L#4Y//57]/4U"T4PN*FFBWED0,$CFV6.?!OSYS^%S,??)^1SONOIO]/
M/7YMQ/W_TH)YY3$'M?P?TY5GM-/ONW F7U;4X&8H6X+!S*'H_882GYE2J3.T
M3-1X@;!87[5)0"95V49+0J?$/U;9*,9+JY=\F/5]62N_\ #SXYFXI+77NDTW
MV!*B\V)3FKY<7AH*EFVM\M?Z$1/I55%B:710J Q^J08V6P(Y7SM D-MFF?UC
M[/2EVE-_3-'D[KLD6PJH\72TP$$&Z-GJ;GGO)0QE1(*JZ3/A3.-(P5!8/  ]
M7\!#"(J.#-#:?-8(F&ZP(T<)M\JB4K,V6X%>$"OZ$$'N-QO1_LU&='^WD99=
M&UEUH N?(Q71(UO'J$REOY7:P6JKH#JV@@$$ZS]&]413]>ZBZ2'7=P#_V,)"
MO9C;34>:[4PQ0-_0N0R0!XGW-U4'__?\RS- '(*4 09(9VJ%OF<(1:J$X"?0
M I!91 W@233@NU6#_G?I"_R5/NH_I)\'\2#MATR"_\OS4\+ JQS_L-1$%> O
M4W!L\IH4@+_]?'>N^M<D%9IM"-N%&.X<!N*-R7*M)*6KM0YSY%UA6<^&RI&Y
MP9)/02:VW^_K2@>=M*J4DMM'"GUFGP\E)!O'-V(/561_O]K2(J6R;:<*?SD]
MG28T72[)V:AM]7%^RZ;2;K&KICK^<^V_-:0!:)41+ .\_S;MGXU7?T@3\'SG
M:2*_F[9YB2[H_[;XWVMAJ33GQW?3(8 Y0\$3?_MEAJF6MWG00K/D!C?(<A=G
MVZ"W)) @!NAS7CO],<\F,P+" #&7S^!G'D 6I7P8H/=2A&K U!)\>&8QZQ_1
M5E_'5K4:MC$T,?2;=1-=U EPS[^M6P3\L'2.$2^#M[1B.>AUN+%M28P.RATR
MH*-/^TSE?4^!-Z9&9,'Q2ZK6)7WPNS+^!S:>,1VS<6W=BTCHE^;=MR2(FTFA
M<D;2H3 =@$F_37IT0=_)+LQ'3:%$*P%W.M)H-8JZ1DB J@&Q4A1U#BQ-V:$?
M/$FLLB/I]GW V[AJ"V!S MU-B/EY#O@J%YD\91N;)E!QX?,3+0*@[PWE?-_2
M&V!$8X$E*7QIUGB-V81S$_AH(,2$.$P_;B=,[0])&SQX\DAZYC>>LL:W'BTB
M/?S;J=$T]Z&>9:3[XKO^+=170(;&S%V:?)!'"#.2 T$UG@X>=H&_-<3'.N7V
M-0Z]Z!4Y^3Y4U/*QY/.;PT<XE&'X2"IGJR$Q,EY3*"<03=!OC'\\"&N("L>&
M*T&/V->3K34_5MU^NN65<X64OY?O8#-SB(FN\.BONT\)D..H6W(' S<OE,37
M^]A13^.D_2[UG>A#"''S(U;NO<-MSG*U5EP4161\:I#0Y,=^ ?"0%P4*I<5J
MVA#O:#DTFMX(G%K.+ZGQ#DI/-*NMKGAJJ-7*66M/=A)D'@0Q"2W,NDF&Y"ZY
MQP]@?:;'!EGI!\O>47WZUM]8MS=KRQ.O%CKC,XF>Z4'OC0_55J27J@ZVB<8^
M=YR,O,87(.C?C%N"[@A:(Z[0POS@CY"<-];'%FG\H[B&AY9;-].^8<7>WM$J
MJP]]01;%59OHEZ:E+@JW:<6G5(?L[/E)&FJT@!S-H]I,%(2ACFKJXG<\Y)H<
M&E+ZEBL?YCK(&]4X7B0E?/^"#7MPUJWL,6K\^:A 62'%B?<AU6NB(+(,?,AW
MZ*>B8777S$/W[(2EI*P@^\ QGXI]"2"P_%=!A_E/DC75?3_L@>%26:A<3'4Y
M.\J!67@L>25&EB->.= /PQ7X<'5.5MG#>TH\VF+M3:)GWVJ22CCHS EO'[OX
M)?,= 5<&J'B( KU61I)X7,U*0#,-&VM'Y<\:<PX/2'<&*3:5ZCHZ!E+J!(\<
M*+CS/FNP;;.<]MK#':RT>SMNZ#@F8O0 B3?2=\3,UD[5CJA..0R13P_*]3 :
M-M2<'T*Z9J9.97@W>)J?![%9Q %>?-\LL04]/OWAP\+HB4Z$,=&ZBUWU2E\>
M_TF?[/Z,BZK%5<PJ+:RA"6_9./TGQ&LCWL=[F)4'JY&U]4FJ5$ZN^OO+.;FN
M?;7JE*CW5&62<"&MZA.%L^%:G-:IY=EO8@B5=G6U-%VVSO0'!DO-*LC=>ZK/
MKL.C($<UC0D<[)0= DN#.6FJV!\IU4T]%\#FG[KNA9V24F@1.#ZYNAK>\?#"
MYKEM9'0!W'2SO.:Y!EAI%ERXN,VRY$3\XB%WQ4X.CZZ3.V!WP^6.T3,E7,IF
M\(F;%\1(/-674NYZ!D4HAL&,#C\WL?KN:9-T_,-G$UT>L;_> BL,V4&,C-V@
M8V%',KJKFRKI+7[?0_!\3IRH285>RNA^%B$-RQ7QJG>#E!3=JNZ5O(G*HMKP
MI>637DG)JJ:Y6?T/=9'V]&XTT0@NA#A#TNW%AOD.H7D#[9WE[LH8N \I2SR>
MC#]1.AJ*.R=T7ID"CWFM&M]\_4-\_84V^9@80[L\>+#,W96\*G!!H!/Z)O%S
MSL/&EHNFB)8:KJZ^VM&4$&B*2SZ1W@KF OQN0M $E,K]\[=[=MB*2(KTJ)58
M"-%,E0'B@D6B'"88H)D?@'_@0SW;9H#(^:R_[3; IN_Y6@;]2P]]JD)[8_NV
M1*T2,"-7QJC&X'X* [2U!J$R,T!/46[CF-V%?C&Z,XMN )K8"N&"S*91N@%O
MK?AKFTR:>@7PUL'_X(@6#T  -#"[7V%;+/_GQK90>A438VS?9J-X:E372^#K
M-6K]^?%,K<W;58$0)[EH7D5I+ZHF*5'Q-<@W6P_%*0^[3J]'$:\(W<=B[\.?
M:(M:83.MYQ3R>N.>M'V!>BF\3O]9G&1N%E8DFK#_'HMVK7Y]4#Z$]Q#WQ^_J
M.2V9SRTMALI&JC2K)Z*^#!_C-W<S?U+L'^U:NBTE1W%89S((RNCRL![W*'=Y
M^DU+@ F2=^-=(+<E^;IY4OQ4D,9N*='K)_[NMO)_W%H>"61/9>!5J"83 W3+
M!DT["KOW6X",0PH'_K%VU$B)_6_7CK3NWI55-OKPL&^4,.\_=?NA^+-O0DCS
M?3W>C7VKQ=Y2^J*..2)G+$PUC@3MKRDCVY"T9L)JCP<2%A:%I>)UJ]*:^S9M
MB7GUXH7IGQ74V2.3RQ*?4B15)6-'<LHH1<3E46/(#4HHP6 9*6KDC*>=\E#I
M(@S:B6\'2B2[(+NS]8\J\'%]'RH_RU&K(L%#[8[$E\%8!(W/[?1Y9!8;^KAC
M%"D!T:XUJOHK+^).D-4J;LVP<QDJ;7BLSG5)$79,K:46VU-N%:>.<\CR9;1Z
M"(C()"_$L=CZQ!7WOPOJ?]PY_.!&N&D_4_9V,&X@C9^BFQFHM] P*)N:6IKH
MD!-8=;7GY]M*IYJNM(D+J7=*U_0$3E]5N#=DL+\"_0C)W$$'_Q2*C0^'%ZR4
M0"-XM]=K)7:N-\N+DKU7GNA!?*8DM@M65OC:W981O-8*T:^[JHHZ5S+[>E>J
MOJPXQ'J%GSGCW>W9HOS)VKV&IFY'OK*%[#:H[CGE*K.X(FMRE56'R6#/NBC3
ME:K"\N[IU669F;)$O@$E#P$'W#XF^_:=/8B+)!9@6ETXV&>WD26?!N8L5VU;
M?9R86T5Y#TM/GWRYI^%H29#VPW>=U#,H4CL>\XBJFVM(X. .C#0E%=L+5E8D
M$VRRM1MO1?7)[B"=GT9L;ULF1K2\BZK7RSNH[3^9VU56U1JL-(3BG!O>D.>K
M_DS)-LWC^?;<KALW.ET:UX*0W29KWGF"ZU-'?05';,,;P>R4.VOU965CQ"2W
M49&BX-[>S&BC ]+.+V^N/G>R(C[@''^HX9PZ70Q^9'^(E!6Z/B9H3;DZ?]RL
M@3\S3R(BK^3,I+%>L-&WI8ZHPTX'.&$*YZO1TA.@U(64 P3+JJ63?I6;^<4Q
M*.?WK_VK KJ6!+T(N8JVHVT6L[01I&AM;^^P_;9LI>*,NM2<L3Y>(E3S#/'+
M)C:EEKTR<<E>J'O#0%-#.\>+S9^K/40Y6QRZD<E[G?.$9[!CG%L*%DC;1WDZ
MM;G=4E/"UU6*T T%63$,4,F(7=VG&T$+$39502G?$X/1SY:&0 XGXMS5AZ6B
MLBZ;VQ*6A-UEW5<7[M2,?I(9TJOL[TKANC5CJK0E6B!K4V5E9)2UXEMIV:NR
M7K'6Q&T".QMRXD_OO03\2OP<_I'X]>8LF8X9EJ[EYY\L>W2$]3N>&YQ-P)P!
M\@'(:C _F!96@%DW#]$ 7&)K=-<,62!.2*=E9]^H7(=#!9=0X8O8]5L-X.6E
MMI"<[9BZ%SZ3U37SN]GC"B&CP@> B=Z0U_'Y'GX[ @L2%1&K?>XN:Y777UHK
M8VT_J_$HPNJ3T2ZNZ3=45M98V5_=G]&27X$EHHM1D4@AJA2EG>0#N(H]^4I)
M1.UTHKY--2D\(@Q%SA/O(WE+3VE8I<?YMQPW/;B/U%+POMJ'E%XW>AI(S53<
M4@^G$-K9W:R7,/721EG6\Y^-@_CBKYB(W[:054FK$ PHP(E%?C'V@RB9EV%T
MEHHKXPR2=9U<^CW9#E^/M^V65M8(,1VY4Y(F\/C&4]&HAFPLR[,F1!(>]F2,
MF6H)I!$X(@,4B7 E\>I]Z6" \,S=-W$I1KB+\\?NL08>LXWQ5SS!=K&"Z8'!
M73;<[MII?'$W$HSL@("K>3^ .1@@YX$QU_MY3[2YJMP+V*QLC._6BX:^3K9)
M/EAY\RK?9SUFYT68-/IV369V@#;AE6U1:44RGVS>1.KQZBT1U^M*7I.QD\XG
MO3DDXMA5#7"+?CMB%9^K2VK+;E\W@DM^?Q27+FE0\ ,R*(S3IY01)\CHOFJ'
M"5VB'3F+9 ,E^O*'3[W&61RUOB$MWM5&U%W3=U)L$3$88'VIX--!K.2(+>%X
M!#Z <4.Q!8(;:@6)N'AIA(!3#C2(V I+9H :%(9>/C(U@GMZ>W@VLDL)Y1J:
MI)T].#2?MK1"<Z4[ACC88?)0WVB^GTG:KSY!O7CRWSGYR+P<NO?L:GX'6!]$
MQ<3>*,5$K#(G\W&Z##O9'5?X3!:)IJY1+,?! _IX!NAQK5 [$6MQ@W["W9ZM
M)VT <>ZCH7?J#\A-&:74SQ<G3BP[*?*<NA+W=D\_JDX!J>&2"FCRJZ^5PF&$
M O96TG[P(?O\5QGL5_=C@CL\A4\W,I<E2W,O-7N9:&HE]6Z6?AH!4/W'OJHB
M[1XHI^NJ.T>6S,8KMZ/YY!*N[)>6/9D!>U:B7UWME2F)N51>7!XQ/WIE,9GW
M<&Q8V$,UM1/Q]1AIE,,*._T'AM@.WH?P(+Q!DB%Q_-C'2S^GTS/<%(T(,35>
M,UXR-3UNUK"BY2T[J[W,3$\/2LPS0!0)N_4T 4K#CG[@,1R8&$N!8O-\,IK3
M-_U1GJ5QRX%'? \5:7PV^;K&SG.6FCV4E?+F(<^YW!"H[M[H:96_.Q?"WMM,
MO4'9&<>$EGH-!Y8UIMH_*O+AM#7:&4"-/''J#W[@.B9,/Z-#-!J?B=*T4D)Z
MSUHHV$G;?;AW-AJ9>QVI3"DB"1#$2TCPYK+14R2>]<&XPFP#QU0K@9,A1UF(
M[]</J8$L9Q!^6*]O#H>NOVNW<)O32AA<'JSQUQ^^!V<Q4G\^?SU%1LUE<*3V
M^[:<RLHL,@_5\)-^("R><O4DD"2QHG?76#0GQN-IAP&S&6=N9X $"KZU-\<W
M8V2 &?_Y&M7^">6+V1)9AU+"S\&HU.Q-[.[*E"U@63/@?:C9 "#4@&11E!$6
M^B$OXB74CQ4..@CXEE1)?4)UH;K\,Q%@Q,8SWX'T< I:"Z%&;<\P0!QJ% #%
MZU3#*'M\?K^W]C7U* /T;E2."JH L+W?%A^EDP)DFD=?J0&9W77Z'&H52$*/
M9$D!GY*T@7QM56+A!>!77B-^=0/_ULT7U="F?8 !ZECA_1_9.0%\,$MB@-J_
MHQ&H+:Z-7LAX)GJ?8Y(EG2O&;]@KN;#BD'96:X$U)8 $;4 =\Q7KU53,<ZV<
M3KLZIM[F=>H=?<$A21N['\.ZT &Y@QH$6]->T*5<Z:)=GF(VMTYE9KF6/RYA
MO4N=G7AWPC%[_H#PQMPD7>&V4]0317X3LL= ^8CR3$Y F0>'AA(Q_]&]U;3]
M&15]V9=_0F0XBY8J=FZ][C1?S[LH9&-45EGF0;2[5*0W-FK!Q[*J?!OS-EVT
MMY.2EJ/';:)[]C\^HD1!T5GO>1'7OH+)/(",.O]8]P#^3@@8Y]@Y-,P S8;"
M> ARU,07!;H,T(=+VVW[@=E>!O<R0'/2%-ZZ6BV<MI!;YD[#=E_VNU&%( _E
MV-:OBY@1,8-O9&6W;@(NNI@!.OZ3<%K3N$"_8'AOD9M4B,2@DQE5>JM5CBD,
MR]/>"6LYVF3YY+J#2D+ Y17]D2!TMVF#2:+W<RX/J]D2NQKV1Y08 G=M\ =<
M2:B/V  F"#D@\0+'?)DOQEG<."-_N5S4-X??N2F>>[:6Q^-0>V/J4G[TT-HM
MGO4H3YV'@G=9CM^\JG?6QY;&K<]GIY&-J=D83@E_V_N:=[C28]-WT:JS)*?]
ML-NU4==-RV.J3YU;TT9U!)]-\JC=^O9--.1@'O@@U9 $?N"1_Z[#C^:@&TW9
M<R]9-<$FES)7?H8/FW>[T^1JR64/=6^WD5<VRZZFL>K1O:?>[&20AY:5VQO9
M@TI8W=/SYL?<BH(RREXM0:?/=W,Z.9W[GB*:+++B./TJ/7#!AKC4_$H6G>N6
MK. R]3/L@B_IE=:,W-0XM2I>0BBXSYR;7F2]:1JP@81-UD[UHW.Z2EZ;U_"B
MMS UF\H;[>"%48GR'O&>DCRS:XD6J_1A'"_T9-5JFP.G([4.*LG!5"KI$4"(
MC*HVP;<:@TU)ATL^NJKL"TG]/DTVO!G)Q%IBB&4*G56__?GCI\!/;9NO<"'V
M-7XK'Z65>=PON);&0,^_CY9ZW?^GLCH:](- )B)1^(X!ZE??88!T+><A\=J"
M@2@".A)F0%*)S*!$&B;UZ7_IR>.<'QFX:AZM)FF@&18GM3KQ+ST7CLS!>H0/
M WX^:NBW-:P-0@HUCI<BLO5M B&_HT%AJ=/F[BD6 M=I<W;YVCFQW0\/3TO<
M=PSW_0*S4^PUJ8<'C]\,5$Y\2\>B#B*D?+Q47A*Q7_D1N.2N@:OD0>9<8TW.
M)X9</!>>>S6<&8\KF>.VG!_N6D9Z?(_7(&(68X@Y=?Q/<*FJ#; ]<Y:6QU:M
MC90SP]Q96]G"[CXKO+XO_3 ?=)]?'@,4 6/1E"#:Z(3(U='Y.Q!RF2UGWBP5
MYQQ?) 1H626?W0/W^>E;;')&M8J9NU0SJP']!1JY#H[&<"K/[5-/CB$9RHCV
M54."707)"G9U?(^'05]G?CS1XS,X\2+,3[RR( *V5Y.':*E?V4T%X^78*;>;
M-\IL+WR8Z[06JYMTJC\]4B?R>B/_2[3@Y.;-]\G8H^/0@1S\3#W-R+2:.!:*
M$'EKYR[9$J*"SKC@(398-FIY^NV7M'&B6V0XRE$N7)N9))-6\AZA1#SV+-=U
M9=IZS&I6Y;.M3>F!X03)_68/]2[,NG=^3$^U:TCR5\N3(]^CH-XA#%XUJ]BS
M$-]DQ<@>=/5[7/R"<ZME_LJ[@,G-<RVY*P,-9-\BVIMUR!%]X7=>>6ZCTK@5
M3?U<-\NCTM[VML/:7B6!U^/D!=TJU&Y@O7\1-[8J7,W[ZOL^6E+O[]XF#]I<
M,B.6HF+119@8JIS+][+4TC32D.,X7PK'<>VFYQS-&)X2&949O1Y/Z169Z9*:
MHJ2WY0_-AT05SC1('6X4C*;-.H[8B^T SJH.4BM([ZHL<DNM17MENN?OK?V0
M>?E$ZMU[FE\OZ&.S^38+6JF7QB]7S!0UW9Q,NB%E-9M1$+*MM.*9BGYW#W*\
MNV6+2/E8=M5STR:K="0M93X7"3&)IIT" I)D("\]8H67 9K$ -$QG2Z8-0[;
M%JBV ]PF T3UQ(@"<03:"&D!4]G!F:C&R]\8H%08A16BZJ4GM1[SU^;Q%.^L
M4-2L)RF ;K0;EU"D@Y3(+2 (AKX%Z"0]8X"4,,1C2$_"$\LY7NHYZ%?,NFI@
M%0,D]MN%!U/0O3-TO15>U._,G(0<V5T")BJ!29Q?(#,I]+WM/X=_9_P,Y1?C
MJ/^>[WC*(ZH.%1CO:\=O3*?]8MH]&(]JD#&;4&T4DJC?5JX:GN?OK1_Z]/%;
MK.'6)%S7O)6K8P_L+1"0ZW@0^[_(KAP+K'LN?%VY_-OVEM\*JJAL,6@<-H#\
M?@L?(IU'ZUHL[_&<7%N1L*\R0E?6D#\R#=9HIM<+]F6*0V!>X4J]B\N#BPDK
M(S6:9,W%[D9J);?8AM@9XSS9W,3EH27*EN=]B8CU0*H&?H%=6UR&)[S:?Q;J
MIWL(DF3WENV0U+:%O$ET]  X]+MQ54U]].E/1_[C4H7_XR; ?QH,J2N K]P"
MT=_^[8LG<;_=E]NRZ((B'ZX%XJ[YMO+.=7JO,!<MMO:(+66B^8O;D5F5E".#
MW_HL\GQ4MFS<;O&^=L:X4:?^I2<92N7Q&:>7D%K)M[NHD/>SEJ.GDN''77SL
MK0:QTY !3K+BO4F4G\,PM 1E$JAXO#JY>VCP-[B7[JY:';![QN7=;A'98#P\
M GF**D.L'DQ^IYU'BNX:W6F(@3MVZ8LJ/A4)NN%US! +&8%?WA3KN152Y?1X
MY79.)%A>*+(&>9G*3@NCRU <R ^)LH4$N4,+*?YC['0QU]%C'<N:3W*%^8M4
MNUF'9VA&FB3V$:(:H;)]8 7/T20C<8.65LV3C9 G3:<A>1'&?<K&P=;EX9 B
MZ\'QD6*%IA-/BPN?G6[U&*QFFXRF/<SD3Z6(T=R0#H>Z=PQV@O'Z2R1B]X18
MUB,;@SY9S@6LV?PUEU)+E0*>G_CN@;ZYTO$E\]/GI?4(W_<;YD_@)9K?B$R
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M/N3OK)7I_W)B[.**%"OJ\QBT<>4WZ"U-</";B;^FY;)W WD;5?<3LJI?R\4
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M1VD^7TM13,NU'%IQ;VZ1<PYLA.4J5]^>%P'SWMG(Y$J16?W"TZS7:1?0^"8
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M2=.6SI<6\Q C[/&[9.XVLD'TX3;;A10&->EWQ.[Q"E)5HK>^RSRZ5D&AFBL
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MWAZ'1*SE:4YHZT,Z!'HY;82P9W?;\-*2$:N[6NV[01[=@BC;^*J_<?19P?$
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M$"7!$,5*SS)4O)G$Y+<8B_-%;U%IIW<10DBX&\=>?&.@I__,M34O25C6CQ,
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MGGUF?=,P\TQ;(J]I=7=3%H^YD.+5TZ]Z:_A^U90IU>1^S=?Y8SU>UU!]H=)
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MGC==>_E#:NSUE#]XP<1'5*V/\&67,TH$3UFH=Z<JT M9DBB]1>4(,AK(!.$
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MM9,=M,+7'IA:?-"3WZ;EZ.4S8^=#&POOD=<FGU"[Y[\/P,QKEKS+^-/FT@]
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M-Z8Z:[E^NE[5<=T/AI<669:*1 @":6::S+-,04(C!IGF!I&H5"5!9-_-[?A
M<^.'+LWQH96UKB8L.VE=FH^= -?B/,<39".318=6)V9=_OJM9[1<>K3Y06VJ
MYFS#T'/LRG8>DM/MV$[</V$?MO-:[#=@L[C^TMS\(V4(JU=/>[^I^PR&5+.I
M9$1;7#0RJ2>F$1'/8,(P#_16,"&)6PKJ$"GFQK7]]/*CA3:K*^->W_]UDW?N
MND\<-'&6&\>QIV/LG>18,W%!VO\ ),>I . BR'<J!C  J^-U 88\;. >5=X_
M%"4MGYI\PJ:TTONJTLR]2&,:$<H2B%/&(4H" C%*,$R)DAF388"4VQ[U^%AS
MX\77AVM_F8SZJ_9D&.2UY,//BD]!;[F=]0/HV-O93LHV%?RJJU372.IQ.WL>
M#J_;V1/#3;N=/:_WB^VLQ2W#"*5I1UDGYUTOEW52<O]'G3<X5I$0(M.;6ZG!
M18%DD(280Q+%@8A3FC 1NW"+W;!SHYF>B%<FY;2MC-#[\6"?O.4\V!&-?W1'
MYAP_P#HSD!M./LG(<N1)><D-C><4Y7CWP(P\O<J;=.'ZH4WD1EOK-"61")2(
MH$3,]+=+8DC#5,)(BC3B2<85<R*HHR/-C9.,H' K:1LZY9AD=Q15.[KQ@M7(
M#',0IO/%=]W3X\YAX34/[NA@TR:\G=/Y16;;V1LNK@*Y6N<B7V[6^:/\+/FF
MK%-"WG[CRXV0PM0>,&%BF\9?^5&]I:7)I:MN9%G;5HTG0Z:*(LXRO8/B 42Q
M0!!KCH%Q$@4RPCS@TLJC/XYX<R.BO=*'/?W 3D'0:=@DQ_5T-#=U6IJ*4LV>
MXU*WE9>WP-6?-?7<3NCHFFI:+RE]Z1']D<IC^I#P>Y70](CNB3*;/D<9' O2
M%.*JZV!',J*A2@6D<99"A%$*F8@4#(E "0M4*.+,,?IC]_2Y\;@)9VBD<P[W
MZ$%FZ1$;"L38/K M!MY+A!]4V7/81F^ J0,U7NIV(#3CP$5#4[.*<FV*'[R1
M;/TA7\GW:WE?+4*B!&8X@K'@,429MMD(S1ADF)#$?*Q$.):O/33,W#[<6DIH
M:JP (R?XW4@*:E%=+:C#L%I:0A>#-;9%,P2G =E%IV#PFR)T<*2)\WQ.:?LR
M6>?DU4/;EU92WW1WO1)OY*-<%G7LPOM577"NJA9"!3S!(H$T#".(PBS1I, I
ME(%(!0XSO==S;&%Z<KRYL<,U_\<F+^OR&/"A$1&4K0IUR);8*>':V?0T\':T
MX1'.D?GC4Q^UGJQU,>1&6I]-3JU@\=OH]/20$S<[M=+_9<-3N]N&Q(#>WI9U
MYMM-L=;/S.GRYWPIJW6QDEV9RP5)$2>,4IA%)#(]1C#$ 6>0QU)Q1AG.J%6"
MM^V LR.;3F3PT,D,[CNAP4-7T-64JE_3\M:V_*0U_J<I9PQ41^:<':!;<<%6
MWBY]VJ78APV*+F&D?M&<*IS4VVOJ&&%JC];I2%.+YTP8<6JOU7[DJ<-]PTS#
MUT;ZU;IL.H[FU=^;W #SMT6L]X))(@.]360((IY%D-$P@8QE4O].,8RMVGY:
MC#4WEMX3U;AJVRP68]<4]0&\D;JJ__VKOK1<TWSEWAGJ%/IVMJ$G3$?FZ'TX
MC7!7':+-/VZ*9<Z?P._M?T=I F4!E4];\=1PD]J)%GH_MQ%M;AG&-V9;:Z*S
M3%'SUT5EVCKPC0E)?+,I\]7M+WI@6MU]+$U8J*:[]M^]R-$%33.:A F&'(4I
M1"20D&89U:P4!6D0(AFST(65+I9H;MSUI@OR+)3^BRGTR(U:>@_6'D7IS1CE
MO&G1H%?RNDZ0(3+:II#L2*X&0F_?ED-;WUT^W78T..DDCDR6M>>M4P;4VH!.
M'=#H UH%]*<'6I6V/^HIY8\[O>'KDV$O%VI2'O:&X7.V]O?@ 7O^CFT^MF13
M"_!)\B6MJESEINC<D:[W"T0$DS)1,&,QABA5%!)*$L@#B91*(XFI?5KH<#G^
M*/Q=]I0Q)1:O;]Z_=MC67C!1%CZ#:> ?G7E;Y#LM6O;MZV%JB>XT 485S<Z@
M56::^7#P/DPS+Q,Y)4:<'S<OQ>6HGG1>7/#XZ7P:EV.PY^KP\+@!J]>-+,U&
MA][*C^KM,J\+//6KY.F-T+K,V<;\_=73V_N'9?$DY2+%*8T2G$")T\C4HZ.0
M(L1AFD810X&D2C'KE6N8#'-;M79:&'>);/702U>OS"7O:6+2/V6KBP-K#IPP
MBQ5L_&D8>?7JS<!'!3H5]@N-]I4 KY[ V\EFP&'-&G\F)EJOWCI]!<:9WNKM
MJU;V94B>7*,&/GJZ]>DRW??6I@L?-;068,'_WB0R-ONX)C2L;G%ZH]_0.UJ9
M@-"Z&N$BY F+0JH@)Z;%0D0)Q#)+(:92LI!G&4D"MYJ ]H//;27:ND[T.O19
MBRTK< U#\]D=2H1N$GCI&OQ;G/PY2'<]PHV;3-^SDO46&7S-UW=-F55 3;Q(
M4U_-M;J@PY3:.;[&FJB1UZI:[#9MNO-I==VR?VOZMW?2U]'UM?P^"P^ZH^:W
M *'#^!,7(G1'YF5!P@'/<"-)(?/%M5[!A5G%WRWI[0)A3C(LM"%.3!G""$E(
M6!)#AF4B99A0Q*R:F+YX\MSH;2L<,-+9$=!+N$ZSRT4@C!WO8:>_-2<<U77W
MP5?=%U])_N?;XO$G?8_YV(GY2VT;];[QE\^;Y ,^JD;W=1Z_8)A]\D'J#U@^
M:S(J5_(K79KXU46(8Y9BB6"6)1PBC@-(F4H@5VF,$RR82ITZX)T9;VZ?Z;.^
MPJ8KQUJ#;URWSJT^ST%M9RIX!'#D3[R1]*K7JJ[K+]R(Z[EOIR4P/@V <T-.
MNN9;ZO]\F;>]S6,YI\\;5G&]TY+BU6;]ZZJI6]3^L&E6\4ERF3_6V:DTUILB
M4W!4$44ABC,)68 E#!4C@F@+ 7-^<=$G%XGF1E%[8IKCI59.#\6?G";*CKXF
MA7]D@CM:2&JG#V";->@TN@+[<_7I_%SYJ3DU!-_1*U,Y"?7]ZU<-P="JRM6@
M!P]DXWQMTH_?KT3^F(L-7=:9K$))G":1@B0DFF%YE$*,XPP2E08J-:%9F5.S
MMH.CS(TU:R&-4V(GIB-A'L32D@0O16AL8GL)CO\TX5,8>"6?@P--2RBG='U!
M$B<O]MZLZ]73S_2_B_*U.:&M7V']2C":Q0RR! F(4B'UCB\-81ISF2'.$&9.
MN<4.8\^-)$[WBC*G/K7\H%; 6W.N%S-B1RHCX3PRU3A![)V$!F V40^N%\//
MI?G6,5P<NFX=?<0%[;:N5^*#GN[E_]J4>25RWJOQQ@E12HD0)HK$$ G.(4L5
M@A%GJ0QQ(E7LE!=]9KRYD5@M[H#^62<0M3W4\H;3Z.=8)D7.!,S7LH*^L".4
MT+,$QGNOK!-#3M\FZ[S^!SMD6=PVC$6Z3+PO15M(H&L4<:-?E?5>]Q'.),\0
MBF"2Q 0B*3)(*=8&4\IX@JD4B<)N?4SM![?Z:B;M7]J=!59FPW!)CYP!,V%'
M1)[1G2@.K$O.-3'BC=C;KC!7H);\JD;98W>8X8#YY"J'T2>E+7=4GC/8@"<,
MS\_;%9:[?J3YTKB/WA7E9[ILZL>9Y,PZ-W/!&%8BX $DJ0@@"O0?1,8Q3,(H
M32D)92RLPF"'##X[8ZE?#+*3'&C1@9&]*:?4+]JM]R=UV!CE:^,D^9FNC=I/
M[NEUUK-E1WECS<'(I%?CNY/[:C<'4!4EK,P<-+4UQTDN'@*;[UPXZ_$G3WMS
M1>90AIOS,P;6RLIO[]8?U:]5L^7\R$QFO]F)OOVFC975K1ET_\SS0YL<^[20
M4<PBEB:0FYY<*,KT?I'C3.\<)28!1I0@)W_X!;+,C1YK56"AX*9JN]6#HE7'
M!%K*5B&@/]8F8&*;<^Q(B9?,GQU#3C0K(Q/F=D*T'HW/#'SL3<C;_H0\B\,
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M^^*!3I7#9>I,=,NS&YK+_+'9Q9CZY+KAPDS*A!=C]IPG+W_@)=4Z&SOO_>I
M6=!MK,FN!LHBP P'2$H89,9W*C&#F,:FS;8,"4\5T;]W+]SI)L3<N+,VC.LP
MZJ9IC9ZHE6QRE.OZVTV?(6HZYE6Y^?$54"8T[?'D@:6_.;/CU[%G8F1J;4N
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M!8%ZSR("FH:A"JQV+6?&F1MGUUU^\KU6)2>.;9P0M2-0#SB-3(<U1-MTCUK
M*Z!%]%]\_0@&8Q1>?S[4=RFZ?D3?8P77CUU^0>Y3F^79E(I8"!1F4<@E%%AI
M2R]*D(D/E9#2#%$1QYF*G0*37@XQM\.9NKS:7L+K__VO. JS_U&W;G6M7W<
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MFPDL4XXR"5*1QP"JS22@',9JDA@J>2[+!!O%BPX-,C72TV)JXZ5V$=J<1E_
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MX?7%1]=7&)L=9H-1;8:W&B_(S4ZW@Y@WRTL=.'ST!MB7 A88S8A:%@1(&<<
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M56FOJ-JP?Q=+LMQ\?'I>KWZ*INXL3K(8TU@ 3IFR=D61 U3"#$@I">0%0ZA
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ML%I+,=]H#]&7E1K\9>\,+<I"2HXE8$FF%HJ<04!%PI4%"ED6"\)Y:M?5P%*
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ML4^FU[FD\1W=N^O-)OB[K>YB_:4IWU(/^5G\4?^IFDEEH@B:845%N@LUS#%
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MFG:K8*\0Q.8)R_/A;KYN?EN_JP]"74,6.Y':<5L?ZRPI.45E3 #FG"ECC%"
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M D"10+4ZI"G 99%S6<@LY<2N^-GQ$%-;#EH)HUI$V])F)_B94<IMJ 2FCP-
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M>UO2S7?R9W<2.A?5E_5*/8*;ER_J<=W<+[EV_SS7=J/D909SR$$J,P$@SPN
M",< 0X8$XK$4B-FU2+"48'K[S@_S/P5OVEP[YN.8@F_FE D!Z,@9.SH$JR?[
M7=1)KW[2\M>^ZYT&_I-W+*$+D<UC*L*KI/=8XG,IW\?V-FX4I^[+A.#U;N1C
M56V)4E6SZ9G"WII;9PDL>(YY 9A,<P"11  +#$&>I#DJ2U9*:K0]<!Q_:MN!
M3OSV6*=5H+%$]L7JCTZH[Z)E4P5V]WUFGZYH.W%F]!AP.@+3X^%,?.S-Q(6V
M 8,EU:W)T1$XG^1H*\*HY.B(SS$YNM[&M4S"\_-"D6];P&66,A*S!%$@!$P
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MRI2 &)4%@)@6 !<%!SEC"<0XCA-FM<<V&71J]N1.T(BW$NH(AW[$@W.'T,O
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MD,IAAHS?U(PK8XZ<:F&&P&GJA.%U#L9@'3%<YU\T3>_W@5D<)1F#4(*\R#(
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M>UQ+>!>D6/X@!EY#J<X.-&Z<U)"N)T%0@U_VG#KX7=VO#=^!"'(:YQ"0 F,
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M-"\Y6T94SK$0CZ%/A2?G6%D,B9Q?0>''&8MCQ*CG66?^VU@P-W+9[9!LA,K
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M]H;JH\\7<[G^*W :,)(3D,9>F>WQV1DYA*PN V7!7$X FXC&SKU8X%E;ZRK
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M('&2P6]S[\US#K6UHE0!5)4R^8W728J[.$\O# ,OBCA$?DPA0B2!F-( )GY
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MWTO&>=P4K_?B<\5W5S!=,24)8I%&DAI$Q *(O"B *4,292Y2YODXP9Y5).Q
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M8';Q0%GO+2GY?V\ERWS\H0YG]D&:5/ H1J'D63G!@ AQ*E>6D0?3-*%)B$3
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M<@I@'7W3N*4.]X3*L_RATV+E3U3[!DKEG$JS?-3B/,SXR,!9[QI0_<1]-O*
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M\N=^#ITAJE,78;(0 W$!UT0*'U8OE9U&QS44>H4W+MX\G9K&-?L/)#*N7CR
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ML,-Y0R<8[O.XAG;LK1X7J-IO -F@Y'0/R*CA:;>!;+ XV0FRNGFH?O;GM?S
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MR>&RR&G5GFV![3I7H:VB-?V&TZT)WPI#=I]93T\T)ES8E.W*F2B1FNYUC?-
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MWRFRX[%!76Q&;V-WW,BLMS._B2U<=)4&+Q57EXY<DR*TIL1;<'3)E(/LF)1
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M=7YYKR(3J\?':M%\TTM,-LLRF@=<[E_#((D@CJ(<%DP58R9YE%-!A6'!^:$
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M*._8ZLTRBEPF:T,"$>M &:ERO=6(X+UQ1C.O8O%M7;0[%(W=#JF7K6X0C?4
MO1OR?P]G].U.6\;+I>G0B\29@9!D;?=4LZ2:_%I+Y)C@E$^N26[Y^Z3UXG<=
MA8&[R!I6(1U [-7;-Y=FV2A?<N$>E*IC&'U)X!51SPTK21J*B=JTP[ZF8&3
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M&1Z_+?8[L9Y[-(B_ANER<ZON-PSU 'Q;)WR -;S_@XXVA7O0-Y =O'[2337
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M.(TJA@XR->LP[ DR5#)&16D@JCJ,IQ 9SJ$!S+(H6:\A7).Q-COV\RKZ[1^
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M/OM?S ^39ILWW#6S]FY!'%[=_]J%(J<D"D'QB+.9(A/AP.D< %&J(C@J^UR
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M]2%*K563&N!7.[%I+[P<.[%I#^%U@,VW\P_+1:+CXNG.K+>EL#RJHKV&E)(
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MA?/@9>"@M+(0M)2UT9MTF3P<6X9=6SZ[3)?3P$X)J'$$,#F4=LU-3<66@#)
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M<!D7K2Z#GI[_<,A=SHY/.OHJ9L@.1[I)>7JI'\:UW+>Y+@:=#.1$)5] 91'
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MWV_G#V\J?KY>5F:3U^F\8-&"E#F!$DR1_YD<"!Z9YEXR49I,V!BTNVE[AS4
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MC49E5T (4@M%3A\$R10(@]$ZEI$BZY/ :(\CCI]1ZGX,OO<(GX=656"16%@
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M*/XA)[0.;LS<W(RAUDKGQ) KHX9TLJ$/?1!"T'?;X<.C5;N9!C9!FOEP]O>
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M&S-9)E0VH#9&3',O/RJ9Y]]Z=E)M:P>IUZ!P3Z0TG^4/2]*;3"JA9"2#Q+D
M+Y.'("*ST3(6V#0O_$<F]/P;UDZJ="UA=0YJ-Y*OK5%GDIX"V@*CX-725X&B
M6B5%<()B6Z6FJ=8]8;S6=3O=<PC8]@'1ZTO#/\L:YY(54FB0U;,FUA1BDK2@
M0Z%ODE+&=%G6-I"^\^\9W$G.?C00O8*SZ^4<[+/<$M**$!D#1\*K [\L1!D8
M\)1\ECY%99J\C9J6[/-ON=QWVG\TR/6BH/%E;L6]_8*/6-^%T,_735E#NKH.
MEY]P^55<&(=:2?3 94)0FM<^+4I"0IZTUE)JV^;)[>EI/?_&TD>K8L?@>@7Z
MM]MOV,4B?L$P.RTC X]8?0A5VR%;#X@A)1F-)A[VJ'\'T'K^O;*GU+_6X'H%
M^K>WM[";<R4S5F+0X&(A2:-.X!BS8+7+5@IO@FR7[>R"!>??T7M*;9T(BKTH
M\?'!]WWZ>-W.^6V=)3!?S=)-EU<7C& I<R#::^6<E[4*@4%FSB0?F<UM6G^?
M@KCS;_C=0>YF//B\ I5Z8'6V&"%T4$&1?%SQ"I0S"%YBAL(3699L?5)=3AG?
M2='YM^'NY&+A"*#THC'C.-N/&<$O.-*!&WT&+1S9#F'(I]:B0- F69(12[S=
MT=.$I/-OT]U)7'8,5'I1FO&3M0\8].;SY^7Z0=NV=8G2I2PR"*UKT_Z2:Y,/
M#=I%Y5C.*&27U<D'4WS^S<0[O!48&6AGU#!VTVUG49ZV5 \?>%<^W+![M;K^
M>O.S\7O)CK2A5FUF6_"KEPZTW$E!WIF-2,K(M0$O!$*,6L9Z"^99DT=4KZ4#
MK94V.J49<,48J-KQVDNI(!6=E&6I%LXT.8G^TX%V3_2VZT"[#P8Z<-L>MZ-D
M6$+.7D 6JKX;4+3Y6.J]FY/DCI+A;M/F\U5VH-T+"<]VH-U'+!U@ZG#&/=.5
M4NC(92)O4;A8.Z5R >0QZGHY;!.JHLEO[*N"_#PZT.Z%K5-TH-U'T!UVH+V=
M0E&G&\_^PH<-4+T57AE73R4B+$8ZGYPMP)/V67L=U'9[[^$-:7>NVGGCPN8
M>:$_[3C2FA"&J^75Q<?*S9MVTD%DKCA22)HRJ!Q(CWWPP!DW.7EG$@XI3*8/
M?6 @Z;MMX_AHU=?2+/:0\_IP]O> F0W4@T[%%P*XL[47%2L$=8\<C#<\>1^D
MRT.\ON&HF=(T'2&Q;9D?P+Z)I?Z/V7SV]?KK9N.NQ!"31I!"4\"4I >/08!G
M/FCZ2K$PI*9ZD-P?K3RQY ^1VV(,)DXM_?"O!QO7@=P[)C444]\?:%D'Q?L
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M;+%*L)J#JZ7^(9$?4BV9CI8[&P,3\LS<X .X,$R-_U-8U!L@S_9H/=X?V<7
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MQ;PFM?!:(CD,@K<9R'C(;CLW9?L@:_?=2"OI=1 ;#"-MG4]-R:*5!J%([^J
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M JN-T#996^)6<+DK\?C24EUBY1"9+IHQ>&JXW*?@[ZA8;<@(,I$S$#EX5YN
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M /^Z_O;M8IJ7UTUX@Y ^)3K^348BW[(,#@4"SU:9$BA^+:(%(+?HZ*=CP.
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MPJ=,AI_)_5Y<'K3L7KCR_S:X&D#V8Z/J%6V$C^5#_OVRB.[UFB1<4X'&%]H
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M>U?KZ@_J+P&7^;__X_\!4$L#!!0    ( .* 6U"<Q2X-/UL  #.\ @ 8
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M*"FGRV%$YF]3JB8X*S)/2Z2L8.O9-D6O;T-@W5NH;/WD\,'#BYY=PO+OG&=
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M\HA2'P@EKJ3?5 6B9H@_%[J<<'>(F92YA6+:;_[>!Q/N9EL4"AB<&<N(,HU
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M'<RDP ^^414V5$*9"<]$MZS$8"P4LP8V&:1%&?T.G"T?X^DMK'!R<LOY0KS
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M(V08WF!K @2O<E7$=$*VDNMMUCU9;O/]L."PC]RCD83Y&,86*1,C4 MGY@2
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MB:$$>CN\)P)M6><_?/_LU>M@N[Y^[Z:N7%]\TB^RHM#X?S"U>:EPY=3KBK7
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MV$8@3>S*< YUJ:+L>:7=A-A[ZGGQG_*FQUW&LQ:;1FX4\8VPZP+>O/0%GU<
MI7:/D[O25>VK*7^HFA^^NK>RRB[U?^?++I5!9G\+N4#QJ43JRG*QV=YJU:Y6
M-199SJF,4!9DDU))=FE?I>J>]]#?]E78H.6NE)!H58(EH:TP[6,!^XG846A*
M5^R^>JM!/R+A1BIXSI%W4:J^KE$W8NR[XJQ1XUS6%\WW?"*\D+R8A(</%,BY
MBG3%A4I@O"8&\SE-%(A3 E8(.A*%QE"5)&60,PJ>GQ=8=[&PWX/#U_K=T+)A
M!]J(@H,GWAB=(.%6BKT>5,OOCA*RAD]A.=B?UTSQM6.YOJ)LSS*'4< DVUM
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M7_*8=,D4Q*[B!C5D(EEYV.M[]T9L,'&JD2*79HU/<=]*]5D'/+T[4Y\US1\
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M=D$P7W7J3K/-)PX*L2_1'0#;$&S3EZ^#8,>@QP,-/7RW,P2M5" >7GEC7:\
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M/[S0@G7FJD]'6J#U%C,@%)4CJMN[%0 [>G0"P&HCI^UM+'J&K[.*>B(*>-D
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M.K:P5-[,8=NNC.7WJ4=]0#652GS5*2B1PM#MLY>OU]HRSY_L/W_5WC6;@]1
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M<G3[V!)@P3^J+*_F]EBW&\@_;;?(ZS%G6YZE+E^(8IVUDM6PIZU+KZN>D/:
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M,=NBN8!-[]"H>F2<DC1[;O["0C>?SMQ6NGF_W_>%')S0RIV"!\:S^_5$Z:O
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MK%@BY,SG%N$]57TAR0,*:GAR/LT4BHI1D*CKM(BYP#,*TDD1DI.MI\G2D!6
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MTDC'.T^.+TQ(Z&V<<17#L81[X!MC$PJ^ NM4V9BTS]]G71MIY.;A!2V]I^9
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M5U9;IFI$]S-!RU*[X!Q+,*>1KNL%7T7D4SE>T0#)-H:IMEMT'X#E;K?AG,6
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M;L+<>J!M=VY '_3<T]-GY*<'GQ&7'NDT>?)>GW+W2+(!R9^OIX:(A\*8Q);
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MEC+!S\>7L YC^/K;_SJ%1S%L%8XVC.-4G@"_HF_(U-HM\ YKPS8$9[>BMAL
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M7UYN43A38^2\_;L+K<R&'1*1&4FTVLI%BZ9#J"9A8$AX-LCLFGAFZ4N?U"?
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MW0D0BJ*NPXQ^'3/7Z$(R,H:C?12 #Q1',>>,O:R-,6(T^3H:[7.VP$,KE.O
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M29B$4;C54QRC3J1;/$CZ!ZA-RY'=ICF'Y=Q,B>B$B:L[1[ND/'^"V6?U\.X
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M ?5TWU#O>=7ZD?7K@&E8!@( ;!G_/CK+R# "FNO=NV"I]QD@K1C)D0>9*Q
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M<2&I7[E^YX=?(57/\GV5?G-V\@]02P,$%     @ XH!;4(.5K@7E!0  O!H
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M?>KLWZJR?UM&]SL[)U:OZWZY_ZN3O]KI64ZO]V\(QMJFUWWJ9%M;I+(*VKK
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MO(DJ'2YTI3[6NJ(](Q 93!W9"W:K2&$@PA$Y[XVTJ?S(1"=^E=45$.OY^=D
MEUY;"^C*-/7&D&BG1SP7K^^>$*^+YMX!W7"[*8UK8!&<3D+D"H@CC&BBEI "
M1@-=C12.<,@,@0N\W*I(%'W0,YVI"?[^$>B+"9QH)M!SI1,7B B'6=HNY%13
M !-5('6 O%"V*;NWK>I@T[3K_QDBQG>T>9N#[?>K8R^65"2J1< 7?0D2LDCK
M,^-0$5="29#<Q.IBJC)B8&!?@ZS,BK)1;/4HU\XQ",D O.[KLBVK -QRO*8R
ME02=UT@&EJ>-7I[*F1+@\]09,.Z,D,/'F=WWQ&F"^, W&0@0A.F'0I 2\/N=
M9$N#3%=LQ>L0+P+AC[9 L>C'$21>P5=H&3ST]C()5T235M%#N!,:7\KK :$.
M3):R$'^A48B/:I+B?X W>]S=+>/I]_7H=R1%H-Q(^W6LULAN0@XMR!8H=D';
M-J2Z8J<L<5.'6U DQ!P#A*^0.].P-<#J8QQG@#:(1R)5229Q@'%E<N%@#<BL
MP_^]CN^Q$] @@"] B0.G@?4^DSJC>8QAQ7L4\1_=\$TC\G,-=ELJV88"&K<F
MJUD.5>*#YBW[K5PSC>V8(HN;F_\,$]HL[GM=L"Z;873/:Y8LWKRTLWD\E;G?
MP;H<\!<1HZVHIKD&'3/J,AQK97#H@!<6[$XJ42@T^<'+M'W\ H231K*2H$3*
M6<BQ0Z\2X)1RD?O9>/6&.*5JY%CD&C+/,RU'.@,K'ZUKV\H@4K0P=SN6C>9$
MB1,M2B2GQ*0"9UHU'EZLOPN4"JV$6NM3K=.LV\$&%[2:; +3\KYMA?A_I3[[
MY1I>('.P($6G\A(MP@$Z]#.XWPM'H,0VF!*\0@HAP#(KTEP%*JR4GO?/Z.**
MS#68=1Q8Z*K-U?#29;_C2<.UOF>P#Z_C<42KY2%&..CN%&>GD)G'8[A.OOP@
M<GI[X+>L@DS$3NLZ#Y?LA+FBX5J?&A%@M]\+EW'MZDIM-ZN]JE$FOI6:XUEO
M3('BTEK<X>V8V+66^\U_GK9BO5_"KA#GF):N#$M7Q$OW_5IAE '$8.OI!!4B
MSOR=FJ 6E=6M"*9W00YO)'^_5NKLFJB\"\L@FV6HPC*08;$BS[05ISF,B(XR
MAQ2;I7QP_^CI"7RLK<-(=TE>POGYV0VIZ'#[J(@7X.6G9"J+B1+G'(+]8M/=
M7MKJBT9A@%I1A"F*2O^<F9',Q'N.N?CH-$S#&ZQVD8],%E(1I^?G%WL^ ;$Y
MM+'=,9=3\#UV+^65,F",@(4:3*3-0?R/Q6Q+3%04D]U,C6_,-/\/<Z"ACC&)
MHI,;A<!"NJN[+^=RONT;L@T.R@>U9*^#8&)7]W!X%*SQ9HM\!0'HNC8%"QLE
M=D+R]^>S\^5TZ82?08NK,CY3*D59CX ^6LAQ4I=B:JJ8R D:<AB\#N)PA*5&
M8*FAI!WI@FX/265,N8$Z#[=J+'M1)'^CT$"X>4R)[A(6S:0\2W#"Q$+)3O @
ME6WPG^P&'P4 E'AN%&$ /P53>RJ1.?H:HG_D <CX#%!_</_QTW4R\N8Z<??@
M*>QOA^./GFPB?=&"/]G(>%=G]0X"?X*O:Z@@X48H?V.CXQHB9:^Z+PK-M\8,
MQ\EVH%>E*8!#3_:P&L87EGF!&0'HO<Z0XKV'':?R@3-,CIR\EC> )_YVQQ.;
M@%P_3W 14;-SV\ 9,0&:>8&5.DYD2H*C]O3Q#X$)? :6#?8>QH@#"G4)7V#!
M#99<Q251':93GT)6&%5,60,LRV&(5&%QERY"QKBH\Q$BUT:XHL%V#AXV7Q/V
MHX57-!8XSI#.;EF:BILR:P#86"?*?[-SN I#Y65F%LHSJ"@S0+U59\W54E9.
M)QK\65#6J6FSUTVDCJM6>$:X9L48DV5.DZ*?3Q7)$3\Z)=R7HNHX<I,-<%B7
M5;'TD/X3RAH5W$R8EY<2\/6=H-@ Y/H%11NV5A]K#*]L@ZCP%/E9UEZK%;5M
M-:@O36.]2WS9UNY)##?!7RH/Q'4J50(,(W*E2 RA*.B4F'!TTB'0>85%*2R
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MI6ZOK!'2?-W0O?B\.0QF^6N;+<%D7T@@?FR[G\WP,'0L@",DLE%>2XKBAYM
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MS:&[#:-F?X&7^55BI_\'4$L! A0#%     @ XH!;4$>*Z@LQM00 NT(S !$
M             ( !     &%L;&\M,C Q.3$R,S$N:'1M4$L! A0#%     @
MXH!;4- +L(F3&   80P! !$              ( !8+4$ &%L;&\M,C Q.3$R
M,S$N>'-D4$L! A0#%     @ XH!;4%ND,4]X)P   J$! !4
M ( !(LX$ &%L;&\M,C Q.3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .* 6U#(
M.$RS3(0  (R0!0 5              "  <WU! !A;&QO+3(P,3DQ,C,Q7V1E
M9BYX;6Q02P$"% ,4    " #B@%M0(/MO,+?;  "5 0$ %
M@ %,>@4 86QL;RTR,#$Y,3(S,5]G,2YJ<&=02P$"% ,4    " #B@%M0LCIY
M)U\_   F7P  %0              @ $U5@8 86QL;RTR,#$Y,3(S,5]G,3 N
M:G!G4$L! A0#%     @ XH!;4.<-.<+!.   ]5D  !4              ( !
MQY4& &%L;&\M,C Q.3$R,S%?9S$Q+FIP9U!+ 0(4 Q0    ( .* 6U!4]^P)
ME:@  $S    5              "  ;O.!@!A;&QO+3(P,3DQ,C,Q7V<Q,BYJ
M<&=02P$"% ,4    " #B@%M06E,@+2W.  #RUP  %0              @ &#
M=P< 86QL;RTR,#$Y,3(S,5]G,3,N:G!G4$L! A0#%     @ XH!;4!L/0@EZ
M+0  /DL  !4              ( !XT4( &%L;&\M,C Q.3$R,S%?9S$T+FIP
M9U!+ 0(4 Q0    ( .* 6U#W9\>CSY$  +R\   5              "  9!S
M" !A;&QO+3(P,3DQ,C,Q7V<Q-2YJ<&=02P$"% ,4    " #B@%M0!*ZP2@2[
M   TP   %               @ &2!0D 86QL;RTR,#$Y,3(S,5]G,BYJ<&=0
M2P$"% ,4    " #B@%M0^X84CD!R  !+FP  %               @ '(P D
M86QL;RTR,#$Y,3(S,5]G,RYJ<&=02P$"% ,4    " #B@%M0O0=2HB"5   +
MR0  %               @ $Z,PH 86QL;RTR,#$Y,3(S,5]G-"YJ<&=02P$"
M% ,4    " #B@%M0P])AT<YG   OD@  %               @ &,R H 86QL
M;RTR,#$Y,3(S,5]G-2YJ<&=02P$"% ,4    " #B@%M0@A?SB'%^   'L
M%               @ &,, L 86QL;RTR,#$Y,3(S,5]G-BYJ<&=02P$"% ,4
M    " #B@%M01TA]NTM@   /B0  %               @ $OKPL 86QL;RTR
M,#$Y,3(S,5]G-RYJ<&=02P$"% ,4    " #B@%M05_(#8<UX  #DG   %
M            @ &L#PP 86QL;RTR,#$Y,3(S,5]G."YJ<&=02P$"% ,4
M" #B@%M0(/MO,+?;  "5 0$ %               @ &KB P 86QL;RTR,#$Y
M,3(S,5]G.2YJ<&=02P$"% ,4    " #B@%M0QXV+6]TV 0 >U0P %0
M        @ &49 T 86QL;RTR,#$Y,3(S,5]L86(N>&UL4$L! A0#%     @
MXH!;4&?<AZ?@NP  *:8( !4              ( !I)L. &%L;&\M,C Q.3$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( .* 6U"<Q2X-/UL  #.\ @ 8
M      "  ;=7#P!A;&QO+3(P,3DQ,C,Q>&5X,3 Q,2YH=&U02P$"% ,4
M" #B@%M0NOU0WV;8   ;YP< &               @ $LLP\ 86QL;RTR,#$Y
M,3(S,7AE>#$P,34N:'1M4$L! A0#%     @ XH!;4'Q-G$?< P  -@X  !<
M             ( !R(L0 &%L;&\M,C Q.3$R,S%X97@R,S$N:'1M4$L! A0#
M%     @ XH!;4(W/_]#""   M3$  !<              ( !V8\0 &%L;&\M
M,C Q.3$R,S%X97@S,3$N:'1M4$L! A0#%     @ XH!;4'5:&>^]"   XC
M !<              ( !T)@0 &%L;&\M,C Q.3$R,S%X97@S,3(N:'1M4$L!
M A0#%     @ XH!;4$^]R/?=!0  E!L  !<              ( !PJ$0 &%L
M;&\M,C Q.3$R,S%X97@S,C$N:'1M4$L! A0#%     @ XH!;4(.5K@7E!0
MO!H  !<              ( !U*<0 &%L;&\M,C Q.3$R,S%X97@S,C(N:'1M
M4$L! A0#%     @ XH!;4#%(_:X%%   87@  !8              ( ![JT0
M &%L;&\M,C Q.3$R,S%X97@T,RYH=&U02P$"% ,4    " #B@%M084+* M(,
M  "E;   &               @ $GPA  86QL;RTR,#$Y>#$R,S%X97@Q,#<N
9:'1M4$L%!@     > !X W0<  "_/$     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782728320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Equity Incentive Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to 5% of the total number of shares of common stock outstanding on December 31</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">st</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzEwODk_5e3a8163-9ab6-4322-bca2-e60302945177">four</span>-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc1MzQ_e0c6a459-876a-4698-840d-09c9bbd3a86c">four</span>-year period but may be granted with different vesting terms. Options shall not have an exercise price less than 100% of the fair market value of the Company&#8217;s common stock on the grant date. If the individual possesses more than 10% of the combined voting power of all classes of stock of the Company, the exercise price shall not be less than 110% of the fair market value of a common share of stock on the date of grant. This requirement is applicable to incentive stock options only.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, there were 9,642,503 and 8,176,125 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.421%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Contract</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,336,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,020,580)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(80,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,235,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.62</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,052,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(711,123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(386,716)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,660,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on December&#160;31, 2019. During the years ended December&#160;31, 2019 and 2018, the estimated weighted-average grant-date fair value of employee options granted was $18.42 per share and $3.75 per share, respectively. As of December&#160;31, 2019 and 2018, there was $74.7 million and $42.8 million, respectively, of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 3 years, 15 days and 3 years, 6 months, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:66.274%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.645%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$25.94 - $31.99</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$2.27 - $26.52</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.27 - 6.08</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99&#160;-&#160;6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.14% - 74.92%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.2% - 77.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54% - 2.62%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.74% - 2.99%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value of common stock</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;For grants before October 2018 when the Company was private and there was no public market for the Company&#8217;s common stock, the fair value of the Company&#8217;s common stock underlying share-based awards was estimated on each grant date by the Company&#8217;s board of directors. In order to determine the fair value of the Company&#8217;s common stock underlying option grants, the Company&#8217;s board of directors considered, among other things, valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. For all grants subsequent to the Company&#8217;s IPO in October 2018, the fair value of common stock was determined by taking the closing price per share of common stock per Nasdaq.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to stock options was $21.9 million and $3.3 million, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes restricted stock unit activity under the 2018 Plan:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.421%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted- Average Grant Date Fair Value per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,982,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.94</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#160;In September 2019, the Company granted 57,361 performance based restricted stock units to a certain executive officer pursuant to the 2018 Plan. These performance awards are subject to the holder's continued service to the Company through each applicable vesting event. Through December 31, 2019, the Company believes that the achievement of the requisite performance conditions for these awards are not probable and as a result, no compensation expense has been recognized related to these awards in the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to restricted stock units was $8.8 million and zero, respectively. As of December 31, 2019 and 2018, there was $43.0 million and zero, respectively, of unrecognized stock-based compensation which is expected to be recognized over a weighted average period of 1.98 years.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2018, the shareholders approved the 2018 Employee Stock Purchase Plan (ESPP), which initially reserved 1,160,000&#160;shares of our common stock for employee purchases under terms and provisions established by the Board of Directors. Effective January 1, 2019, the number of shares authorized under the ESPP for employee purchases increased by 1,214,826 shares. The ESPP is intended to qualify as an &#8216;employee stock purchase plan&#8217; under Section 423 of the Internal Revenue Code. Under the current offering adopted pursuant to the ESPP, each offering period is approximately 24 months, which is generally divided into four purchase periods of approximately six months.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employees are eligible to participate if they are employed by the Company. Under the ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;85%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the purchase date. The ESPP provides for consecutive, overlapping&#160;24-month&#160;offering periods. The offering periods are scheduled to start on the first trading day on or after March 16 or September 16 of each year, except for the first offering period which commenced on October 11, 2018, the first trading day after the effective date of the Company&#8217;s registration statement. Contributions under the ESPP are limited to a maximum of&#160;15%&#160;of an employee&#8217;s eligible compensation.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of the rights granted under the ESPP were calculated using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"/><td style="width:67.610%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.548%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.822%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50 &#8211; 2.00</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.4% - 76.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.7%&#160;-&#160;81.8%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.72%-2.49%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.37% - 2.83%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to ESPP was $1.6 million and $0.4 million, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Founders&#8217; Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense is recognized for shares of founders&#8217; stock as vesting conditions are met. In relation to the modification described in Note 12, 24,230,750 shares of founders&#8217; stock remained unvested at the modification date in April 2018. For the years ended December&#160;31, 2019 and 2018, $13.7 million and $14.9 million of stock-based compensation expense was recognized related to the vesting of 6,057,684 and 6,562,506 shares, respectively, of founders' stock. At December&#160;31, 2019 and 2018, there was $30.9 million and $44.6 million of unrecognized stock-based compensation expense related to 13,629,803 and 19,687,487 shares of unvested founders&#8217; stock which is expected to be recognized over 2 years, 3 months and 3 years, 3 months, respectively. The weighted-average fair value at grant date for founders&#8217; stock was $2.27 per share.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense related to stock options, employee stock purchase plans and vesting of the founders&#8217; common stock was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.471%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercised Options</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the years ended December&#160;31, 2019 and 2018,  zero and 5,020,580 options were early exercised. As of December&#160;31, 2019 and 2018, there was $2.8 million and  $4.6 million recorded in accrued and other liabilities and $3.9 million and $6.8 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the financial statements since the exercise date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790627568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss and Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss and Net Loss Per Share</a></td>
<td class="text">Net Loss and Net Loss Per Share<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,594)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,505)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,061,149&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,948,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,249,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.83)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.31)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,235,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder shares subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,629,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,687,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,992,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,948,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,087,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790754592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedInterestOnShortTermMarketableSecurities', window );">Accrued interest on short-term marketable securities</a></td>
<td class="nump">$ 2,403<span></span>
</td>
<td class="nump">$ 3,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid Insurance</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PrepaidResearchAndDevelopmentExpensesCurrent', window );">Prepaid Research And Development Expenses Current</a></td>
<td class="nump">6,387<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">2,628<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 14,043<span></span>
</td>
<td class="nump">$ 8,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedInterestOnShortTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on short-term marketable securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedInterestOnShortTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PrepaidResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PrepaidResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801595296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 536,629<span></span>
</td>
<td class="nump">$ 714,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">205,011<span></span>
</td>
<td class="nump">244,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">181,894<span></span>
</td>
<td class="nump">342,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">25,824<span></span>
</td>
<td class="nump">62,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">304,794<span></span>
</td>
<td class="nump">403,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">181,894<span></span>
</td>
<td class="nump">342,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">231,835<span></span>
</td>
<td class="nump">311,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">205,011<span></span>
</td>
<td class="nump">244,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">25,824<span></span>
</td>
<td class="nump">62,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6664701968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedCompensationAndRelatedBenefitsCurrent', window );">Accrued compensation and related benefits</a></td>
<td class="nump">$ 9,560<span></span>
</td>
<td class="nump">$ 4,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">7,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedPropertyAndEquipment', window );">Accrued property and equipment</a></td>
<td class="nump">3,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_UnvestedSharesLiabilitiesCurrent', window );">Unvested shares liabilities</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,018<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 23,829<span></span>
</td>
<td class="nump">$ 17,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedCompensationAndRelatedBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and employee related benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedCompensationAndRelatedBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_UnvestedSharesLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested shares liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_UnvestedSharesLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6788508608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details) - Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">60.40%<span></span>
</td>
<td class="nump">67.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk-free interest rate, minimum</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk-free interest rate, maximum</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622837904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="nump">$ 41,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax benefit</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6783666096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text">Description of Business and Summary of Significant Accounting Policies<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the period from November&#160;30, 2017 (inception) to December 31, 2017, the Company incurred $2,000 in start-up costs to establish the Company. Principal operations commenced in April 2018 when Allogene acquired certain assets from Pfizer Inc. (Pfizer) (see Note 6) and completed a Series A and A-1 preferred stock financing (see Note 11).</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offerings</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold 20,700,000 shares of its common stock, which included 2,700,000 shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of $18.00 per share. As a result of the IPO, the Company received $343.3 million in net proceeds, after deducting underwriting discounts and commissions of $26.1 million and offering expenses of $3.2 million payable by the Company. At the closing of the IPO, 11,743,987 shares of outstanding convertible preferred stock were automatically converted into 61,655,922 shares of common stock and the 2018 Notes (see Note 10) were automatically converted into 7,856,176 shares of common stock. Following the IPO, there were no shares of convertible preferred stock or preferred stock outstanding.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. Beginning November 2019 and through the year ended December 31, 2019, the Company sold an aggregate of 1,965,082 shares of common stock in ATM offerings resulting in net proceeds of $54.2 million, after deducting commissions and offering costs of $1.6&#160;million. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Offering Costs</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Offering costs, including legal, accounting and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO. Upon the completion of the IPO in October 2018, $3.2 million of deferred offering costs were reclassified to additional paid in capital. Offering costs, including legal, accounting and filing fees related to the ATM offerings were incurred. Upon the issuance and sale of common stock in ATM offerings in November 2019, $0.5 million of deferred offering costs were reclassified to additional paid in capital. There were no deferred offering costs capitalized as of December&#160;31, 2019 and 2018.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Forward Stock Split</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 1, 2018, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a 1-for-5.25 basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Need for Additional Capital</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to commercialize the Company&#8217;s product candidates. The Company had cash and cash equivalents and investments of&#160;$588.9 million as of December&#160;31, 2019. Since inception through December&#160;31, 2019, the Company has incurred cumulative net losses of $396.1 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the Company&#8217;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit and other Risks and Uncertainties</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has issued letters of credit under separate lease agreements which have been collateralized by restricted cash. This cash is classified as long-term restricted cash on the accompanying balance sheet based on the terms of the underlying leases.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as current.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest and other income, net.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three to seven years. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in other expense.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has determined the estimated life of assets to be as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:68.717%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:27.283%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and purchased software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 - 5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixtures and furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Update (ASU) No. 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> on January 1, 2018. For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company's proportionate share of the net income or loss of these companies is included in other expenses in the statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For entities in which the Company has variable interests, the Company focuses on identifying if one of the entities is the primary beneficiary through having the power to direct the activities that most significantly impact the variable interest entity&#8217;s economic performance and having the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company&#8217;s financial statements. For the year ended December 31, 2019, the Company did not consolidate any variable interest entities because the Company determined that it was not the primary beneficiary.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Research and Development Costs</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records accrued liabilities for estimated costs of research and development activities conducted by collaboration partners and third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities on the balance sheets and within research and development expenses on the statements of operations and comprehensive loss.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its collaboration partners and third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income taxes.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures its stock-based awards granted to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense&#160;is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as&#160;they occur.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss. For the years ended December&#160;31, 2019 and 2018 this was comprised of unrealized gains and losses, net of tax, on the Company&#8217;s investments. For the period from November 30, 2017 (inception) to December 31, 2017, comprehensive net loss was equal to net loss.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Definite-Lived Intangible Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable intangible assets consist of in-process research and development and workforce associated with the Pfizer asset acquisition. Intangible assets with finite lives are amortized over their estimated useful lives on a straight-line basis, generally two years. Acquired in-process research and development intangible assets with no alternative future use are charged to research and development expense when acquired. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible assets. Intangible assets are carried at cost less accumulated amortization. Amortization of intangible assets is included in research and development expenses.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were impairment losses related to equipment disposals of $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development expenses also include costs incurred for internal and sponsored collaborative research and development activities. Costs associated with co-development activities performed under the various license and collaboration agreements are included in research and development expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses for the year ended December 31, 2018 primarily consisted of acquired intangible assets pursuant to the Asset Contribution Agreement with Pfizer (see Note 6) as, at the time of acquisition of the asset, the technology was under development, was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing, had not reached technical feasibility, or otherwise had no foreseeable alternative future use. For the year ended December 31, 2018, the Company recognized expense of $109.4&#160;million related to the acquired intangible in-process research and development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6795719392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,063,000<span></span>
</td>
<td class="nump">$ 18,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Number of shares as percentage of common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,642,503<span></span>
</td>
<td class="nump">8,176,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,123<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CombinedVotingPowerByIndividual', window );">Combined voting power by individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockOptionGrantedPeriod', window );">Stock option granted period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted average grant date fair value of employee options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.42<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,700,000<span></span>
</td>
<td class="nump">$ 42,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 15 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 15 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, grants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,982,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_InitiallyReservedCommonStockForEmployeePurchase', window );">Initially reserved common stock for employee purchase (in shares)</a></td>
<td class="nump">1,160,000<span></span>
</td>
<td class="nump">1,214,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CurrentOfferingPeriod', window );">Current offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue', window );">Purchase of common stock through payroll deductions to equal price of lower fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfEligibleCompensationContributionByEmployee', window );">Percentage of eligible compensation contribution by employee</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_FoundersStockAwardMember', window );">Founders Stock Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900,000<span></span>
</td>
<td class="nump">$ 44,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,057,684<span></span>
</td>
<td class="nump">6,562,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares unvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,629,803<span></span>
</td>
<td class="nump">19,687,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, grants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_FoundersStockAwardMember', window );">Founders Stock Award | Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares unvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,230,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_EarlyExercisedStockOptionsMember', window );">Early Exercised Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CombinedVotingPowerByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined voting power by individual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CombinedVotingPowerByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CurrentOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CurrentOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_InitiallyReservedCommonStockForEmployeePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initially reserved common stock for employee purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_InitiallyReservedCommonStockForEmployeePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as percentage of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfEligibleCompensationContributionByEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible compensation contribution by employee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfEligibleCompensationContributionByEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock through payroll deductions to equal price of lower fair market value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockOptionGrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option granted period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockOptionGrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_FoundersStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_FoundersStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=allo_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=allo_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_EarlyExercisedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_EarlyExercisedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797235104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DiscountRateForValuation', window );">Discount rate for valuation</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregateMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="nump">$ 840,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember', window );">Series A1 Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Share issued in connection with asset acquisition (in shares)</a></td>
<td class="nump">3,187,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Share issued in connection with asset acquisition, fair value</a></td>
<td class="nump">$ 111,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Convertible preferred stock, price per share (in usd per share)</a></td>
<td class="nump">$ 35.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Costs from issuance of preferred shares</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total asset acquisition</a></td>
<td class="nump">$ 113,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DiscountRateForValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate for valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DiscountRateForValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802183968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 144,535<span></span>
</td>
<td class="nump">$ 151,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">57,473<span></span>
</td>
<td class="nump">40,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">202,008<span></span>
</td>
<td class="nump">192,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(202,008)<span></span>
</td>
<td class="num">(192,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,351<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,083<span></span>
</td>
<td class="num">(18,780)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(184,925)<span></span>
</td>
<td class="num">(211,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(184,594)<span></span>
</td>
<td class="num">(211,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (183,755)<span></span>
</td>
<td class="num">$ (211,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (7.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">26,249,993<span></span>
</td>
<td class="nump">101,061,149<span></span>
</td>
<td class="nump">28,948,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6711668912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 5,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">7,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">7,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">8,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2024</a></td>
<td class="nump">63,864<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">93,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(35,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(4,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 53,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Year Five And After Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622792976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,948,931<span></span>
</td>
<td class="nump">32,087,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,190,522<span></span>
</td>
<td class="nump">7,235,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,941,155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember', window );">Expected shares purchased under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">195,161<span></span>
</td>
<td class="nump">144,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember', window );">Founder shares subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,629,803<span></span>
</td>
<td class="nump">19,687,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,992,290<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782685648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest on short-term marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">758&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,534&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,327&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,472)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense for the years ended December&#160;31, 2019 and 2018 was $4.6 million and $1.0 million, respectively. Disposals of property and equipment were $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Amortization</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,055)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:45pt;"><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(452)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the weighted-average remaining amortization period of the assembled workforce was 0.26 years. Amortization expense related to the assembled workforce intangible assets was $0.6 million and $0.5 million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and related benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790646704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text">Equity Method Investment<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the execution of the Notch Agreement (see Note 7), the Company also entered into a Share Purchase Agreement (&#8220;Notch Investment Agreement&#8221;) with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1 million, resulting in a 25% ownership interest in Notch. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s total equity investment in Notch as of December 31, 2019 was $4.9&#160;million and the Company accounted for the investment using the cost method of accounting. During the year ended December 31, 2019, the Company recognized its share of Notch's net loss under the other expenses caption within the statement of operations. The Company's share of Notch's net loss was $0.2 million for the year ended December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790933072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(89)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(332)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(331)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reconciliation of the benefit for income taxes calculated at the statutory rate to our benefit for income taxes is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,834)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,441)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,951)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,652)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,714)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-off of in-process R&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,247&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for incomes taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(331)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities are as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,437&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(531)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use leased assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,453)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,239)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(393)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,888)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(91,904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,916)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our federal and state NOL carryforwards and federal research and development tax credits as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2037</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2037-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2038-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Indefinite </span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply the provisions of ASC Topic 740 to account for uncertain income tax positions.&#160;&#160;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of the year:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to tax position of prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions to tax position of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lapse of the applicable statute of limitations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782706832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepayments and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest on short-term marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">758&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,534&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,327&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,472)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets, Net</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Amortization</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,055)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:45pt;"><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(452)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and related benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the prepayments that will be charged against earnings and carrying amounts of other current assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793505408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">three<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">seven<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and purchased software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">P3Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and purchased software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Fixtures and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790598768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanIn April 2018, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. All employees are eligible to participate, provided they meet the requirements of the plan. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $0.9 million and $0.4 million related to matched contributions for the year ended December&#160;31, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790543248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (unaudited)<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2019 (in thousands, except per share amounts):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,461)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,961)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64,575)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31,586)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,243)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,030)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2018 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,012&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(134,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,497)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,509)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.82)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.37)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622985696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - 2018 Equity Incentive Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.14%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">74.92%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk-free interest rate, minimum</a></td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk-free interest rate, maximum</a></td>
<td class="nump">2.62%<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 25.94<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 31.99<span></span>
</td>
<td class="nump">$ 26.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6795771408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>director </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>director </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,495,000<span></span>
</td>
<td class="nump">$ 33,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=allo_TwoRiverConsultingLimitedLiabiltyCompanyMember', window );">Two River Consulting LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,032,040<span></span>
</td>
<td class="nump">22,032,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfMembersAppointedToBoardOfDirectors', window );">Number of members appointed to board of directors | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable to related party, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Research and development | Transition services agreement | Lab Supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TPGCapitalFOLimitedLiabilityCompanyMember', window );">TPG Capital &#8211; FO LLC | Affiliated with President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Los Angeles California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,333.33<span></span>
</td>
<td class="nump">$ 26,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionCompensationPercentage', window );">Related party transaction compensation percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | General and administrative | Consulting agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartMember', window );">ByHeart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartMember', window );">ByHeart | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfMembersAppointedToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members appointed to board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfMembersAppointedToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly payments in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionMonthlyPaymentsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_TwoRiverConsultingLimitedLiabiltyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_TwoRiverConsultingLimitedLiabiltyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TPGCapitalFOLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TPGCapitalFOLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=allo_AffiliatedWithPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608279328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at federal statutory rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (38,834)<span></span>
</td>
<td class="num">$ (44,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,951)<span></span>
</td>
<td class="num">(10,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,714)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment', window );">Write-off of in-process R&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes', window );">Change in fair value of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,989<span></span>
</td>
<td class="nump">41,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (331)<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation Write-off of in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801455008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property, plant, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 603,000<span></span>
</td>
<td class="nump">452,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=allo_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets, weighted-average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=allo_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=allo_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6659630368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in 1 year or less</a></td>
<td class="nump">$ 355,407<span></span>
</td>
<td class="nump">$ 375,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Due in 1 - 2 years</a></td>
<td class="nump">58,322<span></span>
</td>
<td class="nump">240,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue', window );">Due in 3 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Instruments not due at a single maturity date</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total cash equivalents and investments</a></td>
<td class="nump">$ 536,629<span></span>
</td>
<td class="nump">$ 714,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities within three year fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790546112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (64,575)<span></span>
</td>
<td class="num">$ (55,011)<span></span>
</td>
<td class="num">$ (45,961)<span></span>
</td>
<td class="num">$ (36,461)<span></span>
</td>
<td class="num">$ (33,046)<span></span>
</td>
<td class="num">$ (22,187)<span></span>
</td>
<td class="num">$ (135,012)<span></span>
</td>
<td class="num">$ (2,597)<span></span>
</td>
<td class="num">$ (202,008)<span></span>
</td>
<td class="num">$ (192,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (61,030)<span></span>
</td>
<td class="num">$ (50,735)<span></span>
</td>
<td class="num">$ (41,243)<span></span>
</td>
<td class="num">$ (31,586)<span></span>
</td>
<td class="num">$ (30,509)<span></span>
</td>
<td class="num">$ (43,497)<span></span>
</td>
<td class="num">$ (134,902)<span></span>
</td>
<td class="num">$ (2,597)<span></span>
</td>
<td class="num">$ (184,594)<span></span>
</td>
<td class="num">$ (211,505)<span></span>
</td>
<td class="num">$ (396,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (10.71)<span></span>
</td>
<td class="num">$ (43.82)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (7.31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622922000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions to tax position of prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions to tax position of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of the applicable statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,148<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803096624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 144,535,000<span></span>
</td>
<td class="nump">$ 151,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,829,000<span></span>
</td>
<td class="nump">17,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,892,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostResponsibleFor', window );">Percentage of development cost responsible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments, per target (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | North America, Europe, Asia, Australia and Oceania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget', window );">Maximum payments required per product against selected target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Regulatory and Sales Milestone | Maximum | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostResponsibleFor', window );">Percentage of development cost responsible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments per target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payments required per product against selected target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostResponsibleFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development cost responsible for.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostResponsibleFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NorthAmericaEuropeAsiaAustraliaAndOceaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryAndSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryAndSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6796038144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred stock per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember', window );">Series A1 Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred stock per share | $ / shares</a></td>
<td class="nump">$ 35.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net issuance cost on equity | $</a></td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net issuance cost on equity | $</a></td>
<td class="nump">$ 29,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred stock per share | $ / shares</a></td>
<td class="nump">$ 35.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net issuance cost on equity | $</a></td>
<td class="nump">$ 635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6794755760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 175,126<span></span>
</td>
<td class="nump">$ 92,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">355,407<span></span>
</td>
<td class="nump">366,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,043<span></span>
</td>
<td class="nump">8,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">544,576<span></span>
</td>
<td class="nump">467,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">58,322<span></span>
</td>
<td class="nump">261,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">44,495<span></span>
</td>
<td class="nump">33,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">56,449<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">4,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">717,802<span></span>
</td>
<td class="nump">773,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="nump">12,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">23,829<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,079<span></span>
</td>
<td class="nump">29,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">51,349<span></span>
</td>
<td class="nump">34,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,351<span></span>
</td>
<td class="nump">6,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">88,779<span></span>
</td>
<td class="nump">70,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6, 7 and 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2019 and December 31, 2018, respectively; no shares were issued and outstanding as of December 31, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 200,000,000 authorized as of December 31, 2019 and December 31, 2018; 124,267,358 and 121,482,671 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,023,876<span></span>
</td>
<td class="nump">914,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(396,122)<span></span>
</td>
<td class="num">(211,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">629,023<span></span>
</td>
<td class="nump">703,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 717,802<span></span>
</td>
<td class="nump">$ 773,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802134448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (2018 Notes) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 116,842,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of notes</a></td>
<td class="nump">$ 141,400,000<span></span>
</td>
<td class="nump">120,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt conversion settlement price as a percentage of IPO price per share</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent', window );">Change in fair value of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance of cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of 2018 Notes converted into common stock (in shares)</a></td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790577328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2019 (in thousands, except per share amounts):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,461)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,961)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64,575)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31,586)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,243)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,030)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the selected quarterly financial data for the year ended December&#160;31, 2018 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,012&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(134,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,497)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,509)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.82)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.37)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6783329888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future non-cancellable lease payments under our operating leases as of December&#160;31, 2019 is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:84.032%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,920)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782900960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value MeasurementsThe Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and reports its cash equivalents, restricted cash, investments and convertible notes payable at fair value.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no Level 3 assets or liabilities at December&#160;31, 2019 or 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304,794&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">231,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:49.104%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.783%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds &#185;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">403,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#185; Included within cash and cash equivalents on the Company&#8217;s balance sheet</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no transfers of assets between the fair value measurement levels during the years ended December&#160;31, 2019 or 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782226112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAndCollaborationAgreementsTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Pfizer Agreement (see Note 6), the Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the years ended December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for which an IND is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis. In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement. The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed against an Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i) the expiration of the last to expire of the licensed patents covering such product; (ii) the loss of regulatory exclusivity afforded such product in such country, and (iii) the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses. For the year ended December&#160;31, 2019, $5.0 million of costs were incurred related to the achievement of a clinical development milestone under this agreement, which was recognized in research and development expenses in the statement of operations. No clinical development milestones were achieved for the year ended December&#160;31, 2018. For the years ended December&#160;31, 2019 and 2018, zero and $0.4 million, respectively, of costs have been incurred associated with research services performed by Cellectis. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License and Collaboration Agreement with Servier</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In October 2019, the Company agreed to waive its rights to the one additional target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42 million and &#8364;70.5 million ($79.1 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company recorded $7.3 million and $4.2 million, respectively, of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. As of December&#160;31, 2019 and 2018, amounts due to Servier of $2.2 million and $4.2 million were recorded in accrued and other current liabilities in the accompanying balance sheets. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Notch</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0 million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Notch Agreement, Notch will be eligible to receive up to $7.25 million upon achieving certain agreed research milestones, up to $4.0 million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0 million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has determined that Notch is a variable interest entity as of December 31, 2019. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the year </span></div>ended December 31, 2019, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAndCollaborationAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAndCollaborationAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790608688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (2018 Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable (2018 Notes)</a></td>
<td class="text">Convertible Notes Payable (2018 Notes)<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $120.2 million in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of $116.8 million. On issuance, the fair value of the 2018 Notes was determined to be equal to $120.2 million, which is the principal amount of the 2018 Notes.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2018 Notes did not accrue interest. The 2018 Notes were settled in 7,856,176 shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price equal to 85% of the IPO price per share.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in estimated fair value being recognized through the statements of operations and comprehensive loss until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be $141.4 million upon settlement. For the years ended December&#160;31, 2019 and 2018, the Company recognized zero and $21.2 million, respectively, of expense in the accompanying statements of operations and comprehensive loss for the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of $3.4 million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608301648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 54,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">570,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6675968976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carryforwards</a></td>
<td class="nump">$ 193,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carryforwards</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2038-2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | 2037-2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carryforwards</a></td>
<td class="nump">$ 190,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=allo_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=allo_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=allo_TaxExpiration2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=allo_TaxExpiration2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=allo_TaxExpirationYears2038To2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=allo_TaxExpirationYears2038To2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=allo_TaxExpiration2037To2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=allo_TaxExpiration2037To2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803924832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>operatingLease</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,495,000<span></span>
</td>
<td class="nump">$ 33,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeasesNumberOfLeaseAgreements', window );">Number of operating Leases for office space | operatingLease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShorttermLeaseRentExpense', window );">Rent expense for short-term leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short tem lease total commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeaseAssetRetirementObligation', window );">Asset retirement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_LosAngelesMember', window );">Los Angeles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_NewarkMember', window );">Newark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">188 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LesseeOperatingLeaseOptionToExtendNumber', window );">Operating lease, options to extend term | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extended term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember', window );">127 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">127 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900,000<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember', window );">124 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeOperatingLeaseOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option to Extend, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeOperatingLeaseOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OperatingLeaseAssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Asset Retirement Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OperatingLeaseAssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OperatingLeasesNumberOfLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OperatingLeasesNumberOfLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShorttermLeaseRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term leaser rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShorttermLeaseRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NewarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NewarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802435040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (184,594)<span></span>
</td>
<td class="num">$ (211,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,063<span></span>
</td>
<td class="nump">18,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization/accretion on investment securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,596)<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Non-cash rent expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,777<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs on convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of losses from equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,445)<span></span>
</td>
<td class="num">(8,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,374)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">6,351<span></span>
</td>
<td class="nump">12,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(137,350)<span></span>
</td>
<td class="num">(44,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,791)<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">472,578<span></span>
</td>
<td class="nump">19,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(252,628)<span></span>
</td>
<td class="num">(649,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities', window );">Cash paid for acquisition of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,084<span></span>
</td>
<td class="num">(632,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">299,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">116,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions', window );">Proceeds from early exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of commissions and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,219<span></span>
</td>
<td class="nump">343,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock and upon exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,960<span></span>
</td>
<td class="nump">771,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,694<span></span>
</td>
<td class="nump">93,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">93,731<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,425<span></span>
</td>
<td class="nump">93,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating, investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued on conversion of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">411,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued on conversion of convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">141,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ConvertiblePreferredStockIssuedInAssetAcquisition', window );">Series A-1 convertible preferred stock issued in asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition', window );">PP&amp;E and other assets acquired in asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,827<span></span>
</td>
<td class="nump">33,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,668<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs included in accounts payable and accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,563)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for amounts related to tenant improvement allowances from lessors</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,473<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ConvertiblePreferredStockIssuedInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series A-1 convertible preferred stock issued in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ConvertiblePreferredStockIssuedInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Early Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant &amp; equipment and other assets acquired in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801985168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6796927968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 10, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Nov. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 299,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePurchasePriceSharesValue', window );">Aggregate purchase price, shares value</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable', window );">Subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ModificationOfConvertiblePreferredStockForCommonStock', window );">Modified shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Compensation cost resulting from the modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of convertible preferred stock converted to shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember', window );">Series A1 Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">3,187,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">998,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="nump">$ 35.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 34,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">7,557,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="nump">$ 35.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 264,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePurchasePriceSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Purchase Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePurchasePriceSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ModificationOfConvertiblePreferredStockForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modification of convertible preferred stock for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ModificationOfConvertiblePreferredStockForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate monetary value of a new issue of securities which have been allocated to investors to buy. When security is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the security to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=allo_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782513840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss and Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Basic and Diluted</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184,594)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,505)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,061,149&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,948,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,249,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.83)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.31)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period From November 30, 2017 (Inception) to December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,235,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder shares subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,629,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,687,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,992,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,948,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,087,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782969152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock', window );">Schedule of Fair Value of Assets Acquired</a></td>
<td class="text">The following table summarizes the fair value of assets acquired (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:86.286%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development (IPR&amp;D):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-CD19 CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-BCMA CAR T cell therapy</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assembled workforce</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Assets Acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ScheduleOfFairValueOfAssetsAcquiredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6783395504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders&#8217; Equity</a></td>
<td class="text">Convertible Preferred Stock and Stockholders&#8217; Equity<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note&#160;6, the Company issued 3,187,772 shares of its Series&#160;A-1 convertible preferred stock to Pfizer in connection with the Pfizer Agreement entered into in April 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company issued 7,557,990 shares of its Series&#160;A convertible preferred stock at a price per share of $35.06 for net cash proceeds of $264.4 million and issued 998,225 shares of Series&#160;A-1 convertible preferred stock at a price per share of $35.06 for net cash proceeds of $34.9 million. Fifty percent of the aggregate purchase price of $300.0 million was paid in April 2018. The remaining subscriptions receivable of $150.0 million was received in July and August 2018, at the election of the Company&#8217;s board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the completion of the IPO (see Note 1), all outstanding shares of convertible preferred stock were automatically converted into 61,655,922 shares of common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of 10,000,000&#160;shares of preferred stock, of which no shares were issued and outstanding at December&#160;31, 2019 and 2018.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of 200,000,000&#160;shares of common stock, of which 124,267,358 and 121,482,671 shares were issued and outstanding at December&#160;31, 2019 and 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Company&#8217;s Series A convertible preferred stock in April 2018, the Company&#8217;s founders agreed to modify their common shares outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 26,249,993 modified shares of common stock became compensatory upon such modification. The total compensation cost resulting from the modification is approximately $59.5 million and is being recognized over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4OTk_9cc142d9-55cb-4a93-93b8-502c7e750f35">four</span> year vesting term.</span></div>Common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors subject to the prior rights of the preferred stockholders. As of December&#160;31, 2019 and 2018, no dividends on common stock had been declared by the Company&#8217;s board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790566480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2019 are presented in the following table:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">535,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2018 are presented in the following table:</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:49.248%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial Paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(280)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(320)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">366,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents, and investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of available-for-sale debt investments by contractual maturity as of&#160;December&#160;31, 2019&#160;and 2018 were as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:63.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.812%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.815%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 - 2 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 3 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments not due at a single maturity date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">714,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018,&#160;the remaining contractual maturities of available-for-sale securities were less than two years and three years, respectively. There have been no significant realized losses on available-for-sale securities for the years ended December&#160;31, 2019 and 2018. Based on the Company's review of its available-for-sale securities, the Company believes it had&#160;no&#160;other-than-temporary impairments on these securities as of&#160;December&#160;31, 2019 and 2018, because the Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the years ended&#160;December&#160;31, 2019 and 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790627568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $5.1 million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $1.0 million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $23.2 million and $24.6 million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $30.9 million and $26.3 million, respectively, on the balance sheet. The remaining lease term is 9 years and 2 months, and the estimated incremental borrowing rate is 8.0%.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $0.2 million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $5.9 million and $6.2 million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $6.2 million and $6.3 million, respectively, on the balance sheet. The remaining lease term is 9 years and 2 months, and the estimated incremental borrowing rate is 8.0%.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into two operating leases for office space in New York and Los Angeles for approximately 4,358 and 1,293 square feet respectively. The Company recognized operating lease right-of-use assets of $1.7 million and $2.0 million for New York and $0.1 million and $0.2 million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The Company recognized aggregate lease liabilities of $1.7 million and $2.0 million for New York and $0.2 million and $0.2 million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The lease term for the New York operating lease is 6 years and 7 months, with no option for renewal. The lease term for the Los Angeles operating lease is 3 years with an option to extend the lease term for another 2 years which is not reasonably assured of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintained a letter of credit for the benefit of the landlord in the amount of $0.1 million. The remaining lease terms were 5 years and 6 months for New York and 1 year and 11 months for Los Angeles at December&#160;31, 2019 and the estimated incremental borrowing rates applied were 8.0% and 7.5%, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. Upon certain conditions, the Company has two <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNjc_5253a5b3-7a0c-4331-8539-db7f2e8159f7">ten</span>-year options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company will maintain a letter of credit for the benefit of the landlord in the amount of $3.0 million. The Company started accounting for this lease in October 2019 when tenant improvement work commenced, and recognized an operating lease right-of-use asset of $13.6 million as of December 31, 2019 and an aggregate lease liability of $14.0 million on its balance sheet. The lease term is 188 months, and the estimated incremental borrowing rate is 9.25%. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future non-cancellable lease payments under our operating leases as of December&#160;31, 2019 is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:84.032%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,920)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the Company&#8217;s operating leases was $5.9 million and $1.9 million for the years ended December&#160;31, 2019 and 2018, respectively, net of lease incentives recognized. Rent expense for short-term leases was $2.4 million and $2.6 million for the years ended December&#160;31, 2019 and 2018, respectively. There was a total commitment of zero and $1.6 million at December&#160;31, 2019 and 2018, respectively, related to short-term leases. Variable lease payments for operating expenses were $1.1 million and immaterial for the years ended December&#160;31, 2019 and 2018, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain lease agreements require the Company to return designated areas of leased space to its original condition upon termination of the lease agreement. At the inception of such leases, the Company records an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. To determine the fair value of the obligation, we estimate the cost for a third-party to perform the restoration work. In subsequent periods, for each asset retirement obligation, the Company records interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Asset retirement obligations were $0.4 million and zero as of December&#160;31, 2019 and 2018 respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6790599488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company recorded income tax benefit due to the intraperiod tax allocation of deferred income taxes on unrealized gains on available for sale securities recorded in other comprehensive income. The Company has incurred net operating losses for all the periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(89)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(332)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(331)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reconciliation of the benefit for income taxes calculated at the statutory rate to our benefit for income taxes is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,834)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,441)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,951)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,652)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,714)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-off of in-process R&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,247&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for incomes taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(331)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,437&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(531)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use leased assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,453)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,239)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(393)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,888)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(91,904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,916)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.&#160;&#160;Due to the lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $50.0 million and $41.9 million during the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our federal and state NOL carryforwards and federal research and development tax credits as of December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2037</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating losses, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2037-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2038-2039 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits, state</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Indefinite </span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax credit carryforwards may be limited as a result of such ownership changes. Such a limitation could result in the expiration of carryforwards before they are utilized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income.&#160;&#160;An exception is provided in ASC 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year.&#160;&#160;In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets.&#160;&#160;In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale investments recorded as a component of other comprehensive </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets.&#160;&#160;For the years ended December&#160;31, 2019 and 2018, the Company recorded a tax benefit of $0.3 million and $0.1 million, respectively, in other comprehensive income, related to available-for-sale securities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply the provisions of ASC Topic 740 to account for uncertain income tax positions.&#160;&#160;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.894%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of the year:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to tax position of prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions to tax position of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lapse of the applicable statute of limitations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as a component of interest and other income, net, as necessary.&#160;As of December&#160;31, 2019 and 2018, there were no accrued interest and penalties related to uncertain tax positions.&#160;The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.&#160;Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business.&#160;&#160;We are subject to examination by U.S. federal or state tax authorities for all years since inception.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802157392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Offering Costs</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Offering costs, including legal, accounting and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO. Upon the completion of the IPO in October 2018, $3.2 million of deferred offering costs were reclassified to additional paid in capital. Offering costs, including legal, accounting and filing fees related to the ATM offerings were incurred. Upon the issuance and sale of common stock in ATM offerings in November 2019, $0.5 million of deferred offering costs were reclassified to additional paid in capital. There were no deferred offering costs capitalized as of December&#160;31, 2019 and 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit and other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit and other Risks and Uncertainties</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has issued letters of credit under separate lease agreements which have been collateralized by restricted cash. This cash is classified as long-term restricted cash on the accompanying balance sheet based on the terms of the underlying leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as current.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest and other income, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three to seven years. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in other expense.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has determined the estimated life of assets to be as follows:</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:68.717%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:27.283%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and purchased software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 - 5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixtures and furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Update (ASU) No. 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> on January 1, 2018. For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments and Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company's proportionate share of the net income or loss of these companies is included in other expenses in the statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For entities in which the Company has variable interests, the Company focuses on identifying if one of the entities is the primary beneficiary through having the power to direct the activities that most significantly impact the variable interest entity&#8217;s economic performance and having the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company&#8217;s financial statements. For the year ended December 31, 2019, the Company did not consolidate any variable interest entities because the Company determined that it was not the primary beneficiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Research and Development Costs</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records accrued liabilities for estimated costs of research and development activities conducted by collaboration partners and third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities on the balance sheets and within research and development expenses on the statements of operations and comprehensive loss.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its collaboration partners and third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs </span></div>become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures its stock-based awards granted to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense&#160;is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as&#160;they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss. For the years ended December&#160;31, 2019 and 2018 this was comprised of unrealized gains and losses, net of tax, on the Company&#8217;s investments. For the period from November 30, 2017 (inception) to December 31, 2017, comprehensive net loss was equal to net loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock', window );">Definite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Definite-Lived Intangible Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifiable intangible assets consist of in-process research and development and workforce associated with the Pfizer asset acquisition. Intangible assets with finite lives are amortized over their estimated useful lives on a straight-line basis, generally two years. Acquired in-process research and development intangible assets with no alternative future use are charged to research and development expense when acquired. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible assets. Intangible assets are carried at cost less accumulated amortization. Amortization of intangible assets is included in research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were impairment losses related to equipment disposals of $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development expenses also include costs incurred for internal and sponsored collaborative research and development activities. Costs associated with co-development activities performed under the various license and collaboration agreements are included in research and development expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses for the year ended December 31, 2018 primarily consisted of acquired intangible assets pursuant to the Asset Contribution Agreement with Pfizer (see Note 6) as, at the time of acquisition of the asset, the technology was under development, was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing, had not reached technical feasibility, or otherwise had no foreseeable alternative future use. For the year ended December 31, 2018, the Company recognized expense of $109.4&#160;million related to the acquired intangible in-process research and development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedResearchAndDevelopmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Definite-Lived Intangible Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining compensation cost for share-based payments by either estimating number of forfeitures expected to occur or by recognizing effect of forfeitures when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4549-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>301</ContextCount>
  <ElementCount>476</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Recent Accounting Guidance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RecentAccountingGuidance</Role>
      <ShortName>Recent Accounting Guidance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Convertible Notes Payable (2018 Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://allogene.com/role/ConvertibleNotesPayable2018Notes</Role>
      <ShortName>Convertible Notes Payable (2018 Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2138112 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2140113 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2148114 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2150115 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2152116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2160117 - Disclosure - Net Loss and Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossandNetLossPerShare</Role>
      <ShortName>Net Loss and Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2164118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2166119 - Disclosure - Selected Quarterly Financial Data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited</Role>
      <ShortName>Selected Quarterly Financial Data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/InvestmentTables</Role>
      <ShortName>Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/Investments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetComponents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/AssetAcquisitionTables</Role>
      <ShortName>Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/AssetAcquisition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2353308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2361309 - Disclosure - Net Loss and Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossandNetLossPerShareTables</Role>
      <ShortName>Net Loss and Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossandNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2367310 - Disclosure - Selected Quarterly Financial Data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/SelectedQuarterlyFinancialDataunaudited</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofEstimatedLifeofAssetsDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Estimated Life of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/InvestmentsScheduleofFairValuesofAvailableForSaleDebtInvestmentsbyContractualMaturityDetail</Role>
      <ShortName>Investments - Schedule of Fair Values of Available For Sale Debt Investments by Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Investment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/InvestmentAdditionalInformationDetails</Role>
      <ShortName>Investment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Asset Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/AssetAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Asset Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/AssetAcquisitionScheduleofFairValueofAssetsAcquiredDetails</Role>
      <ShortName>Asset Acquisition - Schedule of Fair Value of Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseandCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestmentDetails</Role>
      <ShortName>Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/EquityMethodInvestment</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Convertible Notes Payable (2018 Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails</Role>
      <ShortName>Convertible Notes Payable (2018 Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/ConvertibleNotesPayable2018Notes</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/ConvertiblePreferredStockandStockholdersDeficitDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/ConvertiblePreferredStockandStockholdersEquity</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationSummaryofStockOptionActivityUnderPlanDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity Under Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/A401kPlan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesSummaryofValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Summary of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsandTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Operating Loss Carryforwards and Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossandNetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss and Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossandNetLossPerShareScheduleofAntidilutiveSharesDetails</Role>
      <ShortName>Net Loss and Net Loss Per Share - Schedule of Anti-dilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2465437 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Selected Quarterly Financial Data (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/SelectedQuarterlyFinancialDataunauditedTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="allo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - allo-20191231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - allo-20191231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="allo-20191231.htm">allo-20191231.htm</File>
    <File>allo-20191231.xsd</File>
    <File>allo-20191231_cal.xml</File>
    <File>allo-20191231_def.xml</File>
    <File>allo-20191231_lab.xml</File>
    <File>allo-20191231_pre.xml</File>
    <File>allo-20191231xex1011.htm</File>
    <File>allo-20191231xex1015.htm</File>
    <File>allo-20191231xex231.htm</File>
    <File>allo-20191231xex311.htm</File>
    <File>allo-20191231xex312.htm</File>
    <File>allo-20191231xex321.htm</File>
    <File>allo-20191231xex322.htm</File>
    <File>allo-20191231xex43.htm</File>
    <File>allo-2019x1231xex107.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>allo-20191231_g1.jpg</File>
    <File>allo-20191231_g10.jpg</File>
    <File>allo-20191231_g11.jpg</File>
    <File>allo-20191231_g12.jpg</File>
    <File>allo-20191231_g13.jpg</File>
    <File>allo-20191231_g14.jpg</File>
    <File>allo-20191231_g15.jpg</File>
    <File>allo-20191231_g2.jpg</File>
    <File>allo-20191231_g3.jpg</File>
    <File>allo-20191231_g4.jpg</File>
    <File>allo-20191231_g5.jpg</File>
    <File>allo-20191231_g6.jpg</File>
    <File>allo-20191231_g7.jpg</File>
    <File>allo-20191231_g8.jpg</File>
    <File>allo-20191231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>allo-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:allo="http://allogene.com/20191231"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="allo-20191231.xsd" xlink:type="simple"/>
    <context id="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie0e078145b0b454b877975418673c149_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i1dcf05e5d867446b9e2cc22d8448cf5a_I20200224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-02-24</instant>
        </period>
    </context>
    <context id="i97a7d47bd645462aa3e6c38d02dd4202_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i539b2ae7956d4b19badf4d751d50af35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i931fe0adef2547279e3d242f0f22774d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i595cd53e82494828a29af14a1c81baba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i99decb5567534b8497dffa86e0b1023e_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="i3201ab4ab1724c7ea1125d924e0873ff_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="i84465143443f4cf0ad45c2485bf6f687_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="i450d417e37254e0ab2024cc5cdb97eeb_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="icbe813e0d64c4e969856a6e3723ab181_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="i4ed9b242005d4eda9f7a3d5117e787a4_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="ia97c507021ed4124b41826a307eef5b4_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="ic178392ea1bb4a2d8265ba3c454059e5_I20171129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2017-11-29</instant>
        </period>
    </context>
    <context id="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5a7717940ad443ac959da4945a7df7df_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8da636562f1e4692894fbc13c7c7b15c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9a3039ba156d4b1da1b438ddb91e2eda_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i371f0794baf348b8a900545a9f712728_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idd581e624e4c4c0ca42cf1cf3eaa1f3f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3c398c33948642ec8719c3f9f261004c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if7f0568066a04dd08c00592b4c8dbb52_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idfdd74767fd7438889e77589cf703193_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib660932f6bce4ad6b6fba62272a8c8a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if03e9aad02914725a696c4b00ae00db6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i824f05079e344862807f10de3ec47704_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia34e8122e6b44424adfde751afcccc0f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i57ba1414023a4bb6a54a2fe2c91369ac_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia0e44d1416c24d019f4334743e7793bf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i894cb9f424d847fd87d8fcba20ed1e12_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iee1bc4e91f584f8a829f502e3581da80_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib6bc6daa75634ee18f23d67b4d5b10be_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3d942c4c69d247dc94894cc3832f4f13_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia6f4099adde245d9a792f996de017db7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4504b4d5097a4954858c46286aa5dba4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdef23c610c643cd98f536491957b5ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd1910421c5c43d585972f790a229f83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionsReceivablesFromPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8800095a2bb4f63b85032f31ca50e7f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea539b4757a94514a3201e3bef9d08e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07b75e8befc040d38153c0e4e0ed8a06_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i56d6273dcf9f4ca4b6c7f19445ea045d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i658fd51e478545beb0ee00eed9c4872f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e5eb452c8e54cac836b9b606a34f81f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6751f2efa70949c0876a6a519a946ac1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ic3f77038b1af4fb8b9344a23d6e30de4_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i9d13410d6cb941fda6060aa13739c84b_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i5ba5824b8755458399cf44363881b72a_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="iee39b6265afd4c15bb48df2ab24035ac_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i08444efecc9e4a61b85b99875e786078_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i821e501b07404b9a9c7d2c5ca11840c7_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ic58cfdcb98b24158bdd7223f565fcd2b_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ic88cc8410c2e4057a11268c203ce1002_D20171130-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b21a198f1184844a973ffb0f8eb7de1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31559d28138348d0ab6ce2d61e8edf3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iccc4fa5d70e04dcaa95ad41bc1ee441d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93e5135b941044599698b944919b6e62_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i972ed925cd2646a487bc5bf253f44bf6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i216ca2a8a747453282fe3a3a74e6cdbf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1dddefdb7f0347409c74598e8d7213a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad4580516611428ea09e371d04ecdcf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41321b51b20b4ec3807a67d0a72c0075_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1f9280b34fd4edca10d8753f9795f1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b5d88729cac494eb409276d41aad939_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i910ae198636f445ab767fe7a98e42da1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10fdb61401b746fca53090e64340f864_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf7a233f74f545049d9e8aa6b0476dc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaec915df35d44a74a0e37fe81e953ea8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06c178fec4d743b7a556aec06c2f821d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic91027a1351f40f6a6ce39d721284794_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab948e17826146478ea922d2d145b16a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied8402dc6dc845bc9113f9d66ed86178_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25faef9ff3c64269b6c008b1dc92e476_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86abab37a4774a968808425797205a1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic67152294c6942b9ba899ab8f21e9ab8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0968abaaa5f7440c8eff4d639ac876db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i689d4094b8024bcc8d34927e5f90f7c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0364d3024ca74ee5b4ea651c2620ca3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb123eb6e34d4fb79ca3d24126047e63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9990cf0b9413469cae5b763d89e229c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i413973bdc4c8478484b252834be4455d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d00b3947da248a9aa0a662b95549a62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i131f8341b44741a8be5ad09784c38587_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6af031995e6847efaf03df708bb7eb62_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if29d551d20ae4eb8962e30ebfd31ed44_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibeaa87c3871d4b7494311fa64fdb63ec_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd83064e20c54412994b903a9de5ffd4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if9a0862545c944c7970f75cf79d47b8d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibdeb525a74b740d4b778fb321271ccce_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia306dfbbd94f4a72aa4930728fb27045_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i769efc364d1b49ad9f1e5c3e1e33a712_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i985e7490d1a549e8a0feb30d7a02d3b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2f6a1cfe504a41018e8e5e0de30f51d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40117c0bb4854d40a4fa2a481a673eec_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4d9f4a396a4241bda2a780ca2c70f3be_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14e9bfa620a94645901e0e79295a81c2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieea078f2b943446d87c87029de76019d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iae09226ae44c493cbda2c9500466d142_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1b4b10265f764f3ab736b5d47b1f9502_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic98c546ec02943d0a92444708d47ad3b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i576dbba691a54312ae4f7f7b9fa27f72_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2b15926b27844890b92923069fc998a2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c7eaa563c1f4ebc81ea162cae253d1e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3e6bcfc30bc543409ce74f21a01801ac_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7af350b1cafc4cd1a2cbfc361f70255a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i712f2cfe4d6b404ab9882f4089185418_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice5f2d0234854debb1249a5a134c8a88_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i92883258851343719809a457e47461f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0083451548d0466897483be2bafb4bd4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb4ea982fa834fa29129f07b46026122_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45fce8d0645e412d8345a84455d09beb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iedec35042c304a2d90f0918f919f1531_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec77988e07a84ed997297aea9582d919_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib5226dd8eae048d5930a130fdebafb8f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id62c57f1c9644743a2437ff300fafb50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8076cdf604b5489895933ef89fc34b2f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9f3ba3d3dc894efaacd3513306d920ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ebbf8f4f5bf4febac60e511f7aa4329_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib08b0bba7d634a958a96f0964cbad763_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3db3a0119c79483e94242db1f548282c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if5852e80f853444996e612e6a78b2caa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38b72e2f0d4e48588b008f53598ce7d2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5647d962561c44b8b5b291742b6f3eb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb2d346af52d45db8ca2a02108d6fb0a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if797f590c7f0479a9a697558f2de76e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23478e60d4914559b5221e0ebd4c4fa8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic080d00e479b47cb866477893266680a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6160b48a66c14241831dadcdf19fd045_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i109b33bc252c4867bdf458174acbbebf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib026706ac7b34638a5206f120c795fcf_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i983a7f491bc342188b274ebaacc4b537_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i418f7561acb7456a9cd8ab2b0b615390_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AntiCDNineteenCARTCellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="id4c667c41352411c9e3641748894a942_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AntiBCMACARTCellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ie103799a43e847da97be9090d9658fdb_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">allo:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="iec3f1d9861bc4aec8c55821fb2f64337_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i209e07dad467461eb9a9d4bec5f07fe7_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id04f9a07e6ef4653bc71b89352bc570b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if4c18293923046afb816ad6ab2d44ca8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7db1990140824815a537851541246079_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i506e30c449204baba23fb44c640ebef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6017f1fd2aeb4f5dae24a3f6a824c26d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9427490ef4a44d8f9b59d11282662b76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifff9430c2ddd4802ba7887cb075336c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NorthAmericaEuropeAsiaAustraliaAndOceaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61808ff845034c22af5a68f40821c91c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryAndSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c06fbacca5f491d8f5469bd4fb315fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75364e669b7b45f1a7aef2c29529fead_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9047b22f877746d385f33c4ed54f6267_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d0e971edbd54b578a622c44aadb4b6e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i026e57edd43d4beb8496539196c89a2a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b9afa63ed9142d29e23a8cc70154a6c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9165b13a059438f9d7dce0930c8b3e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0156b166fd0646f1a182d6801df909d7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9b1db0a202a4ae19712fb80c6cd0e22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i191222ceb5b4462cb69b763179a7d5b9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14f6805421204eae85b427c2f3c6052a_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i0d5aa740645543fbb3c41bb7edf9788d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="ibcc9be9dbd394b6582ca42b028bc5605_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3adabcdd37fd4a4c9feddc86618ac41d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46a7d0cfcf8146eb94cd73bc47ddd879_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icbf3d6643fd944bc90b9feba06c32cda_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="ic0412b597de74f279eae527af0469dbd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic595c56b5f7746d49d315a4a7cde38f2_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i7e9597cce0a04b50aacae109805022c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4a231e4e72e4029ac07d4f130b3076f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iab52ee2110ab4c6bbcf51aecc895a232_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd2210c6df794207907be5b74981ad04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i515685bbda6b4ca09271838cbbbc3a24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i490046a46cbd43ce9bd693d61995f8bd_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i54c6044221fa4585b6ea5a3c74e488dd_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ic80e95b53fb54d0e848be36d0b009f5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id582a2792aa240b5b2ce2ac625929e33_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i245b301a06c44689b7b0147fb93ad43b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie63f9c3516964c56af3104a004c46f95_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ia3471d8f101c4d3ba94220c7aad9494d_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i3f92a81d50e2447da3666732666bc702_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if780bd54cfd745968c9507e6e347e804_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="id87618dee4474bd9a48ad4abc969f130_I20181010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="i4cc5d09c4899434b82706706c931899c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2fe5e85d46bc42af97edd8a33aeb5fac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21acb7c55f624e3ebf064ece42649a1c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia43d81dd97134b1c840f4d8375d51b36_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i79699a85746047d8bd631f0242942e41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11a2bcc9c898478cbaded2c1853112a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i98539d3bf6db493eb4bac0723e6ee092_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i46b4456ea01b4461ba585909bac7d890_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i363161bd29bc4e10850ef908f85ad126_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4ffca6157071428084b3684ac927e28b_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3835f781ec444d7e9271140857371e43_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">allo:FoundersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1e27365619214bc59bfb299e39609936_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64b1551f5cd34b7ca95dd312bcae049d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:FoundersStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6af2cfd2ff1d4e4a9d19b9a090f83467_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ebdfee99c3d44bbba77e1538670e241_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf7d6e8325894802b105e402db61b959_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic335635d76f5410592d7071e11926b5d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5284d2ec96844b179d5bb270bb5844ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e4ee5f686274fdeb535ec2690bb50dc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa574b7418b34ab89121de3fef9eb09d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc3716dab85d4812af96ca87413ed4aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i223cbc3f897946fe81924d54346ad635_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b2d9a5130cd42b0ac8aa561c995521a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14d7dd8cae1641d99d20bd4d0c10c859_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice7bf540651747169b6723b0e5d61cc6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0990713fcec34063915c2606a9dbf9bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifac957e58b7a4baf9cebc33d2887fc43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9628aef98f7b416d9301a00cd797d731_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id0738f70da3241d28d73424c3601e393_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i29aea4b9db71497caa6c78fddc404f98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66c447add08d461688d873b914f5e8ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id80d84bc4ec941a3baa00789f4ab23e7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5c59ac91728042bdb034aae3cbf86b27_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaad7357554cc448cb7cdccb352b3f230_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f25012c47684987b5c8de4583d7013a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice6c8adf2175476b82e13eba7aa65e3b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2ed333deb19e4f8aa30fd212e8437454_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia54626e66f62444da7a1a1a1bd878fa1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b3b4b6820d34ffe8a18270f928c827b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TwoRiverConsultingLimitedLiabiltyCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i46512246cc53487190bb23e1f83b9f1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TwoRiverConsultingLimitedLiabiltyCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i937aa356e7d74904be670337e39f839f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iebe223e780a54b2e9611b6aa31c1b596_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic44e3cf19d214ae795601add9e69e7eb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">allo:AffiliatedWithPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TPGCapitalFOLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i22b5cfb3c05f4d6b822f58dea1aab477_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ice415ea64e2243bc968eb2884b47ca78_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="id14c29c033be4cfbb4eb48f42b7d40c5_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i3fdaf74dec9d4787bdf514649b2cd27f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b77ef1f61024c568c150dd64f256116_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia02a067e56bf46b385d84dbd3ece5417_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibb66cca6e6e14fb0b660ef62239b32cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie27792aefa4b465fa4c423f1df05599c_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ief267c01c710405abd30252861e3e24c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2b8b5580156846e28ce6eb93624129e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16c74cfa985346f494f9d5736c6a5fe4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7523fadedd6b4e51ab3614c36301ac25_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpiration2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib540aeb004f94ffc9bfe1a2e2bed3e89_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpiration2037To2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib08658a06a8a40aaa3b3aa34badf31cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:TaxExpirationYears2038To2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c2150c8f59c49ea84c39db5a3d27693_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">allo:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6c735ffeb0e4728ab0cf9f8a68323c0_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i1685cab5677b4214acd1e61778618c7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3db00b97645d4dfcb5199164cd300fd7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i07955f1bc4d842309fb7054451349500_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i98d07f8ad8e24589b9cd7e9093f0cdb3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96ced67d40264f25905f485ca894893f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e63cc94d1614433bc6dbbf8f222c887_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3b6803e703b349ab84305332583a3b58_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i68b6c63c353f4630aed12ad8c7160e52_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iff8a1d2d642b449f977d62cd68697248_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:ExpectedSharesPurchasedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8943b433f73e48b1b575b63c35b128bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id55c9b66b5bc4d93aaa9151719a26f75_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f3a4d9d806b414bbbbd1501a52e6766_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1b519b46465449bf8e62e676785a0c8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa11e1394d8e429a82692ed6d10cf29e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d1db84ffd5f434f9c56d87b4cbf3f69_D20171130-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="iccb7544972f64173a049364e08f1fd95_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="operatinglease">
        <measure>allo:operatingLease</measure>
    </unit>
    <unit id="option">
        <measure>allo:option</measure>
    </unit>
    <unit id="director">
        <measure>allo:director</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF81LTEtMS0xLTA_ac72a589-a913-456f-801b-62218fdf7d0c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF83LTEtMS0xLTA_142845e4-4605-4eef-858a-6937ae9f1543">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF84LTEtMS0xLTA_87c1c85b-3e57-42f9-9784-ffa3f8a77fd3">0001737287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF8xMS0xLTEtMS0w_fd8fb21d-6bf9-49b9-a676-9e495acda43f">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV80L2ZyYWc6Y2YxY2IzODhiZGIxNDA2MjhiMjc4YjMwYjdlZTIwZWIvdGFibGU6ZDUxYTU3MzYxNTYzNGE0NjhhN2MzMzFlNGJiZmRiMTQvdGFibGVyYW5nZTpkNTFhNTczNjE1NjM0YTQ2OGE3YzMzMWU0YmJmZGIxNF8xMi0xLTEtMS0w_22ff7cc8-b77a-41af-a31e-22ef66b12497">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNi0xLTEtMS0w_45e7abc9-7d60-4b33-82e7-996db9cc09e0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNi0yLTEtMS0w_cbd2b812-98c5-474a-b9f4-a0e96d810e2a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNy0xLTEtMS0w_b120d0c9-dc21-4fc9-88df-e6482286007b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfNy0yLTEtMS0w_dc071f7c-f920-49f7-8cad-f0ad171317d2"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfOC0xLTEtMS0w_78891475-a5c5-4758-8fe5-bacaf02839a3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMi0xLTEtNzIw_257b74d1-0d48-4f3c-8abf-8f84a68f51bd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfOS0xLTEtMS0w_138b50ff-d666-469c-80a3-67d003a455bf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMi0xLTEtNzIw_566d5275-e932-4bc4-aeb0-15da0154f974"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMS0xLTEtMA_d6037c66-676c-446c-b58e-e5ce13f66732"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTAtMi0xLTEtMA_055900d5-f83b-4d50-b913-f3003e14bea8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMS0xLTEtMA_8a4c529a-dfd2-4848-a27c-2d29592cc8f8"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTEtMi0xLTEtMA_5f9201c9-692a-4751-99c7-5bb1292ecf36"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTItMS0xLTEtMA_97043e75-555e-4fba-816e-1e15d1cbc891"
      unitRef="shares">124267358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTItMi0xLTEtMA_40738fe7-9d0a-4e3b-9b80-c5ed8908674c"
      unitRef="shares">121482671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTMtMS0xLTEtMA_b7a6d94c-acab-4afa-ab62-d938a4d8623d"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84OC9mcmFnOmRhOWJjMmVhZmQxMzRkNGRiZWUzNjk5YTNlMjlhN2ViL3RhYmxlOmYwMzk0ZmZiOTYzMTQzNmE5YjkzOWEwZTNlY2ZlZmFiL3RhYmxlcmFuZ2U6ZjAzOTRmZmI5NjMxNDM2YTliOTM5YTBlM2VjZmVmYWJfMTMtMi0xLTEtMA_5ff2218c-a667-4d65-9810-ff93435801b9"
      unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1e5eb452c8e54cac836b9b606a34f81f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzMtMS0xLTEtMA_ed1d41bc-93da-42e8-92f2-edee1b8c571b"
      unitRef="usdPerShare">35.06</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6751f2efa70949c0876a6a519a946ac1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzQtMS0xLTEtMA_aeba6397-66e7-4f19-af1d-1a42a290a91c"
      unitRef="usd">84000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzYtMS0xLTEtMA_2f090002-dfd5-4dd3-8618-8e5a81aa430c"
      unitRef="usd">29272000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzctMS0xLTEtMTk2Ng_c91b9f8c-8d89-4f15-be78-3adc21eca32f"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzgtMS0xLTEtMA_6c470ed1-38b3-4b75-8059-b0f8ba69618d"
      unitRef="usdPerShare">35.06</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDAvZnJhZzo0OWE4MjViZDFjYmY0MzRiOGJlNmQ3OWQ2OWQ1MGRhNC90YWJsZTo5NzM5N2JjZjQ0MGI0NTI3OTE3YzIwMWIzNDk0N2E3ZC90YWJsZXJhbmdlOjk3Mzk3YmNmNDQwYjQ1Mjc5MTdjMjAxYjM0OTQ3YTdkXzktMS0xLTEtMA_f5028d53-10f5-4555-874e-2947fccd3a67"
      unitRef="usd">635000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i93e5135b941044599698b944919b6e62_D20181001-20181001"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTo0ZTQ0NmY1MjUxZWU0NzYyODI4MTQzZTA2NzY3YTM1Yy90YWJsZXJhbmdlOjRlNDQ2ZjUyNTFlZTQ3NjI4MjgxNDNlMDY3NjdhMzVjXzEtMS0xLTEtMA_8a844092-8055-4182-a08d-8bbf7d8615d0"
      unitRef="number">0.1905</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i972ed925cd2646a487bc5bf253f44bf6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTowZjNmZTMxOGFlNTg0YTc5OGRjMGJjZmUzOTZjNjVjOS90YWJsZXJhbmdlOjBmM2ZlMzE4YWU1ODRhNzk4ZGMwYmNmZTM5NmM2NWM5XzEtMS0xLTEtMA_b99586a5-78d0-48dd-a6fb-d2c3dc5d5243">P3Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i216ca2a8a747453282fe3a3a74e6cdbf_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTIvZnJhZzo3MTJhYjZjOGZmYjc0ODM1OTE4YjFjNWUxY2YyZmVlYi90YWJsZTowZjNmZTMxOGFlNTg0YTc5OGRjMGJjZmUzOTZjNjVjOS90YWJsZXJhbmdlOjBmM2ZlMzE4YWU1ODRhNzk4ZGMwYmNmZTM5NmM2NWM5XzItMS0xLTEtMA_117543c9-bad1-4446-8055-7fdd28bdc818">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNjc_5253a5b3-7a0c-4331-8539-db7f2e8159f7">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4OTk_9cc142d9-55cb-4a93-93b8-502c7e750f35">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzEwODk_5e3a8163-9ab6-4322-bca2-e60302945177">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc1MzQ_e0c6a459-876a-4698-840d-09c9bbd3a86c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i223cbc3f897946fe81924d54346ad635_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItMS0xLTEtMA_bd7c31ce-9032-4a0c-8c7c-232fa47e8ed1"
      unitRef="usdPerShare">25.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i1b2d9a5130cd42b0ac8aa561c995521a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItMi0xLTEtMA_b3715242-7c32-49b1-bebb-d7949617fd09"
      unitRef="usdPerShare">31.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i14d7dd8cae1641d99d20bd4d0c10c859_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItNS0xLTEtMTAyMjg_a156e747-70a0-41cd-bd29-1b2e4c0d3c74"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ice7bf540651747169b6723b0e5d61cc6_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzItNi0xLTEtMTAyMjg_29ae867e-5223-4b29-95fc-5b1e9cf5f441"
      unitRef="usdPerShare">26.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0990713fcec34063915c2606a9dbf9bc_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtMS0xLTEtMA_21cf0a1c-99f8-4a38-b3e5-dff0c3a61d70">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifac957e58b7a4baf9cebc33d2887fc43_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtMi0xLTEtMA_a0dec98c-0fc8-49bf-b2fb-bef51018c376">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9628aef98f7b416d9301a00cd797d731_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtNS0xLTEtMTAyMjg_4af24fad-ba8f-4196-a45a-a97adf6597a0">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id0738f70da3241d28d73424c3601e393_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzMtNi0xLTEtMTAyMjg_d7a2abb0-d4d8-468c-85b9-434548cef5a2">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtMS0xLTEtMA_27544abe-3c4d-4a7a-8fa1-a3447eac5c91"
      unitRef="number">0.7414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtMi0xLTEtMA_0714918f-cc69-4480-a255-4bb8312cc1c2"
      unitRef="number">0.7492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtNS0xLTEtMTAyMjg_fb702665-86d6-4488-a353-c082bb2ab65f"
      unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzQtNi0xLTEtMTAyMjg_4fb776ed-6b74-4c63-ac1d-4c85a4d8d217"
      unitRef="number">0.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtMS0xLTEtMA_be7c1522-7859-44e6-a33d-cab2166aa58a"
      unitRef="number">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtMi0xLTEtMA_9befaf36-86f8-43aa-932e-b951264c5743"
      unitRef="number">0.0262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtNS0xLTEtMTAyMjg_867c911d-5773-4e0d-8ce9-eafee40f1ce0"
      unitRef="number">0.0274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZTo4NTBmZTQwMTQ5OTQ0NjZmYTRiYzBmMTE5N2FlZjI2OC90YWJsZXJhbmdlOjg1MGZlNDAxNDk5NDQ2NmZhNGJjMGYxMTk3YWVmMjY4XzUtNi0xLTEtMTAyMjg_960160c8-ef11-4ffd-b767-4fb05d441ad6"
      unitRef="number">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i29aea4b9db71497caa6c78fddc404f98_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItMS0xLTEtMA_427f7da5-0ec5-461b-a2bf-e5a68b7211da">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i66c447add08d461688d873b914f5e8ca_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItMi0xLTEtMA_5e3eee10-77fa-4207-98e9-135d3ad08b98">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id80d84bc4ec941a3baa00789f4ab23e7_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItNS0xLTEtMTAyODg_7cf12ebc-9249-424a-b764-8dde322d2924">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5c59ac91728042bdb034aae3cbf86b27_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzItNi0xLTEtMTAyODg_db205efc-00a4-4c34-acd9-bdda75187efa">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtMS0xLTEtMA_f840a0d6-a43b-46f6-b16e-c916090cf0d4"
      unitRef="number">0.604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtMi0xLTEtMA_f3b533ac-1bdb-4b2a-a4cb-299ef2108fac"
      unitRef="number">0.760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtNS0xLTEtMTAyODg_7b01fac8-931e-4ba7-bfb7-ef9a53f9c89b"
      unitRef="number">0.677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzMtNi0xLTEtMTAyODg_44391cba-ee3c-4a82-85ea-0232dd1657c1"
      unitRef="number">0.818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtMS0xLTEtMA_4fecf541-24fb-4b8e-a558-b488430736f6"
      unitRef="number">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtMi0xLTEtMA_eadb9367-60d3-48a1-b315-1cf7c2371b65"
      unitRef="number">0.0249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtNS0xLTEtMTAyODg_69a47521-e0f5-4a38-9ccd-323b474f9985"
      unitRef="number">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTEvZnJhZzoxOGM4YWNmMWEyNTc0NTE4ODIzODkzNDkyNGIzMjBhMi90YWJsZToxOTNjNjViN2FlNjQ0ZDhlOWU1NTk0MDFmNjViNjFiYi90YWJsZXJhbmdlOjE5M2M2NWI3YWU2NDRkOGU5ZTU1OTQwMWY2NWI2MWJiXzQtNi0xLTEtMTAyODg_9a3b14a0-0179-4833-ba40-8a58a6c62c61"
      unitRef="number">0.0283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMxNTY_6ef0bf0c-3a55-4439-89b6-05ebb3b69460">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentType
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjU1_cfbd0ac3-38d6-47a8-b156-d15733f9a9e0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MTY0_b54502f0-75da-4a60-aa3b-75ce1db11eb8">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjE0_c053d8fa-fb76-46b6-a8ff-8bfdd30bfe6d">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjI4_1d733f97-bf63-4891-acb9-32f6378a5ee5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mjc1_75a598ee-44ba-4960-9124-96edac476751">001-38693</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMw_504e4414-687c-4638-aeb8-4cca20f14c8c">Allogene Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NzEwNzNhNzFkMTI0NDhiM2E4NzcwMjIzMmM0N2M4NjEvdGFibGVyYW5nZTo3MTA3M2E3MWQxMjQ0OGIzYTg3NzAyMjMyYzQ3Yzg2MV8wLTAtMS0xLTQwMQ_2ae2d076-b3b5-405d-996d-dfab807220b7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NzEwNzNhNzFkMTI0NDhiM2E4NzcwMjIzMmM0N2M4NjEvdGFibGVyYW5nZTo3MTA3M2E3MWQxMjQ0OGIzYTg3NzAyMjMyYzQ3Yzg2MV8wLTItMS0xLTQwMg_b411bbcc-0dd6-4732-87f2-12aac529af9e">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMy_917f487c-c565-4346-9d51-a04d80dae988">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjMz_9322996f-e272-4cd4-8419-131b661ca76d">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM0_d5474a9f-c449-441b-96b5-c0475a442cbe">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM1_e08e9eff-51b1-48fc-8999-9532937777ed">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM2_bac5a09b-aeec-4eef-a39e-77d4300fc609">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjM3_aa921ee0-63cc-4b8f-890b-3c7aae51a52f">457-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTAtMS0xLTQyMg_b136a1f5-7269-490f-b651-60481cf167e7">Common Stock, Par Value $0.001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTItMS0xLTkzMDc_0bea2b33-d74f-4dbc-9c3b-7f4c00c8eaa1">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6ZjVkOGMwZTQ0NDU1NDQ5ZDhmNTkzMmQ1OTQ4ZTdkZmUvdGFibGVyYW5nZTpmNWQ4YzBlNDQ0NTU0NDlkOGY1OTMyZDU5NDhlN2RmZV8xLTItMS0xLTQyNQ_36977ecf-4304-4f80-b725-71f5fde9d1ae">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF82NTk3MDY5NzcxMTEy_5fe0bae9-95e2-47a0-8538-8b12a6f2928f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc0_a6b9c9c9-c3c9-49e3-8fd2-95331ce11752">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc3_1e99a1eb-c45a-4cd1-b266-110b1b5a277e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5Mzc5_010a33e2-afd4-4c46-9e49-a0312539c983">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8wLTAtMS0xLTQ0MA_35f5a23f-5cdb-421a-b89a-50eab700fcc1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8xLTQtMS0xLTQ0Mg_7bc3454b-0115-416e-a875-296a0ed414be">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGFibGU6NWJhODRhMWRkMzRjNDRhMzk0ZjJmNGIwMmY2NTAzNTIvdGFibGVyYW5nZTo1YmE4NGExZGQzNGM0NGEzOTRmMmY0YjAyZjY1MDM1Ml8yLTQtMS0xLTQ0Mw_a41f757f-62ea-452b-872e-3b0f811cd0a8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjQz_dbef3b43-a145-4e17-8945-aba8722e1472">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie0e078145b0b454b877975418673c149_I20190628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzMxNzI0_1fcba438-b8a5-430c-8a93-061832a374ba"
      unitRef="usd">1601000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1dcf05e5d867446b9e2cc22d8448cf5a_I20200224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF83Njk2NTgxNDAxMjIx_a5cc4695-567a-4910-9a0b-6c547177545c"
      unitRef="shares">124906945</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xL2ZyYWc6YTk2MzI3YTM3ZjdlNDVlOGJiODgwMzY3ZDM3MDFiNDQvdGV4dHJlZ2lvbjphOTYzMjdhMzdmN2U0NWU4YmI4ODAzNjdkMzcwMWI0NF80OTQ3ODAyMzI5MjQ1_c91ae39f-483c-4046-851e-7acf8a3ec787">Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#x2019;s fiscal&#160;year ended December&#160;31, 2019, are incorporated by reference into Part&#160;III of this Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV81NS9mcmFnOjJiOGI1OTdhZjI5YjQxOTY5ZDNiMGQ0MjY0OTAxOTgxL3RleHRyZWdpb246MmI4YjU5N2FmMjliNDE5NjlkM2IwZDQyNjQ5MDE5ODFfMzg0ODI5MDcxNDA2Nw_9022b838-e7d1-4b8c-9008-dbd2d0bdffab"
      unitRef="usd">120200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV81NS9mcmFnOjJiOGI1OTdhZjI5YjQxOTY5ZDNiMGQ0MjY0OTAxOTgxL3RleHRyZWdpb246MmI4YjU5N2FmMjliNDE5NjlkM2IwZDQyNjQ5MDE5ODFfMzg0ODI5MDcxNDA4Mw_fefa648b-fb02-4290-ac22-651f795c6d63"
      unitRef="usd">116800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMy0xLTEtMS0w_d4d68e5b-0205-41a7-abbc-b397ca3692dc"
      unitRef="usd">175126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMy0zLTEtMS0w_3e123dc3-0676-4d16-b8fc-41337405f9b6"
      unitRef="usd">92432000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNC0xLTEtMS0w_523ee80f-ab1f-48a5-a9f3-bc186268a6ad"
      unitRef="usd">355407000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNC0zLTEtMS0w_70914674-35b3-4e8a-9891-f836785fae0f"
      unitRef="usd">366952000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNS0xLTEtMS0w_4f7a2b6e-4d10-4af3-9c56-6a8cf9582127"
      unitRef="usd">14043000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNS0zLTEtMS0w_52918415-903a-4d70-99bf-20a9edab9471"
      unitRef="usd">8598000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNi0xLTEtMS0w_066ce9da-c71a-463e-a81d-ed6635540ac5"
      unitRef="usd">544576000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNi0zLTEtMS0w_c6784ef4-d5a6-4b6f-a367-1746d9cc4fd7"
      unitRef="usd">467982000</us-gaap:AssetsCurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNy0xLTEtMS0w_f82cabfa-a1da-4911-a2da-d4864216e54b"
      unitRef="usd">58322000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfNy0zLTEtMS0w_16617bf8-64bc-4626-be55-00bbcc415598"
      unitRef="usd">261966000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOC0xLTEtMS0w_ac5d4b93-3cb3-4cef-b2b0-d60406acfe1d"
      unitRef="usd">44495000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOC0zLTEtMS0w_ec7bf0c3-f50f-4653-b996-170e45079c55"
      unitRef="usd">33015000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOS0xLTEtMS0w_c3088c78-c3ba-41b6-a198-190e64ece667"
      unitRef="usd">56449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfOS0zLTEtMS0w_16b172c7-2ee1-4421-93c0-caf4949108d6"
      unitRef="usd">8595000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTAtMS0xLTEtMA_f409c450-97b3-4d00-8f6c-3545c849081b"
      unitRef="usd">151000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTAtMy0xLTEtMA_19425ddf-a079-4e71-9969-0a8d05b0c347"
      unitRef="usd">754000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTEtMS0xLTEtMA_2b217ba5-73b8-42b3-a4da-5b2fd45cebb8"
      unitRef="usd">4299000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTEtMy0xLTEtMA_2e8a12fa-34e9-48ab-a0ac-fca628ff653c"
      unitRef="usd">1299000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTItMS0xLTEtMA_b67ee99a-31fd-498d-a62e-da31ac855075"
      unitRef="usd">4618000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTItMy0xLTEtMA_bfa2e1ad-2f65-46b4-accc-af7be571a96d"
      unitRef="usd">244000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMS0xLTEtMTQ5Mg_4d5042a8-5124-47d6-96e1-40c5194383f7"
      unitRef="usd">4892000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMy0xLTEtMTQ5NQ_0662da6e-380c-41ea-984e-d62d3437119e"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMS0xLTEtMA_7ae45f27-4745-4ce0-a2c6-284775ffea08"
      unitRef="usd">717802000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTMtMy0xLTEtMA_e3bf1730-404d-421e-b2e7-8eecc7d99628"
      unitRef="usd">773855000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTYtMS0xLTEtMA_462f8959-c957-42b0-bbd7-60ecdd066d4d"
      unitRef="usd">9250000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTYtMy0xLTEtMA_3bd32363-64ed-403d-8ff3-28d67e6e3283"
      unitRef="usd">12338000</us-gaap:AccountsPayableCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTctMS0xLTEtMA_bc0133bf-50b0-4765-8a7f-67976873ed93"
      unitRef="usd">23829000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTctMy0xLTEtMA_060b9f5d-e693-485e-9305-b1949b0f42e4"
      unitRef="usd">17121000</allo:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTgtMS0xLTEtMA_3cafa5db-816f-4653-8a5a-6095308a082e"
      unitRef="usd">33079000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTgtMy0xLTEtMA_c41f0adb-50de-4489-b984-95c97ebf0877"
      unitRef="usd">29459000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTktMS0xLTEtMA_32aa3b84-731f-44ee-a22a-886034457fdf"
      unitRef="usd">51349000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMTktMy0xLTEtNjIw_8834d78f-2491-4f01-a97c-3994dfe49aae"
      unitRef="usd">34456000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjAtMS0xLTEtMA_f23d0171-3607-4ce4-b448-c05a32a90bd0"
      unitRef="usd">4351000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjAtMy0xLTEtMA_aa9678de-d2ba-49d0-a24d-ca5fb5daf91e"
      unitRef="usd">6776000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjEtMS0xLTEtMA_d12d3c39-2e15-4b88-a8d0-34b7432b1077"
      unitRef="usd">88779000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjEtMy0xLTEtMA_b163c89d-287e-4f39-8874-4282b30235ed"
      unitRef="usd">70691000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjItMS0xLTEtMA_55ce3590-b4f0-4500-9dba-4ee29b22ab78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjItMy0xLTEtMA_b07f95b9-3af6-48a3-8013-56f59999514a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjUtMS0xLTEtMA_72207e99-fe11-4fdd-8817-7aa673d66fc8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjUtMy0xLTEtMA_e4b77cf9-5c13-4ee8-b1b8-62ad0d0cf9fd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjYtMS0xLTEtMA_daf652be-0d3e-42f8-84ce-2d41107b5816"
      unitRef="usd">124000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjYtMy0xLTEtMA_1d09363f-9014-457c-b283-cc9e120e9705"
      unitRef="usd">121000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjgtMS0xLTEtMA_f910f39e-8503-44c5-b22b-29859daf1983"
      unitRef="usd">1023876000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjgtMy0xLTEtMA_ea326ef3-15ee-4a9a-bbd5-3bbbaec9718d"
      unitRef="usd">914265000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjktMS0xLTEtMA_7ecc802b-0890-4c77-9051-5a6d7bc8e09b"
      unitRef="usd">-396122000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMjktMy0xLTEtMA_b7aa2496-c965-4cff-b279-c8ce5669d4c5"
      unitRef="usd">-211528000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzAtMS0xLTEtMA_8ff51377-f904-40c7-a27c-24c5d1db7558"
      unitRef="usd">1145000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzAtMy0xLTEtMA_403baee9-b0f4-4fe2-9e3c-f20ff641e57b"
      unitRef="usd">306000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzEtMS0xLTEtMA_3fdf8ed0-0e8c-4860-8bd6-767388c68c3b"
      unitRef="usd">629023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzEtMy0xLTEtMA_11aa066c-2d6c-4fdc-afac-57845c3ae9f1"
      unitRef="usd">703164000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzItMS0xLTEtMA_ee72ae0e-370d-412d-ac57-fa90a5dcaa6e"
      unitRef="usd">717802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV84NS9mcmFnOjQ5NzdlZmZlYzdiYTQyYmI5YjhlODMxYzEwYzRlNGYyL3RhYmxlOjQ0MTQ3NTA2MDAxMTRiMjVhNGYyMTQ0NjQ5Njg0ZDNhL3RhYmxlcmFuZ2U6NDQxNDc1MDYwMDExNGIyNWE0ZjIxNDQ2NDk2ODRkM2FfMzItMy0xLTEtMA_27de7aa6-4263-4eb7-bb96-ad4e1d38160b"
      unitRef="usd">773855000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0xLTEtMS03MjM_e0391cad-96f0-4a73-ba52-fa0512c83085"
      unitRef="usd">144535000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0xLTEtMS0w_02102a47-22b7-4a07-823e-083d632bdf1f"
      unitRef="usd">151860000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMi0zLTEtMS0w_3cbef4b7-e1f1-4611-8aca-12167501a0a7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0xLTEtMS03MjM_34d70ea1-84e1-4ba1-9417-175802cae8ba"
      unitRef="usd">57473000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0xLTEtMS0w_75e4c2fa-4b53-41b7-a2d7-4496139094d9"
      unitRef="usd">40982000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMy0zLTEtMS0w_f83b305e-7ab4-45e8-87d9-29990ee503a4"
      unitRef="usd">2000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0xLTEtMS0zMDY_caae18ae-28c2-4d58-b4b7-e0d61c5f6a9e"
      unitRef="usd">202008000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0xLTEtMS0w_f6b5e8b2-e948-43e9-901f-5f723604c2dd"
      unitRef="usd">192842000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNC0zLTEtMS0w_8b079d46-ad05-4eeb-a5f3-1809333d4157"
      unitRef="usd">2000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0xLTEtMS0zMDY_aca6a86f-e19b-4ce0-8ade-381dba4195e0"
      unitRef="usd">-202008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0xLTEtMS0w_9274f9d0-8bbb-48bf-ae5c-c920abb769fd"
      unitRef="usd">-192842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNS0zLTEtMS0w_9262710f-d1da-43e3-8f16-be8e94022772"
      unitRef="usd">-2000</us-gaap:OperatingIncomeLoss>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0xLTEtMS03MjM_225990fd-4492-4d21-a191-bea9ebb6abd3"
      unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0xLTEtMS0w_869b532b-3d07-4d10-991d-4bfe1bf49088"
      unitRef="usd">21211000</allo:ChangeInFairValueOfConvertibleNotePayable>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfNy0zLTEtMS0w_bfb05cdd-1811-4a4d-a0a2-3522134bb29d"
      unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
    <us-gaap:InterestExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0xLTEtMS03MjM_48acede7-9086-43d5-94d8-c3467bce7917"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0xLTEtMS0w_4fd0fad8-f43b-440b-b323-379d1c712df8"
      unitRef="usd">3358000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOC0zLTEtMS0w_220f9363-3a3a-49b7-9e1a-d881cdfc0724"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0xLTEtMS03MjM_6579b4bd-a5c8-464c-af03-eed376871ce4"
      unitRef="usd">17351000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0xLTEtMS0w_c6570a91-4d8d-4946-b843-a19d866dbd59"
      unitRef="usd">5789000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfOS0zLTEtMS0w_449afd1f-25b4-438a-be3f-159ec3476ae7"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherExpenses
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMTYzMA_5b3bca8d-fd46-4ca7-9ea7-88e66a7ea8aa"
      unitRef="usd">268000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMy0xLTEtMTYzNg_b3c181c5-4174-4134-85cf-d8f38dd1eaca"
      unitRef="usd">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtNS0xLTEtMTY0MQ_ba2637b0-4d73-4796-b5c9-3cc66787c972"
      unitRef="usd">0</us-gaap:OtherExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMS0xLTEtMzA2_2eb287cd-9606-40e1-a0fa-11f7a6da0e0d"
      unitRef="usd">17083000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMS0xLTEtMA_50b2a7dd-4b61-49a9-8506-22e31bea0d82"
      unitRef="usd">-18780000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTAtMy0xLTEtMA_b65fb0dc-2229-441d-a599-bc633c5aafc6"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMzA2_32122f0c-a005-4a43-bf84-746a8c5c5191"
      unitRef="usd">-184925000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMS0xLTEtMA_ff1bee91-67e8-4990-a847-0105ab71d248"
      unitRef="usd">-211622000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTEtMy0xLTEtMA_28ea006c-d863-4c97-8c62-9bab8c5a3ffc"
      unitRef="usd">-2000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMS0xLTEtNzIz_3676ac77-fbe0-4ee4-983c-0517280469d7"
      unitRef="usd">-331000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMS0xLTEtMA_3e8272f7-f16f-4efe-8e91-3a85aa6bca1a"
      unitRef="usd">-117000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTItMy0xLTEtMA_494abe85-58b2-4c4f-bae4-b8c9a8922fba"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMS0xLTEtMzA2_8b541334-1d3c-4642-8903-2f030d0586dc"
      unitRef="usd">-184594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMS0xLTEtMA_eb5d8e8d-c3e9-40d3-83fc-40abc11c355c"
      unitRef="usd">-211505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTMtMy0xLTEtMA_df73949a-6dfb-4835-9ea7-f39fa83135e3"
      unitRef="usd">-2000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMS0xLTEtNzIz_b7314dc6-3491-4751-aa6d-c92bbdb96018"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMS0xLTEtMA_65f276d1-166c-4d9c-9068-87d0169c02f5"
      unitRef="usd">306000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTUtMy0xLTEtMA_00bccda5-cc47-4cb8-9756-5b52b1f1486b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMS0xLTEtMzA2_16239e63-12df-42cc-a40b-9a2a826cafe7"
      unitRef="usd">-183755000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMS0xLTEtMA_0ea3b0db-5657-46ab-baea-991ae050e104"
      unitRef="usd">-211199000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTYtMy0xLTEtMA_377a001d-8752-4e45-a859-f58ebbac3d3e"
      unitRef="usd">-2000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMS0xLTEtNzIz_1e00bcf6-e969-4ca9-a3a7-86c894445e2b"
      unitRef="usdPerShare">-1.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMS0xLTEtMA_21473459-b8ac-45af-8b8e-c0c42854547d"
      unitRef="usdPerShare">-7.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTctMy0xLTEtMA_0217b1dc-4a38-4315-a7bd-99575b11ef3b"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMS0xLTEtNzIz_bf8b1058-aad0-4f2b-8969-2fb1b9aa0e31"
      unitRef="shares">101061149</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMS0xLTEtMA_df607a9f-ec1d-493e-a4dc-c7c6611cddf3"
      unitRef="shares">28948386</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85NC9mcmFnOjQ3NDExMmNjNDY1MDQ4ZGM4YWQ4ZjcyMjZmYjAxMmRmL3RhYmxlOjE2ZWI3MGExYzJhYzQ2MjdhNDVjMGNiZGIxZjkyODY5L3RhYmxlcmFuZ2U6MTZlYjcwYTFjMmFjNDYyN2E0NWMwY2JkYjFmOTI4NjlfMTgtMy0xLTEtMA_60c5e074-398c-4248-b569-34ceb57e205f"
      unitRef="shares">26249993</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99decb5567534b8497dffa86e0b1023e_I20171129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xLTEtMS0w_3a74e5db-d15a-4278-a76f-ca24ab7a0ae5"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i99decb5567534b8497dffa86e0b1023e_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0zLTEtMS0w_9b99029f-883f-44f4-981f-28b44a4c7d5c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3201ab4ab1724c7ea1125d924e0873ff_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi01LTEtMS0w_6d7db709-e2ae-49f8-96b4-4d558845d859"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i84465143443f4cf0ad45c2485bf6f687_I20171129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi04LTEtMS0w_b08b12e1-6543-4fba-b2f7-b1198a989557"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84465143443f4cf0ad45c2485bf6f687_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xMC0xLTEtMA_33e6912f-51b5-4c9d-a904-a38a95e2fb96"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i450d417e37254e0ab2024cc5cdb97eeb_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xMi0xLTEtMA_bcf10dbd-6cda-41be-8a93-7cefa8debf80"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbe813e0d64c4e969856a6e3723ab181_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xNC0xLTEtMA_f16cefa0-17c1-46f1-8dba-4de4cbbcbee4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ed9b242005d4eda9f7a3d5117e787a4_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xNi0xLTEtMA_3e239318-34d9-41b1-8dad-dcba7f4af1cc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia97c507021ed4124b41826a307eef5b4_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0xOC0xLTEtMA_4e6ceadb-b4ae-4b08-8e0d-90bf4899e52b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic178392ea1bb4a2d8265ba3c454059e5_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMi0yMC0xLTEtMA_4c717147-8057-4286-a5e6-f0f4da8d020c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy04LTEtMS0w_03e2d4d6-3c01-4b44-9056-51c6725b45b3"
      unitRef="shares">26249993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id44fb0eac33f4685bfc48a9234a2174b_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0xMC0xLTEtMA_08a487fb-64fc-4afe-b008-98d93b1a78be"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0xNi0xLTEtMA_dade7612-257a-43ff-9568-e1e6d58229ea"
      unitRef="usd">-21000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMy0yMC0xLTEtMA_e7026d0f-653e-4b3b-81d8-8fec595c6fa4"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <allo:NotesReceivableFromCommonShareholders
      contextRef="i5a7717940ad443ac959da4945a7df7df_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNC0xMi0xLTEtMA_851b7626-98ea-458a-831e-1434dc70d4c6"
      unitRef="usd">5000</allo:NotesReceivableFromCommonShareholders>
    <allo:NotesReceivableFromCommonShareholders
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNC0yMC0xLTEtMA_12fbddb4-e34c-4385-ac9b-62d227b899a2"
      unitRef="usd">5000</allo:NotesReceivableFromCommonShareholders>
    <us-gaap:NetIncomeLoss
      contextRef="id23abf9193154a06bcf248f7bc2358fe_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNS0xNi0xLTEtMA_6644f228-b2ae-47ff-ae94-462d9e1970d1"
      unitRef="usd">-2000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNS0yMC0xLTEtMA_46175fc6-397d-4976-96e1-64d63642061b"
      unitRef="usd">-2000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xLTEtMS0w_db600994-309c-449f-ad0d-ff369148e183"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1f47dea47d8e4f3aa0d642ba57347ce5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0zLTEtMS0w_bd0d77d5-4483-4364-b091-98fe30485cee"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8da636562f1e4692894fbc13c7c7b15c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi01LTEtMS0w_350cd115-1d0d-4488-a6a9-e4f09ceb80d8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi04LTEtMS0w_cdaa8eb7-683e-4df4-89b1-5318210108e7"
      unitRef="shares">26249993</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58b39d815b114df4bedbfb2c4b6c90e3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xMC0xLTEtMA_f2fa78ce-d761-4339-bcf5-341f32e60b13"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a3039ba156d4b1da1b438ddb91e2eda_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xMi0xLTEtMA_ef513294-8f19-4da4-a3cb-971f5251b61b"
      unitRef="usd">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i371f0794baf348b8a900545a9f712728_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xNC0xLTEtMA_f055fb4f-21fc-4f69-a418-dabbcbc910f5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd581e624e4c4c0ca42cf1cf3eaa1f3f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xNi0xLTEtMA_7dc239c9-b2a2-4afb-9eb3-f143d3f8ec0e"
      unitRef="usd">-23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c398c33948642ec8719c3f9f261004c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0xOC0xLTEtMA_d4e0b3fb-f346-4017-9c74-7a7f7f9a5807"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNi0yMC0xLTEtMA_f809f191-a8b4-4509-ac60-e9250443cf36"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNy0xLTEtMS0w_b41d99da-3682-4707-9837-93cb8a974820"
      unitRef="shares">7557990</allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfNy0zLTEtMS0w_56b4adc4-18a6-4040-885e-a6f5e1d1fc00"
      unitRef="usd">264365000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOC0xLTEtMS0w_36f43ef4-bc0f-4ab1-90a8-72f114ddb050"
      unitRef="shares">3187772</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOC0zLTEtMS0w_14d35912-13a8-43a7-9795-7779b121bd39"
      unitRef="usd">111770000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOS0xLTEtMS0w_a37c3a38-247c-40df-8d7b-ff3eac3df491"
      unitRef="shares">998225</allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="if3a48b67abea4cfab5c0daafa338ae5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfOS0zLTEtMS0w_bc5ce861-0eb0-40a5-91c1-3ce4a8b49db0"
      unitRef="usd">34917000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <allo:StockIssuedDuringPeriodValueCommonStockIssues
      contextRef="idfdd74767fd7438889e77589cf703193_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTAtMTItMS0xLTA_dea784c6-44ce-4748-bdeb-1c2484bbbb6f"
      unitRef="usd">5000</allo:StockIssuedDuringPeriodValueCommonStockIssues>
    <allo:StockIssuedDuringPeriodValueCommonStockIssues
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTAtMjAtMS0xLTA_ee8ed7a8-592f-4e72-8ab2-1f3668f7d5c5"
      unitRef="usd">5000</allo:StockIssuedDuringPeriodValueCommonStockIssues>
    <allo:SubscriptionsReceivableFromPreferredStockholders
      contextRef="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTEtNS0xLTEtMA_6c76c887-7311-4c9b-96bc-e46fc3821474"
      unitRef="usd">150000000</allo:SubscriptionsReceivableFromPreferredStockholders>
    <allo:SubscriptionsReceivableFromPreferredStockholders
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTEtMjAtMS0xLTA_0e861dbd-3ecd-4a4c-bf57-2b4f298a6413"
      unitRef="usd">150000000</allo:SubscriptionsReceivableFromPreferredStockholders>
    <allo:StockIssuedDuringPeriodValuePreferredStockIssues
      contextRef="ie2120c6b331e4295948d3e920ff8d18b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTItNS0xLTEtMA_8853323d-3d9f-4467-83cf-869cbd525b22"
      unitRef="usd">150000000</allo:StockIssuedDuringPeriodValuePreferredStockIssues>
    <allo:StockIssuedDuringPeriodValuePreferredStockIssues
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTItMjAtMS0xLTA_03d2ef3e-46f4-4ec9-826c-0293f36e038b"
      unitRef="usd">150000000</allo:StockIssuedDuringPeriodValuePreferredStockIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtOC0xLTEtMA_f6b0b8eb-d66c-4ce0-8555-8986e8ee3b7c"
      unitRef="shares">5020580</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtMTAtMS0xLTA_c7817d69-add3-4576-b70f-13353f9c8ae7"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTMtMjAtMS0xLTA_8a6abc56-6555-480e-9a90-a49af7abdfc1"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtOC0xLTEtMA_0c10c4be-cd37-4a9f-a642-f0390c814182"
      unitRef="shares">20700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMTAtMS0xLTA_14d9d5de-1520-476c-aeac-ac372a28c9ff"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib660932f6bce4ad6b6fba62272a8c8a4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMTQtMS0xLTA_b423db72-3040-4d9e-a486-226d4d1cbad0"
      unitRef="usd">343308000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5222c8b3d8ac4606a78d0fd3d67747da_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTQtMjAtMS0xLTA_a831a2d7-12f3-4f0e-8ec0-6842d78f3e3b"
      unitRef="usd">343329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMS0xLTEtMA_ce88729f-6726-4cd1-b9ae-5b3204247f03"
      unitRef="shares">11743987</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i0ca6aa0b42964e7f9f16c2d9af7d36c3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMy0xLTEtMA_697797e7-8f5c-467d-96cc-440b7fe91a95"
      unitRef="usd">-411052000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtOC0xLTEtMA_deee3474-65bc-468e-ae4a-27cf99819136"
      unitRef="shares">-61655922</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMTAtMS0xLTA_d8c6ff08-ca2b-4043-8dea-4016f80840ac"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMTQtMS0xLTA_422d612e-9d96-4334-afab-b86a565f3792"
      unitRef="usd">410990000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTUtMjAtMS0xLTA_6fefb1df-c062-4251-9454-a566ab7efbe5"
      unitRef="usd">411052000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i43e36cd74462486dbb1f69b7d048773d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtOC0xLTEtMA_c97a7405-0dea-4b39-b6c6-e50f030932c4"
      unitRef="shares">7856176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie9a4847f981c4190b9ba6c67e4898ae5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMTAtMS0xLTA_c1a4ea3f-8093-466a-b036-08eb843c97c8"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMTQtMS0xLTA_f89976ab-da6d-4bb3-b306-29a34a59fb40"
      unitRef="usd">141403000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTYtMjAtMS0xLTA_b44dd25e-4f04-4c55-a3af-41440af848e5"
      unitRef="usd">141410000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTctMTQtMS0xLTA_92e3fc0d-c72e-41cb-a6d6-7a983703a7bf"
      unitRef="usd">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTctMjAtMS0xLTA_6025b47e-c676-4cf2-92e4-399f5357ca2f"
      unitRef="usd">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1198d434651a42549ada3e5b91fbdcb6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTgtMTQtMS0xLTA_8314e294-ab75-4ad3-bce4-22eb2a48f02c"
      unitRef="usd">18566000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTgtMjAtMS0xLTA_ed276a47-7e34-462d-9344-e1a048141b4c"
      unitRef="usd">18566000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if03e9aad02914725a696c4b00ae00db6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTktMTYtMS0xLTA_5cae7d8e-546d-4069-acc5-afedcb3d52e5"
      unitRef="usd">-211505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMTktMjAtMS0xLTA_380c314a-3079-4cbb-b1c2-fbe3d4913481"
      unitRef="usd">-211505000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i824f05079e344862807f10de3ec47704_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjAtMTgtMS0xLTA_c6b143fd-c34a-43c1-8acd-901dae864b23"
      unitRef="usd">306000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjAtMjAtMS0xLTA_2daf1771-ed7b-492e-94ed-7cd96ccc258e"
      unitRef="usd">306000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMS0xLTEtMA_f2c936a1-367e-4a93-8e17-c88538997ce1"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia34e8122e6b44424adfde751afcccc0f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMy0xLTEtMA_64ef687c-45a2-4f35-be46-fcab812bb9ab"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57ba1414023a4bb6a54a2fe2c91369ac_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtNS0xLTEtMA_f671a479-e6e7-41e2-a3b2-3c08e1c5e385"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia0e44d1416c24d019f4334743e7793bf_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtOC0xLTEtMA_2c167520-695b-4b27-a6e8-e74cd4724f52"
      unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia0e44d1416c24d019f4334743e7793bf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTAtMS0xLTA_965c80d2-ded0-42dc-a9c3-fbf0773cefd5"
      unitRef="usd">121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i894cb9f424d847fd87d8fcba20ed1e12_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTItMS0xLTA_6273ecb6-457b-4405-ad20-714a688d6f28"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee1bc4e91f584f8a829f502e3581da80_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTQtMS0xLTA_7967a458-2b40-40b4-8f58-9f5cfefd3746"
      unitRef="usd">914265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6bc6daa75634ee18f23d67b4d5b10be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTYtMS0xLTA_75a1f0db-db4c-4960-b17d-44c90ccfeb1e"
      unitRef="usd">-211528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d942c4c69d247dc94894cc3832f4f13_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMTgtMS0xLTA_42d40bd9-556b-441b-a31a-57977f4e139f"
      unitRef="usd">306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjEtMjAtMS0xLTA_9392de7e-dce7-4391-a2df-539b307b0e6f"
      unitRef="usd">703164000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItOC0xLTEtMTc1NA_ea89db35-c239-4d37-9540-ca2ddc81cf66"
      unitRef="shares">711623</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMTAtMS0xLTE3NTQ_e52d01b3-1653-4bd0-9438-209edceb69a6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMTQtMS0xLTE3NTQ_05b93da1-51de-426b-9e5b-5ccf39aa6b89"
      unitRef="usd">2958000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjItMjAtMS0xLTE3NTQ_ceea548a-e2f1-4d89-bb14-0a84a85fcabc"
      unitRef="usd">2959000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjMtMTQtMS0xLTE3NDk_d58631c3-e48d-4932-ae3d-2cacb414389b"
      unitRef="usd">4590000</allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjMtMjAtMS0xLTE3NDk_d0bbb9c6-968a-4946-8159-048126a6fec6"
      unitRef="usd">4590000</allo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjQtMTQtMS0xLTE3NDk_57d3ca08-2728-4051-b4cb-74de074bc265"
      unitRef="usd">46063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjQtMjAtMS0xLTE3NDk_2dac44ee-e912-4664-82e7-da01ae2906fa"
      unitRef="usd">46063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtOC0xLTEtMTc0OQ_e59729a2-b925-4728-a486-e74f3de31d46"
      unitRef="shares">107982</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtMTQtMS0xLTE3NDk_d14157fe-147b-487e-ae54-d86e24e367b0"
      unitRef="usd">1783000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjUtMjAtMS0xLTE3NDk_4b6ed7d5-3a3a-47e1-bb71-a4a0a0fa7490"
      unitRef="usd">1783000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtOC0xLTEtMTc0OQ_97623d33-936e-4806-bb7b-efe4ff536d2d"
      unitRef="shares">1965082</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia6f4099adde245d9a792f996de017db7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMTAtMS0xLTE3NDk_c2926b18-a226-4526-9bcc-81e753d3b1d1"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic6392dfccce040eb9831845bcb1e7eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMTQtMS0xLTE3NDk_fb79dce2-8af3-4aae-a90e-9758b03b0a80"
      unitRef="usd">54217000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjYtMjAtMS0xLTE3NDk_cd4f9fc9-1b1b-4c81-8edd-e0787fc79f4e"
      unitRef="usd">54219000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i4504b4d5097a4954858c46286aa5dba4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjctMTYtMS0xLTE3NDk_200ecf10-d329-4e0f-b3c0-5c71b91a70a8"
      unitRef="usd">-184594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjctMjAtMS0xLTE3NDk_a39bf041-cde2-4729-b615-fe362dfd6660"
      unitRef="usd">-184594000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibdef23c610c643cd98f536491957b5ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjgtMTgtMS0xLTE3NDk_90dcc1ee-0abe-4752-a794-c6a636bdd301"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjgtMjAtMS0xLTE3NDk_50284aec-3439-4ef7-8074-1704b7dbb504"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMS0xLTEtMTc0MQ_441fb90b-08f2-4b92-a883-fd228774cd65"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i79252f9e4302446f85ce5bcaa8c8ba1d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMy0xLTEtMTc0MQ_1cc559dd-1a4f-4190-aa77-5cd1c4e9ec75"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd1910421c5c43d585972f790a229f83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktNS0xLTEtMTc0MQ_66cbd61a-bd0f-4421-91b2-23ee4dcf1d8d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8800095a2bb4f63b85032f31ca50e7f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktOC0xLTEtMTc0OQ_6e26a96e-3ad4-43ca-bfec-888d384ef6ee"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id8800095a2bb4f63b85032f31ca50e7f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTAtMS0xLTE3NDk_9a51930c-dc3d-4e2a-8091-e0a3526c7043"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea539b4757a94514a3201e3bef9d08e6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTItMS0xLTE3NDk_b2a64daa-8fb6-4c11-9c5d-84ac345904e4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07b75e8befc040d38153c0e4e0ed8a06_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTQtMS0xLTE3NDk_1bfdac8d-59b7-48c0-96f7-3130471eaff4"
      unitRef="usd">1023876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56d6273dcf9f4ca4b6c7f19445ea045d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTYtMS0xLTE3NDk_ea2bdd79-8661-41ad-a2cb-77cd903810fe"
      unitRef="usd">-396122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i658fd51e478545beb0ee00eed9c4872f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMTgtMS0xLTE3NDk_a4d7c6be-4ccd-49cb-bec0-0d63680bada4"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV85Ny9mcmFnOmEyOTZmNTZiNTY2MDRkMmRiYzVjZGE3YzQ5N2E4OGNjL3RhYmxlOjA1NTY1OWNlMzNiZTQ5MjE4YzRkNGRkNmRjNTU3NTRmL3RhYmxlcmFuZ2U6MDU1NjU5Y2UzM2JlNDkyMThjNGQ0ZGQ2ZGM1NTc1NGZfMjktMjAtMS0xLTE3NDk_fc90567b-c078-48ab-8336-b0ec6e7ea4a3"
      unitRef="usd">629023000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMS0xLTEtMzIy_bbdd21c7-f72b-4622-8215-20249430778f"
      unitRef="usd">-184594000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMS0xLTEtMA_e8e0d5a2-3cd8-49ba-a7de-387f024c6c3d"
      unitRef="usd">-211505000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzItMy0xLTEtMA_9e109efd-86d4-4a9f-9793-ce79df557258"
      unitRef="usd">-2000</us-gaap:ProfitLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMS0xLTEtMzIy_0aae5ec7-3a37-4544-b542-158449c020ec"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMS0xLTEtMA_06fdd018-3219-42ee-9063-3ed3c7d30a4b"
      unitRef="usd">109436000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQtMy0xLTEtMA_eb6a47e6-7113-4db0-9d96-ae643db7650f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMS0xLTEtMzIy_e5f65064-ee25-4f2c-898e-58f5ce74efdf"
      unitRef="usd">46063000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMS0xLTEtMA_c63338b9-c7f8-4a75-8d73-009eb8389a14"
      unitRef="usd">18566000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUtMy0xLTEtMA_ee27384f-584e-489d-a0f8-7e18f516f868"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMS0xLTEtMzIy_9738bfc9-97d2-48e3-9729-fb088631dbab"
      unitRef="usd">603000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMS0xLTEtMA_baa7e3b6-4a3f-4db0-bfd0-efd4f7d75bfc"
      unitRef="usd">452000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzYtMy0xLTEtMA_05bcffee-cd99-4646-9321-325e6d26d09a"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMS0xLTEtMzIy_e52a336b-e99d-4e4b-b71d-5c751f1d5773"
      unitRef="usd">4424000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMS0xLTEtMA_e2d45357-da05-4809-ab79-717aff5694a2"
      unitRef="usd">1048000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzctMy0xLTEtMA_cb8d3dd1-a479-41c5-ae8f-a80e169b2d66"
      unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMS0xLTEtMzIy_0701e3a1-b367-4365-895c-6adddcd39490"
      unitRef="usd">3596000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMS0xLTEtMA_e9e823cc-688e-4b6a-bd26-22a761ed6d47"
      unitRef="usd">1036000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzgtMy0xLTEtMA_5bf1dde6-30b3-4360-9984-76426d1e6a1c"
      unitRef="usd">0</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMS0xLTEtMzIy_2ca96d52-8c30-4ecb-918e-9336588b89db"
      unitRef="usd">6777000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMS0xLTEtMA_cb7d098b-473e-4a10-ae26-ee17b2f65d98"
      unitRef="usd">1832000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzktMy0xLTEtMA_8ae9bb75-ab21-4d76-9bf1-e47aea1c3ed3"
      unitRef="usd">0</us-gaap:LeaseAndRentalExpense>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTEtMS0xLTMyMg_1548b33e-7d42-401b-9b42-d3ccbb9d7507"
      unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTEtMS0xLTA_fcae7cb7-8835-4234-8a73-5783946daaa4"
      unitRef="usd">21211000</allo:ChangeInFairValueOfConvertibleNotePayable>
    <allo:ChangeInFairValueOfConvertibleNotePayable
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEwLTMtMS0xLTA_7cc70ac0-26cc-4bf9-b119-d351b8272a9d"
      unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTEtMS0xLTMyMg_26bf60c8-a5a9-4a3c-9f3c-aad0d3844e3b"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTEtMS0xLTA_005a2f9f-053d-485a-a872-bd5cb071a500"
      unitRef="usd">3358000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzExLTMtMS0xLTA_86cab2ab-b976-4cee-9d2a-c008f0331c9e"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTEtMS0xLTMyMg_7c30b8bb-d730-4307-996d-a1a10b4648c0"
      unitRef="usd">-331000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTEtMS0xLTA_9b4a56c5-2fa2-456d-9f03-52a33d836f7d"
      unitRef="usd">-117000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEyLTMtMS0xLTA_dfdc8bb6-fe48-45d3-bbaf-ada346320c05"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTQwNTg_b4c7ed8e-7568-41cf-9cf5-29e8e16a2d7b"
      unitRef="usd">-182000</allo:IncomeLossFromCostMethodInvestment>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTMtMS0xLTQwNTg_11ad062e-126a-43f3-8410-cd39d5b019d2"
      unitRef="usd">0</allo:IncomeLossFromCostMethodInvestment>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTUtMS0xLTQwNTg_418523de-727a-4a21-bec2-262629348b6c"
      unitRef="usd">0</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTMyMg_31b83b5f-53bf-4209-99fa-cfe2f789dd58"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTEtMS0xLTA_37e70ec7-b6c3-4b83-b834-9787f1d8b5fd"
      unitRef="usd">6000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzEzLTMtMS0xLTA_9b896dad-8763-4259-b6ca-1edd65a70265"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTEtMS0xLTMyMg_9250ca9d-59ed-4857-b7da-a26e10d35ee8"
      unitRef="usd">5445000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTEtMS0xLTA_e175303d-39a1-4c5f-a584-a78231465dc5"
      unitRef="usd">8598000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE1LTMtMS0xLTA_96b3091f-25c5-4426-9796-90ef5f303f13"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTEtMS0xLTMyMg_d85d591d-bfe8-446d-9dc8-f0927b76225e"
      unitRef="usd">4374000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTEtMS0xLTA_f74c7ed4-874e-497e-abea-7fa54c1bd57f"
      unitRef="usd">244000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE2LTMtMS0xLTA_6f97172b-76fa-4d95-8c66-691ab0548f12"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTEtMS0xLTMyMg_aa1dc621-4c8e-41d1-b4c3-055e1065605e"
      unitRef="usd">-985000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTEtMS0xLTA_8f15c5fe-3c7f-4737-a0c7-483d61edf87f"
      unitRef="usd">8800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE3LTMtMS0xLTA_64a9a593-028a-4fb2-8adb-27d9256c2484"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTEtMS0xLTMyMg_a7e220df-0e57-4291-b5d9-97e3d0690df9"
      unitRef="usd">6351000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTEtMS0xLTA_a4d2518a-a01c-4fbf-9346-b69d2f2e4eab"
      unitRef="usd">12138000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE4LTMtMS0xLTA_9e46b5cd-e900-417b-a030-cb4df472ad47"
      unitRef="usd">2000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTE4MTE_dd018a01-7ace-410b-ae35-38473b603916"
      unitRef="usd">-2425000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTMtMS0xLTE4MTE_5f5fa2c6-537f-4a06-b384-b57feed51faf"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTUtMS0xLTE4MTE_2775e149-c23b-408e-8b6a-c4bd94500dc7"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTMyMg_f5773399-00ab-4227-acb8-0eefe620ec5e"
      unitRef="usd">-137350000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTEtMS0xLTA_7f9cb1a9-9675-476c-a4e6-c0002fbc8f73"
      unitRef="usd">-44653000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzE5LTMtMS0xLTA_ac1a5432-4bce-49d0-9588-93dc2f8ecc4b"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTEtMS0xLTMyMg_38112332-df80-4961-ac57-bede8a4cd4d4"
      unitRef="usd">50791000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTEtMS0xLTA_54bed89e-eb92-4a27-80de-55534dbaef95"
      unitRef="usd">3234000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIxLTMtMS0xLTA_6421598a-1af2-4780-bd29-630797981152"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTE4MzE_a0ac62e9-f197-465f-923b-33edc7b9dc0f"
      unitRef="usd">5075000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTMtMS0xLTE4MzE_d0c7b862-11f4-415e-96bb-de54281ea6bd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTUtMS0xLTE4MzE_e705c8e5-9cfb-4907-9549-44d21b7046a5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTEtMS0xLTMyMg_28af1bd2-dd30-4abc-a2f3-55f887533f3c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTEtMS0xLTA_e6095f0f-700d-446a-90f6-15ba6215387c"
      unitRef="usd">2606000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIyLTMtMS0xLTA_1d2d55ce-d6f4-46d7-a9ff-aed622062d3e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTMyMg_df99ef2d-f68e-4372-ba3a-d56b4c990766"
      unitRef="usd">472578000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTEtMS0xLTA_dd0d2da7-826f-4e74-9c4a-64f30ae71c40"
      unitRef="usd">19235000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzIzLTMtMS0xLTA_fe2992db-f727-4a53-b660-7a30e75f353c"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTEtMS0xLTMyMg_47b3658e-6c63-4976-bb0b-9153c2f3dd94"
      unitRef="usd">252628000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTEtMS0xLTA_62904ef3-9622-42d2-b086-5d124a63bcab"
      unitRef="usd">649307000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI0LTMtMS0xLTA_5fb64eb5-06f4-4051-ac4b-d33175f55c4d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireAssetsInvestingActivities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTEtMS0xLTMyMg_90fc15e8-b6c2-4095-bd18-330ac83e63d7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquireAssetsInvestingActivities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTEtMS0xLTA_53e240c1-12e5-4a3f-b706-4dc7ef7e6cda"
      unitRef="usd">2098000</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquireAssetsInvestingActivities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI1LTMtMS0xLTA_31c04a0c-93d4-4dd5-adf3-94f58567799a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTEtMS0xLTMyMg_a69c3444-8925-449c-8b79-afe9c3fc1db8"
      unitRef="usd">164084000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTEtMS0xLTA_3161242c-1bf7-4392-bffb-7315cb999460"
      unitRef="usd">-632798000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI2LTMtMS0xLTA_11250e56-77f5-410c-9be3-c9b41a839f66"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTEtMS0xLTMyMg_d03a9ab7-1603-4823-8411-4b7c7a1fd5bd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTEtMS0xLTA_90d3a903-65e2-4d14-b2bc-38c9adb35e45"
      unitRef="usd">299281000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI4LTMtMS0xLTA_1f8923a5-e6a7-499f-a4fb-2f10036419c3"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTEtMS0xLTMyMg_a010be8f-1af9-40b6-baa3-70aec9809eab"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTEtMS0xLTA_05a0eea9-4cf6-4143-bba6-c47a206509c7"
      unitRef="usd">116842000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzI5LTMtMS0xLTA_06759bd1-06dd-4e9f-9dff-1f8a669c6924"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTE4NTE_c3a2df97-dc92-423c-9278-4d9372e3bb38"
      unitRef="usd">0</allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions>
    <allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTMtMS0xLTE4NTE_493f46e4-b9f4-4dc7-a4de-2ec7910716ff"
      unitRef="usd">11370000</allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions>
    <allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTUtMS0xLTE4NTE_c2be1778-90cc-4e20-b274-914528cfbbcb"
      unitRef="usd">0</allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTEtMS0xLTMyMg_332e1ca2-aca6-4154-ba32-89831cf0876a"
      unitRef="usd">54219000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTEtMS0xLTA_905dee94-cea8-49bb-84ab-bc1e6ad30451"
      unitRef="usd">343689000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMwLTMtMS0xLTA_5463d416-e627-432c-a8c3-86377f149c5f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTEtMS0xLTMyMg_c261a705-1e7d-4792-b573-2e041db1a937"
      unitRef="usd">2958000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTEtMS0xLTA_6588f17e-0b99-4bac-8e46-92c3a038ddc5"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMxLTMtMS0xLTA_de2a0123-a12c-4afb-8256-fa7fb379c6ec"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTEtMS0xLTE4Nzk_75bdb6fc-6170-49f8-8da5-21fade897b1a"
      unitRef="usd">1783000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTMtMS0xLTE4ODQ_a7907e42-99fc-432b-b95d-a4705ae6ea17"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM2LTUtMS0xLTE4ODY_279b5ee4-df5e-4a25-bd9a-d45a55a0ab47"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTEtMS0xLTMyMg_d538cc84-6779-4cf7-a017-8be84391d409"
      unitRef="usd">58960000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTEtMS0xLTA_aa323445-1b51-4410-9a93-36fcedb7960c"
      unitRef="usd">771182000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMyLTMtMS0xLTA_cc24c8d6-bc1c-47a3-a12f-e60cf3288436"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTMyMg_ddc81fd0-f2fa-414a-85fc-1688e78ad765"
      unitRef="usd">85694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTEtMS0xLTA_45bd7c24-52a5-4f06-9e42-ecbd64f7527e"
      unitRef="usd">93731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzMzLTMtMS0xLTA_aa64df9f-c031-4260-9d9f-5c4371429816"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTEtMS0xLTMyMg_02b2d7bc-9129-4d7e-8303-23c427d35be0"
      unitRef="usd">93731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTEtMS0xLTA_d5c3b25d-9616-4394-9705-1dec5c8721e6"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic178392ea1bb4a2d8265ba3c454059e5_I20171129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM0LTMtMS0xLTA_3bb5d287-9c61-4f7b-a278-0783b0d697c4"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTEtMS0xLTMyMg_fa728899-b428-45a9-ba78-b0800d552cc2"
      unitRef="usd">179425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTEtMS0xLTA_c570e122-4d56-4c34-804d-56cee542e5f2"
      unitRef="usd">93731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM1LTMtMS0xLTA_c72694eb-4e8f-4adb-b096-b4b61f985392"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTEtMS0xLTMyMg_a4a87d34-a14b-4f9b-a06b-2c34d64989f5"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTEtMS0xLTA_6b3b961c-28f7-422b-819f-0b005572650c"
      unitRef="usd">411052000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM3LTMtMS0xLTA_2d7cb66f-f96e-4f97-b95c-7bc3b93861da"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTEtMS0xLTMyMg_4bd922f0-7d5b-4d7f-9627-235db23ca887"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTEtMS0xLTA_47def943-8a17-4298-a6d7-4ce4c3e8ae94"
      unitRef="usd">141410000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM4LTMtMS0xLTA_a84d8af1-9113-4c10-8986-90711f0fdd4e"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <allo:ConvertiblePreferredStockIssuedInAssetAcquisition
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTEtMS0xLTMyMg_21e62158-24c2-40c7-bdac-b868557ebc26"
      unitRef="usd">0</allo:ConvertiblePreferredStockIssuedInAssetAcquisition>
    <allo:ConvertiblePreferredStockIssuedInAssetAcquisition
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTEtMS0xLTA_629b29f3-b4b4-4611-bdff-6da87d8b4c3b"
      unitRef="usd">111770000</allo:ConvertiblePreferredStockIssuedInAssetAcquisition>
    <allo:ConvertiblePreferredStockIssuedInAssetAcquisition
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzM5LTMtMS0xLTA_ec64097b-39ce-47ae-af29-2eb70d67f320"
      unitRef="usd">0</allo:ConvertiblePreferredStockIssuedInAssetAcquisition>
    <allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTEtMS0xLTMyMg_f0e2c665-6686-4b8d-bac1-5bf9a0d87584"
      unitRef="usd">0</allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition>
    <allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTEtMS0xLTA_65ac2d49-a686-4da2-b930-7a36da70c643"
      unitRef="usd">111770000</allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition>
    <allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQwLTMtMS0xLTA_09c7e0e0-bed2-419d-b77c-f91453c430a0"
      unitRef="usd">0</allo:PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTEtMS0xLTMyMg_626d0a20-e8dd-48c5-b844-8a5d6703c0ff"
      unitRef="usd">13827000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTEtMS0xLTA_540ea758-f7ca-4e33-8406-16e3b559e122"
      unitRef="usd">33015000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQxLTMtMS0xLTA_f446770a-e389-4747-974c-e8b6b989b000"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTEtMS0xLTMyMg_018e250a-6c68-4865-b4a1-2cf54607a559"
      unitRef="usd">4668000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTEtMS0xLTA_c8aa2ed9-fe3b-4fcc-8ce6-c7e72e86ba2d"
      unitRef="usd">3182000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQyLTMtMS0xLTA_b1e7767c-6351-42d0-8e6c-8e451ecdec99"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTEtMS0xLTMyMg_0091971a-11a9-40df-ad00-fb140e4f1de8"
      unitRef="usd">135000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTEtMS0xLTA_b23daa81-65c3-4653-af35-0e61e0477f83"
      unitRef="usd">356000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQzLTMtMS0xLTA_ce06c8b4-1fca-4baa-a551-67e227f896ff"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTEtMS0xLTMyMg_c92f523c-7ecb-481f-abc8-4c7aad1adda7"
      unitRef="usd">3563000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTEtMS0xLTA_b7d67770-e4e7-42c7-9242-6af5a5aad703"
      unitRef="usd">31000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzQ1LTMtMS0xLTA_f2d0d5fd-2251-4cf4-b93b-b0edecbb876e"
      unitRef="usd">0</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTEtMS0xLTE4OTk_ac13351c-2171-4f96-8739-79e85876f7d4"
      unitRef="usd">-4473000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTMtMS0xLTE5MDM_ab0f3190-e777-4758-a44c-2d33db4da0bc"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDMvZnJhZzpmZTExNDdkNWNmMDQ0MjE0YjEyYWI4NDllZjM2MGQxZC90YWJsZTpkMWExOTI4MmJlNjQ0OGQxOWM1NjNhMjRkYzliZGIwZi90YWJsZXJhbmdlOmQxYTE5MjgyYmU2NDQ4ZDE5YzU2M2EyNGRjOWJkYjBmXzUxLTUtMS0xLTE5MDY_027124b4-155c-435c-93d0-744b998b140a"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDUyNTU_72dd42f0-0106-4028-9550-7a4bf8c93071">Description of Business and Summary of Significant Accounting Policies&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the period from November&#160;30, 2017 (inception) to December 31, 2017, the Company incurred $2,000 in start-up costs to establish the Company. Principal operations commenced in April 2018 when Allogene acquired certain assets from Pfizer Inc. (Pfizer) (see Note 6) and completed a Series A and A-1 preferred stock financing (see Note 11).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold 20,700,000 shares of its common stock, which included 2,700,000 shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of $18.00 per share. As a result of the IPO, the Company received $343.3 million in net proceeds, after deducting underwriting discounts and commissions of $26.1 million and offering expenses of $3.2 million payable by the Company. At the closing of the IPO, 11,743,987 shares of outstanding convertible preferred stock were automatically converted into 61,655,922 shares of common stock and the 2018 Notes (see Note 10) were automatically converted into 7,856,176 shares of common stock. Following the IPO, there were no shares of convertible preferred stock or preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. Beginning November 2019 and through the year ended December 31, 2019, the Company sold an aggregate of 1,965,082 shares of common stock in ATM offerings resulting in net proceeds of $54.2 million, after deducting commissions and offering costs of $1.6&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Offering costs, including legal, accounting and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO. Upon the completion of the IPO in October 2018, $3.2 million of deferred offering costs were reclassified to additional paid in capital. Offering costs, including legal, accounting and filing fees related to the ATM offerings were incurred. Upon the issuance and sale of common stock in ATM offerings in November 2019, $0.5 million of deferred offering costs were reclassified to additional paid in capital. There were no deferred offering costs capitalized as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Forward Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 1, 2018, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#x2019;s common stock on a 1-for-5.25 basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#x2019;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Need for Additional Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities as well as the ability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to commercialize the Company&#x2019;s product candidates. The Company had cash and cash equivalents and investments of&#160;$588.9 million as of December&#160;31, 2019. Since inception through December&#160;31, 2019, the Company has incurred cumulative net losses of $396.1 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the Company&#x2019;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit and other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has issued letters of credit under separate lease agreements which have been collateralized by restricted cash. This cash is classified as long-term restricted cash on the accompanying balance sheet based on the terms of the underlying leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Investments are available-for-sale and are carried at estimated fair value. The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;3&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three to seven years. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in other expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has determined the estimated life of assets to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.717%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 - 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixtures and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company early adopted Accounting Standards Update (ASU) No. 2016-2, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; on January 1, 2018. For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company's proportionate share of the net income or loss of these companies is included in other expenses in the statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;For entities in which the Company has variable interests, the Company focuses on identifying if one of the entities is the primary beneficiary through having the power to direct the activities that most significantly impact the variable interest entity&#x2019;s economic performance and having the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company&#x2019;s financial statements. For the year ended December 31, 2019, the Company did not consolidate any variable interest entities because the Company determined that it was not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by collaboration partners and third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities on the balance sheets and within research and development expenses on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its collaboration partners and third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures its stock-based awards granted to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense&#160;is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as&#160;they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss. For the years ended December&#160;31, 2019 and 2018 this was comprised of unrealized gains and losses, net of tax, on the Company&#x2019;s investments. For the period from November 30, 2017 (inception) to December 31, 2017, comprehensive net loss was equal to net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Definite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Identifiable intangible assets consist of in-process research and development and workforce associated with the Pfizer asset acquisition. Intangible assets with finite lives are amortized over their estimated useful lives on a straight-line basis, generally two years. Acquired in-process research and development intangible assets with no alternative future use are charged to research and development expense when acquired. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible assets. Intangible assets are carried at cost less accumulated amortization. Amortization of intangible assets is included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were impairment losses related to equipment disposals of $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred and consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development expenses also include costs incurred for internal and sponsored collaborative research and development activities. Costs associated with co-development activities performed under the various license and collaboration agreements are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Research and development expenses for the year ended December 31, 2018 primarily consisted of acquired intangible assets pursuant to the Asset Contribution Agreement with Pfizer (see Note 6) as, at the time of acquisition of the asset, the technology was under development, was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing, had not reached technical feasibility, or otherwise had no foreseeable alternative future use. For the year ended December 31, 2018, the Company recognized expense of $109.4&#160;million related to the acquired intangible in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <allo:StartUpCost
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzYzNw_c3a40f8a-5fe2-40be-98b3-9320c11e4d20"
      unitRef="usd">2000000</allo:StartUpCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEwNTM_70eb9a89-e99c-411c-ba27-5fc7cb81a536"
      unitRef="shares">20700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic3f77038b1af4fb8b9344a23d6e30de4_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEwOTk_56546acb-6e4d-45c9-ba9b-10aeae679612"
      unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyMzE_1a8bdc27-d793-4894-90df-93d770f8c00f"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyOTA_77336f67-2145-428e-ae82-a133aa38eb55"
      unitRef="usd">343300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEzNjg_9add02b8-6759-411d-8df4-f8f7fd1f369b"
      unitRef="usd">26100000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEzOTY_4dde47cd-6f06-4c6f-bc27-b28d6ab1fd8b"
      unitRef="usd">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE0NTA_5b0020ee-0324-4263-bc34-a811b79a03b4"
      unitRef="shares">11743987</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i5ba5824b8755458399cf44363881b72a_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE1Mzc_e8e11903-7619-475b-a871-3aa7cce9da87"
      unitRef="shares">61655922</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iee39b6265afd4c15bb48df2ab24035ac_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE2MzA_26659cc6-fb8d-45d8-aeaf-306a81a82ea0"
      unitRef="shares">7856176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9d13410d6cb941fda6060aa13739c84b_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzE2ODc_b8f2bc91-21a0-48d0-b14c-454cf7e07d49"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <allo:StockIssuanceMaximumValue
      contextRef="i08444efecc9e4a61b85b99875e786078_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5Njg_edc2785a-e39a-4fdd-99f9-869a0318950e"
      unitRef="usd">250000000.0</allo:StockIssuanceMaximumValue>
    <allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5ODQ_400b3036-dae9-4ef8-a6c4-7afe96801109"
      unitRef="number">0.030</allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQzOTgwNDY1NDE1MDY_e18d0ffa-34f7-4494-9f0c-8fd2574a0700"
      unitRef="shares">1965082</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQzOTgwNDY1NDE1MTk_8153c20a-679d-407f-814e-0f622ce3b565"
      unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNjU5OTA_47d243f2-3019-450e-9b65-3180ac5ed228"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU1_f3233ce6-fde1-4922-b2ef-6f2c3b724451">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Offering costs, including legal, accounting and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO. Upon the completion of the IPO in October 2018, $3.2 million of deferred offering costs were reclassified to additional paid in capital. Offering costs, including legal, accounting and filing fees related to the ATM offerings were incurred. Upon the issuance and sale of common stock in ATM offerings in November 2019, $0.5 million of deferred offering costs were reclassified to additional paid in capital. There were no deferred offering costs capitalized as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="i821e501b07404b9a9c7d2c5ca11840c7_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMDU_534bc644-e409-4123-bbb4-cd8def8b68ce"
      unitRef="usd">3200000</us-gaap:DeferredOfferingCosts>
    <allo:DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
      contextRef="ic58cfdcb98b24158bdd7223f565fcd2b_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzEyMDk0NjI3OTM4Mjg0_56a2f412-43cf-4f07-98b4-70f1aa2c9aaf"
      unitRef="usd">500000</allo:DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital>
    <us-gaap:DeferredOfferingCosts
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM4NDgyOTA3MzQ5NTk_a9a9985a-2172-4c6a-9564-5ef4d98ab074"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM4NDgyOTA3MzQ5NTk_e0068cfe-09c4-4e79-ab64-f13d9213a2c7"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM1Mzc_d45f468a-c611-4d00-b2b6-ea1a5bd06b0c"
      unitRef="usd">588900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ic88cc8410c2e4057a11268c203ce1002_D20171130-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzM2Mjg_690f99ca-3175-4d45-b28b-fff46127204f"
      unitRef="usd">-396100000</us-gaap:NetIncomeLoss>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ1_fb88e8ee-bea7-4e42-a32d-5cdefae97f26">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ2_3511ff3a-399a-4716-a964-c46850d1a221">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjUx_14162bc1-ea8c-4943-b784-0fca1148a224">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit and other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ3_e40507b5-80fc-4939-9b10-55a5c8c5363c">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ4_da17b049-7faf-4c97-b9b5-64f3252609d8">Cash, Cash Equivalents and Restricted Cash&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has issued letters of credit under separate lease agreements which have been collateralized by restricted cash. This cash is classified as long-term restricted cash on the accompanying balance sheet based on the terms of the underlying leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ5_8c241b62-395c-4902-9fdf-6a6ab7c6e866">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Investments are available-for-sale and are carried at estimated fair value. The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest and other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQy_cdfaa128-a6c6-47bc-8da1-291e30f807bb">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;3&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM3_6c290b0d-a355-47ae-8213-1969d70dc290">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three to seven years. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in other expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has determined the estimated life of assets to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.717%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 - 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixtures and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i9151b9d2545f4446ba00b1da9cbc8bb2_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NTI_13dcedf7-8ea6-4851-ab43-5825f8f6c8af">three</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i0b21a198f1184844a973ffb0f8eb7de1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NjU_be56973c-a92e-4b27-a3d2-7e3cd1c94423">seven</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <allo:EstimatedLifeOfAssetsTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjUy_9505cd03-cacc-4249-9939-6bb614c53a20">The Company has determined the estimated life of assets to be as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.717%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 - 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixtures and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</allo:EstimatedLifeOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i31559d28138348d0ab6ce2d61e8edf3e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90YWJsZTo1OWY5M2MyM2UyNDc0MjM3OWY1Mjc0YTUwMWQzZTU3Zi90YWJsZXJhbmdlOjU5ZjkzYzIzZTI0NzQyMzc5ZjUyNzRhNTAxZDNlNTdmXzAtMS0xLTEtMA_4eb3b43f-24d8-437a-94c9-1f2c520f2e91">5 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="iccc4fa5d70e04dcaa95ad41bc1ee441d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90YWJsZTo1OWY5M2MyM2UyNDc0MjM3OWY1Mjc0YTUwMWQzZTU3Zi90YWJsZXJhbmdlOjU5ZjkzYzIzZTI0NzQyMzc5ZjUyNzRhNTAxZDNlNTdmXzItMS0xLTEtMA_47f12178-02bd-4b5d-8895-a6ad7a933c81">7 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDY4NzA_5d68d37f-159a-4b15-b852-e6b15679624f">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company early adopted Accounting Standards Update (ASU) No. 2016-2, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; on January 1, 2018. For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDY4NzE_f446f409-1c06-4cbe-ad62-c75b58b0d58b">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company's proportionate share of the net income or loss of these companies is included in other expenses in the statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;For entities in which the Company has variable interests, the Company focuses on identifying if one of the entities is the primary beneficiary through having the power to direct the activities that most significantly impact the variable interest entity&#x2019;s economic performance and having the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company&#x2019;s financial statements. For the year ended December 31, 2019, the Company did not consolidate any variable interest entities because the Company determined that it was not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <allo:AccruedResearchAndDevelopmentCostsPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM4_db6582aa-bd0c-4aab-a527-2819ce97a00b">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by collaboration partners and third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities on the balance sheets and within research and development expenses on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its collaboration partners and third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs &lt;/span&gt;&lt;/div&gt;become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</allo:AccruedResearchAndDevelopmentCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjM5_4dd0d90c-7326-4ac8-8646-b3411ad9b7cd">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQw_12020cde-93e0-4b41-bea0-1c6db5dbe7ee">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures its stock-based awards granted to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense&#160;is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as&#160;they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU2_b4dc4af5-9ec2-42c0-9f1d-dd1045340b92">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <allo:ComprehensiveLossPolicyPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQx_f35272fa-3722-4870-bc99-6b06c547269f">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss. For the years ended December&#160;31, 2019 and 2018 this was comprised of unrealized gains and losses, net of tax, on the Company&#x2019;s investments. For the period from November 30, 2017 (inception) to December 31, 2017, comprehensive net loss was equal to net loss.&lt;/span&gt;&lt;/div&gt;</allo:ComprehensiveLossPolicyPolicyTextBlock>
    <allo:IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjU0_f363d4d0-167a-4895-bd06-c198d702bc4d">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Definite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Identifiable intangible assets consist of in-process research and development and workforce associated with the Pfizer asset acquisition. Intangible assets with finite lives are amortized over their estimated useful lives on a straight-line basis, generally two years. Acquired in-process research and development intangible assets with no alternative future use are charged to research and development expense when acquired. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible assets. Intangible assets are carried at cost less accumulated amortization. Amortization of intangible assets is included in research and development expenses.&lt;/span&gt;&lt;/div&gt;</allo:IntangibleAssetsDefiniteLivedPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQz_7a833e21-ed00-4d0e-b78e-8945f005fc4a">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were impairment losses related to equipment disposals of $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0NzI_fc089c2f-8483-49c4-9649-a00334c9a315"
      unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3Xzc2OTY1ODE0MzU0ODY_37755907-9e46-4f21-a85a-3e2891051814"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzIwMjQ0_700736ff-aa4c-4ccd-87fb-f3a382b677b4">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred and consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development expenses also include costs incurred for internal and sponsored collaborative research and development activities. Costs associated with co-development activities performed under the various license and collaboration agreements are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Research and development expenses for the year ended December 31, 2018 primarily consisted of acquired intangible assets pursuant to the Asset Contribution Agreement with Pfizer (see Note 6) as, at the time of acquisition of the asset, the technology was under development, was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing, had not reached technical feasibility, or otherwise had no foreseeable alternative future use. For the year ended December 31, 2018, the Company recognized expense of $109.4&#160;million related to the acquired intangible in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMDkvZnJhZzowNWYzZTgyZjQ2ZTE0ZjNhOGUwMDM3NTc1MWQ4Y2I5Ny90ZXh0cmVnaW9uOjA1ZjNlODJmNDZlMTRmM2E4ZTAwMzc1NzUxZDhjYjk3XzQ5NDc4MDIzNDUyNTc_3767db29-e3e8-4d76-bbe5-2d3150a3f115"
      unitRef="usd">109400000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTUvZnJhZzplMDBiZmJiNGI2ODM0YWNjOTUxMDA3ZTRkOGFlY2FlNi90ZXh0cmVnaW9uOmUwMGJmYmI0YjY4MzRhY2M5NTEwMDdlNGQ4YWVjYWU2XzQ5NDc4MDIzMzE4MDc_dead2541-43a5-4af5-a2c9-1aeac84ffc69">Recent Accounting Guidance&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January&#160;2017, the FASB issued Accounting Standards Update, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASU&#160;2017-01). ASU&#160;2017-01&#160;clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This new accounting guidance is effective for public or private companies for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The new accounting guidance should be applied prospectively on or after the effective date. The Company adopted this guidance on January&#160;1, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the FASB issued Accounting Standards Update No. 2018-07, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASU&#160;2018-07). ASU&#160;2018-07 simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Some of the areas of simplification apply only to nonpublic entities. For all entities, the amendments are effective for annual periods beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2020. Early adoption is permitted for any entity in any interim or annual period for which financial statements have not been issued or made available for issuance, but not before an entity adopts ASC 606. The Company early adopted this guidance on January&#160;1, 2018. As a result, the accounting for share-based payments to nonemployee consultants is consistent with employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2016, the FASB issued Accounting Standards Update No. 2016-18,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Statement of Cash Flows: Restricted Cash&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.&#160;&#160;This ASU&#160;requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.&#160;&#160;This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all periods presented.&#160;The Company adopted this guidance on January 1, 2018.&#160;The adoption of this ASU&#160;increased&#160;our ending cash balances within the statements of cash flows. The adoption had no other material impacts to the statements of cash flows and had no impact on the results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued Accounting Standards Update No.&#160;2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASU 2016-02), which provides revised accounting requirements for both lessees and lessors. Lessees will recognize a right-of-use asset and a lease liability for virtually all leases (other than short-term leases upon election). The liability is recognized at the present value of future lease payments. The asset is recognized based on the liability. For statements of operations purposes, ASU 2016-02 requires leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. ASU 2016-02 is effective for public companies for fiscal years beginning after December&#160;15, 2018. Early adoption is permitted. The standard requires a modified-retrospective transition method and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;provides for certain practical expedients. The Company early adopted the new lease standard on July 1, 2018 with the adoption reflected as of January 1, 2018 in accordance with ASU No. 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842) &#x2013;Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. There were no lease arrangements prior to August 2018 and consequently, the adoption of the standard did not have any impact on periods prior to August 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement &#x2013; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#x2019;s financial instruments that are in the scope of ASU 2016-13 include but not limited to trade receivables and available-for-sale debt securities. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued Accounting Standards Update No. 2018-15, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles &#x2013; Goodwill and other &#x2013; Internal-Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company will adopt this standard on January 1, 2020 and does not anticipate this amendment to have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In January 2020, the FASB issues Accounting Standard Update No. 2020-01, Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323),  which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90ZXh0cmVnaW9uOjcyZmE0MGQ0ZTc1ODRkMzA5MzJhMjZmMzY0OGYwODAyXzQ5NDc4MDIzMjY5MTU_7c0cef86-fb89-4253-b9d3-8da9075dc700">Fair Value MeasurementsThe Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received &lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures and reports its cash equivalents, restricted cash, investments and convertible notes payable at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no Level 3 assets or liabilities at December&#160;31, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2019 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds &#xb9;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#xb9; Included within cash and cash equivalents on the Company&#x2019;s balance sheet&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2018 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.104%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.783%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds &#xb9;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;403,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#xb9; Included within cash and cash equivalents on the Company&#x2019;s balance sheet&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no transfers of assets between the fair value measurement levels during the years ended December&#160;31, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90ZXh0cmVnaW9uOjcyZmE0MGQ0ZTc1ODRkMzA5MzJhMjZmMzY0OGYwODAyXzc2OTY1ODEzOTcxOTM_c510c159-24df-42cf-96a3-68e8660e74b4">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2019 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds &#xb9;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#xb9; Included within cash and cash equivalents on the Company&#x2019;s balance sheet&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2018 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.104%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.783%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds &#xb9;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;403,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#xb9; Included within cash and cash equivalents on the Company&#x2019;s balance sheet&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1dddefdb7f0347409c74598e8d7213a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtMS0xLTEtMA_d06def68-bac5-40f1-9ccf-45b6917a42aa"
      unitRef="usd">122900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad4580516611428ea09e371d04ecdcf0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtMy0xLTEtMA_3196d493-7d3a-4999-ab1f-f05a72ee858b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41321b51b20b4ec3807a67d0a72c0075_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtNS0xLTEtMA_6190f8b0-4958-4944-9786-d421d6cb5511"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1f9280b34fd4edca10d8753f9795f1d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzQtNy0xLTEtMA_5828739c-5c85-41e2-a468-eed48e5b8397"
      unitRef="usd">122900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b5d88729cac494eb409276d41aad939_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtMS0xLTEtMA_779c0b8b-d74f-4e90-9734-b8eae7fbe664"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i910ae198636f445ab767fe7a98e42da1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtMy0xLTEtMA_4ce96b2b-0d13-4941-bc29-92eb1debdee2"
      unitRef="usd">205011000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i10fdb61401b746fca53090e64340f864_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtNS0xLTEtMA_978d8c55-23f9-4888-89e9-7e53ca74f48a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idf7a233f74f545049d9e8aa6b0476dc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzYtNy0xLTEtMA_587ff1c4-b01a-4feb-855f-0213e1c805ad"
      unitRef="usd">205011000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaec915df35d44a74a0e37fe81e953ea8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctMS0xLTEtMA_b223f9b5-15b0-498a-809f-b3f259107bc6"
      unitRef="usd">181894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i06c178fec4d743b7a556aec06c2f821d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctMy0xLTEtMA_03cc2cb1-afb6-4a78-984a-e0335370892c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic91027a1351f40f6a6ce39d721284794_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctNS0xLTEtMA_f8e00bb2-cd55-49c7-8ae5-8720f2034358"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iab948e17826146478ea922d2d145b16a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzctNy0xLTEtMA_2c5b7df2-5720-405d-9d00-44f9a44b3d0b"
      unitRef="usd">181894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ied8402dc6dc845bc9113f9d66ed86178_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtMS0xLTEtMA_415f58df-8a48-4e5a-82e7-ebf8fcadab02"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i25faef9ff3c64269b6c008b1dc92e476_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtMy0xLTEtMA_430c95f4-b511-40e2-9dba-47c101d41f1f"
      unitRef="usd">25824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86abab37a4774a968808425797205a1d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtNS0xLTEtMA_c1342ec3-62b9-4e87-8088-4907dfceff1f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic67152294c6942b9ba899ab8f21e9ab8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzgtNy0xLTEtMA_1802a52b-09ac-49d5-adc2-bb300330f042"
      unitRef="usd">25824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0968abaaa5f7440c8eff4d639ac876db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMS0xLTEtNzEwMg_26d08a91-dab3-40e1-8cba-f0d5cf1eb0f1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i689d4094b8024bcc8d34927e5f90f7c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMy0xLTEtNzEwMg_beaf6e19-c973-44ed-88f7-a11da217d337"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0364d3024ca74ee5b4ea651c2620ca3f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNS0xLTEtNzEwMg_aa363721-bac8-4670-bc5f-db8b5025aa5e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb123eb6e34d4fb79ca3d24126047e63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNy0xLTEtNzEwMg_bc57e533-19ba-4207-8527-4a6368c8ee7d"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9990cf0b9413469cae5b763d89e229c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMS0xLTEtMA_61bc171d-e30e-4c8d-862c-b208e1fdadb0"
      unitRef="usd">304794000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i413973bdc4c8478484b252834be4455d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktMy0xLTEtMA_48a24f3e-c9ce-495a-ac61-4715f58bc22c"
      unitRef="usd">231835000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d00b3947da248a9aa0a662b95549a62_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNS0xLTEtMA_f9bb9262-03cc-4319-829f-d9520f6174a1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i131f8341b44741a8be5ad09784c38587_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTo1Yzg2MDUxNDQ1MDM0M2QyYjU4M2UyYjlmNGZmMTU5NC90YWJsZXJhbmdlOjVjODYwNTE0NDUwMzQzZDJiNTgzZTJiOWY0ZmYxNTk0XzktNy0xLTEtMA_7b8e6840-0042-43e7-b524-dc8da150756a"
      unitRef="usd">536629000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6af031995e6847efaf03df708bb7eb62_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtMS0xLTEtMjI1OA_9e6383fe-2571-4dce-9c0f-6c9a0d246336"
      unitRef="usd">61023000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if29d551d20ae4eb8962e30ebfd31ed44_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtMy0xLTEtMjI1OA_16024f24-cfe1-46ec-b6ef-be72036ec64d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibeaa87c3871d4b7494311fa64fdb63ec_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtNS0xLTEtMjI1OA_642f2a2e-a86d-4bbb-9e90-8406763104ad"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd83064e20c54412994b903a9de5ffd4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzQtNy0xLTEtMjI1OA_d4bb61b5-a39f-4596-bb49-4f69272d9367"
      unitRef="usd">61023000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9a0862545c944c7970f75cf79d47b8d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtMS0xLTEtMjI1OA_6912d8c0-6ad6-4df3-a441-29dec26eb4a5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdeb525a74b740d4b778fb321271ccce_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtMy0xLTEtMjI1OA_e66a6137-f4f9-4727-ab9a-142dab63df64"
      unitRef="usd">4917000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia306dfbbd94f4a72aa4930728fb27045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtNS0xLTEtMjI1OA_079fbbaa-3c60-47cf-aa2a-0e382635bfed"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i769efc364d1b49ad9f1e5c3e1e33a712_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzUtNy0xLTEtMjI1OA_84b9faf2-4be5-428f-8c79-8fa8c78d59db"
      unitRef="usd">4917000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i985e7490d1a549e8a0feb30d7a02d3b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtMS0xLTEtMjI1OA_43ca30c3-aefe-41a0-8059-a4be2393f25e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f6a1cfe504a41018e8e5e0de30f51d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtMy0xLTEtMjI1OA_e9487a94-6e44-423e-871a-5d58b1beb4d1"
      unitRef="usd">244076000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i40117c0bb4854d40a4fa2a481a673eec_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtNS0xLTEtMjI1OA_7415b5b8-d3b3-4e4b-948e-0e6a323bbaf5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d9f4a396a4241bda2a780ca2c70f3be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzYtNy0xLTEtMjI1OA_046c0137-c596-4c6f-8e74-e757a8aecbdc"
      unitRef="usd">244076000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14e9bfa620a94645901e0e79295a81c2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctMS0xLTEtMjI1OA_9460c78b-f612-4dbe-8d72-c38f03950e94"
      unitRef="usd">342001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieea078f2b943446d87c87029de76019d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctMy0xLTEtMjI1OA_d679db00-05c9-4160-a571-cc1377af8b65"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae09226ae44c493cbda2c9500466d142_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctNS0xLTEtMjI1OA_a02a066a-c89b-4eda-8ec3-dfeeb4ed47c9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b4b10265f764f3ab736b5d47b1f9502_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzctNy0xLTEtMjI1OA_c309078f-498a-403f-bc44-3a58a3d9ceb6"
      unitRef="usd">342001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic98c546ec02943d0a92444708d47ad3b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtMS0xLTEtMjI1OA_9741d6b6-4ffd-4483-838f-741938f6355e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i576dbba691a54312ae4f7f7b9fa27f72_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtMy0xLTEtMjI1OA_a2b6fe02-3132-4095-b0ac-987953c7e579"
      unitRef="usd">62115000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b15926b27844890b92923069fc998a2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtNS0xLTEtMjI1OA_b8656f7d-7420-4574-acee-a5c00a529cc0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4c7eaa563c1f4ebc81ea162cae253d1e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzgtNy0xLTEtMjI1OA_47be238a-aff2-44e6-aedb-4b99ad230d5c"
      unitRef="usd">62115000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e6bcfc30bc543409ce74f21a01801ac_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktMS0xLTEtMjI1OA_feed3ee3-f6e5-48c1-845a-c12074cd07fd"
      unitRef="usd">403024000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7af350b1cafc4cd1a2cbfc361f70255a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktMy0xLTEtMjI1OA_68379e91-3c63-4b68-be27-a2424010cc12"
      unitRef="usd">311108000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i712f2cfe4d6b404ab9882f4089185418_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktNS0xLTEtMjI1OA_99d04f65-cc77-4ac1-9188-48c5386b5daa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ice5f2d0234854debb1249a5a134c8a88_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMTgvZnJhZzo3MmZhNDBkNGU3NTg0ZDMwOTMyYTI2ZjM2NDhmMDgwMi90YWJsZTpkYWE5NmQ3NTBlMzg0OGYxODUxYWJhNWY1NWIwMDI4NC90YWJsZXJhbmdlOmRhYTk2ZDc1MGUzODQ4ZjE4NTFhYmE1ZjU1YjAwMjg0XzktNy0xLTEtMjI1OA_9a587b3a-ed1c-472b-9df1-91cd1bb55d16"
      unitRef="usd">714132000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzQ5NDc4MDIzMjU4ODY_009fefc5-bdf3-430e-b3e7-71a976b8338e">Investments&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2019 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents, and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2018 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.248%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;341,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;366,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents, and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of available-for-sale debt investments by contractual maturity as of&#160;December&#160;31, 2019&#160;and 2018 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.812%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.815%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 1 - 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Instruments not due at a single maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018,&#160;the remaining contractual maturities of available-for-sale securities were less than two years and three years, respectively. There have been no significant realized losses on available-for-sale securities for the years ended December&#160;31, 2019 and 2018. Based on the Company's review of its available-for-sale securities, the Company believes it had&#160;no&#160;other-than-temporary impairments on these securities as of&#160;December&#160;31, 2019 and 2018, because the Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the years ended&#160;December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzc2OTY1ODEzOTYxNzc_c378bc40-4ef7-4d00-9c3c-34d6352a5ba0">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2019 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents, and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of December&#160;31, 2018 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.248%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;341,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;366,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents, and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i92883258851343719809a457e47461f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtMS0xLTEtMA_8f6c62c2-4ba9-4510-8241-a7f415fd242c"
      unitRef="usd">122900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i92883258851343719809a457e47461f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtMy0xLTEtMA_99796be5-231a-4b61-8998-485953c7ae7e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i92883258851343719809a457e47461f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtNS0xLTEtMA_e6577c6f-2072-4099-8788-1fe4f508eb13"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92883258851343719809a457e47461f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzMtNy0xLTEtMA_5205c1a5-076a-4d07-814b-c5cb35c88b17"
      unitRef="usd">122900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0083451548d0466897483be2bafb4bd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtMS0xLTEtMA_9ad76fee-1aff-4806-b11b-c394c1c3935e"
      unitRef="usd">204144000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0083451548d0466897483be2bafb4bd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtMy0xLTEtMA_53ea05ae-21fa-45dd-9c10-e2a997d5b919"
      unitRef="usd">871000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0083451548d0466897483be2bafb4bd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtNS0xLTEtMA_4eda28e4-0e6b-423a-8aa9-854a794f460b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0083451548d0466897483be2bafb4bd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzUtNy0xLTEtMA_28f8211f-3404-4e59-b845-bb6f953c0e9c"
      unitRef="usd">205011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtMS0xLTEtMA_c88e37db-7036-4939-98e1-02f297a61367"
      unitRef="usd">181340000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtMy0xLTEtMA_2957081c-3625-4a2d-9771-0b9fe4618719"
      unitRef="usd">557000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtNS0xLTEtMA_07d18673-3f0c-47bc-8e50-bf3887f6a4fa"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb4ea982fa834fa29129f07b46026122_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzYtNy0xLTEtMA_2647c308-d973-4c7f-81a9-48f6536a3d4e"
      unitRef="usd">181894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctMS0xLTEtMA_4ed8912d-a0fd-44ef-8711-8a44a56fec8d"
      unitRef="usd">25658000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctMy0xLTEtMA_1b129015-fcea-4bec-a450-bcf34a64d3b0"
      unitRef="usd">167000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctNS0xLTEtMA_44a53506-3a01-45c9-8725-0f33574c1f99"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45fce8d0645e412d8345a84455d09beb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzctNy0xLTEtMA_60fef9a4-fc35-48b7-a3f8-606f417612ee"
      unitRef="usd">25824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iedec35042c304a2d90f0918f919f1531_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMS0xLTEtMjQ3OQ_652e84aa-07b5-495a-9130-1f66271abc31"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iedec35042c304a2d90f0918f919f1531_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMy0xLTEtMjQ3OQ_2cc2dfc9-5df0-414e-8de1-0b8a41f1d81d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iedec35042c304a2d90f0918f919f1531_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNS0xLTEtMjQ3OQ_bf9597bf-2f8e-45e3-b7aa-75ca41c4d73d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedec35042c304a2d90f0918f919f1531_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNy0xLTEtMjQ4Mw_a12cf680-17c0-4dcd-81d1-f79c50ccd009"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMS0xLTEtMA_d3c7d5d5-0e69-414a-8b65-bc944f03be4f"
      unitRef="usd">535042000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtMy0xLTEtMA_67050d68-193a-4b2e-9307-c41dfe363060"
      unitRef="usd">1595000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNS0xLTEtMA_90ec9bd0-c182-45c0-8b09-7ec06fb5a7b5"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzgtNy0xLTEtMA_ff9e6f9c-be20-4141-80d2-7ad7947784e6"
      unitRef="usd">536629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzExLTctMS0xLTA_d1557b70-7692-481b-a3b0-27b85b546deb"
      unitRef="usd">122900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzEyLTctMS0xLTA_c54b47c8-bd83-4ba9-bc3c-afeb5086e632"
      unitRef="usd">355407000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzEzLTctMS0xLTA_c82d3ff4-a769-4002-8c5b-962babb4e953"
      unitRef="usd">58322000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpiZjNmMzkyZDQzNTI0YThhOWFlNzk5YzY5MzBkMmY2MC90YWJsZXJhbmdlOmJmM2YzOTJkNDM1MjRhOGE5YWU3OTljNjkzMGQyZjYwXzE0LTctMS0xLTA_289a6887-2826-4ad0-a4ce-7695aa3a364d"
      unitRef="usd">536629000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec77988e07a84ed997297aea9582d919_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtMS0xLTEtMjM2OA_e886b070-6edd-4876-b70e-c7cd7547fe76"
      unitRef="usd">61023000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec77988e07a84ed997297aea9582d919_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtMy0xLTEtMjM2OA_9e4bbad9-0789-46b7-ac12-10282252d23d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec77988e07a84ed997297aea9582d919_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtNS0xLTEtMjM2OA_0718987f-6ac0-4482-9b85-9378befc236a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec77988e07a84ed997297aea9582d919_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzMtNy0xLTEtMjM2OA_bf4e130c-c993-4f64-abb0-0a77f0d7dffa"
      unitRef="usd">61023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtMS0xLTEtMjM2OA_51bff37a-7c7c-47a2-a6e5-0271a749f803"
      unitRef="usd">4917000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtMy0xLTEtMjM2OA_a5c48463-1c15-45fc-b055-014a7a57f433"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtNS0xLTEtMjM2OA_13596d09-e29a-41e9-82f2-92e24d58af74"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b6c79c2ff9449a8992e2ff22e4d3c3a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzQtNy0xLTEtMjM2OA_fd913def-cfad-45ac-8859-2d3a4b1e6422"
      unitRef="usd">4917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtMS0xLTEtMjM2OA_45fdef25-b251-48f0-a03c-b7e02a28bc3b"
      unitRef="usd">244136000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtMy0xLTEtMjM2OA_6f9ebed7-aa2a-4045-998a-74245d3543f0"
      unitRef="usd">220000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtNS0xLTEtMjM2OA_54ab3954-910f-487f-9450-08609e71c14f"
      unitRef="usd">280000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5226dd8eae048d5930a130fdebafb8f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzUtNy0xLTEtMjM2OA_a45707c3-c566-4f91-b8bc-68c8f3e4314b"
      unitRef="usd">244076000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtMS0xLTEtMjM2OA_6486c817-176c-4196-b368-3f376cf71308"
      unitRef="usd">341696000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtMy0xLTEtMjM2OA_9e1ed135-adda-47c3-84bf-ebcc819d8178"
      unitRef="usd">342000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtNS0xLTEtMjM2OA_e8cfee06-9085-4e51-81a0-2db0ce099c42"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id62c57f1c9644743a2437ff300fafb50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzYtNy0xLTEtMjM2OA_20ff8e60-766a-43b8-ad2a-eeaed03f71a6"
      unitRef="usd">342001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctMS0xLTEtMjM2OA_7db4b6e0-cf2d-4db0-b7fd-e6e4326f944a"
      unitRef="usd">61937000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctMy0xLTEtMjM2OA_381ecdfc-a68d-4408-845f-858222d54067"
      unitRef="usd">181000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctNS0xLTEtMjM2OA_971db7fe-5447-4021-acfd-343f3136cb24"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8076cdf604b5489895933ef89fc34b2f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzctNy0xLTEtMjM2OA_46527ef9-c340-4d36-a8e3-f39d91a3c5a1"
      unitRef="usd">62115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtMS0xLTEtMjM2OA_7c2a1954-ba41-4118-8b63-91582af016ec"
      unitRef="usd">713709000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtMy0xLTEtMjM2OA_596cc5f0-26f7-4000-9022-7315862eae95"
      unitRef="usd">743000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtNS0xLTEtMjM2OA_f5ad8442-2935-4f97-8f3d-09b32ed318c5"
      unitRef="usd">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzgtNy0xLTEtMjM2OA_7014f5d0-67e8-419f-8179-37ef944c262e"
      unitRef="usd">714132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzExLTctMS0xLTIzNzE_f4423b4d-02da-4dbe-9d3c-c45da987b9fe"
      unitRef="usd">85214000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzEyLTctMS0xLTIzNzE_2b8a8edd-aab2-4319-a9dc-bf8670807651"
      unitRef="usd">366952000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzEzLTctMS0xLTIzNzE_b5ae39cf-9ffb-4c1e-8d02-32310b51e518"
      unitRef="usd">261966000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTpjOTUzZmU2ZGFmNjE0YTZlODk4MmM3NDdiOTQyN2Y3OC90YWJsZXJhbmdlOmM5NTNmZTZkYWY2MTRhNmU4OTgyYzc0N2I5NDI3Zjc4XzE0LTctMS0xLTIzNzE_784e36d0-5b4d-4835-b887-f47b95276bf9"
      unitRef="usd">714132000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzg5Mw_92c22b34-aac3-48f6-8aa9-6c425f4d2486">The fair values of available-for-sale debt investments by contractual maturity as of&#160;December&#160;31, 2019&#160;and 2018 were as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.812%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.815%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 1 - 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Instruments not due at a single maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzItMS0xLTEtMA_3062a76b-cdf1-474b-92d5-292ecc96af60"
      unitRef="usd">355407000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzMtMy0xLTEtMjQ0Mw_da977735-0e04-4726-9146-519d17e46386"
      unitRef="usd">375625000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzMtMS0xLTEtMA_0148a092-6476-4565-b380-90589f65bc67"
      unitRef="usd">58322000</allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzQtMy0xLTEtMjQ0Mw_cff87a53-bbc4-4fd0-85c2-0037fd44bc72"
      unitRef="usd">240614000</allo:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzQtMS0xLTEtMA_3df12920-babf-4003-8aa7-71d1fdb1817a"
      unitRef="usd">0</allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue>
    <allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzUtMy0xLTEtMjQ0Mw_2a309e53-1c58-4cac-b491-bdd1f4d43413"
      unitRef="usd">36870000</allo:AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzUtMS0xLTEtMA_12abb871-221c-4f6a-ae8a-61d4ccd0412d"
      unitRef="usd">122900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzYtMy0xLTEtMjQ0Mw_c46714ac-59e5-4ba9-a423-711a42b18932"
      unitRef="usd">61023000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzYtMS0xLTEtMA_f66153e9-7447-43dd-bdcc-040dc3f3dddd"
      unitRef="usd">536629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90YWJsZTplYzU1YjY4MWU1ZWM0YzQzOWEwNDczODE4MTM1MzcwYi90YWJsZXJhbmdlOmVjNTViNjgxZTVlYzRjNDM5YTA0NzM4MTgxMzUzNzBiXzctMy0xLTEtMjQ0Mw_0219a527-56e4-4526-bcce-cdd1d55b0b93"
      unitRef="usd">714132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzM4NDgyOTA2OTg4MzI_8165c7d7-e7db-45a5-bfa2-0bbfa01a80ba">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzM4NDgyOTA2OTg4MzY_b497cc87-7d8c-4787-98fd-df8e8e29f037">P3Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzU3Mg_c9a41c7b-2333-4a68-bc3a-e07c33536f3f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjEvZnJhZzpkZGI2ZjM5ZjRhYmY0YjhjYWQ0NjUxNjk0Y2FmNmVlMS90ZXh0cmVnaW9uOmRkYjZmMzlmNGFiZjRiOGNhZDQ2NTE2OTRjYWY2ZWUxXzU3Mg_f3dc7e94-20aa-4e20-b950-33c0b12192a8"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjU0Njk_a9fbfa40-38bf-4079-b063-62072e0410f3">Balance Sheet Components&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued interest on short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation expense for the years ended December&#160;31, 2019 and 2018 was $4.6 million and $1.0 million, respectively. Disposals of property and equipment were $0.2&#160;million and zero for the years ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, the weighted-average remaining amortization period of the assembled workforce was 0.26 years. Amortization expense related to the assembled workforce intangible assets was $0.6 million and $0.5 million for the years ended December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3Mw_7090560b-4397-4aec-b2e6-9a7c8d48f2f0">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued interest on short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</allo:ScheduleOfPrepaymentsAndOtherCurrentAssetsTableTextBlock>
    <allo:PrepaidResearchAndDevelopmentExpensesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMS0xLTEtMjU2Ng_8ce585e7-d9e9-4186-a612-9e568d7f4231"
      unitRef="usd">6387000</allo:PrepaidResearchAndDevelopmentExpensesCurrent>
    <allo:PrepaidResearchAndDevelopmentExpensesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMy0xLTEtMjU2Ng_83f852ae-4b7c-4b0e-9d58-05405617a514"
      unitRef="usd">2356000</allo:PrepaidResearchAndDevelopmentExpensesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzQtMS0xLTEtMjU4MQ_a407ce1d-f76b-44b8-9f89-2f1370540551"
      unitRef="usd">2625000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzQtMy0xLTEtMjU4MQ_a24c5a82-987e-4c91-8781-6b5f8259afae"
      unitRef="usd">2376000</us-gaap:PrepaidInsurance>
    <allo:AccruedInterestOnShortTermMarketableSecurities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzItMS0xLTEtMA_bd28b54c-6311-47a6-a463-ae9d3fd63c81"
      unitRef="usd">2403000</allo:AccruedInterestOnShortTermMarketableSecurities>
    <allo:AccruedInterestOnShortTermMarketableSecurities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzMtMy0xLTEtMjUyNw_c4c2a123-4515-4fce-b618-320e4026f74a"
      unitRef="usd">3108000</allo:AccruedInterestOnShortTermMarketableSecurities>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzUtMS0xLTEtMA_22219a23-8ac0-4b4d-98e0-35a88ce4a637"
      unitRef="usd">2628000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzYtMy0xLTEtMjUyNw_ba2b6ed7-78d9-478b-bf64-4efe495c9388"
      unitRef="usd">758000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzYtMS0xLTEtMA_38dbf494-5151-415d-a7b8-33c773a11364"
      unitRef="usd">14043000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpkNTY5YWQxMWE1ZDc0ZTgzODMzYThjYjMzNzFhNTMzZS90YWJsZXJhbmdlOmQ1NjlhZDExYTVkNzRlODM4MzNhOGNiMzM3MWE1MzNlXzctMy0xLTEtMjUyNw_aa288b01-d2db-4638-a8df-360f83c5f071"
      unitRef="usd">8598000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3NA_6821d4d0-6e34-4f50-8f55-7ab353ba3b26">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9f3ba3d3dc894efaacd3513306d920ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMS0xLTEtMjYxNQ_2d219b35-6c30-46b9-9b69-b438994c8004"
      unitRef="usd">29924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ebbf8f4f5bf4febac60e511f7aa4329_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMy0xLTEtMjY1Ng_f793308d-e77b-4622-8dbe-44b45a705688"
      unitRef="usd">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib08b0bba7d634a958a96f0964cbad763_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzItMS0xLTEtMA_0e9640f4-b364-412c-a031-3119de16554d"
      unitRef="usd">13117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3db3a0119c79483e94242db1f548282c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzMtMy0xLTEtMjU0OA_e9195159-6bd2-462f-ad8e-12841b07d36f"
      unitRef="usd">5534000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if5852e80f853444996e612e6a78b2caa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMS0xLTEtMjYzMA_73a53295-e5a2-4e66-829d-3225aae006cb"
      unitRef="usd">12390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i38b72e2f0d4e48588b008f53598ce7d2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMy0xLTEtMjY2Mg_baa85288-7829-45ef-bf3f-3b8b9b7e70cf"
      unitRef="usd">2703000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5647d962561c44b8b5b291742b6f3eb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzQtMS0xLTEtMA_f9e7ae35-c5f1-47e3-a27b-5459f7fa05ec"
      unitRef="usd">3726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb2d346af52d45db8ca2a02108d6fb0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzYtMy0xLTEtMjY2NQ_3e95c5fb-d054-4461-9598-e16846eb9e3e"
      unitRef="usd">1327000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if797f590c7f0479a9a697558f2de76e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzUtMS0xLTEtMA_8a01c3b3-0d8f-44a8-b744-7b07a9d83ce3"
      unitRef="usd">2764000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i23478e60d4914559b5221e0ebd4c4fa8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzctMy0xLTEtMjY2NQ_dadfdf4a-e887-4112-aa4c-e8d33a19481a"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzctMS0xLTEtMA_08d8e530-2abd-43f8-a6d8-6fb7bae73947"
      unitRef="usd">61921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzgtMy0xLTEtMjY2OQ_b60baa8f-f34f-40f8-87bc-050a583a31c2"
      unitRef="usd">9643000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzgtMS0xLTEtMA_c3c76439-9c48-4013-bbd9-d2ab0ee18407"
      unitRef="usd">5472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzktMy0xLTEtMjY2OQ_92f6d7df-6180-4f75-908e-842b257e8775"
      unitRef="usd">1048000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzktMS0xLTEtMA_4757ff34-c1b6-42b7-8357-f26e16022f43"
      unitRef="usd">56449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTpiODU4MzBkMjlmYzA0ZjAwYjQzYzU3YzYxMDNhZmExMS90YWJsZXJhbmdlOmI4NTgzMGQyOWZjMDRmMDBiNDNjNTdjNjEwM2FmYTExXzEwLTMtMS0xLTI2Njk_9a53be12-2a35-4dd5-96c5-4a6659326988"
      unitRef="usd">8595000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzU0OTc1NTgxMzk1Njc_da8e227e-631e-4455-a1e2-52461efe7bc5"
      unitRef="usd">4600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQzOTgwNDY1MTE3NDk_21ec939e-968a-4ad7-8944-9c9395983f48"
      unitRef="usd">1000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjYwNzQ_e0389fee-d30c-424f-bd4d-e0faa4599a53"
      unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ5NDc4MDIzMjYwOTM_02b008a6-6c2e-4dcb-a929-24eeccb0c3ac"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzE1MzkzMTYyNzg5NTIz_0cc95959-0971-4ca6-a496-a31260073f3e">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic080d00e479b47cb866477893266680a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtMS0xLTEtMA_f2c411ef-d074-42ec-b6c4-cbeaa114af51"
      unitRef="usd">1206000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic080d00e479b47cb866477893266680a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtMy0xLTEtMA_ad3f3e58-5e30-4308-be29-d75678b61099"
      unitRef="usd">1055000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic080d00e479b47cb866477893266680a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTo5MTVjNTY0MWNjOGU0MzUzYjcyZWU2Njg3MWM2NDA0Ny90YWJsZXJhbmdlOjkxNWM1NjQxY2M4ZTQzNTNiNzJlZTY2ODcxYzY0MDQ3XzMtNS0xLTEtMA_823af234-55fb-4b92-b24a-903c9df5e9a4"
      unitRef="usd">151000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtMS0xLTEtMjczMg_2c4e3ec9-94aa-4bae-b439-36dab0bd4f19"
      unitRef="usd">1206000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtMy0xLTEtMjczMg_cb79a805-a78e-4151-ab97-5cef1b8e34da"
      unitRef="usd">452000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6160b48a66c14241831dadcdf19fd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZTowYzE3MjhmYzkzODk0MTgxYjRhM2I4YzExNmZkZjE3MC90YWJsZXJhbmdlOjBjMTcyOGZjOTM4OTQxODFiNGEzYjhjMTE2ZmRmMTcwXzMtNS0xLTEtMjczMg_357f2b25-b622-4ab5-a757-37122c234139"
      unitRef="usd">754000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzI5Nw_7067a047-ca33-4cba-a9b9-7008994e0499">P0Y3M3D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i35ab39239b6d44aeb0d2033f2a2a367f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzM3OQ_ed17dd0c-0a5a-40ff-a5e6-bbc9ed1b8d3e"
      unitRef="usd">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i109b33bc252c4867bdf458174acbbebf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzU0OTc1NTgxMzk2Nzk_d3fc682a-cf05-44df-8f61-21993d9f4143"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90ZXh0cmVnaW9uOmQzNjQ1NjczYTUzYzRkNDhhNzk4OTUwZDEzYmYyNDg5XzQ3Ng_d48aee9f-957c-4cfc-b76e-04a7298f81c5">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <allo:AccruedCompensationAndRelatedBenefitsCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMS0xLTEtMjY5MA_9cb7975d-ac69-4e93-af4b-0d7285f49328"
      unitRef="usd">9560000</allo:AccruedCompensationAndRelatedBenefitsCurrent>
    <allo:AccruedCompensationAndRelatedBenefitsCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMy0xLTEtMjY5MA_58c5d4c4-1cc1-405c-8fc8-26e6c8e6c643"
      unitRef="usd">4111000</allo:AccruedCompensationAndRelatedBenefitsCurrent>
    <allo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMS0xLTEtMA_8e44fc84-741a-4771-b7df-478f4630acb0"
      unitRef="usd">4833000</allo:AccruedResearchAndDevelopmentExpenseCurrent>
    <allo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzItMy0xLTEtMA_256a2803-18f8-4118-8ce7-9c4e79d52346"
      unitRef="usd">7808000</allo:AccruedResearchAndDevelopmentExpenseCurrent>
    <allo:AccruedPropertyAndEquipment
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMS0xLTEtODQwOQ_5a1dbd3b-47ba-4c87-adae-d2e9da19d991"
      unitRef="usd">3575000</allo:AccruedPropertyAndEquipment>
    <allo:AccruedPropertyAndEquipment
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMy0xLTEtODQwOQ_ac55d903-4861-4105-a41e-2528da15a5de"
      unitRef="usd">0</allo:AccruedPropertyAndEquipment>
    <allo:UnvestedSharesLiabilitiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzMtMS0xLTEtMA_d3138651-6bbe-4d65-9ab6-526d4139f81d"
      unitRef="usd">2843000</allo:UnvestedSharesLiabilitiesCurrent>
    <allo:UnvestedSharesLiabilitiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzMtMy0xLTEtMA_7d8578c2-0534-4356-954a-0661f02eab70"
      unitRef="usd">4590000</allo:UnvestedSharesLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMS0xLTEtMA_2d70cc3b-ea57-4ba6-b58f-5cc724db3959"
      unitRef="usd">3018000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzUtMy0xLTEtMA_c1130557-92bc-46c8-8b06-43d25afafe03"
      unitRef="usd">612000</us-gaap:OtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzYtMS0xLTEtMA_6b9da7ce-39a7-4eb8-b2d4-04951b4db85e"
      unitRef="usd">23829000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjQvZnJhZzpkMzY0NTY3M2E1M2M0ZDQ4YTc5ODk1MGQxM2JmMjQ4OS90YWJsZToyNzRjYzQ0M2E2NTg0MzA2OGI1OWJlNGJmYWU1OWM1Yi90YWJsZXJhbmdlOjI3NGNjNDQzYTY1ODQzMDY4YjU5YmU0YmZhZTU5YzViXzYtMy0xLTEtMA_9f837af7-1745-46fe-86c7-59971f11f1db"
      unitRef="usd">17121000</allo:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ5NDc4MDIzMjk2MDI_511dbc47-922a-4a8b-8adc-dfc1e3ed1d4c">Asset Acquisition&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts described in Note&#160;7, and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As consideration for the purchased assets, the Company issued Pfizer 3,187,772 shares of its Series&#160;A-1 convertible preferred stock with an estimated fair value of $111.8 million or $35.06&#160;per share. The Company also incurred $2.1 million of direct expenses related to the asset acquisition, bringing the total consideration to $113.9 million. The fair value of the Series&#160;A-1 convertible preferred stock was established using the price per share paid by third-party investors in the concurrent closing of the Series&#160;A and A-1 convertible preferred stock financing at $35.06&#160;per share as well as the price per share paid by Pfizer to purchase additional shares of Series&#160;A-1 convertible preferred stock at $35.06&#160;per share at the same time and at the same price per share as the rest of Series&#160;A and A-1 shares sold in such financing (see Note 11 for additional details). The Series&#160;A-1 convertible preferred shares issued to Pfizer had the same rights, preferences and privileges as the Series&#160;A convertible preferred shares issued to the third-party investors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, anti-CD19 CAR T&#160;cell therapy, thus satisfying the requirements of the screen test in ASU 2017-1. The assets acquired in the transaction were measured based on the fair value of the Series A-1 convertible preferred stock issued to Pfizer and direct transaction costs of $2.1 million, as the fair value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;equity given was more readily determinable than the fair value of the assets received. The following table summarizes the fair value of assets acquired (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In-process research and development (IPR&amp;amp;D):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-CD19 CAR T cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-BCMA CAR T cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair values of anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy were determined using a risk-adjusted discounted cash flow approach, which used the present value of the direct cash flows expected to be generated by anti-CD19 CAR T&#160;cell therapy and anti-BCMA CAR T cell therapy during their estimated economic lives, net of returns on contributory assets such as working capital, property and equipment, and the assembled workforce. The discount rate of 16.5% was based on rates of return available from alternative investments of similar type and quality as of the valuation date. The remaining IPR&amp;amp;D targets were determined to be more conceptual in nature with nominal value being attributed to them. The estimate of the fair value of the assembled workforce was determined using a replacement cost approach, based on the estimated cost of recruiting and training an equivalent workforce as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The amount allocated to intangible IPR&amp;amp;D assets was charged to research and development expenses as these assets had no alternative future use at the time of the acquisition transaction. The remaining intangible asset relates to the assembled workforce which was capitalized and is being amortized over its estimated economic life of two years to research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, under the terms of the Pfizer Agreement, the Company was also required to make milestone payments to Pfizer of $30.0 million or $60.0 million per target (depending on the target, and up to $840.0 million in the aggregate for all targets) upon successful completion of certain regulatory and sales milestones for certain targets covered by the Pfizer Agreement. No milestone payments were made or became due in the years ended December&#160;31, 2019 and 2018. These contingent payments were not part of the consideration for the purchased assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the asset acquisition, the Company also assumed licensing agreements Pfizer had entered into with two third-party entities holding certain intellectual property. Both agreements cover use of the intellectual property held by the parties and certain research collaboration activities. See Note 7 for additional details on these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Pfizer Agreement, the Company was required to use commercially reasonable efforts to develop and seek regulatory approval in and for the United States and the European Union for certain products covered by the Pfizer Agreement and to commercialize each product covered by the Pfizer Agreement in the applicable royalty territory in which regulatory approval for such product has been obtained.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ0OA_cce836b4-419f-47d4-bed6-480bd21715a6"
      unitRef="shares">3187772</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzUzNg_adb89426-ad52-4df6-a3d6-73b9edba98e3"
      unitRef="usd">111800000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzU0Mg_e073f257-7786-4c4b-a2b4-28b5032a9634"
      unitRef="usdPerShare">35.06</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzU4Mg_5b8179f0-c13c-4b13-b918-7c7d4c0c3f3d"
      unitRef="usd">2100000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzY3NA_77504cf6-1ae5-465a-9e97-8cd9ec8d87cb"
      unitRef="usd">113900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzkwMg_35085585-a615-4850-a317-c66cd4b7228c"
      unitRef="usdPerShare">35.06</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzEwMzY_053e27c3-509f-4d67-b134-0362247efaf5"
      unitRef="usdPerShare">35.06</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzE4NDk_29cf9347-c499-403d-8b74-00d2d2aeb006"
      unitRef="usd">2100000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <allo:ScheduleOfFairValueOfAssetsAcquiredTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzQ2MDk_ee23baf3-cc17-4d3c-8f86-958c719e058b">The following table summarizes the fair value of assets acquired (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In-process research and development (IPR&amp;amp;D):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-CD19 CAR T cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-BCMA CAR T cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</allo:ScheduleOfFairValueOfAssetsAcquiredTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzAtMS0xLTEtMA_33a98d25-2089-4d76-be54-fafd3a09eff8"
      unitRef="usd">3258000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i418f7561acb7456a9cd8ab2b0b615390_I20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzItMS0xLTEtMA_66f5d67c-a9cb-41f6-9589-498a12593f73"
      unitRef="usd">103936000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="id4c667c41352411c9e3641748894a942_I20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzMtMS0xLTEtMA_d172bceb-d681-4f0c-89bc-7d4b44481c4a"
      unitRef="usd">5500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie103799a43e847da97be9090d9658fdb_I20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzQtMS0xLTEtMA_dc57bbcb-d7e5-4123-b888-518bf5276b47"
      unitRef="usd">1206000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="iec3f1d9861bc4aec8c55821fb2f64337_I20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90YWJsZToyZDE2ZDE1OTc5ZjM0YTU0OWFhOTU0NjYyYmRhZjg3NC90YWJsZXJhbmdlOjJkMTZkMTU5NzlmMzRhNTQ5YWE5NTQ2NjJiZGFmODc0XzUtMS0xLTEtMA_7cef7f11-daa7-4dcb-81d6-8dc902372a1d"
      unitRef="usd">113900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <allo:DiscountRateForValuation
      contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzI1Mjg_cc5d5c2b-0be4-4215-a3dc-82829f2d8e21"
      unitRef="number">0.165</allo:DiscountRateForValuation>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzMzMjM_4e54153f-4a27-4354-8aa8-76f881d9cb21">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <allo:MilestonePayments
      contextRef="i209e07dad467461eb9a9d4bec5f07fe7_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM0ODc_273b5383-bcf5-4ed7-804a-b914ee3c2d4a"
      unitRef="usd">30000000.0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="id04f9a07e6ef4653bc71b89352bc570b_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM0OTM_451d3d59-8079-4278-9cea-d505adcbe57f"
      unitRef="usd">60000000.0</allo:MilestonePayments>
    <allo:AggregateMilestonePayments
      contextRef="i90a3f94bcbdb49319cff64e82005e418_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM1NDM_03ed091c-e246-4393-951d-d07ef4ea3d22"
      unitRef="usd">840000000.0</allo:AggregateMilestonePayments>
    <allo:MilestonePayments
      contextRef="if4c18293923046afb816ad6ab2d44ca8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM3MDM_0df7331b-5773-4bd0-98ea-b16e16d40ef4"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i7db1990140824815a537851541246079_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMjcvZnJhZzo0ODAxMDgzZDRjMGU0YWI1YWYyOGRhZGE5NTE4NzgwMi90ZXh0cmVnaW9uOjQ4MDEwODNkNGMwZTRhYjVhZjI4ZGFkYTk1MTg3ODAyXzM3MDM_4a17e599-91b3-40ff-8c7b-2b992bbce32d"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:LicenseAndCollaborationAgreementsTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ5NDc4MDIzMzUwMzU_e9241351-9d93-4ee1-ba92-a140eec593f8">License and Collaboration Agreements&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Asset Contribution Agreement with Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the Pfizer Agreement (see Note 6), the Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the years ended December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for which an IND is first filed on or before April&#160;6, 2023. The Company&#x2019;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research Collaboration and License Agreement with Cellectis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis. In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement. The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#x2019;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed against an Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i) the expiration of the last to expire of the licensed patents covering such product; (ii) the loss of regulatory exclusivity afforded such product in such country, and (iii) the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#x2019; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#x2019; prior written notice in the event of the other party&#x2019;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All costs the Company incurred in connection with this agreement were recognized as research and development expenses. For the year ended December&#160;31, 2019, $5.0 million of costs were incurred related to the achievement of a clinical development milestone under this agreement, which was recognized in research and development expenses in the statement of operations. No clinical development milestones were achieved for the year ended December&#160;31, 2018. For the years ended December&#160;31, 2019 and 2018, zero and $0.4 million, respectively, of costs have been incurred associated with research services performed by Cellectis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License and Collaboration Agreement with Servier&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Pfizer Agreement (see Note 6), Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In October 2019, the Company agreed to waive its rights to the one additional target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#x2019;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42 million and &#x20ac;70.5 million ($79.1 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#x2019;s election not to pursue such rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#x2019;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;party&#x2019;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, the Company recorded $7.3 million and $4.2 million, respectively, of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. As of December&#160;31, 2019 and 2018, amounts due to Servier of $2.2 million and $4.2 million were recorded in accrued and other current liabilities in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research Collaboration and License Agreement with Notch&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#x2019;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#x2019;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#x2019;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#x2019;s election, following the joint development committee&#x2019;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#x2019;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0 million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0 million investment in Notch&#x2019;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#x2019;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Notch Agreement, Notch will be eligible to receive up to $7.25 million upon achieving certain agreed research milestones, up to $4.0 million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0 million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#x2019;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#x2019;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#x2019;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#x2019; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has determined that Notch is a variable interest entity as of December 31, 2019. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the year &lt;/span&gt;&lt;/div&gt;ended December 31, 2019, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary.</allo:LicenseAndCollaborationAgreementsTextBlock>
    <allo:MilestonePayments
      contextRef="i506e30c449204baba23fb44c640ebef6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzUzOQ_47958978-5fa6-47ba-bd8c-0e01ad1143d7"
      unitRef="usd">30000000.0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i6017f1fd2aeb4f5dae24a3f6a824c26d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzU0NQ_835c0461-69a9-432f-8f9b-adc559f72dda"
      unitRef="usd">60000000.0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i9427490ef4a44d8f9b59d11282662b76_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2MDI_92959fd2-db39-45b7-8002-157b2291d599"
      unitRef="usd">840000000.0</allo:MilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ifff9430c2ddd4802ba7887cb075336c9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzExMDA_a7835cd3-7572-41d3-9f24-cfd0c7d53fe1"
      unitRef="usd">325000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget
      contextRef="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzMyNjU_8f73aa46-f78d-46d0-bf67-92df90df2c5f"
      unitRef="usd">185000000.0</allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget>
    <allo:AggregatePotentialMilestonePayable
      contextRef="i61808ff845034c22af5a68f40821c91c_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MjU_1ebc36ce-d37b-44b4-a550-29acc78e8c91"
      unitRef="usd">2800000000</allo:AggregatePotentialMilestonePayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6c06fbacca5f491d8f5469bd4fb315fd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU1Njg_2ddc0211-1211-433c-afd3-8ae3b643f4f8"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4e009a35341d451a85149de0373e2c4c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU1OTc_c25a17c5-6656-4a5f-bd91-50e46b28a472"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i75364e669b7b45f1a7aef2c29529fead_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ1MTY_ddf67665-ca45-4e37-be4d-e98ca487a332"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <allo:PercentageOfDevelopmentCostResponsibleFor
      contextRef="i9047b22f877746d385f33c4ed54f6267_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzY5MzI_85fd04bb-1bfd-4ccb-ae72-3b860590803b"
      unitRef="number">0.60</allo:PercentageOfDevelopmentCostResponsibleFor>
    <allo:PercentageOfDevelopmentCostResponsibleFor
      contextRef="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzcwMTU_13e41c4e-1fe3-4af9-8584-ac66b682d41e"
      unitRef="number">0.40</allo:PercentageOfDevelopmentCostResponsibleFor>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i2d0e971edbd54b578a622c44aadb4b6e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzc3Mzk_46549ab3-ed11-44fb-b08f-1817feffd8f1"
      unitRef="usd">137500000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i026e57edd43d4beb8496539196c89a2a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzc4NzE_7953fbbe-adff-44dd-83e4-06d612afe69f"
      unitRef="usd">78000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayable
      contextRef="i4b9afa63ed9142d29e23a8cc70154a6c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzg1NTk_c76f8396-efb9-4889-872d-8a843e498d63"
      unitRef="usd">42000000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayable
      contextRef="if9165b13a059438f9d7dce0930c8b3e1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzg1NjY_6714cf52-e83b-46a2-b2aa-6eb69f19b960"
      unitRef="eur">70500000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayable
      contextRef="if9165b13a059438f9d7dce0930c8b3e1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2MzY_2c84607d-1f16-4369-b0f7-8e52cb50ae2b"
      unitRef="usd">79100000</allo:AggregatePotentialMilestonePayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if21bb326b2bc4fae9dbc2931837a11f1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2NTU_a7b6eb30-37f7-49f4-840d-103d01c2e1f0"
      unitRef="usd">7300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0156b166fd0646f1a182d6801df909d7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzk5MTg_52a15e32-4cd5-4dab-a88c-8ac73b5f9353"
      unitRef="usd">4200000</us-gaap:ResearchAndDevelopmentExpense>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="ib9b1db0a202a4ae19712fb80c6cd0e22_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2NzE_475ab953-ea8e-41f5-b135-bdb30f0daa7f"
      unitRef="usd">2200000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i191222ceb5b4462cb69b763179a7d5b9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU2ODY_a0734792-3ef9-438b-b80c-21077a9ba420"
      unitRef="usd">4200000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i14f6805421204eae85b427c2f3c6052a_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3NDM_3663d14c-91ae-4bb4-9352-269a722fc570"
      unitRef="usd">10000000.0</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0d5aa740645543fbb3c41bb7edf9788d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzQ5NDc4MDIzNjU0NDY_df019476-e87e-4969-ac37-3f45810697b6"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3NjA_e13ea92c-699b-487a-992c-69d40b5ee949"
      unitRef="usd">5000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0e7e7a2f4f23417194037edbd03ce5c5_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3Njg_a2291156-ed99-4d0f-ad4d-7084602efc86"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:AggregatePotentialMilestonePayable
      contextRef="ibcc9be9dbd394b6582ca42b028bc5605_I20191231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU3ODM_6df29491-db05-49f5-ada1-6807176a21a0"
      unitRef="usd">7250000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i3adabcdd37fd4a4c9feddc86618ac41d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MDA_df46fde6-57c4-448b-a540-e7ad6828c9ec"
      unitRef="usd">4000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i46a7d0cfcf8146eb94cd73bc47ddd879_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzAvZnJhZzpkNTM4M2RlNDkyZmM0NGM5OGEyOWI1NDE1YzQ4M2NmYi90ZXh0cmVnaW9uOmQ1MzgzZGU0OTJmYzQ0Yzk4YTI5YjU0MTVjNDgzY2ZiXzM4NDgyOTA3MzU4MTk_eeba042a-db79-4c1d-9b6c-806ceff0bbb9"
      unitRef="usd">283000000.0</allo:AggregatePotentialMilestonePayments>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQ5NDc4MDIzMjgyNjI_99d91a05-9d73-4666-80db-c47dd99a75af">Leases&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $5.1 million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $1.0 million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $23.2 million and $24.6 million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $30.9 million and $26.3 million, respectively, on the balance sheet. The remaining lease term is 9 years and 2 months, and the estimated incremental borrowing rate is 8.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of $0.2 million. In connection with the lease, the Company recognized an operating lease right-of-use asset of $5.9 million and $6.2 million as of December&#160;31, 2019 and 2018, respectively, and an aggregate lease liability of $6.2 million and $6.3 million, respectively, on the balance sheet. The remaining lease term is 9 years and 2 months, and the estimated incremental borrowing rate is 8.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, the Company entered into two operating leases for office space in New York and Los Angeles for approximately 4,358 and 1,293 square feet respectively. The Company recognized operating lease right-of-use assets of $1.7 million and $2.0 million for New York and $0.1 million and $0.2 million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The Company recognized aggregate lease liabilities of $1.7 million and $2.0 million for New York and $0.2 million and $0.2 million for Los Angeles as of December&#160;31, 2019 and 2018, respectively. The lease term for the New York operating lease is 6 years and 7 months, with no option for renewal. The lease term for the Los Angeles operating lease is 3 years with an option to extend the lease term for another 2 years which is not reasonably assured of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintained a letter of credit for the benefit of the landlord in the amount of $0.1 million. The remaining lease terms were 5 years and 6 months for New York and 1 year and 11 months for Los Angeles at December&#160;31, 2019 and the estimated incremental borrowing rates applied were 8.0% and 7.5%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. Upon certain conditions, the Company has two &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNjc_5253a5b3-7a0c-4331-8539-db7f2e8159f7"&gt;ten&lt;/span&gt;-year options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company will maintain a letter of credit for the benefit of the landlord in the amount of $3.0 million. The Company started accounting for this lease in October 2019 when tenant improvement work commenced, and recognized an operating lease right-of-use asset of $13.6 million as of December 31, 2019 and an aggregate lease liability of $14.0 million on its balance sheet. The lease term is 188 months, and the estimated incremental borrowing rate is 9.25%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The undiscounted future non-cancellable lease payments under our operating leases as of December&#160;31, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.032%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.542%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rent expense for the Company&#x2019;s operating leases was $5.9 million and $1.9 million for the years ended December&#160;31, 2019 and 2018, respectively, net of lease incentives recognized. Rent expense for short-term leases was $2.4 million and $2.6 million for the years ended December&#160;31, 2019 and 2018, respectively. There was a total commitment of zero and $1.6 million at December&#160;31, 2019 and 2018, respectively, related to short-term leases. Variable lease payments for operating expenses were $1.1 million and immaterial for the years ended December&#160;31, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain lease agreements require the Company to return designated areas of leased space to its original condition upon termination of the lease agreement. At the inception of such leases, the Company records an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. To determine the fair value of the obligation, we estimate the cost for a third-party to perform the restoration work. In subsequent periods, for each asset retirement obligation, the Company records interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Asset retirement obligations were $0.4 million and zero as of December&#160;31, 2019 and 2018 respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <allo:AreaOfNewOfficeBuilding
      contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY1MzM_7fc944d4-85b0-4f3a-bb2a-f2c2219108f9"
      unitRef="sqft">68000</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzIzNQ_cd9eeb18-4896-4f09-a648-42880fdd08ad">P127M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzMxNw_977d24df-bfc9-405a-9194-d8aebd901b7c">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AllowanceForTenantImprovements
      contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzUwMA_3507e65e-8a48-40b9-a2d2-7f6dea5b8f30"
      unitRef="usd">5100000</allo:AllowanceForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="icbf3d6643fd944bc90b9feba06c32cda_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzY5Nw_bd7d87d6-7840-4e16-966c-11055a8f177e"
      unitRef="usd">1000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic0412b597de74f279eae527af0469dbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwMTA_373441f4-f63c-4fcb-92e4-7c2933e4082d"
      unitRef="usd">23200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwMTk_015c12bd-86f8-452d-b416-1e419ca1347c"
      unitRef="usd">24600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic0412b597de74f279eae527af0469dbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwNTk_e44805b0-870c-480b-9dd7-5cb51b14f0c2"
      unitRef="usd">30900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4811a06ed50f4a5f816b8f383cffaa9b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYwNjg_2a4e5672-5105-444e-9032-9d6400d5e491"
      unitRef="usd">26300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic0412b597de74f279eae527af0469dbd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMTM_f23bd6a7-93fa-4d23-969e-02e5e0c12442">P9Y2M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ic0412b597de74f279eae527af0469dbd_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxMDg_688b73c9-c558-4119-bcc1-7d9c3d33a2b0"
      unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
    <allo:AreaOfNewOfficeBuilding
      contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzExMTA_4ea8d027-99ae-484d-86e4-72bc3aedbecf"
      unitRef="sqft">14943</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzExODc_79c1efa2-e97b-40b6-b8bb-2079a93fec32">P124M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzEyNzI_56bab084-c7a3-47c8-be51-9042361d2a0e">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AllowanceForTenantImprovements
      contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzE0NzQ_558a8388-703d-495c-b09a-24caf23c01ca"
      unitRef="usd">800000</allo:AllowanceForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic595c56b5f7746d49d315a4a7cde38f2_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzE2NDE_d15dc885-d1ef-4248-b0eb-612c495da22d"
      unitRef="usd">200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxMTU_76aae00e-a345-4524-8631-b6377f84e70d"
      unitRef="usd">5900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia4a231e4e72e4029ac07d4f130b3076f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNTM_b8fada93-3110-4e3e-bb91-3283dbc4d3fb"
      unitRef="usd">6200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNDY_655cfe09-f9f8-4a50-8a59-b041d800adee"
      unitRef="usd">6200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia4a231e4e72e4029ac07d4f130b3076f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYxNTY_600971a9-3860-41d4-85ad-becd831e373b"
      unitRef="usd">6300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYyMTA_f662cbaf-86d1-43e4-b8b9-a42f34d9e777">P9Y2M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i7e9597cce0a04b50aacae109805022c9_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY1MzA_efff4a71-39be-4165-9b2d-21d0907b18d3"
      unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
    <allo:OperatingLeasesNumberOfLeaseAgreements
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMTg_b93416f2-172b-4e8a-b803-caf38b26ddf1"
      unitRef="operatinglease">2</allo:OperatingLeasesNumberOfLeaseAgreements>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMjI_1f69a1da-37c1-4112-bcbd-5cc3fbb950c1"
      unitRef="sqft">4358</allo:AreaOfNewOfficeBuilding>
    <allo:AreaOfNewOfficeBuilding
      contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTYzMjU_7b0160cd-4911-4f23-b7a5-623d1c0798b2"
      unitRef="sqft">1293</allo:AreaOfNewOfficeBuilding>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifd2210c6df794207907be5b74981ad04_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3Njc_f2524ca4-3084-4b32-b99d-23c71d289830"
      unitRef="usd">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3NzA_01b580f6-cd5e-4472-8db6-078342c3263f"
      unitRef="usd">2000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3ODE_d280cbab-5012-4523-ad72-1ebc53153c72"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY3OTI_70e829e7-f217-4949-ae91-35aaa95a109a"
      unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifd2210c6df794207907be5b74981ad04_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MDE_cc372e12-4f5c-46a1-9ffc-68af1319e7a4"
      unitRef="usd">1700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MDQ_e0a4f57c-2cee-4595-b829-9b7c4711da0c"
      unitRef="usd">2000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MTU_e72a4cfa-a0a4-44ad-9526-bc14fc72f82c"
      unitRef="usd">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY4MjY_52077835-76e9-44f9-a52c-3bdf94d81a31"
      unitRef="usd">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6c8f54a8c27e479c9d1a5dfa0553ba70_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTY5OTk_8bad4b5c-457e-4ed8-a24a-aa140347cb27">P6Y7M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iab52ee2110ab4c6bbcf51aecc895a232_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMDQ_43eae74e-820a-47c4-8677-17912d21902b">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMDc_54191ad0-06ab-4da5-8b81-22a3f1859184">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ifd2210c6df794207907be5b74981ad04_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMTM_5cb854b9-484c-4030-b327-ddceafa6168b"
      unitRef="usd">100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ifd2210c6df794207907be5b74981ad04_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwMzg_cc544c4d-b49e-48c3-b3f7-74b6edcf0083">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNjM_67e679ed-4929-4816-9741-c17f46d5891c">P1Y11M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ifd2210c6df794207907be5b74981ad04_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNjg_4d89285a-2e8f-42f3-a77c-954d120f0575"
      unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i515685bbda6b4ca09271838cbbbc3a24_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwNzI_dcd1b0f7-a96e-48c1-9f40-1279a492002e"
      unitRef="number">0.075</us-gaap:LesseeOperatingLeaseDiscountRate>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTcwODE_da94ee9a-cd53-44b7-ae86-63dc8966ff02"
      unitRef="sqft">118000</allo:AreaOfNewOfficeBuilding>
    <allo:LesseeOperatingLeaseOptionToExtendNumber
      contextRef="i54c6044221fa4585b6ea5a3c74e488dd_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzc2OTY1ODE0NjQxNzg_10ec3085-f7bb-484f-831e-fe5a2d8a92f5"
      unitRef="option">2</allo:LesseeOperatingLeaseOptionToExtendNumber>
    <allo:AllowanceForTenantImprovements
      contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTczNzQ_eb43ecef-f024-4059-b335-ed3caa6950bf"
      unitRef="usd">2900000</allo:AllowanceForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTczOTE_094c0949-0d3f-4955-9cd2-009847019e40"
      unitRef="usd">3000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3Mjg_295ead7e-62bb-4a1f-a10f-9e490b16885c"
      unitRef="usd">13600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3NDE_a30734ba-f04b-4694-a7c3-d96999dd5c1a"
      unitRef="usd">14000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i490046a46cbd43ce9bd693d61995f8bd_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQ5NDc4MDIzOTQ4MzQ_96da8ee0-683e-4e80-9345-1ee834416be0">P188M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ic80e95b53fb54d0e848be36d0b009f5a_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3ODY_f0faf4bf-aab8-4a67-83d5-975dec6d9edc"
      unitRef="number">0.0925</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzMyNjQ_245d94d8-c046-47b9-bcd3-fb59c6b5396f">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The undiscounted future non-cancellable lease payments under our operating leases as of December&#160;31, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.032%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.542%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzEtMi0xLTEtMA_2d577189-f414-46a8-9bb4-b636832c2508"
      unitRef="usd">5662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzItMi0xLTEtMA_f3bfc496-e117-43a6-ab01-75b72135e9a4"
      unitRef="usd">7632000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzMtMi0xLTEtMA_c9f8ebb6-a4e2-44fa-806f-015ec18109b9"
      unitRef="usd">7951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzQtMi0xLTEtMA_d3080040-2410-4037-b4b2-8ce643a94744"
      unitRef="usd">8203000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <allo:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzUtMi0xLTEtMA_389f26c2-989d-4ffa-a24b-c5783f541123"
      unitRef="usd">63864000</allo:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzYtMi0xLTEtMA_b589d735-5dd8-4aef-ae04-eefabb6c4d1e"
      unitRef="usd">93312000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzctMi0xLTEtMA_c2d33209-3aef-4fce-80c8-8ed601ee289c"
      unitRef="usd">35920000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <allo:AllowanceForTenantImprovements
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzgtMi0xLTEtMA_39c4c785-572e-4888-b4a9-d2122f336b8e"
      unitRef="usd">4367000</allo:AllowanceForTenantImprovements>
    <us-gaap:OperatingLeaseLiability
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90YWJsZTplOGVkODVmNzZkNGI0ZjU5ODIzMmI0MWMyOTZjYThhZS90YWJsZXJhbmdlOmU4ZWQ4NWY3NmQ0YjRmNTk4MjMyYjQxYzI5NmNhOGFlXzktMi0xLTEtMA_df080e30-1512-4df7-929f-4c149804b788"
      unitRef="usd">53025000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc3OTc_b10eca25-84be-4912-aa7d-f91fecb82841"
      unitRef="usd">5900000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4MzA_7ab6ef57-1d5f-4d4c-bb14-635adb9a9322"
      unitRef="usd">1900000</us-gaap:OperatingLeasesRentExpenseNet>
    <allo:ShorttermLeaseRentExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4MzI_78184b45-74c6-475b-9151-1fe814f5b059"
      unitRef="usd">2400000</allo:ShorttermLeaseRentExpense>
    <allo:ShorttermLeaseRentExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4NDA_61bd31a0-9429-428a-8ce9-fc966cf3f896"
      unitRef="usd">2600000</allo:ShorttermLeaseRentExpense>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4Nzg_d50874a5-3aa0-4202-91b3-1005eb171b94"
      unitRef="usd">0</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc4ODM_18e05d9a-8ed5-44f6-8657-93229eaaac1f"
      unitRef="usd">1600000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:VariableLeasePayment
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTc5OTY_0cb163c1-b7df-46af-b78f-f66fa0d21967"
      unitRef="usd">1100000</us-gaap:VariableLeasePayment>
    <allo:OperatingLeaseAssetRetirementObligation
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzYwNDczMTM5NjA1ODA_0fec5484-6d24-4f74-b4a6-a25c8f116fdc"
      unitRef="usd">400000</allo:OperatingLeaseAssetRetirementObligation>
    <allo:OperatingLeaseAssetRetirementObligation
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzMvZnJhZzoyYjI0YjVlZTJlMWM0ZGYzYWE1ZjRmYjNhN2E1ZGVhZS90ZXh0cmVnaW9uOjJiMjRiNWVlMmUxYzRkZjNhYTVmNGZiM2E3YTVkZWFlXzQzOTgwNDY1MTkyNTA_483b1696-2f31-4598-ba03-303be368efa8"
      unitRef="usd">0</allo:OperatingLeaseAssetRetirementObligation>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDEz_34bac431-ff0e-47c8-95b4-f68589849841">Equity Method Investment&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the execution of the Notch Agreement (see Note 7), the Company also entered into a Share Purchase Agreement (&#x201c;Notch Investment Agreement&#x201d;) with the Company acquiring shares of Notch&#x2019;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1 million, resulting in a 25% ownership interest in Notch. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s total equity investment in Notch as of December 31, 2019 was $4.9&#160;million and the Company accounted for the investment using the cost method of accounting. During the year ended December 31, 2019, the Company recognized its share of Notch's net loss under the other expenses caption within the statement of operations. The Company's share of Notch's net loss was $0.2 million for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="id582a2792aa240b5b2ce2ac625929e33_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDMy_b139054d-f77f-41be-a21e-3b183457c90b"
      unitRef="usd">5100000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <allo:CostMethodInvestmentTransactionCosts
      contextRef="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzUy_1d112a8d-b5d1-4cfb-aa32-a0a0d84e8010"
      unitRef="usd">100000</allo:CostMethodInvestmentTransactionCosts>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i245b301a06c44689b7b0147fb93ad43b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzU4_09f86116-3d77-4d2f-bae7-d927c7072945"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i245b301a06c44689b7b0147fb93ad43b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80OTQ3ODAyMzMyMDQ0_ba948523-b7cf-4c6b-8466-9d51f1bbbc99"
      unitRef="usd">4900000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i10d2bf2cbd794c5eb192e9f18361cd47_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8yMDUzL2ZyYWc6MWIzZjY3MTM1Y2M2NGE2NTg5ZTA5MjE5MmYwZWE4NzIvdGV4dHJlZ2lvbjoxYjNmNjcxMzVjYzY0YTY1ODllMDkyMTkyZjBlYTg3Ml80Mzk4MDQ2NTE4NzM3_d9958f96-b708-47fb-afc5-93db9c76a74b"
      unitRef="usd">200000</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xMzkvZnJhZzo2N2Q4ZmQzNDFhMzU0MTE4YmMzNjNmMWMyZGY1ZjIwMi90ZXh0cmVnaW9uOjY3ZDhmZDM0MWEzNTQxMThiYzM2M2YxYzJkZjVmMjAyXzQ5NDc4MDIzMjY1OTY_9cf9403b-0b30-4526-9acf-8261b3a202f9">Commitments and Contingencies&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, and we have entered into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.&#160;The Company&#x2019;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made.&#160;The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accordance with the Company&#x2019;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity.&#160;There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5NDc4MDIzMjYyNzQ_33ed97bb-ef3c-421c-a611-88cf6503e707">Convertible Notes Payable (2018 Notes)&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $120.2 million in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of $116.8 million. On issuance, the fair value of the 2018 Notes was determined to be equal to $120.2 million, which is the principal amount of the 2018 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2018 Notes did not accrue interest. The 2018 Notes were settled in 7,856,176 shares of common stock in connection with the closing of the Company&#x2019;s IPO (see Note 1) at a settlement price equal to 85% of the IPO price per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in estimated fair value being recognized through the statements of operations and comprehensive loss until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be $141.4 million upon settlement. For the years ended December&#160;31, 2019 and 2018, the Company recognized zero and $21.2 million, respectively, of expense in the accompanying statements of operations and comprehensive loss for the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of $3.4 million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzE3Ng_9022b838-e7d1-4b8c-9008-dbd2d0bdffab"
      unitRef="usd">120200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="icda41dabcaa34bdaab4176cab5929a78_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzI4Nw_fefa648b-fb02-4290-ac22-651f795c6d63"
      unitRef="usd">116800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:LongTermDebtFairValue
      contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzM2Nw_0c9fb127-f713-4bff-909a-35070e7a72a2"
      unitRef="usd">120200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia1e77081a4174e0b8f9404acb7712569_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5MQ_6169e23a-7418-4764-af1a-58e02c43fe39"
      unitRef="shares">7856176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="ie63f9c3516964c56af3104a004c46f95_D20181001-20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQ5NDc4MDIzMjYyNzY_3d4d59de-089a-4246-b803-a8391833af17"
      unitRef="number">0.85</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:LongTermDebtFairValue
      contextRef="i821e501b07404b9a9c7d2c5ca11840c7_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzkyNA_eb5bb814-19f0-4d47-9745-5911071e845e"
      unitRef="usd">141400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzQzOTgwNDY1MTI1Njk_91838a71-7de7-42f6-aaa8-b0dfcbdf8a64"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzk5MA_2569ef73-acc4-4969-b5a7-3da1fc9c74c7"
      unitRef="usd">21200000</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i97a7d47bd645462aa3e6c38d02dd4202_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDIvZnJhZzowNTM2Zjc3MzBhMGI0NWRkOTEyMzY2MTgwMjM5MzI0ZC90ZXh0cmVnaW9uOjA1MzZmNzczMGEwYjQ1ZGQ5MTIzNjYxODAyMzkzMjRkXzExNjI_74e89e0a-3309-47f0-b8f0-6e94f462cd22"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQ5NDc4MDIzMjcxNjM_4d79557c-7871-49e1-89f3-5b3c39e1edc6">Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As discussed in Note&#160;6, the Company issued 3,187,772 shares of its Series&#160;A-1 convertible preferred stock to Pfizer in connection with the Pfizer Agreement entered into in April 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company issued 7,557,990 shares of its Series&#160;A convertible preferred stock at a price per share of $35.06 for net cash proceeds of $264.4 million and issued 998,225 shares of Series&#160;A-1 convertible preferred stock at a price per share of $35.06 for net cash proceeds of $34.9 million. Fifty percent of the aggregate purchase price of $300.0 million was paid in April 2018. The remaining subscriptions receivable of $150.0 million was received in July and August 2018, at the election of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On the completion of the IPO (see Note 1), all outstanding shares of convertible preferred stock were automatically converted into 61,655,922 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of 10,000,000&#160;shares of preferred stock, of which no shares were issued and outstanding at December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation filed on October 15, 2018, as amended, the Company is authorized to issue a total of 200,000,000&#160;shares of common stock, of which 124,267,358 and 121,482,671 shares were issued and outstanding at December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the issuance of the Company&#x2019;s Series A convertible preferred stock in April 2018, the Company&#x2019;s founders agreed to modify their common shares outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 26,249,993 modified shares of common stock became compensatory upon such modification. The total compensation cost resulting from the modification is approximately $59.5 million and is being recognized over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4OTk_9cc142d9-55cb-4a93-93b8-502c7e750f35"&gt;four&lt;/span&gt; year vesting term.&lt;/span&gt;&lt;/div&gt;Common stockholders are entitled to dividends if and when declared by the Company&#x2019;s Board of Directors subject to the prior rights of the preferred stockholders. As of December&#160;31, 2019 and 2018, no dividends on common stock had been declared by the Company&#x2019;s board of directors.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE0OA_23a6dabd-0cb3-41c2-9623-a01766f19de6"
      unitRef="shares">3187772</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ia3471d8f101c4d3ba94220c7aad9494d_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzMxNg_d6e58a1d-4421-407a-904e-aa908c91c50d"
      unitRef="shares">7557990</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia3471d8f101c4d3ba94220c7aad9494d_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzM5NA_71091379-62a8-4fa4-bbfd-4767b834b84f"
      unitRef="usdPerShare">35.06</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i3f92a81d50e2447da3666732666bc702_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQyMg_52d985d6-95e4-4cdb-8802-dcc7cd986f36"
      unitRef="usd">264400000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzNg_ebf8ae23-6d4a-4de3-ab9c-9f98e95b5a72"
      unitRef="shares">998225</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib026706ac7b34638a5206f120c795fcf_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzUxMg_ca1f6c08-5e91-4bf1-b54d-05a7cbd6650f"
      unitRef="usdPerShare">35.06</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i11132d1f8e8d4a56ac46785ef02d289e_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzU0MA_93b9b6e6-a714-453d-801f-8cf4f8eaa87c"
      unitRef="usd">34900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <allo:AggregatePurchasePriceSharesValue
      contextRef="i983a7f491bc342188b274ebaacc4b537_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzU5Mw_686f65b2-c4dc-4147-a28c-5db6a9c19730"
      unitRef="usd">300000000.0</allo:AggregatePurchasePriceSharesValue>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable
      contextRef="if780bd54cfd745968c9507e6e347e804_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzY2Mg_4dc02908-bf09-47c6-b2eb-c423505c9859"
      unitRef="usd">150000000.0</us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="id87618dee4474bd9a48ad4abc969f130_I20181010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5Xzg4Nw_95633ee6-5525-48d7-8d5c-7e72b7404e5e"
      unitRef="shares">61655922</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEwODE_4cb46eed-d35a-4993-a43c-c0bb9ae77635"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_07923c8a-5c54-4c66-9ed1-e9c820717518"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_2fdb570b-2bb8-4efa-973b-ea0ef2624cfe"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_36cbb2a8-9344-425a-8a23-f3190087009c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzExMjA_b885b8ea-d875-4fc4-a6a9-9afb4d700026"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzMzA_14ad3dcd-e472-462f-8406-ef1a8c75a793"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzOTgwNDY1MTMzMDA_1b34abc4-f34b-4a48-94c9-2eb867de49ad"
      unitRef="shares">124267358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzQzOTgwNDY1MTMzMDA_2e9c5775-ff92-4b13-83da-8387305dfb3c"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzNjY_1e4a2731-e048-4ad7-aadc-ff339f39dd07"
      unitRef="shares">121482671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzEzNjY_ae239ed7-3955-4b2d-832e-3dabedb2679e"
      unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
    <allo:ModificationOfConvertiblePreferredStockForCommonStock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE3MDc_a6ed6530-fd73-45b0-a4f6-2693b948d142"
      unitRef="shares">26249993</allo:ModificationOfConvertiblePreferredStockForCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzE4NjM_12f86bc5-6ba7-4041-b683-36adbb418312"
      unitRef="usd">59500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzIwODg_0664c6ab-3118-4c62-8350-6b21b36cc473"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDUvZnJhZzplZmYxN2QyNjgzZDk0YjkzOTI2OThhY2VjMTI4YmNjOS90ZXh0cmVnaW9uOmVmZjE3ZDI2ODNkOTRiOTM5MjY5OGFjZWMxMjhiY2M5XzIwODg_4832c564-fb08-4e52-b880-67625215b3d5"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzMyOTY_3bf83780-390c-4006-bab4-2fbc9879ab34">Stock-Based Compensation&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#x2019;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#x2019;s Board of Directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to 5% of the total number of shares of common stock outstanding on December 31&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;st&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options granted typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzEwODk_5e3a8163-9ab6-4322-bca2-e60302945177"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc1MzQ_e0c6a459-876a-4698-840d-09c9bbd3a86c"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms. Options shall not have an exercise price less than 100% of the fair market value of the Company&#x2019;s common stock on the grant date. If the individual possesses more than 10% of the combined voting power of all classes of stock of the Company, the exercise price shall not be less than 110% of the fair market value of a common share of stock on the date of grant. This requirement is applicable to incentive stock options only.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, there were 9,642,503 and 8,176,125 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,336,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,020,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(80,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,235,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,052,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(711,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(386,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,660,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on December&#160;31, 2019. During the years ended December&#160;31, 2019 and 2018, the estimated weighted-average grant-date fair value of employee options granted was $18.42 per share and $3.75 per share, respectively. As of December&#160;31, 2019 and 2018, there was $74.7 million and $42.8 million, respectively, of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 3 years, 15 days and 3 years, 6 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.645%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$25.94 - $31.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$2.27 - $26.52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.99&#160;-&#160;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.14% - 74.92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.2% - 77.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.54% - 2.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.74% - 2.99%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair value of common stock&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;For grants before October 2018 when the Company was private and there was no public market for the Company&#x2019;s common stock, the fair value of the Company&#x2019;s common stock underlying share-based awards was estimated on each grant date by the Company&#x2019;s board of directors. In order to determine the fair value of the Company&#x2019;s common stock underlying option grants, the Company&#x2019;s board of directors considered, among other things, valuations of the Company&#x2019;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. For all grants subsequent to the Company&#x2019;s IPO in October 2018, the fair value of common stock was determined by taking the closing price per share of common stock per Nasdaq.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected term&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected dividend&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to stock options was $21.9 million and $3.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,982,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;&#160;In September 2019, the Company granted 57,361 performance based restricted stock units to a certain executive officer pursuant to the 2018 Plan. These performance awards are subject to the holder's continued service to the Company through each applicable vesting event. Through December 31, 2019, the Company believes that the achievement of the requisite performance conditions for these awards are not probable and as a result, no compensation expense has been recognized related to these awards in the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to restricted stock units was $8.8 million and zero, respectively. As of December 31, 2019 and 2018, there was $43.0 million and zero, respectively, of unrecognized stock-based compensation which is expected to be recognized over a weighted average period of 1.98 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In October 2018, the shareholders approved the 2018 Employee Stock Purchase Plan (ESPP), which initially reserved 1,160,000&#160;shares of our common stock for employee purchases under terms and provisions established by the Board of Directors. Effective January 1, 2019, the number of shares authorized under the ESPP for employee purchases increased by 1,214,826 shares. The ESPP is intended to qualify as an &#x2018;employee stock purchase plan&#x2019; under Section 423 of the Internal Revenue Code. Under the current offering adopted pursuant to the ESPP, each offering period is approximately 24 months, which is generally divided into four purchase periods of approximately six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Employees are eligible to participate if they are employed by the Company. Under the ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;85%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the purchase date. The ESPP provides for consecutive, overlapping&#160;24-month&#160;offering periods. The offering periods are scheduled to start on the first trading day on or after March 16 or September 16 of each year, except for the first offering period which commenced on October 11, 2018, the first trading day after the effective date of the Company&#x2019;s registration statement. Contributions under the ESPP are limited to a maximum of&#160;15%&#160;of an employee&#x2019;s eligible compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of the rights granted under the ESPP were calculated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.610%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.548%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.822%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50 &#x2013; 2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50 &#x2013; 2.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.4% - 76.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.7%&#160;-&#160;81.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.72%-2.49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.37% - 2.83%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, total stock-based compensation expense related to ESPP was $1.6 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Founders&#x2019; Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense is recognized for shares of founders&#x2019; stock as vesting conditions are met. In relation to the modification described in Note 12, 24,230,750 shares of founders&#x2019; stock remained unvested at the modification date in April 2018. For the years ended December&#160;31, 2019 and 2018, $13.7 million and $14.9 million of stock-based compensation expense was recognized related to the vesting of 6,057,684 and 6,562,506 shares, respectively, of founders' stock. At December&#160;31, 2019 and 2018, there was $30.9 million and $44.6 million of unrecognized stock-based compensation expense related to 13,629,803 and 19,687,487 shares of unvested founders&#x2019; stock which is expected to be recognized over 2 years, 3 months and 3 years, 3 months, respectively. The weighted-average fair value at grant date for founders&#x2019; stock was $2.27 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense related to stock options, employee stock purchase plans and vesting of the founders&#x2019; common stock was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.471%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Early Exercised Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#x2019;s lapsing repurchase right upon termination of employment or service on the Company&#x2019;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the years ended December&#160;31, 2019 and 2018,  zero and 5,020,580 options were early exercised. As of December&#160;31, 2019 and 2018, there was $2.8 million and  $4.6 million recorded in accrued and other liabilities and $3.9 million and $6.8 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the financial statements since the exercise date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NjY_437e91bd-ef1b-4ca3-9ce5-dc783ec1c50e"
      unitRef="number">0.05</allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <allo:StockOptionGrantedPeriod
      contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1Njk_ef1b4889-4637-4ca9-8e6b-6aa9b39a8726">P10Y</allo:StockOptionGrantedPeriod>
    <allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate
      contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NzI_6f8b6a0e-76ed-4ef1-921d-94860f865cba"
      unitRef="number">1</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate>
    <allo:CombinedVotingPowerByIndividual
      contextRef="i2fe5e85d46bc42af97edd8a33aeb5fac_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1NzY_e2c79f6b-7315-4e54-9e9e-9450fc8eaf89"
      unitRef="number">0.10</allo:CombinedVotingPowerByIndividual>
    <allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1
      contextRef="id3a979d95a144c5299a2bd154d9cf05c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODA_2ed44749-d4cd-4f80-b8a5-6fad9e6f5984"
      unitRef="number">1.10</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODQ_42715812-fd2e-4b5d-9939-32ea85d738f3"
      unitRef="shares">9642503</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1ODc_4560a6c1-d5ea-4aab-8181-327a2f3dc985"
      unitRef="shares">8176125</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDA_936dd60c-ca9c-4d21-938f-9565529795eb">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,336,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,020,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(80,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,235,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,052,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(711,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(386,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,660,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtMy0xLTEtMA_11cce863-96d1-4a03-a899-7db7a6bc9913"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtNS0xLTEtMA_07777e30-d793-4dd7-ac37-8e39529ebc39"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia43d81dd97134b1c840f4d8375d51b36_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtNy0xLTEtMA_292731fa-1b53-4798-9791-854039898395"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i21acb7c55f624e3ebf064ece42649a1c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzMtOS0xLTEtMA_11f2d267-6c68-4b2a-a4b7-9c68ca1d7ec0"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzUtMy0xLTEtMA_39cec952-86c0-48eb-a1fb-cd8007011672"
      unitRef="shares">12336975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzUtNS0xLTEtMA_8c1e088b-8ca9-4665-8735-2375db3f0fb7"
      unitRef="usdPerShare">5.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtMy0xLTEtMA_984fd4f7-d137-48d3-a63c-63aeecad475c"
      unitRef="shares">5020580</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtNS0xLTEtMA_b9785488-0557-459b-8404-5fd4eec3c478"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzYtOS0xLTEtMA_706058a9-420b-4fb5-a617-d4c018cdae0b"
      unitRef="usd">123808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzctMy0xLTEtMA_548ddeb4-4244-4d5d-bdc3-4812b0edf89d"
      unitRef="shares">80850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzctNS0xLTEtMA_fab0c0d3-69f0-4e4e-9adb-757f24491b65"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMy0xLTEtMA_89a5e2fb-fa20-46a1-8fdb-e59f57ea7b7c"
      unitRef="shares">7235545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtNS0xLTEtMA_a417224c-1513-40f2-83c3-3a16d53259d6"
      unitRef="usdPerShare">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie5f900e1466c4331a1db0fd0a796c321_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtNy0xLTEtMA_2eeb4ed7-5e6a-46bb-89ce-c4b98573d797">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia3b1bbea2dda41ae8378f8f1d16b0782_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtOS0xLTEtMA_56470ed2-299c-40e9-8c30-db472a916023"
      unitRef="usd">139001000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMS0xLTEtMzk5Nw_be8578ce-8ee7-4162-920f-040e14d47d03"
      unitRef="shares">3052816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzgtMy0xLTEtMzk5Nw_a8555ac9-97cc-4339-bfb8-3e7c0fd1b0da"
      unitRef="usdPerShare">27.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMS0xLTEtMzk5Nw_f435a04e-257c-4388-b728-6cafbc1981f8"
      unitRef="shares">711123</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMy0xLTEtMzk5Nw_1daa2f54-c2f4-4e31-9340-dca1eddba555"
      unitRef="usdPerShare">4.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNy0xLTEtMzk5Nw_1235df4a-aad9-464e-a03a-5ce8cc16b129"
      unitRef="usd">17141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTEtMS0xLTM5OTc_c9f73571-f6fd-4348-a6a3-5cddf11dc0a4"
      unitRef="shares">386716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTMtMS0xLTM5OTc_b70c2841-4255-415f-b8fb-cebfb12e4b10"
      unitRef="usdPerShare">8.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTEtMS0xLTM5OTc_b3d735bf-c6d9-4901-8829-8b1dc5156bd5"
      unitRef="shares">9190522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTMtMS0xLTM5OTc_3d6c340c-15db-4931-9f79-7f704fb36b0a"
      unitRef="usdPerShare">14.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTUtMS0xLTM5OTc_75787419-562a-4ca7-9dea-cdc738ff2a12">P8Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzExLTctMS0xLTM5OTc_3f40ffd5-86ef-4bc3-9244-6964ad2665b9"
      unitRef="usd">110490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktMy0xLTEtMA_fe8e1d3a-1326-45cb-bd44-b5023560e9a5"
      unitRef="shares">4660416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNS0xLTEtMA_0d15bfe8-3c49-4137-b4e1-cb401b1143ea"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktNy0xLTEtMA_8597da05-03f8-44db-b8fb-7e4bc75e4f64">P8Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzktOS0xLTEtMA_b86d2c1a-290d-4e89-88c1-a73034caedd1"
      unitRef="usd">69379000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTMtMS0xLTA_8aaac948-3e5d-42cc-8450-9f637c7e92ee"
      unitRef="shares">9190522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9aad8afaedfa4bd5a42bc41fbc93e9ce_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTUtMS0xLTA_2b899c4c-379e-4252-9a76-834c87466b78"
      unitRef="usdPerShare">14.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4cc5d09c4899434b82706706c931899c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTctMS0xLTA_ee8536b3-6463-426a-80f4-bf7793df279f">P8Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5YWY3YTFjMmM4Y2U0MzViOWViZTFiYmQ3ZjNmNzE4Yy90YWJsZXJhbmdlOjlhZjdhMWMyYzhjZTQzNWI5ZWJlMWJiZDdmM2Y3MThjXzEwLTktMS0xLTA_272d83e3-ca77-41a3-a465-818562c9bb9b"
      unitRef="usd">110490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjUyNTY_0ae8228e-b4b3-41d4-b915-b625d78079db"
      unitRef="usdPerShare">18.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk1OTk_b3adb1d0-5d0e-4362-b162-cb4fff84e4b0"
      unitRef="usdPerShare">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i79699a85746047d8bd631f0242942e41_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2MDI_043831f4-25f4-4f8d-ba72-f9692163cd9c"
      unitRef="usd">74700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i11a2bcc9c898478cbaded2c1853112a5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2MDU_c19e9c08-b541-4ebd-bdd5-d75abc0e6a9c"
      unitRef="usd">42800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id0e8afce8c034b9c959b0a59e912d174_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2OTc_7f84e95b-df49-41d1-8850-4419e3abda14">P3Y15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5ed340b4013a46b7851c0f7429b81ca2_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk2NzU_193c59a6-61c5-4c70-a85e-c9f47ddec67d">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDE_cf201f26-4df6-4ba8-9ee7-73b136809d06">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.645%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$25.94 - $31.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$2.27 - $26.52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.99&#160;-&#160;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.14% - 74.92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.2% - 77.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.54% - 2.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.74% - 2.99%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToxZmM0YzYxY2Y4NDM0MWVkYjU3MjgyMmQwY2I0MGUwYS90YWJsZXJhbmdlOjFmYzRjNjFjZjg0MzQxZWRiNTcyODIyZDBjYjQwZTBhXzUtMS0xLTEtNjM1Ng_c6a8701e-f32e-417c-9a94-a01900a99198"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToxZmM0YzYxY2Y4NDM0MWVkYjU3MjgyMmQwY2I0MGUwYS90YWJsZXJhbmdlOjFmYzRjNjFjZjg0MzQxZWRiNTcyODIyZDBjYjQwZTBhXzUtMS0xLTEtMA_d8328448-cb7e-4f94-b7b4-9c529ad6ad2c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f7e49d133e04ec08aa34e5d66eea234_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3MjE_9ae7eb88-6dd7-44f3-8acb-106979ce731a"
      unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95fbfb8dfc2a4a14b739df07a6efcc6a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3MjQ_e47f36da-378c-4d30-b7b5-ea039a18f9a7"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzQ5NDc4MDIzMzc2MDM_f31156a3-4c90-470e-a0db-cc3945f87996">The following summarizes restricted stock unit activity under the 2018 Plan:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,982,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItMS0xLTEtNjI5NQ_d95bdbbe-acef-448c-a2e0-756735fff62f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItMy0xLTEtNjI5NQ_ee445b1a-0c95-4ab4-9dc3-0658741c4212"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzItNy0xLTEtNjI5NQ_37ba1e2c-832e-43b8-809f-898c8647851a"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtMS0xLTEtNjI5NQ_5562315a-6b28-4a5d-9b30-f80763cdf00f"
      unitRef="shares">1982855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtMy0xLTEtNjI5NQ_69189a86-c9da-4984-babc-fe4f359ca41a"
      unitRef="usdPerShare">27.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzMtNS0xLTEtNjI5NQ_27dffa76-4574-4709-a62a-59a044ab73a4">P1Y11M8D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzQtMS0xLTEtNjI5NQ_4dab5410-de11-41d9-a747-83617b691b3c"
      unitRef="shares">500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzQtMy0xLTEtNjI5NQ_4e64d498-ac12-4f6f-a066-58e4f4ed9736"
      unitRef="usdPerShare">25.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzUtMS0xLTEtNjI5NQ_7d32c774-8230-452c-bfe7-530d7882cefa"
      unitRef="shares">41200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzUtMy0xLTEtNjI5NQ_e539cb51-ebcd-4e70-b992-04f53fa69777"
      unitRef="usdPerShare">27.48</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtMS0xLTEtNjI5NQ_e5c65a62-4113-4c7a-9a35-c1e41e5acae2"
      unitRef="shares">1941155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtMy0xLTEtNjI5NQ_860d3fe7-4998-462b-99c0-a6ea589f1c57"
      unitRef="usdPerShare">27.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtNS0xLTEtNjI5NQ_3aba0a37-5ccc-4503-af10-4c840a9e6b0c">P1Y11M23D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzYtNy0xLTEtNjI5NQ_608337c0-a416-4bcf-ab03-fb4529b21b55"
      unitRef="usd">50431000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctMS0xLTEtNjI5NQ_a1e561a6-ccba-424d-a568-4fcdf5bb1cd7"
      unitRef="shares">1941155</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctMy0xLTEtNjI5NQ_2f1c70be-799a-469c-b74f-b072b0eb8fe0"
      unitRef="usdPerShare">27.45</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctNS0xLTEtNjI5NQ_058ea1c1-2458-444f-928c-07400c5e681c">P1Y11M23D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo3YmYyMGI4YmM2Yjg0NGM4OWY5YmQ0YmQ0MTBlYmYwMi90YWJsZXJhbmdlOjdiZjIwYjhiYzZiODQ0Yzg5ZjliZDRiZDQxMGViZjAyXzctNy0xLTEtNjI5NQ_0ea47fcb-8eb4-4659-81af-6cf811b75049"
      unitRef="usd">50431000</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3Mzg_2646c02b-ec15-402b-a6dc-49c5ebae4ccc"
      unitRef="shares">57361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie71c994eac41464291e1753cc1c9e671_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3Mzg_582d6c6c-19e0-4639-aaa4-99cbde2fa1d4"
      unitRef="shares">57361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk3NDY_5c7f98ac-e34f-4254-b542-376b49e2c0fc"
      unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i363161bd29bc4e10850ef908f85ad126_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzM4NDgyOTA3MDkyOTE_d20435de-4917-4318-be9e-5502a9621f9a"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i46b4456ea01b4461ba585909bac7d890_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjQ1MDc_25f8671d-c0f4-48c9-8b0b-9f65e10cfb83"
      unitRef="usd">43000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i98539d3bf6db493eb4bac0723e6ee092_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYwNDczMTM5NjQ1MTQ_9f463151-d140-47b7-9c1d-dbacb9010643"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i36df9625fb37478aa6c2ed8619eb4d52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzcxNDY4MjU1OTMxMTE_673cb693-3314-4a8b-8034-a9a144bbdd2f">P1Y11M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <allo:InitiallyReservedCommonStockForEmployeePurchase
      contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzUwNTY_d25e63b5-8258-499c-9f16-f43e6a6e373e"
      unitRef="shares">1160000</allo:InitiallyReservedCommonStockForEmployeePurchase>
    <allo:InitiallyReservedCommonStockForEmployeePurchase
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzc2OTY1ODE0MDcwMzM_7acedb32-f119-43ff-a108-21880f3b1b17"
      unitRef="shares">1214826</allo:InitiallyReservedCommonStockForEmployeePurchase>
    <allo:CurrentOfferingPeriod
      contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzUzODc_634d37f8-5b29-4073-b06f-c25207c09943">P24M</allo:CurrentOfferingPeriod>
    <allo:PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue
      contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU2NDg_b207c955-4bca-4145-882e-d23a22ff7dfb"
      unitRef="number">0.85</allo:PurchaseOfCommonStockThroughPayrollDeductionsToEqualPriceOfLowerFairMarketValue>
    <allo:CurrentOfferingPeriod
      contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU4MjY_ae7b2037-3f8d-4d32-a716-60039ef8142c">P24M</allo:CurrentOfferingPeriod>
    <allo:PercentageOfEligibleCompensationContributionByEmployee
      contextRef="i4ffca6157071428084b3684ac927e28b_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzYxOTI_baa0276e-44f9-4160-8c35-14e854345e76"
      unitRef="number">0.15</allo:PercentageOfEligibleCompensationContributionByEmployee>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDI_1426a6b1-dedd-480e-b714-0a6baab797e9">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of the rights granted under the ESPP were calculated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.610%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.548%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.822%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50 &#x2013; 2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50 &#x2013; 2.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.4% - 76.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.7%&#160;-&#160;81.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.72%-2.49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.37% - 2.83%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5ODkzY2NjYWRiZWI0NjgyYjc1NDMxODUzMzk2MzY2Mi90YWJsZXJhbmdlOjk4OTNjY2NhZGJlYjQ2ODJiNzU0MzE4NTMzOTYzNjYyXzUtMS0xLTEtMTAzMDA_093bfc47-1df6-4f9b-a180-67d5b4c16fec"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZTo5ODkzY2NjYWRiZWI0NjgyYjc1NDMxODUzMzk2MzY2Mi90YWJsZXJhbmdlOjk4OTNjY2NhZGJlYjQ2ODJiNzU0MzE4NTMzOTYzNjYyXzQtMS0xLTEtMA_3731581d-ec2f-4a3c-b19b-4a604623b4db"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6374c0a7c0d644629d9acbeb8e837f35_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5MTk_d114a71c-b583-4c0d-be50-5ab15ade18e9"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39eea99a0291436bb809b13ca964bc10_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk4OTU_e2edac92-e33e-4d80-9b25-1e2565afca6f"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i3835f781ec444d7e9271140857371e43_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzY2MDM_8fa22dc2-5d9e-4ae0-ad33-1112011ba158"
      unitRef="shares">24230750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5Njk_098cd825-7fdd-42cd-b207-f9375e2815f3"
      unitRef="usd">13700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNDk5Nzc_d1b9312a-2064-4e19-b5cd-418271f4c566"
      unitRef="usd">14900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMDc_f8040516-4296-47a7-813f-774db3e5f146"
      unitRef="shares">6057684</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMTE_0cbf6102-e10e-473e-9b1a-736fa02220d3"
      unitRef="shares">6562506</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1e27365619214bc59bfb299e39609936_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMjM_b299b62e-3d4a-4a9d-8791-d8c536a23211"
      unitRef="usd">30900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i64b1551f5cd34b7ca95dd312bcae049d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwMzk_61ba24c2-8955-41a5-b92c-5a1bd29dd8d7"
      unitRef="usd">44600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i1e27365619214bc59bfb299e39609936_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNTU_61d3e7fe-e37b-493b-bddb-59391c6f7aa6"
      unitRef="shares">13629803</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i64b1551f5cd34b7ca95dd312bcae049d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNjM_cf951550-25ba-4ae1-8318-c0356fba9794"
      unitRef="shares">19687487</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwNjg_36b07457-ca89-4f9b-86e4-e8de49d2e4ae">P2Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2f6c3c5c2cdd43dc91b028947c2ff204_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwODE_300e9949-1df6-4fea-8376-8892e76c7fbf">P3Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie2aa94fd675b402db794cd61b92a3018_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTAwOTA_4baff455-5ec0-40d4-b5d0-007c356215ce"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzgzMDM_09d5f63a-eca1-4233-9405-48493a259036">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense related to stock options, employee stock purchase plans and vesting of the founders&#x2019; common stock was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.471%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6af2cfd2ff1d4e4a9d19b9a090f83467_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzItMS0xLTEtMA_71127d31-e91c-4477-8fed-7b1888c0b67c"
      unitRef="usd">19429000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ebdfee99c3d44bbba77e1538670e241_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzMtMi0xLTEtNjExOQ_2d4bdabe-b5a1-4c25-8f1d-74a45e551924"
      unitRef="usd">1657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf7d6e8325894802b105e402db61b959_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzMtMS0xLTEtMA_86258010-818d-4a5d-86b2-87b3765eac96"
      unitRef="usd">26634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic335635d76f5410592d7071e11926b5d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzQtMi0xLTEtNjExOQ_4fc71f97-5e6a-4946-a0f5-39f88349335f"
      unitRef="usd">16909000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzQtMS0xLTEtMA_c32c1b2e-400e-4cd4-9899-ab32fc59f6c8"
      unitRef="usd">46063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90YWJsZToyZjcxMWZmNmFjYmQ0ODNmOWE2NjYzNjQyMDU0ZmJjNi90YWJsZXJhbmdlOjJmNzExZmY2YWNiZDQ4M2Y5YTY2NjM2NDIwNTRmYmM2XzUtMi0xLTEtNjExOQ_c2016340-8783-4329-8721-412849e4a484"
      unitRef="usd">18566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5284d2ec96844b179d5bb270bb5844ab_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA0ODc_0061f2f4-0032-4fcd-b61e-a561beb5da79"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3e4ee5f686274fdeb535ec2690bb50dc_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA0OTY_3c6b86c9-4372-420e-85b2-cc4a0e20c2c0"
      unitRef="shares">5020580</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1MDk_cad96a0c-e54c-4847-8212-27c1e083924d"
      unitRef="usd">2800000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1Mjg_b205c5c7-ba1d-4107-bf94-bb2e7b876c39"
      unitRef="usd">4600000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="ifa574b7418b34ab89121de3fef9eb09d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1NDM_b6a386d3-0a16-49c8-96dc-49f7b23f2504"
      unitRef="usd">3900000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="ibc3716dab85d4812af96ca87413ed4aa_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNDgvZnJhZzphNDM2MWUxOTdiNjA0NTZiYjFiZTUwYzQ2ZDI0Mzc1Yi90ZXh0cmVnaW9uOmE0MzYxZTE5N2I2MDQ1NmJiMWJlNTBjNDZkMjQzNzViXzU0OTc1NTgxNTA1NTA_3ee0d7f8-d966-4f63-a88d-367b5140f572"
      unitRef="usd">6800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQ5NDc4MDIzMjgyNjk_03c56612-9fd9-4540-90e1-89576f4ec7fc">Related Party Transactions&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, Pfizer held 22,032,040 shares of Common Stock and had appointed one member to the Company&#x2019;s Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the years ended December&#160;31, 2019 and 2018, the costs incurred under the Pfizer TSA were $4.5 million and $10.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also purchased certain lab supplies and services from Pfizer in connection with its research and development activities. For the years ended December&#160;31, 2019 and 2018, total lab supplies and services purchased from Pfizer were $1.4 million and $10.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, the Company had amounts payable to Pfizer of $0.1 million and $5.7 million, respectively, which were recorded in the accompanying balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#x2019;s President and Chief Executive Officer, the Company&#x2019;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.6 million for the years ended December&#160;31, 2019 and&#160;2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018 the Company entered into a consulting services agreement with TPG Capital &#x2013; FO LLC (TPG FO) a firm affiliated with a beneficial owner of more than 5% of the Company&#x2019;s capital stock. The costs incurred for services performed under this agreement were zero and $0.3 million for the years ended December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&#x2019;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#x2019;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $26,250 per month in arrears commencing June 2018. Beginning January 2019, the Company paid Bellco $33,333.33 per month in arrears and, at the Company&#x2019;s discretion, may pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided, bonus and out-of-pocket expenses incurred under this consulting agreement were $0.8 million and $0.5 million for the years ended December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sublease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, the Company entered into a sublease with Bellco for 1,293 square feet of office space in Los Angeles California for a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMxNTY_6ef0bf0c-3a55-4439-89b6-05ebb3b69460"&gt;three&lt;/span&gt; year term. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.2 million at December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, the Company subleased 2,180 square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart). ByHeart is a development-stage infant formula company. Two of the Company&#x2019;s board members have beneficial ownership in ByHeart and one serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to 2,907 square feet. Sublease income for the year ended December&#160;31, 2019 was $0.3 million and was recognized as other income.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzYz_9196c1a0-ac0c-46b8-ab9a-f3ecd04881e1"
      unitRef="shares">22032040</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzYz_95f55b7b-78a7-45d9-93f3-31dce39303d2"
      unitRef="shares">22032040</us-gaap:CommonStockSharesOutstanding>
    <allo:NumberOfMembersAppointedToBoardOfDirectors
      contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzEwNw_3ac3b754-a73e-4e50-8898-ac52a15f1520"
      unitRef="director">1</allo:NumberOfMembersAppointedToBoardOfDirectors>
    <allo:NumberOfMembersAppointedToBoardOfDirectors
      contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzEwNw_b294e403-e4a8-4019-9572-5ac5dc54ac0e"
      unitRef="director">1</allo:NumberOfMembersAppointedToBoardOfDirectors>
    <us-gaap:RelatedPartyCosts
      contextRef="i0f25012c47684987b5c8de4583d7013a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTQ3OTI_80d24eb7-3a72-4a41-ac1f-f7690ede898c"
      unitRef="usd">4500000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="ice6c8adf2175476b82e13eba7aa65e3b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQ3Mw_9a64c093-f549-4cba-b1a8-78e9d3980aaf"
      unitRef="usd">10100000</us-gaap:RelatedPartyCosts>
    <us-gaap:SuppliesExpense
      contextRef="i2ed333deb19e4f8aa30fd212e8437454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTUyMDA_0c58beef-29f6-483a-a468-a2c33faf5d47"
      unitRef="usd">1400000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="ia54626e66f62444da7a1a1a1bd878fa1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzgwMg_05971c6e-95c6-4cc8-9151-85735f5fec59"
      unitRef="usd">10400000</us-gaap:SuppliesExpense>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="iaad7357554cc448cb7cdccb352b3f230_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTUyNzY_65187ea9-fa2f-42ec-9c10-034779f5e852"
      unitRef="usd">100000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="ic91ddb1e1d444d3c9ab3deeb3eea56a0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzkxOA_448f7c44-67a9-410c-9022-3da73bf830b7"
      unitRef="usd">5700000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:RelatedPartyCosts
      contextRef="i3b3b4b6820d34ffe8a18270f928c827b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU1Mjk_3860ee60-0ca8-454d-a7d4-a75fbc0627ed"
      unitRef="usd">600000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i46512246cc53487190bb23e1f83b9f1e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU1Mjk_4c61bb12-25fd-425e-843d-c82eb7d033c5"
      unitRef="usd">600000</us-gaap:RelatedPartyCosts>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i937aa356e7d74904be670337e39f839f_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzE2NzI_3c30e564-012c-460d-ae80-18aceba1f4a5"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iebe223e780a54b2e9611b6aa31c1b596_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTYxNTE_c6dae3cc-6d56-46cb-a79b-bb7d8583b536"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic44e3cf19d214ae795601add9e69e7eb_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzE3NzQ_d7cef854-ec8c-4f7d-972e-353fdada61dc"
      unitRef="usd">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i22b5cfb3c05f4d6b822f58dea1aab477_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI1MjA_9cd64586-3a06-48dc-91bc-d306ed37f384"
      unitRef="usd">26250</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="ice415ea64e2243bc968eb2884b47ca78_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzcxNDY4MjU1ODk4MTc_fc208e76-17b1-4a09-94eb-2da231d06581"
      unitRef="usd">33333.33</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionCompensationPercentage
      contextRef="id14c29c033be4cfbb4eb48f42b7d40c5_D20180801-20180831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI2NTQ_2e44aae9-f6aa-4236-852b-f8bc8883e3b4"
      unitRef="number">0.60</allo:RelatedPartyTransactionCompensationPercentage>
    <us-gaap:RelatedPartyCosts
      contextRef="i3fdaf74dec9d4787bdf514649b2cd27f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTU5OTA_5dede70f-4bf8-491d-ab72-e88596ca9bef"
      unitRef="usd">800000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i1b77ef1f61024c568c150dd64f256116_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzI5NDQ_d47a088e-c9f7-4f2f-b60b-0f5c8c0d04d1"
      unitRef="usd">500000</us-gaap:RelatedPartyCosts>
    <allo:AreaOfNewOfficeBuilding
      contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMwOTM_f8ccb13a-7ffb-4d49-92db-c3137e77c383"
      unitRef="sqft">1293</allo:AreaOfNewOfficeBuilding>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibb66cca6e6e14fb0b660ef62239b32cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzM4NDgyOTA3MDI5NTg_6d02d56a-7c02-48c0-85c9-8fe2dd4d373c"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia02a067e56bf46b385d84dbd3ece5417_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzMyNjg_e93e031b-7d3f-40ba-98b7-b2b3fa6b89d2"
      unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <allo:AreaOfNewOfficeBuilding
      contextRef="ie27792aefa4b465fa4c423f1df05599c_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTk5ODQ_eb5236dd-f465-4cd4-a2c7-195fcbdd50e2"
      unitRef="sqft">2180</allo:AreaOfNewOfficeBuilding>
    <allo:AreaOfNewOfficeBuilding
      contextRef="ief267c01c710405abd30252861e3e24c_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MTk5OTE_fab83634-67c4-4a1b-a537-760afd31f342"
      unitRef="sqft">2907</allo:AreaOfNewOfficeBuilding>
    <us-gaap:SubleaseIncome
      contextRef="i2b8b5580156846e28ce6eb93624129e1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTQvZnJhZzpiYTU5MmY5OTg4OGY0Y2YzYjc0Y2RkYWU0ODQ0YzdjMi90ZXh0cmVnaW9uOmJhNTkyZjk5ODg4ZjRjZjNiNzRjZGRhZTQ4NDRjN2MyXzQzOTgwNDY1MjAwNjc_2fedb7d4-4524-44db-bce8-1a96236dd1e2"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzQ5NDc4MDIzMjUzODc_c57846e1-e96d-4190-a45b-120fb223ea47">401(k) PlanIn April 2018, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. All employees are eligible to participate, provided they meet the requirements of the plan. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $0.9 million and $0.4 million related to matched contributions for the year ended December&#160;31, 2019 and 2018, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzQzOTgwNDY1MTE1MDI_b29cdf80-f7cb-4542-a432-9a82f3284533"
      unitRef="usd">900000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNTcvZnJhZzo1NGVhZDQyZGJmODQ0N2U0OTFlYWI4NDdiMmEzZWVhZS90ZXh0cmVnaW9uOjU0ZWFkNDJkYmY4NDQ3ZTQ5MWVhYjg0N2IyYTNlZWFlXzMzNw_1543ecc7-bcc7-42c3-8279-b41b1664eb27"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQ5NDc4MDIzMjkwMjc_a6735697-909c-48c7-8445-97a6a9c31ca9">Income Taxes&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, the Company recorded income tax benefit due to the intraperiod tax allocation of deferred income taxes on unrealized gains on available for sale securities recorded in other comprehensive income. The Company has incurred net operating losses for all the periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Reconciliation of the benefit for income taxes calculated at the statutory rate to our benefit for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Write-off of in-process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for incomes taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.040%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right of use leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(91,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.&#160;&#160;Due to the lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $50.0 million and $41.9 million during the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth our federal and state NOL carryforwards and federal research and development tax credits as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2037-2039 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2038-2039 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax credit carryforwards may be limited as a result of such ownership changes. Such a limitation could result in the expiration of carryforwards before they are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income.&#160;&#160;An exception is provided in ASC 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year.&#160;&#160;In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets.&#160;&#160;In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale investments recorded as a component of other comprehensive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets.&#160;&#160;For the years ended December&#160;31, 2019 and 2018, the Company recorded a tax benefit of $0.3 million and $0.1 million, respectively, in other comprehensive income, related to available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We apply the provisions of ASC Topic 740 to account for uncertain income tax positions.&#160;&#160;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at beginning of the year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions to tax position of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions to tax position of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lapse of the applicable statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as a component of interest and other income, net, as necessary.&#160;As of December&#160;31, 2019 and 2018, there were no accrued interest and penalties related to uncertain tax positions.&#160;The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.&#160;Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business.&#160;&#160;We are subject to examination by U.S. federal or state tax authorities for all years since inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzA_d14588d5-f9b7-4e89-8960-d9c9342d21d2">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMS0xLTEtMjk5NA_c7632ed1-7cfa-49d8-9692-6ca04abd84d2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzItMS0xLTEtMA_54ffd1c3-18e3-4294-b9ed-76a85ab7cbfe"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzItMy0xLTEtMA_a4f6dac8-35bc-4b1d-a5a8-5b596384d706"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMS0xLTEtMjk5NA_7d7bdcd3-4ba3-41f6-84c3-766b3fb044df"
      unitRef="usd">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMS0xLTEtMA_15f09dcc-9741-4b27-a021-c3b6aa765de2"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzMtMy0xLTEtMA_1bfd5a81-9ce0-4191-9f78-d1e9a36cdf5b"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzUtMS0xLTEtMjk5NA_c3f9039e-e827-4735-9dc5-2f022ef59f80"
      unitRef="usd">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMS0xLTEtMA_98df97ec-0627-4a43-97c3-f786580ea53e"
      unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzQtMy0xLTEtMA_96a80d89-ee73-493e-b811-0164aa3e9f58"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMS0xLTEtMjk5NA_701c6b63-0e97-4a1a-8f34-8175ddb781b7"
      unitRef="usd">-251000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzYtMS0xLTEtMA_491ec7c0-1c89-4124-9eae-62f0d46a6236"
      unitRef="usd">-89000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzYtMy0xLTEtMA_0776bbe2-0a30-4037-8029-9728da500846"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMS0xLTEtMjk5NA_47327859-6b73-41b5-9d46-c13cf605be56"
      unitRef="usd">-81000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMS0xLTEtMA_0ac15766-cfad-4e7f-bd31-22166c5fdbd1"
      unitRef="usd">-30000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzctMy0xLTEtMA_db9e80d6-98c1-402d-8bcb-90e020b798de"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMS0xLTEtMjk5NA_c47d012a-d8a1-4694-b722-76f9d68f1583"
      unitRef="usd">-332000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMS0xLTEtMA_79fb3b07-e4fa-4faf-8317-0073b9ac93a5"
      unitRef="usd">-119000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzgtMy0xLTEtMA_34124933-3b95-463a-8047-008a21834972"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzEwLTEtMS0xLTI5OTQ_92fab677-43d8-4726-ae08-c100b9f0c5f4"
      unitRef="usd">-331000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMS0xLTEtMA_678333b9-e3d6-4378-bdf8-95d20abc113d"
      unitRef="usd">-117000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZToyZDZkYmY2ZDhkYmU0NzU5YjQ1NzBmOWViMDhiMTU5Yi90YWJsZXJhbmdlOjJkNmRiZjZkOGRiZTQ3NTliNDU3MGY5ZWIwOGIxNTliXzktMy0xLTEtMA_8099fb31-f5a4-4db7-a2a9-0a26cfac207d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzE_7e1d83fe-93e8-437b-8430-0d3845a3cbe7">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Reconciliation of the benefit for income taxes calculated at the statutory rate to our benefit for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Write-off of in-process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for incomes taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMS0xLTEtMzA4MQ_d5d03bfb-dabd-49d3-9701-f96eaa6690b3"
      unitRef="usd">-38834000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzItMS0xLTEtMA_7920564c-77d8-4125-b8ba-255e31f764bf"
      unitRef="usd">-44441000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzItMy0xLTEtMA_c8dd102a-8c7f-477c-b44f-85086d7ae11f"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMS0xLTEtMzA4MQ_9a1f11b8-06d3-48be-9248-862cfc3fba58"
      unitRef="usd">-12951000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMS0xLTEtMA_aab9afa6-f6f0-41f9-b1c0-6baa693e8007"
      unitRef="usd">-10652000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzMtMy0xLTEtMA_5b6fcfde-fa5a-41fa-97a6-bb682310d32a"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMS0xLTEtMzA4MQ_4f846148-fd39-4719-8fdc-cd845b7ac828"
      unitRef="usd">2037000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMS0xLTEtMA_f6a97a39-9462-4f50-9e98-240e1c68f151"
      unitRef="usd">3629000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzQtMy0xLTEtMA_8fa5ddfb-9c5e-44e5-a0d0-5df89732c1a3"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMS0xLTEtMzA4MQ_677e5fb2-7836-46ee-9a3c-a342332c7554"
      unitRef="usd">1714000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMS0xLTEtMA_df39ecf4-b3a9-4927-909c-37c47350abc3"
      unitRef="usd">708000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzUtMy0xLTEtMA_bb70ccd7-d723-4041-88f2-a1d852a144a9"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMS0xLTEtMzA4MQ_2b9c780d-b9c9-404c-bee9-32fb3a190b35"
      unitRef="usd">0</allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment>
    <allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMS0xLTEtMA_db565199-f5ba-47ff-9baa-60e6e43f17f0"
      unitRef="usd">5247000</allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment>
    <allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzYtMy0xLTEtMA_66e61c11-f8e2-4219-a2a8-625cf65fc4a6"
      unitRef="usd">0</allo:IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment>
    <allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMS0xLTEtMzA4MQ_c1f7ed96-1467-4d8c-90c3-92b5b8fbd20e"
      unitRef="usd">0</allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes>
    <allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMS0xLTEtMA_ff62d9cd-8989-41fa-a4f0-81f78b7ab439"
      unitRef="usd">4454000</allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes>
    <allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzctMy0xLTEtMA_5cc14b5f-12f5-46f5-82cd-70efa377aff0"
      unitRef="usd">0</allo:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMS0xLTEtMzA4MQ_c967f5e7-30f2-4cfa-9420-f3b392de5a97"
      unitRef="usd">49989000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMS0xLTEtMA_45b47cd1-65a9-42e4-9964-460ed34fb40f"
      unitRef="usd">41916000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzgtMy0xLTEtMA_d752e328-9665-437a-99eb-4e7605730b21"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTEtMS0xLTMwODE_e1b43622-5e32-452b-8f32-dd043ddd1cf4"
      unitRef="usd">1141000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMS0xLTEtMA_11f9cb03-f872-4d2f-8410-fdaee394139d"
      unitRef="usd">438000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzktMy0xLTEtMA_9422a8f1-560a-4402-b097-c9b49933d951"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzExLTEtMS0xLTMwODE_64f61c67-ca51-4744-9910-2b5d20382781"
      unitRef="usd">-331000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTEtMS0xLTA_eb8415c4-aa21-4037-ab27-0f5e9a623d4e"
      unitRef="usd">-117000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo0ZDU2ZmFlZjg2YzQ0NmNhODdiMDFkYjk3ZDRmNzhhNC90YWJsZXJhbmdlOjRkNTZmYWVmODZjNDQ2Y2E4N2IwMWRiOTdkNGY3OGE0XzEwLTMtMS0xLTA_9c3e7ed1-f4f2-4a32-8070-657303b1311f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzI_a9543a3c-8c71-4ce0-8d90-c34857b50367">Significant components of our deferred tax assets and liabilities are as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.040%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&#160;from November&#160;30, 2017 (Inception)&#160;to December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right of use leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(91,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMS0xLTEtMzA5NA_0263e612-6032-4e90-ab6e-9ddbfd0d70fa"
      unitRef="usd">54018000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzMtMS0xLTEtMA_f094c0cf-79e1-4029-b5a1-1efdfde5c131"
      unitRef="usd">16437000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzMtMy0xLTEtMA_3320f686-c81a-4a7c-b1cc-bb052460bc36"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMS0xLTEtMzA5NA_f60217ad-1725-4a26-a344-d486e56347e7"
      unitRef="usd">4239000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMS0xLTEtMA_ea00539d-49c0-4a07-84d0-562d9cf15512"
      unitRef="usd">1239000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzQtMy0xLTEtMA_adac6589-a220-4711-9658-0a5b732080e6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMS0xLTEtMzA5NA_326c64df-3525-4191-9df9-12ac9ccfae8b"
      unitRef="usd">22770000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMS0xLTEtMA_ef8a3e7c-f9f3-4fcc-96a9-dc591949b856"
      unitRef="usd">23086000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzUtMy0xLTEtMA_abae2e0c-8706-4c0e-8ad6-9af5ba9f1c29"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMS0xLTEtMzA5NA_554a5243-a6b9-4538-ac8b-0be5f3ab918b"
      unitRef="usd">2375000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMS0xLTEtMA_2ad7aaa8-2057-44d7-9a54-3f164c48fe5c"
      unitRef="usd">952000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzYtMy0xLTEtMA_a8098a92-354c-4c54-b0e1-15f1f900760d"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <allo:DeferredTaxAssetsLeaseLiabilities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMS0xLTEtMzA5NA_a0649164-4175-4f7b-9d2e-d88640a36381"
      unitRef="usd">14839000</allo:DeferredTaxAssetsLeaseLiabilities>
    <allo:DeferredTaxAssetsLeaseLiabilities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMS0xLTEtMA_145a09ae-1127-4a65-bfb6-113e089520cc"
      unitRef="usd">9730000</allo:DeferredTaxAssetsLeaseLiabilities>
    <allo:DeferredTaxAssetsLeaseLiabilities
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzctMy0xLTEtMA_cb40b0c9-e5e9-4279-91e8-3d643f743900"
      unitRef="usd">0</allo:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMS0xLTEtMzA5NA_5bd6f116-2ea2-415a-8f95-63eccaa9d8f0"
      unitRef="usd">6870000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMS0xLTEtMA_8cdcf81f-6fed-4cde-86a6-8731bd7cd2a2"
      unitRef="usd">360000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzgtMy0xLTEtMA_d3b9274e-9d7b-47ba-9d46-99a72a43d6cd"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTEtMS0xLTMwOTQ_1777abfc-f079-4eb1-8749-5fa18c77dcfb"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMS0xLTEtMA_83f16962-8653-4823-ae23-ccb87bddd95a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzktMy0xLTEtMA_87ff140d-c6cd-407f-abac-7779e38f0872"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzExLTEtMS0xLTMwOTQ_36d4dbf3-7016-471f-9457-823294e168e3"
      unitRef="usd">105111000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTEtMS0xLTA_4b6fa9ae-277c-4a25-9529-fec4b2f7e2d2"
      unitRef="usd">51804000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEwLTMtMS0xLTA_0893aab5-1da5-4aed-bc8a-b9c5972476f4"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTEtMS0xLTMwOTQ_7b2b0e7e-51fe-450e-a205-3db9bdca473b"
      unitRef="usd">361000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEyLTEtMS0xLTA_5e7ce2ff-e41b-4e35-ab64-57a2a5baa6d8"
      unitRef="usd">531000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEyLTMtMS0xLTA_67d30c9b-d859-40ad-bcd4-c5bdc49e75ba"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <allo:DeferredTaxLiabilitiesRightOfUseLeased
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTEtMS0xLTMwOTQ_fa00281c-5782-4d0c-99e7-c9a090bee9c4"
      unitRef="usd">12453000</allo:DeferredTaxLiabilitiesRightOfUseLeased>
    <allo:DeferredTaxLiabilitiesRightOfUseLeased
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTEtMS0xLTA_0feb7971-d278-43c3-953e-36a4e29efd3e"
      unitRef="usd">9239000</allo:DeferredTaxLiabilitiesRightOfUseLeased>
    <allo:DeferredTaxLiabilitiesRightOfUseLeased
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzEzLTMtMS0xLTA_af863590-89b1-4334-a7c7-b2c3c11598ab"
      unitRef="usd">0</allo:DeferredTaxLiabilitiesRightOfUseLeased>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTEtMS0xLTMwOTQ_d52c579a-32c0-42ee-857e-b4f063a01846"
      unitRef="usd">393000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTEtMS0xLTA_07ccdcf5-d746-48dd-b7f3-c8dd8f331626"
      unitRef="usd">118000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE0LTMtMS0xLTA_2c8a7851-197c-4b2b-a75a-705f7cd92461"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTEtMS0xLTMwOTQ_86d9fcc3-a1d2-471a-ac3b-4f117321b979"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTEtMS0xLTA_bf998f07-9adf-4d9f-8356-3efb92d3a499"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE1LTMtMS0xLTA_43e23676-cbc3-4a34-93ae-ac9a430d1837"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTEtMS0xLTMwOTQ_3589c647-3b3c-46fd-9ed4-ee5ac49ec082"
      unitRef="usd">13207000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTEtMS0xLTA_fce58d97-98a8-4e90-9365-5aff2d839bf9"
      unitRef="usd">9888000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE2LTMtMS0xLTA_1b33f599-6bd8-4c9c-b082-03c2077f7b39"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTEtMS0xLTMwOTQ_d7842c0e-4b95-42cd-9a9b-b26a4ef60978"
      unitRef="usd">91904000</allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities>
    <allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTEtMS0xLTA_082bbd8c-83e2-4b2a-95e1-4e37e42be3b7"
      unitRef="usd">41916000</allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities>
    <allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE3LTMtMS0xLTA_c43e29aa-3166-41ab-b8e1-5c2aa8478820"
      unitRef="usd">0</allo:DeferredTaxAssetsNetOfDeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTEtMS0xLTMwOTQ_6901c662-f171-4623-9351-04c19fc135a2"
      unitRef="usd">91904000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
    <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTEtMS0xLTA_c4590046-d196-49c6-bf3a-a76d38183d92"
      unitRef="usd">41916000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
    <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE4LTMtMS0xLTA_c42abcf4-454c-4003-b369-f8cd90d6785a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzIwLTEtMS0xLTMwOTQ_5a4e0bab-d395-47a6-8712-435868dcfe35"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTEtMS0xLTA_1539bcd1-a878-411a-b790-29b2a59a5b5c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpiODNjZDBhMzVmMjM0OWE1ODhkZTZjYTFlN2M3NmUzNS90YWJsZXJhbmdlOmI4M2NkMGEzNWYyMzQ5YTU4OGRlNmNhMWU3Yzc2ZTM1XzE5LTMtMS0xLTA_b43f63e7-a045-4207-819d-01a4cf6b6e84"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQzOTgwNDY1MTUyNjc_8396a5c1-6b1e-43ca-b4aa-b9b493ae901a"
      unitRef="usd">50000000.0</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzE0NzY_4021f068-fc7f-4a5d-a233-502f0f62981a"
      unitRef="usd">41900000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzM_c4087438-2e67-4e48-9b25-d5b93c112e85">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth our federal and state NOL carryforwards and federal research and development tax credits as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2037-2039 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2038-2039 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Indefinite &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i16c74cfa985346f494f9d5736c6a5fe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzItMS0xLTEtMA_41c57a73-bfe2-4e53-933e-a3211f2c29a8"
      unitRef="usd">193991000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7523fadedd6b4e51ab3614c36301ac25_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzMtMS0xLTEtOTczNg_efc18cef-c6b1-4c88-8a35-ea9a74f9dc0d"
      unitRef="usd">2000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib540aeb004f94ffc9bfe1a2e2bed3e89_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzQtMS0xLTEtMA_ee451d2f-0d58-4416-8c3d-6d49d26b6dc0"
      unitRef="usd">190159000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib08658a06a8a40aaa3b3aa34badf31cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzUtMS0xLTEtMA_0d02e0ee-5035-4f29-9048-cb4c1189468d"
      unitRef="usd">4037000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0c2150c8f59c49ea84c39db5a3d27693_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTpjYzdjNTExYTFmODM0Nzc3OTY1Y2Q4Y2IxNzIwZDAyNi90YWJsZXJhbmdlOmNjN2M1MTFhMWY4MzQ3Nzc5NjVjZDhjYjE3MjBkMDI2XzYtMS0xLTEtMA_3291c273-e05d-45d6-a6a5-ca9f4dff456e"
      unitRef="usd">3832000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQzOTgwNDY1MTU1MDk_6b08874e-b2ff-4768-9727-360f59ef1e3f"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzMxMDY_9b343fcb-2663-48ad-bfe2-ed0721927351"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzQwMzQ_868783e0-2469-44a2-8f2a-d5d05fc78c09">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We apply the provisions of ASC Topic 740 to account for uncertain income tax positions.&#160;&#160;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.600%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at beginning of the year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions to tax position of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions to tax position of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lapse of the applicable statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzItMS0xLTEtMTE1OA_6237013a-a83f-4ed3-8788-22070e5b225a"
      unitRef="usd">920000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzItMy0xLTEtMTE1OA_6094c04f-97c0-42ea-b03f-132f1fbfc257"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia6c735ffeb0e4728ab0cf9f8a68323c0_I20171130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtNS0xLTEtODExNQ_5c2d75c0-b8f4-4616-a5f0-dff037148317"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtMS0xLTEtMA_e4ae372c-5735-4130-a98f-3d66d2517e7b"
      unitRef="usd">2228000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtMy0xLTEtMA_481a473a-55e4-4fdb-ac98-05df35d0c500"
      unitRef="usd">920000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzMtNS0xLTEtMzE1Nw_09bb57e9-606f-4031-94e8-14b732aef7bc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtMS0xLTEtMA_a9d0f031-74d9-430f-8528-0615dcc0b10f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtMy0xLTEtMA_530dfc70-b65a-4429-a1c4-ddfd9d6e0d15"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzQtNS0xLTEtMzE1Nw_6b576afa-b32c-4676-a8b0-6bf539bfa2af"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtMS0xLTEtODExMg_d894ec1f-12e2-4b6f-8a9d-788522e2aa99"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtMy0xLTEtODExMg_27f4cfe4-c6f9-40d3-95a7-01529c341526"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzYtNS0xLTEtODExMg_89efea1c-a048-486d-a1ee-36a2da1f2d4b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctMS0xLTEtODExMg_d9b59b99-db47-4812-bb5a-444e93b2ae37"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctMy0xLTEtODExMg_f7dea57e-f1f6-45f0-8b2c-77b4fd8e9f32"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzctNS0xLTEtODExMg_b2e2cc55-04b9-4af8-8c03-bc72eae79b07"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtMS0xLTEtMA_39b59065-2d29-4dbb-94f5-100c58d2ffcd"
      unitRef="usd">3148000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtMy0xLTEtMA_c2934f4e-c844-4e71-a5f0-99724db8040b"
      unitRef="usd">920000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if7f0568066a04dd08c00592b4c8dbb52_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90YWJsZTo3OWY2Zjk2NDI3ZjI0OTlhOTVmZDM1YTY0MTk4MGYyNS90YWJsZXJhbmdlOjc5ZjZmOTY0MjdmMjQ5OWE5NWZkMzVhNjQxOTgwZjI1XzUtNS0xLTEtMzE1Nw_7a60c866-c36a-42b0-af9e-0cbeff5a5890"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i931fe0adef2547279e3d242f0f22774d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzM1NDg_8358aac7-ab45-424c-a4b3-796416056ecb"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i539b2ae7956d4b19badf4d751d50af35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjAvZnJhZzo3ODBhMjIxZmZmODg0MjE5YTk0MDY0ZGYxODQ4M2ZkNC90ZXh0cmVnaW9uOjc4MGEyMjFmZmY4ODQyMTlhOTQwNjRkZjE4NDgzZmQ0XzM1NDg_f03a20e3-27ab-4874-9f0f-fec741a28609"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzQ5NDc4MDIzMjU1NTA_9891f674-9400-447c-b38b-3ec3d9d393f6">Net Loss and Net Loss Per Share&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period From November 30, 2017 (Inception) to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(184,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(211,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,061,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,948,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,249,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period From November 30, 2017 (Inception) to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,235,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected shares purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Founder shares subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,629,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,687,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,992,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,948,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,087,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzU1Ng_3cc459c9-97c7-4a23-86c3-b77892d776bd">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period From November 30, 2017 (Inception) to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(184,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(211,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,061,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,948,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,249,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtMS0xLTEtMA_460ae5e1-e99d-441b-9f77-d037b66d6f2f"
      unitRef="usd">-184594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtMy0xLTEtMA_6be146dd-3dac-46cc-806f-e3da4d12bc80"
      unitRef="usd">-211505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzMtNS0xLTEtMTMxMg_780bff73-3c63-4749-ad41-a16c200cdd10"
      unitRef="usd">-2000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtMS0xLTEtMA_1fd9afd2-218e-44e7-8a62-04583cf9d3fb"
      unitRef="shares">101061149</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtMy0xLTEtMA_ce539bae-894e-41e4-a550-bc18718a32e2"
      unitRef="shares">28948386</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzUtNS0xLTEtMTMxMg_5104be35-5932-446e-8d35-ffe4e87a0234"
      unitRef="shares">26249993</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtMS0xLTEtMA_7826bbb2-9678-41d4-9932-bdaa2c270037"
      unitRef="usdPerShare">-1.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtMy0xLTEtMA_2c0cc0c2-0d29-45c5-a88d-3d7b642892a9"
      unitRef="usdPerShare">-7.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo4YWU5ZTExNmIwM2M0ZDMxYjg2ZmVhNDljY2YzN2FhMC90YWJsZXJhbmdlOjhhZTllMTE2YjAzYzRkMzFiODZmZWE0OWNjZjM3YWEwXzYtNS0xLTEtMTMxMg_03ec3598-60ee-42d5-a537-28c54010d43a"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90ZXh0cmVnaW9uOjZlMmZiN2RhZjAwNzRlMDI5NmQzNTMyNDNlZjQzNmYyXzU1Nw_cbbdc320-5d81-4b54-8774-52ee2e0a7314">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period From November 30, 2017 (Inception) to December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,235,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected shares purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Founder shares subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,629,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,687,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,992,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,948,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,087,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1685cab5677b4214acd1e61778618c7a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItMS0xLTEtMA_bda0dc72-731c-4482-b69e-0cba004016c7"
      unitRef="shares">9190522</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3db00b97645d4dfcb5199164cd300fd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItMy0xLTEtMA_8164e200-dc51-42b4-9bad-4308f5a48a5b"
      unitRef="shares">7235545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i07955f1bc4d842309fb7054451349500_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzItNS0xLTEtMTM4NQ_7f65e760-23de-4861-ad2e-159e393189bf"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i98d07f8ad8e24589b9cd7e9093f0cdb3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMS0xLTEtMTM4Nw_e09faecc-5a61-47bd-8cab-576caaaf4340"
      unitRef="shares">1941155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96ced67d40264f25905f485ca894893f_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMy0xLTEtMTM4Nw_16004a13-11f4-45ca-8f78-a17c078793f1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e63cc94d1614433bc6dbbf8f222c887_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtNS0xLTEtMTM4Nw_b5157296-3af7-44b0-b896-bb11ec27011a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b6803e703b349ab84305332583a3b58_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMS0xLTEtMTM4Nw_c43b4aad-43a6-4f9a-bfc5-ad9a0efae74c"
      unitRef="shares">195161</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68b6c63c353f4630aed12ad8c7160e52_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMy0xLTEtMTM4Nw_42d27602-84de-464c-9f1c-68eac16027aa"
      unitRef="shares">144272</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff8a1d2d642b449f977d62cd68697248_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtNS0xLTEtMTM4Nw_831db36e-4ecf-4dfe-8f06-202a7354c93f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8943b433f73e48b1b575b63c35b128bc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMS0xLTEtMA_84845bc6-a623-47d2-ba44-34e32448a588"
      unitRef="shares">13629803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id55c9b66b5bc4d93aaa9151719a26f75_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzMtMy0xLTEtMA_0919bc12-5ae2-4e60-a8d2-cae2c3776827"
      unitRef="shares">19687487</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f3a4d9d806b414bbbbd1501a52e6766_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtNS0xLTEtMTM4NQ_a8e379d5-39bb-4ba4-bb71-3ebaa502e859"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b519b46465449bf8e62e676785a0c8f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMS0xLTEtMA_c3a5938f-8758-4247-b159-75e410f95c35"
      unitRef="shares">2992290</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa11e1394d8e429a82692ed6d10cf29e_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzQtMy0xLTEtMA_aaa25905-dbc8-43d3-b3e9-5ca14132725b"
      unitRef="shares">5020580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d1db84ffd5f434f9c56d87b4cbf3f69_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzYtNS0xLTEtMTM4NQ_5be60166-762a-42ff-aa66-737617309d7f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtMS0xLTEtMA_8b664294-d490-4fb6-87a4-419b3e2787a5"
      unitRef="shares">27948931</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i595cd53e82494828a29af14a1c81baba_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzUtMy0xLTEtMA_45a3916d-ecd6-4c5c-882c-3bf38a3b36d9"
      unitRef="shares">32087884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09c2ba98a7384e76b8dcfe77decf72cf_D20171130-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjMvZnJhZzo2ZTJmYjdkYWYwMDc0ZTAyOTZkMzUzMjQzZWY0MzZmMi90YWJsZTo0ZTUwZTRkOTZjMTc0ZjFiOWQ2NjI3ZWJjMzJiMjk4Yy90YWJsZXJhbmdlOjRlNTBlNGQ5NmMxNzRmMWI5ZDY2MjdlYmMzMmIyOThjXzctNS0xLTEtMTM4NQ_8a348c80-db02-4fd8-a57c-d7ee3b2fcc3f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MzQ_7e1515f0-a51e-4509-a2c0-84ecf091d8d7">Subsequent EventsFrom January 6 to January 17, 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MTE_07d6f27e-6843-47bf-b9c5-899f7a5a0db3"
      unitRef="shares">570839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i790517d4f8044fcfa24438e86ef25ae6_D20200106-20200117"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNjYvZnJhZzowNDA2NzdlMDc4ODg0ODU1YjRjNjBhNzViZGI4NmRhYy90ZXh0cmVnaW9uOjA0MDY3N2UwNzg4ODQ4NTViNGM2MGE3NWJkYjg2ZGFjXzcxNDY4MjU1ODQ0MjA_50801495-1e17-4bd0-91a9-73b7343f8753"
      unitRef="usd">14800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90ZXh0cmVnaW9uOjViZGYyMzBiNDk0MDQ0ZjA4NGU3YWY3MjkyNzliNmYzXzQ5NDc4MDIzMjU0NjE_8da92301-68a1-4d0d-826c-e55eb8ca5149">Selected Quarterly Financial Data (unaudited)&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides the selected quarterly financial data for the year ended December&#160;31, 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(64,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(31,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides the selected quarterly financial data for the year ended December&#160;31, 2018 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(134,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i8c21c9005e6a427291725a65818c2c6b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90ZXh0cmVnaW9uOjViZGYyMzBiNDk0MDQ0ZjA4NGU3YWY3MjkyNzliNmYzXzQ2Nw_0c2d4e04-5c47-484b-9e1e-e5e9877665c0">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides the selected quarterly financial data for the year ended December&#160;31, 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(64,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(31,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides the selected quarterly financial data for the year ended December&#160;31, 2018 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(134,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItMS0xLTEtMjkxMQ_5d0b0064-4398-47b9-a135-f2c8f4e17257"
      unitRef="usd">-36461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItMy0xLTEtMjkxMQ_bd4363ae-53cd-4560-b587-cd37202a87b8"
      unitRef="usd">-45961000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItNS0xLTEtMjkxMQ_a80c0a8b-5413-4f23-a9cf-207b50b4aa05"
      unitRef="usd">-55011000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzItNy0xLTEtMjkxMQ_3e2bae8e-6241-4c70-968a-2ac7aac3660e"
      unitRef="usd">-64575000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtMS0xLTEtMjkxMQ_22a19920-0c6a-4228-b372-3f73f95fac0c"
      unitRef="usd">-31586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtMy0xLTEtMjkxMQ_97fcf47f-fa80-42c8-9803-61ba2e45a44a"
      unitRef="usd">-41243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtNS0xLTEtMjkxMQ_22100965-a258-4170-8c32-b4a559dfb76c"
      unitRef="usd">-50735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzMtNy0xLTEtMjkxMQ_12b45808-39da-43e0-b1d2-dfa778d4421e"
      unitRef="usd">-61030000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i34c9674830a8496ea200b381f58eb7f3_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtMS0xLTEtMjkxMQ_b20142e1-3844-4eec-afd5-48cc84467ade"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0a50b37ad0374092aee6b3ae326db25e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtMy0xLTEtMjkxMQ_4e8f08b1-b2d5-4421-81f4-5ac44dcaddb5"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id2988a8643e94cc8adf6669f7ea2c135_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtNS0xLTEtMjkxMQ_c9d416a7-c3c2-4401-99aa-432c410a319d"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i16aa33389c324a9f961f14e7ec128be5_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTozYWQ3MjVkYWE5MTk0NDExYWIwNTdjMjMzNjg4OWM5NS90YWJsZXJhbmdlOjNhZDcyNWRhYTkxOTQ0MTFhYjA1N2MyMzM2ODg5Yzk1XzQtNy0xLTEtMjkxMQ_db5df723-a3b2-4df7-8e63-d899abebcd56"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:OperatingIncomeLoss
      contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItMS0xLTEtMA_c771eea8-6557-4d46-8eb8-144f81727a18"
      unitRef="usd">-2597000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItMy0xLTEtMA_7f97493f-a55f-4880-8d19-0320512e0675"
      unitRef="usd">-135012000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItNS0xLTEtMA_e4cc0c9d-0667-4b3c-b9ff-e2fa978ab271"
      unitRef="usd">-22187000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzItNy0xLTEtMA_21e53976-e0f9-4e07-b5d7-88ae0171e0ad"
      unitRef="usd">-33046000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtMS0xLTEtMA_a5250d72-fc5e-4297-9dfc-d60534654dd6"
      unitRef="usd">-2597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtMy0xLTEtMA_0ad945db-4846-4936-9593-b76395850b36"
      unitRef="usd">-134902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtNS0xLTEtMA_ce0a5236-6970-441d-b40e-2a21b62d17fa"
      unitRef="usd">-43497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzMtNy0xLTEtMA_08d35c5c-0eff-4bbc-9361-bb04b9d6108c"
      unitRef="usd">-30509000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icabf881662b64e1f8ebda5fe33b6056c_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtMS0xLTEtMA_dff36e18-9e54-4814-8a70-7043c5e2334f"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iccb7544972f64173a049364e08f1fd95_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtMy0xLTEtMA_af72da34-5d4b-42f8-bbc3-afe5fb1fe7d4"
      unitRef="usdPerShare">-43.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i775c3d8c0acf4d3385f869e08d8a0065_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtNS0xLTEtMA_ad0dce79-2f6e-4f54-9d11-76e1ddf3bcb7"
      unitRef="usdPerShare">-10.71</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i10ccb47afb2b487c90353ecadb88e2a9_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiYmQ4OTFhNGFlOTRmYjFiNjA3MGI4ZjU1MWE2NTQ5L3NlYzo0YmJkODkxYTRhZTk0ZmIxYjYwNzBiOGY1NTFhNjU0OV8xNzIvZnJhZzo1YmRmMjMwYjQ5NDA0NGYwODRlN2FmNzI5Mjc5YjZmMy90YWJsZTo4ZDQ0MTEzOGViYWI0NTA0YmI5OGRiNDE0OTQxYzEwMC90YWJsZXJhbmdlOjhkNDQxMTM4ZWJhYjQ1MDRiYjk4ZGI0MTQ5NDFjMTAwXzQtNy0xLTEtMA_b6853353-e8bf-4e18-8d5e-2ec91a26cf17"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606560320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 54,018<span></span>
</td>
<td class="nump">$ 16,437<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,239<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">22,770<span></span>
</td>
<td class="nump">23,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">14,839<span></span>
</td>
<td class="nump">9,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">105,111<span></span>
</td>
<td class="nump">51,804<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DeferredTaxLiabilitiesRightOfUseLeased', window );">Right of use leased assets</a></td>
<td class="num">(12,453)<span></span>
</td>
<td class="num">(9,239)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(13,207)<span></span>
</td>
<td class="num">(9,888)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities', window );">Net deferred tax assets</a></td>
<td class="nump">91,904<span></span>
</td>
<td class="nump">41,916<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent', window );">Valuation allowance</a></td>
<td class="num">(91,904)<span></span>
</td>
<td class="num">(41,916)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets net of deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DeferredTaxAssetsNetOfDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_DeferredTaxLiabilitiesRightOfUseLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use leased assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_DeferredTaxLiabilitiesRightOfUseLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31928-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6607685856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted stock units subject to vesting<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares) | shares</a></td>
<td class="nump">1,982,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested (in shares) | shares</a></td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units, forfeited (in shares) | shares</a></td>
<td class="num">(41,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, ending balance (in shares) | shares</a></td>
<td class="nump">1,941,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock units, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">1,941,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, grants (in dollars per share) | $ / shares</a></td>
<td class="nump">27.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, vested (in dollars per share) | $ / shares</a></td>
<td class="nump">25.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">27.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units, weighted average grant date fair value, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">27.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Restricted stock units, weighted average grant date fair value, vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms', window );">Restricted stock units, granted, weighted average remaining vesting life</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Restricted stock units, unvested, weighted average remaining vesting life</a></td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm', window );">Restricted stock units, vested and expected to vest, weighted average remaining vesting life</a></td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Restricted stock units, aggregate intrinsic value, beginning balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Restricted stock units, aggregate intrinsic value, ending balance | $</a></td>
<td class="nump">50,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">Restricted stock units, aggregate intrinsic value, vested and expected to vest | $</a></td>
<td class="nump">$ 50,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608235888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contribution expenses</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=112275985&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e2709-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6796858128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 61,921<span></span>
</td>
<td class="nump">$ 9,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,472)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">56,449<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">13,117<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">29,924<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember', window );">Computers equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">3,726<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 12,390<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804346784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 535,042<span></span>
</td>
<td class="nump">$ 713,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">536,629<span></span>
</td>
<td class="nump">714,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">85,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">355,407<span></span>
</td>
<td class="nump">366,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">58,322<span></span>
</td>
<td class="nump">261,966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashEquivalentsAndShortTermInvestments', window );">Total cash equivalents, and investments</a></td>
<td class="nump">536,629<span></span>
</td>
<td class="nump">714,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">122,900<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">204,144<span></span>
</td>
<td class="nump">244,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">205,011<span></span>
</td>
<td class="nump">244,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">181,340<span></span>
</td>
<td class="nump">341,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">181,894<span></span>
</td>
<td class="nump">342,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">25,658<span></span>
</td>
<td class="nump">61,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">25,824<span></span>
</td>
<td class="nump">$ 62,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
